<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="0" size="11" family="Times" color="#000000"/>
	<fontspec id="1" size="16" family="Times" color="#000000"/>
	<fontspec id="2" size="16" family="Times" color="#000000"/>
	<fontspec id="3" size="12" family="Times" color="#000000"/>
	<fontspec id="4" size="12" family="Times" color="#000000"/>
	<fontspec id="5" size="14" family="Times" color="#000000"/>
<text top="1117" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="1117" left="774" width="39" height="17" font="0">Page 1 </text>
<text top="108" left="134" width="654" height="23" font="1"><b>2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease </b></text>
<text top="130" left="459" width="4" height="23" font="2"> </text>
<text top="152" left="390" width="141" height="23" font="1"><b>Data Supplements </b></text>
<text top="174" left="286" width="350" height="19" font="3"><b>(Section numbers correspond to the full-text guideline.) </b></text>
<text top="192" left="459" width="3" height="19" font="3"><b> </b></text>
<text top="210" left="393" width="136" height="23" font="1"><b>Table of Contents </b></text>
<text top="232" left="459" width="3" height="19" font="3"><b> </b></text>
<text top="251" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#5">Data Supplement 1. Anatomic and Physiologic Terms – Section 2.1 ............................................................................ 5</a></text>
<text top="249" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#5"> </a></text>
<text top="269" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#7">Data Supplement 2. Severity of ACHD – Section 2.2 ..................................................................................................... 7</a></text>
<text top="268" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#7"> </a></text>
<text top="287" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#16">Data Supplement 3. Access to Care and Delivery of Care – Sections 3.2 and 3.3 ....................................................... 16</a></text>
<text top="286" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#16"> </a></text>
<text top="306" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#17">Data Supplement 4. Catheter Interventions ................................................................................................................ 17</a></text>
<text top="304" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#17"> </a></text>
<text top="324" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#18">Data Supplement 5. Surgery ........................................................................................................................................ 18</a></text>
<text top="322" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#18"> </a></text>
<text top="342" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#20">Data Supplement 6. Ionizing Radiation Principles – Section 3.4.2 .............................................................................. 20</a></text>
<text top="341" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#20"> </a></text>
<text top="361" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#21">Data Supplement 7. Echocardiography – Section 3.4.3 ............................................................................................... 21</a></text>
<text top="359" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#21"> </a></text>
<text top="379" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#24">Data Supplement 8. CMR Imaging – Section 3.4.4 ...................................................................................................... 24</a></text>
<text top="377" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#24"> </a></text>
<text top="397" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#28">Data Supplement 9. Cardiac Computed Tomography – Section 3.4.5 ........................................................................ 28</a></text>
<text top="396" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#28"> </a></text>
<text top="416" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#30">Data Supplement 10. Cardiac Catheterization – Section 3.4.6 .................................................................................... 30</a></text>
<text top="414" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#30"> </a></text>
<text top="434" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#34">Data Supplement 11. Exercise Testing – Section 3.4.7 ................................................................................................ 34</a></text>
<text top="432" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#34"> </a></text>
<text top="452" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#35">Data Supplement 12. Transition Education – Section 3.5 ........................................................................................... 35</a></text>
<text top="451" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#35"> </a></text>
<text top="471" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#36">Data Supplement 13. Exercise and Sports – Section 3.6 ............................................................................................. 36</a></text>
<text top="469" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#36"> </a></text>
<text top="489" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#39">Data Supplement 14. Mental Health and Neurodevelopmental Issues – Section 3.7................................................. 39</a></text>
<text top="487" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#39"> </a></text>
<text top="507" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#41">Data Supplement 15. Endocarditis Prevention – Section 3.8 ...................................................................................... 41</a></text>
<text top="505" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#41"> </a></text>
<text top="525" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#43">Data Supplement 16. Concomitant Syndromes – Section 3.9 ..................................................................................... 43</a></text>
<text top="524" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#43"> </a></text>
<text top="544" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#45">Data Supplement 17. Acquired Cardiovascular Disease – Section 3.10 ...................................................................... 45</a></text>
<text top="542" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#45"> </a></text>
<text top="562" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#54">Data Supplement 18. Noncardiac Medical Issues and Noncardiac Surgery – Sections 3.11 and 3.12 ........................ 54</a></text>
<text top="561" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#54"> </a></text>
<text top="580" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#58">Data Supplement 19. Pregnancy – Section 3.13.1 ....................................................................................................... 58</a></text>
<text top="579" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#58"> </a></text>
<text top="599" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#69">Data Supplement 20. Contraception – Section 3.13.2 ................................................................................................ 69</a></text>
<text top="597" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#69"> </a></text>
<text top="617" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#70">Data Supplement 21. Sexual Function – Section 3.13.4 .............................................................................................. 70</a></text>
<text top="615" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#70"> </a></text>
<text top="635" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#71">Data Supplement 22. Pharmacological Therapy for ACHD – Section 3.17 .................................................................. 71</a></text>
<text top="634" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#71"> </a></text>
<text top="654" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#76">Data Supplement 23. Heart Failure and Transplant – Section 3.14.2 .......................................................................... 76</a></text>
<text top="652" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#76"> </a></text>
<text top="672" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#78">Data Supplement 24. Palliative Care – Section 3.15 .................................................................................................... 78</a></text>
<text top="670" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#78"> </a></text>
<text top="690" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#78">Data Supplement 25. Cyanosis – Section 3.16............................................................................................................. 78</a></text>
<text top="689" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#78"> </a></text>
<text top="708" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#80">Data Supplement 26. Atrial Septal Defect – Section 4.1.1 .......................................................................................... 80</a></text>
<text top="707" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#80"> </a></text>
<text top="727" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#92">Data Supplement 27. Anomalous Pulmonary Venous Connections – Section 4.1.2 ................................................... 92</a></text>
<text top="725" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#92"> </a></text>
<text top="745" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#96">Data Supplement 28. Ventricular Septal Defect – Section 4.1.3 ................................................................................. 96</a></text>
<text top="744" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#96"> </a></text>
<text top="763" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#98">Data Supplement 29. Atrioventricular Septal Defect – Section 4.1.4 .......................................................................... 98</a></text>
<text top="762" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#98"> </a></text>
<text top="782" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#99">Data Supplement 30. Patent Ductus Arteriosus – Section 4.1.5 ................................................................................. 99</a></text>
<text top="780" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#99"> </a></text>
<text top="800" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#101">Data Supplement 31. Cor Triatriatum – Section 4.2.1 ............................................................................................... 101</a></text>
<text top="799" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#101"> </a></text>
<text top="818" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#101">Data Supplement 32. Congenital Mitral Stenosis – Section 4.2.2 ............................................................................. 101</a></text>
<text top="817" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#101"> </a></text>
<text top="837" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#102">Data Supplement 33. Subaortic Stenosis – Section 4.2.3 .......................................................................................... 102</a></text>
<text top="835" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#102"> </a></text>
<text top="855" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#108">Data Supplement 34. Congenital Valvular Aortic Stenosis – Sections 4.2.4 .............................................................. 108</a></text>
<text top="853" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#108"> </a></text>
<text top="873" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#109">Data Supplement 35. Turner Syndrome – Section 4.2.4.1 ........................................................................................ 109</a></text>
<text top="872" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#109"> </a></text>
<text top="892" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#110">Data Supplement 36. Aortopathies – Section 4.2.4.2 ............................................................................................... 110</a></text>
<text top="890" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#110"> </a></text>
<text top="910" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#112">Data Supplement 37. Supravalvular Aortic Stenosis – Section 4.2.5 ......................................................................... 112</a></text>
<text top="908" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#112"> </a></text>
<text top="928" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#116">Data Supplement 38. Coarctation of the Aorta – Section 4.2.6 ................................................................................ 116</a></text>
<text top="927" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#116"> </a></text>
<text top="947" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#123">Data Supplement 39. Valvular Pulmonary Stenosis – Section 4.3.1 .......................................................................... 123</a></text>
<text top="945" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#123"> </a></text>
<text top="965" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#125">Data Supplement 40. Branch and Peripheral Pulmonary Stenosis – Section 4.3.2 ................................................... 125</a></text>
<text top="963" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#125"> </a></text>
<text top="983" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#128">Data Supplement 41. Double-Chambered Right Ventricular – Section 4.3.3 ............................................................ 128</a></text>
<text top="982" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#128"> </a></text>
<text top="1002" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#129">Data Supplement 42. Ebstein Anomaly – Section 4.3.4............................................................................................. 129</a></text>
<text top="1000" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#129"> </a></text>
<text top="1020" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#132">Data Supplement 43. Tetralogy of Fallot – Section 4.3.5 .......................................................................................... 132</a></text>
<text top="1018" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#132"> </a></text>
<text top="1038" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#147">Data Supplement 44. Right Ventricle to Pulmonary Artery Conduit – Section 4.3.6 ................................................ 147</a></text>
<text top="1036" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#147"> </a></text>
<text top="1056" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#158">Data Supplement 45. Transposition of the Great Arteries with Atrial Switch – Section 4.4.1.1 ............................... 158</a></text>
<text top="1055" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#158"> </a></text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1117" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="1117" left="774" width="39" height="17" font="0">Page 2 </text>
<text top="108" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#165">Data Supplement 46. Transposition of the Great Arteries with Arterial Switch – Section 4.4.1.2 ............................ 165</a></text>
<text top="106" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#165"> </a></text>
<text top="126" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#167">Data Supplement 47. Congenitally Corrected Transposition of the Great Arteries – Section 4.4.1.4 ....................... 167</a></text>
<text top="125" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#167"> </a></text>
<text top="145" left="108" width="688" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#176">Data Supplement 48. Fontan Palliation of Single Ventricle Physiology Including Tricuspid Atresia and Double Inlet </a></text>
<text top="163" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#176">Right Ventricle – Section 4.4.2 ................................................................................................................................... 176</a></text>
<text top="161" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#176"> </a></text>
<text top="181" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#186">Data Supplement 49. Severe Pulmonary Arterial Hypertension – Section 4.4.6.1 .................................................... 186</a></text>
<text top="180" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#186"> </a></text>
<text top="199" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#193">Data Supplement 50. Eisenmenger Syndrome – Section 4.4.6.2 .............................................................................. 193</a></text>
<text top="198" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#193"> </a></text>
<text top="218" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#206">Data Supplement 51. Anomalous Coronary Artery Evaluation – Section 4.4.7.1 ...................................................... 206</a></text>
<text top="216" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#206"> </a></text>
<text top="236" left="108" width="702" height="19" font="4"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">References ................................................................................................................................................................. 213</a></text>
<text top="235" left="810" width="4" height="21" font="5"><a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213"> </a></text>
<text top="254" left="459" width="3" height="19" font="3"><b> </b></text>
<text top="273" left="108" width="3" height="19" font="4"> </text>
<text top="291" left="108" width="3" height="19" font="4"> </text>
</page>
<page number="3" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="6" size="7" family="Times" color="#000000"/>
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1044" width="39" height="17" font="0">Page 3 </text>
<text top="108" left="54" width="1012" height="19" font="4">~ indicates approximately; 1°, primary; 2°, secondary; 2D, 2-dimensional; 3D, 3-dimensional; 4D, 4-dimensional; 6MWT, 6-minute walk test; AAOCA, anomalous aortic </text>
<text top="126" left="54" width="1025" height="19" font="4">origin of the coronary artery; AAOLCA, anomalous aortic origin of the left coronary artery; AAORCA, anomalous aortic origin of the right coronary artery; ACC, American </text>
<text top="145" left="54" width="1005" height="19" font="4">College of Cardiology; ACEI, angiotensin-converting-enzyme inhibitor; ACHD, adult congenital heart disease; AE, adverse events; AF, atrial fibrillation; AHA, American </text>
<text top="163" left="54" width="1006" height="19" font="4">Heart Association; ALCAPA, anomalous left coronary artery arising from the pulmonary artery; ANP, atrial natriuretic peptide; ARB, angiotensin-receptor blocker; AS, </text>
<text top="181" left="54" width="1009" height="19" font="4">aortic stenosis; ASD, atrial septal defect; ASO, arterial switch operation; AT, anaerobic threshold; AVC, atrioventricular canal; AVNRT, atrioventricular nodal reentrant </text>
<text top="199" left="54" width="997" height="19" font="4">tachycardia; AV, atrioventricular; AVS, aortic valve stenosis; AVSD, atrioventricular septal defect; BAV, bicuspid aortic valve; BB, beta blockers; BDCPA, bidirectional </text>
<text top="218" left="54" width="964" height="19" font="4">cavopulmonary anastomosis; BMI, body mass index; BNP, brain natriuretic peptide; BP, blood pressure; BREATHE-5, Bosentan Randomized Trial of Endothelin </text>
<text top="236" left="54" width="957" height="19" font="4">Antagonist Therapy-5; CABG, coronary artery bypass grafting; CAC, coronary artery calcium; CAD, coronary artery disease; CAMPHOR, Cambridge Pulmonary </text>
<text top="255" left="54" width="1017" height="19" font="4">Hypertension Outcome Review; CACH, Canadian Adult Congenital Heart; CCT, cardiac computed tomography; CCTGA, congenitally corrected transposition of the great </text>
<text top="273" left="54" width="983" height="19" font="4">arteries; CHD, congenital heart disease; CI, confidence interval; CKD, chronic kidney disease; CK-MB, creatine kinase-MB; CMR, cardiac magnetic resonance; CoA, </text>
<text top="291" left="54" width="993" height="19" font="4">coarctation of the aorta; COR, class of recommendation; CPB, cardiopulmonary bypass; CPET, cardiopulmonary exercise stress test; CRT, cardiac resynchronization </text>
<text top="309" left="54" width="1002" height="19" font="4">therapy; CT, computed tomography; CTA, computed tomography angiography; CV, cardiovascular; CVA, cerebrovascular accident; CVD, cardiovascular disease; CXR, </text>
<text top="328" left="54" width="1004" height="19" font="4">chest x-ray; DBP, diastolic blood pressure; DCCV, direct current cardioversion; DCM, dilated cardiomyopathy; DCRV, double-chambered right ventricle; DM, diabetes </text>
<text top="346" left="54" width="1015" height="19" font="4">mellitus; double outlet right ventricle; dp/dt, measurement of the rate of systolic right ventricular pressure increase; d-TGA, dextro-transposition of the great arteries; </text>
<text top="364" left="54" width="881" height="19" font="4">echo, echocardiography; ECG, electrocardiogram; ED, emergency department; EDA, end diastolic area; EF, ejection fraction; EOL, end-of-life; EP, </text>
<text top="383" left="54" width="1012" height="19" font="4">electrophysiology/electrophysiologic; EPS, electrophysiological studies; ERA, endothelin receptor antagonist; FC, functional class; FDA, Food and Drug Administration; </text>
<text top="401" left="54" width="975" height="19" font="4">FDR, first-degree relative; GI, gastrointestinal; GUCH, grown up congenital heart; HCT, hematocrit; HD, heart disease; HF, heart failure; HGB, hemoglobin; HLHS, </text>
<text top="419" left="54" width="1016" height="19" font="4">hypoplastic left heart syndrome; HR, hazard ratio; HTN, hypertension; IART, intra-atrial reentrant tachycardia; ICD-9-CM, International Classification of Diseases, Ninth </text>
<text top="438" left="54" width="999" height="19" font="4">Revision, Clinical Modification; ICE, intracardiac echocardiography; ICD, implantable cardioverter-defibrillator; ICU, intensive care unit; IE, infective endocarditis; IQ, </text>
<text top="456" left="54" width="1020" height="19" font="4">intelligence quotient; IQR, interquartile range; IV, intravenous; LDL, low-density lipoprotein; LIMA, left internal mammary artery; LMCA, left main coronary artery; LOE, </text>
<text top="474" left="54" width="1003" height="19" font="4">level of evidence; LOS, length of stay; LV, left ventricular; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; LVOT, left ventricular </text>
<text top="493" left="54" width="995" height="19" font="4">outflow tract; LVOTO, left ventricular outflow obstruction; MACE, major adverse cardiac events; MCV, mean corpuscular volume; MDCTA, multidetector computed </text>
<text top="511" left="54" width="894" height="19" font="4">tomographic angiography; MI, myocardial infarction; mPAP, mean pulmonary artery pressure; MR, mitral regurgitation; MRA, magnetic resonance </text>
<text top="529" left="54" width="974" height="19" font="4">angiogram/angiography; MRCA, magnetic resonance coronary angiography; MRI, magnetic resonance imaging; MS, mitral stenosis; MSCT, multi-slice computer </text>
<text top="547" left="54" width="979" height="19" font="4">tomography; N/A, not applicable; NHLBI, National Heart, Lung, and Blood Institute; NPV, negative predictive value; NS, not significant; NT-BNP, N-terminal-brain </text>
<text top="566" left="54" width="997" height="19" font="4">natriuretic peptide; NT-proANP, N-terminal pro-atrial natriuretic peptide; NT-proBNP, N-terminal-pro-brain natriuretic peptide; NYHA, New York Heart Association; </text>
<text top="584" left="54" width="474" height="19" font="4">NSVT, nonsustained ventricular tachycardia; NVE, native valve endocarditis; O</text>
<text top="590" left="528" width="5" height="12" font="6">2</text>
<text top="584" left="533" width="512" height="19" font="4">, oxygen; OR, odds ratio; PA, pulmonary artery; PAD, patent ductus arteriosus; PAH, </text>
<text top="602" left="54" width="991" height="19" font="4">pulmonary arterial hypertension; PAP, pulmonary artery pressure; PAPVC, partial anomalous pulmonary venous connection; PAPVR, partial anomalous pulmonary </text>
<text top="621" left="54" width="1018" height="19" font="4">venous drainage; PASP, pulmonary artery systolic pressure; PCI, percutaneous coronary intervention; PDA, patent ductus arteriosus; PDE-5, phosphodiesterase type-5; </text>
<text top="639" left="54" width="1013" height="19" font="4">PFO, patent foramen ovale; PH, pulmonary hypertension; PLE, protein losing enteropathy; PPVI, percutaneous pulmonary valve implant; PR, pulmonary regurgitation; </text>
<text top="657" left="54" width="1008" height="19" font="4">PS, pulmonary stenosis; PVR, pulmonary vascular resistance; pt, patient; PV, pulmonary valve; PVE, prosthetic valve endocarditis; QOL, quality of life; Qpeff, effective </text>
<text top="676" left="54" width="1013" height="19" font="4">pulmonary blood flow; Qpi, pulmonary blood flow index; Qp:Qs, pulmonary to systemic flow ratio; RACHS-1, Risk Adjusted Classification for Congenital Heart Surgery; </text>
<text top="694" left="54" width="996" height="19" font="4">RCT, randomized controlled trial; RT3DE real-time 3-dimensional echocardiography; RV, right ventricular; RVEDV, right ventricular end diastolic volume; RVEF, right </text>
<text top="712" left="54" width="1016" height="19" font="4">ventricular ejection fraction; RVESV, right ventricular end systolic volume; RVOT, right ventricular outflow tract; RVOTO; right ventricular outflow tract obstruction; RV-</text>
<text top="730" left="54" width="1027" height="19" font="4">PA, right ventricular to pulmonary artery; Rx, medical prescription; SBP, systolic blood pressure; SCD, sudden cardiac death; SD, standard deviation; SEM, standard error </text>
<text top="749" left="54" width="849" height="19" font="4">of the mean; SF-12, Short Form Health Survey; s/p, status post; SND, sinus node dysfunction; SPAP, systolic pulmonary artery pressure; SpO</text>
<text top="755" left="903" width="5" height="12" font="6">2</text>
<text top="749" left="908" width="162" height="19" font="4">, oxygen saturation; STAT, </text>
<text top="767" left="54" width="1013" height="19" font="4">Stending in Aneurysm Treatments Trial; STS, Society of Thoracic Surgeons; SVA, supraventricular arrhythmia; SVC, superior vena cava; SVG, saphenous vein graft; SVT, </text>
<text top="786" left="54" width="998" height="19" font="4">supraventricular tachycardia; TA, tricuspid annulus; TEE, transesophageal echocardiography; TGA, transposition of the great arteries; TIA, transient ischemic attack; </text>
</page>
<page number="4" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1044" width="39" height="17" font="0">Page 4 </text>
<text top="108" left="54" width="971" height="19" font="4">TOF, tetralogy of Fallot; TOF/PA, tetralogy of Fallot with pulmonary atresia; TPVR, transcatheter pulmonary valve replacement; TR, tricuspid regurgitation; TTE, </text>
<text top="126" left="54" width="1008" height="19" font="4">transthoracic echocardiogram; TV, tricuspid valve; TVR, tricuspid valve replacement; UK, United Kingdom; UL, upper limbs; UNOS, United Network for Organ Sharing; </text>
<text top="145" left="54" width="837" height="19" font="4">U.S., United States; VA, ventricular arrhythmias; VAD, ventricular assist device; VF, ventricular fibrillation; VHD, valvular heart disease; VO</text>
<text top="150" left="891" width="5" height="12" font="6">2</text>
<text top="145" left="896" width="173" height="19" font="4">, oxygen consumption; VSD, </text>
<text top="163" left="54" width="1016" height="19" font="4">ventricular septal defect; VT, ventricular tachycardia; VTE, venous thromboembolism; WHO, World Health Organization; WPW, Wolf-Parkinson-White; and WU, Wood </text>
<text top="181" left="54" width="37" height="19" font="4">units. </text>
<text top="181" left="304" width="3" height="19" font="4"> </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="7" size="12" family="Times" color="#650715"/>
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1044" width="39" height="17" font="0">Page 5 </text>
<text top="106" left="108" width="472" height="24" font="1"><b>Data Supplement 1. Anatomic and Physiologic Terms – Section 2.1 </b></text>
<text top="128" left="92" width="38" height="20" font="3"><b>Study </b></text>
<text top="145" left="67" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="162" left="96" width="30" height="20" font="3"><b>Year </b></text>
<text top="128" left="180" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="145" left="194" width="44" height="20" font="3"><b>Design </b></text>
<text top="128" left="300" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="128" left="406" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="145" left="442" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="128" left="546" width="83" height="20" font="3"><b>Classification </b></text>
<text top="145" left="565" width="47" height="20" font="3"><b>System </b></text>
<text top="128" left="661" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="128" left="789" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="128" left="935" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="180" left="64" width="80" height="20" font="4">Afilalo J, et al. </text>
<text top="197" left="64" width="49" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(1)</a> </text>
<text top="215" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21939837?dopt=Citation">21939837</a></text>
<text top="215" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21939837?dopt=Citation"> </a></text>
<text top="180" left="170" width="83" height="20" font="4">Observational, </text>
<text top="197" left="170" width="73" height="20" font="4">case control, </text>
<text top="215" left="170" width="41" height="20" font="4">cohort, </text>
<text top="232" left="170" width="74" height="20" font="4">retrospective </text>
<text top="180" left="276" width="71" height="20" font="4">n=3,239 pts; </text>
<text top="197" left="276" width="76" height="20" font="4">Quebec CHD </text>
<text top="215" left="276" width="56" height="20" font="4">Database </text>
<text top="180" left="402" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="197" left="402" width="107" height="20" font="4">≥65 y, 1990–2005, </text>
<text top="215" left="402" width="91" height="20" font="4">ACHD, Quebec, </text>
<text top="232" left="402" width="118" height="20" font="4">healthcare interaction</text>
<text top="233" left="520" width="2" height="13" font="6"> </text>
<text top="180" left="542" width="72" height="20" font="4">Bethesda 32 </text>
<text top="197" left="542" width="85" height="20" font="4">(severe, shunt, </text>
<text top="215" left="542" width="50" height="20" font="4">valvular) </text>
<text top="180" left="648" width="50" height="20" font="4">Mortality </text>
<text top="180" left="761" width="33" height="20" font="4">● NS </text>
<text top="180" left="933" width="139" height="20" font="4">● A rare study that deals </text>
<text top="197" left="933" width="117" height="20" font="4">with older adults with </text>
<text top="215" left="933" width="33" height="20" font="4">CHD. </text>
<text top="232" left="933" width="93" height="20" font="4">● Administrative </text>
<text top="249" left="933" width="139" height="20" font="4">database has limitations. </text>
<text top="267" left="64" width="88" height="20" font="4">Tutarel O, et al. </text>
<text top="284" left="64" width="49" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(2)</a> </text>
<text top="301" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23882067?dopt=Citation">23882067</a></text>
<text top="301" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23882067?dopt=Citation"> </a></text>
<text top="267" left="170" width="83" height="20" font="4">Observational, </text>
<text top="284" left="170" width="41" height="20" font="4">cohort, </text>
<text top="301" left="170" width="74" height="20" font="4">retrospective </text>
<text top="267" left="276" width="58" height="20" font="4">n=375 pts </text>
<text top="267" left="402" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="284" left="402" width="124" height="20" font="4">≥60 y, ACHD January </text>
<text top="301" left="402" width="99" height="20" font="4">2000–March 2012</text>
<text top="303" left="501" width="2" height="13" font="6"> </text>
<text top="267" left="542" width="73" height="20" font="4">Bethesda 32 </text>
<text top="267" left="648" width="68" height="20" font="4">Prevalence, </text>
<text top="284" left="648" width="84" height="20" font="4">demographics, </text>
<text top="301" left="648" width="76" height="20" font="4">interventions, </text>
<text top="319" left="648" width="50" height="20" font="4">mortality </text>
<text top="267" left="761" width="140" height="20" font="4">● Mortality: standardized </text>
<text top="284" left="761" width="137" height="20" font="4">mortality ratio simple 0.6 </text>
<text top="301" left="761" width="136" height="20" font="4">(p=0.06), moderate 1.89 </text>
<text top="319" left="761" width="136" height="20" font="4">(p=0.002), complex 2.91 </text>
<text top="336" left="761" width="123" height="20" font="4">(p=0.01); overall 1.82. </text>
<text top="353" left="761" width="139" height="20" font="4">● (p&lt;0.05 univariate, not </text>
<text top="370" left="761" width="129" height="20" font="4">multivariate as HF, FC, </text>
<text top="387" left="761" width="133" height="20" font="4">ventricular function took </text>
<text top="405" left="761" width="35" height="20" font="4">over). </text>
<text top="267" left="933" width="108" height="20" font="4">● The study shows </text>
<text top="284" left="933" width="122" height="20" font="4">increase in number of </text>
<text top="301" left="933" width="139" height="20" font="4">pts ≥60 y for follow-up at </text>
<text top="319" left="933" width="85" height="20" font="4">ACHD centers. </text>
<text top="336" left="933" width="131" height="20" font="4">● Acquired comorbidity </text>
<text top="353" left="933" width="135" height="20" font="4">in ACHD pts determines </text>
<text top="370" left="933" width="60" height="20" font="4">outcomes. </text>
<text top="441" left="64" width="78" height="20" font="4">Kim YY, et al. </text>
<text top="458" left="64" width="49" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(3)</a> </text>
<text top="476" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22010202?dopt=Citation">22010202</a></text>
<text top="476" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22010202?dopt=Citation"> </a></text>
<text top="441" left="170" width="83" height="20" font="4">Observational, </text>
<text top="458" left="170" width="73" height="20" font="4">case control, </text>
<text top="476" left="170" width="74" height="20" font="4">retrospective </text>
<text top="493" left="170" width="54" height="20" font="4">database </text>
<text top="441" left="276" width="68" height="20" font="4">n=3,061 pts </text>
<text top="441" left="402" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="458" left="402" width="119" height="20" font="4">18–49 y, 2000–2008, </text>
<text top="476" left="402" width="96" height="20" font="4">ACHD surgery in </text>
<text top="493" left="402" width="126" height="20" font="4">pediatric hospital, total </text>
<text top="510" left="402" width="122" height="20" font="4">compared to pediatric </text>
<text top="527" left="402" width="107" height="20" font="4">surgical pts, ACHD </text>
<text top="544" left="402" width="78" height="20" font="4">high resource </text>
<text top="562" left="402" width="121" height="20" font="4">utilization vs. nonhigh </text>
<text top="579" left="402" width="102" height="20" font="4">resource utilization</text>
<text top="580" left="505" width="2" height="13" font="6"> </text>
<text top="441" left="542" width="57" height="20" font="4">RACHS-1 </text>
<text top="441" left="648" width="56" height="20" font="4">Resource </text>
<text top="458" left="648" width="87" height="20" font="4">utilization, cost, </text>
<text top="476" left="648" width="28" height="20" font="4">LOS </text>
<text top="441" left="761" width="146" height="20" font="4">● OR: 3–30 for increasing </text>
<text top="458" left="761" width="157" height="20" font="4">RACHS classification (much </text>
<text top="476" left="761" width="145" height="20" font="4">tighter RACHS 3 and 4 as </text>
<text top="493" left="761" width="90" height="20" font="4">compared to 2). </text>
<text top="441" left="933" width="93" height="20" font="4">● Administrative </text>
<text top="458" left="933" width="100" height="20" font="4">database limited.  </text>
<text top="476" left="933" width="132" height="20" font="4">● The number of adults </text>
<text top="493" left="933" width="124" height="20" font="4">undergoing congenital </text>
<text top="510" left="933" width="88" height="20" font="4">heart surgery is </text>
<text top="527" left="933" width="66" height="20" font="4">increasing.  </text>
<text top="544" left="933" width="92" height="20" font="4">● High resource </text>
<text top="562" left="933" width="120" height="20" font="4">utilization admissions </text>
<text top="579" left="933" width="125" height="20" font="4">associated with higher </text>
<text top="596" left="933" width="68" height="20" font="4">death rates. </text>
<text top="614" left="64" width="78" height="20" font="4">Kim YY, et al. </text>
<text top="631" left="64" width="49" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(4)</a> </text>
<text top="648" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21693722?dopt=Citation">21693722</a></text>
<text top="648" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21693722?dopt=Citation"> </a></text>
<text top="614" left="170" width="83" height="20" font="4">Observational, </text>
<text top="631" left="170" width="73" height="20" font="4">case control, </text>
<text top="648" left="170" width="74" height="20" font="4">retrospective </text>
<text top="614" left="276" width="105" height="20" font="4">n=3,061 pts Public </text>
<text top="631" left="276" width="104" height="20" font="4">Health Information </text>
<text top="648" left="276" width="98" height="20" font="4">System database </text>
<text top="614" left="402" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="631" left="402" width="119" height="20" font="4">18–49 y, 2000–2008, </text>
<text top="648" left="402" width="96" height="20" font="4">ACHD surgery in </text>
<text top="666" left="402" width="126" height="20" font="4">pediatric hospital, total </text>
<text top="683" left="402" width="122" height="20" font="4">compared to pediatric </text>
<text top="700" left="402" width="107" height="20" font="4">surgical pts, ACHD </text>
<text top="717" left="402" width="69" height="20" font="4">mortality vs. </text>
<text top="734" left="402" width="64" height="20" font="4">nonmorality</text>
<text top="736" left="466" width="2" height="13" font="6"> </text>
<text top="614" left="542" width="57" height="20" font="4">RACHS-1 </text>
<text top="614" left="648" width="50" height="20" font="4">Mortality </text>
<text top="614" left="761" width="153" height="20" font="4">● OR: 2–22 (NS RACHS 2, </text>
<text top="631" left="761" width="156" height="20" font="4">significant for RACHS 3 and </text>
<text top="648" left="761" width="18" height="20" font="4">4). </text>
<text top="614" left="933" width="90" height="20" font="4">● Pt death after </text>
<text top="631" left="933" width="135" height="20" font="4">congenital heart surgery </text>
<text top="648" left="933" width="108" height="20" font="4">is lower in pediatric </text>
<text top="666" left="933" width="104" height="20" font="4">hospitals with high </text>
<text top="683" left="933" width="135" height="20" font="4">congenital heart surgery </text>
<text top="700" left="933" width="46" height="20" font="4">volume. </text>
<text top="752" left="64" width="88" height="20" font="4">Opotowsky AR, </text>
<text top="769" left="64" width="30" height="20" font="4">et al. </text>
<text top="787" left="64" width="49" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(5)</a> </text>
<text top="752" left="170" width="83" height="20" font="4">Observational, </text>
<text top="769" left="170" width="73" height="20" font="4">case control, </text>
<text top="787" left="170" width="74" height="20" font="4">retrospective </text>
<text top="752" left="276" width="85" height="20" font="4">n=622,000 pts  </text>
<text top="752" left="402" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="769" left="402" width="78" height="20" font="4">in 1998–2007 </text>
<text top="752" left="542" width="73" height="20" font="4">Bethesda 32 </text>
<text top="752" left="648" width="63" height="20" font="4">Combined: </text>
<text top="769" left="648" width="61" height="20" font="4">death, HF, </text>
<text top="787" left="648" width="97" height="20" font="4">arrhythmia, CVA, </text>
<text top="752" left="761" width="140" height="20" font="4">● Severe: OR combined: </text>
<text top="769" left="761" width="116" height="20" font="4">2.0–2.7; HF 3.9–6.0; </text>
<text top="752" left="933" width="106" height="20" font="4">● Maternal CHD is </text>
<text top="769" left="933" width="129" height="20" font="4">linked with higher rates </text>
<text top="787" left="933" width="135" height="20" font="4">of CV events and death. </text>
</page>
<page number="6" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1044" width="39" height="17" font="0">Page 6 </text>
<text top="107" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21990383?dopt=Citation">21990383</a></text>
<text top="107" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21990383?dopt=Citation"> </a></text>
<text top="107" left="402" width="112" height="20" font="4">nationwide inpatient </text>
<text top="124" left="402" width="40" height="20" font="4">sample</text>
<text top="126" left="442" width="2" height="13" font="6"> </text>
<text top="107" left="648" width="89" height="20" font="4">embolic events, </text>
<text top="124" left="648" width="92" height="20" font="4">“unclassified CV </text>
<text top="141" left="648" width="78" height="20" font="4">events,” LOS, </text>
<text top="159" left="648" width="32" height="20" font="4">costs </text>
<text top="107" left="761" width="159" height="20" font="4">arrhythmia 2, LOS 1.9, costs </text>
<text top="124" left="761" width="48" height="20" font="4">1.5–2.0. </text>
<text top="177" left="64" width="81" height="20" font="4">Gurvitz MZ, et </text>
<text top="194" left="64" width="16" height="20" font="4">al. </text>
<text top="211" left="64" width="49" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(6)</a> </text>
<text top="228" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23542112?dopt=Citation">23542112</a></text>
<text top="228" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23542112?dopt=Citation"> </a></text>
<text top="177" left="170" width="79" height="20" font="4">Observational </text>
<text top="194" left="170" width="85" height="20" font="4">cross-sectional </text>
<text top="211" left="170" width="64" height="20" font="4">multicenter </text>
<text top="228" left="170" width="66" height="20" font="4">prospective </text>
<text top="245" left="170" width="77" height="20" font="4">questionnaire </text>
<text top="177" left="276" width="58" height="20" font="4">n=922 pts </text>
<text top="177" left="402" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="194" left="402" width="62" height="20" font="4">≥18 y, first </text>
<text top="211" left="402" width="123" height="20" font="4">presentation to ACHD </text>
<text top="228" left="402" width="27" height="20" font="4">clinic</text>
<text top="230" left="430" width="2" height="13" font="6"> </text>
<text top="177" left="542" width="73" height="20" font="4">Bethesda 32 </text>
<text top="177" left="648" width="84" height="20" font="4">&gt;3 y gap in CV </text>
<text top="194" left="648" width="27" height="20" font="4">care </text>
<text top="177" left="761" width="140" height="20" font="4">● 59%, 42%, 26% gap in </text>
<text top="194" left="761" width="133" height="20" font="4">care (simple, moderate, </text>
<text top="211" left="761" width="115" height="20" font="4">complex); p&lt;0.0001. </text>
<text top="177" left="933" width="130" height="20" font="4">● The study provides a </text>
<text top="194" left="933" width="107" height="20" font="4">basis for improving </text>
<text top="211" left="933" width="118" height="20" font="4">strategies for dealing </text>
<text top="228" left="933" width="135" height="20" font="4">with the barriers to care. </text>
<text top="263" left="64" width="89" height="20" font="4">Mylotte D, et al. </text>
<text top="281" left="64" width="49" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(7)</a> </text>
<text top="298" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24589851?dopt=Citation">24589851</a></text>
<text top="298" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24589851?dopt=Citation"> </a></text>
<text top="263" left="170" width="76" height="20" font="4">Case-control, </text>
<text top="281" left="170" width="92" height="20" font="4">cohort, and time </text>
<text top="298" left="170" width="88" height="20" font="4">series analyses </text>
<text top="263" left="276" width="103" height="20" font="4">n=71,467 pts from </text>
<text top="281" left="276" width="76" height="20" font="4">Quebec CHD </text>
<text top="298" left="276" width="109" height="20" font="4">Registry; nN=2,092 </text>
<text top="315" left="276" width="108" height="20" font="4">ACHD death cases </text>
<text top="263" left="402" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="281" left="402" width="111" height="20" font="4">with ACHD,18–65 y </text>
<text top="298" left="402" width="90" height="20" font="4">from 1983–2005</text>
<text top="300" left="492" width="2" height="13" font="6"> </text>
<text top="263" left="542" width="72" height="20" font="4">Bethesda 32 </text>
<text top="281" left="542" width="64" height="20" font="4">(severe vs. </text>
<text top="298" left="542" width="36" height="20" font="4">other) </text>
<text top="263" left="648" width="98" height="20" font="4">Pts in specialized </text>
<text top="281" left="648" width="84" height="20" font="4">care had lower </text>
<text top="298" left="648" width="92" height="20" font="4">mortality; mostly </text>
<text top="315" left="648" width="74" height="20" font="4">driven by the </text>
<text top="332" left="648" width="79" height="20" font="4">most complex </text>
<text top="350" left="648" width="65" height="20" font="4">CHD group </text>
<text top="263" left="761" width="155" height="20" font="4">● Increased care for severe </text>
<text top="281" left="761" width="146" height="20" font="4">in specialty ACHD centers </text>
<text top="298" left="761" width="160" height="20" font="4">(&lt;0.001); increased mortality </text>
<text top="315" left="761" width="126" height="20" font="4">for severe ACHD (OR: </text>
<text top="332" left="761" width="35" height="20" font="4">1.93). </text>
<text top="263" left="933" width="102" height="20" font="4">● Study promotes </text>
<text top="281" left="933" width="130" height="20" font="4">specialized care for the </text>
<text top="298" left="933" width="23" height="20" font="4">pts. </text>
<text top="368" left="64" width="93" height="20" font="4">Zomer AC, et al. </text>
<text top="385" left="64" width="49" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(8)</a> </text>
<text top="402" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23602867?dopt=Citation">23602867</a></text>
<text top="402" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23602867?dopt=Citation"> </a></text>
<text top="368" left="170" width="83" height="20" font="4">Observational, </text>
<text top="385" left="170" width="73" height="20" font="4">case control, </text>
<text top="402" left="170" width="74" height="20" font="4">retrospective </text>
<text top="368" left="276" width="86" height="20" font="4">n=274 pts from </text>
<text top="385" left="276" width="102" height="20" font="4">CONCOR registry </text>
<text top="368" left="402" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="385" left="402" width="116" height="20" font="4">Adult pts 1995–2007 </text>
<text top="402" left="402" width="125" height="20" font="4">with at least 1 HF 1°or </text>
<text top="419" left="402" width="110" height="20" font="4">2° ACHD admission</text>
<text top="421" left="512" width="2" height="13" font="6"> </text>
<text top="368" left="542" width="64" height="20" font="4">Right heart </text>
<text top="385" left="542" width="36" height="20" font="4">lesion </text>
<text top="368" left="648" width="91" height="20" font="4">Association with </text>
<text top="385" left="648" width="70" height="20" font="4">HF mortality </text>
<text top="368" left="761" width="81" height="20" font="4">● p&lt;0.05; NS. </text>
<text top="368" left="933" width="129" height="20" font="4">● It is critical to identify </text>
<text top="385" left="933" width="93" height="20" font="4">high-risk HF pts. </text>
<text top="437" left="64" width="83" height="20" font="4">Rodriguez FH, </text>
<text top="454" left="64" width="30" height="20" font="4">et al. </text>
<text top="472" left="64" width="49" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(9)</a> </text>
<text top="489" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23164196?dopt=Citation">23164196</a></text>
<text top="489" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23164196?dopt=Citation"> </a></text>
<text top="437" left="170" width="83" height="20" font="4">Observational, </text>
<text top="454" left="170" width="73" height="20" font="4">case control, </text>
<text top="472" left="170" width="74" height="20" font="4">retrospective </text>
<text top="437" left="276" width="108" height="20" font="4">n=17,193 HF pts of </text>
<text top="454" left="276" width="95" height="20" font="4">N=84,308 ACHD </text>
<text top="472" left="276" width="93" height="20" font="4">admissions from </text>
<text top="489" left="276" width="112" height="20" font="4">nationwide inpatient </text>
<text top="506" left="276" width="43" height="20" font="4">sample </text>
<text top="437" left="402" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="454" left="402" width="107" height="20" font="4">Adult, 2207, ACHD </text>
<text top="472" left="402" width="113" height="20" font="4">admission vs.≥1 HF </text>
<text top="489" left="402" width="99" height="20" font="4">1° or 2° coding in </text>
<text top="506" left="402" width="93" height="20" font="4">ACHD admission</text>
<text top="508" left="496" width="2" height="13" font="6"> </text>
<text top="437" left="542" width="55" height="20" font="4">Individual </text>
<text top="454" left="542" width="60" height="20" font="4">diagnoses </text>
<text top="437" left="648" width="91" height="20" font="4">Association with </text>
<text top="454" left="648" width="57" height="20" font="4">HF, death </text>
<text top="437" left="761" width="148" height="20" font="4">● Association: VSD outlier </text>
<text top="454" left="761" width="116" height="20" font="4">OR: 1.54 vs. MI: 1.8  </text>
<text top="472" left="761" width="143" height="20" font="4">● Death: VSD outlier OR: </text>
<text top="489" left="761" width="146" height="20" font="4">3.2 similar to MI; TOF and </text>
<text top="506" left="761" width="132" height="20" font="4">TGA suggesting severe </text>
<text top="523" left="761" width="139" height="20" font="4">Bethesda categorization. </text>
<text top="437" left="933" width="97" height="20" font="4">● Mortality risk is </text>
<text top="454" left="933" width="102" height="20" font="4">increased with the </text>
<text top="472" left="933" width="126" height="20" font="4">presence of VSDs and </text>
<text top="489" left="933" width="120" height="20" font="4">certain comorbidities. </text>
<text top="541" left="64" width="88" height="20" font="4">Opotowsky AR, </text>
<text top="558" left="64" width="30" height="20" font="4">et al. </text>
<text top="575" left="64" width="56" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(10)</a> </text>
<text top="593" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19628123?dopt=Citation">19628123</a></text>
<text top="593" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19628123?dopt=Citation"> </a></text>
<text top="541" left="170" width="83" height="20" font="4">Observational, </text>
<text top="558" left="170" width="73" height="20" font="4">case control, </text>
<text top="575" left="170" width="74" height="20" font="4">retrospective </text>
<text top="541" left="276" width="100" height="20" font="4">n=35,000–72,450 </text>
<text top="558" left="276" width="38" height="20" font="4">ACHD </text>
<text top="575" left="276" width="97" height="20" font="4">hospitalizations/y </text>
<text top="541" left="402" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="558" left="402" width="100" height="20" font="4">US, ACHD, ≥18 y </text>
<text top="575" left="402" width="108" height="20" font="4">admit to acute care </text>
<text top="593" left="402" width="46" height="20" font="4">hospital </text>
<text top="541" left="542" width="73" height="20" font="4">Bethesda 32 </text>
<text top="541" left="648" width="41" height="20" font="4">Rise in </text>
<text top="558" left="648" width="68" height="20" font="4">admissions, </text>
<text top="575" left="648" width="53" height="20" font="4">mortality, </text>
<text top="593" left="648" width="70" height="20" font="4">comorbidity, </text>
<text top="610" left="648" width="64" height="20" font="4">LOS, costs </text>
<text top="541" left="761" width="154" height="20" font="4">● Rise 0.0001 (complex vs. </text>
<text top="558" left="761" width="111" height="20" font="4">simple, not seen for </text>
<text top="575" left="761" width="154" height="20" font="4">unclassified), comorbidities: </text>
<text top="593" left="761" width="123" height="20" font="4">0.006 (complex), LOS </text>
<text top="610" left="761" width="140" height="20" font="4">longer complex (&lt;0.001), </text>
<text top="627" left="761" width="113" height="20" font="4">costs greater simple </text>
<text top="644" left="761" width="128" height="20" font="4">(&lt;0.0003) (unclassified </text>
<text top="662" left="761" width="121" height="20" font="4">shorter and cheaper). </text>
<text top="541" left="933" width="119" height="20" font="4">● Number of hospital </text>
<text top="558" left="933" width="121" height="20" font="4">admissions and costs </text>
<text top="575" left="933" width="64" height="20" font="4">have risen. </text>
<text top="679" left="64" width="83" height="20" font="4">O’Leary JM, et </text>
<text top="697" left="64" width="16" height="20" font="4">al. </text>
<text top="714" left="64" width="56" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(11)</a> </text>
<text top="731" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23471480?dopt=Citation">23471480</a></text>
<text top="731" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23471480?dopt=Citation"> </a></text>
<text top="679" left="170" width="83" height="20" font="4">Observational, </text>
<text top="697" left="170" width="73" height="20" font="4">case control, </text>
<text top="714" left="170" width="74" height="20" font="4">retrospective </text>
<text top="679" left="276" width="85" height="20" font="4">n=950,00 adult </text>
<text top="697" left="276" width="62" height="20" font="4">ACHD and </text>
<text top="714" left="276" width="108" height="20" font="4">1,900,000 pediatric </text>
<text top="731" left="276" width="109" height="20" font="4">CHD pt admissions </text>
<text top="748" left="276" width="90" height="20" font="4">from nationwide </text>
<text top="766" left="276" width="93" height="20" font="4">inpatient sample </text>
<text top="679" left="402" width="126" height="20" font="3"><b>Inclusion criteria</b>: US </text>
<text top="697" left="402" width="125" height="20" font="4">pts with ACHD, ≥18 y, </text>
<text top="714" left="402" width="108" height="20" font="4">admit to acute care </text>
<text top="731" left="402" width="46" height="20" font="4">hospital </text>
<text top="679" left="542" width="73" height="20" font="4">Bethesda 32 </text>
<text top="679" left="648" width="41" height="20" font="4">Rise in </text>
<text top="697" left="648" width="65" height="20" font="4">admissions </text>
<text top="679" left="761" width="153" height="20" font="4">● From beginning to end of </text>
<text top="697" left="761" width="156" height="20" font="4">study period, admissions for </text>
<text top="714" left="761" width="132" height="20" font="4">simple defects changed </text>
<text top="731" left="761" width="154" height="20" font="4">112% unclassified 52% and </text>
<text top="748" left="761" width="112" height="20" font="4">complex 52%. Adult </text>
<text top="766" left="761" width="150" height="20" font="4">admissions increased from </text>
<text top="679" left="933" width="131" height="20" font="4">● Adults account for an </text>
<text top="697" left="933" width="132" height="20" font="4">increasing proportion of </text>
<text top="714" left="933" width="123" height="20" font="4">CHD admissions from </text>
<text top="731" left="933" width="68" height="20" font="4">1998–2010. </text>
</page>
<page number="7" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1044" width="39" height="17" font="0">Page 7 </text>
<text top="107" left="761" width="124" height="20" font="4">28.9%–36.5% of CHD </text>
<text top="124" left="761" width="62" height="20" font="4">admission. </text>
<text top="142" left="64" width="91" height="20" font="4">Marelli AJ, et al. </text>
<text top="159" left="64" width="56" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(12)</a> </text>
<text top="177" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24944314?dopt=Citation">24944314</a></text>
<text top="177" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24944314?dopt=Citation"> </a></text>
<text top="142" left="170" width="79" height="20" font="4">Observational </text>
<text top="142" left="276" width="76" height="20" font="4">Quebec CHD </text>
<text top="159" left="276" width="49" height="20" font="4">Registry </text>
<text top="142" left="402" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="159" left="402" width="118" height="20" font="4">1983–2000, Quebec, </text>
<text top="177" left="402" width="113" height="20" font="4">≥18 y, ACHD health </text>
<text top="194" left="402" width="111" height="20" font="4">interaction, 107,559 </text>
<text top="142" left="542" width="72" height="20" font="4">Bethesda 32 </text>
<text top="159" left="542" width="64" height="20" font="4">(severe vs. </text>
<text top="177" left="542" width="36" height="20" font="4">other) </text>
<text top="142" left="648" width="70" height="20" font="4">Lifetime and </text>
<text top="159" left="648" width="94" height="20" font="4">point prevalence </text>
<text top="177" left="648" width="47" height="20" font="4">of CHD. </text>
<text top="142" left="761" width="152" height="20" font="4">● In 2010, adults represent </text>
<text top="159" left="761" width="125" height="20" font="4">60% (57%, 62%) of all </text>
<text top="177" left="761" width="153" height="20" font="4">severe CHD vs. 49% (47%, </text>
<text top="194" left="761" width="143" height="20" font="4">51%) in 2000; prevalence </text>
<text top="211" left="761" width="139" height="20" font="4">severe lesions increased </text>
<text top="228" left="761" width="145" height="20" font="4">55% (51%, 62%) in adults </text>
<text top="246" left="761" width="115" height="20" font="4">vs. 19% (17%, 21%) </text>
<text top="263" left="761" width="113" height="20" font="4">increase in children. </text>
<text top="142" left="933" width="119" height="20" font="4">● There is a need for </text>
<text top="159" left="933" width="139" height="20" font="4">longitudinal data sources </text>
<text top="177" left="933" width="40" height="20" font="4">in U.S. </text>
<text top="281" left="108" width="3" height="20" font="4"> </text>
<text top="298" left="108" width="3" height="20" font="4"> </text>
<text top="315" left="108" width="362" height="24" font="1"><b>Data Supplement 2. Severity of ACHD – Section 2.2 </b></text>
<text top="336" left="92" width="38" height="20" font="3"><b>Study </b></text>
<text top="354" left="67" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="371" left="95" width="30" height="20" font="3"><b>Year </b></text>
<text top="336" left="195" width="38" height="20" font="3"><b>Study </b></text>
<text top="354" left="175" width="76" height="20" font="3"><b>Type/Design </b></text>
<text top="336" left="280" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="336" left="388" width="61" height="20" font="3"><b>Inclusion/ </b></text>
<text top="354" left="388" width="62" height="20" font="3"><b>Exclusion </b></text>
<text top="371" left="396" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="336" left="499" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="336" left="703" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="336" left="928" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="389" left="64" width="82" height="20" font="4">Koyak Z, et al. </text>
<text top="406" left="64" width="56" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(13)</a> </text>
<text top="423" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24071387?dopt=Citation">24071387</a></text>
<text top="423" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24071387?dopt=Citation"> </a></text>
<text top="389" left="170" width="82" height="20" font="4">Retrospective, </text>
<text top="406" left="170" width="67" height="20" font="4">multicenter  </text>
<text top="389" left="269" width="61" height="20" font="4">n=419 pts  </text>
<text top="406" left="269" width="77" height="20" font="4">(mean 38 y ± </text>
<text top="423" left="269" width="34" height="20" font="4">14 y)  </text>
<text top="389" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="406" left="369" width="82" height="20" font="3"><b>criteria</b>: &gt;18 y </text>
<text top="423" left="369" width="87" height="20" font="4">who underwent </text>
<text top="440" left="369" width="73" height="20" font="4">CHD cardiac </text>
<text top="458" left="369" width="94" height="20" font="4">surgery between </text>
<text top="475" left="369" width="83" height="20" font="4">Jan 2009–Dec </text>
<text top="492" left="369" width="31" height="20" font="4">2011 </text>
<text top="389" left="482" width="78" height="20" font="4">Prevalence of </text>
<text top="406" left="482" width="100" height="20" font="4">postop in-hospital </text>
<text top="423" left="482" width="92" height="20" font="4">arrhythmias and </text>
<text top="440" left="482" width="100" height="20" font="4">clinical outcomes  </text>
<text top="389" left="601" width="299" height="20" font="4">● Arrhythmias occurred in 134 pts (32%) and included </text>
<text top="406" left="601" width="293" height="20" font="4">SVT (n=100), bradycardias (n=47), and VT (n=19). In </text>
<text top="423" left="601" width="284" height="20" font="4">multivariate analysis age ≥40 y at surgery (p=0.03), </text>
<text top="440" left="601" width="299" height="20" font="4">NYHA class ≥II (p=0.09), significant subpulmonary AV </text>
<text top="458" left="601" width="287" height="20" font="4">valve regurgitation (p=0.018), coronary bypass time, </text>
<text top="475" left="601" width="301" height="20" font="4">(p=0.019), and CK-MB (p=0.021) were associated with </text>
<text top="492" left="601" width="273" height="20" font="4">in-hospital arrhythmias. Overall, 58 clinical events </text>
<text top="509" left="601" width="304" height="20" font="4">occurred in 55 pts (13%) and included in the majority of </text>
<text top="527" left="601" width="305" height="20" font="4">the cases permanent pacemaker implantation (5%), HF </text>
<text top="544" left="601" width="127" height="20" font="4">(4%), and death (2%).  </text>
<text top="561" left="601" width="250" height="20" font="4">● In-hospital arrhythmias were independently </text>
<text top="578" left="601" width="216" height="20" font="4">associated with clinical events; p=0.01. </text>
<text top="389" left="920" width="138" height="20" font="4">● Arrhythmias are highly </text>
<text top="406" left="920" width="141" height="20" font="4">prevalent after congenital </text>
<text top="423" left="920" width="149" height="20" font="4">heart surgery in adults and </text>
<text top="440" left="920" width="145" height="20" font="4">are associated with worse </text>
<text top="458" left="920" width="98" height="20" font="4">clinical outcome.  </text>
<text top="475" left="920" width="142" height="20" font="4">● Older and symptomatic </text>
<text top="492" left="920" width="146" height="20" font="4">pts with significant VHD at </text>
<text top="509" left="920" width="134" height="20" font="4">baseline are at risk of in-</text>
<text top="527" left="920" width="117" height="20" font="4">hospital arrhythmias. </text>
<text top="596" left="64" width="89" height="20" font="4">Bouchardy J, et </text>
<text top="613" left="64" width="16" height="20" font="4">al. </text>
<text top="631" left="64" width="56" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(14)</a> </text>
<text top="648" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19822808?dopt=Citation">19822808</a></text>
<text top="648" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19822808?dopt=Citation"> </a></text>
<text top="596" left="170" width="66" height="20" font="4">Population- </text>
<text top="613" left="170" width="37" height="20" font="4">based </text>
<text top="631" left="170" width="77" height="20" font="4">retrospective  </text>
<text top="596" left="269" width="68" height="20" font="4">n=5,812 pts </text>
<text top="613" left="269" width="55" height="20" font="4">with atrial </text>
<text top="631" left="269" width="68" height="20" font="4">arrhythmias </text>
<text top="648" left="269" width="65" height="20" font="4">(38,428 pts </text>
<text top="665" left="269" width="59" height="20" font="4">with CHD) </text>
<text top="596" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="613" left="369" width="85" height="20" font="3"><b>criteria</b>: Adults </text>
<text top="631" left="369" width="55" height="20" font="4">with CHD </text>
<text top="648" left="369" width="84" height="20" font="4">between 1983–</text>
<text top="665" left="369" width="98" height="20" font="4">2005 found in the </text>
<text top="682" left="369" width="46" height="20" font="4">Quebec </text>
<text top="699" left="369" width="79" height="20" font="4">administrative </text>
<text top="717" left="369" width="57" height="20" font="4">database  </text>
<text top="596" left="482" width="68" height="20" font="4">Prevalence, </text>
<text top="613" left="482" width="68" height="20" font="4">lifetime risk, </text>
<text top="631" left="482" width="77" height="20" font="4">mortality, and </text>
<text top="648" left="482" width="53" height="20" font="4">morbidity </text>
<text top="665" left="482" width="87" height="20" font="4">associated with </text>
<text top="682" left="482" width="105" height="20" font="4">atrial arrhythmia in </text>
<text top="699" left="482" width="92" height="20" font="4">adults with CHD </text>
<text top="596" left="601" width="297" height="20" font="4">● Overall, the 20-y risk of developing atrial arrhythmia </text>
<text top="613" left="601" width="288" height="20" font="4">was 7% in a 20-y subject and 38% in a 50-y subject. </text>
<text top="631" left="601" width="302" height="20" font="4">&gt;50% of pts with severe CHD reaching 18 y developed </text>
<text top="648" left="601" width="292" height="20" font="4">atrial arrhythmias by 65 y. In pts with CHD, the HR of </text>
<text top="665" left="601" width="290" height="20" font="4">any AE in those with atrial arrhythmia compared with </text>
<text top="682" left="601" width="304" height="20" font="4">those without was 2.50 (95% CI: 2.38–2.62; p=0.0001), </text>
<text top="699" left="601" width="292" height="20" font="4">with a near 50% increase in mortality (HR: 1.47; 95% </text>
<text top="717" left="601" width="292" height="20" font="4">CI: 1.37–1.58; p=0.001), more than double the risk of </text>
<text top="734" left="601" width="301" height="20" font="4">morbidity (stroke or HF) (HR: 2.21; 95% CI: 2.07–2.36; </text>
<text top="751" left="601" width="296" height="20" font="4">p=0.001), and 3 times the risk of cardiac interventions </text>
<text top="768" left="601" width="224" height="20" font="4">(HR: 3.00; 95% CI: 2.81–3.20; p=0.001). </text>
<text top="596" left="920" width="111" height="20" font="4">● Atrial arrhythmias </text>
<text top="613" left="920" width="151" height="20" font="4">occurred in 15% of pts with </text>
<text top="631" left="920" width="37" height="20" font="4">CHD.  </text>
<text top="648" left="920" width="114" height="20" font="4">● Lifetime incidence </text>
<text top="665" left="920" width="151" height="20" font="4">increased steadily with age </text>
<text top="682" left="920" width="147" height="20" font="4">and was associated with a </text>
<text top="699" left="920" width="147" height="20" font="4">doubling of the risk of AE.  </text>
<text top="717" left="920" width="145" height="20" font="4">● An increase in resource </text>
<text top="734" left="920" width="112" height="20" font="4">allocation should be </text>
<text top="751" left="920" width="151" height="20" font="4">anticipated to deal with this </text>
<text top="768" left="920" width="105" height="20" font="4">increasing burden. </text>
</page>
<page number="8" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1044" width="39" height="17" font="0">Page 8 </text>
<text top="107" left="64" width="82" height="20" font="4">Koyak Z, et al. </text>
<text top="124" left="64" width="56" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(15)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22991410?dopt=Citation">22991410</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22991410?dopt=Citation"> </a></text>
<text top="107" left="170" width="64" height="20" font="4">Multicenter </text>
<text top="124" left="170" width="70" height="20" font="4">case control </text>
<text top="141" left="170" width="36" height="20" font="4">study  </text>
<text top="107" left="269" width="52" height="20" font="4">n=1,189  </text>
<text top="107" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="124" left="369" width="93" height="20" font="3"><b>criteria</b>: Pts &gt;18 </text>
<text top="141" left="369" width="85" height="20" font="4">y with CHD s/p </text>
<text top="159" left="369" width="87" height="20" font="4">SCD presumed </text>
<text top="176" left="369" width="90" height="20" font="4">arrhythmic vs. 2 </text>
<text top="193" left="369" width="87" height="20" font="4">cases of ACHD </text>
<text top="210" left="369" width="92" height="20" font="4">pts without SCD </text>
<text top="107" left="482" width="81" height="20" font="4">Determine the </text>
<text top="124" left="482" width="60" height="20" font="4">adult CHD </text>
<text top="141" left="482" width="96" height="20" font="4">population at risk </text>
<text top="159" left="482" width="87" height="20" font="4">of SCD and the </text>
<text top="176" left="482" width="106" height="20" font="4">clinical parameters </text>
<text top="193" left="482" width="87" height="20" font="4">associated with </text>
<text top="210" left="482" width="29" height="20" font="4">SCD </text>
<text top="107" left="601" width="268" height="20" font="4">● Arrhythmic death occurred in 171 of 1,189 pts. </text>
<text top="124" left="601" width="289" height="20" font="4">Underlying cardiac lesions were mild, moderate, and </text>
<text top="141" left="601" width="301" height="20" font="4">severe CHD in 12%, 33%, and 55% of the SCD cases, </text>
<text top="159" left="601" width="284" height="20" font="4">respectively. Clinical variables associated with SCD </text>
<text top="176" left="601" width="279" height="20" font="4">were SVT (p=0.004), moderate-to-severe systemic </text>
<text top="193" left="601" width="296" height="20" font="4">ventricular dysfunction (p=0.034), moderate-to-severe </text>
<text top="210" left="601" width="266" height="20" font="4">subpulmonary ventricular dysfunction (p=0.030), </text>
<text top="228" left="601" width="298" height="20" font="4">increased QRS duration (p=0.008), and QT dispersion </text>
<text top="245" left="601" width="60" height="20" font="4">(p=0.008). </text>
<text top="107" left="920" width="121" height="20" font="4">● Clinical parameters </text>
<text top="124" left="920" width="152" height="20" font="4">found to be associated with </text>
<text top="141" left="920" width="149" height="20" font="4">SCD in adults with a broad </text>
<text top="159" left="920" width="153" height="20" font="4">spectrum of CHD, including </text>
<text top="176" left="920" width="152" height="20" font="4">SRV, are similar to those in </text>
<text top="193" left="920" width="79" height="20" font="4">ischemic HD.  </text>
<text top="210" left="920" width="128" height="20" font="4">● Pts with mild cardiac </text>
<text top="227" left="920" width="135" height="20" font="4">lesions are potentially at </text>
<text top="245" left="920" width="73" height="20" font="4">risk for SCD. </text>
<text top="263" left="64" width="79" height="20" font="4">Yap SC, et al. </text>
<text top="280" left="64" width="56" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(16)</a> </text>
<text top="297" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21684512?dopt=Citation">21684512</a></text>
<text top="297" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21684512?dopt=Citation"> </a></text>
<text top="263" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="280" left="170" width="54" height="20" font="4">database </text>
<text top="297" left="170" width="42" height="20" font="4">review  </text>
<text top="263" left="269" width="68" height="20" font="4">n=378 adult </text>
<text top="280" left="269" width="75" height="20" font="4">pts with CHD </text>
<text top="297" left="269" width="84" height="20" font="4">(mean 39 ± 13 </text>
<text top="314" left="269" width="68" height="20" font="4">y) and atrial </text>
<text top="332" left="269" width="62" height="20" font="4">arrhythmia </text>
<text top="349" left="269" width="83" height="20" font="4">who had serial </text>
<text top="366" left="269" width="76" height="20" font="4">follow-up in a </text>
<text top="383" left="269" width="84" height="20" font="4">tertiary referral </text>
<text top="401" left="269" width="66" height="20" font="4">center from </text>
<text top="418" left="269" width="68" height="20" font="4">1999–2009. </text>
<text top="263" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="280" left="369" width="99" height="20" font="3"><b>criteria</b>: Adult pts </text>
<text top="297" left="369" width="79" height="20" font="4">with CHD and </text>
<text top="314" left="369" width="92" height="20" font="4">atrial arrhythmia </text>
<text top="332" left="369" width="56" height="20" font="4">who were </text>
<text top="349" left="369" width="90" height="20" font="4">followed serially </text>
<text top="366" left="369" width="85" height="20" font="4">from Jan 1999–</text>
<text top="383" left="369" width="89" height="20" font="4">Dec 2009 in the </text>
<text top="401" left="369" width="46" height="20" font="4">Toronto </text>
<text top="418" left="369" width="62" height="20" font="4">Congenital </text>
<text top="435" left="369" width="86" height="20" font="4">Cardiac Centre </text>
<text top="452" left="369" width="59" height="20" font="4">for Adults  </text>
<text top="263" left="482" width="100" height="20" font="4">Identify predictors </text>
<text top="280" left="482" width="107" height="20" font="4">of mortality in adult </text>
<text top="297" left="482" width="79" height="20" font="4">with CHD and </text>
<text top="314" left="482" width="92" height="20" font="4">atrial arrhythmia </text>
<text top="332" left="482" width="100" height="20" font="4">and to establish a </text>
<text top="349" left="482" width="56" height="20" font="4">risk score </text>
<text top="263" left="601" width="285" height="20" font="4">● During a median follow-up of 5.2 y, there were 40 </text>
<text top="280" left="601" width="281" height="20" font="4">deaths (11%). Overall mortality rate was 2.0%/pt-y. </text>
<text top="297" left="601" width="289" height="20" font="4">Common modes of death included HF–related death </text>
<text top="314" left="601" width="285" height="20" font="4">(35%), SCD (20%), and perioperative death (18%).  </text>
<text top="332" left="601" width="287" height="20" font="4">● Independent predictors of mortality were poor FC, </text>
<text top="349" left="601" width="290" height="20" font="4">(p=0.001), single ventricle physiology, (p=0.003), PH </text>
<text top="366" left="601" width="180" height="20" font="4">(p=0.004), and VHD, (p=0.006).  </text>
<text top="383" left="601" width="296" height="20" font="4">● A risk score was constructed using these predictors </text>
<text top="400" left="601" width="297" height="20" font="4">in which pts were assigned 1 point for the presence of </text>
<text top="418" left="601" width="293" height="20" font="4">each risk factor. Mortality rates in the low-risk (no risk </text>
<text top="435" left="601" width="294" height="20" font="4">factor), moderate-risk (1 risk factor), and high-risk (&gt;1 </text>
<text top="452" left="601" width="284" height="20" font="4">risk factor) groups were 0.5%, 1.9%, and 6.5%/pt y, </text>
<text top="469" left="601" width="176" height="20" font="4">respectively (log-rank p&lt;0.001). </text>
<text top="263" left="920" width="152" height="20" font="4">● Specific clinical variables </text>
<text top="280" left="920" width="131" height="20" font="4">identify pts with CHD at </text>
<text top="297" left="920" width="108" height="20" font="4">high risk for death.  </text>
<text top="314" left="920" width="133" height="20" font="4">● Absence of these risk </text>
<text top="332" left="920" width="140" height="20" font="4">factors is associated with </text>
<text top="349" left="920" width="114" height="20" font="4">an excellent survival </text>
<text top="366" left="920" width="131" height="20" font="4">despite the presence of </text>
<text top="383" left="920" width="101" height="20" font="4">atrial arrhythmias. </text>
<text top="487" left="64" width="78" height="20" font="4">Giannakoulas </text>
<text top="504" left="64" width="46" height="20" font="4">G, et al. </text>
<text top="522" left="64" width="56" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(17)</a> </text>
<text top="539" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21196055?dopt=Citation">21196055</a></text>
<text top="539" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21196055?dopt=Citation"> </a></text>
<text top="487" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="504" left="170" width="54" height="20" font="4">database </text>
<text top="522" left="170" width="42" height="20" font="4">review  </text>
<text top="487" left="269" width="54" height="20" font="4">n=98 pts, </text>
<text top="504" left="269" width="73" height="20" font="4">mean 31.5 ± </text>
<text top="522" left="269" width="72" height="20" font="4">8.9 y, 43.8% </text>
<text top="539" left="269" width="72" height="20" font="4">male, 31.6% </text>
<text top="556" left="269" width="62" height="20" font="4">with a total </text>
<text top="573" left="269" width="77" height="20" font="4">cavopulmonar</text>
<text top="591" left="269" width="72" height="20" font="4">y connection </text>
<text top="608" left="269" width="83" height="20" font="4">were identified </text>
<text top="487" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="504" left="369" width="94" height="20" font="3"><b>criteria</b>: Pts with </text>
<text top="522" left="369" width="92" height="20" font="4">previous Fontan </text>
<text top="539" left="369" width="55" height="20" font="4">operation </text>
<text top="556" left="369" width="83" height="20" font="4">followed at our </text>
<text top="573" left="369" width="87" height="20" font="4">institution since </text>
<text top="591" left="369" width="61" height="20" font="4">1999 were </text>
<text top="608" left="369" width="81" height="20" font="4">identified from </text>
<text top="625" left="369" width="76" height="20" font="4">the electronic </text>
<text top="642" left="369" width="78" height="20" font="4">database and </text>
<text top="659" left="369" width="85" height="20" font="4">included in this </text>
<text top="677" left="369" width="33" height="20" font="4">study </text>
<text top="487" left="482" width="84" height="20" font="4">Impact of atrial </text>
<text top="504" left="482" width="79" height="20" font="4">arrhythmia on </text>
<text top="522" left="482" width="95" height="20" font="4">adult Fontan pts  </text>
<text top="487" left="601" width="280" height="20" font="4">● Atrial tachyarrhythmia was present at baseline in </text>
<text top="504" left="601" width="301" height="20" font="4">60.2% of pts who were older (33.0 ± 8.3 vs. 29.1 ± 9.4 </text>
<text top="522" left="601" width="292" height="20" font="4">y; p=0.002), less likely to have a total cavopulmonary </text>
<text top="539" left="601" width="277" height="20" font="4">connection (13.5% vs. 58.9%; p&lt;0.001), and more </text>
<text top="556" left="601" width="264" height="20" font="4">symptomatic in terms of NYHA class (51.9% vs. </text>
<text top="573" left="601" width="279" height="20" font="4">26.7%; p=0.007) compared to arrhythmia-free pts.  </text>
<text top="591" left="601" width="293" height="20" font="4">● During a median follow-up of 6.7 y, 18 pts died and </text>
<text top="608" left="601" width="280" height="20" font="4">64 pts were hospitalized. Even after adjustment for </text>
<text top="625" left="601" width="296" height="20" font="4">baseline clinical characteristics, atrial tachyarrhythmia </text>
<text top="642" left="601" width="277" height="20" font="4">was an independent predictor of death (propensity </text>
<text top="659" left="601" width="299" height="20" font="4">score adjusted HR: 9.35; 95% CI: 1.10–79.18; p=0.04; </text>
<text top="677" left="601" width="232" height="20" font="4">c-statistic 0.88) and composite of death or </text>
<text top="694" left="601" width="284" height="20" font="4">hospitalization (propensity score adjusted HR: 5.00; </text>
<text top="711" left="601" width="178" height="20" font="4">95% CI: 2.47–10.09; p&lt;0.0001). </text>
<text top="487" left="920" width="111" height="20" font="4">● In adult pts with a </text>
<text top="504" left="920" width="148" height="20" font="4">Fontan-type operation, the </text>
<text top="522" left="920" width="98" height="20" font="4">presence of atrial </text>
<text top="539" left="920" width="109" height="20" font="4">tachyarrhythmias is </text>
<text top="556" left="920" width="125" height="20" font="4">associated with higher </text>
<text top="573" left="920" width="141" height="20" font="4">morbidity and mortality at </text>
<text top="591" left="920" width="104" height="20" font="4">midterm follow-up. </text>
<text top="729" left="64" width="77" height="20" font="4">Collins RT, et </text>
<text top="746" left="64" width="16" height="20" font="4">al. </text>
<text top="763" left="64" width="56" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(18)</a> </text>
<text top="781" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24102747">24102747</a></text>
<text top="781" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24102747"> </a></text>
<text top="729" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="746" left="170" width="54" height="20" font="4">database </text>
<text top="763" left="170" width="42" height="20" font="4">review  </text>
<text top="729" left="269" width="58" height="20" font="4">n=803 pts </text>
<text top="746" left="269" width="56" height="20" font="4">with1,333 </text>
<text top="763" left="269" width="46" height="20" font="4">hospital </text>
<text top="781" left="269" width="78" height="20" font="4">admissions of </text>
<text top="729" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="746" left="369" width="93" height="20" font="3"><b>criteria</b>: Pts &gt;18 </text>
<text top="763" left="369" width="84" height="20" font="4">y of with single </text>
<text top="781" left="369" width="100" height="20" font="4">ventricle admitted </text>
<text top="729" left="482" width="103" height="20" font="4">Identify the impact </text>
<text top="746" left="482" width="57" height="20" font="4">of cardiac </text>
<text top="763" left="482" width="85" height="20" font="4">arrhythmias on </text>
<text top="781" left="482" width="101" height="20" font="4">hospitalizations in </text>
<text top="729" left="601" width="284" height="20" font="4">● There were 642 admissions in 424 pts with single </text>
<text top="746" left="601" width="288" height="20" font="4">ventricle CHD and an arrhythmia diagnosis. A single </text>
<text top="763" left="601" width="288" height="20" font="4">arrhythmia diagnosis was present in 454 admissions </text>
<text top="781" left="601" width="43" height="20" font="4">(71%).  </text>
<text top="729" left="920" width="123" height="20" font="4">● In adults with single </text>
<text top="746" left="920" width="150" height="20" font="4">ventricle CHD, arrhythmias </text>
<text top="763" left="920" width="120" height="20" font="4">are affected by single </text>
<text top="781" left="920" width="149" height="20" font="4">ventricle anatomic subtype </text>
</page>
<page number="9" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="8" size="12" family="Times" color="#000000"/>
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1044" width="39" height="17" font="0">Page 9 </text>
<text top="107" left="269" width="77" height="20" font="4">TA, HLHS, or </text>
<text top="124" left="269" width="66" height="20" font="4">CV from 43 </text>
<text top="141" left="269" width="70" height="20" font="4">participating </text>
<text top="159" left="269" width="52" height="20" font="4">hospitals </text>
<text top="107" left="369" width="55" height="20" font="4">to 1 of 43 </text>
<text top="124" left="369" width="50" height="20" font="4">pediatric </text>
<text top="141" left="369" width="52" height="20" font="4">hospitals </text>
<text top="159" left="369" width="84" height="20" font="4">between 2004–</text>
<text top="176" left="369" width="31" height="20" font="4">2011 </text>
<text top="107" left="482" width="97" height="20" font="4">adults with single </text>
<text top="124" left="482" width="79" height="20" font="4">ventricle CHD </text>
<text top="107" left="601" width="298" height="20" font="4">● Total hospital charges were $80.7 million with mean </text>
<text top="124" left="601" width="277" height="20" font="4">charge per admission of $127,296 ± 243,094. The </text>
<text top="141" left="601" width="292" height="20" font="4">mean charge per hospital was $16,653 ± 17,516 and </text>
<text top="159" left="601" width="244" height="20" font="4">increased across the study period (p&lt;0.01).  </text>
<text top="176" left="601" width="280" height="20" font="4">● Arrhythmia distributions were impacted by single </text>
<text top="193" left="601" width="212" height="20" font="4">ventricle anatomic subtype (p&lt;0.001).  </text>
<text top="210" left="601" width="258" height="20" font="4">● Hospital resource utilization was significantly </text>
<text top="227" left="601" width="251" height="20" font="4">different among arrhythmia groups (p&lt;0.001). </text>
<text top="107" left="920" width="150" height="20" font="4">and impact adversely upon </text>
<text top="124" left="920" width="97" height="20" font="4">hospital resource </text>
<text top="141" left="920" width="58" height="20" font="4">utilization. </text>
<text top="245" left="64" width="86" height="20" font="4">Diller GP, et al. </text>
<text top="263" left="64" width="56" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(19)</a> </text>
<text top="280" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20929979?dopt=Citation">20929979</a></text>
<text top="280" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20929979?dopt=Citation"> </a></text>
<text top="245" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="263" left="170" width="54" height="20" font="4">database </text>
<text top="280" left="170" width="42" height="20" font="4">review  </text>
<text top="245" left="269" width="80" height="20" font="4">n=321 Fontan </text>
<text top="263" left="269" width="85" height="20" font="4">pts (57% male, </text>
<text top="280" left="269" width="85" height="20" font="4">mean age 20.9 </text>
<text top="297" left="269" width="46" height="20" font="4">± 8.6 y) </text>
<text top="245" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="263" left="369" width="89" height="20" font="3"><b>criteria</b>: Fontan </text>
<text top="280" left="369" width="46" height="20" font="4">pts who </text>
<text top="297" left="369" width="97" height="20" font="4">underwent CPET </text>
<text top="314" left="369" width="58" height="20" font="4">at 4 major </text>
<text top="332" left="369" width="57" height="20" font="4">European </text>
<text top="349" left="369" width="94" height="20" font="4">centers between </text>
<text top="366" left="369" width="95" height="20" font="4">1997–2008 were </text>
<text top="383" left="369" width="49" height="20" font="4">included </text>
<text top="245" left="482" width="63" height="20" font="4">To clarify if </text>
<text top="263" left="482" width="49" height="20" font="4">exercise </text>
<text top="280" left="482" width="76" height="20" font="4">intolerance is </text>
<text top="297" left="482" width="87" height="20" font="4">associated with </text>
<text top="314" left="482" width="92" height="20" font="4">poor outcome in </text>
<text top="332" left="482" width="99" height="20" font="4">Fontan pts and to </text>
<text top="349" left="482" width="105" height="20" font="4">identify risk factors </text>
<text top="366" left="482" width="71" height="20" font="4">for mortality, </text>
<text top="383" left="482" width="87" height="20" font="4">transplantation, </text>
<text top="401" left="482" width="68" height="20" font="4">and cardiac-</text>
<text top="418" left="482" width="41" height="20" font="4">related </text>
<text top="435" left="482" width="85" height="20" font="4">hospitalization. </text>
<text top="245" left="601" width="301" height="20" font="4">● During a median follow-up of 21 mo, 22 pts died and </text>
<text top="263" left="601" width="261" height="20" font="4">6 pts underwent cardiac transplantation (8.7%), </text>
<text top="280" left="601" width="298" height="20" font="4">resulting in an estimated 5 y transplant-free survival of </text>
<text top="297" left="601" width="35" height="20" font="4">86%.  </text>
<text top="314" left="601" width="261" height="20" font="4">● Parameters of CPET were strongly related to </text>
<text top="332" left="601" width="300" height="20" font="4">increased risk of hospitalization, but with the exception </text>
<text top="349" left="601" width="268" height="20" font="4">of heart rate reserve-unrelated to risk of death or </text>
<text top="366" left="601" width="293" height="20" font="4">transplantation. In contrast, pts with clinically relevant </text>
<text top="383" left="601" width="284" height="20" font="4">arrhythmia had a 6.0–fold increased risk of death or </text>
<text top="401" left="601" width="264" height="20" font="4">transplantation (p&lt;0.001). Furthermore, pts with </text>
<text top="418" left="601" width="265" height="20" font="4">atriopulmonary/ventricular Fontan had a 3.7-fold </text>
<text top="435" left="601" width="284" height="20" font="4">increased risk of death or transplantation compared </text>
<text top="452" left="601" width="285" height="20" font="4">with total cavopulmonary connection pts (p=0.009).  </text>
<text top="469" left="601" width="282" height="20" font="4">● The combination of clinically relevant arrhythmia, </text>
<text top="487" left="601" width="260" height="20" font="4">atriopulmonary/ventricular Fontan, and signs of </text>
<text top="504" left="601" width="285" height="20" font="4">symptomatic or decompensated HF was associated </text>
<text top="521" left="601" width="287" height="20" font="4">with a particularly poor outcome (3 y mortality 25%). </text>
<text top="245" left="920" width="122" height="20" font="4">● Most parameters of </text>
<text top="263" left="920" width="145" height="20" font="4">CPET are associated with </text>
<text top="280" left="920" width="93" height="20" font="4">increased risk of </text>
<text top="297" left="920" width="122" height="20" font="4">hospitalization but not </text>
<text top="314" left="920" width="146" height="20" font="4">death or transplantation in </text>
<text top="332" left="920" width="147" height="20" font="4">contemporary Fontan pts.  </text>
<text top="349" left="920" width="133" height="20" font="4">● Only decreased heart </text>
<text top="366" left="920" width="143" height="20" font="4">rate reserve and a history </text>
<text top="383" left="920" width="110" height="20" font="4">of clinically relevant </text>
<text top="400" left="920" width="65" height="20" font="4">arrhythmia, </text>
<text top="418" left="920" width="145" height="20" font="4">atriopulmonary/ventricular </text>
<text top="435" left="920" width="103" height="20" font="4">Fontan, and/or HF </text>
<text top="452" left="920" width="139" height="20" font="4">requiring diuretic therapy </text>
<text top="469" left="920" width="137" height="20" font="4">are associated with poor </text>
<text top="487" left="920" width="119" height="20" font="4">prognosis, potentially </text>
<text top="504" left="920" width="130" height="20" font="4">identifying pts requiring </text>
<text top="521" left="920" width="130" height="20" font="4">medical and/or surgical </text>
<text top="538" left="920" width="54" height="20" font="4">attention. </text>
<text top="556" left="64" width="90" height="20" font="4">Shamszad P, et </text>
<text top="573" left="64" width="16" height="20" font="4">al. </text>
<text top="591" left="64" width="56" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(20)</a> </text>
<text top="608" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23682693?dopt=Citation">23682693</a></text>
<text top="608" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23682693?dopt=Citation"> </a></text>
<text top="556" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="573" left="170" width="42" height="20" font="4">review  </text>
<text top="556" left="269" width="72" height="20" font="4">n=3,800,964 </text>
<text top="573" left="269" width="78" height="20" font="4">hospitalization</text>
<text top="591" left="269" width="10" height="20" font="4">s </text>
<text top="556" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="573" left="369" width="98" height="20" font="3"><b>criteria</b>: All index </text>
<text top="591" left="369" width="93" height="20" font="4">cases of pts &lt;30 </text>
<text top="608" left="369" width="78" height="20" font="4">y hospitalized </text>
<text top="625" left="369" width="59" height="20" font="4">with aortic </text>
<text top="642" left="369" width="81" height="20" font="4">dissection Jan </text>
<text top="659" left="369" width="95" height="20" font="4">2004–June 2011 </text>
<text top="556" left="482" width="88" height="20" font="4">To describe the </text>
<text top="573" left="482" width="59" height="20" font="4">incidence, </text>
<text top="591" left="482" width="85" height="20" font="4">characteristics, </text>
<text top="608" left="482" width="94" height="20" font="4">and outcomes of </text>
<text top="625" left="482" width="68" height="20" font="4">hospitalized </text>
<text top="642" left="482" width="70" height="20" font="4">children and </text>
<text top="659" left="482" width="98" height="20" font="4">young adults with </text>
<text top="677" left="482" width="21" height="20" font="4">AD </text>
<text top="556" left="601" width="293" height="20" font="4">● AD was identified in 124 (&lt;1%), accounting for 110 </text>
<text top="573" left="601" width="280" height="20" font="4">pts (69% male; p=0.003) at a median age of 12.9 y </text>
<text top="591" left="601" width="294" height="20" font="4">(IQR 3.9–16.8 y) with a bimodal distribution in infancy </text>
<text top="608" left="601" width="127" height="20" font="4">and late adolescence.  </text>
<text top="625" left="601" width="296" height="20" font="4">● Associated diagnoses included CHD (38%), trauma </text>
<text top="642" left="601" width="293" height="20" font="4">(24%), connective tissue disease (16%), and isolated </text>
<text top="659" left="601" width="65" height="20" font="4">HTN (8%).  </text>
<text top="677" left="601" width="302" height="20" font="4">● Common CHD diagnoses included aortic arch (24%) </text>
<text top="694" left="601" width="270" height="20" font="4">and valve (21%) disease, HLHS (10%), and TGA </text>
<text top="711" left="601" width="40" height="20" font="4">(10%). </text>
<text top="728" left="601" width="289" height="20" font="4">● CHD<i> </i>pts were younger and more likely to undergo </text>
<text top="745" left="601" width="283" height="20" font="4">inpatient non-AD–related CV procedures compared<i> </i></text>
<text top="763" left="601" width="304" height="20" font="4">with other diagnostic groups (p&lt;0.001 for both). Marfan </text>
<text top="556" left="920" width="154" height="20" font="4">● AD is rare in children and </text>
<text top="573" left="920" width="124" height="20" font="4">young adults but most </text>
<text top="591" left="920" width="142" height="20" font="4">commonly occurs in CHD </text>
<text top="608" left="920" width="121" height="20" font="4">and connective tissue </text>
<text top="625" left="920" width="122" height="20" font="4">disease and in males. </text>
<text top="642" left="920" width="133" height="20" font="4">● AD is associated with </text>
<text top="659" left="920" width="130" height="20" font="4">high inpatient mortality. </text>
</page>
<page number="10" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="9" size="12" family="Times" color="#212121"/>
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 10 </text>
<text top="107" left="601" width="301" height="20" font="4">and Ehlers-Danlos syndrome were present in 72% and </text>
<text top="124" left="601" width="284" height="20" font="4">11% of connective tissue disease pts, respectively.  </text>
<text top="141" left="601" width="256" height="20" font="4">● Overall in-hospital mortality in pts with aortic </text>
<text top="159" left="601" width="304" height="20" font="4">dissection was 13% compared with 1% in the database </text>
<text top="176" left="601" width="303" height="20" font="4">population (OR: 12.0; 95% CI: 6.9–21.1). By diagnostic </text>
<text top="193" left="601" width="243" height="20" font="4">category, mortality was 22% in HTN, 22% in </text>
<text top="210" left="601" width="280" height="20" font="4">connective tissue disease, 12% in CHD, and 4% in </text>
<text top="227" left="601" width="45" height="20" font="4">trauma. </text>
<text top="245" left="64" width="91" height="20" font="4">Roberts CS and </text>
<text top="263" left="64" width="70" height="20" font="4">Roberts WC </text>
<text top="280" left="64" width="56" height="20" font="4">1991 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(21)</a> </text>
<text top="297" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1993792?dopt=Citation">1993792</a></text>
<text top="297" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1993792?dopt=Citation"> </a></text>
<text top="245" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="263" left="170" width="42" height="20" font="4">review  </text>
<text top="245" left="269" width="83" height="20" font="4">n=186 pts with </text>
<text top="263" left="269" width="77" height="20" font="4">noniatrogenic </text>
<text top="280" left="269" width="33" height="20" font="4">aortic </text>
<text top="297" left="269" width="58" height="20" font="4">dissection </text>
<text top="314" left="269" width="73" height="20" font="4">were studied </text>
<text top="332" left="269" width="67" height="20" font="4">at necropsy </text>
<text top="245" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="263" left="369" width="48" height="20" font="3"><b>criteria</b>: </text>
<text top="280" left="369" width="79" height="20" font="4">Noniatrogenic </text>
<text top="297" left="369" width="91" height="20" font="4">aortic dissection </text>
<text top="314" left="369" width="48" height="20" font="4">found at </text>
<text top="332" left="369" width="81" height="20" font="4">necropsy over </text>
<text top="349" left="369" width="68" height="20" font="4">30-y period  </text>
<text top="245" left="482" width="103" height="20" font="4">The association of </text>
<text top="263" left="482" width="93" height="20" font="4">congenital aortic </text>
<text top="280" left="482" width="107" height="20" font="4">valve malformation </text>
<text top="297" left="482" width="57" height="20" font="4">and aortic </text>
<text top="314" left="482" width="58" height="20" font="4">dissection </text>
<text top="245" left="601" width="264" height="20" font="4">● The aortic valve was tricuspid in 170 (91.4%), </text>
<text top="263" left="601" width="267" height="20" font="4">bicuspid in 14 (7.5%), and unicuspid in 2 (1.1%). </text>
<text top="280" left="601" width="251" height="20" font="4">Among the 16 pts with aortic dissection and a </text>
<text top="297" left="601" width="300" height="20" font="4">congenitally malformed valve, the age at death ranged </text>
<text top="314" left="601" width="282" height="20" font="4">from 17–82 y (mean 52 y) and 13 (81%) were men. </text>
<text top="245" left="920" width="154" height="20" font="4">● A congenitally malformed </text>
<text top="263" left="920" width="144" height="20" font="4">aortic valve appears to be </text>
<text top="280" left="920" width="130" height="20" font="4">present at least 5 times </text>
<text top="297" left="920" width="127" height="20" font="4">more frequently in with </text>
<text top="314" left="920" width="98" height="20" font="4">aortic dissection,  </text>
<text top="332" left="920" width="149" height="20" font="4">● In this sample of pts, the </text>
<text top="349" left="920" width="101" height="20" font="4">entrance tear was </text>
<text top="366" left="920" width="101" height="20" font="4">consistently in the </text>
<text top="383" left="920" width="129" height="20" font="4">ascending aorta, which </text>
<text top="400" left="920" width="145" height="20" font="4">usually had severe loss of </text>
<text top="418" left="920" width="141" height="20" font="4">elastic fibers in its media. </text>
<text top="436" left="64" width="91" height="20" font="4">Schwartz ML, et </text>
<text top="453" left="64" width="16" height="20" font="4">al. </text>
<text top="470" left="64" width="56" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(22)</a> </text>
<text top="487" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15364851?dopt=Citation">15364851</a></text>
<text top="487" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15364851?dopt=Citation"> </a></text>
<text top="436" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="453" left="170" width="42" height="20" font="4">review  </text>
<text top="436" left="269" width="58" height="20" font="4">n=335 pts </text>
<text top="436" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="453" left="369" width="99" height="20" font="3"><b>criteria</b>: Pts were </text>
<text top="470" left="369" width="78" height="20" font="4">identified who </text>
<text top="487" left="369" width="90" height="20" font="4">underwent ASO </text>
<text top="504" left="369" width="83" height="20" font="4">for d-TGA with </text>
<text top="522" left="369" width="93" height="20" font="4">intact ventricular </text>
<text top="539" left="369" width="90" height="20" font="4">septum or VSD, </text>
<text top="556" left="369" width="94" height="20" font="4">including DORV, </text>
<text top="573" left="369" width="94" height="20" font="4">before 2001 with </text>
<text top="591" left="369" width="53" height="20" font="4">at least 1 </text>
<text top="608" left="369" width="77" height="20" font="4">postoperative </text>
<text top="625" left="369" width="65" height="20" font="4">echo at our </text>
<text top="642" left="369" width="72" height="20" font="4">institution, at </text>
<text top="659" left="369" width="77" height="20" font="4">least 1 y after </text>
<text top="677" left="369" width="74" height="20" font="4">ASO, and no </text>
<text top="694" left="369" width="79" height="20" font="4">previous ASO </text>
<text top="711" left="369" width="83" height="20" font="4">(median follow-</text>
<text top="728" left="369" width="65" height="20" font="4">up of 5.0 y) </text>
<text top="436" left="482" width="76" height="20" font="4">We sought to </text>
<text top="453" left="482" width="100" height="20" font="4">identify predictors </text>
<text top="470" left="482" width="72" height="20" font="4">of aortic root </text>
<text top="487" left="482" width="82" height="20" font="4">dissection and </text>
<text top="504" left="482" width="86" height="20" font="4">aortic root after </text>
<text top="522" left="482" width="33" height="20" font="4">ASO. </text>
<text top="436" left="601" width="305" height="20" font="4">● Probability of freedom from aortic root dissection was </text>
<text top="453" left="601" width="276" height="20" font="4">97%, 92%, 82%, and 51%, from at least moderate </text>
<text top="470" left="601" width="285" height="20" font="4">aortic root was 98%, 97%, 96%, and 93%, and from </text>
<text top="487" left="601" width="275" height="20" font="4">neo-aortic valve or root surgery was 100%, 100%, </text>
<text top="504" left="601" width="289" height="20" font="4">99%, and 95%, at 1, 2, 5, and 10 y, respectively. For </text>
<text top="522" left="601" width="249" height="20" font="4">pts in whom aortic root dissection developed, </text>
<text top="539" left="601" width="270" height="20" font="4">progressive dilation was not observed during late </text>
<text top="556" left="601" width="59" height="20" font="4">follow-up.  </text>
<text top="573" left="601" width="300" height="20" font="4">● By Kaplan–Meier method, independent predictors of </text>
<text top="591" left="601" width="285" height="20" font="4">aortic root dissection, with neo-aortic root z-score of </text>
<text top="608" left="601" width="292" height="20" font="4">≥3.0, were previous PA band (HR: 2.4; p=0.002) and </text>
<text top="625" left="601" width="298" height="20" font="4">later time period when ASO was performed (HR: 19.0; </text>
<text top="642" left="601" width="292" height="20" font="4">p&lt;0.002). Risk factor for at least moderate aortic root </text>
<text top="659" left="601" width="289" height="20" font="4">was age ≥1 y at ASO (HR: 5.8; p=0.002), which was </text>
<text top="677" left="601" width="283" height="20" font="4">closely related to VSD repair at ASO (p&lt;0.001) and </text>
<text top="694" left="601" width="104" height="20" font="4">previous PA band. </text>
<text top="436" left="920" width="131" height="20" font="4">● Significant aortic root </text>
<text top="453" left="920" width="140" height="20" font="4">dissection and aortic root </text>
<text top="470" left="920" width="137" height="20" font="4">continue to develop over </text>
<text top="487" left="920" width="141" height="20" font="4">time after ASO, but aortic </text>
<text top="504" left="920" width="133" height="20" font="4">root dissection does not </text>
<text top="522" left="920" width="125" height="20" font="4">tend to be progressive </text>
<text top="539" left="920" width="120" height="20" font="4">during late follow-up.  </text>
<text top="556" left="920" width="150" height="20" font="4">● Previous PA band was a </text>
<text top="573" left="920" width="132" height="20" font="4">significant risk factor for </text>
<text top="591" left="920" width="123" height="20" font="4">aortic root dissection.  </text>
<text top="608" left="920" width="124" height="20" font="4">● Older age at time of </text>
<text top="625" left="920" width="132" height="20" font="4">ASO, presence of VSD, </text>
<text top="642" left="920" width="124" height="20" font="4">and previous PA band </text>
<text top="659" left="920" width="135" height="20" font="4">were risk factors for AR. </text>
<text top="746" left="64" width="78" height="20" font="9">Cohen MS, et </text>
<text top="763" left="64" width="16" height="20" font="9">al. </text>
<text top="781" left="64" width="56" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(23)</a> </text>
<text top="746" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="763" left="170" width="42" height="20" font="4">review  </text>
<text top="746" left="269" width="51" height="20" font="4">n=53 pts </text>
<text top="746" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="763" left="369" width="94" height="20" font="3"><b>criteria</b>: Pts with </text>
<text top="781" left="369" width="64" height="20" font="4">HLHS born </text>
<text top="746" left="482" width="76" height="20" font="4">We sought to </text>
<text top="763" left="482" width="62" height="20" font="4">assess the </text>
<text top="781" left="482" width="87" height="20" font="4">prevalence and </text>
<text top="746" left="601" width="287" height="20" font="4">● During follow-up, the neo-aortic root progressively </text>
<text top="763" left="601" width="302" height="20" font="4">dilated out of proportion to body size over time, with 52 </text>
<text top="781" left="601" width="305" height="20" font="4">pts (98%) having a z-score &gt;2 at most recent follow-up. </text>
<text top="746" left="920" width="82" height="20" font="4">● After staged </text>
<text top="763" left="920" width="138" height="20" font="4">reconstruction for HLHS, </text>
<text top="781" left="920" width="145" height="20" font="4">neoaortic root dilation and </text>
</page>
<page number="11" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 11 </text>
<text top="107" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12906985?dopt=Citation">12906985</a></text>
<text top="107" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12906985?dopt=Citation"> </a></text>
<text top="107" left="369" width="85" height="20" font="4">before January </text>
<text top="124" left="369" width="81" height="20" font="4">1995 who had </text>
<text top="141" left="369" width="62" height="20" font="4">the Fontan </text>
<text top="159" left="369" width="79" height="20" font="4">operation and </text>
<text top="176" left="369" width="93" height="20" font="4">had serial echos </text>
<text top="193" left="369" width="79" height="20" font="4">were included </text>
<text top="107" left="482" width="81" height="20" font="4">progression of </text>
<text top="124" left="482" width="83" height="20" font="4">neo-aortic root </text>
<text top="141" left="482" width="102" height="20" font="4">dilation and valvar </text>
<text top="159" left="482" width="100" height="20" font="4">regurgitation after </text>
<text top="176" left="482" width="40" height="20" font="4">staged </text>
<text top="193" left="482" width="98" height="20" font="4">reconstruction for </text>
<text top="210" left="482" width="36" height="20" font="4">HLHS </text>
<text top="107" left="601" width="273" height="20" font="4">Neo-aortic root was present in 61% of pts at most </text>
<text top="124" left="601" width="291" height="20" font="4">recent follow-up, with progression over time in 26 pts </text>
<text top="141" left="601" width="40" height="20" font="4">(49%). </text>
<text top="107" left="920" width="134" height="20" font="4">neo-aortic root progress </text>
<text top="124" left="920" width="61" height="20" font="4">over time.  </text>
<text top="141" left="920" width="144" height="20" font="4">● Early volume unloading </text>
<text top="159" left="920" width="146" height="20" font="4">does not have a beneficial </text>
<text top="176" left="920" width="133" height="20" font="4">impact on dilation of the </text>
<text top="193" left="920" width="90" height="20" font="4">neo-aortic root.  </text>
<text top="210" left="920" width="126" height="20" font="4">● These findings raise </text>
<text top="227" left="920" width="128" height="20" font="4">concerns about neoAV </text>
<text top="245" left="920" width="131" height="20" font="4">function into adulthood. </text>
<text top="263" left="64" width="89" height="20" font="4">Carlo WF, et al. </text>
<text top="280" left="64" width="56" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(24)</a> </text>
<text top="297" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21545468?dopt=Citation">21545468</a></text>
<text top="297" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21545468?dopt=Citation"> </a></text>
<text top="263" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="280" left="170" width="42" height="20" font="4">review  </text>
<text top="263" left="269" width="76" height="20" font="4">n=76 pts with </text>
<text top="280" left="269" width="44" height="20" font="4">truncus </text>
<text top="297" left="269" width="57" height="20" font="4">arteriosus </text>
<text top="263" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="280" left="369" width="96" height="20" font="3"><b>criteria</b>: Truncus </text>
<text top="297" left="369" width="81" height="20" font="4">arteriosus and </text>
<text top="314" left="369" width="71" height="20" font="4">recent echo  </text>
<text top="263" left="482" width="76" height="20" font="4">We sought to </text>
<text top="280" left="482" width="78" height="20" font="4">delineate root </text>
<text top="297" left="482" width="105" height="20" font="4">dimensions across </text>
<text top="314" left="482" width="104" height="20" font="4">a population of pts </text>
<text top="332" left="482" width="69" height="20" font="4">with truncus </text>
<text top="349" left="482" width="61" height="20" font="4">arteriosus. </text>
<text top="263" left="601" width="282" height="20" font="4">● 76 pts whose most recent study was at a median </text>
<text top="280" left="601" width="168" height="20" font="4">age of 5.4 y (range 0–32.7 y).  </text>
<text top="297" left="601" width="304" height="20" font="4">● Mean truncal root z-score was 5.1 ± 2.3. All but 3 pts </text>
<text top="314" left="601" width="280" height="20" font="4">had truncal root z-scores ≥2. Truncal root z-scores </text>
<text top="332" left="601" width="302" height="20" font="4">remained stable with increasing body surface area and </text>
<text top="349" left="601" width="31" height="20" font="4">age.  </text>
<text top="366" left="601" width="293" height="20" font="4">● There were no cases of dissection or rupture. 6 pts </text>
<text top="383" left="601" width="300" height="20" font="4">underwent truncal root surgery, typically for indications </text>
<text top="400" left="601" width="237" height="20" font="4">of root dilation with significant truncal valve </text>
<text top="418" left="601" width="159" height="20" font="4">insufficiency and LV dilation. </text>
<text top="263" left="920" width="148" height="20" font="4">● Although repeat surgical </text>
<text top="280" left="920" width="141" height="20" font="4">intervention was rare and </text>
<text top="297" left="920" width="153" height="20" font="4">major complications related </text>
<text top="314" left="920" width="121" height="20" font="4">to root dilation did not </text>
<text top="332" left="920" width="148" height="20" font="4">occur in our cohort, further </text>
<text top="349" left="920" width="133" height="20" font="4">studies with longitudinal </text>
<text top="366" left="920" width="133" height="20" font="4">follow-up into adulthood </text>
<text top="383" left="920" width="69" height="20" font="4">are needed. </text>
<text top="436" left="64" width="79" height="20" font="4">Egan M, et al. </text>
<text top="453" left="64" width="56" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(25)</a> </text>
<text top="470" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19357906?dopt=Citation">19357906</a></text>
<text top="470" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19357906?dopt=Citation"><b> </b></a></text>
<text top="436" left="170" width="71" height="20" font="4">Case report  </text>
<text top="436" left="269" width="67" height="20" font="4">Single-case </text>
<text top="453" left="269" width="83" height="20" font="4">report of aortic </text>
<text top="470" left="269" width="58" height="20" font="4">dissection </text>
<text top="436" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="453" left="369" width="75" height="20" font="3"><b>criteria</b>: N/A  </text>
<text top="436" left="482" width="87" height="20" font="4">Single ventricle </text>
<text top="453" left="482" width="45" height="20" font="4">Fontan  </text>
<text top="436" left="601" width="293" height="20" font="4">● 26-y-old man with a history of HLHS, mitral and PV </text>
<text top="453" left="601" width="284" height="20" font="4">atresia, and malposed great vessels presented with </text>
<text top="470" left="601" width="136" height="20" font="4">atypical chest pressure.  </text>
<text top="487" left="601" width="299" height="20" font="4">● Previous palliation included a lateral tunnel modified </text>
<text top="504" left="601" width="49" height="20" font="4">Fontan.  </text>
<text top="522" left="601" width="267" height="20" font="4">● The man’s physical exam demonstrated aortic </text>
<text top="539" left="601" width="297" height="20" font="4">insufficiency. TTE showed severe dilation of the aortic </text>
<text top="556" left="601" width="302" height="20" font="4">root measuring 7.8 cm, severe aortic regurgitation, and </text>
<text top="573" left="601" width="225" height="20" font="4">moderate global RV systolic dysfunction. </text>
<text top="436" left="920" width="111" height="20" font="4">● Those with single </text>
<text top="453" left="920" width="148" height="20" font="4">ventricle Fontan are at risk </text>
<text top="470" left="920" width="45" height="20" font="4">for AD.  </text>
<text top="591" left="64" width="80" height="20" font="4">Van der Linde </text>
<text top="608" left="64" width="46" height="20" font="4">D, et al. </text>
<text top="626" left="64" width="56" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(26)</a> </text>
<text top="643" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23164590?dopt=Citation">23164590</a></text>
<text top="643" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23164590?dopt=Citation"> </a></text>
<text top="591" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="608" left="170" width="42" height="20" font="4">review  </text>
<text top="591" left="269" width="61" height="20" font="4">n=414 pts  </text>
<text top="591" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="608" left="369" width="95" height="20" font="3"><b>criteria</b>: All adult </text>
<text top="626" left="369" width="45" height="20" font="4">pts with </text>
<text top="643" left="369" width="59" height="20" font="4">congenital </text>
<text top="660" left="369" width="95" height="20" font="4">valvular AS, who </text>
<text top="677" left="369" width="72" height="20" font="4">attended the </text>
<text top="694" left="369" width="79" height="20" font="4">outpt clinic for </text>
<text top="712" left="369" width="84" height="20" font="4">adult CHD of a </text>
<text top="729" left="369" width="70" height="20" font="4">participating </text>
<text top="746" left="369" width="91" height="20" font="4">center, between </text>
<text top="763" left="369" width="78" height="20" font="4">January 2005 </text>
<text top="781" left="369" width="71" height="20" font="4">and October </text>
<text top="591" left="482" width="88" height="20" font="4">To evaluate the </text>
<text top="608" left="482" width="106" height="20" font="4">progression rate of </text>
<text top="626" left="482" width="77" height="20" font="4">AS and aortic </text>
<text top="643" left="482" width="107" height="20" font="4">dilatation in a large </text>
<text top="660" left="482" width="64" height="20" font="4">multicenter </text>
<text top="677" left="482" width="74" height="20" font="4">retrospective </text>
<text top="694" left="482" width="51" height="20" font="4">cohort of </text>
<text top="712" left="482" width="79" height="20" font="4">asymptomatic </text>
<text top="729" left="482" width="98" height="20" font="4">young adults with </text>
<text top="746" left="482" width="105" height="20" font="4">congenital valvular </text>
<text top="763" left="482" width="20" height="20" font="4">AS </text>
<text top="591" left="601" width="284" height="20" font="4">● A total of 414 pts (age 29 ±10 y, 68% male) were </text>
<text top="608" left="601" width="301" height="20" font="4">included. Median follow-up duration was 4.1 y (2.5–5.1 </text>
<text top="626" left="601" width="87" height="20" font="4">y) (1,587 pt-y).  </text>
<text top="643" left="601" width="297" height="20" font="4">● Aortic dilatation was present in 34% at baseline and </text>
<text top="660" left="601" width="264" height="20" font="4">48% at follow-up (p&lt;0.001). The aortic diameter </text>
<text top="677" left="601" width="280" height="20" font="4">linearly increased over time with a rate of 0.7 ± 0.2 </text>
<text top="694" left="601" width="283" height="20" font="4">mm/y. Rate of aortic dissection was 0.06% per pt y. </text>
<text top="591" left="920" width="144" height="20" font="4">● ADs rarely occur; aortic </text>
<text top="608" left="920" width="139" height="20" font="4">dilatation is common and </text>
<text top="626" left="920" width="137" height="20" font="4">steadily progresses over </text>
<text top="643" left="920" width="124" height="20" font="4">time, warranting serial </text>
<text top="660" left="920" width="83" height="20" font="4">aortic imaging. </text>
</page>
<page number="12" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 12 </text>
<text top="107" left="369" width="61" height="20" font="4">2011 were </text>
<text top="124" left="369" width="99" height="20" font="4">identified. Eligible </text>
<text top="141" left="369" width="99" height="20" font="4">pts were selected </text>
<text top="159" left="369" width="94" height="20" font="4">from prospective </text>
<text top="176" left="369" width="84" height="20" font="4">databases: the </text>
<text top="193" left="369" width="58" height="20" font="4">CONCOR </text>
<text top="210" left="369" width="79" height="20" font="4">database (the </text>
<text top="228" left="369" width="97" height="20" font="4">Dutch registry for </text>
<text top="245" left="369" width="75" height="20" font="4">adult pts with </text>
<text top="262" left="369" width="78" height="20" font="4">CHD, and the </text>
<text top="279" left="369" width="68" height="20" font="4">Leuven and </text>
<text top="296" left="369" width="100" height="20" font="4">Toronto database </text>
<text top="314" left="369" width="79" height="20" font="4">for adults with </text>
<text top="331" left="369" width="85" height="20" font="4">CHD. Inclusion </text>
<text top="348" left="369" width="91" height="20" font="4">criteria were 18–</text>
<text top="365" left="369" width="61" height="20" font="4">55 y and a </text>
<text top="383" left="369" width="79" height="20" font="4">baseline peak </text>
<text top="400" left="369" width="78" height="20" font="4">aortic velocity </text>
<text top="417" left="369" width="99" height="20" font="4">&gt;2.5 m/s. Pts had </text>
<text top="434" left="369" width="76" height="20" font="4">to have serial </text>
<text top="451" left="369" width="94" height="20" font="4">echocardiographi</text>
<text top="469" left="369" width="99" height="20" font="4">c examinations at </text>
<text top="486" left="369" width="81" height="20" font="4">least 1 y apart </text>
<text top="504" left="64" width="86" height="20" font="4">Lowe BS, et al. </text>
<text top="521" left="64" width="56" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(27)</a> </text>
<text top="538" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21777753?dopt=Citation">21777753</a></text>
<text top="538" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21777753?dopt=Citation"><b> </b></a></text>
<text top="504" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="521" left="170" width="65" height="20" font="4">longitudinal </text>
<text top="538" left="170" width="74" height="20" font="4">cohort study  </text>
<text top="504" left="269" width="85" height="20" font="4">n=38,430 adult </text>
<text top="521" left="269" width="76" height="20" font="4">pts living with </text>
<text top="538" left="269" width="74" height="20" font="4">CHD in 2005 </text>
<text top="504" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="521" left="369" width="58" height="20" font="3"><b>criteria</b>: 2 </text>
<text top="538" left="369" width="74" height="20" font="4">retrospective </text>
<text top="555" left="369" width="72" height="20" font="4">cohorts from </text>
<text top="573" left="369" width="85" height="20" font="4">Quebec’s CHD </text>
<text top="590" left="369" width="78" height="20" font="4">database that </text>
<text top="607" left="369" width="93" height="20" font="4">included pts age </text>
<text top="624" left="369" width="96" height="20" font="4">≥18 y. The study </text>
<text top="641" left="369" width="98" height="20" font="4">population for the </text>
<text top="659" left="369" width="64" height="20" font="4">prevalence </text>
<text top="676" left="369" width="52" height="20" font="4">objective </text>
<text top="693" left="369" width="65" height="20" font="4">included all </text>
<text top="710" left="369" width="91" height="20" font="4">adults with CHD </text>
<text top="727" left="369" width="76" height="20" font="4">alive in 2005, </text>
<text top="745" left="369" width="90" height="20" font="4">irrespective of a </text>
<text top="762" left="369" width="89" height="20" font="4">PH diagnosis in </text>
<text top="779" left="369" width="75" height="20" font="4">the database </text>
<text top="504" left="482" width="84" height="20" font="4">The aim of this </text>
<text top="521" left="482" width="72" height="20" font="4">study was to </text>
<text top="538" left="482" width="102" height="20" font="4">assess the impact </text>
<text top="555" left="482" width="103" height="20" font="4">of the diagnosis of </text>
<text top="573" left="482" width="91" height="20" font="4">PH on mortality, </text>
<text top="590" left="482" width="81" height="20" font="4">morbidity, and </text>
<text top="607" left="482" width="85" height="20" font="4">health services </text>
<text top="624" left="482" width="85" height="20" font="4">utilization in an </text>
<text top="641" left="482" width="102" height="20" font="4">ACHD population. </text>
<text top="504" left="601" width="293" height="20" font="4">● 2,212 (5.8%) had diagnoses of PH (median age 67 </text>
<text top="521" left="601" width="299" height="20" font="4">y, 59% women). The diagnosis of PH increased the all-</text>
<text top="538" left="601" width="286" height="20" font="4">cause mortality rate of adults with CHD more than 2-</text>
<text top="555" left="601" width="299" height="20" font="4">fold compared with pts without PH (HR: 2.69; 95%; CI: </text>
<text top="573" left="601" width="66" height="20" font="4">2.41–2.99). </text>
<text top="590" left="601" width="289" height="20" font="4">● Morbid complications including HF and arrhythmia </text>
<text top="607" left="601" width="284" height="20" font="4">occurred with a 3-fold higher risk compared with pts </text>
<text top="624" left="601" width="239" height="20" font="4">without PH (HR: 3.01; 95% CI: 2.80–3.22).  </text>
<text top="641" left="601" width="285" height="20" font="4">● The utilization of inpatient and outpatient services </text>
<text top="659" left="601" width="273" height="20" font="4">was increased, especially cardiac catheterization. </text>
<text top="504" left="920" width="127" height="20" font="4">● A diagnosis of PH in </text>
<text top="521" left="920" width="104" height="20" font="4">adults with CHD is </text>
<text top="538" left="920" width="129" height="20" font="4">associated with a more </text>
<text top="555" left="920" width="139" height="20" font="4">than 2-fold higher risk for </text>
<text top="573" left="920" width="137" height="20" font="4">all-cause mortality and 3-</text>
<text top="590" left="920" width="142" height="20" font="4">fold higher rates of health </text>
<text top="607" left="920" width="107" height="20" font="4">services utilization, </text>
<text top="624" left="920" width="137" height="20" font="4">reflecting high morbidity. </text>
</page>
<page number="13" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 13 </text>
<text top="107" left="369" width="92" height="20" font="4">over the past 23 </text>
<text top="124" left="369" width="10" height="20" font="4">y </text>
<text top="142" left="64" width="89" height="20" font="4">Verheugt CL, et </text>
<text top="159" left="64" width="16" height="20" font="4">al. </text>
<text top="177" left="64" width="56" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(28)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20207625?dopt=Citation">20207625</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20207625?dopt=Citation"> </a></text>
<text top="142" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="159" left="170" width="54" height="20" font="4">database </text>
<text top="177" left="170" width="42" height="20" font="4">review  </text>
<text top="142" left="269" width="68" height="20" font="4">n=6,933 pts </text>
<text top="159" left="269" width="86" height="20" font="4">from CONCOR </text>
<text top="177" left="269" width="38" height="20" font="4">ACHD </text>
<text top="194" left="269" width="57" height="20" font="4">database  </text>
<text top="142" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="159" left="369" width="48" height="20" font="3"><b>criteria</b>: </text>
<text top="177" left="369" width="58" height="20" font="4">CONCOR </text>
<text top="194" left="369" width="88" height="20" font="4">database 2001–</text>
<text top="211" left="369" width="96" height="20" font="4">2009, adults with </text>
<text top="228" left="369" width="67" height="20" font="4">CHD &gt;18 y  </text>
<text top="142" left="482" width="93" height="20" font="4">Dutch CONCOR </text>
<text top="159" left="482" width="46" height="20" font="4">national </text>
<text top="177" left="482" width="98" height="20" font="4">registry for adults </text>
<text top="194" left="482" width="69" height="20" font="4">with CHD to </text>
<text top="211" left="482" width="91" height="20" font="4">assess mortality </text>
<text top="228" left="482" width="80" height="20" font="4">and causes of </text>
<text top="246" left="482" width="75" height="20" font="4">death, and to </text>
<text top="263" left="482" width="93" height="20" font="4">determine which </text>
<text top="280" left="482" width="98" height="20" font="4">CV complications </text>
<text top="297" left="482" width="103" height="20" font="4">predict mortality in </text>
<text top="314" left="482" width="95" height="20" font="4">adults with CHD. </text>
<text top="142" left="601" width="291" height="20" font="4">● Of 6,933 pts, 197 (2.8%) died during a follow-up of </text>
<text top="159" left="601" width="266" height="20" font="4">24,865 pt-y. Compared with the general national </text>
<text top="177" left="601" width="291" height="20" font="4">population, there was excess mortality, particularly in </text>
<text top="194" left="601" width="64" height="20" font="4">the young.  </text>
<text top="211" left="601" width="298" height="20" font="4">● Median age at death was 48.8 y. Of all deaths, 77% </text>
<text top="228" left="601" width="286" height="20" font="4">had a CV origin; 45% were due to chronic HF (26%, </text>
<text top="246" left="601" width="292" height="20" font="4">age 51.0 y) or SCD (19%, age 39.1 y). Age predicted </text>
<text top="263" left="601" width="274" height="20" font="4">mortality, as did sex, severity of defect, number of </text>
<text top="280" left="601" width="290" height="20" font="4">interventions, and number of complications (HR: 1.1–</text>
<text top="297" left="601" width="302" height="20" font="4">5.9; p=0.05). Several complications predicted all-cause </text>
<text top="314" left="601" width="258" height="20" font="4">mortality, i.e., IE, SVA, ventricular arrhythmias, </text>
<text top="332" left="601" width="281" height="20" font="4">conduction disturbances, MI, and PH (HR: 1.4–3.1; </text>
<text top="349" left="601" width="300" height="20" font="4">p=0.05). These risks were similar in pts ± 40 y. Almost </text>
<text top="366" left="601" width="292" height="20" font="4">all complications predicted death due to HF (HR: 2.0–</text>
<text top="383" left="601" width="253" height="20" font="4">5.1; p=0.05); conduction disturbances and PH </text>
<text top="400" left="601" width="209" height="20" font="4">predicted SCD (HR: 2.0–4.7; p=0.05). </text>
<text top="142" left="920" width="144" height="20" font="4">● Mortality is increased in </text>
<text top="159" left="920" width="95" height="20" font="4">adults with CHD, </text>
<text top="177" left="920" width="140" height="20" font="4">particularly in the young.  </text>
<text top="194" left="920" width="129" height="20" font="4">● The vast majority die </text>
<text top="211" left="920" width="144" height="20" font="4">from CV causes. Mortality </text>
<text top="228" left="920" width="141" height="20" font="4">risk, particularly by HF, is </text>
<text top="246" left="920" width="134" height="20" font="4">increased by virtually all </text>
<text top="263" left="920" width="85" height="20" font="4">complications.  </text>
<text top="280" left="920" width="114" height="20" font="4">● Complications are </text>
<text top="297" left="920" width="116" height="20" font="4">equally hazardous in </text>
<text top="314" left="920" width="131" height="20" font="4">younger as in older pts. </text>
<text top="418" left="64" width="86" height="20" font="4">Chen SS, et al. </text>
<text top="436" left="64" width="56" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(29)</a> </text>
<text top="453" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24631116?dopt=Citation">24631116</a></text>
<text top="453" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24631116?dopt=Citation"> </a></text>
<text top="418" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="436" left="170" width="54" height="20" font="4">database </text>
<text top="453" left="170" width="42" height="20" font="4">review  </text>
<text top="418" left="269" width="58" height="20" font="4">n=247 pts </text>
<text top="436" left="269" width="84" height="20" font="4">(33.0 ± 12.8 y, </text>
<text top="453" left="269" width="62" height="20" font="4">60% male) </text>
<text top="418" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="436" left="369" width="86" height="20" font="3"><b>criteria</b>: ACHD </text>
<text top="453" left="369" width="98" height="20" font="4">pts with CoA who </text>
<text top="470" left="369" width="96" height="20" font="4">had undergone a </text>
<text top="487" left="369" width="81" height="20" font="4">CMR imaging  </text>
<text top="418" left="482" width="102" height="20" font="4">The prevalence of </text>
<text top="436" left="482" width="83" height="20" font="4">restenosis and </text>
<text top="453" left="482" width="87" height="20" font="4">dilatation at the </text>
<text top="470" left="482" width="102" height="20" font="4">repair site and the </text>
<text top="487" left="482" width="106" height="20" font="4">long-term outcome </text>
<text top="504" left="482" width="107" height="20" font="4">in pts with repaired </text>
<text top="522" left="482" width="27" height="20" font="4">CoA </text>
<text top="418" left="601" width="293" height="20" font="4">● Restenosis (repair site-diaphragm ratio ≤70%) was </text>
<text top="436" left="601" width="301" height="20" font="4">present in 31% of pts (and significant in 9% [repair site-</text>
<text top="453" left="601" width="271" height="20" font="4">diaphragm ratio&lt;50%]), and dilatation (repair site-</text>
<text top="470" left="601" width="302" height="20" font="4">diaphragm ratio&gt;150%) in 13.0%. A discrete aneurysm </text>
<text top="487" left="601" width="298" height="20" font="4">at the repair site was observed in 9%. Restenosis was </text>
<text top="504" left="601" width="292" height="20" font="4">more likely after resection and end-end anastomosis, </text>
<text top="522" left="601" width="206" height="20" font="4">whereas dilatation after patch repair.  </text>
<text top="539" left="601" width="246" height="20" font="4">● Systemic HTN was present in 69% of pts.  </text>
<text top="556" left="601" width="292" height="20" font="4">● Of the hypertensive pts, BP (133 ± 20/73 ± 10 mm </text>
<text top="573" left="601" width="289" height="20" font="4">Hg) was well controlled in 93% with antihypertensive </text>
<text top="591" left="601" width="284" height="20" font="4">therapy. Mortality rate over a median length of 5.9 y </text>
<text top="608" left="601" width="303" height="20" font="4">was low (0.69%/y; 95% CI: 0.33–1.26), but significantly </text>
<text top="625" left="601" width="230" height="20" font="4">higher than age-matched healthy controls </text>
<text top="642" left="601" width="298" height="20" font="4">(standardized mortality ratio: 2.86; 95% CI: 1.43–5.72; </text>
<text top="659" left="601" width="56" height="20" font="4">p&lt;0.001). </text>
<text top="418" left="920" width="144" height="20" font="4">● Restenosis or dilatation </text>
<text top="436" left="920" width="135" height="20" font="4">at the CoA repair site as </text>
<text top="453" left="920" width="136" height="20" font="4">assessed by CMR is not </text>
<text top="470" left="920" width="143" height="20" font="4">uncommon. Medium term </text>
<text top="487" left="920" width="126" height="20" font="4">survival remains good; </text>
<text top="504" left="920" width="146" height="20" font="4">however, albeit lower than </text>
<text top="522" left="920" width="145" height="20" font="4">in the general population.  </text>
<text top="539" left="920" width="139" height="20" font="4">● Life-long follow-up and </text>
<text top="556" left="920" width="124" height="20" font="4">optimal BP control are </text>
<text top="573" left="920" width="126" height="20" font="4">likely to secure a good </text>
<text top="591" left="920" width="122" height="20" font="4">longer-term outlook in </text>
<text top="608" left="920" width="57" height="20" font="4">these pts. </text>
<text top="677" left="64" width="83" height="20" font="4">Dimopoulos K, </text>
<text top="694" left="64" width="30" height="20" font="4">et al. </text>
<text top="712" left="64" width="56" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(30)</a> </text>
<text top="729" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20026774?dopt=Citation">20026774</a></text>
<text top="729" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20026774?dopt=Citation"> </a></text>
<text top="677" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="694" left="170" width="42" height="20" font="4">review  </text>
<text top="677" left="269" width="58" height="20" font="4">n=229 pts </text>
<text top="694" left="269" width="74" height="20" font="4">(aged 34.5 ± </text>
<text top="712" left="269" width="78" height="20" font="4">12.6 y; 35.4% </text>
<text top="729" left="269" width="34" height="20" font="4">male) </text>
<text top="677" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="694" left="369" width="79" height="20" font="3"><b>criteria</b>: Adult </text>
<text top="712" left="369" width="96" height="20" font="4">Eisenmenger pts </text>
<text top="729" left="369" width="62" height="20" font="4">followed at </text>
<text top="746" left="369" width="79" height="20" font="4">tertiary center </text>
<text top="763" left="369" width="81" height="20" font="4">over past 10 y </text>
<text top="677" left="482" width="78" height="20" font="4">Examined the </text>
<text top="694" left="482" width="97" height="20" font="4">potential effect of </text>
<text top="712" left="482" width="77" height="20" font="4">advanced PH </text>
<text top="729" left="482" width="107" height="20" font="4">therapy on survival </text>
<text top="746" left="482" width="101" height="20" font="4">with Eisenmenger </text>
<text top="763" left="482" width="57" height="20" font="4">syndrome </text>
<text top="677" left="601" width="299" height="20" font="4">● During a median follow-up of 4.0 y, 52 pts died, only </text>
<text top="694" left="601" width="303" height="20" font="4">2 of them while on advanced therapy. Pts on advanced </text>
<text top="712" left="601" width="300" height="20" font="4">therapy were at a significantly lower risk of death, both </text>
<text top="729" left="601" width="286" height="20" font="4">unadjusted and after adjustment for baseline clinical </text>
<text top="746" left="601" width="298" height="20" font="4">differences by propensity score regression adjustment </text>
<text top="763" left="601" width="305" height="20" font="4">(HR: 0.16; 95% CI: 0.04–0.71; p=0.015) and propensity </text>
<text top="677" left="920" width="133" height="20" font="4">● Advanced therapy for </text>
<text top="694" left="920" width="154" height="20" font="4">pulmonary arterial HTN in a </text>
<text top="712" left="920" width="130" height="20" font="4">contemporary cohort of </text>
<text top="729" left="920" width="137" height="20" font="4">adults with Eisenmenger </text>
<text top="746" left="920" width="145" height="20" font="4">syndrome was associated </text>
<text top="763" left="920" width="146" height="20" font="4">with a lower risk of death.  </text>
</page>
<page number="14" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 14 </text>
<text top="107" left="601" width="255" height="20" font="4">score matching (HR: 0.10; 95% CI: 0.01–0.78; </text>
<text top="124" left="601" width="56" height="20" font="4">p=0.028). </text>
<text top="107" left="920" width="146" height="20" font="4">● Survival benefits should </text>
<text top="124" left="920" width="129" height="20" font="4">be considered together </text>
<text top="141" left="920" width="79" height="20" font="4">with improved </text>
<text top="159" left="920" width="130" height="20" font="4">hemodynamics and FC </text>
<text top="176" left="920" width="143" height="20" font="4">when decisions are made </text>
<text top="193" left="920" width="148" height="20" font="4">about advanced therapy in </text>
<text top="210" left="920" width="86" height="20" font="4">this population. </text>
<text top="228" left="64" width="86" height="20" font="4">Drenthen W, et </text>
<text top="245" left="64" width="16" height="20" font="4">al. </text>
<text top="263" left="64" width="56" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(31)</a> </text>
<text top="280" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20584777?dopt=Citation">20584777</a></text>
<text top="280" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20584777?dopt=Citation"> </a></text>
<text top="228" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="245" left="170" width="42" height="20" font="4">review  </text>
<text top="228" left="269" width="68" height="20" font="4">n=1,802 pts </text>
<text top="228" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="245" left="369" width="98" height="20" font="3"><b>criteria</b>: Females </text>
<text top="263" left="369" width="87" height="20" font="4">in large dataset </text>
<text top="280" left="369" width="55" height="20" font="4">with CHD </text>
<text top="297" left="369" width="63" height="20" font="4">completing </text>
<text top="314" left="369" width="61" height="20" font="4">pregnancy </text>
<text top="228" left="482" width="67" height="20" font="4">Outcome of </text>
<text top="245" left="482" width="74" height="20" font="4">pregnancy in </text>
<text top="263" left="482" width="98" height="20" font="4">women with CHD </text>
<text top="228" left="601" width="280" height="20" font="4">● The most prevalent cardiac complications during </text>
<text top="245" left="601" width="289" height="20" font="4">pregnancy were arrhythmias (4.7%) and HF (1.6%).  </text>
<text top="263" left="601" width="276" height="20" font="4">● Factors independently associated with maternal </text>
<text top="280" left="601" width="288" height="20" font="4">cardiac complications were the presence of cyanotic </text>
<text top="297" left="601" width="277" height="20" font="4">HD (corrected/uncorrected) (p&lt;0.0001), the use of </text>
<text top="314" left="601" width="296" height="20" font="4">cardiac medication before pregnancy (p&lt;0.0001), and </text>
<text top="332" left="601" width="291" height="20" font="4">left heart obstruction (p&lt;0.0001). New characteristics </text>
<text top="349" left="601" width="290" height="20" font="4">were mechanical valve replacement (p=0.0014), and </text>
<text top="366" left="601" width="300" height="20" font="4">systemic (p=0.04) or pulmonary AV valve regurgitation </text>
<text top="383" left="601" width="299" height="20" font="4">related with the underlying (moderately) complex CHD </text>
<text top="401" left="601" width="53" height="20" font="4">(p=0.03). </text>
<text top="228" left="920" width="148" height="20" font="4">● In a tertiary CHD cohort, </text>
<text top="245" left="920" width="148" height="20" font="4">cardiac, obstetric, and neo-</text>
<text top="263" left="920" width="138" height="20" font="4">natal complications were </text>
<text top="280" left="920" width="133" height="20" font="4">frequently encountered, </text>
<text top="297" left="920" width="139" height="20" font="4">and (new) correlations of </text>
<text top="314" left="920" width="153" height="20" font="4">maternal baseline data with </text>
<text top="332" left="920" width="119" height="20" font="4">adverse outcome are </text>
<text top="349" left="920" width="53" height="20" font="4">reported. </text>
<text top="366" left="920" width="124" height="20" font="4">● A new risk score for </text>
<text top="383" left="920" width="90" height="20" font="4">adverse cardiac </text>
<text top="400" left="920" width="148" height="20" font="4">complications is proposed, </text>
<text top="418" left="920" width="117" height="20" font="4">although prospective </text>
<text top="435" left="920" width="102" height="20" font="4">validation remains </text>
<text top="452" left="920" width="63" height="20" font="4">necessary. </text>
<text top="470" left="64" width="86" height="20" font="4">Cook SC, et al. </text>
<text top="487" left="64" width="56" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(32)</a> </text>
<text top="504" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23279961?dopt=Citation">23279961</a></text>
<text top="504" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23279961?dopt=Citation"> </a></text>
<text top="470" left="170" width="67" height="20" font="4">Prospective </text>
<text top="487" left="170" width="66" height="20" font="4">case study  </text>
<text top="470" left="269" width="76" height="20" font="4">n=43 pts with </text>
<text top="487" left="269" width="31" height="20" font="4">CoA  </text>
<text top="470" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="487" left="369" width="85" height="20" font="3"><b>criteria</b>: Adults </text>
<text top="504" left="369" width="79" height="20" font="4">with CoA who </text>
<text top="522" left="369" width="61" height="20" font="4">underwent </text>
<text top="539" left="369" width="48" height="20" font="4">cerebral </text>
<text top="556" left="369" width="66" height="20" font="4">CTA/MRA.  </text>
<text top="470" left="482" width="76" height="20" font="4">Prospectively </text>
<text top="487" left="482" width="87" height="20" font="4">perform CTA of </text>
<text top="504" left="482" width="84" height="20" font="4">the intracranial </text>
<text top="522" left="482" width="94" height="20" font="4">vessels in adults </text>
<text top="539" left="482" width="66" height="20" font="4">with CoA to </text>
<text top="556" left="482" width="70" height="20" font="4">evaluate the </text>
<text top="573" left="482" width="87" height="20" font="4">prevalence and </text>
<text top="591" left="482" width="92" height="20" font="4">identify high-risk </text>
<text top="608" left="482" width="84" height="20" font="4">features of this </text>
<text top="625" left="482" width="72" height="20" font="4">complication </text>
<text top="470" left="601" width="252" height="20" font="4">● 5 pts (11%) were found to have IA. Pts with </text>
<text top="487" left="601" width="291" height="20" font="4">intercranial aneurysms were older than those without </text>
<text top="504" left="601" width="232" height="20" font="4">(45.6 ± 8.17 vs. 30.89 ± 7.89; p=0.0003).  </text>
<text top="522" left="601" width="280" height="20" font="4">● There were no statistically significant differences </text>
<text top="539" left="601" width="264" height="20" font="4">detected between measurements of fasting lipid </text>
<text top="556" left="601" width="286" height="20" font="4">profiles, C-reactive protein, BNP, and homocysteine </text>
<text top="573" left="601" width="278" height="20" font="4">levels among CoA pts with and without intercranial </text>
<text top="591" left="601" width="113" height="20" font="4">aneurysms (p= NS). </text>
<text top="470" left="920" width="150" height="20" font="4">● Prospective screening of </text>
<text top="487" left="920" width="146" height="20" font="4">adults with CoA confirmed </text>
<text top="504" left="920" width="141" height="20" font="4">the increased prevalence </text>
<text top="522" left="920" width="141" height="20" font="4">of intercranial aneurysms </text>
<text top="539" left="920" width="99" height="20" font="4">but also identified </text>
<text top="556" left="920" width="143" height="20" font="4">increased age as the sole </text>
<text top="573" left="920" width="125" height="20" font="4">risk factor. These data </text>
<text top="591" left="920" width="153" height="20" font="4">suggested that screening is </text>
<text top="608" left="920" width="141" height="20" font="4">justified particularly in the </text>
<text top="625" left="920" width="7" height="20" font="4">4</text>
<text top="627" left="926" width="7" height="13" font="6">th</text>
<text top="625" left="933" width="38" height="20" font="4"> and 5t</text>
<text top="627" left="971" width="4" height="13" font="6">h</text>
<text top="625" left="975" width="93" height="20" font="4"> decades of life.  </text>
<text top="642" left="920" width="119" height="20" font="4">● Further studies are </text>
<text top="659" left="920" width="143" height="20" font="4">required that focus on the </text>
<text top="677" left="920" width="118" height="20" font="4">development, natural </text>
<text top="694" left="920" width="136" height="20" font="4">history, and treatment of </text>
<text top="711" left="920" width="19" height="20" font="4">IA. </text>
<text top="729" left="64" width="83" height="20" font="4">Bottega NA, et </text>
<text top="746" left="64" width="16" height="20" font="4">al. </text>
<text top="763" left="64" width="56" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(33)</a> </text>
<text top="781" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20934761?dopt=Citation">20934761</a></text>
<text top="781" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20934761?dopt=Citation"> </a></text>
<text top="729" left="170" width="183" height="20" font="4">Retrospective   n=112 pts with </text>
<text top="746" left="269" width="40" height="20" font="4">d-TGA </text>
<text top="763" left="269" width="51" height="20" font="4">Mustard  </text>
<text top="729" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="746" left="369" width="93" height="20" font="3"><b>criteria</b>: Pts &gt;18 </text>
<text top="763" left="369" width="98" height="20" font="4">y with d-TGA and </text>
<text top="781" left="369" width="58" height="20" font="4">a Mustard </text>
<text top="729" left="482" width="75" height="20" font="4">Frequency of </text>
<text top="746" left="482" width="74" height="20" font="4">superior limb </text>
<text top="763" left="482" width="101" height="20" font="4">stenosis in d-TGA </text>
<text top="781" left="482" width="48" height="20" font="4">Mustard </text>
<text top="729" left="601" width="288" height="20" font="4">● Narrowing of the superior limb of systemic venous </text>
<text top="746" left="601" width="297" height="20" font="4">baffle was observed in 49/112 pts (70 males) 31 ± 6 y </text>
<text top="763" left="601" width="299" height="20" font="4">(range 18c49) and was hemodynamically significant in </text>
<text top="781" left="601" width="41" height="20" font="4">15/49.  </text>
<text top="729" left="920" width="148" height="20" font="4">● In this cohort of Mustard </text>
<text top="746" left="920" width="115" height="20" font="4">pts, narrowing of the </text>
<text top="763" left="920" width="152" height="20" font="4">systemic venous baffle had </text>
<text top="781" left="920" width="139" height="20" font="4">a prevalence of 44% and </text>
</page>
<page number="15" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 15 </text>
<text top="107" left="369" width="84" height="20" font="4">procedure with </text>
<text top="124" left="369" width="76" height="20" font="4">and without a </text>
<text top="141" left="369" width="89" height="20" font="4">pacemaker/ICD </text>
<text top="159" left="369" width="83" height="20" font="4">were identified </text>
<text top="176" left="369" width="62" height="20" font="4">through an </text>
<text top="193" left="369" width="65" height="20" font="4">institutional </text>
<text top="210" left="369" width="54" height="20" font="4">database </text>
<text top="107" left="601" width="272" height="20" font="4">● Of 29 pts with a pacemaker (23) or ICD (6) and </text>
<text top="124" left="601" width="277" height="20" font="4">cardiac imaging, 17 had narrowing of the systemic </text>
<text top="141" left="601" width="297" height="20" font="4">venous baffle, which was hemodynamically significant </text>
<text top="159" left="601" width="30" height="20" font="4">in 8.  </text>
<text top="176" left="601" width="290" height="20" font="4">● Nonechocardiographic imaging had a sensitivity of </text>
<text top="193" left="601" width="281" height="20" font="4">88% at detecting narrowing of the systemic venous </text>
<text top="210" left="601" width="300" height="20" font="4">baffle in contrast to pulse-wave Doppler, which yielded </text>
<text top="228" left="601" width="302" height="20" font="4">a sensitivity of 16% (61% NPV, 88% positive predictive </text>
<text top="245" left="601" width="40" height="20" font="4">value). </text>
<text top="107" left="920" width="118" height="20" font="4">was more likely to be </text>
<text top="124" left="920" width="67" height="20" font="4">detected by </text>
<text top="141" left="920" width="124" height="20" font="4">nonechocardiographic </text>
<text top="159" left="920" width="53" height="20" font="4">imaging.  </text>
<text top="176" left="920" width="150" height="20" font="4">● Baffle patency should be </text>
<text top="193" left="920" width="95" height="20" font="4">evaluated before </text>
<text top="210" left="920" width="109" height="20" font="4">transvenous device </text>
<text top="228" left="920" width="73" height="20" font="4">implantation. </text>
<text top="263" left="64" width="90" height="20" font="4">Gupte PA, et al. </text>
<text top="280" left="64" width="56" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(34)</a> </text>
<text top="297" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23834022?dopt=Citation">23834022</a></text>
<text top="297" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23834022?dopt=Citation"> </a></text>
<text top="263" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="280" left="170" width="73" height="20" font="4">case control  </text>
<text top="263" left="269" width="31" height="20" font="4">n=50 </text>
<text top="280" left="269" width="57" height="20" font="4">autopsied </text>
<text top="297" left="269" width="49" height="20" font="4">cases of </text>
<text top="314" left="269" width="82" height="20" font="4">cyanotic CHD  </text>
<text top="263" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="280" left="369" width="99" height="20" font="3"><b>criteria</b>: Cyanotic </text>
<text top="297" left="369" width="76" height="20" font="4">CHD pts who </text>
<text top="314" left="369" width="61" height="20" font="4">underwent </text>
<text top="332" left="369" width="50" height="20" font="4">autopsy  </text>
<text top="263" left="482" width="85" height="20" font="4">This study was </text>
<text top="280" left="482" width="100" height="20" font="4">undertaken for an </text>
<text top="297" left="482" width="100" height="20" font="4">objective analysis </text>
<text top="314" left="482" width="14" height="20" font="4">of </text>
<text top="332" left="482" width="95" height="20" font="4">histopathological </text>
<text top="349" left="482" width="64" height="20" font="4">changes of </text>
<text top="366" left="482" width="48" height="20" font="4">cyanotic </text>
<text top="383" left="482" width="85" height="20" font="4">nephropathy at </text>
<text top="400" left="482" width="46" height="20" font="4">autopsy </text>
<text top="263" left="601" width="302" height="20" font="4">● The renal changes observed were glomerulomegaly, </text>
<text top="280" left="601" width="237" height="20" font="4">glomerulosclerosis, periglomerular fibrosis, </text>
<text top="297" left="601" width="297" height="20" font="4">hyperplastic arteriolosclerosis, and interstitial fibrosis.  </text>
<text top="314" left="601" width="302" height="20" font="4">● The objectively measured parameters were higher in </text>
<text top="332" left="601" width="303" height="20" font="4">cases as compared with controls in all age groups, and </text>
<text top="349" left="601" width="304" height="20" font="4">further these were also found to be higher in pts having </text>
<text top="366" left="601" width="282" height="20" font="4">decreased pulmonary arterial blood flow than those </text>
<text top="383" left="601" width="287" height="20" font="4">having normal to increased pulmonary arterial blood </text>
<text top="400" left="601" width="29" height="20" font="4">flow. </text>
<text top="263" left="920" width="127" height="20" font="4">● Pts with critical CHD </text>
<text top="280" left="920" width="153" height="20" font="4">show significant changes in </text>
<text top="297" left="920" width="137" height="20" font="4">the kidneys as assessed </text>
<text top="314" left="920" width="143" height="20" font="4">morphometrically, leading </text>
<text top="332" left="920" width="137" height="20" font="4">to renal dysfunction, and </text>
<text top="349" left="920" width="141" height="20" font="4">the age of the pts plays a </text>
<text top="366" left="920" width="141" height="20" font="4">role in their development. </text>
<text top="418" left="64" width="88" height="20" font="4">Ammash N and </text>
<text top="436" left="64" width="66" height="20" font="4">Warnes CA </text>
<text top="453" left="64" width="56" height="20" font="4">1996 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(35)</a> </text>
<text top="470" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8772770?dopt=Citation">8772770</a></text>
<text top="470" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8772770?dopt=Citation"> </a></text>
<text top="418" left="170" width="183" height="20" font="4">Retrospective   n=162 pts with </text>
<text top="436" left="269" width="79" height="20" font="4">cyanotic CHD </text>
<text top="453" left="269" width="79" height="20" font="4">(mean age 37 </text>
<text top="470" left="269" width="68" height="20" font="4">y, range 19–</text>
<text top="487" left="269" width="21" height="20" font="4">70) </text>
<text top="418" left="369" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="436" left="369" width="94" height="20" font="3"><b>criteria</b>: Pts with </text>
<text top="453" left="369" width="79" height="20" font="4">cyanotic CHD </text>
<text top="470" left="369" width="84" height="20" font="4">between 1988–</text>
<text top="487" left="369" width="56" height="20" font="4">1995 with </text>
<text top="504" left="369" width="91" height="20" font="4">cerebrovascular </text>
<text top="522" left="369" width="64" height="20" font="4">events that </text>
<text top="539" left="369" width="103" height="20" font="4">occurred at ≥18 y  </text>
<text top="418" left="482" width="76" height="20" font="4">We sought to </text>
<text top="436" left="482" width="79" height="20" font="4">determine the </text>
<text top="453" left="482" width="71" height="20" font="4">frequency of </text>
<text top="470" left="482" width="74" height="20" font="4">spontaneous </text>
<text top="487" left="482" width="91" height="20" font="4">cerebrovascular </text>
<text top="504" left="482" width="102" height="20" font="4">events in adult pts </text>
<text top="522" left="482" width="104" height="20" font="4">with cyanotic CHD </text>
<text top="539" left="482" width="87" height="20" font="4">and to evaluate </text>
<text top="556" left="482" width="90" height="20" font="4">any contributing </text>
<text top="573" left="482" width="44" height="20" font="4">factors. </text>
<text top="418" left="601" width="268" height="20" font="4">● 22 pts (13.6%) had 29 cerebrovascular events </text>
<text top="436" left="601" width="73" height="20" font="4">(1/100/pt-y).  </text>
<text top="453" left="601" width="289" height="20" font="4">● There was no significant difference between those </text>
<text top="470" left="601" width="287" height="20" font="4">with and without a cerebrovascular event in terms of </text>
<text top="487" left="601" width="295" height="20" font="4">age, smoking history, degree of erythrocytosis, EF, or </text>
<text top="504" left="601" width="290" height="20" font="4">use of aspirin or warfarin (Coumadin). Pts who had a </text>
<text top="522" left="601" width="282" height="20" font="4">cerebrovascular event had a significantly increased </text>
<text top="539" left="601" width="278" height="20" font="4">tendency to develop HTN, AF, microcytosis (mean </text>
<text top="556" left="601" width="283" height="20" font="4">corpuscular volume &lt;82) and history of phlebotomy </text>
<text top="573" left="601" width="255" height="20" font="4">(p&lt;0.05). Even when pts with HTN or AF were </text>
<text top="591" left="601" width="223" height="20" font="4">excluded, there was an increased risk of </text>
<text top="608" left="601" width="289" height="20" font="4">cerebrovascular events associated with microcytosis </text>
<text top="625" left="601" width="53" height="20" font="4">(p&lt;0.01). </text>
<text top="418" left="920" width="154" height="20" font="4">● Adults with cyanotic CHD </text>
<text top="436" left="920" width="111" height="20" font="4">are at risk of having </text>
<text top="453" left="920" width="134" height="20" font="4">cerebrovascular events. </text>
<text top="470" left="920" width="130" height="20" font="4">Risk is increased in the </text>
<text top="487" left="920" width="122" height="20" font="4">presence of HTN, AF, </text>
<text top="504" left="920" width="148" height="20" font="4">history of phlebotomy, and </text>
<text top="522" left="920" width="126" height="20" font="4">microcytosis, the latter </text>
<text top="539" left="920" width="113" height="20" font="4">condition having the </text>
<text top="556" left="920" width="121" height="20" font="4">strongest significance </text>
<text top="573" left="920" width="63" height="20" font="4">(p&lt;0.005).  </text>
<text top="591" left="920" width="141" height="20" font="4">● This finding leads us to </text>
<text top="608" left="920" width="90" height="20" font="4">endorse a more </text>
<text top="625" left="920" width="127" height="20" font="4">conservative approach </text>
<text top="642" left="920" width="141" height="20" font="4">toward phlebotomy and a </text>
<text top="659" left="920" width="149" height="20" font="4">more aggressive approach </text>
<text top="677" left="920" width="85" height="20" font="4">toward treating </text>
<text top="694" left="920" width="145" height="20" font="4">microcytosis in adults with </text>
<text top="711" left="920" width="82" height="20" font="4">cyanotic CHD.<b> </b></text>
<text top="729" left="108" width="3" height="20" font="4"> </text>
<text top="746" left="108" width="3" height="20" font="4"> </text>
</page>
<page number="16" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 16 </text>
<text top="106" left="108" width="560" height="24" font="1"><b>Data Supplement 3. Access to Care and Delivery of Care – Sections 3.2 and 3.3  </b></text>
<text top="128" left="95" width="38" height="20" font="3"><b>Study </b></text>
<text top="145" left="70" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="162" left="99" width="30" height="20" font="3"><b>Year </b></text>
<text top="128" left="183" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="145" left="198" width="44" height="20" font="3"><b>Design </b></text>
<text top="128" left="290" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="128" left="386" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="145" left="422" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="128" left="565" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="128" left="716" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="128" left="895" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="180" left="64" width="85" height="20" font="4">Meijboom F, et </text>
<text top="197" left="64" width="16" height="20" font="4">al. </text>
<text top="215" left="64" width="56" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(36)</a> </text>
<text top="232" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20800805">20800805</a></text>
<text top="232" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20800805"> </a></text>
<text top="180" left="177" width="123" height="20" font="4">Review article  N/A </text>
<text top="180" left="383" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="197" left="383" width="20" height="20" font="4">N/A</text>
<text top="199" left="403" width="2" height="13" font="6"> </text>
<text top="180" left="521" width="24" height="20" font="4">N/A </text>
<text top="180" left="694" width="24" height="20" font="4">N/A </text>
<text top="180" left="853" width="212" height="20" font="4">● Too few ACHD centers in Europe to </text>
<text top="197" left="853" width="183" height="20" font="4">care for the predicted population. </text>
<text top="250" left="64" width="90" height="20" font="4">Gurvitz M, et al. </text>
<text top="267" left="64" width="49" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(6)</a> </text>
<text top="284" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23542112">23542112</a></text>
<text top="284" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23542112"> </a></text>
<text top="250" left="177" width="79" height="20" font="4">Observational </text>
<text top="267" left="177" width="85" height="20" font="4">cross-sectional </text>
<text top="284" left="177" width="64" height="20" font="4">multicenter </text>
<text top="301" left="177" width="66" height="20" font="4">prospective </text>
<text top="319" left="177" width="77" height="20" font="4">questionnaire </text>
<text top="250" left="276" width="58" height="20" font="4">n=922 pts </text>
<text top="250" left="383" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="267" left="383" width="82" height="20" font="4">Pts &gt;18 y, first </text>
<text top="284" left="383" width="123" height="20" font="4">presentation to ACHD </text>
<text top="301" left="383" width="31" height="20" font="4">clinic </text>
<text top="250" left="521" width="112" height="20" font="4">&gt;3 y gap in CV care </text>
<text top="250" left="694" width="122" height="20" font="4">● Disease complexity </text>
<text top="267" left="694" width="134" height="20" font="4">predictive of gap in care </text>
<text top="284" left="694" width="139" height="20" font="4">in 59% of simple, 42% of </text>
<text top="301" left="694" width="124" height="20" font="4">moderate, and 26% of </text>
<text top="319" left="694" width="122" height="20" font="4">complex pts (p&lt;0.01). </text>
<text top="250" left="853" width="180" height="20" font="4">● The study provides a basis for </text>
<text top="267" left="853" width="200" height="20" font="4">improving strategies for dealing with </text>
<text top="284" left="853" width="110" height="20" font="4">the barriers to care. </text>
<text top="336" left="64" width="96" height="20" font="4">Beauchesne LM, </text>
<text top="354" left="64" width="30" height="20" font="4">et al. </text>
<text top="371" left="64" width="56" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(37)</a> </text>
<text top="388" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21190745?dopt=Citation">21190745</a></text>
<text top="388" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21190745?dopt=Citation"> </a></text>
<text top="336" left="177" width="71" height="20" font="4">Prospective  </text>
<text top="336" left="276" width="55" height="20" font="4">15 CACH </text>
<text top="354" left="276" width="47" height="20" font="4">centers; </text>
<text top="371" left="276" width="68" height="20" font="4">~21,000 pts </text>
<text top="336" left="383" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="354" left="383" width="84" height="20" font="4">Outpatient and </text>
<text top="371" left="383" width="111" height="20" font="4">procedural volumes </text>
<text top="388" left="383" width="27" height="20" font="4">data </text>
<text top="336" left="521" width="132" height="20" font="4">Number of pts in ACHD </text>
<text top="354" left="521" width="130" height="20" font="4">care, time to nonurgent </text>
<text top="371" left="521" width="116" height="20" font="4">consult, intervention, </text>
<text top="388" left="521" width="44" height="20" font="4">surgery </text>
<text top="336" left="694" width="142" height="20" font="4">● Only a small proportion </text>
<text top="354" left="694" width="106" height="20" font="4">of ACHD in care at </text>
<text top="371" left="694" width="126" height="20" font="4">centers, longer waiting </text>
<text top="388" left="694" width="105" height="20" font="4">times than targets. </text>
<text top="336" left="853" width="205" height="20" font="4">● The ACHD guidelines and process </text>
<text top="354" left="853" width="189" height="20" font="4">measures are not being complied. </text>
<text top="406" left="64" width="77" height="20" font="4">Patel MS and </text>
<text top="423" left="64" width="59" height="20" font="4">Kogon BE </text>
<text top="440" left="64" width="56" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(38)</a> </text>
<text top="458" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20063158?dopt=Citation">20063158</a></text>
<text top="458" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20063158?dopt=Citation"> </a></text>
<text top="406" left="177" width="56" height="20" font="4">Database </text>
<text top="423" left="177" width="39" height="20" font="4">review </text>
<text top="406" left="276" width="84" height="20" font="4">Clinic directory </text>
<text top="406" left="383" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="423" left="383" width="106" height="20" font="4">Data for number of </text>
<text top="440" left="383" width="118" height="20" font="4">pts, provider training, </text>
<text top="458" left="383" width="55" height="20" font="4">and other </text>
<text top="475" left="383" width="82" height="20" font="4">characteristics </text>
<text top="406" left="521" width="147" height="20" font="4">Numbers of pts in centers, </text>
<text top="423" left="521" width="149" height="20" font="4">procedures performed well </text>
<text top="440" left="521" width="98" height="20" font="4">below estimates.  </text>
<text top="406" left="694" width="24" height="20" font="4">N/A </text>
<text top="406" left="853" width="208" height="20" font="4">● The data should provide a basis for </text>
<text top="423" left="853" width="189" height="20" font="4">improved accessibility of services. </text>
<text top="493" left="64" width="91" height="20" font="4">Marelli AJ, et al. </text>
<text top="510" left="64" width="56" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(39)</a> </text>
<text top="527" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19081390?dopt=Citation">19081390</a></text>
<text top="527" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19081390?dopt=Citation"> </a></text>
<text top="493" left="177" width="77" height="20" font="4">Data analysis </text>
<text top="493" left="276" width="61" height="20" font="4">Population </text>
<text top="510" left="276" width="70" height="20" font="4">based study </text>
<text top="493" left="383" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="510" left="383" width="119" height="20" font="4">ACHD pts in U.S and </text>
<text top="527" left="383" width="46" height="20" font="4">Canada </text>
<text top="493" left="521" width="131" height="20" font="4">Estimates of population </text>
<text top="510" left="521" width="131" height="20" font="4">size, number of centers </text>
<text top="527" left="521" width="140" height="20" font="4">needed per population to </text>
<text top="544" left="521" width="114" height="20" font="4">allow access to care </text>
<text top="493" left="694" width="24" height="20" font="4">N/A </text>
<text top="493" left="853" width="184" height="20" font="4">● 1 regional ACHD center for a 2 </text>
<text top="510" left="853" width="203" height="20" font="4">million adult pt population is required </text>
<text top="527" left="853" width="210" height="20" font="4">for specialized care of pts with ACHD. </text>
<text top="562" left="64" width="97" height="20" font="4">Gurvitz MZ, et al. </text>
<text top="580" left="64" width="56" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(40)</a> </text>
<text top="597" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17320746?dopt=Citation">17320746</a></text>
<text top="597" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17320746?dopt=Citation"> </a></text>
<text top="562" left="177" width="78" height="20" font="4">Retrospective </text>
<text top="580" left="177" width="75" height="20" font="4">data analysis </text>
<text top="562" left="276" width="75" height="20" font="4">Population of </text>
<text top="580" left="276" width="55" height="20" font="4">California </text>
<text top="562" left="383" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="580" left="383" width="123" height="20" font="4">Pts 12–44 y, with a 1° </text>
<text top="597" left="383" width="119" height="20" font="4">or 2° ICD-9-CM code </text>
<text top="614" left="383" width="48" height="20" font="4">for CHD </text>
<text top="562" left="521" width="145" height="20" font="4">Increase in admit from ED </text>
<text top="580" left="521" width="152" height="20" font="4">around transition age. Care </text>
<text top="597" left="521" width="145" height="20" font="4">divided among ACHD and </text>
<text top="614" left="521" width="107" height="20" font="4">non-ACHD centers </text>
<text top="562" left="694" width="24" height="20" font="4">N/A </text>
<text top="562" left="853" width="210" height="20" font="4">● More studies into clinical outcomes, </text>
<text top="580" left="853" width="174" height="20" font="4">use of services, and healthcare </text>
<text top="597" left="853" width="141" height="20" font="4">disparities are warranted. </text>
<text top="632" left="64" width="98" height="20" font="4">Shirodaria CC, et </text>
<text top="649" left="64" width="16" height="20" font="4">al. </text>
<text top="667" left="64" width="56" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(41)</a> </text>
<text top="684" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16061123?dopt=Citation">16061123</a></text>
<text top="684" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16061123?dopt=Citation"> </a></text>
<text top="632" left="177" width="68" height="20" font="4">Case report </text>
<text top="632" left="276" width="84" height="20" font="4">Output clinic in </text>
<text top="649" left="276" width="41" height="20" font="4">the UK </text>
<text top="632" left="383" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="649" left="383" width="24" height="20" font="4">N/A </text>
<text top="632" left="521" width="149" height="20" font="4">Evaluating a model of care </text>
<text top="649" left="521" width="128" height="20" font="4">for pts in a local/district </text>
<text top="667" left="521" width="145" height="20" font="4">clinic. Program successful </text>
<text top="684" left="521" width="159" height="20" font="4">and no-show rate lower than </text>
<text top="701" left="521" width="60" height="20" font="4">spec clinic </text>
<text top="632" left="694" width="24" height="20" font="4">N/A </text>
<text top="632" left="853" width="186" height="20" font="4">● Data useful for planning a CHD </text>
<text top="649" left="853" width="41" height="20" font="4">center. </text>
<text top="719" left="64" width="96" height="20" font="4">Mackie AS, et al. </text>
<text top="736" left="64" width="56" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(42)</a> </text>
<text top="753" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24842870?dopt=Citation">24842870</a></text>
<text top="753" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24842870?dopt=Citation"> </a></text>
<text top="719" left="177" width="71" height="20" font="4">Prospective  </text>
<text top="719" left="276" width="51" height="20" font="4">n=58 pts </text>
<text top="719" left="383" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="736" left="383" width="94" height="20" font="4">Pts 15–17 y with </text>
<text top="753" left="383" width="119" height="20" font="4">moderate or complex </text>
<text top="771" left="383" width="30" height="20" font="4">CHD </text>
<text top="719" left="521" width="24" height="20" font="4">N/A </text>
<text top="719" left="694" width="33" height="20" font="4">● NS </text>
<text top="719" left="853" width="172" height="20" font="4">● Educational intervention was </text>
<text top="736" left="853" width="165" height="20" font="4">beneficial to CHD knowledge. </text>
</page>
<page number="17" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 17 </text>
<text top="107" left="64" width="89" height="20" font="4">Mylotte D, et al. </text>
<text top="124" left="64" width="49" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(7)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24589851?dopt=Citation">24589851</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24589851?dopt=Citation"> </a></text>
<text top="107" left="177" width="174" height="20" font="4">Epidemiologic  n=71,467 pts </text>
<text top="124" left="276" width="75" height="20" font="4">from Quebec </text>
<text top="141" left="276" width="82" height="20" font="4">CHD Registry; </text>
<text top="159" left="276" width="72" height="20" font="4">2,092 ACHD </text>
<text top="176" left="276" width="70" height="20" font="4">death cases </text>
<text top="107" left="383" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="383" width="122" height="20" font="4">Pts with ACHD,18–65 </text>
<text top="141" left="383" width="97" height="20" font="4">y, between 1983–</text>
<text top="159" left="383" width="31" height="20" font="4">2005 </text>
<text top="107" left="521" width="150" height="20" font="4">Pts in specialized care had </text>
<text top="124" left="521" width="125" height="20" font="4">lower mortality; mostly </text>
<text top="141" left="521" width="153" height="20" font="4">driven by the most complex </text>
<text top="159" left="521" width="65" height="20" font="4">CHD group </text>
<text top="107" left="694" width="115" height="20" font="4">● Increased care for </text>
<text top="124" left="694" width="143" height="20" font="4">severe in specialty ACHD </text>
<text top="141" left="694" width="97" height="20" font="4">centers (p&lt;0.01); </text>
<text top="159" left="694" width="124" height="20" font="4">increased mortality for </text>
<text top="176" left="694" width="143" height="20" font="4">severe ACHD (OR: 1.93). </text>
<text top="107" left="853" width="211" height="20" font="4">● Study promotes specialized care for </text>
<text top="124" left="853" width="44" height="20" font="4">the pts. </text>
<text top="194" left="64" width="81" height="20" font="4">Sable C, et al. </text>
<text top="211" left="64" width="56" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(43)</a> </text>
<text top="228" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21357825?dopt=Citation">21357825</a></text>
<text top="228" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21357825?dopt=Citation"> </a></text>
<text top="194" left="177" width="53" height="20" font="4">Scientific </text>
<text top="211" left="177" width="59" height="20" font="4">Statement </text>
<text top="228" left="177" width="57" height="20" font="4">from AHA </text>
<text top="194" left="276" width="24" height="20" font="4">N/A </text>
<text top="194" left="383" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="211" left="383" width="24" height="20" font="4">N/A </text>
<text top="194" left="521" width="24" height="20" font="4">N/A </text>
<text top="194" left="694" width="24" height="20" font="4">N/A </text>
<text top="194" left="853" width="131" height="20" font="4">● Discusses topics and </text>
<text top="211" left="853" width="156" height="20" font="4">recommendations related to </text>
<text top="228" left="853" width="207" height="20" font="4">transitioning and transferring pts from </text>
<text top="245" left="853" width="176" height="20" font="4">pediatric to adult-centered care. </text>
<text top="263" left="64" width="98" height="20" font="4">Christman MP, et </text>
<text top="281" left="64" width="16" height="20" font="4">al. </text>
<text top="298" left="64" width="60" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(44)</a>  </text>
<text top="315" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23984096?dopt=Citation">23984096</a></text>
<text top="315" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23984096?dopt=Citation"> </a></text>
<text top="263" left="177" width="79" height="20" font="4">Retrospective </text>
<text top="263" left="276" width="78" height="20" font="4">n=175 female </text>
<text top="281" left="276" width="68" height="20" font="4">pts in single </text>
<text top="298" left="276" width="38" height="20" font="4">center </text>
<text top="315" left="276" width="72" height="20" font="4">compared to </text>
<text top="332" left="276" width="44" height="20" font="4">general </text>
<text top="350" left="276" width="60" height="20" font="4">population </text>
<text top="263" left="383" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="281" left="383" width="120" height="20" font="4">Pts ≥18 y with ACHD </text>
<text top="298" left="383" width="98" height="20" font="4">or non-ACHD HD </text>
<text top="263" left="521" width="136" height="20" font="4">Preventive screening for </text>
<text top="281" left="521" width="152" height="20" font="4">Cancer based on American </text>
<text top="298" left="521" width="146" height="20" font="4">Cancer Society guidelines </text>
<text top="263" left="694" width="125" height="20" font="4">● Cancer screening in </text>
<text top="281" left="694" width="139" height="20" font="4">ACHD pts does not meet </text>
<text top="298" left="694" width="122" height="20" font="4">recommended overall </text>
<text top="315" left="694" width="87" height="20" font="4">screening rates </text>
<text top="263" left="853" width="186" height="20" font="4">● Improve screening practices by </text>
<text top="281" left="853" width="207" height="20" font="4">1°care and CHD providers and better </text>
<text top="298" left="853" width="187" height="20" font="4">communication for long-term care </text>
<text top="315" left="853" width="53" height="20" font="4">planning. </text>
<text top="368" left="64" width="84" height="20" font="4">Karamlou T, et </text>
<text top="385" left="64" width="16" height="20" font="4">al. </text>
<text top="402" left="64" width="60" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(45)</a>  </text>
<text top="419" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18997167?dopt=Citation">18997167</a></text>
<text top="419" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18997167?dopt=Citation"> </a></text>
<text top="368" left="177" width="171" height="20" font="4">Epidemiologic  National inpt </text>
<text top="385" left="276" width="77" height="20" font="4">sample 1988–</text>
<text top="402" left="276" width="31" height="20" font="4">2003 </text>
<text top="368" left="383" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="385" left="383" width="81" height="20" font="4">Pts ≥18 y with </text>
<text top="402" left="383" width="120" height="20" font="4">operation and 1 of 12 </text>
<text top="419" left="383" width="90" height="20" font="4">CHD diagnoses </text>
<text top="368" left="521" width="125" height="20" font="4">In-hospital death rates </text>
<text top="385" left="521" width="97" height="20" font="4">following surgical </text>
<text top="402" left="521" width="65" height="20" font="4">procedures </text>
<text top="368" left="694" width="106" height="20" font="4">● Congenital heart </text>
<text top="385" left="694" width="103" height="20" font="4">surgeries in adults </text>
<text top="402" left="694" width="126" height="20" font="4">performed by pediatric </text>
<text top="419" left="694" width="142" height="20" font="4">heart surgeons had lower </text>
<text top="436" left="694" width="128" height="20" font="4">in-hospital death rates. </text>
<text top="368" left="853" width="217" height="20" font="4">● Study promotes that congenital heart </text>
<text top="385" left="853" width="210" height="20" font="4">surgery in adults should be performed </text>
<text top="402" left="853" width="178" height="20" font="4">by experienced congenital heart </text>
<text top="419" left="853" width="57" height="20" font="4">surgeons. </text>
<text top="454" left="108" width="3" height="20" font="4"> </text>
<text top="472" left="54" width="3" height="20" font="4"> </text>
<text top="488" left="108" width="302" height="24" font="1"><b>Data Supplement 4. Catheter Interventions </b></text>
<text top="510" left="73" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="527" left="73" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="510" left="218" width="90" height="20" font="3"><b>Document Aim </b></text>
<text top="510" left="374" width="70" height="20" font="3"><b>Study Type </b></text>
<text top="527" left="382" width="52" height="20" font="3"><b>(Size, N) </b></text>
<text top="510" left="471" width="111" height="20" font="3"><b>Patient Population </b></text>
<text top="510" left="689" width="80" height="20" font="3"><b>1° Endpoints </b></text>
<text top="510" left="930" width="70" height="20" font="3"><b> Comments </b></text>
<text top="545" left="64" width="82" height="20" font="4">Ruiz CE, et al. </text>
<text top="562" left="64" width="56" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(46)</a> </text>
<text top="580" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20850086?dopt=Citation">20850086</a></text>
<text top="580" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20850086?dopt=Citation"> </a></text>
<text top="545" left="172" width="180" height="20" font="4">N/A –Training recommendations </text>
<text top="562" left="172" width="160" height="20" font="4">for Structural and Congenital </text>
<text top="580" left="172" width="123" height="20" font="4">Interventions in adults </text>
<text top="545" left="368" width="24" height="20" font="4">N/A </text>
<text top="545" left="462" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="562" left="462" width="107" height="20" font="4">Adults with CHD or </text>
<text top="580" left="462" width="75" height="20" font="4">structural HD </text>
<text top="545" left="604" width="241" height="20" font="4">Describes necessary training competencies </text>
<text top="562" left="604" width="228" height="20" font="4">for interventional cardiologists performing </text>
<text top="580" left="604" width="230" height="20" font="4">procedures in adults with CHD and adults </text>
<text top="597" left="604" width="100" height="20" font="4">with structural HD </text>
<text top="545" left="867" width="184" height="20" font="4">● Document is expert consensus </text>
<text top="562" left="867" width="131" height="20" font="4">from Society of Cardiac </text>
<text top="580" left="867" width="185" height="20" font="4">Angiography and Intervention but </text>
<text top="597" left="867" width="182" height="20" font="4">does not have specific outcomes </text>
<text top="614" left="867" width="31" height="20" font="4">data. </text>
<text top="632" left="64" width="89" height="20" font="4">Armsby L, et al. </text>
<text top="649" left="64" width="56" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(47)</a> </text>
<text top="667" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24890705?dopt=Citation">24890705</a></text>
<text top="667" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24890705?dopt=Citation"> </a></text>
<text top="632" left="172" width="82" height="20" font="4">N/A – Training </text>
<text top="649" left="172" width="181" height="20" font="4">recommendations for Congenital </text>
<text top="667" left="172" width="136" height="20" font="4">Interventions in Children </text>
<text top="632" left="368" width="24" height="20" font="4">N/A </text>
<text top="632" left="462" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="649" left="462" width="114" height="20" font="4">Pediatric cardiac pts </text>
<text top="632" left="604" width="241" height="20" font="4">Describes necessary training competencies </text>
<text top="649" left="604" width="204" height="20" font="4">for pediatric interventional cardiology </text>
<text top="667" left="604" width="65" height="20" font="4">procedures </text>
<text top="632" left="867" width="184" height="20" font="4">● Document is expert consensus </text>
<text top="649" left="867" width="131" height="20" font="4">from Society of Cardiac </text>
<text top="667" left="867" width="185" height="20" font="4">Angiography and Intervention but </text>
<text top="684" left="867" width="182" height="20" font="4">does not have specific outcomes </text>
<text top="701" left="867" width="31" height="20" font="4">data. </text>
<text top="719" left="54" width="3" height="20" font="4"> </text>
<text top="736" left="54" width="3" height="20" font="4"> </text>
</page>
<page number="18" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 18 </text>
<text top="106" left="108" width="201" height="24" font="1"><b>Data Supplement 5. Surgery </b></text>
<text top="128" left="73" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="145" left="73" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="128" left="206" width="114" height="20" font="3"><b>Study Type/Design </b></text>
<text top="128" left="375" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="128" left="467" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="145" left="503" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="128" left="635" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="128" left="768" width="105" height="20" font="3"><b>Results/ p Values </b></text>
<text top="128" left="914" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="163" left="64" width="84" height="20" font="4">Karamlou T, et </text>
<text top="180" left="64" width="16" height="20" font="4">al. </text>
<text top="197" left="64" width="56" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(45)</a> </text>
<text top="215" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18997167?dopt=Citation">18997167</a></text>
<text top="215" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18997167?dopt=Citation"> </a></text>
<text top="163" left="172" width="106" height="20" font="4">Systematic review  </text>
<text top="163" left="368" width="55" height="20" font="4">n=30,250 </text>
<text top="180" left="368" width="36" height="20" font="4">cases </text>
<text top="163" left="462" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="180" left="462" width="109" height="20" font="4">Children and adults </text>
<text top="197" left="462" width="120" height="20" font="4">with CHD undergoing </text>
<text top="215" left="462" width="103" height="20" font="4">surgery for 1 of 12 </text>
<text top="232" left="462" width="90" height="20" font="4">CHD diagnoses </text>
<text top="163" left="604" width="126" height="20" font="4">In hospital death lower </text>
<text top="180" left="604" width="123" height="20" font="4">for pts operated on by </text>
<text top="197" left="604" width="135" height="20" font="4">pediatric heart surgeons </text>
<text top="163" left="752" width="24" height="20" font="4">N/A </text>
<text top="163" left="901" width="126" height="20" font="4">● Study promotes that </text>
<text top="180" left="901" width="148" height="20" font="4">congenital heart surgery in </text>
<text top="197" left="901" width="152" height="20" font="4">adults should be performed </text>
<text top="215" left="901" width="146" height="20" font="4">by experienced congenital </text>
<text top="232" left="901" width="85" height="20" font="4">heart surgeons </text>
<text top="250" left="64" width="82" height="20" font="4">Lamour JM, et </text>
<text top="267" left="64" width="16" height="20" font="4">al. </text>
<text top="284" left="64" width="56" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(48)</a> </text>
<text top="301" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19573734?dopt=Citation">19573734</a></text>
<text top="301" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19573734?dopt=Citation"> </a></text>
<text top="250" left="172" width="106" height="20" font="4">Systematic review  </text>
<text top="250" left="368" width="58" height="20" font="4">n=488 pts </text>
<text top="250" left="462" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="267" left="462" width="109" height="20" font="4">Children and adults </text>
<text top="284" left="462" width="122" height="20" font="4">undergoing transplant </text>
<text top="301" left="462" width="48" height="20" font="4">for CHD </text>
<text top="250" left="604" width="118" height="20" font="4">Survival at 3 mo, 1 y, </text>
<text top="267" left="604" width="51" height="20" font="4">and 5 y   </text>
<text top="250" left="752" width="132" height="20" font="4">● Population mean age </text>
<text top="267" left="752" width="133" height="20" font="4">12.4 y. Single ventricles </text>
<text top="284" left="752" width="124" height="20" font="4">(36%), d-transposition </text>
<text top="301" left="752" width="119" height="20" font="4">(12%), RVOT lesions </text>
<text top="319" left="752" width="96" height="20" font="4">(10%) were most </text>
<text top="336" left="752" width="113" height="20" font="4">common diagnoses. </text>
<text top="353" left="752" width="133" height="20" font="4">93% were reoperations. </text>
<text top="370" left="752" width="128" height="20" font="4">Survival at 3 mo worse </text>
<text top="387" left="752" width="102" height="20" font="4">than pediatric with </text>
<text top="405" left="752" width="131" height="20" font="4">cardiomyopathy but not </text>
<text top="422" left="752" width="133" height="20" font="4">adults. 5-y survival 80% </text>
<text top="439" left="752" width="116" height="20" font="4">with lower survival in </text>
<text top="456" left="752" width="118" height="20" font="4">Fontan pts (77% and </text>
<text top="473" left="752" width="99" height="20" font="4">70% at 1 and 5 y. </text>
<text top="250" left="901" width="156" height="20" font="4">● Single ventricles (36%), d-</text>
<text top="267" left="901" width="150" height="20" font="4">transposition (12%), RVOT </text>
<text top="284" left="901" width="138" height="20" font="4">lesions (10%) were most </text>
<text top="301" left="901" width="141" height="20" font="4">common diagnoses. 93% </text>
<text top="319" left="901" width="109" height="20" font="4">were reoperations.  </text>
<text top="336" left="901" width="140" height="20" font="4">● Survival at 3 mo worse </text>
<text top="353" left="901" width="102" height="20" font="4">than pediatric with </text>
<text top="370" left="901" width="131" height="20" font="4">cardiomyopathy but not </text>
<text top="387" left="901" width="158" height="20" font="4">adults. 5-y survival 80% with </text>
<text top="405" left="901" width="152" height="20" font="4">lower survival in Fontan pts </text>
<text top="422" left="901" width="159" height="20" font="4">(77% and 70% at 1 and 5 y). </text>
<text top="491" left="64" width="80" height="20" font="4">Mascio CE, et </text>
<text top="509" left="64" width="16" height="20" font="4">al. </text>
<text top="526" left="64" width="56" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(49)</a> </text>
<text top="543" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21911232?dopt=Citation">21911232</a></text>
<text top="543" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21911232?dopt=Citation"> </a></text>
<text top="491" left="172" width="178" height="20" font="4">Systematic review from the STS </text>
<text top="509" left="172" width="54" height="20" font="4">database </text>
<text top="491" left="368" width="68" height="20" font="4">n=5,265 pts </text>
<text top="509" left="368" width="45" height="20" font="4">from 68 </text>
<text top="526" left="368" width="47" height="20" font="4">centers  </text>
<text top="491" left="462" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="509" left="462" width="102" height="20" font="4">Adults undergoing </text>
<text top="526" left="462" width="75" height="20" font="4">CHD surgery </text>
<text top="491" left="604" width="50" height="20" font="4">Mortality </text>
<text top="491" left="752" width="101" height="20" font="4">● Mean age 25 y, </text>
<text top="509" left="752" width="135" height="20" font="4">preoperative risk factors </text>
<text top="526" left="752" width="113" height="20" font="4">included noncardiac </text>
<text top="543" left="752" width="80" height="20" font="4">abnormalities, </text>
<text top="560" left="752" width="121" height="20" font="4">arrhythmias. Mortality </text>
<text top="577" left="752" width="100" height="20" font="4">overall was 2.1%, </text>
<text top="595" left="752" width="116" height="20" font="4">common procedures </text>
<text top="612" left="752" width="132" height="20" font="4">were RVOT procedures </text>
<text top="629" left="752" width="128" height="20" font="4">(21%) and pacemaker/ </text>
<text top="646" left="752" width="113" height="20" font="4">arrhythmias. Fontan </text>
<text top="664" left="752" width="134" height="20" font="4">revision was the highest </text>
<text top="681" left="752" width="113" height="20" font="4">risk procedure (11% </text>
<text top="698" left="752" width="54" height="20" font="4">mortality) </text>
<text top="491" left="901" width="101" height="20" font="4">● Mean age 25 y, </text>
<text top="509" left="901" width="135" height="20" font="4">preoperative risk factors </text>
<text top="526" left="901" width="113" height="20" font="4">included noncardiac </text>
<text top="543" left="901" width="151" height="20" font="4">abnormalities, arrhythmias. </text>
<text top="560" left="901" width="150" height="20" font="4">Mortality overall was 2.1%, </text>
<text top="577" left="901" width="146" height="20" font="4">common procedures were </text>
<text top="595" left="901" width="163" height="20" font="4">RVOT procedures (21%) and </text>
<text top="612" left="901" width="135" height="20" font="4">pacemaker/arrhythmias. </text>
<text top="629" left="901" width="133" height="20" font="4">Fontan revision was the </text>
<text top="646" left="901" width="156" height="20" font="4">highest risk procedure (11% </text>
<text top="664" left="901" width="57" height="20" font="4">mortality). </text>
<text top="716" left="64" width="77" height="20" font="4">Horer J, et al. </text>
<text top="733" left="64" width="56" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(50)</a> </text>
<text top="750" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22491664?dopt=Citation">22491664</a></text>
<text top="750" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22491664?dopt=Citation"> </a></text>
<text top="716" left="172" width="173" height="20" font="4">Systematic review of European </text>
<text top="733" left="172" width="175" height="20" font="4">Association for Cardio-Thoracic </text>
<text top="750" left="172" width="165" height="20" font="4">Surgery Congenital Database </text>
<text top="716" left="368" width="38" height="20" font="4">n=542 </text>
<text top="733" left="368" width="64" height="20" font="4">operations, </text>
<text top="750" left="368" width="24" height="20" font="4">773 </text>
<text top="768" left="368" width="65" height="20" font="4">procedures </text>
<text top="716" left="462" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="733" left="462" width="85" height="20" font="4">CHD pts ≥16 y </text>
<text top="750" left="462" width="123" height="20" font="4">undergoing surgery at </text>
<text top="768" left="462" width="94" height="20" font="4">1 institution from </text>
<text top="785" left="462" width="65" height="20" font="4">2005–2008 </text>
<text top="716" left="604" width="127" height="20" font="4">Morbidity and mortality </text>
<text top="733" left="604" width="58" height="20" font="4">of surgery </text>
<text top="716" left="752" width="132" height="20" font="4">● Mean age 30 y. Early </text>
<text top="733" left="752" width="115" height="20" font="4">mortality 2.4%, early </text>
<text top="750" left="752" width="132" height="20" font="4">complications in 53.7%. </text>
<text top="768" left="752" width="97" height="20" font="4">TVR, mitral valve </text>
<text top="785" left="752" width="124" height="20" font="4">replacement, elevated </text>
<text top="716" left="901" width="132" height="20" font="4">● Mean age 30 y. Early </text>
<text top="733" left="901" width="115" height="20" font="4">mortality 2.4%, early </text>
<text top="750" left="901" width="132" height="20" font="4">complications in 53.7%. </text>
<text top="768" left="901" width="97" height="20" font="4">TVR, mitral valve </text>
<text top="785" left="901" width="151" height="20" font="4">replacement, elevated lung </text>
</page>
<page number="19" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 19 </text>
<text top="107" left="752" width="89" height="20" font="4">lung resistance, </text>
<text top="124" left="752" width="113" height="20" font="4">hypothyroidism, and </text>
<text top="141" left="752" width="92" height="20" font="4">redo sternotomy </text>
<text top="159" left="752" width="125" height="20" font="4">associated with higher </text>
<text top="176" left="752" width="102" height="20" font="4">30-d mortality and </text>
<text top="193" left="752" width="129" height="20" font="4">complications. Aristotle </text>
<text top="210" left="752" width="130" height="20" font="4">score may be helpful in </text>
<text top="227" left="752" width="85" height="20" font="4">risk estimation. </text>
<text top="107" left="901" width="152" height="20" font="4">resistance, hypothyroidism, </text>
<text top="124" left="901" width="116" height="20" font="4">and redo sternotomy </text>
<text top="141" left="901" width="153" height="20" font="4">associated with higher 30-d </text>
<text top="159" left="901" width="155" height="20" font="4">mortality and complications. </text>
<text top="176" left="901" width="125" height="20" font="4">Aristotle score may be </text>
<text top="193" left="901" width="138" height="20" font="4">helpful in risk estimation. </text>
<text top="245" left="64" width="95" height="20" font="4">van Gameren M, </text>
<text top="263" left="64" width="30" height="20" font="4">et al. </text>
<text top="280" left="64" width="56" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(51)</a> </text>
<text top="297" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20846873%5Buid%5D">20846873</a></text>
<text top="297" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20846873%5Buid%5D"> </a></text>
<text top="245" left="172" width="113" height="20" font="4">Single center cohort </text>
<text top="245" left="368" width="58" height="20" font="4">n=963 pts </text>
<text top="245" left="462" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="263" left="462" width="101" height="20" font="4">Adult pts who had </text>
<text top="280" left="462" width="102" height="20" font="4">congenital cardiac </text>
<text top="297" left="462" width="104" height="20" font="4">surgery at a single </text>
<text top="314" left="462" width="105" height="20" font="4">institution between </text>
<text top="332" left="462" width="65" height="20" font="4">1990–2007 </text>
<text top="245" left="604" width="127" height="20" font="4">Morbidity and mortality </text>
<text top="263" left="604" width="58" height="20" font="4">of surgery </text>
<text top="245" left="752" width="132" height="20" font="4">● Applied existing CHD </text>
<text top="263" left="752" width="122" height="20" font="4">surgical risk scores to </text>
<text top="280" left="752" width="122" height="20" font="4">ACHD pts. RACHS-1, </text>
<text top="297" left="752" width="116" height="20" font="4">Basic Aristotle, STS, </text>
<text top="314" left="752" width="123" height="20" font="4">European Association </text>
<text top="332" left="752" width="109" height="20" font="4">for Cardio-Thoracic </text>
<text top="349" left="752" width="74" height="20" font="4">Surgery, and </text>
<text top="366" left="752" width="89" height="20" font="4">Comprehensive </text>
<text top="383" left="752" width="113" height="20" font="4">Aristotle Score were </text>
<text top="401" left="752" width="127" height="20" font="4">calculated, and an age </text>
<text top="418" left="752" width="115" height="20" font="4">component was also </text>
<text top="435" left="752" width="113" height="20" font="4">added to each. Best </text>
<text top="452" left="752" width="133" height="20" font="4">performing risk tool was </text>
<text top="469" left="752" width="89" height="20" font="4">Comprehensive </text>
<text top="487" left="752" width="124" height="20" font="4">Aristotle score with an </text>
<text top="504" left="752" width="95" height="20" font="4">age component.  </text>
<text top="245" left="901" width="132" height="20" font="4">● Applied existing CHD </text>
<text top="263" left="901" width="160" height="20" font="4">surgical risk scores to ACHD </text>
<text top="280" left="901" width="118" height="20" font="4">pts. RACHS-1, Basic </text>
<text top="297" left="901" width="139" height="20" font="4">Aristotle, STS, European </text>
<text top="314" left="901" width="124" height="20" font="4">Association for Cardio-</text>
<text top="332" left="901" width="124" height="20" font="4">Thoracic Surgery, and </text>
<text top="349" left="901" width="137" height="20" font="4">Comprehensive Aristotle </text>
<text top="366" left="901" width="148" height="20" font="4">Score were calculated and </text>
<text top="383" left="901" width="156" height="20" font="4">an age component was also </text>
<text top="401" left="901" width="113" height="20" font="4">added to each. Best </text>
<text top="418" left="901" width="133" height="20" font="4">performing risk tool was </text>
<text top="435" left="901" width="137" height="20" font="4">Comprehensive Aristotle </text>
<text top="452" left="901" width="102" height="20" font="4">Score with an age </text>
<text top="469" left="901" width="71" height="20" font="4">component.  </text>
<text top="522" left="64" width="84" height="20" font="4">Kogon B, et al. </text>
<text top="539" left="64" width="56" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(52)</a> </text>
<text top="556" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24252941?dopt=Citation">24252941</a></text>
<text top="556" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24252941?dopt=Citation"> </a></text>
<text top="522" left="172" width="156" height="20" font="4">Comparison of pediatric risk </text>
<text top="539" left="172" width="161" height="20" font="4">scoring systems in predicting </text>
<text top="556" left="172" width="152" height="20" font="4">outcomes in ACHD surgery </text>
<text top="522" left="368" width="38" height="20" font="4">n=458 </text>
<text top="539" left="368" width="61" height="20" font="4">operations </text>
<text top="522" left="462" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="539" left="462" width="102" height="20" font="4">Adults undergoing </text>
<text top="556" left="462" width="75" height="20" font="4">CHD surgery </text>
<text top="522" left="604" width="108" height="20" font="4">Mortality and major </text>
<text top="539" left="604" width="40" height="20" font="4">events </text>
<text top="522" left="752" width="126" height="20" font="4">● Aristotle, STAT, and </text>
<text top="539" left="752" width="134" height="20" font="4">RACHS-1 are predictive </text>
<text top="556" left="752" width="120" height="20" font="4">of outcomes in adults </text>
<text top="573" left="752" width="95" height="20" font="4">undergoing CHD </text>
<text top="591" left="752" width="110" height="20" font="4">surgery, STAT, and </text>
<text top="608" left="752" width="108" height="20" font="4">Aristotle were most </text>
<text top="625" left="752" width="60" height="20" font="4">predictive. </text>
<text top="522" left="901" width="126" height="20" font="4">● Aristotle, STAT, and </text>
<text top="539" left="901" width="148" height="20" font="4">RACHS-1 are predictive of </text>
<text top="556" left="901" width="154" height="20" font="4">outcomes in pts undergoing </text>
<text top="573" left="901" width="137" height="20" font="4">CHD surgery; STAT and </text>
<text top="591" left="901" width="108" height="20" font="4">Aristotle were most </text>
<text top="608" left="901" width="60" height="20" font="4">predictive. </text>
<text top="643" left="64" width="89" height="20" font="4">Gajjar TP, et al. </text>
<text top="660" left="64" width="56" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(53)</a> </text>
<text top="677" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21793931?dopt=Citation">21793931</a></text>
<text top="677" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21793931?dopt=Citation"> </a></text>
<text top="643" left="172" width="141" height="20" font="4">Single-center case series </text>
<text top="643" left="368" width="51" height="20" font="4">n=48 pts </text>
<text top="643" left="462" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="660" left="462" width="100" height="20" font="4">with sinus venous </text>
<text top="677" left="462" width="115" height="20" font="4">ASD who underwent </text>
<text top="694" left="462" width="94" height="20" font="4">transcaval repair </text>
<text top="712" left="462" width="76" height="20" font="4">between Jan. </text>
<text top="729" left="462" width="96" height="20" font="4">2007―Oct. 2010 </text>
<text top="643" left="604" width="98" height="20" font="4">Surgical outcome </text>
<text top="643" left="752" width="100" height="20" font="4">● All pts came off </text>
<text top="660" left="752" width="132" height="20" font="4">bypass in sinus rhythm. </text>
<text top="677" left="752" width="113" height="20" font="4">● Average pressure </text>
<text top="694" left="752" width="135" height="20" font="4">gradient across patch: 3 </text>
<text top="712" left="752" width="46" height="20" font="4">mm/Hg. </text>
<text top="729" left="752" width="114" height="20" font="4">● Immediate postop </text>
<text top="746" left="752" width="96" height="20" font="4">ECGs and echos </text>
<text top="763" left="752" width="126" height="20" font="4">showed all pts in sinus </text>
<text top="781" left="752" width="130" height="20" font="4">rhythm with no residual </text>
<text top="643" left="901" width="152" height="20" font="4">● Single patch technique is </text>
<text top="660" left="901" width="139" height="20" font="4">safe and simple for sinus </text>
<text top="677" left="901" width="153" height="20" font="4">venous ASD and preserves </text>
<text top="694" left="901" width="158" height="20" font="4">sinoatrial node function after </text>
<text top="712" left="901" width="48" height="20" font="4">surgery. </text>
</page>
<page number="20" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 20 </text>
<text top="107" left="752" width="135" height="20" font="4">shunt and no pulmonary </text>
<text top="124" left="752" width="109" height="20" font="4">or systemic venous </text>
<text top="141" left="752" width="130" height="20" font="4">obstruction, except 1 pt </text>
<text top="159" left="752" width="103" height="20" font="4">who required SVC </text>
<text top="176" left="752" width="81" height="20" font="4">augmentation. </text>
<text top="194" left="108" width="3" height="20" font="4"> </text>
<text top="211" left="108" width="3" height="20" font="4"> </text>
<text top="228" left="108" width="454" height="24" font="1"><b>Data Supplement 6. Ionizing Radiation Principles – Section 3.4.2 </b></text>
<text top="250" left="69" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="267" left="70" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="250" left="171" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="267" left="186" width="44" height="20" font="3"><b>Design </b></text>
<text top="250" left="268" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="250" left="363" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="267" left="399" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="250" left="526" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="250" left="686" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="250" left="888" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="285" left="64" width="82" height="20" font="4">Johnson JN et </text>
<text top="302" left="64" width="16" height="20" font="4">al. </text>
<text top="319" left="64" width="56" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(54)</a> </text>
<text top="336" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24914037?dopt=Citation">24914037</a></text>
<text top="336" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24914037?dopt=Citation"> </a></text>
<text top="285" left="166" width="78" height="20" font="4">Retrospective </text>
<text top="302" left="166" width="39" height="20" font="4">review </text>
<text top="285" left="263" width="58" height="20" font="4">n=337 pts </text>
<text top="285" left="352" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="302" left="352" width="102" height="20" font="4">Children ≤6 y with </text>
<text top="319" left="352" width="90" height="20" font="4">specific surgical </text>
<text top="336" left="352" width="73" height="20" font="4">interventions </text>
<text top="285" left="505" width="65" height="20" font="4">Cumulative </text>
<text top="302" left="505" width="105" height="20" font="4">radiation exposure </text>
<text top="319" left="505" width="66" height="20" font="4">and lifetime </text>
<text top="336" left="505" width="113" height="20" font="4">estimation of cancer </text>
<text top="354" left="505" width="22" height="20" font="4">risk </text>
<text top="285" left="633" width="205" height="20" font="4">● Overall, radiation exposure low but </text>
<text top="302" left="633" width="204" height="20" font="4">most is attributable to catheterization </text>
<text top="319" left="633" width="196" height="20" font="4">and CT. Select cohorts have higher </text>
<text top="336" left="633" width="172" height="20" font="4">exposure and higher estimated </text>
<text top="354" left="633" width="66" height="20" font="4">cancer risk. </text>
<text top="285" left="853" width="202" height="20" font="4">● Some cohorts of CHD children will </text>
<text top="302" left="853" width="179" height="20" font="4">have elevated lifetime estimated </text>
<text top="319" left="853" width="173" height="20" font="4">cancer risk based on childhood </text>
<text top="336" left="853" width="200" height="20" font="4">radiation exposure. Attention should </text>
<text top="354" left="853" width="150" height="20" font="4">be paid to limiting radiation </text>
<text top="371" left="853" width="57" height="20" font="4">exposure. </text>
<text top="389" left="64" width="86" height="20" font="4">Glatz AC, et al. </text>
<text top="406" left="64" width="60" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(55)</a>  </text>
<text top="423" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24321535?dopt=Citation">24321535</a></text>
<text top="423" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24321535?dopt=Citation"> </a></text>
<text top="389" left="166" width="78" height="20" font="4">Retrospective </text>
<text top="406" left="166" width="82" height="20" font="4">data collection </text>
<text top="389" left="263" width="216" height="20" font="4">n=4,132 pts   <b>Inclusion criteria</b>: Pts </text>
<text top="406" left="352" width="134" height="20" font="4">&lt;18 y with CHD surgery </text>
<text top="423" left="352" width="114" height="20" font="4">from 1/1/00–7/31/09 </text>
<text top="389" left="505" width="100" height="20" font="4">Cumulative per pt </text>
<text top="406" left="505" width="105" height="20" font="4">radiation exposure </text>
<text top="423" left="505" width="91" height="20" font="4">total and annual </text>
<text top="389" left="633" width="192" height="20" font="4">● Majority with low exposure; &gt;5% </text>
<text top="406" left="633" width="179" height="20" font="4">with high exposure (&gt;20 mSv/y). </text>
<text top="423" left="633" width="204" height="20" font="4">Higher exposures in neonates, those </text>
<text top="440" left="633" width="173" height="20" font="4">with more complex intracardiac </text>
<text top="458" left="633" width="53" height="20" font="4">disease.  </text>
<text top="389" left="853" width="180" height="20" font="4">● Some children with CHD have </text>
<text top="406" left="853" width="166" height="20" font="4">higher radiation exposure and </text>
<text top="423" left="853" width="161" height="20" font="4">possibly higher cancer risk in </text>
<text top="440" left="853" width="46" height="20" font="4">lifetime. </text>
<text top="476" left="64" width="82" height="20" font="4">Eisenberg MJ, </text>
<text top="493" left="64" width="30" height="20" font="4">et al. </text>
<text top="510" left="64" width="56" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(56)</a> </text>
<text top="527" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21324846?dopt=Citation">21324846</a></text>
<text top="527" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21324846?dopt=Citation"> </a></text>
<text top="476" left="166" width="78" height="20" font="4">Retrospective </text>
<text top="493" left="166" width="85" height="20" font="4">data collection  </text>
<text top="476" left="263" width="216" height="20" font="4">n=82,861 pts   <b>Inclusion criteria</b>: Pts </text>
<text top="493" left="352" width="104" height="20" font="4">with acute MI from </text>
<text top="510" left="352" width="113" height="20" font="4">4/1/1996–3/31/2006 </text>
<text top="527" left="352" width="137" height="20" font="4">identified from Canadian </text>
<text top="544" left="352" width="107" height="20" font="4">administrative data </text>
<text top="476" left="505" width="113" height="20" font="4">Radiation exposure, </text>
<text top="493" left="505" width="100" height="20" font="4">cancer cases and </text>
<text top="510" left="505" width="97" height="20" font="4">estimated cancer </text>
<text top="527" left="505" width="101" height="20" font="4">risk from radiation </text>
<text top="476" left="633" width="205" height="20" font="4">● 3% increased cancer risk for every </text>
<text top="493" left="633" width="103" height="20" font="4">10 mSv exposure. </text>
<text top="476" left="853" width="179" height="20" font="4">● Increasing risk of age and sex </text>
<text top="493" left="853" width="206" height="20" font="4">adjusted cancer rates with increasing </text>
<text top="510" left="853" width="108" height="20" font="4">radiation exposure. </text>
<text top="562" left="64" width="85" height="20" font="4">Yakoumakis E, </text>
<text top="580" left="64" width="30" height="20" font="4">et al. </text>
<text top="597" left="64" width="56" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(57)</a> </text>
<text top="614" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23093098?dopt=Citation">23093098</a></text>
<text top="614" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23093098?dopt=Citation"> </a></text>
<text top="562" left="166" width="67" height="20" font="4">Prospective </text>
<text top="580" left="166" width="82" height="20" font="4">data collection </text>
<text top="597" left="166" width="83" height="20" font="4">and simulation </text>
<text top="614" left="166" width="33" height="20" font="4">study </text>
<text top="562" left="263" width="51" height="20" font="4">n=53 pts </text>
<text top="562" left="352" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="580" left="352" width="123" height="20" font="4">&lt;18 y with ASD, VSD, </text>
<text top="597" left="352" width="118" height="20" font="4">and PDA undergoing </text>
<text top="614" left="352" width="127" height="20" font="4">cardiac catheterization </text>
<text top="562" left="505" width="82" height="20" font="4">Organ specific </text>
<text top="580" left="505" width="107" height="20" font="4">simulated radiation </text>
<text top="597" left="505" width="78" height="20" font="4">exposure and </text>
<text top="614" left="505" width="63" height="20" font="4">cancer risk </text>
<text top="562" left="633" width="199" height="20" font="4">● Increased radiation exposure and </text>
<text top="580" left="633" width="205" height="20" font="4">death risk for each lesion with ASD &gt; </text>
<text top="597" left="633" width="71" height="20" font="4">VSD &gt; PDA. </text>
<text top="562" left="853" width="199" height="20" font="4">● Strategies to implement reduction </text>
<text top="580" left="853" width="202" height="20" font="4">in radiation exposure are necessary. </text>
<text top="632" left="64" width="83" height="20" font="4">Brenner DJ, et </text>
<text top="649" left="64" width="16" height="20" font="4">al. </text>
<text top="667" left="64" width="56" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(58)</a> </text>
<text top="684" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14610281?dopt=Citation">14610281</a></text>
<text top="684" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14610281?dopt=Citation"> </a></text>
<text top="632" left="166" width="121" height="20" font="4">Review article  N/A </text>
<text top="632" left="352" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="632" left="505" width="24" height="20" font="4">N/A </text>
<text top="632" left="633" width="194" height="20" font="4">● Radiation doses where evidence </text>
<text top="649" left="633" width="189" height="20" font="4">suggests increased risk of cancer: </text>
<text top="667" left="633" width="156" height="20" font="4">acute exposure 10–50 mSv; </text>
<text top="684" left="633" width="190" height="20" font="4">prolonged or chronic exposure 50–</text>
<text top="701" left="633" width="55" height="20" font="4">100 mSv. </text>
<text top="632" left="853" width="24" height="20" font="4">N/A </text>
<text top="719" left="64" width="85" height="20" font="4">Andreassi MG, </text>
<text top="736" left="64" width="30" height="20" font="4">et al. </text>
<text top="753" left="64" width="56" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(59)</a> </text>
<text top="771" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16717079?dopt=Citation">16717079</a></text>
<text top="771" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16717079?dopt=Citation"> </a></text>
<text top="719" left="166" width="67" height="20" font="4">Prospective </text>
<text top="736" left="166" width="82" height="20" font="4">data collection </text>
<text top="719" left="263" width="70" height="20" font="4">n=32 cases, </text>
<text top="736" left="263" width="31" height="20" font="4">n=32 </text>
<text top="753" left="263" width="50" height="20" font="4">controls, </text>
<text top="771" left="263" width="31" height="20" font="4">n=10 </text>
<text top="788" left="263" width="57" height="20" font="4">newborns </text>
<text top="719" left="352" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="736" left="352" width="104" height="20" font="4">Cases – CHD with </text>
<text top="753" left="352" width="118" height="20" font="4">exposure to radiation </text>
<text top="771" left="352" width="124" height="20" font="4">testing between 1965–</text>
<text top="788" left="352" width="137" height="20" font="4">2000; Controls – healthy </text>
<text top="719" left="505" width="80" height="20" font="4">Chromosomal </text>
<text top="736" left="505" width="48" height="20" font="4">damage </text>
<text top="719" left="633" width="196" height="20" font="4">● Chromosomal damage greater in </text>
<text top="736" left="633" width="178" height="20" font="4">exposed subjects vs. controls or </text>
<text top="753" left="633" width="57" height="20" font="4">neonates. </text>
<text top="719" left="853" width="146" height="20" font="4">● Evidence of long-lasting </text>
<text top="736" left="853" width="188" height="20" font="4">chromosomal abnormality may be </text>
<text top="753" left="853" width="163" height="20" font="4">related to radiation exposure. </text>
</page>
<page number="21" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 21 </text>
<text top="107" left="352" width="124" height="20" font="4">age and sex matched; </text>
<text top="124" left="352" width="134" height="20" font="4">Neonates – CHD but no </text>
<text top="141" left="352" width="65" height="20" font="4">procedures </text>
<text top="161" left="108" width="3" height="19" font="4"> </text>
<text top="178" left="108" width="3" height="20" font="4"> </text>
<text top="195" left="108" width="381" height="24" font="1"><b>Data Supplement 7. Echocardiography – Section 3.4.3 </b></text>
<text top="216" left="87" width="38" height="20" font="3"><b>Study </b></text>
<text top="234" left="62" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="251" left="91" width="30" height="20" font="3"><b>Year</b> </text>
<text top="216" left="177" width="114" height="20" font="3"><b>Study Type/Design</b> </text>
<text top="216" left="327" width="66" height="20" font="3"><b>Study Size</b> </text>
<text top="216" left="425" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="234" left="461" width="46" height="20" font="3"><b>Criteria</b> </text>
<text top="216" left="579" width="73" height="20" font="3"><b>1° Endpoint</b> </text>
<text top="216" left="727" width="102" height="20" font="3"><b>Results/p Values</b> </text>
<text top="216" left="905" width="137" height="20" font="3"><b>Summary/Conclusions</b> </text>
<text top="269" left="62" width="80" height="20" font="4">Bartel T, et al. </text>
<text top="286" left="62" width="56" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(60)</a> </text>
<text top="303" left="62" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15760685?dopt=Citation">15760685</a></text>
<text top="304" left="117" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15760685?dopt=Citation"> </a></text>
<text top="269" left="163" width="129" height="20" font="4">Randomized controlled </text>
<text top="286" left="163" width="121" height="20" font="4">trial comparing ICE to </text>
<text top="303" left="163" width="140" height="20" font="4">TEE during transcatheter </text>
<text top="320" left="163" width="114" height="20" font="4">closure of ASD/PFO </text>
<text top="269" left="319" width="72" height="20" font="4">n=80 pts (50 </text>
<text top="286" left="319" width="77" height="20" font="4">using ICE, 30 </text>
<text top="303" left="319" width="64" height="20" font="4">using TEE) </text>
<text top="269" left="413" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="286" left="413" width="104" height="20" font="4">undergoing device </text>
<text top="303" left="413" width="125" height="20" font="4">closure of ASD (12) or </text>
<text top="320" left="413" width="54" height="20" font="4">PFO (68) </text>
<text top="269" left="568" width="72" height="20" font="4">Adequacy of </text>
<text top="286" left="568" width="74" height="20" font="4">visualization; </text>
<text top="303" left="568" width="90" height="20" font="4">fluoroscopy and </text>
<text top="320" left="568" width="85" height="20" font="4">procedure time </text>
<text top="269" left="676" width="170" height="20" font="4">● Spatial relationship between </text>
<text top="286" left="676" width="189" height="20" font="4">device and cardiac structures was </text>
<text top="303" left="676" width="182" height="20" font="4">accurately demonstrated by ICE. </text>
<text top="320" left="676" width="185" height="20" font="4">Image resolution provided by ICE </text>
<text top="338" left="676" width="179" height="20" font="4">was superior to that of TEE, and </text>
<text top="355" left="676" width="138" height="20" font="4">fluoroscopy time shorter. </text>
<text top="269" left="892" width="156" height="20" font="4">● ICE is a safe tool to guide </text>
<text top="286" left="892" width="150" height="20" font="4">device closure of interatrial </text>
<text top="303" left="892" width="155" height="20" font="4">communications. For the pt, </text>
<text top="320" left="892" width="122" height="20" font="4">procedural stress and </text>
<text top="338" left="892" width="126" height="20" font="4">radiation exposure are </text>
<text top="355" left="892" width="59" height="20" font="4">negligible. </text>
<text top="373" left="62" width="83" height="20" font="4">Boccalandro F </text>
<text top="390" left="62" width="30" height="20" font="4">et al. </text>
<text top="407" left="62" width="56" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(61)</a> </text>
<text top="424" left="62" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15224315?dopt=Citation">15224315</a></text>
<text top="426" left="117" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15224315?dopt=Citation"> </a></text>
<text top="373" left="163" width="67" height="20" font="4">Prospective </text>
<text top="390" left="163" width="127" height="20" font="4">observational study for </text>
<text top="407" left="163" width="124" height="20" font="4">evaluation of TEE and </text>
<text top="424" left="163" width="119" height="20" font="4">ICE for sizing of ASD </text>
<text top="442" left="163" width="116" height="20" font="4">during percutaneous </text>
<text top="459" left="163" width="94" height="20" font="4">catheter closure, </text>
<text top="476" left="163" width="138" height="20" font="4">compared to quantitative </text>
<text top="493" left="163" width="117" height="20" font="4">fluoroscopic analysis </text>
<text top="373" left="319" width="72" height="20" font="4">n=42 pts (21 </text>
<text top="390" left="319" width="67" height="20" font="4">having TEE </text>
<text top="407" left="319" width="81" height="20" font="4">and 21 having </text>
<text top="424" left="319" width="28" height="20" font="4">ICE) </text>
<text top="374" left="413" width="3" height="19" font="4"> </text>
<text top="373" left="568" width="77" height="20" font="4">Correlation of </text>
<text top="390" left="568" width="79" height="20" font="4">ASD size with </text>
<text top="407" left="568" width="66" height="20" font="4">quantitative </text>
<text top="424" left="568" width="69" height="20" font="4">fluoroscopic </text>
<text top="442" left="568" width="79" height="20" font="4">measurement </text>
<text top="373" left="676" width="177" height="20" font="4">● Correlation between TEE and </text>
<text top="390" left="676" width="186" height="20" font="4">quantitative fluoroscopy (r=0.898; </text>
<text top="407" left="676" width="174" height="20" font="4">p&lt;0.001) and between ICE and </text>
<text top="424" left="676" width="186" height="20" font="4">quantitative fluoroscopy (r=0.876; </text>
<text top="442" left="676" width="149" height="20" font="4">p&lt;0.001), with a significant </text>
<text top="459" left="676" width="122" height="20" font="4">agreement (p&lt;0.001). </text>
<text top="373" left="892" width="161" height="20" font="4">● TEE and ICE are excellent </text>
<text top="390" left="892" width="155" height="20" font="4">methods of interatrial defect </text>
<text top="407" left="892" width="151" height="20" font="4">sizing when compared with </text>
<text top="424" left="892" width="135" height="20" font="4">quantitative fluoroscopic </text>
<text top="442" left="892" width="88" height="20" font="4">measurements. </text>
<text top="511" left="62" width="73" height="20" font="4">Cao Q, et al. </text>
<text top="528" left="62" width="56" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(62)</a> </text>
<text top="546" left="62" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10806019?dopt=Citation">10806019</a></text>
<text top="547" left="117" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10806019?dopt=Citation"> </a></text>
<text top="511" left="163" width="67" height="20" font="4">Prospective </text>
<text top="528" left="163" width="123" height="20" font="4">observational study to </text>
<text top="546" left="163" width="126" height="20" font="4">determine feasibility of </text>
<text top="563" left="163" width="132" height="20" font="4">transcatheter closure of </text>
<text top="580" left="163" width="124" height="20" font="4">multiple ASDs using 2 </text>
<text top="597" left="163" width="104" height="20" font="4">Amplatzer devices </text>
<text top="615" left="163" width="129" height="20" font="4">simultaneously and the </text>
<text top="632" left="163" width="127" height="20" font="4">role of 2D and 3D TEE </text>
<text top="511" left="319" width="51" height="20" font="4">n=22 pts </text>
<text top="511" left="413" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="528" left="413" width="123" height="20" font="4">with more than 1 ASD </text>
<text top="511" left="568" width="63" height="20" font="4">Successful </text>
<text top="528" left="568" width="57" height="20" font="4">closure of </text>
<text top="546" left="568" width="80" height="20" font="4">multiple ASDs </text>
<text top="563" left="568" width="70" height="20" font="4">with devices </text>
<text top="511" left="676" width="189" height="20" font="4">● 2D TEE was helpful in selection </text>
<text top="528" left="676" width="202" height="20" font="4">and in guiding correct deployment of </text>
<text top="546" left="676" width="73" height="20" font="4">the devices.  </text>
<text top="563" left="676" width="157" height="20" font="4">● 3D TEE provided superior </text>
<text top="580" left="676" width="170" height="20" font="4">imaging and demonstrated the </text>
<text top="597" left="676" width="202" height="20" font="4">number, shape, and the surrounding </text>
<text top="615" left="676" width="179" height="20" font="4">structures of the ASD in 1 single </text>
<text top="632" left="676" width="182" height="20" font="4">view. Closure successful in 98%. </text>
<text top="511" left="892" width="152" height="20" font="4">● 2D and 3D TEE provided </text>
<text top="528" left="892" width="118" height="20" font="4">useful information for </text>
<text top="546" left="892" width="132" height="20" font="4">transcatheter closure of </text>
<text top="563" left="892" width="124" height="20" font="4">multiple ASDs using 2 </text>
<text top="580" left="892" width="52" height="20" font="4">devices.  </text>
<text top="597" left="892" width="151" height="20" font="4">● 3D TEE enhanced ability </text>
<text top="614" left="892" width="160" height="20" font="4">to image and understand the </text>
<text top="632" left="892" width="139" height="20" font="4">spatial relationship of the </text>
<text top="649" left="892" width="83" height="20" font="4">ASD anatomy. </text>
<text top="667" left="62" width="87" height="20" font="4">Chien JC, et al. </text>
<text top="684" left="62" width="56" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(63)</a> </text>
<text top="701" left="62" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18772119?dopt=Citation">18772119</a></text>
<text top="703" left="117" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18772119?dopt=Citation"> </a></text>
<text top="667" left="163" width="67" height="20" font="4">Prospective </text>
<text top="684" left="163" width="123" height="20" font="4">observational study to </text>
<text top="701" left="163" width="136" height="20" font="4">determine feasibility and </text>
<text top="719" left="163" width="108" height="20" font="4">accuracy of ICE for </text>
<text top="736" left="163" width="128" height="20" font="4">sizing ASDs compared </text>
<text top="753" left="163" width="98" height="20" font="4">with conventional </text>
<text top="770" left="163" width="51" height="20" font="4">methods </text>
<text top="667" left="319" width="58" height="20" font="4">n=270 pts </text>
<text top="684" left="319" width="52" height="20" font="4">(142 had </text>
<text top="701" left="319" width="78" height="20" font="4">TEE, 128 had </text>
<text top="719" left="319" width="28" height="20" font="4">ICE) </text>
<text top="667" left="413" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="684" left="413" width="127" height="20" font="4">going for transcatheter </text>
<text top="701" left="413" width="117" height="20" font="4">closure of secundum </text>
<text top="719" left="413" width="90" height="20" font="4">ASD with septal </text>
<text top="736" left="413" width="56" height="20" font="4">occluders </text>
<text top="667" left="568" width="83" height="20" font="4">Comparison of </text>
<text top="684" left="568" width="72" height="20" font="4">ASD balloon </text>
<text top="701" left="568" width="79" height="20" font="4">stretched size </text>
<text top="719" left="568" width="67" height="20" font="4">using sizing </text>
<text top="736" left="568" width="80" height="20" font="4">plate with size </text>
<text top="753" left="568" width="81" height="20" font="4">determined by </text>
<text top="770" left="568" width="85" height="20" font="4">ICE, TEE, TTE </text>
<text top="787" left="568" width="95" height="20" font="4">and angiography </text>
<text top="667" left="676" width="203" height="20" font="4">● ASD diameters measured with the </text>
<text top="684" left="676" width="162" height="20" font="4">sizing plate were significantly </text>
<text top="701" left="676" width="200" height="20" font="4">correlated with those measured with </text>
<text top="719" left="676" width="165" height="20" font="4">ICE (r=0.963), TEE (r=0.912), </text>
<text top="736" left="676" width="172" height="20" font="4">angiography (r=0.88), and TTE </text>
<text top="753" left="676" width="183" height="20" font="4">(r=0.85). The predicted stretched </text>
<text top="770" left="676" width="148" height="20" font="4">diameter of the ASDs (i.e., </text>
<text top="787" left="676" width="184" height="20" font="4">nonstretched diameter measured </text>
<text top="667" left="892" width="157" height="20" font="4">● ASD diameters measured </text>
<text top="684" left="892" width="132" height="20" font="4">with ICE correlated with </text>
<text top="701" left="892" width="150" height="20" font="4">sizing-plate measurements </text>
<text top="719" left="892" width="161" height="20" font="4">better than those determined </text>
<text top="736" left="892" width="145" height="20" font="4">with TEE, angiography, or </text>
<text top="753" left="892" width="30" height="20" font="4">TTE. </text>
</page>
<page number="22" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 22 </text>
<text top="107" left="676" width="169" height="20" font="4">with ICE null 1.07) + 3.23 mm) </text>
<text top="124" left="676" width="190" height="20" font="4">agreed well with that measured by </text>
<text top="141" left="676" width="165" height="20" font="4">using a sizing plate (r=0.974). </text>
<text top="159" left="62" width="76" height="20" font="4">Mullen MJ, et </text>
<text top="177" left="62" width="16" height="20" font="4">al. </text>
<text top="194" left="62" width="56" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(64)</a> </text>
<text top="211" left="62" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12535824?dopt=Citation">12535824</a></text>
<text top="212" left="117" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12535824?dopt=Citation"> </a></text>
<text top="159" left="163" width="67" height="20" font="4">Prospective </text>
<text top="177" left="163" width="123" height="20" font="4">observational study to </text>
<text top="194" left="163" width="112" height="20" font="4">determine feasibility </text>
<text top="211" left="163" width="127" height="20" font="4">study of ICE for device </text>
<text top="228" left="163" width="85" height="20" font="4">closure of ASD </text>
<text top="159" left="319" width="54" height="20" font="4">n=24 pts  </text>
<text top="159" left="413" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="177" left="413" width="104" height="20" font="4">undergoing device </text>
<text top="194" left="413" width="135" height="20" font="4">closure of ASD who had </text>
<text top="211" left="413" width="75" height="20" font="4">ICE and TEE </text>
<text top="159" left="568" width="86" height="20" font="4">Success in use </text>
<text top="177" left="568" width="85" height="20" font="4">of ICE to guide </text>
<text top="194" left="568" width="82" height="20" font="4">device closure </text>
<text top="211" left="568" width="42" height="20" font="4">of ASD </text>
<text top="159" left="676" width="190" height="20" font="4">● ICE successfully guided closure </text>
<text top="177" left="676" width="183" height="20" font="4">of 24 out of 25 ASDs (96%) in 23 </text>
<text top="194" left="676" width="27" height="20" font="4">pts.  </text>
<text top="211" left="676" width="168" height="20" font="4">● There was close agreement </text>
<text top="228" left="676" width="165" height="20" font="4">between ICE and TEE in their </text>
<text top="246" left="676" width="192" height="20" font="4">assessment of device position and </text>
<text top="263" left="676" width="172" height="20" font="4">the adequacy of septal capture </text>
<text top="280" left="676" width="194" height="20" font="4">before device release (98%) and in </text>
<text top="297" left="676" width="147" height="20" font="4">identifying the presence of </text>
<text top="314" left="676" width="172" height="20" font="4">significant residual shunts. ICE </text>
<text top="332" left="676" width="145" height="20" font="4">detected all potentially AE </text>
<text top="159" left="892" width="157" height="20" font="4">● ICE may be used to guide </text>
<text top="177" left="892" width="145" height="20" font="4">routine closure of ASDs in </text>
<text top="194" left="892" width="148" height="20" font="4">adults without the need for </text>
<text top="211" left="892" width="162" height="20" font="4">TEE and general anesthesia. </text>
<text top="350" left="62" width="80" height="20" font="4">Ewert P, et al. </text>
<text top="367" left="62" width="56" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(65)</a> </text>
<text top="384" left="62" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10694522?dopt=Citation">10694522</a></text>
<text top="385" left="117" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10694522?dopt=Citation"> </a></text>
<text top="350" left="163" width="134" height="20" font="4">Case series: description </text>
<text top="367" left="163" width="88" height="20" font="4">of technique for </text>
<text top="384" left="163" width="132" height="20" font="4">transcatheter closure of </text>
<text top="401" left="163" width="97" height="20" font="4">ASDs under TEE </text>
<text top="418" left="163" width="96" height="20" font="4">guidance without </text>
<text top="436" left="163" width="66" height="20" font="4">fluoroscopy </text>
<text top="350" left="319" width="69" height="20" font="4">n=22 pts for </text>
<text top="367" left="319" width="72" height="20" font="4">ASD or PFO </text>
<text top="384" left="319" width="76" height="20" font="4">closure using </text>
<text top="401" left="319" width="51" height="20" font="4">TEE and </text>
<text top="418" left="319" width="75" height="20" font="4">control group </text>
<text top="436" left="319" width="57" height="20" font="4">of 131 pts </text>
<text top="453" left="319" width="50" height="20" font="4">who had </text>
<text top="470" left="319" width="76" height="20" font="4">closure using </text>
<text top="487" left="319" width="72" height="20" font="4">conventional </text>
<text top="504" left="319" width="66" height="20" font="4">fluoroscopy </text>
<text top="351" left="413" width="3" height="19" font="4"> </text>
<text top="350" left="568" width="63" height="20" font="4">Procedural </text>
<text top="367" left="568" width="48" height="20" font="4">success </text>
<text top="350" left="676" width="176" height="20" font="4">● In the study group, Amplatzer </text>
<text top="367" left="676" width="181" height="20" font="4">septal occluder was successfully </text>
<text top="384" left="676" width="172" height="20" font="4">implanted in 19 defects without </text>
<text top="401" left="676" width="163" height="20" font="4">fluoroscopy with documented </text>
<text top="418" left="676" width="169" height="20" font="4">complete defect closure in all.  </text>
<text top="436" left="676" width="199" height="20" font="4">● Similar procedure times to control </text>
<text top="453" left="676" width="38" height="20" font="4">group. </text>
<text top="350" left="892" width="149" height="20" font="4">● Transcatheter closure of </text>
<text top="367" left="892" width="146" height="20" font="4">interatrial communications </text>
<text top="384" left="892" width="141" height="20" font="4">with the Amplatzer septal </text>
<text top="401" left="892" width="150" height="20" font="4">occluder can be safely and </text>
<text top="418" left="892" width="129" height="20" font="4">successfully performed </text>
<text top="436" left="892" width="139" height="20" font="4">under echocardiographic </text>
<text top="453" left="892" width="96" height="20" font="4">guidance without </text>
<text top="470" left="892" width="70" height="20" font="4">fluoroscopy. </text>
<text top="522" left="62" width="85" height="20" font="4">Grewal J, et al. </text>
<text top="540" left="62" width="56" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(66)</a> </text>
<text top="557" left="62" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19962272?dopt=Citation">19962272</a></text>
<text top="558" left="117" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19962272?dopt=Citation"> </a></text>
<text top="522" left="163" width="67" height="20" font="4">Prospective </text>
<text top="540" left="163" width="123" height="20" font="4">observational study to </text>
<text top="557" left="163" width="124" height="20" font="4">compare 3D echo and </text>
<text top="574" left="163" width="82" height="20" font="4">cardiac MRI in </text>
<text top="591" left="163" width="103" height="20" font="4">assessment of RV </text>
<text top="522" left="319" width="51" height="20" font="4">n=25 pts </text>
<text top="522" left="413" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="540" left="413" width="124" height="20" font="4">ACHD pts with severe </text>
<text top="557" left="413" width="135" height="20" font="4">PR following TOF repair </text>
<text top="574" left="413" width="134" height="20" font="4">or pulmonary valvotomy </text>
<text top="522" left="568" width="89" height="20" font="4">RVEF, RVEDV, </text>
<text top="540" left="568" width="45" height="20" font="4">RVESV </text>
<text top="522" left="676" width="203" height="20" font="4">● Mean RV EF were 42 ± 8% on 3D </text>
<text top="540" left="676" width="178" height="20" font="4">ultrasound and 44 ± 7% on MRI </text>
<text top="557" left="676" width="192" height="20" font="4">(r=0.89; p&lt;0.0001). The mean end-</text>
<text top="574" left="676" width="180" height="20" font="4">diastolic volumes were 249 ± 66 </text>
<text top="591" left="676" width="176" height="20" font="4">and 274 ± 82 mL and the mean </text>
<text top="608" left="676" width="194" height="20" font="4">end-systolic volumes 147 ± 50 and </text>
<text top="626" left="676" width="194" height="20" font="4">159 ± 60 mL on 3D ultrasound and </text>
<text top="643" left="676" width="105" height="20" font="4">MRI, respectively.  </text>
<text top="660" left="676" width="165" height="20" font="4">● Similarly, there were strong </text>
<text top="677" left="676" width="180" height="20" font="4">correlations of both end-diastolic </text>
<text top="694" left="676" width="196" height="20" font="4">volume and end-systolic volume on </text>
<text top="712" left="676" width="197" height="20" font="4">3D ultrasound and MRI (r=0.88 and </text>
<text top="729" left="676" width="118" height="20" font="4">r=0.89, respectively). </text>
<text top="522" left="892" width="118" height="20" font="4">● 3D ultrasound was </text>
<text top="540" left="892" width="132" height="20" font="4">comparable with MRI in </text>
<text top="557" left="892" width="137" height="20" font="4">determining RV size and </text>
<text top="574" left="892" width="154" height="20" font="4">function in pts with complex </text>
<text top="591" left="892" width="37" height="20" font="4">CHD.  </text>
<text top="747" left="62" width="87" height="20" font="4">Van der Zwaan </text>
<text top="764" left="62" width="54" height="20" font="4">HB, et al. </text>
<text top="781" left="62" width="56" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(67)</a> </text>
<text top="747" left="163" width="67" height="20" font="4">Prospective </text>
<text top="764" left="163" width="123" height="20" font="4">observational study to </text>
<text top="781" left="163" width="124" height="20" font="4">compare 3D echo and </text>
<text top="747" left="319" width="54" height="20" font="4">n=62 pts  </text>
<text top="747" left="413" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="764" left="413" width="119" height="20" font="4">Various sorts of CHD </text>
<text top="747" left="568" width="89" height="20" font="4">RVEF, RVEDV, </text>
<text top="764" left="568" width="45" height="20" font="4">RVESV </text>
<text top="747" left="676" width="177" height="20" font="4">● Compared with CMR, RT3DE </text>
<text top="764" left="676" width="180" height="20" font="4">imaging underestimated RV end-</text>
<text top="781" left="676" width="189" height="20" font="4">diastolic and end-systolic volumes </text>
<text top="747" left="892" width="107" height="20" font="4">● In the majority of </text>
<text top="764" left="892" width="157" height="20" font="4">unselected pts with complex </text>
<text top="781" left="892" width="124" height="20" font="4">CHD, RT3DE imaging </text>
</page>
<page number="23" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 23 </text>
<text top="107" left="62" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20152693?dopt=Citation">20152693</a></text>
<text top="108" left="117" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20152693?dopt=Citation"> </a></text>
<text top="107" left="163" width="82" height="20" font="4">cardiac MRI in </text>
<text top="124" left="163" width="103" height="20" font="4">assessment of RV </text>
<text top="107" left="676" width="165" height="20" font="4">and EF, with highly significant </text>
<text top="124" left="676" width="179" height="20" font="4">correlations (r=0.93, r=0.91, and </text>
<text top="141" left="676" width="170" height="20" font="4">r=0.74, respectively; p&lt;0.001). </text>
<text top="159" left="676" width="156" height="20" font="4">Interobserver variability was </text>
<text top="176" left="676" width="68" height="20" font="4">reasonable. </text>
<text top="107" left="892" width="107" height="20" font="4">provides a fast and </text>
<text top="124" left="892" width="154" height="20" font="4">reproducible assessment of </text>
<text top="141" left="892" width="158" height="20" font="4">RV volumes and EF with fair </text>
<text top="159" left="892" width="155" height="20" font="4">to good accuracy compared </text>
<text top="176" left="892" width="143" height="20" font="4">with CMR reference data. </text>
<text top="194" left="62" width="77" height="20" font="4">Kaku K, et al. </text>
<text top="211" left="62" width="56" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(68)</a> </text>
<text top="228" left="62" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27278380">27278380</a></text>
<text top="229" left="117" width="3" height="19" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27278380"> </a></text>
<text top="194" left="163" width="67" height="20" font="4">Prospective </text>
<text top="211" left="163" width="123" height="20" font="4">observational study to </text>
<text top="228" left="163" width="141" height="20" font="4">compare characterization </text>
<text top="246" left="163" width="108" height="20" font="4">of ASD by 3D echo </text>
<text top="263" left="163" width="121" height="20" font="4">compared to 2D echo </text>
<text top="194" left="319" width="54" height="20" font="4">n=17 pts  </text>
<text top="194" left="413" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="211" left="413" width="87" height="20" font="4">with ASD being </text>
<text top="228" left="413" width="112" height="20" font="4">assessed for device </text>
<text top="246" left="413" width="43" height="20" font="4">closure </text>
<text top="194" left="568" width="64" height="20" font="4">Descriptive </text>
<text top="211" left="568" width="49" height="20" font="4">report of </text>
<text top="228" left="568" width="76" height="20" font="4">usefulness of </text>
<text top="246" left="568" width="44" height="20" font="4">RT3DE </text>
<text top="194" left="676" width="160" height="20" font="4">● Real-time 3D TEE allowed </text>
<text top="211" left="676" width="183" height="20" font="4">delineation of the en-face view of </text>
<text top="228" left="676" width="198" height="20" font="4">the ASDs. Successful delineation of </text>
<text top="246" left="676" width="179" height="20" font="4">rim length to the specific cardiac </text>
<text top="263" left="676" width="198" height="20" font="4">structure was 100% by 3D TEE and </text>
<text top="280" left="676" width="91" height="20" font="4">88% by 2D TEE </text>
<text top="194" left="892" width="152" height="20" font="4">● Real-time 3D TEE allows </text>
<text top="211" left="892" width="119" height="20" font="4">measurements of the </text>
<text top="228" left="892" width="114" height="20" font="4">temporal and spatial </text>
<text top="246" left="892" width="141" height="20" font="4">changes of ASD size and </text>
<text top="263" left="892" width="141" height="20" font="4">shape. This methodology </text>
<text top="280" left="892" width="161" height="20" font="4">provides detailed information </text>
<text top="297" left="892" width="113" height="20" font="4">on defect dynamics. </text>
<text top="315" left="62" width="76" height="20" font="4">Lodato JA, et </text>
<text top="332" left="62" width="16" height="20" font="4">al. </text>
<text top="350" left="62" width="56" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(69)</a> </text>
<text top="367" left="62" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19179363?dopt=Citation">19179363</a></text>
<text top="368" left="117" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19179363?dopt=Citation"> </a></text>
<text top="315" left="163" width="67" height="20" font="4">Prospective </text>
<text top="332" left="163" width="123" height="20" font="4">observational study to </text>
<text top="350" left="163" width="121" height="20" font="4">compare real time 3D </text>
<text top="367" left="163" width="111" height="20" font="4">echo vs. ICE during </text>
<text top="384" left="163" width="132" height="20" font="4">transcatheter closure of </text>
<text top="401" left="163" width="29" height="20" font="4">ASD </text>
<text top="315" left="319" width="54" height="20" font="4">n=13 pts  </text>
<text top="315" left="413" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="332" left="413" width="140" height="20" font="4">undergoing transcatheter </text>
<text top="350" left="413" width="85" height="20" font="4">closure of ASD </text>
<text top="315" left="568" width="83" height="20" font="4">Comparison of </text>
<text top="332" left="568" width="82" height="20" font="4">imaging with 3 </text>
<text top="350" left="568" width="59" height="20" font="4">modalities </text>
<text top="315" left="676" width="159" height="20" font="4">● Real-time 3D imaging was </text>
<text top="332" left="676" width="198" height="20" font="4">feasible in all pts with similar results </text>
<text top="350" left="676" width="158" height="20" font="4">but larger balloon dimension </text>
<text top="367" left="676" width="82" height="20" font="4">measurement. </text>
<text top="315" left="892" width="159" height="20" font="4">● RT3D TEE can be used to </text>
<text top="332" left="892" width="137" height="20" font="4">guide transcatheter ASD </text>
<text top="350" left="892" width="156" height="20" font="4">closure with the advantages </text>
<text top="367" left="892" width="151" height="20" font="4">of lower cost than ICE, and </text>
<text top="384" left="892" width="143" height="20" font="4">ability to visualize en-face </text>
<text top="401" left="892" width="100" height="20" font="4">views of the ASD. </text>
<text top="419" left="62" width="88" height="20" font="4">Mojadidi MK, et </text>
<text top="436" left="62" width="16" height="20" font="4">al. </text>
<text top="454" left="62" width="56" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(70)</a> </text>
<text top="471" left="62" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24740212?dopt=Citation">24740212</a></text>
<text top="472" left="117" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24740212?dopt=Citation"> </a></text>
<text top="419" left="163" width="93" height="20" font="4">Meta-analysis of </text>
<text top="436" left="163" width="109" height="20" font="4">prospective studies </text>
<text top="454" left="163" width="120" height="20" font="4">comparing TTE with 2</text>
<text top="455" left="283" width="9" height="13" font="6">nd</text>
<text top="454" left="292" width="3" height="20" font="4"> </text>
<text top="471" left="163" width="124" height="20" font="4">harmonic imaging and </text>
<text top="488" left="163" width="134" height="20" font="4">TEE for the diagnosis of </text>
<text top="505" left="163" width="129" height="20" font="4">intracardiac left-to-right </text>
<text top="522" left="163" width="33" height="20" font="4">shunt </text>
<text top="419" left="319" width="68" height="20" font="4">n=1,995 pts </text>
<text top="419" left="413" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="436" left="413" width="110" height="20" font="4">Prospective studies </text>
<text top="454" left="413" width="76" height="20" font="4">assessing for </text>
<text top="471" left="413" width="129" height="20" font="4">intracardiac right-to-left </text>
<text top="488" left="413" width="124" height="20" font="4">shunts using TTE with </text>
<text top="505" left="413" width="97" height="20" font="4">second harmonic </text>
<text top="522" left="413" width="118" height="20" font="4">imaging compared to </text>
<text top="540" left="413" width="123" height="20" font="4">TEE as the reference; </text>
<text top="557" left="413" width="122" height="20" font="4">both TTE with second </text>
<text top="574" left="413" width="124" height="20" font="4">harmonic imaging and </text>
<text top="591" left="413" width="142" height="20" font="4">TEE were performed with </text>
<text top="608" left="413" width="126" height="20" font="4">a contrast agent and a </text>
<text top="626" left="413" width="119" height="20" font="4">maneuver to provoke </text>
<text top="643" left="413" width="141" height="20" font="4">right-to-left shunting in all </text>
<text top="660" left="413" width="42" height="20" font="4">studies </text>
<text top="419" left="568" width="69" height="20" font="4">Detection of </text>
<text top="436" left="568" width="62" height="20" font="4">right-to-left </text>
<text top="454" left="568" width="33" height="20" font="4">shunt </text>
<text top="419" left="676" width="183" height="20" font="4">● Weighted mean sensitivity and </text>
<text top="436" left="676" width="169" height="20" font="4">specificity for TTE with second </text>
<text top="454" left="676" width="201" height="20" font="4">harmonic imaging were 90.5% (95% </text>
<text top="471" left="676" width="195" height="20" font="4">CI: 88.1–92.6) and 92.6% (95% CI: </text>
<text top="488" left="676" width="198" height="20" font="4">91.0–94.0) respectively. The overall </text>
<text top="505" left="676" width="187" height="20" font="4">positive likelihood ratio was 13.52 </text>
<text top="522" left="676" width="165" height="20" font="4">(95% CI: 6.99–26.12) and the </text>
<text top="540" left="676" width="197" height="20" font="4">overall negative likelihood ratio was </text>
<text top="557" left="676" width="144" height="20" font="4">0.13 (95% CI: 0.07–0.24.) </text>
<text top="419" left="892" width="161" height="20" font="4">● TTE with second harmonic </text>
<text top="436" left="892" width="115" height="20" font="4">imaging is a reliable, </text>
<text top="454" left="892" width="128" height="20" font="4">noninvasive alternative </text>
<text top="471" left="892" width="149" height="20" font="4">diagnostic modality to TEE </text>
<text top="488" left="892" width="158" height="20" font="4">which is highly sensitive and </text>
<text top="505" left="892" width="158" height="20" font="4">specific for detecting right-to-</text>
<text top="522" left="892" width="57" height="20" font="4">left shunt. </text>
<text top="678" left="62" width="81" height="20" font="4">Randolph GR, </text>
<text top="695" left="62" width="30" height="20" font="4">et al. </text>
<text top="712" left="62" width="56" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(71)</a> </text>
<text top="730" left="62" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12447184?dopt=Citation">12447184</a></text>
<text top="731" left="117" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12447184?dopt=Citation"> </a></text>
<text top="678" left="163" width="68" height="20" font="4">Case series </text>
<text top="678" left="319" width="71" height="20" font="4">n=1,002 pts  </text>
<text top="678" left="413" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="695" left="413" width="125" height="20" font="4">Pediatric and adult pts </text>
<text top="712" left="413" width="115" height="20" font="4">who had TEE during </text>
<text top="730" left="413" width="122" height="20" font="4">surgery for congenital </text>
<text top="747" left="413" width="74" height="20" font="4">heart defects </text>
<text top="678" left="568" width="54" height="20" font="4">Impact of </text>
<text top="695" left="568" width="78" height="20" font="4">intraoperative </text>
<text top="712" left="568" width="85" height="20" font="4">TEE on pt care </text>
<text top="730" left="568" width="78" height="20" font="4">(major impact </text>
<text top="747" left="568" width="84" height="20" font="4">was when new </text>
<text top="764" left="568" width="64" height="20" font="4">information </text>
<text top="781" left="568" width="62" height="20" font="4">altered the </text>
<text top="678" left="676" width="198" height="20" font="4">● TEE had major impact prebypass </text>
<text top="695" left="676" width="180" height="20" font="4">or postbypass in 13.8% of cases </text>
<text top="712" left="676" width="190" height="20" font="4">(n=138/1002). Routine use of TEE </text>
<text top="730" left="676" width="169" height="20" font="4">for all pts with congenital heart </text>
<text top="747" left="676" width="163" height="20" font="4">defects proved cost-effective. </text>
<text top="678" left="892" width="160" height="20" font="4">● Routine use of TEE during </text>
<text top="695" left="892" width="152" height="20" font="4">most intracardiac repairs of </text>
<text top="712" left="892" width="146" height="20" font="4">congenital heart defects is </text>
<text top="730" left="892" width="149" height="20" font="4">justified, particularly for pts </text>
<text top="747" left="892" width="103" height="20" font="4">undergoing repeat </text>
<text top="764" left="892" width="68" height="20" font="4">operations.  </text>
</page>
<page number="24" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 24 </text>
<text top="107" left="568" width="47" height="20" font="4">planned </text>
<text top="124" left="568" width="93" height="20" font="4">procedure or led </text>
<text top="141" left="568" width="83" height="20" font="4">to a revision of </text>
<text top="159" left="568" width="91" height="20" font="4">the initial repair) </text>
<text top="177" left="62" width="77" height="20" font="4">Rigatelli G, et </text>
<text top="194" left="62" width="16" height="20" font="4">al. </text>
<text top="211" left="62" width="56" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(72)</a> </text>
<text top="228" left="62" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16821119?dopt=Citation">16821119</a></text>
<text top="229" left="117" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16821119?dopt=Citation"> </a></text>
<text top="177" left="163" width="67" height="20" font="4">Prospective </text>
<text top="194" left="163" width="123" height="20" font="4">observational study to </text>
<text top="211" left="163" width="102" height="20" font="4">measure radiation </text>
<text top="228" left="163" width="141" height="20" font="4">exposure as a function of </text>
<text top="246" left="163" width="61" height="20" font="4">use of ICE </text>
<text top="177" left="319" width="72" height="20" font="4">n=25 pts (15 </text>
<text top="194" left="319" width="49" height="20" font="4">with ICE </text>
<text top="211" left="319" width="77" height="20" font="4">guidance and </text>
<text top="228" left="319" width="63" height="20" font="4">10 without) </text>
<text top="177" left="413" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="194" left="413" width="140" height="20" font="4">undergoing transcatheter </text>
<text top="211" left="413" width="111" height="20" font="4">closure of interatrial </text>
<text top="228" left="413" width="92" height="20" font="4">communications </text>
<text top="177" left="568" width="46" height="20" font="4">Multiple </text>
<text top="194" left="568" width="71" height="20" font="4">measures of </text>
<text top="211" left="568" width="51" height="20" font="4">radiation </text>
<text top="228" left="568" width="54" height="20" font="4">exposure </text>
<text top="177" left="676" width="198" height="20" font="4">● In pts who underwent ICE-guided </text>
<text top="194" left="676" width="177" height="20" font="4">transcatheter closure procedure </text>
<text top="211" left="676" width="167" height="20" font="4">multiple measures of radiation </text>
<text top="228" left="676" width="184" height="20" font="4">exposure were significantly lower </text>
<text top="246" left="676" width="179" height="20" font="4">than in control pts, but the mean </text>
<text top="263" left="676" width="184" height="20" font="4">procedural time, was significantly </text>
<text top="280" left="676" width="41" height="20" font="4">higher  </text>
<text top="177" left="892" width="159" height="20" font="4">● Radiation exposure during </text>
<text top="194" left="892" width="140" height="20" font="4">ICE-guided transcatheter </text>
<text top="211" left="892" width="111" height="20" font="4">closure of interatrial </text>
<text top="228" left="892" width="150" height="20" font="4">communications was lower </text>
<text top="246" left="892" width="146" height="20" font="4">than radiation exposure of </text>
<text top="263" left="892" width="156" height="20" font="4">pts in whom the intervention </text>
<text top="280" left="892" width="151" height="20" font="4">was performed without ICE </text>
<text top="297" left="892" width="57" height="20" font="4">guidance. </text>
<text top="315" left="62" width="77" height="20" font="4">Rigatelli G, et </text>
<text top="332" left="62" width="16" height="20" font="4">al. </text>
<text top="350" left="62" width="56" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(73)</a> </text>
<text top="367" left="62" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22010972?dopt=Citation">22010972</a></text>
<text top="368" left="117" width="3" height="19" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22010972?dopt=Citation"> </a></text>
<text top="315" left="163" width="67" height="20" font="4">Prospective </text>
<text top="332" left="163" width="113" height="20" font="4">observational study, </text>
<text top="350" left="163" width="63" height="20" font="4">multicenter </text>
<text top="315" left="319" width="54" height="20" font="4">n=56 pts  </text>
<text top="315" left="413" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="332" left="413" width="117" height="20" font="4">Referred for catheter </text>
<text top="350" left="413" width="94" height="20" font="4">based closure of </text>
<text top="367" left="413" width="138" height="20" font="4">complex secundum ASD </text>
<text top="315" left="568" width="63" height="20" font="4">Procedural </text>
<text top="332" left="568" width="48" height="20" font="4">success </text>
<text top="315" left="676" width="183" height="20" font="4">16 pts excluded by preprocedure </text>
<text top="332" left="676" width="34" height="20" font="4">TEE.  </text>
<text top="350" left="676" width="175" height="20" font="4">● 40 pts underwent ICE-guided </text>
<text top="367" left="676" width="180" height="20" font="4">attempt at closure. TEE-planned </text>
<text top="384" left="676" width="181" height="20" font="4">device and size were modified in </text>
<text top="401" left="676" width="198" height="20" font="4">32/40 pts based on ICE. Procedural </text>
<text top="418" left="676" width="161" height="20" font="4">success 100%; predischarge </text>
<text top="436" left="676" width="194" height="20" font="4">complete elimination of shunt 90%. </text>
<text top="315" left="892" width="127" height="20" font="4">● ICE-guided complex </text>
<text top="332" left="892" width="89" height="20" font="4">secundum ASD </text>
<text top="350" left="892" width="157" height="20" font="4">transcatheter closure is safe </text>
<text top="367" left="892" width="159" height="20" font="4">and effective and appears to </text>
<text top="384" left="892" width="137" height="20" font="4">have excellent long-term </text>
<text top="401" left="892" width="43" height="20" font="4">results. </text>
<text top="455" left="108" width="3" height="19" font="4"> </text>
<text top="474" left="108" width="3" height="19" font="4"> </text>
<text top="490" left="54" width="3" height="20" font="4"> </text>
<text top="507" left="108" width="346" height="24" font="1"><b>Data Supplement 8. CMR Imaging – Section 3.4.4 </b></text>
<text top="529" left="92" width="38" height="20" font="3"><b>Study </b></text>
<text top="546" left="67" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="563" left="96" width="30" height="20" font="3"><b>Year </b></text>
<text top="529" left="181" width="118" height="20" font="3"><b>Study Type/ Design </b></text>
<text top="529" left="336" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="529" left="433" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="546" left="469" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="529" left="578" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="529" left="716" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="529" left="905" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="581" left="64" width="79" height="20" font="4">Arheden H, et </text>
<text top="598" left="64" width="16" height="20" font="4">al. </text>
<text top="616" left="64" width="56" height="20" font="4">1999 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(74)</a> </text>
<text top="633" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10228528?dopt=Citation">10228528</a></text>
<text top="633" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10228528?dopt=Citation"> </a></text>
<text top="581" left="170" width="106" height="20" font="4">Comparison of MR </text>
<text top="598" left="170" width="119" height="20" font="4">velocity mapping and </text>
<text top="616" left="170" width="70" height="20" font="4">radionuclide </text>
<text top="633" left="170" width="122" height="20" font="4">angiography done the </text>
<text top="650" left="170" width="130" height="20" font="4">same. Validation of MR </text>
<text top="667" left="170" width="118" height="20" font="4">velocity mapping in a </text>
<text top="684" left="170" width="122" height="20" font="4">phantom and controls </text>
<text top="581" left="323" width="85" height="20" font="4">n=24 pts; n=12 </text>
<text top="598" left="323" width="46" height="20" font="4">controls </text>
<text top="581" left="429" width="122" height="20" font="3"><b>Inclusion criteria</b>: 16 </text>
<text top="598" left="429" width="105" height="20" font="4">adults (20–68 y), 2 </text>
<text top="616" left="429" width="114" height="20" font="4">adolescents (13 and </text>
<text top="633" left="429" width="115" height="20" font="4">17 y), and 6 children </text>
<text top="650" left="429" width="52" height="20" font="4">(2–12 y). </text>
<text top="667" left="429" width="3" height="20" font="4"> </text>
<text top="684" left="429" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="702" left="429" width="96" height="20" font="4">Nonsinus rhythm </text>
<text top="581" left="568" width="92" height="20" font="4">Measurement of </text>
<text top="598" left="568" width="75" height="20" font="4">systemic and </text>
<text top="616" left="568" width="86" height="20" font="4">pulmonary flow </text>
<text top="581" left="674" width="172" height="20" font="4">● In pts, Qp/Qs at radionuclide </text>
<text top="598" left="674" width="150" height="20" font="4">angiography was 14% ± 3, </text>
<text top="616" left="674" width="145" height="20" font="4">higher than at MR velocity </text>
<text top="633" left="674" width="153" height="20" font="4">mapping, and interobserver </text>
<text top="650" left="674" width="182" height="20" font="4">variability was 4 times higher 0% </text>
<text top="667" left="674" width="129" height="20" font="4">+ 16 vs. 0% ± 4 (n=12) </text>
<text top="581" left="873" width="193" height="20" font="4">● MR velocity mapping is accurate </text>
<text top="598" left="873" width="183" height="20" font="4">and precise for measurements of </text>
<text top="616" left="873" width="191" height="20" font="4">shunt size over the whole range of </text>
<text top="633" left="873" width="133" height="20" font="4">possible QP/QS values. </text>
<text top="720" left="64" width="80" height="20" font="4">Blalock SE, et </text>
<text top="737" left="64" width="16" height="20" font="4">al. </text>
<text top="754" left="64" width="56" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(75)</a> </text>
<text top="771" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23418153?dopt=Citation">23418153</a></text>
<text top="771" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23418153?dopt=Citation"> </a></text>
<text top="720" left="170" width="67" height="20" font="4">Prospective </text>
<text top="737" left="170" width="123" height="20" font="4">observational study of </text>
<text top="754" left="170" width="139" height="20" font="4">paired MRI examinations </text>
<text top="771" left="170" width="89" height="20" font="4">interpreted by 2 </text>
<text top="788" left="170" width="57" height="20" font="4">observers </text>
<text top="720" left="323" width="54" height="20" font="4">n=30 pts  </text>
<text top="720" left="429" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="737" left="429" width="102" height="20" font="4">with repaired TOF </text>
<text top="754" left="429" width="66" height="20" font="4">having MRI </text>
<text top="720" left="568" width="57" height="20" font="4">Degree of </text>
<text top="737" left="568" width="62" height="20" font="4">agreement </text>
<text top="754" left="568" width="92" height="20" font="4">between studies </text>
<text top="771" left="568" width="74" height="20" font="4">and between </text>
<text top="788" left="568" width="57" height="20" font="4">observers </text>
<text top="720" left="674" width="24" height="20" font="4">N/A </text>
<text top="720" left="873" width="201" height="20" font="4">● CMR measures of ventricular size </text>
<text top="737" left="873" width="163" height="20" font="4">and function have acceptable </text>
<text top="754" left="873" width="142" height="20" font="4">repeatability across serial </text>
<text top="771" left="873" width="183" height="20" font="4">examinations in pts with repaired </text>
<text top="788" left="873" width="35" height="20" font="4">TOF.  </text>
</page>
<page number="25" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 25 </text>
<text top="107" left="873" width="185" height="20" font="4">● Measurements of RV mass are </text>
<text top="124" left="873" width="174" height="20" font="4">subject to higher variability. For </text>
<text top="141" left="873" width="193" height="20" font="4">most parameters, agreement limits </text>
<text top="159" left="873" width="193" height="20" font="4">are wider when measurements are </text>
<text top="176" left="873" width="181" height="20" font="4">performed by multiple operators. </text>
<text top="194" left="64" width="90" height="20" font="4">Bonello B, et al. </text>
<text top="211" left="64" width="56" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(76)</a> </text>
<text top="228" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23177489?dopt=Citation">23177489</a></text>
<text top="228" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23177489?dopt=Citation"> </a></text>
<text top="194" left="170" width="47" height="20" font="4">Review  </text>
<text top="194" left="323" width="24" height="20" font="4">N/A </text>
<text top="194" left="429" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="211" left="429" width="98" height="20" font="4">ACHD studies on </text>
<text top="228" left="429" width="101" height="20" font="4">repaired TOF, the </text>
<text top="246" left="429" width="96" height="20" font="4">systemic RV and </text>
<text top="263" left="429" width="98" height="20" font="4">Ebstein anomaly. </text>
<text top="194" left="568" width="24" height="20" font="4">N/A </text>
<text top="194" left="674" width="24" height="20" font="4">N/A </text>
<text top="194" left="873" width="170" height="20" font="4">● CMR contributes to decision </text>
<text top="211" left="873" width="176" height="20" font="4">making regarding the types and </text>
<text top="228" left="873" width="136" height="20" font="4">timings of interventions.  </text>
<text top="245" left="873" width="194" height="20" font="4">● A dedicated CMR service should </text>
<text top="263" left="873" width="194" height="20" font="4">be regarded as a necessary facility </text>
<text top="280" left="873" width="189" height="20" font="4">of a center specializing in the care </text>
<text top="297" left="873" width="75" height="20" font="4">of ACHD pts. </text>
<text top="315" left="64" width="85" height="20" font="4">Boxt, LM, et al. </text>
<text top="332" left="64" width="56" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(77)</a> </text>
<text top="350" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15170787?dopt=Citation">15170787</a></text>
<text top="350" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15170787?dopt=Citation"> </a></text>
<text top="315" left="170" width="132" height="20" font="4">Review of relative utility </text>
<text top="332" left="170" width="138" height="20" font="4">of contrast enhanced CT </text>
<text top="350" left="170" width="93" height="20" font="4">and MRI in CHD </text>
<text top="315" left="323" width="24" height="20" font="4">N/A </text>
<text top="315" left="429" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="332" left="429" width="24" height="20" font="4">N/A </text>
<text top="315" left="568" width="72" height="20" font="4">Adequacy of </text>
<text top="332" left="568" width="89" height="20" font="4">imaging in CHD </text>
<text top="350" left="568" width="71" height="20" font="4">comparing 2 </text>
<text top="367" left="568" width="46" height="20" font="4">imaging </text>
<text top="384" left="568" width="59" height="20" font="4">modalities </text>
<text top="315" left="674" width="155" height="20" font="4">● Intracardiac anatomy well </text>
<text top="332" left="674" width="139" height="20" font="4">depicted by MRI, and CT </text>
<text top="350" left="674" width="179" height="20" font="4">provides exquisite images of the </text>
<text top="367" left="674" width="167" height="20" font="4">great vessels. MR and CT are </text>
<text top="384" left="674" width="158" height="20" font="4">helpful in demonstrating and </text>
<text top="401" left="674" width="181" height="20" font="4">quantitating physiologic changes </text>
<text top="418" left="674" width="168" height="20" font="4">superimposed by acquired CV </text>
<text top="436" left="674" width="143" height="20" font="4">disease on the underlying </text>
<text top="453" left="674" width="147" height="20" font="4">congenital malformations.  </text>
<text top="470" left="674" width="133" height="20" font="4">● Using MRI, spin echo </text>
<text top="487" left="674" width="169" height="20" font="4">acquisitions provide the image </text>
<text top="504" left="674" width="118" height="20" font="4">data for evaluation of </text>
<text top="522" left="674" width="148" height="20" font="4">morphologic changes, and </text>
<text top="539" left="674" width="182" height="20" font="4">gradient reversal techniques add </text>
<text top="556" left="674" width="146" height="20" font="4">functional and flow data to </text>
<text top="573" left="674" width="141" height="20" font="4">complement morphologic </text>
<text top="591" left="674" width="57" height="20" font="4">changes.  </text>
<text top="608" left="674" width="185" height="20" font="4">● Contrast-enhanced ECG-gated </text>
<text top="625" left="674" width="179" height="20" font="4">multidetector and electron beam </text>
<text top="642" left="674" width="133" height="20" font="4">CT examination provide </text>
<text top="659" left="674" width="185" height="20" font="4">morphologic information and may </text>
<text top="677" left="674" width="179" height="20" font="4">be used as a data set for off-line </text>
<text top="694" left="674" width="127" height="20" font="4">functional quantitation. </text>
<text top="315" left="873" width="188" height="20" font="4">● MRI and contrast-enhanced CT </text>
<text top="332" left="873" width="171" height="20" font="4">are complementary modalities. </text>
<text top="712" left="64" width="93" height="20" font="4">Bunce NH, et al. </text>
<text top="729" left="64" width="56" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(78)</a> </text>
<text top="746" left="64" width="55" height="20" font="7"><a href="file:///C:%5CUsers%5Cabeale%5CAppData%5CRoaming%5CMicrosoft%5CWord%5CSearch%20databaseAll%20DatabasesAssemblyBioProjectBioSampleBioSystemsBooksClinVarCloneConserved%20DomainsdbGaPdbVarEpigenomicsESTGeneGenomeGEO%20DataSetsGEO%20ProfilesGSSGTRHomoloGeneMedGenMeSHNCBI%20Web%20SiteNLM%20CatalogNucleotideOMIMPMCPopSetProbeProteinProtein%20ClustersPubChem%20BioAssayPubChem%20CompoundPubChem%20SubstancePubMedPubMed%20HealthSNPSRAStructureTaxonomyToolKitToolKitAllToolKitBookUniGene">12601193</a></text>
<text top="746" left="119" width="3" height="20" font="4"><a href="file:///C:%5CUsers%5Cabeale%5CAppData%5CRoaming%5CMicrosoft%5CWord%5CSearch%20databaseAll%20DatabasesAssemblyBioProjectBioSampleBioSystemsBooksClinVarCloneConserved%20DomainsdbGaPdbVarEpigenomicsESTGeneGenomeGEO%20DataSetsGEO%20ProfilesGSSGTRHomoloGeneMedGenMeSHNCBI%20Web%20SiteNLM%20CatalogNucleotideOMIMPMCPopSetProbeProteinProtein%20ClustersPubChem%20BioAssayPubChem%20CompoundPubChem%20SubstancePubMedPubMed%20HealthSNPSRAStructureTaxonomyToolKitToolKitAllToolKitBookUniGene"> </a></text>
<text top="712" left="170" width="116" height="20" font="4">Evaluate a simplified </text>
<text top="729" left="170" width="122" height="20" font="4">protocol by using free-</text>
<text top="746" left="170" width="125" height="20" font="4">breathing 3D coronary </text>
<text top="763" left="170" width="123" height="20" font="4">MRA to determine the </text>
<text top="712" left="323" width="51" height="20" font="4">n=26 pts </text>
<text top="712" left="429" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="729" left="429" width="115" height="20" font="4">Suspected of having </text>
<text top="746" left="429" width="86" height="20" font="4">coronary artery </text>
<text top="763" left="429" width="60" height="20" font="4">anomalies </text>
<text top="712" left="568" width="72" height="20" font="4">Adequacy of </text>
<text top="729" left="568" width="60" height="20" font="4">imaging of </text>
<text top="746" left="568" width="50" height="20" font="4">proximal </text>
<text top="763" left="568" width="64" height="20" font="4">anatomy of </text>
<text top="781" left="568" width="64" height="20" font="4">anomalous </text>
<text top="712" left="674" width="145" height="20" font="4">● In 8 pts with anomalous </text>
<text top="729" left="674" width="186" height="20" font="4">arteries that coursed between the </text>
<text top="746" left="674" width="143" height="20" font="4">aortic root and the RVOT, </text>
<text top="763" left="674" width="124" height="20" font="4">conventional coronary </text>
<text top="781" left="674" width="172" height="20" font="4">angiography could not be used </text>
<text top="712" left="873" width="198" height="20" font="4">● Free-breathing 3D coronary MRA </text>
<text top="729" left="873" width="197" height="20" font="4">can be used to identify the proximal </text>
<text top="746" left="873" width="179" height="20" font="4">anatomy of anomalous coronary </text>
<text top="763" left="873" width="48" height="20" font="4">arteries. </text>
</page>
<page number="26" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 26 </text>
<text top="107" left="170" width="128" height="20" font="4">anatomy of anomalous </text>
<text top="124" left="170" width="96" height="20" font="4">coronary arteries </text>
<text top="107" left="568" width="51" height="20" font="4">coronary </text>
<text top="124" left="568" width="77" height="20" font="4">arteries using </text>
<text top="141" left="568" width="72" height="20" font="4">conventional </text>
<text top="159" left="568" width="51" height="20" font="4">coronary </text>
<text top="176" left="568" width="92" height="20" font="4">arteriography as </text>
<text top="193" left="568" width="62" height="20" font="4">a standard </text>
<text top="107" left="674" width="139" height="20" font="4">confidently to identify the </text>
<text top="124" left="674" width="90" height="20" font="4">proximal course </text>
<text top="211" left="64" width="92" height="20" font="4">Crean AM, et al. </text>
<text top="228" left="64" width="56" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(79)</a> </text>
<text top="245" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22152255?dopt=Citation">22152255</a></text>
<text top="245" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22152255?dopt=Citation"> </a></text>
<text top="211" left="170" width="83" height="20" font="4">Comparison of </text>
<text top="228" left="170" width="59" height="20" font="4">volumetric </text>
<text top="245" left="170" width="119" height="20" font="4">measurements of RV </text>
<text top="263" left="170" width="124" height="20" font="4">between CMR and 3D </text>
<text top="280" left="170" width="30" height="20" font="4">echo </text>
<text top="211" left="323" width="21" height="20" font="4">25  </text>
<text top="211" left="429" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="228" left="429" width="109" height="20" font="4">ACHD, expected to </text>
<text top="245" left="429" width="114" height="20" font="4">have a) near normal </text>
<text top="263" left="429" width="78" height="20" font="4">RV size, or b) </text>
<text top="280" left="429" width="97" height="20" font="4">expected to have </text>
<text top="297" left="429" width="126" height="20" font="4">moderate or worse RV </text>
<text top="314" left="429" width="72" height="20" font="4">enlargement </text>
<text top="211" left="568" width="83" height="20" font="4">Comparison of </text>
<text top="228" left="568" width="90" height="20" font="4">results obtained </text>
<text top="245" left="568" width="80" height="20" font="4">with CMR and </text>
<text top="263" left="568" width="64" height="20" font="4">3D echo or </text>
<text top="280" left="568" width="49" height="20" font="4">RVEDV, </text>
<text top="297" left="568" width="69" height="20" font="4">RVESV and </text>
<text top="314" left="568" width="36" height="20" font="4">RVEF </text>
<text top="211" left="674" width="155" height="20" font="4">● Compared to CMR as the </text>
<text top="228" left="674" width="168" height="20" font="4">reference standard, significant </text>
<text top="245" left="674" width="176" height="20" font="4">and systematic underestimation </text>
<text top="263" left="674" width="180" height="20" font="4">of volume by 3D echo, which led </text>
<text top="280" left="674" width="163" height="20" font="4">to a mean underestimation of </text>
<text top="297" left="674" width="181" height="20" font="4">RVEDV by -34% (95% CI: -91%–</text>
<text top="314" left="674" width="39" height="20" font="4">23%).  </text>
<text top="332" left="674" width="183" height="20" font="4">● The degree of underestimation </text>
<text top="349" left="674" width="164" height="20" font="4">was more marked for RVESV </text>
<text top="366" left="674" width="162" height="20" font="4">with a bias of -42% (95% CI: -</text>
<text top="383" left="674" width="77" height="20" font="4">117%–32%).  </text>
<text top="400" left="674" width="176" height="20" font="4">● There was also a tendency to </text>
<text top="418" left="674" width="176" height="20" font="4">overestimate RVEF by 3D echo </text>
<text top="435" left="674" width="166" height="20" font="4">with a bias of ~13% (95% CI: -</text>
<text top="452" left="674" width="64" height="20" font="4">52%–27%) </text>
<text top="211" left="873" width="152" height="20" font="4">● Meaningful differences in </text>
<text top="228" left="873" width="174" height="20" font="4">volumetric measurements were </text>
<text top="245" left="873" width="135" height="20" font="4">observed between the 2 </text>
<text top="263" left="873" width="70" height="20" font="4">techniques.  </text>
<text top="280" left="873" width="186" height="20" font="4">● 3D echo is not interchangeable </text>
<text top="297" left="873" width="134" height="20" font="4">with CMR for volumetric </text>
<text top="314" left="873" width="197" height="20" font="4">assessment of ACHD pts who have </text>
<text top="332" left="873" width="161" height="20" font="4">more than mild RV dilatation. </text>
<text top="470" left="64" width="79" height="20" font="4">Festa P, et al. </text>
<text top="487" left="64" width="56" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(80)</a> </text>
<text top="504" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16547601?dopt=Citation">16547601</a></text>
<text top="504" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16547601?dopt=Citation"> </a></text>
<text top="470" left="170" width="100" height="20" font="4">To test diagnostic </text>
<text top="487" left="170" width="120" height="20" font="4">accuracy of magnetic </text>
<text top="504" left="170" width="64" height="20" font="4">resonance  </text>
<text top="470" left="323" width="54" height="20" font="4">n=20 pts  </text>
<text top="470" left="429" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="487" left="429" width="121" height="20" font="4">with suspected PAPV </text>
<text top="504" left="429" width="36" height="20" font="4">return </text>
<text top="470" left="568" width="83" height="20" font="4">Comparison of </text>
<text top="487" left="568" width="79" height="20" font="4">MRI results to </text>
<text top="504" left="568" width="43" height="20" font="4">cardiac </text>
<text top="522" left="568" width="83" height="20" font="4">catheterization </text>
<text top="539" left="568" width="70" height="20" font="4">and surgical </text>
<text top="556" left="568" width="51" height="20" font="4">anatomy </text>
<text top="470" left="674" width="152" height="20" font="4">● Among pts who had both </text>
<text top="487" left="674" width="181" height="20" font="4">magnetic resonance and cardiac </text>
<text top="504" left="674" width="129" height="20" font="4">catheterization (14 pts) </text>
<text top="522" left="674" width="139" height="20" font="4">anatomical findings were </text>
<text top="539" left="674" width="172" height="20" font="4">concordant in 12 of them. In all </text>
<text top="556" left="674" width="167" height="20" font="4">operated pts, surgical findings </text>
<text top="573" left="674" width="188" height="20" font="4">were concordant with MRI report.  </text>
<text top="591" left="674" width="172" height="20" font="4">●There was a good correlation </text>
<text top="608" left="674" width="164" height="20" font="4">between magnetic resonance </text>
<text top="625" left="674" width="150" height="20" font="4">and cardiac catheterization </text>
<text top="642" left="674" width="173" height="20" font="4">QP/QS evaluation (mean value </text>
<text top="659" left="674" width="148" height="20" font="4">2.23 and 2.4, respectively) </text>
<text top="470" left="873" width="185" height="20" font="4">● MRI provides a comprehensive </text>
<text top="487" left="873" width="177" height="20" font="4">evaluation of pulmonary venous </text>
<text top="504" left="873" width="196" height="20" font="4">return and the amount of shunt and </text>
<text top="522" left="873" width="183" height="20" font="4">can be considered a noninvasive </text>
<text top="539" left="873" width="117" height="20" font="4">alternative to cardiac </text>
<text top="556" left="873" width="87" height="20" font="4">catheterization. </text>
<text top="677" left="64" width="86" height="20" font="4">Kilner PJ, et al. </text>
<text top="694" left="64" width="56" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(81)</a> </text>
<text top="712" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22723533?dopt=Citation">22723533</a></text>
<text top="712" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22723533?dopt=Citation"> </a></text>
<text top="677" left="170" width="44" height="20" font="4">Review </text>
<text top="677" left="323" width="24" height="20" font="4">N/A </text>
<text top="677" left="429" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="694" left="429" width="24" height="20" font="4">N/A </text>
<text top="677" left="568" width="24" height="20" font="4">N/A </text>
<text top="677" left="674" width="168" height="20" font="4">●TTE is the first-line modality, </text>
<text top="694" left="674" width="143" height="20" font="4">but rarely adequate for all </text>
<text top="712" left="674" width="160" height="20" font="4">regions of interest. Choice of </text>
<text top="729" left="674" width="174" height="20" font="4">further imaging depends on the </text>
<text top="746" left="674" width="175" height="20" font="4">clinical questions that remain to </text>
<text top="763" left="674" width="152" height="20" font="4">be addressed, discussed in </text>
<text top="781" left="674" width="39" height="20" font="4">review </text>
<text top="677" left="873" width="176" height="20" font="4">● Adults with relatively complex </text>
<text top="694" left="873" width="198" height="20" font="4">conditions should ideally be imaged </text>
<text top="712" left="873" width="194" height="20" font="4">in a specialist ACHD center, where </text>
<text top="729" left="873" width="185" height="20" font="4">dedicated echocardiographic and </text>
<text top="746" left="873" width="186" height="20" font="4">CV MRI services are a necessary </text>
<text top="763" left="873" width="41" height="20" font="4">facility. </text>
</page>
<page number="27" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 27 </text>
<text top="107" left="64" width="88" height="20" font="4">Lewis MJ, et al. </text>
<text top="124" left="64" width="56" height="20" font="4">2017 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(82)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27893192">27893192</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27893192"> </a></text>
<text top="107" left="170" width="111" height="20" font="4">Retrospective study </text>
<text top="107" left="323" width="60" height="20" font="4">ns=27 pts  </text>
<text top="107" left="429" width="122" height="20" font="3"><b>Inclusion criteria</b>: All </text>
<text top="124" left="429" width="85" height="20" font="4">adult pts with a </text>
<text top="141" left="429" width="68" height="20" font="4">Fontan who </text>
<text top="159" left="429" width="94" height="20" font="4">underwent serial </text>
<text top="176" left="429" width="41" height="20" font="4">CMRs  </text>
<text top="107" left="568" width="89" height="20" font="4">Results of CMR </text>
<text top="124" left="568" width="73" height="20" font="4">evaluation of </text>
<text top="141" left="568" width="89" height="20" font="4">hepatic disease </text>
<text top="159" left="568" width="62" height="20" font="4">over mean </text>
<text top="176" left="568" width="90" height="20" font="4">follow-up of 5.1. </text>
<text top="193" left="568" width="33" height="20" font="4">years </text>
<text top="107" left="674" width="180" height="20" font="4">● CMR detects progressive liver </text>
<text top="124" left="674" width="168" height="20" font="4">and hepatic vein enlargement. </text>
<text top="141" left="674" width="174" height="20" font="4">Progressive hepatic congestion </text>
<text top="159" left="674" width="167" height="20" font="4">is common in adult Fontan pts </text>
<text top="176" left="674" width="155" height="20" font="4">and may be associated with </text>
<text top="193" left="674" width="129" height="20" font="4">ventricular dysfunction. </text>
<text top="107" left="873" width="161" height="20" font="4">● Extending the MRA field to </text>
<text top="124" left="873" width="169" height="20" font="4">include hepatic imaging during </text>
<text top="141" left="873" width="194" height="20" font="4">CMR of adult Fontan pts should be </text>
<text top="159" left="873" width="166" height="20" font="4">considered as a cost-effective </text>
<text top="176" left="873" width="197" height="20" font="4">method to detect early liver disease </text>
<text top="193" left="873" width="99" height="20" font="4">in this population. </text>
<text top="211" left="64" width="78" height="20" font="4">van der Linde </text>
<text top="228" left="64" width="46" height="20" font="4">D, et al. </text>
<text top="245" left="64" width="56" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(83)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23305528?dopt=Citation">23305528</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23305528?dopt=Citation"> </a></text>
<text top="211" left="170" width="134" height="20" font="4">Comparison of TTE and </text>
<text top="228" left="170" width="109" height="20" font="4">CMR for evaluating </text>
<text top="245" left="170" width="59" height="20" font="4">aortic size </text>
<text top="211" left="323" width="54" height="20" font="4">n=59 pts  </text>
<text top="211" left="429" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="228" left="429" width="104" height="20" font="4">with congenital AS </text>
<text top="245" left="429" width="52" height="20" font="4">and BAV </text>
<text top="211" left="568" width="86" height="20" font="4">Size of aorta at </text>
<text top="228" left="568" width="81" height="20" font="4">multiple levels </text>
<text top="211" left="674" width="182" height="20" font="4">● CMR was found to be superior </text>
<text top="228" left="674" width="183" height="20" font="4">to TTE for imaging of the aorta in </text>
<text top="245" left="674" width="185" height="20" font="4">pts with congenital AS, especially </text>
<text top="263" left="674" width="147" height="20" font="4">at the level of the proximal </text>
<text top="280" left="674" width="174" height="20" font="4">ascending aorta when an aortic </text>
<text top="297" left="674" width="118" height="20" font="4">aneurysm is present. </text>
<text top="211" left="873" width="199" height="20" font="4">● Ideally CMR should be performed </text>
<text top="228" left="873" width="191" height="20" font="4">at least once in pts with congenital </text>
<text top="245" left="873" width="185" height="20" font="4">AS to ensure an ascending aortic </text>
<text top="263" left="873" width="136" height="20" font="4">aneurysm is not missed. </text>
<text top="315" left="64" width="79" height="20" font="4">Prasad SK, et </text>
<text top="332" left="64" width="16" height="20" font="4">al. </text>
<text top="350" left="64" width="56" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(84)</a> </text>
<text top="367" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14718402?dopt=Citation">14718402</a></text>
<text top="367" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14718402?dopt=Citation"> </a></text>
<text top="315" left="170" width="109" height="20" font="4">Comparative study: </text>
<text top="332" left="170" width="82" height="20" font="4">CMR vs. other </text>
<text top="350" left="170" width="92" height="20" font="4">modalities in the </text>
<text top="367" left="170" width="103" height="20" font="4">diagnosis of major </text>
<text top="384" left="170" width="89" height="20" font="4">aortopulmonary </text>
<text top="401" left="170" width="121" height="20" font="4">collateral arteries and </text>
<text top="418" left="170" width="45" height="20" font="4">PAPVC </text>
<text top="315" left="323" width="51" height="20" font="4">n=29 pts </text>
<text top="315" left="429" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="332" left="429" width="94" height="20" font="4">with diagnosis of </text>
<text top="350" left="429" width="123" height="20" font="4">major aortopulmonary </text>
<text top="367" left="429" width="111" height="20" font="4">collateral arteries or </text>
<text top="384" left="429" width="99" height="20" font="4">PAPVC, made by </text>
<text top="401" left="429" width="90" height="20" font="4">other modalities </text>
<text top="315" left="568" width="64" height="20" font="4">Correlation </text>
<text top="332" left="568" width="80" height="20" font="4">between MRA </text>
<text top="350" left="568" width="67" height="20" font="4">and cardiac </text>
<text top="367" left="568" width="87" height="20" font="4">catheterization, </text>
<text top="384" left="568" width="48" height="20" font="4">echo, or </text>
<text top="401" left="568" width="46" height="20" font="4">surgical </text>
<text top="418" left="568" width="59" height="20" font="4">inspection </text>
<text top="315" left="674" width="127" height="20" font="4">● Excellent correlation </text>
<text top="332" left="674" width="159" height="20" font="4">● Additional information was </text>
<text top="350" left="674" width="137" height="20" font="4">gained for pts with major </text>
<text top="367" left="674" width="186" height="20" font="4">aortopulmonary collateral arteries </text>
<text top="384" left="674" width="186" height="20" font="4">on confluence and size of PA, PA </text>
<text top="401" left="674" width="185" height="20" font="4">stenosis, aneurysmal dilatation of </text>
<text top="418" left="674" width="163" height="20" font="4">PA and additional anomalous </text>
<text top="436" left="674" width="156" height="20" font="4">vascular abnormality (n=3).  </text>
<text top="453" left="674" width="157" height="20" font="4">● Shunt assessment, where </text>
<text top="470" left="674" width="165" height="20" font="4">present showed patency in all </text>
<text top="487" left="674" width="171" height="20" font="4">cases. For adults with PAPVD, </text>
<text top="504" left="674" width="179" height="20" font="4">further information was obtained </text>
<text top="522" left="674" width="109" height="20" font="4">on drainage origin.  </text>
<text top="315" left="873" width="170" height="20" font="4">● Contrast-enhanced 3D MRA </text>
<text top="332" left="873" width="158" height="20" font="4">provides a fast, noninvasive, </text>
<text top="350" left="873" width="185" height="20" font="4">radiation-free method of accurate </text>
<text top="367" left="873" width="180" height="20" font="4">and comprehensive diagnosis of </text>
<text top="384" left="873" width="176" height="20" font="4">major aortopulmonary collateral </text>
<text top="401" left="873" width="180" height="20" font="4">arteries and PAPVC in adult pts. </text>
<text top="540" left="64" width="82" height="20" font="4">Puchalski MD, </text>
<text top="557" left="64" width="30" height="20" font="4">et al. </text>
<text top="574" left="64" width="56" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(85)</a> </text>
<text top="591" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18377513?dopt=Citation">18377513</a></text>
<text top="591" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18377513?dopt=Citation"> </a></text>
<text top="540" left="170" width="106" height="20" font="4">Comparative study </text>
<text top="540" left="323" width="54" height="20" font="4">n=22 pts  </text>
<text top="540" left="429" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="557" left="429" width="119" height="20" font="4">with right sided CHD, </text>
<text top="574" left="429" width="113" height="20" font="4">having had MRI and </text>
<text top="591" left="429" width="122" height="20" font="4">TTE within 6 mo each </text>
<text top="608" left="429" width="31" height="20" font="4">other </text>
<text top="540" left="568" width="83" height="20" font="4">Comparison of </text>
<text top="557" left="568" width="74" height="20" font="4">standardized </text>
<text top="574" left="568" width="50" height="20" font="4">“eyeball” </text>
<text top="591" left="568" width="83" height="20" font="4">assessment of </text>
<text top="608" left="568" width="69" height="20" font="4">RV size and </text>
<text top="626" left="568" width="73" height="20" font="4">function by 4 </text>
<text top="643" left="568" width="85" height="20" font="4">echocardiograp</text>
<text top="660" left="568" width="41" height="20" font="4">hers to </text>
<text top="677" left="568" width="85" height="20" font="4">assessment by </text>
<text top="694" left="568" width="26" height="20" font="4">MRI </text>
<text top="540" left="674" width="150" height="20" font="4">● Using echo, reliability for </text>
<text top="557" left="674" width="178" height="20" font="4">accurately identifying a severely </text>
<text top="574" left="674" width="162" height="20" font="4">dilated RV was &#34;slight&#34; with a </text>
<text top="591" left="674" width="141" height="20" font="4">prevalence-adjusted bias-</text>
<text top="608" left="674" width="175" height="20" font="4">adjusted Kappa of 0.25; and for </text>
<text top="626" left="674" width="186" height="20" font="4">identifying moderately to severely </text>
<text top="643" left="674" width="173" height="20" font="4">diminished RV systolic function </text>
<text top="660" left="674" width="145" height="20" font="4">was fair with a prevalence-</text>
<text top="677" left="674" width="179" height="20" font="4">adjusted bias-adjusted Kappa of </text>
<text top="694" left="674" width="151" height="20" font="4">0.43. Inter-rater agreement </text>
<text top="712" left="674" width="172" height="20" font="4">analysis was poor for both with </text>
<text top="729" left="674" width="160" height="20" font="4">Kappas of 0.07 (p=0.22) and </text>
<text top="746" left="674" width="152" height="20" font="4">0.12 (p=0.09), respectively. </text>
<text top="540" left="873" width="133" height="20" font="4">● The usefulness of the </text>
<text top="557" left="873" width="200" height="20" font="4">echocardiographic &#34;eyeball&#34; method </text>
<text top="574" left="873" width="177" height="20" font="4">to estimate RV size and systolic </text>
<text top="591" left="873" width="176" height="20" font="4">function in pts with right HD has </text>
<text top="608" left="873" width="174" height="20" font="4">limitations when compared with </text>
<text top="626" left="873" width="178" height="20" font="4">MRI, specifically in regard to the </text>
<text top="643" left="873" width="104" height="20" font="4">variability between </text>
<text top="660" left="873" width="116" height="20" font="4">echocardiographers. </text>
<text top="764" left="64" width="212" height="20" font="4">Taylor AM, et al.  Comparative study </text>
<text top="764" left="323" width="51" height="20" font="4">n=25 pts </text>
<text top="764" left="429" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="781" left="429" width="125" height="20" font="4">Various types of CHD, </text>
<text top="764" left="568" width="68" height="20" font="4">Definition of </text>
<text top="781" left="568" width="85" height="20" font="4">coronary origin </text>
<text top="764" left="674" width="184" height="20" font="4">● MRCA results were more likely </text>
<text top="781" left="674" width="174" height="20" font="4">to agree with the consensus for </text>
<text top="764" left="873" width="178" height="20" font="4">● The use of the combination of </text>
<text top="781" left="873" width="147" height="20" font="4">MRCA with x-ray coronary </text>
</page>
<page number="28" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 28 </text>
<text top="107" left="64" width="56" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(86)</a> </text>
<text top="124" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10758049?dopt=Citation">10758049</a></text>
<text top="124" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10758049?dopt=Citation"> </a></text>
<text top="107" left="429" width="87" height="20" font="4">studied both by </text>
<text top="124" left="429" width="124" height="20" font="4">conventional coronary </text>
<text top="141" left="429" width="111" height="20" font="4">angiography and by </text>
<text top="159" left="429" width="114" height="20" font="4">magnetic resonance </text>
<text top="176" left="429" width="122" height="20" font="4">coronary angiography </text>
<text top="107" left="568" width="74" height="20" font="4">and proximal </text>
<text top="124" left="568" width="57" height="20" font="4">course by </text>
<text top="141" left="568" width="90" height="20" font="4">consensus after </text>
<text top="159" left="568" width="71" height="20" font="4">independent </text>
<text top="176" left="568" width="43" height="20" font="4">blinded </text>
<text top="193" left="568" width="69" height="20" font="4">assessment </text>
<text top="107" left="674" width="177" height="20" font="4">definition of the proximal course </text>
<text top="124" left="674" width="130" height="20" font="4">of the coronary arteries </text>
<text top="107" left="873" width="198" height="20" font="4">angiography improves the definition </text>
<text top="124" left="873" width="170" height="20" font="4">of the proximal coronary artery </text>
<text top="141" left="873" width="47" height="20" font="4">course.  </text>
<text top="159" left="873" width="182" height="20" font="4">● MRCA provides correct spatial </text>
<text top="176" left="873" width="156" height="20" font="4">relationships, whereas x-ray </text>
<text top="193" left="873" width="194" height="20" font="4">angiography provides a view of the </text>
<text top="210" left="873" width="162" height="20" font="4">entire coronary length and its </text>
<text top="227" left="873" width="100" height="20" font="4">peripheral run-off. </text>
<text top="245" left="64" width="85" height="20" font="4">Grewal J, et al. </text>
<text top="263" left="64" width="56" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(66)</a> </text>
<text top="280" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19962272?dopt=Citation">19962272</a></text>
<text top="280" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19962272?dopt=Citation"> </a></text>
<text top="245" left="170" width="128" height="20" font="4">Comparative study: 3D </text>
<text top="263" left="170" width="136" height="20" font="4">echo and cardiac MRI in </text>
<text top="280" left="170" width="103" height="20" font="4">assessment of RV </text>
<text top="245" left="323" width="54" height="20" font="4">n=25 pts  </text>
<text top="245" left="429" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="263" left="429" width="124" height="20" font="4">ACHD pts with severe </text>
<text top="280" left="429" width="100" height="20" font="4">PR following TOF </text>
<text top="297" left="429" width="110" height="20" font="4">repair or pulmonary </text>
<text top="314" left="429" width="59" height="20" font="4">valvotomy </text>
<text top="245" left="568" width="89" height="20" font="4">RVEF, RVEDV, </text>
<text top="263" left="568" width="45" height="20" font="4">RVESV </text>
<text top="245" left="674" width="163" height="20" font="4">● Mean RV ejection fractions </text>
<text top="263" left="674" width="177" height="20" font="4">were 42 ± 8% on 3D ultrasound </text>
<text top="280" left="674" width="163" height="20" font="4">and 44 ± 7% on MRI (r=0.89; </text>
<text top="297" left="674" width="146" height="20" font="4">p&lt;0.0001). The mean end-</text>
<text top="314" left="674" width="180" height="20" font="4">diastolic volumes were 249 ± 66 </text>
<text top="332" left="674" width="176" height="20" font="4">and 274 ± 82 mL and the mean </text>
<text top="349" left="674" width="170" height="20" font="4">end-systolic volumes 147 ± 50 </text>
<text top="366" left="674" width="133" height="20" font="4">and 159 ± 60 mL on 3D </text>
<text top="383" left="674" width="186" height="20" font="4">ultrasound and MRI, respectively. </text>
<text top="401" left="674" width="152" height="20" font="4">Similarly, there were strong </text>
<text top="418" left="674" width="180" height="20" font="4">correlations of both end-diastolic </text>
<text top="435" left="674" width="178" height="20" font="4">volume and end-systolic volume </text>
<text top="452" left="674" width="147" height="20" font="4">on 3D ultrasound and MRI </text>
<text top="469" left="674" width="181" height="20" font="4">(r=0.88 and r=0.89, respectively) </text>
<text top="245" left="873" width="185" height="20" font="4">● 3D ultrasound was comparable </text>
<text top="263" left="873" width="178" height="20" font="4">with MRI in determining RV size </text>
<text top="280" left="873" width="178" height="20" font="4">and function in pts with complex </text>
<text top="297" left="873" width="37" height="20" font="4">CHD.  </text>
<text top="487" left="64" width="90" height="20" font="4">Van der Zwaan, </text>
<text top="504" left="64" width="30" height="20" font="4">et al. </text>
<text top="522" left="64" width="56" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(67)</a> </text>
<text top="539" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20152693?dopt=Citation">20152693</a></text>
<text top="539" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20152693?dopt=Citation"> </a></text>
<text top="487" left="170" width="128" height="20" font="4">Comparative study: 3D </text>
<text top="504" left="170" width="136" height="20" font="4">echo and cardiac MRI in </text>
<text top="522" left="170" width="103" height="20" font="4">assessment of RV </text>
<text top="487" left="323" width="21" height="20" font="4">62  </text>
<text top="487" left="429" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="504" left="429" width="119" height="20" font="4">Various sorts of CHD </text>
<text top="487" left="568" width="89" height="20" font="4">RVEF, RVEDV, </text>
<text top="504" left="568" width="45" height="20" font="4">RVESV </text>
<text top="487" left="674" width="177" height="20" font="4">● Compared with CMR, RT3DE </text>
<text top="504" left="674" width="180" height="20" font="4">imaging underestimated RV end-</text>
<text top="522" left="674" width="140" height="20" font="4">diastolic and end-systolic </text>
<text top="539" left="674" width="156" height="20" font="4">volumes and EF, with highly </text>
<text top="556" left="674" width="171" height="20" font="4">significant correlations (r=0.93, </text>
<text top="573" left="674" width="180" height="20" font="4">r=0.91, and r=0.74, respectively; </text>
<text top="591" left="674" width="132" height="20" font="4">p&lt;0.001). Interobserver </text>
<text top="608" left="674" width="144" height="20" font="4">variability was reasonable </text>
<text top="487" left="873" width="190" height="20" font="4">● In the majority of unselected pts </text>
<text top="504" left="873" width="177" height="20" font="4">with complex CHD, RT 3D echo </text>
<text top="522" left="873" width="154" height="20" font="4">imaging provides a fast and </text>
<text top="539" left="873" width="174" height="20" font="4">reproducible assessment of RV </text>
<text top="556" left="873" width="183" height="20" font="4">volumes and EF with fair to good </text>
<text top="573" left="873" width="167" height="20" font="4">accuracy compared with CMR </text>
<text top="591" left="873" width="86" height="20" font="4">reference data. </text>
<text top="626" left="64" width="83" height="20" font="4">Brenner DJ, et </text>
<text top="643" left="64" width="16" height="20" font="4">al. </text>
<text top="660" left="64" width="56" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(87)</a> </text>
<text top="677" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18046031?dopt=Citation">18046031</a></text>
<text top="677" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18046031?dopt=Citation"> </a></text>
<text top="626" left="170" width="44" height="20" font="4">Review </text>
<text top="626" left="323" width="24" height="20" font="4">N/A </text>
<text top="626" left="429" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="643" left="429" width="24" height="20" font="4">N/A </text>
<text top="626" left="568" width="24" height="20" font="4">N/A </text>
<text top="626" left="674" width="24" height="20" font="4">N/A </text>
<text top="626" left="873" width="187" height="20" font="4">● A review of use of CT, benefits, </text>
<text top="643" left="873" width="176" height="20" font="4">and level of ionizing radiation to </text>
<text top="660" left="873" width="183" height="20" font="4">which subjects are exposed, with </text>
<text top="677" left="873" width="186" height="20" font="4">discussion of strategies to reduce </text>
<text top="694" left="873" width="81" height="20" font="4">that exposure. </text>
<text top="712" left="108" width="3" height="20" font="4"> </text>
<text top="730" left="108" width="3" height="20" font="4"> </text>
<text top="747" left="108" width="476" height="24" font="1"><b>Data Supplement 9. Cardiac Computed Tomography – Section 3.4.5 </b></text>
<text top="768" left="92" width="38" height="20" font="3"><b>Study </b></text>
<text top="768" left="181" width="118" height="20" font="3"><b>Study Type/ Design </b></text>
<text top="768" left="340" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="768" left="436" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="785" left="472" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="768" left="580" width="69" height="20" font="3"><b>1°Endpoint </b></text>
<text top="768" left="716" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="768" left="873" width="3" height="20" font="3"><b> </b></text>
<text top="768" left="907" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="768" left="1071" width="3" height="20" font="3"><b> </b></text>
</page>
<page number="29" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="10" size="12" family="Times" color="#ff0000"/>
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 29 </text>
<text top="107" left="67" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="124" left="96" width="30" height="20" font="3"><b>Year </b></text>
<text top="142" left="64" width="89" height="20" font="4">Bazzocchi G, et </text>
<text top="159" left="64" width="16" height="20" font="4">al. </text>
<text top="177" left="64" width="56" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(88)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21293945?dopt=Citation">21293945</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21293945?dopt=Citation"> </a></text>
<text top="142" left="170" width="138" height="20" font="4">Retrospective evaluation </text>
<text top="159" left="170" width="91" height="20" font="4">of prevalence of </text>
<text top="177" left="170" width="133" height="20" font="4">coronary artery variants </text>
<text top="194" left="170" width="135" height="20" font="4">and congenital coronary </text>
<text top="211" left="170" width="138" height="20" font="4">anomalies using 64-slice </text>
<text top="228" left="170" width="20" height="20" font="4">CT </text>
<text top="142" left="323" width="71" height="20" font="4">n=3,236 pts  </text>
<text top="142" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="159" left="435" width="102" height="20" font="4">All pts undergoing </text>
<text top="177" left="435" width="71" height="20" font="4">CT coronary </text>
<text top="194" left="435" width="114" height="20" font="4">arteriography during </text>
<text top="211" left="435" width="68" height="20" font="4">a 4-y period </text>
<text top="142" left="568" width="64" height="20" font="4">Descriptive </text>
<text top="159" left="568" width="49" height="20" font="4">report of </text>
<text top="177" left="568" width="46" height="20" font="4">findings </text>
<text top="142" left="674" width="173" height="20" font="4">● Coronary anomalies of origin </text>
<text top="159" left="674" width="173" height="20" font="4">and course, of termination, and </text>
<text top="177" left="674" width="139" height="20" font="4">intrinsic anomalies had a </text>
<text top="194" left="674" width="116" height="20" font="4">prevalence of 5.7%.  </text>
<text top="142" left="873" width="201" height="20" font="4">● 64-slice CT coronary angiography </text>
<text top="159" left="873" width="193" height="20" font="4">provides accurate 3D evaluation of </text>
<text top="177" left="873" width="198" height="20" font="4">the coronary artery tree with correct </text>
<text top="194" left="873" width="195" height="20" font="4">visualization of coronary anomalies.</text>
<text top="194" left="1068" width="3" height="20" font="10"> </text>
<text top="194" left="1072" width="3" height="20" font="4"> </text>
<text top="246" left="64" width="84" height="20" font="4">Cheng Z, et al. </text>
<text top="263" left="64" width="56" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(89)</a> </text>
<text top="281" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20797468?dopt=Citation">20797468</a></text>
<text top="281" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20797468?dopt=Citation"> </a></text>
<text top="246" left="170" width="118" height="20" font="4">Retrospective review </text>
<text top="246" left="323" width="68" height="20" font="4">n=3,625 pts </text>
<text top="246" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="263" left="435" width="108" height="20" font="4">Pts who underwent </text>
<text top="281" left="435" width="90" height="20" font="4">dual source CT. </text>
<text top="298" left="435" width="61" height="20" font="4">Some also </text>
<text top="315" left="435" width="61" height="20" font="4">underwent </text>
<text top="332" left="435" width="72" height="20" font="4">conventional </text>
<text top="350" left="435" width="51" height="20" font="4">coronary </text>
<text top="367" left="435" width="75" height="20" font="4">angiography  </text>
<text top="246" left="568" width="70" height="20" font="4">Incidence of </text>
<text top="263" left="568" width="86" height="20" font="4">coronary artery </text>
<text top="281" left="568" width="60" height="20" font="4">anomalies </text>
<text top="246" left="674" width="133" height="20" font="4">● Incidence of coronary </text>
<text top="263" left="674" width="177" height="20" font="4">angiography anomalies was 1% </text>
<text top="281" left="674" width="175" height="20" font="4">(36 pts). Conventional coronary </text>
<text top="298" left="674" width="180" height="20" font="4">angiography identified the lesion </text>
<text top="315" left="674" width="182" height="20" font="4">in 10/19 or 53% of pts in whom it </text>
<text top="332" left="674" width="60" height="20" font="4">was done. </text>
<text top="246" left="873" width="196" height="20" font="4">● Dual source CT is a good tool for </text>
<text top="263" left="873" width="138" height="20" font="4">coronary anomalies, and </text>
<text top="281" left="873" width="196" height="20" font="4">recognizes anomalies not identified </text>
<text top="298" left="873" width="140" height="20" font="4">by conventional coronary </text>
<text top="315" left="873" width="75" height="20" font="4">angiography. </text>
<text top="385" left="64" width="81" height="20" font="4">Doganay S, et </text>
<text top="402" left="64" width="16" height="20" font="4">al. </text>
<text top="419" left="64" width="56" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(90)</a> </text>
<text top="436" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21717303?dopt=Citation">21717303</a></text>
<text top="436" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21717303?dopt=Citation"> </a></text>
<text top="385" left="170" width="93" height="20" font="4">To prospectively </text>
<text top="402" left="170" width="132" height="20" font="4">evaluate the usefulness </text>
<text top="419" left="170" width="125" height="20" font="4">of noninvasive cardiac </text>
<text top="436" left="170" width="105" height="20" font="4">vein imaging using </text>
<text top="454" left="170" width="94" height="20" font="4">multidetector CT </text>
<text top="471" left="170" width="138" height="20" font="4">angiography before CRT </text>
<text top="385" left="323" width="54" height="20" font="4">n=34 pts  </text>
<text top="385" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="402" left="435" width="77" height="20" font="4">Pts studied in </text>
<text top="419" left="435" width="92" height="20" font="4">advance of CRT </text>
<text top="385" left="568" width="86" height="20" font="4">Identification of </text>
<text top="402" left="568" width="92" height="20" font="4">anatomic details </text>
<text top="419" left="568" width="65" height="20" font="4">of coronary </text>
<text top="436" left="568" width="85" height="20" font="4">venous system </text>
<text top="454" left="568" width="74" height="20" font="4">to guide lead </text>
<text top="471" left="568" width="78" height="20" font="4">placement for </text>
<text top="488" left="568" width="29" height="20" font="4">CRT </text>
<text top="385" left="674" width="24" height="20" font="4">N/A </text>
<text top="385" left="873" width="190" height="20" font="4">● Multidetector CT can be used to </text>
<text top="402" left="873" width="169" height="20" font="4">guide interventions for CRT by </text>
<text top="419" left="873" width="189" height="20" font="4">providing anatomical details of the </text>
<text top="436" left="873" width="192" height="20" font="4">cardiac venous system rapidly and </text>
<text top="454" left="873" width="81" height="20" font="4">noninvasively. </text>
<text top="506" left="64" width="90" height="20" font="4">Ghoshhajra BB, </text>
<text top="523" left="64" width="30" height="20" font="4">et al. </text>
<text top="540" left="64" width="56" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(91)</a> </text>
<text top="558" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23075048?dopt=Citation">23075048</a></text>
<text top="558" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23075048?dopt=Citation"> </a></text>
<text top="506" left="170" width="131" height="20" font="4">Case series and review </text>
<text top="523" left="170" width="118" height="20" font="4">of benefits of second-</text>
<text top="540" left="170" width="129" height="20" font="4">generation dual source </text>
<text top="558" left="170" width="71" height="20" font="4">CT in ACHD </text>
<text top="506" left="323" width="91" height="20" font="4">N/A (description </text>
<text top="523" left="323" width="91" height="20" font="4">with 5 illustrated </text>
<text top="540" left="323" width="40" height="20" font="4">cases) </text>
<text top="506" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="523" left="435" width="24" height="20" font="4">N/A </text>
<text top="506" left="568" width="64" height="20" font="4">Descriptive </text>
<text top="523" left="568" width="49" height="20" font="4">report of </text>
<text top="540" left="568" width="46" height="20" font="4">imaging </text>
<text top="558" left="568" width="63" height="20" font="4">techniques </text>
<text top="575" left="568" width="74" height="20" font="4">possible with </text>
<text top="592" left="568" width="92" height="20" font="4">new technology, </text>
<text top="609" left="568" width="44" height="20" font="4">second-</text>
<text top="626" left="568" width="89" height="20" font="4">generation dual-</text>
<text top="644" left="568" width="60" height="20" font="4">source CT </text>
<text top="506" left="674" width="168" height="20" font="4">● High-spatial resolution, high-</text>
<text top="523" left="674" width="185" height="20" font="4">temporal resolution, and the wide </text>
<text top="540" left="674" width="154" height="20" font="4">z-axis coverage allow novel </text>
<text top="558" left="674" width="172" height="20" font="4">protocols that markedly reduce </text>
<text top="575" left="674" width="167" height="20" font="4">scan time, significantly reduce </text>
<text top="592" left="674" width="176" height="20" font="4">radiation exposure, and expand </text>
<text top="609" left="674" width="131" height="20" font="4">the physiologic imaging </text>
<text top="626" left="674" width="144" height="20" font="4">capabilities of cardiac CT. </text>
<text top="506" left="873" width="183" height="20" font="4">● Complicated ACHD pts can be </text>
<text top="523" left="873" width="186" height="20" font="4">imaged by the second-generation </text>
<text top="540" left="873" width="182" height="20" font="4">dual-source CT scanner with low-</text>
<text top="558" left="873" width="200" height="20" font="4">radiation doses and excellent image </text>
<text top="575" left="873" width="42" height="20" font="4">quality. </text>
<text top="662" left="64" width="92" height="20" font="4">Torres FS, et al. </text>
<text top="679" left="64" width="56" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(92)</a> </text>
<text top="696" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20444667?dopt=Citation">20444667</a></text>
<text top="696" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20444667?dopt=Citation"> </a></text>
<text top="662" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="679" left="170" width="103" height="20" font="4">comparative study </text>
<text top="662" left="323" width="80" height="20" font="4">n=15 cases of </text>
<text top="679" left="323" width="83" height="20" font="4">anomalous left </text>
<text top="696" left="323" width="86" height="20" font="4">coronary artery </text>
<text top="713" left="323" width="90" height="20" font="4">with intraarterial </text>
<text top="730" left="323" width="87" height="20" font="4">course found in </text>
<text top="748" left="323" width="34" height="20" font="4">6,000 </text>
<text top="765" left="323" width="68" height="20" font="4">consecutive </text>
<text top="782" left="323" width="94" height="20" font="4">multidetector CT </text>
<text top="662" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="679" left="435" width="105" height="20" font="4">LMCA arising from </text>
<text top="696" left="435" width="102" height="20" font="4">right sinus or from </text>
<text top="713" left="435" width="114" height="20" font="4">right coronary artery </text>
<text top="730" left="435" width="100" height="20" font="4">coursing between </text>
<text top="748" left="435" width="105" height="20" font="4">aorta and main PA </text>
<text top="662" left="568" width="64" height="20" font="4">Descriptive </text>
<text top="679" left="568" width="87" height="20" font="4">classification of </text>
<text top="696" left="568" width="83" height="20" font="4">anomalous left </text>
<text top="713" left="568" width="86" height="20" font="4">coronary artery </text>
<text top="662" left="674" width="173" height="20" font="4">● 4 subtypes identified, a more </text>
<text top="679" left="674" width="182" height="20" font="4">granular classification than could </text>
<text top="696" left="674" width="169" height="20" font="4">be recognized by conventional </text>
<text top="713" left="674" width="122" height="20" font="4">coronary angiography </text>
<text top="662" left="873" width="198" height="20" font="4">● Anatomic spectrum of anomalous </text>
<text top="679" left="873" width="183" height="20" font="4">left coronary arteries detected by </text>
<text top="696" left="873" width="145" height="20" font="4">multidetector CT coronary </text>
<text top="713" left="873" width="178" height="20" font="4">angiography that challenges the </text>
<text top="730" left="873" width="184" height="20" font="4">traditional classification based on </text>
<text top="748" left="873" width="198" height="20" font="4">conventional coronary angiography. </text>
</page>
<page number="30" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 30 </text>
<text top="107" left="323" width="51" height="20" font="4">coronary </text>
<text top="124" left="323" width="68" height="20" font="4">angiograms </text>
<text top="142" left="64" width="83" height="20" font="4">Brenner DJ, et </text>
<text top="159" left="64" width="16" height="20" font="4">al. </text>
<text top="177" left="64" width="56" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(87)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18046031?dopt=Citation">18046031</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18046031?dopt=Citation"> </a></text>
<text top="142" left="170" width="44" height="20" font="4">Review </text>
<text top="142" left="323" width="24" height="20" font="4">N/A </text>
<text top="142" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="159" left="435" width="24" height="20" font="4">N/A </text>
<text top="142" left="568" width="24" height="20" font="4">N/A </text>
<text top="142" left="674" width="24" height="20" font="4">N/A </text>
<text top="142" left="873" width="187" height="20" font="4">● A review of use of CT, benefits, </text>
<text top="159" left="873" width="176" height="20" font="4">and level of ionizing radiation to </text>
<text top="177" left="873" width="154" height="20" font="4">which pts are exposed, with </text>
<text top="194" left="873" width="186" height="20" font="4">discussion of strategies to reduce </text>
<text top="211" left="873" width="81" height="20" font="4">that exposure. </text>
<text top="229" left="54" width="3" height="20" font="4"> </text>
<text top="246" left="54" width="3" height="20" font="4"> </text>
<text top="263" left="108" width="425" height="24" font="1"><b>Data Supplement 10. Cardiac Catheterization – Section 3.4.6 </b></text>
<text top="285" left="75" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="302" left="76" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="285" left="182" width="118" height="20" font="3"><b>Study Type/ Design </b></text>
<text top="285" left="340" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="285" left="452" width="165" height="20" font="3"><b>Inclusion/Exclusion Criteria </b></text>
<text top="285" left="668" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="285" left="882" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="344" left="64" width="93" height="20" font="4">Moore JW, et al. </text>
<text top="361" left="64" width="56" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(93)</a> </text>
<text top="379" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25500227?dopt=Citation">25500227</a></text>
<text top="379" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25500227?dopt=Citation"> </a></text>
<text top="344" left="178" width="89" height="20" font="4">Report from the </text>
<text top="361" left="178" width="109" height="20" font="4">Improving Pediatric </text>
<text top="379" left="178" width="118" height="20" font="4">and Adult Congenital </text>
<text top="396" left="178" width="103" height="20" font="4">Treatment registry </text>
<text top="413" left="178" width="54" height="20" font="4">database </text>
<text top="344" left="316" width="48" height="20" font="4">n=4,152 </text>
<text top="361" left="316" width="83" height="20" font="4">catheterization </text>
<text top="379" left="316" width="68" height="20" font="4">procedures  </text>
<text top="344" left="442" width="181" height="20" font="3"><b>Inclusion criteria</b>: Registry data </text>
<text top="361" left="442" width="186" height="20" font="4">from pts enrolled in the Improving </text>
<text top="379" left="442" width="169" height="20" font="4">Pediatric and Adult Congenital </text>
<text top="396" left="442" width="181" height="20" font="4">Treatment Registry between Jan </text>
<text top="413" left="442" width="129" height="20" font="4">2011–March 2013 who </text>
<text top="430" left="442" width="156" height="20" font="4">underwent 1 of the following </text>
<text top="447" left="442" width="153" height="20" font="4">isolated procedures: device </text>
<text top="465" left="442" width="185" height="20" font="4">closure of ASD; device closure of </text>
<text top="482" left="442" width="170" height="20" font="4">PDA; pulmonary valvuloplasty; </text>
<text top="499" left="442" width="138" height="20" font="4">aortic valvuloplasty; CoA </text>
<text top="516" left="442" width="183" height="20" font="4">angioplasty and stenting; and PA </text>
<text top="534" left="442" width="46" height="20" font="4">stenting.</text>
<text top="535" left="489" width="2" height="13" font="6"> </text>
<text top="344" left="641" width="120" height="20" font="4">● Pt data, procedural </text>
<text top="361" left="641" width="118" height="20" font="4">data and results, and </text>
<text top="379" left="641" width="29" height="20" font="4">AEs. </text>
<text top="344" left="780" width="294" height="20" font="4">● In 4,152 catheterizations, 1 isolated procedure was </text>
<text top="361" left="780" width="56" height="20" font="4">reported.  </text>
<text top="379" left="780" width="280" height="20" font="4">● There were 1,286 single-ASD procedures, 1,375 </text>
<text top="396" left="780" width="280" height="20" font="4">PDA procedures, 270 &#34;typical&#34; PV procedures, 305 </text>
<text top="413" left="780" width="284" height="20" font="4">aortic valve procedures, 671 aortic procedures, and </text>
<text top="430" left="780" width="112" height="20" font="4">245 PA procedures. </text>
<text top="447" left="780" width="292" height="20" font="4">● The reported procedure was performed in &gt;95% of </text>
<text top="465" left="780" width="93" height="20" font="4">catheterizations. </text>
<text top="482" left="780" width="279" height="20" font="4">● Stated outcomes were accomplished in &gt;98% of </text>
<text top="499" left="780" width="288" height="20" font="4">ASD and PDA procedures, but less commonly in the </text>
<text top="516" left="780" width="294" height="20" font="4">others, with coarctation angioplasty procedures being </text>
<text top="534" left="780" width="154" height="20" font="4">the least successful (51%).  </text>
<text top="551" left="780" width="291" height="20" font="4">● Reported major AE rates ranged from 0% to 3.3%; </text>
<text top="568" left="780" width="224" height="20" font="4">total AE rates ranged from 5.3%–24.3%. </text>
<text top="586" left="64" width="89" height="20" font="4">Learn CP, et al. </text>
<text top="603" left="64" width="56" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(94)</a> </text>
<text top="620" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23345073?dopt=Citation">23345073</a></text>
<text top="620" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23345073?dopt=Citation"> </a></text>
<text top="586" left="178" width="106" height="20" font="4">The C3PO collects </text>
<text top="603" left="178" width="60" height="20" font="4">data on all </text>
<text top="620" left="178" width="113" height="20" font="4">catheterizations at 8 </text>
<text top="638" left="178" width="115" height="20" font="4">pediatric institutions. </text>
<text top="586" left="316" width="102" height="20" font="4">2,061 cases (15% </text>
<text top="603" left="316" width="75" height="20" font="4">of total) were </text>
<text top="620" left="316" width="113" height="20" font="4">performed on adults </text>
<text top="638" left="316" width="100" height="20" font="4">and 11,422 cases </text>
<text top="655" left="316" width="66" height="20" font="4">(85%) were </text>
<text top="672" left="316" width="77" height="20" font="4">performed on </text>
<text top="689" left="316" width="46" height="20" font="4">children </text>
<text top="586" left="442" width="180" height="20" font="3"><b>Inclusion criteria</b>: Adult (≥18 y) </text>
<text top="603" left="442" width="185" height="20" font="4">case characteristics and AE were </text>
<text top="620" left="442" width="160" height="20" font="4">reviewed and compared with </text>
<text top="638" left="442" width="178" height="20" font="4">those of pediatric (&lt;18 y) cases. </text>
<text top="586" left="641" width="81" height="20" font="4">● Cases were </text>
<text top="603" left="641" width="77" height="20" font="4">classified into </text>
<text top="620" left="641" width="81" height="20" font="4">procedure risk </text>
<text top="638" left="641" width="112" height="20" font="4">categories from 1–4 </text>
<text top="655" left="641" width="120" height="20" font="4">based on highest risk </text>
<text top="672" left="641" width="126" height="20" font="4">procedure/intervention </text>
<text top="689" left="641" width="113" height="20" font="4">performed. AE were </text>
<text top="707" left="641" width="126" height="20" font="4">categorized by level of </text>
<text top="724" left="641" width="94" height="20" font="4">severity. Using a </text>
<text top="741" left="641" width="121" height="20" font="4">multivariate model for </text>
<text top="758" left="641" width="98" height="20" font="4">High severity AE, </text>
<text top="775" left="641" width="124" height="20" font="4">standardized AE rates </text>
<text top="586" left="780" width="302" height="20" font="4">● 2,061 cases (15% of total) were performed on adults </text>
<text top="603" left="780" width="293" height="20" font="4">and 11,422 cases (85%) were performed on children. </text>
<text top="620" left="780" width="290" height="20" font="4">Adults less frequently underwent high-risk procedure </text>
<text top="638" left="780" width="267" height="20" font="4">category cases than children (19% vs. 30%). AE </text>
<text top="655" left="780" width="287" height="20" font="4">occurred in 10% of adult cases and 13% of pediatric </text>
<text top="672" left="780" width="289" height="20" font="4">cases (p&lt;0.001). High severity AE occurred in 4% of </text>
<text top="689" left="780" width="295" height="20" font="4">adult and 5% of pediatric cases (p=0.006). Procedure-</text>
<text top="707" left="780" width="300" height="20" font="4">type risk category (Category 2, 3, 4 OR=4.8, 6.0, 12.9) </text>
<text top="724" left="780" width="297" height="20" font="4">and systemic ventricle end diastolic pressure ≥18 mm </text>
<text top="741" left="780" width="293" height="20" font="4">Hg (OR 3.1) were associated with high severity AE, c-</text>
<text top="758" left="780" width="286" height="20" font="4">statistic 0.751. There were no statistically significant </text>
</page>
<page number="31" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 31 </text>
<text top="107" left="641" width="105" height="20" font="4">were calculated by </text>
<text top="124" left="641" width="120" height="20" font="4">dividing the observed </text>
<text top="141" left="641" width="117" height="20" font="4">rates of high severity </text>
<text top="159" left="641" width="110" height="20" font="4">AE by the expected </text>
<text top="176" left="641" width="34" height="20" font="4">rates. </text>
<text top="107" left="780" width="242" height="20" font="4">differences in standardized AE rates among </text>
<text top="124" left="780" width="65" height="20" font="4">institutions. </text>
<text top="195" left="64" width="91" height="20" font="4">Sutton NJ, et al. </text>
<text top="212" left="64" width="56" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(95)</a> </text>
<text top="229" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23006871?dopt=Citation">23006871</a></text>
<text top="229" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23006871?dopt=Citation"> </a></text>
<text top="195" left="178" width="115" height="20" font="4">Retrospective single-</text>
<text top="212" left="178" width="76" height="20" font="4">center review </text>
<text top="195" left="316" width="31" height="20" font="4">n=57 </text>
<text top="212" left="316" width="89" height="20" font="4">catheterizations </text>
<text top="229" left="316" width="90" height="20" font="4">performed in 53 </text>
<text top="247" left="316" width="84" height="20" font="4">adult pts; n=59 </text>
<text top="264" left="316" width="89" height="20" font="4">catheterizations </text>
<text top="281" left="316" width="90" height="20" font="4">performed in 47 </text>
<text top="298" left="316" width="83" height="20" font="4">adolescent pts </text>
<text top="195" left="442" width="167" height="20" font="3"><b>Inclusion criteria</b>: Adults and </text>
<text top="212" left="442" width="119" height="20" font="4">adolescents who had </text>
<text top="229" left="442" width="159" height="20" font="4">catheterization performed by </text>
<text top="247" left="442" width="153" height="20" font="4">pediatric interventional staff </text>
<text top="264" left="442" width="118" height="20" font="4">between 2005–2009. </text>
<text top="195" left="641" width="91" height="20" font="4">● Description of </text>
<text top="212" left="641" width="118" height="20" font="4">procedural outcomes </text>
<text top="229" left="641" width="44" height="20" font="4">and AE </text>
<text top="195" left="780" width="279" height="20" font="4">● 57 catheterizations were performed in 53 adults, </text>
<text top="212" left="780" width="295" height="20" font="4">while 59 were performed in 47 adolescents. The male </text>
<text top="229" left="780" width="287" height="20" font="4">to female ratio differed significantly between groups; </text>
<text top="247" left="780" width="296" height="20" font="4">only 15/53 (28%) of adults were male vs. 26/47 (55%) </text>
<text top="264" left="780" width="266" height="20" font="4">of adolescents (p=0.006). Among adults, 27 had </text>
<text top="281" left="780" width="281" height="20" font="4">previously corrected CHD, 16 with ASD, and 6 with </text>
<text top="298" left="780" width="291" height="20" font="4">PFO. This differed significantly from the adolescents, </text>
<text top="316" left="780" width="286" height="20" font="4">where only 30 had previously corrected CHD, 7 with </text>
<text top="333" left="780" width="285" height="20" font="4">ASD, and 1 with PFO (p=0.012). Among adults who </text>
<text top="350" left="780" width="284" height="20" font="4">were catheterized, interventions were performed on </text>
<text top="367" left="780" width="279" height="20" font="4">28/53 (53%). All interventions were successful and </text>
<text top="384" left="780" width="303" height="20" font="4">included ASD/PFO closure, PDA occlusion, coarctation </text>
<text top="402" left="780" width="302" height="20" font="4">dilation, PA dilations, and 1 SVG aneurysm closure. 19 </text>
<text top="419" left="780" width="289" height="20" font="4">adults had coronary angiography performed by adult </text>
<text top="436" left="780" width="226" height="20" font="4">interventionalists in consult with pediatric </text>
<text top="453" left="780" width="279" height="20" font="4">interventionalists. 2 complications occurred among </text>
<text top="470" left="780" width="275" height="20" font="4">adults (3.8%) vs. 1 complication (2%; p=1) among </text>
<text top="488" left="780" width="267" height="20" font="4">adolescents. No femoral vessel complications or </text>
<text top="505" left="780" width="251" height="20" font="4">catheterization-associated mortality occurred. </text>
<text top="523" left="64" width="88" height="20" font="4">Opotowsky AR, </text>
<text top="540" left="64" width="30" height="20" font="4">et al. </text>
<text top="557" left="64" width="56" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(96)</a> </text>
<text top="574" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19376313?dopt=Citation">19376313</a></text>
<text top="574" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19376313?dopt=Citation"> </a></text>
<text top="523" left="178" width="68" height="20" font="4">Cohort from </text>
<text top="540" left="178" width="115" height="20" font="4">Nationwide Inpatient </text>
<text top="557" left="178" width="45" height="20" font="4">Sample </text>
<text top="523" left="316" width="287" height="20" font="4">n=2,555 procedures  <b>Inclusion criteria</b>: Pts ≥20 y </text>
<text top="540" left="442" width="142" height="20" font="4">admitted to an acute care </text>
<text top="557" left="442" width="178" height="20" font="4">hospital for PFO or ASD closure </text>
<text top="574" left="442" width="121" height="20" font="4">on hospital day 1 or 2 </text>
<text top="523" left="641" width="85" height="20" font="4">● Outcomes of </text>
<text top="540" left="641" width="124" height="20" font="4">interest included LOS, </text>
<text top="557" left="641" width="101" height="20" font="4">charges, and AEs </text>
<text top="523" left="780" width="247" height="20" font="4">● The study included 2,555 (weighted to U.S </text>
<text top="540" left="780" width="255" height="20" font="4">population: 12,544 ± 1,987) PFO/ASD closure </text>
<text top="557" left="780" width="298" height="20" font="4">procedures. Mean age was 52.0 ± 0.4 y, and 57.3% ± </text>
<text top="574" left="780" width="293" height="20" font="4">1.0% were women. Annual hospital volume averaged </text>
<text top="592" left="780" width="290" height="20" font="4">40.8 ± 7.7 procedures (range: 1–114). Overall, 8.2 ± </text>
<text top="609" left="780" width="276" height="20" font="4">0.8% of admissions involved an AE. Older pts and </text>
<text top="626" left="780" width="283" height="20" font="4">those with comorbidities were more likely to sustain </text>
<text top="643" left="780" width="303" height="20" font="4">AE. Use of ICE was associated with fewer AE. The risk </text>
<text top="660" left="780" width="279" height="20" font="4">of AE was inversely proportional to annual hospital </text>
<text top="678" left="780" width="246" height="20" font="4">volume OR: 0.91; 95% CI: 0.86–0.96, per 10 </text>
<text top="695" left="780" width="254" height="20" font="4">procedures), even after limiting the analysis to </text>
<text top="712" left="780" width="283" height="20" font="4">hospitals performing ≥10 procedures annually (OR: </text>
<text top="729" left="780" width="294" height="20" font="4">0.91; 95% CI: 0.85–0.98). AEs were more frequent at </text>
<text top="747" left="780" width="284" height="20" font="4">hospitals in the lowest volume quintile as compared </text>
<text top="764" left="780" width="296" height="20" font="4">with the highest volume quintile (13.3% vs. 5.4%; OR: </text>
<text top="781" left="780" width="144" height="20" font="4">2.42; 95% CI: 1.55–3.78). </text>
</page>
<page number="32" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="11" size="12" family="Times" color="#2a2a2a"/>
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 32 </text>
<text top="107" left="64" width="83" height="20" font="4">Gilard M, et al. </text>
<text top="124" left="64" width="56" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(97)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16697319?dopt=Citation">16697319</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16697319?dopt=Citation"> </a></text>
<text top="107" left="178" width="113" height="20" font="4">Single-center cohort </text>
<text top="124" left="178" width="48" height="20" font="4">analysis </text>
<text top="107" left="316" width="54" height="20" font="4">n=55 pts  </text>
<text top="107" left="442" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="124" left="442" width="137" height="20" font="4">severe AS scheduled for </text>
<text top="141" left="442" width="123" height="20" font="4">preoperative coronary </text>
<text top="159" left="442" width="184" height="20" font="4">angiography who also underwent </text>
<text top="176" left="442" width="150" height="20" font="4">16-slice MSCT 24 h before </text>
<text top="193" left="442" width="122" height="20" font="4">coronary angiography </text>
<text top="107" left="641" width="93" height="20" font="4">● Determine the </text>
<text top="124" left="641" width="80" height="20" font="4">sensitivity and </text>
<text top="141" left="641" width="122" height="20" font="4">specificity of MSCT in </text>
<text top="159" left="641" width="111" height="20" font="4">detecting significant </text>
<text top="176" left="641" width="86" height="20" font="4">coronary artery </text>
<text top="193" left="641" width="52" height="20" font="4">stenosis. </text>
<text top="107" left="780" width="291" height="20" font="11">● The sensitivity of the MSCT in detecting significant </text>
<text top="124" left="780" width="244" height="20" font="11">stenosis was 100%, and its specificity 80%.  </text>
<text top="141" left="780" width="106" height="20" font="11">● The positive and </text>
<text top="141" left="886" width="25" height="20" font="4">NPV</text>
<text top="141" left="912" width="160" height="20" font="11">s were respectively 55% and </text>
<text top="159" left="780" width="42" height="20" font="11">100%.  </text>
<text top="176" left="780" width="269" height="20" font="11">● For calcium scores&lt;1,000 (77% of pts), MSCT </text>
<text top="193" left="780" width="280" height="20" font="11">detected all pts without CAD enabling conventional </text>
<text top="210" left="780" width="119" height="20" font="4">coronary angiography</text>
<text top="210" left="899" width="177" height="20" font="11"> to be avoided in 35 of 55 cases </text>
<text top="228" left="780" width="43" height="20" font="11">(80%).  </text>
<text top="245" left="780" width="249" height="20" font="11">● For calcium scores &gt;1,000, MSCT enabled </text>
<text top="262" left="780" width="72" height="20" font="11">conventional </text>
<text top="262" left="853" width="119" height="20" font="4">coronary angiography</text>
<text top="262" left="972" width="94" height="20" font="11"> to be avoided in </text>
<text top="279" left="780" width="291" height="20" font="11">only 6% of cases, either because significant stenosis </text>
<text top="296" left="780" width="213" height="20" font="11">was found with a possible indication of </text>
<text top="314" left="780" width="299" height="20" font="11">revascularization, or because the examination was not </text>
<text top="331" left="780" width="72" height="20" font="11">interpretable.</text>
<text top="331" left="852" width="3" height="20" font="4"> </text>
<text top="349" left="64" width="89" height="20" font="4">Manghat NE, et </text>
<text top="366" left="64" width="16" height="20" font="4">al. </text>
<text top="383" left="64" width="56" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(98)</a> </text>
<text top="400" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16905381?dopt=Citation">16905381</a></text>
<text top="400" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16905381?dopt=Citation"> </a></text>
<text top="349" left="178" width="113" height="20" font="4">Single-center cohort </text>
<text top="366" left="178" width="48" height="20" font="4">analysis </text>
<text top="349" left="316" width="54" height="20" font="4">n=40 pts  </text>
<text top="349" left="442" width="171" height="20" font="3"><b>Inclusion criteria</b>: Pts with AS </text>
<text top="366" left="442" width="149" height="20" font="4">scheduled for preoperative </text>
<text top="383" left="442" width="126" height="20" font="4">cardiac catheterization </text>
<text top="400" left="442" width="145" height="20" font="4">underwent 16-slice MSCT </text>
<text top="418" left="442" width="139" height="20" font="4">evaluation within 1 mo of </text>
<text top="435" left="442" width="122" height="20" font="4">coronary angiography </text>
<text top="349" left="641" width="81" height="20" font="4">● All 13 major </text>
<text top="366" left="641" width="86" height="20" font="4">coronary artery </text>
<text top="383" left="641" width="87" height="20" font="4">segments were </text>
<text top="400" left="641" width="95" height="20" font="4">evaluated for the </text>
<text top="418" left="641" width="104" height="20" font="4">presence of ≥50% </text>
<text top="435" left="641" width="52" height="20" font="4">stenosis. </text>
<text top="349" left="780" width="12" height="20" font="11">● </text>
<text top="349" left="793" width="252" height="20" font="4">A total of 412/450 segments from 35 pts were </text>
<text top="366" left="780" width="118" height="20" font="4">suitable for analysis.  </text>
<text top="383" left="780" width="12" height="20" font="11">● </text>
<text top="383" left="793" width="254" height="20" font="4">The overall accuracy of MSCT for detection of </text>
<text top="400" left="780" width="258" height="20" font="4">segments with ≥50% stenosis was high, with a </text>
<text top="418" left="780" width="256" height="20" font="4">sensitivity of 81.3%, specificity 95.0%, positive </text>
<text top="435" left="780" width="228" height="20" font="4">predictive value 57.8%, and NPV 98.4%.  </text>
<text top="452" left="780" width="12" height="20" font="11">● </text>
<text top="452" left="793" width="260" height="20" font="4">On a &#34;whole-pt&#34; basis, 100% (19/19) of pts with </text>
<text top="469" left="780" width="276" height="20" font="4">significant CAD were correctly identified and there </text>
<text top="487" left="780" width="140" height="20" font="4">were no false-negatives.  </text>
<text top="504" left="780" width="269" height="20" font="4">Excluding pts with CAC &gt;1,000 from the analysis </text>
<text top="521" left="780" width="293" height="20" font="4">improved the accuracy of MDCTA to: sensitivity 90%, </text>
<text top="538" left="780" width="293" height="20" font="4">specificity 98.1%, positive predictive value 60%, NPV </text>
<text top="555" left="780" width="42" height="20" font="4">99.7%. </text>
<text top="573" left="64" width="97" height="20" font="4">Meijboom WB, et </text>
<text top="591" left="64" width="16" height="20" font="4">al. </text>
<text top="608" left="64" width="56" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(99)</a> </text>
<text top="625" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17045904?dopt=Citation">17045904</a></text>
<text top="625" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17045904?dopt=Citation"> </a></text>
<text top="573" left="178" width="76" height="20" font="4">Single-center </text>
<text top="591" left="178" width="104" height="20" font="4">prospective cohort </text>
<text top="608" left="178" width="48" height="20" font="4">analysis </text>
<text top="573" left="316" width="54" height="20" font="4">n=70 pts  </text>
<text top="573" left="442" width="149" height="20" font="3"><b>Inclusion criteria</b>: 145 pts </text>
<text top="591" left="442" width="166" height="20" font="4">prospectively identified from a </text>
<text top="608" left="442" width="142" height="20" font="4">consecutive pt population </text>
<text top="625" left="442" width="154" height="20" font="4">scheduled for valve surgery </text>
<text top="642" left="442" width="3" height="20" font="4"> </text>
<text top="659" left="442" width="146" height="20" font="3"><b>Exclusion criteria</b>: 35 pts </text>
<text top="677" left="442" width="165" height="20" font="4">excluded because of irregular </text>
<text top="694" left="442" width="155" height="20" font="4">rhythm, renal dysfunction or </text>
<text top="711" left="442" width="179" height="20" font="4">contrast allergy. Other exclusion </text>
<text top="728" left="442" width="176" height="20" font="4">criteria included: Hospitalization </text>
<text top="745" left="442" width="185" height="20" font="4">in a community hospital, previous </text>
<text top="763" left="442" width="174" height="20" font="4">coronary bypass or stenting. Of </text>
<text top="573" left="641" width="126" height="20" font="4">● Diagnostic accuracy </text>
<text top="591" left="641" width="120" height="20" font="4">of 64-slice MDCTA to </text>
<text top="608" left="641" width="95" height="20" font="4">detect significant </text>
<text top="625" left="641" width="33" height="20" font="4">CAD. </text>
<text top="573" left="780" width="295" height="20" font="4">● Prevalence of significant CAD, defined as having at </text>
<text top="591" left="780" width="209" height="20" font="4">least 1≥50% stenosis/pt, was 25.7%.  </text>
<text top="608" left="780" width="12" height="20" font="11">● </text>
<text top="608" left="793" width="282" height="20" font="4">On a per-pt analysis, the sensitivity, specificity, and </text>
<text top="625" left="780" width="295" height="20" font="4">positive and NPVs were: 100% (18 of 18; 95% CI: 78–</text>
<text top="642" left="780" width="291" height="20" font="4">100), 92% (48 of 52; 95% CI: 81–98), 82% (18 of 22; </text>
<text top="659" left="780" width="274" height="20" font="4">95% CI: 59–94), and 100% (48 of 48; 95% CI: 91–</text>
<text top="677" left="780" width="103" height="20" font="4">100), respectively. </text>
</page>
<page number="33" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 33 </text>
<text top="107" left="442" width="176" height="20" font="4">the remaining 97 pts, 27 did not </text>
<text top="124" left="442" width="50" height="20" font="4">consent. </text>
<text top="141" left="442" width="3" height="20" font="4"> </text>
<text top="159" left="442" width="173" height="20" font="4">The study population consisted </text>
<text top="176" left="442" width="54" height="20" font="4">of 70 pts. </text>
<text top="194" left="64" width="81" height="20" font="4">Reant P, et al. </text>
<text top="211" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(100)</a> </text>
<text top="228" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16679094?dopt=Citation">16679094</a></text>
<text top="228" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16679094?dopt=Citation"> </a></text>
<text top="194" left="178" width="76" height="20" font="4">Single-center </text>
<text top="211" left="178" width="104" height="20" font="4">prospective cohort </text>
<text top="228" left="178" width="48" height="20" font="4">analysis </text>
<text top="194" left="316" width="54" height="20" font="4">n=40 pts  </text>
<text top="194" left="442" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="211" left="442" width="158" height="20" font="4">severe acquired valvular HD </text>
<text top="228" left="442" width="180" height="20" font="4">underwent 16-slice MSCT within </text>
<text top="246" left="442" width="160" height="20" font="4">2 d of coronary angiography. </text>
<text top="194" left="641" width="84" height="20" font="4">● Evaluate the </text>
<text top="211" left="641" width="109" height="20" font="4">predictive values of </text>
<text top="228" left="641" width="117" height="20" font="4">16-slice MSCT in the </text>
<text top="246" left="641" width="125" height="20" font="4">detection of significant </text>
<text top="263" left="641" width="100" height="20" font="4">coronary stenosis </text>
<text top="194" left="780" width="280" height="20" font="4">● 458/600 coronary artery segments (77.3%) were </text>
<text top="211" left="780" width="190" height="20" font="4">considered assessable by MSCT.  </text>
<text top="228" left="780" width="289" height="20" font="4">● In a per-segment analysis, the sensitivity of MSCT </text>
<text top="245" left="780" width="293" height="20" font="4">for the detection of significant coronary lesions ≥50% </text>
<text top="263" left="780" width="267" height="20" font="4">was 77.7%, the specificity was 98%, the positive </text>
<text top="280" left="780" width="289" height="20" font="4">predictive value was 42.4%, and the NPV was 99%.  </text>
<text top="297" left="780" width="287" height="20" font="4">● The main cause of false-positive or false-negative </text>
<text top="314" left="780" width="271" height="20" font="4">results or nonassessable evaluations was severe </text>
<text top="332" left="780" width="245" height="20" font="4">coronary calcification. In a per-pt analysis, in </text>
<text top="349" left="780" width="284" height="20" font="4">comparison with quantitative coronary angiography, </text>
<text top="366" left="780" width="246" height="20" font="4">MSCT correctly classified 33/40 pts (82.5%). </text>
<text top="384" left="64" width="94" height="20" font="4">Scheffel H, et al. </text>
<text top="401" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(101)</a> </text>
<text top="418" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17697832?dopt=Citation">17697832</a></text>
<text top="418" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17697832?dopt=Citation"> </a></text>
<text top="384" left="178" width="113" height="20" font="4">Single-center cohort </text>
<text top="401" left="178" width="48" height="20" font="4">analysis </text>
<text top="384" left="316" width="31" height="20" font="4">n=50 </text>
<text top="384" left="442" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="401" left="442" width="148" height="20" font="4">chronic aortic regurgitation </text>
<text top="418" left="442" width="154" height="20" font="4">referred for elective surgery </text>
<text top="436" left="442" width="169" height="20" font="4">underwent 64-slice MSCT and </text>
<text top="453" left="442" width="122" height="20" font="4">coronary angiography </text>
<text top="384" left="641" width="12" height="20" font="11">● </text>
<text top="384" left="653" width="72" height="20" font="4">Evaluate the </text>
<text top="401" left="641" width="125" height="20" font="4">diagnostic accuracy of </text>
<text top="418" left="641" width="123" height="20" font="4">MSCT for detection of </text>
<text top="436" left="641" width="109" height="20" font="4">significant coronary </text>
<text top="453" left="641" width="83" height="20" font="4">artery stenosis </text>
<text top="384" left="780" width="12" height="20" font="11">● </text>
<text top="384" left="793" width="284" height="20" font="4">50 consecutive pts with chronic aortic root (38 men, </text>
<text top="401" left="780" width="271" height="20" font="4">mean age 54 ± 14 y) scheduled for valve surgery </text>
<text top="418" left="780" width="298" height="20" font="4">underwent 64-slice MSCT and coronary angiography.  </text>
<text top="436" left="780" width="12" height="20" font="11">● </text>
<text top="436" left="793" width="247" height="20" font="4">Significant stenosis was defined as a luminal </text>
<text top="453" left="780" width="144" height="20" font="4">diameter decrease &gt;50%. </text>
<text top="470" left="780" width="12" height="20" font="11">● </text>
<text top="470" left="793" width="257" height="20" font="4">Mean Agatston score was 136 ± 278 (range 0–</text>
<text top="487" left="780" width="273" height="20" font="4">1,207); prevalence of significant CAD in the study </text>
<text top="504" left="780" width="183" height="20" font="4">population was 26% (13/50 pts).  </text>
<text top="522" left="780" width="12" height="20" font="11">● </text>
<text top="522" left="793" width="288" height="20" font="4">13 of 742 segments (1.8%) in 3 pts were considered </text>
<text top="539" left="780" width="275" height="20" font="4">nondiagnostic with CT because of motion artifacts </text>
<text top="556" left="780" width="131" height="20" font="4">(n=9) or calcium (n=4).  </text>
<text top="573" left="780" width="12" height="20" font="11">● </text>
<text top="573" left="793" width="239" height="20" font="4">In a pt-based analysis taking nonevaluative </text>
<text top="591" left="780" width="304" height="20" font="4">segments as falsely positive, sensitivity, specificity, and </text>
<text top="608" left="780" width="293" height="20" font="4">positive and NPVs of CT were 100%, 95%, 87%, and </text>
<text top="625" left="780" width="114" height="20" font="4">100%, respectively.  </text>
<text top="642" left="780" width="12" height="20" font="11">● </text>
<text top="642" left="793" width="289" height="20" font="4">Preoperative coronary angiography could have been </text>
<text top="659" left="780" width="289" height="20" font="4">avoided in 70% of pts (35/50), coronary angiography </text>
<text top="677" left="780" width="254" height="20" font="4">would have been performed to confirm the CT </text>
<text top="694" left="780" width="291" height="20" font="4">diagnosis in 26% (13/50), and unnecessary coronary </text>
<text top="711" left="780" width="297" height="20" font="4">angiography would have been performed in 4% (2/50) </text>
<text top="728" left="780" width="222" height="20" font="4">on the basis of false-positive CT ratings. </text>
<text top="746" left="64" width="81" height="20" font="4">Galas A, et al. </text>
<text top="763" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(102)</a> </text>
<text top="781" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22992993?dopt=Citation">22992993</a></text>
<text top="781" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22992993?dopt=Citation"> </a></text>
<text top="746" left="178" width="113" height="20" font="4">Single-center cohort </text>
<text top="763" left="178" width="48" height="20" font="4">analysis </text>
<text top="746" left="316" width="54" height="20" font="4">n=98 pts  </text>
<text top="746" left="442" width="181" height="20" font="3"><b>Inclusion criteria</b>: Pts with VHD </text>
<text top="763" left="442" width="167" height="20" font="4">scheduled for elective surgery </text>
<text top="746" left="641" width="84" height="20" font="4">● Evaluate the </text>
<text top="763" left="641" width="114" height="20" font="4">usefulness of MSCT </text>
<text top="781" left="641" width="85" height="20" font="4">before planned </text>
<text top="746" left="780" width="234" height="20" font="4">● Mean pt age was 58.8 (range 30–78) y.  </text>
</page>
<page number="34" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 34 </text>
<text top="107" left="442" width="172" height="20" font="4">underwent MSCT in addition to </text>
<text top="124" left="442" width="126" height="20" font="4">coronary angiography. </text>
<text top="141" left="442" width="3" height="20" font="4"> </text>
<text top="159" left="442" width="152" height="20" font="3"><b>Exclusion criteria</b>: Criteria </text>
<text top="176" left="442" width="151" height="20" font="4">included arrhythmias, renal </text>
<text top="193" left="442" width="185" height="20" font="4">dysfunction, iodine allergy or lack </text>
<text top="210" left="442" width="77" height="20" font="4">of pt consent. </text>
<text top="107" left="641" width="89" height="20" font="4">cardiac valvular </text>
<text top="124" left="641" width="44" height="20" font="4">surgery </text>
<text top="107" left="780" width="295" height="20" font="4">● CAC score was first determined in all pts. Coronary </text>
<text top="124" left="780" width="294" height="20" font="4">CT angiography was not performed if CAC score was </text>
<text top="141" left="780" width="48" height="20" font="4">&gt;1,000.  </text>
<text top="159" left="780" width="285" height="20" font="4">● In the remaining pts, complete CT evaluation was </text>
<text top="176" left="780" width="294" height="20" font="4">performed with the administration of a contrast agent. </text>
<text top="193" left="780" width="271" height="20" font="4">Conventional invasive coronary angiography was </text>
<text top="210" left="780" width="278" height="20" font="4">subsequently performed in pts with at least 1&gt;50% </text>
<text top="228" left="780" width="267" height="20" font="4">stenosis, artifacts due to calcifications, or motion </text>
<text top="245" left="780" width="50" height="20" font="4">artifacts. </text>
<text top="262" left="780" width="277" height="20" font="4">● In 79 (80.6%) pts, CT angiography excluded the </text>
<text top="279" left="780" width="271" height="20" font="4">presence of a significant coronary artery stenosis </text>
<text top="296" left="780" width="234" height="20" font="4">without the need for invasive angiography. </text>
<text top="314" left="780" width="302" height="20" font="4">Conventional coronary angiography was required in 19 </text>
<text top="331" left="780" width="276" height="20" font="4">(19.4%) pts, including 13 (13.3%) pts with a &gt;50% </text>
<text top="348" left="780" width="240" height="20" font="4">stenosis in CT angiography, 2 (2%) pts with </text>
<text top="365" left="780" width="296" height="20" font="4">calcification artifacts, 1 (1%) pt with motion artifacts, 2 </text>
<text top="383" left="780" width="248" height="20" font="4">(2%) pts with CAC score &gt;1,000 in whom CT </text>
<text top="400" left="780" width="282" height="20" font="4">angiography was not performed, and 1 (1%) pt with </text>
<text top="417" left="780" width="297" height="20" font="4">allergic symptoms during administration of a test dose </text>
<text top="434" left="780" width="119" height="20" font="4">of the contrast agent. </text>
<text top="451" left="780" width="269" height="20" font="4">● Ultimately, significant CAD was diagnosed in 9 </text>
<text top="469" left="780" width="282" height="20" font="4">(9.2%) pts in whom coronary artery bypass surgery </text>
<text top="486" left="780" width="118" height="20" font="4">was also performed.  </text>
<text top="503" left="780" width="300" height="20" font="4">● In addition, vascular anomalies were diagnosed with </text>
<text top="520" left="780" width="224" height="20" font="4">cardiac CT angiography in 5 (5.1%) pts.  </text>
<text top="537" left="780" width="257" height="20" font="4">● In 14 pts, CT angiography was also used for </text>
<text top="555" left="780" width="281" height="20" font="4">previously planned evaluation of a coexisting aortic </text>
<text top="572" left="780" width="61" height="20" font="4">aneurysm. </text>
<text top="590" left="108" width="3" height="20" font="4"> </text>
<text top="607" left="108" width="3" height="20" font="4"> </text>
<text top="624" left="108" width="377" height="24" font="1"><b>Data Supplement 11. Exercise Testing – Section 3.4.7 </b></text>
<text top="646" left="92" width="38" height="20" font="3"><b>Study </b></text>
<text top="663" left="67" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="680" left="96" width="30" height="20" font="3"><b>Year </b></text>
<text top="646" left="178" width="118" height="20" font="3"><b>Study Type/ Design </b></text>
<text top="646" left="333" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="646" left="433" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="663" left="469" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="646" left="579" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="646" left="716" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="646" left="905" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="698" left="64" width="86" height="20" font="4">Diller GP, et al. </text>
<text top="715" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(103)</a> </text>
<text top="732" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16061735?dopt=Citation">16061735</a></text>
<text top="732" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16061735?dopt=Citation"> </a></text>
<text top="698" left="170" width="128" height="20" font="4">Case series of pts who </text>
<text top="715" left="170" width="118" height="20" font="4">had cardiopulmonary </text>
<text top="732" left="170" width="96" height="20" font="4">exercise testing.  </text>
<text top="698" left="316" width="99" height="20" font="4">n=335 ACHD pts; </text>
<text top="715" left="316" width="31" height="20" font="4">n=40 </text>
<text top="732" left="316" width="100" height="20" font="4">noncongenital HF </text>
<text top="750" left="316" width="94" height="20" font="4">pts n=11 healthy </text>
<text top="767" left="316" width="49" height="20" font="4">subjects </text>
<text top="698" left="429" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="715" left="429" width="109" height="20" font="4">Consecutive ACHD </text>
<text top="732" left="429" width="93" height="20" font="4">pts and selected </text>
<text top="750" left="429" width="111" height="20" font="4">controls undergoing </text>
<text top="767" left="429" width="94" height="20" font="4">cardiopulmonary </text>
<text top="784" left="429" width="40" height="20" font="4">testing </text>
<text top="698" left="569" width="41" height="20" font="4">Peak O</text>
<text top="704" left="610" width="4" height="13" font="6">2</text>
<text top="698" left="614" width="3" height="20" font="4"> </text>
<text top="715" left="569" width="73" height="20" font="4">consumption </text>
<text top="698" left="674" width="62" height="20" font="4">● Peak VO</text>
<text top="704" left="736" width="4" height="13" font="6">2</text>
<text top="698" left="740" width="89" height="20" font="4"> was reduced in </text>
<text top="715" left="674" width="185" height="20" font="4">ACHD pts compared with healthy </text>
<text top="732" left="674" width="168" height="20" font="4">subjects of similar age (21.7 ± </text>
<text top="750" left="674" width="177" height="20" font="4">8.5 vs. 45.1 ± 8.6; p&lt;0.001). No </text>
<text top="767" left="674" width="176" height="20" font="4">significant difference in peak VO</text>
<text top="773" left="851" width="4" height="13" font="6">2</text>
<text top="767" left="855" width="3" height="20" font="4"> </text>
<text top="784" left="674" width="171" height="20" font="4">was found between ACHD and </text>
<text top="698" left="873" width="198" height="20" font="4">● Exercise capacity is depressed in </text>
<text top="715" left="873" width="157" height="20" font="4">ACHD pts (even in allegedly </text>
<text top="732" left="873" width="177" height="20" font="4">asymptomatic pts) on a par with </text>
<text top="750" left="873" width="115" height="20" font="4">chronic HF subjects. </text>
</page>
<page number="35" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 35 </text>
<text top="107" left="674" width="172" height="20" font="4">HF pts of corresponding NYHA </text>
<text top="124" left="674" width="152" height="20" font="4">class. On multivariable Cox </text>
<text top="141" left="674" width="99" height="20" font="4">analysis, peak VO</text>
<text top="148" left="773" width="4" height="13" font="6">2</text>
<text top="141" left="778" width="57" height="20" font="4"> predicted </text>
<text top="159" left="674" width="158" height="20" font="4">hospitalization or death (HR: </text>
<text top="176" left="674" width="173" height="20" font="4">0.937; p=0.01) and was related </text>
<text top="193" left="674" width="177" height="20" font="4">to the frequency and duration of </text>
<text top="210" left="674" width="182" height="20" font="4">hospitalization (p=0.01 for each). </text>
<text top="107" left="873" width="192" height="20" font="4">● Poor exercise capacity identifies </text>
<text top="124" left="873" width="193" height="20" font="4">ACHD pts at risk for hospitalization </text>
<text top="141" left="873" width="52" height="20" font="4">or death. </text>
<text top="228" left="64" width="82" height="20" font="4">Hager A, et al. </text>
<text top="245" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(104)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15772218?dopt=Citation">15772218</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15772218?dopt=Citation"> </a></text>
<text top="228" left="170" width="101" height="20" font="4">Prospective cross-</text>
<text top="245" left="170" width="125" height="20" font="4">sectional clinical study </text>
<text top="228" left="316" width="61" height="20" font="4">n=149 pts  </text>
<text top="228" left="429" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="245" left="429" width="103" height="20" font="4">ACHD pts from an </text>
<text top="263" left="429" width="118" height="20" font="4">ACHD referral center </text>
<text top="228" left="569" width="74" height="20" font="4">Peak oxygen </text>
<text top="245" left="569" width="40" height="20" font="4">uptake </text>
<text top="228" left="674" width="53" height="20" font="4">● Peak O</text>
<text top="234" left="728" width="4" height="13" font="6">2</text>
<text top="228" left="732" width="102" height="20" font="4"> uptake correlated </text>
<text top="245" left="674" width="161" height="20" font="4">significantly with the physical </text>
<text top="263" left="674" width="175" height="20" font="4">functioning (r=0.521; p&lt;0.0005) </text>
<text top="280" left="674" width="143" height="20" font="4">and general health scales </text>
<text top="297" left="674" width="179" height="20" font="4">(r=0.313; p&lt;0.0005) but not with </text>
<text top="314" left="674" width="182" height="20" font="4">role physical, bodily pain, vitality, </text>
<text top="332" left="674" width="186" height="20" font="4">social functioning, role-emotional, </text>
<text top="349" left="674" width="141" height="20" font="4">mental health, and health </text>
<text top="366" left="674" width="98" height="20" font="4">transition scales.  </text>
<text top="228" left="873" width="146" height="20" font="4">● Exercise tests and QOL </text>
<text top="245" left="873" width="154" height="20" font="4">instruments should be used </text>
<text top="263" left="873" width="180" height="20" font="4">together to get a comprehensive </text>
<text top="280" left="873" width="170" height="20" font="4">health status of a pt with CHD. </text>
<text top="384" left="64" width="90" height="20" font="4">Gungor H, et al. </text>
<text top="401" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(105)</a> </text>
<text top="418" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23861135?dopt=Citation">23861135</a></text>
<text top="418" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23861135?dopt=Citation"> </a></text>
<text top="384" left="170" width="108" height="20" font="4">Case series (single-</text>
<text top="401" left="170" width="42" height="20" font="4">center) </text>
<text top="384" left="316" width="54" height="20" font="4">n=23 pts  </text>
<text top="384" left="429" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="401" left="429" width="101" height="20" font="4">with Eisenmenger </text>
<text top="418" left="429" width="109" height="20" font="4">syndrome; awaiting </text>
<text top="436" left="429" width="116" height="20" font="4">heart-lung transplant </text>
<text top="384" left="569" width="66" height="20" font="4">Association </text>
<text top="401" left="569" width="74" height="20" font="4">between and </text>
<text top="418" left="569" width="90" height="20" font="4">TTE and 6MWT </text>
<text top="436" left="569" width="82" height="20" font="4">CPET findings </text>
<text top="384" left="674" width="162" height="20" font="4">● Result of 6MWT correlated </text>
<text top="401" left="674" width="94" height="20" font="4">only with SPAP.  </text>
<text top="418" left="674" width="165" height="20" font="4">● SPAP did not correlate with </text>
<text top="436" left="674" width="109" height="20" font="4">any CPET findings. </text>
<text top="384" left="873" width="176" height="20" font="4">● 6MWT distance may be more </text>
<text top="401" left="873" width="195" height="20" font="4">suitable than CPET in the follow-up </text>
<text top="418" left="873" width="195" height="20" font="4">of pts with Eisenmenger syndrome. </text>
<text top="454" left="64" width="87" height="20" font="4">Ross RM, et al. </text>
<text top="471" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(106)</a> </text>
<text top="488" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20504351?dopt=Citation">20504351</a></text>
<text top="488" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20504351?dopt=Citation"> </a></text>
<text top="454" left="170" width="116" height="20" font="4">Meta-analysis: linear </text>
<text top="471" left="170" width="121" height="20" font="4">mixed model analysis </text>
<text top="488" left="170" width="115" height="20" font="4">of multiple studies in </text>
<text top="505" left="170" width="128" height="20" font="4">which 6MWT and peak </text>
<text top="522" left="170" width="18" height="20" font="4">VO</text>
<text top="529" left="188" width="4" height="13" font="6">2</text>
<text top="522" left="192" width="98" height="20" font="4"> from CPET were </text>
<text top="540" left="170" width="52" height="20" font="4">available </text>
<text top="454" left="316" width="71" height="20" font="4">n=1,083 pts  </text>
<text top="454" left="429" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="471" left="429" width="45" height="20" font="4">Diverse </text>
<text top="488" left="429" width="94" height="20" font="4">cardiopulmonary </text>
<text top="505" left="429" width="54" height="20" font="4">disorders </text>
<text top="454" left="569" width="89" height="20" font="4">Development of </text>
<text top="471" left="569" width="67" height="20" font="4">generalized </text>
<text top="488" left="569" width="51" height="20" font="4">equation </text>
<text top="505" left="569" width="87" height="20" font="4">predicting peak </text>
<text top="522" left="569" width="18" height="20" font="4">VO</text>
<text top="529" left="586" width="4" height="13" font="6">2</text>
<text top="522" left="591" width="31" height="20" font="4"> from </text>
<text top="540" left="569" width="40" height="20" font="4">6MWT </text>
<text top="454" left="674" width="142" height="20" font="4">● Large standard error of </text>
<text top="471" left="674" width="139" height="20" font="4">estimate when applied to </text>
<text top="488" left="674" width="78" height="20" font="4">individual pts. </text>
<text top="454" left="873" width="170" height="20" font="4">● General correlation between </text>
<text top="471" left="873" width="81" height="20" font="4">6MWT and VO</text>
<text top="477" left="955" width="4" height="13" font="6">2</text>
<text top="471" left="959" width="83" height="20" font="4"> max shown to </text>
<text top="488" left="873" width="90" height="20" font="4">apply in groups. </text>
<text top="558" left="54" width="3" height="20" font="4"> </text>
<text top="575" left="108" width="3" height="20" font="4"> </text>
<text top="592" left="108" width="399" height="24" font="1"><b>Data Supplement 12. Transition Education – Section 3.5  </b></text>
<text top="613" left="93" width="38" height="20" font="3"><b>Study </b></text>
<text top="631" left="68" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="648" left="96" width="30" height="20" font="3"><b>Year </b></text>
<text top="613" left="194" width="38" height="20" font="3"><b>Study </b></text>
<text top="631" left="174" width="76" height="20" font="3"><b>Type/Design </b></text>
<text top="613" left="278" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="613" left="389" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="631" left="426" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="613" left="571" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="613" left="742" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="613" left="934" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="666" left="64" width="75" height="20" font="4">Wray J, et al. </text>
<text top="683" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(107)</a> </text>
<text top="700" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23257171">23257171</a></text>
<text top="700" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23257171"> </a></text>
<text top="666" left="172" width="40" height="20" font="4">Cohort </text>
<text top="666" left="266" width="71" height="20" font="4">n=1,085 pts  </text>
<text top="666" left="368" width="159" height="20" font="3"><b>Inclusion criteria</b>: TOF with </text>
<text top="683" left="368" width="113" height="20" font="4">surgery 1964–2009; </text>
<text top="700" left="368" width="126" height="20" font="4">excluded extra cardiac </text>
<text top="717" left="368" width="146" height="20" font="4">conduits and overseas pts </text>
<text top="666" left="543" width="127" height="20" font="4">Survival, freedom from </text>
<text top="683" left="543" width="122" height="20" font="4">surgery, loss of follow-</text>
<text top="700" left="543" width="17" height="20" font="4">up </text>
<text top="666" left="685" width="213" height="20" font="4">● 24% followed by general cardiology; </text>
<text top="683" left="685" width="190" height="20" font="4">48% of late death in this group; no </text>
<text top="700" left="685" width="153" height="20" font="4">PVR in this group vs. 28%.  </text>
<text top="666" left="914" width="162" height="20" font="4">● Loss of specialist follow-up </text>
<text top="683" left="914" width="135" height="20" font="4">impacts pt management </text>
<text top="735" left="64" width="81" height="20" font="4">Gurvitz MZ, et </text>
<text top="753" left="64" width="16" height="20" font="4">al. </text>
<text top="770" left="64" width="56" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(40)</a> </text>
<text top="787" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17320746?dopt=Citation">17320746</a></text>
<text top="787" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17320746?dopt=Citation"> </a></text>
<text top="735" left="172" width="61" height="20" font="4">Population </text>
<text top="753" left="172" width="33" height="20" font="4">study </text>
<text top="735" left="266" width="48" height="20" font="4">n=9,017 </text>
<text top="753" left="266" width="87" height="20" font="4">hospitalizations </text>
<text top="735" left="368" width="161" height="20" font="3"><b>Inclusion criteria</b>: California </text>
<text top="753" left="368" width="109" height="20" font="4">hospital discharges </text>
<text top="735" left="543" width="117" height="20" font="4">12–44 y, with a 1° or </text>
<text top="753" left="543" width="123" height="20" font="4">2° ICD-9-CM code for </text>
<text top="770" left="543" width="30" height="20" font="4">CHD </text>
<text top="735" left="685" width="203" height="20" font="4">● Percentage of pts admitted via ED </text>
<text top="753" left="685" width="117" height="20" font="4">doubled in early 20s. </text>
<text top="735" left="914" width="152" height="20" font="4">● No private insurance and </text>
<text top="753" left="914" width="137" height="20" font="4">&gt;17 more likely admitted </text>
<text top="770" left="914" width="69" height="20" font="4">through ED. </text>
</page>
<page number="36" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 36 </text>
<text top="107" left="64" width="91" height="20" font="4">Goossens, E, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(108)</a> </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23420323">23420323</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23420323"> </a></text>
<text top="107" left="172" width="36" height="20" font="4">Cross-</text>
<text top="124" left="172" width="52" height="20" font="4">sectional </text>
<text top="107" left="266" width="61" height="20" font="4">n=317 pts  </text>
<text top="107" left="368" width="139" height="20" font="3"><b>Inclusion criteria</b>: CHD, </text>
<text top="124" left="368" width="136" height="20" font="4">literate, Dutch speakers, </text>
<text top="141" left="368" width="83" height="20" font="4">verbal consent </text>
<text top="159" left="368" width="3" height="20" font="4"> </text>
<text top="176" left="368" width="161" height="20" font="3"><b>Exclusion criteria</b>: Learning </text>
<text top="193" left="368" width="148" height="20" font="4">disability, no regular follow-</text>
<text top="210" left="368" width="159" height="20" font="4">up, newly diagnosed ASD or </text>
<text top="227" left="368" width="97" height="20" font="4">PFO after stroke  </text>
<text top="107" left="543" width="97" height="20" font="4">Knowledge using </text>
<text top="124" left="543" width="108" height="20" font="4">Leuven Knowledge </text>
<text top="141" left="543" width="128" height="20" font="4">Questionnaire for CHD </text>
<text top="107" left="685" width="196" height="20" font="4">● Pts in structured education group </text>
<text top="124" left="685" width="194" height="20" font="4">had mean total knowledge score of </text>
<text top="141" left="685" width="190" height="20" font="4">57% vs. 43% in comparison group </text>
<text top="159" left="685" width="56" height="20" font="4">(p&lt;0.001) </text>
<text top="107" left="914" width="168" height="20" font="4">● Structured pt education with </text>
<text top="124" left="914" width="161" height="20" font="4">advanced practice nurse can </text>
<text top="141" left="914" width="165" height="20" font="4">be effective in improving level </text>
<text top="159" left="914" width="122" height="20" font="4">of knowledge in CHD. </text>
<text top="245" left="64" width="90" height="20" font="4">Gurvitz M, et al. </text>
<text top="263" left="64" width="53" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(6)</a>  </text>
<text top="280" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23542112">23542112</a></text>
<text top="280" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23542112"> </a></text>
<text top="245" left="172" width="64" height="20" font="4">Multicenter </text>
<text top="263" left="172" width="66" height="20" font="4">prospective </text>
<text top="280" left="172" width="37" height="20" font="4">cross- </text>
<text top="297" left="172" width="52" height="20" font="4">sectional </text>
<text top="314" left="172" width="33" height="20" font="4">study </text>
<text top="245" left="266" width="86" height="20" font="4">n=922 pts from </text>
<text top="263" left="266" width="61" height="20" font="4">12 centers </text>
<text top="245" left="368" width="151" height="20" font="3"><b>Inclusion criteria</b>: Pts &gt;18 </text>
<text top="263" left="368" width="151" height="20" font="4">y, CHD on 1st presentation </text>
<text top="280" left="368" width="158" height="20" font="4">to CHD care between Jan 1, </text>
<text top="297" left="368" width="118" height="20" font="4">2009–Dec 31, 2010.  </text>
<text top="314" left="368" width="3" height="20" font="4"> </text>
<text top="332" left="368" width="158" height="20" font="3"><b>Exclusion criteria</b>: No CHD </text>
<text top="349" left="368" width="132" height="20" font="4">or unable to fill form at 8</text>
<text top="351" left="500" width="7" height="13" font="6">th</text>
<text top="349" left="506" width="3" height="20" font="4"> </text>
<text top="366" left="368" width="108" height="20" font="4">grade reading level </text>
<text top="245" left="543" width="103" height="20" font="4">Gaps in care &gt;3 y; </text>
<text top="263" left="543" width="86" height="20" font="4">barriers to care </text>
<text top="245" left="685" width="205" height="20" font="4">● 42% reported gap in care; typically </text>
<text top="263" left="685" width="199" height="20" font="4">at 19.9 y; more common in mild and </text>
<text top="280" left="685" width="206" height="20" font="4">moderate CHD; Western states more </text>
<text top="297" left="685" width="102" height="20" font="4">likely to have gap. </text>
<text top="245" left="914" width="172" height="20" font="4">● Gaps in care common in late </text>
<text top="263" left="914" width="163" height="20" font="4">teenage years, during time of </text>
<text top="280" left="914" width="109" height="20" font="4">transition to ACHD. </text>
<text top="384" left="64" width="79" height="20" font="4">Mackie AS, et </text>
<text top="401" left="64" width="16" height="20" font="4">al. </text>
<text top="418" left="64" width="56" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(42)</a> </text>
<text top="436" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24842870">24842870</a></text>
<text top="436" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24842870"> </a></text>
<text top="384" left="172" width="66" height="20" font="4">Clinical trial </text>
<text top="384" left="266" width="54" height="20" font="4">n=58 pts  </text>
<text top="384" left="368" width="153" height="20" font="3"><b>Inclusion criteria</b>: 15–17 y </text>
<text top="401" left="368" width="144" height="20" font="4">with moderate or complex </text>
<text top="418" left="368" width="138" height="20" font="4">CHD or cardiomyopathy. </text>
<text top="436" left="368" width="153" height="20" font="4">Allocated to usual care or 1-</text>
<text top="453" left="368" width="154" height="20" font="4">h nurse-led 1-on-1 teaching </text>
<text top="384" left="543" width="120" height="20" font="4">Determine the impact </text>
<text top="401" left="543" width="102" height="20" font="4">of a transition (1 h </text>
<text top="418" left="543" width="125" height="20" font="4">nurse led) intervention </text>
<text top="436" left="543" width="74" height="20" font="4">on improving </text>
<text top="453" left="543" width="109" height="20" font="4">knowledge and self-</text>
<text top="470" left="543" width="105" height="20" font="4">management skills </text>
<text top="384" left="685" width="170" height="20" font="4">● Mean self-management true </text>
<text top="401" left="685" width="204" height="20" font="4">advertising quality score was 3.59 (± </text>
<text top="418" left="685" width="197" height="20" font="4">0.83) vs. 3.16 (± 1.05), respectively </text>
<text top="436" left="685" width="214" height="20" font="4">(p=0.048, adjusted for baseline score); </text>
<text top="453" left="685" width="158" height="20" font="4">the mean self-advocacy true </text>
<text top="470" left="685" width="204" height="20" font="4">advertising quality score was 4.38 (± </text>
<text top="487" left="685" width="199" height="20" font="4">0.56) vs. 4.01 (± 0.95) (p=0.18) and </text>
<text top="504" left="685" width="207" height="20" font="4">the mean MyHeart score was 75% (± </text>
<text top="522" left="685" width="165" height="20" font="4">15) vs. 61% (± 25) (p=0.019). </text>
<text top="384" left="914" width="157" height="20" font="4">● The transition intervention </text>
<text top="401" left="914" width="118" height="20" font="4">resulted in significant </text>
<text top="418" left="914" width="111" height="20" font="4">improvement in self-</text>
<text top="436" left="914" width="142" height="20" font="4">management and cardiac </text>
<text top="453" left="914" width="109" height="20" font="4">knowledge scores.  </text>
<text top="470" left="914" width="164" height="20" font="4">● An educational intervention </text>
<text top="487" left="914" width="174" height="20" font="4">should be routine for youth with </text>
<text top="504" left="914" width="149" height="20" font="4">congenital or acquired HD. </text>
<text top="540" left="64" width="84" height="20" font="4">Lotstein DS, et </text>
<text top="557" left="64" width="16" height="20" font="4">al. </text>
<text top="574" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(109)</a>  </text>
<text top="591" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23530167">23530167</a></text>
<text top="591" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23530167"> </a></text>
<text top="540" left="172" width="49" height="20" font="4">Analysis </text>
<text top="540" left="266" width="61" height="20" font="4">n=185 pts  </text>
<text top="540" left="368" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="557" left="368" width="156" height="20" font="4">Adolescent pts with recently </text>
<text top="574" left="368" width="120" height="20" font="4">diagnosed type 1 DM </text>
<text top="540" left="543" width="52" height="20" font="4">Describe </text>
<text top="557" left="543" width="127" height="20" font="4">sociodemographic and </text>
<text top="574" left="543" width="111" height="20" font="4">clinical correlates of </text>
<text top="591" left="543" width="120" height="20" font="4">poor glycemic control </text>
<text top="608" left="543" width="108" height="20" font="4">associated with the </text>
<text top="626" left="543" width="114" height="20" font="4">transfer of care from </text>
<text top="643" left="543" width="94" height="20" font="4">pediatric to adult </text>
<text top="660" left="543" width="54" height="20" font="4">providers </text>
<text top="540" left="685" width="201" height="20" font="4">● 57% transitioned to adult DM care </text>
<text top="557" left="685" width="154" height="20" font="4">providers by follow-up visit.  </text>
<text top="574" left="685" width="192" height="20" font="4">● Odds of poor glycemic control at </text>
<text top="591" left="685" width="192" height="20" font="4">follow-up were 2.5 times higher for </text>
<text top="608" left="685" width="204" height="20" font="4">participants transitioned to adult care </text>
<text top="626" left="685" width="211" height="20" font="4">compared with those who remained in </text>
<text top="643" left="685" width="81" height="20" font="4">pediatric care. </text>
<text top="540" left="914" width="170" height="20" font="4">●Transferring from pediatric to </text>
<text top="557" left="914" width="170" height="20" font="4">adult care was associated with </text>
<text top="574" left="914" width="138" height="20" font="4">an increased risk of poor </text>
<text top="591" left="914" width="165" height="20" font="4">glycemic control during follow-</text>
<text top="608" left="914" width="24" height="20" font="4">up.  </text>
<text top="626" left="914" width="152" height="20" font="4">● This suggests that young </text>
<text top="643" left="914" width="167" height="20" font="4">adults need additional support </text>
<text top="660" left="914" width="150" height="20" font="4">when moving to adult care. </text>
<text top="678" left="108" width="3" height="20" font="4"> </text>
<text top="697" left="108" width="3" height="19" font="4"> </text>
<text top="713" left="108" width="394" height="24" font="1"><b>Data Supplement 13. Exercise and Sports – Section 3.6  </b></text>
<text top="735" left="93" width="38" height="20" font="3"><b>Study </b></text>
<text top="752" left="68" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="769" left="96" width="30" height="20" font="3"><b>Year </b></text>
<text top="735" left="178" width="70" height="20" font="3"><b>Study Type </b></text>
<text top="735" left="278" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="735" left="373" width="165" height="20" font="3"><b>Inclusion/Exclusion Criteria </b></text>
<text top="735" left="571" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="735" left="749" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="735" left="981" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
</page>
<page number="37" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 37 </text>
<text top="107" left="64" width="80" height="20" font="4">Myers J, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(110)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15629729?dopt=Citation">15629729</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15629729?dopt=Citation"> </a></text>
<text top="107" left="172" width="75" height="20" font="4">Convenience </text>
<text top="124" left="172" width="57" height="20" font="4">sample of </text>
<text top="141" left="172" width="68" height="20" font="4">consecutive </text>
<text top="159" left="172" width="20" height="20" font="4">pts </text>
<text top="107" left="266" width="58" height="20" font="4">n=842 pts </text>
<text top="107" left="368" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="368" width="151" height="20" font="4">Consecutive pts referred to </text>
<text top="141" left="368" width="140" height="20" font="4">single center for exercise </text>
<text top="159" left="368" width="158" height="20" font="4">testing for clinical reasons. 1 </text>
<text top="176" left="368" width="141" height="20" font="4">d/wk, research assistants </text>
<text top="193" left="368" width="165" height="20" font="4">available to administer survey </text>
<text top="107" left="557" width="54" height="20" font="4">All-cause </text>
<text top="124" left="557" width="101" height="20" font="4">mortality by social </text>
<text top="141" left="557" width="80" height="20" font="4">security death </text>
<text top="159" left="557" width="33" height="20" font="4">index </text>
<text top="107" left="671" width="224" height="20" font="4">● Using age-adjusted quartiles, exercise </text>
<text top="124" left="671" width="237" height="20" font="4">capacity was stronger predictor of mortality </text>
<text top="141" left="671" width="170" height="20" font="4">than activity pattern (p&lt;0.001). </text>
<text top="159" left="671" width="222" height="20" font="4">● Multivariate analysis showed exercise </text>
<text top="176" left="671" width="233" height="20" font="4">capacity p&lt;0.001, and energy expenditure </text>
<text top="193" left="671" width="242" height="20" font="4">from adulthood recreational activity p&lt;0.002 </text>
<text top="210" left="671" width="138" height="20" font="4">were the only predictors. </text>
<text top="107" left="941" width="206" height="20" font="4">● Fitness and physical activity confer </text>
<text top="124" left="941" width="176" height="20" font="4">a survival benefit and should be </text>
<text top="141" left="941" width="72" height="20" font="4">encouraged. </text>
<text top="228" left="64" width="85" height="20" font="4">Warburton DE, </text>
<text top="245" left="64" width="30" height="20" font="4">et al. </text>
<text top="263" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(111)</a> </text>
<text top="280" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16534088?dopt=Citation">16534088</a></text>
<text top="280" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16534088?dopt=Citation"> </a></text>
<text top="228" left="172" width="44" height="20" font="4">Review </text>
<text top="228" left="266" width="61" height="20" font="4">n=152 pts  </text>
<text top="228" left="368" width="148" height="20" font="3"><b>Inclusion criteria</b>: Papers </text>
<text top="245" left="368" width="164" height="20" font="4">addressing 1° or 2° effects of </text>
<text top="263" left="368" width="140" height="20" font="4">exercise on mortality and </text>
<text top="280" left="368" width="89" height="20" font="4">chronic disease </text>
<text top="228" left="557" width="24" height="20" font="4">N/A </text>
<text top="228" left="671" width="253" height="20" font="4">● Analysis reaffirmed “irrefutable” evidence of </text>
<text top="245" left="671" width="230" height="20" font="4">a positive association between increasing </text>
<text top="263" left="671" width="239" height="20" font="4">levels of physical activity and lower rates of </text>
<text top="280" left="671" width="219" height="20" font="4">chronic disease and all-cause mortality. </text>
<text top="228" left="941" width="182" height="20" font="4">● Health benefits of exercise are </text>
<text top="245" left="941" width="199" height="20" font="4">greatest among those who are least </text>
<text top="263" left="941" width="201" height="20" font="4">active. Promotion of physical activity </text>
<text top="280" left="941" width="146" height="20" font="4">should begin in childhood. </text>
<text top="298" left="64" width="82" height="20" font="4">King AC, et al. </text>
<text top="315" left="64" width="66" height="20" font="4">1989 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(112)</a>  </text>
<text top="332" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2767021?dopt=Citation">2767021</a></text>
<text top="332" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2767021?dopt=Citation"> </a></text>
<text top="298" left="172" width="29" height="20" font="4">RCT </text>
<text top="298" left="266" width="79" height="20" font="4">n=120 pts (60 </text>
<text top="315" left="266" width="51" height="20" font="4">male, 60 </text>
<text top="332" left="266" width="44" height="20" font="4">female) </text>
<text top="298" left="368" width="169" height="20" font="3"><b>Inclusion criteria</b>: Employees </text>
<text top="315" left="368" width="172" height="20" font="4">of 1 company&lt;25% overweight </text>
<text top="332" left="368" width="158" height="20" font="4">willing to be randomized. No </text>
<text top="350" left="368" width="155" height="20" font="4">medical contraindications to </text>
<text top="367" left="368" width="49" height="20" font="4">exercise </text>
<text top="298" left="557" width="81" height="20" font="4">Score on a 14-</text>
<text top="315" left="557" width="62" height="20" font="4">point scale </text>
<text top="332" left="557" width="58" height="20" font="4">assessing </text>
<text top="350" left="557" width="46" height="20" font="4">multiple </text>
<text top="367" left="557" width="77" height="20" font="4">psychological </text>
<text top="384" left="557" width="83" height="20" font="4">variables;body </text>
<text top="401" left="557" width="79" height="20" font="4">weight; CPET </text>
<text top="418" left="557" width="73" height="20" font="4">performance </text>
<text top="298" left="671" width="30" height="20" font="4">● VO</text>
<text top="304" left="701" width="4" height="13" font="6">2</text>
<text top="298" left="706" width="213" height="20" font="4"> max increased 15% in men and 9% in </text>
<text top="315" left="671" width="141" height="20" font="4">women (p&lt;0.01 for both). </text>
<text top="332" left="671" width="243" height="20" font="4">● Improvement in 3 psychic measures were </text>
<text top="350" left="671" width="118" height="20" font="4">significant (p&lt;0.004). </text>
<text top="298" left="941" width="164" height="20" font="4">● Regular aerobic exercise is </text>
<text top="315" left="941" width="213" height="20" font="4">associated with improved measures of </text>
<text top="332" left="941" width="188" height="20" font="4">psychological health, especially in </text>
<text top="350" left="941" width="209" height="20" font="4">areas of satisfaction with body image, </text>
<text top="367" left="941" width="109" height="20" font="4">fitness, and weight. </text>
<text top="436" left="64" width="73" height="20" font="4">Reybrouck T </text>
<text top="454" left="64" width="85" height="20" font="4">and Mertens L, </text>
<text top="471" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(113)</a> </text>
<text top="488" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16210938?dopt=Citation">16210938</a></text>
<text top="488" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16210938?dopt=Citation"> </a></text>
<text top="436" left="172" width="44" height="20" font="4">Review </text>
<text top="436" left="266" width="58" height="20" font="4">38 papers </text>
<text top="436" left="368" width="16" height="20" font="4">--- </text>
<text top="436" left="557" width="16" height="20" font="4">--- </text>
<text top="436" left="671" width="237" height="20" font="4">● Most ACHD pts are less active than their </text>
<text top="454" left="671" width="256" height="20" font="4">peers. They can safely participate in moderate </text>
<text top="471" left="671" width="44" height="20" font="4">activity. </text>
<text top="436" left="941" width="188" height="20" font="4">● Cardiologists should encourage </text>
<text top="454" left="941" width="161" height="20" font="4">GUCH pts to be more active. </text>
<text top="506" left="64" width="85" height="20" font="4">Pemberton VL, </text>
<text top="523" left="64" width="30" height="20" font="4">et al. </text>
<text top="540" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(114)</a> </text>
<text top="558" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20212294">20212294</a></text>
<text top="558" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20212294"> </a></text>
<text top="506" left="172" width="39" height="20" font="4">NHLBI </text>
<text top="523" left="172" width="81" height="20" font="4">working group </text>
<text top="540" left="172" width="36" height="20" font="4">report </text>
<text top="506" left="266" width="24" height="20" font="4">N/A </text>
<text top="506" left="368" width="130" height="20" font="3"><b>Inclusion criteria: </b>N/A </text>
<text top="506" left="557" width="24" height="20" font="4">N/A </text>
<text top="506" left="671" width="228" height="20" font="4">● Obesity is a significant issue in pts with </text>
<text top="523" left="671" width="37" height="20" font="4">CHD.  </text>
<text top="540" left="671" width="248" height="20" font="4">● Associated comorbidities that increase risk </text>
<text top="558" left="671" width="181" height="20" font="4">of acquired HD are also present. </text>
<text top="506" left="941" width="197" height="20" font="4">● A call for research, infrastructure, </text>
<text top="523" left="941" width="199" height="20" font="4">and resources to study and address </text>
<text top="540" left="941" width="200" height="20" font="4">the issue of obesity in pts with CHD. </text>
<text top="575" left="64" width="84" height="20" font="4">Graham TP, et </text>
<text top="593" left="64" width="16" height="20" font="4">al. </text>
<text top="610" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(115)</a> </text>
<text top="627" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15837282?dopt=Citation">15837282</a></text>
<text top="627" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15837282?dopt=Citation"> </a></text>
<text top="575" left="172" width="72" height="20" font="4">Bethesda 36 </text>
<text top="593" left="172" width="62" height="20" font="4">consensus </text>
<text top="610" left="172" width="64" height="20" font="4">conference </text>
<text top="575" left="266" width="24" height="20" font="4">N/A </text>
<text top="575" left="368" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="575" left="557" width="24" height="20" font="4">N/A </text>
<text top="575" left="671" width="243" height="20" font="4">● Recommendations for sports participation </text>
<text top="593" left="671" width="195" height="20" font="4">based on evidence when available. </text>
<text top="575" left="941" width="198" height="20" font="4">● Lesion-specific recommendations </text>
<text top="593" left="941" width="75" height="20" font="4">are provided. </text>
<text top="645" left="64" width="87" height="20" font="4">Pellicia A, et al. </text>
<text top="662" left="64" width="66" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(116)</a>  </text>
<text top="679" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15923204?dopt=Citation">15923204</a></text>
<text top="679" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15923204?dopt=Citation"> </a></text>
<text top="645" left="172" width="65" height="20" font="4">Consensus </text>
<text top="662" left="172" width="64" height="20" font="4">conference </text>
<text top="645" left="266" width="24" height="20" font="4">N/A </text>
<text top="645" left="368" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="645" left="557" width="24" height="20" font="4">N/A </text>
<text top="645" left="671" width="222" height="20" font="4">● Recommendations for participation by </text>
<text top="662" left="671" width="200" height="20" font="4">(young) adults in competitive sports. </text>
<text top="645" left="941" width="160" height="20" font="4">● Lesion-specific: evaluation </text>
<text top="662" left="941" width="178" height="20" font="4">techniques, criteria for eligibility, </text>
<text top="679" left="941" width="204" height="20" font="4">recommendations for specific sports, </text>
<text top="697" left="941" width="115" height="20" font="4">follow-up guidelines. </text>
<text top="715" left="64" width="92" height="20" font="4">Duppen N, et al. </text>
<text top="732" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(117)</a> </text>
<text top="749" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23746621?dopt=Citation">23746621</a></text>
<text top="749" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23746621?dopt=Citation"> </a></text>
<text top="715" left="172" width="63" height="20" font="4">Systematic </text>
<text top="732" left="172" width="39" height="20" font="4">review </text>
<text top="715" left="266" width="60" height="20" font="4">31 studies </text>
<text top="715" left="368" width="150" height="20" font="3"><b>Inclusion criteria</b>: Studies </text>
<text top="732" left="368" width="139" height="20" font="4">between 1960–2012 that </text>
<text top="749" left="368" width="159" height="20" font="4">addressed exercise program </text>
<text top="766" left="368" width="54" height="20" font="4">and CHD </text>
<text top="715" left="557" width="61" height="20" font="4">Positive or </text>
<text top="732" left="557" width="89" height="20" font="4">negative effects </text>
<text top="749" left="557" width="61" height="20" font="4">of physical </text>
<text top="766" left="557" width="93" height="20" font="4">exercise training </text>
<text top="784" left="557" width="88" height="20" font="4">in pts with CHD </text>
<text top="715" left="671" width="237" height="20" font="4">● 23 of 31 studies reported positive effects </text>
<text top="732" left="671" width="76" height="20" font="4">(improved VO</text>
<text top="738" left="747" width="4" height="13" font="6">2</text>
<text top="732" left="752" width="147" height="20" font="4"> max); no studies reported </text>
<text top="749" left="671" width="90" height="20" font="4">adverse effects. </text>
<text top="715" left="941" width="207" height="20" font="4">● Exercise training in pts with CHD is </text>
<text top="732" left="941" width="199" height="20" font="4">safe and beneficial. CHD pts should </text>
<text top="749" left="941" width="166" height="20" font="4">participate in exercise training </text>
<text top="766" left="941" width="59" height="20" font="4">programs. </text>
</page>
<page number="38" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 38 </text>
<text top="107" left="64" width="77" height="20" font="4">Dua JS, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(118)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19217676?dopt=Citation">19217676</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19217676?dopt=Citation"> </a></text>
<text top="107" left="172" width="75" height="20" font="4">Convenience </text>
<text top="124" left="172" width="46" height="20" font="4">sample, </text>
<text top="141" left="172" width="66" height="20" font="4">prospective </text>
<text top="159" left="172" width="72" height="20" font="4">pretest, post-</text>
<text top="176" left="172" width="23" height="20" font="4">test </text>
<text top="107" left="266" width="74" height="20" font="4">n=50 pts in 3 </text>
<text top="124" left="266" width="57" height="20" font="4">groups by </text>
<text top="141" left="266" width="69" height="20" font="4">NYHA class </text>
<text top="107" left="368" width="170" height="20" font="3"><b>Inclusion criteria</b>: Pts seen at </text>
<text top="124" left="368" width="175" height="20" font="4">1 ACHD center; able to walk on </text>
<text top="141" left="368" width="160" height="20" font="4">treadmill; no surgery within 6 </text>
<text top="159" left="368" width="137" height="20" font="4">m; no contraindication to </text>
<text top="176" left="368" width="49" height="20" font="4">exercise </text>
<text top="107" left="557" width="78" height="20" font="4">Quality of life; </text>
<text top="124" left="557" width="101" height="20" font="4">exercise capacity; </text>
<text top="141" left="557" width="76" height="20" font="4">activity levels </text>
<text top="107" left="671" width="232" height="20" font="4">● Quality of life scores improved p=0.004; </text>
<text top="124" left="671" width="257" height="20" font="4">mean exercise time improved p=0.003; activity </text>
<text top="141" left="671" width="242" height="20" font="4">level increased p=0.002; no AE or mortality. </text>
<text top="107" left="941" width="210" height="20" font="4">● Exercise training programs are safe </text>
<text top="124" left="941" width="166" height="20" font="4">and feasible for pts with CHD. </text>
<text top="194" left="64" width="91" height="20" font="4">Holloway TM, et </text>
<text top="211" left="64" width="16" height="20" font="4">al. </text>
<text top="228" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(119)</a> </text>
<text top="245" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21641052?dopt=Citation">21641052</a></text>
<text top="245" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21641052?dopt=Citation"> </a></text>
<text top="194" left="172" width="78" height="20" font="4">Retrospective </text>
<text top="211" left="172" width="53" height="20" font="4">review of </text>
<text top="228" left="172" width="74" height="20" font="4">single-center </text>
<text top="246" left="172" width="70" height="20" font="4">experience.  </text>
<text top="194" left="266" width="79" height="20" font="4">n=11 pts (7 of </text>
<text top="211" left="266" width="37" height="20" font="4">11 pts </text>
<text top="228" left="266" width="60" height="20" font="4">completed </text>
<text top="246" left="266" width="43" height="20" font="4">cardiac </text>
<text top="263" left="266" width="77" height="20" font="4">rehabilitation) </text>
<text top="194" left="368" width="157" height="20" font="3"><b>Inclusion criteria</b>: ACHD pt </text>
<text top="211" left="368" width="155" height="20" font="4">seen at 1 center; referred to </text>
<text top="228" left="368" width="116" height="20" font="4">cardiac rehabilitation </text>
<text top="194" left="557" width="50" height="20" font="4">Exercise </text>
<text top="211" left="557" width="92" height="20" font="4">capacity; safety  </text>
<text top="194" left="671" width="461" height="20" font="4">● Exercise capacity increased p&lt;0.05; no AE.  ● A traditionally structured cardiac </text>
<text top="211" left="941" width="203" height="20" font="4">rehabilitation is effective and safe for </text>
<text top="228" left="941" width="79" height="20" font="4">pts with CHD. </text>
<text top="281" left="64" width="83" height="20" font="4">Cordina RL, et </text>
<text top="298" left="64" width="16" height="20" font="4">al. </text>
<text top="315" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(120)</a> </text>
<text top="332" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23846614?dopt=Citation">23846614</a></text>
<text top="332" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23846614?dopt=Citation"> </a></text>
<text top="281" left="172" width="40" height="20" font="4">Cohort </text>
<text top="298" left="172" width="67" height="20" font="4">comparison </text>
<text top="281" left="266" width="72" height="20" font="4">n=24 pts (16 </text>
<text top="298" left="266" width="45" height="20" font="4">pts with </text>
<text top="315" left="266" width="55" height="20" font="4">Fontan; 8 </text>
<text top="332" left="266" width="43" height="20" font="4">healthy </text>
<text top="350" left="266" width="51" height="20" font="4">controls) </text>
<text top="281" left="368" width="173" height="20" font="3"><b>Inclusion criteria</b>: NYHA FC I, </text>
<text top="298" left="368" width="107" height="20" font="4">II; Fontan palliation </text>
<text top="315" left="368" width="3" height="20" font="4"> </text>
<text top="332" left="368" width="158" height="20" font="3"><b>Exclusion criteria</b>: Smoker, </text>
<text top="350" left="368" width="174" height="20" font="4">clinical HF, recurrent significant </text>
<text top="367" left="368" width="68" height="20" font="4">arrhythmias </text>
<text top="281" left="557" width="49" height="20" font="4">Peak VO</text>
<text top="287" left="606" width="4" height="13" font="6">2</text>
<text top="281" left="610" width="33" height="20" font="4">; lean </text>
<text top="298" left="557" width="101" height="20" font="4">mass, calf muscle </text>
<text top="315" left="557" width="102" height="20" font="4">MRI spectroscopy </text>
<text top="281" left="671" width="30" height="20" font="4">● VO</text>
<text top="287" left="701" width="4" height="13" font="6">2</text>
<text top="281" left="706" width="114" height="20" font="4"> was 66% predicted; </text>
<text top="298" left="671" width="211" height="20" font="4">pts had significantly less muscle mass </text>
<text top="315" left="671" width="67" height="20" font="4">(p&lt;0.0001). </text>
<text top="332" left="671" width="253" height="20" font="4">● 4/16 pts were sarcopenic; low muscle mass </text>
<text top="350" left="671" width="164" height="20" font="4">correlated with lower peak VO</text>
<text top="356" left="835" width="4" height="13" font="6">2</text>
<text top="350" left="840" width="63" height="20" font="4"> (p=0.004); </text>
<text top="367" left="671" width="244" height="20" font="4">muscle aerobic activity diminished in Fontan </text>
<text top="384" left="671" width="89" height="20" font="4">pts vs. controls. </text>
<text top="281" left="941" width="183" height="20" font="4">● Pts with Fontan palliation have </text>
<text top="298" left="941" width="214" height="20" font="4">significantly reduced muscle mass that </text>
<text top="315" left="941" width="182" height="20" font="4">correlates with significantly lower </text>
<text top="332" left="941" width="178" height="20" font="4">exercise capacity. Pts also have </text>
<text top="350" left="941" width="189" height="20" font="4">impaired muscle aerobic capacity. </text>
<text top="402" left="64" width="83" height="20" font="4">Cordina RL, et </text>
<text top="419" left="64" width="16" height="20" font="4">al. </text>
<text top="436" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(121)</a> </text>
<text top="454" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23154055?dopt=Citation">23154055</a></text>
<text top="454" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23154055?dopt=Citation"> </a></text>
<text top="402" left="172" width="29" height="20" font="4">RCT </text>
<text top="402" left="266" width="51" height="20" font="4">n=16 pts </text>
<text top="402" left="368" width="150" height="20" font="3"><b>Inclusion criteria</b>: Fontan; </text>
<text top="419" left="368" width="153" height="20" font="4">NYHA class I or II; exercise </text>
<text top="436" left="368" width="172" height="20" font="4">program participation; 20 wk of </text>
<text top="454" left="368" width="135" height="20" font="4">high-intensity resistance </text>
<text top="471" left="368" width="44" height="20" font="4">training </text>
<text top="402" left="557" width="18" height="20" font="4">VO</text>
<text top="408" left="574" width="4" height="13" font="6">2</text>
<text top="402" left="579" width="49" height="20" font="4">; muscle </text>
<text top="419" left="557" width="94" height="20" font="4">strength; muscle </text>
<text top="436" left="557" width="96" height="20" font="4">mass; inspiratory </text>
<text top="454" left="557" width="62" height="20" font="4">dependent </text>
<text top="471" left="557" width="79" height="20" font="4">venous return </text>
<text top="402" left="671" width="164" height="20" font="4">● After training: Increased VO</text>
<text top="408" left="836" width="4" height="13" font="6">2</text>
<text top="402" left="840" width="64" height="20" font="4">; increased </text>
<text top="419" left="671" width="229" height="20" font="4">muscle strength; increased muscle mass; </text>
<text top="436" left="671" width="226" height="20" font="4">increased venous return during exercise. </text>
<text top="402" left="941" width="182" height="20" font="4">● Resistance training in isolation </text>
<text top="419" left="941" width="200" height="20" font="4">improves muscle mass and strength </text>
<text top="436" left="941" width="199" height="20" font="4">with associated improvements in VO</text>
<text top="442" left="1140" width="4" height="13" font="6">2</text>
<text top="436" left="1145" width="3" height="20" font="4"> </text>
<text top="454" left="941" width="155" height="20" font="4">and Fontan hemodynamics. </text>
<text top="489" left="64" width="94" height="20" font="4">Kempny A, et al. </text>
<text top="506" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(122)</a> </text>
<text top="523" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22199119?dopt=Citation">22199119</a></text>
<text top="523" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22199119?dopt=Citation"> </a></text>
<text top="489" left="172" width="78" height="20" font="4">Retrospective </text>
<text top="506" left="172" width="63" height="20" font="4">review and </text>
<text top="523" left="172" width="51" height="20" font="4">literature </text>
<text top="540" left="172" width="39" height="20" font="4">review </text>
<text top="489" left="266" width="81" height="20" font="4">n=2,129 pts in </text>
<text top="506" left="266" width="76" height="20" font="4">single center; </text>
<text top="523" left="266" width="58" height="20" font="4">23 papers </text>
<text top="540" left="266" width="86" height="20" font="4">including 2,286 </text>
<text top="558" left="266" width="20" height="20" font="4">pts </text>
<text top="489" left="368" width="157" height="20" font="3"><b>Inclusion criteria</b>: ACHD pt </text>
<text top="506" left="368" width="101" height="20" font="4">undergoing CPET </text>
<text top="489" left="557" width="44" height="20" font="4">Max VO</text>
<text top="495" left="601" width="4" height="13" font="6">2</text>
<text top="489" left="606" width="3" height="20" font="4"> </text>
<text top="489" left="671" width="251" height="20" font="4">● ACHD pts showed consistently significantly </text>
<text top="506" left="671" width="50" height="20" font="4">lower VO</text>
<text top="512" left="722" width="4" height="13" font="6">2</text>
<text top="506" left="726" width="79" height="20" font="4"> than normal.  </text>
<text top="523" left="671" width="199" height="20" font="4">● Within ACHD diagnoses, peak VO</text>
<text top="529" left="870" width="4" height="13" font="6">2</text>
<text top="523" left="875" width="29" height="20" font="4"> was </text>
<text top="540" left="671" width="215" height="20" font="4">significantly lower with increasing CHD </text>
<text top="558" left="671" width="65" height="20" font="4">complexity. </text>
<text top="489" left="941" width="206" height="20" font="4">● Provides reference values for peak </text>
<text top="506" left="941" width="18" height="20" font="4">VO</text>
<text top="512" left="959" width="4" height="13" font="6">2</text>
<text top="506" left="964" width="146" height="20" font="4"> among a variety of ACHD </text>
<text top="523" left="941" width="63" height="20" font="4">diagnoses. </text>
<text top="575" left="64" width="86" height="20" font="4">Diller GP, et al. </text>
<text top="593" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(103)</a> </text>
<text top="610" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16061735?dopt=Citation">16061735</a></text>
<text top="610" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16061735?dopt=Citation"> </a></text>
<text top="575" left="172" width="40" height="20" font="4">Cohort </text>
<text top="593" left="172" width="67" height="20" font="4">comparison </text>
<text top="575" left="266" width="38" height="20" font="4">n=335 </text>
<text top="593" left="266" width="68" height="20" font="4">consecutive </text>
<text top="610" left="266" width="78" height="20" font="4">ACHD pts; 40 </text>
<text top="627" left="266" width="83" height="20" font="4">non-ACHD HF </text>
<text top="644" left="266" width="83" height="20" font="4">pts; 23 healthy </text>
<text top="662" left="266" width="46" height="20" font="4">controls </text>
<text top="575" left="368" width="157" height="20" font="3"><b>Inclusion criteria</b>: ACHD pt </text>
<text top="593" left="368" width="171" height="20" font="4">performing CPET between Jan </text>
<text top="610" left="368" width="92" height="20" font="4">2003–May 2004 </text>
<text top="575" left="557" width="49" height="20" font="4">Peak VO</text>
<text top="582" left="606" width="4" height="13" font="6">2</text>
<text top="575" left="610" width="3" height="20" font="4"> </text>
<text top="575" left="671" width="30" height="20" font="4">● VO</text>
<text top="582" left="701" width="4" height="13" font="6">2</text>
<text top="575" left="706" width="219" height="20" font="4"> reduced in ACHD compared to normal. </text>
<text top="593" left="671" width="30" height="20" font="4">● VO</text>
<text top="599" left="701" width="4" height="13" font="6">2</text>
<text top="593" left="706" width="222" height="20" font="4"> similar between ACHD and HF of same </text>
<text top="610" left="671" width="73" height="20" font="4">NYHA class. </text>
<text top="627" left="671" width="30" height="20" font="4">● VO</text>
<text top="633" left="701" width="4" height="13" font="6">2</text>
<text top="627" left="706" width="168" height="20" font="4"> declined with increasing CHD </text>
<text top="644" left="671" width="65" height="20" font="4">complexity. </text>
<text top="662" left="671" width="67" height="20" font="4">● Lower VO</text>
<text top="668" left="738" width="4" height="13" font="6">2</text>
<text top="662" left="743" width="152" height="20" font="4"> conferred increased risk of </text>
<text top="679" left="671" width="133" height="20" font="4">hospitalization or death. </text>
<text top="575" left="941" width="194" height="20" font="4">● Even in asymptomatic ACHD pts </text>
<text top="593" left="941" width="18" height="20" font="4">VO</text>
<text top="599" left="959" width="4" height="13" font="6">2</text>
<text top="593" left="964" width="163" height="20" font="4"> provides risk assessment for </text>
<text top="610" left="941" width="133" height="20" font="4">hospitalization or death. </text>
<text top="697" left="64" width="88" height="20" font="4">Takken T, et al. </text>
<text top="714" left="64" width="66" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(123)</a>  </text>
<text top="731" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23126001?dopt=Citation">23126001</a></text>
<text top="731" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23126001?dopt=Citation"> </a></text>
<text top="697" left="172" width="65" height="20" font="4">Consensus </text>
<text top="714" left="172" width="36" height="20" font="4">report </text>
<text top="697" left="266" width="24" height="20" font="4">N/A </text>
<text top="697" left="368" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="697" left="557" width="24" height="20" font="4">N/A </text>
<text top="697" left="671" width="228" height="20" font="4">● Recommendations for physical activity, </text>
<text top="714" left="671" width="232" height="20" font="4">recreational sport, and exercise training in </text>
<text top="731" left="671" width="103" height="20" font="4">pediatric CHD pts. </text>
<text top="697" left="941" width="159" height="20" font="4">● Physical activity should be </text>
<text top="714" left="941" width="200" height="20" font="4">promoted, not restricted in CHD pts. </text>
<text top="731" left="941" width="182" height="20" font="4">Physical activity is generally safe </text>
<text top="748" left="941" width="192" height="20" font="4">although certain conditions require </text>
<text top="766" left="941" width="78" height="20" font="4">more caution. </text>
</page>
<page number="39" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 39 </text>
<text top="107" left="64" width="91" height="20" font="4">Longmuir PE, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="63" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(124)</a> </text>
<text top="107" left="172" width="51" height="20" font="4">Chapter  </text>
<text top="107" left="266" width="24" height="20" font="4">N/A </text>
<text top="107" left="368" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="107" left="557" width="24" height="20" font="4">N/A </text>
<text top="107" left="671" width="221" height="20" font="4">● Strategies for making physical activity </text>
<text top="124" left="671" width="207" height="20" font="4">achievable for pts with special needs. </text>
<text top="107" left="941" width="215" height="20" font="4">● Physical activity can be incorporated </text>
<text top="124" left="941" width="198" height="20" font="4">into the lifestyle of most people with </text>
<text top="141" left="941" width="106" height="20" font="4">some modification. </text>
<text top="159" left="64" width="80" height="20" font="4">Mitchell JH, et </text>
<text top="177" left="64" width="16" height="20" font="4">al. </text>
<text top="194" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(125)</a> </text>
<text top="211" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15837288?dopt=Citation">15837288</a></text>
<text top="211" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15837288?dopt=Citation"> </a></text>
<text top="159" left="172" width="65" height="20" font="4">Consensus </text>
<text top="177" left="172" width="36" height="20" font="4">report </text>
<text top="159" left="266" width="24" height="20" font="4">N/A </text>
<text top="159" left="368" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="159" left="557" width="24" height="20" font="4">N/A </text>
<text top="159" left="671" width="211" height="20" font="4">● Relative intensity of activities during </text>
<text top="177" left="671" width="174" height="20" font="4">competitive sports based on VO</text>
<text top="183" left="846" width="4" height="13" font="6">2</text>
<text top="177" left="850" width="28" height="20" font="4"> and </text>
<text top="194" left="671" width="222" height="20" font="4">isometric maximal voluntary contraction. </text>
<text top="159" left="941" width="208" height="20" font="4">● Competition may be less strenuous </text>
<text top="177" left="941" width="198" height="20" font="4">than training, so that modification of </text>
<text top="194" left="941" width="191" height="20" font="4">training programs may be needed. </text>
<text top="229" left="64" width="86" height="20" font="4">Westhoff-Bleck </text>
<text top="246" left="64" width="47" height="20" font="4">M, et al. </text>
<text top="263" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(126)</a> </text>
<text top="281" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24207068?dopt=Citation">24207068</a></text>
<text top="281" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24207068?dopt=Citation"> </a></text>
<text top="229" left="172" width="42" height="20" font="4">RCT to </text>
<text top="246" left="172" width="62" height="20" font="4">investigate </text>
<text top="263" left="172" width="68" height="20" font="4">the effect of </text>
<text top="281" left="172" width="44" height="20" font="4">aerobic </text>
<text top="298" left="172" width="61" height="20" font="4">training on </text>
<text top="315" left="172" width="49" height="20" font="4">exercise </text>
<text top="332" left="172" width="72" height="20" font="4">capacity and </text>
<text top="350" left="172" width="72" height="20" font="4">systemic RV </text>
<text top="367" left="172" width="59" height="20" font="4">function in </text>
<text top="384" left="172" width="64" height="20" font="4">adults after </text>
<text top="401" left="172" width="48" height="20" font="4">Mustard </text>
<text top="418" left="172" width="59" height="20" font="4">procedure </text>
<text top="229" left="266" width="72" height="20" font="4">n=48 pts (24 </text>
<text top="246" left="266" width="83" height="20" font="4">controls vs. 24 </text>
<text top="263" left="266" width="61" height="20" font="4">in training) </text>
<text top="229" left="368" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="246" left="368" width="141" height="20" font="4">previous atrial redirection </text>
<text top="263" left="368" width="174" height="20" font="4">surgery for d-TGA, NYHA class </text>
<text top="281" left="368" width="143" height="20" font="4">I/II HF, same medications </text>
<text top="298" left="368" width="152" height="20" font="4">(ACE, BB) for last 6 mo, no </text>
<text top="315" left="368" width="157" height="20" font="4">physical training at inclusion </text>
<text top="332" left="368" width="3" height="20" font="4"> </text>
<text top="350" left="368" width="150" height="20" font="3"><b>Exclusion criteria</b>: Known </text>
<text top="367" left="368" width="159" height="20" font="4">pulmonary vascular disease, </text>
<text top="384" left="368" width="159" height="20" font="4">significant baffle-obstruction, </text>
<text top="401" left="368" width="143" height="20" font="4">pregnancy, pacemaker or </text>
<text top="418" left="368" width="137" height="20" font="4">defibrillator implantation, </text>
<text top="436" left="368" width="133" height="20" font="4">history of VA, renal/liver </text>
<text top="453" left="368" width="161" height="20" font="4">insufficiency, claustrophobia, </text>
<text top="470" left="368" width="130" height="20" font="4">and mental retardation. </text>
<text top="229" left="557" width="76" height="20" font="4">Change peak </text>
<text top="246" left="557" width="18" height="20" font="4">VO</text>
<text top="252" left="574" width="4" height="13" font="6">2</text>
<text top="246" left="579" width="3" height="20" font="4"> </text>
<text top="229" left="671" width="186" height="20" font="4">● After 24 wk, in trainers peak VO</text>
<text top="235" left="858" width="4" height="13" font="6">2</text>
<text top="229" left="862" width="57" height="20" font="4"> improved </text>
<text top="246" left="671" width="230" height="20" font="4">(1.8 ± 2.3 mL/kg/min; +7.7%); whereas, it </text>
<text top="263" left="671" width="152" height="20" font="4">dropped in controls (−1.9 ± </text>
<text top="281" left="671" width="187" height="20" font="4">4.2 mL/kg/min; −7.5%) (p=0.001). </text>
<text top="229" left="941" width="193" height="20" font="4">● Aerobic exercise is safe and can </text>
<text top="246" left="941" width="206" height="20" font="4">improve exercise capacity and NYHA </text>
<text top="263" left="941" width="35" height="20" font="4">class. </text>
<text top="281" left="941" width="215" height="20" font="4">● The results cannot be generalized to </text>
<text top="298" left="941" width="203" height="20" font="4">NYHA III/IV symptoms. The drop-out </text>
<text top="315" left="941" width="92" height="20" font="4">rate was 20.8%. </text>
<text top="488" left="64" width="92" height="20" font="4">Ubeda TA, et al. </text>
<text top="505" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(127)</a> </text>
<text top="522" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23962775?dopt=Citation">23962775</a></text>
<text top="522" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23962775?dopt=Citation"> </a></text>
<text top="488" left="172" width="78" height="20" font="4">Retrospective </text>
<text top="505" left="172" width="38" height="20" font="4">cohort </text>
<text top="488" left="266" width="58" height="20" font="4">n=146 pts </text>
<text top="488" left="368" width="163" height="20" font="3"><b>Inclusion criteria</b>: ACHD pts </text>
<text top="505" left="368" width="173" height="20" font="4">≥21 y that had cycle ergometry </text>
<text top="522" left="368" width="144" height="20" font="4">exercise testing at Boston </text>
<text top="540" left="368" width="132" height="20" font="4">Children’s Hospital Jan. </text>
<text top="557" left="368" width="99" height="20" font="4">2006―July 2011. </text>
<text top="488" left="557" width="66" height="20" font="4">Changes in </text>
<text top="505" left="557" width="98" height="20" font="4">exercise capacity </text>
<text top="488" left="671" width="254" height="20" font="4">● Those who participated in frequent exercise </text>
<text top="505" left="671" width="167" height="20" font="4">tended to have improved p VO</text>
<text top="511" left="838" width="4" height="13" font="6">2</text>
<text top="505" left="843" width="27" height="20" font="4"> (∆p </text>
<text top="522" left="671" width="18" height="20" font="4">VO</text>
<text top="529" left="689" width="4" height="13" font="6">2</text>
<text top="522" left="694" width="210" height="20" font="4">=+1.63±2.67 mL/kg/min) compared to </text>
<text top="540" left="671" width="222" height="20" font="4">those who had low or occasional activity </text>
<text top="557" left="671" width="99" height="20" font="4">frequency (∆p VO</text>
<text top="563" left="770" width="4" height="13" font="6">2</text>
<text top="557" left="775" width="138" height="20" font="4">=+0.06±2.13 mL/kg/min; </text>
<text top="574" left="671" width="255" height="20" font="4">p=0.003) over a median follow-up of 13.2 mo.  </text>
<text top="591" left="671" width="254" height="20" font="4">● The difference was independent of baseline </text>
<text top="608" left="671" width="235" height="20" font="4">clinical characteristics, time between tests, </text>
<text top="626" left="671" width="230" height="20" font="4">medication changes, and weight change.  </text>
<text top="643" left="671" width="230" height="20" font="4">● Those who engaged in frequent activity </text>
<text top="660" left="671" width="245" height="20" font="4">were more likely to have an increase of p VO</text>
<text top="666" left="916" width="4" height="13" font="6">2</text>
<text top="660" left="921" width="3" height="20" font="4"> </text>
<text top="677" left="671" width="228" height="20" font="4">of ≥1SD between tests as compared with </text>
<text top="694" left="671" width="246" height="20" font="4">sedentary pts (OR: 7.4; 95% CI: 1.5―35.7).  </text>
<text top="488" left="941" width="203" height="20" font="4">● ACHD pts who engage in frequent </text>
<text top="505" left="941" width="214" height="20" font="4">physical activity tend to have improved </text>
<text top="522" left="941" width="155" height="20" font="4">exercise capacity over time. </text>
<text top="712" left="54" width="3" height="20" font="4"> </text>
<text top="730" left="54" width="3" height="20" font="4"> </text>
<text top="747" left="108" width="574" height="24" font="1"><b>Data Supplement 14. Mental Health and Neurodevelopmental Issues – Section 3.7 </b></text>
<text top="768" left="93" width="38" height="20" font="3"><b>Study </b></text>
<text top="768" left="178" width="70" height="20" font="3"><b>Study Type </b></text>
<text top="768" left="275" width="38" height="20" font="3"><b>Study </b></text>
<text top="785" left="280" width="28" height="20" font="3"><b>Size </b></text>
<text top="768" left="343" width="165" height="20" font="3"><b>Inclusion/Exclusion Criteria </b></text>
<text top="768" left="561" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="768" left="745" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="768" left="973" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
</page>
<page number="40" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 40 </text>
<text top="107" left="68" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="124" left="96" width="30" height="20" font="3"><b>Year </b></text>
<text top="142" left="64" width="93" height="20" font="4">Amianto F, et al. </text>
<text top="159" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(128)</a> </text>
<text top="177" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21659976?dopt=Citation">21659976</a></text>
<text top="177" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21659976?dopt=Citation"> </a></text>
<text top="142" left="172" width="63" height="20" font="4">Systematic </text>
<text top="159" left="172" width="39" height="20" font="4">review </text>
<text top="142" left="266" width="17" height="20" font="4">66 </text>
<text top="159" left="266" width="42" height="20" font="4">articles </text>
<text top="142" left="334" width="170" height="20" font="3"><b>Inclusion criteria</b>: 1989–2009 </text>
<text top="159" left="334" width="98" height="20" font="4">studies in Medline</text>
<text top="161" left="432" width="2" height="13" font="6"> </text>
<text top="142" left="530" width="135" height="20" font="4">Describe neurocognitive </text>
<text top="159" left="530" width="120" height="20" font="4">and psychopathology </text>
<text top="177" left="530" width="57" height="20" font="4">outcomes </text>
<text top="142" left="678" width="216" height="20" font="4">● IQ of pts &lt; controls but within normal </text>
<text top="159" left="678" width="219" height="20" font="4">range; not consistent finding associated </text>
<text top="177" left="678" width="159" height="20" font="4">with younger age at surgery. </text>
<text top="194" left="678" width="215" height="20" font="4">Other factors include familial education </text>
<text top="211" left="678" width="148" height="20" font="4">and socioeconomic status. </text>
<text top="228" left="678" width="199" height="20" font="4">● Psychopathology is inconsistently </text>
<text top="245" left="678" width="202" height="20" font="4">associated with CHD; environmental </text>
<text top="263" left="678" width="154" height="20" font="4">factors may also contribute. </text>
<text top="142" left="926" width="227" height="20" font="4">● Limitation is nonquantitative evaluation </text>
<text top="159" left="926" width="68" height="20" font="4">of literature. </text>
<text top="281" left="64" width="86" height="20" font="4">Granberg M, et </text>
<text top="298" left="64" width="16" height="20" font="4">al. </text>
<text top="315" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(129)</a> </text>
<text top="332" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18489626?dopt=Citation">18489626</a></text>
<text top="332" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18489626?dopt=Citation"> </a></text>
<text top="281" left="172" width="145" height="20" font="4">Cohort control  n=28 pts </text>
<text top="298" left="266" width="51" height="20" font="4">matched </text>
<text top="315" left="266" width="43" height="20" font="4">in pairs </text>
<text top="281" left="334" width="182" height="20" font="3"><b>Inclusion criteria</b>: 14 pts 3–14 y </text>
<text top="298" left="334" width="156" height="20" font="4">with complex CHD paired to </text>
<text top="315" left="334" width="169" height="20" font="4">age- and sex-matched healthy </text>
<text top="332" left="334" width="46" height="20" font="4">controls </text>
<text top="281" left="530" width="128" height="20" font="4">Examine differences in </text>
<text top="298" left="530" width="121" height="20" font="4">children with complex </text>
<text top="315" left="530" width="113" height="20" font="4">CHD and normal re: </text>
<text top="332" left="530" width="86" height="20" font="4">performance of </text>
<text top="350" left="530" width="124" height="20" font="4">activities of daily living </text>
<text top="367" left="530" width="92" height="20" font="4">and school work </text>
<text top="281" left="678" width="213" height="20" font="4">● Pts with CHD had significantly lower </text>
<text top="298" left="678" width="201" height="20" font="4">mean activities of daily living, school </text>
<text top="315" left="678" width="220" height="20" font="4">motor and school process performance. </text>
<text top="281" left="926" width="229" height="20" font="4">● Significant difference in performance of </text>
<text top="298" left="926" width="169" height="20" font="4">both ADL and schoolwork task </text>
<text top="315" left="926" width="217" height="20" font="4">performance between pts with complex </text>
<text top="332" left="926" width="146" height="20" font="4">CHD vs. healthy controls.  </text>
<text top="385" left="64" width="90" height="20" font="4">Karsdorp PA, et </text>
<text top="402" left="64" width="16" height="20" font="4">al. </text>
<text top="419" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(130)</a> </text>
<text top="436" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17182669?dopt=Citation">17182669</a></text>
<text top="436" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17182669?dopt=Citation"> </a></text>
<text top="385" left="172" width="112" height="20" font="4">Meta-analysis  11 </text>
<text top="402" left="266" width="42" height="20" font="4">studies </text>
<text top="385" left="334" width="170" height="20" font="3"><b>Inclusion criteria</b>: 1980–2005 </text>
<text top="402" left="334" width="176" height="20" font="4">studies in Medline and PsycInfo </text>
<text top="385" left="530" width="96" height="20" font="4">Effect of CHD on </text>
<text top="402" left="530" width="76" height="20" font="4">cognitive and </text>
<text top="419" left="530" width="124" height="20" font="4">psychological function </text>
<text top="436" left="530" width="83" height="20" font="4">in children and </text>
<text top="454" left="530" width="73" height="20" font="4">adolescents  </text>
<text top="385" left="678" width="79" height="20" font="4">● Effect sizes </text>
<text top="402" left="678" width="227" height="20" font="4">● Psych: pt &gt; control, overall, internalize, </text>
<text top="419" left="678" width="63" height="20" font="4">externalize </text>
<text top="436" left="678" width="231" height="20" font="4">● Cognitive: pt &lt; control, performance IQ, </text>
<text top="454" left="678" width="57" height="20" font="4">verbal IQ. </text>
<text top="385" left="926" width="181" height="20" font="4">● R=0.67; p=0.005 overall effect </text>
<text top="402" left="926" width="187" height="20" font="4">● R=0.77; p=0.001 internalization </text>
<text top="419" left="926" width="190" height="20" font="4">● R=0.73; p=0.003 externalization </text>
<text top="436" left="926" width="180" height="20" font="4">● R=0.62; p=0.003 performance </text>
<text top="454" left="926" width="161" height="20" font="4">● R=0.59; p=0.006 verbal IQ </text>
<text top="472" left="64" width="82" height="20" font="4">van der Rijken </text>
<text top="489" left="64" width="54" height="20" font="4">RE, et al. </text>
<text top="506" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(131)</a> </text>
<text top="523" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17184562?dopt=Citation">17184562</a></text>
<text top="523" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17184562?dopt=Citation"> </a></text>
<text top="472" left="172" width="76" height="20" font="4">Cohort study, </text>
<text top="489" left="172" width="40" height="20" font="4">survey </text>
<text top="472" left="266" width="38" height="20" font="4">n=101 </text>
<text top="489" left="266" width="20" height="20" font="4">pts </text>
<text top="472" left="334" width="153" height="20" font="3"><b>Inclusion criteria</b>: Surgical </text>
<text top="489" left="334" width="166" height="20" font="4">correction of CHD 1992–2000 </text>
<text top="506" left="334" width="92" height="20" font="4">while pts 6–16 y </text>
<text top="472" left="530" width="100" height="20" font="4">Explore long-term </text>
<text top="489" left="530" width="121" height="20" font="4">physical, educational, </text>
<text top="506" left="530" width="114" height="20" font="4">emotional outcomes </text>
<text top="472" left="678" width="225" height="20" font="4">● 46/101&gt;18 y at time of survey; pts had </text>
<text top="489" left="678" width="222" height="20" font="4">more use of special education, repeated </text>
<text top="506" left="678" width="219" height="20" font="4">grades, or used remedial education: pts </text>
<text top="523" left="678" width="187" height="20" font="4">had lower educational attainment. </text>
<text top="472" left="926" width="140" height="20" font="4">p&lt;0.01 special education </text>
<text top="489" left="926" width="134" height="20" font="4">p&lt;0.01 repeated grades </text>
<text top="506" left="926" width="149" height="20" font="4">p&lt;0.05 remedial education </text>
<text top="541" left="64" width="94" height="20" font="4">Kirshbom PM, et </text>
<text top="558" left="64" width="16" height="20" font="4">al. </text>
<text top="575" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(132)</a> </text>
<text top="593" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15867785?dopt=Citation">15867785</a></text>
<text top="593" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15867785?dopt=Citation"> </a></text>
<text top="541" left="172" width="73" height="20" font="4">Cohort study </text>
<text top="541" left="266" width="241" height="20" font="4">n=30 pts   <b>Inclusion criteria</b>: School age, </text>
<text top="558" left="334" width="171" height="20" font="4">s/p total anomalous pulmonary </text>
<text top="575" left="334" width="165" height="20" font="4">venous return at single center </text>
<text top="541" left="530" width="91" height="20" font="4">Describe neuro- </text>
<text top="558" left="530" width="83" height="20" font="4">developmental </text>
<text top="575" left="530" width="123" height="20" font="4">outcomes of survivors </text>
<text top="593" left="530" width="104" height="20" font="4">of total anomalous </text>
<text top="610" left="530" width="104" height="20" font="4">pulmonary venous </text>
<text top="627" left="530" width="36" height="20" font="4">return </text>
<text top="541" left="678" width="148" height="20" font="4">● Age at follow-up 6–19 y. </text>
<text top="558" left="678" width="195" height="20" font="4">● Full scale IQ within normal limits. </text>
<text top="575" left="678" width="157" height="20" font="4">● Performance IQ &lt; control. </text>
<text top="593" left="678" width="116" height="20" font="4">● Reading = control. </text>
<text top="610" left="678" width="91" height="20" font="4">● Math&lt;control. </text>
<text top="627" left="678" width="120" height="20" font="4">● Attention&lt;average. </text>
<text top="541" left="926" width="143" height="20" font="4">● p=0.02 performance IQ </text>
<text top="558" left="926" width="85" height="20" font="4">● p&lt;0.01 math </text>
<text top="575" left="926" width="105" height="20" font="4">● p&lt;0.01 attention </text>
<text top="645" left="64" width="94" height="20" font="4">Wernovsky G, et </text>
<text top="662" left="64" width="16" height="20" font="4">al. </text>
<text top="679" left="64" width="63" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(133)</a> </text>
<text top="697" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10952957?dopt=Citation">10952957</a></text>
<text top="697" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10952957?dopt=Citation"> </a></text>
<text top="645" left="172" width="73" height="20" font="4">Cohort study </text>
<text top="645" left="266" width="38" height="20" font="4">n=133 </text>
<text top="662" left="266" width="20" height="20" font="4">pts </text>
<text top="645" left="334" width="157" height="20" font="3"><b>Inclusion criteria</b>: Regional </text>
<text top="662" left="334" width="174" height="20" font="4">survivors of Fontan palliation at </text>
<text top="679" left="334" width="73" height="20" font="4">single center </text>
<text top="645" left="530" width="128" height="20" font="4">Describe cognitive and </text>
<text top="662" left="530" width="113" height="20" font="4">academic outcomes </text>
<text top="679" left="530" width="70" height="20" font="4">after Fontan </text>
<text top="645" left="678" width="222" height="20" font="4">● Median age at evaluation n=11 y (3.7–</text>
<text top="662" left="678" width="44" height="20" font="4">41.0 y). </text>
<text top="679" left="678" width="191" height="20" font="4">● Full scale IQ &lt; normal; p&lt;0.006. </text>
<text top="697" left="678" width="206" height="20" font="4">● Adjusted for socioeconomic status, </text>
<text top="714" left="678" width="224" height="20" font="4">lower IQ associated with HLHS, and use </text>
<text top="731" left="678" width="75" height="20" font="4">of circ arrest. </text>
<text top="645" left="926" width="209" height="20" font="4">● Most Fontan pts from 1970s–1980s </text>
<text top="662" left="926" width="224" height="20" font="4">have cognitive in normal range but lower </text>
<text top="679" left="926" width="135" height="20" font="4">than general population. </text>
<text top="749" left="64" width="83" height="20" font="4">Callus E, et al. </text>
<text top="766" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(134)</a> </text>
<text top="784" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23750687?dopt=Citation">23750687</a></text>
<text top="784" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23750687?dopt=Citation"> </a></text>
<text top="749" left="172" width="63" height="20" font="4">Systematic </text>
<text top="766" left="172" width="39" height="20" font="4">review </text>
<text top="749" left="266" width="3" height="20" font="4"> </text>
<text top="749" left="334" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="766" left="334" width="139" height="20" font="4">CHD, studies addressing </text>
<text top="749" left="530" width="125" height="20" font="4">Psychological function </text>
<text top="766" left="530" width="51" height="20" font="4">in ACHD </text>
<text top="749" left="678" width="215" height="20" font="4">● Variation among studies whether pts </text>
<text top="766" left="678" width="230" height="20" font="4">psychological functioning is better, worse, </text>
<text top="784" left="678" width="213" height="20" font="4">or the same as the general population. </text>
<text top="749" left="926" width="178" height="20" font="4">● Structured assessment of pts’ </text>
<text top="766" left="926" width="199" height="20" font="4">psychological function may be more </text>
<text top="784" left="926" width="210" height="20" font="4">reliable and identify more dysfunction. </text>
</page>
<page number="41" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 41 </text>
<text top="107" left="334" width="143" height="20" font="4">psychological functioning, </text>
<text top="124" left="334" width="119" height="20" font="4">published since 1990 </text>
<text top="141" left="334" width="3" height="20" font="4"> </text>
<text top="159" left="334" width="169" height="20" font="3"><b>Exclusion criteria</b>: studies on </text>
<text top="176" left="334" width="180" height="20" font="4">acquired HD, neurodevelopment </text>
<text top="193" left="334" width="181" height="20" font="4">or multidimensional quality of life </text>
<text top="107" left="678" width="233" height="20" font="4">● Disease severity does not correlate with </text>
<text top="124" left="678" width="144" height="20" font="4">psychological functioning. </text>
<text top="141" left="678" width="232" height="20" font="4">● Significant risk of under treatment when </text>
<text top="159" left="678" width="160" height="20" font="4">assessment is by self-report. </text>
<text top="211" left="64" width="81" height="20" font="4">Kovacs AH, et </text>
<text top="228" left="64" width="16" height="20" font="4">al. </text>
<text top="245" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(135)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18707776?dopt=Citation">18707776</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18707776?dopt=Citation"> </a></text>
<text top="211" left="172" width="36" height="20" font="4">Cross-</text>
<text top="228" left="172" width="52" height="20" font="4">sectional </text>
<text top="245" left="172" width="33" height="20" font="4">study </text>
<text top="211" left="266" width="38" height="20" font="4">n=280 </text>
<text top="228" left="266" width="20" height="20" font="4">pts </text>
<text top="211" left="334" width="182" height="20" font="3"><b>Inclusion criteria</b>: Adult pts with </text>
<text top="228" left="334" width="180" height="20" font="4">CHD being seen at 1 of 2 ACHD </text>
<text top="245" left="334" width="44" height="20" font="4">centers </text>
<text top="211" left="530" width="123" height="20" font="4">Describe predictors of </text>
<text top="228" left="530" width="119" height="20" font="4">symptoms of anxiety, </text>
<text top="245" left="530" width="64" height="20" font="4">depression </text>
<text top="211" left="678" width="205" height="20" font="4">● Self-reported symptoms correlated </text>
<text top="228" left="678" width="192" height="20" font="4">significantly with loneliness, fear of </text>
<text top="245" left="678" width="230" height="20" font="4">negative evaluation, and perceived health </text>
<text top="263" left="678" width="40" height="20" font="4">status. </text>
<text top="280" left="678" width="191" height="20" font="4">● Symptoms did not correlate with </text>
<text top="297" left="678" width="95" height="20" font="4">disease severity. </text>
<text top="314" left="678" width="219" height="20" font="4">● Subgroup of interviewed pts revealed </text>
<text top="332" left="678" width="209" height="20" font="4">50% with lifetime mood disorder, 39% </text>
<text top="349" left="678" width="79" height="20" font="4">never treated. </text>
<text top="211" left="926" width="218" height="20" font="4">● Symptoms of anxiety and depression </text>
<text top="228" left="926" width="212" height="20" font="4">are prevalent among ACHD pts but do </text>
<text top="245" left="926" width="192" height="20" font="4">not correlate with disease severity. </text>
<text top="367" left="64" width="81" height="20" font="4">Kovacs AH, et </text>
<text top="384" left="64" width="16" height="20" font="4">al. </text>
<text top="401" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(136)</a> </text>
<text top="418" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16086917?dopt=Citation">16086917</a></text>
<text top="418" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16086917?dopt=Citation"> </a></text>
<text top="367" left="172" width="55" height="20" font="4">Literature </text>
<text top="384" left="172" width="39" height="20" font="4">review </text>
<text top="367" left="266" width="231" height="20" font="4">8 studies  <b>Inclusion criteria</b>: ACHD pts </text>
<text top="384" left="334" width="139" height="20" font="4">and psychological and/or </text>
<text top="401" left="334" width="120" height="20" font="4">emotional functioning </text>
<text top="367" left="530" width="89" height="20" font="4">Prevalence and </text>
<text top="384" left="530" width="113" height="20" font="4">predictors of anxiety </text>
<text top="401" left="530" width="129" height="20" font="4">and depression among </text>
<text top="418" left="530" width="58" height="20" font="4">ACHD pts </text>
<text top="367" left="678" width="206" height="20" font="4">● U.S. studies report ACHD pts have </text>
<text top="384" left="678" width="218" height="20" font="4">worse emotional functioning reported in </text>
<text top="401" left="678" width="228" height="20" font="4">both interviews and self-report. European </text>
<text top="418" left="678" width="232" height="20" font="4">studies do not demonstrate these results.  </text>
<text top="367" left="926" width="212" height="20" font="4">● Interview data identify more disease </text>
<text top="384" left="926" width="90" height="20" font="4">than self-report. </text>
<text top="401" left="926" width="214" height="20" font="4">● International differences are not well </text>
<text top="418" left="926" width="80" height="20" font="4">substantiated. </text>
<text top="436" left="926" width="213" height="20" font="4">● Symptoms do not correlate well with </text>
<text top="453" left="926" width="95" height="20" font="4">disease severity. </text>
<text top="471" left="64" width="92" height="20" font="4">van Rijen EH, et </text>
<text top="488" left="64" width="16" height="20" font="4">al. </text>
<text top="505" left="64" width="63" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(137)</a> </text>
<text top="522" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12657226?dopt=Citation">12657226</a></text>
<text top="522" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12657226?dopt=Citation"> </a></text>
<text top="471" left="172" width="73" height="20" font="4">Cohort study </text>
<text top="471" left="266" width="38" height="20" font="4">n=362 </text>
<text top="488" left="266" width="20" height="20" font="4">pts </text>
<text top="471" left="334" width="143" height="20" font="3"><b>Inclusion criteria</b>: Single </text>
<text top="488" left="334" width="165" height="20" font="4">center, CHD surgery between </text>
<text top="505" left="334" width="162" height="20" font="4">1968―1980, &lt;15 y at time of </text>
<text top="522" left="334" width="173" height="20" font="4">surgery, 1 of 5 congenital heart </text>
<text top="540" left="334" width="43" height="20" font="4">defects </text>
<text top="471" left="530" width="118" height="20" font="4">Describe relationship </text>
<text top="488" left="530" width="120" height="20" font="4">between biographical </text>
<text top="505" left="530" width="88" height="20" font="4">information and </text>
<text top="522" left="530" width="101" height="20" font="4">psychological and </text>
<text top="540" left="530" width="81" height="20" font="4">social function </text>
<text top="471" left="678" width="213" height="20" font="4">● Pts were more likely to have been in </text>
<text top="488" left="678" width="235" height="20" font="4">special education, to have lower academic </text>
<text top="505" left="678" width="176" height="20" font="4">and occupational achievement.  </text>
<text top="522" left="678" width="216" height="20" font="4">● Pts scored favorable on measures of </text>
<text top="540" left="678" width="208" height="20" font="4">self-esteem, hostility, and neuroticism </text>
<text top="557" left="678" width="94" height="20" font="4">(Cohens D=0.5). </text>
<text top="471" left="926" width="201" height="20" font="4">● Long-term impact of CHD is lower </text>
<text top="488" left="926" width="229" height="20" font="4">academic and occupational achievement; </text>
<text top="505" left="926" width="189" height="20" font="4">however, psychological and social </text>
<text top="522" left="926" width="178" height="20" font="4">function may not be significantly </text>
<text top="540" left="926" width="54" height="20" font="4">impaired. </text>
<text top="575" left="54" width="3" height="20" font="4"> </text>
<text top="592" left="54" width="3" height="20" font="4"> </text>
<text top="592" left="463" width="3" height="20" font="4"> </text>
<text top="609" left="108" width="422" height="24" font="1"><b>Data Supplement 15. Endocarditis Prevention – Section 3.8  </b></text>
<text top="631" left="93" width="38" height="20" font="3"><b>Study </b></text>
<text top="648" left="68" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="665" left="96" width="30" height="20" font="3"><b>Year </b></text>
<text top="631" left="178" width="70" height="20" font="3"><b>Study Type </b></text>
<text top="631" left="291" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="631" left="403" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="648" left="439" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="631" left="571" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="631" left="762" width="95" height="20" font="3"><b>Results/p Value </b></text>
<text top="631" left="984" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="683" left="64" width="82" height="20" font="4">Chirouze C, et </text>
<text top="700" left="64" width="16" height="20" font="4">al. </text>
<text top="717" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(138)</a> </text>
<text top="735" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23517406?dopt=Citation">23517406</a></text>
<text top="735" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23517406?dopt=Citation"> </a></text>
<text top="683" left="172" width="64" height="20" font="4">Multicenter </text>
<text top="700" left="172" width="66" height="20" font="4">prospective </text>
<text top="717" left="172" width="76" height="20" font="4">observational </text>
<text top="735" left="172" width="38" height="20" font="4">cohort </text>
<text top="683" left="266" width="111" height="20" font="4">n=4,974 IE pts (500 </text>
<text top="700" left="266" width="96" height="20" font="4">with enterococci) </text>
<text top="683" left="395" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="700" left="395" width="88" height="20" font="4">Documented IE </text>
<text top="702" left="483" width="2" height="13" font="6"> </text>
<text top="683" left="543" width="72" height="20" font="4">Predictors of </text>
<text top="700" left="543" width="88" height="20" font="4">enterococcal IE </text>
<text top="683" left="685" width="104" height="20" font="4">● Mean age: 65 y. </text>
<text top="700" left="685" width="74" height="20" font="4">● 72% male. </text>
<text top="717" left="685" width="146" height="20" font="4">● 23% healthcare related. </text>
<text top="735" left="685" width="132" height="20" font="4">● 10% Vanco resistant. </text>
<text top="752" left="685" width="207" height="20" font="4">● More common than oral or group D </text>
<text top="769" left="685" width="178" height="20" font="4">streptococcus in North America. </text>
<text top="786" left="685" width="107" height="20" font="4">● Mortality: 28.9%. </text>
<text top="683" left="948" width="198" height="20" font="4">● Enterococcus is important source </text>
<text top="700" left="948" width="196" height="20" font="4">of IE with associated high morbidity </text>
<text top="717" left="948" width="77" height="20" font="4">and mortality. </text>
</page>
<page number="42" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 42 </text>
<text top="107" left="685" width="218" height="20" font="4">● Predictors of congestive HF, cerebral </text>
<text top="124" left="685" width="129" height="20" font="4">vascular accident, age. </text>
<text top="142" left="64" width="82" height="20" font="4">Thuny F, et al. </text>
<text top="159" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(139)</a> </text>
<text top="177" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22795288?dopt=Citation">22795288</a></text>
<text top="177" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22795288?dopt=Citation"> </a></text>
<text top="142" left="172" width="76" height="20" font="4">Single-center </text>
<text top="159" left="172" width="76" height="20" font="4">observational </text>
<text top="177" left="172" width="38" height="20" font="4">cohort </text>
<text top="142" left="266" width="58" height="20" font="4">n=328 pts </text>
<text top="142" left="395" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="159" left="395" width="88" height="20" font="4">Documented IE </text>
<text top="142" left="543" width="108" height="20" font="4">Survival at 1, 3, 5 y </text>
<text top="159" left="543" width="42" height="20" font="4">post IE </text>
<text top="142" left="685" width="140" height="20" font="4">● Relative survival rates: </text>
<text top="159" left="685" width="52" height="20" font="4">1 y=92% </text>
<text top="177" left="685" width="52" height="20" font="4">3 y=86% </text>
<text top="194" left="685" width="55" height="20" font="4">5 y=82%. </text>
<text top="211" left="685" width="192" height="20" font="4">● Most excess mortality as well as </text>
<text top="228" left="685" width="239" height="20" font="4">recurrence and late surgery occurred in the </text>
<text top="245" left="685" width="36" height="20" font="4">first y. </text>
<text top="142" left="948" width="164" height="20" font="4">● IE confers increased risk of </text>
<text top="159" left="948" width="201" height="20" font="4">mortality, especially in the first y and </text>
<text top="177" left="948" width="204" height="20" font="4">indicates close monitoring of pts who </text>
<text top="194" left="948" width="61" height="20" font="4">survive IE. </text>
<text top="263" left="64" width="89" height="20" font="4">Verheugt CL, et </text>
<text top="281" left="64" width="16" height="20" font="4">al. </text>
<text top="298" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(140)</a> </text>
<text top="315" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21217144?dopt=Citation">21217144</a></text>
<text top="315" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21217144?dopt=Citation"> </a></text>
<text top="263" left="172" width="48" height="20" font="4">Registry </text>
<text top="281" left="172" width="39" height="20" font="4">review </text>
<text top="263" left="266" width="102" height="20" font="4">n=10,210 pts; 233 </text>
<text top="281" left="266" width="63" height="20" font="4">IE cases in </text>
<text top="298" left="266" width="57" height="20" font="4">adulthood </text>
<text top="263" left="395" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="281" left="395" width="88" height="20" font="4">Documented IE </text>
<text top="263" left="543" width="124" height="20" font="4">Prediction model of IE </text>
<text top="281" left="543" width="95" height="20" font="4">at transition from </text>
<text top="298" left="543" width="124" height="20" font="4">pediatric to adult CHD </text>
<text top="315" left="543" width="27" height="20" font="4">care </text>
<text top="263" left="685" width="124" height="20" font="4">● Predictors included: </text>
<text top="281" left="685" width="25" height="20" font="4">Sex </text>
<text top="298" left="685" width="89" height="20" font="4">Multiple defects </text>
<text top="315" left="685" width="70" height="20" font="4">Main defect. </text>
<text top="332" left="685" width="114" height="20" font="4">● Childhood events: </text>
<text top="350" left="685" width="19" height="20" font="4"> IE </text>
<text top="367" left="685" width="32" height="20" font="4"> CVA </text>
<text top="384" left="685" width="34" height="20" font="4"> SVT. </text>
<text top="263" left="948" width="203" height="20" font="4">● Model predicted risk of IE up to 60 </text>
<text top="281" left="948" width="177" height="20" font="4">y and can help guide practice to </text>
<text top="298" left="948" width="187" height="20" font="4">identify individual pts at increased </text>
<text top="315" left="948" width="55" height="20" font="4">risk of IE. </text>
<text top="402" left="64" width="81" height="20" font="4">Lalani T, et al. </text>
<text top="419" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(141)</a> </text>
<text top="436" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16767483?dopt=Citation">16767483</a></text>
<text top="436" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16767483?dopt=Citation"> </a></text>
<text top="402" left="172" width="71" height="20" font="4">International </text>
<text top="419" left="172" width="76" height="20" font="4">Collaboration </text>
<text top="436" left="172" width="17" height="20" font="4">on </text>
<text top="454" left="172" width="71" height="20" font="4">Endocarditis </text>
<text top="471" left="172" width="45" height="20" font="4">merged </text>
<text top="488" left="172" width="54" height="20" font="4">database </text>
<text top="402" left="266" width="91" height="20" font="4">n=54 coagulase-</text>
<text top="419" left="266" width="78" height="20" font="4">negative PVE </text>
<text top="436" left="266" width="82" height="20" font="4">cases; n=58 <i>S </i></text>
<text top="454" left="266" width="108" height="20" font="8"><i>aureus</i> PVE cases; </text>
<text top="471" left="266" width="108" height="20" font="4">n=63 strep viridans </text>
<text top="488" left="266" width="64" height="20" font="4">PVE cases </text>
<text top="402" left="395" width="133" height="20" font="3"><b>Inclusion criteria</b>: PVE </text>
<text top="419" left="395" width="112" height="20" font="4">from coagulase-neg </text>
<text top="436" left="395" width="53" height="20" font="4">staph vs. </text>
<text top="454" left="395" width="96" height="20" font="8"><i>Staphylococcus . </i></text>
<text top="471" left="395" width="132" height="20" font="8"><i>aureus</i> or strep viridans </text>
<text top="402" left="543" width="109" height="20" font="4">Characteristics and </text>
<text top="419" left="543" width="109" height="20" font="4">outcome of pts with </text>
<text top="436" left="543" width="116" height="20" font="4">PVE from coagulase-</text>
<text top="454" left="543" width="50" height="20" font="4">negative </text>
<text top="471" left="543" width="87" height="20" font="4">staphylococcus </text>
<text top="402" left="685" width="232" height="20" font="4">● Congestive HF more common (p=0.03). </text>
<text top="419" left="685" width="242" height="20" font="4">● Valvular abscess greater (p=0.06; 0.001). </text>
<text top="436" left="685" width="248" height="20" font="4">● Mortality from any staph &gt; strep (p=0.002). </text>
<text top="402" left="948" width="188" height="20" font="4">● Coagulase-negative staph is an </text>
<text top="419" left="948" width="171" height="20" font="4">aggressive pathogen in IE with </text>
<text top="436" left="948" width="173" height="20" font="4">greater morbidity and mortality. </text>
<text top="506" left="64" width="91" height="20" font="4">Anderson DJ, et </text>
<text top="523" left="64" width="16" height="20" font="4">al. </text>
<text top="540" left="64" width="66" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(142)</a>  </text>
<text top="558" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16244853?dopt=Citation">16244853</a></text>
<text top="558" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16244853?dopt=Citation"> </a></text>
<text top="506" left="172" width="71" height="20" font="4">International </text>
<text top="523" left="172" width="76" height="20" font="4">Collaboration </text>
<text top="540" left="172" width="17" height="20" font="4">on </text>
<text top="558" left="172" width="71" height="20" font="4">Endocarditis </text>
<text top="575" left="172" width="45" height="20" font="4">merged </text>
<text top="592" left="172" width="54" height="20" font="4">database </text>
<text top="506" left="266" width="71" height="20" font="4">n=159 pts of </text>
<text top="523" left="266" width="88" height="20" font="4">enterococcal IE </text>
<text top="506" left="395" width="133" height="20" font="3"><b>Inclusion criteria</b>: PVE </text>
<text top="523" left="395" width="124" height="20" font="4">from enterococcus vs. </text>
<text top="540" left="395" width="63" height="20" font="4">NVEs from </text>
<text top="558" left="395" width="77" height="20" font="4">enterococcus </text>
<text top="506" left="543" width="125" height="20" font="4">Clinical characteristics </text>
<text top="523" left="543" width="81" height="20" font="4">and outcomes </text>
<text top="506" left="685" width="151" height="20" font="4">● 45/159 cases were PVE. </text>
<text top="523" left="685" width="217" height="20" font="4">● PVE had more abscesses (p=0.009), </text>
<text top="540" left="685" width="231" height="20" font="4">fewer vegetations (p=0.001) and less new </text>
<text top="558" left="685" width="125" height="20" font="4">regurgitation (p=0.01). </text>
<text top="575" left="685" width="104" height="20" font="4">● Mean age: 73 y. </text>
<text top="592" left="685" width="207" height="20" font="4">● Similar mortality and surgical rates. </text>
<text top="506" left="948" width="190" height="20" font="4">● Enterococcal PVE is more likely </text>
<text top="523" left="948" width="189" height="20" font="4">than enterococcal NVE to develop </text>
<text top="540" left="948" width="52" height="20" font="4">abscess. </text>
<text top="610" left="64" width="80" height="20" font="4">Chu VH, et al. </text>
<text top="627" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(143)</a> </text>
<text top="644" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16007540?dopt=Citation">16007540</a></text>
<text top="644" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16007540?dopt=Citation"> </a></text>
<text top="610" left="172" width="54" height="20" font="4">Cohort to </text>
<text top="627" left="172" width="51" height="20" font="4">compare </text>
<text top="644" left="172" width="64" height="20" font="4">time-based </text>
<text top="662" left="172" width="81" height="20" font="4">and molecular </text>
<text top="679" left="172" width="40" height="20" font="4">criteria </text>
<text top="610" left="266" width="114" height="20" font="4">n=13 pts with repeat </text>
<text top="627" left="266" width="15" height="20" font="4">IE </text>
<text top="610" left="395" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="627" left="395" width="105" height="20" font="4">Repeat case of IE  </text>
<text top="610" left="543" width="121" height="20" font="4">Distinguish relapse or </text>
<text top="627" left="543" width="60" height="20" font="4">reinfection </text>
<text top="610" left="685" width="220" height="20" font="4">● 10 of 13 cases molecular agreed with </text>
<text top="627" left="685" width="122" height="20" font="4">clinical determination. </text>
<text top="610" left="948" width="197" height="20" font="4">● Clinical timelines can be useful in </text>
<text top="627" left="948" width="204" height="20" font="4">determining reinfection vs. relapse of </text>
<text top="644" left="948" width="81" height="20" font="4">prior infection. </text>
<text top="697" left="64" width="94" height="20" font="4">McDonald JR, et </text>
<text top="714" left="64" width="16" height="20" font="4">al. </text>
<text top="731" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(144)</a> </text>
<text top="748" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15989910?dopt=Citation">15989910</a></text>
<text top="748" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15989910?dopt=Citation"> </a></text>
<text top="697" left="172" width="71" height="20" font="4">International </text>
<text top="714" left="172" width="76" height="20" font="4">Collaboration </text>
<text top="731" left="172" width="17" height="20" font="4">on </text>
<text top="748" left="172" width="71" height="20" font="4">Endocarditis </text>
<text top="766" left="172" width="45" height="20" font="4">merged </text>
<text top="783" left="172" width="54" height="20" font="4">database </text>
<text top="697" left="266" width="95" height="20" font="4">n=1,285 pts; 107 </text>
<text top="714" left="266" width="77" height="20" font="4">enterococcus </text>
<text top="697" left="395" width="130" height="20" font="3"><b>Inclusion criteria</b>: Left-</text>
<text top="714" left="395" width="62" height="20" font="4">sided NVE </text>
<text top="697" left="543" width="92" height="20" font="4">Describe clinical </text>
<text top="714" left="543" width="129" height="20" font="4">features and outcomes </text>
<text top="731" left="543" width="115" height="20" font="4">of enterococcal NVE </text>
<text top="748" left="543" width="70" height="20" font="4">on left sided </text>
<text top="697" left="685" width="177" height="20" font="4">● Most common in elderly men. </text>
<text top="714" left="685" width="193" height="20" font="4">● Involved aortic valve more often. </text>
<text top="731" left="685" width="151" height="20" font="4">● Congestive HF &gt; emboli. </text>
<text top="748" left="685" width="162" height="20" font="4">● Lower short-term mortality: </text>
<text top="766" left="685" width="165" height="20" font="4">OR: 0.49; 95% CI: 0.24–0.97. </text>
<text top="697" left="948" width="196" height="20" font="4">● Enterococcal NVE has distinctive </text>
<text top="714" left="948" width="164" height="20" font="4">features with good prognosis. </text>
</page>
<page number="43" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 43 </text>
<text top="107" left="64" width="80" height="20" font="4">Chu VH, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(145)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15546091?dopt=Citation">15546091</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15546091?dopt=Citation"> </a></text>
<text top="107" left="172" width="71" height="20" font="4">International </text>
<text top="124" left="172" width="76" height="20" font="4">Collaboration </text>
<text top="141" left="172" width="17" height="20" font="4">on </text>
<text top="159" left="172" width="71" height="20" font="4">Endocarditis </text>
<text top="176" left="172" width="45" height="20" font="4">merged </text>
<text top="193" left="172" width="54" height="20" font="4">database </text>
<text top="107" left="266" width="83" height="20" font="4">1,504 NVE; 99 </text>
<text top="124" left="266" width="110" height="20" font="4">coagulase-negative </text>
<text top="141" left="266" width="87" height="20" font="4">staphylococcus </text>
<text top="107" left="395" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="395" width="88" height="20" font="4">Documented IE </text>
<text top="107" left="543" width="92" height="20" font="4">Describe clinical </text>
<text top="124" left="543" width="129" height="20" font="4">features and outcomes </text>
<text top="141" left="543" width="124" height="20" font="4">of coagulase-negative </text>
<text top="159" left="543" width="116" height="20" font="4">staphylococcus NVE </text>
<text top="176" left="543" width="128" height="20" font="4">compared to <i>S. aureus</i> </text>
<text top="193" left="543" width="100" height="20" font="4">and strep viridans </text>
<text top="107" left="685" width="200" height="20" font="4">● 85% <i>Staphylococcus epidermidis</i>. </text>
<text top="124" left="685" width="114" height="20" font="4">● Median age: 68 y. </text>
<text top="141" left="685" width="74" height="20" font="4">● 77% male. </text>
<text top="159" left="685" width="211" height="20" font="4">● 20% long-term indwelling catheters. </text>
<text top="176" left="685" width="161" height="20" font="4">● 40% healthcare related IE. </text>
<text top="193" left="685" width="97" height="20" font="4">● Mortality: 19%. </text>
<text top="107" left="948" width="188" height="20" font="4">● Coagulase-negative staph is an </text>
<text top="124" left="948" width="158" height="20" font="4">important cause of NVE with </text>
<text top="141" left="948" width="176" height="20" font="4">significant risk for morbidity and </text>
<text top="159" left="948" width="53" height="20" font="4">mortality. </text>
<text top="211" left="64" width="92" height="20" font="4">Renzulli A, et al. </text>
<text top="228" left="64" width="63" height="20" font="4">2001 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(146)</a> </text>
<text top="245" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11465227?dopt=Citation">11465227</a></text>
<text top="245" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11465227?dopt=Citation"> </a></text>
<text top="211" left="172" width="78" height="20" font="4">Retrospective </text>
<text top="228" left="172" width="54" height="20" font="4">database </text>
<text top="245" left="172" width="61" height="20" font="4">analysis of </text>
<text top="263" left="172" width="68" height="20" font="4">consecutive </text>
<text top="280" left="172" width="20" height="20" font="4">pts </text>
<text top="211" left="266" width="86" height="20" font="4">n=271 pts (308 </text>
<text top="228" left="266" width="109" height="20" font="4">valve replacements </text>
<text top="245" left="266" width="37" height="20" font="4">for IE) </text>
<text top="211" left="395" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="228" left="395" width="117" height="20" font="4">that underwent valve </text>
<text top="245" left="395" width="104" height="20" font="4">replacement for IE </text>
<text top="263" left="395" width="115" height="20" font="4">between 1979–2000 </text>
<text top="211" left="543" width="114" height="20" font="4">Identify predictors of </text>
<text top="228" left="543" width="96" height="20" font="4">recurrent IE after </text>
<text top="245" left="543" width="78" height="20" font="4">surgical valve </text>
<text top="263" left="543" width="71" height="20" font="4">replacement </text>
<text top="211" left="685" width="122" height="20" font="4">● 22.5% recurrent IE. </text>
<text top="228" left="685" width="75" height="20" font="4">● Predictors: </text>
<text top="245" left="685" width="141" height="20" font="4"> PVE at index (p=0.0001) </text>
<text top="263" left="685" width="186" height="20" font="4"> Positive valve culture (p=0.0039) </text>
<text top="280" left="685" width="217" height="20" font="4"> Persistent fever at postoperative day 7 </text>
<text top="297" left="685" width="67" height="20" font="4">(p=0.0001). </text>
<text top="211" left="948" width="184" height="20" font="4">● Close attention to antimicrobial </text>
<text top="228" left="948" width="197" height="20" font="4">treatment and surgical debridement </text>
<text top="245" left="948" width="139" height="20" font="4">may reduce recurrent IE. </text>
<text top="315" left="64" width="79" height="20" font="4">Mansur AJ, et </text>
<text top="332" left="64" width="16" height="20" font="4">al. </text>
<text top="350" left="64" width="63" height="20" font="4">2001 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(147)</a> </text>
<text top="367" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11136490?dopt=Citation">11136490</a></text>
<text top="367" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11136490?dopt=Citation"> </a></text>
<text top="315" left="172" width="53" height="20" font="4">Inception </text>
<text top="332" left="172" width="74" height="20" font="4">cohort study, </text>
<text top="350" left="172" width="73" height="20" font="4">single center </text>
<text top="315" left="266" width="61" height="20" font="4">n=420 pts  </text>
<text top="315" left="395" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="332" left="395" width="127" height="20" font="4">discharged from single </text>
<text top="350" left="395" width="102" height="20" font="4">academic medical </text>
<text top="367" left="395" width="121" height="20" font="4">center after treatment </text>
<text top="384" left="395" width="33" height="20" font="4">for IE </text>
<text top="315" left="543" width="59" height="20" font="4">Describe:  </text>
<text top="332" left="543" width="58" height="20" font="4"> Relapses </text>
<text top="350" left="543" width="70" height="20" font="4"> Recurrence </text>
<text top="367" left="543" width="109" height="20" font="4"> Valve replacement </text>
<text top="384" left="543" width="57" height="20" font="4"> Mortality  </text>
<text top="315" left="685" width="99" height="20" font="4">● Relapse: 3.3%. </text>
<text top="332" left="685" width="125" height="20" font="4">● Recurrence: 12.3%. </text>
<text top="350" left="685" width="163" height="20" font="4">● Valve replacement: 19.7%. </text>
<text top="367" left="685" width="107" height="20" font="4">● Mortality: 12.3%. </text>
<text top="315" left="948" width="195" height="20" font="4">● Long-term survival is reduced for </text>
<text top="332" left="948" width="121" height="20" font="4">survivors of index IE.  </text>
<text top="350" left="948" width="207" height="20" font="4">● Predictors of mortality include male </text>
<text top="367" left="948" width="208" height="20" font="4">sex, increasing age, and recurrent IE. </text>
<text top="402" left="54" width="3" height="20" font="4"> </text>
<text top="419" left="54" width="3" height="20" font="4"> </text>
<text top="436" left="108" width="423" height="24" font="1"><b>Data Supplement 16. Concomitant Syndromes – Section 3.9 </b></text>
<text top="458" left="93" width="38" height="20" font="3"><b>Study </b></text>
<text top="475" left="68" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="492" left="96" width="30" height="20" font="3"><b>Year </b></text>
<text top="458" left="178" width="70" height="20" font="3"><b>Study Type </b></text>
<text top="458" left="271" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="458" left="359" width="165" height="20" font="3"><b>Inclusion/Exclusion Criteria </b></text>
<text top="458" left="564" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="458" left="769" width="48" height="20" font="3"><b>Results </b></text>
<text top="458" left="974" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="510" left="64" width="87" height="20" font="4">van Engelen K, </text>
<text top="527" left="64" width="30" height="20" font="4">et al. </text>
<text top="544" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(148)</a> </text>
<text top="562" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20357389?dopt=Citation">20357389</a></text>
<text top="562" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20357389?dopt=Citation"> </a></text>
<text top="510" left="172" width="40" height="20" font="4">Cohort </text>
<text top="510" left="266" width="58" height="20" font="4">n=479 pts </text>
<text top="510" left="354" width="168" height="20" font="3"><b>Inclusion criteria</b>: Adults with </text>
<text top="527" left="354" width="113" height="20" font="4">TOF and pulmonary </text>
<text top="544" left="354" width="167" height="20" font="4">atresia/VSD and availability of </text>
<text top="562" left="354" width="29" height="20" font="4">DNA </text>
<text top="510" left="543" width="363" height="20" font="4">Diagnosis of 22Q11  ● 20 pts already known to have diagnosis. </text>
<text top="527" left="671" width="205" height="20" font="4">● Another 24 diagnosed with 22Q11. </text>
<text top="510" left="926" width="205" height="20" font="4">● 9% of pts with TOF and pulmonary </text>
<text top="527" left="926" width="137" height="20" font="4">atresia/VSD have 22q11 </text>
<text top="544" left="926" width="215" height="20" font="4">Diagnosis unrecognized in half the pts. </text>
<text top="562" left="926" width="230" height="20" font="4">● Diagnostic test should be considered in </text>
<text top="579" left="926" width="204" height="20" font="4">all adult pts with TOF and pulmonary </text>
<text top="596" left="926" width="73" height="20" font="4">atresia/VSD. </text>
<text top="614" left="64" width="77" height="20" font="4">Piran S, et al. </text>
<text top="631" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(149)</a> </text>
<text top="649" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21167345?dopt=Citation">21167345</a></text>
<text top="649" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21167345?dopt=Citation"> </a></text>
<text top="614" left="172" width="67" height="20" font="4">Prospective </text>
<text top="631" left="172" width="38" height="20" font="4">cohort </text>
<text top="614" left="266" width="58" height="20" font="4">n=447 pts </text>
<text top="614" left="354" width="168" height="20" font="3"><b>Inclusion criteria</b>: Adults with </text>
<text top="631" left="354" width="174" height="20" font="4">TOF classified into syndromic if </text>
<text top="649" left="354" width="66" height="20" font="4">≥2 features </text>
<text top="614" left="543" width="104" height="20" font="4">Compared cardiac </text>
<text top="631" left="543" width="94" height="20" font="4">and extracardiac </text>
<text top="649" left="543" width="48" height="20" font="4">features </text>
<text top="614" left="671" width="208" height="20" font="4">● More frequent late onset conditions </text>
<text top="631" left="671" width="174" height="20" font="4">(neuropsych, thyroid, hearing).  </text>
<text top="614" left="926" width="205" height="20" font="4">● Extracardiac abnormalities warrant </text>
<text top="631" left="926" width="106" height="20" font="4">regular monitoring. </text>
<text top="676" left="64" width="87" height="20" font="4">Fung WL, et al. </text>
<text top="693" left="64" width="66" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(150)</a>  </text>
<text top="710" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18191243?dopt=Citation">18191243</a></text>
<text top="710" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18191243?dopt=Citation"> </a></text>
<text top="676" left="172" width="67" height="20" font="4">Prospective </text>
<text top="693" left="172" width="38" height="20" font="4">cohort </text>
<text top="676" left="266" width="58" height="20" font="4">n=103 pts </text>
<text top="676" left="354" width="156" height="20" font="3"><b>Inclusion criteria</b>: Adult pts </text>
<text top="693" left="354" width="144" height="20" font="4">with TOF and conotruncal </text>
<text top="710" left="354" width="46" height="20" font="4">defects  </text>
<text top="676" left="543" width="110" height="20" font="4">Clinical and genetic </text>
<text top="693" left="543" width="40" height="20" font="4">screen </text>
<text top="676" left="671" width="112" height="20" font="4">● 31 had 22q11DS. </text>
<text top="693" left="671" width="176" height="20" font="4">● Combining 2 clinical features; </text>
<text top="710" left="671" width="132" height="20" font="4">discriminate ability 82% </text>
<text top="727" left="671" width="240" height="20" font="4">● 4 features and discriminant ability &gt;85%.  </text>
<text top="676" left="926" width="203" height="20" font="4">● Clinicians who consider ≥2 clinical </text>
<text top="693" left="926" width="181" height="20" font="4">features can help identify 22q11. </text>
<text top="745" left="64" width="92" height="20" font="4">Swaby JA, et al. </text>
<text top="762" left="64" width="66" height="20" font="4">2001 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(151)</a>  </text>
<text top="780" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21257016?dopt=Citation">21257016</a></text>
<text top="780" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21257016?dopt=Citation"> </a></text>
<text top="745" left="172" width="40" height="20" font="4">Cohort </text>
<text top="745" left="266" width="58" height="20" font="4">n=104 pts </text>
<text top="762" left="266" width="63" height="20" font="4">with 22q11 </text>
<text top="745" left="354" width="164" height="20" font="3"><b>Inclusion criteria</b>: &gt;17 y with </text>
<text top="762" left="354" width="38" height="20" font="4">22q11 </text>
<text top="780" left="354" width="3" height="20" font="4"> </text>
<text top="745" left="543" width="24" height="20" font="4">N/A </text>
<text top="745" left="671" width="195" height="20" font="4">● Prevalence of severe CHD in the </text>
<text top="762" left="671" width="225" height="20" font="4">Relatives of probands with 22q11 is 0.36 </text>
<text top="745" left="926" width="204" height="20" font="4">● Heritable susceptibility for CHD for </text>
<text top="762" left="926" width="207" height="20" font="4">family members of 22q11, even more </text>
<text top="780" left="926" width="147" height="20" font="4">than expected with 22q11. </text>
</page>
<page number="44" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 44 </text>
<text top="107" left="354" width="130" height="20" font="3"><b>Exclusion criteria</b>: Pts </text>
<text top="124" left="354" width="161" height="20" font="4">adopted and with inadequate </text>
<text top="141" left="354" width="75" height="20" font="4">family history </text>
<text top="107" left="671" width="180" height="20" font="4">(p=0.007 compared with general </text>
<text top="124" left="671" width="71" height="20" font="4">population).  </text>
<text top="159" left="64" width="73" height="20" font="4">Liu AP, et al. </text>
<text top="177" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(152)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24721633?dopt=Citation">24721633</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24721633?dopt=Citation"> </a></text>
<text top="159" left="172" width="67" height="20" font="4">Prospective </text>
<text top="177" left="172" width="33" height="20" font="4">study </text>
<text top="159" left="266" width="58" height="20" font="4">n=156 pts </text>
<text top="177" left="266" width="68" height="20" font="4">consecutive </text>
<text top="194" left="266" width="45" height="20" font="4">pts with </text>
<text top="211" left="266" width="67" height="20" font="4">conotruncal </text>
<text top="228" left="266" width="43" height="20" font="4">defects </text>
<text top="159" left="354" width="154" height="20" font="3"><b>Inclusion criteria</b>: Pts from </text>
<text top="177" left="354" width="147" height="20" font="4">ACHD clinic in Hong Kong </text>
<text top="159" left="543" width="60" height="20" font="4">Determine </text>
<text top="177" left="543" width="77" height="20" font="4">prevalence of </text>
<text top="194" left="543" width="111" height="20" font="4">undiagnosed 22q11 </text>
<text top="211" left="543" width="111" height="20" font="4">in adult Chinese pts </text>
<text top="228" left="543" width="92" height="20" font="4">with conotruncal </text>
<text top="246" left="543" width="83" height="20" font="4">anomalies and </text>
<text top="263" left="543" width="109" height="20" font="4">phenotypic findings </text>
<text top="159" left="671" width="222" height="20" font="4">● 18 pts (11.5%) diagnosed with 22q11. </text>
<text top="177" left="671" width="196" height="20" font="4">● Dysmorphic features detected by </text>
<text top="194" left="671" width="87" height="20" font="4">geneticist in all. </text>
<text top="211" left="671" width="208" height="20" font="4">● Only 2/3 considered dysmorphic by </text>
<text top="228" left="671" width="187" height="20" font="4">cardiologist on initial assessment. </text>
<text top="245" left="671" width="229" height="20" font="4">● Significant extra cardiac manifestations </text>
<text top="263" left="671" width="178" height="20" font="4">(33% neurodevelopmental, 28% </text>
<text top="280" left="671" width="135" height="20" font="4">thrombocytopenia etc.).  </text>
<text top="159" left="926" width="219" height="20" font="4">● Underdiagnosis of 22q11 is common. </text>
<text top="177" left="926" width="215" height="20" font="4">Facial features may not be recognized. </text>
<text top="194" left="926" width="222" height="20" font="4">● Testing and genetic referral should be </text>
<text top="211" left="926" width="214" height="20" font="4">offered to pts with conotruncal defects. </text>
<text top="298" left="64" width="87" height="20" font="4">Monteiro FP, et </text>
<text top="315" left="64" width="16" height="20" font="4">al. </text>
<text top="332" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(153)</a> </text>
<text top="350" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23440478?dopt=Citation">23440478</a></text>
<text top="350" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23440478?dopt=Citation"> </a></text>
<text top="298" left="172" width="40" height="20" font="4">Cohort </text>
<text top="298" left="266" width="58" height="20" font="4">n=194 pts </text>
<text top="298" left="354" width="154" height="20" font="3"><b>Inclusion criteria</b>: Variable </text>
<text top="315" left="354" width="99" height="20" font="4">features of 22q11 </text>
<text top="332" left="354" width="3" height="20" font="4"> </text>
<text top="350" left="354" width="157" height="20" font="4">Group 1: clinical with palatal </text>
<text top="367" left="354" width="174" height="20" font="4">Group 2: clinical without palatal </text>
<text top="384" left="354" width="137" height="20" font="4">Group 3: cardiac defects </text>
<text top="401" left="354" width="125" height="20" font="4">associated with 22q11 </text>
<text top="418" left="354" width="130" height="20" font="4">Group 4: juvenile onset </text>
<text top="436" left="354" width="79" height="20" font="4">schizophrenia </text>
<text top="298" left="543" width="78" height="20" font="4">Delineation of </text>
<text top="315" left="543" width="99" height="20" font="4">features of 22q11 </text>
<text top="298" left="671" width="136" height="20" font="4">● 22q11 in 45 pts (23%) </text>
<text top="315" left="671" width="102" height="20" font="4">● Group 1: 34.7% </text>
<text top="332" left="671" width="105" height="20" font="4">● Group 2: 22.2%  </text>
<text top="350" left="671" width="141" height="20" font="4">● Group 3: 6/52 (11.5%). </text>
<text top="298" left="926" width="205" height="20" font="4">● Propose screening pts with distinct </text>
<text top="315" left="926" width="86" height="20" font="4">manifestations. </text>
<text top="454" left="64" width="93" height="20" font="4">Hinton RB, et al. </text>
<text top="471" left="64" width="66" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(154)</a>  </text>
<text top="488" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17936159?dopt=Citation">17936159</a></text>
<text top="488" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17936159?dopt=Citation"> </a></text>
<text top="454" left="172" width="40" height="20" font="4">Cohort </text>
<text top="454" left="266" width="31" height="20" font="4">n=38 </text>
<text top="471" left="266" width="55" height="20" font="4">probands </text>
<text top="488" left="266" width="62" height="20" font="4">with HLHS </text>
<text top="454" left="354" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="454" left="543" width="106" height="20" font="4">Determine the size </text>
<text top="471" left="543" width="111" height="20" font="4">of the genetic effect </text>
<text top="488" left="543" width="80" height="20" font="4">(heritability) in </text>
<text top="505" left="543" width="114" height="20" font="4">families identified by </text>
<text top="522" left="543" width="98" height="20" font="4">a HLHS proband. </text>
<text top="454" left="671" width="235" height="20" font="4">● 21 of 38 (55%) families had more than 1 </text>
<text top="471" left="671" width="235" height="20" font="4">affected individual, and 36% of pts had CV </text>
<text top="488" left="671" width="218" height="20" font="4">malformation, including 11% with BAV.  </text>
<text top="505" left="671" width="228" height="20" font="4">● The heritability of HLHS alone and with </text>
<text top="522" left="671" width="239" height="20" font="4">associated CV malformation were 99% and </text>
<text top="540" left="671" width="177" height="20" font="4">74% (p&lt;0.00001), respectively.  </text>
<text top="557" left="671" width="239" height="20" font="4">● The sibling recurrence risk for HLHS was </text>
<text top="574" left="671" width="218" height="20" font="4">8%, and for CV malformation was 22%. </text>
<text top="454" left="926" width="224" height="20" font="4">● Increased prevalence of BAV in family </text>
<text top="471" left="926" width="58" height="20" font="4">members. </text>
<text top="592" left="64" width="49" height="20" font="4">Robledo </text>
<text top="609" left="64" width="81" height="20" font="4">Carmona J, et </text>
<text top="626" left="64" width="16" height="20" font="4">al. </text>
<text top="644" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(155)</a> </text>
<text top="661" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23684596?dopt=Citation">23684596</a></text>
<text top="661" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23684596?dopt=Citation"> </a></text>
<text top="592" left="172" width="36" height="20" font="4">Cross-</text>
<text top="609" left="172" width="55" height="20" font="4">sectional  </text>
<text top="592" left="266" width="58" height="20" font="4">n=553 pts </text>
<text top="609" left="266" width="57" height="20" font="4">(348 FDR </text>
<text top="626" left="266" width="48" height="20" font="4">and 105 </text>
<text top="644" left="266" width="51" height="20" font="4">controls) </text>
<text top="592" left="354" width="171" height="20" font="3"><b>Inclusion criteria</b>:100 families </text>
<text top="609" left="354" width="62" height="20" font="4">of BAV pts </text>
<text top="592" left="543" width="87" height="20" font="4">16 BAV in FDR </text>
<text top="609" left="543" width="98" height="20" font="4">(15% for families, </text>
<text top="626" left="543" width="71" height="20" font="4">4.6 for FDR) </text>
<text top="592" left="671" width="239" height="20" font="4">● Aortic dimensions of FDR with TV similar </text>
<text top="609" left="671" width="57" height="20" font="4">to control. </text>
<text top="592" left="926" width="193" height="20" font="4">● BAV recurrence was low (4.6%). </text>
<text top="679" left="64" width="84" height="20" font="4">Panayotova R, </text>
<text top="696" left="64" width="30" height="20" font="4">et al. </text>
<text top="713" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(156)</a> </text>
<text top="730" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23798202?dopt=Citation">23798202</a></text>
<text top="730" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23798202?dopt=Citation"> </a></text>
<text top="679" left="172" width="67" height="20" font="4">Prospective </text>
<text top="696" left="172" width="38" height="20" font="4">cohort </text>
<text top="679" left="266" width="62" height="20" font="4">n=47 initial </text>
<text top="696" left="266" width="20" height="20" font="4">pts </text>
<text top="679" left="354" width="133" height="20" font="3"><b>Inclusion criteria</b>: N/A  </text>
<text top="679" left="543" width="24" height="20" font="4">N/A </text>
<text top="679" left="671" width="242" height="20" font="4">● 14% prevalence of aortic valve disease in </text>
<text top="696" left="671" width="226" height="20" font="4">FDR of pts who had aortic valve surgery. </text>
<text top="679" left="926" width="222" height="20" font="4">● High prevalence of BAV in FDR of pts </text>
<text top="696" left="926" width="220" height="20" font="4">with BAV who have undergone surgery. </text>
<text top="748" left="64" width="84" height="20" font="4">McBride KL, et </text>
<text top="766" left="64" width="16" height="20" font="4">al. </text>
<text top="748" left="172" width="56" height="20" font="4">Screened </text>
<text top="766" left="172" width="38" height="20" font="4">cohort </text>
<text top="748" left="266" width="67" height="20" font="4">n=413 FDR </text>
<text top="766" left="266" width="59" height="20" font="4">of pts with </text>
<text top="783" left="266" width="49" height="20" font="4">LVOTO. </text>
<text top="748" left="354" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="766" left="354" width="127" height="20" font="4">Nonsyndromic LVOTO </text>
<text top="748" left="543" width="24" height="20" font="4">N/A </text>
<text top="748" left="671" width="212" height="20" font="4">32/413 (7.7%) had LVOTO (18 BAV, 5 </text>
<text top="766" left="671" width="202" height="20" font="4">HLHS, 3 CoA, 3 AVS) or other CHD. </text>
<text top="748" left="926" width="211" height="20" font="4">● Increased risk of CHD in FDR of pts </text>
<text top="766" left="926" width="74" height="20" font="4">with LVOTO. </text>
</page>
<page number="45" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 45 </text>
<text top="107" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(157)</a> </text>
<text top="124" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15690347?dopt=Citation">15690347</a></text>
<text top="124" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15690347?dopt=Citation"> </a></text>
<text top="107" left="266" width="67" height="20" font="4">351 echoes </text>
<text top="142" left="64" width="83" height="20" font="4">Majdalany DS, </text>
<text top="159" left="64" width="30" height="20" font="4">et al. </text>
<text top="177" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(158)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20136856?dopt=Citation">20136856</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20136856?dopt=Citation"> </a></text>
<text top="142" left="172" width="78" height="20" font="4">Retrospective </text>
<text top="159" left="172" width="39" height="20" font="4">review </text>
<text top="142" left="266" width="72" height="20" font="4">n=50 pts (57 </text>
<text top="159" left="266" width="58" height="20" font="4">surgeries) </text>
<text top="142" left="354" width="155" height="20" font="3"><b>Inclusion criteria</b>: &gt;18 with </text>
<text top="159" left="354" width="118" height="20" font="4">Down syndrome who </text>
<text top="177" left="354" width="148" height="20" font="4">underwent cardiac surgery </text>
<text top="142" left="543" width="24" height="20" font="4">N/A </text>
<text top="142" left="671" width="156" height="20" font="4">● Atrial arrhythmias in 25%. </text>
<text top="159" left="671" width="218" height="20" font="4">● 12% had postop pulmonary infection. </text>
<text top="142" left="926" width="201" height="20" font="4">● At an experienced center, pts with </text>
<text top="159" left="926" width="207" height="20" font="4">Down syndrome can undergo cardiac </text>
<text top="177" left="926" width="202" height="20" font="4">surgery with low risk of mortality and </text>
<text top="194" left="926" width="60" height="20" font="4">morbidity.  </text>
<text top="211" left="926" width="225" height="20" font="4">● Atrial arrhythmias and postop infection </text>
<text top="228" left="926" width="54" height="20" font="4">common. </text>
<text top="246" left="64" width="89" height="20" font="4">Crepaz R, et al. </text>
<text top="263" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(159)</a>  </text>
<text top="281" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24047157?dopt=Citation">24047157</a></text>
<text top="281" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24047157?dopt=Citation"> </a></text>
<text top="246" left="172" width="139" height="20" font="4">Observational  n=7 pts </text>
<text top="246" left="354" width="168" height="20" font="3"><b>Inclusion criteria</b>: Adults with </text>
<text top="263" left="354" width="174" height="20" font="4">trisomy 21 and pulmonary HTN </text>
<text top="246" left="543" width="109" height="20" font="4">125 mcg Bosentan  </text>
<text top="263" left="543" width="114" height="20" font="4">Follow up 46–55 mo </text>
<text top="246" left="671" width="157" height="20" font="4">● Improved 6MWT and SPO</text>
<text top="248" left="828" width="4" height="13" font="6">2</text>
<text top="246" left="833" width="7" height="20" font="4">. </text>
<text top="263" left="671" width="226" height="20" font="4">● Increased pulmonary flow acceleration </text>
<text top="281" left="671" width="30" height="20" font="4">time. </text>
<text top="246" left="926" width="216" height="20" font="4">● Downs syndrome does not affect the </text>
<text top="263" left="926" width="175" height="20" font="4">response to Bosentan Therapy. </text>
<text top="299" left="64" width="83" height="20" font="4">Troost E, et al. </text>
<text top="316" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(160)</a> </text>
<text top="333" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21744698?dopt=Citation">21744698</a></text>
<text top="333" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21744698?dopt=Citation"> </a></text>
<text top="299" left="172" width="78" height="20" font="4">Retrospective </text>
<text top="316" left="172" width="48" height="20" font="4">analysis </text>
<text top="299" left="266" width="61" height="20" font="4">n=134 pts  </text>
<text top="299" left="354" width="168" height="20" font="3"><b>Inclusion criteria</b>: Adults with </text>
<text top="316" left="354" width="133" height="20" font="4">Eisenmenger syndrome </text>
<text top="299" left="543" width="72" height="20" font="4">Survival rate </text>
<text top="299" left="671" width="235" height="20" font="4">● Mean survival was 44.9 y ± 2.2; survival </text>
<text top="316" left="671" width="238" height="20" font="4">of pts with trisomy 21 did not differ from pts </text>
<text top="333" left="671" width="106" height="20" font="4">without trisomy 21. </text>
<text top="299" left="926" width="219" height="20" font="4">● Survival of pts with trisomy 21 did not </text>
<text top="316" left="926" width="185" height="20" font="4">differ from pts without trisomy 21. </text>
<text top="351" left="64" width="93" height="20" font="4">Carlson M, et al. </text>
<text top="368" left="64" width="66" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(161)</a>  </text>
<text top="385" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23032325?dopt=Citation">23032325</a></text>
<text top="385" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23032325?dopt=Citation"> </a></text>
<text top="351" left="172" width="145" height="20" font="4">Retrospective  n=20 pts </text>
<text top="368" left="266" width="71" height="20" font="4">with Turners </text>
<text top="385" left="266" width="24" height="20" font="4">and </text>
<text top="403" left="266" width="58" height="20" font="4">dissection </text>
<text top="351" left="354" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="351" left="543" width="92" height="20" font="4">Ascending aorta </text>
<text top="368" left="543" width="58" height="20" font="4">size index </text>
<text top="351" left="671" width="216" height="20" font="4">● In 9 pts with Type A dissection mean </text>
<text top="368" left="671" width="199" height="20" font="4">ascending aorta size 2.7 ± 0.6 cm/m</text>
<text top="370" left="870" width="4" height="13" font="6">2</text>
<text top="368" left="875" width="7" height="20" font="4">. </text>
<text top="351" left="926" width="229" height="20" font="4">● Adults with Turner syndrome should be </text>
<text top="368" left="926" width="213" height="20" font="4">considered for aortic operation if aortic </text>
<text top="385" left="926" width="116" height="20" font="4">size index &gt;2.5 cm/m</text>
<text top="387" left="1042" width="4" height="13" font="6">2</text>
<text top="385" left="1047" width="7" height="20" font="4">. </text>
<text top="421" left="108" width="3" height="20" font="4"> </text>
<text top="438" left="108" width="491" height="24" font="1"><b>Data Supplement 17. Acquired Cardiovascular Disease – Section 3.10 </b></text>
<text top="459" left="92" width="38" height="20" font="3"><b>Study </b></text>
<text top="476" left="67" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="494" left="95" width="30" height="20" font="3"><b>Year </b></text>
<text top="459" left="183" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="476" left="198" width="44" height="20" font="3"><b>Design </b></text>
<text top="459" left="296" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="459" left="389" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="476" left="426" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="459" left="549" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="459" left="730" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="459" left="934" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="512" left="64" width="381" height="20" font="3"><b>(Late) CV Events, Mortality, Acquired Comorbidities in ACHD Pts </b></text>
<text top="530" left="64" width="85" height="20" font="4">Pillutla P, et al. </text>
<text top="547" left="64" width="66" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(162)</a>  </text>
<text top="564" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19853711?dopt=Citation">19853711</a></text>
<text top="564" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19853711?dopt=Citation"> </a></text>
<text top="530" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="547" left="170" width="76" height="20" font="4">analysis from </text>
<text top="564" left="170" width="76" height="20" font="4">CDC multiple </text>
<text top="581" left="170" width="85" height="20" font="4">cause-of-death </text>
<text top="598" left="170" width="44" height="20" font="4">registry </text>
<text top="530" left="283" width="211" height="20" font="4">U.S. population   <b>Inclusion criteria</b>: </text>
<text top="547" left="389" width="100" height="20" font="4">Pts with CHD and </text>
<text top="564" left="389" width="116" height="20" font="4">death records, 1979–</text>
<text top="581" left="389" width="31" height="20" font="4">2005 </text>
<text top="530" left="522" width="105" height="20" font="4">Trends in mortality </text>
<text top="547" left="522" width="93" height="20" font="4">from 1979–2005 </text>
<text top="564" left="522" width="102" height="20" font="4">among individuals </text>
<text top="581" left="522" width="116" height="20" font="4">with CHD in the U.S. </text>
<text top="530" left="662" width="229" height="20" font="4">● Significant decline in mortality in ACHD </text>
<text top="547" left="662" width="215" height="20" font="4">including VSD, PDA, CoA, and Ebstein </text>
<text top="564" left="662" width="177" height="20" font="4">anomaly. 71% decline in deaths </text>
<text top="581" left="662" width="235" height="20" font="4">associated with TGA (p=0.001) and a 40% </text>
<text top="598" left="662" width="223" height="20" font="4">reduction in deaths associated with TOF </text>
<text top="616" left="662" width="238" height="20" font="4">(p&lt;0.001). Mortality related to other lesions </text>
<text top="633" left="662" width="198" height="20" font="4">declined as well. Among adults with </text>
<text top="650" left="662" width="234" height="20" font="4">cyanotic lesions, the 1° contributing cause </text>
<text top="667" left="662" width="223" height="20" font="4">of death was arrhythmia followed by HF. </text>
<text top="685" left="662" width="218" height="20" font="4">For adults with noncyanotic lesions, the </text>
<text top="702" left="662" width="232" height="20" font="4">major contributing cause before 1990 was </text>
<text top="719" left="662" width="212" height="20" font="4">arrhythmia; after 1990, MI became the </text>
<text top="736" left="662" width="201" height="20" font="4">leading contributing cause of death.  </text>
<text top="753" left="662" width="218" height="20" font="4">● There was an overall decrease in the </text>
<text top="771" left="662" width="217" height="20" font="4">incidence of arrhythmia as the cause of </text>
<text top="530" left="914" width="141" height="20" font="4">● Pts with CHD are living </text>
<text top="547" left="914" width="41" height="20" font="4">longer. </text>
<text top="564" left="914" width="143" height="20" font="4">● Arrhythmia remains the </text>
<text top="581" left="914" width="164" height="20" font="4">1°contributing cause of death </text>
<text top="598" left="914" width="174" height="20" font="4">for those with cyanotic lesions.  </text>
<text top="616" left="914" width="131" height="20" font="4">● MI is now the leading </text>
<text top="633" left="914" width="157" height="20" font="4">contributing cause for adults </text>
<text top="650" left="914" width="124" height="20" font="4">with noncyanotic CHD </text>
<text top="667" left="914" width="176" height="20" font="4">consistent with late survival and </text>
<text top="685" left="914" width="130" height="20" font="4">an increasing impact of </text>
<text top="702" left="914" width="75" height="20" font="4">acquired HD. </text>
</page>
<page number="46" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 46 </text>
<text top="107" left="662" width="200" height="20" font="4">death in all ages, particularly among </text>
<text top="124" left="662" width="50" height="20" font="4">children. </text>
<text top="142" left="64" width="73" height="20" font="4">Lin YS, et al. </text>
<text top="159" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(163)</a> </text>
<text top="177" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24655794?dopt=Citation">24655794</a></text>
<text top="177" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24655794?dopt=Citation"> </a></text>
<text top="142" left="170" width="67" height="20" font="4">Prospective </text>
<text top="159" left="170" width="66" height="20" font="4">cohort from </text>
<text top="177" left="170" width="52" height="20" font="4">Taiwan’s </text>
<text top="194" left="170" width="87" height="20" font="4">National Health </text>
<text top="211" left="170" width="57" height="20" font="4">Insurance </text>
<text top="228" left="170" width="56" height="20" font="4">Research </text>
<text top="246" left="170" width="60" height="20" font="4">Database  </text>
<text top="142" left="283" width="78" height="20" font="4">n=3,267 adult </text>
<text top="159" left="283" width="83" height="20" font="4">pts with ACHD </text>
<text top="177" left="283" width="53" height="20" font="4">identified </text>
<text top="194" left="283" width="84" height="20" font="4">between 2000–</text>
<text top="211" left="283" width="78" height="20" font="4">2003, median </text>
<text top="228" left="283" width="83" height="20" font="4">follow-up of 11 </text>
<text top="246" left="283" width="47" height="20" font="4">y; 6,534 </text>
<text top="263" left="283" width="46" height="20" font="4">controls </text>
<text top="142" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="159" left="389" width="83" height="20" font="4">ACHD pts with </text>
<text top="177" left="389" width="115" height="20" font="4">ASDs, VSDs, PDAs, </text>
<text top="194" left="389" width="116" height="20" font="4">TOF, and pulmonary </text>
<text top="211" left="389" width="49" height="20" font="4">stenosis </text>
<text top="142" left="522" width="112" height="20" font="4">Incidence of MACE. </text>
<text top="159" left="522" width="117" height="20" font="4">(MI, HF, PCI, CABG, </text>
<text top="177" left="522" width="57" height="20" font="4">malignant </text>
<text top="194" left="522" width="116" height="20" font="4">dysrhythmia, cardiac </text>
<text top="211" left="522" width="105" height="20" font="4">shock, implantable </text>
<text top="228" left="522" width="110" height="20" font="4">cardiac defibrillator, </text>
<text top="246" left="522" width="62" height="20" font="4">and death) </text>
<text top="142" left="662" width="220" height="20" font="4">● MACE was 4-fold higher in the ACHD </text>
<text top="159" left="662" width="218" height="20" font="4">group compared with the controls (after </text>
<text top="177" left="662" width="237" height="20" font="4">adjustment for age and sex, ACHD pts had </text>
<text top="194" left="662" width="190" height="20" font="4">an increased risk of HF, malignant </text>
<text top="211" left="662" width="219" height="20" font="4">dysrhythmia, acute coronary syndrome, </text>
<text top="228" left="662" width="68" height="20" font="4">and stroke). </text>
<text top="142" left="914" width="174" height="20" font="4">● ACHD pts have an increased </text>
<text top="159" left="914" width="125" height="20" font="4">life-long risk of MACE. </text>
<text top="281" left="64" width="84" height="20" font="4">Engelfriet P, et </text>
<text top="298" left="64" width="16" height="20" font="4">al. </text>
<text top="315" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(164)</a> </text>
<text top="332" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15996978?dopt=Citation">15996978</a></text>
<text top="332" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15996978?dopt=Citation"> </a></text>
<text top="281" left="170" width="94" height="20" font="4">European cohort </text>
<text top="298" left="170" width="75" height="20" font="4">of adults with </text>
<text top="315" left="170" width="30" height="20" font="4">CHD </text>
<text top="281" left="283" width="71" height="20" font="4">n=4,110 pts  </text>
<text top="281" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="298" left="389" width="84" height="20" font="4">ACHD pts who </text>
<text top="315" left="389" width="115" height="20" font="4">consecutively visited </text>
<text top="332" left="389" width="119" height="20" font="4">the output clinics of 1 </text>
<text top="350" left="389" width="104" height="20" font="4">of the participating </text>
<text top="367" left="389" width="87" height="20" font="4">centers in 1998 </text>
<text top="281" left="522" width="127" height="20" font="4">Mortality and morbidity </text>
<text top="298" left="522" width="110" height="20" font="4">(NYHA class) in 5 y </text>
<text top="281" left="662" width="227" height="20" font="4">● NYHA FC worsened in 6% (In cyanotic </text>
<text top="298" left="662" width="222" height="20" font="4">defects and in the Fontan circulation, 21 </text>
<text top="315" left="662" width="205" height="20" font="4">and 17%). In only 1% of CoA pts, the </text>
<text top="332" left="662" width="159" height="20" font="4">NYHA class became worse.  </text>
<text top="350" left="662" width="196" height="20" font="4">● Among ASD pts, the NYHA class </text>
<text top="367" left="662" width="217" height="20" font="4">improved more often than it worsened.  </text>
<text top="384" left="662" width="169" height="20" font="4">● Arrhythmias were common.  </text>
<text top="281" left="914" width="148" height="20" font="4">● Outcomes were worst in </text>
<text top="298" left="914" width="149" height="20" font="4">cyanotic defects and in the </text>
<text top="315" left="914" width="135" height="20" font="4">Fontan circulation, but a </text>
<text top="332" left="914" width="166" height="20" font="4">considerable proportion of the </text>
<text top="350" left="914" width="153" height="20" font="4">other pts also suffered from </text>
<text top="367" left="914" width="109" height="20" font="4">cardiac symptoms.  </text>
<text top="402" left="64" width="93" height="20" font="4">Zomer AC, et al. </text>
<text top="419" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(165)</a> </text>
<text top="436" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20207625?dopt=Citation">20674998</a></text>
<text top="436" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20207625?dopt=Citation"> </a></text>
<text top="402" left="170" width="82" height="20" font="4">The CONCOR </text>
<text top="419" left="170" width="85" height="20" font="4">registry of over </text>
<text top="436" left="170" width="77" height="20" font="4">10,000 adults </text>
<text top="454" left="170" width="99" height="20" font="4">with CHD used to </text>
<text top="471" left="170" width="96" height="20" font="4">verify the causes </text>
<text top="488" left="170" width="98" height="20" font="4">of death provided </text>
<text top="505" left="170" width="70" height="20" font="4">by the WHO </text>
<text top="522" left="170" width="96" height="20" font="4">guidelines based </text>
<text top="540" left="170" width="96" height="20" font="4">national mortality </text>
<text top="557" left="170" width="64" height="20" font="4">registry, by </text>
<text top="574" left="170" width="46" height="20" font="4">linkage. </text>
<text top="402" left="283" width="68" height="20" font="4">n=7,277 pts </text>
<text top="419" left="283" width="67" height="20" font="4">(196 (2.4%) </text>
<text top="436" left="283" width="82" height="20" font="4">were recorded </text>
<text top="454" left="283" width="76" height="20" font="4">deceased vs. </text>
<text top="471" left="283" width="81" height="20" font="4">228 deceased </text>
<text top="488" left="283" width="59" height="20" font="4">pts (3.1%) </text>
<text top="505" left="283" width="85" height="20" font="4">recorded in the </text>
<text top="522" left="283" width="58" height="20" font="4">CONCOR </text>
<text top="540" left="283" width="85" height="20" font="4">registry, during </text>
<text top="557" left="283" width="76" height="20" font="4">a follow-up of </text>
<text top="574" left="283" width="68" height="20" font="4">25,900 pt y. </text>
<text top="402" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="419" left="389" width="93" height="20" font="4">Registry pts with </text>
<text top="436" left="389" width="79" height="20" font="4">death records </text>
<text top="402" left="522" width="87" height="20" font="4">Cause of death </text>
<text top="402" left="662" width="197" height="20" font="4">● Median age at death was 48.9 y.  </text>
<text top="419" left="662" width="224" height="20" font="4">● Of all deaths in the CONCOR registry, </text>
<text top="436" left="662" width="239" height="20" font="4">77% had a CV origin; nearly 50% were due </text>
<text top="454" left="662" width="220" height="20" font="4">to progressive HF and arrhythmias. The </text>
<text top="471" left="662" width="226" height="20" font="4">national mortality registry recorded death </text>
<text top="488" left="662" width="229" height="20" font="4">due to progressive HF and arrhythmias in </text>
<text top="505" left="662" width="238" height="20" font="4">only 8.5%. Registry recorded death with an </text>
<text top="522" left="662" width="208" height="20" font="4">'unspecified' cause in ~30%, primarily </text>
<text top="540" left="662" width="237" height="20" font="4">containing pts who died due to progressive </text>
<text top="557" left="662" width="209" height="20" font="4">HF and arrhythmias according to their </text>
<text top="574" left="662" width="94" height="20" font="4">medical records. </text>
<text top="402" left="914" width="164" height="20" font="4">● National mortality registries </text>
<text top="419" left="914" width="126" height="20" font="4">lack the specificity and </text>
<text top="436" left="914" width="141" height="20" font="4">completeness needed for </text>
<text top="454" left="914" width="175" height="20" font="4">accurate research on causes of </text>
<text top="471" left="914" width="112" height="20" font="4">death in ACHD pts.  </text>
<text top="592" left="64" width="89" height="20" font="4">Verheugt CL, et </text>
<text top="609" left="64" width="16" height="20" font="4">al. </text>
<text top="626" left="64" width="60" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(28)</a>  </text>
<text top="644" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20207625%5Buid%5D">20207625</a></text>
<text top="644" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20207625%5Buid%5D"> </a></text>
<text top="592" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="609" left="170" width="97" height="20" font="4">Analysis of death </text>
<text top="626" left="170" width="85" height="20" font="4">cause in Dutch </text>
<text top="644" left="170" width="58" height="20" font="4">CONCOR </text>
<text top="661" left="170" width="90" height="20" font="4">national registry </text>
<text top="678" left="170" width="96" height="20" font="4">linked to national </text>
<text top="695" left="170" width="94" height="20" font="4">mortality registry </text>
<text top="592" left="283" width="68" height="20" font="4">n=6,933 pts </text>
<text top="592" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="609" left="389" width="92" height="20" font="4">Pts in CONCOR </text>
<text top="626" left="389" width="119" height="20" font="4">registry of ACHD and </text>
<text top="644" left="389" width="85" height="20" font="4">also with death </text>
<text top="661" left="389" width="73" height="20" font="4">records from </text>
<text top="678" left="389" width="94" height="20" font="4">mortality registry </text>
<text top="592" left="522" width="124" height="20" font="4">Mortality and cause of </text>
<text top="609" left="522" width="34" height="20" font="4">death </text>
<text top="592" left="662" width="234" height="20" font="4">● 197 (2.8%) died during a follow-up of 24 </text>
<text top="609" left="662" width="236" height="20" font="4">865 pt-y. Median age at death was 48.8 y.  </text>
<text top="626" left="662" width="236" height="20" font="4">● Of all deaths, 77% had a CV origin; 45% </text>
<text top="644" left="662" width="179" height="20" font="4">were due to chronic HF. Several </text>
<text top="661" left="662" width="235" height="20" font="4">complications predicted all-cause mortality </text>
<text top="678" left="662" width="225" height="20" font="4">beyond the effects of age, sex, and CHD </text>
<text top="695" left="662" width="208" height="20" font="4">severity, i.e., IE, SVA, VA, conduction </text>
<text top="712" left="662" width="239" height="20" font="4">disturbances, MI, and pulmonary HTN (HR: </text>
<text top="730" left="662" width="232" height="20" font="4">1.4–3.1; p&lt;0.05). These risks were similar </text>
<text top="747" left="662" width="108" height="20" font="4">in pts &gt; and &lt;40 y.  </text>
<text top="764" left="662" width="235" height="20" font="4">● Almost all complications predicted death </text>
<text top="781" left="662" width="183" height="20" font="4">due to HF (HR: 2.0–5.1; p&lt;0.05); </text>
<text top="592" left="914" width="163" height="20" font="4">● Compared with the general </text>
<text top="609" left="914" width="167" height="20" font="4">national population, there was </text>
<text top="626" left="914" width="171" height="20" font="4">excess mortality, particularly in </text>
<text top="644" left="914" width="64" height="20" font="4">the young.  </text>
<text top="661" left="914" width="161" height="20" font="4">● Age predicted mortality, as </text>
<text top="678" left="914" width="145" height="20" font="4">did sex, severity of defect, </text>
<text top="695" left="914" width="159" height="20" font="4">number of interventions, and </text>
<text top="712" left="914" width="165" height="20" font="4">number of complications (HR: </text>
<text top="730" left="914" width="97" height="20" font="4">1.1–5.9; p&lt;0.05). </text>
</page>
<page number="47" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 47 </text>
<text top="107" left="662" width="221" height="20" font="4">conduction disturbances and pulmonary </text>
<text top="124" left="662" width="238" height="20" font="4">HTN predicted SCD (HR: 2.0–4.7; p&lt;0.05). </text>
<text top="142" left="64" width="88" height="20" font="4">Tutarel O, et al. </text>
<text top="159" left="64" width="53" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(2)</a>  </text>
<text top="177" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23882067?dopt=Citation">23882067</a></text>
<text top="177" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23882067?dopt=Citation"> </a></text>
<text top="142" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="159" left="170" width="74" height="20" font="4">cohort study  </text>
<text top="142" left="283" width="85" height="20" font="4">n=375 pts 64.8 </text>
<text top="159" left="283" width="45" height="20" font="4">± 5.9 y  </text>
<text top="142" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="159" left="389" width="110" height="20" font="4">All ACHD pts ≥60 y </text>
<text top="177" left="389" width="106" height="20" font="4">under active follow-</text>
<text top="194" left="389" width="17" height="20" font="4">up </text>
<text top="142" left="522" width="104" height="20" font="4">All-cause mortality </text>
<text top="159" left="522" width="92" height="20" font="4">during a median </text>
<text top="177" left="522" width="96" height="20" font="4">follow-up of 5.5 y </text>
<text top="142" left="662" width="226" height="20" font="4">● 55 of the 375 pts died. CAD (HR: 5.04; </text>
<text top="159" left="662" width="238" height="20" font="4">95% CI: 1.88–13.51; p=0.0014), symptoms </text>
<text top="177" left="662" width="202" height="20" font="4">of HF (HR: 2.36; 95% CI: 1.05–5.29; </text>
<text top="194" left="662" width="224" height="20" font="4">p&lt;0.05), NYHA class (HR: 1.96; 95% CI: </text>
<text top="211" left="662" width="202" height="20" font="4">1.18-3.26; p&lt;0.01), and moderate-to-</text>
<text top="228" left="662" width="219" height="20" font="4">severe reduction in systemic ventricular </text>
<text top="246" left="662" width="228" height="20" font="4">systolic function (HR: 1.90; 95% CI: 1.20–</text>
<text top="263" left="662" width="188" height="20" font="4">2.99; p&lt;0.001) were the strongest </text>
<text top="280" left="662" width="104" height="20" font="4">prognostic factors. </text>
<text top="142" left="914" width="176" height="20" font="4">● Acquired morbidities, such as </text>
<text top="159" left="914" width="165" height="20" font="4">CAD are reasons for mortality </text>
<text top="177" left="914" width="152" height="20" font="4">in aging ACHD population.  </text>
<text top="298" left="64" width="80" height="20" font="4">Afilalo J, et al. </text>
<text top="315" left="64" width="49" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(1)</a> </text>
<text top="332" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21939837?dopt=Citation">21939837</a></text>
<text top="332" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21939837?dopt=Citation"> </a></text>
<text top="298" left="170" width="99" height="20" font="4">Population-based </text>
<text top="315" left="170" width="70" height="20" font="4">cohort study </text>
<text top="332" left="170" width="100" height="20" font="4">using the Quebec </text>
<text top="350" left="170" width="86" height="20" font="4">CHD Database </text>
<text top="298" left="283" width="68" height="20" font="4">n=3,239 pts </text>
<text top="298" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="315" left="389" width="92" height="20" font="4">All pts with CHD </text>
<text top="332" left="389" width="109" height="20" font="4">coming into contact </text>
<text top="350" left="389" width="92" height="20" font="4">with the Quebec </text>
<text top="367" left="389" width="103" height="20" font="4">healthcare system </text>
<text top="384" left="389" width="115" height="20" font="4">between 1983–2005 </text>
<text top="298" left="522" width="89" height="20" font="4">Types of ACHD </text>
<text top="315" left="522" width="122" height="20" font="4">lesions in older adults </text>
<text top="332" left="522" width="105" height="20" font="4">were shunt lesions </text>
<text top="350" left="522" width="127" height="20" font="4">(60%), valvular lesions </text>
<text top="367" left="522" width="104" height="20" font="4">(37%), and severe </text>
<text top="384" left="522" width="91" height="20" font="4">congenital heart </text>
<text top="401" left="522" width="71" height="20" font="4">lesions (3%) </text>
<text top="298" left="662" width="238" height="20" font="4">● The most powerful predictors of mortality </text>
<text top="315" left="662" width="211" height="20" font="4">in the Cox proportional hazards model </text>
<text top="332" left="662" width="225" height="20" font="4">were: dementia (HR: 3.24; 95% CI: 1.53–</text>
<text top="350" left="662" width="222" height="20" font="4">6.85), GI bleed (HR: 2.79; 95% CI: 1.66–</text>
<text top="367" left="662" width="226" height="20" font="4">4.69), and CKD (HR: 2.50; 95% CI: 1.72–</text>
<text top="384" left="662" width="38" height="20" font="4">3.65).  </text>
<text top="401" left="662" width="199" height="20" font="4">● Type of ACHD and ACHD-related </text>
<text top="418" left="662" width="203" height="20" font="4">complications had a minor impact on </text>
<text top="436" left="662" width="53" height="20" font="4">mortality. </text>
<text top="298" left="914" width="161" height="20" font="4">● The prevalence of geriatric </text>
<text top="315" left="914" width="167" height="20" font="4">ACHD is substantial, although </text>
<text top="332" left="914" width="123" height="20" font="4">severe lesions remain </text>
<text top="350" left="914" width="71" height="20" font="4">uncommon.  </text>
<text top="367" left="914" width="143" height="20" font="4">● ACHD pts that live long </text>
<text top="384" left="914" width="133" height="20" font="4">enough acquire general </text>
<text top="401" left="914" width="160" height="20" font="4">medical comorbidities, which </text>
<text top="418" left="914" width="111" height="20" font="4">are the pre-eminent </text>
<text top="436" left="914" width="169" height="20" font="4">determinants of their mortality. </text>
<text top="454" left="64" width="93" height="20" font="4">Nieminen HP, et </text>
<text top="471" left="64" width="16" height="20" font="4">al. </text>
<text top="488" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(166)</a> </text>
<text top="505" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17888844?dopt=Citation">17888844</a></text>
<text top="505" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17888844?dopt=Citation"> </a></text>
<text top="454" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="471" left="170" width="84" height="20" font="4">cohort study of </text>
<text top="488" left="170" width="98" height="20" font="4">ACHD in Finland  </text>
<text top="454" left="283" width="68" height="20" font="4">n=6,024 pts </text>
<text top="471" left="283" width="75" height="20" font="4">who survived </text>
<text top="488" left="283" width="51" height="20" font="4">their first </text>
<text top="505" left="283" width="55" height="20" font="4">operation </text>
<text top="454" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="471" left="389" width="76" height="20" font="4">Deaths of pts </text>
<text top="488" left="389" width="117" height="20" font="4">operated on for CHD </text>
<text top="505" left="389" width="94" height="20" font="4">in Finland during </text>
<text top="522" left="389" width="65" height="20" font="4">1953–1989 </text>
<text top="540" left="389" width="96" height="20" font="4">compared to non-</text>
<text top="557" left="389" width="112" height="20" font="4">CHD-related deaths </text>
<text top="574" left="389" width="81" height="20" font="4">to those of the </text>
<text top="591" left="389" width="105" height="20" font="4">general population </text>
<text top="454" left="522" width="50" height="20" font="4">Mortality </text>
<text top="454" left="662" width="231" height="20" font="4">● 592 (9%) died during the 45-y follow-up </text>
<text top="471" left="662" width="211" height="20" font="4">period. Majority of pts (397, 67%) died </text>
<text top="488" left="662" width="233" height="20" font="4">owing to the CHD. Furthermore, non-CHD-</text>
<text top="505" left="662" width="219" height="20" font="4">related mortality was twice as high (RR: </text>
<text top="522" left="662" width="218" height="20" font="4">1.9; 95% CI: 1.5–2.4) as expected. The </text>
<text top="540" left="662" width="233" height="20" font="4">main mode for CHD-related death was HF </text>
<text top="557" left="662" width="238" height="20" font="4">(40%). Other modes included perioperative </text>
<text top="574" left="662" width="204" height="20" font="4">(26%), sudden (22%), and CV (12%) </text>
<text top="591" left="662" width="44" height="20" font="4">deaths. </text>
<text top="454" left="914" width="138" height="20" font="4">● Most pts died owing to </text>
<text top="471" left="914" width="156" height="20" font="4">CHDs, but non-CHD-related </text>
<text top="488" left="914" width="131" height="20" font="4">mortality was also high. </text>
<text top="609" left="64" width="90" height="20" font="4">Bradley E, et al. </text>
<text top="626" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(167)</a> </text>
<text top="644" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24082371?dopt=Citation">24082371</a></text>
<text top="644" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24082371?dopt=Citation"> </a></text>
<text top="609" left="170" width="76" height="20" font="4">Single-center </text>
<text top="626" left="170" width="74" height="20" font="4">retrospective </text>
<text top="644" left="170" width="48" height="20" font="4">analysis </text>
<text top="609" left="283" width="58" height="20" font="4">n=208 pts </text>
<text top="609" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="626" left="389" width="113" height="20" font="4">Pts with TOF. Rates </text>
<text top="644" left="389" width="97" height="20" font="4">and mean values </text>
<text top="661" left="389" width="108" height="20" font="4">from the AHA 2011 </text>
<text top="678" left="389" width="84" height="20" font="4">HD and Stroke </text>
<text top="695" left="389" width="96" height="20" font="4">Statistics Update </text>
<text top="712" left="389" width="76" height="20" font="4">were used as </text>
<text top="730" left="389" width="116" height="20" font="4">population estimates </text>
<text top="747" left="389" width="85" height="20" font="4">for comparison </text>
<text top="609" left="522" width="77" height="20" font="4">CV outcomes </text>
<text top="609" left="662" width="236" height="20" font="4">● CV disease prevalence was not different </text>
<text top="626" left="662" width="226" height="20" font="4">in TOF pts from general population (40% </text>
<text top="644" left="662" width="220" height="20" font="4">vs. 36%; p=0.3). There was significantly </text>
<text top="661" left="662" width="237" height="20" font="4">more CV disease due to higher prevalence </text>
<text top="678" left="662" width="232" height="20" font="4">of coronary disease (12% vs. 7%; p&lt;0.05) </text>
<text top="695" left="662" width="182" height="20" font="4">and HF (16% vs. 2%; p&lt;0.0001). </text>
<text top="609" left="914" width="167" height="20" font="4">● Increased prevalence of HF </text>
<text top="626" left="914" width="148" height="20" font="4">(regardless of PV disease) </text>
<text top="644" left="914" width="162" height="20" font="4">accounts for the frequency of </text>
<text top="661" left="914" width="172" height="20" font="4">CV disease in TOF mean aged </text>
<text top="678" left="914" width="51" height="20" font="4">20–59 y. </text>
</page>
<page number="48" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 48 </text>
<text top="107" left="64" width="91" height="20" font="4">Stuart AG, et al. </text>
<text top="124" left="64" width="66" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(168)</a>  </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22413988?dopt=Citation">22413988</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22413988?dopt=Citation"> </a></text>
<text top="107" left="170" width="44" height="20" font="4">Review </text>
<text top="107" left="283" width="24" height="20" font="4">N/A </text>
<text top="107" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="389" width="24" height="20" font="4">N/A </text>
<text top="107" left="522" width="91" height="20" font="4">Changing lesion </text>
<text top="124" left="522" width="115" height="20" font="4">demographics of the </text>
<text top="141" left="522" width="92" height="20" font="4">adults with CHD </text>
<text top="107" left="662" width="183" height="20" font="4">● The ACHD population are now </text>
<text top="124" left="662" width="238" height="20" font="4">developing problems associated with aging </text>
<text top="141" left="662" width="231" height="20" font="4">and there is a new population of geriatrics </text>
<text top="159" left="662" width="59" height="20" font="4">with CHD. </text>
<text top="107" left="914" width="171" height="20" font="4">● ACHD pts develop problems </text>
<text top="124" left="914" width="134" height="20" font="4">related to aging such as </text>
<text top="141" left="914" width="83" height="20" font="4">acquired CVD. </text>
<text top="177" left="64" width="622" height="20" font="3"><b>Risk Factor Modification Assessment and Management (Hyperlipidemia, Obesity, Hypertension, Smoking) </b></text>
<text top="195" left="64" width="85" height="20" font="4">Pemberton VL, </text>
<text top="212" left="64" width="30" height="20" font="4">et al. </text>
<text top="229" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(114)</a> </text>
<text top="246" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20212294?dopt=Citation">20212294</a></text>
<text top="246" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20212294?dopt=Citation"> </a></text>
<text top="195" left="170" width="92" height="20" font="4">NHLBI Scientific </text>
<text top="212" left="170" width="60" height="20" font="4">Statement </text>
<text top="195" left="283" width="24" height="20" font="4">N/A </text>
<text top="195" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="212" left="389" width="108" height="20" font="4">Research indicates </text>
<text top="229" left="389" width="92" height="20" font="4">that a significant </text>
<text top="246" left="389" width="101" height="20" font="4">portion of children </text>
<text top="264" left="389" width="102" height="20" font="4">with CHD are also </text>
<text top="281" left="389" width="114" height="20" font="4">obese or overweight </text>
<text top="195" left="522" width="118" height="20" font="4">Prevention of obesity </text>
<text top="195" left="662" width="200" height="20" font="4">● Authors discuss the prevalence of </text>
<text top="212" left="662" width="198" height="20" font="4">obesity, potential etiological factors, </text>
<text top="229" left="662" width="239" height="20" font="4">possible sequelae, and obesity and CV risk </text>
<text top="246" left="662" width="213" height="20" font="4">management and treatment in pts with </text>
<text top="264" left="662" width="33" height="20" font="4">CHD. </text>
<text top="195" left="914" width="136" height="20" font="4">● Recommendations for </text>
<text top="212" left="914" width="163" height="20" font="4">prevention of obesity in CHD. </text>
<text top="299" left="64" width="92" height="20" font="4">Kavey RE, et al. </text>
<text top="316" left="64" width="66" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(169)</a>  </text>
<text top="333" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22413988?dopt=Citation">17130340</a></text>
<text top="333" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22413988?dopt=Citation"> </a></text>
<text top="299" left="170" width="81" height="20" font="4">AHA Scientific </text>
<text top="316" left="170" width="60" height="20" font="4">Statement </text>
<text top="299" left="283" width="24" height="20" font="4">N/A </text>
<text top="299" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="316" left="389" width="110" height="20" font="4">CV risk reduction in </text>
<text top="333" left="389" width="120" height="20" font="4">high-risk pediatric pts </text>
<text top="299" left="522" width="102" height="20" font="4">Reduction of CVD </text>
<text top="316" left="522" width="119" height="20" font="4">incidence and events </text>
<text top="299" left="662" width="223" height="20" font="4">● Identifies the importance of premature </text>
<text top="316" left="662" width="207" height="20" font="4">CVD in the course of certain pediatric </text>
<text top="333" left="662" width="232" height="20" font="4">diagnoses and addresses the response to </text>
<text top="350" left="662" width="114" height="20" font="4">risk factor reduction. </text>
<text top="299" left="914" width="154" height="20" font="4">● There are no randomized </text>
<text top="316" left="914" width="163" height="20" font="4">trials documenting the effects </text>
<text top="333" left="914" width="176" height="20" font="4">of risk reduction on hard clinical </text>
<text top="350" left="914" width="60" height="20" font="4">outcomes. </text>
<text top="368" left="64" width="93" height="20" font="4">James PA, et al. </text>
<text top="385" left="64" width="66" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(170)</a>  </text>
<text top="403" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24352797?dopt=Citation">24352797</a></text>
<text top="403" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24352797?dopt=Citation"> </a></text>
<text top="368" left="170" width="53" height="20" font="4">Scientific </text>
<text top="385" left="170" width="95" height="20" font="4">Statement report </text>
<text top="403" left="170" width="82" height="20" font="4">from the panel </text>
<text top="420" left="170" width="55" height="20" font="4">members </text>
<text top="437" left="170" width="92" height="20" font="4">appointed to the </text>
<text top="454" left="170" width="67" height="20" font="4">Eighth Joint </text>
<text top="472" left="170" width="48" height="20" font="4">National </text>
<text top="489" left="170" width="94" height="20" font="4">Committee (JNC </text>
<text top="506" left="170" width="18" height="20" font="4">8)  </text>
<text top="368" left="283" width="24" height="20" font="4">N/A </text>
<text top="368" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="385" left="389" width="24" height="20" font="4">N/A </text>
<text top="368" left="522" width="107" height="20" font="4">HTN Definition and </text>
<text top="385" left="522" width="105" height="20" font="4">Treatment Targets </text>
<text top="368" left="662" width="220" height="20" font="4">● Writing group discusses the definition </text>
<text top="385" left="662" width="184" height="20" font="4">and targets for treatment of HTN. </text>
<text top="368" left="914" width="136" height="20" font="4">● Recommendations for </text>
<text top="385" left="914" width="163" height="20" font="4">treatment of HTN for different </text>
<text top="403" left="914" width="168" height="20" font="4">age and risk groups reviewed. </text>
<text top="524" left="64" width="78" height="20" font="4">Rabus MB, et </text>
<text top="541" left="64" width="16" height="20" font="4">al. </text>
<text top="558" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(171)</a> </text>
<text top="575" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19267822?dopt=Citation">19267822</a></text>
<text top="575" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19267822?dopt=Citation"> </a></text>
<text top="524" left="170" width="76" height="20" font="4">Single-center </text>
<text top="541" left="170" width="66" height="20" font="4">case series </text>
<text top="524" left="283" width="58" height="20" font="4">n=988 pts </text>
<text top="524" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="541" left="389" width="107" height="20" font="4">Pts with rheumatic, </text>
<text top="558" left="389" width="77" height="20" font="4">congenital, or </text>
<text top="575" left="389" width="98" height="20" font="4">degenerative AS, </text>
<text top="593" left="389" width="120" height="20" font="4">who underwent aortic </text>
<text top="610" left="389" width="117" height="20" font="4">valve replacement at </text>
<text top="627" left="389" width="111" height="20" font="4">Koşuyolu Heart and </text>
<text top="644" left="389" width="104" height="20" font="4">Research Hospital </text>
<text top="662" left="389" width="115" height="20" font="4">between 1985–2005 </text>
<text top="524" left="522" width="55" height="20" font="4">Effects of </text>
<text top="541" left="522" width="120" height="20" font="4">hypercholesterolemia </text>
<text top="558" left="522" width="122" height="20" font="4">and high LDL level on </text>
<text top="575" left="522" width="123" height="20" font="4">calcific AS or massive </text>
<text top="593" left="522" width="66" height="20" font="4">aortic valve </text>
<text top="610" left="522" width="67" height="20" font="4">calcification </text>
<text top="524" left="662" width="206" height="20" font="4">● High serum cholesterol level (&gt;200 </text>
<text top="541" left="662" width="236" height="20" font="4">mg/dL) was related to massive aortic valve </text>
<text top="558" left="662" width="175" height="20" font="4">calcification in all pts (p=0.003). </text>
<text top="575" left="662" width="224" height="20" font="4">● Hypercholesterolemia linked to calcific </text>
<text top="593" left="662" width="217" height="20" font="4">AS and massive calcification in pts with </text>
<text top="610" left="662" width="235" height="20" font="4">degenerative etiology (p=0.02 and p=0.01, </text>
<text top="627" left="662" width="225" height="20" font="4">respectively) and massive calcification in </text>
<text top="644" left="662" width="241" height="20" font="4">pts with congenital bicuspid aorta (p=0.02).  </text>
<text top="662" left="662" width="237" height="20" font="4">● Other independent risk factors were high </text>
<text top="679" left="662" width="196" height="20" font="4">LDL level (&gt;130 mg/dL; p=0.03 and </text>
<text top="696" left="662" width="234" height="20" font="4">p=0.05) and high serum C-reactive protein </text>
<text top="713" left="662" width="147" height="20" font="4">level (p=0.04 and p=0.05). </text>
<text top="524" left="914" width="147" height="20" font="4">● Hypercholesterolemia is </text>
<text top="541" left="914" width="148" height="20" font="4">related to increased risk of </text>
<text top="558" left="914" width="165" height="20" font="4">aortic valve calcification in pts </text>
<text top="575" left="914" width="172" height="20" font="4">with congenital etiology as well </text>
<text top="593" left="914" width="144" height="20" font="4">as degenerative etiology.  </text>
<text top="610" left="914" width="143" height="20" font="4">● Preventive treatment of </text>
<text top="627" left="914" width="153" height="20" font="4">hypercholesterolemia could </text>
<text top="644" left="914" width="135" height="20" font="4">play an important role to </text>
<text top="662" left="914" width="104" height="20" font="4">decrease or inhibit </text>
<text top="679" left="914" width="153" height="20" font="4">development of aortic valve </text>
<text top="696" left="914" width="70" height="20" font="4">calcification. </text>
</page>
<page number="49" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 49 </text>
<text top="107" left="64" width="78" height="20" font="4">Smith-Parrish </text>
<text top="124" left="64" width="47" height="20" font="4">M, et al. </text>
<text top="141" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(172)</a> </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24607241?dopt=Citation">24607241</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24607241?dopt=Citation"> </a></text>
<text top="107" left="170" width="76" height="20" font="4">Single-center </text>
<text top="124" left="170" width="85" height="20" font="4">cross-sectional </text>
<text top="141" left="170" width="33" height="20" font="4">study </text>
<text top="107" left="283" width="78" height="20" font="4">n=160 pts s/p </text>
<text top="124" left="283" width="62" height="20" font="4">CoA repair </text>
<text top="141" left="283" width="89" height="20" font="4">compared to 96 </text>
<text top="159" left="283" width="93" height="20" font="4">adults with other </text>
<text top="176" left="283" width="80" height="20" font="4">isolated forms </text>
<text top="193" left="283" width="47" height="20" font="4">of CHD, </text>
<text top="210" left="283" width="83" height="20" font="4">including AVS, </text>
<text top="228" left="283" width="86" height="20" font="4">PV stenosis, or </text>
<text top="245" left="283" width="29" height="20" font="4">ASD </text>
<text top="107" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="389" width="108" height="20" font="4">Pts who underwent </text>
<text top="141" left="389" width="112" height="20" font="4">CoA repair between </text>
<text top="159" left="389" width="68" height="20" font="4">1974–2009. </text>
<text top="107" left="522" width="123" height="20" font="4">To determine whether </text>
<text top="124" left="522" width="102" height="20" font="4">pts with CoA were </text>
<text top="141" left="522" width="122" height="20" font="4">more likely to develop </text>
<text top="159" left="522" width="126" height="20" font="4">obesity compared with </text>
<text top="176" left="522" width="125" height="20" font="4">the general population </text>
<text top="193" left="522" width="123" height="20" font="4">or others with isolated </text>
<text top="210" left="522" width="78" height="20" font="4">forms of CHD </text>
<text top="107" left="662" width="186" height="20" font="4">● After age 5 y, pts with CoA had </text>
<text top="124" left="662" width="218" height="20" font="4">significantly greater BMI compared with </text>
<text top="141" left="662" width="226" height="20" font="4">age-sex matched normal data (p&lt;0.001). </text>
<text top="159" left="662" width="225" height="20" font="4">The proportion of obesity in pts with CoA </text>
<text top="176" left="662" width="241" height="20" font="4">significantly increased over time (p&lt;0.001).  </text>
<text top="193" left="662" width="212" height="20" font="4">● Adults with repaired CoA developed </text>
<text top="210" left="662" width="219" height="20" font="4">obesity at a greater rate than those with </text>
<text top="228" left="662" width="227" height="20" font="4">either AVS (p=0.004) or with PV stenosis </text>
<text top="245" left="662" width="103" height="20" font="4">or ASD (p&lt;0.001). </text>
<text top="107" left="914" width="168" height="20" font="4">● There is a greater incidence </text>
<text top="124" left="914" width="156" height="20" font="4">of obesity that progressively </text>
<text top="141" left="914" width="163" height="20" font="4">increases with age in pts with </text>
<text top="159" left="914" width="170" height="20" font="4">repaired CoA, at a greater rate </text>
<text top="176" left="914" width="163" height="20" font="4">than those with other isolated </text>
<text top="193" left="914" width="85" height="20" font="4">forms of CHD.  </text>
<text top="263" left="64" width="83" height="20" font="4">Shustak RJ, et </text>
<text top="280" left="64" width="16" height="20" font="4">al. </text>
<text top="297" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(173)</a> </text>
<text top="314" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21892630?dopt=Citation">21892630</a></text>
<text top="314" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21892630?dopt=Citation"> </a></text>
<text top="263" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="280" left="170" width="85" height="20" font="4">cross-sectional </text>
<text top="297" left="170" width="36" height="20" font="4">study  </text>
<text top="263" left="283" width="58" height="20" font="4">n=795 pts </text>
<text top="263" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="280" left="389" width="113" height="20" font="4">Pts presenting to an </text>
<text top="297" left="389" width="81" height="20" font="4">urban center's </text>
<text top="314" left="389" width="113" height="20" font="4">Pediatric Cardiology </text>
<text top="332" left="389" width="100" height="20" font="4">Program between </text>
<text top="349" left="389" width="117" height="20" font="4">Jan 1–Dec 31, 2006. </text>
<text top="263" left="522" width="78" height="20" font="4">Prevalence of </text>
<text top="280" left="522" width="87" height="20" font="4">overweight and </text>
<text top="297" left="522" width="102" height="20" font="4">obesity in children </text>
<text top="314" left="522" width="104" height="20" font="4">with HD compared </text>
<text top="332" left="522" width="117" height="20" font="4">against national data </text>
<text top="349" left="522" width="124" height="20" font="4">of children without HD </text>
<text top="263" left="662" width="229" height="20" font="4">● No significant differences in overweight </text>
<text top="280" left="662" width="218" height="20" font="4">or obesity rates were detected between </text>
<text top="297" left="662" width="139" height="20" font="4">HD and non-HD groups.  </text>
<text top="314" left="662" width="239" height="20" font="4">● Hispanic ethnicity and male sex were the </text>
<text top="332" left="662" width="146" height="20" font="4">only predictors of obesity.  </text>
<text top="263" left="914" width="146" height="20" font="4">● Children with HD are as </text>
<text top="280" left="914" width="171" height="20" font="4">prone to obesity as noncardiac </text>
<text top="297" left="914" width="23" height="20" font="4">pts. </text>
<text top="367" left="64" width="92" height="20" font="4">Pederson TA, et </text>
<text top="384" left="64" width="16" height="20" font="4">al. </text>
<text top="401" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(174)</a> </text>
<text top="418" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22459728?dopt=Citation">22459728</a></text>
<text top="418" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22459728?dopt=Citation"> </a></text>
<text top="367" left="170" width="79" height="20" font="4">Observational </text>
<text top="384" left="170" width="70" height="20" font="4">cohort study </text>
<text top="367" left="283" width="78" height="20" font="4">n=133 adults; </text>
<text top="384" left="283" width="68" height="20" font="4">s/p repair of </text>
<text top="401" left="283" width="43" height="20" font="4">COA in </text>
<text top="418" left="283" width="93" height="20" font="4">childhood/youth. </text>
<text top="436" left="283" width="69" height="20" font="4">36 age- and </text>
<text top="453" left="283" width="74" height="20" font="4">sex-matched </text>
<text top="470" left="283" width="79" height="20" font="4">healthy pts as </text>
<text top="487" left="283" width="46" height="20" font="4">controls </text>
<text top="367" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="384" left="389" width="111" height="20" font="4">s/p repair of COA in </text>
<text top="401" left="389" width="90" height="20" font="4">childhood/youth </text>
<text top="367" left="522" width="107" height="20" font="4">Prevalence of HTN </text>
<text top="384" left="522" width="44" height="20" font="4">and CV </text>
<text top="401" left="522" width="84" height="20" font="4">reinterventions </text>
<text top="367" left="662" width="227" height="20" font="4">● The prevalence of HTN was high (44% </text>
<text top="384" left="662" width="209" height="20" font="4">of the cohort, 1/2 despite medication). </text>
<text top="401" left="662" width="213" height="20" font="4">Reinterventions common (26%) due to </text>
<text top="418" left="662" width="238" height="20" font="4">aortic valve dysfunction and re-CoA. half of </text>
<text top="436" left="662" width="127" height="20" font="4">the cohort had a BAV.  </text>
<text top="453" left="662" width="193" height="20" font="4">● Increased LV mass, systolic and </text>
<text top="470" left="662" width="182" height="20" font="4">diastolic dysfunction, aortic valve </text>
<text top="487" left="662" width="217" height="20" font="4">dysfunction, aortopathy, and HTN were </text>
<text top="504" left="662" width="54" height="20" font="4">common. </text>
<text top="367" left="914" width="159" height="20" font="4">● Surgical correction of CoA </text>
<text top="384" left="914" width="150" height="20" font="4">only repairs the anatomical </text>
<text top="401" left="914" width="122" height="20" font="4">narrowing, but not the </text>
<text top="418" left="914" width="135" height="20" font="4">associated vasculo- and </text>
<text top="436" left="914" width="79" height="20" font="4">valvulopathy.  </text>
<text top="522" left="64" width="93" height="20" font="4">Zomer AC, et al. </text>
<text top="540" left="64" width="66" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(175)</a>  </text>
<text top="557" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22444325?dopt=Citation">22444325</a></text>
<text top="557" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22444325?dopt=Citation"> </a></text>
<text top="522" left="170" width="88" height="20" font="4">Cross-sectional </text>
<text top="540" left="170" width="33" height="20" font="4">study </text>
<text top="522" left="283" width="68" height="20" font="4">n=1,496 pts </text>
<text top="540" left="283" width="58" height="20" font="4">compared </text>
<text top="557" left="283" width="77" height="20" font="4">against 6,810 </text>
<text top="574" left="283" width="81" height="20" font="4">unaffected pts </text>
<text top="522" left="389" width="117" height="20" font="3"><b>Inclusion criteria</b>: A </text>
<text top="540" left="389" width="116" height="20" font="4">random sample from </text>
<text top="557" left="389" width="78" height="20" font="4">the CONCOR </text>
<text top="574" left="389" width="87" height="20" font="4">(n=11,047), the </text>
<text top="591" left="389" width="82" height="20" font="4">Dutch national </text>
<text top="608" left="389" width="107" height="20" font="4">registry of adult pts </text>
<text top="626" left="389" width="55" height="20" font="4">with CHD </text>
<text top="522" left="522" width="100" height="20" font="4">Smoking, obesity, </text>
<text top="540" left="522" width="104" height="20" font="4">sport participation, </text>
<text top="557" left="522" width="107" height="20" font="4">social support, and </text>
<text top="574" left="522" width="101" height="20" font="4">access to medical </text>
<text top="591" left="522" width="27" height="20" font="4">care </text>
<text top="522" left="662" width="215" height="20" font="4">● Overall, the CHD population smoked </text>
<text top="540" left="662" width="233" height="20" font="4">less (adjusted OR: 0.5; p&lt;0.05), had more </text>
<text top="557" left="662" width="220" height="20" font="4">sports participation (adjusted OR: 1.2; p </text>
<text top="574" left="662" width="237" height="20" font="4">&lt;0.05), and had less obesity (adjusted OR: </text>
<text top="591" left="662" width="211" height="20" font="4">0.7; p&lt;0.05) than the reference group. </text>
<text top="522" left="914" width="146" height="20" font="4">● There was a substantial </text>
<text top="540" left="914" width="174" height="20" font="4">social disadvantage in adult pts </text>
<text top="557" left="914" width="159" height="20" font="4">with CHD. In contrast, adults </text>
<text top="574" left="914" width="130" height="20" font="4">with CHD had healthier </text>
<text top="591" left="914" width="143" height="20" font="4">lifestyles compared to the </text>
<text top="608" left="914" width="94" height="20" font="4">reference group. </text>
<text top="644" left="64" width="511" height="20" font="3"><b>Risk Factor Modification Assessment and Management: Promotion of Physical Activity </b></text>
<text top="662" left="64" width="91" height="20" font="4">Longmuir PE, et </text>
<text top="679" left="64" width="16" height="20" font="4">al. </text>
<text top="696" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(176)</a> </text>
<text top="713" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23630128?dopt=Citation">23630128</a></text>
<text top="713" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23630128?dopt=Citation"> </a></text>
<text top="662" left="170" width="81" height="20" font="4">AHA Scientific </text>
<text top="679" left="170" width="60" height="20" font="4">Statement </text>
<text top="662" left="283" width="24" height="20" font="4">N/A </text>
<text top="662" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="679" left="389" width="24" height="20" font="4">N/A </text>
<text top="662" left="522" width="101" height="20" font="4">Reduction in CVD </text>
<text top="679" left="522" width="119" height="20" font="4">incidence and events </text>
<text top="662" left="662" width="180" height="20" font="4">● This statement recognizes the </text>
<text top="679" left="662" width="234" height="20" font="4">importance of physically active lifestyles to </text>
<text top="696" left="662" width="224" height="20" font="4">the health and well-being of children and </text>
<text top="713" left="662" width="199" height="20" font="4">adults with congenital heart defects. </text>
<text top="662" left="914" width="175" height="20" font="4">● Counseling of pts with ACHD </text>
<text top="679" left="914" width="123" height="20" font="4">should emphasize the </text>
<text top="696" left="914" width="154" height="20" font="4">importance of daily physical </text>
<text top="713" left="914" width="128" height="20" font="4">activity and decreasing </text>
<text top="730" left="914" width="124" height="20" font="4">sedentary behavior as </text>
<text top="748" left="914" width="167" height="20" font="4">appropriate for the pt’s clinical </text>
<text top="765" left="914" width="40" height="20" font="4">status. </text>
<text top="783" left="64" width="328" height="20" font="3"><b>Management of Pts with Coronary Disease in ACHD Pts </b></text>
</page>
<page number="50" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 50 </text>
<text top="107" left="64" width="91" height="20" font="4">Stulak JM, et al. </text>
<text top="124" left="64" width="66" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(177)</a>  </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22098921?dopt=Citation">22098921</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22098921?dopt=Citation"> </a></text>
<text top="107" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="124" left="170" width="68" height="20" font="4">case review </text>
<text top="107" left="283" width="83" height="20" font="4">n=122 pts with </text>
<text top="124" left="283" width="90" height="20" font="4">CAD at the time </text>
<text top="141" left="283" width="85" height="20" font="4">of correction of </text>
<text top="159" left="283" width="30" height="20" font="4">CHD </text>
<text top="107" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="389" width="108" height="20" font="4">Pts who underwent </text>
<text top="141" left="389" width="108" height="20" font="4">concomitant CABG </text>
<text top="159" left="389" width="113" height="20" font="4">at the time of ACHD </text>
<text top="176" left="389" width="88" height="20" font="4">repair; between </text>
<text top="193" left="389" width="107" height="20" font="4">February 1972 and </text>
<text top="210" left="389" width="106" height="20" font="4">August 2009. Most </text>
<text top="228" left="389" width="106" height="20" font="4">common 1°cardiac </text>
<text top="245" left="389" width="109" height="20" font="4">diagnoses included </text>
<text top="262" left="389" width="119" height="20" font="4">secundum ASD in 73 </text>
<text top="279" left="389" width="104" height="20" font="4">pts (60%), Ebstein </text>
<text top="296" left="389" width="100" height="20" font="4">anomaly in 14 pts </text>
<text top="314" left="389" width="100" height="20" font="4">(11%), and partial </text>
<text top="331" left="389" width="64" height="20" font="4">anomalous </text>
<text top="348" left="389" width="104" height="20" font="4">pulmonary venous </text>
<text top="365" left="389" width="106" height="20" font="4">connection in 8 pts </text>
<text top="382" left="389" width="33" height="20" font="4">(7%). </text>
<text top="107" left="522" width="111" height="20" font="4">Outcomes of CABG </text>
<text top="107" left="662" width="229" height="20" font="4">● Median age was 64 y (range 40–85 y).  </text>
<text top="124" left="662" width="235" height="20" font="4">● 30 pts (25%) had preoperative angina, 7 </text>
<text top="141" left="662" width="227" height="20" font="4">pts (6%) had previous MI, and 6 pts (5%) </text>
<text top="159" left="662" width="226" height="20" font="4">had previous percutaneous intervention.  </text>
<text top="176" left="662" width="192" height="20" font="4">● During a median follow-up of 6 y </text>
<text top="193" left="662" width="201" height="20" font="4">(maximum follow-up, 32 y), actuarial </text>
<text top="210" left="662" width="231" height="20" font="4">survival was 76% at 5 y and 56% at 10 y.  </text>
<text top="228" left="662" width="237" height="20" font="4">● In pts with left anterior descending artery </text>
<text top="245" left="662" width="232" height="20" font="4">disease, survival was higher when a LIMA </text>
<text top="262" left="662" width="219" height="20" font="4">graft was used (5 y, 86% vs. 66%; 10 y, </text>
<text top="279" left="662" width="128" height="20" font="4">66% vs. 36%; p&lt;0.05). </text>
<text top="107" left="914" width="167" height="20" font="4">● Concomitant CABG may be </text>
<text top="124" left="914" width="123" height="20" font="4">required at the time of </text>
<text top="141" left="914" width="164" height="20" font="4">correction of CHD. Survival is </text>
<text top="159" left="914" width="153" height="20" font="4">higher when a LIMA graft is </text>
<text top="176" left="914" width="137" height="20" font="4">used, and late functional </text>
<text top="193" left="914" width="154" height="20" font="4">outcome is good, with a low </text>
<text top="210" left="914" width="156" height="20" font="4">incidence of late angina and </text>
<text top="228" left="914" width="130" height="20" font="4">need for reintervention. </text>
<text top="400" left="64" width="78" height="20" font="4">Giannakoulas </text>
<text top="418" left="64" width="46" height="20" font="4">G, et al. </text>
<text top="435" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(178)</a> </text>
<text top="452" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19427444?dopt=Citation">19427444</a></text>
<text top="452" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19427444?dopt=Citation"> </a></text>
<text top="400" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="418" left="170" width="83" height="20" font="4">chart review of </text>
<text top="435" left="170" width="76" height="20" font="4">ACHD cohort </text>
<text top="400" left="283" width="76" height="20" font="4">n=250 ACHD </text>
<text top="418" left="283" width="23" height="20" font="4">pts  </text>
<text top="400" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="418" left="389" width="58" height="20" font="4">ACHD pts </text>
<text top="435" left="389" width="116" height="20" font="4">undergoing selective </text>
<text top="452" left="389" width="51" height="20" font="4">coronary </text>
<text top="469" left="389" width="89" height="20" font="4">angiography for </text>
<text top="487" left="389" width="106" height="20" font="4">reasons other than </text>
<text top="504" left="389" width="92" height="20" font="4">suspected CAD; </text>
<text top="521" left="389" width="117" height="20" font="4">mean age 51 ± 15 y; </text>
<text top="538" left="389" width="59" height="20" font="4">53% men) </text>
<text top="400" left="522" width="115" height="20" font="4">Presence of CAD by </text>
<text top="418" left="522" width="122" height="20" font="4">coronary angiography </text>
<text top="400" left="662" width="220" height="20" font="4">● Significant CAD was found in 9.2% of </text>
<text top="418" left="662" width="232" height="20" font="4">adult pts with CHD. No pt with cyanosis or </text>
<text top="435" left="662" width="152" height="20" font="4">&lt;40 y had significant CAD.  </text>
<text top="452" left="662" width="181" height="20" font="4">● Systolic and diastolic systemic </text>
<text top="469" left="662" width="223" height="20" font="4">ventricular dimensions were significantly </text>
<text top="487" left="662" width="187" height="20" font="4">higher in pts with CAD, even after </text>
<text top="504" left="662" width="232" height="20" font="4">adjustment for age. Systemic arterial HTN </text>
<text top="521" left="662" width="232" height="20" font="4">and hyperlipidemia were strong predictors </text>
<text top="538" left="662" width="212" height="20" font="4">of CAD (OR: 4.54; 95% CI: 1.82–12.0; </text>
<text top="555" left="662" width="223" height="20" font="4">p=0.001; OR: 9.08; 95% CI: 3.56–24.54; </text>
<text top="573" left="662" width="205" height="20" font="4">p&lt;0.0001, respectively); whereas, no </text>
<text top="590" left="662" width="183" height="20" font="4">relation to chest pain was found.  </text>
<text top="400" left="914" width="149" height="20" font="4">● Prevalence of significant </text>
<text top="418" left="914" width="158" height="20" font="4">CAD in a hospital adult CHD </text>
<text top="435" left="914" width="173" height="20" font="4">cohort was similar to that in the </text>
<text top="452" left="914" width="161" height="20" font="4">general population. Supports </text>
<text top="469" left="914" width="174" height="20" font="4">selective coronary angiography </text>
<text top="487" left="914" width="174" height="20" font="4">in pts &gt;40 y referred for cardiac </text>
<text top="504" left="914" width="51" height="20" font="4">surgery.  </text>
<text top="521" left="914" width="174" height="20" font="4">● Traditional CV risk factors for </text>
<text top="538" left="914" width="107" height="20" font="4">CAD played a role, </text>
<text top="555" left="914" width="133" height="20" font="4">1°prevention of CAD as </text>
<text top="573" left="914" width="149" height="20" font="4">important as in the general </text>
<text top="590" left="914" width="64" height="20" font="4">population. </text>
<text top="608" left="64" width="86" height="20" font="4">Deva DV, et al. </text>
<text top="625" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(179)</a> </text>
<text top="642" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24044501?dopt=Citation">24044501</a></text>
<text top="642" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24044501?dopt=Citation"> </a></text>
<text top="608" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="625" left="170" width="87" height="20" font="4">cohort, Toronto </text>
<text top="608" left="283" width="67" height="20" font="4">n=34 stress </text>
<text top="625" left="283" width="74" height="20" font="4">perfusion CV </text>
<text top="642" left="283" width="53" height="20" font="4">magnetic </text>
<text top="659" left="283" width="61" height="20" font="4">resonance </text>
<text top="677" left="283" width="76" height="20" font="4">examinations </text>
<text top="608" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="625" left="389" width="106" height="20" font="4">Cases of perfusion </text>
<text top="642" left="389" width="74" height="20" font="4">CV magnetic </text>
<text top="659" left="389" width="94" height="20" font="4">resonance in pts </text>
<text top="677" left="389" width="95" height="20" font="4">referred from the </text>
<text top="694" left="389" width="87" height="20" font="4">ACHD service.  </text>
<text top="608" left="522" width="54" height="20" font="4">Coronary </text>
<text top="625" left="522" width="76" height="20" font="4">abnormalities </text>
<text top="608" left="662" width="154" height="20" font="4">● 11 studies were positive.  </text>
<text top="625" left="662" width="178" height="20" font="4">● Stress perfusion CV magnetic </text>
<text top="642" left="662" width="220" height="20" font="4">resonance demonstrated a sensitivity of </text>
<text top="659" left="662" width="164" height="20" font="4">82% and specificity of 100%.  </text>
<text top="677" left="662" width="239" height="20" font="4">● Coronary abnormalities were identified in </text>
<text top="694" left="662" width="216" height="20" font="4">71% of cases who had coronary MRA.  </text>
<text top="608" left="914" width="125" height="20" font="4">● Stress perfusion CV </text>
<text top="625" left="914" width="173" height="20" font="4">magnetic resonance is a useful </text>
<text top="642" left="914" width="116" height="20" font="4">and accurate tool for </text>
<text top="659" left="914" width="148" height="20" font="4">investigation of myocardial </text>
<text top="677" left="914" width="163" height="20" font="4">ischemia in ACHD population </text>
<text top="694" left="914" width="85" height="20" font="4">with suspected </text>
<text top="711" left="914" width="155" height="20" font="4">nonatherosclerotic coronary </text>
<text top="728" left="914" width="80" height="20" font="4">abnormalities. </text>
<text top="746" left="64" width="240" height="20" font="3"><b>Management of Pts with HF in ACHD Pts </b></text>
<text top="764" left="64" width="71" height="20" font="4">Niazi I, et al. </text>
<text top="781" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(180)</a> </text>
<text top="764" left="170" width="44" height="20" font="4">Review </text>
<text top="764" left="283" width="24" height="20" font="4">N/A </text>
<text top="764" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="781" left="389" width="24" height="20" font="4">N/A </text>
<text top="764" left="522" width="82" height="20" font="4">CRT insertion  </text>
<text top="764" left="662" width="212" height="20" font="4">● Approach to CRT implant in pts with </text>
<text top="781" left="662" width="33" height="20" font="4">CHD. </text>
<text top="764" left="914" width="163" height="20" font="4">● While CRT device implants </text>
<text top="781" left="914" width="152" height="20" font="4">have become routine in the </text>
</page>
<page number="51" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 51 </text>
<text top="107" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24645638?dopt=Citation">24645638</a></text>
<text top="107" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24645638?dopt=Citation"> </a></text>
<text top="107" left="914" width="167" height="20" font="4">adult ischemic or nonischemic </text>
<text top="124" left="914" width="160" height="20" font="4">cardiomyopathy populations, </text>
<text top="141" left="914" width="145" height="20" font="4">pts with CHD offer special </text>
<text top="159" left="914" width="146" height="20" font="4">challenges due to unusual </text>
<text top="176" left="914" width="113" height="20" font="4">anatomic variations. </text>
<text top="194" left="64" width="80" height="20" font="4">Stefanescu A, </text>
<text top="211" left="64" width="30" height="20" font="4">et al. </text>
<text top="228" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(181)</a> </text>
<text top="245" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24411285?dopt=Citation">24411285</a></text>
<text top="245" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24411285?dopt=Citation"> </a></text>
<text top="194" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="211" left="170" width="48" height="20" font="4">analysis </text>
<text top="194" left="283" width="61" height="20" font="4">n=153 pts  </text>
<text top="194" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="211" left="389" width="95" height="20" font="4">Adults with TGA, </text>
<text top="228" left="389" width="98" height="20" font="4">Ebstein anomaly, </text>
<text top="246" left="389" width="98" height="20" font="4">TOF, DORV, and </text>
<text top="263" left="389" width="113" height="20" font="4">single ventricle from </text>
<text top="280" left="389" width="96" height="20" font="4">2 ACHD centers. </text>
<text top="194" left="522" width="93" height="20" font="4">CV death, with a </text>
<text top="211" left="522" width="120" height="20" font="4">secondary composite </text>
<text top="228" left="522" width="102" height="20" font="4">outcome of death, </text>
<text top="246" left="522" width="113" height="20" font="4">transplant, VAD, CV </text>
<text top="263" left="522" width="86" height="20" font="4">admission, and </text>
<text top="280" left="522" width="73" height="20" font="4">treatment for </text>
<text top="297" left="522" width="92" height="20" font="4">arrhythmia. Risk </text>
<text top="314" left="522" width="95" height="20" font="4">groups based on </text>
<text top="332" left="522" width="116" height="20" font="4">Seattle Heart Failure </text>
<text top="349" left="522" width="111" height="20" font="4">Model 5-y predicted </text>
<text top="366" left="522" width="75" height="20" font="4">survival: high </text>
<text top="383" left="522" width="103" height="20" font="4">(predicted survival </text>
<text top="401" left="522" width="114" height="20" font="4">&lt;70%), intermediate </text>
<text top="418" left="522" width="117" height="20" font="4">(70%–85%), and low </text>
<text top="435" left="522" width="69" height="20" font="4">risk (&gt;85%). </text>
<text top="194" left="662" width="236" height="20" font="4">● 10 pts had the 1° outcome of death, and </text>
<text top="211" left="662" width="228" height="20" font="4">46 the combined endpoint. The hazard of </text>
<text top="228" left="662" width="221" height="20" font="4">death in the Seattle Heart Failure Model </text>
<text top="246" left="662" width="232" height="20" font="4">high- vs. intermediate-risk group was 7.09 </text>
<text top="263" left="662" width="221" height="20" font="4">(95% CI: 1.5–33.4; p=0.01; no deaths in </text>
<text top="280" left="662" width="224" height="20" font="4">the low-risk group) and the hazard of the </text>
<text top="297" left="662" width="230" height="20" font="4">composite outcome between the high- vs. </text>
<text top="314" left="662" width="232" height="20" font="4">low-risk group was 6.64 (95% CI: 2.5–7.6; </text>
<text top="332" left="662" width="66" height="20" font="4">p=0.0001).  </text>
<text top="349" left="662" width="205" height="20" font="4">● There was greater probability of all-</text>
<text top="366" left="662" width="226" height="20" font="4">cause mortality (p=0.003) in the high-risk </text>
<text top="383" left="662" width="42" height="20" font="4">group.  </text>
<text top="194" left="914" width="165" height="20" font="4">● Seattle Heart Failure Model </text>
<text top="211" left="914" width="166" height="20" font="4">can help identify subjects with </text>
<text top="228" left="914" width="139" height="20" font="4">ACHD at risk for adverse </text>
<text top="246" left="914" width="103" height="20" font="4">outcome and poor </text>
<text top="263" left="914" width="152" height="20" font="4">cardiopulmonary efficiency. </text>
<text top="453" left="64" width="89" height="20" font="4">Mylotte D, et al. </text>
<text top="470" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(182)</a> </text>
<text top="487" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24275303?dopt=Citation">24275303</a></text>
<text top="487" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24275303?dopt=Citation"> </a></text>
<text top="453" left="170" width="44" height="20" font="4">Review </text>
<text top="453" left="283" width="24" height="20" font="4">N/A </text>
<text top="453" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="470" left="389" width="120" height="20" font="4">HF in pts with ACHD. </text>
<text top="453" left="522" width="24" height="20" font="4">N/A </text>
<text top="453" left="662" width="232" height="20" font="4">● A range of transcatheter therapies have </text>
<text top="470" left="662" width="176" height="20" font="4">recently emerged to expand the </text>
<text top="487" left="662" width="237" height="20" font="4">therapeutic potential of the more traditional </text>
<text top="504" left="662" width="226" height="20" font="4">surgical and medical interventions for HF </text>
<text top="522" left="662" width="95" height="20" font="4">in pts with CHD.  </text>
<text top="453" left="914" width="138" height="20" font="4">● These complementary </text>
<text top="470" left="914" width="159" height="20" font="4">interventions aim to treat the </text>
<text top="487" left="914" width="145" height="20" font="4">growing pt population with </text>
<text top="504" left="914" width="45" height="20" font="4">ACHD.  </text>
<text top="540" left="64" width="81" height="20" font="4">Motonaga KS, </text>
<text top="557" left="64" width="30" height="20" font="4">et al. </text>
<text top="574" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(183)</a> </text>
<text top="591" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24275296?dopt=Citation">24275296</a></text>
<text top="591" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24275296?dopt=Citation"> </a></text>
<text top="540" left="170" width="44" height="20" font="4">Review </text>
<text top="540" left="283" width="24" height="20" font="4">N/A </text>
<text top="540" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="557" left="389" width="113" height="20" font="4">Arrhythmias and EP </text>
<text top="574" left="389" width="105" height="20" font="4">therapies in ACHD </text>
<text top="591" left="389" width="20" height="20" font="4">pts </text>
<text top="540" left="522" width="24" height="20" font="4">N/A </text>
<text top="540" left="662" width="237" height="20" font="4">● This review discusses the most common </text>
<text top="557" left="662" width="235" height="20" font="4">arrhythmias encountered in this population </text>
<text top="574" left="662" width="207" height="20" font="4">and the therapeutic options available. </text>
<text top="540" left="914" width="174" height="20" font="4">● Specific issues unique to this </text>
<text top="557" left="914" width="122" height="20" font="4">population need to be </text>
<text top="574" left="914" width="64" height="20" font="4">addressed. </text>
<text top="609" left="64" width="78" height="20" font="4">Ohuchi H and </text>
<text top="626" left="64" width="53" height="20" font="4">Diller GP </text>
<text top="644" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(184)</a> </text>
<text top="661" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24275294?dopt=Citation">24275294</a></text>
<text top="661" left="119" width="7" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24275294?dopt=Citation"> </a> </text>
<text top="609" left="170" width="44" height="20" font="4">Review </text>
<text top="609" left="283" width="24" height="20" font="4">N/A </text>
<text top="609" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="626" left="389" width="24" height="20" font="4">N/A </text>
<text top="609" left="522" width="24" height="20" font="4">N/A </text>
<text top="609" left="662" width="208" height="20" font="4">● Most ACHD pts show high levels of </text>
<text top="626" left="662" width="217" height="20" font="4">natriuretic peptide when compared with </text>
<text top="644" left="662" width="233" height="20" font="4">normal controls. Other biomarkers may be </text>
<text top="661" left="662" width="105" height="20" font="4">elevated in ACHD. </text>
<text top="609" left="914" width="170" height="20" font="4">● Role of biomarkers in ACHD </text>
<text top="626" left="914" width="76" height="20" font="4">is expanding. </text>
<text top="679" left="64" width="42" height="20" font="4">Alonso-</text>
<text top="696" left="64" width="97" height="20" font="4">Gonzalez R, et </text>
<text top="713" left="64" width="16" height="20" font="4">al. </text>
<text top="730" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(185)</a> </text>
<text top="748" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23750686?dopt=Citation">23750686</a></text>
<text top="748" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23750686?dopt=Citation"> </a></text>
<text top="679" left="170" width="44" height="20" font="4">Review </text>
<text top="679" left="283" width="24" height="20" font="4">N/A </text>
<text top="679" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="696" left="389" width="27" height="20" font="4">N/A  </text>
<text top="679" left="522" width="24" height="20" font="4">N/A </text>
<text top="679" left="662" width="207" height="20" font="4">● This review highlights the impact of </text>
<text top="696" left="662" width="230" height="20" font="4">neurohormonal activation in pts with CHD </text>
<text top="713" left="662" width="212" height="20" font="4">as well as the usefulness of assessing </text>
<text top="730" left="662" width="234" height="20" font="4">natriuretic peptide levels in specific clinical </text>
<text top="748" left="662" width="59" height="20" font="4">situations. </text>
<text top="679" left="914" width="159" height="20" font="4">● There is growing evidence </text>
<text top="696" left="914" width="160" height="20" font="4">that natriuretic peptide levels </text>
<text top="713" left="914" width="152" height="20" font="4">are elevated in some of the </text>
<text top="730" left="914" width="62" height="20" font="4">ACHD pts. </text>
</page>
<page number="52" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 52 </text>
<text top="107" left="64" width="81" height="20" font="4">Dinardo JA, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(186)</a>  </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23264549?dopt=Citation">23264549</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23264549?dopt=Citation"> </a></text>
<text top="107" left="170" width="44" height="20" font="4">Review </text>
<text top="107" left="283" width="24" height="20" font="4">N/A </text>
<text top="107" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="389" width="71" height="20" font="4">HF in ACHD </text>
<text top="141" left="389" width="60" height="20" font="4">population </text>
<text top="107" left="522" width="24" height="20" font="4">N/A </text>
<text top="107" left="662" width="230" height="20" font="4">● The ACHD pts currently at greatest risk </text>
<text top="124" left="662" width="203" height="20" font="4">for HF are those with single-ventricle </text>
<text top="141" left="662" width="194" height="20" font="4">physiology, those with a 2-ventricle </text>
<text top="159" left="662" width="218" height="20" font="4">circulation with the right ventricle as the </text>
<text top="176" left="662" width="235" height="20" font="4">systemic ventricle, and those with repaired </text>
<text top="193" left="662" width="149" height="20" font="4">TOF and PV insufficiency.  </text>
<text top="107" left="914" width="141" height="20" font="4">● This article reviews the </text>
<text top="124" left="914" width="166" height="20" font="4">demographics, diagnosis, FC, </text>
<text top="141" left="914" width="146" height="20" font="4">and treatment of HF in the </text>
<text top="159" left="914" width="105" height="20" font="4">ACHD population.  </text>
<text top="211" left="64" width="83" height="20" font="4">Shaddy RE, et </text>
<text top="228" left="64" width="16" height="20" font="4">al. </text>
<text top="245" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(187)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18248271?dopt=Citation">18248271</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18248271?dopt=Citation"> </a></text>
<text top="211" left="170" width="44" height="20" font="4">Review </text>
<text top="211" left="283" width="24" height="20" font="4">N/A </text>
<text top="211" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="228" left="389" width="71" height="20" font="4">HF in ACHD </text>
<text top="245" left="389" width="60" height="20" font="4">population </text>
<text top="211" left="522" width="24" height="20" font="4">N/A </text>
<text top="211" left="662" width="206" height="20" font="4">● Pts at greatest risk of HF are those </text>
<text top="228" left="662" width="222" height="20" font="4">without a systemic left ventricle, such as </text>
<text top="245" left="662" width="207" height="20" font="4">Mustard and Senning repairs of TGA, </text>
<text top="263" left="662" width="226" height="20" font="4">CCTGA, and pts who have had a Fontan </text>
<text top="280" left="662" width="66" height="20" font="4">procedure.  </text>
<text top="297" left="662" width="194" height="20" font="4">● Exercise intolerance may predict </text>
<text top="314" left="662" width="209" height="20" font="4">hospitalization and death in such pts.  </text>
<text top="211" left="914" width="164" height="20" font="4">● For those pts with systemic </text>
<text top="228" left="914" width="122" height="20" font="4">left ventricles, may be </text>
<text top="245" left="914" width="141" height="20" font="4">reasonable to use the HF </text>
<text top="263" left="914" width="156" height="20" font="4">guidelines developed for pts </text>
<text top="280" left="914" width="176" height="20" font="4">with acquired HD. For those pts </text>
<text top="297" left="914" width="173" height="20" font="4">without a systemic left ventricle </text>
<text top="314" left="914" width="120" height="20" font="4">(e.g., a SRV or single </text>
<text top="332" left="914" width="152" height="20" font="4">ventricle), no foundation for </text>
<text top="349" left="914" width="138" height="20" font="4">evidence-based therapy. </text>
<text top="367" left="64" width="77" height="20" font="4">Piran S, et al. </text>
<text top="384" left="64" width="63" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(188)</a> </text>
<text top="401" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11889012?dopt=Citation">11889012</a></text>
<text top="401" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11889012?dopt=Citation"> </a></text>
<text top="367" left="170" width="67" height="20" font="4">Prospective </text>
<text top="384" left="170" width="38" height="20" font="4">cohort </text>
<text top="367" left="283" width="61" height="20" font="4">n=188 pts  </text>
<text top="367" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="384" left="389" width="101" height="20" font="4">Consecutive adult </text>
<text top="401" left="389" width="95" height="20" font="4">pts with single or </text>
<text top="418" left="389" width="109" height="20" font="4">SRV assessed with </text>
<text top="436" left="389" width="104" height="20" font="4">gated radionuclide </text>
<text top="453" left="389" width="117" height="20" font="4">angiography (n=135) </text>
<text top="470" left="389" width="110" height="20" font="4">or 2D echo (n=188) </text>
<text top="487" left="389" width="89" height="20" font="4">and followed up </text>
<text top="504" left="389" width="53" height="20" font="4">clinically  </text>
<text top="367" left="522" width="113" height="20" font="4">Development of HF, </text>
<text top="384" left="522" width="79" height="20" font="4">severity of HF </text>
<text top="367" left="662" width="238" height="20" font="4">● 82.4% of the pts were in NYHA class I or </text>
<text top="384" left="662" width="229" height="20" font="4">II, 13.3% were in class III, and 4.3% were </text>
<text top="401" left="662" width="66" height="20" font="4">in class IV.  </text>
<text top="418" left="662" width="222" height="20" font="4">● HF occurred in 22.2% of pts with TGA </text>
<text top="436" left="662" width="216" height="20" font="4">and a Mustard procedure, 32.3% of pts </text>
<text top="453" left="662" width="232" height="20" font="4">with CCTGA, and 40% of Fontan-palliated </text>
<text top="470" left="662" width="221" height="20" font="4">pts. ● Symptomatic pts had significantly </text>
<text top="487" left="662" width="221" height="20" font="4">lower anaerobic thresholds (p&lt;0.0003).  </text>
<text top="504" left="662" width="231" height="20" font="4">● Systemic ventricular EF in symptomatic </text>
<text top="522" left="662" width="220" height="20" font="4">vs. asymptomatic pts at rest was 34.8 ± </text>
<text top="539" left="662" width="201" height="20" font="4">15.7% vs. 46.7 ± 3.4% (p=0.00001). </text>
<text top="367" left="914" width="168" height="20" font="4">● Pts with single or SRV have </text>
<text top="384" left="914" width="118" height="20" font="4">significant risk for HF </text>
<text top="401" left="914" width="176" height="20" font="4">accompanied by high mortality.  </text>
<text top="418" left="914" width="165" height="20" font="4">● Best predictors for mortality </text>
<text top="436" left="914" width="176" height="20" font="4">were NYHA class, systemic EF, </text>
<text top="453" left="914" width="123" height="20" font="4">and age at operation.  </text>
<text top="470" left="914" width="167" height="20" font="4">● Mortality was 47.1% among </text>
<text top="487" left="914" width="137" height="20" font="4">symptomatic pts and 5% </text>
<text top="504" left="914" width="154" height="20" font="4">among asymptomatic pts at </text>
<text top="522" left="914" width="163" height="20" font="4">15.7 y of postoperative follow-</text>
<text top="539" left="914" width="21" height="20" font="4">up. </text>
<text top="557" left="64" width="87" height="20" font="4">Reardon LC, et </text>
<text top="574" left="64" width="16" height="20" font="4">al. </text>
<text top="591" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(189)</a> </text>
<text top="608" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11889012?dopt=Citation">22863176</a></text>
<text top="608" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11889012?dopt=Citation"> </a></text>
<text top="557" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="574" left="170" width="70" height="20" font="4">chart review </text>
<text top="557" left="283" width="51" height="20" font="4">n=53 pts </text>
<text top="557" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="574" left="389" width="108" height="20" font="4">ACHD pts who had </text>
<text top="591" left="389" width="107" height="20" font="4">BNP measurement </text>
<text top="557" left="522" width="95" height="20" font="4">The 1° endpoint: </text>
<text top="574" left="522" width="127" height="20" font="4">death or HF admission </text>
<text top="557" left="662" width="235" height="20" font="4">● 15 pts (28%) met the 1° endpoint (death </text>
<text top="574" left="662" width="217" height="20" font="4">in 7, HF hospitalization in 8). Mean and </text>
<text top="591" left="662" width="238" height="20" font="4">median baseline BNP in pts meeting the 1° </text>
<text top="608" left="662" width="222" height="20" font="4">endpoint were 322±346 and 179 pg/mL, </text>
<text top="626" left="662" width="216" height="20" font="4">compared to 100±157 and 41 pg/mL in </text>
<text top="643" left="662" width="189" height="20" font="4">those not meeting the 1° endpoint </text>
<text top="660" left="662" width="70" height="20" font="4">(p=0.0029).  </text>
<text top="677" left="662" width="235" height="20" font="4">● A Cox proportional hazards model using </text>
<text top="694" left="662" width="200" height="20" font="4">baseline BNP between the 2 groups </text>
<text top="712" left="662" width="228" height="20" font="4">yielded a HR of 1.84 (95% CI: 1.19–2.85; </text>
<text top="729" left="662" width="213" height="20" font="4">p=0.006). The relative risk for baseline </text>
<text top="746" left="662" width="230" height="20" font="4">BNP level &gt;140 pg/mL was 4.62 (95% CI: </text>
<text top="763" left="662" width="121" height="20" font="4">1.80–11.3; p=0.008).  </text>
<text top="557" left="914" width="148" height="20" font="4">● Elevated BNP levels are </text>
<text top="574" left="914" width="138" height="20" font="4">predictive of death or HF </text>
<text top="591" left="914" width="172" height="20" font="4">admission in pts with the ES. A </text>
<text top="608" left="914" width="176" height="20" font="4">serum BNP level &gt;140 pg/mL is </text>
<text top="626" left="914" width="169" height="20" font="4">a useful tool in identifying high-</text>
<text top="643" left="914" width="46" height="20" font="4">risk pts. </text>
</page>
<page number="53" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 53 </text>
<text top="107" left="64" width="64" height="20" font="4">Parekh DR </text>
<text top="124" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(190)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21685844?dopt=Citation">21685844</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21685844?dopt=Citation"> </a></text>
<text top="107" left="170" width="44" height="20" font="4">Review </text>
<text top="107" left="283" width="24" height="20" font="4">N/A </text>
<text top="107" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="389" width="88" height="20" font="4">HF treatment in </text>
<text top="141" left="389" width="58" height="20" font="4">ACHD pts </text>
<text top="107" left="522" width="24" height="20" font="4">N/A </text>
<text top="107" left="662" width="209" height="20" font="4">● Conventional HF therapy of BB and </text>
<text top="124" left="662" width="198" height="20" font="4">ACEIs have not demonstrated clear </text>
<text top="141" left="662" width="188" height="20" font="4">survival benefit in this population.  </text>
<text top="107" left="914" width="152" height="20" font="4">● Adequately powered and </text>
<text top="124" left="914" width="167" height="20" font="4">controlled randomized studies </text>
<text top="141" left="914" width="109" height="20" font="4">are grossly lacking. </text>
<text top="159" left="64" width="92" height="20" font="4">Bolger AP, et al. </text>
<text top="177" left="64" width="66" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(191)</a>  </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12093776?dopt=Citation">12093776</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12093776?dopt=Citation"> </a></text>
<text top="159" left="170" width="97" height="20" font="4">Prospective case </text>
<text top="177" left="170" width="36" height="20" font="4">series </text>
<text top="159" left="283" width="72" height="20" font="4">n=68 pts (53 </text>
<text top="177" left="283" width="82" height="20" font="4">ACHD pts and </text>
<text top="194" left="283" width="60" height="20" font="4">15 healthy </text>
<text top="211" left="283" width="51" height="20" font="4">controls) </text>
<text top="159" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="177" left="389" width="111" height="20" font="4">Pts with ACHD who </text>
<text top="194" left="389" width="106" height="20" font="4">had blood levels of </text>
<text top="211" left="389" width="64" height="20" font="4">biomarkers </text>
<text top="159" left="522" width="100" height="20" font="4">Concentrations of </text>
<text top="177" left="522" width="64" height="20" font="4">ANP, BNP, </text>
<text top="194" left="522" width="109" height="20" font="4">endothelin-1, renin, </text>
<text top="211" left="522" width="71" height="20" font="4">aldosterone, </text>
<text top="228" left="522" width="113" height="20" font="4">norepinephrine, and </text>
<text top="246" left="522" width="68" height="20" font="4">epinephrine </text>
<text top="159" left="662" width="221" height="20" font="4">● ACHD pts had elevated levels of ANP </text>
<text top="177" left="662" width="219" height="20" font="4">(56.6 vs. 3.1 pmol/L), BNP (35.8 vs. 5.7 </text>
<text top="194" left="662" width="202" height="20" font="4">pmol/L), ET-1 (2.5 vs. 0.7 pmol/L; all </text>
<text top="211" left="662" width="216" height="20" font="4">p&lt;0.0001), renin (147 vs. 16.3 pmol/L), </text>
<text top="228" left="662" width="221" height="20" font="4">norepinephrine (2.2 vs. 1.6 pmol/L; both </text>
<text top="246" left="662" width="208" height="20" font="4">p&lt;0.01) and aldosterone (546 vs. 337 </text>
<text top="263" left="662" width="96" height="20" font="4">pmol/L; p&lt;0.05).  </text>
<text top="280" left="662" width="228" height="20" font="4">● There was a highly significant stepwise </text>
<text top="297" left="662" width="185" height="20" font="4">increase in ANP, BNP, ET-1, and </text>
<text top="314" left="662" width="235" height="20" font="4">norepinephrine according NYHA class and </text>
<text top="332" left="662" width="161" height="20" font="4">systemic ventricular function. </text>
<text top="159" left="914" width="169" height="20" font="4">● Neurohormonal activation in </text>
<text top="177" left="914" width="151" height="20" font="4">ACHD was associated with </text>
<text top="194" left="914" width="137" height="20" font="4">presence and severity of </text>
<text top="211" left="914" width="70" height="20" font="4">chronic HF.  </text>
<text top="228" left="914" width="124" height="20" font="4">● There was no direct </text>
<text top="245" left="914" width="147" height="20" font="4">relationship between the 4 </text>
<text top="263" left="914" width="175" height="20" font="4">anatomic subgroups and any of </text>
<text top="280" left="914" width="157" height="20" font="4">the neurohormones studied. </text>
<text top="350" left="64" width="84" height="20" font="4">Norozi K, et al. </text>
<text top="367" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(192)</a> </text>
<text top="384" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16236924?dopt=Citation">16236924</a></text>
<text top="384" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16236924?dopt=Citation"> </a></text>
<text top="350" left="170" width="72" height="20" font="4">Case control </text>
<text top="367" left="170" width="33" height="20" font="4">study </text>
<text top="350" left="283" width="81" height="20" font="4">n=50 adult pts </text>
<text top="367" left="283" width="77" height="20" font="4">(mean 27.8 ± </text>
<text top="384" left="283" width="76" height="20" font="4">1.7 y ± SEM) </text>
<text top="401" left="283" width="81" height="20" font="4">with TOF after </text>
<text top="418" left="283" width="81" height="20" font="4">surgical repair </text>
<text top="436" left="283" width="82" height="20" font="4">(NYHA FC 1.1 </text>
<text top="453" left="283" width="84" height="20" font="4">± 0.1) and 100 </text>
<text top="470" left="283" width="90" height="20" font="4">healthy controls </text>
<text top="350" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="367" left="389" width="104" height="20" font="4">Adult pts with TOF </text>
<text top="384" left="389" width="108" height="20" font="4">&gt;20 y after surgical </text>
<text top="401" left="389" width="35" height="20" font="4">repair </text>
<text top="418" left="389" width="3" height="20" font="4"> </text>
<text top="436" left="389" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="453" left="389" width="98" height="20" font="4">Symptomatic HF, </text>
<text top="470" left="389" width="86" height="20" font="4">acute infection, </text>
<text top="487" left="389" width="119" height="20" font="4">chronic lung disease, </text>
<text top="504" left="389" width="81" height="20" font="4">severe mental </text>
<text top="522" left="389" width="90" height="20" font="4">retardation, and </text>
<text top="539" left="389" width="90" height="20" font="4">medication (i.e., </text>
<text top="556" left="389" width="86" height="20" font="4">ACEIs and BB) </text>
<text top="350" left="522" width="120" height="20" font="4">Concentrations of NT-</text>
<text top="367" left="522" width="120" height="20" font="4">proANP, NT-proBNP, </text>
<text top="384" left="522" width="109" height="20" font="4">endothelin-1, renin, </text>
<text top="401" left="522" width="71" height="20" font="4">aldosterone, </text>
<text top="418" left="522" width="81" height="20" font="4">adrenalin, and </text>
<text top="436" left="522" width="72" height="20" font="4">noradrenalin </text>
<text top="350" left="662" width="203" height="20" font="4">● TOF pts had elevated levels of NT-</text>
<text top="367" left="662" width="237" height="20" font="4">proBNP compared with healthy individuals: </text>
<text top="384" left="662" width="215" height="20" font="4">NT-proBNP (women: 180 pg/mL vs. 43 </text>
<text top="401" left="662" width="235" height="20" font="4">pg/mL, and men: 147 pg/mL vs. 32 pg/mL; </text>
<text top="418" left="662" width="214" height="20" font="4">p&lt;0.0001) and ET-1 (2.5 fmol/L vs. 0.7 </text>
<text top="436" left="662" width="48" height="20" font="4">fmol/L).  </text>
<text top="453" left="662" width="216" height="20" font="4">● There was a significant correlation of </text>
<text top="470" left="662" width="221" height="20" font="4">NT-proBNP to dimension and estimated </text>
<text top="487" left="662" width="237" height="20" font="4">peak systolic pressure of the RV as well as </text>
<text top="504" left="662" width="96" height="20" font="4">impairment of VO</text>
<text top="511" left="757" width="4" height="13" font="6">2</text>
<text top="504" left="762" width="34" height="20" font="4"> max. </text>
<text top="350" left="914" width="165" height="20" font="4">● RV dysfunction detected by </text>
<text top="367" left="914" width="164" height="20" font="4">echo and plasma NT-proBNP </text>
<text top="384" left="914" width="161" height="20" font="4">in asymptomatic or minimally </text>
<text top="401" left="914" width="124" height="20" font="4">symptomatic TOF pts; </text>
<text top="418" left="914" width="107" height="20" font="4">correlates well with </text>
<text top="436" left="914" width="143" height="20" font="4">cardiopulmonary exercise </text>
<text top="453" left="914" width="52" height="20" font="4">capacity. </text>
<text top="574" left="64" width="84" height="20" font="4">Norozi K, et al. </text>
<text top="591" left="64" width="66" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(193)</a>  </text>
<text top="608" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16635615?dopt=Citation">16635615</a></text>
<text top="608" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16635615?dopt=Citation"> </a></text>
<text top="574" left="170" width="72" height="20" font="4">Case control </text>
<text top="591" left="170" width="33" height="20" font="4">study </text>
<text top="574" left="283" width="79" height="20" font="4">n=111 (59 pts </text>
<text top="591" left="283" width="80" height="20" font="4">with surgically </text>
<text top="608" left="283" width="83" height="20" font="4">corrected TOF </text>
<text top="626" left="283" width="86" height="20" font="4">and 52 pts with </text>
<text top="643" left="283" width="87" height="20" font="4">operated left-to-</text>
<text top="660" left="283" width="62" height="20" font="4">right-shunt </text>
<text top="677" left="283" width="46" height="20" font="4">defects  </text>
<text top="574" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="591" left="389" width="111" height="20" font="4">Surgically corrected </text>
<text top="608" left="389" width="48" height="20" font="4">TOF pts </text>
<text top="574" left="522" width="105" height="20" font="4">Echocardiographic </text>
<text top="591" left="522" width="73" height="20" font="4">indices M VO</text>
<text top="597" left="595" width="4" height="13" font="6">2</text>
<text top="591" left="599" width="27" height="20" font="4">, NT-</text>
<text top="608" left="522" width="81" height="20" font="4">proBNP levels </text>
<text top="574" left="662" width="200" height="20" font="4">● Pts with TOF showed significantly </text>
<text top="591" left="662" width="233" height="20" font="4">greater LV and RV Tei indexes than those </text>
<text top="608" left="662" width="235" height="20" font="4">with left-to-right-shunt defects (p&lt;0.0001).  </text>
<text top="626" left="662" width="53" height="20" font="4">● Peak O</text>
<text top="632" left="715" width="4" height="13" font="6">2</text>
<text top="626" left="720" width="136" height="20" font="4"> uptake was significantly </text>
<text top="643" left="662" width="218" height="20" font="4">reduced in the pts with TOF (p&lt;0.0001) </text>
<text top="660" left="662" width="224" height="20" font="4">and was correlated inversely with the LV </text>
<text top="677" left="662" width="208" height="20" font="4">Tei index p&lt;0.0001). NT-proBNP was </text>
<text top="694" left="662" width="238" height="20" font="4">significantly increased in pts with TOF (150 </text>
<text top="712" left="662" width="210" height="20" font="4">+/ 141 vs. 57 ± 39 pg/mL; p&lt;0.0001).  </text>
<text top="574" left="914" width="149" height="20" font="4">● Biventricular dysfunction </text>
<text top="591" left="914" width="124" height="20" font="4">detected by Tei index. </text>
<text top="608" left="914" width="148" height="20" font="4">Increased NT-proBNP and </text>
<text top="626" left="914" width="90" height="20" font="4">impaired peak O</text>
<text top="632" left="1004" width="4" height="13" font="6">2</text>
<text top="626" left="1009" width="65" height="20" font="4"> uptake are </text>
<text top="643" left="914" width="141" height="20" font="4">also signs of biventricular </text>
<text top="660" left="914" width="73" height="20" font="4">dysfunction.  </text>
<text top="730" left="64" width="66" height="20" font="4">Krieger EV, </text>
<text top="747" left="64" width="87" height="20" font="4">Valente, AM, et </text>
<text top="764" left="64" width="16" height="20" font="4">al. </text>
<text top="730" left="170" width="44" height="20" font="4">Review </text>
<text top="730" left="283" width="24" height="20" font="4">N/A </text>
<text top="730" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="747" left="389" width="24" height="20" font="4">N/A </text>
<text top="730" left="522" width="24" height="20" font="4">N/A </text>
<text top="730" left="662" width="227" height="20" font="4">● Not appropriate to extrapolate from the </text>
<text top="747" left="662" width="224" height="20" font="4">acquired HF literature and apply it to this </text>
<text top="764" left="662" width="216" height="20" font="4">heterogeneous population of CHD pts.  </text>
<text top="730" left="914" width="150" height="20" font="4">● Pts with CHD have been </text>
<text top="747" left="914" width="171" height="20" font="4">excluded from most large trials </text>
<text top="764" left="914" width="163" height="20" font="4">of HF small retrospective and </text>
</page>
<page number="54" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 54 </text>
<text top="107" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(194)</a> </text>
<text top="124" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24924621?dopt=Citation">24924621</a></text>
<text top="124" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24924621?dopt=Citation"> </a></text>
<text top="107" left="914" width="158" height="20" font="4">underpowered studies in the </text>
<text top="124" left="914" width="94" height="20" font="4">CHD population. </text>
<text top="142" left="108" width="3" height="20" font="4"> </text>
<text top="159" left="108" width="3" height="20" font="4"> </text>
<text top="176" left="108" width="691" height="24" font="1"><b>Data Supplement 18. Noncardiac Medical Issues and Noncardiac Surgery – Sections 3.11 and 3.12 </b></text>
<text top="198" left="92" width="38" height="20" font="3"><b>Study </b></text>
<text top="215" left="67" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="233" left="95" width="30" height="20" font="3"><b>Year </b></text>
<text top="198" left="173" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="215" left="188" width="44" height="20" font="3"><b>Design </b></text>
<text top="198" left="280" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="198" left="389" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="215" left="426" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="198" left="555" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="198" left="726" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="198" left="927" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="250" left="64" width="81" height="20" font="4">Wang A, et al. </text>
<text top="268" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(195)</a> </text>
<text top="285" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17920376?dopt=Citation">17920376</a></text>
<text top="285" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17920376?dopt=Citation"> </a></text>
<text top="250" left="170" width="151" height="20" font="4">Cohort study  n=198 pts </text>
<text top="250" left="375" width="122" height="20" font="3"><b>Inclusion criteria</b>: All </text>
<text top="268" left="375" width="128" height="20" font="4">ACHD pts with surgery </text>
<text top="285" left="375" width="73" height="20" font="4">prior to 1992 </text>
<text top="250" left="535" width="63" height="20" font="4">Hepatitis C </text>
<text top="268" left="535" width="90" height="20" font="4">antibody testing </text>
<text top="250" left="661" width="202" height="20" font="4">● 17 (8.6%) had positive Hepatitis C </text>
<text top="268" left="661" width="191" height="20" font="4">antibody results, and 8 (4.0%) had </text>
<text top="285" left="661" width="197" height="20" font="4">positive Hepatitis C ribonucleic acid </text>
<text top="302" left="661" width="43" height="20" font="4">results. </text>
<text top="250" left="906" width="162" height="20" font="4">● Positivity rate was nearly 5-</text>
<text top="268" left="906" width="133" height="20" font="4">fold higher than general </text>
<text top="285" left="906" width="64" height="20" font="4">population. </text>
<text top="320" left="64" width="86" height="20" font="4">Maxwell BG, et </text>
<text top="337" left="64" width="16" height="20" font="4">al. </text>
<text top="354" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(196)</a> </text>
<text top="372" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23907357?dopt=Citation">23907357</a></text>
<text top="372" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23907357?dopt=Citation"> </a></text>
<text top="320" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="337" left="170" width="48" height="20" font="4">analysis </text>
<text top="354" left="170" width="33" height="20" font="4">using </text>
<text top="372" left="170" width="79" height="20" font="4">administrative </text>
<text top="389" left="170" width="68" height="20" font="4">database of </text>
<text top="406" left="170" width="76" height="20" font="4">ACHD cohort </text>
<text top="423" left="170" width="49" height="20" font="4">and non-</text>
<text top="440" left="170" width="38" height="20" font="4">ACHD </text>
<text top="458" left="170" width="51" height="20" font="4">matched </text>
<text top="475" left="170" width="67" height="20" font="4">comparison </text>
<text top="492" left="170" width="38" height="20" font="4">cohort </text>
<text top="320" left="263" width="72" height="20" font="4">Study cohort </text>
<text top="337" left="263" width="58" height="20" font="4">n=10,004; </text>
<text top="354" left="263" width="51" height="20" font="4">matched </text>
<text top="372" left="263" width="67" height="20" font="4">comparison </text>
<text top="389" left="263" width="93" height="20" font="4">cohort n=37,581 </text>
<text top="320" left="375" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="337" left="375" width="128" height="20" font="4">with ACHD undergoing </text>
<text top="354" left="375" width="141" height="20" font="4">noncardiac surgery in the </text>
<text top="372" left="375" width="115" height="20" font="4">Nationwide Inpatient </text>
<text top="389" left="375" width="100" height="20" font="4">sample database, </text>
<text top="406" left="375" width="144" height="20" font="4">compared with a matched </text>
<text top="423" left="375" width="141" height="20" font="4">non-ACHD control cohort </text>
<text top="320" left="535" width="87" height="20" font="4">Input mortality.  </text>
<text top="337" left="535" width="62" height="20" font="4">Secondary </text>
<text top="354" left="535" width="54" height="20" font="4">endpoint: </text>
<text top="372" left="535" width="110" height="20" font="4">composite endpoint </text>
<text top="389" left="535" width="88" height="20" font="4">of perioperative </text>
<text top="406" left="535" width="53" height="20" font="4">morbidity </text>
<text top="320" left="661" width="203" height="20" font="4">● Mortality: 407 of 10,004 (4.1%) vs. </text>
<text top="337" left="661" width="221" height="20" font="4">1,355 of 37,581 (3.6%); unadjusted OR: </text>
<text top="354" left="661" width="188" height="20" font="4">1.13; p=0.031; adjusted OR: 1.29; </text>
<text top="372" left="661" width="52" height="20" font="4">p&lt;0.001. </text>
<text top="389" left="661" width="231" height="20" font="4">● Morbidity: ACHD group 2,145 of 10,004 </text>
<text top="406" left="661" width="230" height="20" font="4">(21.4%) vs. 6,003 of 37,581 (16.0%); OR: </text>
<text top="423" left="661" width="82" height="20" font="4">1.44; p&lt;0.001. </text>
<text top="320" left="906" width="135" height="20" font="4">● ACHD pts undergoing </text>
<text top="337" left="906" width="108" height="20" font="4">noncardiac surgery </text>
<text top="354" left="906" width="127" height="20" font="4">experienced increased </text>
<text top="372" left="906" width="152" height="20" font="4">perioperative morbidity and </text>
<text top="389" left="906" width="119" height="20" font="4">mortality vs. controls. </text>
<text top="510" left="64" width="86" height="20" font="4">Maxwell BG, et </text>
<text top="527" left="64" width="16" height="20" font="4">al. </text>
<text top="544" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(197)</a> </text>
<text top="562" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24887660?dopt=Citation">24887660</a></text>
<text top="562" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24887660?dopt=Citation"> </a></text>
<text top="510" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="527" left="170" width="38" height="20" font="4">cohort </text>
<text top="544" left="170" width="61" height="20" font="4">analysis of </text>
<text top="562" left="170" width="69" height="20" font="4">the National </text>
<text top="579" left="170" width="48" height="20" font="4">Surgical </text>
<text top="596" left="170" width="42" height="20" font="4">Quality </text>
<text top="613" left="170" width="75" height="20" font="4">Improvement </text>
<text top="631" left="170" width="51" height="20" font="4">Program </text>
<text top="648" left="170" width="54" height="20" font="4">database </text>
<text top="510" left="263" width="72" height="20" font="4">Study cohort </text>
<text top="527" left="263" width="52" height="20" font="4">n=1,191; </text>
<text top="544" left="263" width="67" height="20" font="4">comparison </text>
<text top="562" left="263" width="86" height="20" font="4">cohort n=5,127 </text>
<text top="510" left="375" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="527" left="375" width="129" height="20" font="4">18-39 y with prior heart </text>
<text top="544" left="375" width="129" height="20" font="4">surgery that underwent </text>
<text top="562" left="375" width="108" height="20" font="4">noncardiac surgery </text>
<text top="579" left="375" width="118" height="20" font="4">between 2005–2010. </text>
<text top="596" left="375" width="129" height="20" font="4">Matched cohort had no </text>
<text top="613" left="375" width="104" height="20" font="4">prior heart surgery </text>
<text top="510" left="535" width="76" height="20" font="4">Perioperative </text>
<text top="527" left="535" width="57" height="20" font="4">outcomes </text>
<text top="510" left="661" width="226" height="20" font="4">● Observed rates of death, perioperative </text>
<text top="527" left="661" width="204" height="20" font="4">cardiac arrest, MI, stroke, respiratory </text>
<text top="544" left="661" width="225" height="20" font="4">complications, renal failure, sepsis, VTE, </text>
<text top="562" left="661" width="231" height="20" font="4">perioperative transfusion, and reoperation </text>
<text top="579" left="661" width="201" height="20" font="4">were significantly higher in the study </text>
<text top="596" left="661" width="128" height="20" font="4">cohort (p&lt;0.01 for all).  </text>
<text top="613" left="661" width="233" height="20" font="4">● Mean postoperative LOS was greater in </text>
<text top="631" left="661" width="218" height="20" font="4">the study cohort (5.8 vs. 3.6 d; p&lt;0.01). </text>
<text top="510" left="906" width="139" height="20" font="4">● History of prior cardiac </text>
<text top="527" left="906" width="122" height="20" font="4">surgery is a marker of </text>
<text top="544" left="906" width="163" height="20" font="4">substantial perioperative risk; </text>
<text top="562" left="906" width="172" height="20" font="4">that is not accounted for by the </text>
<text top="579" left="906" width="160" height="20" font="4">matched variables. Note: not </text>
<text top="596" left="906" width="135" height="20" font="4">matched on all available </text>
<text top="613" left="906" width="60" height="20" font="4">variables.  </text>
<text top="631" left="906" width="171" height="20" font="4">● Multivariable analysis shows </text>
<text top="648" left="906" width="143" height="20" font="4">prior CV surgery is not an </text>
<text top="665" left="906" width="173" height="20" font="4">independent marker of risk, but </text>
<text top="682" left="906" width="152" height="20" font="4">a marker of more extensive </text>
<text top="699" left="906" width="103" height="20" font="4">comorbid disease. </text>
<text top="717" left="64" width="93" height="20" font="4">Christensen RE, </text>
<text top="735" left="64" width="30" height="20" font="4">et al. </text>
<text top="752" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(198)</a> </text>
<text top="769" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22717725?dopt=Citation">22717725</a></text>
<text top="769" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22717725?dopt=Citation"> </a></text>
<text top="717" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="735" left="170" width="39" height="20" font="4">review </text>
<text top="717" left="263" width="93" height="20" font="4">n=40 pts with 73 </text>
<text top="735" left="263" width="68" height="20" font="4">procedures  </text>
<text top="717" left="375" width="141" height="20" font="3"><b>Inclusion criteria</b>: HLHS </text>
<text top="735" left="375" width="128" height="20" font="4">undergoing anesthesia </text>
<text top="752" left="375" width="68" height="20" font="4">2002–2008  </text>
<text top="717" left="535" width="96" height="20" font="4">Perioperative AE </text>
<text top="717" left="661" width="196" height="20" font="4">● 11 AE (15%). 13 ICU admissions </text>
<text top="735" left="661" width="40" height="20" font="4">(18%). </text>
<text top="717" left="906" width="177" height="20" font="4">● High rate of AE; perioperative </text>
<text top="735" left="906" width="161" height="20" font="4">care should be individualized </text>
<text top="752" left="906" width="142" height="20" font="4">based on the presence of </text>
<text top="769" left="906" width="168" height="20" font="4">known risk factors such as the </text>
<text top="786" left="906" width="149" height="20" font="4">stage of palliation, residual </text>
</page>
<page number="55" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 55 </text>
<text top="107" left="906" width="172" height="20" font="4">cardiac disease and severity of </text>
<text top="124" left="906" width="95" height="20" font="4">planned surgery. </text>
<text top="142" left="64" width="93" height="20" font="4">Christensen RE, </text>
<text top="159" left="64" width="30" height="20" font="4">et al. </text>
<text top="177" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(199)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19933174?dopt=Citation">19933174</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19933174?dopt=Citation"> </a></text>
<text top="142" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="159" left="170" width="48" height="20" font="4">analysis </text>
<text top="142" left="263" width="96" height="20" font="4">n=50 procedures </text>
<text top="159" left="263" width="85" height="20" font="4">(43 pediatric; 7 </text>
<text top="177" left="263" width="34" height="20" font="4">adult) </text>
<text top="142" left="375" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="159" left="375" width="112" height="20" font="4">Records for pts with </text>
<text top="177" left="375" width="120" height="20" font="4">surgically corrected d-</text>
<text top="194" left="375" width="138" height="20" font="4">TGA undergoing general </text>
<text top="211" left="375" width="144" height="20" font="4">anesthesia for noncardiac </text>
<text top="228" left="375" width="141" height="20" font="4">surgery between October </text>
<text top="246" left="375" width="123" height="20" font="4">2000–April 2008 were </text>
<text top="263" left="375" width="53" height="20" font="4">reviewed </text>
<text top="142" left="535" width="96" height="20" font="4">Perioperative AE </text>
<text top="142" left="661" width="210" height="20" font="4">● 4 AE: bradycardia, failed extubation </text>
<text top="159" left="661" width="165" height="20" font="4">after 2 of the procedures, and </text>
<text top="177" left="661" width="228" height="20" font="4">postoperative bleeding requiring return to </text>
<text top="194" left="661" width="120" height="20" font="4">the operating theatre. </text>
<text top="142" left="906" width="142" height="20" font="4">● The majority of pts with </text>
<text top="159" left="906" width="172" height="20" font="4">surgically corrected d-TGA can </text>
<text top="177" left="906" width="129" height="20" font="4">safely undergo general </text>
<text top="194" left="906" width="154" height="20" font="4">anesthesia, often as outpts, </text>
<text top="211" left="906" width="158" height="20" font="4">with no invasive monitoring.  </text>
<text top="228" left="906" width="172" height="20" font="4">● Perioperative care should be </text>
<text top="245" left="906" width="152" height="20" font="4">individualized based on the </text>
<text top="263" left="906" width="174" height="20" font="4">presence of comorbidities, type </text>
<text top="280" left="906" width="141" height="20" font="4">of repair, residual cardiac </text>
<text top="297" left="906" width="156" height="20" font="4">disease, severity of planned </text>
<text top="314" left="906" width="170" height="20" font="4">surgery, and experience of the </text>
<text top="332" left="906" width="51" height="20" font="4">provider. </text>
<text top="350" left="64" width="83" height="20" font="4">Rabbitts JA, et </text>
<text top="367" left="64" width="16" height="20" font="4">al. </text>
<text top="384" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(200)</a> </text>
<text top="401" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22998356?dopt=Citation">22998356</a></text>
<text top="401" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22998356?dopt=Citation"> </a></text>
<text top="350" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="367" left="170" width="48" height="20" font="4">analysis </text>
<text top="350" left="263" width="72" height="20" font="4">n=31 pts (39 </text>
<text top="367" left="263" width="69" height="20" font="4">procedures) </text>
<text top="350" left="375" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="367" left="375" width="122" height="20" font="4">Fontan pts ≥16 y who </text>
<text top="384" left="375" width="105" height="20" font="4">underwent general </text>
<text top="401" left="375" width="144" height="20" font="4">anesthesia for noncardiac </text>
<text top="418" left="375" width="125" height="20" font="4">surgery at Mayo Clinic </text>
<text top="350" left="535" width="76" height="20" font="4">Perioperative </text>
<text top="367" left="535" width="78" height="20" font="4">complications </text>
<text top="350" left="661" width="231" height="20" font="4">● Perioperative complications occurred in </text>
<text top="367" left="661" width="173" height="20" font="4">31% of noncardiac surgeries, 1 </text>
<text top="384" left="661" width="221" height="20" font="4">postoperative death and 13 after ventral </text>
<text top="401" left="661" width="79" height="20" font="4">hernia repair.  </text>
<text top="418" left="661" width="219" height="20" font="4">● The 2 pts who had complications that </text>
<text top="436" left="661" width="211" height="20" font="4">did not resolve (long-term dialysis and </text>
<text top="453" left="661" width="225" height="20" font="4">death) had LVEF below the mean for the </text>
<text top="470" left="661" width="127" height="20" font="4">group (22% and 28%). </text>
<text top="350" left="906" width="164" height="20" font="4">● It may be more appropriate </text>
<text top="367" left="906" width="142" height="20" font="4">for Fontan pts to undergo </text>
<text top="384" left="906" width="144" height="20" font="4">anesthesia for noncardiac </text>
<text top="401" left="906" width="167" height="20" font="4">surgery in a tertiary institution, </text>
<text top="418" left="906" width="166" height="20" font="4">particularly pts with a LVEF of </text>
<text top="436" left="906" width="42" height="20" font="4">&lt;30%.  </text>
<text top="453" left="906" width="152" height="20" font="4">● Intraoperative arterial BP </text>
<text top="470" left="906" width="139" height="20" font="4">monitoring and overnight </text>
<text top="487" left="906" width="176" height="20" font="4">admission are likely appropriate </text>
<text top="504" left="906" width="87" height="20" font="4">for most cases. </text>
<text top="522" left="64" width="78" height="20" font="4">Eagle SS and </text>
<text top="540" left="64" width="60" height="20" font="4">Daves SM </text>
<text top="557" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(201)</a> </text>
<text top="574" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21477759?dopt=Citation">21477759</a></text>
<text top="574" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21477759?dopt=Citation"> </a></text>
<text top="522" left="170" width="47" height="20" font="4">Review  </text>
<text top="522" left="263" width="24" height="20" font="4">N/A </text>
<text top="522" left="375" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="522" left="535" width="64" height="20" font="4">Descriptive </text>
<text top="540" left="535" width="69" height="20" font="4">treatment of </text>
<text top="557" left="535" width="89" height="20" font="4">management of </text>
<text top="574" left="535" width="107" height="20" font="4">Fontan pts through </text>
<text top="591" left="535" width="108" height="20" font="4">noncardiac surgery </text>
<text top="522" left="661" width="24" height="20" font="4">N/A </text>
<text top="522" left="906" width="159" height="20" font="4">● Summarizes the approach </text>
<text top="540" left="906" width="161" height="20" font="4">and management issues that </text>
<text top="557" left="906" width="170" height="20" font="4">arise in Fontan pts undergoing </text>
<text top="574" left="906" width="111" height="20" font="4">noncardiac surgery. </text>
<text top="609" left="64" width="91" height="20" font="4">Ammash NM, et </text>
<text top="626" left="64" width="16" height="20" font="4">al. </text>
<text top="644" left="64" width="66" height="20" font="4">1999 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(202)</a>  </text>
<text top="661" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9935034?dopt=Citation">9935034</a></text>
<text top="661" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9935034?dopt=Citation"> </a></text>
<text top="609" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="626" left="170" width="48" height="20" font="4">analysis </text>
<text top="609" left="263" width="76" height="20" font="4">n=58 pts with </text>
<text top="626" left="263" width="76" height="20" font="4">Eisenmenger </text>
<text top="644" left="263" width="61" height="20" font="4">syndrome  </text>
<text top="609" left="375" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="626" left="375" width="101" height="20" font="4">with Eisenmenger </text>
<text top="644" left="375" width="92" height="20" font="4">syndrome ≥17 y </text>
<text top="661" left="375" width="129" height="20" font="4">undergoing noncardiac </text>
<text top="678" left="375" width="44" height="20" font="4">surgery </text>
<text top="609" left="535" width="76" height="20" font="4">Perioperative </text>
<text top="626" left="535" width="102" height="20" font="4">complications and </text>
<text top="644" left="535" width="34" height="20" font="4">death </text>
<text top="609" left="661" width="229" height="20" font="4">● 2 deaths (7%), 1 following spinal fusion </text>
<text top="626" left="661" width="232" height="20" font="4">and the other following appendectomy. 10 </text>
<text top="644" left="661" width="156" height="20" font="4">pts were discharged without </text>
<text top="661" left="661" width="204" height="20" font="4">complications. 1 death occurred 10 d </text>
<text top="678" left="661" width="211" height="20" font="4">following spinal fusion. This pt had the </text>
<text top="695" left="661" width="165" height="20" font="4">longest anesthesia (525 min). </text>
<text top="609" left="906" width="136" height="20" font="4">● In majority noncardiac </text>
<text top="626" left="906" width="165" height="20" font="4">surgery accomplished without </text>
<text top="644" left="906" width="169" height="20" font="4">substantial morbidity, mortality </text>
<text top="661" left="906" width="162" height="20" font="4">but even with relatively minor </text>
<text top="678" left="906" width="106" height="20" font="4">surgery, significant </text>
<text top="695" left="906" width="171" height="20" font="4">complications, including death, </text>
<text top="712" left="906" width="60" height="20" font="4">can occur. </text>
<text top="730" left="64" width="83" height="20" font="4">Warner MA, et </text>
<text top="748" left="64" width="16" height="20" font="4">al. </text>
<text top="765" left="64" width="66" height="20" font="4">1998 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(203)</a>  </text>
<text top="782" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9703297?dopt=Citation">9703297</a></text>
<text top="782" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9703297?dopt=Citation"> </a></text>
<text top="730" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="748" left="170" width="70" height="20" font="4">cohort study </text>
<text top="765" left="170" width="75" height="20" font="4">of 6-y period  </text>
<text top="730" left="263" width="58" height="20" font="4">n=276 pts </text>
<text top="748" left="263" width="89" height="20" font="4">undergoing 480 </text>
<text top="765" left="263" width="64" height="20" font="4">noncardiac </text>
<text top="782" left="263" width="68" height="20" font="4">procedures  </text>
<text top="730" left="375" width="137" height="20" font="3"><b>Inclusion criteria</b>: Adult </text>
<text top="748" left="375" width="146" height="20" font="4">(&lt;50 y) and pediatric CHD </text>
<text top="765" left="375" width="142" height="20" font="4">pts, surgical or diagnostic </text>
<text top="730" left="535" width="103" height="20" font="4">30-d perioperative </text>
<text top="748" left="535" width="77" height="20" font="4">morbidity and </text>
<text top="765" left="535" width="50" height="20" font="4">mortality </text>
<text top="730" left="661" width="222" height="20" font="4">● Complication rate was 5.8%; only 1 pt </text>
<text top="748" left="661" width="120" height="20" font="4">died intraoperatively.  </text>
<text top="765" left="661" width="168" height="20" font="4">● Risk factors associated with </text>
<text top="782" left="661" width="193" height="20" font="4">complications: cyanosis (p=0.002), </text>
<text top="730" left="906" width="166" height="20" font="4">● Perioperative complications </text>
<text top="748" left="906" width="51" height="20" font="4">risk low.  </text>
<text top="765" left="906" width="166" height="20" font="4">● Pulmonary HTN, congenital </text>
<text top="782" left="906" width="176" height="20" font="4">HF, or cyanosis associated with </text>
</page>
<page number="56" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 56 </text>
<text top="107" left="375" width="84" height="20" font="4">procedure with </text>
<text top="124" left="375" width="63" height="20" font="4">anesthesia </text>
<text top="107" left="661" width="223" height="20" font="4">current treatment for HF (p&lt;0.001), poor </text>
<text top="124" left="661" width="213" height="20" font="4">general health (p&lt;0.001), and younger </text>
<text top="141" left="661" width="178" height="20" font="4">age at the time of the procedure </text>
<text top="159" left="661" width="63" height="20" font="4">(p=0.027).  </text>
<text top="176" left="661" width="192" height="20" font="4">● Respiratory and nervous system </text>
<text top="193" left="661" width="209" height="20" font="4">procedures were associated with high </text>
<text top="210" left="661" width="162" height="20" font="4">frequencies of complications. </text>
<text top="228" left="661" width="178" height="20" font="4">Complications in pts undergoing </text>
<text top="245" left="661" width="205" height="20" font="4">ambulatory surgical procedures were </text>
<text top="262" left="661" width="101" height="20" font="4">infrequent (1.7%). </text>
<text top="107" left="906" width="131" height="20" font="4">increased perioperative </text>
<text top="124" left="906" width="57" height="20" font="4">morbidity. </text>
<text top="280" left="64" width="86" height="20" font="4">Maxwell BG, et </text>
<text top="297" left="64" width="16" height="20" font="4">al. </text>
<text top="314" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(204)</a> </text>
<text top="332" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24869762?dopt=Citation">24869762</a></text>
<text top="332" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24869762?dopt=Citation"> </a></text>
<text top="280" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="297" left="170" width="48" height="20" font="4">analysis </text>
<text top="280" left="263" width="69" height="20" font="4">n=21 ACHD </text>
<text top="297" left="263" width="80" height="20" font="4">Claims cases  </text>
<text top="280" left="375" width="143" height="20" font="3"><b>Inclusion criteria</b>: Cases </text>
<text top="297" left="375" width="113" height="20" font="4">from the Anesthesia </text>
<text top="314" left="375" width="124" height="20" font="4">Closed Claims Project </text>
<text top="332" left="375" width="57" height="20" font="4">database. </text>
<text top="280" left="535" width="76" height="20" font="4">Perioperative </text>
<text top="297" left="535" width="107" height="20" font="4">factors contributing </text>
<text top="314" left="535" width="54" height="20" font="4">to an AE  </text>
<text top="280" left="661" width="193" height="20" font="4">● 11 cases (52%) involved cardiac </text>
<text top="297" left="661" width="206" height="20" font="4">procedures and 10 (48%) noncardiac </text>
<text top="314" left="661" width="229" height="20" font="4">procedures. Common factors contributing </text>
<text top="332" left="661" width="197" height="20" font="4">to the AE in noncardiac cases were </text>
<text top="349" left="661" width="205" height="20" font="4">postoperative monitoring/care (50%), </text>
<text top="366" left="661" width="231" height="20" font="4">CHD (50%) and preoperative assessment </text>
<text top="383" left="661" width="188" height="20" font="4">or optimization (40%). The factors </text>
<text top="401" left="661" width="178" height="20" font="4">contributing to the pt injury were </text>
<text top="418" left="661" width="226" height="20" font="4">postoperative monitoring/care (50%) and </text>
<text top="435" left="661" width="182" height="20" font="4">CHD (50%) in noncardiac cases. </text>
<text top="280" left="906" width="174" height="20" font="4">● This small study summarizes </text>
<text top="297" left="906" width="169" height="20" font="4">the role of anesthesiologists in </text>
<text top="314" left="906" width="112" height="20" font="4">adult pts with CHD.  </text>
<text top="332" left="906" width="141" height="20" font="4">● Emphasizes that risk is </text>
<text top="349" left="906" width="104" height="20" font="4">substantially in the </text>
<text top="366" left="906" width="177" height="20" font="4">postoperative phase rather than </text>
<text top="383" left="906" width="135" height="20" font="4">during the surgery itself. </text>
<text top="453" left="64" width="86" height="20" font="4">Maxwell BG, et </text>
<text top="470" left="64" width="16" height="20" font="4">al. </text>
<text top="487" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(204)</a> </text>
<text top="504" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23648140?dopt=Citation">23648140</a></text>
<text top="504" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23648140?dopt=Citation"> </a></text>
<text top="453" left="170" width="42" height="20" font="4">Survey </text>
<text top="470" left="170" width="48" height="20" font="4">analysis </text>
<text top="453" left="263" width="38" height="20" font="4">n=168 </text>
<text top="470" left="263" width="98" height="20" font="4">anesthesiologists </text>
<text top="487" left="263" width="3" height="20" font="4"> </text>
<text top="504" left="263" width="3" height="20" font="4"> </text>
<text top="522" left="263" width="3" height="20" font="4"> </text>
<text top="539" left="263" width="3" height="20" font="4"> </text>
<text top="556" left="263" width="3" height="20" font="4"> </text>
<text top="453" left="375" width="3" height="20" font="4"> </text>
<text top="453" left="535" width="105" height="20" font="4">Survey responses, </text>
<text top="470" left="535" width="109" height="20" font="4">including true/false, </text>
<text top="487" left="535" width="112" height="20" font="4">multiple choice, and </text>
<text top="504" left="535" width="66" height="20" font="4">Likert scale </text>
<text top="522" left="535" width="60" height="20" font="4">questions. </text>
<text top="453" left="661" width="207" height="20" font="4">● Higher scores in those with cardiac </text>
<text top="470" left="661" width="212" height="20" font="4">(median IQR: 11 (7–15); p=0.005) and </text>
<text top="487" left="661" width="231" height="20" font="4">pediatric (median IQR: 12 (6–15); p=0.00) </text>
<text top="504" left="661" width="217" height="20" font="4">fellowship training, but not in those with </text>
<text top="522" left="661" width="214" height="20" font="4">critical care, obstetric, regional, or pain </text>
<text top="539" left="661" width="126" height="20" font="4">management training.  </text>
<text top="556" left="661" width="225" height="20" font="4">● Only moderate levels of comfort with a </text>
<text top="573" left="661" width="192" height="20" font="4">range of questions about providing </text>
<text top="591" left="661" width="218" height="20" font="4">perioperative or obstetric care to ACHD </text>
<text top="608" left="661" width="205" height="20" font="4">pts, with decreasing levels of comfort </text>
<text top="625" left="661" width="188" height="20" font="4">reported in pts with more complex </text>
<text top="642" left="661" width="45" height="20" font="4">lesions. </text>
<text top="453" left="906" width="163" height="20" font="4">● Providers may benefit from </text>
<text top="470" left="906" width="175" height="20" font="4">improved training and protocols </text>
<text top="487" left="906" width="123" height="20" font="4">for ensuring adequate </text>
<text top="504" left="906" width="158" height="20" font="4">preparedness for the care of </text>
<text top="522" left="906" width="62" height="20" font="4">ACHD pts. </text>
<text top="660" left="64" width="83" height="20" font="4">Kaemmerer H, </text>
<text top="677" left="64" width="30" height="20" font="4">et al. </text>
<text top="694" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(205)</a> </text>
<text top="712" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18312770?dopt=Citation">18312770</a></text>
<text top="712" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18312770?dopt=Citation"> </a></text>
<text top="660" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="677" left="170" width="51" height="20" font="4">analysis, </text>
<text top="694" left="170" width="64" height="20" font="4">multicenter </text>
<text top="712" left="170" width="33" height="20" font="4">study </text>
<text top="660" left="263" width="48" height="20" font="4">n=1,033 </text>
<text top="677" left="263" width="78" height="20" font="4">admissions of </text>
<text top="694" left="263" width="96" height="20" font="4">160 adult pts (16-</text>
<text top="712" left="263" width="89" height="20" font="4">71 y) with CHD, </text>
<text top="729" left="263" width="72" height="20" font="4">of which 201 </text>
<text top="746" left="263" width="30" height="20" font="4">were </text>
<text top="763" left="263" width="74" height="20" font="4">emergencies </text>
<text top="660" left="375" width="122" height="20" font="3"><b>Inclusion criteria</b>: All </text>
<text top="677" left="375" width="143" height="20" font="4">emergency admissions to </text>
<text top="694" left="375" width="132" height="20" font="4">1 of 5 centers for adults </text>
<text top="712" left="375" width="113" height="20" font="4">with CHD within 1 y  </text>
<text top="660" left="535" width="84" height="20" font="4">Cause-specific </text>
<text top="677" left="535" width="65" height="20" font="4">admissions </text>
<text top="660" left="661" width="214" height="20" font="4">● 46 pts underwent surgery (CV n=41, </text>
<text top="677" left="661" width="209" height="20" font="4">general n=5) or EP treatment (n=41).  </text>
<text top="694" left="661" width="233" height="20" font="4">● 126 of 201 emergencies (63%) required </text>
<text top="712" left="661" width="202" height="20" font="4">cooperation with another specialized </text>
<text top="729" left="661" width="200" height="20" font="4">department: surgery (n=46), internal </text>
<text top="746" left="661" width="196" height="20" font="4">medicine (n=42), neurology (n=12), </text>
<text top="763" left="661" width="230" height="20" font="4">ophthalmology (n=6), otorhinolaryngology </text>
<text top="781" left="661" width="232" height="20" font="4">(n=5), gynecology (n=5), psychiatry (n=4), </text>
<text top="660" left="906" width="165" height="20" font="4">● Consultants attending adult </text>
<text top="677" left="906" width="151" height="20" font="4">pts with ACHD need a high </text>
<text top="694" left="906" width="120" height="20" font="4">degree of specialized </text>
<text top="712" left="906" width="125" height="20" font="4">experience to manage </text>
<text top="729" left="906" width="154" height="20" font="4">emergencies properly. Data </text>
<text top="746" left="906" width="141" height="20" font="4">support the demand for a </text>
<text top="763" left="906" width="158" height="20" font="4">multidisciplinary approach in </text>
<text top="781" left="906" width="115" height="20" font="4">specialized centers.  </text>
</page>
<page number="57" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="12" size="12" family="Times" color="#303030"/>
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 57 </text>
<text top="107" left="661" width="220" height="20" font="4">radiology (n=3), dermatology (n=2), and </text>
<text top="124" left="661" width="106" height="20" font="4">orthopedics (n=2).  </text>
<text top="142" left="64" width="76" height="20" font="4">Niwa K, et al. </text>
<text top="159" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(206)</a> </text>
<text top="177" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15262035?dopt=Citation">15262035</a></text>
<text top="177" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15262035?dopt=Citation"> </a></text>
<text top="142" left="170" width="45" height="20" font="4">Survey  </text>
<text top="142" left="263" width="42" height="20" font="4">Written </text>
<text top="159" left="263" width="77" height="20" font="4">questionnaire </text>
<text top="177" left="263" width="98" height="20" font="4">sent to 6 facilities </text>
<text top="194" left="263" width="95" height="20" font="4">in North America </text>
<text top="211" left="263" width="70" height="20" font="4">and Europe. </text>
<text top="142" left="375" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="142" left="535" width="69" height="20" font="4">Admissions, </text>
<text top="159" left="535" width="95" height="20" font="4">surgeries, facility </text>
<text top="177" left="535" width="72" height="20" font="4">and provider </text>
<text top="194" left="535" width="82" height="20" font="4">characteristics </text>
<text top="142" left="661" width="222" height="20" font="4">● Hospital admissions ranged from 100–</text>
<text top="159" left="661" width="203" height="20" font="4">660 pts/unit/y. Of the total number of </text>
<text top="177" left="661" width="227" height="20" font="4">registered pts, 52%–81% had undergone </text>
<text top="194" left="661" width="172" height="20" font="4">1 or more reparative surgeries. </text>
<text top="211" left="661" width="222" height="20" font="4">Reoperations constituted 25–80% of the </text>
<text top="228" left="661" width="218" height="20" font="4">50–170 operations/unit/y. Overall mean </text>
<text top="246" left="661" width="169" height="20" font="4">surgical mortality was 1.9%/y.  </text>
<text top="142" left="906" width="146" height="20" font="4">● Comprehensive care by </text>
<text top="159" left="906" width="127" height="20" font="4">multidisciplinary teams </text>
<text top="177" left="906" width="156" height="20" font="4">including adult and pediatric </text>
<text top="194" left="906" width="176" height="20" font="4">cardiologists, cardiac surgeons, </text>
<text top="211" left="906" width="163" height="20" font="4">specialized nurses, and other </text>
<text top="228" left="906" width="131" height="20" font="4">cardiac and noncardiac </text>
<text top="246" left="906" width="157" height="20" font="4">consultants was the unifying </text>
<text top="263" left="906" width="154" height="20" font="4">feature for all 6 tertiary care </text>
<text top="280" left="906" width="54" height="20" font="4">facilities.  </text>
<text top="298" left="64" width="81" height="20" font="4">Mott AR, et al. </text>
<text top="315" left="64" width="63" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(207)</a> </text>
<text top="332" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12530496?dopt=Citation">12530496</a></text>
<text top="332" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12530496?dopt=Citation"> </a></text>
<text top="298" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="315" left="170" width="53" height="20" font="4">review of </text>
<text top="332" left="170" width="74" height="20" font="4">single-center </text>
<text top="350" left="170" width="64" height="20" font="4">experience </text>
<text top="298" left="263" width="99" height="20" font="4">n=112 operations </text>
<text top="315" left="263" width="64" height="20" font="4">(81 cardiac </text>
<text top="332" left="263" width="91" height="20" font="4">operations in 79 </text>
<text top="350" left="263" width="61" height="20" font="4">pts and 31 </text>
<text top="367" left="263" width="64" height="20" font="4">noncardiac </text>
<text top="384" left="263" width="91" height="20" font="4">operations in 23 </text>
<text top="401" left="263" width="24" height="20" font="4">pts) </text>
<text top="298" left="375" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="315" left="375" width="85" height="20" font="4">≥18 y who had </text>
<text top="332" left="375" width="142" height="20" font="4">undergone cardiothoracic </text>
<text top="350" left="375" width="111" height="20" font="4">operations at Texas </text>
<text top="367" left="375" width="106" height="20" font="4">Children’s Hospital </text>
<text top="384" left="375" width="139" height="20" font="4">between July 1995–June </text>
<text top="401" left="375" width="34" height="20" font="4">2000  </text>
<text top="298" left="535" width="57" height="20" font="4">Operative </text>
<text top="315" left="535" width="102" height="20" font="4">complications and </text>
<text top="332" left="535" width="34" height="20" font="4">death </text>
<text top="298" left="661" width="211" height="20" font="4">● The overall early operative mortality </text>
<text top="315" left="661" width="192" height="20" font="4">was 6% (6/101). There were 3 late </text>
<text top="332" left="661" width="217" height="20" font="4">deaths. New-onset cardiac arrhythmias </text>
<text top="350" left="661" width="225" height="20" font="4">requiring treatment were diagnosed after </text>
<text top="367" left="661" width="168" height="20" font="4">5/81 (6%) cardiac operations.  </text>
<text top="298" left="906" width="176" height="20" font="4">● Agreeable mortality rates can </text>
<text top="315" left="906" width="127" height="20" font="4">be attained in adult pts </text>
<text top="332" left="906" width="166" height="20" font="4">undergoing cardiac surgery at </text>
<text top="350" left="906" width="91" height="20" font="4">pediatric facility. </text>
<text top="419" left="64" width="86" height="20" font="4">Maxwell BG, et </text>
<text top="436" left="64" width="16" height="20" font="4">al. </text>
<text top="454" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(208)</a> </text>
<text top="471" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25247694?dopt=Citation">25247694</a></text>
<text top="471" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25247694?dopt=Citation"> </a></text>
<text top="419" left="170" width="80" height="20" font="4">Review of site </text>
<text top="436" left="170" width="58" height="20" font="4">of surgery </text>
<text top="454" left="170" width="72" height="20" font="4">(CHD center </text>
<text top="471" left="170" width="77" height="20" font="4">or not) for pts </text>
<text top="488" left="170" width="55" height="20" font="4">with CHD </text>
<text top="505" left="170" width="49" height="20" font="4">from the </text>
<text top="522" left="170" width="55" height="20" font="4">California </text>
<text top="540" left="170" width="65" height="20" font="4">Ambulatory </text>
<text top="557" left="170" width="46" height="20" font="4">Surgery </text>
<text top="574" left="170" width="56" height="20" font="4">Database </text>
<text top="591" left="170" width="65" height="20" font="4">2005–2011 </text>
<text top="419" left="263" width="55" height="20" font="4">n=10,547 </text>
<text top="436" left="263" width="74" height="20" font="4">operations in </text>
<text top="454" left="263" width="94" height="20" font="4">adults; 11,254 in </text>
<text top="471" left="263" width="70" height="20" font="4">pediatric pts </text>
<text top="419" left="375" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="436" left="375" width="146" height="20" font="4">that had surgery at a CHD </text>
<text top="454" left="375" width="124" height="20" font="4">center or nonspecialty </text>
<text top="471" left="375" width="38" height="20" font="4">center </text>
<text top="419" left="535" width="104" height="20" font="4">Proportion of adult </text>
<text top="436" left="535" width="94" height="20" font="4">and pediatric pts </text>
<text top="454" left="535" width="105" height="20" font="4">with CHD who had </text>
<text top="471" left="535" width="98" height="20" font="4">surgery at a CHD </text>
<text top="488" left="535" width="110" height="20" font="4">center, analyzed by </text>
<text top="505" left="535" width="83" height="20" font="4">distance to the </text>
<text top="522" left="535" width="112" height="20" font="4">CHD center and the </text>
<text top="540" left="535" width="95" height="20" font="4">center where the </text>
<text top="557" left="535" width="70" height="20" font="4">surgery was </text>
<text top="574" left="535" width="59" height="20" font="4">performed </text>
<text top="419" left="661" width="12" height="20" font="12">● </text>
<text top="419" left="673" width="201" height="20" font="4">Only 2,741 (26.0%) adults with CHD </text>
<text top="436" left="661" width="231" height="20" font="4">had surgery in a CHD center compared to </text>
<text top="454" left="661" width="197" height="20" font="4">6,403 (56.9%) children (p&lt;0.0001).  </text>
<text top="471" left="661" width="212" height="20" font="4">● Adult CHD pts who had surgery at a </text>
<text top="488" left="661" width="212" height="20" font="4">nonspecialty center (11.9 ± 15.4 miles </text>
<text top="505" left="661" width="227" height="20" font="4">away) lived farther from the nearest CHD </text>
<text top="522" left="661" width="232" height="20" font="4">center (37.9 ± 43.0 miles) than adult CHD </text>
<text top="540" left="661" width="206" height="20" font="4">pts who had surgery at a CHD center </text>
<text top="557" left="661" width="165" height="20" font="4">(23.2±28.4 miles; p&lt;0.0001).  </text>
<text top="574" left="661" width="232" height="20" font="4">● Pediatric CHD pts who had surgery at a </text>
<text top="591" left="661" width="212" height="20" font="4">nonspecialty center (18.0 ± 20.7 miles </text>
<text top="608" left="661" width="227" height="20" font="4">away) lived farther from the nearest CHD </text>
<text top="626" left="661" width="222" height="20" font="4">center (35.7 ± 45.2 miles) than pediatric </text>
<text top="643" left="661" width="198" height="20" font="4">CHD pts who had surgery at a CHD </text>
<text top="660" left="661" width="206" height="20" font="4">center (22.4 ± 26.0 miles; p&lt;0.0001). </text>
<text top="419" left="906" width="155" height="20" font="4">● Unlike children with CHD, </text>
<text top="436" left="906" width="175" height="20" font="4">most adults with CHD (74%) do </text>
<text top="454" left="906" width="150" height="20" font="4">not have outpt surgery at a </text>
<text top="471" left="906" width="71" height="20" font="4">CHD center. </text>
<text top="488" left="906" width="168" height="20" font="4">● For both adults and children </text>
<text top="505" left="906" width="150" height="20" font="4">with CHD, greater distance </text>
<text top="522" left="906" width="118" height="20" font="4">from a CHD center is </text>
<text top="540" left="906" width="172" height="20" font="4">associated with having surgery </text>
<text top="557" left="906" width="133" height="20" font="4">at a nonspecialty center.</text>
<text top="557" left="1040" width="3" height="20" font="12"> </text>
<text top="557" left="1043" width="3" height="20" font="4"> </text>
<text top="678" left="64" width="89" height="20" font="4">Mylotte D, et al. </text>
<text top="695" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(209)</a> </text>
<text top="712" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24485223">24485223</a></text>
<text top="712" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24485223"> </a></text>
<text top="678" left="170" width="151" height="20" font="4">Meta-analysis  n=718 pts </text>
<text top="678" left="375" width="143" height="20" font="3"><b>Inclusion criteria</b>: Adults </text>
<text top="695" left="375" width="115" height="20" font="4">who underwent ASD </text>
<text top="712" left="375" width="130" height="20" font="4">closure in Quebec from </text>
<text top="730" left="375" width="74" height="20" font="4">1998―2005. </text>
<text top="678" left="535" width="86" height="20" font="4">Long-term cost </text>
<text top="695" left="535" width="75" height="20" font="4">effectiveness </text>
<text top="678" left="661" width="9" height="20" font="12">●</text>
<text top="678" left="670" width="3" height="20" font="4"> </text>
<text top="678" left="673" width="199" height="20" font="12">The 5-y cost of surgical closure was </text>
<text top="695" left="661" width="220" height="20" font="12">$15,304 ± $4,581 vs. $11,060 ± $5,169 </text>
<text top="712" left="661" width="181" height="20" font="12">for the transcatheter alternative.  </text>
<text top="730" left="661" width="194" height="20" font="12">● At 5 y, transcatheter closure was </text>
<text top="747" left="661" width="212" height="20" font="12">marginally more effective than surgery </text>
<text top="764" left="661" width="213" height="20" font="12">(4.683 ± 0.379 life-y vs. 4.618 ± 0.638 </text>
<text top="781" left="661" width="40" height="20" font="12">life-y).  </text>
<text top="678" left="906" width="163" height="20" font="4">● Transcatheter ASD closure </text>
<text top="695" left="906" width="158" height="20" font="4">was a cost-effective strategy </text>
<text top="712" left="906" width="128" height="20" font="4">associated with slightly </text>
<text top="730" left="906" width="175" height="20" font="4">improved clinical outcomes and </text>
<text top="747" left="906" width="145" height="20" font="4">reduced costs vs. surgical </text>
<text top="764" left="906" width="133" height="20" font="4">closure at 5-y follow-up. </text>
</page>
<page number="58" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 58 </text>
<text top="107" left="661" width="191" height="20" font="12">● Probabilistic sensitivity analyses </text>
<text top="124" left="661" width="206" height="20" font="12">demonstrated that transcatheter ASD </text>
<text top="141" left="661" width="222" height="20" font="12">closure was a dominant strategy with an </text>
<text top="159" left="661" width="230" height="20" font="12">80% probability of cost savings and equal </text>
<text top="176" left="661" width="219" height="20" font="12">or greater efficacy compared to surgical </text>
<text top="193" left="661" width="59" height="20" font="12">treatment. </text>
<text top="211" left="108" width="3" height="20" font="4"> </text>
<text top="228" left="108" width="3" height="20" font="4"> </text>
<text top="245" left="108" width="344" height="24" font="1"><b>Data Supplement 19. Pregnancy – Section 3.13.1 </b></text>
<text top="267" left="71" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="284" left="72" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="267" left="191" width="38" height="20" font="3"><b>Study </b></text>
<text top="284" left="172" width="76" height="20" font="3"><b>Type/Design </b></text>
<text top="267" left="265" width="69" height="20" font="3"><b>Study Size, </b></text>
<text top="284" left="293" width="12" height="20" font="3"><b>N </b></text>
<text top="267" left="363" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="284" left="399" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="267" left="536" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="267" left="718" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="267" left="919" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="303" left="64" width="90" height="20" font="4">Chan WS, et al. </text>
<text top="320" left="64" width="63" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(210)</a> </text>
<text top="337" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10647757?dopt=Citation">10647757</a></text>
<text top="337" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10647757?dopt=Citation"> </a></text>
<text top="303" left="170" width="55" height="20" font="4">Literature </text>
<text top="320" left="170" width="39" height="20" font="4">review </text>
<text top="303" left="263" width="38" height="20" font="4">n=976 </text>
<text top="320" left="263" width="68" height="20" font="4">women with </text>
<text top="337" left="263" width="34" height="20" font="4">1,234 </text>
<text top="354" left="263" width="70" height="20" font="4">pregnancies </text>
<text top="303" left="349" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="320" left="349" width="121" height="20" font="4">Pregnant women with </text>
<text top="337" left="349" width="137" height="20" font="4">prosthetic heart valve on </text>
<text top="354" left="349" width="142" height="20" font="4">anticoagulation published </text>
<text top="372" left="349" width="111" height="20" font="4">in English language </text>
<text top="389" left="349" width="42" height="20" font="4">articles </text>
<text top="406" left="349" width="3" height="20" font="4"> </text>
<text top="423" left="349" width="141" height="20" font="3"><b>Exclusion criteria</b>: Case </text>
<text top="440" left="349" width="136" height="20" font="4">reports and if pregnancy </text>
<text top="458" left="349" width="108" height="20" font="4">was not followed to </text>
<text top="475" left="349" width="63" height="20" font="4">completion </text>
<text top="303" left="508" width="124" height="20" font="4">Maternal and fetal risk </text>
<text top="320" left="508" width="118" height="20" font="4">of anticoagulation for </text>
<text top="337" left="508" width="127" height="20" font="4">prosthetic heart valves </text>
<text top="303" left="649" width="188" height="20" font="4">● Oral anticoagulation throughout </text>
<text top="320" left="649" width="195" height="20" font="4">pregnancy associated with warfarin </text>
<text top="337" left="649" width="213" height="20" font="4">embryopathy in 6.4% of livebirths. The </text>
<text top="354" left="649" width="236" height="20" font="4">change of oral anticoagulants to heparin at </text>
<text top="372" left="649" width="202" height="20" font="4">or before 6 wk gestations until 12 wk </text>
<text top="389" left="649" width="221" height="20" font="4">eliminated risk of warfarin embryopathy. </text>
<text top="406" left="649" width="237" height="20" font="4">Risk of fetal or neonatal deaths was similar </text>
<text top="423" left="649" width="230" height="20" font="4">in women treated with oral anticoagulants </text>
<text top="440" left="649" width="235" height="20" font="4">throughout pregnancy and in those treated </text>
<text top="458" left="649" width="233" height="20" font="4">with heparin in first trimester. The regimen </text>
<text top="475" left="649" width="194" height="20" font="4">associated with lowest risk of valve </text>
<text top="492" left="649" width="232" height="20" font="4">thrombosis was use of oral anticoagulants </text>
<text top="509" left="649" width="224" height="20" font="4">throughout pregnancy and using heparin </text>
<text top="527" left="649" width="198" height="20" font="4">between 6 and 12 wk gestation was </text>
<text top="544" left="649" width="230" height="20" font="4">associated with an increased risk of valve </text>
<text top="561" left="649" width="107" height="20" font="4">thrombosis (9.2%). </text>
<text top="303" left="901" width="165" height="20" font="4">● Anticoagulation in pregnant </text>
<text top="320" left="901" width="165" height="20" font="4">women with mechanical heart </text>
<text top="337" left="901" width="155" height="20" font="4">valves is best achieved with </text>
<text top="354" left="901" width="114" height="20" font="4">oral anticoagulants.  </text>
<text top="371" left="901" width="156" height="20" font="4">● The associated increased </text>
<text top="389" left="901" width="158" height="20" font="4">the risk of fetal embryopathy </text>
<text top="406" left="901" width="108" height="20" font="4">may be reduced by </text>
<text top="423" left="901" width="89" height="20" font="4">substituting oral </text>
<text top="440" left="901" width="152" height="20" font="4">anticoagulants with heparin </text>
<text top="458" left="901" width="156" height="20" font="4">between 6–12 wk gestation. </text>
<text top="579" left="64" width="77" height="20" font="4">Pieper PG, et </text>
<text top="596" left="64" width="16" height="20" font="4">al. </text>
<text top="613" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(211)</a> </text>
<text top="631" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24192800?dopt=Citation">24192800</a></text>
<text top="631" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24192800?dopt=Citation"> </a></text>
<text top="579" left="170" width="71" height="20" font="4">Prospective, </text>
<text top="596" left="170" width="64" height="20" font="4">multicenter </text>
<text top="613" left="170" width="38" height="20" font="4">cohort </text>
<text top="579" left="263" width="68" height="20" font="4">n=209 CHD </text>
<text top="596" left="263" width="40" height="20" font="4">pts, 70 </text>
<text top="613" left="263" width="43" height="20" font="4">healthy </text>
<text top="631" left="263" width="46" height="20" font="4">controls </text>
<text top="579" left="349" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="596" left="349" width="123" height="20" font="4">Female pts with CHD, </text>
<text top="613" left="349" width="142" height="20" font="4">≥18 y, pregnancy &lt;20 wk </text>
<text top="631" left="349" width="53" height="20" font="4">gestation </text>
<text top="648" left="349" width="3" height="20" font="4"> </text>
<text top="665" left="349" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="682" left="349" width="76" height="20" font="4">Miscarriages, </text>
<text top="699" left="349" width="126" height="20" font="4">terminations, and drug </text>
<text top="717" left="349" width="23" height="20" font="4">use </text>
<text top="579" left="508" width="83" height="20" font="4">Uteroplacental </text>
<text top="596" left="508" width="72" height="20" font="4">Doppler flow </text>
<text top="613" left="508" width="66" height="20" font="4">parameters </text>
<text top="579" left="649" width="233" height="20" font="4">● Uteroplacental Doppler flow parameters </text>
<text top="596" left="649" width="229" height="20" font="4">were impaired in CHD women at 32 wk in </text>
<text top="613" left="649" width="135" height="20" font="4">CHD vs. healthy women </text>
<text top="631" left="649" width="218" height="20" font="4">● Multivariable analysis: 1) RV function </text>
<text top="648" left="649" width="239" height="20" font="4">(tricuspid annular plane systolic excursion), </text>
<text top="665" left="649" width="219" height="20" font="4">2) high NT-proBNP, 3) systemic, and 4) </text>
<text top="682" left="649" width="188" height="20" font="4">pulmonary AV valve regurgitation. </text>
<text top="579" left="901" width="154" height="20" font="4">● CV function is associated </text>
<text top="596" left="901" width="152" height="20" font="4">with an abnormal pattern of </text>
<text top="613" left="901" width="158" height="20" font="4">Uteroplacental Doppler flow. </text>
<text top="734" left="64" width="89" height="20" font="4">Roos-Hesselink </text>
<text top="752" left="64" width="55" height="20" font="4">JW, et al. </text>
<text top="769" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(212)</a> </text>
<text top="786" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22968232?dopt=Citation">22968232</a></text>
<text top="786" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22968232?dopt=Citation"> </a></text>
<text top="734" left="170" width="76" height="20" font="4">Registry data </text>
<text top="752" left="170" width="69" height="20" font="4">60 hospitals </text>
<text top="769" left="170" width="30" height="20" font="4">in 28 </text>
<text top="786" left="170" width="53" height="20" font="4">countries </text>
<text top="734" left="263" width="192" height="20" font="4">n=1,321 pts  <b>Inclusion criteria</b>: </text>
<text top="752" left="349" width="121" height="20" font="4">Pregnant women with </text>
<text top="769" left="349" width="130" height="20" font="4">CHD (66%), VHD 25%, </text>
<text top="786" left="349" width="124" height="20" font="4">cardiac myopathy 7%, </text>
<text top="734" left="508" width="126" height="20" font="4">Pregnancy outcome in </text>
<text top="752" left="508" width="113" height="20" font="4">pts with structural or </text>
<text top="769" left="508" width="72" height="20" font="4">ischemic HD </text>
<text top="734" left="649" width="236" height="20" font="4">● 338 pts (26%) were hospitalized, 133 for </text>
<text top="752" left="649" width="27" height="20" font="4">HF.  </text>
<text top="769" left="649" width="216" height="20" font="4">● Caesarean section was performed in </text>
<text top="786" left="649" width="35" height="20" font="4">41%.  </text>
<text top="734" left="901" width="166" height="20" font="4">● The vast majority of pts can </text>
<text top="752" left="901" width="159" height="20" font="4">go safely through pregnancy </text>
<text top="769" left="901" width="129" height="20" font="4">and delivery as long as </text>
<text top="786" left="901" width="133" height="20" font="4">adequate prepregnancy </text>
</page>
<page number="59" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 59 </text>
<text top="107" left="349" width="134" height="20" font="4">and ischemic HD in 2%. </text>
<text top="124" left="349" width="86" height="20" font="4">2007 and 2011 </text>
<text top="107" left="649" width="234" height="20" font="4">● Maternal death 1%, fetal mortality 1.7%, </text>
<text top="124" left="649" width="172" height="20" font="4">and neonatal mortality in 0.6%. </text>
<text top="107" left="901" width="148" height="20" font="4">evaluation and specialized </text>
<text top="124" left="901" width="131" height="20" font="4">high-quality care during </text>
<text top="141" left="901" width="152" height="20" font="4">pregnancy and delivery are </text>
<text top="159" left="901" width="55" height="20" font="4">available. </text>
<text top="177" left="64" width="66" height="20" font="4">Liu H, et al. </text>
<text top="194" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(213)</a> </text>
<text top="211" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23245675?dopt=Citation">23245675</a></text>
<text top="211" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23245675?dopt=Citation"> </a></text>
<text top="177" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="194" left="170" width="77" height="20" font="4">observational </text>
<text top="177" left="263" width="58" height="20" font="4">n=529 pts </text>
<text top="177" left="349" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="194" left="349" width="139" height="20" font="4">Pregnant female pts with </text>
<text top="211" left="349" width="127" height="20" font="4">CHD who gave birth at </text>
<text top="228" left="349" width="138" height="20" font="4">the Shanghai Obstetrical </text>
<text top="246" left="349" width="145" height="20" font="4">Cardiology Intensive Care </text>
<text top="263" left="349" width="141" height="20" font="4">Center, Shanghai, China, </text>
<text top="280" left="349" width="115" height="20" font="4">between 1993–2010 </text>
<text top="177" left="508" width="109" height="20" font="4">Maternal, fetal, and </text>
<text top="194" left="508" width="51" height="20" font="4">neonatal </text>
<text top="211" left="508" width="78" height="20" font="4">complications </text>
<text top="177" left="649" width="215" height="20" font="4">● Maternal cardiac complications were </text>
<text top="194" left="649" width="226" height="20" font="4">reported in 33 (6.2%) of the women; fetal </text>
<text top="211" left="649" width="232" height="20" font="4">and neonatal complications were reported </text>
<text top="228" left="649" width="90" height="20" font="4">in 145 (27.4%).  </text>
<text top="245" left="649" width="238" height="20" font="4">● Significant predictive factors for maternal </text>
<text top="263" left="649" width="234" height="20" font="4">cardiac complications were cardiac events </text>
<text top="280" left="649" width="230" height="20" font="4">before pregnancy, NYHA FC greater than </text>
<text top="297" left="649" width="23" height="20" font="4">II, O</text>
<text top="303" left="672" width="4" height="13" font="6">2</text>
<text top="297" left="677" width="170" height="20" font="4"> saturation below 90%, and LV </text>
<text top="314" left="649" width="161" height="20" font="4">Obstruction (aorta stenosis).  </text>
<text top="332" left="649" width="224" height="20" font="4">● Factors significantly predictive for fetal </text>
<text top="349" left="649" width="220" height="20" font="4">and neonatal complications were NYHA </text>
<text top="366" left="649" width="50" height="20" font="4">FC &gt;2, O</text>
<text top="372" left="699" width="4" height="13" font="6">2</text>
<text top="366" left="704" width="152" height="20" font="4"> saturation &lt;90%, and PAH </text>
<text top="383" left="649" width="175" height="20" font="4">(systolic pressure ≥50 mm Hg). </text>
<text top="177" left="901" width="153" height="20" font="4">● Identification of maternal, </text>
<text top="194" left="901" width="105" height="20" font="4">fetal, and neonatal </text>
<text top="211" left="901" width="162" height="20" font="4">complications among women </text>
<text top="228" left="901" width="161" height="20" font="4">with CHD may guide medical </text>
<text top="246" left="901" width="144" height="20" font="4">intervention and therefore </text>
<text top="263" left="901" width="165" height="20" font="4">reduce pregnancy-associated </text>
<text top="280" left="901" width="97" height="20" font="4">risk for these pts. </text>
<text top="401" left="64" width="46" height="20" font="4">Wacker-</text>
<text top="418" left="64" width="91" height="20" font="4">Gussmann A, et </text>
<text top="436" left="64" width="16" height="20" font="4">al. </text>
<text top="453" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(214)</a> </text>
<text top="470" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23179135?dopt=Citation">23179135</a></text>
<text top="470" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23179135?dopt=Citation"> </a></text>
<text top="401" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="418" left="170" width="77" height="20" font="4">observational </text>
<text top="401" left="263" width="58" height="20" font="4">n=267 pts </text>
<text top="401" left="349" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="418" left="349" width="121" height="20" font="4">Pregnant women with </text>
<text top="436" left="349" width="130" height="20" font="4">CHD who were seen at </text>
<text top="453" left="349" width="142" height="20" font="4">the German Heart Centre </text>
<text top="470" left="349" width="38" height="20" font="4">Berlin. </text>
<text top="401" left="508" width="93" height="20" font="4">FC, health, work </text>
<text top="418" left="508" width="82" height="20" font="4">capability, and </text>
<text top="436" left="508" width="89" height="20" font="4">physical activity </text>
<text top="401" left="649" width="233" height="20" font="4">● The maternal cardiac data revealed that </text>
<text top="418" left="649" width="215" height="20" font="4">30% of the pts lost at least 1 FC during </text>
<text top="436" left="649" width="232" height="20" font="4">pregnancy. Onset arrhythmias (12%). The </text>
<text top="453" left="649" width="232" height="20" font="4">most prevalent neonatal complication was </text>
<text top="470" left="649" width="127" height="20" font="4">premature birth (12%). </text>
<text top="401" left="901" width="138" height="20" font="4">● 2/3 of the pts tolerated </text>
<text top="418" left="901" width="124" height="20" font="4">pregnancy without CV </text>
<text top="436" left="901" width="131" height="20" font="4">complications. Most pts </text>
<text top="453" left="901" width="141" height="20" font="4">displayed good long-term </text>
<text top="470" left="901" width="152" height="20" font="4">health, work capability, and </text>
<text top="487" left="901" width="149" height="20" font="4">physical activity outcomes. </text>
<text top="505" left="64" width="88" height="20" font="4">Ohuchi H, et al. </text>
<text top="522" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(215)</a> </text>
<text top="540" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23059769?dopt=Citation">23059769</a></text>
<text top="540" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23059769?dopt=Citation"> </a></text>
<text top="505" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="522" left="170" width="77" height="20" font="4">observational </text>
<text top="505" left="263" width="51" height="20" font="4">n=33 pts </text>
<text top="505" left="349" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="522" left="349" width="121" height="20" font="4">Pregnant women with </text>
<text top="540" left="349" width="142" height="20" font="4">CHD who had undergone </text>
<text top="557" left="349" width="137" height="20" font="4">CPET 1.8 ± 2.2 y before </text>
<text top="574" left="349" width="46" height="20" font="4">delivery </text>
<text top="505" left="508" width="99" height="20" font="4">Exercise capacity </text>
<text top="505" left="649" width="228" height="20" font="4">● Maternal, cardiac, and neonatal events </text>
<text top="522" left="649" width="212" height="20" font="4">occurred in 8 (24%), 12 (36%), and 14 </text>
<text top="540" left="649" width="115" height="20" font="4">(42%), respectively.  </text>
<text top="557" left="649" width="215" height="20" font="4">● All CPET parameters correlated with </text>
<text top="574" left="649" width="211" height="20" font="4">neonatal birth weight (p&lt;0.05–0.001).  </text>
<text top="591" left="649" width="213" height="20" font="4">● Exercise time, peak heart rate, peak </text>
<text top="608" left="649" width="131" height="20" font="4">systolic BP, and peak O</text>
<text top="615" left="780" width="4" height="13" font="6">2</text>
<text top="608" left="784" width="62" height="20" font="4"> uptake VO</text>
<text top="615" left="846" width="4" height="13" font="6">2</text>
<text top="608" left="850" width="33" height="20" font="4"> were </text>
<text top="626" left="649" width="219" height="20" font="4">associated with cardiac events (p&lt;0.05–</text>
<text top="643" left="649" width="206" height="20" font="4">0.01), and exercise time and peak VO</text>
<text top="649" left="855" width="4" height="13" font="6">2</text>
<text top="643" left="860" width="3" height="20" font="4"> </text>
<text top="660" left="649" width="234" height="20" font="4">were also associated with neonatal events </text>
<text top="677" left="649" width="223" height="20" font="4">(p&lt;0.05). Exercise time, peak heart rate, </text>
<text top="694" left="649" width="72" height="20" font="4">and peak VO</text>
<text top="701" left="721" width="4" height="13" font="6">2</text>
<text top="694" left="725" width="135" height="20" font="4"> were associated with at </text>
<text top="712" left="649" width="208" height="20" font="4">least 1 of the 3 events (p&lt;0.05–0.01). </text>
<text top="505" left="901" width="155" height="20" font="4">● CPET parameters predict </text>
<text top="522" left="901" width="165" height="20" font="4">pregnancy outcome and peak </text>
<text top="540" left="901" width="145" height="20" font="4">heart rate ≥150 beats/min </text>
<text top="557" left="901" width="86" height="20" font="4">and/or peak VO</text>
<text top="563" left="987" width="7" height="13" font="6">2 </text>
<text top="557" left="994" width="25" height="20" font="4">≥25 </text>
<text top="574" left="901" width="159" height="20" font="4">mL/kg/min may be reference </text>
<text top="591" left="901" width="167" height="20" font="4">value(s) for a safer pregnancy </text>
<text top="608" left="901" width="165" height="20" font="4">outcome in women with CHD. </text>
<text top="730" left="64" width="88" height="20" font="4">Opotowsky AR, </text>
<text top="747" left="64" width="30" height="20" font="4">et al. </text>
<text top="764" left="64" width="49" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(5)</a> </text>
<text top="781" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21990383?dopt=Citation">21990383</a></text>
<text top="781" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21990383?dopt=Citation"> </a></text>
<text top="730" left="170" width="56" height="20" font="4">Database </text>
<text top="747" left="170" width="39" height="20" font="4">review </text>
<text top="730" left="263" width="62" height="20" font="4">n=622,000 </text>
<text top="747" left="263" width="20" height="20" font="4">pts </text>
<text top="730" left="349" width="139" height="20" font="3"><b>Inclusion criteria</b>: 1998–</text>
<text top="747" left="349" width="145" height="20" font="4">2007 Nationwide Inpatient </text>
<text top="764" left="349" width="45" height="20" font="4">Sample </text>
<text top="730" left="508" width="124" height="20" font="4">Combined: death, HF, </text>
<text top="747" left="508" width="97" height="20" font="4">arrhythmia, CVA, </text>
<text top="764" left="508" width="89" height="20" font="4">embolic events, </text>
<text top="730" left="649" width="226" height="20" font="4">● Annual deliveries for women with CHD </text>
<text top="747" left="649" width="188" height="20" font="4">increased 34.9% from 1998–2007 </text>
<text top="764" left="649" width="236" height="20" font="4">compared with an increase of 21.3% in the </text>
<text top="781" left="649" width="111" height="20" font="4">general population.  </text>
<text top="730" left="901" width="168" height="20" font="4">● Maternal CHD is associated </text>
<text top="747" left="901" width="168" height="20" font="4">with a markedly increased risk </text>
<text top="764" left="901" width="145" height="20" font="4">of adverse CV events and </text>
</page>
<page number="60" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 60 </text>
<text top="107" left="508" width="92" height="20" font="4">“unclassified CV </text>
<text top="124" left="508" width="111" height="20" font="4">events,” LOS, costs </text>
<text top="107" left="649" width="219" height="20" font="4">● Women with CHD were more likely to </text>
<text top="124" left="649" width="212" height="20" font="4">sustain a CV event (4,042/100,000 vs. </text>
<text top="141" left="649" width="213" height="20" font="4">278/100,000 deliveries, univariate OR: </text>
<text top="159" left="649" width="237" height="20" font="4">15.1; 95% CI: 13.1–17.4; multivariable OR: </text>
<text top="176" left="649" width="217" height="20" font="4">8.4; 95% CI: 7.0–10.0). Arrhythmia, the </text>
<text top="193" left="649" width="195" height="20" font="4">most common CV event, was more </text>
<text top="210" left="649" width="188" height="20" font="4">frequent among women with CHD </text>
<text top="228" left="649" width="234" height="20" font="4">(2637/100,000 vs. 210/100,000, univariate </text>
<text top="245" left="649" width="237" height="20" font="4">OR: 12.9; 95% CI: 10.9–15.3, multivariable </text>
<text top="262" left="649" width="159" height="20" font="4">OR: 8.3; 95% CI: 6.7–10.1).  </text>
<text top="279" left="649" width="230" height="20" font="4">● Death occurred in 150/100,000 pts with </text>
<text top="296" left="649" width="202" height="20" font="4">CHD compared with 8.2/100,000 pts </text>
<text top="314" left="649" width="226" height="20" font="4">without CHD (multivariable OR: 6.7; 95% </text>
<text top="331" left="649" width="81" height="20" font="4">CI: 2.9–15.4).  </text>
<text top="348" left="649" width="207" height="20" font="4">● Complex CHD was associated with </text>
<text top="365" left="649" width="210" height="20" font="4">greater odds of having an adverse CV </text>
<text top="382" left="649" width="232" height="20" font="4">event than simple CHD (8158/100,000 vs. </text>
<text top="400" left="649" width="232" height="20" font="4">3166/100,000, multivariable OR: 2.0; 95% </text>
<text top="417" left="649" width="71" height="20" font="4">CI: 1.4–3.0). </text>
<text top="107" left="901" width="148" height="20" font="4">death during admission for </text>
<text top="124" left="901" width="49" height="20" font="4">delivery. </text>
<text top="435" left="64" width="92" height="20" font="4">Jastrow N, et al. </text>
<text top="452" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(216)</a> </text>
<text top="469" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20659773?dopt=Citation">20659773</a></text>
<text top="469" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20659773?dopt=Citation"> </a></text>
<text top="435" left="170" width="131" height="20" font="4">Retrospective  n=227 </text>
<text top="452" left="263" width="60" height="20" font="4">female pts </text>
<text top="469" left="263" width="68" height="20" font="4">with cardiac </text>
<text top="487" left="263" width="46" height="20" font="4">disease </text>
<text top="504" left="263" width="66" height="20" font="4">followed for </text>
<text top="521" left="263" width="24" height="20" font="4">312 </text>
<text top="538" left="263" width="70" height="20" font="4">pregnancies </text>
<text top="555" left="263" width="35" height="20" font="4">at our </text>
<text top="573" left="263" width="41" height="20" font="4">tertiary </text>
<text top="590" left="263" width="66" height="20" font="4">center from </text>
<text top="607" left="263" width="68" height="20" font="4">1992–2007. </text>
<text top="435" left="349" width="135" height="20" font="3"><b>Inclusion criteria</b>: CHD </text>
<text top="452" left="349" width="144" height="20" font="4">(81%) or acquired cardiac </text>
<text top="469" left="349" width="126" height="20" font="4">lesions followed at Ste-</text>
<text top="487" left="349" width="141" height="20" font="4">Justine Hospital Montreal </text>
<text top="504" left="349" width="116" height="20" font="4">July 1992–Dec 2007 </text>
<text top="521" left="349" width="3" height="20" font="4"> </text>
<text top="538" left="349" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="555" left="349" width="142" height="20" font="4">Miscarriage or pregnancy </text>
<text top="573" left="349" width="64" height="20" font="4">termination </text>
<text top="435" left="508" width="109" height="20" font="4">Cardiac, obstetrical </text>
<text top="452" left="508" width="75" height="20" font="4">and neonatal </text>
<text top="469" left="508" width="78" height="20" font="4">complications </text>
<text top="435" left="649" width="215" height="20" font="4">● CARPREG risk was low (score=0) in </text>
<text top="452" left="649" width="202" height="20" font="4">66.3% and intermediate (score=1) in </text>
<text top="469" left="649" width="116" height="20" font="4">33.7% pregnancies.  </text>
<text top="487" left="649" width="215" height="20" font="4">● Maternal cardiac events complicated </text>
<text top="504" left="649" width="233" height="20" font="4">7.4% pregnancies, with pulmonary edema </text>
<text top="521" left="649" width="203" height="20" font="4">occurring most frequently (3.8%). An </text>
<text top="538" left="649" width="228" height="20" font="4">intermediate score was associated with a </text>
<text top="555" left="649" width="220" height="20" font="4">higher rate of cardiac events (19.0% vs. </text>
<text top="573" left="649" width="193" height="20" font="4">1.4%; OR: 15.6; 95% CI: 4.5–54.4; </text>
<text top="590" left="649" width="63" height="20" font="4">p=0.0001). </text>
<text top="607" left="649" width="196" height="20" font="4">● AE occurred in 27.5% neonates.  </text>
<text top="624" left="649" width="217" height="20" font="4">● Preterm deliveries occurred in 16.7% </text>
<text top="641" left="649" width="223" height="20" font="4">pregnancies, more commonly in pts with </text>
<text top="659" left="649" width="235" height="20" font="4">intermediate scores (OR: 2.4; 95% CI: 1.2–</text>
<text top="676" left="649" width="76" height="20" font="4">4.6; p=0.01).  </text>
<text top="693" left="649" width="232" height="20" font="4">● The sensitivity and NPVs of a low score </text>
<text top="710" left="649" width="223" height="20" font="4">were respectively 87% and 99% for total </text>
<text top="727" left="649" width="203" height="20" font="4">cardiac events and both 100% for 1° </text>
<text top="745" left="649" width="199" height="20" font="4">cardiac events, including pulmonary </text>
<text top="762" left="649" width="186" height="20" font="4">edema and sustained arrhythmia. </text>
<text top="435" left="901" width="157" height="20" font="4">● The CARPREG risk index </text>
<text top="452" left="901" width="169" height="20" font="4">has a high sensitivity and NPV </text>
<text top="469" left="901" width="127" height="20" font="4">with regards to cardiac </text>
<text top="487" left="901" width="143" height="20" font="4">complications in pregnant </text>
<text top="504" left="901" width="93" height="20" font="4">women with HD. </text>
</page>
<page number="61" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 61 </text>
<text top="107" left="64" width="87" height="20" font="4">Ouyang DW, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(217)</a> </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19411123?dopt=Citation">19411123</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19411123?dopt=Citation"> </a></text>
<text top="107" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="124" left="170" width="38" height="20" font="4">cohort </text>
<text top="107" left="263" width="71" height="20" font="4">n=65 female </text>
<text top="124" left="263" width="45" height="20" font="4">pts with </text>
<text top="141" left="263" width="55" height="20" font="4">CHD with </text>
<text top="159" left="263" width="24" height="20" font="4">112 </text>
<text top="176" left="263" width="70" height="20" font="4">pregnancies </text>
<text top="107" left="349" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="124" left="349" width="125" height="20" font="4">with CHD delivering at </text>
<text top="141" left="349" width="127" height="20" font="4">Brigham and Women's </text>
<text top="159" left="349" width="121" height="20" font="4">Hospital between Jan </text>
<text top="176" left="349" width="90" height="20" font="4">1998–Dec 2005 </text>
<text top="193" left="349" width="3" height="20" font="4"> </text>
<text top="210" left="349" width="131" height="20" font="3"><b>Exclusion criteria</b>: Pts </text>
<text top="227" left="349" width="117" height="20" font="4">with acquired HD, 1° </text>
<text top="245" left="349" width="121" height="20" font="4">arrhythmia diagnoses </text>
<text top="262" left="349" width="102" height="20" font="4">without underlying </text>
<text top="279" left="349" width="130" height="20" font="4">congenital defects, and </text>
<text top="296" left="349" width="111" height="20" font="4">isolated mitral valve </text>
<text top="314" left="349" width="51" height="20" font="4">prolapse </text>
<text top="107" left="508" width="98" height="20" font="4">Adverse obstetric </text>
<text top="124" left="508" width="33" height="20" font="4">event </text>
<text top="107" left="649" width="226" height="20" font="4">● An adverse obstetric event occurred in </text>
<text top="124" left="649" width="212" height="20" font="4">32.6% (n=32) preterm delivery (n=19), </text>
<text top="141" left="649" width="201" height="20" font="4">postpartum hemorrhage (n=13), and </text>
<text top="159" left="649" width="230" height="20" font="4">preterm premature rupture of membranes </text>
<text top="176" left="649" width="203" height="20" font="4">(n=9). Pts who avoided Valsalva had </text>
<text top="193" left="649" width="236" height="20" font="4">increased rates of postpartum hemorrhage </text>
<text top="210" left="649" width="174" height="20" font="4">and 3rd/4th degree lacerations. </text>
<text top="107" left="901" width="147" height="20" font="4">● 1/3 of pregnancies were </text>
<text top="124" left="901" width="152" height="20" font="4">associated with an adverse </text>
<text top="141" left="901" width="164" height="20" font="4">obstetric outcome, but events </text>
<text top="159" left="901" width="141" height="20" font="4">could not be predicted by </text>
<text top="176" left="901" width="129" height="20" font="4">baseline hemodynamic </text>
<text top="193" left="901" width="89" height="20" font="4">characteristics.  </text>
<text top="210" left="901" width="138" height="20" font="4">● The routine practice of </text>
<text top="228" left="901" width="143" height="20" font="4">avoiding Valsalva may be </text>
<text top="245" left="901" width="158" height="20" font="4">associated with high rates of </text>
<text top="262" left="901" width="159" height="20" font="4">postpartum hemorrhage and </text>
<text top="279" left="901" width="7" height="20" font="4">3</text>
<text top="281" left="908" width="7" height="13" font="6">rd</text>
<text top="279" left="915" width="10" height="20" font="4">/4</text>
<text top="281" left="925" width="7" height="13" font="6">th</text>
<text top="279" left="932" width="111" height="20" font="4"> degree lacerations. </text>
<text top="332" left="64" width="75" height="20" font="4">Lui GK, et al. </text>
<text top="349" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(218)</a> </text>
<text top="366" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21220738?dopt=Citation">21220738</a></text>
<text top="366" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21220738?dopt=Citation"> </a></text>
<text top="332" left="170" width="67" height="20" font="4">Multicenter, </text>
<text top="349" left="170" width="74" height="20" font="4">retrospective </text>
<text top="366" left="170" width="77" height="20" font="4">observational </text>
<text top="332" left="263" width="51" height="20" font="4">n=83 pts </text>
<text top="349" left="263" width="42" height="20" font="4">with 89 </text>
<text top="366" left="263" width="70" height="20" font="4">pregnancies </text>
<text top="332" left="349" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="349" left="349" width="127" height="20" font="4">Women with CHD who </text>
<text top="366" left="349" width="140" height="20" font="4">were pregnant Jan 1997–</text>
<text top="383" left="349" width="120" height="20" font="4">Dec 2008. Must have </text>
<text top="400" left="349" width="141" height="20" font="4">completed CPET within 2 </text>
<text top="418" left="349" width="127" height="20" font="4">y prior to pregnancy or </text>
<text top="435" left="349" width="130" height="20" font="4">within the first trimester </text>
<text top="452" left="349" width="3" height="20" font="4"> </text>
<text top="469" left="349" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="487" left="349" width="118" height="20" font="4">History of permanent </text>
<text top="504" left="349" width="64" height="20" font="4">pacemaker </text>
<text top="332" left="508" width="89" height="20" font="4">CPET variables </text>
<text top="349" left="508" width="89" height="20" font="4">included peak O</text>
<text top="355" left="597" width="4" height="13" font="6">2</text>
<text top="349" left="602" width="3" height="20" font="4"> </text>
<text top="366" left="508" width="97" height="20" font="4">consumption and </text>
<text top="383" left="508" width="71" height="20" font="4">measures of </text>
<text top="400" left="508" width="71" height="20" font="4">chronotropic </text>
<text top="418" left="508" width="119" height="20" font="4">response: peak heart </text>
<text top="435" left="508" width="107" height="20" font="4">rate, percentage of </text>
<text top="452" left="508" width="81" height="20" font="4">maximum age </text>
<text top="469" left="508" width="114" height="20" font="4">predicted heart rate, </text>
<text top="487" left="508" width="101" height="20" font="4">heart rate reserve </text>
<text top="504" left="508" width="91" height="20" font="4">(peak heart rate-</text>
<text top="521" left="508" width="128" height="20" font="4">resting heart rate), and </text>
<text top="538" left="508" width="104" height="20" font="4">chronotropic index </text>
<text top="555" left="508" width="105" height="20" font="4">([heart rate-resting </text>
<text top="573" left="508" width="116" height="20" font="4">heart rate]/ [220-age-</text>
<text top="590" left="508" width="107" height="20" font="4">resting heart rate]). </text>
<text top="332" left="649" width="198" height="20" font="4">● 1 or more adverse cardiac events </text>
<text top="349" left="649" width="184" height="20" font="4">occurred in 18%; HF in 14%, and </text>
<text top="366" left="649" width="218" height="20" font="4">sustained arrhythmia in 7%. Peak heart </text>
<text top="383" left="649" width="187" height="20" font="4">rate, percentage of maximum age </text>
<text top="400" left="649" width="224" height="20" font="4">predicted heart rate (OR: 0.93; 95% CIL: </text>
<text top="418" left="649" width="238" height="20" font="4">0.88, 0.98; p=0.01), and chronotropic index </text>
<text top="435" left="649" width="214" height="20" font="4">(OR: 0.65; 95% CI: 0.47, 0.90; p=0.01) </text>
<text top="452" left="649" width="211" height="20" font="4">were associated with a cardiac event.  </text>
<text top="469" left="649" width="232" height="20" font="4">● Neonatal events occurred in 20%. Peak </text>
<text top="487" left="649" width="225" height="20" font="4">heart rate (OR: 0.75; 95% CI: 0.58, 0.98; </text>
<text top="504" left="649" width="208" height="20" font="4">p=0.04), percentage of maximum age </text>
<text top="521" left="649" width="217" height="20" font="4">predicted heart rate (OR: 0.94; 95% CI: </text>
<text top="538" left="649" width="211" height="20" font="4">0.89, 0.99; p=0.02), heart rate reserve </text>
<text top="555" left="649" width="235" height="20" font="4">(OR: 0.8; 95% CI: 0.64, 0.99; p=0.04), and </text>
<text top="573" left="649" width="211" height="20" font="4">chronotropic index (OR: 0.73; 95% CI: </text>
<text top="590" left="649" width="201" height="20" font="4">0.54, 0.98; p=0.04) correlated with a </text>
<text top="607" left="649" width="91" height="20" font="4">neonatal event.  </text>
<text top="624" left="649" width="53" height="20" font="4">● Peak O</text>
<text top="630" left="702" width="4" height="13" font="6">2</text>
<text top="624" left="707" width="122" height="20" font="4"> consumption was not </text>
<text top="641" left="649" width="213" height="20" font="4">associated with an adverse pregnancy </text>
<text top="659" left="649" width="54" height="20" font="4">outcome. </text>
<text top="332" left="901" width="140" height="20" font="4">● Abnormal chronotropic </text>
<text top="349" left="901" width="137" height="20" font="4">response correlates with </text>
<text top="366" left="901" width="165" height="20" font="4">adverse pregnancy outcomes </text>
<text top="383" left="901" width="135" height="20" font="4">in women with CHD and </text>
<text top="400" left="901" width="133" height="20" font="4">should be considered in </text>
<text top="418" left="901" width="135" height="20" font="4">refining risk stratification </text>
<text top="435" left="901" width="56" height="20" font="4">schemes. </text>
<text top="677" left="64" width="90" height="20" font="4">Balint OH, et al. </text>
<text top="694" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(219)</a> </text>
<text top="711" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20937754?dopt=Citation">20937754</a></text>
<text top="711" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20937754?dopt=Citation"> </a></text>
<text top="677" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="694" left="170" width="77" height="20" font="4">observational </text>
<text top="677" left="263" width="58" height="20" font="4">n=318 pts </text>
<text top="694" left="263" width="49" height="20" font="4">with 405 </text>
<text top="711" left="263" width="74" height="20" font="4">pregnancies  </text>
<text top="677" left="349" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="694" left="349" width="123" height="20" font="4">Consecutive pregnant </text>
<text top="711" left="349" width="98" height="20" font="4">women with CHD </text>
<text top="728" left="349" width="141" height="20" font="4">receiving care or referred </text>
<text top="745" left="349" width="137" height="20" font="4">for consultation between </text>
<text top="763" left="349" width="68" height="20" font="4">1995–2007  </text>
<text top="780" left="349" width="3" height="20" font="4"> </text>
<text top="677" left="508" width="110" height="20" font="4">Late cardiac events </text>
<text top="694" left="508" width="92" height="20" font="4">included cardiac </text>
<text top="711" left="508" width="73" height="20" font="4">death/arrest, </text>
<text top="728" left="508" width="105" height="20" font="4">pulmonary edema, </text>
<text top="745" left="508" width="116" height="20" font="4">arrhythmia, or stroke </text>
<text top="677" left="649" width="230" height="20" font="4">● Late cardiac events occurred after 12% </text>
<text top="694" left="649" width="140" height="20" font="4">(50/405) of pregnancies.  </text>
<text top="711" left="649" width="227" height="20" font="4">● The 5-y rate of late cardiac events was </text>
<text top="728" left="649" width="209" height="20" font="4">higher in women with adverse cardiac </text>
<text top="745" left="649" width="212" height="20" font="4">events during pregnancy than in those </text>
<text top="763" left="649" width="49" height="20" font="4">without.  </text>
<text top="677" left="901" width="128" height="20" font="4">● In women with CHD, </text>
<text top="694" left="901" width="130" height="20" font="4">prepregnancy maternal </text>
<text top="711" left="901" width="145" height="20" font="4">characteristics can help to </text>
<text top="728" left="901" width="156" height="20" font="4">identify women at increased </text>
<text top="745" left="901" width="153" height="20" font="4">risk for late cardiac events.  </text>
<text top="763" left="901" width="144" height="20" font="4">● Adverse cardiac events </text>
<text top="780" left="901" width="120" height="20" font="4">during pregnancy are </text>
</page>
<page number="62" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 62 </text>
<text top="107" left="349" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="124" left="349" width="109" height="20" font="4">Pregnancies ended </text>
<text top="141" left="349" width="144" height="20" font="4">before 20 wk gestation; pt </text>
<text top="159" left="349" width="136" height="20" font="4">death during pregnancy; </text>
<text top="176" left="349" width="140" height="20" font="4">pts pregnant again within </text>
<text top="193" left="349" width="76" height="20" font="4">6 mo delivery </text>
<text top="107" left="649" width="222" height="20" font="4">● Women at highest risk for late cardiac </text>
<text top="124" left="649" width="185" height="20" font="4">events were those with functional </text>
<text top="141" left="649" width="226" height="20" font="4">limitations/cyanosis, subaortic ventricular </text>
<text top="159" left="649" width="210" height="20" font="4">dysfunction, subpulmonary ventricular </text>
<text top="176" left="649" width="237" height="20" font="4">dysfunction and/or significant PR, left heart </text>
<text top="193" left="649" width="223" height="20" font="4">obstruction and cardiac events before or </text>
<text top="210" left="649" width="222" height="20" font="4">during pregnancy. In women with 0, 1 or </text>
<text top="228" left="649" width="200" height="20" font="4">&gt;1 risk predictors the 5-y rate of late </text>
<text top="245" left="649" width="228" height="20" font="4">cardiac events was 7 ± 2%, 23 ± 5% and </text>
<text top="262" left="649" width="132" height="20" font="4">44 ± 10%, respectively. </text>
<text top="107" left="901" width="162" height="20" font="4">important and are associated </text>
<text top="124" left="901" width="158" height="20" font="4">with an increased risk in late </text>
<text top="141" left="901" width="86" height="20" font="4">cardiac events. </text>
<text top="280" left="64" width="86" height="20" font="4">Drenthen W, et </text>
<text top="297" left="64" width="16" height="20" font="4">al. </text>
<text top="314" left="64" width="56" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(31)</a> </text>
<text top="332" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20584777?dopt=Citation">20584777</a></text>
<text top="332" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20584777?dopt=Citation"> </a></text>
<text top="280" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="297" left="170" width="77" height="20" font="4">observational </text>
<text top="280" left="263" width="68" height="20" font="4">n=1,802 pts </text>
<text top="297" left="263" width="59" height="20" font="4">with 1,302 </text>
<text top="314" left="263" width="74" height="20" font="4">pregnancies  </text>
<text top="280" left="349" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="297" left="349" width="139" height="20" font="4">Women with CHD 18–58 </text>
<text top="314" left="349" width="128" height="20" font="4">y enrolled in the nation-</text>
<text top="332" left="349" width="130" height="20" font="4">wide CONCOR registry </text>
<text top="349" left="349" width="3" height="20" font="4"> </text>
<text top="366" left="349" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="383" left="349" width="142" height="20" font="4">Miscarriages and elective </text>
<text top="400" left="349" width="54" height="20" font="4">abortions </text>
<text top="280" left="508" width="72" height="20" font="4">Independent </text>
<text top="297" left="508" width="118" height="20" font="4">predictors of cardiac, </text>
<text top="314" left="508" width="124" height="20" font="4">obstetric and neonatal </text>
<text top="332" left="508" width="78" height="20" font="4">complications </text>
<text top="280" left="649" width="164" height="20" font="4">● The most prevalent cardiac </text>
<text top="297" left="649" width="206" height="20" font="4">complications during pregnancy were </text>
<text top="314" left="649" width="198" height="20" font="4">arrhythmias (4.7%) and HF (1.6%).  </text>
<text top="332" left="649" width="224" height="20" font="4">● Factors independently associated with </text>
<text top="349" left="649" width="223" height="20" font="4">maternal cardiac complications were the </text>
<text top="366" left="649" width="137" height="20" font="4">presence of cyanotic HD </text>
<text top="383" left="649" width="219" height="20" font="4">(corrected/uncorrected) (p&lt;0.0001), the </text>
<text top="400" left="649" width="181" height="20" font="4">use of cardiac medication before </text>
<text top="418" left="649" width="203" height="20" font="4">pregnancy (p&lt;0.0001), and left heart </text>
<text top="435" left="649" width="158" height="20" font="4">obstruction (p&lt;0.0001). New </text>
<text top="452" left="649" width="210" height="20" font="4">characteristics were mechanical valve </text>
<text top="469" left="649" width="213" height="20" font="4">replacement (p=0.0014), and systemic </text>
<text top="487" left="649" width="177" height="20" font="4">(p=0.04) or pulmonary AV valve </text>
<text top="504" left="649" width="219" height="20" font="4">regurgitation related with the underlying </text>
<text top="521" left="649" width="208" height="20" font="4">(moderately) complex CHD (p=0.03).  </text>
<text top="538" left="649" width="167" height="20" font="4">● A new risk score for cardiac </text>
<text top="555" left="649" width="152" height="20" font="4">complications is proposed.  </text>
<text top="573" left="649" width="171" height="20" font="4">● The most prevalent obstetric </text>
<text top="590" left="649" width="181" height="20" font="4">complications were hypertensive </text>
<text top="607" left="649" width="222" height="20" font="4">complications (12.2%). No correlation of </text>
<text top="624" left="649" width="206" height="20" font="4">maternal characteristics with adverse </text>
<text top="641" left="649" width="218" height="20" font="4">obstetric outcome was found. The most </text>
<text top="659" left="649" width="213" height="20" font="4">prevalent neonatal complications were </text>
<text top="676" left="649" width="176" height="20" font="4">premature birth (12%), small for </text>
<text top="693" left="649" width="233" height="20" font="4">gestational age (14%), and mortality (4%). </text>
<text top="710" left="649" width="204" height="20" font="4">Cyanotic HD (corrected/uncorrected) </text>
<text top="727" left="649" width="235" height="20" font="4">(p=0.0003), mechanical valve replacement </text>
<text top="745" left="649" width="213" height="20" font="4">(p=0.03), maternal smoking (p=0.007), </text>
<text top="762" left="649" width="233" height="20" font="4">multiple gestation (p=0.0014), and the use </text>
<text top="280" left="901" width="161" height="20" font="4">● In this tertiary CHD cohort, </text>
<text top="297" left="901" width="124" height="20" font="4">cardiac, obstetric, and </text>
<text top="314" left="901" width="159" height="20" font="4">neonatal complications were </text>
<text top="332" left="901" width="153" height="20" font="4">frequently encountered and </text>
<text top="349" left="901" width="166" height="20" font="4">(new) correlations of maternal </text>
<text top="366" left="901" width="149" height="20" font="4">baseline data with adverse </text>
<text top="383" left="901" width="128" height="20" font="4">outcome are reported.  </text>
<text top="400" left="901" width="171" height="20" font="4">● A new risk score for adverse </text>
<text top="418" left="901" width="133" height="20" font="4">cardiac complications is </text>
<text top="435" left="901" width="109" height="20" font="4">proposed, although </text>
<text top="452" left="901" width="169" height="20" font="4">prospective validation remains </text>
<text top="469" left="901" width="63" height="20" font="4">necessary. </text>
</page>
<page number="63" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 63 </text>
<text top="107" left="649" width="183" height="20" font="4">of cardiac medication (p=0.0009) </text>
<text top="124" left="649" width="232" height="20" font="4">correlated with adverse neonatal outcome </text>
<text top="142" left="64" width="87" height="20" font="4">Uebing A, et al. </text>
<text top="159" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(220)</a> </text>
<text top="177" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18835051?dopt=Citation">18835051</a></text>
<text top="177" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18835051?dopt=Citation"> </a></text>
<text top="142" left="170" width="73" height="20" font="4">Case control </text>
<text top="142" left="263" width="70" height="20" font="4">n=93 cases, </text>
<text top="159" left="263" width="31" height="20" font="4">n=40 </text>
<text top="177" left="263" width="46" height="20" font="4">controls </text>
<text top="142" left="349" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="159" left="349" width="132" height="20" font="4">Women who underwent </text>
<text top="177" left="349" width="64" height="20" font="4">clinical and </text>
<text top="194" left="349" width="104" height="20" font="4">echocardiographic </text>
<text top="211" left="349" width="122" height="20" font="4">evaluation before and </text>
<text top="228" left="349" width="89" height="20" font="4">after pregnancy </text>
<text top="142" left="508" width="121" height="20" font="4">End diastolic and end </text>
<text top="159" left="508" width="68" height="20" font="4">systolic and </text>
<text top="177" left="508" width="118" height="20" font="4">shortening fraction of </text>
<text top="194" left="508" width="122" height="20" font="4">the morphological LV. </text>
<text top="211" left="508" width="87" height="20" font="4">Pregnancy was </text>
<text top="228" left="508" width="87" height="20" font="4">associated with </text>
<text top="246" left="508" width="57" height="20" font="4">increased </text>
<text top="263" left="508" width="81" height="20" font="4">subpulmonary </text>
<text top="280" left="508" width="85" height="20" font="4">ventricular size </text>
<text top="142" left="649" width="229" height="20" font="4">● NYHA FC remained unchanged in both </text>
<text top="159" left="649" width="200" height="20" font="4">groups during follow-up. Pregnancy, </text>
<text top="177" left="649" width="232" height="20" font="4">however, was associated with a persisting </text>
<text top="194" left="649" width="229" height="20" font="4">increase in subpulmonary ventricular size </text>
<text top="211" left="649" width="228" height="20" font="4">in pts with TOF, which was not present in </text>
<text top="228" left="649" width="230" height="20" font="4">tetralogy controls. Furthermore, diagnosis </text>
<text top="246" left="649" width="196" height="20" font="4">of TOF was the only predictor of an </text>
<text top="263" left="649" width="229" height="20" font="4">increase in subpulmonary ventricular size </text>
<text top="280" left="649" width="204" height="20" font="4">after pregnancy on univariate logistic </text>
<text top="297" left="649" width="230" height="20" font="4">regression analysis (OR: 8.8; 95% CI: 1.9-</text>
<text top="314" left="649" width="87" height="20" font="4">41.1; p=0.006). </text>
<text top="142" left="901" width="143" height="20" font="4">● No deleterious midterm </text>
<text top="159" left="901" width="172" height="20" font="4">effects of pregnancy on clinical </text>
<text top="177" left="901" width="169" height="20" font="4">status and RV and LV function </text>
<text top="194" left="901" width="71" height="20" font="4">were found.  </text>
<text top="211" left="901" width="162" height="20" font="4">● Pregnancy was associated </text>
<text top="228" left="901" width="154" height="20" font="4">with a persisting increase in </text>
<text top="246" left="901" width="169" height="20" font="4">subpulmonary ventricular size, </text>
<text top="263" left="901" width="172" height="20" font="4">attributable to pts with repaired </text>
<text top="280" left="901" width="31" height="20" font="4">TOF. </text>
<text top="332" left="64" width="83" height="20" font="4">Khairy P, et al. </text>
<text top="350" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(221)</a> </text>
<text top="367" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16449731?dopt=Citation">16449731</a></text>
<text top="367" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16449731?dopt=Citation"> </a></text>
<text top="332" left="170" width="144" height="20" font="4">Retrospective  n=53 pts </text>
<text top="350" left="263" width="42" height="20" font="4">with 90 </text>
<text top="367" left="263" width="70" height="20" font="4">pregnancies </text>
<text top="332" left="349" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="350" left="349" width="101" height="20" font="4">Women with CHD </text>
<text top="367" left="349" width="126" height="20" font="4">delivered between Jan </text>
<text top="384" left="349" width="94" height="20" font="4">1998–Sept 2004 </text>
<text top="401" left="349" width="3" height="20" font="4"> </text>
<text top="418" left="349" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="436" left="349" width="146" height="20" font="4">Women with acquired HD, </text>
<text top="453" left="349" width="137" height="20" font="4">1° arrhythmia diagnoses </text>
<text top="470" left="349" width="102" height="20" font="4">without underlying </text>
<text top="487" left="349" width="130" height="20" font="4">congenital defects, and </text>
<text top="504" left="349" width="111" height="20" font="4">isolated mitral valve </text>
<text top="522" left="349" width="51" height="20" font="4">prolapse </text>
<text top="332" left="508" width="93" height="20" font="4">1° cardiac event </text>
<text top="350" left="508" width="112" height="20" font="4">consisted of cardiac </text>
<text top="367" left="508" width="119" height="20" font="4">death, cardiac arrest, </text>
<text top="384" left="508" width="113" height="20" font="4">stroke, symptomatic </text>
<text top="401" left="508" width="91" height="20" font="4">sustained Brady </text>
<text top="418" left="508" width="76" height="20" font="4">arrhythmia or </text>
<text top="436" left="508" width="91" height="20" font="4">tachyarrhythmia </text>
<text top="453" left="508" width="114" height="20" font="4">requiring therapy, or </text>
<text top="470" left="508" width="102" height="20" font="4">pulmonary edema </text>
<text top="487" left="508" width="87" height="20" font="4">documented by </text>
<text top="504" left="508" width="117" height="20" font="4">physical examination </text>
<text top="522" left="508" width="83" height="20" font="4">or radiography </text>
<text top="332" left="649" width="232" height="20" font="4">● 1° maternal cardiac events complicated </text>
<text top="350" left="649" width="198" height="20" font="4">19.4% of ongoing pregnancies, with </text>
<text top="367" left="649" width="233" height="20" font="4">pulmonary edema in 16.7% and sustained </text>
<text top="384" left="649" width="237" height="20" font="4">arrhythmias in 2.8%. Univariate risk factors </text>
<text top="401" left="649" width="215" height="20" font="4">included prior history of HF (OR: 15.5), </text>
<text top="418" left="649" width="210" height="20" font="4">NYHA FC 2 (OR: 5.4), and decreased </text>
<text top="436" left="649" width="221" height="20" font="4">subpulmonary ventricular EF (OR: 7.7).  </text>
<text top="453" left="649" width="233" height="20" font="4">● Independent predictors were decreased </text>
<text top="470" left="649" width="239" height="20" font="4">subpulmonary ventricular EF and/or severe </text>
<text top="487" left="649" width="217" height="20" font="4">PR (OR: 9.0) and smoking history (OR: </text>
<text top="504" left="649" width="191" height="20" font="4">27.2). Adverse neonatal outcomes </text>
<text top="522" left="649" width="234" height="20" font="4">occurred in 27.8% of ongoing pregnancies </text>
<text top="539" left="649" width="215" height="20" font="4">and included preterm delivery (20.8%), </text>
<text top="556" left="649" width="180" height="20" font="4">small for gestational age (8.3%), </text>
<text top="573" left="649" width="208" height="20" font="4">respiratory distress syndrome (8.3%), </text>
<text top="591" left="649" width="197" height="20" font="4">intraventricular hemorrhage (1.4%), </text>
<text top="608" left="649" width="202" height="20" font="4">intrauterine fetal demise (2.8%), and </text>
<text top="625" left="649" width="193" height="20" font="4">neonatal death (1.4%). A subaortic </text>
<text top="642" left="649" width="238" height="20" font="4">ventricular outflow tract gradient 30 mm Hg </text>
<text top="659" left="649" width="198" height="20" font="4">independently predicted an adverse </text>
<text top="677" left="649" width="227" height="20" font="4">neonatal outcome (OR: 7.5). Cardiac risk </text>
<text top="694" left="649" width="217" height="20" font="4">assessment was improved by including </text>
<text top="711" left="649" width="202" height="20" font="4">decreased subpulmonary ventricular </text>
<text top="728" left="649" width="219" height="20" font="4">systolic function and/or severe PR (OR: </text>
<text top="745" left="649" width="224" height="20" font="4">10.3) in a previously proposed risk index </text>
<text top="763" left="649" width="194" height="20" font="4">developed in pregnant women with </text>
<text top="780" left="649" width="108" height="20" font="4">acquired and CHD. </text>
<text top="332" left="901" width="109" height="20" font="4">● Pts with impaired </text>
<text top="350" left="901" width="141" height="20" font="4">subpulmonary ventricular </text>
<text top="367" left="901" width="169" height="20" font="4">systolic function and/or severe </text>
<text top="384" left="901" width="152" height="20" font="4">PR are at increased risk for </text>
<text top="401" left="901" width="150" height="20" font="4">adverse cardiac outcomes. </text>
</page>
<page number="64" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 64 </text>
<text top="107" left="64" width="66" height="20" font="4">Siu S, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(222)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11994252?dopt=Citation">11994252</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11994252?dopt=Citation"> </a></text>
<text top="107" left="170" width="66" height="20" font="4">Preplanned </text>
<text top="124" left="170" width="66" height="20" font="4">substudy of </text>
<text top="141" left="170" width="64" height="20" font="4">CARPREG </text>
<text top="107" left="263" width="38" height="20" font="4">n=302 </text>
<text top="124" left="263" width="70" height="20" font="4">pregnancies </text>
<text top="141" left="263" width="56" height="20" font="4">in women </text>
<text top="159" left="263" width="50" height="20" font="4">with HD; </text>
<text top="176" left="263" width="40" height="20" font="4">control </text>
<text top="193" left="263" width="35" height="20" font="4">group </text>
<text top="210" left="263" width="63" height="20" font="4">without HD </text>
<text top="228" left="263" width="62" height="20" font="4">during 572 </text>
<text top="245" left="263" width="70" height="20" font="4">pregnancies </text>
<text top="107" left="349" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="349" width="121" height="20" font="4">Pregnant women with </text>
<text top="141" left="349" width="139" height="20" font="4">structural cardiac lesions </text>
<text top="159" left="349" width="112" height="20" font="4">or with symptomatic </text>
<text top="176" left="349" width="111" height="20" font="4">cardiac arrhythmias </text>
<text top="193" left="349" width="145" height="20" font="4">requiring treatment before </text>
<text top="210" left="349" width="64" height="20" font="4">pregnancy. </text>
<text top="227" left="349" width="3" height="20" font="4"> </text>
<text top="245" left="349" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="262" left="349" width="117" height="20" font="4">Women with isolated </text>
<text top="279" left="349" width="146" height="20" font="4">mitral valve prolapse (mild </text>
<text top="296" left="349" width="27" height="20" font="4">MR) </text>
<text top="107" left="508" width="24" height="20" font="4">N/A </text>
<text top="107" left="649" width="237" height="20" font="4">● The frequency of neonatal complications </text>
<text top="124" left="649" width="228" height="20" font="4">was higher in the HD group (18% vs. 7%; </text>
<text top="141" left="649" width="98" height="20" font="4">HD vs. controls).  </text>
<text top="159" left="649" width="230" height="20" font="4">● The NE complication rate was lowest in </text>
<text top="176" left="649" width="220" height="20" font="4">pregnancies of women 20–35 y who did </text>
<text top="193" left="649" width="202" height="20" font="4">not smoke during pregnancy, did not </text>
<text top="210" left="649" width="194" height="20" font="4">receive anticoagulants, and had no </text>
<text top="228" left="649" width="235" height="20" font="4">obstetric risk factors: 4% in control pts, 5% </text>
<text top="245" left="649" width="220" height="20" font="4">in HD pts with no cardiac risk factors for </text>
<text top="262" left="649" width="221" height="20" font="4">NE complications (left heart obstruction, </text>
<text top="279" left="649" width="223" height="20" font="4">poor FC, or cyanosis), and 7% in HD pts </text>
<text top="296" left="649" width="210" height="20" font="4">with 1 such risk factor. In contrast, the </text>
<text top="314" left="649" width="226" height="20" font="4">event rate in pregnancies of controls age </text>
<text top="331" left="649" width="233" height="20" font="4">20 or 35 y that had obstetric risk factors or </text>
<text top="348" left="649" width="217" height="20" font="4">multiple gestations or who smoked was </text>
<text top="365" left="649" width="239" height="20" font="4">11%. In the HD group, women 20-35 y who </text>
<text top="383" left="649" width="197" height="20" font="4">had obstetric risk factors or multiple </text>
<text top="400" left="649" width="229" height="20" font="4">gestations, who smoked, or who received </text>
<text top="417" left="649" width="238" height="20" font="4">anticoagulants experienced an even higher </text>
<text top="434" left="649" width="235" height="20" font="4">NE complication rate (27% with no cardiac </text>
<text top="451" left="649" width="192" height="20" font="4">risks for NE events and 33% in the </text>
<text top="469" left="649" width="210" height="20" font="4">presence of 1 cardiac risk factor). The </text>
<text top="486" left="649" width="232" height="20" font="4">frequency of CV complications was higher </text>
<text top="503" left="649" width="206" height="20" font="4">in the HD group (17% vs. 0%; HD vs. </text>
<text top="520" left="649" width="54" height="20" font="4">controls). </text>
<text top="107" left="901" width="131" height="20" font="4">● The risk for NE AE in </text>
<text top="124" left="901" width="154" height="20" font="4">pregnant women with HD is </text>
<text top="141" left="901" width="142" height="20" font="4">highest in those with both </text>
<text top="159" left="901" width="139" height="20" font="4">obstetric and cardiac risk </text>
<text top="176" left="901" width="160" height="20" font="4">factors for NE complications. </text>
<text top="538" left="64" width="66" height="20" font="4">Siu S, et al. </text>
<text top="555" left="64" width="63" height="20" font="4">2001 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(223)</a> </text>
<text top="573" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11479246?dopt=Citation">11479246</a></text>
<text top="573" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11479246?dopt=Citation"> </a></text>
<text top="538" left="170" width="67" height="20" font="4">Prospective </text>
<text top="555" left="170" width="64" height="20" font="4">multicenter </text>
<text top="573" left="170" width="38" height="20" font="4">cohort </text>
<text top="538" left="263" width="38" height="20" font="4">n=562 </text>
<text top="555" left="263" width="68" height="20" font="4">consecutive </text>
<text top="573" left="263" width="72" height="20" font="4">pregnant pts </text>
<text top="590" left="263" width="60" height="20" font="4">with HD of </text>
<text top="607" left="263" width="24" height="20" font="4">599 </text>
<text top="624" left="263" width="70" height="20" font="4">pregnancies </text>
<text top="538" left="349" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="555" left="349" width="137" height="20" font="4">Women with HD from 13 </text>
<text top="573" left="349" width="122" height="20" font="4">Canadian centers Oct </text>
<text top="590" left="349" width="90" height="20" font="4">1994–Nov 1999 </text>
<text top="607" left="349" width="3" height="20" font="4"> </text>
<text top="624" left="349" width="131" height="20" font="3"><b>Exclusion criteria</b>: Pts </text>
<text top="641" left="349" width="137" height="20" font="4">with isolated mitral valve </text>
<text top="659" left="349" width="124" height="20" font="4">prolapse (moderate of </text>
<text top="676" left="349" width="140" height="20" font="4">mild MR); pts referred for </text>
<text top="693" left="349" width="139" height="20" font="4">termination of pregnancy </text>
<text top="538" left="508" width="99" height="20" font="4">1° cardiac events </text>
<text top="555" left="508" width="127" height="20" font="4">were defined as any of </text>
<text top="573" left="508" width="75" height="20" font="4">the following: </text>
<text top="590" left="508" width="102" height="20" font="4">pulmonary edema </text>
<text top="607" left="508" width="125" height="20" font="4">(documented on chest </text>
<text top="624" left="508" width="93" height="20" font="4">radiograph or by </text>
<text top="641" left="508" width="111" height="20" font="4">crackles heard over </text>
<text top="659" left="508" width="93" height="20" font="4">more than 1/3 of </text>
<text top="676" left="508" width="118" height="20" font="4">posterior lung fields), </text>
<text top="693" left="508" width="56" height="20" font="4">sustained </text>
<text top="710" left="508" width="72" height="20" font="4">symptomatic </text>
<text top="727" left="508" width="105" height="20" font="4">tachyarrhythmia or </text>
<text top="745" left="508" width="92" height="20" font="4">bradyarrhythmia </text>
<text top="762" left="508" width="110" height="20" font="4">requiring treatment, </text>
<text top="538" left="649" width="239" height="20" font="4">● Pulmonary edema, arrhythmia, stroke, or </text>
<text top="555" left="649" width="188" height="20" font="4">cardiac death complicated 13% of </text>
<text top="573" left="649" width="200" height="20" font="4">pregnancies. Prior cardiac events or </text>
<text top="590" left="649" width="233" height="20" font="4">arrhythmia, poor FC or cyanosis, left heart </text>
<text top="607" left="649" width="219" height="20" font="4">obstruction, and LV systolic dysfunction </text>
<text top="624" left="649" width="228" height="20" font="4">independently predicted maternal cardiac </text>
<text top="641" left="649" width="85" height="20" font="4">complications.  </text>
<text top="659" left="649" width="189" height="20" font="4">● Neonatal complications (20% of </text>
<text top="676" left="649" width="220" height="20" font="4">pregnancies) were associated with poor </text>
<text top="693" left="649" width="207" height="20" font="4">FC or cyanosis, left heart obstruction, </text>
<text top="710" left="649" width="212" height="20" font="4">anticoagulation, smoking, and multiple </text>
<text top="727" left="649" width="63" height="20" font="4">gestations. </text>
<text top="538" left="901" width="156" height="20" font="4">● Pregnancy in women with </text>
<text top="555" left="901" width="121" height="20" font="4">HD is associated with </text>
<text top="573" left="901" width="125" height="20" font="4">significant cardiac and </text>
<text top="590" left="901" width="132" height="20" font="4">neonatal complications, </text>
<text top="607" left="901" width="125" height="20" font="4">despite state of the art </text>
<text top="624" left="901" width="151" height="20" font="4">obstetric and cardiac care.  </text>
<text top="641" left="901" width="170" height="20" font="4">● Maternal cardiac risk can be </text>
<text top="659" left="901" width="169" height="20" font="4">predicted with the use of a risk </text>
<text top="676" left="901" width="36" height="20" font="4">index. </text>
</page>
<page number="65" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 65 </text>
<text top="107" left="508" width="122" height="20" font="4">stroke, cardiac arrest, </text>
<text top="124" left="508" width="95" height="20" font="4">or cardiac death. </text>
<text top="142" left="64" width="85" height="20" font="4">Egidy Assenza </text>
<text top="159" left="64" width="46" height="20" font="4">G, et al. </text>
<text top="177" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(224)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23369674?dopt=Citation">23369674</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23369674?dopt=Citation"> </a></text>
<text top="142" left="170" width="71" height="20" font="4">2:1 matched </text>
<text top="159" left="170" width="73" height="20" font="4">case control: </text>
<text top="177" left="170" width="57" height="20" font="4">(matching </text>
<text top="194" left="170" width="53" height="20" font="4">variables </text>
<text top="211" left="170" width="60" height="20" font="4">were QRS </text>
<text top="228" left="170" width="72" height="20" font="4">duration, RV </text>
<text top="246" left="170" width="69" height="20" font="4">EF, indexed </text>
<text top="263" left="170" width="79" height="20" font="4">RV EDV, time </text>
<text top="280" left="170" width="50" height="20" font="4">between </text>
<text top="297" left="170" width="73" height="20" font="4">baseline and </text>
<text top="314" left="170" width="53" height="20" font="4">follow-up </text>
<text top="332" left="170" width="59" height="20" font="4">CMR, and </text>
<text top="349" left="170" width="58" height="20" font="4">age at the </text>
<text top="366" left="170" width="49" height="20" font="4">baseline </text>
<text top="383" left="170" width="35" height="20" font="4">CMR) </text>
<text top="142" left="263" width="63" height="20" font="4">n=13 rTOF </text>
<text top="159" left="263" width="70" height="20" font="4">pts who had </text>
<text top="177" left="263" width="62" height="20" font="4">undergone </text>
<text top="194" left="263" width="61" height="20" font="4">pregnancy </text>
<text top="211" left="263" width="64" height="20" font="4">matched to </text>
<text top="228" left="263" width="17" height="20" font="4">26 </text>
<text top="246" left="263" width="63" height="20" font="4">nulliparous </text>
<text top="263" left="263" width="28" height="20" font="4">TOF </text>
<text top="280" left="263" width="46" height="20" font="4">controls </text>
<text top="142" left="349" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="159" left="349" width="143" height="20" font="4">Associated complex CHD </text>
<text top="177" left="349" width="102" height="20" font="4">(such as AV canal </text>
<text top="194" left="349" width="118" height="20" font="4">defect); syndromic or </text>
<text top="211" left="349" width="145" height="20" font="4">genetic disease; history of </text>
<text top="228" left="349" width="121" height="20" font="4">completed pregnancy </text>
<text top="246" left="349" width="143" height="20" font="4">before the baseline CMR; </text>
<text top="263" left="349" width="141" height="20" font="4">PV replacement between </text>
<text top="280" left="349" width="38" height="20" font="4">CMRs </text>
<text top="142" left="508" width="24" height="20" font="4">N/A </text>
<text top="142" left="648" width="222" height="20" font="4">● The rate of increase of RV EDV in the </text>
<text top="159" left="648" width="206" height="20" font="4">pregnancy group was higher than the </text>
<text top="177" left="648" width="189" height="20" font="4">comparison group (4.1 ± 1.1 mL/m</text>
<text top="178" left="837" width="4" height="13" font="6">2</text>
<text top="177" left="842" width="32" height="20" font="4">/y vs. </text>
<text top="194" left="648" width="83" height="20" font="4">1.6 ± 0.6 mL/m</text>
<text top="196" left="731" width="4" height="13" font="6">2</text>
<text top="194" left="736" width="142" height="20" font="4">/y; p=0.07). RVEF did not </text>
<text top="211" left="648" width="200" height="20" font="4">change significantly in either group.  </text>
<text top="228" left="648" width="235" height="20" font="4">● No definitive interaction between degree </text>
<text top="245" left="648" width="193" height="20" font="4">of PR and increase of RVEDV was </text>
<text top="263" left="648" width="56" height="20" font="4">identified. </text>
<text top="142" left="899" width="160" height="20" font="4">● Women with repaired TOF </text>
<text top="159" left="899" width="116" height="20" font="4">who have completed </text>
<text top="177" left="899" width="116" height="20" font="4">pregnancy appear to </text>
<text top="194" left="899" width="172" height="20" font="4">experience an accelerated rate </text>
<text top="211" left="899" width="162" height="20" font="4">of RV remodeling, defined as </text>
<text top="228" left="899" width="152" height="20" font="4">an increase in end-diastolic </text>
<text top="246" left="899" width="164" height="20" font="4">volume; however, RV systolic </text>
<text top="263" left="899" width="163" height="20" font="4">function does not deteriorate. </text>
<text top="401" left="64" width="82" height="20" font="4">Kamiya CA, et </text>
<text top="418" left="64" width="16" height="20" font="4">al. </text>
<text top="436" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(225)</a> </text>
<text top="453" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22277318?dopt=Citation">22277318</a></text>
<text top="453" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22277318?dopt=Citation"> </a></text>
<text top="401" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="418" left="170" width="77" height="20" font="4">observational </text>
<text top="401" left="263" width="51" height="20" font="4">n=25 pts </text>
<text top="418" left="263" width="42" height="20" font="4">with 40 </text>
<text top="436" left="263" width="74" height="20" font="4">pregnancies  </text>
<text top="401" left="349" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="418" left="349" width="135" height="20" font="4">Spontaneous or elective </text>
<text top="436" left="349" width="54" height="20" font="4">abortions </text>
<text top="401" left="508" width="89" height="20" font="4">Cardiac events, </text>
<text top="418" left="508" width="93" height="20" font="4">obstetric events, </text>
<text top="436" left="508" width="94" height="20" font="4">offspring events  </text>
<text top="401" left="648" width="231" height="20" font="4">● There were 23 pts in NYHA class I, and </text>
<text top="418" left="648" width="201" height="20" font="4">2 in classes II–III before pregnancy.  </text>
<text top="436" left="648" width="217" height="20" font="4">● The mean age at delivery was 29.1 y </text>
<text top="453" left="648" width="232" height="20" font="4">and the mean gestational period was 37.8 </text>
<text top="470" left="648" width="222" height="20" font="4">wk. 7 pregnancies (17.5%) in 7 pts were </text>
<text top="487" left="648" width="237" height="20" font="4">complicated with cardiac events, such as a </text>
<text top="504" left="648" width="217" height="20" font="4">decline in NYHA class and arrhythmia.  </text>
<text top="522" left="648" width="208" height="20" font="4">● History of ablation and the baseline </text>
<text top="539" left="648" width="226" height="20" font="4">cardiothoracic ratio on chest radiography </text>
<text top="556" left="648" width="128" height="20" font="4">were predictors of AE.  </text>
<text top="573" left="648" width="236" height="20" font="4">● Peak plasma BNP level after the second </text>
<text top="591" left="648" width="215" height="20" font="4">trimester was higher in pts with cardiac </text>
<text top="608" left="648" width="46" height="20" font="4">events.  </text>
<text top="625" left="648" width="228" height="20" font="4">● LV size and contraction did not change </text>
<text top="642" left="648" width="213" height="20" font="4">from before to after pregnancy, but the </text>
<text top="659" left="648" width="226" height="20" font="4">right ventricle was enlarged at 6 mo after </text>
<text top="677" left="648" width="49" height="20" font="4">delivery. </text>
<text top="401" left="899" width="163" height="20" font="4">● Many women with repaired </text>
<text top="418" left="899" width="113" height="20" font="4">TOF had successful </text>
<text top="436" left="899" width="169" height="20" font="4">pregnancies. However, careful </text>
<text top="453" left="899" width="154" height="20" font="4">management is required for </text>
<text top="470" left="899" width="161" height="20" font="4">some pts and BNP level may </text>
<text top="487" left="899" width="161" height="20" font="4">be a useful marker to identify </text>
<text top="504" left="899" width="60" height="20" font="4">these pts.  </text>
<text top="522" left="899" width="155" height="20" font="4">● Pregnancy may affect the </text>
<text top="539" left="899" width="171" height="20" font="4">long-term prognosis of pts with </text>
<text top="556" left="899" width="144" height="20" font="4">repaired TOF, as the right </text>
<text top="573" left="899" width="133" height="20" font="4">heart tended to become </text>
<text top="591" left="899" width="120" height="20" font="4">enlarged postpartum. </text>
<text top="694" left="64" width="80" height="20" font="4">Jain VD, et al. </text>
<text top="712" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(226)</a> </text>
<text top="729" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21418534?dopt=Citation">21418534</a></text>
<text top="729" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21418534?dopt=Citation"> </a></text>
<text top="694" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="712" left="170" width="77" height="20" font="4">observational </text>
<text top="694" left="263" width="58" height="20" font="4">n=114 pts </text>
<text top="712" left="263" width="49" height="20" font="4">with 146 </text>
<text top="729" left="263" width="74" height="20" font="4">pregnancies  </text>
<text top="694" left="349" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="712" left="349" width="137" height="20" font="4">Women with mitral valve </text>
<text top="729" left="349" width="91" height="20" font="4">prolapse only or </text>
<text top="746" left="349" width="123" height="20" font="4">noncongenital cardiac </text>
<text top="763" left="349" width="49" height="20" font="4">disease  </text>
<text top="694" left="508" width="99" height="20" font="4">Composite of HF, </text>
<text top="712" left="508" width="105" height="20" font="4">arrhythmia, stroke, </text>
<text top="729" left="508" width="112" height="20" font="4">cardiac arrest/death </text>
<text top="746" left="508" width="113" height="20" font="4">during pregnancy or </text>
<text top="763" left="508" width="65" height="20" font="4">postpartum </text>
<text top="694" left="648" width="217" height="20" font="4">● 146 pregnancies in 114 women were </text>
<text top="712" left="648" width="235" height="20" font="4">included; 15 (10.3%) pregnancies involved </text>
<text top="729" left="648" width="238" height="20" font="4">a SRV. CARDCOMP complicated 12.3% of </text>
<text top="746" left="648" width="111" height="20" font="4">these pregnancies.  </text>
<text top="763" left="648" width="228" height="20" font="4">● Women with a SRV were more likely to </text>
<text top="781" left="648" width="180" height="20" font="4">develop CARDCOMP even after </text>
<text top="694" left="899" width="167" height="20" font="4">● In women with CHD, a SRV </text>
<text top="712" left="899" width="147" height="20" font="4">is associated with adverse </text>
<text top="729" left="899" width="128" height="20" font="4">cardiac and pregnancy </text>
<text top="746" left="899" width="60" height="20" font="4">outcomes. </text>
</page>
<page number="66" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 66 </text>
<text top="107" left="648" width="231" height="20" font="4">adjustment for confounders. PREGCOMP </text>
<text top="124" left="648" width="211" height="20" font="4">complicated 40.4% of all pregnancies. </text>
<text top="141" left="648" width="228" height="20" font="4">Women with a SRV were also more likely </text>
<text top="159" left="648" width="219" height="20" font="4">to develop PREGCOMP compared with </text>
<text top="176" left="648" width="227" height="20" font="4">women with a systemic left ventricle after </text>
<text top="193" left="648" width="152" height="20" font="4">controlling for confounders. </text>
<text top="211" left="64" width="75" height="20" font="4">Balci A, et al. </text>
<text top="228" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(227)</a> </text>
<text top="245" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21315213?dopt=Citation">21315213</a></text>
<text top="245" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21315213?dopt=Citation"> </a></text>
<text top="211" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="228" left="170" width="70" height="20" font="4">international </text>
<text top="245" left="170" width="64" height="20" font="4">multicenter </text>
<text top="263" left="170" width="76" height="20" font="4">study using 2 </text>
<text top="280" left="170" width="30" height="20" font="4">CHD </text>
<text top="297" left="170" width="53" height="20" font="4">registries </text>
<text top="314" left="170" width="62" height="20" font="4">(CONCOR </text>
<text top="332" left="170" width="76" height="20" font="4">and Belgium) </text>
<text top="211" left="263" width="58" height="20" font="4">n=204 pts </text>
<text top="228" left="263" width="53" height="20" font="4">with TOF </text>
<text top="245" left="263" width="65" height="20" font="4">(74 pts had </text>
<text top="263" left="263" width="24" height="20" font="4">157 </text>
<text top="280" left="263" width="67" height="20" font="4">pregnancies</text>
<text top="297" left="263" width="8" height="20" font="4">) </text>
<text top="211" left="349" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="211" left="508" width="126" height="20" font="4">Pregnancy outcome in </text>
<text top="228" left="508" width="123" height="20" font="4">women with corrected </text>
<text top="245" left="508" width="28" height="20" font="4">TOF </text>
<text top="211" left="648" width="218" height="20" font="4">● CV events occurred during 10 (8.1%) </text>
<text top="228" left="648" width="182" height="20" font="4">pregnancies, mainly (supra) VA.  </text>
<text top="245" left="648" width="231" height="20" font="4">● Obstetric and offspring events occurred </text>
<text top="263" left="648" width="238" height="20" font="4">in 73 (58.9%) and 42 (33.9%) pregnancies, </text>
<text top="280" left="648" width="237" height="20" font="4">respectively, including offspring mortality in </text>
<text top="297" left="648" width="214" height="20" font="4">8 (6.4%). The most important predictor </text>
<text top="314" left="648" width="207" height="20" font="4">was use of cardiac medication before </text>
<text top="332" left="648" width="222" height="20" font="4">pregnancy (OR for cardiac events: 11.7; </text>
<text top="349" left="648" width="235" height="20" font="4">95% CI: 2.2–62.7; OR for offspring events: </text>
<text top="366" left="648" width="133" height="20" font="4">8.4; 95% CI: 1.4–48.6).  </text>
<text top="383" left="648" width="186" height="20" font="4">● In pregnancies with CV events, </text>
<text top="400" left="648" width="237" height="20" font="4">significantly more small-for-gestational-age </text>
<text top="418" left="648" width="158" height="20" font="4">children were born (p=0.01). </text>
<text top="211" left="899" width="164" height="20" font="4">● CV, obstetric, and offspring </text>
<text top="228" left="899" width="168" height="20" font="4">events occur frequently during </text>
<text top="245" left="899" width="152" height="20" font="4">pregnancies in women with </text>
<text top="263" left="899" width="31" height="20" font="4">TOF. </text>
<text top="280" left="899" width="121" height="20" font="4">● Maternal use of CV </text>
<text top="297" left="899" width="163" height="20" font="4">medication is associated with </text>
<text top="314" left="899" width="139" height="20" font="4">pregnancy outcome, and </text>
<text top="332" left="899" width="149" height="20" font="4">maternal CV events during </text>
<text top="349" left="899" width="118" height="20" font="4">pregnancy are highly </text>
<text top="366" left="899" width="138" height="20" font="4">associated with offspring </text>
<text top="383" left="899" width="43" height="20" font="4">events. </text>
<text top="436" left="64" width="84" height="20" font="4">Tobler D, et al. </text>
<text top="453" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(228)</a> </text>
<text top="470" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20643256?dopt=Citation">20643256</a></text>
<text top="470" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20643256?dopt=Citation"> </a></text>
<text top="436" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="453" left="170" width="41" height="20" font="4">cohort  </text>
<text top="436" left="263" width="69" height="20" font="4">n=9 pts with </text>
<text top="453" left="263" width="17" height="20" font="4">17 </text>
<text top="470" left="263" width="74" height="20" font="4">pregnancies  </text>
<text top="436" left="349" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="436" left="508" width="126" height="20" font="4">Pregnancy outcome in </text>
<text top="453" left="508" width="123" height="20" font="4">women with TGA who </text>
<text top="470" left="508" width="70" height="20" font="4">had an ASO </text>
<text top="436" left="648" width="230" height="20" font="4">● 6 women (67%) had clinically important </text>
<text top="453" left="648" width="223" height="20" font="4">valve (n=5) and ventricular (n=1) lesions </text>
<text top="470" left="648" width="209" height="20" font="4">before the index pregnancy. 2 women </text>
<text top="487" left="648" width="219" height="20" font="4">developed cardiac complications during </text>
<text top="504" left="648" width="212" height="20" font="4">pregnancy; 1 woman with impaired LV </text>
<text top="522" left="648" width="228" height="20" font="4">systolic function had NSVT and 1 woman </text>
<text top="539" left="648" width="204" height="20" font="4">with a mechanical systemic AV valve </text>
<text top="556" left="648" width="228" height="20" font="4">developed postpartum valve thrombosis.  </text>
<text top="573" left="648" width="190" height="20" font="4">● There were no maternal deaths. </text>
<text top="436" left="899" width="148" height="20" font="4">● Young women with TGA </text>
<text top="453" left="899" width="167" height="20" font="4">from this early cohort repaired </text>
<text top="470" left="899" width="126" height="20" font="4">with ASO are reaching </text>
<text top="487" left="899" width="101" height="20" font="4">childbearing age.  </text>
<text top="504" left="899" width="164" height="20" font="4">● A significant proportion has </text>
<text top="522" left="899" width="162" height="20" font="4">residual and/or sequelae that </text>
<text top="539" left="899" width="148" height="20" font="4">can confer risk for adverse </text>
<text top="556" left="899" width="160" height="20" font="4">cardiac events in pregnancy. </text>
<text top="573" left="899" width="158" height="20" font="4">Coordinated care between a </text>
<text top="591" left="899" width="168" height="20" font="4">CHD specialist and a high-risk </text>
<text top="608" left="899" width="123" height="20" font="4">obstetrician should be </text>
<text top="625" left="899" width="77" height="20" font="4">implemented. </text>
<text top="643" left="64" width="82" height="20" font="4">Greutmann M, </text>
<text top="660" left="64" width="30" height="20" font="4">et al. </text>
<text top="677" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(229)</a> </text>
<text top="694" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20511325?dopt=Citation">20511325</a></text>
<text top="694" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20511325?dopt=Citation"> </a></text>
<text top="643" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="660" left="170" width="38" height="20" font="4">cohort </text>
<text top="643" left="263" width="51" height="20" font="4">n=47 pts </text>
<text top="660" left="263" width="42" height="20" font="4">with 76 </text>
<text top="677" left="263" width="74" height="20" font="4">pregnancies  </text>
<text top="643" left="349" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="660" left="349" width="143" height="20" font="4">Miscarriage or terminated </text>
<text top="677" left="349" width="48" height="20" font="4">abortion </text>
<text top="643" left="508" width="124" height="20" font="4">Cardiac complications </text>
<text top="660" left="508" width="89" height="20" font="4">including death, </text>
<text top="677" left="508" width="118" height="20" font="4">arrhythmias, HF, and </text>
<text top="694" left="508" width="99" height="20" font="4">hospitalization for </text>
<text top="712" left="508" width="102" height="20" font="4">cardiac indication. </text>
<text top="729" left="508" width="121" height="20" font="4">Right HF was defined </text>
<text top="746" left="508" width="109" height="20" font="4">as new elevation of </text>
<text top="763" left="508" width="104" height="20" font="4">the jugular venous </text>
<text top="781" left="508" width="125" height="20" font="4">pressure &gt;4 cm above </text>
<text top="643" left="648" width="221" height="20" font="4">● At conception 20% had RVOTO, 32% </text>
<text top="660" left="648" width="228" height="20" font="4">had PR and 49% had mixed RVOTO and </text>
<text top="677" left="648" width="238" height="20" font="4">PR. Moderate-to-severe PR was present in </text>
<text top="694" left="648" width="223" height="20" font="4">30 (39%) and RVOTO ≥30 mm Hg in 12 </text>
<text top="712" left="648" width="127" height="20" font="4">(16%) of pregnancies.  </text>
<text top="729" left="648" width="238" height="20" font="4">● 7 pregnancies (9%) were complicated by </text>
<text top="746" left="648" width="54" height="20" font="4">right HF.  </text>
<text top="763" left="648" width="207" height="20" font="4">● No arrhythmias were documented.  </text>
<text top="643" left="899" width="172" height="20" font="4">● In pts with CHD and residual </text>
<text top="660" left="899" width="143" height="20" font="4">RVOT lesions, pregnancy </text>
<text top="677" left="899" width="172" height="20" font="4">outcomes were successful. Pts </text>
<text top="694" left="899" width="156" height="20" font="4">with moderate-to-severe PR </text>
<text top="712" left="899" width="156" height="20" font="4">were at risk for symptomatic </text>
<text top="729" left="899" width="161" height="20" font="4">right HF only if additional risk </text>
<text top="746" left="899" width="154" height="20" font="4">factors were present. When </text>
<text top="763" left="899" width="158" height="20" font="4">treated by a multidisciplinary </text>
</page>
<page number="67" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 67 </text>
<text top="107" left="508" width="109" height="20" font="4">the sternal angle) + </text>
<text top="124" left="508" width="73" height="20" font="4">symptoms of </text>
<text top="141" left="508" width="110" height="20" font="4">decreased exercise </text>
<text top="159" left="508" width="116" height="20" font="4">tolerance ± dyspnea </text>
<text top="176" left="508" width="118" height="20" font="4">(a common symptom </text>
<text top="193" left="508" width="109" height="20" font="4">in those with RVOT </text>
<text top="210" left="508" width="79" height="20" font="4">lesions due to </text>
<text top="228" left="508" width="55" height="20" font="4">abnormal </text>
<text top="245" left="508" width="84" height="20" font="4">interventricular </text>
<text top="262" left="508" width="99" height="20" font="4">interactions) 14 ± </text>
<text top="279" left="508" width="94" height="20" font="4">pitting peripheral </text>
<text top="296" left="508" width="41" height="20" font="4">edema </text>
<text top="107" left="648" width="222" height="20" font="4">● Predictors for right HF were moderate-</text>
<text top="124" left="648" width="237" height="20" font="4">to-severe PR in combination with at least 1 </text>
<text top="141" left="648" width="206" height="20" font="4">additional risk factor (twin pregnancy, </text>
<text top="159" left="648" width="177" height="20" font="4">branch PA stenosis, RV systolic </text>
<text top="176" left="648" width="169" height="20" font="4">dysfunction, RV hypertrophy).  </text>
<text top="193" left="648" width="223" height="20" font="4">● All pts responded to diuretic treatment </text>
<text top="210" left="648" width="200" height="20" font="4">and had a good pregnancy outcome </text>
<text top="228" left="648" width="147" height="20" font="4">without fetal complications </text>
<text top="107" left="899" width="136" height="20" font="4">team, maternal and fetal </text>
<text top="124" left="899" width="110" height="20" font="4">outcome was good. </text>
<text top="141" left="899" width="82" height="20" font="4">● The general </text>
<text top="159" left="899" width="139" height="20" font="4">recommendation that PV </text>
<text top="176" left="899" width="128" height="20" font="4">replacement should be </text>
<text top="193" left="899" width="168" height="20" font="4">undertaken prior to pregnancy </text>
<text top="210" left="899" width="169" height="20" font="4">in pts with moderate-to-severe </text>
<text top="228" left="899" width="168" height="20" font="4">PR and RV dilatation needs to </text>
<text top="245" left="899" width="95" height="20" font="4">be reconsidered. </text>
<text top="314" left="64" width="93" height="20" font="4">Tzemos N, et al. </text>
<text top="332" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(230)</a> </text>
<text top="349" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19249417?dopt=Citation">19249417</a></text>
<text top="349" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19249417?dopt=Citation"> </a></text>
<text top="314" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="332" left="170" width="38" height="20" font="4">cohort </text>
<text top="314" left="263" width="51" height="20" font="4">n=51 pts </text>
<text top="332" left="263" width="42" height="20" font="4">with 70 </text>
<text top="349" left="263" width="74" height="20" font="4">pregnancies  </text>
<text top="314" left="349" width="144" height="20" font="3"><b>Exclusion criteria</b>: Pts in </text>
<text top="332" left="349" width="89" height="20" font="4">whom their only </text>
<text top="349" left="349" width="86" height="20" font="4">pregnancy was </text>
<text top="366" left="349" width="145" height="20" font="4">terminated or complicated </text>
<text top="383" left="349" width="114" height="20" font="4">by miscarriage (fetal </text>
<text top="400" left="349" width="95" height="20" font="4">demise by 20 wk </text>
<text top="418" left="349" width="134" height="20" font="4">gestation) as well as pts </text>
<text top="435" left="349" width="96" height="20" font="4">with hypertrophic </text>
<text top="452" left="349" width="144" height="20" font="4">cardiomyopathy (n=11) or </text>
<text top="469" left="349" width="129" height="20" font="4">prosthetic aortic valves </text>
<text top="487" left="349" width="39" height="20" font="4">(n=24) </text>
<text top="314" left="508" width="110" height="20" font="4">Late cardiac events </text>
<text top="332" left="508" width="109" height="20" font="4">(pulmonary edema, </text>
<text top="349" left="508" width="108" height="20" font="4">cardiac arrhythmia, </text>
<text top="366" left="508" width="124" height="20" font="4">cardiac death, cardiac </text>
<text top="383" left="508" width="100" height="20" font="4">interventions &gt;1 y </text>
<text top="400" left="508" width="81" height="20" font="4">since baseline </text>
<text top="418" left="508" width="70" height="20" font="4">evaluation).  </text>
<text top="314" left="648" width="215" height="20" font="4">● During the follow-up period (6 + 4 y), </text>
<text top="332" left="648" width="189" height="20" font="4">43% of women underwent cardiac </text>
<text top="349" left="648" width="207" height="20" font="4">interventions which comprised all late </text>
<text top="366" left="648" width="90" height="20" font="4">cardiac events.  </text>
<text top="383" left="648" width="228" height="20" font="4">● Independent baseline predictors of late </text>
<text top="400" left="648" width="237" height="20" font="4">cardiac events were 1) moderate or severe </text>
<text top="418" left="648" width="231" height="20" font="4">AS (HR: 4.5; p=0.045), and 2) NYHA FCII </text>
<text top="435" left="648" width="112" height="20" font="4">(HR: 4.6; p=0.014).  </text>
<text top="452" left="648" width="227" height="20" font="4">● When outcomes in 26 women from the </text>
<text top="469" left="648" width="229" height="20" font="4">postpregnant group were compared to 26 </text>
<text top="487" left="648" width="238" height="20" font="4">age- and lesion-matched women who have </text>
<text top="504" left="648" width="216" height="20" font="4">never been pregnant, the postpregnant </text>
<text top="521" left="648" width="231" height="20" font="4">group had a higher late cardiac event rate </text>
<text top="538" left="648" width="221" height="20" font="4">than the never-pregnant group (31% vs. </text>
<text top="555" left="648" width="80" height="20" font="4">0%; p=0.021). </text>
<text top="314" left="899" width="153" height="20" font="4">● Women with moderate or </text>
<text top="332" left="899" width="157" height="20" font="4">severe AS and symptomatic </text>
<text top="349" left="899" width="160" height="20" font="4">during pregnancy are at high </text>
<text top="366" left="899" width="163" height="20" font="4">likelihood of requiring cardiac </text>
<text top="383" left="899" width="124" height="20" font="4">interventions late after </text>
<text top="400" left="899" width="64" height="20" font="4">pregnancy. </text>
<text top="418" left="899" width="163" height="20" font="4">● Women with congenital AS </text>
<text top="435" left="899" width="118" height="20" font="4">who have undergone </text>
<text top="452" left="899" width="139" height="20" font="4">pregnancy have a higher </text>
<text top="469" left="899" width="137" height="20" font="4">frequency of late cardiac </text>
<text top="487" left="899" width="171" height="20" font="4">events compared to those who </text>
<text top="504" left="899" width="154" height="20" font="4">have never been pregnant.  </text>
<text top="521" left="899" width="168" height="20" font="4">● Late cardiac outcomes after </text>
<text top="538" left="899" width="118" height="20" font="4">pregnancy should be </text>
<text top="555" left="899" width="173" height="20" font="4">considered in the counseling of </text>
<text top="573" left="899" width="135" height="20" font="4">women with AS who are </text>
<text top="590" left="899" width="144" height="20" font="4">contemplating pregnancy. </text>
<text top="608" left="64" width="85" height="20" font="4">Kampman MA, </text>
<text top="625" left="64" width="30" height="20" font="4">et al. </text>
<text top="642" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(231)</a> </text>
<text top="659" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24334717?dopt=Citation">24334717</a></text>
<text top="659" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24334717?dopt=Citation"> </a></text>
<text top="608" left="170" width="67" height="20" font="4">Prospective </text>
<text top="625" left="170" width="64" height="20" font="4">multicenter </text>
<text top="642" left="170" width="38" height="20" font="4">cohort </text>
<text top="608" left="263" width="38" height="20" font="4">n=213 </text>
<text top="625" left="263" width="70" height="20" font="4">pregnancies </text>
<text top="608" left="349" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="625" left="349" width="87" height="20" font="4">Miscarriages or </text>
<text top="642" left="349" width="132" height="20" font="4">pregnancies terminated </text>
<text top="659" left="349" width="131" height="20" font="4">before 20 wk gestation, </text>
<text top="677" left="349" width="135" height="20" font="4">women with known drug </text>
<text top="694" left="349" width="94" height="20" font="4">or alcohol abuse </text>
<text top="608" left="508" width="67" height="20" font="4">NT-proBNP </text>
<text top="608" left="648" width="237" height="20" font="4">● Adverse CV events occurred in 10.3% of </text>
<text top="625" left="648" width="231" height="20" font="4">213 pregnancies. NT-proBNP levels &gt;128 </text>
<text top="642" left="648" width="232" height="20" font="4">pg/mL at 20 wk gestation, the presence of </text>
<text top="659" left="648" width="216" height="20" font="4">a mechanical valve, and subpulmonary </text>
<text top="677" left="648" width="227" height="20" font="4">ventricular dysfunction before conception </text>
<text top="694" left="648" width="237" height="20" font="4">were independently associated with events </text>
<text top="711" left="648" width="215" height="20" font="4">OR: 10.6; p=0.039, OR: 12.0; p=0.016, </text>
<text top="728" left="648" width="200" height="20" font="4">and OR: 4.2; p=0.041, respectively.  </text>
<text top="745" left="648" width="212" height="20" font="4">● The NPV of NT-proBNP levels &lt;128 </text>
<text top="763" left="648" width="238" height="20" font="4">pg/mL was 96.9%. NT-proBNP levels &gt;128 </text>
<text top="780" left="648" width="195" height="20" font="4">pg/mL at 20 wk of gestation had an </text>
<text top="608" left="899" width="172" height="20" font="4">● Increased NT-proBNP levels </text>
<text top="625" left="899" width="154" height="20" font="4">at 20 wk of gestation are an </text>
<text top="642" left="899" width="159" height="20" font="4">independent risk predictor of </text>
<text top="659" left="899" width="172" height="20" font="4">CV events during pregnancy in </text>
<text top="677" left="899" width="102" height="20" font="4">women with CHD. </text>
</page>
<page number="68" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 68 </text>
<text top="107" left="648" width="179" height="20" font="4">additional value in predicting the </text>
<text top="124" left="648" width="223" height="20" font="4">occurrence of adverse CV events on the </text>
<text top="141" left="648" width="229" height="20" font="4">top of the other identified predictors (area </text>
<text top="159" left="648" width="219" height="20" font="4">under the curve 0.90 vs. 0.78; p=0.035) </text>
<text top="177" left="64" width="75" height="20" font="4">Gill HK, et al. </text>
<text top="194" left="64" width="63" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(232)</a> </text>
<text top="211" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12957444">12957444</a></text>
<text top="211" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12957444"> </a></text>
<text top="177" left="170" width="68" height="20" font="4">Data review </text>
<text top="177" left="263" width="216" height="20" font="4">n=6,640 pts  <b>Inclusion criteria</b>: N/A </text>
<text top="177" left="508" width="61" height="20" font="4">Fetal CHD </text>
<text top="177" left="648" width="222" height="20" font="4">● A recurrence of CHD was seen in 178 </text>
<text top="194" left="648" width="165" height="20" font="4">(2.7%) of 6,640 pregnancies.  </text>
<text top="211" left="648" width="190" height="20" font="4">● The referral numbers for sibling, </text>
<text top="228" left="648" width="213" height="20" font="4">maternal, or paternal CHD cases were </text>
<text top="246" left="648" width="198" height="20" font="4">5,151, 1,119, and 370, respectively. </text>
<text top="263" left="648" width="231" height="20" font="4">● Exact concordance was seen in 37% of </text>
<text top="280" left="648" width="193" height="20" font="4">cases (range 0%–80%), and group </text>
<text top="297" left="648" width="232" height="20" font="4">concordance was seen in 44%. In families </text>
<text top="314" left="648" width="209" height="20" font="4">where there were ≥2 recurrences, the </text>
<text top="332" left="648" width="222" height="20" font="4">exact concordance rate was 55%. Exact </text>
<text top="349" left="648" width="224" height="20" font="4">concordance rates were particularly high </text>
<text top="366" left="648" width="202" height="20" font="4">for isolated AVSD (4 of 5 [80%]) and </text>
<text top="383" left="648" width="176" height="20" font="4">laterality defects (7 of 11 [64%]) </text>
<text top="177" left="899" width="154" height="20" font="4">● Accurate diagnosis of the </text>
<text top="194" left="899" width="144" height="20" font="4">index case is essential for </text>
<text top="211" left="899" width="170" height="20" font="4">reliable counseling on patterns </text>
<text top="228" left="899" width="79" height="20" font="4">of recurrence. </text>
<text top="245" left="899" width="172" height="20" font="4">● Minor CHD in the index case </text>
<text top="263" left="899" width="168" height="20" font="4">does not exclude more severe </text>
<text top="280" left="899" width="131" height="20" font="4">disease in recurrences. </text>
<text top="401" left="64" width="86" height="20" font="4">Drenthen W, et </text>
<text top="418" left="64" width="16" height="20" font="4">al. </text>
<text top="436" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(233)</a> </text>
<text top="453" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17572244?dopt=Citation">17572244</a></text>
<text top="453" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17572244?dopt=Citation"> </a></text>
<text top="401" left="170" width="55" height="20" font="4">Literature </text>
<text top="418" left="170" width="39" height="20" font="4">review </text>
<text top="401" left="263" width="48" height="20" font="4">n=2,491 </text>
<text top="418" left="263" width="70" height="20" font="4">pregnancies </text>
<text top="401" left="349" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="418" left="349" width="145" height="20" font="4">Reviews and case reports </text>
<text top="436" left="349" width="138" height="20" font="4">describing ≤1 completed </text>
<text top="453" left="349" width="144" height="20" font="4">pregnancy were excluded </text>
<text top="401" left="508" width="86" height="20" font="4">Identification of </text>
<text top="418" left="508" width="71" height="20" font="4">independent </text>
<text top="436" left="508" width="118" height="20" font="4">predictors of cardiac, </text>
<text top="453" left="508" width="124" height="20" font="4">obstetric and neonatal </text>
<text top="470" left="508" width="78" height="20" font="4">complications </text>
<text top="401" left="648" width="219" height="20" font="4">● This review describes the outcome of </text>
<text top="418" left="648" width="184" height="20" font="4">2,491 pregnancies, including 377 </text>
<text top="436" left="648" width="202" height="20" font="4">miscarriages (15%) and 114 elective </text>
<text top="453" left="648" width="90" height="20" font="4">abortions (5%).  </text>
<text top="470" left="648" width="219" height="20" font="4">● Important cardiac complications were </text>
<text top="487" left="648" width="232" height="20" font="4">seen in 11% of the pregnancies. Obstetric </text>
<text top="504" left="648" width="220" height="20" font="4">complications do not appear to be more </text>
<text top="522" left="648" width="61" height="20" font="4">prevalent.  </text>
<text top="539" left="648" width="214" height="20" font="4">● In complex CHD, premature delivery </text>
<text top="556" left="648" width="237" height="20" font="4">rates are high, and more children are small </text>
<text top="573" left="648" width="108" height="20" font="4">for gestational age. </text>
<text top="401" left="899" width="163" height="20" font="4">● The offspring mortality was </text>
<text top="418" left="899" width="163" height="20" font="4">high throughout the spectrum </text>
<text top="436" left="899" width="124" height="20" font="4">and was related to the </text>
<text top="453" left="899" width="117" height="20" font="4">relatively high rate of </text>
<text top="470" left="899" width="129" height="20" font="4">premature delivery and </text>
<text top="487" left="899" width="109" height="20" font="4">recurrence of CHD. </text>
<text top="591" left="64" width="85" height="20" font="4">Cutts BA, et al. </text>
<text top="608" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(234)</a> </text>
<text top="626" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22840412?dopt=Citation">22840412</a></text>
<text top="626" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22840412?dopt=Citation"> </a></text>
<text top="591" left="170" width="44" height="20" font="4">Review </text>
<text top="591" left="263" width="24" height="20" font="4">N/A </text>
<text top="591" left="349" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="591" left="508" width="24" height="20" font="4">N/A </text>
<text top="591" left="648" width="24" height="20" font="4">N/A </text>
<text top="591" left="899" width="129" height="20" font="4">● Clinical trials for new </text>
<text top="608" left="899" width="130" height="20" font="4">anticoagulant agents to </text>
<text top="626" left="899" width="165" height="20" font="4">manage pulmonary embolism </text>
<text top="643" left="899" width="101" height="20" font="4">must be explored. </text>
<text top="661" left="64" width="80" height="20" font="4">Holland BJ, et </text>
<text top="678" left="64" width="16" height="20" font="4">al. </text>
<text top="695" left="64" width="63" height="20" font="4">2015 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(235)</a> </text>
<text top="712" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25904437?dopt=Citation">25904437</a></text>
<text top="712" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25904437?dopt=Citation"> </a></text>
<text top="661" left="170" width="63" height="20" font="4">Systematic </text>
<text top="678" left="170" width="39" height="20" font="4">review </text>
<text top="661" left="263" width="37" height="20" font="4">N/A, 8 </text>
<text top="678" left="263" width="42" height="20" font="4">studies </text>
<text top="661" left="349" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="661" left="508" width="122" height="20" font="4">Survival after planned </text>
<text top="678" left="508" width="87" height="20" font="4">cardiac surgery </text>
<text top="661" left="648" width="193" height="20" font="4">● In pts with comparable anatomy, </text>
<text top="678" left="648" width="238" height="20" font="4">standard risk, a parental desire to treat and </text>
<text top="695" left="648" width="214" height="20" font="4">optimal care, newborns with a prenatal </text>
<text top="712" left="648" width="234" height="20" font="4">diagnosis of critical CHD were significantly </text>
<text top="730" left="648" width="222" height="20" font="4">less likely to die prior to planned cardiac </text>
<text top="747" left="648" width="239" height="20" font="4">surgery than were those with a comparable </text>
<text top="764" left="648" width="209" height="20" font="4">postnatal diagnosis (pooled OR: 0.26; </text>
<text top="781" left="648" width="122" height="20" font="4">95%; CI: 0.08―0.84). </text>
<text top="661" left="899" width="165" height="20" font="4">● For newborns most likely to </text>
<text top="678" left="899" width="142" height="20" font="4">benefit from treatment for </text>
<text top="695" left="899" width="170" height="20" font="4">critical congenital HD, prenatal </text>
<text top="712" left="899" width="160" height="20" font="4">diagnosis reduced the risk of </text>
<text top="730" left="899" width="166" height="20" font="4">death prior to planned cardiac </text>
<text top="747" left="899" width="156" height="20" font="4">surgery relative to pts with a </text>
<text top="764" left="899" width="121" height="20" font="4">comparable postnatal </text>
<text top="781" left="899" width="59" height="20" font="4">diagnosis. </text>
</page>
<page number="69" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 69 </text>
<text top="106" left="108" width="3" height="20" font="4"> </text>
<text top="123" left="108" width="3" height="20" font="4"> </text>
<text top="140" left="108" width="368" height="24" font="1"><b>Data Supplement 20. Contraception – Section 3.13.2 </b></text>
<text top="162" left="93" width="38" height="20" font="3"><b>Study </b></text>
<text top="179" left="68" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="197" left="96" width="30" height="20" font="3"><b>Year </b></text>
<text top="162" left="178" width="70" height="20" font="3"><b>Study Type </b></text>
<text top="162" left="273" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="162" left="372" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="179" left="408" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="162" left="547" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="162" left="720" width="105" height="20" font="3"><b>Results/ p Values </b></text>
<text top="162" left="927" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="215" left="64" width="38" height="20" font="4">Pijuan-</text>
<text top="232" left="64" width="91" height="20" font="4">Domenech A, et </text>
<text top="249" left="64" width="16" height="20" font="4">al. </text>
<text top="266" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(236)</a> </text>
<text top="283" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23706389?dopt=Citation">23706389</a></text>
<text top="283" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23706389?dopt=Citation"> </a></text>
<text top="215" left="172" width="152" height="20" font="4">Retrospective   n=237 pts </text>
<text top="215" left="359" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="232" left="359" width="98" height="20" font="4">referred to ACHD </text>
<text top="249" left="359" width="108" height="20" font="4">preconception clinic</text>
<text top="251" left="467" width="2" height="13" font="6"> </text>
<text top="215" left="516" width="124" height="20" font="4">Progesterone use and </text>
<text top="232" left="516" width="36" height="20" font="4">safety </text>
<text top="215" left="665" width="164" height="20" font="4">● 1 y: 73% of pts who started </text>
<text top="232" left="665" width="185" height="20" font="4">progesterone remained on meds; </text>
<text top="249" left="665" width="205" height="20" font="4">gynecological side effects in 25%; no </text>
<text top="266" left="665" width="112" height="20" font="4">cardiac side effects. </text>
<text top="215" left="894" width="189" height="20" font="4">● “Acceptable” gynecological side </text>
<text top="232" left="894" width="185" height="20" font="4">effects and no thrombogenic side </text>
<text top="249" left="894" width="97" height="20" font="4">effects (1 y only). </text>
<text top="301" left="64" width="80" height="20" font="4">Hinze A, et al. </text>
<text top="319" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(237)</a> </text>
<text top="336" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22691053?dopt=Citation">22691053</a></text>
<text top="336" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22691053?dopt=Citation"> </a></text>
<text top="301" left="172" width="40" height="20" font="4">Cross- </text>
<text top="319" left="172" width="52" height="20" font="4">sectional </text>
<text top="336" left="172" width="40" height="20" font="4">survey </text>
<text top="301" left="266" width="51" height="20" font="4">n=83 pts </text>
<text top="301" left="359" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="319" left="359" width="115" height="20" font="4">Female pts ≥19 with </text>
<text top="336" left="359" width="30" height="20" font="4">CHD </text>
<text top="301" left="516" width="124" height="20" font="4">Receipt of counselling </text>
<text top="319" left="516" width="116" height="20" font="4">regarding pregnancy </text>
<text top="336" left="516" width="101" height="20" font="4">and contraception </text>
<text top="301" left="665" width="200" height="20" font="4">● 63% did not know if contraception </text>
<text top="319" left="665" width="90" height="20" font="4">contraindicated. </text>
<text top="301" left="894" width="186" height="20" font="4">● Individual counseling regarding </text>
<text top="319" left="894" width="192" height="20" font="4">pregnancy and contraception must </text>
<text top="336" left="894" width="105" height="20" font="4">be improved upon. </text>
<text top="354" left="64" width="92" height="20" font="4">Kaemerrer M, et </text>
<text top="371" left="64" width="16" height="20" font="4">al. </text>
<text top="388" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(238)</a> </text>
<text top="405" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22584383">22584383</a></text>
<text top="405" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22584383"> </a></text>
<text top="354" left="172" width="43" height="20" font="4">Clinical </text>
<text top="371" left="172" width="69" height="20" font="4">assessment </text>
<text top="388" left="172" width="24" height="20" font="4">and </text>
<text top="405" left="172" width="77" height="20" font="4">questionnaire </text>
<text top="354" left="266" width="58" height="20" font="4">n=536 pts </text>
<text top="354" left="359" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="371" left="359" width="115" height="20" font="4">Female pts ≥18 with </text>
<text top="388" left="359" width="30" height="20" font="4">CHD </text>
<text top="354" left="516" width="120" height="20" font="4">Sources of info about </text>
<text top="371" left="516" width="85" height="20" font="4">pregnancy and </text>
<text top="388" left="516" width="77" height="20" font="4">contraception </text>
<text top="354" left="665" width="207" height="20" font="4">● Women rated level of information 5 </text>
<text top="371" left="665" width="42" height="20" font="4">(1–10). </text>
<text top="354" left="894" width="176" height="20" font="4">● Current level of information is </text>
<text top="371" left="894" width="68" height="20" font="4">inadequate. </text>
<text top="423" left="64" width="71" height="20" font="4">Vigl M, et al. </text>
<text top="440" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(239)</a> </text>
<text top="458" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21029831?dopt=Citation">21029831</a></text>
<text top="458" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21029831?dopt=Citation"> </a></text>
<text top="423" left="172" width="43" height="20" font="4">Clinical </text>
<text top="440" left="172" width="69" height="20" font="4">assessment </text>
<text top="458" left="172" width="24" height="20" font="4">and </text>
<text top="475" left="172" width="77" height="20" font="4">questionnaire </text>
<text top="423" left="266" width="58" height="20" font="4">n=536 pts </text>
<text top="423" left="359" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="440" left="359" width="135" height="20" font="4">Female ≥18 y with CHD </text>
<text top="423" left="516" width="120" height="20" font="4">Counseling regarding </text>
<text top="440" left="516" width="121" height="20" font="4">risk of pregnancy and </text>
<text top="458" left="516" width="77" height="20" font="4">contraception </text>
<text top="423" left="665" width="160" height="20" font="4">● 20% using contraindicated </text>
<text top="440" left="665" width="80" height="20" font="4">contraceptive. </text>
<text top="458" left="665" width="199" height="20" font="4">● 28% of high pregnancy risk group </text>
<text top="475" left="665" width="206" height="20" font="4">not using contraceptive. 43% had not </text>
<text top="492" left="665" width="205" height="20" font="4">been counselled about contraception </text>
<text top="509" left="665" width="150" height="20" font="4">and 48% about pregnancy. </text>
<text top="423" left="894" width="202" height="20" font="4">● Timely and competent counselling </text>
<text top="440" left="894" width="187" height="20" font="4">is important for women with CHD. </text>
<text top="527" left="64" width="81" height="20" font="4">Kovacs AH, et </text>
<text top="544" left="64" width="16" height="20" font="4">al. </text>
<text top="562" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(240)</a> </text>
<text top="579" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18687254?dopt=Citation">18687254</a></text>
<text top="579" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18687254?dopt=Citation"> </a></text>
<text top="527" left="172" width="152" height="20" font="4">Questionnaire  n=116 pts </text>
<text top="527" left="359" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="544" left="359" width="106" height="20" font="4">Females with CHD </text>
<text top="562" left="359" width="115" height="20" font="4">(mean age 31 ± 9 y) </text>
<text top="527" left="516" width="104" height="20" font="4">Contraception and </text>
<text top="544" left="516" width="123" height="20" font="4">pregnancy knowledge </text>
<text top="527" left="665" width="207" height="20" font="4">● 51% recalled receiving specific info </text>
<text top="544" left="665" width="192" height="20" font="4">about birth control; 37% had never </text>
<text top="562" left="665" width="183" height="20" font="4">been informed of pregnancy risk. </text>
<text top="527" left="894" width="198" height="20" font="4">● Women with ACHD lack accurate </text>
<text top="544" left="894" width="180" height="20" font="4">knowledge about pregnancy risk </text>
<text top="562" left="894" width="105" height="20" font="4">and contraception. </text>
<text top="597" left="64" width="88" height="20" font="4">Lidegaard O, et </text>
<text top="614" left="64" width="16" height="20" font="4">al. </text>
<text top="631" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(241)</a> </text>
<text top="649" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19679613?dopt=Citation">19679613</a></text>
<text top="649" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19679613?dopt=Citation"> </a></text>
<text top="597" left="172" width="48" height="20" font="4">National </text>
<text top="614" left="172" width="38" height="20" font="4">cohort </text>
<text top="597" left="266" width="80" height="20" font="4">n=10.4 million </text>
<text top="614" left="266" width="78" height="20" font="4">women y with </text>
<text top="631" left="266" width="59" height="20" font="4">3.3 million </text>
<text top="649" left="266" width="70" height="20" font="4">women y on </text>
<text top="666" left="266" width="24" height="20" font="4">oral </text>
<text top="683" left="266" width="76" height="20" font="4">contraceptive </text>
<text top="700" left="266" width="19" height="20" font="4">pill </text>
<text top="597" left="359" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="614" left="359" width="115" height="20" font="4">Female pts ≥18 with </text>
<text top="631" left="359" width="139" height="20" font="4">CHD Danish females 15–</text>
<text top="649" left="359" width="111" height="20" font="4">49 y between 1995–</text>
<text top="666" left="359" width="34" height="20" font="4">2005. </text>
<text top="597" left="516" width="68" height="20" font="4">Risk of VTE </text>
<text top="597" left="665" width="107" height="20" font="4">● 4,13 VTE events </text>
<text top="614" left="665" width="165" height="20" font="4">● Absolute risk of 3.01/10000 </text>
<text top="631" left="665" width="54" height="20" font="4">nonusers </text>
<text top="649" left="665" width="102" height="20" font="4">6.29/10,000 users </text>
<text top="597" left="894" width="167" height="20" font="4">● Risk of VTE decreased with </text>
<text top="614" left="894" width="172" height="20" font="4">duration of use and decreasing </text>
<text top="631" left="894" width="85" height="20" font="4">estrogen dose. </text>
<text top="649" left="894" width="165" height="20" font="4">● Progesterone-only pills and </text>
<text top="666" left="894" width="170" height="20" font="4">hormone releasing intrauterine </text>
<text top="683" left="894" width="183" height="20" font="4">devices were not associated with </text>
<text top="700" left="894" width="124" height="20" font="4">increased risk of VTE. </text>
<text top="718" left="64" width="82" height="20" font="4">Famuyide AO, </text>
<text top="735" left="64" width="30" height="20" font="4">et al. </text>
<text top="753" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(242)</a> </text>
<text top="770" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18380988?dopt=Citation">18380988</a></text>
<text top="770" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18380988?dopt=Citation"> </a></text>
<text top="718" left="172" width="78" height="20" font="4">Retrospective </text>
<text top="735" left="172" width="41" height="20" font="4">cohort  </text>
<text top="718" left="266" width="56" height="20" font="4">n=18 with </text>
<text top="735" left="266" width="54" height="20" font="4">CHD and </text>
<text top="753" left="266" width="38" height="20" font="4">n=157 </text>
<text top="770" left="266" width="42" height="20" font="4">without </text>
<text top="718" left="359" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="735" left="359" width="118" height="20" font="4">with high-risk cardiac </text>
<text top="753" left="359" width="108" height="20" font="4">conditions in whom </text>
<text top="770" left="359" width="86" height="20" font="4">pregnancy was </text>
<text top="718" left="516" width="123" height="20" font="4">Successful placement </text>
<text top="735" left="516" width="77" height="20" font="4">of microinsert </text>
<text top="753" left="516" width="78" height="20" font="4">hysteroscopic </text>
<text top="770" left="516" width="65" height="20" font="4">sterilization </text>
<text top="718" left="665" width="206" height="20" font="4">● There was no significant difference </text>
<text top="735" left="665" width="161" height="20" font="4">in use of general anesthesia, </text>
<text top="753" left="665" width="210" height="20" font="4">successful bilateral device placement, </text>
<text top="770" left="665" width="203" height="20" font="4">postoperative pain score or length of </text>
<text top="787" left="665" width="88" height="20" font="4">hospitalization.  </text>
<text top="718" left="894" width="192" height="20" font="4">● For women with cardiac disease </text>
<text top="735" left="894" width="122" height="20" font="4">in whom pregnancy is </text>
<text top="753" left="894" width="154" height="20" font="4">contraindicated, microinsert </text>
<text top="770" left="894" width="167" height="20" font="4">hysteroscopic sterilization can </text>
</page>
<page number="70" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 70 </text>
<text top="107" left="266" width="43" height="20" font="4">cardiac </text>
<text top="124" left="266" width="46" height="20" font="4">disease </text>
<text top="107" left="359" width="126" height="20" font="4">contraindicated vs. pts </text>
<text top="124" left="359" width="131" height="20" font="4">without cardiac disease </text>
<text top="107" left="894" width="170" height="20" font="4">provide minimally invasive and </text>
<text top="124" left="894" width="143" height="20" font="4">permanent contraception. </text>
<text top="183" left="108" width="3" height="20" font="4"> </text>
<text top="200" left="108" width="3" height="20" font="4"> </text>
<text top="217" left="108" width="382" height="24" font="1"><b>Data Supplement 21. Sexual Function – Section 3.13.4 </b></text>
<text top="239" left="90" width="38" height="20" font="3"><b>Study </b></text>
<text top="256" left="65" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="274" left="94" width="30" height="20" font="3"><b>Year </b></text>
<text top="239" left="180" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="256" left="195" width="44" height="20" font="3"><b>Design </b></text>
<text top="239" left="289" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="239" left="381" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="256" left="417" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="239" left="547" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="239" left="715" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="239" left="913" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="292" left="64" width="85" height="20" font="4">Moons P, et al. </text>
<text top="309" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(243)</a> </text>
<text top="326" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17182130?dopt=Citation">17182130</a></text>
<text top="326" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17182130?dopt=Citation"> </a></text>
<text top="292" left="167" width="80" height="20" font="4">Matched case </text>
<text top="309" left="167" width="44" height="20" font="4">control  </text>
<text top="292" left="280" width="58" height="20" font="4">n=441 pts </text>
<text top="309" left="280" width="54" height="20" font="4">n=control </text>
<text top="292" left="376" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="309" left="376" width="118" height="20" font="4">≥18 y, literate, Dutch </text>
<text top="326" left="376" width="96" height="20" font="4">speaking, able to </text>
<text top="343" left="376" width="46" height="20" font="4">consent </text>
<text top="360" left="376" width="3" height="20" font="4"> </text>
<text top="378" left="376" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="395" left="376" width="96" height="20" font="4">First visit, mental </text>
<text top="412" left="376" width="122" height="20" font="4">delay, diagnosed with </text>
<text top="429" left="376" width="75" height="20" font="4">ASD, or PFO </text>
<text top="292" left="518" width="114" height="20" font="4">Frequency of sexual </text>
<text top="309" left="518" width="72" height="20" font="4">problem, the </text>
<text top="326" left="518" width="108" height="20" font="4">associated distress </text>
<text top="292" left="661" width="176" height="20" font="4">● Perceived sexual problems in </text>
<text top="309" left="661" width="96" height="20" font="4">10%–20% of pts. </text>
<text top="326" left="661" width="132" height="20" font="4">● Pts &lt;controls p=0.03. </text>
<text top="343" left="661" width="193" height="20" font="4">● Associated distress pt &gt; controls </text>
<text top="360" left="661" width="52" height="20" font="4">p=0.032. </text>
<text top="292" left="883" width="176" height="20" font="4">● Perceived sexual problems in </text>
<text top="309" left="883" width="169" height="20" font="4">cases occurred less frequently </text>
<text top="326" left="883" width="146" height="20" font="4">than in controls, but cases </text>
<text top="343" left="883" width="161" height="20" font="4">experienced more distress in </text>
<text top="360" left="883" width="153" height="20" font="4">worrying about sex life than </text>
<text top="378" left="883" width="50" height="20" font="4">controls. </text>
<text top="395" left="883" width="182" height="20" font="4">● Frequency not associated with </text>
<text top="412" left="883" width="194" height="20" font="4">CHD severity but with NYHA class. </text>
<text top="429" left="883" width="179" height="20" font="4">● Sexual functioning in CHD pts </text>
<text top="446" left="883" width="186" height="20" font="4">not particularly problematic in this </text>
<text top="464" left="883" width="38" height="20" font="4">group. </text>
<text top="482" left="64" width="86" height="20" font="4">Cook SC, et al. </text>
<text top="499" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(244)</a> </text>
<text top="516" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19064032?dopt=Citation">19064032</a></text>
<text top="516" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19064032?dopt=Citation"> </a></text>
<text top="482" left="167" width="75" height="20" font="4">Convenience </text>
<text top="499" left="167" width="83" height="20" font="4">sample survey </text>
<text top="482" left="280" width="54" height="20" font="4">n=86 pts  </text>
<text top="482" left="376" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="499" left="376" width="102" height="20" font="4">≥18 y, male, CHD </text>
<text top="482" left="518" width="107" height="20" font="4">Sexual dysfunction </text>
<text top="482" left="661" width="174" height="20" font="4">● 38% of men reported erectile </text>
<text top="499" left="661" width="69" height="20" font="4">dysfunction. </text>
<text top="482" left="883" width="185" height="20" font="4">● Erectile dysfunction is common </text>
<text top="499" left="883" width="187" height="20" font="4">in young men with CHD and does </text>
<text top="516" left="883" width="192" height="20" font="4">not correlate with disease severity. </text>
<text top="533" left="883" width="174" height="20" font="4">● 3 times more likely if on BBs. </text>
<text top="551" left="64" width="71" height="20" font="4">Vigl M, et al. </text>
<text top="568" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(245)</a> </text>
<text top="586" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19364753?dopt=Citation">19364753</a></text>
<text top="586" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19364753?dopt=Citation"> </a></text>
<text top="551" left="167" width="85" height="20" font="4">Consecutive pt </text>
<text top="568" left="167" width="98" height="20" font="4">surveys including </text>
<text top="586" left="167" width="71" height="20" font="4">International </text>
<text top="603" left="167" width="91" height="20" font="4">Index of Erectile </text>
<text top="620" left="167" width="94" height="20" font="4">Function, SF-12, </text>
<text top="637" left="166" width="64" height="20" font="4">Allgemeine </text>
<text top="654" left="166" width="100" height="20" font="4">Depressionsskala </text>
<text top="551" left="280" width="61" height="20" font="4">n=332 pts  </text>
<text top="551" left="376" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="568" left="376" width="102" height="20" font="4">≥18 y, male, CHD </text>
<text top="586" left="376" width="3" height="20" font="4"> </text>
<text top="603" left="376" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="620" left="376" width="98" height="20" font="4">Mental incapacity </text>
<text top="551" left="518" width="113" height="20" font="4">Erectile dysfunction, </text>
<text top="568" left="518" width="117" height="20" font="4">subjective well-being </text>
<text top="551" left="661" width="148" height="20" font="4">● 10% of men had erectile </text>
<text top="568" left="661" width="69" height="20" font="4">dysfunction. </text>
<text top="586" left="661" width="160" height="20" font="4">● Lower SF-12 mental score </text>
<text top="603" left="661" width="52" height="20" font="4">p&lt;0.001. </text>
<text top="620" left="661" width="168" height="20" font="4">● Lower SF-12 physical score </text>
<text top="637" left="661" width="45" height="20" font="4">p=0.02. </text>
<text top="654" left="661" width="180" height="20" font="4">● 10-fold increase in depression </text>
<text top="672" left="661" width="52" height="20" font="4">p&lt;0.001. </text>
<text top="551" left="883" width="153" height="20" font="4">● Men with CHD and &lt;40 y </text>
<text top="568" left="883" width="130" height="20" font="4">engage in fewer sexual </text>
<text top="586" left="883" width="181" height="20" font="4">relationships than healthy peers. </text>
<text top="603" left="883" width="190" height="20" font="4">● Presence of erectile dysfunction </text>
<text top="620" left="883" width="187" height="20" font="4">is associated with significant QOL </text>
<text top="637" left="883" width="74" height="20" font="4">impairments. </text>
<text top="690" left="64" width="80" height="20" font="4">Winter MM, et </text>
<text top="707" left="64" width="16" height="20" font="4">al. </text>
<text top="724" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(246)</a> </text>
<text top="741" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20920658?dopt=Citation">20920658</a></text>
<text top="741" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20920658?dopt=Citation"> </a></text>
<text top="690" left="167" width="72" height="20" font="4">Case control </text>
<text top="707" left="167" width="68" height="20" font="4">survey (169 </text>
<text top="724" left="167" width="37" height="20" font="4">items) </text>
<text top="690" left="280" width="61" height="20" font="4">n=133 pts, </text>
<text top="707" left="280" width="70" height="20" font="4">(52% male); </text>
<text top="724" left="280" width="69" height="20" font="4">73 partners; </text>
<text top="741" left="280" width="81" height="20" font="4">3,642 controls </text>
<text top="690" left="376" width="106" height="20" font="3"><b>Inclusion criteria:</b> </text>
<text top="707" left="376" width="68" height="20" font="4">≥18 y, CHD </text>
<text top="690" left="518" width="101" height="20" font="4">Subjective health, </text>
<text top="707" left="518" width="122" height="20" font="4">relational satisfaction, </text>
<text top="724" left="518" width="107" height="20" font="4">sexual satisfaction, </text>
<text top="741" left="518" width="85" height="20" font="4">sexual function </text>
<text top="690" left="661" width="191" height="20" font="4">● 71% pts in relationship (vs. 79% </text>
<text top="707" left="661" width="109" height="20" font="4">population p&lt;0.05). </text>
<text top="690" left="883" width="156" height="20" font="4">● Fewer pts in relationship.  </text>
<text top="707" left="883" width="93" height="20" font="4">● More distress. </text>
<text top="724" left="883" width="131" height="20" font="4">● Frequency of erectile </text>
<text top="741" left="883" width="195" height="20" font="4">dysfunction = 42% (no greater than </text>
<text top="758" left="883" width="54" height="20" font="4">controls). </text>
</page>
<page number="71" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 71 </text>
<text top="107" left="64" width="74" height="20" font="4">Opic P, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(247)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23859255?dopt=Citation">23859255</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23859255?dopt=Citation"> </a></text>
<text top="107" left="167" width="70" height="20" font="4">Longitudinal </text>
<text top="124" left="167" width="77" height="20" font="4">cohort survey </text>
<text top="107" left="280" width="44" height="20" font="4">254 pts </text>
<text top="124" left="280" width="76" height="20" font="4">(53.5% male) </text>
<text top="107" left="376" width="106" height="20" font="3"><b>Inclusion criteria:</b> </text>
<text top="124" left="376" width="90" height="20" font="4">First open heart </text>
<text top="141" left="376" width="116" height="20" font="4">surgery at age &lt;15 y </text>
<text top="159" left="376" width="115" height="20" font="4">between 1968–1980 </text>
<text top="176" left="376" width="119" height="20" font="4">for diagnosis of ASD, </text>
<text top="193" left="376" width="92" height="20" font="4">VSD, TOF, TGA </text>
<text top="107" left="518" width="81" height="20" font="4">Overall sexual </text>
<text top="124" left="518" width="96" height="20" font="4">function, disease-</text>
<text top="141" left="518" width="83" height="20" font="4">specific sexual </text>
<text top="159" left="518" width="54" height="20" font="4">problems </text>
<text top="107" left="661" width="194" height="20" font="4">● Erectile dysfunction in 13.7% pts </text>
<text top="124" left="661" width="52" height="20" font="4">p=0.002. </text>
<text top="107" left="883" width="190" height="20" font="4">● Broad range of sexual concerns </text>
<text top="124" left="883" width="190" height="20" font="4">in pts, decreased satisfaction, and </text>
<text top="141" left="883" width="124" height="20" font="4">body image concerns. </text>
<text top="211" left="108" width="3" height="20" font="4"> </text>
<text top="228" left="54" width="3" height="20" font="4"> </text>
<text top="245" left="108" width="506" height="24" font="1"><b>Data Supplement 22. Pharmacological Therapy for ACHD – Section 3.17 </b></text>
<text top="267" left="72" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="284" left="72" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="267" left="195" width="38" height="20" font="3"><b>Study </b></text>
<text top="284" left="175" width="76" height="20" font="3"><b>Type/Design </b></text>
<text top="267" left="270" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="267" left="370" width="165" height="20" font="3"><b>Inclusion/Exclusion Criteria </b></text>
<text top="267" left="578" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="267" left="720" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="267" left="908" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="302" left="64" width="84" height="20" font="4">Norozi K, et al. </text>
<text top="319" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(248)</a> </text>
<text top="336" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17572925?dopt=Citation">17572925</a></text>
<text top="336" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17572925?dopt=Citation"> </a></text>
<text top="302" left="170" width="67" height="20" font="4">Prospective </text>
<text top="319" left="170" width="70" height="20" font="4">double-blind </text>
<text top="336" left="170" width="29" height="20" font="4">RCT </text>
<text top="302" left="269" width="51" height="20" font="4">n=33 pts </text>
<text top="302" left="349" width="174" height="20" font="3"><b>Inclusion criteria</b>: 30.9 ± 9.5 y </text>
<text top="319" left="349" width="189" height="20" font="4">NYHA class 1 or 2 with BNP &gt;100 </text>
<text top="336" left="349" width="204" height="20" font="4">pg/mL and a reduced peak uptake of </text>
<text top="354" left="349" width="10" height="20" font="4">O</text>
<text top="360" left="359" width="7" height="13" font="6">2 </text>
<text top="354" left="365" width="84" height="20" font="4">&lt;25 mL/kg/min </text>
<text top="371" left="349" width="3" height="20" font="4"> </text>
<text top="388" left="349" width="169" height="20" font="3"><b>Exclusion criteria</b>: Significant </text>
<text top="405" left="349" width="195" height="20" font="4">bradycardia, average HR &lt;50 bpm, </text>
<text top="423" left="349" width="81" height="20" font="4">already on BB </text>
<text top="302" left="568" width="86" height="20" font="4">Cardiac failure: </text>
<text top="319" left="568" width="83" height="20" font="4">present if level </text>
<text top="336" left="568" width="42" height="20" font="4">of BNP </text>
<text top="354" left="568" width="67" height="20" font="4">significantly </text>
<text top="371" left="568" width="69" height="20" font="4">&gt;100 pg/mL </text>
<text top="302" left="674" width="136" height="20" font="4">● No change in peak VO</text>
<text top="308" left="811" width="4" height="13" font="6">2</text>
<text top="302" left="815" width="7" height="20" font="4">, </text>
<text top="319" left="674" width="172" height="20" font="4">ventricular size or NYHA class. </text>
<text top="302" left="880" width="175" height="20" font="4">● Beta blockade with bisoprolol </text>
<text top="319" left="880" width="190" height="20" font="4">seems to have no beneficial effect </text>
<text top="336" left="880" width="145" height="20" font="4">on asymptomatic or mildly </text>
<text top="354" left="880" width="138" height="20" font="4">symptomatic pts with RV </text>
<text top="371" left="880" width="172" height="20" font="4">dysfunction secondary to rTOF </text>
<text top="388" left="880" width="191" height="20" font="4">with residual PR and/or pulmonary </text>
<text top="405" left="880" width="52" height="20" font="4">stenosis. </text>
<text top="440" left="64" width="83" height="20" font="4">Babu-Narayan </text>
<text top="458" left="64" width="53" height="20" font="4">SV, et al. </text>
<text top="475" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(249)</a> </text>
<text top="492" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20970202?dopt=Citation">20970202</a></text>
<text top="492" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20970202?dopt=Citation"> </a></text>
<text top="440" left="170" width="67" height="20" font="4">Prospective </text>
<text top="458" left="170" width="70" height="20" font="4">double-blind </text>
<text top="475" left="170" width="29" height="20" font="4">RCT </text>
<text top="440" left="269" width="51" height="20" font="4">n=64 pts </text>
<text top="440" left="349" width="176" height="20" font="3"><b>Inclusion criteria</b>: Moderate-to-</text>
<text top="458" left="349" width="96" height="20" font="4">severe PR; CMR </text>
<text top="475" left="349" width="3" height="20" font="4"> </text>
<text top="492" left="349" width="172" height="20" font="3"><b>Exclusion criteria</b>: Pulmonary </text>
<text top="509" left="349" width="154" height="20" font="4">stenosis, drug allergy, renal </text>
<text top="527" left="349" width="66" height="20" font="4">dysfunction </text>
<text top="440" left="568" width="68" height="20" font="4">CMR RVEF </text>
<text top="440" left="674" width="181" height="20" font="4">● There was no difference in the </text>
<text top="458" left="674" width="179" height="20" font="4">1° endpoint RVEF. RV long-axis </text>
<text top="475" left="674" width="182" height="20" font="4">shortening significantly improved </text>
<text top="492" left="674" width="184" height="20" font="4">in the ramipril group compared to </text>
<text top="509" left="674" width="185" height="20" font="4">placebo (RV: 2.3 ± 3.8 vs. 0.02 ± </text>
<text top="527" left="674" width="182" height="20" font="4">2.7 mm; p=0.017) as did LV long-</text>
<text top="544" left="674" width="187" height="20" font="4">axis shortening (1.9 ± 4.5 vs. -0.2 </text>
<text top="561" left="674" width="190" height="20" font="4">± 3.7 mm, respectively; p=0.030).  </text>
<text top="578" left="674" width="155" height="20" font="4">● No clear differences were </text>
<text top="595" left="674" width="168" height="20" font="4">detected between ramipril and </text>
<text top="613" left="674" width="181" height="20" font="4">placebo for other measures. In a </text>
<text top="630" left="674" width="190" height="20" font="4">subgroup of pts with restrictive RV </text>
<text top="647" left="674" width="169" height="20" font="4">physiology, ramipril resulted in </text>
<text top="664" left="674" width="154" height="20" font="4">decrease in LV end-systolic </text>
<text top="681" left="674" width="163" height="20" font="4">volume index and increase in </text>
<text top="699" left="674" width="163" height="20" font="4">LVEF (2.4 ± 5.0 vs. 2.7 ± 3.6 </text>
<text top="716" left="674" width="31" height="20" font="4">mL/m</text>
<text top="718" left="705" width="4" height="13" font="6">2</text>
<text top="716" left="710" width="155" height="20" font="4">; p=0.005, 2.5 ± 5.0 vs. -1.3 </text>
<text top="733" left="674" width="184" height="20" font="4">± 3.5%; p=0.03). Ramipril did not </text>
<text top="750" left="674" width="185" height="20" font="4">cause AE and was well tolerated. </text>
<text top="440" left="880" width="160" height="20" font="4">● Ramipril is a well-tolerated </text>
<text top="458" left="880" width="171" height="20" font="4">therapy, improves biventricular </text>
<text top="475" left="880" width="187" height="20" font="4">function in pts with rTOF and may </text>
<text top="492" left="880" width="176" height="20" font="4">have a particular role in pts with </text>
<text top="509" left="880" width="184" height="20" font="4">restrictive RV physiology. Larger, </text>
<text top="527" left="880" width="188" height="20" font="4">longer-term studies are needed to </text>
<text top="544" left="880" width="176" height="20" font="4">determine if ACEIs can improve </text>
<text top="561" left="880" width="176" height="20" font="4">both ventricular remodeling and </text>
<text top="578" left="880" width="100" height="20" font="4">clinical outcomes. </text>
</page>
<page number="72" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 72 </text>
<text top="107" left="64" width="89" height="20" font="4">Lester SJ, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2001 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(250)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11728365?dopt=Citation">11728365</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11728365?dopt=Citation"> </a></text>
<text top="107" left="170" width="64" height="20" font="4">RCT with a </text>
<text top="124" left="170" width="57" height="20" font="4">crossover </text>
<text top="141" left="170" width="64" height="20" font="4">design and </text>
<text top="159" left="170" width="60" height="20" font="4">each pt as </text>
<text top="176" left="170" width="53" height="20" font="4">their own </text>
<text top="193" left="170" width="40" height="20" font="4">control </text>
<text top="210" left="170" width="51" height="20" font="4">Losartan </text>
<text top="107" left="269" width="44" height="20" font="4">n=7 pts </text>
<text top="107" left="349" width="202" height="20" font="3"><b>Inclusion criteria</b>: D-loop TGA after </text>
<text top="124" left="349" width="68" height="20" font="4">atrial switch </text>
<text top="141" left="349" width="3" height="20" font="4"> </text>
<text top="159" left="349" width="147" height="20" font="3"><b>Exclusion criteria</b>: &gt;13 y  </text>
<text top="107" left="568" width="91" height="20" font="4">Bicycle exercise </text>
<text top="124" left="568" width="23" height="20" font="4">test </text>
<text top="107" left="674" width="183" height="20" font="4">● No adverse effects of afterload </text>
<text top="124" left="674" width="57" height="20" font="4">reduction. </text>
<text top="141" left="674" width="188" height="20" font="4">● Decreased BP (0.04), improved </text>
<text top="159" left="674" width="174" height="20" font="4">EF, (0.04), decreased systemic </text>
<text top="176" left="674" width="157" height="20" font="4">AV valve regurgitant volume </text>
<text top="193" left="674" width="169" height="20" font="4">(0.01), and increased exercise </text>
<text top="210" left="674" width="69" height="20" font="4">time (0.02).  </text>
<text top="107" left="880" width="170" height="20" font="4">● Improved outcome variables </text>
<text top="124" left="880" width="163" height="20" font="4">and no adverse effects in this </text>
<text top="141" left="880" width="70" height="20" font="4">small group. </text>
<text top="228" left="64" width="81" height="20" font="4">Hechter SJ, et </text>
<text top="245" left="64" width="16" height="20" font="4">al. </text>
<text top="263" left="64" width="63" height="20" font="4">2001 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(251)</a> </text>
<text top="280" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11230861?dopt=Citation">11230861</a></text>
<text top="280" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11230861?dopt=Citation"> </a></text>
<text top="228" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="245" left="170" width="75" height="20" font="4">data analysis </text>
<text top="228" left="269" width="51" height="20" font="4">n=14 pts </text>
<text top="228" left="349" width="202" height="20" font="3"><b>Inclusion criteria</b>: D-loop TGA after </text>
<text top="245" left="349" width="68" height="20" font="4">atrial switch </text>
<text top="263" left="349" width="3" height="20" font="4"> </text>
<text top="280" left="349" width="147" height="20" font="3"><b>Exclusion criteria</b>: &gt;18 y  </text>
<text top="228" left="568" width="74" height="20" font="4">CPET before </text>
<text top="245" left="568" width="87" height="20" font="4">ACEI had been </text>
<text top="263" left="568" width="70" height="20" font="4">initiated and </text>
<text top="280" left="568" width="52" height="20" font="4">repeated </text>
<text top="228" left="674" width="160" height="20" font="4">● No significant difference in </text>
<text top="245" left="674" width="183" height="20" font="4">resting variables before and after </text>
<text top="263" left="674" width="35" height="20" font="4">ACEI. </text>
<text top="280" left="674" width="182" height="20" font="4">● MRI: significantly lower resting </text>
<text top="297" left="674" width="171" height="20" font="4">RVEF and larger right ventricle </text>
<text top="314" left="674" width="186" height="20" font="4">volumes compared with controls.  </text>
<text top="228" left="880" width="160" height="20" font="4">● ACEIs: No effect on CPET </text>
<text top="245" left="880" width="43" height="20" font="4">results. </text>
<text top="263" left="880" width="151" height="20" font="4">● No effect on MR studies. </text>
<text top="280" left="880" width="30" height="20" font="4">● VO</text>
<text top="286" left="910" width="4" height="13" font="6">2</text>
<text top="280" left="915" width="151" height="20" font="4"> max and exercise duration </text>
<text top="297" left="880" width="107" height="20" font="4">increased in some. </text>
<text top="332" left="64" width="75" height="20" font="4">Dore A, et al. </text>
<text top="350" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(252)</a> </text>
<text top="367" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16216961?dopt=Citation">16216961</a></text>
<text top="367" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16216961?dopt=Citation"> </a></text>
<text top="332" left="170" width="67" height="20" font="4">Prospective </text>
<text top="350" left="170" width="70" height="20" font="4">double-blind </text>
<text top="367" left="170" width="80" height="20" font="4">crossover trial </text>
<text top="332" left="269" width="51" height="20" font="4">n=29 pts </text>
<text top="332" left="349" width="204" height="20" font="3"><b>Inclusion criteria</b>: L-loop TGA (8) or </text>
<text top="350" left="349" width="187" height="20" font="4">D-loop TGA with atrial switch (21) </text>
<text top="367" left="349" width="3" height="20" font="4"> </text>
<text top="384" left="349" width="195" height="20" font="3"><b>Exclusion criteria</b>: NYHA class III, </text>
<text top="401" left="349" width="189" height="20" font="4">IV, unable to exercise, pregnancy, </text>
<text top="418" left="349" width="192" height="20" font="4">rate-fixed pacer, renal dysfunction, </text>
<text top="436" left="349" width="124" height="20" font="4">history of angioedema </text>
<text top="332" left="568" width="18" height="20" font="4">VO</text>
<text top="338" left="586" width="4" height="13" font="6">2</text>
<text top="332" left="590" width="33" height="20" font="4"> max, </text>
<text top="350" left="568" width="60" height="20" font="4">RVEF, NT-</text>
<text top="367" left="568" width="46" height="20" font="4">proBNP </text>
<text top="332" left="674" width="183" height="20" font="4">● Comparing losartan to placebo </text>
<text top="350" left="674" width="157" height="20" font="4">showed no differences in VO</text>
<text top="356" left="832" width="4" height="13" font="6">2</text>
<text top="350" left="836" width="30" height="20" font="4"> max </text>
<text top="367" left="674" width="142" height="20" font="4">(29.9 ± 5.4 vs. 29.4 ± 6.2 </text>
<text top="384" left="674" width="166" height="20" font="4">mL/kg/·min; p=0.43), exercise </text>
<text top="401" left="674" width="185" height="20" font="4">duration (632.3 ± 123.0 vs. 629.9 </text>
<text top="418" left="674" width="152" height="20" font="4">± 140.7 s; p=0.76), and NT-</text>
<text top="436" left="674" width="184" height="20" font="4">proBNP levels: 201.2 ± 267.8 vs. </text>
<text top="453" left="674" width="170" height="20" font="4">229.7 ± 291.5 pg/mL; p=0.10), </text>
<text top="470" left="674" width="182" height="20" font="4">despite a trend toward increased </text>
<text top="487" left="674" width="182" height="20" font="4">angiotensin II levels (15.2 ± 13.8 </text>
<text top="504" left="674" width="169" height="20" font="4">vs. 8.8 ± 12.5 pg/mL; p=0.08). </text>
<text top="332" left="880" width="169" height="20" font="4">● In adults with systemic RVs, </text>
<text top="350" left="880" width="184" height="20" font="4">losartan did not improve exercise </text>
<text top="367" left="880" width="171" height="20" font="4">capacity or reduce NT-proBNP </text>
<text top="384" left="880" width="38" height="20" font="4">levels. </text>
<text top="522" left="64" width="91" height="20" font="4">Giardini A, et al. </text>
<text top="540" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(253)</a> </text>
<text top="557" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21882492?dopt=Citation">21882492</a></text>
<text top="557" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21882492?dopt=Citation"> </a></text>
<text top="522" left="170" width="60" height="20" font="4">Pilot study </text>
<text top="522" left="269" width="44" height="20" font="4">n=8 pts </text>
<text top="522" left="349" width="190" height="20" font="3"><b>Inclusion criteria</b>: L-loop TGA (2) </text>
<text top="540" left="349" width="169" height="20" font="4">or D-loop TGA atrial switch (6) </text>
<text top="557" left="349" width="3" height="20" font="4"> </text>
<text top="574" left="349" width="181" height="20" font="3"><b>Exclusion criteria</b>: Pacemakers </text>
<text top="522" left="568" width="77" height="20" font="4">RVEF, LVEF, </text>
<text top="540" left="568" width="66" height="20" font="4">by CMR VO</text>
<text top="546" left="634" width="4" height="13" font="6">2</text>
<text top="540" left="638" width="3" height="20" font="4"> </text>
<text top="557" left="568" width="30" height="20" font="4">max, </text>
<text top="574" left="568" width="49" height="20" font="4">exercise </text>
<text top="591" left="568" width="48" height="20" font="4">duration </text>
<text top="522" left="674" width="178" height="20" font="4">● RV end-diastolic (119 ±31 vs. </text>
<text top="540" left="674" width="83" height="20" font="4">112 ± 28 mL/m</text>
<text top="541" left="758" width="4" height="13" font="6">2</text>
<text top="540" left="762" width="101" height="20" font="4">; p=0.01) and end-</text>
<text top="557" left="674" width="187" height="20" font="4">systolic volumes decreased (79 ± </text>
<text top="574" left="674" width="113" height="20" font="4">17 vs. 65 ± 14 mL/m</text>
<text top="576" left="787" width="4" height="13" font="6">2</text>
<text top="574" left="792" width="63" height="20" font="4">; p=0.006), </text>
<text top="591" left="674" width="176" height="20" font="4">and RVEF improved (34 ± 6 vs. </text>
<text top="608" left="674" width="113" height="20" font="4">42 ± 7%; p=0.004).  </text>
<text top="626" left="674" width="166" height="20" font="4">● LVEF increased (44 ± 8 vs. </text>
<text top="643" left="674" width="175" height="20" font="4">49 ± 9%; p=0.01), suggesting a </text>
<text top="660" left="674" width="186" height="20" font="4">positive biventricular remodeling.  </text>
<text top="677" left="674" width="53" height="20" font="4">● Peak O</text>
<text top="684" left="728" width="7" height="13" font="6">2 </text>
<text top="677" left="734" width="125" height="20" font="4">uptake did not change </text>
<text top="694" left="674" width="191" height="20" font="4">with carvedilol (26.8 ± 5.3 vs. 27.3 </text>
<text top="712" left="674" width="62" height="20" font="4">± 5.7 mL O</text>
<text top="718" left="737" width="4" height="13" font="6">2</text>
<text top="712" left="741" width="95" height="20" font="4">/kg/min; p=0.58); </text>
<text top="729" left="674" width="150" height="20" font="4">whereas, exercise duration </text>
<text top="746" left="674" width="179" height="20" font="4">increased (13.4 ± 2.6 vs. 17.3 ± </text>
<text top="763" left="674" width="93" height="20" font="4">3.1 m; p=0.008). </text>
<text top="522" left="880" width="176" height="20" font="4">● Carvedilol administration was </text>
<text top="540" left="880" width="176" height="20" font="4">safe, and it was associated with </text>
<text top="557" left="880" width="187" height="20" font="4">positive RV remodeling as well as </text>
<text top="574" left="880" width="155" height="20" font="4">improved exercise duration. </text>
</page>
<page number="73" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 73 </text>
<text top="107" left="64" width="91" height="20" font="4">Doughan AR, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(254)</a> </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17317376?dopt=Citation">17317376</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17317376?dopt=Citation"> </a></text>
<text top="107" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="124" left="170" width="70" height="20" font="4">chart review </text>
<text top="141" left="170" width="74" height="20" font="4">(carvedilol or </text>
<text top="159" left="170" width="65" height="20" font="4">metoprolol) </text>
<text top="107" left="269" width="52" height="20" font="4">n=60 (31 </text>
<text top="124" left="269" width="50" height="20" font="4">received </text>
<text top="141" left="269" width="44" height="20" font="4">BB) pts </text>
<text top="107" left="349" width="199" height="20" font="3"><b>Inclusion criteria</b>: D-loop TGA with </text>
<text top="124" left="349" width="68" height="20" font="4">atrial switch </text>
<text top="107" left="568" width="93" height="20" font="4">NYHA class, RV </text>
<text top="124" left="568" width="72" height="20" font="4">size by ECG </text>
<text top="107" left="674" width="129" height="20" font="4">● Only pts with cardiac </text>
<text top="124" left="674" width="182" height="20" font="4">pacemakers had improvement in </text>
<text top="141" left="674" width="140" height="20" font="4">functional status after BB </text>
<text top="159" left="674" width="189" height="20" font="4">compared with pts without cardiac </text>
<text top="176" left="674" width="143" height="20" font="4">pacemakers (p&lt;0.05). No </text>
<text top="193" left="674" width="166" height="20" font="4">significant changes in RV end-</text>
<text top="210" left="674" width="184" height="20" font="4">diastolic area, the RVEF, and the </text>
<text top="227" left="674" width="130" height="20" font="4">degree of systemic TR. </text>
<text top="107" left="880" width="180" height="20" font="4">● BB resulted in improvement in </text>
<text top="124" left="880" width="179" height="20" font="4">NYHA FC in pts with d-TGA and </text>
<text top="141" left="880" width="144" height="20" font="4">systemic RV dysfunction.  </text>
<text top="159" left="880" width="187" height="20" font="4">● This improvement was found to </text>
<text top="176" left="880" width="165" height="20" font="4">be more significant in pts with </text>
<text top="193" left="880" width="184" height="20" font="4">pacemakers who received higher </text>
<text top="210" left="880" width="150" height="20" font="4">maintenance doses of BB.  </text>
<text top="245" left="64" width="92" height="20" font="4">Therrien J, et al. </text>
<text top="263" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(255)</a> </text>
<text top="280" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18672299?dopt=Citation">18672299</a></text>
<text top="280" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18672299?dopt=Citation"> </a></text>
<text top="245" left="170" width="29" height="20" font="4">RCT </text>
<text top="245" left="269" width="51" height="20" font="4">n=17 pts </text>
<text top="245" left="349" width="199" height="20" font="3"><b>Inclusion criteria</b>: D-loop TGA with </text>
<text top="263" left="349" width="68" height="20" font="4">atrial switch </text>
<text top="245" left="568" width="85" height="20" font="4">RVEF, RVEDV </text>
<text top="245" left="674" width="170" height="20" font="4">● RVEF did not improve in the </text>
<text top="263" left="674" width="189" height="20" font="4">ramipril group from baseline to 1 y </text>
<text top="280" left="674" width="174" height="20" font="4">(43.8 ± 7.1% vs. 40.9 ± 13.3%; </text>
<text top="297" left="674" width="188" height="20" font="4">p=0.52) and remain unchanged in </text>
<text top="314" left="674" width="185" height="20" font="4">the placebo group (44.3 ± 6.3 vs. </text>
<text top="332" left="674" width="172" height="20" font="4">46.3 ± 9.6%; p= 0.42). RVEDV </text>
<text top="349" left="674" width="117" height="20" font="4">(184.5 ± 56.4 mL vs. </text>
<text top="366" left="674" width="170" height="20" font="4">179.6 ± 66.4 mL; p= 0.64) and </text>
<text top="383" left="674" width="162" height="20" font="4">RVESV (109.5 ± 19.4 mL vs. </text>
<text top="401" left="674" width="180" height="20" font="4">111.8 ± 30.1; p= 0.74) remained </text>
<text top="418" left="674" width="176" height="20" font="4">unchanged in the ramipril group </text>
<text top="435" left="674" width="181" height="20" font="4">from baseline to 1 y as well as in </text>
<text top="452" left="674" width="102" height="20" font="4">the placebo group </text>
<text top="469" left="674" width="117" height="20" font="4">(228.1 ± 89.2 mL vs. </text>
<text top="487" left="674" width="166" height="20" font="4">204.5 ± 50.4 mL; p= 0.42 and </text>
<text top="504" left="674" width="113" height="20" font="4">117.5 ± 36.9 mL vs. </text>
<text top="521" left="674" width="145" height="20" font="4">117.4 ± 26.2 mL; p= 0.99, </text>
<text top="538" left="674" width="76" height="20" font="4">respectively). </text>
<text top="245" left="880" width="188" height="20" font="4">● 1-y treatment with ramipril does </text>
<text top="263" left="880" width="183" height="20" font="4">not seem to affect RV function or </text>
<text top="280" left="880" width="180" height="20" font="4">size in adult pts with SRV after a </text>
<text top="297" left="880" width="173" height="20" font="4">Mustard or Senning procedure. </text>
<text top="556" left="64" width="93" height="20" font="4">Bouallal R, et al. </text>
<text top="573" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(256)</a> </text>
<text top="591" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20519056?dopt=Citation">20519056</a></text>
<text top="591" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20519056?dopt=Citation"> </a></text>
<text top="556" left="170" width="40" height="20" font="4">Cohort </text>
<text top="556" left="269" width="51" height="20" font="4">n=14 pts </text>
<text top="556" left="349" width="199" height="20" font="3"><b>Inclusion criteria</b>: L-loop TGA or D-</text>
<text top="573" left="349" width="127" height="20" font="4">loop TGA atrial switch  </text>
<text top="556" left="568" width="69" height="20" font="4">NYHA class </text>
<text top="573" left="568" width="66" height="20" font="4">QOL RVEF </text>
<text top="556" left="674" width="166" height="20" font="4">● Change in NYHA class was </text>
<text top="573" left="674" width="147" height="20" font="4">significant (p=0.016). QOL </text>
<text top="591" left="674" width="183" height="20" font="4">improved significantly throughout </text>
<text top="608" left="674" width="181" height="20" font="4">the study from a median grade 2 </text>
<text top="625" left="674" width="190" height="20" font="4">with a range from 1–3 to a median </text>
<text top="642" left="674" width="168" height="20" font="4">grade 1 with a range from 1–2 </text>
<text top="659" left="674" width="63" height="20" font="4">(p=0.008).  </text>
<text top="677" left="674" width="174" height="20" font="4">● Systemic RVEF assessed by </text>
<text top="694" left="674" width="163" height="20" font="4">radionuclide ventriculography </text>
<text top="711" left="674" width="159" height="20" font="4">improved significantly from a </text>
<text top="728" left="674" width="192" height="20" font="4">median of 41% (range: 29%–53%) </text>
<text top="745" left="674" width="147" height="20" font="4">to 49% (range: 29%–62%; </text>
<text top="763" left="674" width="188" height="20" font="4">p=0.031). However, the change in </text>
<text top="780" left="674" width="183" height="20" font="4">the EF assessed by MRI was NS </text>
<text top="556" left="880" width="189" height="20" font="4">● In pts with cardiac failure due to </text>
<text top="573" left="880" width="161" height="20" font="4">systemic RV dysfunction, BB </text>
<text top="591" left="880" width="176" height="20" font="4">improve NYHA class, QOL, and </text>
<text top="608" left="880" width="159" height="20" font="4">systemic RVEF assessed by </text>
<text top="625" left="880" width="167" height="20" font="4">radionuclide ventriculography. </text>
</page>
<page number="74" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 74 </text>
<text top="107" left="674" width="166" height="20" font="4">from a median of 29% (range: </text>
<text top="124" left="674" width="179" height="20" font="4">12%–47%) to 32% (range: 22%–</text>
<text top="141" left="674" width="87" height="20" font="4">63%; p=0.063). </text>
<text top="159" left="64" width="88" height="20" font="4">Tutarel O, et al. </text>
<text top="177" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(257)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20843567?dopt=Citation">20843567</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20843567?dopt=Citation"> </a></text>
<text top="159" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="177" left="170" width="75" height="20" font="4">data analysis </text>
<text top="159" left="269" width="51" height="20" font="4">n=14 pts </text>
<text top="159" left="349" width="202" height="20" font="3"><b>Inclusion criteria</b>: D-loop TGA after </text>
<text top="177" left="349" width="68" height="20" font="4">atrial switch </text>
<text top="159" left="568" width="84" height="20" font="4">Echo, exercise </text>
<text top="177" left="568" width="84" height="20" font="4">and proBNP at </text>
<text top="194" left="568" width="73" height="20" font="4">baseline and </text>
<text top="211" left="568" width="77" height="20" font="4">after 13.3 ± 4 </text>
<text top="228" left="568" width="74" height="20" font="4">mo enalapril. </text>
<text top="159" left="674" width="49" height="20" font="4">● Max O</text>
<text top="166" left="723" width="4" height="13" font="6">2</text>
<text top="159" left="728" width="98" height="20" font="4"> uptake and echo </text>
<text top="177" left="674" width="174" height="20" font="4">parameters did not change, but </text>
<text top="194" left="674" width="178" height="20" font="4">proBNP decreased significantly. </text>
<text top="159" left="880" width="155" height="20" font="4">● ACEI is safe and reduces </text>
<text top="177" left="880" width="120" height="20" font="4">proBNP significantly.  </text>
<text top="246" left="64" width="89" height="20" font="4">Van der Bom T, </text>
<text top="263" left="64" width="30" height="20" font="4">et al. </text>
<text top="281" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(258)</a> </text>
<text top="298" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23247302?dopt=Citation">23247302</a></text>
<text top="298" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23247302?dopt=Citation"> </a></text>
<text top="246" left="170" width="67" height="20" font="4">Prospective </text>
<text top="263" left="170" width="70" height="20" font="4">double-blind </text>
<text top="281" left="170" width="29" height="20" font="4">RCT </text>
<text top="246" left="269" width="51" height="20" font="4">n=88 pts </text>
<text top="246" left="349" width="197" height="20" font="3"><b>Inclusion criteria</b>: L-loop TGA (25) </text>
<text top="263" left="349" width="176" height="20" font="4">or D-loop TGA atrial switch (53) </text>
<text top="246" left="568" width="59" height="20" font="4">1°: RVEF. </text>
<text top="263" left="568" width="65" height="20" font="4">Secondary: </text>
<text top="281" left="568" width="67" height="20" font="4">RVEDV, VO</text>
<text top="287" left="635" width="4" height="13" font="6">2</text>
<text top="281" left="640" width="3" height="20" font="4"> </text>
<text top="298" left="568" width="60" height="20" font="4">max, QOL </text>
<text top="246" left="674" width="152" height="20" font="4">● No effect of 3 y valsartan </text>
<text top="263" left="674" width="150" height="20" font="4">therapy on RVEF, exercise </text>
<text top="281" left="674" width="99" height="20" font="4">capacity or QOL.  </text>
<text top="298" left="674" width="139" height="20" font="4">● The RVEDV and mass </text>
<text top="315" left="674" width="168" height="20" font="4">increased more in the placebo </text>
<text top="332" left="674" width="38" height="20" font="4">group. </text>
<text top="246" left="880" width="192" height="20" font="4">● No significant treatment effect of </text>
<text top="263" left="880" width="159" height="20" font="4">valsartan on RVEF, exercise </text>
<text top="281" left="880" width="130" height="20" font="4">capacity or QOL. Small </text>
<text top="298" left="880" width="170" height="20" font="4">differences seen in RV volume </text>
<text top="315" left="880" width="60" height="20" font="4">and mass. </text>
<text top="350" left="64" width="69" height="20" font="4">Dos L, et al. </text>
<text top="368" left="64" width="60" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(259)</a></text>
<text top="368" left="123" width="3" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23972966?dopt=Citation"> </a></text>
<text top="385" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23972966?dopt=Citation">23972966</a></text>
<text top="385" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23972966?dopt=Citation"> </a></text>
<text top="350" left="170" width="72" height="20" font="4">Double-blind </text>
<text top="368" left="170" width="47" height="20" font="4">placebo-</text>
<text top="385" left="170" width="57" height="20" font="4">controlled </text>
<text top="402" left="170" width="68" height="20" font="4">eplerenone  </text>
<text top="350" left="269" width="54" height="20" font="4">n=14 pts, </text>
<text top="368" left="269" width="64" height="20" font="4">12 controls </text>
<text top="350" left="349" width="194" height="20" font="3"><b>Inclusion criteria</b>: Atrial switch pts </text>
<text top="350" left="568" width="74" height="20" font="4">Systemic RV </text>
<text top="368" left="568" width="76" height="20" font="4">mass and EF </text>
<text top="385" left="568" width="24" height="20" font="4">and </text>
<text top="402" left="568" width="86" height="20" font="4">neurohormonal </text>
<text top="419" left="568" width="73" height="20" font="4">and collagen </text>
<text top="436" left="568" width="49" height="20" font="4">turnover </text>
<text top="454" left="568" width="93" height="20" font="4">biomarker levels </text>
<text top="350" left="674" width="174" height="20" font="4">● Pts had good baseline profile </text>
<text top="368" left="674" width="185" height="20" font="4">(SRV Mass and EF) Elevated NT-</text>
<text top="385" left="674" width="185" height="20" font="4">proBNP. C-terminal propeptide of </text>
<text top="402" left="674" width="192" height="20" font="4">type 1 procollagen and C Terminal </text>
<text top="419" left="674" width="67" height="20" font="4">telopeptide. </text>
<text top="436" left="674" width="165" height="20" font="4">● After 1 y of therapy, a trend </text>
<text top="454" left="674" width="174" height="20" font="4">towards reduction of C-terminal </text>
<text top="471" left="674" width="179" height="20" font="4">propeptide of type I procollagen, </text>
<text top="488" left="674" width="70" height="20" font="4">NT-proBNP. </text>
<text top="350" left="880" width="152" height="20" font="4">● Eplerenone pts improved </text>
<text top="368" left="880" width="147" height="20" font="4">baseline collagen turnover </text>
<text top="385" left="880" width="185" height="20" font="4">biomarkers, suggesting reduction </text>
<text top="402" left="880" width="122" height="20" font="4">of myocardial fibrosis. </text>
<text top="506" left="64" width="78" height="20" font="4">Kouatli AA, et </text>
<text top="523" left="64" width="16" height="20" font="4">al. </text>
<text top="540" left="64" width="66" height="20" font="4">1997 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(260)</a>  </text>
<text top="558" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9315539?dopt=Citation">9315539</a></text>
<text top="558" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9315539?dopt=Citation"> </a></text>
<text top="506" left="170" width="67" height="20" font="4">Prospective </text>
<text top="523" left="170" width="70" height="20" font="4">double-blind </text>
<text top="540" left="170" width="80" height="20" font="4">crossover trial </text>
<text top="506" left="269" width="51" height="20" font="4">n=18 pts </text>
<text top="506" left="349" width="177" height="20" font="3"><b>Inclusion criteria</b>: &gt;7 y; Fontan </text>
<text top="523" left="349" width="205" height="20" font="4">procedure a minimum of 6 mo before </text>
<text top="540" left="349" width="59" height="20" font="4">this study  </text>
<text top="558" left="349" width="3" height="20" font="4"> </text>
<text top="575" left="349" width="163" height="20" font="3"><b>Exclusion criteria</b>: HF, were </text>
<text top="592" left="349" width="205" height="20" font="4">dependent on ACEIs, were unable to </text>
<text top="609" left="349" width="154" height="20" font="4">exercise, had protein-losing </text>
<text top="626" left="349" width="150" height="20" font="4">enteropathy, had fixed-rate </text>
<text top="644" left="349" width="198" height="20" font="4">pacemakers, were pregnant, or had </text>
<text top="661" left="349" width="135" height="20" font="4">a history of angioedema </text>
<text top="506" left="568" width="18" height="20" font="4">VO</text>
<text top="512" left="586" width="4" height="13" font="6">2</text>
<text top="506" left="590" width="30" height="20" font="4"> max </text>
<text top="523" left="568" width="49" height="20" font="4">exercise </text>
<text top="540" left="568" width="48" height="20" font="4">duration </text>
<text top="506" left="674" width="178" height="20" font="4">● No difference was detected in </text>
<text top="523" left="674" width="180" height="20" font="4">resting heart rate, BP, or cardiac </text>
<text top="540" left="674" width="40" height="20" font="4">index.  </text>
<text top="558" left="674" width="172" height="20" font="4">● Diastolic filling patterns were </text>
<text top="575" left="674" width="192" height="20" font="4">also similar. Exercise duration was </text>
<text top="592" left="674" width="182" height="20" font="4">not different (6.4 ± 2.6 [enalapril] </text>
<text top="609" left="674" width="157" height="20" font="4">vs. 6.7 ± 2.6 mo [placebo]).  </text>
<text top="626" left="674" width="179" height="20" font="4">● The mean percent increase in </text>
<text top="644" left="674" width="141" height="20" font="4">cardiac index from rest to </text>
<text top="661" left="674" width="193" height="20" font="4">maximum exercise was slightly but </text>
<text top="678" left="674" width="189" height="20" font="4">significantly decreased in subjects </text>
<text top="695" left="674" width="172" height="20" font="4">after 10 wk of enalapril therapy </text>
<text top="712" left="674" width="179" height="20" font="4">(102 ± 34% [enalapril] vs. 125 ± </text>
<text top="730" left="674" width="149" height="20" font="4">34% [placebo]; p&lt;0.02). At </text>
<text top="747" left="674" width="178" height="20" font="4">maximal exercise, cardiac index </text>
<text top="764" left="674" width="185" height="20" font="4">(3.5 ± 0.9 [enalapril] vs. 3.8 ± 0.9 </text>
<text top="781" left="674" width="33" height="20" font="4">L; min</text>
<text top="783" left="708" width="7" height="13" font="6">-1</text>
<text top="781" left="715" width="17" height="20" font="4">; m</text>
<text top="783" left="732" width="4" height="13" font="6">2</text>
<text top="781" left="737" width="74" height="20" font="4"> [placebo]), O</text>
<text top="788" left="811" width="4" height="13" font="6">2</text>
<text top="781" left="815" width="3" height="20" font="4"> </text>
<text top="506" left="880" width="24" height="20" font="4">N/A </text>
</page>
<page number="75" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 75 </text>
<text top="107" left="674" width="183" height="20" font="4">consumption (18.3 ± 9 [enalapril] </text>
<text top="124" left="674" width="112" height="20" font="4">vs. 20.5 ± 7 mL; min</text>
<text top="126" left="787" width="7" height="13" font="6">-1</text>
<text top="124" left="794" width="20" height="20" font="4">; kg</text>
<text top="126" left="814" width="7" height="13" font="6">-1</text>
<text top="124" left="821" width="3" height="20" font="4"> </text>
<text top="141" left="674" width="186" height="20" font="4">[placebo]), min ventilation (57.5 ± </text>
<text top="159" left="674" width="182" height="20" font="4">17 [enalapril] vs. 55.4 ± 19 L/min </text>
<text top="176" left="674" width="180" height="20" font="4">[placebo]), and total work (247 ± </text>
<text top="193" left="674" width="174" height="20" font="4">181 [enalapril] vs. 261 ± 197 W </text>
<text top="210" left="674" width="159" height="20" font="4">[placebo]) were not different. </text>
<text top="228" left="64" width="91" height="20" font="4">Giardini A, et al. </text>
<text top="245" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(261)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18534975?dopt=Citation">18534975</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18534975?dopt=Citation"> </a></text>
<text top="228" left="170" width="67" height="20" font="4">Prospective </text>
<text top="245" left="170" width="70" height="20" font="4">double-blind </text>
<text top="263" left="170" width="29" height="20" font="4">RCT </text>
<text top="228" left="269" width="51" height="20" font="4">n=27 pts </text>
<text top="228" left="349" width="139" height="20" font="3"><b>Inclusion criteria</b>: &gt;16 y </text>
<text top="245" left="349" width="3" height="20" font="4"> </text>
<text top="263" left="349" width="197" height="20" font="3"><b>Exclusion criteria</b>: NYHA class IV, </text>
<text top="280" left="349" width="150" height="20" font="4">liver or renal dysfunction, O</text>
<text top="286" left="499" width="7" height="13" font="6">2 </text>
<text top="297" left="349" width="175" height="20" font="4">saturation &lt;85% at rest, Fontan </text>
<text top="314" left="349" width="169" height="20" font="4">pathway obstruction, history of </text>
<text top="332" left="349" width="137" height="20" font="4">exercise-induced severe </text>
<text top="349" left="349" width="132" height="20" font="4">arrhythmias, pregnancy </text>
<text top="228" left="568" width="18" height="20" font="4">VO</text>
<text top="234" left="586" width="4" height="13" font="6">2</text>
<text top="228" left="590" width="30" height="20" font="4"> max </text>
<text top="245" left="568" width="87" height="20" font="4">Cardiac output, </text>
<text top="263" left="568" width="61" height="20" font="4">pulmonary </text>
<text top="280" left="568" width="59" height="20" font="4">blood flow </text>
<text top="228" left="674" width="141" height="20" font="4">● The change in peak VO</text>
<text top="234" left="816" width="4" height="13" font="6">2</text>
<text top="228" left="820" width="44" height="20" font="4">, the 1° </text>
<text top="245" left="674" width="155" height="20" font="4">endpoint, was greater in the </text>
<text top="263" left="674" width="185" height="20" font="4">sildenafil group (9.4 ± 5.2%) than </text>
<text top="280" left="674" width="179" height="20" font="4">in the control group (0.3 ± 4.1%’ </text>
<text top="297" left="674" width="52" height="20" font="4">p&lt;0.05).  </text>
<text top="314" left="674" width="170" height="20" font="4">● Sildenafil increased rest and </text>
<text top="332" left="674" width="174" height="20" font="4">peak exercise pulmonary blood </text>
<text top="349" left="674" width="188" height="20" font="4">flow index (p&lt;0.01 and p&lt;0.05 vs. </text>
<text top="366" left="674" width="171" height="20" font="4">control group, respectively), as </text>
<text top="383" left="674" width="184" height="20" font="4">well as rest and peak exercise CI </text>
<text top="401" left="674" width="177" height="20" font="4">(p&lt;0.001 and p&lt;0.05 vs. control </text>
<text top="418" left="674" width="156" height="20" font="4">group, respectively), without </text>
<text top="435" left="674" width="161" height="20" font="4">altering rest or peak exercise </text>
<text top="452" left="674" width="172" height="20" font="4">transcutaneous arterial blood O</text>
<text top="458" left="846" width="4" height="13" font="6">2</text>
<text top="452" left="851" width="3" height="20" font="4"> </text>
<text top="469" left="674" width="168" height="20" font="4">saturations (p&gt;0.05 vs. control </text>
<text top="487" left="674" width="87" height="20" font="4">group for both). </text>
<text top="228" left="880" width="115" height="20" font="4">● In Fontan pts, oral </text>
<text top="245" left="880" width="183" height="20" font="4">administration of a single dose of </text>
<text top="263" left="880" width="154" height="20" font="4">sildenafil improves exercise </text>
<text top="280" left="880" width="152" height="20" font="4">capacity and hemodynamic </text>
<text top="297" left="880" width="120" height="20" font="4">response to exercise. </text>
<text top="504" left="64" width="89" height="20" font="4">Goldberg DJ, et </text>
<text top="522" left="64" width="16" height="20" font="4">al. </text>
<text top="539" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(262)</a> </text>
<text top="556" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21382896?dopt=Citation">21382896</a></text>
<text top="556" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21382896?dopt=Citation"> </a></text>
<text top="504" left="170" width="67" height="20" font="4">Prospective </text>
<text top="522" left="170" width="70" height="20" font="4">double-blind </text>
<text top="539" left="170" width="80" height="20" font="4">crossover trial </text>
<text top="504" left="269" width="51" height="20" font="4">n=28 pts </text>
<text top="504" left="349" width="132" height="20" font="3"><b>Inclusion criteria</b>: &gt;8 y </text>
<text top="522" left="349" width="3" height="20" font="4"> </text>
<text top="539" left="349" width="185" height="20" font="3"><b>Exclusion criteria</b>: Liver or renal </text>
<text top="556" left="349" width="160" height="20" font="4">dysfunction, Fontan pathway </text>
<text top="573" left="349" width="201" height="20" font="4">obstruction or other residual lesions, </text>
<text top="591" left="349" width="31" height="20" font="4">ICDs </text>
<text top="504" left="568" width="37" height="20" font="4">1°: VO</text>
<text top="511" left="606" width="4" height="13" font="6">2</text>
<text top="504" left="610" width="33" height="20" font="4"> max; </text>
<text top="522" left="568" width="65" height="20" font="4">Secondary: </text>
<text top="539" left="568" width="59" height="20" font="4">ventilatory </text>
<text top="556" left="568" width="73" height="20" font="4">equivalent of </text>
<text top="573" left="568" width="87" height="20" font="4">elimination rate </text>
<text top="591" left="568" width="32" height="20" font="4">of CO</text>
<text top="597" left="600" width="7" height="13" font="6">2 </text>
<text top="591" left="607" width="33" height="20" font="4">slope </text>
<text top="504" left="674" width="163" height="20" font="4">● At the anaerobic threshold, </text>
<text top="522" left="674" width="139" height="20" font="4">subjects had significantly </text>
<text top="539" left="674" width="186" height="20" font="4">decreased ventilatory equivalents </text>
<text top="556" left="674" width="32" height="20" font="4">of CO</text>
<text top="562" left="707" width="4" height="13" font="6">2</text>
<text top="556" left="711" width="141" height="20" font="4">. There was no change in </text>
<text top="573" left="674" width="10" height="20" font="4">O</text>
<text top="579" left="684" width="4" height="13" font="6">2</text>
<text top="573" left="689" width="144" height="20" font="4"> consumption during peak </text>
<text top="591" left="674" width="170" height="20" font="4">exercise, although there was a </text>
<text top="608" left="674" width="140" height="20" font="4">suggestion of improved O</text>
<text top="614" left="815" width="4" height="13" font="6">2</text>
<text top="608" left="819" width="3" height="20" font="4"> </text>
<text top="625" left="674" width="165" height="20" font="4">consumption at the anaerobic </text>
<text top="642" left="674" width="57" height="20" font="4">threshold. </text>
<text top="504" left="880" width="187" height="20" font="4">● Sildenafil significantly improved </text>
<text top="522" left="880" width="182" height="20" font="4">ventilatory efficiency during peak </text>
<text top="539" left="880" width="146" height="20" font="4">and submaximal exercise. </text>
<text top="660" left="64" width="89" height="20" font="4">Rhodes J, et al. </text>
<text top="677" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(263)</a> </text>
<text top="694" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23545150?dopt=Citation">23545150</a></text>
<text top="694" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23545150?dopt=Citation"> </a></text>
<text top="660" left="170" width="67" height="20" font="4">Prospective </text>
<text top="677" left="170" width="70" height="20" font="4">double-blind </text>
<text top="694" left="170" width="29" height="20" font="4">RCT </text>
<text top="660" left="269" width="51" height="20" font="4">n=18 pts </text>
<text top="660" left="349" width="139" height="20" font="3"><b>Inclusion criteria</b>: &gt;12 y </text>
<text top="677" left="349" width="3" height="20" font="4"> </text>
<text top="694" left="349" width="200" height="20" font="3"><b>Exclusion criteria</b>: Reactive airway </text>
<text top="712" left="349" width="182" height="20" font="4">disease, history of malignant VA; </text>
<text top="729" left="349" width="193" height="20" font="4">history of syncope during exercise; </text>
<text top="746" left="349" width="201" height="20" font="4">history of hypersensitivity to iloprost  </text>
<text top="660" left="568" width="18" height="20" font="4">VO</text>
<text top="666" left="586" width="4" height="13" font="6">2</text>
<text top="660" left="590" width="43" height="20" font="4"> max, O</text>
<text top="666" left="633" width="4" height="13" font="6">2</text>
<text top="660" left="638" width="3" height="20" font="4"> </text>
<text top="677" left="568" width="33" height="20" font="4">pulse </text>
<text top="660" left="674" width="22" height="20" font="4">● O</text>
<text top="666" left="696" width="4" height="13" font="6">2</text>
<text top="660" left="701" width="124" height="20" font="4"> pulse (a surrogate for </text>
<text top="677" left="674" width="172" height="20" font="4">forward stroke volume) at peak </text>
<text top="694" left="674" width="163" height="20" font="4">exercise was higher following </text>
<text top="712" left="674" width="141" height="20" font="4">iloprost (median increase </text>
<text top="729" left="674" width="131" height="20" font="4">1.2 mL/beat; p&lt;0.001).  </text>
<text top="746" left="674" width="62" height="20" font="4">● Peak VO</text>
<text top="752" left="736" width="4" height="13" font="6">2</text>
<text top="746" left="741" width="105" height="20" font="4"> also rose (median </text>
<text top="763" left="674" width="183" height="20" font="4">increase 1.3 mL/kg/min; p&lt;0.04). </text>
<text top="781" left="674" width="84" height="20" font="4">9 pts had peak </text>
<text top="660" left="880" width="170" height="20" font="4">● Iloprost improves the peak O</text>
<text top="666" left="1050" width="4" height="13" font="6">2</text>
<text top="660" left="1054" width="3" height="20" font="4"> </text>
<text top="677" left="880" width="104" height="20" font="4">pulse and peak VO</text>
<text top="684" left="984" width="4" height="13" font="6">2</text>
<text top="677" left="989" width="62" height="20" font="4"> of pts with </text>
<text top="694" left="880" width="189" height="20" font="4">Fontan physiology and appears to </text>
<text top="712" left="880" width="176" height="20" font="4">be particularly beneficial among </text>
<text top="729" left="880" width="145" height="20" font="4">pts with impaired exercise </text>
<text top="746" left="880" width="53" height="20" font="4">function.  </text>
</page>
<page number="76" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="13" size="12" family="Times" color="#131413"/>
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 76 </text>
<text top="107" left="674" width="18" height="20" font="4">VO</text>
<text top="113" left="692" width="4" height="13" font="6">2</text>
<text top="107" left="697" width="165" height="20" font="4">&lt;30 mL/kg/min; each of these </text>
<text top="124" left="674" width="129" height="20" font="4">pts had higher peak VO</text>
<text top="130" left="804" width="4" height="13" font="6">2</text>
<text top="124" left="808" width="55" height="20" font="4"> following </text>
<text top="141" left="674" width="171" height="20" font="4">iloprost. Only 3/6 pts with peak </text>
<text top="159" left="674" width="18" height="20" font="4">VO</text>
<text top="165" left="692" width="4" height="13" font="6">2</text>
<text top="159" left="697" width="146" height="20" font="4">&gt;30 mL/kg/min had higher </text>
<text top="176" left="674" width="48" height="20" font="4">peak VO</text>
<text top="182" left="722" width="4" height="13" font="6">2</text>
<text top="176" left="727" width="98" height="20" font="4"> following iloprost </text>
<text top="193" left="674" width="53" height="20" font="4">(p&lt;0.04). </text>
<text top="211" left="64" width="78" height="20" font="13">Galiè N, et al. </text>
<text top="228" left="64" width="63" height="20" font="13">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(264)</a> </text>
<text top="245" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16801459?dopt=Citation">16801459</a></text>
<text top="245" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16801459?dopt=Citation"> </a></text>
<text top="211" left="170" width="67" height="20" font="4">Multicenter, </text>
<text top="228" left="170" width="74" height="20" font="4">double-blind, </text>
<text top="245" left="170" width="47" height="20" font="4">placebo-</text>
<text top="263" left="170" width="85" height="20" font="4">controlled RCT </text>
<text top="211" left="269" width="51" height="20" font="4">n=54 pts </text>
<text top="211" left="349" width="184" height="20" font="3"><b>Inclusion criteria</b>: WHO class III </text>
<text top="211" left="568" width="87" height="20" font="4">Pulse oximetry: </text>
<text top="228" left="568" width="29" height="20" font="4">PVR </text>
<text top="211" left="674" width="148" height="20" font="4">● Compared with placebo, </text>
<text top="228" left="674" width="171" height="20" font="4">bosentan reduced PVR index (-</text>
<text top="245" left="674" width="182" height="20" font="4">472.0 dyne.s.cm (-5); p=0.0383). </text>
<text top="263" left="674" width="176" height="20" font="4">The mean PAP decreased (-5.5 </text>
<text top="280" left="674" width="154" height="20" font="4">mm Hg; p=0.0363), and the </text>
<text top="297" left="674" width="186" height="20" font="4">exercise capacity increased (53.1 </text>
<text top="314" left="674" width="83" height="20" font="4">m; p=0.0079).  </text>
<text top="332" left="674" width="189" height="20" font="4">● 4 pts discontinued as a result of </text>
<text top="349" left="674" width="187" height="20" font="4">AE, 2 (5%) in the Bosentan group </text>
<text top="366" left="674" width="189" height="20" font="4">and 2 (12%) in the placebo group. </text>
<text top="211" left="880" width="149" height="20" font="4">● Eisenmenger syndrome, </text>
<text top="228" left="880" width="179" height="20" font="4">bosentan was well tolerated and </text>
<text top="245" left="880" width="176" height="20" font="4">improved exercise capacity and </text>
<text top="263" left="880" width="128" height="20" font="4">hemodynamics without </text>
<text top="280" left="880" width="148" height="20" font="4">compromising peripheral O</text>
<text top="286" left="1028" width="4" height="13" font="6">2</text>
<text top="280" left="1032" width="3" height="20" font="4"> </text>
<text top="297" left="880" width="61" height="20" font="4">saturation. </text>
<text top="384" left="54" width="3" height="20" font="4"> </text>
<text top="401" left="108" width="3" height="20" font="4"> </text>
<text top="418" left="108" width="469" height="24" font="1"><b>Data Supplement 23. Heart Failure and Transplant – Section 3.14.2 </b></text>
<text top="440" left="73" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="457" left="73" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="440" left="176" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="457" left="190" width="44" height="20" font="3"><b>Design </b></text>
<text top="440" left="275" width="38" height="20" font="3"><b>Study </b></text>
<text top="457" left="280" width="28" height="20" font="3"><b>Size </b></text>
<text top="440" left="337" width="99" height="20" font="3"><b>Length of follow-</b></text>
<text top="457" left="379" width="22" height="20" font="3"><b>up  </b></text>
<text top="440" left="500" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="440" left="675" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="440" left="897" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="479" left="64" width="86" height="20" font="4">Seddio F, et al. </text>
<text top="496" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(265)</a>  </text>
<text top="513" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22733841">22733841</a></text>
<text top="513" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22733841"> </a></text>
<text top="479" left="172" width="79" height="20" font="4">Single-center, </text>
<text top="496" left="172" width="74" height="20" font="4">retrospective </text>
<text top="513" left="172" width="38" height="20" font="4">cohort </text>
<text top="479" left="266" width="31" height="20" font="4">n=85 </text>
<text top="479" left="334" width="64" height="20" font="4">Mean 7.8 y </text>
<text top="496" left="334" width="81" height="20" font="4">posttransplant </text>
<text top="479" left="455" width="137" height="20" font="4">Risks factors for survival </text>
<text top="479" left="631" width="138" height="20" font="4">● PLE and pretransplant </text>
<text top="496" left="631" width="177" height="20" font="4">mechanical ventilation were risk </text>
<text top="513" left="631" width="189" height="20" font="4">factors for mortality, but transplant </text>
<text top="530" left="631" width="108" height="20" font="4">was also curative.   </text>
<text top="479" left="833" width="262" height="20" font="4">● Data also presented for pediatric age groups, </text>
<text top="496" left="833" width="215" height="20" font="4">but not all results differentiated by age. </text>
<text top="548" left="64" width="90" height="20" font="4">Boucek D, et al. </text>
<text top="566" left="64" width="66" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(266)</a>  </text>
<text top="583" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24433616">24433616</a></text>
<text top="583" left="119" width="7" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24433616"> </a> </text>
<text top="548" left="172" width="64" height="20" font="4">Multicenter </text>
<text top="548" left="266" width="145" height="20" font="4">n=45 pts  5 y with study </text>
<text top="566" left="334" width="103" height="20" font="4">period 2000–2012 </text>
<text top="548" left="455" width="135" height="20" font="4">Transplant vs. those not </text>
<text top="566" left="455" width="107" height="20" font="4">listed for transplant </text>
<text top="548" left="631" width="131" height="20" font="4">● 45 pts considered for </text>
<text top="566" left="631" width="183" height="20" font="4">transplant, 27 listed, 13 not listed </text>
<text top="583" left="631" width="169" height="20" font="4">because of high risk (cirrhosis, </text>
<text top="600" left="631" width="181" height="20" font="4">irreversible pulmonary HTN) and </text>
<text top="617" left="631" width="170" height="20" font="4">5 not listed because they were </text>
<text top="634" left="631" width="64" height="20" font="4">“too well.”   </text>
<text top="652" left="631" width="161" height="20" font="4">● Mortality at 5 y no different </text>
<text top="669" left="631" width="158" height="20" font="4">between those transplanted, </text>
<text top="686" left="631" width="188" height="20" font="4">those not transplanted; p=0.72 for </text>
<text top="703" left="631" width="169" height="20" font="4">those too high risk for HTN vs. </text>
<text top="721" left="631" width="175" height="20" font="4">those too well; p=0.59 for those </text>
<text top="738" left="631" width="176" height="20" font="4">listed for HTN vs. those too well </text>
<text top="755" left="631" width="189" height="20" font="4">for listing. 85% of transplanted pts </text>
<text top="772" left="631" width="186" height="20" font="4">alive at 5 y, all deaths occurred in </text>
<text top="789" left="631" width="75" height="20" font="4">the first 30 d. </text>
<text top="548" left="833" width="223" height="20" font="4">● Overall survival of transplanted ACHD </text>
<text top="566" left="833" width="251" height="20" font="4">compares favorably to other populations, with </text>
<text top="583" left="833" width="201" height="20" font="4">all deaths occurring in the first 30 d.  </text>
<text top="600" left="833" width="220" height="20" font="4">● For those deemed not appropriate for </text>
<text top="617" left="833" width="254" height="20" font="4">transplant, survival probability was statistically </text>
<text top="634" left="833" width="243" height="20" font="4">similar, though a larger percentage (38%) of </text>
<text top="652" left="833" width="239" height="20" font="4">those too high risk for transplant died in the </text>
<text top="669" left="833" width="262" height="20" font="4">follow-up period than those transplanted (15%). </text>
</page>
<page number="77" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 77 </text>
<text top="107" left="64" width="86" height="20" font="4">Patel ND, et al. </text>
<text top="124" left="64" width="66" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(267)</a>  </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19699904">19699904</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19699904"> </a></text>
<text top="107" left="172" width="66" height="20" font="4">UNOS data </text>
<text top="107" left="266" width="38" height="20" font="4">n=689 </text>
<text top="124" left="266" width="20" height="20" font="4">pts </text>
<text top="107" left="334" width="86" height="20" font="4">Up to 10 y post </text>
<text top="124" left="334" width="57" height="20" font="4">transplant </text>
<text top="107" left="455" width="131" height="20" font="4">Transplant outcomes in </text>
<text top="124" left="455" width="120" height="20" font="4">ACHD vs. non-ACHD </text>
<text top="107" left="631" width="183" height="20" font="4">● Overall higher 30-d mortality in </text>
<text top="124" left="631" width="170" height="20" font="4">ACHD (16% vs. 6%; p&lt;0.001), </text>
<text top="141" left="631" width="151" height="20" font="4">but long-term mortality was </text>
<text top="159" left="631" width="42" height="20" font="4">similar. </text>
<text top="107" left="833" width="245" height="20" font="4">● Risks for mortality included Ischemic time, </text>
<text top="124" left="833" width="225" height="20" font="4">African American race, and PVR &gt;4 WU. </text>
<text top="177" left="64" width="84" height="20" font="4">Karamlou T, et </text>
<text top="194" left="64" width="16" height="20" font="4">al. </text>
<text top="211" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(268)</a> </text>
<text top="228" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20434179">20434179</a></text>
<text top="228" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20434179"> </a></text>
<text top="177" left="172" width="66" height="20" font="4">UNOS data </text>
<text top="177" left="266" width="38" height="20" font="4">n=575 </text>
<text top="194" left="266" width="20" height="20" font="4">pts </text>
<text top="177" left="334" width="100" height="20" font="4">N/A, evaluated by </text>
<text top="194" left="334" width="103" height="20" font="4">era of transplant.   </text>
<text top="177" left="455" width="120" height="20" font="4">ACHD vs. non-ACHD </text>
<text top="177" left="631" width="153" height="20" font="4">● Higher mortality in ACHD </text>
<text top="194" left="631" width="163" height="20" font="4">(p=0.003) mainly due to early </text>
<text top="211" left="631" width="53" height="20" font="4">mortality. </text>
<text top="177" left="833" width="263" height="20" font="4">● More early hemorrhage in ACHD. Prevalence </text>
<text top="194" left="833" width="237" height="20" font="4">of transplantation rose in ACHD over time.  </text>
<text top="211" left="833" width="203" height="20" font="4">● Less induction therapy and steroid </text>
<text top="228" left="833" width="242" height="20" font="4">maintenance in ACHD. More extracorporeal </text>
<text top="245" left="833" width="238" height="20" font="4">membrane oxygenation support in ACHD.   </text>
<text top="263" left="64" width="81" height="20" font="4">Gelow J, et al. </text>
<text top="281" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(269)</a> </text>
<text top="298" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23921356">23921356</a></text>
<text top="298" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23921356"> </a></text>
<text top="263" left="172" width="39" height="20" font="4">UNOS </text>
<text top="281" left="172" width="54" height="20" font="4">database </text>
<text top="263" left="266" width="48" height="20" font="4">n=1,250 </text>
<text top="281" left="266" width="20" height="20" font="4">pts </text>
<text top="263" left="334" width="24" height="20" font="4">N/A </text>
<text top="263" left="455" width="138" height="20" font="4">Listing VAD in ACHD vs. </text>
<text top="281" left="455" width="100" height="20" font="4">non-ACHD by era </text>
<text top="263" left="631" width="185" height="20" font="4">● Higher use of VAD over time in </text>
<text top="281" left="631" width="176" height="20" font="4">non-ACHD pts. Fewer VAD and </text>
<text top="298" left="631" width="108" height="20" font="4">1A listing in ACHD. </text>
<text top="263" left="833" width="224" height="20" font="4">● More ACHD pts with VAD died prior to </text>
<text top="281" left="833" width="155" height="20" font="4">transplant than non-ACHD.  </text>
<text top="316" left="64" width="94" height="20" font="4">Everitt MD, et al. </text>
<text top="333" left="64" width="66" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(270)</a>  </text>
<text top="350" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21036067">21036067</a></text>
<text top="350" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21036067"> </a></text>
<text top="316" left="172" width="39" height="20" font="4">UNOS </text>
<text top="333" left="172" width="54" height="20" font="4">database </text>
<text top="316" left="266" width="38" height="20" font="4">n=314 </text>
<text top="333" left="266" width="20" height="20" font="4">pts </text>
<text top="316" left="334" width="24" height="20" font="4">N/A </text>
<text top="316" left="455" width="147" height="20" font="4">Wait list mortality in ACHD </text>
<text top="333" left="455" width="82" height="20" font="4">vs. non-ACHD </text>
<text top="316" left="631" width="173" height="20" font="4">● More CV deaths in ACHD on </text>
<text top="333" left="631" width="129" height="20" font="4">wait list, fewer devices. </text>
<text top="316" left="833" width="235" height="20" font="4">● More likely to be listed with lower status. </text>
<text top="333" left="833" width="230" height="20" font="4">Overall deaths were not different while on </text>
<text top="350" left="833" width="64" height="20" font="4">waiting list. </text>
<text top="368" left="64" width="79" height="20" font="4">Davies RR, et </text>
<text top="385" left="64" width="16" height="20" font="4">al. </text>
<text top="403" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(271)</a> </text>
<text top="420" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21300954">21300954</a></text>
<text top="420" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21300954"> </a></text>
<text top="368" left="172" width="39" height="20" font="4">UNOS </text>
<text top="385" left="172" width="54" height="20" font="4">database </text>
<text top="368" left="266" width="48" height="20" font="4">n=1,035 </text>
<text top="385" left="266" width="20" height="20" font="4">pts </text>
<text top="368" left="334" width="60" height="20" font="4">Up to 10 y </text>
<text top="368" left="455" width="159" height="20" font="4">Outcome of transplant listing </text>
<text top="385" left="455" width="133" height="20" font="4">in ACHD vs. non-ACHD </text>
<text top="368" left="631" width="175" height="20" font="4">● VAD doesn't improve wait list </text>
<text top="385" left="631" width="174" height="20" font="4">survival; long-term survival was </text>
<text top="403" left="631" width="114" height="20" font="4">same (54% at 10 y). </text>
<text top="368" left="833" width="249" height="20" font="4">● ACHD pts were younger, smaller BMI, with </text>
<text top="385" left="833" width="113" height="20" font="4">fewer comorbidities. </text>
<text top="438" left="64" width="79" height="20" font="4">Davies RR, et </text>
<text top="455" left="64" width="16" height="20" font="4">al. </text>
<text top="472" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(272)</a> </text>
<text top="489" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22500594">22500594</a></text>
<text top="489" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22500594"> </a></text>
<text top="438" left="172" width="132" height="20" font="4">Single center  n=155 </text>
<text top="455" left="266" width="20" height="20" font="4">pts </text>
<text top="438" left="334" width="60" height="20" font="4">Up to 15 y </text>
<text top="438" left="455" width="146" height="20" font="4">Transplant outcomes after </text>
<text top="455" left="455" width="122" height="20" font="4">Fontan vs. other CHD </text>
<text top="438" left="631" width="188" height="20" font="4">● 90-d mortality greater in Fontan </text>
<text top="455" left="631" width="189" height="20" font="4">than other ACHD pts (35 vs. 20%; </text>
<text top="472" left="631" width="56" height="20" font="4">p=0.055). </text>
<text top="438" left="833" width="245" height="20" font="4">● Pediatric pts fared worse; PVR index level </text>
<text top="455" left="833" width="237" height="20" font="4">was contested as an indicator of outcome.  </text>
<text top="472" left="833" width="213" height="20" font="4">● Renal dysfunction was a risk factor.  </text>
<text top="507" left="64" width="90" height="20" font="4">Goerler H, et al. </text>
<text top="525" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(273)</a> </text>
<text top="542" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17900918">17900918</a></text>
<text top="542" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17900918"> </a></text>
<text top="507" left="172" width="226" height="20" font="4">Single center  n=46 pts  Mean 5.1 y </text>
<text top="507" left="455" width="111" height="20" font="4">Heart-lung and lung </text>
<text top="525" left="455" width="100" height="20" font="4">transplant in CHD </text>
<text top="507" left="631" width="149" height="20" font="4">● 12% 30-d mortality. 10-y </text>
<text top="525" left="631" width="76" height="20" font="4">survival 53%. </text>
<text top="507" left="833" width="258" height="20" font="4">● Similar high upfront mortality, same or better </text>
<text top="525" left="833" width="104" height="20" font="4">long-term survival. </text>
<text top="560" left="64" width="95" height="20" font="4">Harper AR, et al. </text>
<text top="577" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(274)</a>  </text>
<text top="594" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22588032">22588032</a></text>
<text top="594" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22588032"> </a></text>
<text top="560" left="172" width="132" height="20" font="4">Single center  n=126 </text>
<text top="577" left="266" width="20" height="20" font="4">pts </text>
<text top="560" left="334" width="74" height="20" font="4">Median 1.2 y </text>
<text top="560" left="455" width="160" height="20" font="4">Comparison of transplant vs. </text>
<text top="577" left="455" width="124" height="20" font="4">nontransplant surgical </text>
<text top="594" left="455" width="67" height="20" font="4">intervention </text>
<text top="560" left="631" width="181" height="20" font="4">● 14 pts who underwent surgery </text>
<text top="577" left="631" width="170" height="20" font="4">instead; still 1-y mortality 28%. </text>
<text top="560" left="833" width="220" height="20" font="4">● Best outcomes in those with normal 2 </text>
<text top="577" left="833" width="110" height="20" font="4">ventricle anatomy.   </text>
<text top="612" left="64" width="84" height="20" font="4">Karamlou T, et </text>
<text top="629" left="64" width="16" height="20" font="4">al. </text>
<text top="647" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(275)</a> </text>
<text top="664" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22884603">22884603</a></text>
<text top="664" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22884603"> </a></text>
<text top="612" left="172" width="64" height="20" font="4">Nationwide </text>
<text top="629" left="172" width="50" height="20" font="4">inpatient </text>
<text top="647" left="172" width="43" height="20" font="4">sample </text>
<text top="664" left="172" width="54" height="20" font="4">database </text>
<text top="612" left="266" width="38" height="20" font="4">n=509 </text>
<text top="629" left="266" width="20" height="20" font="4">pts </text>
<text top="612" left="334" width="24" height="20" font="4">N/A </text>
<text top="612" left="455" width="106" height="20" font="4">Single ventricle vs. </text>
<text top="629" left="455" width="127" height="20" font="4">biventricular transplant </text>
<text top="612" left="631" width="164" height="20" font="4">● Mortality was 23% in single </text>
<text top="629" left="631" width="136" height="20" font="4">ventricle (n=143) vs. 8% </text>
<text top="647" left="631" width="120" height="20" font="4">(p&lt;0.001), which was </text>
<text top="664" left="631" width="146" height="20" font="4">independent risk factor for </text>
<text top="681" left="631" width="107" height="20" font="4">mortality (OR: 3.9). </text>
<text top="612" left="833" width="179" height="20" font="4">● No differences in newer eras.  </text>
<text top="699" left="64" width="86" height="20" font="4">Maxwell BG, et </text>
<text top="716" left="64" width="16" height="20" font="4">al. </text>
<text top="733" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(276)</a> </text>
<text top="751" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24135956">24135956</a></text>
<text top="751" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24135956"> </a></text>
<text top="699" left="172" width="53" height="20" font="4">Scientific </text>
<text top="716" left="172" width="62" height="20" font="4">Registry of </text>
<text top="733" left="172" width="62" height="20" font="4">Transplant </text>
<text top="751" left="172" width="61" height="20" font="4">Recipients </text>
<text top="699" left="266" width="91" height="20" font="4">n=83 pts  N/A </text>
<text top="699" left="455" width="155" height="20" font="4">Mechanical support pts with </text>
<text top="716" left="455" width="154" height="20" font="4">CHD vs. those not requiring </text>
<text top="733" left="455" width="117" height="20" font="4">mechanical support.  </text>
<text top="699" left="631" width="172" height="20" font="4">● Similar 30-d mortality (11 vs. </text>
<text top="716" left="631" width="145" height="20" font="4">14%), but longer LOS and </text>
<text top="733" left="631" width="185" height="20" font="4">transfusion requirements in those </text>
<text top="751" left="631" width="59" height="20" font="4">with MCS. </text>
<text top="699" left="833" width="237" height="20" font="4">● Mechanical support was less common in </text>
<text top="716" left="833" width="147" height="20" font="4">CHD than other non-CHD. </text>
</page>
<page number="78" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 78 </text>
<text top="107" left="64" width="93" height="20" font="4">Paniagua Martin </text>
<text top="124" left="64" width="53" height="20" font="4">MJ, et al. </text>
<text top="141" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(277)</a> </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22463464?dopt=Citation">22463464</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22463464?dopt=Citation"> </a></text>
<text top="107" left="172" width="48" height="20" font="4">Spanish </text>
<text top="124" left="172" width="57" height="20" font="4">transplant </text>
<text top="141" left="172" width="44" height="20" font="4">registry </text>
<text top="107" left="266" width="91" height="20" font="4">n=55 pts  N/A </text>
<text top="107" left="455" width="158" height="20" font="4">Transplant outcome by CHD </text>
<text top="124" left="455" width="46" height="20" font="4">subtype </text>
<text top="107" left="631" width="167" height="20" font="4">● Early mortality was different </text>
<text top="124" left="631" width="157" height="20" font="4">among types of CHD; worse </text>
<text top="141" left="631" width="172" height="20" font="4">mortality for single ventricle pts </text>
<text top="159" left="631" width="40" height="20" font="4">(25%). </text>
<text top="107" left="833" width="248" height="20" font="4">● Overall mortality was not different between </text>
<text top="124" left="833" width="71" height="20" font="4">subgroups.   </text>
<text top="177" left="54" width="453" height="20" font="4">*Many studies include data on non-ACHD pt groups in addition to the n given here. </text>
<text top="194" left="54" width="3" height="20" font="4"> </text>
<text top="211" left="108" width="3" height="20" font="4"> </text>
<text top="228" left="108" width="357" height="24" font="1"><b>Data Supplement 24. Palliative Care – Section 3.15 </b></text>
<text top="250" left="92" width="38" height="20" font="3"><b>Study </b></text>
<text top="267" left="67" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="284" left="96" width="30" height="20" font="3"><b>Year </b></text>
<text top="250" left="174" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="267" left="188" width="44" height="20" font="3"><b>Design </b></text>
<text top="250" left="274" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="250" left="370" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="267" left="406" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="250" left="538" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="250" left="696" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="250" left="888" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="302" left="64" width="84" height="20" font="4">Tobler D, et al. </text>
<text top="319" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(278)</a> </text>
<text top="336" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21094550?dopt=Citation">21094550</a></text>
<text top="336" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21094550?dopt=Citation"> </a></text>
<text top="302" left="170" width="45" height="20" font="4"> Survey </text>
<text top="302" left="263" width="61" height="20" font="4">n=200 pts; </text>
<text top="319" left="263" width="75" height="20" font="4">n=48 doctors </text>
<text top="302" left="363" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="319" left="363" width="93" height="20" font="4">&gt;18 y with CHD  </text>
<text top="302" left="508" width="104" height="20" font="4">78% of pts wanted </text>
<text top="319" left="508" width="124" height="20" font="4">doctor to discuss EOL </text>
<text top="336" left="508" width="3" height="20" font="4"> </text>
<text top="354" left="508" width="122" height="20" font="4">62% pts favored early </text>
<text top="371" left="508" width="92" height="20" font="4">EOL discussion  </text>
<text top="302" left="654" width="168" height="20" font="4">● 78% of pts wanted doctor to </text>
<text top="319" left="654" width="76" height="20" font="4">discuss EOL. </text>
<text top="336" left="654" width="163" height="20" font="4">● 62% pts favored early EOL </text>
<text top="354" left="654" width="68" height="20" font="4">discussion.  </text>
<text top="302" left="853" width="172" height="20" font="4">● Health care providers should </text>
<text top="319" left="853" width="203" height="20" font="4">discuss EOL issues and preferences </text>
<text top="336" left="853" width="114" height="20" font="4">with their ACHD pts. </text>
<text top="389" left="64" width="84" height="20" font="4">Tobler D, et al. </text>
<text top="406" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(279)</a> </text>
<text top="423" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21697263?dopt=Citation">21697263</a></text>
<text top="423" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21697263?dopt=Citation"> </a></text>
<text top="389" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="406" left="170" width="38" height="20" font="4">cohort </text>
<text top="389" left="263" width="31" height="20" font="4">n=48 </text>
<text top="406" left="263" width="68" height="20" font="4">hospitalized </text>
<text top="423" left="263" width="20" height="20" font="4">pts </text>
<text top="389" left="363" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="406" left="363" width="119" height="20" font="4">Adults with CHD who </text>
<text top="423" left="363" width="27" height="20" font="4">died </text>
<text top="389" left="508" width="128" height="20" font="4">Review documentation </text>
<text top="406" left="508" width="124" height="20" font="4">of EOL issues and the </text>
<text top="423" left="508" width="82" height="20" font="4">circumstances </text>
<text top="440" left="508" width="129" height="20" font="4">surrounding the deaths </text>
<text top="389" left="654" width="186" height="20" font="4">● EOL discussion documented in </text>
<text top="406" left="654" width="179" height="20" font="4">5 (10%) pts. EOL discussion will </text>
<text top="423" left="654" width="150" height="20" font="4">surrogate medical decision </text>
<text top="440" left="654" width="143" height="20" font="4">maker in 21 cases (41%). </text>
<text top="458" left="654" width="178" height="20" font="4">Referral to EOL care services in </text>
<text top="475" left="654" width="76" height="20" font="4">20 pts (21%). </text>
<text top="389" left="853" width="157" height="20" font="4">● Only a minority of pts with </text>
<text top="406" left="853" width="163" height="20" font="4">advanced HF and ACHD had </text>
<text top="423" left="853" width="187" height="20" font="4">documented discussion regarding </text>
<text top="440" left="853" width="196" height="20" font="4">EOL issues. Earlier discussion may </text>
<text top="458" left="853" width="192" height="20" font="4">avoid unnecessary treatments and </text>
<text top="475" left="853" width="174" height="20" font="4">improve the quality of the dying </text>
<text top="492" left="853" width="50" height="20" font="4">process. </text>
<text top="510" left="64" width="84" height="20" font="4">Tobler D, et al. </text>
<text top="527" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(280)</a> </text>
<text top="544" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22459306?dopt=Citation">22459306</a></text>
<text top="544" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22459306?dopt=Citation"> </a></text>
<text top="510" left="170" width="42" height="20" font="4">Survey </text>
<text top="510" left="263" width="61" height="20" font="4">n=200 pts; </text>
<text top="527" left="263" width="75" height="20" font="4">n=48 doctors </text>
<text top="510" left="363" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="527" left="363" width="93" height="20" font="4">&gt;18 y with CHD  </text>
<text top="510" left="508" width="97" height="20" font="4">87% pts reported </text>
<text top="527" left="508" width="130" height="20" font="4">preference for advance </text>
<text top="544" left="508" width="49" height="20" font="4">directive </text>
<text top="510" left="654" width="172" height="20" font="4">● 87% pts reported preference </text>
<text top="527" left="654" width="120" height="20" font="4">for advance directive. </text>
<text top="510" left="853" width="203" height="20" font="4">● CHD providers should educate pts </text>
<text top="527" left="853" width="203" height="20" font="4">about EOL issues and assist them in </text>
<text top="544" left="853" width="146" height="20" font="4">documenting EOL wishes. </text>
<text top="562" left="64" width="82" height="20" font="4">Greutmann M, </text>
<text top="580" left="64" width="30" height="20" font="4">et al. </text>
<text top="597" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(281)</a> </text>
<text top="614" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23279997?dopt=Citation">23279997</a></text>
<text top="614" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23279997?dopt=Citation"> </a></text>
<text top="562" left="170" width="68" height="20" font="4">Prospective </text>
<text top="580" left="170" width="40" height="20" font="4">survey </text>
<text top="562" left="263" width="64" height="20" font="4">200 pts; 48 </text>
<text top="580" left="263" width="44" height="20" font="4">doctors </text>
<text top="562" left="363" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="580" left="363" width="93" height="20" font="4">&gt;18 y with CHD  </text>
<text top="562" left="508" width="83" height="20" font="4">85% pts report </text>
<text top="580" left="508" width="116" height="20" font="4">discussion facilitated </text>
<text top="597" left="508" width="124" height="20" font="4">when doctor is trusted </text>
<text top="562" left="654" width="157" height="20" font="4">● 85% pts report discussion </text>
<text top="580" left="654" width="183" height="20" font="4">facilitated when doctor is trusted. </text>
<text top="562" left="853" width="205" height="20" font="4">● The close physician-pt relationship </text>
<text top="580" left="853" width="179" height="20" font="4">enables early discussion of EOL </text>
<text top="597" left="853" width="45" height="20" font="4">issues.  </text>
<text top="632" left="108" width="3" height="20" font="4"> </text>
<text top="649" left="108" width="3" height="20" font="4"> </text>
<text top="666" left="108" width="322" height="24" font="1"><b>Data Supplement 25. Cyanosis – Section 3.16 </b></text>
<text top="688" left="85" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="705" left="86" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="688" left="206" width="73" height="20" font="3"><b>Study Type  </b></text>
<text top="688" left="313" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="688" left="441" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="688" left="597" width="111" height="20" font="3"><b>Study Intervention </b></text>
<text top="688" left="841" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="727" left="64" width="94" height="20" font="4">Dedkov EI, et al. </text>
<text top="744" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(282)</a> </text>
<text top="761" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16831984?dopt=Citation">16831984</a></text>
<text top="761" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16831984?dopt=Citation"> </a></text>
<text top="727" left="197" width="64" height="20" font="4">Descriptive </text>
<text top="727" left="298" width="44" height="20" font="4">n=5 pts </text>
<text top="727" left="406" width="89" height="20" font="4">Microcirculation </text>
<text top="727" left="562" width="163" height="20" font="4">● Measured arteriolar length, </text>
<text top="744" left="562" width="166" height="20" font="4">volume and surface densities. </text>
<text top="761" left="562" width="150" height="20" font="4">Other pt groups studied for </text>
<text top="778" left="562" width="67" height="20" font="4">comparison </text>
<text top="727" left="757" width="205" height="20" font="4">● Microcirculation adapts to hypoxia. </text>
</page>
<page number="79" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 79 </text>
<text top="107" left="64" width="98" height="20" font="4">Duffels MG, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(283)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20526039?dopt=Citation">20526039</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20526039?dopt=Citation"> </a></text>
<text top="107" left="197" width="64" height="20" font="4">Descriptive </text>
<text top="107" left="298" width="51" height="20" font="4">n=54 pts </text>
<text top="107" left="406" width="87" height="20" font="4">Atherosclerosis </text>
<text top="107" left="562" width="162" height="20" font="4">Intima-media thickness in pts </text>
<text top="124" left="562" width="70" height="20" font="4">and controls </text>
<text top="107" left="757" width="205" height="20" font="4">● Microcirculation adapts to hypoxia. </text>
<text top="159" left="64" width="75" height="20" font="4">Hirth A, et al. </text>
<text top="177" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(284)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18380761?dopt=Citation">18380761</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18380761?dopt=Citation"> </a></text>
<text top="159" left="197" width="64" height="20" font="4">Descriptive </text>
<text top="159" left="298" width="51" height="20" font="4">n=29 pts </text>
<text top="159" left="406" width="57" height="20" font="4">Migraines </text>
<text top="159" left="562" width="24" height="20" font="4">N/A </text>
<text top="159" left="757" width="301" height="20" font="4">● High prevalence of headaches in a small population. </text>
<text top="212" left="64" width="103" height="20" font="4">Horigome H, et al. </text>
<text top="229" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(285)</a> </text>
<text top="246" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16415201?dopt=Citation">16415201</a></text>
<text top="246" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16415201?dopt=Citation"> </a></text>
<text top="212" left="197" width="64" height="20" font="4">Descriptive </text>
<text top="212" left="298" width="51" height="20" font="4">n=15 pts </text>
<text top="212" left="406" width="58" height="20" font="4">Brain MRI </text>
<text top="212" left="562" width="24" height="20" font="4">N/A </text>
<text top="212" left="757" width="261" height="20" font="4">● High prevalence of cerebral ischemic events, </text>
<text top="229" left="757" width="173" height="20" font="4">correlating with lower statistics. </text>
<text top="264" left="64" width="96" height="20" font="4">Jensen AS, et al. </text>
<text top="281" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(286)</a> </text>
<text top="299" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22727966?dopt=Citation">22727966</a></text>
<text top="299" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22727966?dopt=Citation"> </a></text>
<text top="264" left="197" width="64" height="20" font="4">Descriptive </text>
<text top="264" left="298" width="51" height="20" font="4">n=75 pts </text>
<text top="264" left="406" width="108" height="20" font="4">Fibrinogen function </text>
<text top="281" left="406" width="51" height="20" font="4">impaired </text>
<text top="264" left="562" width="175" height="20" font="4">● Fibrinogen function related to </text>
<text top="281" left="562" width="171" height="20" font="4">blood count and clinical events </text>
<text top="264" left="757" width="291" height="20" font="4">● Reduced fibrinogen function, related to hematocrit. </text>
<text top="281" left="757" width="151" height="20" font="4">Has impact on hemostasis. </text>
<text top="317" left="64" width="96" height="20" font="4">Jensen AS, et al. </text>
<text top="334" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(287)</a> </text>
<text top="351" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22578951?dopt=Citation">22578951</a></text>
<text top="351" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22578951?dopt=Citation"> </a></text>
<text top="317" left="197" width="67" height="20" font="4">Prospective </text>
<text top="334" left="197" width="64" height="20" font="4">multicenter </text>
<text top="317" left="298" width="52" height="20" font="4">n=98 (21 </text>
<text top="334" left="298" width="61" height="20" font="4">underwent </text>
<text top="351" left="298" width="71" height="20" font="4">phlebotomy) </text>
<text top="317" left="406" width="87" height="20" font="4">Hematocrit and </text>
<text top="334" left="406" width="66" height="20" font="4">hemostasis </text>
<text top="317" left="562" width="164" height="20" font="4">● Thromboelastography after </text>
<text top="334" left="562" width="163" height="20" font="4">phlebotomy s. baseline in the </text>
<text top="351" left="562" width="119" height="20" font="4">setting of hemoptysis </text>
<text top="317" left="757" width="252" height="20" font="4">● Thromboelastography showed reduced clot </text>
<text top="334" left="757" width="286" height="20" font="4">formation and strength, relationship with hematocrit. </text>
<text top="351" left="757" width="216" height="20" font="4">Smaller subset underwent phlebotomy. </text>
<text top="369" left="64" width="97" height="20" font="4">Kajimoto H, et al. </text>
<text top="386" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(288)</a> </text>
<text top="403" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17526995?dopt=Citation">17526995</a></text>
<text top="403" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17526995?dopt=Citation"> </a></text>
<text top="369" left="197" width="3" height="20" font="4"> </text>
<text top="369" left="298" width="51" height="20" font="4">n=35 pts </text>
<text top="369" left="406" width="94" height="20" font="4">Thrombogenicity </text>
<text top="369" left="562" width="168" height="20" font="4">● Thrombosis related proteins </text>
<text top="386" left="562" width="173" height="20" font="4">measured compared to healthy </text>
<text top="403" left="562" width="46" height="20" font="4">controls </text>
<text top="369" left="757" width="280" height="20" font="4">● Higher levels of AT3, lower Protein C suggesting </text>
<text top="386" left="757" width="228" height="20" font="4">platelet activation and hypercoagulability. </text>
<text top="421" left="64" width="89" height="20" font="4">Legault S, et al. </text>
<text top="439" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(289)</a> </text>
<text top="456" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17643525?dopt=Citation">17643525</a></text>
<text top="456" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17643525?dopt=Citation"> </a></text>
<text top="421" left="197" width="3" height="20" font="4"> </text>
<text top="421" left="298" width="51" height="20" font="4">n=10 pts </text>
<text top="421" left="406" width="111" height="20" font="4">Nocturnal breathing </text>
<text top="421" left="562" width="24" height="20" font="4">N/A </text>
<text top="421" left="757" width="203" height="20" font="4">● Desaturations, but not obstruction. </text>
<text top="474" left="64" width="120" height="20" font="4">Martinez-Quintana E, </text>
<text top="491" left="64" width="30" height="20" font="4">et al. </text>
<text top="508" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(290)</a> </text>
<text top="525" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19489941?dopt=Citation">19489941</a></text>
<text top="525" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19489941?dopt=Citation"> </a></text>
<text top="474" left="197" width="64" height="20" font="4">Descriptive </text>
<text top="474" left="298" width="51" height="20" font="4">n=14 pts </text>
<text top="474" left="406" width="57" height="20" font="4">Urinalysis </text>
<text top="474" left="562" width="24" height="20" font="4">N/A </text>
<text top="474" left="757" width="147" height="20" font="4">● Microalbuminuria found. </text>
<text top="543" left="64" width="112" height="20" font="4">Pedersen CM, et al. </text>
<text top="560" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(291)</a> </text>
<text top="578" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19641842?dopt=Citation">19641842</a></text>
<text top="578" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19641842?dopt=Citation"> </a></text>
<text top="543" left="197" width="64" height="20" font="4">Descriptive </text>
<text top="543" left="298" width="51" height="20" font="4">n=13 pts </text>
<text top="543" left="406" width="126" height="20" font="4">Flow mediated dilation </text>
<text top="543" left="562" width="148" height="20" font="4">● Flow mediated dilatation </text>
<text top="560" left="562" width="118" height="20" font="4">compared to controls </text>
<text top="543" left="757" width="274" height="20" font="4">● Vasodilatation intact, flow mediated dilatation is </text>
<text top="560" left="757" width="62" height="20" font="4">preserved. </text>
<text top="596" left="64" width="90" height="20" font="4">Reiss UM, et al. </text>
<text top="613" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(292)</a> </text>
<text top="630" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17506064?dopt=Citation">17506064</a></text>
<text top="630" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17506064?dopt=Citation"> </a></text>
<text top="596" left="197" width="79" height="20" font="4">Observational </text>
<text top="596" left="298" width="44" height="20" font="4">n=4 pts </text>
<text top="596" left="406" width="73" height="20" font="4">Hydroxyurea </text>
<text top="596" left="562" width="24" height="20" font="4">N/A </text>
<text top="596" left="757" width="274" height="20" font="4">● Favorable response to hydroxyurea, lower HCT </text>
<text top="613" left="757" width="209" height="20" font="4">higher MCV to HGB stayed the same. </text>
<text top="648" left="64" width="76" height="20" font="4">Tay EL, et al. </text>
<text top="665" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(293)</a> </text>
<text top="683" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20580108?dopt=Citation">20580108</a></text>
<text top="683" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20580108?dopt=Citation"> </a></text>
<text top="648" left="197" width="79" height="20" font="4">Observational </text>
<text top="648" left="298" width="51" height="20" font="4">n=25 pts </text>
<text top="648" left="406" width="118" height="20" font="4">Iron supplementation </text>
<text top="648" left="562" width="183" height="20" font="4">● Iron supplementation for 3 mo, </text>
<text top="665" left="562" width="177" height="20" font="4">measuring response in exercise </text>
<text top="683" left="562" width="49" height="20" font="4">capacity </text>
<text top="648" left="757" width="276" height="20" font="4">● Better walk distance with improved iron stores.   </text>
<text top="665" left="757" width="53" height="20" font="4">● Peak O</text>
<text top="671" left="811" width="4" height="13" font="6">2</text>
<text top="665" left="815" width="174" height="20" font="4"> consumption was not different. </text>
<text top="701" left="64" width="108" height="20" font="4">Trojnarska O, et al. </text>
<text top="718" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(294)</a> </text>
<text top="735" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19042041?dopt=Citation">19042041</a></text>
<text top="735" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19042041?dopt=Citation"> </a></text>
<text top="701" left="197" width="64" height="20" font="4">Descriptive </text>
<text top="701" left="298" width="51" height="20" font="4">n=53 pts </text>
<text top="701" left="406" width="102" height="20" font="4">BNP and exercise </text>
<text top="701" left="562" width="24" height="20" font="4">N/A </text>
<text top="701" left="757" width="244" height="20" font="4">● Higher BNP, lower exercise than controls. </text>
<text top="753" left="64" width="67" height="20" font="4">Tsui I, et al. </text>
<text top="770" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(295)</a> </text>
<text top="787" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19954382?dopt=Citation">19954382</a></text>
<text top="787" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19954382?dopt=Citation"> </a></text>
<text top="753" left="197" width="64" height="20" font="4">Descriptive </text>
<text top="753" left="298" width="44" height="20" font="4">n=4 pts </text>
<text top="753" left="406" width="108" height="20" font="4">Retinal vasculature </text>
<text top="753" left="562" width="24" height="20" font="4">N/A </text>
<text top="753" left="757" width="251" height="20" font="4">● Tortuous vessels described in cyanotic pts. </text>
</page>
<page number="80" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 80 </text>
<text top="107" left="64" width="118" height="20" font="4">Wykretowicz A, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(296)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18377491?dopt=Citation">18377491</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18377491?dopt=Citation"> </a></text>
<text top="107" left="197" width="64" height="20" font="4">Descriptive </text>
<text top="107" left="298" width="51" height="20" font="4">n=14 pts </text>
<text top="107" left="406" width="91" height="20" font="4">Arterial stiffness </text>
<text top="107" left="562" width="24" height="20" font="4">N/A </text>
<text top="107" left="757" width="202" height="20" font="4">● Stiffness not significantly different. </text>
<text top="159" left="64" width="101" height="20" font="4">Broberg CS, et al. </text>
<text top="177" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(297)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24331639?dopt=Citation">24331639</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24331639?dopt=Citation"> </a></text>
<text top="159" left="197" width="64" height="20" font="4">Descriptive </text>
<text top="159" left="298" width="51" height="20" font="4">n=32 pts </text>
<text top="159" left="406" width="77" height="20" font="4">Lung function </text>
<text top="159" left="562" width="24" height="20" font="4">N/A </text>
<text top="159" left="757" width="246" height="20" font="4">● Lung function/gas exchange abnormalities </text>
<text top="177" left="757" width="67" height="20" font="4">described.   </text>
<text top="194" left="757" width="179" height="20" font="4">● Pts have respiratory alkalosis. </text>
<text top="212" left="64" width="101" height="20" font="4">Broberg CS, et al. </text>
<text top="229" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(298)</a> </text>
<text top="246" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17164484?dopt=Citation">17164484</a></text>
<text top="246" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17164484?dopt=Citation"> </a></text>
<text top="212" left="197" width="64" height="20" font="4">Descriptive </text>
<text top="212" left="298" width="51" height="20" font="4">n=55 pts </text>
<text top="212" left="406" width="83" height="20" font="4">PA thrombosis </text>
<text top="212" left="562" width="24" height="20" font="4">N/A </text>
<text top="212" left="757" width="279" height="20" font="4">● Risk factors for PA thrombosis included poor RV </text>
<text top="229" left="757" width="211" height="20" font="4">function and LV function, and PA size. </text>
<text top="264" left="64" width="101" height="20" font="4">Broberg CS, et al. </text>
<text top="281" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(299)</a> </text>
<text top="299" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16843187?dopt=Citation">16843187</a></text>
<text top="299" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16843187?dopt=Citation"> </a></text>
<text top="264" left="197" width="64" height="20" font="4">Descriptive </text>
<text top="264" left="298" width="51" height="20" font="4">n=39 pts </text>
<text top="264" left="406" width="107" height="20" font="4">Iron deficiency and </text>
<text top="281" left="406" width="50" height="20" font="4">viscosity </text>
<text top="264" left="562" width="24" height="20" font="4">N/A </text>
<text top="264" left="757" width="249" height="20" font="4">● Iron deficiency does not increase viscosity. </text>
<text top="317" left="64" width="101" height="20" font="4">Broberg CS, et al. </text>
<text top="334" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(300)</a> </text>
<text top="351" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21295176?dopt=Citation">21295176</a></text>
<text top="351" left="119" width="7" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21295176?dopt=Citation"> </a> </text>
<text top="317" left="197" width="64" height="20" font="4">Descriptive </text>
<text top="317" left="298" width="51" height="20" font="4">n=65 pts </text>
<text top="317" left="406" width="69" height="20" font="4">Hemoglobin </text>
<text top="317" left="562" width="24" height="20" font="4">N/A </text>
<text top="317" left="757" width="288" height="20" font="4">● Optimal hemoglobin defined, and relationship with </text>
<text top="334" left="757" width="10" height="20" font="4">O</text>
<text top="340" left="767" width="4" height="13" font="6">2</text>
<text top="334" left="771" width="92" height="20" font="4"> sat determined. </text>
<text top="369" left="64" width="101" height="20" font="4">Broberg CS, et al. </text>
<text top="386" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(298)</a> </text>
<text top="403" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17164484?dopt=Citation">17164484</a></text>
<text top="403" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17164484?dopt=Citation"> </a></text>
<text top="369" left="197" width="64" height="20" font="4">Descriptive </text>
<text top="369" left="298" width="51" height="20" font="4">n=53 pts </text>
<text top="369" left="406" width="52" height="20" font="4">Air travel </text>
<text top="369" left="562" width="170" height="20" font="4">● Pts described all air travel in </text>
<text top="386" left="562" width="175" height="20" font="4">10 y, and any AE. Compared to </text>
<text top="403" left="562" width="89" height="20" font="4">noncyanotic pts </text>
<text top="369" left="757" width="181" height="20" font="4">● No major AE, 1 possible TIA.   </text>
<text top="386" left="757" width="239" height="20" font="4">● Extensive travel reported, generally safe. </text>
<text top="421" left="64" width="98" height="20" font="4">Sandoval J, et al. </text>
<text top="439" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(301)</a> </text>
<text top="456" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22360787">22360787</a></text>
<text top="456" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22360787"> </a></text>
<text top="421" left="197" width="79" height="20" font="4">Observational </text>
<text top="421" left="298" width="51" height="20" font="4">n=92 pts </text>
<text top="421" left="406" width="119" height="20" font="4">Warfarin and survival </text>
<text top="421" left="562" width="176" height="20" font="4">● Compared anticoagulated vs. </text>
<text top="439" left="562" width="152" height="20" font="4">nonanticoagulated pts after </text>
<text top="456" left="562" width="152" height="20" font="4">mean follow-up of 7 ± 5.4 y </text>
<text top="421" left="757" width="264" height="20" font="4">● No difference in survival or bleeding events in </text>
<text top="439" left="757" width="107" height="20" font="4">anticoagulated pts. </text>
<text top="474" left="108" width="3" height="20" font="4"> </text>
<text top="491" left="108" width="3" height="20" font="4"> </text>
<text top="508" left="108" width="395" height="24" font="1"><b>Data Supplement 26. Atrial Septal Defect – Section 4.1.1 </b></text>
<text top="530" left="73" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="547" left="73" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="530" left="178" width="82" height="20" font="3"><b>Study Design </b></text>
<text top="530" left="288" width="38" height="20" font="3"><b>Study </b></text>
<text top="547" left="293" width="28" height="20" font="3"><b>Size </b></text>
<text top="530" left="365" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="547" left="402" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="530" left="522" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="530" left="767" width="48" height="20" font="3"><b>Results </b></text>
<text top="530" left="994" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="568" left="64" width="91" height="20" font="4">Peirone A, et al. </text>
<text top="585" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(302)</a> </text>
<text top="602" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24677704?dopt=Citation">24677704</a></text>
<text top="602" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24677704?dopt=Citation"> </a></text>
<text top="568" left="172" width="67" height="20" font="4">Prospective </text>
<text top="585" left="172" width="61" height="20" font="4">single-arm </text>
<text top="602" left="172" width="76" height="20" font="4">observational </text>
<text top="620" left="172" width="36" height="20" font="4">study, </text>
<text top="637" left="172" width="64" height="20" font="4">multicenter </text>
<text top="568" left="280" width="173" height="20" font="4">n=74 pts  <b>Inclusion criteria</b>: </text>
<text top="585" left="347" width="91" height="20" font="4">Consecutive pts </text>
<text top="602" left="347" width="154" height="20" font="4">undergoing secundum ASD </text>
<text top="620" left="347" width="115" height="20" font="4">closure using the Nit-</text>
<text top="637" left="347" width="122" height="20" font="4">Occlud ASD-R device </text>
<text top="654" left="347" width="115" height="20" font="4">between 2011–2013 </text>
<text top="568" left="515" width="85" height="20" font="4">Immediate and </text>
<text top="585" left="515" width="60" height="20" font="4">short-term </text>
<text top="602" left="515" width="70" height="20" font="4">outcomes of </text>
<text top="620" left="515" width="82" height="20" font="4">device closure </text>
<text top="568" left="614" width="240" height="20" font="4">● Implantation was successful in 73/74 pts. </text>
<text top="585" left="614" width="110" height="20" font="4">● Median age 17 y. </text>
<text top="602" left="614" width="308" height="20" font="4">● Excluded pts with ASD diameter &gt;28 mm by stop flow </text>
<text top="620" left="614" width="60" height="20" font="4">technique. </text>
<text top="637" left="614" width="341" height="20" font="4">● Complete occlusion of ASD on 6 mo follow-up ECG in 99%. </text>
<text top="654" left="614" width="294" height="20" font="4">● At a mean follow-up of 11 ± 7 mo, no embolization, </text>
<text top="671" left="614" width="124" height="20" font="4">perforation or erosion. </text>
<text top="689" left="614" width="211" height="20" font="4">● No arrhythmias post device closure. </text>
<text top="706" left="614" width="322" height="20" font="4">● No embolic events, no wire fracture, no infections noted. </text>
<text top="568" left="981" width="149" height="20" font="4">● ASD closure with the Nit-</text>
<text top="585" left="981" width="134" height="20" font="4">Occlud ASD-R device is </text>
<text top="602" left="981" width="160" height="20" font="4">feasible, safe and has a high </text>
<text top="620" left="981" width="76" height="20" font="4">success rate. </text>
</page>
<page number="81" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 81 </text>
<text top="107" left="64" width="89" height="20" font="4">Mylotte D, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#223">(209)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24485223?dopt=Citation">24485223</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24485223?dopt=Citation"> </a></text>
<text top="107" left="172" width="63" height="20" font="4">Systematic </text>
<text top="124" left="172" width="89" height="20" font="4">review; use of a </text>
<text top="141" left="172" width="94" height="20" font="4">decision-analytic </text>
<text top="159" left="172" width="55" height="20" font="4">model for </text>
<text top="176" left="172" width="83" height="20" font="4">assessment of </text>
<text top="193" left="172" width="91" height="20" font="4">clinical outcome </text>
<text top="210" left="172" width="79" height="20" font="4">parameters of </text>
<text top="228" left="172" width="89" height="20" font="4">secundum ASD </text>
<text top="245" left="172" width="87" height="20" font="4">closure method </text>
<text top="262" left="172" width="95" height="20" font="4">from the Quebec </text>
<text top="279" left="172" width="89" height="20" font="4">CHD Database. </text>
<text top="296" left="172" width="38" height="20" font="4">A cost-</text>
<text top="314" left="172" width="75" height="20" font="4">effectiveness </text>
<text top="331" left="172" width="73" height="20" font="4">analysis was </text>
<text top="348" left="172" width="60" height="20" font="4">performed </text>
<text top="365" left="172" width="61" height="20" font="4">comparing </text>
<text top="383" left="172" width="65" height="20" font="4">surgical vs. </text>
<text top="400" left="172" width="75" height="20" font="4">transcatheter </text>
<text top="417" left="172" width="72" height="20" font="4">ASD closure </text>
<text top="107" left="280" width="38" height="20" font="4">n=718 </text>
<text top="124" left="280" width="20" height="20" font="4">pts </text>
<text top="107" left="347" width="137" height="20" font="3"><b>Inclusion criteria</b>: Adult </text>
<text top="124" left="347" width="145" height="20" font="4">pts undergoing surgical or </text>
<text top="141" left="347" width="135" height="20" font="4">transcatheter secundum </text>
<text top="159" left="347" width="131" height="20" font="4">ASD closure in Quebec </text>
<text top="107" left="515" width="29" height="20" font="4">Cost </text>
<text top="124" left="515" width="57" height="20" font="4">difference </text>
<text top="141" left="515" width="50" height="20" font="4">between </text>
<text top="159" left="515" width="70" height="20" font="4">surgical and </text>
<text top="176" left="515" width="75" height="20" font="4">transcatheter </text>
<text top="193" left="515" width="60" height="20" font="4">secundum </text>
<text top="210" left="515" width="72" height="20" font="4">ASD closure </text>
<text top="107" left="614" width="326" height="20" font="4">● Between 1998–2005, 718 pts underwent secundum ASD </text>
<text top="124" left="614" width="301" height="20" font="4">closure, 335 underwent transcatheter closure, and 383 </text>
<text top="141" left="614" width="153" height="20" font="4">underwent surgical closure. </text>
<text top="159" left="614" width="326" height="20" font="4">● The 5-y cost of surgical closure was $15,304 vs. $11,060 </text>
<text top="176" left="614" width="243" height="20" font="4">(Canadian dollars) for transcatheter closure. </text>
<text top="193" left="614" width="294" height="20" font="4">● Probabilistic sensitivity analyses demonstrated that </text>
<text top="210" left="614" width="305" height="20" font="4">transcatheter ASD closure was associated with an 80% </text>
<text top="228" left="614" width="304" height="20" font="4">probability of cost savings and equal or greater efficacy </text>
<text top="245" left="614" width="176" height="20" font="4">compared to surgical treatment. </text>
<text top="107" left="981" width="152" height="20" font="4">● Transcatheter secundum </text>
<text top="124" left="981" width="146" height="20" font="4">ASD closure is associated </text>
<text top="141" left="981" width="129" height="20" font="4">with reduced costs and </text>
<text top="159" left="981" width="135" height="20" font="4">slightly improved clinical </text>
<text top="176" left="981" width="129" height="20" font="4">outcomes compared to </text>
<text top="193" left="981" width="158" height="20" font="4">surgical closure at 5-y follow-</text>
<text top="210" left="981" width="21" height="20" font="4">up. </text>
<text top="435" left="64" width="88" height="20" font="4">Stroker E, et al. </text>
<text top="452" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(303)</a> </text>
<text top="469" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23705553?dopt=Citation">23705553</a></text>
<text top="469" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23705553?dopt=Citation"> </a></text>
<text top="435" left="172" width="78" height="20" font="4">Retrospective </text>
<text top="452" left="172" width="74" height="20" font="4">single-center </text>
<text top="469" left="172" width="39" height="20" font="4">review </text>
<text top="435" left="280" width="218" height="20" font="4">n=47 pts  <b>Inclusion criteria</b>: Pts &gt;60 </text>
<text top="452" left="347" width="94" height="20" font="4">y that underwent </text>
<text top="469" left="347" width="135" height="20" font="4">transcatheter secundum </text>
<text top="487" left="347" width="72" height="20" font="4">ASD closure </text>
<text top="435" left="515" width="60" height="20" font="4">Long-term </text>
<text top="452" left="515" width="57" height="20" font="4">outcomes </text>
<text top="435" left="614" width="151" height="20" font="4">● 47 pts, mean age 69.5 y. </text>
<text top="452" left="614" width="142" height="20" font="4">● Median follow-up 3.3 y. </text>
<text top="469" left="614" width="327" height="20" font="4">● Post closure, the PAP and RV size decreased but did not </text>
<text top="487" left="614" width="60" height="20" font="4">normalize. </text>
<text top="504" left="614" width="248" height="20" font="4">● LV size, left atrial size, LVEF all increased. </text>
<text top="521" left="614" width="249" height="20" font="4">● NYHA class improved after device closure. </text>
<text top="538" left="614" width="340" height="20" font="4">● 6 pts died during 3.3 y of follow-up, 16 were hospitalized for </text>
<text top="555" left="614" width="86" height="20" font="4">cardiac events. </text>
<text top="435" left="981" width="152" height="20" font="4">● Transcatheter secundum </text>
<text top="452" left="981" width="145" height="20" font="4">ASD closure in the elderly </text>
<text top="469" left="981" width="98" height="20" font="4">improved FC, RV </text>
<text top="487" left="981" width="118" height="20" font="4">dimensions and PAP </text>
<text top="573" left="64" width="80" height="20" font="4">Rhodes JF, et </text>
<text top="591" left="64" width="16" height="20" font="4">al. </text>
<text top="608" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(304)</a> </text>
<text top="625" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23674380?dopt=Citation">23674380</a></text>
<text top="625" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23674380?dopt=Citation"> </a></text>
<text top="573" left="172" width="72" height="20" font="4">Case series; </text>
<text top="591" left="172" width="83" height="20" font="4">Clinical results </text>
<text top="608" left="172" width="91" height="20" font="4">of the feasibility, </text>
<text top="625" left="172" width="42" height="20" font="4">pivotal, </text>
<text top="642" left="172" width="57" height="20" font="4">continued </text>
<text top="659" left="172" width="69" height="20" font="4">access, and </text>
<text top="677" left="172" width="77" height="20" font="4">post approval </text>
<text top="694" left="172" width="64" height="20" font="4">studies are </text>
<text top="711" left="172" width="40" height="20" font="4">pooled </text>
<text top="573" left="280" width="38" height="20" font="4">n=435 </text>
<text top="591" left="280" width="20" height="20" font="4">pts </text>
<text top="573" left="347" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="591" left="347" width="141" height="20" font="4">a secundum ASD treated </text>
<text top="608" left="347" width="107" height="20" font="4">with a Helex septal </text>
<text top="625" left="347" width="113" height="20" font="4">occluder device and </text>
<text top="642" left="347" width="140" height="20" font="4">included in the feasibility, </text>
<text top="659" left="347" width="141" height="20" font="4">pivotal, continued access </text>
<text top="677" left="347" width="141" height="20" font="4">or post approval studies.  </text>
<text top="694" left="347" width="3" height="20" font="4"> </text>
<text top="711" left="347" width="131" height="20" font="3"><b>Exclusion criteria</b>: Pts </text>
<text top="728" left="347" width="145" height="20" font="4">with large secundum ASD </text>
<text top="745" left="347" width="106" height="20" font="4">(&gt;22 mm stretched </text>
<text top="763" left="347" width="59" height="20" font="4">diameter). </text>
<text top="573" left="515" width="72" height="20" font="4">Intermediate </text>
<text top="591" left="515" width="81" height="20" font="4">(12 mo) follow-</text>
<text top="608" left="515" width="44" height="20" font="4">up data </text>
<text top="573" left="614" width="342" height="20" font="4">● Of the 435 subjects enrolled, 412 were eligible for follow-up. </text>
<text top="591" left="614" width="339" height="20" font="4">● Clinical ASD closure was achieved in 98% of subjects at 12 </text>
<text top="608" left="614" width="262" height="20" font="4">mo; freedom from major AE at 12 mo was 95%. </text>
<text top="573" left="981" width="139" height="20" font="4">● The Gore Helex septal </text>
<text top="591" left="981" width="148" height="20" font="4">occluder is efficacious and </text>
<text top="608" left="981" width="146" height="20" font="4">safe for closing secundum </text>
<text top="625" left="981" width="152" height="20" font="4">ASD measuring ≤22 mm in </text>
<text top="642" left="981" width="105" height="20" font="4">stretched diameter </text>
</page>
<page number="82" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 82 </text>
<text top="107" left="64" width="90" height="20" font="4">Aytemir K, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(305)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23601507?dopt=Citation">23601507</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23601507?dopt=Citation"> </a></text>
<text top="107" left="172" width="79" height="20" font="4">Single-center, </text>
<text top="124" left="172" width="74" height="20" font="4">retrospective </text>
<text top="141" left="172" width="39" height="20" font="4">review </text>
<text top="107" left="280" width="38" height="20" font="4">n=193 </text>
<text top="124" left="280" width="23" height="20" font="4">pts  </text>
<text top="107" left="347" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="124" left="347" width="113" height="20" font="4">secundum ASD that </text>
<text top="141" left="347" width="136" height="20" font="4">underwent transcatheter </text>
<text top="159" left="347" width="82" height="20" font="4">device closure </text>
<text top="107" left="515" width="72" height="20" font="4">intermediate-</text>
<text top="124" left="515" width="81" height="20" font="4">term follow-up </text>
<text top="107" left="614" width="321" height="20" font="4">● Out of a total of 414 pts, 193 underwent secundum ASD </text>
<text top="124" left="614" width="348" height="20" font="4">closure using a variety of devices, 221 underwent PFO closure. </text>
<text top="141" left="614" width="241" height="20" font="4">● Median follow-up was 43 mo for ASD pts. </text>
<text top="159" left="614" width="172" height="20" font="4">● Device embolization in 2 pts. </text>
<text top="176" left="614" width="329" height="20" font="4">● No residual shunts noted on follow-up transthoracic ECG. </text>
<text top="193" left="614" width="164" height="20" font="4">● Device thrombosis in 2 pts. </text>
<text top="107" left="981" width="120" height="20" font="4">● Transcatheter ASD </text>
<text top="124" left="981" width="143" height="20" font="4">closure is associated with </text>
<text top="141" left="981" width="90" height="20" font="4">good short- and </text>
<text top="159" left="981" width="160" height="20" font="4">intermediate-term outcomes. </text>
<text top="211" left="64" width="73" height="20" font="4">Du ZD, et al. </text>
<text top="228" left="64" width="63" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(306)</a> </text>
<text top="245" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12039500?dopt=Citation">12039500</a></text>
<text top="245" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12039500?dopt=Citation"> </a></text>
<text top="211" left="172" width="67" height="20" font="4">Multicenter, </text>
<text top="228" left="172" width="66" height="20" font="4">prospective </text>
<text top="245" left="172" width="88" height="20" font="4">nonrandomized </text>
<text top="263" left="172" width="27" height="20" font="4">trial  </text>
<text top="211" left="280" width="38" height="20" font="4">n=614 </text>
<text top="228" left="280" width="20" height="20" font="4">pts </text>
<text top="211" left="347" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="228" left="347" width="120" height="20" font="4">secundum ASD at 29 </text>
<text top="245" left="347" width="140" height="20" font="4">centers were assigned to </text>
<text top="263" left="347" width="94" height="20" font="4">either surgical or </text>
<text top="280" left="347" width="114" height="20" font="4">transcatheter device </text>
<text top="297" left="347" width="96" height="20" font="4">closure using the </text>
<text top="314" left="347" width="145" height="20" font="4">Amplatzer septal occluder </text>
<text top="332" left="347" width="115" height="20" font="4">between 1998–2000 </text>
<text top="211" left="515" width="61" height="20" font="4">Short- and </text>
<text top="228" left="515" width="72" height="20" font="4">intermediate-</text>
<text top="245" left="515" width="68" height="20" font="4">term results </text>
<text top="211" left="614" width="351" height="20" font="4">● A total of 614 pts enrolled, 442 in the device group and 154 in </text>
<text top="228" left="614" width="352" height="20" font="4">the surgical group; secundum ASD diameter in the device group </text>
<text top="245" left="614" width="336" height="20" font="4">was a median of 13.3 mm vs. 14.2 mm for the surgery group. </text>
<text top="263" left="614" width="345" height="20" font="4">89% of the device group pts had a single ASD vs. 80.5% in the </text>
<text top="280" left="614" width="83" height="20" font="4">surgery group. </text>
<text top="297" left="614" width="236" height="20" font="4">● Successful device deployment in 95.7%. </text>
<text top="314" left="614" width="347" height="20" font="4">● Mean age in device group was 18.1 y vs. 5.9 y in the surgery </text>
<text top="332" left="614" width="38" height="20" font="4">group. </text>
<text top="349" left="614" width="138" height="20" font="4">● 1 device embolization. </text>
<text top="366" left="614" width="354" height="20" font="4">● Immediate successful closure (≤ mild residual shunt) in 97.6% </text>
<text top="383" left="614" width="76" height="20" font="4">of device pts. </text>
<text top="401" left="614" width="317" height="20" font="4">● All pts in the surgical group had a successful operation. </text>
<text top="418" left="614" width="323" height="20" font="4">● At 12 mo post procedure 98.5% of device pts had ≤ mild </text>
<text top="435" left="614" width="83" height="20" font="4">residual shunt. </text>
<text top="452" left="614" width="351" height="20" font="4">● No device or surgical deaths; major complications occurred in </text>
<text top="469" left="614" width="310" height="20" font="4">1.6% of the device group and 5.4% of the surgical group </text>
<text top="487" left="614" width="53" height="20" font="4">(p=0.03). </text>
<text top="504" left="614" width="348" height="20" font="4">● Minor complications in 6.1% of the device group vs. 18.8% of </text>
<text top="521" left="614" width="161" height="20" font="4">the surgical group (p&lt;0.001). </text>
<text top="538" left="614" width="334" height="20" font="4">● Total complications in 7.2% of the device group vs. 24% of </text>
<text top="555" left="614" width="161" height="20" font="4">the surgical group (p&lt;0.001). </text>
<text top="573" left="614" width="311" height="20" font="4">● Mean LOS was 1 d in the device group vs. 3.4 d in the </text>
<text top="590" left="614" width="139" height="20" font="4">surgery group (p&lt;0.001). </text>
<text top="211" left="981" width="152" height="20" font="4">● Transcatheter secundum </text>
<text top="228" left="981" width="117" height="20" font="4">ASD closure with the </text>
<text top="245" left="981" width="157" height="20" font="4">Amplatzer septal occluder is </text>
<text top="263" left="981" width="122" height="20" font="4">a safe and efficacious </text>
<text top="280" left="981" width="122" height="20" font="4">alternative to surgery. </text>
<text top="608" left="64" width="77" height="20" font="4">Kutty S, et al. </text>
<text top="625" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(307)</a> </text>
<text top="642" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22335856?dopt=Citation">22335856</a></text>
<text top="642" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22335856?dopt=Citation"> </a></text>
<text top="608" left="172" width="76" height="20" font="4">Single-center </text>
<text top="625" left="172" width="74" height="20" font="4">retrospective </text>
<text top="642" left="172" width="39" height="20" font="4">review </text>
<text top="608" left="280" width="38" height="20" font="4">n=375 </text>
<text top="625" left="280" width="20" height="20" font="4">pts </text>
<text top="608" left="347" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="625" left="347" width="113" height="20" font="4">secundum ASD that </text>
<text top="642" left="347" width="121" height="20" font="4">underwent surgical or </text>
<text top="659" left="347" width="118" height="20" font="4">transcatheter closure </text>
<text top="677" left="347" width="115" height="20" font="4">between 1986–2005 </text>
<text top="608" left="515" width="60" height="20" font="4">Long-term </text>
<text top="625" left="515" width="80" height="20" font="4">clinical results </text>
<text top="608" left="614" width="321" height="20" font="4">● 375 pts identified, 207 had surgical closure and 168 had </text>
<text top="625" left="614" width="85" height="20" font="4">device closure. </text>
<text top="642" left="614" width="347" height="20" font="4">● &gt;5-y follow-up data available on 300 pts (median follow-up of </text>
<text top="659" left="614" width="300" height="20" font="4">11.9 y in 152 surgical and 8.1 y in 148 device closure). </text>
<text top="677" left="614" width="334" height="20" font="4">● No significant differences found between the 2 groups with </text>
<text top="694" left="614" width="319" height="20" font="4">regard to survival, FC, atrial arrhythmia or embolic events. </text>
<text top="711" left="614" width="142" height="20" font="4">● 3% died in each group. </text>
<text top="728" left="614" width="333" height="20" font="4">● Clinically significant arrhythmia in 9% of pts in each group. </text>
<text top="745" left="614" width="345" height="20" font="4">● Multivariate predictors of late arrhythmias included older age </text>
<text top="763" left="614" width="354" height="20" font="4">at repair (OR: 4.7 for pts &gt;40 y at time of repair) and pre-existing </text>
<text top="780" left="614" width="95" height="20" font="4">atrial arrhythmia. </text>
<text top="608" left="981" width="150" height="20" font="4">● Long-term outcomes are </text>
<text top="625" left="981" width="151" height="20" font="4">favorable following surgical </text>
<text top="642" left="981" width="110" height="20" font="4">or device closure of </text>
<text top="659" left="981" width="92" height="20" font="4">secundum ASD. </text>
<text top="677" left="981" width="159" height="20" font="4">● Closure of the ASD before </text>
<text top="694" left="981" width="137" height="20" font="4">40 y is associated with a </text>
<text top="711" left="981" width="92" height="20" font="4">lower risk of late </text>
<text top="728" left="981" width="71" height="20" font="4">arrhythmias. </text>
</page>
<page number="83" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 83 </text>
<text top="107" left="64" width="89" height="20" font="4">Roos-Hesselink </text>
<text top="124" left="64" width="55" height="20" font="4">JW, et al. </text>
<text top="141" left="64" width="63" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(308)</a> </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12573276?dopt=Citation">12573276</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12573276?dopt=Citation"> </a></text>
<text top="107" left="172" width="76" height="20" font="4">Single-center </text>
<text top="124" left="172" width="65" height="20" font="4">longitudinal </text>
<text top="141" left="172" width="56" height="20" font="4">follow-up  </text>
<text top="107" left="280" width="38" height="20" font="4">n=135 </text>
<text top="124" left="280" width="20" height="20" font="4">pts </text>
<text top="107" left="347" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="124" left="347" width="141" height="20" font="4">secundum ASD operated </text>
<text top="141" left="347" width="152" height="20" font="4">on in childhood at Erasmus </text>
<text top="159" left="347" width="89" height="20" font="4">Medical Center, </text>
<text top="176" left="347" width="70" height="20" font="4">Netherlands </text>
<text top="107" left="515" width="60" height="20" font="4">Long-term </text>
<text top="124" left="515" width="80" height="20" font="4">clinical results </text>
<text top="107" left="614" width="324" height="20" font="4">● 135 consecutive pts with secundum ASD that underwent </text>
<text top="124" left="614" width="153" height="20" font="4">surgical repair in childhood. </text>
<text top="141" left="614" width="336" height="20" font="4">● Pts studied longitudinally with ECG, echo, exercise testing, </text>
<text top="159" left="614" width="260" height="20" font="4">and Holter monitor at 15 and 26 y post surgery. </text>
<text top="176" left="614" width="307" height="20" font="4">● No CV mortality, stroke, HF or pulmonary HTN noted; </text>
<text top="193" left="614" width="352" height="20" font="4">Symptomatic atrial arrhythmia in 6% after 15 y and an additional </text>
<text top="210" left="614" width="296" height="20" font="4">2% at 26 y; pacemaker implantation performed in 5%; </text>
<text top="227" left="614" width="314" height="20" font="4">● Exercise capacity is comparable with the normal Dutch </text>
<text top="245" left="614" width="64" height="20" font="4">population. </text>
<text top="107" left="981" width="149" height="20" font="4">● The long-term outcomes </text>
<text top="124" left="981" width="148" height="20" font="4">of surgical secundum ASD </text>
<text top="141" left="981" width="133" height="20" font="4">closure in childhood are </text>
<text top="159" left="981" width="55" height="20" font="4">excellent. </text>
<text top="264" left="64" width="84" height="20" font="4">Konstantinides </text>
<text top="281" left="64" width="45" height="20" font="4">S, et al. </text>
<text top="299" left="64" width="63" height="20" font="4">1995 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(309)</a> </text>
<text top="316" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7623878?dopt=Citation">7623878</a></text>
<text top="316" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7623878?dopt=Citation"> </a></text>
<text top="264" left="172" width="76" height="20" font="4">Single-center </text>
<text top="281" left="172" width="74" height="20" font="4">retrospective </text>
<text top="299" left="172" width="39" height="20" font="4">review </text>
<text top="264" left="280" width="38" height="20" font="4">n=179 </text>
<text top="281" left="280" width="20" height="20" font="4">pts </text>
<text top="264" left="347" width="151" height="20" font="3"><b>Inclusion criteria</b>: Pts &gt;40 </text>
<text top="281" left="347" width="141" height="20" font="4">y with isolated secundum </text>
<text top="299" left="347" width="103" height="20" font="4">type ASD that had </text>
<text top="316" left="347" width="131" height="20" font="4">undergone a right heart </text>
<text top="333" left="347" width="131" height="20" font="4">catheterization and had </text>
<text top="350" left="347" width="143" height="20" font="4">predominantly left-to-right </text>
<text top="368" left="347" width="147" height="20" font="4">shunt with a Qp:Qs ≥1.5:1 </text>
<text top="264" left="515" width="60" height="20" font="4">Long-term </text>
<text top="281" left="515" width="80" height="20" font="4">clinical results </text>
<text top="264" left="614" width="346" height="20" font="4">● 179 consecutive pts with isolated secundum ASD and &gt;40 y; </text>
<text top="281" left="614" width="321" height="20" font="4">84 pts (47%) underwent surgical repair, 95 pts (53%) were </text>
<text top="299" left="614" width="100" height="20" font="4">treated medically. </text>
<text top="316" left="614" width="348" height="20" font="4">● Follow-up period was 8.9 ± 5.2 y (range 1–26 y); multivariate </text>
<text top="333" left="614" width="314" height="20" font="4">analysis demonstrated a significant reduction in all-cause </text>
<text top="350" left="614" width="336" height="20" font="4">mortality in pts undergoing surgical treatment (RR: 0.31; 95% </text>
<text top="368" left="614" width="85" height="20" font="4">CI: 0.11–0.85). </text>
<text top="385" left="614" width="343" height="20" font="4">● The adjusted 10 y survival rate for surgically treated pts was </text>
<text top="402" left="614" width="282" height="20" font="4">95% as compared to 84% for medically treated pts. </text>
<text top="419" left="614" width="353" height="20" font="4">Surgical treatment prevented deterioration in FC (RR: 0.21; 95% </text>
<text top="437" left="614" width="85" height="20" font="4">CI: 0.08–0.55). </text>
<text top="454" left="614" width="340" height="20" font="4">● No difference in incidence of new atrial arrhythmia or stroke </text>
<text top="471" left="614" width="125" height="20" font="4">between the 2 groups. </text>
<text top="264" left="981" width="155" height="20" font="4">● Surgical repair of isolated </text>
<text top="281" left="981" width="114" height="20" font="4">secundum ASD with </text>
<text top="299" left="981" width="134" height="20" font="4">predominant left-to-right </text>
<text top="316" left="981" width="113" height="20" font="4">shunt in pts ≥40 y is </text>
<text top="333" left="981" width="141" height="20" font="4">associated with improved </text>
<text top="350" left="981" width="150" height="20" font="4">survival and less functional </text>
<text top="368" left="981" width="105" height="20" font="4">deterioration when </text>
<text top="385" left="981" width="118" height="20" font="4">compared to medical </text>
<text top="402" left="981" width="48" height="20" font="4">therapy. </text>
<text top="489" left="64" width="84" height="20" font="4">Engelfriet P, et </text>
<text top="506" left="64" width="16" height="20" font="4">al. </text>
<text top="523" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(310)</a> </text>
<text top="541" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17586067?dopt=Citation">17586067</a></text>
<text top="541" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17586067?dopt=Citation"> </a></text>
<text top="489" left="172" width="79" height="20" font="4">Analysis of all </text>
<text top="506" left="172" width="55" height="20" font="4">pts with a </text>
<text top="523" left="172" width="69" height="20" font="4">diagnosis of </text>
<text top="541" left="172" width="89" height="20" font="4">secundum ASD </text>
<text top="558" left="172" width="87" height="20" font="4">in the database </text>
<text top="575" left="172" width="64" height="20" font="4">of the Euro </text>
<text top="592" left="172" width="78" height="20" font="4">Heart Survey. </text>
<text top="609" left="172" width="91" height="20" font="4">Consecutive pts </text>
<text top="627" left="172" width="94" height="20" font="4">with diagnosis of </text>
<text top="644" left="172" width="87" height="20" font="4">ASD visiting an </text>
<text top="661" left="172" width="88" height="20" font="4">outpatient clinic </text>
<text top="678" left="172" width="83" height="20" font="4">of participating </text>
<text top="695" left="172" width="57" height="20" font="4">European </text>
<text top="713" left="172" width="87" height="20" font="4">centers in 1998 </text>
<text top="730" left="172" width="83" height="20" font="4">were identified </text>
<text top="747" left="172" width="91" height="20" font="4">and their clinical </text>
<text top="764" left="172" width="40" height="20" font="4">course </text>
<text top="781" left="172" width="84" height="20" font="4">documented in </text>
<text top="489" left="280" width="38" height="20" font="4">n=882 </text>
<text top="506" left="280" width="20" height="20" font="4">pts </text>
<text top="489" left="347" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="506" left="347" width="139" height="20" font="4">a diagnosis of secundum </text>
<text top="523" left="347" width="144" height="20" font="4">ASD visiting output clinics </text>
<text top="541" left="347" width="140" height="20" font="4">of participating European </text>
<text top="558" left="347" width="87" height="20" font="4">centers in 1998 </text>
<text top="489" left="515" width="76" height="20" font="4">Intermediate- </text>
<text top="506" left="515" width="79" height="20" font="4">and long-term </text>
<text top="523" left="515" width="80" height="20" font="4">clinical results </text>
<text top="489" left="614" width="112" height="20" font="4">● 882 pts analyzed. </text>
<text top="506" left="614" width="133" height="20" font="4">● Mean follow-up 4.2 y. </text>
<text top="523" left="614" width="350" height="20" font="4">● At baseline, 377 pts (mean age 39.2 y) had ASD closure, 505 </text>
<text top="541" left="614" width="200" height="20" font="4">pts (mean age 41 y) had open ASD. </text>
<text top="558" left="614" width="330" height="20" font="4">● Pts with open defects were more likely to have pulmonary </text>
<text top="575" left="614" width="347" height="20" font="4">arterial HTN (35% vs. 13%), RV dysfunction (31% vs. 8%), and </text>
<text top="592" left="614" width="214" height="20" font="4">severe volume overload (18% vs. 1%). </text>
<text top="609" left="614" width="347" height="20" font="4">● Pulmonary arterial HTN prevalence increased with age in pts </text>
<text top="627" left="614" width="353" height="20" font="4">with unrepaired ASD with moderate or large sized defects; small </text>
<text top="644" left="614" width="325" height="20" font="4">defects (Qp:Qs&lt;1.5:1) that were not closed did not result in </text>
<text top="661" left="614" width="239" height="20" font="4">worsening hemodynamics during follow-up. </text>
<text top="678" left="614" width="301" height="20" font="4">● Functional limitations were more common in pts with </text>
<text top="695" left="614" width="160" height="20" font="4">moderate/large open shunts. </text>
<text top="713" left="614" width="324" height="20" font="4">● In a multivariable model, the best predictors of functional </text>
<text top="730" left="614" width="306" height="20" font="4">limitations were pulmonary arterial HTN and RV volume </text>
<text top="747" left="614" width="54" height="20" font="4">overload. </text>
<text top="764" left="614" width="305" height="20" font="4">● No difference in the prevalence of arrhythmias noted. </text>
<text top="489" left="981" width="159" height="20" font="4">● Pts with open moderate or </text>
<text top="506" left="981" width="152" height="20" font="4">large left-to-right atrial level </text>
<text top="523" left="981" width="137" height="20" font="4">shunts due to secundum </text>
<text top="541" left="981" width="111" height="20" font="4">ASD (Qp:Qs≥1.5:1) </text>
<text top="558" left="981" width="108" height="20" font="4">demonstrate worse </text>
<text top="575" left="981" width="160" height="20" font="4">hemodynamic and functional </text>
<text top="592" left="981" width="148" height="20" font="4">profiles when compared to </text>
<text top="609" left="981" width="150" height="20" font="4">those that have undergone </text>
<text top="627" left="981" width="75" height="20" font="4">ASD closure. </text>
<text top="644" left="981" width="150" height="20" font="4">● Pts with small atrial level </text>
<text top="661" left="981" width="145" height="20" font="4">shunts (Qp:Qs&lt;1.5:1) that </text>
<text top="678" left="981" width="141" height="20" font="4">have not undergone ASD </text>
<text top="695" left="981" width="152" height="20" font="4">closure are unlikely to have </text>
<text top="713" left="981" width="139" height="20" font="4">worsening hemodynamic </text>
<text top="730" left="981" width="81" height="20" font="4">profiles or FC. </text>
</page>
<page number="84" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 84 </text>
<text top="107" left="172" width="86" height="20" font="4">retrospect from </text>
<text top="124" left="172" width="65" height="20" font="4">1998–2004 </text>
<text top="107" left="614" width="331" height="20" font="4">● During follow-up, 9 pts died and 294 of 505 pts underwent </text>
<text top="124" left="614" width="349" height="20" font="4">defect closure, 180 pts had surgical closure and 114 underwent </text>
<text top="141" left="614" width="122" height="20" font="4">transcatheter closure. </text>
<text top="159" left="614" width="329" height="20" font="4">● Surgical pts were more likely to have larger shunts, larger </text>
<text top="176" left="614" width="267" height="20" font="4">defects, worse RV function and pulmonary HTN. </text>
<text top="194" left="64" width="80" height="20" font="4">Kardon RE, et </text>
<text top="211" left="64" width="16" height="20" font="4">al. </text>
<text top="228" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(311)</a> </text>
<text top="245" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15246918?dopt=Citation">15246918</a></text>
<text top="245" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15246918?dopt=Citation"> </a></text>
<text top="194" left="172" width="76" height="20" font="4">Single-center </text>
<text top="211" left="172" width="66" height="20" font="4">case series </text>
<text top="194" left="280" width="219" height="20" font="4">n=74 pts  <b>Inclusion criteria</b>: Pts with </text>
<text top="211" left="347" width="154" height="20" font="4">secundum ASD undergoing </text>
<text top="228" left="347" width="146" height="20" font="4">TTE-guided percutaneous </text>
<text top="246" left="347" width="46" height="20" font="4">closure  </text>
<text top="194" left="515" width="63" height="20" font="4">Procedural </text>
<text top="211" left="515" width="57" height="20" font="4">outcomes </text>
<text top="194" left="614" width="300" height="20" font="4">● 74 pts were evaluated for TTE-guided ASD closure.  </text>
<text top="211" left="614" width="302" height="20" font="4">● 56 pts had successful device implantation using TTE </text>
<text top="228" left="614" width="343" height="20" font="4">guidance. 12 pts were referred for surgical ASD closure on the </text>
<text top="246" left="614" width="314" height="20" font="4">basis of TTE evaluation. 5 pts with multiple ASDs or poor </text>
<text top="263" left="614" width="348" height="20" font="4">transthoracic acoustic windows had ASD device closure guided </text>
<text top="280" left="614" width="47" height="20" font="4">by TEE. </text>
<text top="194" left="981" width="157" height="20" font="4">● TTE can be used to guide </text>
<text top="211" left="981" width="153" height="20" font="4">percutaneous ASD closure, </text>
<text top="228" left="981" width="139" height="20" font="4">a minority of pts required </text>
<text top="246" left="981" width="84" height="20" font="4">TEE guidance. </text>
<text top="298" left="64" width="81" height="20" font="4">Mazic U, et al. </text>
<text top="315" left="64" width="66" height="20" font="4">2001 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(312)</a>  </text>
<text top="332" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11526362?dopt=Citation">11526362</a></text>
<text top="332" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11526362?dopt=Citation"> </a></text>
<text top="298" left="172" width="76" height="20" font="4">Single-center </text>
<text top="315" left="172" width="66" height="20" font="4">case series </text>
<text top="298" left="280" width="38" height="20" font="4">n=240 </text>
<text top="315" left="280" width="20" height="20" font="4">pts </text>
<text top="298" left="347" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="315" left="347" width="119" height="20" font="4">secundum ASD were </text>
<text top="332" left="347" width="143" height="20" font="4">examined by 2D TTE and </text>
<text top="350" left="347" width="147" height="20" font="4">TEE with TEE guidance of </text>
<text top="367" left="347" width="143" height="20" font="4">transcatheter closure with </text>
<text top="384" left="347" width="137" height="20" font="4">the atrial septal occluder </text>
<text top="401" left="347" width="38" height="20" font="4">(ASO) </text>
<text top="298" left="515" width="63" height="20" font="4">Procedural </text>
<text top="315" left="515" width="57" height="20" font="4">outcomes </text>
<text top="298" left="614" width="345" height="20" font="4">● 16 (6%) pts were found not suitable for transcatheter closure </text>
<text top="315" left="614" width="327" height="20" font="4">with TTE, 35 (14%) with TEE, and 2 during catheterization.  </text>
<text top="332" left="614" width="322" height="20" font="4">28 pts (18%) had partial or total deficiency of the posterior, </text>
<text top="350" left="614" width="336" height="20" font="4">inferoanterior, or inferoposterior rim, 54 (27%) had a centrally </text>
<text top="367" left="614" width="337" height="20" font="4">positioned ASD, 92 (46%) had insufficient superoanterior rim, </text>
<text top="384" left="614" width="330" height="20" font="4">and 9 had multiple ASDs, whereas 8 had a septal aneurysm </text>
<text top="401" left="614" width="300" height="20" font="4">associated with a single defect and 4 a multiperforated </text>
<text top="418" left="614" width="64" height="20" font="4">aneurysm.  </text>
<text top="436" left="614" width="339" height="20" font="4">● A total of 170 pts underwent implantation of ASO. The ASO </text>
<text top="453" left="614" width="311" height="20" font="4">was correctly positioned in 144 at the first attempt. In the </text>
<text top="470" left="614" width="342" height="20" font="4">remainder TEE revealed unstable position of the left atrial disk </text>
<text top="487" left="614" width="291" height="20" font="4">(12), opening of both atrial disks in the left atrium (5), </text>
<text top="504" left="614" width="344" height="20" font="4">deployment of the device through the smaller defect in pts with </text>
<text top="522" left="614" width="332" height="20" font="4">multiple ASDs (3), and, in 1 pt, the device was too small and </text>
<text top="539" left="614" width="194" height="20" font="4">had to be replaced by a larger one. </text>
<text top="298" left="981" width="152" height="20" font="4">● Morphologic variations of </text>
<text top="315" left="981" width="110" height="20" font="4">secundum ASD are </text>
<text top="332" left="981" width="150" height="20" font="4">common. TEE is crucial for </text>
<text top="350" left="981" width="161" height="20" font="4">the determination of the ASD </text>
<text top="367" left="981" width="122" height="20" font="4">morphologic features, </text>
<text top="384" left="981" width="143" height="20" font="4">diameter, and rims, which </text>
<text top="401" left="981" width="131" height="20" font="4">are crucial for proper pt </text>
<text top="418" left="981" width="120" height="20" font="4">selection. TEE allows </text>
<text top="436" left="981" width="110" height="20" font="4">precise guiding and </text>
<text top="453" left="981" width="129" height="20" font="4">positioning of the ASO, </text>
<text top="470" left="981" width="143" height="20" font="4">which is essential for safe </text>
<text top="487" left="981" width="148" height="20" font="4">and effective transcatheter </text>
<text top="504" left="981" width="75" height="20" font="4">ASD closure. </text>
<text top="557" left="64" width="78" height="20" font="4">Teo KS, et al. </text>
<text top="574" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(313)</a> </text>
<text top="591" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Citation&amp;list_uids=20663157">20663157</a></text>
<text top="591" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Citation&amp;list_uids=20663157"> </a></text>
<text top="557" left="172" width="76" height="20" font="4">Single-center </text>
<text top="574" left="172" width="81" height="20" font="4">comparison of </text>
<text top="591" left="172" width="83" height="20" font="4">CMR and TEE </text>
<text top="608" left="172" width="91" height="20" font="4">for evaluation of </text>
<text top="626" left="172" width="61" height="20" font="4">ASD in pts </text>
<text top="643" left="172" width="75" height="20" font="4">evaluated for </text>
<text top="660" left="172" width="78" height="20" font="4">percutaneous </text>
<text top="677" left="172" width="72" height="20" font="4">ASD closure </text>
<text top="557" left="280" width="173" height="20" font="4">n=20 pts  <b>Inclusion criteria</b>: </text>
<text top="574" left="347" width="151" height="20" font="4">Consecutive pts with ASDs </text>
<text top="591" left="347" width="104" height="20" font="4">diagnosed on TTE </text>
<text top="608" left="347" width="150" height="20" font="4">underwent TEE and CMR.  </text>
<text top="557" left="515" width="83" height="20" font="4">Comparison of </text>
<text top="574" left="515" width="59" height="20" font="4">diagnostic </text>
<text top="591" left="515" width="59" height="20" font="4">modalities </text>
<text top="557" left="614" width="353" height="20" font="4">● Total CMR scan time was 20 min, and comparable to the TEE </text>
<text top="574" left="614" width="332" height="20" font="4">examination time. A total of 20 pts (male:female=5:15, mean </text>
<text top="591" left="614" width="276" height="20" font="4">age 42.8 y ± 15.7) were included in the analyses.  </text>
<text top="608" left="614" width="337" height="20" font="4">● There was an excellent agreement between CMR and TEE </text>
<text top="626" left="614" width="335" height="20" font="4">for estimation of maximum defect size (R=0.87). The anterior </text>
<text top="643" left="614" width="351" height="20" font="4">inferior, anterior superior and posterior inferior margins could be </text>
<text top="660" left="614" width="329" height="20" font="4">assessed in all pts with CMR. The posterior superior margin </text>
<text top="677" left="614" width="353" height="20" font="4">could not be assessed in only 1 pt. Furthermore, in 1 pt in whom </text>
<text top="694" left="614" width="287" height="20" font="4">TEE was unable to be performed, CMR was used to </text>
<text top="712" left="614" width="256" height="20" font="4">successfully direct percutaneous ASD closure. </text>
<text top="557" left="981" width="137" height="20" font="4">● CMR agrees with TEE </text>
<text top="574" left="981" width="151" height="20" font="4">assessment of ASDs in the </text>
<text top="591" left="981" width="143" height="20" font="4">work-up for percutaneous </text>
<text top="608" left="981" width="138" height="20" font="4">closure. Potentially CMR </text>
<text top="626" left="981" width="137" height="20" font="4">could be used instead of </text>
<text top="643" left="981" width="119" height="20" font="4">TEE for this purpose. </text>
<text top="730" left="64" width="89" height="20" font="4">Zanchetta M, et </text>
<text top="747" left="64" width="16" height="20" font="4">al. </text>
<text top="764" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(314)</a> </text>
<text top="781" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15104772?dopt=Citation">15104772</a></text>
<text top="781" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15104772?dopt=Citation"> </a></text>
<text top="730" left="172" width="76" height="20" font="4">Single-center </text>
<text top="747" left="172" width="66" height="20" font="4">case series </text>
<text top="730" left="280" width="38" height="20" font="4">n=135 </text>
<text top="747" left="280" width="20" height="20" font="4">pts </text>
<text top="730" left="347" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="747" left="347" width="146" height="20" font="4">Describe the 3-y results of </text>
<text top="764" left="347" width="147" height="20" font="4">transcatheter ASD closure </text>
<text top="781" left="347" width="107" height="20" font="4">using the ASO and </text>
<text top="730" left="515" width="60" height="20" font="4">Long-term </text>
<text top="747" left="515" width="70" height="20" font="4">outcomes of </text>
<text top="764" left="515" width="75" height="20" font="4">transcatheter </text>
<text top="781" left="515" width="72" height="20" font="4">ASD closure </text>
<text top="730" left="614" width="317" height="20" font="4">● Under local anesthesia, 135 consecutive pts with ASDs </text>
<text top="747" left="614" width="327" height="20" font="4">(male:female=45:90; mean age 42.2 ± 19.2 y; body surface </text>
<text top="764" left="614" width="98" height="20" font="4">area 1.71 ± 0.7 m</text>
<text top="766" left="712" width="4" height="13" font="6">2</text>
<text top="764" left="716" width="240" height="20" font="4">; mean pulmonary arterial pressure 30.4 +/- </text>
<text top="730" left="981" width="139" height="20" font="4">● ICE is an effective and </text>
<text top="747" left="981" width="152" height="20" font="4">safe alternative to TEE and </text>
<text top="764" left="981" width="137" height="20" font="4">balloon-sizing maneuver </text>
</page>
<page number="85" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 85 </text>
<text top="107" left="347" width="67" height="20" font="4">intracardiac </text>
<text top="124" left="347" width="145" height="20" font="4">echocadiography (ICE) as </text>
<text top="141" left="347" width="143" height="20" font="4">the sole imaging tool both </text>
<text top="159" left="347" width="134" height="20" font="4">to select the device size </text>
<text top="176" left="347" width="103" height="20" font="4">and to monitor the </text>
<text top="193" left="347" width="62" height="20" font="4">procedure. </text>
<text top="107" left="515" width="57" height="20" font="4">using ICE </text>
<text top="124" left="515" width="53" height="20" font="4">guidance </text>
<text top="107" left="614" width="292" height="20" font="4">11.5 mm Hg; mean Qp/Qs ratio 2.1 ± 0.6) underwent </text>
<text top="124" left="614" width="235" height="20" font="4">transcatheter closure using ASO and ICE.  </text>
<text top="141" left="614" width="336" height="20" font="4">● A 9F-9MHz mechanical transducer was used. 2 orthogonal </text>
<text top="159" left="614" width="336" height="20" font="4">views on the transverse aortic valve and on the longitudinal 4-</text>
<text top="176" left="614" width="280" height="20" font="4">chamber planes were obtained for quantitative ICE </text>
<text top="193" left="614" width="352" height="20" font="4">measurements, from which the diameters of the implanting ASO </text>
<text top="210" left="614" width="143" height="20" font="4">waist were to be derived.  </text>
<text top="228" left="614" width="316" height="20" font="4">● In all cases, ICE ASD measurements led to device size </text>
<text top="245" left="614" width="310" height="20" font="4">selection (mean size 25.0 ± 6.7 mm). Moreover, the ICE </text>
<text top="262" left="614" width="297" height="20" font="4">allowed the monitoring of device deployment and post </text>
<text top="279" left="614" width="133" height="20" font="4">deployment evaluation.  </text>
<text top="296" left="614" width="335" height="20" font="4">● There were no complications related to the procedure or to </text>
<text top="314" left="614" width="353" height="20" font="4">the use of ICE. During a mean follow-up period of 21.5 ± 12 mo, </text>
<text top="331" left="614" width="344" height="20" font="4">the cumulative complete occlusion rates were 97.7, 97.0, 97.1, </text>
<text top="348" left="614" width="287" height="20" font="4">and 98% at 24 h, 3 mo, and 1 and 3 y, respectively.  </text>
<text top="107" left="981" width="141" height="20" font="4">during transcatheter ASD </text>
<text top="124" left="981" width="46" height="20" font="4">closure. </text>
<text top="366" left="64" width="91" height="20" font="4">Ammash NM, et </text>
<text top="383" left="64" width="16" height="20" font="4">al. </text>
<text top="400" left="64" width="63" height="20" font="4">1997 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(315)</a> </text>
<text top="418" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Citation&amp;list_uids=9137235">9137235</a></text>
<text top="418" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Citation&amp;list_uids=9137235"> </a></text>
<text top="366" left="172" width="76" height="20" font="4">Single-center </text>
<text top="383" left="172" width="66" height="20" font="4">case series </text>
<text top="366" left="280" width="173" height="20" font="4">n=43 pts  <b>Inclusion criteria</b>: </text>
<text top="383" left="347" width="126" height="20" font="4">Describe the anatomic </text>
<text top="400" left="347" width="104" height="20" font="4">aspects of PAPVC </text>
<text top="418" left="347" width="141" height="20" font="4">identified by TEE and the </text>
<text top="435" left="347" width="144" height="20" font="4">presenting symptoms and </text>
<text top="452" left="347" width="36" height="20" font="4">signs. </text>
<text top="366" left="515" width="63" height="20" font="4">Procedural </text>
<text top="383" left="515" width="60" height="20" font="4">outcomes  </text>
<text top="366" left="614" width="332" height="20" font="4">● A total of 66 PAPVCs were detected in 43 pts (1.5/pt); in 2 </text>
<text top="383" left="614" width="343" height="20" font="4">additional pts, TEE suggested, but did not diagnose, PAPVCs. </text>
<text top="400" left="614" width="311" height="20" font="4">● Shortness of breath was the most common presenting </text>
<text top="418" left="614" width="300" height="20" font="4">symptom (42.2%), followed by heart murmur and SVT  </text>
<text top="435" left="614" width="306" height="20" font="4">● Right-sided anomalous veins were identified in 35 pts </text>
<text top="452" left="614" width="345" height="20" font="4">(81.4%), left-sided in 7 (16.3%) and bilateral in 1 (2.3%). There </text>
<text top="469" left="614" width="347" height="20" font="4">was a single anomalous connecting vein in 23 pts (53.5%), 2 in </text>
<text top="487" left="614" width="354" height="20" font="4">18 (41.9%), 3 in 1 (2.3%), and 4 in 1 (2.3%). The connecting site </text>
<text top="504" left="614" width="342" height="20" font="4">was the SVC in 39 veins (59.1%), right atrial-SVC junction in 6 </text>
<text top="521" left="614" width="348" height="20" font="4">(9.1%), right atrium in 8 (12.1%), inferior vena cava in 1 (1.5%), </text>
<text top="538" left="614" width="295" height="20" font="4">and the coronary sinus in 2 (3.0%). 10 anomalous left </text>
<text top="555" left="614" width="312" height="20" font="4">pulmonary veins were connected by a vertical vein to the </text>
<text top="573" left="614" width="143" height="20" font="4">innominate vein (15.1%).  </text>
<text top="590" left="614" width="307" height="20" font="4">● Sinus venous ASD was the most common associated </text>
<text top="607" left="614" width="346" height="20" font="4">anomaly in 22 pts (49%), followed by ostium secundum ASD in </text>
<text top="624" left="614" width="321" height="20" font="4">6 and patent foramen ovale in 4. 15 pts had an intact atrial </text>
<text top="641" left="614" width="51" height="20" font="4">septum.  </text>
<text top="659" left="614" width="311" height="20" font="4">● 31 pts (68.8%) underwent surgical repair. PAPVC was </text>
<text top="676" left="614" width="328" height="20" font="4">confirmed in all pts, including the 2 whose TEE results were </text>
<text top="693" left="614" width="128" height="20" font="4">suggestive of PAPVC.  </text>
<text top="710" left="614" width="303" height="20" font="4">● All 49 PAPVCs detected by TEE preoperatively were </text>
<text top="727" left="614" width="190" height="20" font="4">confirmed at the time of operation. </text>
<text top="366" left="981" width="146" height="20" font="4">● TEE is highly diagnostic </text>
<text top="383" left="981" width="118" height="20" font="4">for PAPVC. Accurate </text>
<text top="400" left="981" width="135" height="20" font="4">anatomic diagnosis may </text>
<text top="418" left="981" width="122" height="20" font="4">influence the need for </text>
<text top="435" left="981" width="115" height="20" font="4">medical and surgical </text>
<text top="452" left="981" width="82" height="20" font="4">management.  </text>
<text top="469" left="981" width="156" height="20" font="4">● TEE should be performed </text>
<text top="487" left="981" width="121" height="20" font="4">in pts with RV volume </text>
<text top="504" left="981" width="122" height="20" font="4">overload when TTE is </text>
<text top="521" left="981" width="74" height="20" font="4">inconclusive. </text>
<text top="745" left="64" width="82" height="20" font="4">Harmati LB, et </text>
<text top="763" left="64" width="16" height="20" font="4">al. </text>
<text top="780" left="64" width="63" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(316)</a> </text>
<text top="745" left="172" width="64" height="20" font="4">Multicenter </text>
<text top="763" left="172" width="74" height="20" font="4">retrospective </text>
<text top="780" left="172" width="39" height="20" font="4">review </text>
<text top="745" left="280" width="173" height="20" font="4">n=29 pts  <b>Inclusion criteria</b>: </text>
<text top="763" left="347" width="89" height="20" font="4">Prevalence and </text>
<text top="745" left="515" width="63" height="20" font="4">Procedural </text>
<text top="763" left="515" width="46" height="20" font="4">findings </text>
<text top="745" left="614" width="305" height="20" font="4">● 29 adults with a PAPVC on CCT were retrospectively </text>
<text top="763" left="614" width="347" height="20" font="4">identified. There were 19 women and 10 men, with a mean age </text>
<text top="780" left="614" width="131" height="20" font="4">of 53 (range: 19–83) y.  </text>
<text top="745" left="981" width="159" height="20" font="4">● The prevalence of PAPVC </text>
<text top="763" left="981" width="93" height="20" font="4">on CCT is 0.2%. </text>
</page>
<page number="86" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 86 </text>
<text top="107" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14501365?dopt=Citation">14501365</a></text>
<text top="107" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14501365?dopt=Citation"> </a></text>
<text top="107" left="347" width="141" height="20" font="4">characteristics of PAPVC </text>
<text top="124" left="347" width="46" height="20" font="4">on CCT </text>
<text top="107" left="614" width="341" height="20" font="4">● 4 cases were identified by review of 1,825 consecutive CCT </text>
<text top="124" left="614" width="351" height="20" font="4">reports, and 25 cases were culled from chest radiology teaching </text>
<text top="141" left="614" width="118" height="20" font="4">files at 3 institutions.  </text>
<text top="159" left="614" width="340" height="20" font="4">● The prevalence of a PAVC connection was 0.2% (4 of 1825 </text>
<text top="176" left="614" width="81" height="20" font="4">CCT reports).  </text>
<text top="193" left="614" width="328" height="20" font="4">● 79% (23 of 29 pts) had an anomalous left upper lobe vein </text>
<text top="210" left="614" width="351" height="20" font="4">connecting to a persistent left vertical vein, only 5% (1 of 23 pts) </text>
<text top="227" left="614" width="319" height="20" font="4">of whom had a left upper lobe vein in the normal location.  </text>
<text top="245" left="614" width="329" height="20" font="4">● 17% (5 of 29 pts) had an anomalous right upper lobe vein </text>
<text top="262" left="614" width="351" height="20" font="4">draining into the SVC, 60% (3 of 5 pts) of whom also had a right </text>
<text top="279" left="614" width="349" height="20" font="4">upper lobe pulmonary vein in the normal location. 1 pt (3%) had </text>
<text top="296" left="614" width="284" height="20" font="4">an anomalous right lower lobe vein draining into the </text>
<text top="314" left="614" width="181" height="20" font="4">suprahepatic inferior vena cava.  </text>
<text top="331" left="614" width="335" height="20" font="4">● Chest radiographic findings were abnormal left mediastinal </text>
<text top="348" left="614" width="313" height="20" font="4">contour in 64% (15 of 25 pts), abnormal right mediastinal </text>
<text top="365" left="614" width="338" height="20" font="4">contour in 8% (2 of 25 pts), and cardiomegaly in 24% (6 of 25 </text>
<text top="382" left="614" width="329" height="20" font="4">pts). CCT findings were cardiomegaly in 48% (14 of 29 pts), </text>
<text top="400" left="614" width="348" height="20" font="4">right atrial enlargement in 31% (9 of 29 pts), RV enlargement in </text>
<text top="417" left="614" width="333" height="20" font="4">31% (9 of 29 pts), and PA enlargement in 14% (4 of 29 pts).  </text>
<text top="434" left="614" width="336" height="20" font="4">● Pulmonary or CV symptoms were present in 69% (20 of 29 </text>
<text top="451" left="614" width="310" height="20" font="4">pts), 55% (11 of 20 pts) of whom had specific alternative </text>
<text top="469" left="614" width="332" height="20" font="4">diagnoses (excluding congestive HF and pulmonary HTN) to </text>
<text top="486" left="614" width="336" height="20" font="4">explain the symptoms. Only 1 pat (3%) was diagnosed with a </text>
<text top="503" left="614" width="92" height="20" font="4">secundum ASD. </text>
<text top="107" left="981" width="142" height="20" font="4">● The majority of PAPVC </text>
<text top="124" left="981" width="134" height="20" font="4">incidentally identified on </text>
<text top="141" left="981" width="159" height="20" font="4">CCT is anomalous left upper </text>
<text top="159" left="981" width="56" height="20" font="4">lobe vein. </text>
<text top="521" left="64" width="93" height="20" font="4">Nordmeyer S, et </text>
<text top="538" left="64" width="16" height="20" font="4">al. </text>
<text top="555" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(317)</a> </text>
<text top="573" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21554824?dopt=Citation">21554824</a></text>
<text top="573" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21554824?dopt=Citation"> </a></text>
<text top="521" left="172" width="76" height="20" font="4">Single-center </text>
<text top="538" left="172" width="66" height="20" font="4">case series </text>
<text top="521" left="280" width="44" height="20" font="4">n=6 pts </text>
<text top="521" left="347" width="137" height="20" font="3"><b>Inclusion criteria</b>: CMR </text>
<text top="538" left="347" width="141" height="20" font="4">characteristics of PAPVC </text>
<text top="555" left="347" width="103" height="20" font="4">suspected on TTE </text>
<text top="521" left="515" width="63" height="20" font="4">Procedural </text>
<text top="538" left="515" width="46" height="20" font="4">findings </text>
<text top="521" left="614" width="350" height="20" font="4">● In all pts, the diagnosis of PAPVR was confirmed by standard </text>
<text top="538" left="614" width="29" height="20" font="4">MRI. </text>
<text top="555" left="614" width="239" height="20" font="4">● Shunt volumes ranged from 1.4:1–4.7:1.  </text>
<text top="573" left="614" width="318" height="20" font="4">● Drainage sites were the superior caval vein (n=5) or the </text>
<text top="590" left="614" width="108" height="20" font="4">vertical vein (n=1).  </text>
<text top="607" left="614" width="332" height="20" font="4">● Multiple maldraining pulmonary veins were found in 3 pts.  </text>
<text top="624" left="614" width="339" height="20" font="4">● Pulmonary arteries and veins could be clearly distinguished </text>
<text top="641" left="614" width="341" height="20" font="4">by selective visualization using 4D velocity-encoded cine MRI. </text>
<text top="659" left="614" width="347" height="20" font="4">Flow measured individually in maldraining pulmonary veins in 6 </text>
<text top="676" left="614" width="348" height="20" font="4">pts and across the interatrial communication in 3 pts revealed a </text>
<text top="693" left="614" width="351" height="20" font="4">percentage of the overall shunt volume of 30%–100% and 58%–</text>
<text top="710" left="614" width="103" height="20" font="4">70%, respectively. </text>
<text top="521" left="981" width="123" height="20" font="4">● Vessel selective 4D </text>
<text top="538" left="981" width="144" height="20" font="4">cardiac MRI facilitates the </text>
<text top="555" left="981" width="120" height="20" font="4">accurate diagnosis of </text>
<text top="573" left="981" width="113" height="20" font="4">PAPVC. By detailed </text>
<text top="590" left="981" width="123" height="20" font="4">quantification of shunt </text>
<text top="607" left="981" width="109" height="20" font="4">volumes, additional </text>
<text top="624" left="981" width="146" height="20" font="4">information for planning of </text>
<text top="641" left="981" width="124" height="20" font="4">treatment strategies is </text>
<text top="659" left="981" width="57" height="20" font="4">provided.  </text>
<text top="728" left="64" width="92" height="20" font="4">Altindag T, et al. </text>
<text top="745" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(318)</a> </text>
<text top="763" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Citation&amp;list_uids=21113378">21113378</a></text>
<text top="763" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Citation&amp;list_uids=21113378"> </a></text>
<text top="728" left="172" width="76" height="20" font="4">Single-center </text>
<text top="745" left="172" width="66" height="20" font="4">case series </text>
<text top="728" left="280" width="173" height="20" font="4">n=47 pts  <b>Inclusion criteria</b>: </text>
<text top="745" left="347" width="151" height="20" font="4">Transcatheter ASD closure </text>
<text top="763" left="347" width="88" height="20" font="4">in adults ≥40 y  </text>
<text top="728" left="515" width="63" height="20" font="4">Procedural </text>
<text top="745" left="515" width="24" height="20" font="4">and </text>
<text top="763" left="515" width="72" height="20" font="4">intermediate-</text>
<text top="780" left="515" width="85" height="20" font="4">term outcomes </text>
<text top="728" left="614" width="319" height="20" font="4">● Of the 130 pts who were referred for interventional ASD </text>
<text top="745" left="614" width="343" height="20" font="4">closure, 47 were 40 y and older and all of them had the device </text>
<text top="763" left="614" width="304" height="20" font="4">inserted. There were no major complications during the </text>
<text top="780" left="614" width="74" height="20" font="4">intervention.  </text>
<text top="728" left="981" width="131" height="20" font="4">● Transcatheter device </text>
<text top="745" left="981" width="108" height="20" font="4">closure of ASD is a </text>
<text top="763" left="981" width="134" height="20" font="4">successful and effective </text>
<text top="780" left="981" width="164" height="20" font="4">treatment, also for pts ≥40 y.  </text>
</page>
<page number="87" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 87 </text>
<text top="107" left="614" width="343" height="20" font="4">● Mean follow-up time was 15 ±15 mo. During follow-up, 3 pts </text>
<text top="124" left="614" width="343" height="20" font="4">needed surgical reintervention because of device embolization </text>
<text top="141" left="614" width="148" height="20" font="4">(n=2) or dislocation (n=1).  </text>
<text top="159" left="614" width="351" height="20" font="4">● Of the pts with severe RV dilatation, more than 1/2 (58%) had </text>
<text top="176" left="614" width="348" height="20" font="4">no or mild dilatation at last follow-up. Reduction of RV dilatation </text>
<text top="193" left="614" width="329" height="20" font="4">was not related to age. Pulmonary HTN was present in 63% </text>
<text top="210" left="614" width="330" height="20" font="4">before the procedure and was reduced to 38% at follow-up.  </text>
<text top="227" left="614" width="351" height="20" font="4">● NYHA FC improved in all age groups, also in pts over 60 y. In </text>
<text top="245" left="614" width="322" height="20" font="4">2 of the 3 pts who died during follow-up, no cause of death </text>
<text top="262" left="614" width="346" height="20" font="4">could be established, but both had responded well to treatment </text>
<text top="279" left="614" width="293" height="20" font="4">regarding the echocardiographic and clinical findings. </text>
<text top="107" left="981" width="154" height="20" font="4">● Pts showed regression of </text>
<text top="124" left="981" width="133" height="20" font="4">RV enlargement and an </text>
<text top="141" left="981" width="111" height="20" font="4">improvement in FC. </text>
<text top="297" left="64" width="73" height="20" font="4">Attie F, et al. </text>
<text top="314" left="64" width="63" height="20" font="4">2001 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(319)</a> </text>
<text top="332" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11738312?dopt=Citation">11738312</a></text>
<text top="332" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11738312?dopt=Citation"> </a></text>
<text top="297" left="172" width="67" height="20" font="4">Prospective </text>
<text top="314" left="172" width="68" height="20" font="4">randomized </text>
<text top="332" left="172" width="64" height="20" font="4">clinical trial </text>
<text top="297" left="280" width="38" height="20" font="4">n=521 </text>
<text top="314" left="280" width="20" height="20" font="4">pts </text>
<text top="297" left="347" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="314" left="347" width="130" height="20" font="4">Secundum ASDs in pts </text>
<text top="332" left="347" width="143" height="20" font="4">≥40 y improves their long-</text>
<text top="349" left="347" width="122" height="20" font="4">term clinical outcome. </text>
<text top="297" left="515" width="60" height="20" font="4">Long-term </text>
<text top="314" left="515" width="40" height="20" font="4">clinical </text>
<text top="332" left="515" width="57" height="20" font="4">outcomes </text>
<text top="297" left="614" width="351" height="20" font="4">● Recruited 521 pts &gt;40 y old with secundum ASDs referred for </text>
<text top="314" left="614" width="162" height="20" font="4">treatment; 48 were excluded. </text>
<text top="332" left="614" width="334" height="20" font="4">● Pts were randomly assigned to surgical closure (n=232) or </text>
<text top="349" left="614" width="151" height="20" font="4">medical treatment (n=241). </text>
<text top="366" left="614" width="318" height="20" font="4">● The 1° and 2° endpoints were a composite of major CV </text>
<text top="383" left="614" width="334" height="20" font="4">events (death, pulmonary embolism, major arrhythmic event, </text>
<text top="400" left="614" width="340" height="20" font="4">embolic cerebrovascular event, recurrent pulmonary infection, </text>
<text top="418" left="614" width="319" height="20" font="4">FC deterioration or HF) and overall mortality, respectively. </text>
<text top="435" left="614" width="332" height="20" font="4">● The analysis was performed on an intention-to-treat basis. </text>
<text top="452" left="614" width="352" height="20" font="4">The median follow-up period was 7.3 y (range 2–13). The risk of </text>
<text top="469" left="614" width="336" height="20" font="4">having the 1° endpoint was significantly higher in the medical </text>
<text top="487" left="614" width="340" height="20" font="4">group, which had a univariate HR of 1.99 (95% CI: 1.23–3.22) </text>
<text top="504" left="614" width="283" height="20" font="4">and a multivariate HR of 1.85 (95% CI: 1.08–3.17).  </text>
<text top="521" left="614" width="332" height="20" font="4">● Although the survival analysis did not reveal differences in </text>
<text top="538" left="614" width="337" height="20" font="4">overall mortality between the surgical and medical treatments </text>
<text top="555" left="614" width="310" height="20" font="4">(HR: 1.71; 95% CI: 0.76–3.86), the multivariate analysis, </text>
<text top="573" left="614" width="280" height="20" font="4">adjusted by age at entry, mPAP and cardiac index, </text>
<text top="590" left="614" width="345" height="20" font="4">demonstrated significant differences between the study groups </text>
<text top="607" left="614" width="343" height="20" font="4">(HR: 4.09; 95% CI: 1.41–11.89). Surgical closure was superior </text>
<text top="624" left="614" width="340" height="20" font="4">to medical treatment in improving both the composite of major </text>
<text top="641" left="614" width="345" height="20" font="4">CV events and overall mortality in pts &gt;40 y old with secundum </text>
<text top="659" left="614" width="305" height="20" font="4">ASDs. This superiority was related to the mPAP, age at </text>
<text top="676" left="614" width="162" height="20" font="4">diagnosis and cardiac index.  </text>
<text top="297" left="981" width="158" height="20" font="4">● Because of the higher risk </text>
<text top="314" left="981" width="144" height="20" font="4">of morbidity and mortality, </text>
<text top="332" left="981" width="157" height="20" font="4">the authors recommend that </text>
<text top="349" left="981" width="136" height="20" font="4">anatomic closure should </text>
<text top="366" left="981" width="153" height="20" font="4">always be attempted as the </text>
<text top="383" left="981" width="152" height="20" font="4">initial treatment for ASDs in </text>
<text top="401" left="981" width="151" height="20" font="4">adults &gt;40 y old with PASP </text>
<text top="418" left="981" width="102" height="20" font="4">&lt;70 mm Hg and a </text>
<text top="435" left="981" width="150" height="20" font="4">pulmonary/systemic output </text>
<text top="452" left="981" width="139" height="20" font="4">ratio ≥1.7. The operation </text>
<text top="469" left="981" width="153" height="20" font="4">must be performed as soon </text>
<text top="487" left="981" width="128" height="20" font="4">as possible, even if the </text>
<text top="504" left="981" width="94" height="20" font="4">symptoms or the </text>
<text top="521" left="981" width="159" height="20" font="4">hemodynamic impact seems </text>
<text top="538" left="981" width="80" height="20" font="4">to be minimal. </text>
<text top="694" left="64" width="82" height="20" font="4">Brochu MC, et </text>
<text top="711" left="64" width="16" height="20" font="4">al. </text>
<text top="728" left="64" width="63" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(320)</a> </text>
<text top="745" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12356636?dopt=Citation">12356636</a></text>
<text top="745" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12356636?dopt=Citation"> </a></text>
<text top="694" left="172" width="76" height="20" font="4">Single-center </text>
<text top="711" left="172" width="66" height="20" font="4">case series </text>
<text top="694" left="280" width="173" height="20" font="4">n=37 pts  <b>Inclusion criteria</b>: </text>
<text top="711" left="347" width="151" height="20" font="4">Transcatheter ASD closure </text>
<text top="728" left="347" width="111" height="20" font="4">on asymptomatic or </text>
<text top="745" left="347" width="127" height="20" font="4">minimally symptomatic </text>
<text top="763" left="347" width="40" height="20" font="4">adults  </text>
<text top="694" left="515" width="63" height="20" font="4">Procedural </text>
<text top="711" left="515" width="24" height="20" font="4">and </text>
<text top="728" left="515" width="72" height="20" font="4">intermediate-</text>
<text top="745" left="515" width="85" height="20" font="4">term outcomes </text>
<text top="694" left="614" width="331" height="20" font="4">● 37 pts (24 females; mean age 49.4 y, range 19–76) with a </text>
<text top="711" left="614" width="178" height="20" font="4">Qp:Qs of 2.1 (1.2–3.4) had a VO</text>
<text top="717" left="791" width="4" height="13" font="6">2</text>
<text top="711" left="796" width="132" height="20" font="4"> max determination and </text>
<text top="728" left="614" width="345" height="20" font="4">echocardiographic measurement of RV dimensions before and </text>
<text top="745" left="614" width="274" height="20" font="4">6 mo after elective percutaneous closure of ASD.  </text>
<text top="763" left="614" width="132" height="20" font="4">● At baseline, mean VO</text>
<text top="769" left="746" width="4" height="13" font="6">2</text>
<text top="763" left="750" width="199" height="20" font="4"> max was 23.5 ± 6.4 mL/kg/min and </text>
<text top="780" left="614" width="345" height="20" font="4">was higher in the 15 NYHA I pts than in the 22 NYHA II pts (27 </text>
<text top="694" left="981" width="159" height="20" font="4">● Adult ASD pts significantly </text>
<text top="711" left="981" width="125" height="20" font="4">increase their FC after </text>
<text top="728" left="981" width="161" height="20" font="4">percutaneous defect closure. </text>
<text top="745" left="981" width="156" height="20" font="4">This is observed even in pts </text>
<text top="763" left="981" width="153" height="20" font="4">classified as asymptomatic, </text>
<text top="780" left="981" width="151" height="20" font="4">in those with lesser shunts, </text>
</page>
<page number="88" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 88 </text>
<text top="107" left="614" width="255" height="20" font="4">± 6.9 vs. 20.8 ± 4.6 mL/kg/min; p=0.0015). VO</text>
<text top="113" left="869" width="4" height="13" font="6">2</text>
<text top="107" left="873" width="87" height="20" font="4"> max increased </text>
<text top="124" left="614" width="295" height="20" font="4">significantly at 6 mo (23.5 ± 6.4–26.9 ± 6.9 mL/kg/mi; </text>
<text top="141" left="614" width="324" height="20" font="4">p&lt;0.0001). Improvement was as marked in NYHA I (+22%; </text>
<text top="159" left="614" width="320" height="20" font="4">p&lt;0.0001) as in NYHA II pts (+12%; p&lt;0.0001), in pts with </text>
<text top="176" left="614" width="327" height="20" font="4">Qp:Qs 1.2–2.0 (+16%; p&lt;0.0001) as in those with Qp:Qs&gt;2 </text>
<text top="193" left="614" width="353" height="20" font="4">(+12%; p&lt;0.0001), and in pts ≥40 y of age (+14%; p&lt;0.0001) as </text>
<text top="210" left="614" width="340" height="20" font="4">in those &lt;40 y (+16%; p&lt;0.0001). Compared with 15 of 37 pts </text>
<text top="228" left="614" width="308" height="20" font="4">before closure, 35 of 37 pts were in NYHA I at 6 mo. RV </text>
<text top="245" left="614" width="260" height="20" font="4">dimensions decreased significantly (p&lt;0.0001). </text>
<text top="107" left="981" width="129" height="20" font="4">and in older pts. These </text>
<text top="124" left="981" width="145" height="20" font="4">findings suggest that ASD </text>
<text top="141" left="981" width="103" height="20" font="4">closure in an adult </text>
<text top="159" left="981" width="117" height="20" font="4">population should be </text>
<text top="176" left="981" width="127" height="20" font="4">considered even in the </text>
<text top="193" left="981" width="127" height="20" font="4">absence of symptoms. </text>
<text top="263" left="64" width="78" height="20" font="4">Shah D, et al. </text>
<text top="280" left="64" width="63" height="20" font="4">1994 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(321)</a> </text>
<text top="297" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8142189?dopt=Citation">8142189</a></text>
<text top="297" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8142189?dopt=Citation"> </a></text>
<text top="263" left="172" width="76" height="20" font="4">Single-center </text>
<text top="280" left="172" width="74" height="20" font="4">retrospective </text>
<text top="297" left="172" width="39" height="20" font="4">review </text>
<text top="263" left="280" width="219" height="20" font="4">n=82 pts  <b>Inclusion criteria</b>: Pts with </text>
<text top="280" left="347" width="140" height="20" font="4">ASD followed since 1955 </text>
<text top="297" left="347" width="139" height="20" font="4">who fulfilled entry criteria </text>
<text top="314" left="347" width="91" height="20" font="4">and were &gt;45 y  </text>
<text top="263" left="515" width="60" height="20" font="4">Long-term </text>
<text top="280" left="515" width="70" height="20" font="4">outcomes of </text>
<text top="297" left="515" width="65" height="20" font="4">surgical vs. </text>
<text top="314" left="515" width="85" height="20" font="4">nonsurgical Rx </text>
<text top="332" left="515" width="42" height="20" font="4">of ASD </text>
<text top="263" left="614" width="143" height="20" font="4">● Mean follow-up of 25 y. </text>
<text top="280" left="614" width="350" height="20" font="4">● There was no difference in survival or symptoms between the </text>
<text top="297" left="614" width="349" height="20" font="4">2 groups and no difference in the incidence of new arrhythmias, </text>
<text top="314" left="614" width="347" height="20" font="4">stroke, or other embolic phenomena, or cardiac failure. No pt in </text>
<text top="332" left="614" width="306" height="20" font="4">either group developed progressive pulmonary vascular </text>
<text top="349" left="614" width="49" height="20" font="4">disease. </text>
<text top="263" left="981" width="140" height="20" font="4">● Outcome in adults with </text>
<text top="280" left="981" width="145" height="20" font="4">ASD was not improved by </text>
<text top="297" left="981" width="143" height="20" font="4">surgical closure. Because </text>
<text top="314" left="981" width="128" height="20" font="4">progressive pulmonary </text>
<text top="332" left="981" width="135" height="20" font="4">vascular disease did not </text>
<text top="349" left="981" width="150" height="20" font="4">develop in any of these pts </text>
<text top="366" left="981" width="161" height="20" font="4">its prevention is not a reason </text>
<text top="383" left="981" width="152" height="20" font="4">for advising closure of ASD </text>
<text top="400" left="981" width="53" height="20" font="4">in adults. </text>
<text top="418" left="64" width="85" height="20" font="4">Varma C, et al. </text>
<text top="436" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(322)</a> </text>
<text top="453" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14696173?dopt=Citation">14696173</a></text>
<text top="453" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14696173?dopt=Citation"> </a></text>
<text top="418" left="172" width="76" height="20" font="4">Single-center </text>
<text top="436" left="172" width="66" height="20" font="4">case series </text>
<text top="418" left="280" width="38" height="20" font="4">n=172 </text>
<text top="436" left="280" width="20" height="20" font="4">pts </text>
<text top="418" left="347" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="436" left="347" width="132" height="20" font="4">transcatheter closure of </text>
<text top="453" left="347" width="137" height="20" font="4">small or large secundum </text>
<text top="470" left="347" width="29" height="20" font="4">ASD </text>
<text top="418" left="515" width="63" height="20" font="4">Procedural </text>
<text top="436" left="515" width="83" height="20" font="4">and short-term </text>
<text top="453" left="515" width="70" height="20" font="4">outcomes of </text>
<text top="470" left="515" width="75" height="20" font="4">transcatheter </text>
<text top="487" left="515" width="72" height="20" font="4">ASD closure </text>
<text top="418" left="614" width="328" height="20" font="4">● Outcomes of device closure of large and small secundum </text>
<text top="436" left="614" width="348" height="20" font="4">ASDs as related to rim anatomy with the Amplatzer atrial septal </text>
<text top="453" left="614" width="145" height="20" font="4">occluder were compared.  </text>
<text top="470" left="614" width="351" height="20" font="4">● Rim adequacy (≥5 mm) of the anterior, inferior, posterior, and </text>
<text top="487" left="614" width="228" height="20" font="4">superior rims was determined using TEE. </text>
<text top="504" left="614" width="353" height="20" font="4">● Balloon-stretched defect size defined pts into 2 groups: Group </text>
<text top="522" left="614" width="255" height="20" font="4">1, ≤25 mm (n=138); group 2, &gt;25 mm (n=34).  </text>
<text top="539" left="614" width="299" height="20" font="4">● Rim deficiency (n=62) was more frequent in group 2 </text>
<text top="556" left="614" width="350" height="20" font="4">compared to Group 1 (50% vs. 33%; p=0.07), especially inferior </text>
<text top="573" left="614" width="210" height="20" font="4">rim deficiency (35% vs. 2%; p=0.005). </text>
<text top="591" left="614" width="339" height="20" font="4">● Device deployment was successful in Group 1 and Group 2 </text>
<text top="608" left="614" width="314" height="20" font="4">(100% vs. 91%; p=0.007). Unsuccessful deployment was </text>
<text top="625" left="614" width="337" height="20" font="4">associated with an ASD of &gt;25 mm (p=0.007) and inferior rim </text>
<text top="642" left="614" width="341" height="20" font="4">deficiency (p=0.001). At first follow-up (54 ± 16 d), RV systolic </text>
<text top="659" left="614" width="274" height="20" font="4">pressure had improved in both groups (p&lt;0.001).  </text>
<text top="418" left="981" width="142" height="20" font="4">● Closure of a large ASD </text>
<text top="436" left="981" width="137" height="20" font="4">associated with a lack of </text>
<text top="453" left="981" width="140" height="20" font="4">support in the inferior rim </text>
<text top="470" left="981" width="131" height="20" font="4">may warrant alternative </text>
<text top="487" left="981" width="137" height="20" font="4">strategies to position the </text>
<text top="504" left="981" width="112" height="20" font="4">device successfully. </text>
<text top="677" left="64" width="76" height="20" font="4">Amin Z, et al. </text>
<text top="694" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(323)</a> </text>
<text top="712" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15558755?dopt=Citation">15558755</a></text>
<text top="712" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15558755?dopt=Citation"> </a></text>
<text top="677" left="172" width="87" height="20" font="4">Registry review </text>
<text top="677" left="280" width="219" height="20" font="4">n=28 pts  <b>Inclusion criteria</b>: Pts with </text>
<text top="694" left="347" width="150" height="20" font="4">hemodynamic compromise </text>
<text top="712" left="347" width="118" height="20" font="4">after ASO placement </text>
<text top="677" left="515" width="57" height="20" font="4">Review of </text>
<text top="694" left="515" width="44" height="20" font="4">registry </text>
<text top="712" left="515" width="58" height="20" font="4">records to </text>
<text top="729" left="515" width="65" height="20" font="4">identify risk </text>
<text top="746" left="515" width="58" height="20" font="4">factors for </text>
<text top="763" left="515" width="68" height="20" font="4">ASO device </text>
<text top="781" left="515" width="47" height="20" font="4">erosion. </text>
<text top="677" left="614" width="326" height="20" font="4">● In all pts who developed hemodynamic compromise after </text>
<text top="694" left="614" width="342" height="20" font="4">ASO placement, echos (pre-, intra-, and post procedure), ASD </text>
<text top="712" left="614" width="301" height="20" font="4">size (nonstretched, stretched), size of the device used, </text>
<text top="729" left="614" width="325" height="20" font="4">cineangiograms, and operative records were reviewed by a </text>
<text top="746" left="614" width="346" height="20" font="4">panel selected by AGA Medical Corporation. The findings were </text>
<text top="763" left="614" width="336" height="20" font="4">compared to the premarket approval data obtained from FDA-</text>
<text top="677" left="981" width="156" height="20" font="4">● The risk of device erosion </text>
<text top="694" left="981" width="113" height="20" font="4">with ASO is low and </text>
<text top="712" left="981" width="118" height="20" font="4">complications can be </text>
<text top="729" left="981" width="136" height="20" font="4">decreased by identifying </text>
<text top="746" left="981" width="145" height="20" font="4">high-risk pts and following </text>
<text top="763" left="981" width="121" height="20" font="4">them closely. Pts with </text>
<text top="781" left="981" width="141" height="20" font="4">deficient aortic rim and/or </text>
</page>
<page number="89" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 89 </text>
<text top="107" left="614" width="338" height="20" font="4">approved clinical trials that were conducted in the U.S, before </text>
<text top="124" left="614" width="146" height="20" font="4">the device was approved.  </text>
<text top="141" left="614" width="335" height="20" font="4">● A total of 28 cases (14 in U.S) of AE were reported to AGA </text>
<text top="159" left="614" width="338" height="20" font="4">Medical Corporation. All erosions occurred at the dome of the </text>
<text top="176" left="614" width="343" height="20" font="4">atria, near the aortic root. Deficient aortic rim was seen in 89% </text>
<text top="193" left="614" width="325" height="20" font="4">and the defect described as high ASD, suggesting deficient </text>
<text top="210" left="614" width="298" height="20" font="4">superior rim. The device to unstretched ASD ratio was </text>
<text top="228" left="614" width="343" height="20" font="4">significantly larger in the AE group when compared to the FDA </text>
<text top="245" left="614" width="321" height="20" font="4">trial group. The incidence of device erosion in the U.S was </text>
<text top="262" left="614" width="38" height="20" font="4">0.1%.  </text>
<text top="107" left="981" width="126" height="20" font="4">superior rim may be at </text>
<text top="124" left="981" width="117" height="20" font="4">higher risk for device </text>
<text top="141" left="981" width="162" height="20" font="4">erosion. Oversized ASO may </text>
<text top="159" left="981" width="154" height="20" font="4">increase the risk of erosion. </text>
<text top="176" left="981" width="139" height="20" font="4">The defect should not be </text>
<text top="193" left="981" width="159" height="20" font="4">overstretched during balloon </text>
<text top="210" left="981" width="117" height="20" font="4">sizing. Pts with small </text>
<text top="228" left="981" width="148" height="20" font="4">pericardial effusion at 24-h </text>
<text top="245" left="981" width="162" height="20" font="4">should have closer follow-up. </text>
<text top="280" left="64" width="73" height="20" font="4">Du ZD, et al. </text>
<text top="297" left="64" width="63" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(306)</a> </text>
<text top="314" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12039500?dopt=Citation">12039500</a></text>
<text top="314" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12039500?dopt=Citation"> </a></text>
<text top="280" left="172" width="64" height="20" font="4">Multicenter </text>
<text top="297" left="172" width="88" height="20" font="4">nonrandomized </text>
<text top="314" left="172" width="94" height="20" font="4">concurrent study </text>
<text top="280" left="280" width="38" height="20" font="4">n=442 </text>
<text top="297" left="280" width="20" height="20" font="4">pts </text>
<text top="280" left="347" width="132" height="20" font="3"><b>Inclusion criteria</b>: This </text>
<text top="297" left="347" width="138" height="20" font="4">study sought to compare </text>
<text top="314" left="347" width="129" height="20" font="4">the safety, efficacy and </text>
<text top="332" left="347" width="153" height="20" font="4">clinical utility of the ASO for </text>
<text top="349" left="347" width="145" height="20" font="4">closure of secundum ASD </text>
<text top="366" left="347" width="118" height="20" font="4">with surgical closure. </text>
<text top="280" left="515" width="72" height="20" font="4">intermediate-</text>
<text top="297" left="515" width="81" height="20" font="4">term follow-up </text>
<text top="314" left="515" width="55" height="20" font="4">post ASD </text>
<text top="332" left="515" width="43" height="20" font="4">closure </text>
<text top="280" left="614" width="311" height="20" font="4">● A total of 442 pts were in the group undergoing device </text>
<text top="297" left="614" width="313" height="20" font="4">closure, whereas 154 pts were in the surgical group. The </text>
<text top="314" left="614" width="328" height="20" font="4">median age was 9.8 y for the device group and 4.1 y for the </text>
<text top="332" left="614" width="342" height="20" font="4">surgical group (p&lt;0.001). In the device group, 395 (89.4%) pts </text>
<text top="349" left="614" width="346" height="20" font="4">had a single ASD; in the surgical group, 124 (80.5%) (p=0.008) </text>
<text top="366" left="614" width="339" height="20" font="4">had a single ASD. The size of the 1° ASD was 13.3 ± 5.4 mm </text>
<text top="383" left="614" width="337" height="20" font="4">for the device group and 14.2 ± 6.3 mm for the surgery group </text>
<text top="400" left="614" width="344" height="20" font="4">(p=0.099). The procedural attempt success rate was 95.7% for </text>
<text top="418" left="614" width="332" height="20" font="4">the device group and 100% for the surgical group (p=0.006). </text>
<text top="435" left="614" width="323" height="20" font="4">● The early, 1° and 2° efficacy success rates were 94.8%, </text>
<text top="452" left="614" width="319" height="20" font="4">98.5%, and 91.6%, respectively, for the device group, and </text>
<text top="469" left="614" width="330" height="20" font="4">96.1%, 100%, and 89.0% for the surgical group (all p&gt;0.05). </text>
<text top="487" left="614" width="326" height="20" font="4">● The complication rate was 7.2% for the device group and </text>
<text top="504" left="614" width="221" height="20" font="4">24.0% for the surgical group (p&lt;0.001).  </text>
<text top="521" left="614" width="320" height="20" font="4">● The mean length of hospital stay was 1.0 ± 0.3 d for the </text>
<text top="538" left="614" width="343" height="20" font="4">device group and 3.4 ± 1.2 d for the surgical group (p&lt;0.001).  </text>
<text top="555" left="614" width="202" height="20" font="4">● Mortality was 0% for both groups.  </text>
<text top="280" left="981" width="127" height="20" font="4">● The early, 1° and 2° </text>
<text top="297" left="981" width="142" height="20" font="4">efficacy success rates for </text>
<text top="314" left="981" width="161" height="20" font="4">surgical vs. device closure of </text>
<text top="332" left="981" width="142" height="20" font="4">ASD were not statistically </text>
<text top="349" left="981" width="125" height="20" font="4">different; however, the </text>
<text top="366" left="981" width="154" height="20" font="4">complication rate was lower </text>
<text top="383" left="981" width="141" height="20" font="4">and the length of hospital </text>
<text top="401" left="981" width="150" height="20" font="4">stay was shorter for device </text>
<text top="418" left="981" width="134" height="20" font="4">closure than for surgical </text>
<text top="435" left="981" width="38" height="20" font="4">repair. </text>
<text top="452" left="981" width="148" height="20" font="4">● Transcatheter closure of </text>
<text top="469" left="981" width="142" height="20" font="4">secundum ASD using the </text>
<text top="487" left="981" width="152" height="20" font="4">ASO is a safe and effective </text>
<text top="504" left="981" width="158" height="20" font="4">alternative to surgical repair. </text>
<text top="573" left="64" width="82" height="20" font="4">Lopez K, et al. </text>
<text top="591" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(324)</a> </text>
<text top="608" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16216021?dopt=Citation">16216021</a></text>
<text top="608" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16216021?dopt=Citation"> </a></text>
<text top="573" left="172" width="76" height="20" font="4">Single-center </text>
<text top="591" left="172" width="36" height="20" font="4">series </text>
<text top="573" left="280" width="173" height="20" font="4">n=32 pts  <b>Inclusion criteria</b>: </text>
<text top="591" left="347" width="134" height="20" font="4">Describe the procedural </text>
<text top="608" left="347" width="129" height="20" font="4">factors and outcome of </text>
<text top="625" left="347" width="134" height="20" font="4">ASD closure with the 40 </text>
<text top="642" left="347" width="53" height="20" font="4">mm ASO </text>
<text top="573" left="515" width="63" height="20" font="4">Procedural </text>
<text top="591" left="515" width="60" height="20" font="4">outcomes  </text>
<text top="573" left="614" width="321" height="20" font="4">● 33 pts (22 female, 11 male) with a large secundum ASD </text>
<text top="591" left="614" width="349" height="20" font="4">underwent attempted device closure using the 40 mm ASO at a </text>
<text top="608" left="614" width="339" height="20" font="4">median age of 40 y (range, 14–81 y) and median weight of 65 </text>
<text top="625" left="614" width="352" height="20" font="4">kg (range, 48–98 kg). The median size of the ASD measured on </text>
<text top="642" left="614" width="334" height="20" font="4">TEE (27 pts) or ICE (6 pts) was 30.5 mm (range, 24–39 mm) </text>
<text top="659" left="614" width="314" height="20" font="4">and the median balloon-stretched diameter was 37.7 mm </text>
<text top="677" left="614" width="125" height="20" font="4">(range, 32–43.7 mm).  </text>
<text top="694" left="614" width="270" height="20" font="4">● The median Qp:Qs was 3.2:1 (range, 1.4–6.2). </text>
<text top="711" left="614" width="301" height="20" font="4">● The attempt was unsuccessful in 5 pts; 2 had device </text>
<text top="728" left="614" width="322" height="20" font="4">embolization and 1had left atrial wall perforation due to the </text>
<text top="745" left="614" width="222" height="20" font="4">sheath; all 3 required emergent surgery. </text>
<text top="763" left="614" width="349" height="20" font="4">● The attempt was successful in the 28 remaining pts, resulting </text>
<text top="780" left="614" width="346" height="20" font="4">in complete immediate closure in 14 and a trivial residual shunt </text>
<text top="573" left="981" width="146" height="20" font="4">● The 40 mm ASO is safe </text>
<text top="591" left="981" width="161" height="20" font="4">and effective in most pts with </text>
<text top="608" left="981" width="162" height="20" font="4">a large ASD up to a diameter </text>
<text top="625" left="981" width="157" height="20" font="4">of 39 mm. However, the use </text>
<text top="642" left="981" width="123" height="20" font="4">of this device requires </text>
<text top="659" left="981" width="128" height="20" font="4">careful attention as the </text>
<text top="677" left="981" width="103" height="20" font="4">procedure may be </text>
<text top="694" left="981" width="148" height="20" font="4">unsuccessful or the device </text>
<text top="711" left="981" width="83" height="20" font="4">may embolize. </text>
</page>
<page number="90" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 90 </text>
<text top="107" left="614" width="354" height="20" font="4">in 14. Fluoroscopy time ranged from 8.6–37.8 min (median: 12.2 </text>
<text top="124" left="614" width="34" height="20" font="4">min).  </text>
<text top="141" left="614" width="335" height="20" font="4">● At 24-h follow-up, 2D TTE with color flow Doppler revealed </text>
<text top="159" left="614" width="334" height="20" font="4">complete closure in 23 pts, and 5 had a trivial residual shunt. </text>
<text top="176" left="614" width="341" height="20" font="4">There were no complications encountered in pts who received </text>
<text top="193" left="614" width="261" height="20" font="4">the device. On follow-up, all pts are doing well.  </text>
<text top="211" left="64" width="82" height="20" font="4">Bradley EA, et </text>
<text top="228" left="64" width="16" height="20" font="4">al. </text>
<text top="245" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(325)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23993122?dopt=Citation">23993122</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23993122?dopt=Citation"> </a></text>
<text top="211" left="172" width="76" height="20" font="4">Single-center </text>
<text top="228" left="172" width="66" height="20" font="4">case series </text>
<text top="211" left="280" width="221" height="20" font="4">n=12 pts  <b>Inclusion criteria</b>: ASD pts </text>
<text top="228" left="347" width="129" height="20" font="4">with PAH may undergo </text>
<text top="245" left="347" width="141" height="20" font="4">treatment with pulmonary </text>
<text top="263" left="347" width="142" height="20" font="4">vasodilators and undergo </text>
<text top="280" left="347" width="118" height="20" font="4">delayed ASD closure </text>
<text top="211" left="515" width="72" height="20" font="4">intermediate-</text>
<text top="228" left="515" width="85" height="20" font="4">term outcomes </text>
<text top="245" left="515" width="42" height="20" font="4">of PAH </text>
<text top="263" left="515" width="79" height="20" font="4">treatment and </text>
<text top="280" left="515" width="72" height="20" font="4">ASD closure </text>
<text top="211" left="614" width="336" height="20" font="4">● Invasive hemodynamic and clinical parameters from 12 pts </text>
<text top="228" left="614" width="347" height="20" font="4">with an open ASD and PAH PVR, 8.8 ± 1.2 WU; mPAP, 55 ± 6 </text>
<text top="245" left="614" width="347" height="20" font="4">mm Hg; Qp:Qs 1.1 ± 0.1; and 6MWT of 1,046 ± 116 feet) were </text>
<text top="263" left="614" width="352" height="20" font="4">analyzed. Responders (n=5) underwent successful ASD closure </text>
<text top="280" left="614" width="310" height="20" font="4">at 1.3 ± 0.3 y after initiation of medical therapy and were </text>
<text top="297" left="614" width="337" height="20" font="4">characterized by &gt;30% reduction in PVR (7.2 ± 1.5–4.6 ± 0.9 </text>
<text top="314" left="614" width="349" height="20" font="4">WU) vs. &lt;20% in nonresponders (n=7; 9.9 ± 1.7–8.2 ± 1.5 WU; </text>
<text top="332" left="614" width="336" height="20" font="4">p&lt;0.03), increased 6MWT (1,087 ± 174 vs. 1,405 ± 109 feet; </text>
<text top="349" left="614" width="354" height="20" font="4">p=0.05), and higher Qp:Qs after therapy (1.9 ± 0.2 vs. 1.1 ± 0.2; </text>
<text top="366" left="614" width="327" height="20" font="4">p&lt;0.02). BMI was a significant clinical predictor of response </text>
<text top="383" left="614" width="169" height="20" font="4">(23.3 ± 1.9 vs. 30.0 ± 2.1 kg/m</text>
<text top="385" left="783" width="4" height="13" font="6">2</text>
<text top="383" left="787" width="154" height="20" font="4">; p&lt;0.05) and the change in </text>
<text top="400" left="614" width="352" height="20" font="4">arterial saturation with exercise correlated inversely with change </text>
<text top="418" left="614" width="151" height="20" font="4">in PVR (r=-0.739; p&lt;0.01).  </text>
<text top="211" left="981" width="146" height="20" font="4">● Medical therapy led to a </text>
<text top="228" left="981" width="145" height="20" font="4">significant improvement in </text>
<text top="245" left="981" width="144" height="20" font="4">hemodynamic and clinical </text>
<text top="263" left="981" width="162" height="20" font="4">parameters in a subset of pts </text>
<text top="280" left="981" width="158" height="20" font="4">with an open ASD and PAH, </text>
<text top="297" left="981" width="132" height="20" font="4">who were able to safely </text>
<text top="314" left="981" width="124" height="20" font="4">undergo delayed ASD </text>
<text top="332" left="981" width="46" height="20" font="4">closure. </text>
<text top="436" left="64" width="80" height="20" font="4">Cho YH, et al. </text>
<text top="453" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(326)</a> </text>
<text top="470" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22543336?dopt=Citation">22543336</a></text>
<text top="470" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22543336?dopt=Citation"> </a></text>
<text top="436" left="172" width="76" height="20" font="4">Single-center </text>
<text top="453" left="172" width="66" height="20" font="4">case series </text>
<text top="436" left="280" width="219" height="20" font="4">n=16 pts  <b>Inclusion criteria</b>: Pts with </text>
<text top="453" left="347" width="144" height="20" font="4">fenestrated surgical patch </text>
<text top="470" left="347" width="121" height="20" font="4">in ASD pt with severe </text>
<text top="487" left="347" width="89" height="20" font="4">pulmonary HTN </text>
<text top="436" left="515" width="75" height="20" font="4">intermediate- </text>
<text top="453" left="515" width="79" height="20" font="4">and long-term </text>
<text top="470" left="515" width="57" height="20" font="4">outcomes </text>
<text top="436" left="614" width="324" height="20" font="4">● All pts had a secundum type ASD and severe pulmonary </text>
<text top="453" left="614" width="341" height="20" font="4">HTN. Pts ranged in age from 6–57 y (mean ± SD, 34.9 ± 13.5 </text>
<text top="470" left="614" width="352" height="20" font="4">y). The follow-up period was 9 –59 mo (mean, 34.5 ± 13.1 mo).  </text>
<text top="487" left="614" width="346" height="20" font="4">● The ranges of preoperative systemic systolic and PA systolic </text>
<text top="504" left="614" width="348" height="20" font="4">pressure were 63–119 mm Hg (mean, 83.8 ± 13.9 mm Hg) and </text>
<text top="522" left="614" width="319" height="20" font="4">37–77 mm Hg (mean, 51.1 ± 10.1 mm Hg). The ranges of </text>
<text top="539" left="614" width="331" height="20" font="4">preoperative values for the ratio of the pulmonary flow to the </text>
<text top="556" left="614" width="354" height="20" font="4">systemic flow and for pulmonary arterial resistance were 1.1–2.7 </text>
<text top="573" left="614" width="330" height="20" font="4">(mean, 1.95 ± 0.5) and 3.9–16.7 WU (mean, 9.8 ± 2.9 WU), </text>
<text top="591" left="614" width="72" height="20" font="4">respectively. </text>
<text top="608" left="614" width="337" height="20" font="4">● There was no early or late mortality. Tricuspid annuloplasty </text>
<text top="625" left="614" width="352" height="20" font="4">was performed in 14 pts (87.5%). The peak TR gradient and the </text>
<text top="642" left="614" width="341" height="20" font="4">ratio of the systolic PAP to the systemic arterial pressure were </text>
<text top="659" left="614" width="113" height="20" font="4">decreased in all pts. </text>
<text top="677" left="614" width="353" height="20" font="4">● The NYHA class and the grade of TR were improved in 13 pts </text>
<text top="694" left="614" width="233" height="20" font="4">(81.2%) and 15 pts (93.7%), respectively.  </text>
<text top="436" left="981" width="142" height="20" font="4">● ASD closure in pts with </text>
<text top="453" left="981" width="153" height="20" font="4">severe pulmonary HTN can </text>
<text top="470" left="981" width="153" height="20" font="4">be performed safely if there </text>
<text top="487" left="981" width="147" height="20" font="4">is a fenestration. Tricuspid </text>
<text top="504" left="981" width="132" height="20" font="4">annuloplasty and a Cox </text>
<text top="522" left="981" width="119" height="20" font="4">Maze procedure may </text>
<text top="539" left="981" width="145" height="20" font="4">improve the clinical result. </text>
<text top="712" left="64" width="79" height="20" font="4">Shim M, et al. </text>
<text top="729" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(327)</a> </text>
<text top="746" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23614094?dopt=Citation">23614094</a></text>
<text top="746" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23614094?dopt=Citation"> </a></text>
<text top="712" left="172" width="76" height="20" font="4">Single-center </text>
<text top="729" left="172" width="66" height="20" font="4">case series </text>
<text top="712" left="280" width="194" height="20" font="4">n=46 pts  <b>Inclusion criteria</b>: Pts </text>
<text top="729" left="347" width="119" height="20" font="4">undergoing the Maze </text>
<text top="746" left="347" width="137" height="20" font="4">procedure in conjunction </text>
<text top="763" left="347" width="97" height="20" font="4">with ASD closure </text>
<text top="712" left="515" width="60" height="20" font="4">Long-term </text>
<text top="729" left="515" width="53" height="20" font="4">follow-up </text>
<text top="712" left="614" width="320" height="20" font="4">● 46 pts underwent the Maze procedure as a concomitant </text>
<text top="729" left="614" width="159" height="20" font="4">operation with ASD closure.  </text>
<text top="746" left="614" width="266" height="20" font="4">● The mean follow-up duration was 3.2 ± 2.5 y.  </text>
<text top="763" left="614" width="350" height="20" font="4">● ECG was performed 1 mo, 3 mo, 6 mo, and 1 y after surgery, </text>
<text top="781" left="614" width="178" height="20" font="4">and checked annually after that. </text>
<text top="712" left="981" width="140" height="20" font="4">● Concomitant treatment </text>
<text top="729" left="981" width="162" height="20" font="4">with the Maze procedure and </text>
<text top="746" left="981" width="134" height="20" font="4">ASD closure is safe and </text>
<text top="763" left="981" width="139" height="20" font="4">effective for restoring the </text>
<text top="781" left="981" width="76" height="20" font="4">sinus rhythm. </text>
</page>
<page number="91" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 91 </text>
<text top="107" left="614" width="341" height="20" font="4">● AF persisted in 4 pts after surgery. 1 y after surgery, among </text>
<text top="124" left="614" width="342" height="20" font="4">38 pts, 55.3% remained in sinus rhythm without antiarrhythmic </text>
<text top="141" left="614" width="351" height="20" font="4">drugs. However, when including the pts who took antiarrhythmic </text>
<text top="159" left="614" width="199" height="20" font="4">drugs, 92.1% were in sinus rhythm.  </text>
<text top="176" left="614" width="350" height="20" font="4">● Freedom from AF recurrence at 3 mo, 6 mo, 1 y, 2 y, 3 y, and </text>
<text top="193" left="614" width="351" height="20" font="4">5 y after surgery were 97.4 ± 2.6, 94.4 ± 3.8, 91.2 ± 4.9, 87.8 ± </text>
<text top="210" left="614" width="330" height="20" font="4">5.8, 79.5 ± 7.6, and 68.2 ± 12.4, respectively. There was no </text>
<text top="227" left="614" width="166" height="20" font="4">early mortality after operation. </text>
<text top="245" left="64" width="85" height="20" font="4">Giamberti A, et </text>
<text top="263" left="64" width="16" height="20" font="4">al. </text>
<text top="280" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(328)</a> </text>
<text top="297" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16996928?dopt=Citation">16996928</a></text>
<text top="297" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16996928?dopt=Citation"> </a></text>
<text top="245" left="172" width="68" height="20" font="4">Case series </text>
<text top="245" left="280" width="218" height="20" font="4">n=15 pts  <b>Inclusion criteria</b>: Pts &gt;40 </text>
<text top="263" left="347" width="117" height="20" font="4">y with ASD and atrial </text>
<text top="280" left="347" width="111" height="20" font="4">arrhythmia who had </text>
<text top="297" left="347" width="134" height="20" font="4">elective surgical closure </text>
<text top="314" left="347" width="150" height="20" font="4">and intraoperative irrigated </text>
<text top="332" left="347" width="131" height="20" font="4">radiofrequency ablation </text>
<text top="349" left="347" width="78" height="20" font="4">(IRF) ablation </text>
<text top="245" left="515" width="63" height="20" font="4">Procedural </text>
<text top="263" left="515" width="24" height="20" font="4">and </text>
<text top="280" left="515" width="71" height="20" font="4">intermediate </text>
<text top="297" left="515" width="57" height="20" font="4">outcomes </text>
<text top="245" left="614" width="348" height="20" font="4">● All pts had supraventricular arrhythmia: 8 had permanent AF; </text>
<text top="263" left="614" width="341" height="20" font="4">whereas, 7 had previous episodes of atrial flutter or intra-atrial </text>
<text top="280" left="614" width="111" height="20" font="4">reentry tachycardia. </text>
<text top="297" left="614" width="350" height="20" font="4">● The biatrial approach (Cox-Maze III procedure) was used in 7 </text>
<text top="314" left="614" width="351" height="20" font="4">pts and a right-sided Maze procedure (ablation lines on the right </text>
<text top="332" left="614" width="279" height="20" font="4">atrium only) was carried out in the remaining 8 pts. </text>
<text top="349" left="614" width="345" height="20" font="4">● All pts survived the procedure. 14 pts left the operating room </text>
<text top="366" left="614" width="282" height="20" font="4">in sinus rhythm and 1 had a pacemaker implanted.  </text>
<text top="383" left="614" width="320" height="20" font="4">● There were no complications resulting from the irrigated </text>
<text top="401" left="614" width="349" height="20" font="4">radiofrequency ablation. No deaths during an average follow-up </text>
<text top="418" left="614" width="96" height="20" font="4">period of 24 mo.  </text>
<text top="435" left="614" width="333" height="20" font="4">● 13 pts were still in sinus rhythm, 1 had pacemaker rhythm, </text>
<text top="452" left="614" width="328" height="20" font="4">and only 1 (1 of 15; 6.5%) suffered a recurrence of AF 3 mo </text>
<text top="469" left="614" width="111" height="20" font="4">after the procedure. </text>
<text top="245" left="981" width="152" height="20" font="4">● Addition of intraoperative </text>
<text top="263" left="981" width="133" height="20" font="4">irrigated radiofrequency </text>
<text top="280" left="981" width="130" height="20" font="4">ablation during surgical </text>
<text top="297" left="981" width="145" height="20" font="4">closure of an ASD in adult </text>
<text top="314" left="981" width="154" height="20" font="4">ASD pts with arrhythmias is </text>
<text top="332" left="981" width="134" height="20" font="4">beneficial in maintaining </text>
<text top="349" left="981" width="76" height="20" font="4">sinus rhythm. </text>
<text top="366" left="981" width="85" height="20" font="4">● The irrigated </text>
<text top="383" left="981" width="143" height="20" font="4">radiofrequency ablation is </text>
<text top="400" left="981" width="146" height="20" font="4">easy to perform, safe, and </text>
<text top="418" left="981" width="53" height="20" font="4">effective. </text>
<text top="487" left="64" width="94" height="20" font="4">Kouchoukos NT, </text>
<text top="504" left="64" width="30" height="20" font="4">et al. </text>
<text top="522" left="64" width="63" height="20" font="4">1978 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(329)</a> </text>
<text top="539" left="64" width="41" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/619518?dopt=Citation">619518</a></text>
<text top="539" left="105" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/619518?dopt=Citation"> </a></text>
<text top="487" left="172" width="44" height="20" font="4">Review </text>
<text top="487" left="280" width="24" height="20" font="4">N/A </text>
<text top="487" left="347" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="504" left="347" width="147" height="20" font="4">large VSD prior to surgical </text>
<text top="522" left="347" width="43" height="20" font="4">closure </text>
<text top="487" left="515" width="53" height="20" font="4">Mortality  </text>
<text top="487" left="614" width="348" height="20" font="4">● Mortality related to age at operations (older did worse) and to </text>
<text top="504" left="614" width="104" height="20" font="4">preoperative PVR. </text>
<text top="487" left="981" width="155" height="20" font="4">● Prepulmonary vasodilator </text>
<text top="504" left="981" width="158" height="20" font="4">era. Careful consideration of </text>
<text top="522" left="981" width="137" height="20" font="4">mortality and late effects </text>
<text top="539" left="981" width="151" height="20" font="4">prior to considering closure </text>
<text top="556" left="981" width="76" height="20" font="4">of large VSD. </text>
<text top="574" left="64" width="94" height="20" font="4">Shohtsu A, et al. </text>
<text top="591" left="64" width="63" height="20" font="4">1976 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(330)</a> </text>
<text top="608" left="64" width="41" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/950729?dopt=Citation">950729</a></text>
<text top="608" left="105" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/950729?dopt=Citation"> </a></text>
<text top="574" left="172" width="78" height="20" font="4">Retrospective </text>
<text top="591" left="172" width="38" height="20" font="4">cohort </text>
<text top="574" left="280" width="219" height="20" font="4">n=64 pts  <b>Inclusion criteria</b>: Pts with </text>
<text top="591" left="347" width="145" height="20" font="4">large VSD, PH; also small </text>
<text top="608" left="347" width="152" height="20" font="4">number with PDA and ASD </text>
<text top="574" left="515" width="50" height="20" font="4">Mortality </text>
<text top="574" left="614" width="353" height="20" font="4">● Optimal timing of closure is at 1-3y for VSD with PH; PDA and </text>
<text top="591" left="614" width="83" height="20" font="4">ASD not clear. </text>
<text top="574" left="981" width="139" height="20" font="4">● Closure of large septal </text>
<text top="591" left="981" width="145" height="20" font="4">defects with PH should be </text>
<text top="608" left="981" width="150" height="20" font="4">considered for closure only </text>
<text top="626" left="981" width="141" height="20" font="4">at young ages to improve </text>
<text top="643" left="981" width="53" height="20" font="4">mortality. </text>
<text top="661" left="64" width="89" height="20" font="4">Gajjar TP, et al. </text>
<text top="678" left="64" width="56" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#215">(53)</a> </text>
<text top="695" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21793931%5Buid%5D">21793931</a></text>
<text top="695" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21793931%5Buid%5D"> </a></text>
<text top="661" left="172" width="76" height="20" font="4">Single-center </text>
<text top="678" left="172" width="69" height="20" font="4">case series  </text>
<text top="661" left="280" width="31" height="20" font="4">n=48 </text>
<text top="661" left="347" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="678" left="347" width="130" height="20" font="4">sinus venous ASD who </text>
<text top="695" left="347" width="120" height="20" font="4">underwent transcaval </text>
<text top="712" left="347" width="111" height="20" font="4">repair between Jan. </text>
<text top="730" left="347" width="96" height="20" font="4">2007―Oct. 2010 </text>
<text top="661" left="515" width="48" height="20" font="4">Surgical </text>
<text top="678" left="515" width="51" height="20" font="4">outcome </text>
<text top="661" left="614" width="232" height="20" font="4">● All pts came off bypass in sinus rhythm. </text>
<text top="678" left="614" width="294" height="20" font="4">● Average pressure gradient across patch: 3 mm/Hg. </text>
<text top="695" left="614" width="336" height="20" font="4">● Immediate postop ECGs and echos showed all pts in sinus </text>
<text top="712" left="614" width="331" height="20" font="4">rhythm with no residual shunt and no pulmonary or systemic </text>
<text top="730" left="614" width="277" height="20" font="4">venous obstruction, except 1 pt who required SVC </text>
<text top="747" left="614" width="81" height="20" font="4">augmentation. </text>
<text top="661" left="981" width="152" height="20" font="4">● Single patch technique is </text>
<text top="678" left="981" width="139" height="20" font="4">safe and simple for sinus </text>
<text top="695" left="981" width="153" height="20" font="4">venous ASD and preserves </text>
<text top="712" left="981" width="158" height="20" font="4">sinoatrial node function after </text>
<text top="730" left="981" width="48" height="20" font="4">surgery. </text>
<text top="765" left="108" width="3" height="20" font="4"> </text>
<text top="782" left="108" width="3" height="20" font="4"> </text>
</page>
<page number="92" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 92 </text>
<text top="106" left="108" width="572" height="24" font="1"><b>Data Supplement 27. Anomalous Pulmonary Venous Connections – Section 4.1.2 </b></text>
<text top="128" left="88" width="38" height="20" font="3"><b>Study </b></text>
<text top="145" left="89" width="37" height="20" font="3"><b>Name </b></text>
<text top="128" left="167" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="145" left="181" width="44" height="20" font="3"><b>Design </b></text>
<text top="128" left="264" width="38" height="20" font="3"><b>Study </b></text>
<text top="145" left="269" width="28" height="20" font="3"><b>Size </b></text>
<text top="128" left="326" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="145" left="363" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="128" left="479" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="128" left="686" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="128" left="914" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="187" left="64" width="83" height="20" font="4">Festa, P, et al. </text>
<text top="204" left="64" width="56" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(80)</a> </text>
<text top="222" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16547601?dopt=Citation">16547601</a></text>
<text top="222" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16547601?dopt=Citation"> </a></text>
<text top="187" left="163" width="76" height="20" font="4">Single-center </text>
<text top="204" left="163" width="74" height="20" font="4">retrospective </text>
<text top="222" left="163" width="33" height="20" font="4">study<b> </b></text>
<text top="187" left="256" width="193" height="20" font="4">n=20 pts<b>  Inclusion criteria</b>: Pts </text>
<text top="204" left="323" width="85" height="20" font="4">with suspected </text>
<text top="222" left="323" width="69" height="20" font="4">PAPVC that </text>
<text top="239" left="323" width="87" height="20" font="4">underwent MRI<b> </b></text>
<text top="187" left="462" width="62" height="20" font="4">To test the </text>
<text top="204" left="462" width="59" height="20" font="4">diagnostic </text>
<text top="222" left="462" width="105" height="20" font="4">accuracy of MRI in </text>
<text top="239" left="462" width="45" height="20" font="4">PAPVR<b> </b></text>
<text top="187" left="581" width="294" height="20" font="4">● 20 consecutive pts (10 male, mean age: 27 ± 20 y) </text>
<text top="204" left="581" width="254" height="20" font="4">with suspected PAPVC underwent a magnetic </text>
<text top="222" left="581" width="260" height="20" font="4">resonance study comprehensive of Gadolinium-</text>
<text top="239" left="581" width="306" height="20" font="4">enhanced 3D MRA and phase-velocity-contrast in order </text>
<text top="256" left="581" width="293" height="20" font="4">to evaluate pulmonary and systemic venous anatomy </text>
<text top="273" left="581" width="66" height="20" font="4">and Qp:Qs. </text>
<text top="290" left="581" width="254" height="20" font="4">● In 14 pts, a cardiac catheterization was also </text>
<text top="308" left="581" width="298" height="20" font="4">performed. Anatomy findings and Qp:Qs result of both </text>
<text top="325" left="581" width="135" height="20" font="4">exams were compared.  </text>
<text top="342" left="581" width="293" height="20" font="4">● 16 pts underwent surgical correction. In the other 4 </text>
<text top="359" left="581" width="261" height="20" font="4">pts with Qp:Qs&lt;1.5, surgical correction was not </text>
<text top="376" left="581" width="66" height="20" font="4">performed.  </text>
<text top="394" left="581" width="290" height="20" font="4">● Among pts who had both magnetic resonance and </text>
<text top="411" left="581" width="310" height="20" font="4">cardiac catheterization (14 pts) anatomical findings were </text>
<text top="428" left="581" width="293" height="20" font="4">concordant in 12 of them. In all operated pts, surgical </text>
<text top="445" left="581" width="234" height="20" font="4">findings were concordant with MRI report.  </text>
<text top="462" left="581" width="278" height="20" font="4">● There was a good correlation between magnetic </text>
<text top="480" left="581" width="310" height="20" font="4">resonance and cardiac catheterization Qp:Qs evaluation </text>
<text top="497" left="581" width="222" height="20" font="4">(mean value 2.23 and 2.4, respectively).<b> </b></text>
<text top="187" left="906" width="131" height="20" font="4">● In pts with suspected </text>
<text top="204" left="906" width="124" height="20" font="4">anomalous pulmonary </text>
<text top="222" left="906" width="109" height="20" font="4">venous connection, </text>
<text top="239" left="906" width="114" height="20" font="4">magnetic resonance </text>
<text top="256" left="906" width="147" height="20" font="4">provides a comprehensive </text>
<text top="273" left="906" width="134" height="20" font="4">evaluation of pulmonary </text>
<text top="290" left="906" width="136" height="20" font="4">venous connections and </text>
<text top="308" left="906" width="66" height="20" font="4">the Qp:Qs. <b> </b></text>
<text top="515" left="64" width="86" height="20" font="4">Nordemeyer S, </text>
<text top="532" left="64" width="30" height="20" font="4">et al. </text>
<text top="549" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(317)</a> </text>
<text top="566" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21554824?dopt=Citation">21554824</a></text>
<text top="566" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21554824?dopt=Citation"> </a></text>
<text top="515" left="163" width="76" height="20" font="4">Single-center </text>
<text top="532" left="163" width="66" height="20" font="4">prospective </text>
<text top="549" left="163" width="79" height="20" font="4">imaging study </text>
<text top="515" left="256" width="193" height="20" font="4">n=6 pts   <b>Inclusion criteria</b>: Pts </text>
<text top="532" left="323" width="85" height="20" font="4">with suspected </text>
<text top="549" left="323" width="91" height="20" font="4">PAPVC by echo </text>
<text top="566" left="323" width="109" height="20" font="4">referred for 4D MRI </text>
<text top="515" left="462" width="84" height="20" font="4">Functional and </text>
<text top="532" left="462" width="101" height="20" font="4">anatomic analysis </text>
<text top="549" left="462" width="62" height="20" font="4">by 4D MRI </text>
<text top="515" left="581" width="280" height="20" font="4">● 6 pts with PAPVC suspected on echo underwent </text>
<text top="532" left="581" width="60" height="20" font="4">MRI/MRA. </text>
<text top="549" left="581" width="299" height="20" font="4">● Functional analysis included shunt calculations from </text>
<text top="566" left="581" width="277" height="20" font="4">flow measurements. The authors used 4D velocity-</text>
<text top="584" left="581" width="268" height="20" font="4">encoded cine MRI for visualization of anomalous </text>
<text top="601" left="581" width="271" height="20" font="4">pulmonary veins and quantification of flow via the </text>
<text top="618" left="581" width="279" height="20" font="4">anomalous veins and interatrial communications, if </text>
<text top="635" left="581" width="48" height="20" font="4">present. </text>
<text top="652" left="581" width="299" height="20" font="4">● In all pts, the diagnosis of PAPVC was confirmed by </text>
<text top="670" left="581" width="306" height="20" font="4">MRI. Shunt volumes ranged from 1.4:1–4.7:1. Drainage </text>
<text top="687" left="581" width="295" height="20" font="4">sites were the superior caval vein (n=5) or the vertical </text>
<text top="704" left="581" width="65" height="20" font="4">vein (n=1).  </text>
<text top="721" left="581" width="302" height="20" font="4">● Multiple anomalous pulmonary veins were found in 3 </text>
<text top="739" left="581" width="275" height="20" font="4">pts. Pulmonary arteries and veins could be clearly </text>
<text top="756" left="581" width="265" height="20" font="4">distinguished by selective visualization using 4D </text>
<text top="773" left="581" width="302" height="20" font="4">velocity-encoded cine MRI. Flow measured individually </text>
<text top="790" left="581" width="297" height="20" font="4">in anomalous pulmonary veins in 6 pts and across the </text>
<text top="515" left="906" width="150" height="20" font="4">● Selective visualization of </text>
<text top="532" left="906" width="150" height="20" font="4">individual vessels and their </text>
<text top="549" left="906" width="143" height="20" font="4">flow characteristics by 4D </text>
<text top="566" left="906" width="148" height="20" font="4">velocity-encoded cine MRI </text>
<text top="584" left="906" width="135" height="20" font="4">is feasible and improves </text>
<text top="601" left="906" width="140" height="20" font="4">the accurate diagnosis of </text>
<text top="618" left="906" width="113" height="20" font="4">PAPVC. By detailed </text>
<text top="635" left="906" width="123" height="20" font="4">quantification of shunt </text>
<text top="653" left="906" width="109" height="20" font="4">volumes, additional </text>
<text top="670" left="906" width="146" height="20" font="4">information for planning of </text>
<text top="687" left="906" width="124" height="20" font="4">treatment strategies is </text>
<text top="704" left="906" width="57" height="20" font="4">provided.  </text>
</page>
<page number="93" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 93 </text>
<text top="107" left="581" width="309" height="20" font="4">interatrial communication in 3 pts revealed a percentage </text>
<text top="124" left="581" width="286" height="20" font="4">of the overall shunt volume of 30%–100% and 58%–</text>
<text top="141" left="581" width="103" height="20" font="4">70%, respectively. </text>
<text top="166" left="64" width="85" height="20" font="4">Dyme JL, et al. </text>
<text top="184" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(331)</a> </text>
<text top="201" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16784931?dopt=Citation">16784931</a></text>
<text top="201" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16784931?dopt=Citation"> </a></text>
<text top="166" left="163" width="78" height="20" font="4">Retrospective </text>
<text top="184" left="163" width="68" height="20" font="4">case review </text>
<text top="201" left="163" width="38" height="20" font="4">from 2 </text>
<text top="218" left="163" width="62" height="20" font="4">institutions </text>
<text top="166" left="256" width="193" height="20" font="4">n=6 pts   <b>Inclusion criteria</b>: Pts </text>
<text top="184" left="323" width="116" height="20" font="4">with isolated PAPVC </text>
<text top="201" left="323" width="93" height="20" font="4">from 2002–2005 </text>
<text top="218" left="323" width="126" height="20" font="4">identified by searching </text>
<text top="235" left="323" width="120" height="20" font="4">the MRI databases of </text>
<text top="253" left="323" width="126" height="20" font="4">2 institutions. Subjects </text>
<text top="270" left="323" width="106" height="20" font="4">with &gt;1 anomalous </text>
<text top="287" left="323" width="115" height="20" font="4">vein or ASD or other </text>
<text top="304" left="323" width="104" height="20" font="4">associated lesions </text>
<text top="321" left="323" width="83" height="20" font="4">were excluded </text>
<text top="166" left="462" width="104" height="20" font="4">Assessment of the </text>
<text top="184" left="462" width="95" height="20" font="4">magnitude of left-</text>
<text top="201" left="462" width="99" height="20" font="4">to-right shunt and </text>
<text top="218" left="462" width="76" height="20" font="4">RV dilation in </text>
<text top="235" left="462" width="72" height="20" font="4">patients with </text>
<text top="253" left="462" width="99" height="20" font="4">single anomalous </text>
<text top="270" left="462" width="45" height="20" font="4">PAPVR </text>
<text top="166" left="581" width="302" height="20" font="4">● In the 6 subjects identified, the median pulmonary-to-</text>
<text top="184" left="581" width="306" height="20" font="4">systemic flow ratio was 1.55 (range 1.3–1.6). The mean </text>
<text top="201" left="581" width="290" height="20" font="4">RVEDV indexed to body surface area in the subjects </text>
<text top="218" left="581" width="312" height="20" font="4">was significantly larger than in a normal reference cohort </text>
<text top="235" left="581" width="138" height="20" font="4">(108 ± 16 vs. 78 ± 18 cm</text>
<text top="237" left="719" width="4" height="13" font="6">3</text>
<text top="235" left="724" width="14" height="20" font="4">/m</text>
<text top="237" left="737" width="4" height="13" font="6">2</text>
<text top="235" left="742" width="118" height="20" font="4">; p=0.0009) and &gt;the </text>
<text top="253" left="581" width="209" height="20" font="4">upper limit of normal in all 6 subjects.  </text>
<text top="270" left="581" width="304" height="20" font="4">● Older age did not correlate with increased magnitude </text>
<text top="287" left="581" width="266" height="20" font="4">of shunting (r=0.3; p=0.5), but increased age did </text>
<text top="304" left="581" width="284" height="20" font="4">correlate with RVEDV indexed to body surface area </text>
<text top="321" left="581" width="95" height="20" font="4">(r=0.96; p=0.01). </text>
<text top="166" left="906" width="96" height="20" font="4">● Isolated partial </text>
<text top="184" left="906" width="124" height="20" font="4">anomalous pulmonary </text>
<text top="201" left="906" width="131" height="20" font="4">venous connection with </text>
<text top="218" left="906" width="125" height="20" font="4">only 1 vein connecting </text>
<text top="235" left="906" width="135" height="20" font="4">anomalously results in a </text>
<text top="253" left="906" width="139" height="20" font="4">modest left-to-right shunt </text>
<text top="270" left="906" width="116" height="20" font="4">and mild RV dilation. </text>
<text top="339" left="64" width="83" height="20" font="4">Majdalany DS, </text>
<text top="357" left="64" width="30" height="20" font="4">et al. </text>
<text top="374" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(332)</a> </text>
<text top="391" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21106012?dopt=Citation">21106012</a></text>
<text top="391" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21106012?dopt=Citation"> </a></text>
<text top="339" left="163" width="78" height="20" font="4">Retrospective </text>
<text top="357" left="163" width="74" height="20" font="4">single-center </text>
<text top="374" left="163" width="33" height="20" font="4">study </text>
<text top="339" left="256" width="193" height="20" font="4">n=43 pts  <b>Inclusion criteria</b>: Pts </text>
<text top="357" left="323" width="116" height="20" font="4">with isolated PAPVC </text>
<text top="374" left="323" width="121" height="20" font="4">&gt;18 y attending Mayo </text>
<text top="391" left="323" width="97" height="20" font="4">ACHD clinic from </text>
<text top="408" left="323" width="65" height="20" font="4">1998–2008 </text>
<text top="339" left="462" width="98" height="20" font="4">Review of clinical </text>
<text top="357" left="462" width="106" height="20" font="4">characteristics and </text>
<text top="374" left="462" width="57" height="20" font="4">outcomes </text>
<text top="339" left="581" width="179" height="20" font="4">● 43 pts 20–73 y were included. </text>
<text top="357" left="581" width="275" height="20" font="4">● 15 pts had no surgery, 11 of whom had a single </text>
<text top="374" left="581" width="154" height="20" font="4">anomalous pulmonary vein. </text>
<text top="391" left="581" width="295" height="20" font="4">● Surgical repair was performed in 28 pts: 27 had RV </text>
<text top="408" left="581" width="271" height="20" font="4">volume overload, 21 had more than 1 anomalous </text>
<text top="425" left="581" width="298" height="20" font="4">pulmonary vein, and 1 had stenosed pulmonary veins. </text>
<text top="443" left="581" width="309" height="20" font="4">● RV systolic pressure was elevated (&gt;35 mm Hg) in 12 </text>
<text top="460" left="581" width="27" height="20" font="4">pts.  </text>
<text top="477" left="581" width="294" height="20" font="4">● 11 pts had anomalous left pulmonary veins: 10 had </text>
<text top="494" left="581" width="269" height="20" font="4">the pulmonary vein anastomosed to the left atrial </text>
<text top="511" left="581" width="296" height="20" font="4">appendage and 1 pt had anastomosis to the left lower </text>
<text top="529" left="581" width="309" height="20" font="4">pulmonary vein. 1 pt had bilateral anomalous pulmonary </text>
<text top="546" left="581" width="247" height="20" font="4">veins anastomosed directly to the left atrium. </text>
<text top="563" left="581" width="312" height="20" font="4">● 16 pts had anomalous right pulmonary veins: 15 had a </text>
<text top="580" left="581" width="307" height="20" font="4">baffle through a surgically-created ASD, while 1 had the </text>
<text top="597" left="581" width="282" height="20" font="4">anomalous pulmonary vein anastomosed to the left </text>
<text top="615" left="581" width="44" height="20" font="4">atrium.  </text>
<text top="632" left="581" width="257" height="20" font="4">● There was no early mortality. There were 10 </text>
<text top="649" left="581" width="297" height="20" font="4">postoperative complications including 2 baffle leaks, 2 </text>
<text top="666" left="581" width="85" height="20" font="4">baffle stenosis. </text>
<text top="684" left="581" width="289" height="20" font="4">● During mean echo follow-up of 2.7 y, 19 pts (68%) </text>
<text top="701" left="581" width="310" height="20" font="4">had reduced RV size and 5 had improved RV function. 7 </text>
<text top="718" left="581" width="302" height="20" font="4">pts with increased pulmonary pressure had a decrease </text>
<text top="735" left="581" width="90" height="20" font="4">postoperatively. </text>
<text top="339" left="906" width="114" height="20" font="4">● Partial anomalous </text>
<text top="357" left="906" width="152" height="20" font="4">pulmonary veins can cause </text>
<text top="374" left="906" width="126" height="20" font="4">symptoms, RV volume </text>
<text top="391" left="906" width="139" height="20" font="4">overload, and pulmonary </text>
<text top="408" left="906" width="128" height="20" font="4">HTN, particularly when </text>
<text top="425" left="906" width="130" height="20" font="4">more than 1 pulmonary </text>
<text top="443" left="906" width="109" height="20" font="4">vein is anomalous.  </text>
<text top="460" left="906" width="135" height="20" font="4">● Surgical repair can be </text>
<text top="477" left="906" width="126" height="20" font="4">accomplished with low </text>
<text top="494" left="906" width="130" height="20" font="4">morbidity and mortality, </text>
<text top="511" left="906" width="133" height="20" font="4">with improvement in the </text>
<text top="529" left="906" width="130" height="20" font="4">RV size and pulmonary </text>
<text top="546" left="906" width="61" height="20" font="4">pressures. </text>
<text top="753" left="64" width="82" height="20" font="4">Jemielity M, et </text>
<text top="770" left="64" width="16" height="20" font="4">al. </text>
<text top="788" left="64" width="63" height="20" font="4">1998 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(333)</a> </text>
<text top="753" left="163" width="78" height="20" font="4">Retrospective </text>
<text top="770" left="163" width="74" height="20" font="4">single-center </text>
<text top="788" left="163" width="33" height="20" font="4">study </text>
<text top="753" left="256" width="172" height="20" font="4">n=25 pts  <b>Inclusion criteria</b>: </text>
<text top="770" left="323" width="91" height="20" font="4">Consecutive pts </text>
<text top="788" left="323" width="115" height="20" font="4">between 1981–1995 </text>
<text top="753" left="462" width="72" height="20" font="4">Surgical and </text>
<text top="770" left="462" width="100" height="20" font="4">intermediate-term </text>
<text top="788" left="462" width="83" height="20" font="4">outcomes post </text>
<text top="753" left="581" width="301" height="20" font="4">● Mean age at surgery was 37.8 ± 13.0 (range: 16–62 </text>
<text top="770" left="581" width="21" height="20" font="4">y).  </text>
<text top="753" left="906" width="141" height="20" font="4">● Patch repair of PAPVC </text>
<text top="770" left="906" width="142" height="20" font="4">with sinus venous ASD in </text>
<text top="788" left="906" width="98" height="20" font="4">adults with use of </text>
</page>
<page number="94" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 94 </text>
<text top="107" left="64" width="51" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9697063?dopt=Citation"> 9697063</a></text>
<text top="107" left="115" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9697063?dopt=Citation"> </a></text>
<text top="107" left="323" width="85" height="20" font="4">that underwent </text>
<text top="124" left="323" width="94" height="20" font="4">surgical repair of </text>
<text top="141" left="323" width="103" height="20" font="4">PAPVC with ASD. </text>
<text top="107" left="462" width="98" height="20" font="4">PAPVC and ASD </text>
<text top="124" left="462" width="35" height="20" font="4">repair </text>
<text top="107" left="581" width="280" height="20" font="4">● All pts underwent the procedure of covering both </text>
<text top="124" left="581" width="312" height="20" font="4">defect and vein with pericardial patch to direct blood flow </text>
<text top="141" left="581" width="302" height="20" font="4">from anomalous pulmonary veins through the ASD into </text>
<text top="159" left="581" width="85" height="20" font="4">the left atrium.  </text>
<text top="176" left="581" width="296" height="20" font="4">● Mean follow-up was 7.8 ± 4.0 y (range: 2–16 y). No </text>
<text top="193" left="581" width="142" height="20" font="4">pts were lost to follow-up. </text>
<text top="210" left="581" width="285" height="20" font="4">● There were no early deaths. 1 pt died 11 mo after </text>
<text top="227" left="581" width="166" height="20" font="4">surgery from progressive HF.  </text>
<text top="245" left="581" width="246" height="20" font="4">● At follow-up, 10 (42.7%) pts were clinically </text>
<text top="262" left="581" width="312" height="20" font="4">asymptomatic.1 pt had clinical signs of SVC obstruction.  </text>
<text top="279" left="581" width="278" height="20" font="4">● ECG showed no abnormalities in 7 (29.2%) pts.  </text>
<text top="296" left="581" width="269" height="20" font="4">● Chest radiography revealed normal pulmonary </text>
<text top="314" left="581" width="285" height="20" font="4">vascularity in 22 (91.7%) pts and no residual shunts </text>
<text top="331" left="581" width="130" height="20" font="4">were found in the SVC. </text>
<text top="107" left="906" width="143" height="20" font="4">autologous pericardium is </text>
<text top="124" left="906" width="110" height="20" font="4">a safe and effective </text>
<text top="141" left="906" width="62" height="20" font="4">procedure. </text>
<text top="349" left="64" width="71" height="20" font="4">Brink J et al. </text>
<text top="366" left="64" width="63" height="20" font="4">2015 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(334)</a> </text>
<text top="383" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25288102?dopt=Citation">25288102</a></text>
<text top="383" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25288102?dopt=Citation"> </a></text>
<text top="349" left="163" width="78" height="20" font="4">Retrospective </text>
<text top="366" left="163" width="74" height="20" font="4">single-center </text>
<text top="383" left="163" width="33" height="20" font="4">study </text>
<text top="349" left="256" width="193" height="20" font="4">n=21 pts   <b>Inclusion criteria</b>: Pts </text>
<text top="366" left="323" width="71" height="20" font="4">with scimitar </text>
<text top="383" left="323" width="81" height="20" font="4">syndrome that </text>
<text top="400" left="323" width="118" height="20" font="4">underwent corrective </text>
<text top="418" left="323" width="94" height="20" font="4">surgery between </text>
<text top="435" left="323" width="65" height="20" font="4">1974–2001 </text>
<text top="349" left="462" width="99" height="20" font="4">Surgical and long-</text>
<text top="366" left="462" width="85" height="20" font="4">term outcomes </text>
<text top="349" left="581" width="298" height="20" font="4">● The mean age of surgery was 5.4 y (2.5 mo–6.7 y).  </text>
<text top="366" left="581" width="304" height="20" font="4">● 16 (76.2%) pts were symptomatic at presentation. 15 </text>
<text top="383" left="581" width="278" height="20" font="4">(71.4%) pts presented with the infantile form and 6 </text>
<text top="400" left="581" width="274" height="20" font="4">(28.6%) with the adult form of scimitar syndrome.  </text>
<text top="418" left="581" width="280" height="20" font="4">● Operative techniques included baffle repair in 15 </text>
<text top="435" left="581" width="264" height="20" font="4">(71.4%) pts, reimplantation in 5 (23.8%) pts and </text>
<text top="452" left="581" width="178" height="20" font="4">pneumonectomy in 1 (4.8%) pt.  </text>
<text top="469" left="581" width="309" height="20" font="4">● 6 (28.6%) pts were operated in infancy at a mean of 4 </text>
<text top="487" left="581" width="97" height="20" font="4">mo (2.5–9.6 mo). </text>
<text top="504" left="581" width="297" height="20" font="4">● There was 1 (4.8%) hospital death and 3 (15%) late </text>
<text top="521" left="581" width="248" height="20" font="4">deaths. The risk factors for mortality included </text>
<text top="538" left="581" width="286" height="20" font="4">preoperative pulmonary HTN (p=0.006) and surgery </text>
<text top="555" left="581" width="143" height="20" font="4">during infancy (p=0.003).  </text>
<text top="573" left="581" width="270" height="20" font="4">● The incidence of postoperative pulmonary vein </text>
<text top="590" left="581" width="285" height="20" font="4">stenosis was 23.8% (n=5). 3 (14.3%) pts underwent </text>
<text top="607" left="581" width="222" height="20" font="4">reoperation for pulmonary vein stenosis. </text>
<text top="624" left="581" width="283" height="20" font="4">● Neither baffle (p=0.6) nor reimplantation (p=0.55) </text>
<text top="641" left="581" width="283" height="20" font="4">surgical techniques influenced the rate of stenosis.  </text>
<text top="659" left="581" width="311" height="20" font="4">● The follow-up was complete in 15 (88%) survivors at a </text>
<text top="676" left="581" width="161" height="20" font="4">mean of 13.7 y (1.3–38.5 y).  </text>
<text top="693" left="581" width="306" height="20" font="4">● All surviving pts were asymptomatic and had a NYHA </text>
<text top="710" left="581" width="64" height="20" font="4">FC Class I. </text>
<text top="349" left="906" width="122" height="20" font="4">● Surgical mortality is </text>
<text top="366" left="906" width="145" height="20" font="4">highest in pts operated on </text>
<text top="383" left="906" width="120" height="20" font="4">before 1 y of age and </text>
<text top="400" left="906" width="152" height="20" font="4">those with pulmonary HTN. </text>
<text top="418" left="906" width="122" height="20" font="4">● Baffle/vein stenosis </text>
<text top="435" left="906" width="128" height="20" font="4">occurs in 23.8% of pts. </text>
<text top="452" left="906" width="116" height="20" font="4">● Most survivors are </text>
<text top="469" left="906" width="148" height="20" font="4">asymptomatic at long-term </text>
<text top="487" left="906" width="56" height="20" font="4">follow-up. </text>
<text top="728" left="64" width="75" height="20" font="4">Sachweh JS, </text>
<text top="745" left="64" width="30" height="20" font="4">et al. </text>
<text top="763" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(335)</a> </text>
<text top="780" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16368366?dopt=Citation">16368366</a></text>
<text top="780" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16368366?dopt=Citation"> </a></text>
<text top="728" left="163" width="78" height="20" font="4">Retrospective </text>
<text top="745" left="163" width="74" height="20" font="4">single-center </text>
<text top="763" left="163" width="33" height="20" font="4">study </text>
<text top="728" left="256" width="172" height="20" font="4">n=75 pts  <b>Inclusion criteria</b>: </text>
<text top="745" left="323" width="75" height="20" font="4">Adult pts that </text>
<text top="763" left="323" width="107" height="20" font="4">underwent surgical </text>
<text top="780" left="323" width="117" height="20" font="4">closure of secundum </text>
<text top="728" left="462" width="63" height="20" font="4">Assess the </text>
<text top="745" left="462" width="87" height="20" font="4">prevalence and </text>
<text top="763" left="462" width="96" height="20" font="4">histologic degree </text>
<text top="780" left="462" width="87" height="20" font="4">of hypertensive </text>
<text top="728" left="581" width="301" height="20" font="4">● Lung biopsies of 75 pts, mean age 44 ± 14 y (18–71 </text>
<text top="745" left="581" width="310" height="20" font="4">y), with secundum ASD or sinus venous defect including </text>
<text top="763" left="581" width="288" height="20" font="4">10 pts with PAPVC were analyzed. Lung biopsy was </text>
<text top="728" left="906" width="119" height="20" font="4">● Histologic changes </text>
<text top="745" left="906" width="84" height="20" font="4">consistent with </text>
<text top="763" left="906" width="134" height="20" font="4">hypertensive pulmonary </text>
<text top="780" left="906" width="116" height="20" font="4">vascular disease are </text>
</page>
<page number="95" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 95 </text>
<text top="107" left="323" width="118" height="20" font="4">or sinus venous ASD </text>
<text top="124" left="323" width="124" height="20" font="4">along with lung biopsy </text>
<text top="141" left="323" width="118" height="20" font="4">between 1981–1999. </text>
<text top="159" left="323" width="86" height="20" font="4">Pts with ostium </text>
<text top="176" left="323" width="76" height="20" font="4">primum ASD, </text>
<text top="193" left="323" width="125" height="20" font="4">congenital mitral valve </text>
<text top="210" left="323" width="125" height="20" font="4">disease, or other CHD </text>
<text top="228" left="323" width="83" height="20" font="4">were excluded </text>
<text top="107" left="462" width="61" height="20" font="4">pulmonary </text>
<text top="124" left="462" width="98" height="20" font="4">vascular disease  </text>
<text top="107" left="581" width="263" height="20" font="4">performed at the time of defect closure and was </text>
<text top="124" left="581" width="239" height="20" font="4">classified according to Heath and Edwards. </text>
<text top="141" left="581" width="310" height="20" font="4">● Structural changes of the pulmonary vasculature were </text>
<text top="159" left="581" width="299" height="20" font="4">found in 59% of pts; grade 3 and higher changes were </text>
<text top="176" left="581" width="92" height="20" font="4">present in 19%.  </text>
<text top="193" left="581" width="266" height="20" font="4">● There were no statistically significant relations </text>
<text top="210" left="581" width="310" height="20" font="4">between histologic findings and preoperative clinical and </text>
<text top="227" left="581" width="262" height="20" font="4">hemodynamic data, intraoperative findings, and </text>
<text top="245" left="581" width="108" height="20" font="4">operative outcome. </text>
<text top="262" left="581" width="283" height="20" font="4">● The prevalence of moderate (32–50 mm Hg) and </text>
<text top="279" left="581" width="302" height="20" font="4">severe (&gt;50 mm Hg) systolic pulmonary HTN was 27% </text>
<text top="296" left="581" width="131" height="20" font="4">and 17%, respectively.  </text>
<text top="314" left="581" width="292" height="20" font="4">● Increased systolic pulmonary arterial pressure was </text>
<text top="331" left="581" width="300" height="20" font="4">associated with increased PVR (p&lt;0.000) and pts' age </text>
<text top="348" left="581" width="305" height="20" font="4">(p=0.001). Pts with a lower FC had a higher prevalence </text>
<text top="365" left="581" width="163" height="20" font="4">of pulmonary HTN (p=0.011). </text>
<text top="107" left="906" width="144" height="20" font="4">present in 59% of pts with </text>
<text top="124" left="906" width="150" height="20" font="4">secundum or sinus venous </text>
<text top="141" left="906" width="139" height="20" font="4">ASD, advanced changes </text>
<text top="159" left="906" width="110" height="20" font="4">are present in 19%. </text>
<text top="176" left="906" width="145" height="20" font="4">Interestingly, preoperative </text>
<text top="193" left="906" width="148" height="20" font="4">hemodynamic data did not </text>
<text top="210" left="906" width="116" height="20" font="4">predict the degree of </text>
<text top="228" left="906" width="144" height="20" font="4">histologic changes in lung </text>
<text top="245" left="906" width="105" height="20" font="4">biopsy specimens. </text>
<text top="383" left="64" width="63" height="20" font="4">Dusenbery </text>
<text top="400" left="64" width="55" height="20" font="4">SM, et al. </text>
<text top="418" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(336)</a> </text>
<text top="435" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23622914?dopt=Citation">23622914</a></text>
<text top="435" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23622914?dopt=Citation"> </a></text>
<text top="383" left="163" width="76" height="20" font="4">Single-center </text>
<text top="400" left="163" width="38" height="20" font="4">cohort </text>
<text top="383" left="256" width="193" height="20" font="4">n=80 pts  <b>Inclusion criteria</b>: Pts </text>
<text top="400" left="323" width="71" height="20" font="4">with scimitar </text>
<text top="418" left="323" width="114" height="20" font="4">syndrome evaluated </text>
<text top="435" left="323" width="120" height="20" font="4">between 1964―2011 </text>
<text top="383" left="462" width="78" height="20" font="4">Postoperative </text>
<text top="400" left="462" width="87" height="20" font="4">pulmonary vein </text>
<text top="418" left="462" width="97" height="20" font="4">stenosis or death </text>
<text top="383" left="581" width="146" height="20" font="4">● Median follow-up: 4.5 y. </text>
<text top="400" left="581" width="254" height="20" font="4">● Pts &gt;1 y had higher incidence of symptoms, </text>
<text top="418" left="581" width="255" height="20" font="4">aortopulmonary collaterals, CHD, extracardiac </text>
<text top="435" left="581" width="180" height="20" font="4">anomalies, and pulmonary HTN. </text>
<text top="452" left="581" width="252" height="20" font="4">● Of 36 pts with scimitar vein surgery, 18 had </text>
<text top="469" left="581" width="303" height="20" font="4">postoperative pulmonary vein obstruction that occurred </text>
<text top="487" left="581" width="278" height="20" font="4">with similar frequency after baffle or reimplantation </text>
<text top="504" left="581" width="308" height="20" font="4">procedures, early or late in the study period, and tended </text>
<text top="521" left="581" width="222" height="20" font="4">to be more common in infants (p=0.10).  </text>
<text top="538" left="581" width="302" height="20" font="4">● Overall, 19 (24%) of 80 died. Multivariate risk factors </text>
<text top="555" left="581" width="285" height="20" font="4">for death included systolic pulmonary pressure &gt;0.5 </text>
<text top="573" left="581" width="267" height="20" font="4">systemic level (p=0.007) and left pulmonary vein </text>
<text top="590" left="581" width="112" height="20" font="4">stenosis (p=0.009).  </text>
<text top="607" left="581" width="294" height="20" font="4">● PASP &lt;0.5 systemic level (p=0.01) and absence of </text>
<text top="624" left="581" width="303" height="20" font="4">CHD excluding ASD (p=0.01) were predictive factors in </text>
<text top="641" left="581" width="278" height="20" font="4">28 pts who survived and did not have scimitar vein </text>
<text top="659" left="581" width="307" height="20" font="4">surgery; these pts had no or mild RV dilation and a ratio </text>
<text top="676" left="581" width="294" height="20" font="4">of pulmonary-to-systemic flow &lt;1.6 either at baseline, </text>
<text top="693" left="581" width="295" height="20" font="4">after coiling aortopulmonary collaterals or nonscimitar </text>
<text top="710" left="581" width="96" height="20" font="4">vein intervention. </text>
<text top="383" left="906" width="152" height="20" font="4">● Postoperative pulmonary </text>
<text top="400" left="906" width="152" height="20" font="4">vein obstruction is common </text>
<text top="418" left="906" width="144" height="20" font="4">after scimitar vein surgery </text>
<text top="435" left="906" width="135" height="20" font="4">regardless of redirection </text>
<text top="452" left="906" width="151" height="20" font="4">technique. Pulmonary HTN </text>
<text top="469" left="906" width="131" height="20" font="4">and left pulmonary vein </text>
<text top="487" left="906" width="150" height="20" font="4">stenosis are risk factors for </text>
<text top="504" left="906" width="153" height="20" font="4">death; whereas, pts without </text>
<text top="521" left="906" width="147" height="20" font="4">significant pulmonary HTN </text>
<text top="538" left="906" width="151" height="20" font="4">or associated CHD did well </text>
<text top="555" left="906" width="114" height="20" font="4">without scimitar vein </text>
<text top="573" left="906" width="51" height="20" font="4">surgery.  </text>
<text top="728" left="64" width="75" height="20" font="4">Haramati LB, </text>
<text top="745" left="64" width="30" height="20" font="4">et al. </text>
<text top="763" left="64" width="66" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(316)</a>  </text>
<text top="780" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/14501365">14501365</a></text>
<text top="780" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/14501365"> </a></text>
<text top="728" left="163" width="78" height="20" font="4">Retrospective </text>
<text top="745" left="163" width="38" height="20" font="4">cohort </text>
<text top="728" left="256" width="193" height="20" font="4">n=29 pts  <b>Inclusion criteria</b>: Pts </text>
<text top="745" left="323" width="111" height="20" font="4">with CT evidence of </text>
<text top="763" left="323" width="45" height="20" font="4">PAPVC </text>
<text top="728" left="462" width="72" height="20" font="4">Describe the </text>
<text top="745" left="462" width="62" height="20" font="4">features of </text>
<text top="763" left="462" width="64" height="20" font="4">anomalous </text>
<text top="728" left="581" width="302" height="20" font="4">● 79% (23 of 29 pts) had an anomalous left upper lobe </text>
<text top="745" left="581" width="265" height="20" font="4">vein connecting to a persistent left vertical vein,  </text>
<text top="763" left="581" width="303" height="20" font="4">● 17% (5 of 29 pts) had an anomalous right upper lobe </text>
<text top="780" left="581" width="294" height="20" font="4">vein draining into the superior vena cava, 60% (3 of 5 </text>
<text top="728" left="906" width="113" height="20" font="4">● CTA identifies the </text>
<text top="745" left="906" width="111" height="20" font="4">course and types of </text>
<text top="763" left="906" width="124" height="20" font="4">anomalous pulmonary </text>
<text top="780" left="906" width="36" height="20" font="4">veins. </text>
</page>
<page number="96" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 96 </text>
<text top="107" left="462" width="93" height="20" font="4">pulmonary veins </text>
<text top="124" left="462" width="83" height="20" font="4">as seen by CT </text>
<text top="107" left="581" width="310" height="20" font="4">pts) of whom also had a right upper lobe pulmonary vein </text>
<text top="124" left="581" width="298" height="20" font="4">in the normal location. One pt (3%) had an anomalous </text>
<text top="141" left="581" width="278" height="20" font="4">right lower lobe vein draining into the suprahepatic </text>
<text top="159" left="581" width="107" height="20" font="4">inferior vena cava.  </text>
<text top="176" left="581" width="270" height="20" font="4">● Chest radiographic findings were abnormal left </text>
<text top="193" left="581" width="285" height="20" font="4">mediastinal contour in 64% (15 of 25 pts), abnormal </text>
<text top="210" left="581" width="268" height="20" font="4">right mediastinal contour in 8% (2 of 25 pts), and </text>
<text top="227" left="581" width="194" height="20" font="4">cardiomegaly in 24% (6 of 25 pts).  </text>
<text top="245" left="581" width="306" height="20" font="4">● Computed tomography findings were cardiomegaly in </text>
<text top="262" left="581" width="306" height="20" font="4">48% (14 of 29 pts), right atrial enlargement in 31% (9 of </text>
<text top="279" left="581" width="290" height="20" font="4">29 pts), right ventricular enlargement in 31% (9 of 29 </text>
<text top="296" left="581" width="305" height="20" font="4">pts), and pulmonary artery enlargement in 14% (4 of 29 </text>
<text top="314" left="581" width="31" height="20" font="4">pts).  </text>
<text top="331" left="581" width="306" height="20" font="4">● Pulmonary or cardiovascular symptoms were present </text>
<text top="348" left="581" width="298" height="20" font="4">in 69% (20 of 29 pts), 55% (11 of 20 pts) of whom had </text>
<text top="365" left="581" width="286" height="20" font="4">specific alternative diagnoses (excluding congestive </text>
<text top="382" left="581" width="308" height="20" font="4">heart failure and pulmonary hypertension) to explain the </text>
<text top="400" left="581" width="266" height="20" font="4">symptoms. Only 1 pt (3%) was diagnosed with a </text>
<text top="417" left="581" width="167" height="20" font="4">secundum atrial septal defect. </text>
<text top="107" left="906" width="129" height="20" font="4">● Right-sided chamber </text>
<text top="124" left="906" width="138" height="20" font="4">enlargement is common. </text>
<text top="435" left="108" width="3" height="20" font="4"> </text>
<text top="452" left="108" width="3" height="20" font="4"> </text>
<text top="469" left="108" width="435" height="24" font="1"><b>Data Supplement 28. Ventricular Septal Defect – Section 4.1.3 </b></text>
<text top="491" left="73" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="508" left="73" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="491" left="184" width="38" height="20" font="3"><b>Study </b></text>
<text top="508" left="188" width="28" height="20" font="3"><b>Size </b></text>
<text top="491" left="283" width="82" height="20" font="3"><b>Study Design </b></text>
<text top="491" left="430" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="508" left="466" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="491" left="612" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="491" left="827" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="491" left="1042" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="526" left="64" width="89" height="20" font="4">Corone P, et al. </text>
<text top="543" left="64" width="66" height="20" font="4">1977 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(337)</a>  </text>
<text top="560" left="64" width="41" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/858186?dopt=Citation">858186</a></text>
<text top="560" left="105" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/858186?dopt=Citation"> </a></text>
<text top="526" left="172" width="188" height="20" font="4">n=790 pts   Single-center cohort </text>
<text top="526" left="415" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="543" left="415" width="130" height="20" font="4">with VSD cared for at a </text>
<text top="560" left="415" width="91" height="20" font="4">single institution </text>
<text top="526" left="577" width="100" height="20" font="4">Long-term clinical </text>
<text top="543" left="577" width="115" height="20" font="4">outcomes of pts with </text>
<text top="560" left="577" width="84" height="20" font="4">untreated VSD </text>
<text top="526" left="732" width="261" height="20" font="4">● The mean observation interval is 6 y, and the </text>
<text top="543" left="732" width="274" height="20" font="4">average age at the latest data is 19.5 y; this study </text>
<text top="560" left="732" width="101" height="20" font="4">covers 4,717 pt y. </text>
<text top="577" left="732" width="268" height="20" font="4">● For the entire population, the incidence rate or </text>
<text top="595" left="732" width="260" height="20" font="4">aortic regurgitation is 6.3% (4.3 for 1,000 pt y).  </text>
<text top="612" left="732" width="275" height="20" font="4">● The bacterial IE rate is 3.7% (2.4 for 1000 pt y). </text>
<text top="629" left="732" width="286" height="20" font="4">● 25 pts died, 15 of them between the ages of 1–39 </text>
<text top="646" left="732" width="13" height="20" font="4">y. </text>
<text top="663" left="732" width="217" height="20" font="4">● Of the 499 cases with several clinical </text>
<text top="681" left="732" width="202" height="20" font="4">examinations, 71% remained stable. </text>
<text top="698" left="732" width="289" height="20" font="4">● In 21%, changes suggesting some level of closure </text>
<text top="715" left="732" width="268" height="20" font="4">developed; in 7%, infundibular stenosis began to </text>
<text top="732" left="732" width="291" height="20" font="4">evolve and in 1% pulmonary vascular disease began </text>
<text top="749" left="732" width="191" height="20" font="4">to appear or became accentuated  </text>
<text top="526" left="1036" width="109" height="20" font="4">● Natural history of </text>
<text top="543" left="1036" width="94" height="20" font="4">unrepaired VSD. </text>
</page>
<page number="97" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 97 </text>
<text top="107" left="64" width="91" height="20" font="4">Yoshimura N, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(338)</a> </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21031514?dopt=Citation">21031514</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21031514?dopt=Citation"> </a></text>
<text top="107" left="172" width="51" height="20" font="4">n=23 pts </text>
<text top="107" left="246" width="114" height="20" font="4">Single-center cohort </text>
<text top="107" left="415" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="124" left="415" width="136" height="20" font="4">with suspected coronary </text>
<text top="141" left="415" width="138" height="20" font="4">cusp prolapse in pts with </text>
<text top="159" left="415" width="29" height="20" font="4">VSD </text>
<text top="107" left="577" width="126" height="20" font="4">Concordance between </text>
<text top="124" left="577" width="93" height="20" font="4">echo and MRI in </text>
<text top="141" left="577" width="55" height="20" font="4">diagnosis </text>
<text top="107" left="732" width="237" height="20" font="4">● 19 pts with right coronary cusp prolapse. </text>
<text top="124" left="732" width="97" height="20" font="4">● Mean age 9 y.  </text>
<text top="141" left="732" width="266" height="20" font="4">● 17 pts with outlet defects, 6 with membranous </text>
<text top="159" left="732" width="46" height="20" font="4">defects. </text>
<text top="107" left="1036" width="122" height="20" font="4">● MRI correlated with </text>
<text top="124" left="1036" width="131" height="20" font="4">echo for outlet VSD but </text>
<text top="141" left="1036" width="127" height="20" font="4">less so for other types. </text>
<text top="177" left="64" width="83" height="20" font="4">D’Alto M, et al. </text>
<text top="194" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(339)</a> </text>
<text top="211" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23850317?dopt=Citation">23850317</a></text>
<text top="211" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23850317?dopt=Citation"> </a></text>
<text top="177" left="172" width="51" height="20" font="4">n=22 pts </text>
<text top="177" left="246" width="137" height="20" font="4">Single-center open-label </text>
<text top="194" left="246" width="38" height="20" font="4">cohort </text>
<text top="177" left="415" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="194" left="415" width="126" height="20" font="4">Presence of PAH after </text>
<text top="211" left="415" width="121" height="20" font="4">closure of ASD, VSD, </text>
<text top="228" left="415" width="147" height="20" font="4">PDA, AVSD, with pre- and </text>
<text top="246" left="415" width="66" height="20" font="4">postclosure </text>
<text top="263" left="415" width="86" height="20" font="4">hemodynamics </text>
<text top="177" left="577" width="86" height="20" font="4">Demographics, </text>
<text top="194" left="577" width="86" height="20" font="4">hemodynamics </text>
<text top="211" left="577" width="141" height="20" font="4">(catheterization) pre- and </text>
<text top="228" left="577" width="107" height="20" font="4">post-defect closure </text>
<text top="177" left="732" width="283" height="20" font="4">● Mean age at closure 25.3 ± 20.1 y (3 mo–56.7 y) </text>
<text top="194" left="732" width="277" height="20" font="4">Mean age at PAH diagnosis 37.0 ± 20.8 y (5–61.2 </text>
<text top="211" left="732" width="21" height="20" font="4">y).  </text>
<text top="228" left="732" width="279" height="20" font="4">● At preclosure catheterization 18/22 subjects had </text>
<text top="245" left="732" width="234" height="20" font="4">PVR ≥5 U, 21/22 had PVR index ≥6 U × m</text>
<text top="247" left="966" width="4" height="13" font="6">2</text>
<text top="245" left="971" width="41" height="20" font="4">, 21/22 </text>
<text top="263" left="732" width="77" height="20" font="4">Rp/Rs ≥0.33. </text>
<text top="177" left="1036" width="146" height="20" font="4">● Preclosure PVR (≥5 U), </text>
<text top="194" left="1036" width="117" height="20" font="4">PVR index (≥6 U × m</text>
<text top="196" left="1153" width="4" height="13" font="6">2</text>
<text top="194" left="1158" width="7" height="20" font="4">) </text>
<text top="211" left="1036" width="97" height="20" font="4">and Rp/Rs ≥0.33 </text>
<text top="228" left="1036" width="146" height="20" font="4">appeared to correlate with </text>
<text top="246" left="1036" width="113" height="20" font="4">PAH late after shunt </text>
<text top="263" left="1036" width="46" height="20" font="4">closure. </text>
<text top="281" left="64" width="95" height="20" font="4">Janjua AM, et al. </text>
<text top="298" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(340)</a> </text>
<text top="315" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21453613?dopt=Citation">21453613</a></text>
<text top="315" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21453613?dopt=Citation"> </a></text>
<text top="281" left="172" width="51" height="20" font="4">n=40 pts </text>
<text top="281" left="246" width="40" height="20" font="4">Cohort </text>
<text top="281" left="415" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="298" left="415" width="128" height="20" font="4">with VSD and elevated </text>
<text top="315" left="415" width="141" height="20" font="4">PVR treated with surgical </text>
<text top="332" left="415" width="109" height="20" font="4">double patch repair </text>
<text top="281" left="577" width="50" height="20" font="4">Mortality </text>
<text top="281" left="732" width="94" height="20" font="4">● Mean age 7 y. </text>
<text top="298" left="732" width="267" height="20" font="4">● PVR 9.6 WU, double patch technique allowing </text>
<text top="315" left="732" width="282" height="20" font="4">“fenestrated” closure of VSD. Modified ultrafiltration </text>
<text top="332" left="732" width="162" height="20" font="4">and sildenafil used for all pts. </text>
<text top="281" left="1036" width="125" height="20" font="4">● Only 1 death (2.5%) </text>
<text top="298" left="1036" width="143" height="20" font="4">with patch that essentially </text>
<text top="315" left="1036" width="147" height="20" font="4">allows continued, but less, </text>
<text top="332" left="1036" width="129" height="20" font="4">right-to-left shunt in pts </text>
<text top="350" left="1036" width="107" height="20" font="4">with elevated PVR. </text>
<text top="368" left="64" width="85" height="20" font="4">Talwar S, et al. </text>
<text top="385" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(341)</a> </text>
<text top="402" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24332111?dopt=Citation">24332111</a></text>
<text top="402" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24332111?dopt=Citation"> </a></text>
<text top="368" left="172" width="51" height="20" font="4">n=13 pts </text>
<text top="368" left="246" width="114" height="20" font="4">Single-center cohort </text>
<text top="368" left="415" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="385" left="415" width="128" height="20" font="4">with VSD and elevated </text>
<text top="402" left="415" width="94" height="20" font="4">PVR undergoing </text>
<text top="419" left="415" width="148" height="20" font="4">unidirectional patch repair  </text>
<text top="368" left="577" width="103" height="20" font="4">Mortality/morbidity </text>
<text top="368" left="732" width="193" height="20" font="4">● Mean follow-up 34.7 ± 18.6 mo.  </text>
<text top="385" left="732" width="246" height="20" font="4">● VSD with PAH &gt;8 WU, mean preoperative </text>
<text top="402" left="732" width="282" height="20" font="4">systemic saturation 94.1% ± 3.4%, mean age of 20 </text>
<text top="419" left="732" width="280" height="20" font="4">pts, 13 agreed to postoperative catheterization and </text>
<text top="436" left="732" width="86" height="20" font="4">were included.  </text>
<text top="454" left="732" width="108" height="20" font="4">● Mean age 8.5 y.  </text>
<text top="471" left="732" width="290" height="20" font="4">● At follow-up catheterization, mean saturation 98%, </text>
<text top="488" left="732" width="281" height="20" font="4">PVR 5.8 WU, no severe PAH, all NYHA Class I, no </text>
<text top="505" left="732" width="44" height="20" font="4">deaths. </text>
<text top="368" left="1036" width="146" height="20" font="4">● “Fenestrated” closure of </text>
<text top="385" left="1036" width="111" height="20" font="4">VSD in severe PAH </text>
<text top="402" left="1036" width="53" height="20" font="4">improves </text>
<text top="419" left="1036" width="145" height="20" font="4">symptoms/hemodynamics </text>
<text top="436" left="1036" width="100" height="20" font="4">without significant </text>
<text top="454" left="1036" width="53" height="20" font="4">mortality. </text>
<text top="523" left="64" width="94" height="20" font="4">Kouchoukos NT, </text>
<text top="540" left="64" width="30" height="20" font="4">et al. </text>
<text top="558" left="64" width="63" height="20" font="4">1978 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(329)</a> </text>
<text top="575" left="64" width="41" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/619518?dopt=Citation">619518</a></text>
<text top="575" left="105" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/619518?dopt=Citation"> </a></text>
<text top="523" left="172" width="44" height="20" font="4">Review </text>
<text top="523" left="246" width="24" height="20" font="4">N/A </text>
<text top="523" left="415" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="540" left="415" width="126" height="20" font="4">with large VSD prior to </text>
<text top="558" left="415" width="89" height="20" font="4">surgical closure </text>
<text top="523" left="577" width="53" height="20" font="4">Mortality  </text>
<text top="523" left="732" width="270" height="20" font="4">● Mortality related to age at operations (older did </text>
<text top="540" left="732" width="182" height="20" font="4">worse) and to preoperative PVR. </text>
<text top="523" left="1036" width="92" height="20" font="4">● Prepulmonary </text>
<text top="540" left="1036" width="130" height="20" font="4">vasodilator era. Careful </text>
<text top="558" left="1036" width="140" height="20" font="4">consideration of mortality </text>
<text top="575" left="1036" width="129" height="20" font="4">and late effects prior to </text>
<text top="592" left="1036" width="123" height="20" font="4">considering closure of </text>
<text top="609" left="1036" width="63" height="20" font="4">large VSD. </text>
<text top="627" left="64" width="94" height="20" font="4">Shohtsu A, et al. </text>
<text top="644" left="64" width="66" height="20" font="4">1976 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(330)</a>  </text>
<text top="662" left="64" width="41" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/950729?dopt=Citation">950729</a></text>
<text top="662" left="105" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/950729?dopt=Citation"> </a></text>
<text top="627" left="172" width="56" height="20" font="4">Retrospec</text>
<text top="644" left="172" width="22" height="20" font="4">tive </text>
<text top="627" left="246" width="51" height="20" font="4">n=64 pts </text>
<text top="627" left="415" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="644" left="415" width="138" height="20" font="4">with large VSD, PH; also </text>
<text top="662" left="415" width="131" height="20" font="4">small number with PDA </text>
<text top="679" left="415" width="53" height="20" font="4">and ASD </text>
<text top="627" left="577" width="50" height="20" font="4">Mortality </text>
<text top="627" left="732" width="290" height="20" font="4">● Optimal timing of closure is 1-3 y for VSD with PH; </text>
<text top="644" left="732" width="135" height="20" font="4">PDA and ASD not clear. </text>
<text top="627" left="1036" width="139" height="20" font="4">● Closure of large septal </text>
<text top="644" left="1036" width="145" height="20" font="4">defects with PH should be </text>
<text top="662" left="1036" width="140" height="20" font="4">considered only at young </text>
<text top="679" left="1036" width="144" height="20" font="4">ages to improve mortality. </text>
<text top="697" left="64" width="82" height="20" font="4">Nishimura RA, </text>
<text top="714" left="64" width="30" height="20" font="4">et al. </text>
<text top="731" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(342)</a> </text>
<text top="748" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24603191?dopt=Citation">24603191</a></text>
<text top="748" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24603191?dopt=Citation"> </a></text>
<text top="697" left="172" width="58" height="20" font="4">ACC/AHA </text>
<text top="714" left="172" width="53" height="20" font="4">guideline </text>
<text top="697" left="246" width="24" height="20" font="4">N/A </text>
<text top="697" left="415" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="697" left="577" width="24" height="20" font="4">N/A </text>
<text top="697" left="732" width="24" height="20" font="4">N/A </text>
<text top="697" left="1036" width="24" height="20" font="4">N/A </text>
<text top="766" left="108" width="3" height="20" font="4"> </text>
<text top="784" left="108" width="3" height="20" font="4"> </text>
</page>
<page number="98" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 98 </text>
<text top="106" left="108" width="468" height="24" font="1"><b>Data Supplement 29. Atrioventricular Septal Defect – Section 4.1.4 </b></text>
<text top="128" left="92" width="38" height="20" font="3"><b>Study </b></text>
<text top="145" left="67" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="162" left="96" width="30" height="20" font="3"><b>Year </b></text>
<text top="128" left="173" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="145" left="188" width="44" height="20" font="3"><b>Design </b></text>
<text top="128" left="267" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="128" left="362" width="165" height="20" font="3"><b>Inclusion/Exclusion Criteria </b></text>
<text top="128" left="564" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="128" left="716" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="128" left="944" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="180" left="64" width="88" height="20" font="4">Hoohenkirk GJ, </text>
<text top="197" left="64" width="30" height="20" font="4">et al. </text>
<text top="215" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(343)</a> </text>
<text top="232" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19660422?dopt=Citation">19660422</a></text>
<text top="232" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19660422?dopt=Citation"> </a></text>
<text top="180" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="197" left="170" width="39" height="20" font="4">review </text>
<text top="180" left="263" width="54" height="20" font="4">n=21 pts; </text>
<text top="197" left="263" width="73" height="20" font="4">follow-up out </text>
<text top="215" left="263" width="40" height="20" font="4">to 25 y </text>
<text top="180" left="349" width="188" height="20" font="3"><b>Inclusion criteria</b>: Surgical repair </text>
<text top="197" left="349" width="178" height="20" font="4">of AVSD with dual orifice left AV </text>
<text top="215" left="349" width="185" height="20" font="4">valve. Surgeries done from 1975–</text>
<text top="232" left="349" width="31" height="20" font="4">2006 </text>
<text top="233" left="380" width="2" height="13" font="6"> </text>
<text top="180" left="553" width="59" height="20" font="4">Outcomes </text>
<text top="197" left="553" width="72" height="20" font="4">compared to </text>
<text top="215" left="553" width="62" height="20" font="4">291 typical </text>
<text top="232" left="553" width="37" height="20" font="4">AVSD </text>
<text top="180" left="661" width="196" height="20" font="4">● 3 late deaths, 12 reoperation in 7 </text>
<text top="197" left="661" width="150" height="20" font="4">pts, most for regurgitation.  </text>
<text top="215" left="661" width="192" height="20" font="4">● No association with mortality but </text>
<text top="232" left="661" width="179" height="20" font="4">was a risk factor for reoperation. </text>
<text top="180" left="886" width="246" height="20" font="4">● AVSD with double orifice left AV valve can </text>
<text top="197" left="886" width="185" height="20" font="4">be repaired safely but is a risk for </text>
<text top="215" left="886" width="69" height="20" font="4">reoperation. </text>
<text top="250" left="64" width="83" height="20" font="4">Majdalany DS, </text>
<text top="267" left="64" width="30" height="20" font="4">et al. </text>
<text top="284" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(158)</a> </text>
<text top="301" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20136856?dopt=Citation">20136856</a></text>
<text top="301" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20136856?dopt=Citation"> </a></text>
<text top="250" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="267" left="170" width="39" height="20" font="4">review </text>
<text top="250" left="263" width="51" height="20" font="4">n=50 pts </text>
<text top="267" left="263" width="41" height="20" font="4">and 57 </text>
<text top="284" left="263" width="61" height="20" font="4">operations </text>
<text top="301" left="263" width="58" height="20" font="4">(17 partial </text>
<text top="319" left="263" width="61" height="20" font="4">AVSD): 15 </text>
<text top="336" left="263" width="24" height="20" font="4">had </text>
<text top="353" left="263" width="56" height="20" font="4">childhood </text>
<text top="370" left="263" width="58" height="20" font="4">surgery, 9 </text>
<text top="387" left="263" width="67" height="20" font="4">were AVSD </text>
<text top="405" left="263" width="51" height="20" font="4">or partial </text>
<text top="422" left="263" width="51" height="20" font="4">AVSD or </text>
<text top="439" left="263" width="65" height="20" font="4">TOF/AVSD </text>
<text top="250" left="349" width="140" height="20" font="3"><b>Inclusion criteria</b>: Down </text>
<text top="267" left="349" width="180" height="20" font="4">syndrome with CHD and cardiac </text>
<text top="284" left="349" width="79" height="20" font="4">surgery ≥18 y </text>
<text top="250" left="553" width="70" height="20" font="4">Survival 2 y: </text>
<text top="267" left="553" width="92" height="20" font="4">ventilator d/LOS </text>
<text top="284" left="553" width="74" height="20" font="4">/arrhythmias/ </text>
<text top="301" left="553" width="61" height="20" font="4">pulmonary </text>
<text top="319" left="553" width="49" height="20" font="4">infection </text>
<text top="250" left="661" width="193" height="20" font="4">● 1 in hospital death; 8 late deaths </text>
<text top="267" left="661" width="205" height="20" font="4">(average 15 y later); vent support 2.4 </text>
<text top="284" left="661" width="198" height="20" font="4">d; hospital stay 10.6 d; 6 pulmonary </text>
<text top="301" left="661" width="53" height="20" font="4">infection. </text>
<text top="250" left="886" width="237" height="20" font="4">● Surgery can be considered in adults with </text>
<text top="267" left="886" width="238" height="20" font="4">Down syndrome with fairly good outcomes. </text>
<text top="457" left="64" width="82" height="20" font="4">Liberman L, et </text>
<text top="474" left="64" width="16" height="20" font="4">al. </text>
<text top="491" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(344)</a> </text>
<text top="509" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17768649?dopt=Citation">17768649</a></text>
<text top="509" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17768649?dopt=Citation"> </a></text>
<text top="457" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="474" left="170" width="54" height="20" font="4">database </text>
<text top="491" left="170" width="39" height="20" font="4">review </text>
<text top="457" left="263" width="51" height="20" font="4">n=15 pts </text>
<text top="474" left="263" width="51" height="20" font="4">with new </text>
<text top="491" left="263" width="49" height="20" font="4">need for </text>
<text top="509" left="263" width="64" height="20" font="4">pacemaker </text>
<text top="526" left="263" width="65" height="20" font="4">1998–2006 </text>
<text top="543" left="263" width="28" height="20" font="4">after </text>
<text top="560" left="263" width="57" height="20" font="4">discharge </text>
<text top="577" left="263" width="28" height="20" font="4">from </text>
<text top="595" left="263" width="71" height="20" font="4">hospital with </text>
<text top="612" left="263" width="41" height="20" font="4">normal </text>
<text top="629" left="263" width="63" height="20" font="4">conduction </text>
<text top="457" left="349" width="133" height="20" font="3"><b>Inclusion criteria</b>: New </text>
<text top="474" left="349" width="171" height="20" font="4">pacemaker and history of CHD </text>
<text top="491" left="349" width="160" height="20" font="4">surgery and discharged from </text>
<text top="509" left="349" width="175" height="20" font="4">hospital with normal conduction </text>
<text top="457" left="553" width="89" height="20" font="4">CHD diagnosis, </text>
<text top="474" left="553" width="82" height="20" font="4">y from surgery </text>
<text top="491" left="553" width="51" height="20" font="4">to pacer; </text>
<text top="509" left="553" width="59" height="20" font="4">symptoms </text>
<text top="526" left="553" width="71" height="20" font="4">presentation </text>
<text top="457" left="661" width="203" height="20" font="4">● 15 cases: 9 VSD, 4 AVSD, 2 other </text>
<text top="474" left="661" width="190" height="20" font="4">● Last ECG was average 5 y after </text>
<text top="491" left="661" width="172" height="20" font="4">surgery; average time between </text>
<text top="509" left="661" width="204" height="20" font="4">surgery/pacemaker 6.8 y (2 mo to 19 </text>
<text top="526" left="661" width="178" height="20" font="4">y; 7 pts were more than 6 y post </text>
<text top="543" left="661" width="62" height="20" font="4">operation). </text>
<text top="457" left="886" width="229" height="20" font="4">● Unending need to monitor for complete </text>
<text top="474" left="886" width="67" height="20" font="4">heart block. </text>
<text top="647" left="64" width="93" height="20" font="4">Agarwal V, et al. </text>
<text top="664" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(345)</a> </text>
<text top="681" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19258062?dopt=Citation">19258062</a></text>
<text top="681" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19258062?dopt=Citation"> </a></text>
<text top="647" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="664" left="170" width="77" height="20" font="4">record review </text>
<text top="647" left="263" width="51" height="20" font="4">n=51 pts </text>
<text top="647" left="349" width="165" height="20" font="3"><b>Inclusion criteria</b>: ≥18 y with </text>
<text top="664" left="349" width="108" height="20" font="4">primum ASD repair </text>
<text top="647" left="553" width="66" height="20" font="4">Mitral valve </text>
<text top="664" left="553" width="85" height="20" font="4">function (mean </text>
<text top="681" left="553" width="70" height="20" font="4">follow-up 36 </text>
<text top="699" left="553" width="86" height="20" font="4">mo); mean age </text>
<text top="716" left="553" width="85" height="20" font="4">at surgery 27 y </text>
<text top="647" left="661" width="184" height="20" font="4">● Pre: 80% NYHA class I/II; 88% </text>
<text top="664" left="661" width="204" height="20" font="4">cleft; 35% moderate MR; 4% severe; </text>
<text top="681" left="661" width="172" height="20" font="4">27% moderate PH, 8% severe. </text>
<text top="699" left="661" width="200" height="20" font="4">● Post: 1.9% in hospital death; 94% </text>
<text top="716" left="661" width="206" height="20" font="4">NYHA class I; 21% moderate MR/8% </text>
<text top="733" left="661" width="120" height="20" font="4">severe preoperation.  </text>
<text top="647" left="886" width="231" height="20" font="4">● Surgical repair of primum ASD in adults </text>
<text top="664" left="886" width="232" height="20" font="4">can be performed successfully. Continued </text>
<text top="681" left="886" width="229" height="20" font="4">monitoring for residual or progressive MR </text>
<text top="699" left="886" width="237" height="20" font="4">especially in females or pts with pulmonary </text>
<text top="716" left="886" width="35" height="20" font="4">HTN.  </text>
<text top="751" left="64" width="88" height="20" font="4">Malhotra SP, et </text>
<text top="768" left="64" width="16" height="20" font="4">al. </text>
<text top="751" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="768" left="170" width="39" height="20" font="4">review </text>
<text top="751" left="263" width="66" height="20" font="4">n= 31 pt for </text>
<text top="768" left="263" width="72" height="20" font="4">left AV valve </text>
<text top="785" left="263" width="66" height="20" font="4">reoperation </text>
<text top="751" left="349" width="159" height="20" font="3"><b>Inclusion criteria</b>: All young </text>
<text top="768" left="349" width="46" height="20" font="4">children </text>
<text top="751" left="553" width="50" height="20" font="4">Survival, </text>
<text top="768" left="553" width="77" height="20" font="4">freedom from </text>
<text top="785" left="553" width="78" height="20" font="4">reintervention </text>
<text top="751" left="661" width="123" height="20" font="4">● 10-y survival: 88%.  </text>
<text top="768" left="661" width="208" height="20" font="4">● Freedom reintervention 10 y: 67%.  </text>
<text top="751" left="886" width="248" height="20" font="4">● Left AV valve repair can be performed with </text>
<text top="768" left="886" width="252" height="20" font="4">good short- and mid-term results but had high </text>
<text top="785" left="886" width="157" height="20" font="4">need for further reoperation. </text>
</page>
<page number="99" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1037" width="46" height="17" font="0">Page 99 </text>
<text top="107" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(346)</a> </text>
<text top="124" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18573414?dopt=Citation">18573414</a></text>
<text top="124" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18573414?dopt=Citation"> </a></text>
<text top="107" left="263" width="44" height="20" font="4">(AVSD, </text>
<text top="124" left="263" width="49" height="20" font="4">primum) </text>
<text top="107" left="661" width="187" height="20" font="4">● 23 repair/8 replace; patch more </text>
<text top="124" left="661" width="152" height="20" font="4">durable repair than 1° cleft. </text>
<text top="142" left="64" width="90" height="20" font="4">Bianchi G, et al. </text>
<text top="159" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(347)</a> </text>
<text top="177" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21398648?dopt=Citation">21398648</a></text>
<text top="177" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21398648?dopt=Citation"> </a></text>
<text top="142" left="170" width="149" height="20" font="4">Meta-analysis  8 articles. </text>
<text top="159" left="263" width="59" height="20" font="4">Repair vs. </text>
<text top="177" left="263" width="71" height="20" font="4">replacement </text>
<text top="194" left="263" width="53" height="20" font="4">of left AV </text>
<text top="211" left="263" width="32" height="20" font="4">valve </text>
<text top="142" left="349" width="159" height="20" font="3"><b>Inclusion criteria</b>: All adults </text>
<text top="142" left="553" width="71" height="20" font="4">Survival and </text>
<text top="159" left="553" width="56" height="20" font="4">additional </text>
<text top="177" left="553" width="77" height="20" font="4">interventions  </text>
<text top="142" left="661" width="184" height="20" font="4">● 109 papers initially identified; 8 </text>
<text top="159" left="661" width="191" height="20" font="4">used for meta-analysis. Most were </text>
<text top="177" left="661" width="109" height="20" font="4">small series of pts.  </text>
<text top="194" left="661" width="200" height="20" font="4">● In general, repair is first choice as </text>
<text top="211" left="661" width="134" height="20" font="4">replacements with more </text>
<text top="228" left="661" width="88" height="20" font="4">complications.   </text>
<text top="245" left="661" width="197" height="20" font="4">● May differ in pts with complex left </text>
<text top="263" left="661" width="191" height="20" font="4">AV valve and LV outflow anatomy. </text>
<text top="142" left="886" width="198" height="20" font="4">● Repair is generally first choice for </text>
<text top="159" left="886" width="219" height="20" font="4">reoperation on left AV valve when other </text>
<text top="177" left="886" width="173" height="20" font="4">abnormalities are not present.   </text>
<text top="194" left="886" width="242" height="20" font="4">● Replacement had higher rate of complete </text>
<text top="211" left="886" width="207" height="20" font="4">heart block and need for pacemaker.  </text>
<text top="281" left="64" width="92" height="20" font="4">Hoohenkerk GJ, </text>
<text top="298" left="64" width="30" height="20" font="4">et al. </text>
<text top="315" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(348)</a> </text>
<text top="332" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22265201?dopt=Citation">22265201</a></text>
<text top="332" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22265201?dopt=Citation"> </a></text>
<text top="281" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="298" left="170" width="39" height="20" font="4">review </text>
<text top="281" left="263" width="54" height="20" font="4">n=45 pts  </text>
<text top="281" left="349" width="178" height="20" font="3"><b>Inclusion criteria</b>: Children and </text>
<text top="298" left="349" width="159" height="20" font="4">adults reoperated after initial </text>
<text top="315" left="349" width="85" height="20" font="4">repair of AVSD </text>
<text top="281" left="553" width="73" height="20" font="4">Survival; risk </text>
<text top="298" left="553" width="58" height="20" font="4">factors for </text>
<text top="315" left="553" width="78" height="20" font="4">reintervention </text>
<text top="281" left="661" width="154" height="20" font="4">● 88% survival at 15 y after </text>
<text top="298" left="661" width="206" height="20" font="4">reoperation; 31 repair, 14 replace; 10 </text>
<text top="315" left="661" width="180" height="20" font="4">pts with repair needed additional </text>
<text top="332" left="661" width="73" height="20" font="4">reoperation.  </text>
<text top="281" left="886" width="224" height="20" font="4">● Left AV valve repair can be completed </text>
<text top="298" left="886" width="252" height="20" font="4">successfully but there is a reasonable chance </text>
<text top="315" left="886" width="168" height="20" font="4">of requiring another operation. </text>
<text top="350" left="64" width="91" height="20" font="4">Stulak JM, et al. </text>
<text top="368" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(349)</a> </text>
<text top="385" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23804729?dopt=Citation">23804729</a></text>
<text top="385" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23804729?dopt=Citation"> </a></text>
<text top="350" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="368" left="170" width="39" height="20" font="4">review </text>
<text top="350" left="263" width="58" height="20" font="4">n=146 pts </text>
<text top="368" left="263" width="65" height="20" font="4">(partial and </text>
<text top="385" left="263" width="53" height="20" font="4">complete </text>
<text top="402" left="263" width="41" height="20" font="4">AVSD) </text>
<text top="350" left="349" width="178" height="20" font="3"><b>Inclusion criteria</b>: Children and </text>
<text top="368" left="349" width="159" height="20" font="4">adults reoperated after initial </text>
<text top="385" left="349" width="85" height="20" font="4">repair of AVSD </text>
<text top="350" left="553" width="50" height="20" font="4">Survival, </text>
<text top="368" left="553" width="66" height="20" font="4">reoperation </text>
<text top="350" left="661" width="195" height="20" font="4">● Mostly left AV valve regurgitation </text>
<text top="368" left="661" width="71" height="20" font="4">and sub-AS. </text>
<text top="385" left="661" width="199" height="20" font="4">● Freedom from reoperation at 10 y </text>
<text top="402" left="661" width="165" height="20" font="4">from initial repair was 48% for </text>
<text top="419" left="661" width="167" height="20" font="4">complete and 84% for partial.  </text>
<text top="350" left="886" width="230" height="20" font="4">● Reoperation is common after childhood </text>
<text top="368" left="886" width="247" height="20" font="4">AVSD repair and can involve left AV valve or </text>
<text top="385" left="886" width="64" height="20" font="4">LV outflow. </text>
<text top="437" left="64" width="93" height="20" font="4">Digilio MC, et al. </text>
<text top="454" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(350)</a> </text>
<text top="472" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22781091?dopt=Citation">22781091</a></text>
<text top="472" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22781091?dopt=Citation"> </a></text>
<text top="437" left="170" width="154" height="20" font="4">Retrospective  n=101 pts  </text>
<text top="437" left="349" width="167" height="20" font="3"><b>Inclusion criteria</b>: Congenital </text>
<text top="454" left="349" width="158" height="20" font="4">heart defect and molecularly </text>
<text top="472" left="349" width="123" height="20" font="4">confirmed RASopathy </text>
<text top="437" left="553" width="73" height="20" font="4">Gene testing </text>
<text top="437" left="661" width="190" height="20" font="4">● 8% of RASopathy with AVSD or </text>
<text top="454" left="661" width="157" height="20" font="4">partial AVSD; most PTPN11 </text>
<text top="472" left="661" width="58" height="20" font="4">(Noonan). </text>
<text top="437" left="886" width="192" height="20" font="4">● Consideration of genetic testing. </text>
<text top="489" left="64" width="84" height="20" font="4">Bando K, et al. </text>
<text top="507" left="64" width="63" height="20" font="4">1995 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(351)</a> </text>
<text top="524" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7475207?dopt=Citation">7475207</a></text>
<text top="524" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7475207?dopt=Citation"> </a></text>
<text top="489" left="170" width="154" height="20" font="4">Retrospective  n=203 pts  </text>
<text top="489" left="349" width="170" height="20" font="3"><b>Inclusion criteria</b>: Infants and </text>
<text top="507" left="349" width="46" height="20" font="4">children </text>
<text top="489" left="553" width="94" height="20" font="4">Mortality and left </text>
<text top="507" left="553" width="87" height="20" font="4">AV valve repair </text>
<text top="524" left="553" width="37" height="20" font="4">failure </text>
<text top="489" left="661" width="209" height="20" font="4">● Decreasing operative mortality over </text>
<text top="507" left="661" width="211" height="20" font="4">time, risk factors for major reoperation </text>
<text top="524" left="661" width="201" height="20" font="4">included preoperative severe left AV </text>
<text top="541" left="661" width="198" height="20" font="4">valve regurgitation or severe left AV </text>
<text top="558" left="661" width="197" height="20" font="4">valve regurgitation postoperatively.  </text>
<text top="489" left="886" width="205" height="20" font="4">● Infant repair of AVSD now with low </text>
<text top="507" left="886" width="243" height="20" font="4">mortality and good outcome. Cleft closure is </text>
<text top="524" left="886" width="219" height="20" font="4">typically safe, and most pts do not have </text>
<text top="541" left="886" width="209" height="20" font="4">significant left AV valve regurgitation.  </text>
<text top="576" left="64" width="71" height="20" font="4">Kouchoukos </text>
<text top="593" left="64" width="53" height="20" font="4">NT, et al. </text>
<text top="611" left="64" width="66" height="20" font="4">1978 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(329)</a>  </text>
<text top="628" left="64" width="41" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/619518?dopt=Citation">619518</a></text>
<text top="628" left="105" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/619518?dopt=Citation"> </a></text>
<text top="576" left="170" width="44" height="20" font="4">Review </text>
<text top="576" left="263" width="24" height="20" font="4">N/A </text>
<text top="576" left="349" width="182" height="20" font="3"><b>Inclusion criteria</b>: Pts with large </text>
<text top="593" left="349" width="159" height="20" font="4">VSD prior to surgical closure </text>
<text top="576" left="553" width="53" height="20" font="4">Mortality  </text>
<text top="576" left="661" width="155" height="20" font="4">● Mortality related to age at </text>
<text top="593" left="661" width="194" height="20" font="4">operations (older did worse) and to </text>
<text top="611" left="661" width="104" height="20" font="4">preoperative PVR. </text>
<text top="576" left="886" width="223" height="20" font="4">● Prepulmonary vasodilator era. Careful </text>
<text top="593" left="886" width="227" height="20" font="4">consideration of mortality and late effects </text>
<text top="611" left="886" width="228" height="20" font="4">prior to considering closure of large VSD. </text>
<text top="646" left="64" width="77" height="20" font="4">Shohtsu A, et </text>
<text top="663" left="64" width="16" height="20" font="4">al. </text>
<text top="680" left="64" width="66" height="20" font="4">1976 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(330)</a>  </text>
<text top="697" left="64" width="41" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/950729?dopt=Citation">950729</a></text>
<text top="697" left="105" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/950729?dopt=Citation"> </a></text>
<text top="646" left="170" width="144" height="20" font="4">Retrospective  n=64 pts </text>
<text top="646" left="349" width="182" height="20" font="3"><b>Inclusion criteria</b>: Pts with large </text>
<text top="663" left="349" width="185" height="20" font="4">VSD, PH; also small number with </text>
<text top="680" left="349" width="81" height="20" font="4">PDA and ASD </text>
<text top="646" left="553" width="50" height="20" font="4">Mortality </text>
<text top="646" left="661" width="212" height="20" font="4">● Optimal timing of closure is 1-3 y for </text>
<text top="663" left="661" width="180" height="20" font="4">VSD with PH; PDA and ASD not </text>
<text top="680" left="661" width="33" height="20" font="4">clear. </text>
<text top="646" left="886" width="228" height="20" font="4">● Closure of large septal defects with PH </text>
<text top="663" left="886" width="221" height="20" font="4">should be considered for closure only at </text>
<text top="680" left="886" width="181" height="20" font="4">young ages to improve mortality. </text>
<text top="715" left="47" width="3" height="20" font="4"> </text>
<text top="733" left="47" width="3" height="20" font="4"> </text>
<text top="750" left="108" width="437" height="24" font="1"><b>Data Supplement 30. Patent Ductus Arteriosus – Section 4.1.5 </b></text>
<text top="771" left="92" width="38" height="20" font="3"><b>Study </b></text>
<text top="771" left="177" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="789" left="191" width="44" height="20" font="3"><b>Design </b></text>
<text top="771" left="280" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="771" left="373" width="165" height="20" font="3"><b>Inclusion/Exclusion Criteria </b></text>
<text top="771" left="565" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="771" left="717" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="771" left="944" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
</page>
<page number="100" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 100 </text>
<text top="107" left="67" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="124" left="96" width="30" height="20" font="3"><b>Year </b></text>
<text top="142" left="64" width="82" height="20" font="4">El-Said HG, et </text>
<text top="159" left="64" width="16" height="20" font="4">al. </text>
<text top="177" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(352)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24284214?dopt=Citation">24284214</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24284214?dopt=Citation"> </a></text>
<text top="142" left="170" width="82" height="20" font="4">Retrospective, </text>
<text top="159" left="170" width="64" height="20" font="4">multicenter </text>
<text top="142" left="269" width="61" height="20" font="4">n=496 pts  </text>
<text top="142" left="369" width="156" height="20" font="3"><b>Inclusion criteria</b>: All ages, </text>
<text top="159" left="369" width="126" height="20" font="4">PDA, devices and coils</text>
<text top="161" left="495" width="2" height="13" font="6"> </text>
<text top="142" left="555" width="63" height="20" font="4">Successful </text>
<text top="159" left="555" width="43" height="20" font="4">closure </text>
<text top="142" left="661" width="165" height="20" font="4">● ~60% &lt;3 y; only 4% adults. </text>
<text top="142" left="887" width="247" height="20" font="4">● High success, low event rate, more events </text>
<text top="159" left="887" width="111" height="20" font="4">in younger children. </text>
<text top="212" left="64" width="85" height="20" font="4">Chen LY, et al. </text>
<text top="229" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(353)</a> </text>
<text top="246" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24088423?dopt=Citation">24088423</a></text>
<text top="246" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24088423?dopt=Citation"> </a></text>
<text top="212" left="170" width="83" height="20" font="4">Observational, </text>
<text top="229" left="170" width="73" height="20" font="4">single center </text>
<text top="212" left="269" width="86" height="20" font="4">n=150 pts (108 </text>
<text top="229" left="269" width="75" height="20" font="4">transvenous) </text>
<text top="212" left="369" width="166" height="20" font="3"><b>Inclusion criteria</b>: Only PDA, </text>
<text top="229" left="369" width="148" height="20" font="4">&gt;6 mo, no pulmonary HTN </text>
<text top="212" left="555" width="63" height="20" font="4">Successful </text>
<text top="229" left="555" width="43" height="20" font="4">closure </text>
<text top="246" left="555" width="64" height="20" font="4">(secondary </text>
<text top="263" left="555" width="82" height="20" font="4">complications) </text>
<text top="212" left="661" width="159" height="20" font="4">● Similar closure rates (98% </text>
<text top="229" left="661" width="209" height="20" font="4">vs.100%), more complications, longer </text>
<text top="246" left="661" width="166" height="20" font="4">LOS, higher cost with surgical </text>
<text top="263" left="661" width="58" height="20" font="4">approach. </text>
<text top="212" left="887" width="234" height="20" font="4">● Equally successful, choose transvenous </text>
<text top="229" left="887" width="63" height="20" font="4">when able. </text>
<text top="281" left="64" width="79" height="20" font="4">Chen H, et al. </text>
<text top="299" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(354)</a> </text>
<text top="316" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22037885?dopt=Citation">22037885</a></text>
<text top="316" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22037885?dopt=Citation"> </a></text>
<text top="281" left="170" width="75" height="20" font="4">Single center </text>
<text top="281" left="269" width="66" height="20" font="4">n=294 (196 </text>
<text top="299" left="269" width="82" height="20" font="4">video-assisted </text>
<text top="316" left="269" width="79" height="20" font="4">thoracoscopic </text>
<text top="333" left="269" width="65" height="20" font="4">surgery, 98 </text>
<text top="350" left="269" width="79" height="20" font="4">transcatheter) </text>
<text top="281" left="369" width="152" height="20" font="3"><b>Inclusion criteria</b>: Isolated </text>
<text top="299" left="369" width="29" height="20" font="4">PDA </text>
<text top="281" left="555" width="49" height="20" font="4">Closure, </text>
<text top="299" left="555" width="81" height="20" font="4">complications, </text>
<text top="316" left="555" width="26" height="20" font="4">cost </text>
<text top="281" left="661" width="191" height="20" font="4">● Video-assisted thoracic surgery: </text>
<text top="299" left="661" width="188" height="20" font="4">100% closure, 1.5% complication, </text>
<text top="316" left="661" width="210" height="20" font="4">LOS=6 d, ~40% cost vs. transvenous: </text>
<text top="333" left="661" width="204" height="20" font="4">98% success (+ 4 residual leak late), </text>
<text top="350" left="661" width="165" height="20" font="4">10% complications, LOS=4 d. </text>
<text top="281" left="887" width="222" height="20" font="4">● Video-assisted thoracic surgery better </text>
<text top="299" left="887" width="237" height="20" font="4">closure rate, fewer complications (1.5% vs. </text>
<text top="316" left="887" width="226" height="20" font="4">10%), lower cost; video-assisted thoracic </text>
<text top="333" left="887" width="245" height="20" font="4">surgery was longer LOS and procedure time </text>
<text top="350" left="887" width="243" height="20" font="4">(very diff numbers than El-Said study 2013). </text>
<text top="368" left="64" width="85" height="20" font="4">Brunetti MA, et </text>
<text top="385" left="64" width="16" height="20" font="4">al. </text>
<text top="403" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(355)</a> </text>
<text top="420" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20690153?dopt=Citation">20690153</a></text>
<text top="420" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20690153?dopt=Citation"> </a></text>
<text top="368" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="385" left="170" width="53" height="20" font="4">review of </text>
<text top="403" left="170" width="66" height="20" font="4">prospective </text>
<text top="420" left="170" width="64" height="20" font="4">multicenter </text>
<text top="437" left="170" width="71" height="20" font="4">data registry </text>
<text top="368" left="269" width="61" height="20" font="4">n=359 pts  </text>
<text top="368" left="369" width="152" height="20" font="3"><b>Inclusion criteria</b>: Isolated </text>
<text top="385" left="369" width="159" height="20" font="4">PDA, predominantly children </text>
<text top="368" left="555" width="63" height="20" font="4">Successful </text>
<text top="385" left="555" width="46" height="20" font="4">closure, </text>
<text top="403" left="555" width="81" height="20" font="4">complications, </text>
<text top="420" left="555" width="80" height="20" font="4">cost, radiation </text>
<text top="368" left="661" width="144" height="20" font="4">● 357 successful closure. </text>
<text top="368" left="887" width="199" height="20" font="4">● Gianturco coils, the arterial defect </text>
<text top="385" left="887" width="244" height="20" font="4">occluders were successful, low complication </text>
<text top="403" left="887" width="170" height="20" font="4">profiles, predominate devices.  </text>
<text top="455" left="64" width="81" height="20" font="4">Fortescue EB, </text>
<text top="472" left="64" width="30" height="20" font="4">et al. </text>
<text top="489" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(356)</a> </text>
<text top="507" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20653702?dopt=Citation">20653702</a></text>
<text top="507" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20653702?dopt=Citation"> </a></text>
<text top="455" left="170" width="123" height="20" font="4">Review article  N/A </text>
<text top="455" left="369" width="152" height="20" font="3"><b>Inclusion criteria</b>: Isolated </text>
<text top="472" left="369" width="29" height="20" font="4">PDA </text>
<text top="455" left="555" width="55" height="20" font="4">Literature </text>
<text top="472" left="555" width="53" height="20" font="4">review of </text>
<text top="489" left="555" width="91" height="20" font="4">comparison and </text>
<text top="507" left="555" width="91" height="20" font="4">complications of </text>
<text top="524" left="555" width="77" height="20" font="4">closure of the </text>
<text top="541" left="555" width="91" height="20" font="4">very small/small </text>
<text top="558" left="555" width="29" height="20" font="4">PDA </text>
<text top="455" left="661" width="203" height="20" font="4">● Closure of small or silent PDA can </text>
<text top="472" left="661" width="200" height="20" font="4">be done safely but not zero risk. For </text>
<text top="489" left="661" width="209" height="20" font="4">small not hemodynamically significant </text>
<text top="507" left="661" width="179" height="20" font="4">PDA, closure to prevent the rare </text>
<text top="524" left="661" width="172" height="20" font="4">episode of endarteritis may not </text>
<text top="541" left="661" width="103" height="20" font="4">outweigh the risk.  </text>
<text top="455" left="887" width="241" height="20" font="4">● Unlike large PDA, the small or silent PDA </text>
<text top="472" left="887" width="226" height="20" font="4">creates controversy surrounding closure. </text>
<text top="489" left="887" width="219" height="20" font="4">Risk and benefit of closure or continued </text>
<text top="507" left="887" width="245" height="20" font="4">observation must be considered carefully for </text>
<text top="524" left="887" width="102" height="20" font="4">each individual pt. </text>
<text top="576" left="64" width="80" height="20" font="4">Gamboa R, et </text>
<text top="593" left="64" width="16" height="20" font="4">al. </text>
<text top="611" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(357)</a> </text>
<text top="628" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20515630?dopt=Citation">20515630</a></text>
<text top="628" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20515630?dopt=Citation"> </a></text>
<text top="576" left="170" width="36" height="20" font="4">Cross-</text>
<text top="593" left="170" width="55" height="20" font="4">sectional, </text>
<text top="611" left="170" width="81" height="20" font="4">retrospective   </text>
<text top="576" left="269" width="54" height="20" font="4">n=23 pts  </text>
<text top="576" left="369" width="152" height="20" font="3"><b>Inclusion criteria</b>: Isolated </text>
<text top="593" left="369" width="94" height="20" font="4">PDA, adults only </text>
<text top="576" left="555" width="63" height="20" font="4">Successful </text>
<text top="593" left="555" width="67" height="20" font="4">closure and </text>
<text top="611" left="555" width="78" height="20" font="4">complications </text>
<text top="576" left="661" width="199" height="20" font="4">● Closure in 85%–100% depending </text>
<text top="593" left="661" width="206" height="20" font="4">on device used; 1 minor complication </text>
<text top="611" left="661" width="116" height="20" font="4">(inguinal hematoma) </text>
<text top="576" left="887" width="249" height="20" font="4">● Isolated PDA can be successfully closed in </text>
<text top="593" left="887" width="40" height="20" font="4">adults. </text>
<text top="646" left="64" width="80" height="20" font="4">Zabal C, et al. </text>
<text top="663" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(358)</a> </text>
<text top="680" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20357390?dopt=Citation">20357390</a></text>
<text top="680" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20357390?dopt=Citation"> </a></text>
<text top="646" left="170" width="75" height="20" font="4">Single center </text>
<text top="646" left="269" width="67" height="20" font="4">168 (mostly </text>
<text top="663" left="269" width="51" height="20" font="4">children) </text>
<text top="646" left="369" width="152" height="20" font="3"><b>Inclusion criteria</b>: Isolated </text>
<text top="663" left="369" width="132" height="20" font="4">PDA with elevated PAP </text>
<text top="646" left="555" width="49" height="20" font="4">Closure, </text>
<text top="663" left="555" width="81" height="20" font="4">complications, </text>
<text top="680" left="555" width="36" height="20" font="4">PASP </text>
<text top="646" left="661" width="201" height="20" font="4">● Device placed in 98%, trivial or no </text>
<text top="663" left="661" width="162" height="20" font="4">leak in 75%, 6 complications. </text>
<text top="646" left="887" width="246" height="20" font="4">● Success in most; reduced PASP (selected </text>
<text top="663" left="887" width="42" height="20" font="4">group). </text>
<text top="698" left="64" width="91" height="20" font="4">Jeong YH, et al. </text>
<text top="715" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(359)</a> </text>
<text top="733" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17719286?dopt=Citation">17719286</a></text>
<text top="733" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17719286?dopt=Citation"> </a></text>
<text top="698" left="170" width="78" height="20" font="4">Single center, </text>
<text top="715" left="170" width="77" height="20" font="4">retrospective  </text>
<text top="698" left="269" width="54" height="20" font="4">n=45 pts  </text>
<text top="698" left="369" width="152" height="20" font="3"><b>Inclusion criteria</b>: Isolated </text>
<text top="715" left="369" width="115" height="20" font="4">PDA in adults, some </text>
<text top="733" left="369" width="161" height="20" font="4">surgical/some device closure </text>
<text top="698" left="555" width="67" height="20" font="4">LV size and </text>
<text top="715" left="555" width="75" height="20" font="4">function after </text>
<text top="733" left="555" width="46" height="20" font="4">closure; </text>
<text top="750" left="555" width="93" height="20" font="4">immediately and </text>
<text top="767" left="555" width="38" height="20" font="4">&gt;6 mo </text>
<text top="698" left="661" width="191" height="20" font="4">● All had decreased LVEF and LV </text>
<text top="715" left="661" width="204" height="20" font="4">end diastolic dimension immediately; </text>
<text top="733" left="661" width="196" height="20" font="4">those with preprocedure decreased </text>
<text top="750" left="661" width="202" height="20" font="4">EF more likely to have below normal </text>
<text top="767" left="661" width="112" height="20" font="4">LVEF even at 6 mo. </text>
<text top="698" left="887" width="240" height="20" font="4">● Most pts will have immediate decrease in </text>
<text top="715" left="887" width="244" height="20" font="4">LVEF immediately after closure. In most this </text>
<text top="733" left="887" width="195" height="20" font="4">will recover to normal range but not </text>
<text top="750" left="887" width="194" height="20" font="4">necessarily to baseline. Those with </text>
<text top="767" left="887" width="247" height="20" font="4">preprocedure decreased LVEF more likely to </text>
<text top="784" left="887" width="106" height="20" font="4">not recover LVEF.  </text>
</page>
<page number="101" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 101 </text>
<text top="107" left="64" width="71" height="20" font="4">Yan C, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(360)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16954130?dopt=Citation">16954130</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16954130?dopt=Citation"> </a></text>
<text top="107" left="170" width="78" height="20" font="4">Single center, </text>
<text top="124" left="170" width="77" height="20" font="4">observational </text>
<text top="107" left="269" width="54" height="20" font="4">n=29 pts  </text>
<text top="107" left="369" width="146" height="20" font="3"><b>Inclusion criteria</b>: Adults, </text>
<text top="124" left="369" width="169" height="20" font="4">isolated PDA with severe PAH </text>
<text top="107" left="555" width="89" height="20" font="4">Closure, PASP, </text>
<text top="124" left="555" width="10" height="20" font="4">O</text>
<text top="130" left="564" width="4" height="13" font="6">2</text>
<text top="124" left="569" width="61" height="20" font="4"> saturation </text>
<text top="107" left="661" width="207" height="20" font="4">● 20 pts had closure, all of those had </text>
<text top="124" left="661" width="208" height="20" font="4">decreased PASP and improvement in </text>
<text top="141" left="661" width="174" height="20" font="4">saturations; also had increased </text>
<text top="159" left="661" width="200" height="20" font="4">LV/LA/PA size on follow-up; in other </text>
<text top="176" left="661" width="213" height="20" font="4">9, closure not tried as were worse with </text>
<text top="193" left="661" width="83" height="20" font="4">trial of closure. </text>
<text top="107" left="887" width="229" height="20" font="4">● Closure can be done safely in the short </text>
<text top="124" left="887" width="222" height="20" font="4">term for pts with PDA and reactive PAH. </text>
<text top="211" left="64" width="71" height="20" font="4">Kouchoukos </text>
<text top="228" left="64" width="53" height="20" font="4">NT, et al. </text>
<text top="245" left="64" width="66" height="20" font="4">1978 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(329)</a>  </text>
<text top="263" left="64" width="41" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/619518?dopt=Citation">619518</a></text>
<text top="263" left="105" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/619518?dopt=Citation"> </a></text>
<text top="211" left="170" width="44" height="20" font="4">Review </text>
<text top="211" left="269" width="24" height="20" font="4">N/A </text>
<text top="211" left="369" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="228" left="369" width="147" height="20" font="4">large VSD prior to surgical </text>
<text top="245" left="369" width="43" height="20" font="4">closure </text>
<text top="211" left="555" width="53" height="20" font="4">Mortality  </text>
<text top="211" left="661" width="155" height="20" font="4">● Mortality related to age at </text>
<text top="228" left="661" width="194" height="20" font="4">operations (older did worse) and to </text>
<text top="245" left="661" width="104" height="20" font="4">preoperative PVR. </text>
<text top="211" left="887" width="223" height="20" font="4">● Prepulmonary vasodilator era. Careful </text>
<text top="228" left="887" width="227" height="20" font="4">consideration of mortality and late effects </text>
<text top="245" left="887" width="228" height="20" font="4">prior to considering closure of large VSD. </text>
<text top="281" left="64" width="77" height="20" font="4">Shohtsu A, et </text>
<text top="298" left="64" width="16" height="20" font="4">al. </text>
<text top="315" left="64" width="66" height="20" font="4">1976 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#228">(330)</a>  </text>
<text top="332" left="64" width="41" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/950729?dopt=Citation">950729</a></text>
<text top="332" left="105" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/950729?dopt=Citation"> </a></text>
<text top="281" left="170" width="79" height="20" font="4">Retrospective </text>
<text top="281" left="269" width="51" height="20" font="4">n=64 pts </text>
<text top="281" left="369" width="152" height="20" font="3"><b>Inclusion criteria</b>: Pts with </text>
<text top="298" left="369" width="145" height="20" font="4">large VSD, PH; also small </text>
<text top="315" left="369" width="152" height="20" font="4">number with PDA and ASD </text>
<text top="281" left="555" width="50" height="20" font="4">Mortality </text>
<text top="281" left="661" width="208" height="20" font="4">● Optimal timing of closure is 1-3 y of </text>
<text top="298" left="661" width="201" height="20" font="4">age for VSD with PH; PDA and ASD </text>
<text top="315" left="661" width="54" height="20" font="4">not clear. </text>
<text top="281" left="887" width="228" height="20" font="4">● Closure of large septal defects with PH </text>
<text top="298" left="887" width="221" height="20" font="4">should be considered for closure only at </text>
<text top="315" left="887" width="181" height="20" font="4">young ages to improve mortality. </text>
<text top="350" left="108" width="3" height="20" font="4"> </text>
<text top="368" left="108" width="3" height="20" font="4"> </text>
<text top="384" left="108" width="367" height="24" font="1"><b>Data Supplement 31. Cor Triatriatum – Section 4.2.1 </b></text>
<text top="406" left="73" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="423" left="73" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="406" left="176" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="423" left="190" width="44" height="20" font="3"><b>Design </b></text>
<text top="406" left="271" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="406" left="367" width="62" height="20" font="3"><b>Follow-up </b></text>
<text top="423" left="384" width="29" height="20" font="3"><b>time </b></text>
<text top="440" left="397" width="3" height="20" font="4"> </text>
<text top="406" left="457" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="423" left="493" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="406" left="605" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="406" left="746" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="406" left="961" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="458" left="64" width="83" height="20" font="4">Ozyuksel A, et </text>
<text top="476" left="64" width="16" height="20" font="4">al. </text>
<text top="493" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(361)</a> </text>
<text top="510" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25312520?dopt=Citation">25312520</a></text>
<text top="510" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25312520?dopt=Citation"><b> </b></a></text>
<text top="458" left="172" width="145" height="20" font="4">Observational<b>  </b>n=15 pts<b> </b></text>
<text top="458" left="354" width="30" height="20" font="4">5.2 y<b> </b></text>
<text top="458" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="476" left="455" width="95" height="20" font="4">Children with cor </text>
<text top="493" left="455" width="62" height="20" font="4">triatriatum <b> </b></text>
<text top="458" left="590" width="86" height="20" font="4">Clinical events <b> </b></text>
<text top="458" left="705" width="429" height="20" font="4">● 2 late deaths, 14 reoperations.<b>  </b>● Common association with ASD/PAPVR.<b> </b></text>
<text top="528" left="64" width="90" height="20" font="4">Saxena P, et al. </text>
<text top="545" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(362)</a> </text>
<text top="562" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24630764?dopt=Citation">24630764</a></text>
<text top="562" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24630764?dopt=Citation"><b> </b></a></text>
<text top="528" left="172" width="145" height="20" font="4">Observational<b>  </b>n=25 pts<b> </b></text>
<text top="528" left="354" width="37" height="20" font="4">12.8 y<b> </b></text>
<text top="528" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="545" left="455" width="115" height="20" font="4">Cor triatriatum, ages </text>
<text top="562" left="455" width="40" height="20" font="4">0–73 y<b> </b></text>
<text top="528" left="590" width="83" height="20" font="4">Clinical events<b> </b></text>
<text top="528" left="705" width="155" height="20" font="4">● No residual obstruction in </text>
<text top="545" left="705" width="56" height="20" font="4">follow-up.<b> </b></text>
<text top="528" left="901" width="254" height="20" font="4">● 84% with ASD/VSD/PAPVR. Mean gradient </text>
<text top="545" left="901" width="249" height="20" font="4">was 8 mm Hg (range 8–40 mm Hg) at time of </text>
<text top="562" left="901" width="48" height="20" font="4">surgery.<b> </b></text>
<text top="580" left="64" width="91" height="20" font="4">Yaroglu Karanzi </text>
<text top="598" left="64" width="45" height="20" font="4">S, et al. </text>
<text top="615" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(363)</a> </text>
<text top="632" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22078218?dopt=Citation">22078218</a></text>
<text top="632" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22078218?dopt=Citation"><b> </b></a></text>
<text top="580" left="172" width="145" height="20" font="4">Observational<b>  </b>n=65 pts<b> </b></text>
<text top="580" left="354" width="30" height="20" font="4">5.4 y<b> </b></text>
<text top="580" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="598" left="455" width="81" height="20" font="4">Cor triatriatum<b> </b></text>
<text top="580" left="590" width="83" height="20" font="4">Clinical events<b> </b></text>
<text top="580" left="705" width="135" height="20" font="4">● 8 with pulmonary vein </text>
<text top="598" left="705" width="52" height="20" font="4">stenosis.<b> </b></text>
<text top="580" left="901" width="175" height="20" font="4">● 75% with ASD/VSD/PAPVR. <b> </b></text>
<text top="650" left="108" width="3" height="20" font="4"> </text>
<text top="667" left="108" width="3" height="20" font="4"> </text>
<text top="684" left="108" width="445" height="24" font="1"><b>Data Supplement 32. Congenital Mitral Stenosis – Section 4.2.2 </b></text>
<text top="706" left="73" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="723" left="73" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="706" left="176" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="723" left="190" width="44" height="20" font="3"><b>Design </b></text>
<text top="706" left="271" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="706" left="367" width="62" height="20" font="3"><b>Follow-up </b></text>
<text top="723" left="384" width="29" height="20" font="3"><b>time </b></text>
<text top="740" left="397" width="3" height="20" font="4"> </text>
<text top="706" left="457" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="723" left="493" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="706" left="605" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="706" left="746" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="706" left="961" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
</page>
<page number="102" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 102 </text>
<text top="107" left="64" width="94" height="20" font="4">Marino BS, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(364)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19185158?dopt=Citation">19185158</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19185158?dopt=Citation"> </a></text>
<text top="107" left="172" width="145" height="20" font="4">Observational  n=86 pts </text>
<text top="107" left="354" width="30" height="20" font="4">6.4 y </text>
<text top="107" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="455" width="113" height="20" font="4">Children ages 0–6 y </text>
<text top="141" left="455" width="109" height="20" font="4">undergoing surgery </text>
<text top="107" left="590" width="86" height="20" font="4">Clinical events, </text>
<text top="124" left="590" width="44" height="20" font="4">MS/MR </text>
<text top="107" left="705" width="163" height="20" font="4">● Progression to MS and MR </text>
<text top="124" left="705" width="62" height="20" font="4">was seen.  </text>
<text top="107" left="901" width="215" height="20" font="4">● Outcome associated with associated </text>
<text top="124" left="901" width="255" height="20" font="4">anomalies; &#34;true&#34; parachute with MS, mortality </text>
<text top="141" left="901" width="252" height="20" font="4">associated with coexisting congenital defects. </text>
<text top="159" left="64" width="90" height="20" font="4">Schaverien MV, </text>
<text top="177" left="64" width="30" height="20" font="4">et al. </text>
<text top="194" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(365)</a> </text>
<text top="211" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15117833?dopt=Citation">15117833</a></text>
<text top="211" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15117833?dopt=Citation"> </a></text>
<text top="159" left="172" width="145" height="20" font="4">Observational  n=86 pts </text>
<text top="159" left="354" width="60" height="20" font="4">Up to 10 y </text>
<text top="159" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="177" left="455" width="113" height="20" font="4">Children ages 0–5 y </text>
<text top="159" left="590" width="51" height="20" font="4">Need for </text>
<text top="177" left="590" width="59" height="20" font="4">valvotomy </text>
<text top="159" left="705" width="112" height="20" font="4">● Needed in 75 pts. </text>
<text top="159" left="901" width="124" height="20" font="4">● No progressive MS. </text>
<text top="229" left="64" width="85" height="20" font="4">Brauner RA, et </text>
<text top="246" left="64" width="16" height="20" font="4">al. </text>
<text top="263" left="64" width="66" height="20" font="4">1997 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(366)</a>  </text>
<text top="281" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9307464?dopt=Citation">9307464</a></text>
<text top="281" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9307464?dopt=Citation"> </a></text>
<text top="229" left="172" width="145" height="20" font="4">Observational  n=19 pts </text>
<text top="229" left="354" width="20" height="20" font="4">8 y </text>
<text top="229" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="246" left="455" width="95" height="20" font="4">Shone’s with MS </text>
<text top="229" left="590" width="556" height="20" font="4">Death/reoperation  ● 2 late deaths, 14 reoperations.  ● Not progressive MS or MR. Operations for </text>
<text top="246" left="901" width="73" height="20" font="4">other issues. </text>
<text top="299" left="64" width="93" height="20" font="4">Ozuksel A, et al. </text>
<text top="316" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(361)</a> </text>
<text top="333" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25312520?dopt=Citation">25312520</a></text>
<text top="333" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25312520?dopt=Citation"> </a></text>
<text top="299" left="172" width="145" height="20" font="4">Observational  n=15 pts </text>
<text top="299" left="354" width="30" height="20" font="4">5.2 y </text>
<text top="299" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="316" left="455" width="95" height="20" font="4">Children with cor </text>
<text top="333" left="455" width="62" height="20" font="4">triatriatum  </text>
<text top="299" left="590" width="86" height="20" font="4">Clinical events  </text>
<text top="299" left="705" width="429" height="20" font="4">● 2 late deaths, 14 reoperations.  ● Common association with ASD/PAPVR. </text>
<text top="351" left="64" width="90" height="20" font="4">Saxena P, et al. </text>
<text top="368" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(362)</a> </text>
<text top="385" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24630764?dopt=Citation">24630764</a></text>
<text top="385" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24630764?dopt=Citation"> </a></text>
<text top="351" left="172" width="145" height="20" font="4">Observational  n=25 pts </text>
<text top="351" left="354" width="37" height="20" font="4">12.8 y </text>
<text top="351" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="368" left="455" width="115" height="20" font="4">Cor triatriatum, ages </text>
<text top="385" left="455" width="40" height="20" font="4">0–73 y </text>
<text top="351" left="590" width="83" height="20" font="4">Clinical events </text>
<text top="351" left="705" width="155" height="20" font="4">● No residual obstruction in </text>
<text top="368" left="705" width="56" height="20" font="4">follow-up. </text>
<text top="351" left="901" width="254" height="20" font="4">● 84% with ASD/VSD/PAPVR. Mean gradient </text>
<text top="368" left="901" width="249" height="20" font="4">was 8 mm Hg (range 8–40 mm Hg) at time of </text>
<text top="385" left="901" width="48" height="20" font="4">surgery. </text>
<text top="403" left="64" width="91" height="20" font="4">Yaroglu Karanzi </text>
<text top="421" left="64" width="45" height="20" font="4">S, et al. </text>
<text top="438" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(363)</a> </text>
<text top="455" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22078218?dopt=Citation">22078218</a></text>
<text top="455" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22078218?dopt=Citation"> </a></text>
<text top="403" left="172" width="145" height="20" font="4">Observational  n=65 pts </text>
<text top="403" left="354" width="30" height="20" font="4">5.4 y </text>
<text top="403" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="421" left="455" width="81" height="20" font="4">Cor triatriatum </text>
<text top="403" left="590" width="83" height="20" font="4">Clinical events </text>
<text top="403" left="705" width="135" height="20" font="4">● 8 with pulmonary vein </text>
<text top="421" left="705" width="52" height="20" font="4">stenosis. </text>
<text top="403" left="901" width="175" height="20" font="4">● 75% with ASD/VSD/PAPVR.  </text>
<text top="473" left="64" width="84" height="20" font="4">Alphonso N, et </text>
<text top="490" left="64" width="16" height="20" font="4">al. </text>
<text top="507" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(367)</a> </text>
<text top="525" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16242436?dopt=Citation">16242436</a></text>
<text top="525" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16242436?dopt=Citation"> </a></text>
<text top="473" left="172" width="145" height="20" font="4">Observational  n=28 pts </text>
<text top="473" left="354" width="20" height="20" font="4">8 y </text>
<text top="473" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="490" left="455" width="115" height="20" font="4">Cor triatriatum, ages </text>
<text top="507" left="455" width="40" height="20" font="4">0–20 y </text>
<text top="473" left="590" width="83" height="20" font="4">Clinical events </text>
<text top="473" left="705" width="84" height="20" font="4">● 1 late death. </text>
<text top="473" left="901" width="173" height="20" font="4">● No reoperations for stenosis. </text>
<text top="542" left="108" width="3" height="20" font="4"> </text>
<text top="560" left="108" width="3" height="20" font="4"> </text>
<text top="577" left="108" width="394" height="24" font="1"><b>Data Supplement 33. Subaortic Stenosis – Section 4.2.3 </b></text>
<text top="598" left="73" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="616" left="73" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="598" left="177" width="38" height="20" font="3"><b>Study </b></text>
<text top="616" left="182" width="28" height="20" font="3"><b>Size </b></text>
<text top="598" left="255" width="38" height="20" font="3"><b>Study </b></text>
<text top="616" left="251" width="44" height="20" font="3"><b>Design </b></text>
<text top="598" left="332" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="616" left="368" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="598" left="487" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="598" left="739" width="48" height="20" font="3"><b>Results </b></text>
<text top="598" left="1014" width="77" height="20" font="3"><b>Conclusions </b></text>
<text top="634" left="64" width="89" height="20" font="4">Oliver JM, et al. </text>
<text top="651" left="64" width="63" height="20" font="4">2001 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(368)</a> </text>
<text top="668" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11527642?dopt=Citation">11527642</a></text>
<text top="668" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11527642?dopt=Citation"> </a></text>
<text top="634" left="172" width="38" height="20" font="4">n=134 </text>
<text top="651" left="172" width="30" height="20" font="4">adult </text>
<text top="668" left="172" width="20" height="20" font="4">pts </text>
<text top="634" left="233" width="76" height="20" font="4">Single-center </text>
<text top="651" left="233" width="74" height="20" font="4">retrospective </text>
<text top="668" left="233" width="66" height="20" font="4">case series </text>
<text top="634" left="327" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="651" left="327" width="102" height="20" font="4">2,057 consecutive </text>
<text top="668" left="327" width="115" height="20" font="4">ACHD pts evaluated </text>
<text top="685" left="327" width="85" height="20" font="4">for presence of </text>
<text top="703" left="327" width="86" height="20" font="4">discrete subAS </text>
<text top="634" left="469" width="51" height="20" font="4">Evaluate </text>
<text top="651" left="469" width="87" height="20" font="4">prevalence and </text>
<text top="668" left="469" width="40" height="20" font="4">clinical </text>
<text top="685" left="469" width="96" height="20" font="4">characteristics of </text>
<text top="703" left="469" width="86" height="20" font="4">discrete subAS </text>
<text top="634" left="590" width="339" height="20" font="4">● 134 adults (mean age 31 ± 17 y): the prevalence was 6.5% </text>
<text top="651" left="590" width="308" height="20" font="4">for all adults with CHD 44% had other associated CHD. -</text>
<text top="668" left="590" width="287" height="20" font="4">29/134 underwent surgery as adults, mean age 56 y </text>
<text top="685" left="590" width="328" height="20" font="4">compared to 27 y for those that had not undergone surgery. </text>
<text top="703" left="590" width="335" height="20" font="4">● A significant relationship between LVOT obstruction and pt </text>
<text top="720" left="590" width="344" height="20" font="4">age (r=0.61; p&lt;0.0001) was found: 21 ± 16 mm Hg in pts&lt;25 y </text>
<text top="737" left="590" width="334" height="20" font="4">old, 51 ± 47 mm Hg for those between 25–50 y, and 78 ± 36 </text>
<text top="754" left="590" width="135" height="20" font="4">mm Hg for those &gt;50 y.  </text>
<text top="634" left="948" width="205" height="20" font="4">● Discrete subAS is progressive with </text>
<text top="651" left="948" width="27" height="20" font="4">age. </text>
<text top="668" left="948" width="194" height="20" font="4">● Pts operated on in adulthood are </text>
<text top="685" left="948" width="207" height="20" font="4">likely to be older than those that have </text>
<text top="703" left="948" width="207" height="20" font="4">not undergone operative intervention. </text>
<text top="720" left="948" width="207" height="20" font="4">● Pts with resting peak echo gradient </text>
<text top="737" left="948" width="164" height="20" font="4">≥50 mm Hg are likely to have </text>
<text top="754" left="948" width="110" height="20" font="4">progressive subAS. </text>
<text top="771" left="948" width="184" height="20" font="4">● AR is common but typically not </text>
<text top="789" left="948" width="44" height="20" font="4">severe. </text>
</page>
<page number="103" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 103 </text>
<text top="107" left="590" width="322" height="20" font="4">● LVOT obstruction increased from 39.2 ± 28 to 46.8 ± 34 </text>
<text top="124" left="590" width="333" height="20" font="4">mm Hg (p=0.01) during a mean follow-up of 4.8 ± 1.8 y in 25 </text>
<text top="141" left="590" width="27" height="20" font="4">pts.  </text>
<text top="159" left="590" width="325" height="20" font="4">● In the overall group, 4 of 8 pts with gradients &gt;50 mm Hg </text>
<text top="176" left="590" width="321" height="20" font="4">significantly increased the severity of obstruction, whereas </text>
<text top="193" left="590" width="338" height="20" font="4">only 3 of 18 pts with initial gradients under 50 mm Hg showed </text>
<text top="210" left="590" width="337" height="20" font="4">significant, albeit mild, progression of the subaortic gradients. </text>
<text top="228" left="590" width="345" height="20" font="4">● The slope of the change in LVOT obstruction was 2.25 ± 4.7 </text>
<text top="245" left="590" width="126" height="20" font="4">mm Hg/y of follow-up.  </text>
<text top="262" left="590" width="323" height="20" font="4">● AR was detected by Doppler in 109 pts (81%), but it was </text>
<text top="279" left="590" width="326" height="20" font="4">hemodynamically significant in&lt;20%. Increase in aortic root </text>
<text top="296" left="590" width="103" height="20" font="4">over time was NS  </text>
<text top="314" left="64" width="93" height="20" font="4">McMahon CJ, et </text>
<text top="332" left="64" width="16" height="20" font="4">al. </text>
<text top="349" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(369)</a> </text>
<text top="366" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15325929?dopt=Citation">15325929</a></text>
<text top="366" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15325929?dopt=Citation"> </a></text>
<text top="314" left="172" width="38" height="20" font="4">n=220 </text>
<text top="332" left="172" width="29" height="20" font="4">child </text>
<text top="349" left="172" width="23" height="20" font="4">pts  </text>
<text top="314" left="233" width="78" height="20" font="4">Retrospective </text>
<text top="332" left="233" width="74" height="20" font="4">single-center </text>
<text top="349" left="233" width="66" height="20" font="4">case series </text>
<text top="314" left="327" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="332" left="327" width="114" height="20" font="4">Evidence of discrete </text>
<text top="349" left="327" width="90" height="20" font="4">subAS by echo  </text>
<text top="314" left="469" width="85" height="20" font="4">Evaluate aortic </text>
<text top="332" left="469" width="98" height="20" font="4">valve dysfunction </text>
<text top="349" left="469" width="99" height="20" font="4">in discrete subAS </text>
<text top="314" left="590" width="334" height="20" font="4">● 220 pts with subAS (109 with previous surgery 111 had no </text>
<text top="332" left="590" width="55" height="20" font="4">surgery).  </text>
<text top="349" left="590" width="343" height="20" font="4">● Age at diagnosis, sex, and duration of follow-up (median 7.2 </text>
<text top="366" left="590" width="336" height="20" font="4">y, range 1–20.4 y) did not differ significantly between medical </text>
<text top="383" left="590" width="93" height="20" font="4">and surgical pts. </text>
<text top="400" left="590" width="333" height="20" font="4">● Independent risk factors for moderate to severe aortic root </text>
<text top="418" left="590" width="330" height="20" font="4">(n=30) were older age at diagnosis (OR for age ≥17 y: 5.13; </text>
<text top="435" left="590" width="316" height="20" font="4">p=0.024), previous balloon or surgical aortic valvuloplasty </text>
<text top="452" left="590" width="342" height="20" font="4">(OR: 19.6; p&lt;0.001), and a longer follow-up period (OR for 1-y </text>
<text top="469" left="590" width="143" height="20" font="4">increase: 1.15; p=0.032).  </text>
<text top="487" left="590" width="301" height="20" font="4">● Excluding pts with previous surgical or balloon aortic </text>
<text top="504" left="590" width="311" height="20" font="4">valvuloplasty, a higher maximal Doppler gradient was an </text>
<text top="521" left="590" width="339" height="20" font="4">independent risk factor for moderate to severe aortic root (OR </text>
<text top="538" left="590" width="258" height="20" font="4">for peak gradient ≥50 mm Hg: 10.8; p=0.001).  </text>
<text top="555" left="590" width="335" height="20" font="4">● Independent predictors of low-risk pts (none or trivial aortic </text>
<text top="573" left="590" width="335" height="20" font="4">root and peak gradient ≤30 mm Hg) included thin and mobile </text>
<text top="590" left="590" width="244" height="20" font="4">aortic valve leaflets and an associated VSD. </text>
<text top="314" left="948" width="163" height="20" font="4">● Aortic valve regurgitation is </text>
<text top="332" left="948" width="123" height="20" font="4">progressive in subAS. </text>
<text top="349" left="948" width="203" height="20" font="4">● A resting peak Doppler gradient of </text>
<text top="366" left="948" width="165" height="20" font="4">≥50 mm Hg is a risk factor for </text>
<text top="383" left="948" width="120" height="20" font="4">moderate/severe AR. </text>
<text top="400" left="948" width="179" height="20" font="4">● Moderate/severe aortic root is </text>
<text top="418" left="948" width="207" height="20" font="4">additionally associated with older age </text>
<text top="435" left="948" width="188" height="20" font="4">and prior aortic valve intervention. </text>
<text top="452" left="948" width="203" height="20" font="4">● A resting peak Doppler gradient of </text>
<text top="469" left="948" width="200" height="20" font="4">≤30 mm Hg is associated with trivial </text>
<text top="487" left="948" width="24" height="20" font="4">AR. </text>
<text top="608" left="64" width="93" height="20" font="4">Brauner R, et al. </text>
<text top="625" left="64" width="66" height="20" font="4">1997 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(370)</a>  </text>
<text top="642" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9385915?dopt=Citation">9385915</a></text>
<text top="642" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9385915?dopt=Citation"> </a></text>
<text top="608" left="172" width="31" height="20" font="4">n=75 </text>
<text top="625" left="172" width="23" height="20" font="4">pts  </text>
<text top="608" left="233" width="78" height="20" font="4">Retrospective </text>
<text top="625" left="233" width="74" height="20" font="4">single-center </text>
<text top="642" left="233" width="66" height="20" font="4">case series </text>
<text top="608" left="327" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="625" left="327" width="115" height="20" font="4">Consecutive pts that </text>
<text top="642" left="327" width="107" height="20" font="4">underwent surgical </text>
<text top="659" left="327" width="93" height="20" font="4">subAS resection </text>
<text top="608" left="469" width="106" height="20" font="4">Evaluate long-term </text>
<text top="625" left="469" width="97" height="20" font="4">clinical outcomes </text>
<text top="642" left="469" width="86" height="20" font="4">and associated </text>
<text top="659" left="469" width="97" height="20" font="4">factors in pts that </text>
<text top="677" left="469" width="92" height="20" font="4">have undergone </text>
<text top="694" left="469" width="85" height="20" font="4">surgical subAS </text>
<text top="711" left="469" width="53" height="20" font="4">resection </text>
<text top="608" left="590" width="131" height="20" font="4">● Follow-up was 6.7 y.  </text>
<text top="625" left="590" width="336" height="20" font="4">● SubAS was discrete in 68 pts (91%) and of a tunnel type in </text>
<text top="642" left="590" width="203" height="20" font="4">7, with associated VSD in 28 (37%).  </text>
<text top="659" left="590" width="320" height="20" font="4">● All underwent transaortic resection, no deaths occurred. </text>
<text top="677" left="590" width="314" height="20" font="4">● 18 recurrences of subAS in 15 pts (20%). 13 pts (17%) </text>
<text top="694" left="590" width="153" height="20" font="4">underwent 17 reoperations. </text>
<text top="711" left="590" width="317" height="20" font="4">● Residual end-operative LVOT gradient &gt;10 mm Hg and </text>
<text top="728" left="590" width="249" height="20" font="4">tunnel lesions were predictors of recurrence.  </text>
<text top="745" left="590" width="326" height="20" font="4">● 2 recurrences were noted in pts with a preoperative peak </text>
<text top="763" left="590" width="336" height="20" font="4">LVOT gradient ≤40 mm Hg (n=40), whereas higher gradients </text>
<text top="608" left="948" width="172" height="20" font="4">● Peak-to-peak catheter LVOT </text>
<text top="625" left="948" width="191" height="20" font="4">gradient ≥40 mm Hg is associated </text>
<text top="642" left="948" width="174" height="20" font="4">with worse long-term outcomes </text>
<text top="659" left="948" width="206" height="20" font="4">following surgical resection, including </text>
<text top="677" left="948" width="195" height="20" font="4">a higher recurrence rate and worse </text>
<text top="694" left="948" width="24" height="20" font="4">AR. </text>
<text top="711" left="948" width="208" height="20" font="4">● Tunnel type subAS is more likely to </text>
<text top="728" left="948" width="121" height="20" font="4">recur postoperatively. </text>
</page>
<page number="104" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 104 </text>
<text top="107" left="590" width="334" height="20" font="4">(n=35) were associated with a greater than 7-fold recurrence </text>
<text top="124" left="590" width="31" height="20" font="4">rate.  </text>
<text top="141" left="590" width="334" height="20" font="4">● The aortic valve required concomitant repair in 17 cases in </text>
<text top="159" left="590" width="301" height="20" font="4">the high gradient group (48.6%) but in only 8 in the low </text>
<text top="176" left="590" width="174" height="20" font="4">gradient group (20%; p=0.018). </text>
<text top="193" left="590" width="289" height="20" font="4">● Despite relief of the obstruction, progressive aortic </text>
<text top="210" left="590" width="341" height="20" font="4">regurgitation was noted at follow-up after 14 procedures in the </text>
<text top="228" left="590" width="329" height="20" font="4">high gradient group (40%) but after only 5 procedures in the </text>
<text top="245" left="590" width="111" height="20" font="4">low gradient group.  </text>
<text top="263" left="64" width="84" height="20" font="4">Parry AJ, et al. </text>
<text top="280" left="64" width="63" height="20" font="4">1999 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(371)</a> </text>
<text top="297" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10386409?dopt=Citation">10386409</a></text>
<text top="297" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10386409?dopt=Citation"> </a></text>
<text top="263" left="172" width="31" height="20" font="4">n=37 </text>
<text top="280" left="172" width="23" height="20" font="4">pts  </text>
<text top="263" left="233" width="78" height="20" font="4">Retrospective </text>
<text top="280" left="233" width="74" height="20" font="4">single-center </text>
<text top="297" left="233" width="66" height="20" font="4">case series </text>
<text top="263" left="327" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="280" left="327" width="116" height="20" font="4">that have undergone </text>
<text top="297" left="327" width="92" height="20" font="4">discrete surgical </text>
<text top="314" left="327" width="93" height="20" font="4">subAS resection </text>
<text top="263" left="469" width="98" height="20" font="4">Evaluate whether </text>
<text top="280" left="469" width="80" height="20" font="4">an aggressive </text>
<text top="297" left="469" width="100" height="20" font="4">surgical approach </text>
<text top="314" left="469" width="101" height="20" font="4">could reduce both </text>
<text top="332" left="469" width="80" height="20" font="4">the severity of </text>
<text top="349" left="469" width="107" height="20" font="4">aortic root and rate </text>
<text top="366" left="469" width="90" height="20" font="4">of recurrence of </text>
<text top="383" left="469" width="86" height="20" font="4">discrete subAS </text>
<text top="263" left="590" width="341" height="20" font="4">● 37 pts aged 0.5–35 y (median 7.5) underwent resection of a </text>
<text top="280" left="590" width="169" height="20" font="4">discrete subaortic membrane.  </text>
<text top="297" left="590" width="324" height="20" font="4">● 10 underwent reoperation for recurrent obstruction and 8 </text>
<text top="314" left="590" width="177" height="20" font="4">followed previous VSD closure.  </text>
<text top="332" left="590" width="332" height="20" font="4">● The preoperative peak Doppler gradient in pts with mild or </text>
<text top="349" left="590" width="328" height="20" font="4">moderate preoperative aortic root (73.9 ± 27.7 mm Hg) was </text>
<text top="366" left="590" width="319" height="20" font="4">greater than in pts with none/trace preoperative aortic root </text>
<text top="383" left="590" width="121" height="20" font="4">(57.3 ± 32.0 mm Hg). </text>
<text top="401" left="590" width="336" height="20" font="4">● Postoperative assessment was performed early (1 wk) and </text>
<text top="418" left="590" width="218" height="20" font="4">at mid-term (27.0 mo; range 2–59 mo).  </text>
<text top="435" left="590" width="305" height="20" font="4">● There was significant improvement in aortic root from </text>
<text top="452" left="590" width="283" height="20" font="4">mild/moderate to none/trivial (<i>p</i>=0.019) immediately </text>
<text top="469" left="590" width="341" height="20" font="4">postoperatively and LVOT gradient from 66.9 ± 30.4 to 15.1 ± </text>
<text top="487" left="590" width="147" height="22" font="4">12.2 mm Hg (<i>p</i>≪0.0001).  </text>
<text top="504" left="590" width="303" height="20" font="4">● By stepwise logistic regression preoperative gradient </text>
<text top="521" left="590" width="343" height="20" font="4">correlated significantly with postoperative mild/moderate aortic </text>
<text top="539" left="590" width="255" height="20" font="4">root (<i>p</i>=0.015) and LVOT gradient (<i>p</i>=0.0036). </text>
<text top="556" left="590" width="334" height="20" font="4">● Preoperative mild/moderate aortic root also correlated with </text>
<text top="573" left="590" width="280" height="20" font="4">postoperative mild/moderate aortic root (<i>p</i>=0.034).  </text>
<text top="590" left="590" width="345" height="20" font="4">● At mid-term follow-up, there was no increase in aortic root or </text>
<text top="607" left="590" width="204" height="20" font="4">LVOT gradient (14.8 ± 12.8 mm Hg). </text>
<text top="625" left="590" width="344" height="20" font="4">● Early postoperative aortic root was the strongest predictor of </text>
<text top="642" left="590" width="324" height="20" font="4">late mild/moderate aortic root <i>(p</i>=0.02). Early postoperative </text>
<text top="659" left="590" width="231" height="20" font="4">gradient was a weaker predictor <i>(p</i>=0.04). </text>
<text top="676" left="590" width="295" height="20" font="4">● Preoperative and early postoperative gradient were </text>
<text top="693" left="590" width="207" height="20" font="4">significant predictors of late gradient.  </text>
<text top="263" left="948" width="173" height="20" font="4">● A higher preoperative subAS </text>
<text top="280" left="948" width="203" height="20" font="4">gradient is associated with more AR. </text>
<text top="297" left="948" width="181" height="20" font="4">● Degree of aortic root improves </text>
<text top="314" left="948" width="154" height="20" font="4">following surgical resection. </text>
<text top="332" left="948" width="173" height="20" font="4">● A higher preoperative subAS </text>
<text top="349" left="948" width="196" height="20" font="4">gradient is associated with a higher </text>
<text top="366" left="948" width="205" height="20" font="4">likelihood of recurrence post surgery. </text>
</page>
<page number="105" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 105 </text>
<text top="107" left="64" width="89" height="20" font="4">Suarez de Lezo </text>
<text top="124" left="64" width="43" height="20" font="4">J, et al. </text>
<text top="141" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(372)</a> </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15868319?dopt=Citation">15868319</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15868319?dopt=Citation"> </a></text>
<text top="107" left="172" width="31" height="20" font="4">n=76 </text>
<text top="124" left="172" width="20" height="20" font="4">pts </text>
<text top="107" left="233" width="78" height="20" font="4">Retrospective </text>
<text top="124" left="233" width="74" height="20" font="4">single-center </text>
<text top="141" left="233" width="66" height="20" font="4">case series </text>
<text top="107" left="327" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="124" left="327" width="111" height="20" font="4">with discrete subAS </text>
<text top="141" left="327" width="128" height="20" font="4">that underwent balloon </text>
<text top="159" left="327" width="66" height="20" font="4">angioplasty </text>
<text top="107" left="469" width="64" height="20" font="4">Immediate, </text>
<text top="124" left="469" width="99" height="20" font="4">intermediate- and </text>
<text top="141" left="469" width="96" height="20" font="4">long-term clinical </text>
<text top="159" left="469" width="57" height="20" font="4">outcomes </text>
<text top="107" left="590" width="291" height="20" font="4">● 76 pts with isolated thin discrete subAS underwent </text>
<text top="124" left="590" width="328" height="20" font="4">percutaneous transluminal balloon tearing of the membrane </text>
<text top="141" left="590" width="277" height="20" font="4">and were followed up for a mean period of 16.6 y.  </text>
<text top="159" left="590" width="224" height="20" font="4">● Mean age at treatment was 19 ± 16 y. </text>
<text top="176" left="590" width="291" height="20" font="4">Immediately after treatment, the subvalvular gradient </text>
<text top="193" left="590" width="173" height="20" font="4">decreased from 70–18 mm Hg. </text>
<text top="210" left="590" width="270" height="20" font="4">● No significant postprocedural aortic root noted. </text>
<text top="228" left="590" width="209" height="20" font="4">● 11 pts developed recurrent subAS.  </text>
<text top="245" left="590" width="285" height="20" font="4">● 12 (16%) pts were redilated at a mean of 5 y post </text>
<text top="262" left="590" width="62" height="20" font="4">procedure. </text>
<text top="279" left="590" width="324" height="20" font="4">● 4 pts (5%) underwent surgery at a mean of 3 y after their </text>
<text top="296" left="590" width="85" height="20" font="4">first treatment.  </text>
<text top="314" left="590" width="343" height="20" font="4">● 58 pts (77%) remained alive and free of redilation or surgery </text>
<text top="331" left="590" width="73" height="20" font="4">at follow-up.  </text>
<text top="348" left="590" width="313" height="20" font="4">● Larger annulus diameter and thinner membranes were </text>
<text top="365" left="590" width="332" height="20" font="4">independent factors associated with better long-term results. </text>
<text top="107" left="948" width="200" height="20" font="4">● Transcatheter balloon dilation is a </text>
<text top="124" left="948" width="209" height="20" font="4">reasonable option for the treatment of </text>
<text top="141" left="948" width="187" height="20" font="4">discrete membranous subAS with </text>
<text top="159" left="948" width="170" height="20" font="4">good immediate and long-term </text>
<text top="176" left="948" width="54" height="20" font="4">outcome. </text>
<text top="383" left="64" width="78" height="20" font="4">Geva A, et al. </text>
<text top="400" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(373)</a> </text>
<text top="418" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17919571?dopt=Citation">17919571</a></text>
<text top="418" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17919571?dopt=Citation"> </a></text>
<text top="383" left="172" width="38" height="20" font="4">n=111 </text>
<text top="400" left="172" width="20" height="20" font="4">pts </text>
<text top="383" left="233" width="78" height="20" font="4">Retrospective </text>
<text top="400" left="233" width="74" height="20" font="4">single-center </text>
<text top="418" left="233" width="36" height="20" font="4">series </text>
<text top="383" left="327" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="400" left="327" width="111" height="20" font="4">with discrete subAS </text>
<text top="418" left="327" width="85" height="20" font="4">that underwent </text>
<text top="435" left="327" width="113" height="20" font="4">surgical intervention </text>
<text top="452" left="327" width="94" height="20" font="4">and had ≥36 mo </text>
<text top="469" left="327" width="67" height="20" font="4">follow-up or </text>
<text top="487" left="327" width="66" height="20" font="4">reoperation </text>
<text top="383" left="469" width="91" height="20" font="4">The 1° outcome </text>
<text top="400" left="469" width="64" height="20" font="4">was repeat </text>
<text top="418" left="469" width="99" height="20" font="4">surgical resection </text>
<text top="435" left="469" width="105" height="20" font="4">after successful 1° </text>
<text top="452" left="469" width="104" height="20" font="4">resection (residual </text>
<text top="469" left="469" width="76" height="20" font="4">peak Doppler </text>
<text top="487" left="469" width="96" height="20" font="4">gradient &lt;40 mm </text>
<text top="504" left="469" width="23" height="20" font="4">Hg) </text>
<text top="383" left="590" width="287" height="20" font="4">● 16 pts (14%) required reoperation. Median time to </text>
<text top="400" left="590" width="228" height="20" font="4">reoperation was 6.9 y (range 1.7–11.2 y). </text>
<text top="418" left="590" width="339" height="20" font="4">● Younger age at first surgery, smaller aortic velocity annulus </text>
<text top="435" left="590" width="324" height="20" font="4">diameter, shorter distance between the obstruction and the </text>
<text top="452" left="590" width="328" height="20" font="4">aortic velocity, and higher preoperation peak gradient (peak </text>
<text top="469" left="590" width="284" height="20" font="4">Doppler gradient ≥60 mm Hg) were associated with </text>
<text top="487" left="590" width="73" height="20" font="4">reoperation.  </text>
<text top="504" left="590" width="312" height="20" font="4">● Peeling of the obstructive fibrous tissue from the aortic </text>
<text top="521" left="590" width="314" height="20" font="4">velocity or mitral valve and myomectomy during the initial </text>
<text top="538" left="590" width="269" height="20" font="4">surgery were associated with future reoperation.  </text>
<text top="383" left="948" width="196" height="20" font="4">● Pts with preoperative LVOT peak </text>
<text top="400" left="948" width="184" height="20" font="4">Doppler gradient ≥60 mm Hg are </text>
<text top="418" left="948" width="183" height="20" font="4">more likely to require reoperation </text>
<text top="435" left="948" width="200" height="20" font="4">following successful initial resection. </text>
<text top="452" left="948" width="192" height="20" font="4">● Other factors predicting need for </text>
<text top="469" left="948" width="183" height="20" font="4">reoperation include earlier age at </text>
<text top="487" left="948" width="166" height="20" font="4">initial operation, smaller aortic </text>
<text top="504" left="948" width="192" height="20" font="4">annulus diameter, and proximity of </text>
<text top="521" left="948" width="180" height="20" font="4">the obstructive membrane to the </text>
<text top="538" left="948" width="69" height="20" font="4">aortic valve. </text>
<text top="556" left="64" width="86" height="20" font="4">Diller GP, et al. </text>
<text top="573" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#217">(103)</a> </text>
<text top="591" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16061735?dopt=Citation">16061735</a></text>
<text top="591" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16061735?dopt=Citation"> </a></text>
<text top="556" left="172" width="38" height="20" font="4">n=335 </text>
<text top="573" left="172" width="20" height="20" font="4">pts </text>
<text top="556" left="233" width="78" height="20" font="4">Retrospective </text>
<text top="573" left="233" width="74" height="20" font="4">single-center </text>
<text top="591" left="233" width="53" height="20" font="4">review of </text>
<text top="608" left="233" width="74" height="20" font="4">cardiopulmon</text>
<text top="625" left="233" width="70" height="20" font="4">ary exercise </text>
<text top="642" left="233" width="27" height="20" font="4">data </text>
<text top="556" left="327" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="573" left="327" width="102" height="20" font="4">335 ACHD pts, 63 </text>
<text top="591" left="327" width="70" height="20" font="4">controls that </text>
<text top="608" left="327" width="61" height="20" font="4">underwent </text>
<text top="625" left="327" width="94" height="20" font="4">cardiopulmonary </text>
<text top="642" left="327" width="89" height="20" font="4">exercise testing </text>
<text top="556" left="469" width="84" height="20" font="4">Assessment of </text>
<text top="573" left="469" width="94" height="20" font="4">cardiopulmonary </text>
<text top="591" left="469" width="98" height="20" font="4">exercise capacity </text>
<text top="608" left="469" width="79" height="20" font="4">and degree of </text>
<text top="625" left="469" width="77" height="20" font="4">impairment in </text>
<text top="642" left="469" width="58" height="20" font="4">ACHD pts </text>
<text top="556" left="590" width="62" height="20" font="4">● Peak VO</text>
<text top="562" left="652" width="4" height="13" font="6">2</text>
<text top="556" left="656" width="274" height="20" font="4"> was reduced in ACHD pts compared with healthy </text>
<text top="573" left="590" width="330" height="20" font="4">subjects of similar age (21.7 ± 8.5 vs. 45.1 ± 8.6; p&lt;0.001).  </text>
<text top="591" left="590" width="309" height="20" font="4">● No significant difference in peak v was found between </text>
<text top="608" left="590" width="322" height="20" font="4">ACHD and HF pts of corresponding NYHA class (p=NS for </text>
<text top="625" left="590" width="110" height="20" font="4">each NYHA class).  </text>
<text top="642" left="590" width="188" height="20" font="4">Within ACHD subgroups, peak VO</text>
<text top="648" left="778" width="4" height="13" font="6">2</text>
<text top="642" left="783" width="134" height="20" font="4"> gradually declined from </text>
<text top="659" left="590" width="329" height="20" font="4">aortic coarctation (28.7 ± 10.4) to Eisenmenger (11.5 ± 3.6) </text>
<text top="677" left="590" width="83" height="20" font="4">pts (p&lt;0.001).  </text>
<text top="694" left="590" width="191" height="20" font="4">Multivariable correlates of peak VO</text>
<text top="700" left="782" width="4" height="13" font="6">2</text>
<text top="694" left="786" width="120" height="20" font="4"> were peak heart rate </text>
<text top="711" left="590" width="328" height="20" font="4">(r=0.33), forced expiratory volume (r=0.33), pulmonary HTN </text>
<text top="728" left="590" width="238" height="20" font="4">(r=-0.26), sex (r=-0.23), and BMI (r=-0.19).  </text>
<text top="745" left="590" width="317" height="20" font="4">● After a median follow-up of 10 mo, 62 pts (18.5%) were </text>
<text top="763" left="590" width="140" height="20" font="4">hospitalized or had died.  </text>
<text top="556" left="948" width="198" height="20" font="4">● Exercise capacity is depressed in </text>
<text top="573" left="948" width="209" height="20" font="4">ACHD pts (even in asymptomatic pts) </text>
<text top="591" left="948" width="192" height="20" font="4">on a par with chronic HF subjects.  </text>
<text top="608" left="948" width="179" height="20" font="4">● Lack of heart rate response to </text>
<text top="625" left="948" width="187" height="20" font="4">exercise, pulmonary arterial HTN, </text>
<text top="642" left="948" width="203" height="20" font="4">and impaired pulmonary function are </text>
<text top="659" left="948" width="175" height="20" font="4">important correlates of exercise </text>
<text top="677" left="948" width="184" height="20" font="4">capacity, as is underlying cardiac </text>
<text top="694" left="948" width="57" height="20" font="4">anatomy.  </text>
<text top="711" left="948" width="192" height="20" font="4">● Poor exercise capacity identifies </text>
<text top="728" left="948" width="208" height="20" font="4">ACHD pts at risk for hospitalization or </text>
<text top="745" left="948" width="38" height="20" font="4">death. </text>
</page>
<page number="106" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 106 </text>
<text top="107" left="590" width="229" height="20" font="4">● On multivariable Cox analysis, peak VO</text>
<text top="113" left="820" width="4" height="13" font="6">2</text>
<text top="107" left="824" width="57" height="20" font="4"> predicted </text>
<text top="124" left="590" width="332" height="20" font="4">hospitalization or death (HR: 0.937; p=0.01) and was related </text>
<text top="141" left="590" width="322" height="20" font="4">to the frequency and duration of hospitalization (p=0.01 for </text>
<text top="159" left="590" width="38" height="20" font="4">each). </text>
<text top="235" left="64" width="85" height="20" font="4">Trinchero R, et </text>
<text top="252" left="64" width="16" height="20" font="4">al. </text>
<text top="269" left="64" width="63" height="20" font="4">1988 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(374)</a> </text>
<text top="286" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3234666?dopt=Citation">3234666</a></text>
<text top="286" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3234666?dopt=Citation"> </a></text>
<text top="235" left="172" width="31" height="20" font="4">n=55 </text>
<text top="252" left="172" width="23" height="20" font="4">pts  </text>
<text top="235" left="233" width="78" height="20" font="4">Retrospective </text>
<text top="252" left="233" width="74" height="20" font="4">single-center </text>
<text top="269" left="233" width="39" height="20" font="4">review </text>
<text top="235" left="327" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="252" left="327" width="100" height="20" font="4">Diagnosis of fixed </text>
<text top="269" left="327" width="40" height="20" font="4">subAS </text>
<text top="235" left="469" width="79" height="20" font="4">Operated and </text>
<text top="252" left="469" width="66" height="20" font="4">unoperated </text>
<text top="269" left="469" width="99" height="20" font="4">outcomes in fixed </text>
<text top="286" left="469" width="40" height="20" font="4">subAS </text>
<text top="235" left="590" width="331" height="20" font="4">● 55 pts, 37 men and 18 women, 8– 71 y (median age 23 y) </text>
<text top="252" left="590" width="335" height="20" font="4">with a diagnosis of fixed sub-AS were seen between January </text>
<text top="269" left="590" width="152" height="20" font="4">1966 and December 1983.  </text>
<text top="286" left="590" width="328" height="20" font="4">● Their subvalvular gradient varied between 0–135 mm Hg. </text>
<text top="303" left="590" width="297" height="20" font="4">Aortic regurgitation was present in 44 pts. 38 pts were </text>
<text top="321" left="590" width="76" height="20" font="4">operated on.  </text>
<text top="338" left="590" width="289" height="20" font="4">● 16 pts had some additional cardiac disease, either </text>
<text top="355" left="590" width="135" height="20" font="4">congenital, or acquired.  </text>
<text top="372" left="590" width="223" height="20" font="4">● There were 2 early and 2 late deaths.  </text>
<text top="390" left="590" width="331" height="20" font="4">● 15 pts were studied again after surgery: the average peak-</text>
<text top="407" left="590" width="334" height="20" font="4">to-peak gradient has decreased from 88 ± 28 to 19 ± 16 mm </text>
<text top="424" left="590" width="252" height="20" font="4">Hg and is 0 in 5. No pt needed a reoperation.  </text>
<text top="441" left="590" width="324" height="20" font="4">● Of the 17 nonoperated pts, 13 had a gradient of &lt;50 mm </text>
<text top="458" left="590" width="324" height="20" font="4">Hg; they were all in Class I–II after 1–5 y. The gradient had </text>
<text top="476" left="590" width="329" height="20" font="4">increased to 70 mm Hg in 1 of the 4 recatheterized cases. 4 </text>
<text top="493" left="590" width="341" height="20" font="4">pts had died, 2 suddenly, 2 of HF. They all had a gradient ≥55 </text>
<text top="510" left="590" width="46" height="20" font="4">mm Hg. </text>
<text top="235" left="948" width="195" height="20" font="4">● In asymptomatic with sub-AS, an </text>
<text top="252" left="948" width="174" height="20" font="4">operation can be deferred if the </text>
<text top="269" left="948" width="205" height="20" font="4">pressure gradient is less than 50 mm </text>
<text top="286" left="948" width="178" height="20" font="4">Hg, and there are no associated </text>
<text top="303" left="948" width="49" height="20" font="4">lesions.  </text>
<text top="321" left="948" width="206" height="20" font="4">● Identification of pts running the risk </text>
<text top="338" left="948" width="135" height="20" font="4">of SCD remains elusive. </text>
</page>
<page number="107" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 107 </text>
<text top="107" left="64" width="88" height="20" font="4">Dall’Agata A, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="63" height="20" font="4">1999 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(375)</a> </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10190410?dopt=Citation">10190410</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10190410?dopt=Citation"> </a></text>
<text top="107" left="172" width="31" height="20" font="4">n=28 </text>
<text top="124" left="172" width="23" height="20" font="4">pts  </text>
<text top="107" left="233" width="76" height="20" font="4">Single-center </text>
<text top="124" left="233" width="66" height="20" font="4">prospective </text>
<text top="141" left="233" width="38" height="20" font="4">cohort </text>
<text top="107" left="327" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="124" left="327" width="85" height="20" font="4">with LVOT and </text>
<text top="141" left="327" width="112" height="20" font="4">RVOTO undergoing </text>
<text top="159" left="327" width="92" height="20" font="4">2D and 3D echo </text>
<text top="176" left="327" width="60" height="20" font="4">evaluation </text>
<text top="107" left="469" width="72" height="20" font="4">Evaluate the </text>
<text top="124" left="469" width="78" height="20" font="4">feasibility and </text>
<text top="141" left="469" width="85" height="20" font="4">accuracy of 3D </text>
<text top="159" left="469" width="104" height="20" font="4">echo in analysis of </text>
<text top="176" left="469" width="97" height="20" font="4">RVOT and LVOT </text>
<text top="193" left="469" width="64" height="20" font="4">obstruction </text>
<text top="107" left="590" width="332" height="20" font="4">● 3D echo was performed in 28 pts, 4 mo–36 y, with outflow </text>
<text top="124" left="590" width="317" height="20" font="4">tract pathology. Type of lesion and relation to valves were </text>
<text top="141" left="590" width="338" height="20" font="4">assessed. Length and degree of obstruction were measured.  </text>
<text top="159" left="590" width="340" height="20" font="4">3D data sets were adequate for reconstruction in 25 of 28 pts; </text>
<text top="176" left="590" width="175" height="20" font="4">47 reconstructions were made.  </text>
<text top="193" left="590" width="342" height="20" font="4">● In 13 pts with LVOT obstruction, 3D echo was used to study </text>
<text top="210" left="590" width="341" height="20" font="4">subvalvular details in 8, valvular in 13, and supravalvular in 1.  </text>
<text top="228" left="590" width="288" height="20" font="4">4 of these 13 pts had complex subaortic obstruction. </text>
<text top="245" left="590" width="322" height="20" font="4">● In 12 pts with RVOT lesions, 3D echo was used to study </text>
<text top="262" left="590" width="345" height="20" font="4">subvalvular details in 11, valvular in 12, and supravalvular in 2. </text>
<text top="279" left="590" width="309" height="20" font="4">3D reconstructions were suitable for analysis in 100% of </text>
<text top="296" left="590" width="329" height="20" font="4">subvalvular LVOT, 77% valvular LVOT, 100% supravalvular </text>
<text top="314" left="590" width="319" height="20" font="4">LVOT, 100% subvalvular RVOT, 50% valvular RVOT, and </text>
<text top="331" left="590" width="149" height="20" font="4">50% supravalvular RVOT.  </text>
<text top="348" left="590" width="341" height="20" font="4">● 20 pts underwent operation, and surgical findings served as </text>
<text top="365" left="590" width="312" height="20" font="4">morphologic control for 34 3D reconstructions (LVOT 17, </text>
<text top="383" left="590" width="66" height="20" font="4">RVOT 17).  </text>
<text top="400" left="590" width="333" height="20" font="4">● Operative findings revealed accuracy at subvalvular LVOT </text>
<text top="417" left="590" width="315" height="20" font="4">of 100%, valvular LVOT 90%, supravalvular LVOT 100%, </text>
<text top="434" left="590" width="287" height="20" font="4">subvalvular RVOT 100%, valvular RVOT 100%, and </text>
<text top="451" left="590" width="156" height="20" font="4">supravalvular RVOT 100%.  </text>
<text top="469" left="590" width="343" height="20" font="4">● Quantitative measurements could adequately be performed. </text>
<text top="107" left="948" width="194" height="20" font="4">● 3D echo is feasible and accurate </text>
<text top="124" left="948" width="190" height="20" font="4">for analyzing both outflow tracts of </text>
<text top="141" left="948" width="207" height="20" font="4">the heart and allows a good definition </text>
<text top="159" left="948" width="198" height="20" font="4">of extension and severity of lesions. </text>
<text top="487" left="64" width="86" height="20" font="4">Diller GP, et al. </text>
<text top="504" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(376)</a> </text>
<text top="521" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16979014?dopt=Citation">16979014</a></text>
<text top="521" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16979014?dopt=Citation"> </a></text>
<text top="487" left="172" width="38" height="20" font="4">n=727 </text>
<text top="504" left="172" width="23" height="20" font="4">pts  </text>
<text top="487" left="233" width="76" height="20" font="4">Single-center </text>
<text top="504" left="233" width="74" height="20" font="4">retrospective </text>
<text top="521" left="233" width="38" height="20" font="4">cohort </text>
<text top="487" left="327" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="504" left="327" width="109" height="20" font="4">Consecutive ACHD </text>
<text top="521" left="327" width="85" height="20" font="4">pts undergoing </text>
<text top="538" left="327" width="94" height="20" font="4">cardiopulmonary </text>
<text top="555" left="327" width="89" height="20" font="4">exercise testing </text>
<text top="487" left="469" width="103" height="20" font="4">Assess prognostic </text>
<text top="504" left="469" width="103" height="20" font="4">value of heart rate </text>
<text top="521" left="469" width="68" height="20" font="4">response to </text>
<text top="538" left="469" width="100" height="20" font="4">exercise in ACHD </text>
<text top="555" left="469" width="20" height="20" font="4">pts </text>
<text top="487" left="590" width="324" height="20" font="4">● 727 consecutive ACHD pts (mean age [± SD] 33 ± 13 y) </text>
<text top="504" left="590" width="293" height="20" font="4">with varying diagnoses and without pacemaker under </text>
<text top="521" left="590" width="187" height="20" font="4">cardiopulmonary exercise testing. </text>
<text top="538" left="590" width="62" height="20" font="4">● Peak VO</text>
<text top="544" left="652" width="4" height="13" font="6">2</text>
<text top="538" left="656" width="270" height="20" font="4">, resting heart rate, and the increase in heart rate </text>
<text top="555" left="590" width="338" height="20" font="4">from resting level to peak exercise (&#34;heart rate reserve&#34;) were </text>
<text top="573" left="590" width="65" height="20" font="4">measured.  </text>
<text top="590" left="590" width="327" height="20" font="4">Quantified the decrease in heart rate (&#34;heart rate recovery&#34;) </text>
<text top="607" left="590" width="150" height="20" font="4">after cessation of exercise. </text>
<text top="624" left="590" width="280" height="20" font="4">● During a median follow-up of 28 mo, 38 pts died. </text>
<text top="641" left="590" width="327" height="20" font="4">● Lower values of heart rate reserve, peak heart rate, heart </text>
<text top="659" left="590" width="150" height="20" font="4">rate recovery, and peak VO</text>
<text top="665" left="741" width="4" height="13" font="6">2</text>
<text top="659" left="745" width="131" height="20" font="4"> (p&lt;0.01 for each) were </text>
<text top="676" left="590" width="315" height="20" font="4">associated with increased mortality in univariate analysis. </text>
<text top="693" left="590" width="313" height="20" font="4">● Heart rate reserve predicted mortality independently of </text>
<text top="710" left="590" width="223" height="20" font="4">antiarrhythmic therapy, FC, and peak VO</text>
<text top="716" left="814" width="4" height="13" font="6">2</text>
<text top="710" left="818" width="10" height="20" font="4">.  </text>
<text top="727" left="590" width="324" height="20" font="4">● Stratifying pts by diagnostic groups revealed that a lower </text>
<text top="745" left="590" width="328" height="20" font="4">heart rate reserve was also associated with a greater risk of </text>
<text top="762" left="590" width="323" height="20" font="4">death in pts with complex anatomy, Fontan circulation, and </text>
<text top="779" left="590" width="129" height="20" font="4">TOF (p&lt;0.05 for each). </text>
<text top="487" left="948" width="209" height="20" font="4">● An abnormal heart rate response to </text>
<text top="504" left="948" width="195" height="20" font="4">exercise identifies ACHD pts with a </text>
<text top="521" left="948" width="209" height="20" font="4">higher risk of mortality in the midterm. </text>
</page>
<page number="108" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 108 </text>
<text top="106" left="108" width="3" height="20" font="4"> </text>
<text top="123" left="108" width="3" height="20" font="4"> </text>
<text top="140" left="108" width="527" height="24" font="1"><b>Data Supplement 34. Congenital Valvular Aortic Stenosis – Sections 4.2.4   </b></text>
<text top="162" left="73" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="179" left="73" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="162" left="176" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="179" left="190" width="44" height="20" font="3"><b>Design </b></text>
<text top="162" left="271" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="162" left="357" width="62" height="20" font="3"><b>Follow-up </b></text>
<text top="179" left="374" width="29" height="20" font="3"><b>time </b></text>
<text top="162" left="437" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="179" left="473" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="162" left="584" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="162" left="735" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="162" left="961" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="201" left="64" width="92" height="20" font="4">Mookadam F, et </text>
<text top="218" left="64" width="16" height="20" font="4">al. </text>
<text top="236" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(377)</a> </text>
<text top="253" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20329493?dopt=Citation">20329493</a></text>
<text top="253" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20329493?dopt=Citation"> </a></text>
<text top="201" left="172" width="52" height="20" font="4">Series of </text>
<text top="218" left="172" width="56" height="20" font="4">published </text>
<text top="236" left="172" width="36" height="20" font="4">cases </text>
<text top="201" left="266" width="58" height="20" font="4">n=231 pts </text>
<text top="201" left="354" width="24" height="20" font="4">N/A </text>
<text top="201" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="218" left="435" width="96" height="20" font="4">Unicuspid valves </text>
<text top="201" left="570" width="24" height="20" font="4">N/A </text>
<text top="201" left="685" width="153" height="20" font="4">● Most associated with AS. </text>
<text top="201" left="901" width="212" height="20" font="4">● Often not diagnosed until surgery or </text>
<text top="218" left="901" width="50" height="20" font="4">autopsy. </text>
<text top="271" left="64" width="87" height="20" font="4">Gleason TG, et </text>
<text top="288" left="64" width="16" height="20" font="4">al. </text>
<text top="305" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(378)</a> </text>
<text top="322" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24930615?dopt=Citation">24930615</a></text>
<text top="322" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24930615?dopt=Citation"> </a></text>
<text top="271" left="172" width="145" height="20" font="4">Observational  n=32 pts </text>
<text top="271" left="354" width="30" height="20" font="4">2.9 y </text>
<text top="271" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="288" left="435" width="87" height="20" font="4">BAV with aortic </text>
<text top="305" left="435" width="92" height="20" font="4">root/valve repair </text>
<text top="271" left="570" width="83" height="20" font="4">Clinical events </text>
<text top="271" left="685" width="107" height="20" font="4">● No reoperations. </text>
<text top="271" left="901" width="148" height="20" font="4">● Minimal AR in follow-up. </text>
<text top="340" left="64" width="78" height="20" font="4">Kari FA, et al. </text>
<text top="357" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(379)</a> </text>
<text top="375" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23260433?dopt=Citation">23260433</a></text>
<text top="375" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23260433?dopt=Citation"> </a></text>
<text top="340" left="172" width="145" height="20" font="4">Observational  n=75 pts </text>
<text top="340" left="354" width="30" height="20" font="4">2.9 y </text>
<text top="340" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="357" left="435" width="87" height="20" font="4">BAV with aortic </text>
<text top="375" left="435" width="92" height="20" font="4">root/valve repair </text>
<text top="340" left="570" width="83" height="20" font="4">Clinical events </text>
<text top="340" left="685" width="201" height="20" font="4">● Freedom from reoperation 90% at </text>
<text top="357" left="685" width="23" height="20" font="4">6 y. </text>
<text top="340" left="901" width="240" height="20" font="4">● Reasonable mid-term results from repair. </text>
<text top="393" left="64" width="85" height="20" font="4">Alsoufi B, et al. </text>
<text top="410" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(380)</a> </text>
<text top="427" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16359055?dopt=Citation">16359055</a></text>
<text top="427" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16359055?dopt=Citation"> </a></text>
<text top="393" left="172" width="145" height="20" font="4">Observational  n=71 pts </text>
<text top="393" left="354" width="24" height="20" font="4">N/A </text>
<text top="393" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="410" left="435" width="119" height="20" font="4">BAV with aortic valve </text>
<text top="427" left="435" width="35" height="20" font="4">repair </text>
<text top="393" left="570" width="83" height="20" font="4">Clinical events </text>
<text top="393" left="685" width="177" height="20" font="4">● Moderate aortic root in &gt;50%, </text>
<text top="410" left="685" width="110" height="20" font="4">reoperation in 18%. </text>
<text top="393" left="901" width="229" height="20" font="4">● Dilation of the aortic root leads to aortic </text>
<text top="410" left="901" width="74" height="20" font="4">insufficiency. </text>
<text top="445" left="64" width="90" height="20" font="4">Davierwala PM, </text>
<text top="462" left="64" width="30" height="20" font="4">et al. </text>
<text top="479" left="64" width="63" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(381)</a> </text>
<text top="497" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14658805?dopt=Citation">14658805</a></text>
<text top="497" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14658805?dopt=Citation"> </a></text>
<text top="445" left="172" width="70" height="20" font="4">Case cohort </text>
<text top="445" left="266" width="51" height="20" font="4">n=88 pts </text>
<text top="445" left="354" width="30" height="20" font="4">2.6 y </text>
<text top="445" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="462" left="435" width="116" height="20" font="4">aortic root, repair vs. </text>
<text top="479" left="435" width="71" height="20" font="4">replacement </text>
<text top="445" left="570" width="102" height="20" font="4">Aortic root or redo </text>
<text top="462" left="570" width="44" height="20" font="4">surgery </text>
<text top="445" left="685" width="156" height="20" font="4">● 4 redo after repair, 2 after </text>
<text top="462" left="685" width="78" height="20" font="4">replacement.  </text>
<text top="445" left="901" width="253" height="20" font="4">● Moderate/severe aortic insufficiency 79% in </text>
<text top="462" left="901" width="170" height="20" font="4">repair vs. 94% in replacement. </text>
<text top="515" left="64" width="94" height="20" font="4">Svensson LG, et </text>
<text top="532" left="64" width="16" height="20" font="4">al. </text>
<text top="549" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(382)</a> </text>
<text top="566" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24680032?dopt=Citation">24680032</a></text>
<text top="566" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24680032?dopt=Citation"> </a></text>
<text top="515" left="172" width="68" height="20" font="4">Case series </text>
<text top="515" left="266" width="58" height="20" font="4">n=728 pts </text>
<text top="515" left="354" width="30" height="20" font="4">9.0 y </text>
<text top="515" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="532" left="435" width="63" height="20" font="4">BAV repair </text>
<text top="515" left="570" width="83" height="20" font="4">Clinical events </text>
<text top="515" left="685" width="192" height="20" font="4">● 3 early deaths, 2.6 y reoperation </text>
<text top="532" left="685" width="28" height="20" font="4">rate. </text>
<text top="515" left="901" width="190" height="20" font="4">● Usually aortic root was cause of </text>
<text top="532" left="901" width="69" height="20" font="4">reoperation. </text>
<text top="584" left="64" width="77" height="20" font="4">Biner S, et al. </text>
<text top="602" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(383)</a> </text>
<text top="619" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19520254?dopt=Citation">19520254</a></text>
<text top="619" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19520254?dopt=Citation"> </a></text>
<text top="584" left="172" width="145" height="20" font="4">Observational  n=48 pts </text>
<text top="584" left="354" width="24" height="20" font="4">N/A </text>
<text top="584" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="602" left="435" width="84" height="20" font="4">FDR of BAV pt </text>
<text top="584" left="570" width="94" height="20" font="4">Aortic dimension </text>
<text top="602" left="570" width="46" height="20" font="4">by echo </text>
<text top="584" left="685" width="130" height="20" font="4">● Enlargement in 32%. </text>
<text top="584" left="901" width="219" height="20" font="4">● Leaflet morphology is part of a bigger </text>
<text top="602" left="901" width="64" height="20" font="4">phenotype. </text>
<text top="637" left="64" width="77" height="20" font="4">Tutar E, et al. </text>
<text top="654" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(384)</a> </text>
<text top="671" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16169333?dopt=Citation">16169333</a></text>
<text top="671" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16169333?dopt=Citation"> </a></text>
<text top="637" left="172" width="206" height="20" font="4">Observational  n=1,075 pts  N/A </text>
<text top="637" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="654" left="435" width="74" height="20" font="4">All newborns </text>
<text top="637" left="570" width="102" height="20" font="4">Finding of BAV by </text>
<text top="654" left="570" width="30" height="20" font="4">echo </text>
<text top="637" left="685" width="146" height="20" font="4">● 4.6 in 1,000 live births.   </text>
<text top="637" left="901" width="179" height="20" font="4">● 4 times as common in males.  </text>
<text top="689" left="64" width="91" height="20" font="4">Huntington K, et </text>
<text top="706" left="64" width="16" height="20" font="4">al. </text>
<text top="723" left="64" width="63" height="20" font="4">1997 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(385)</a> </text>
<text top="741" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9385911?dopt=Citation">9385911</a></text>
<text top="741" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9385911?dopt=Citation"> </a></text>
<text top="689" left="172" width="152" height="20" font="4">Observational  n=186 pts </text>
<text top="689" left="354" width="24" height="20" font="4">N/A </text>
<text top="689" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="706" left="435" width="94" height="20" font="4">FDR of BAV pts  </text>
<text top="689" left="570" width="100" height="20" font="4">Aortic dimensions </text>
<text top="706" left="570" width="46" height="20" font="4">by echo </text>
<text top="689" left="685" width="157" height="20" font="4">● 17 (9.1%) also had BAV.   </text>
<text top="689" left="901" width="198" height="20" font="4">● More equitable male/female ratio. </text>
</page>
<page number="109" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 109 </text>
<text top="107" left="64" width="83" height="20" font="4">Sandhu SK, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="63" height="20" font="4">1995 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(386)</a> </text>
<text top="159" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8829832?dopt=Citation">8829832</a></text>
<text top="159" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8829832?dopt=Citation"> </a></text>
<text top="107" left="172" width="68" height="20" font="4">Case series </text>
<text top="107" left="266" width="51" height="20" font="4">n=15 pts </text>
<text top="107" left="354" width="30" height="20" font="4">1.5 y </text>
<text top="107" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="435" width="107" height="20" font="4">Adolescents/young </text>
<text top="141" left="435" width="121" height="20" font="4">adults with congenital </text>
<text top="159" left="435" width="20" height="20" font="4">AS </text>
<text top="107" left="570" width="100" height="20" font="4">Catheterization to </text>
<text top="124" left="570" width="99" height="20" font="4">measure gradient </text>
<text top="141" left="570" width="66" height="20" font="4">in follow-up </text>
<text top="107" left="685" width="167" height="20" font="4">● Gradients unchanged in the </text>
<text top="124" left="685" width="180" height="20" font="4">majority of those with successful </text>
<text top="141" left="685" width="75" height="20" font="4">procedures.   </text>
<text top="107" left="901" width="243" height="20" font="4">● 3 pts with inadequate relief of obstruction. </text>
<text top="124" left="901" width="210" height="20" font="4">Includes both BAV and TV stenosis. 3 </text>
<text top="141" left="901" width="169" height="20" font="4">required surgery in follow-up.   </text>
<text top="177" left="64" width="79" height="20" font="4">Arora R, et al. </text>
<text top="194" left="64" width="63" height="20" font="4">1989 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(387)</a> </text>
<text top="211" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2599541?dopt=Citation">2599541</a></text>
<text top="211" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2599541?dopt=Citation"> </a></text>
<text top="177" left="172" width="68" height="20" font="4">Case series </text>
<text top="177" left="266" width="51" height="20" font="4">n=25 pts </text>
<text top="177" left="354" width="38" height="20" font="4">16 mo </text>
<text top="177" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="194" left="435" width="113" height="20" font="4">AS (age range 6–66 </text>
<text top="211" left="435" width="14" height="20" font="4">y) </text>
<text top="177" left="570" width="57" height="20" font="4">Follow-up </text>
<text top="194" left="570" width="54" height="20" font="4">gradients </text>
<text top="177" left="685" width="182" height="20" font="4">● Almost half had progression of </text>
<text top="194" left="685" width="186" height="20" font="4">gradients compared to immediate </text>
<text top="211" left="685" width="129" height="20" font="4">post procedure results. </text>
<text top="177" left="901" width="249" height="20" font="4">● BAV pts more prevalent in the pts who had </text>
<text top="194" left="901" width="119" height="20" font="4">progressive stenosis. </text>
<text top="229" left="64" width="87" height="20" font="4">Fernandes SM, </text>
<text top="246" left="64" width="30" height="20" font="4">et al. </text>
<text top="263" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(388)</a> </text>
<text top="281" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15489098?dopt=Citation">15489098</a></text>
<text top="281" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15489098?dopt=Citation"> </a></text>
<text top="229" left="172" width="68" height="20" font="4">Case series </text>
<text top="229" left="266" width="58" height="20" font="4">n=569 pts </text>
<text top="229" left="354" width="24" height="20" font="4">N/A </text>
<text top="229" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="246" left="435" width="62" height="20" font="4">All pts with </text>
<text top="263" left="435" width="108" height="20" font="4">interpretable echos </text>
<text top="281" left="435" width="53" height="20" font="4">with BAV </text>
<text top="229" left="570" width="66" height="20" font="4">Coarctation </text>
<text top="246" left="570" width="58" height="20" font="4">coexisting </text>
<text top="229" left="685" width="183" height="20" font="4">● ~11% of pts had a coarctation. </text>
<text top="229" left="901" width="250" height="20" font="4">● Among isolated coarctation pts, 55% had a </text>
<text top="246" left="901" width="31" height="20" font="4">BAV. </text>
<text top="299" left="64" width="76" height="20" font="4">Nistri S, et al. </text>
<text top="316" left="64" width="63" height="20" font="4">1999 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(389)</a> </text>
<text top="333" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10377302?dopt=Citation">10377302</a></text>
<text top="333" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10377302?dopt=Citation"> </a></text>
<text top="299" left="172" width="68" height="20" font="4">Case series </text>
<text top="299" left="266" width="51" height="20" font="4">n=66 pts </text>
<text top="299" left="354" width="24" height="20" font="4">N/A </text>
<text top="299" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="316" left="435" width="113" height="20" font="4">BAV pts undergoing </text>
<text top="333" left="435" width="30" height="20" font="4">echo </text>
<text top="299" left="570" width="86" height="20" font="4">Aortic diameter </text>
<text top="316" left="570" width="46" height="20" font="4">by echo </text>
<text top="299" left="685" width="188" height="20" font="4">● AR was significantly larger than </text>
<text top="316" left="685" width="111" height="20" font="4">controls at all levels </text>
<text top="299" left="901" width="231" height="20" font="4">● Independent of valve function, age, and </text>
<text top="316" left="901" width="59" height="20" font="4">body size. </text>
<text top="351" left="64" width="93" height="20" font="4">Della Corte A, et </text>
<text top="368" left="64" width="16" height="20" font="4">al. </text>
<text top="385" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(390)</a> </text>
<text top="403" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17236783?dopt=Citation">17236783</a></text>
<text top="403" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17236783?dopt=Citation"> </a></text>
<text top="351" left="172" width="68" height="20" font="4">Case series </text>
<text top="351" left="266" width="58" height="20" font="4">n=280 pts </text>
<text top="351" left="354" width="24" height="20" font="4">N/A </text>
<text top="351" left="435" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="368" left="435" width="113" height="20" font="4">BAV pts undergoing </text>
<text top="385" left="435" width="30" height="20" font="4">echo </text>
<text top="351" left="570" width="86" height="20" font="4">Aortic diameter </text>
<text top="368" left="570" width="46" height="20" font="4">by echo </text>
<text top="351" left="685" width="186" height="20" font="4">● 83% of pts had abnormal aortic </text>
<text top="368" left="685" width="76" height="20" font="4">dimensions.   </text>
<text top="351" left="901" width="239" height="20" font="4">● 43% of pts had surgical indications. Male </text>
<text top="368" left="901" width="253" height="20" font="4">sex, age, and severe aortic regurgitation were </text>
<text top="385" left="901" width="73" height="20" font="4">risk factors.   </text>
<text top="421" left="54" width="3" height="20" font="4"> </text>
<text top="438" left="54" width="3" height="20" font="4"> </text>
<text top="455" left="108" width="404" height="24" font="1"><b>Data Supplement 35. Turner Syndrome – Section 4.2.4.1   </b></text>
<text top="476" left="73" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="494" left="73" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="476" left="190" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="494" left="204" width="44" height="20" font="3"><b>Design </b></text>
<text top="476" left="295" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="476" left="387" width="90" height="20" font="3"><b>Follow-up time </b></text>
<text top="476" left="504" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="494" left="540" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="476" left="662" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="476" left="813" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="476" left="995" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="515" left="64" width="93" height="20" font="4">Carlson M, et al. </text>
<text top="533" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(161)</a> </text>
<text top="550" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23032325?dopt=Citation">23032325</a></text>
<text top="550" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23032325?dopt=Citation"> </a></text>
<text top="515" left="172" width="68" height="20" font="4">Registry pts </text>
<text top="515" left="293" width="51" height="20" font="4">n=20 pts </text>
<text top="515" left="374" width="97" height="20" font="4">Turner syndrome </text>
<text top="533" left="374" width="83" height="20" font="4">with dissection </text>
<text top="515" left="503" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="533" left="503" width="24" height="20" font="4">N/A </text>
<text top="515" left="638" width="78" height="20" font="4">Size 2.7 cm/m</text>
<text top="517" left="715" width="4" height="13" font="6">2</text>
<text top="515" left="720" width="17" height="20" font="4"> at </text>
<text top="533" left="638" width="98" height="20" font="4">time of dissection </text>
<text top="515" left="773" width="24" height="20" font="4">N/A </text>
<text top="515" left="968" width="24" height="20" font="4">N/A </text>
<text top="568" left="64" width="73" height="20" font="4">Lin AE, et al. </text>
<text top="585" left="64" width="63" height="20" font="4">1998 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(391)</a> </text>
<text top="602" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9651464?dopt=Citation">9651464</a></text>
<text top="602" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9651464?dopt=Citation"> </a></text>
<text top="568" left="172" width="97" height="20" font="4">Survey of society </text>
<text top="585" left="172" width="55" height="20" font="4">members </text>
<text top="568" left="293" width="58" height="20" font="4">n=245 pts </text>
<text top="568" left="374" width="97" height="20" font="4">Turner syndrome </text>
<text top="568" left="503" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="585" left="503" width="24" height="20" font="4">N/A </text>
<text top="568" left="638" width="114" height="20" font="4">CV medicine in 52% </text>
<text top="568" left="773" width="172" height="20" font="4">● 15 dissections, 80% of those </text>
<text top="585" left="773" width="152" height="20" font="4">with CV malformation/HTN. </text>
<text top="568" left="968" width="24" height="20" font="4">N/A </text>
<text top="620" left="64" width="92" height="20" font="4">Sybert VP, et al. </text>
<text top="637" left="64" width="63" height="20" font="4">1998 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(392)</a> </text>
<text top="655" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9417175?dopt=Citation">9417175</a></text>
<text top="655" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9417175?dopt=Citation"> </a></text>
<text top="620" left="172" width="79" height="20" font="4">Observational </text>
<text top="620" left="293" width="58" height="20" font="4">n=244 pts </text>
<text top="620" left="374" width="97" height="20" font="4">Turner syndrome </text>
<text top="637" left="374" width="36" height="20" font="4">adults </text>
<text top="620" left="503" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="637" left="503" width="24" height="20" font="4">N/A </text>
<text top="620" left="638" width="74" height="20" font="4">56% with CV </text>
<text top="637" left="638" width="53" height="20" font="4">medicine </text>
<text top="620" left="773" width="124" height="20" font="4">● 3 aortic dissections. </text>
<text top="620" left="968" width="24" height="20" font="4">N/A </text>
<text top="673" left="64" width="94" height="20" font="4">Matura LA, et al. </text>
<text top="690" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(393)</a> </text>
<text top="707" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17875973?dopt=Citation">17875973</a></text>
<text top="707" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17875973?dopt=Citation"> </a></text>
<text top="673" left="172" width="105" height="20" font="4">Observational MRI </text>
<text top="690" left="172" width="33" height="20" font="4">study </text>
<text top="673" left="293" width="58" height="20" font="4">n=166 pts </text>
<text top="673" left="374" width="97" height="20" font="4">Turner syndrome </text>
<text top="690" left="374" width="36" height="20" font="4">adults </text>
<text top="673" left="503" width="116" height="20" font="3"><b>Inclusion criteria</b>: 3 </text>
<text top="690" left="503" width="10" height="20" font="4">y </text>
<text top="673" left="638" width="24" height="20" font="4">N/A </text>
<text top="673" left="773" width="183" height="20" font="4">● 3 dissections, all with diameter </text>
<text top="690" left="773" width="58" height="20" font="4">&gt;2.5 cm/m</text>
<text top="691" left="830" width="4" height="13" font="6">2</text>
<text top="690" left="835" width="7" height="20" font="4">. </text>
<text top="673" left="968" width="24" height="20" font="4">N/A </text>
<text top="725" left="64" width="79" height="20" font="4">Hjerrild BE, et </text>
<text top="742" left="64" width="16" height="20" font="4">al. </text>
<text top="759" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(394)</a> </text>
<text top="777" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20222980?dopt=Citation">20222980</a></text>
<text top="777" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20222980?dopt=Citation"> </a></text>
<text top="725" left="172" width="105" height="20" font="4">Observational MRI </text>
<text top="742" left="172" width="33" height="20" font="4">study </text>
<text top="725" left="293" width="58" height="20" font="4">n=102 pts </text>
<text top="725" left="374" width="97" height="20" font="4">Turner syndrome </text>
<text top="742" left="374" width="36" height="20" font="4">adults </text>
<text top="725" left="503" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="742" left="503" width="24" height="20" font="4">N/A </text>
<text top="725" left="638" width="53" height="20" font="4">23% with </text>
<text top="742" left="638" width="75" height="20" font="4">enlargement. </text>
<text top="759" left="638" width="117" height="20" font="4">Associated with BAV </text>
<text top="777" left="638" width="44" height="20" font="4">and BP </text>
<text top="725" left="773" width="24" height="20" font="4">N/A </text>
<text top="725" left="968" width="24" height="20" font="4">N/A </text>
</page>
<page number="110" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 110 </text>
<text top="107" left="64" width="80" height="20" font="4">Cleeman L, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(395)</a> </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20063160?dopt=Citation">20063160</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20063160?dopt=Citation"> </a></text>
<text top="107" left="172" width="105" height="20" font="4">Observational MRI </text>
<text top="124" left="172" width="33" height="20" font="4">study </text>
<text top="107" left="293" width="51" height="20" font="4">n=41 pts </text>
<text top="107" left="374" width="97" height="20" font="4">Turner syndrome </text>
<text top="124" left="374" width="73" height="20" font="4">young adults </text>
<text top="107" left="503" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="503" width="24" height="20" font="4">N/A </text>
<text top="107" left="638" width="104" height="20" font="4">Dilatation in only 4 </text>
<text top="124" left="638" width="20" height="20" font="4">pts </text>
<text top="107" left="773" width="33" height="20" font="4">None </text>
<text top="107" left="968" width="24" height="20" font="4">N/A </text>
<text top="177" left="54" width="3" height="20" font="4"> </text>
<text top="194" left="108" width="368" height="24" font="1"><b>Data Supplement 36. Aortopathies – Section 4.2.4.2  </b></text>
<text top="215" left="73" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="233" left="73" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="215" left="176" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="233" left="190" width="44" height="20" font="3"><b>Design </b></text>
<text top="215" left="271" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="215" left="377" width="44" height="20" font="3"><b>Cohort </b></text>
<text top="233" left="374" width="49" height="20" font="3"><b>Studied </b></text>
<text top="215" left="476" width="62" height="20" font="3"><b>Follow-up </b></text>
<text top="233" left="460" width="93" height="20" font="3"><b>Duration (Mean </b></text>
<text top="250" left="474" width="66" height="20" font="3"><b>or Median) </b></text>
<text top="215" left="595" width="39" height="20" font="3"><b>Aortic </b></text>
<text top="233" left="575" width="78" height="20" font="3"><b>Enlargement </b></text>
<text top="215" left="675" width="155" height="20" font="3"><b>Aortic Rupture/Dissection </b></text>
<text top="215" left="876" width="77" height="20" font="3"><b>Risk Factors </b></text>
<text top="215" left="1030" width="67" height="20" font="3"><b>Comments </b></text>
<text top="268" left="64" width="161" height="20" font="3"><b>Conotruncal Abnormalities </b></text>
<text top="286" left="64" width="73" height="20" font="4">Rutz T, et al. </text>
<text top="303" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(396)</a> </text>
<text top="320" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22459299?dopt=Citation">22459299</a></text>
<text top="320" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22459299?dopt=Citation"> </a></text>
<text top="286" left="172" width="145" height="20" font="4">Observational  n=39 pts </text>
<text top="286" left="354" width="60" height="20" font="4">TOF, TGA </text>
<text top="286" left="456" width="24" height="20" font="4">N/A </text>
<text top="286" left="570" width="24" height="20" font="4">N/A </text>
<text top="286" left="671" width="10" height="20" font="4">0 </text>
<text top="286" left="847" width="24" height="20" font="4">N/A </text>
<text top="286" left="995" width="85" height="20" font="4">● Larger aortic </text>
<text top="303" left="995" width="129" height="20" font="4">diameter than controls. </text>
<text top="338" left="64" width="89" height="20" font="4">Christensen JT, </text>
<text top="355" left="64" width="30" height="20" font="4">et al. </text>
<text top="372" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(397)</a> </text>
<text top="390" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24480147?dopt=Citation">24480147</a></text>
<text top="390" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24480147?dopt=Citation"> </a></text>
<text top="338" left="172" width="152" height="20" font="4">Observational  n=124 pts </text>
<text top="338" left="354" width="28" height="20" font="4">TOF </text>
<text top="338" left="456" width="24" height="20" font="4">N/A </text>
<text top="338" left="570" width="24" height="20" font="4">N/A </text>
<text top="338" left="671" width="10" height="20" font="4">0 </text>
<text top="338" left="847" width="24" height="20" font="4">N/A </text>
<text top="338" left="995" width="127" height="20" font="4">● Pulse wave velocity; </text>
<text top="355" left="995" width="121" height="20" font="4">correlated with age at </text>
<text top="372" left="995" width="38" height="20" font="4">repair. </text>
<text top="407" left="64" width="91" height="20" font="4">Mongeon FP, et </text>
<text top="425" left="64" width="16" height="20" font="4">al. </text>
<text top="442" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(398)</a> </text>
<text top="459" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23224208?dopt=Citation">23224208</a></text>
<text top="459" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23224208?dopt=Citation"> </a></text>
<text top="407" left="172" width="152" height="20" font="4">Observational  n=474 pts </text>
<text top="407" left="354" width="28" height="20" font="4">TOF </text>
<text top="407" left="456" width="24" height="20" font="4">N/A </text>
<text top="407" left="570" width="28" height="20" font="4">29% </text>
<text top="407" left="671" width="10" height="20" font="4">0 </text>
<text top="407" left="847" width="90" height="20" font="4">● Diameter &gt;40 </text>
<text top="425" left="847" width="117" height="20" font="4">associated with male </text>
<text top="442" left="847" width="121" height="20" font="4">sex, PA, AR, not arch </text>
<text top="459" left="847" width="69" height="20" font="4">sidedness.   </text>
<text top="407" left="995" width="125" height="20" font="4">● 3.5% with moderate-</text>
<text top="425" left="995" width="79" height="20" font="4">to-severe AR. </text>
<text top="477" left="64" width="76" height="20" font="4">Niwa K, et al. </text>
<text top="494" left="64" width="63" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(399)</a> </text>
<text top="512" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12221055?dopt=Citation">12221055</a></text>
<text top="512" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12221055?dopt=Citation"> </a></text>
<text top="477" left="172" width="152" height="20" font="4">Observational  n=216 pts </text>
<text top="477" left="354" width="28" height="20" font="4">TOF </text>
<text top="477" left="456" width="24" height="20" font="4">N/A </text>
<text top="477" left="570" width="28" height="20" font="4">15% </text>
<text top="477" left="671" width="10" height="20" font="4">0 </text>
<text top="477" left="847" width="130" height="20" font="4">● Shunt-repair interval, </text>
<text top="494" left="847" width="114" height="20" font="4">PA, right sided arch, </text>
<text top="512" left="847" width="107" height="20" font="4">increased CT ratio. </text>
<text top="477" left="995" width="24" height="20" font="4">N/A </text>
<text top="530" left="64" width="91" height="20" font="4">Stulak JM, et al. </text>
<text top="547" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(400)</a> </text>
<text top="564" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21092798?dopt=Citation">21092798</a></text>
<text top="564" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21092798?dopt=Citation"> </a></text>
<text top="530" left="172" width="48" height="20" font="4">Surgical </text>
<text top="547" left="172" width="36" height="20" font="4">series </text>
<text top="530" left="266" width="51" height="20" font="4">n=81 pts </text>
<text top="530" left="354" width="70" height="20" font="4">Conotruncal </text>
<text top="530" left="456" width="24" height="20" font="4">N/A </text>
<text top="530" left="570" width="24" height="20" font="4">N/A </text>
<text top="530" left="671" width="10" height="20" font="4">0 </text>
<text top="530" left="847" width="131" height="20" font="4">● Surgeries performed. </text>
<text top="547" left="847" width="128" height="20" font="4">4 reoperations. No late </text>
<text top="564" left="847" width="68" height="20" font="4">dissections. </text>
<text top="530" left="995" width="106" height="20" font="4">● Authors argue in </text>
<text top="547" left="995" width="93" height="20" font="4">favor of watchful </text>
<text top="564" left="995" width="45" height="20" font="4">waiting. </text>
<text top="582" left="64" width="98" height="20" font="3"><b>Ross Procedure </b></text>
<text top="600" left="64" width="79" height="20" font="4">Aljassim O, et </text>
<text top="617" left="64" width="16" height="20" font="4">al. </text>
<text top="634" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(401)</a> </text>
<text top="652" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21277595?dopt=Citation">21277595</a></text>
<text top="652" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21277595?dopt=Citation"> </a></text>
<text top="600" left="172" width="145" height="20" font="4">Observational  n=91 pts </text>
<text top="600" left="354" width="20" height="20" font="4">AS </text>
<text top="600" left="456" width="21" height="20" font="4">8.9 </text>
<text top="600" left="570" width="28" height="20" font="4">33% </text>
<text top="600" left="671" width="10" height="20" font="4">0 </text>
<text top="600" left="847" width="24" height="20" font="4">N/A </text>
<text top="600" left="995" width="116" height="20" font="4">● 44% had enlarged </text>
<text top="617" left="995" width="129" height="20" font="4">proximal aorta (native). </text>
<text top="670" left="64" width="86" height="20" font="4">de Kerchove L, </text>
<text top="687" left="64" width="30" height="20" font="4">et al. </text>
<text top="704" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(402)</a> </text>
<text top="721" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19101277?dopt=Citation">19101277</a></text>
<text top="721" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19101277?dopt=Citation"> </a></text>
<text top="670" left="172" width="152" height="20" font="4">Observational  n=218 pts </text>
<text top="670" left="354" width="20" height="20" font="4">AS </text>
<text top="670" left="456" width="21" height="20" font="4">7.8 </text>
<text top="670" left="570" width="28" height="20" font="4">17% </text>
<text top="670" left="671" width="10" height="20" font="4">0 </text>
<text top="670" left="847" width="24" height="20" font="4">N/A </text>
<text top="670" left="995" width="71" height="20" font="4">● ~17% had </text>
<text top="687" left="995" width="117" height="20" font="4">reoperation, most for </text>
<text top="704" left="995" width="108" height="20" font="4">autograft dilatation. </text>
<text top="739" left="64" width="80" height="20" font="4">Luciani GB, et </text>
<text top="756" left="64" width="16" height="20" font="4">al. </text>
<text top="774" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(403)</a> </text>
<text top="739" left="172" width="152" height="20" font="4">Observational  n=112 pts </text>
<text top="739" left="354" width="20" height="20" font="4">AS </text>
<text top="739" left="456" width="21" height="20" font="4">5.1 </text>
<text top="739" left="570" width="28" height="20" font="4">29% </text>
<text top="739" left="671" width="10" height="20" font="4">0 </text>
<text top="739" left="847" width="24" height="20" font="4">N/A </text>
<text top="739" left="995" width="129" height="20" font="4">● Reoperation in 5 pts. </text>
</page>
<page number="111" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 111 </text>
<text top="107" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16359057?dopt=Citation">16359057</a></text>
<text top="107" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16359057?dopt=Citation"> </a></text>
<text top="155" left="64" width="80" height="20" font="4">Luciani GB, et </text>
<text top="172" left="64" width="16" height="20" font="4">al. </text>
<text top="190" left="64" width="63" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(404)</a> </text>
<text top="207" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12970210?dopt=Citation">12970210</a></text>
<text top="207" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12970210?dopt=Citation"> </a></text>
<text top="155" left="172" width="145" height="20" font="4">Observational  n=91 pts </text>
<text top="155" left="354" width="20" height="20" font="4">AS </text>
<text top="155" left="456" width="10" height="20" font="4">4 </text>
<text top="155" left="570" width="28" height="20" font="4">34% </text>
<text top="155" left="671" width="10" height="20" font="4">0 </text>
<text top="155" left="847" width="24" height="20" font="4">N/A </text>
<text top="155" left="995" width="24" height="20" font="4">N/A </text>
<text top="225" left="64" width="151" height="20" font="3"><b>Arterial Switch Operation </b></text>
<text top="243" left="64" width="94" height="20" font="4">Kempny A, et al. </text>
<text top="260" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(405)</a> </text>
<text top="277" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22884697?dopt=Citation">22884697</a></text>
<text top="277" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22884697?dopt=Citation"> </a></text>
<text top="243" left="172" width="152" height="20" font="4">Observational  n=145 pts </text>
<text top="243" left="354" width="29" height="20" font="4">ASO </text>
<text top="243" left="456" width="24" height="20" font="4">N/A </text>
<text top="243" left="570" width="24" height="20" font="4">N/A </text>
<text top="243" left="671" width="21" height="20" font="4">0% </text>
<text top="243" left="847" width="24" height="20" font="4">N/A </text>
<text top="243" left="995" width="127" height="20" font="4">● 1% reoperation rate. </text>
<text top="295" left="64" width="90" height="20" font="4">Fricke TA, et al. </text>
<text top="312" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(406)</a> </text>
<text top="329" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22607787?dopt=Citation">22607787</a></text>
<text top="329" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22607787?dopt=Citation"> </a></text>
<text top="295" left="172" width="152" height="20" font="4">Observational  n=618 pts </text>
<text top="295" left="354" width="29" height="20" font="4">ASO </text>
<text top="295" left="456" width="24" height="20" font="4">N/A </text>
<text top="295" left="570" width="24" height="20" font="4">N/A </text>
<text top="295" left="671" width="21" height="20" font="4">0% </text>
<text top="295" left="847" width="92" height="20" font="4">● LVOTO, arch, </text>
<text top="312" left="847" width="49" height="20" font="4">premier. </text>
<text top="295" left="995" width="127" height="20" font="4">● 1% reoperation rate. </text>
<text top="347" left="64" width="79" height="20" font="4">Lim HG, et al. </text>
<text top="365" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(407)</a> </text>
<text top="382" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22573720?dopt=Citation">22573720</a></text>
<text top="382" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22573720?dopt=Citation"> </a></text>
<text top="347" left="172" width="152" height="20" font="4">Observational  n=220 pts </text>
<text top="347" left="354" width="29" height="20" font="4">ASO </text>
<text top="347" left="456" width="24" height="20" font="4">N/A </text>
<text top="347" left="570" width="24" height="20" font="4">N/A </text>
<text top="347" left="671" width="21" height="20" font="4">0% </text>
<text top="347" left="847" width="123" height="20" font="4">● Size of aorta, aorta. </text>
<text top="347" left="995" width="127" height="20" font="4">● 2% reoperation rate. </text>
<text top="400" left="64" width="87" height="20" font="4">van der Bom T, </text>
<text top="417" left="64" width="30" height="20" font="4">et al. </text>
<text top="434" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(408)</a> </text>
<text top="451" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24837983?dopt=Citation">24837983</a></text>
<text top="451" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24837983?dopt=Citation"> </a></text>
<text top="400" left="172" width="152" height="20" font="4">Observational  n=116 pts </text>
<text top="400" left="354" width="29" height="20" font="4">ASO </text>
<text top="400" left="456" width="10" height="20" font="4">7 </text>
<text top="400" left="570" width="24" height="20" font="4">N/A </text>
<text top="400" left="671" width="10" height="20" font="4">0 </text>
<text top="400" left="847" width="24" height="20" font="4">N/A </text>
<text top="400" left="995" width="107" height="20" font="4">● There was linear </text>
<text top="417" left="995" width="127" height="20" font="4">growth of the neoaorta </text>
<text top="434" left="995" width="135" height="20" font="4">3 pts underwent surgery </text>
<text top="451" left="995" width="98" height="20" font="4">(7 y of follow-up). </text>
<text top="469" left="64" width="130" height="20" font="3"><b>Bicuspid Aortic Valve </b></text>
<text top="487" left="64" width="91" height="20" font="4">Avadhani SA, et </text>
<text top="505" left="64" width="16" height="20" font="4">al. </text>
<text top="522" left="64" width="63" height="20" font="4">2015 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(409)</a> </text>
<text top="539" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25644322?dopt=Citation">25644322</a></text>
<text top="539" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25644322?dopt=Citation"> </a></text>
<text top="487" left="172" width="47" height="20" font="4">Referral </text>
<text top="505" left="172" width="60" height="20" font="4">population </text>
<text top="487" left="266" width="58" height="20" font="4">n=115 pts </text>
<text top="487" left="354" width="28" height="20" font="4">BAV </text>
<text top="487" left="456" width="10" height="20" font="4">5 </text>
<text top="487" left="570" width="24" height="20" font="4">N/A </text>
<text top="487" left="671" width="10" height="20" font="4">0 </text>
<text top="487" left="847" width="97" height="20" font="4">● Age and family </text>
<text top="505" left="847" width="132" height="20" font="4">history were regurgitant </text>
<text top="522" left="847" width="129" height="20" font="4">fraction for progressive </text>
<text top="539" left="847" width="75" height="20" font="4">enlargement. </text>
<text top="487" left="995" width="107" height="20" font="4">● Ascending aortic </text>
<text top="505" left="995" width="130" height="20" font="4">dilatation of 0.47 mm/y. </text>
<text top="522" left="995" width="117" height="20" font="4">20% had aortic valve </text>
<text top="539" left="995" width="114" height="20" font="4">surgery in follow-up. </text>
<text top="557" left="64" width="86" height="20" font="4">Ohnemus D, et </text>
<text top="574" left="64" width="16" height="20" font="4">al. </text>
<text top="591" left="64" width="63" height="20" font="4">2015 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(410)</a> </text>
<text top="609" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24735381?dopt=Citation">24735381</a></text>
<text top="609" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24735381?dopt=Citation"> </a></text>
<text top="557" left="172" width="42" height="20" font="4">referral </text>
<text top="574" left="172" width="60" height="20" font="4">population </text>
<text top="557" left="266" width="58" height="20" font="4">n=141 pts </text>
<text top="557" left="354" width="88" height="20" font="4">Adolescent and </text>
<text top="574" left="354" width="73" height="20" font="4">young adults </text>
<text top="591" left="354" width="53" height="20" font="4">with BAV </text>
<text top="557" left="456" width="21" height="20" font="4">3.1 </text>
<text top="557" left="570" width="24" height="20" font="4">N/A </text>
<text top="557" left="671" width="10" height="20" font="4">0 </text>
<text top="557" left="847" width="24" height="20" font="4">N/A </text>
<text top="557" left="995" width="116" height="20" font="4">● Aortic change was </text>
<text top="574" left="995" width="132" height="20" font="4">not different in those on </text>
<text top="591" left="995" width="35" height="20" font="4">ACEI. </text>
<text top="627" left="64" width="87" height="20" font="4">Roberts WC, et </text>
<text top="644" left="64" width="16" height="20" font="4">al. </text>
<text top="661" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(411)</a> </text>
<text top="678" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23117850?dopt=Citation">23117850</a></text>
<text top="678" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23117850?dopt=Citation"> </a></text>
<text top="627" left="172" width="152" height="20" font="4">Autopsy study  n=218 pts </text>
<text top="627" left="354" width="67" height="20" font="4">Aortic valve </text>
<text top="644" left="354" width="81" height="20" font="4">malformations </text>
<text top="627" left="456" width="24" height="20" font="4">N/A </text>
<text top="627" left="570" width="24" height="20" font="4">N/A </text>
<text top="627" left="671" width="21" height="20" font="4">8% </text>
<text top="627" left="847" width="24" height="20" font="4">N/A </text>
<text top="627" left="995" width="126" height="20" font="4">● 13% were unicuspid </text>
<text top="644" left="995" width="42" height="20" font="4">valves. </text>
<text top="696" left="64" width="92" height="20" font="4">Michelena HI, et </text>
<text top="713" left="64" width="16" height="20" font="4">al. </text>
<text top="731" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(412)</a> </text>
<text top="748" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21917581?dopt=Citation">21917581</a></text>
<text top="748" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21917581?dopt=Citation"> </a></text>
<text top="696" left="172" width="61" height="20" font="4">Population </text>
<text top="713" left="172" width="33" height="20" font="4">study </text>
<text top="696" left="266" width="58" height="20" font="4">n=416 pts </text>
<text top="696" left="354" width="31" height="20" font="4">BAV  </text>
<text top="696" left="456" width="17" height="20" font="4">16 </text>
<text top="696" left="570" width="24" height="20" font="4">N/A </text>
<text top="696" left="671" width="31" height="20" font="4">0.5% </text>
<text top="696" left="847" width="112" height="20" font="4">● Older age (&gt;50 y) </text>
<text top="713" left="847" width="83" height="20" font="4">and those with </text>
<text top="731" left="847" width="68" height="20" font="4">aneurysm.   </text>
<text top="696" left="995" width="90" height="20" font="4">● 49 underwent </text>
<text top="713" left="995" width="48" height="20" font="4">surgery. </text>
</page>
<page number="112" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 112 </text>
<text top="107" left="64" width="89" height="20" font="4">Oliver JM, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(413)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19766771?dopt=Citation">19766771</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19766771?dopt=Citation"> </a></text>
<text top="107" left="172" width="47" height="20" font="4">Referral </text>
<text top="124" left="172" width="60" height="20" font="4">population </text>
<text top="107" left="266" width="58" height="20" font="4">n=341 pts </text>
<text top="107" left="354" width="68" height="20" font="4">BAV with or </text>
<text top="124" left="354" width="69" height="20" font="4">without CoA </text>
<text top="141" left="354" width="50" height="20" font="4">who had </text>
<text top="159" left="354" width="77" height="20" font="4">follow-up &gt;12 </text>
<text top="176" left="354" width="21" height="20" font="4">mo </text>
<text top="107" left="456" width="10" height="20" font="4">7 </text>
<text top="107" left="570" width="81" height="20" font="4">3% developed </text>
<text top="124" left="570" width="80" height="20" font="4">aorta &gt;55 mm </text>
<text top="107" left="671" width="31" height="20" font="4">0.9% </text>
<text top="107" left="847" width="119" height="20" font="4">● BAV plus CoA was </text>
<text top="124" left="847" width="119" height="20" font="4">more associated with </text>
<text top="141" left="847" width="93" height="20" font="4">ascending aortic </text>
<text top="159" left="847" width="121" height="20" font="4">complications (1.3 vs. </text>
<text top="176" left="847" width="75" height="20" font="4">0.2/100 pt y). </text>
<text top="107" left="995" width="24" height="20" font="4">N/A </text>
<text top="194" left="64" width="79" height="20" font="4">Davies RR, et </text>
<text top="211" left="64" width="16" height="20" font="4">al. </text>
<text top="228" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(414)</a> </text>
<text top="245" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17383337?dopt=Citation">17383337</a></text>
<text top="245" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17383337?dopt=Citation"> </a></text>
<text top="194" left="172" width="46" height="20" font="4">Pts with </text>
<text top="211" left="172" width="57" height="20" font="4">aneurysm </text>
<text top="194" left="266" width="51" height="20" font="4">n=70 pts </text>
<text top="194" left="354" width="53" height="20" font="4">BAV with </text>
<text top="211" left="354" width="57" height="20" font="4">aneurysm </text>
<text top="194" left="456" width="21" height="20" font="4">3.5 </text>
<text top="194" left="570" width="24" height="20" font="4">N/A </text>
<text top="194" left="671" width="31" height="20" font="4">8.6% </text>
<text top="194" left="847" width="133" height="20" font="4">● AS, AR, or CAD were </text>
<text top="211" left="847" width="101" height="20" font="4">not risk factors for </text>
<text top="228" left="847" width="118" height="20" font="4">rupture or dissection. </text>
<text top="194" left="995" width="107" height="20" font="4">● Growth rate 0.19 </text>
<text top="211" left="995" width="124" height="20" font="4">cm/y. AS, AR, or CAD </text>
<text top="228" left="995" width="131" height="20" font="4">were not risk factors for </text>
<text top="245" left="995" width="118" height="20" font="4">rupture or dissection. </text>
<text top="263" left="54" width="3" height="20" font="4"> </text>
<text top="281" left="54" width="3" height="20" font="4"> </text>
<text top="298" left="108" width="470" height="24" font="1"><b>Data Supplement 37. Supravalvular Aortic Stenosis – Section 4.2.5 </b></text>
<text top="319" left="92" width="38" height="20" font="3"><b>Study </b></text>
<text top="336" left="92" width="37" height="20" font="3"><b>Name </b></text>
<text top="319" left="190" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="336" left="204" width="44" height="20" font="3"><b>Design </b></text>
<text top="319" left="297" width="202" height="20" font="3"><b>Study Size  Inclusion/Exclusion </b></text>
<text top="336" left="416" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="319" left="549" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="319" left="825" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="379" left="64" width="81" height="20" font="4">Bruno E, et al. </text>
<text top="396" left="64" width="63" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(415)</a> </text>
<text top="413" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14982294?dopt=Citation">14982294</a></text>
<text top="413" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14982294?dopt=Citation"> </a></text>
<text top="379" left="170" width="76" height="20" font="4">Single-center </text>
<text top="396" left="170" width="110" height="20" font="4">retrospective study  </text>
<text top="379" left="296" width="54" height="20" font="4">n=53 pts  </text>
<text top="379" left="376" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="396" left="376" width="83" height="20" font="4">with confirmed </text>
<text top="413" left="376" width="118" height="20" font="4">diagnosis of Williams </text>
<text top="430" left="376" width="61" height="20" font="4">syndrome  </text>
<text top="379" left="515" width="120" height="20" font="4">Description of the CV </text>
<text top="396" left="515" width="124" height="20" font="4">anomalies and clinical </text>
<text top="413" left="515" width="99" height="20" font="4">course of pts with </text>
<text top="430" left="515" width="107" height="20" font="4">Williams syndrome </text>
<text top="379" left="668" width="341" height="20" font="4">● The mean age was 3.6 y and period of follow-up was 5.3 y.  </text>
<text top="396" left="668" width="214" height="20" font="4">● 45/53 pts (85%) had CV anomalies.  </text>
<text top="413" left="668" width="295" height="20" font="4">● Males presented earlier than females: 2.1 vs. 4.5 y. </text>
<text top="430" left="668" width="407" height="20" font="4">● Supravalvular AS occurred in 32 pts (71%), PAS in 17 (38%), and mitral </text>
<text top="447" left="668" width="358" height="20" font="4">valvar prolapse in 12 (27%), 9 of these having regurgitant valves. </text>
<text top="465" left="668" width="329" height="20" font="4">● Pulmonary valvar stenosis, VSD, CoA, PDA, hypertrophic </text>
<text top="482" left="668" width="315" height="20" font="4">cardiomyopathy, and sub-AS all occurred less frequently. </text>
<text top="499" left="668" width="356" height="20" font="4">● In 21 pts (47%), 24 surgical or catheter interventions had been </text>
<text top="516" left="668" width="389" height="20" font="4">performed, most often for repair of supravalvular AS, undertaken on 16 </text>
<text top="534" left="668" width="391" height="20" font="4">occasions with just 1 recurrence, and in 4 also had surgery to the mitral </text>
<text top="551" left="668" width="39" height="20" font="4">valve.  </text>
<text top="568" left="668" width="417" height="20" font="4">● Other lesions requiring intervention were pulmonary valvar stenosis, PAS, </text>
<text top="585" left="668" width="102" height="20" font="4">CoA, and sub-AS. </text>
<text top="602" left="668" width="398" height="20" font="4">● 3 pts died (7%), with severe supravalvular AS and moderate or severe </text>
<text top="620" left="668" width="200" height="20" font="4">MR, 2 early and 1 late after surgery. </text>
</page>
<page number="113" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 113 </text>
<text top="107" left="64" width="79" height="20" font="4">Wren C, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">1990 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(416)</a> </text>
<text top="141" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2345244?dopt=Citation">2345244</a></text>
<text top="141" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2345244?dopt=Citation"> </a></text>
<text top="107" left="170" width="76" height="20" font="4">Single-center </text>
<text top="124" left="170" width="110" height="20" font="4">retrospective study  </text>
<text top="107" left="296" width="54" height="20" font="4">n=35 pts  </text>
<text top="107" left="376" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="124" left="376" width="102" height="20" font="4">with supravalvular </text>
<text top="141" left="376" width="118" height="20" font="4">aortic or PAS or both </text>
<text top="159" left="376" width="110" height="20" font="4">that had undergone </text>
<text top="176" left="376" width="126" height="20" font="4">cardiac catheterization </text>
<text top="193" left="376" width="105" height="20" font="4">between 1973 and </text>
<text top="210" left="376" width="117" height="20" font="4">1989 were included.  </text>
<text top="227" left="376" width="3" height="20" font="4"> </text>
<text top="245" left="376" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="262" left="376" width="87" height="20" font="4">Pts with rubella </text>
<text top="279" left="376" width="113" height="20" font="4">syndrome, Alagille’s </text>
<text top="296" left="376" width="85" height="20" font="4">syndrome, and </text>
<text top="314" left="376" width="77" height="20" font="4">chromosomal </text>
<text top="331" left="376" width="107" height="20" font="4">abnormalities were </text>
<text top="348" left="376" width="56" height="20" font="4">excluded. </text>
<text top="107" left="515" width="113" height="20" font="4">Description of the pt </text>
<text top="124" left="515" width="106" height="20" font="4">characteristics and </text>
<text top="141" left="515" width="57" height="20" font="4">outcomes </text>
<text top="107" left="668" width="384" height="20" font="4">● Data from 35 pts with supravalvular AS or PAS, or both, undergoing </text>
<text top="124" left="668" width="345" height="20" font="4">cardiac catheterization between 1973 and 1989 were analyzed </text>
<text top="141" left="668" width="86" height="20" font="4">retrospectively. </text>
<text top="159" left="668" width="411" height="20" font="4">● 27 pts had supravalvular AS: Most were asymptomatic and referred for a </text>
<text top="176" left="668" width="408" height="20" font="4">murmur, 11 required surgery after the first investigation, and 8 (80%) of 10 </text>
<text top="193" left="668" width="417" height="20" font="4">others undergoing serial investigation showed an increase in the LV to aorta </text>
<text top="210" left="668" width="399" height="20" font="4">pressure gradient. Angiography demonstrated failure of normal growth of </text>
<text top="228" left="668" width="157" height="20" font="4">the ascending aortic lumen.  </text>
<text top="245" left="668" width="417" height="20" font="4">● 19 pts had PAS, with a RV pressure &gt;33 mm Hg. At restudy, RV pressure </text>
<text top="262" left="668" width="389" height="20" font="4">had decreased in 9 (82%) of 11 pts. This decrease in RV pressure was </text>
<text top="279" left="668" width="386" height="20" font="4">associated with an increase in the systolic distensibility of the proximal </text>
<text top="296" left="668" width="364" height="20" font="4">pulmonary arteries, although there was no increase in the diastolic </text>
<text top="314" left="668" width="396" height="20" font="4">diameters. In 2 pts, multiple peripheral PA stenosis became evident with </text>
<text top="331" left="668" width="215" height="20" font="4">time and produced persistent RV HTN. </text>
<text top="366" left="64" width="90" height="20" font="4">Eronen M, et al. </text>
<text top="383" left="64" width="63" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(417)</a> </text>
<text top="400" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12161592?dopt=Citation">12161592</a></text>
<text top="400" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12161592?dopt=Citation"> </a></text>
<text top="366" left="170" width="75" height="20" font="4">Single center </text>
<text top="383" left="170" width="107" height="20" font="4">retrospective study </text>
<text top="366" left="296" width="54" height="20" font="4">n=75 pts  </text>
<text top="366" left="376" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="383" left="376" width="74" height="20" font="4">with Williams </text>
<text top="400" left="376" width="115" height="20" font="4">syndrome confirmed </text>
<text top="418" left="376" width="107" height="20" font="4">by genetic analysis </text>
<text top="366" left="515" width="104" height="20" font="4">Assessment of the </text>
<text top="383" left="515" width="134" height="20" font="4">prevalence and types of </text>
<text top="400" left="515" width="137" height="20" font="4">CV conditions present in </text>
<text top="418" left="515" width="94" height="20" font="4">pts with Williams </text>
<text top="435" left="515" width="138" height="20" font="4">syndrome and outcomes </text>
<text top="452" left="515" width="139" height="20" font="4">following cardiac surgery </text>
<text top="469" left="515" width="97" height="20" font="4">and interventions </text>
<text top="366" left="668" width="405" height="20" font="4">● The diagnosis of Williams syndrome was in each case confirmed by the </text>
<text top="383" left="668" width="405" height="20" font="4">clinical phenotype and by a fluorescence in situ hybridization test showing </text>
<text top="400" left="668" width="117" height="20" font="4">elastin hemizygosity. </text>
<text top="418" left="668" width="416" height="20" font="4">● CV symptoms were evident in 35 of 75 (47%) Williams syndrome children </text>
<text top="435" left="668" width="48" height="20" font="4">at birth.  </text>
<text top="452" left="668" width="397" height="20" font="4">● During follow-up, 44 of 75 (53%) Williams syndrome pts were found to </text>
<text top="469" left="668" width="410" height="20" font="4">have CV defects. Among them, the definitive diagnosis was made before 1 </text>
<text top="487" left="668" width="410" height="20" font="4">y in 23 (52%) infants, between 1 y and 15 y in 14 (32%) children, and older </text>
<text top="504" left="668" width="157" height="20" font="4">than 15 y in 7 (16%) adults.  </text>
<text top="521" left="668" width="403" height="20" font="4">● Multiple obstructive CVD were found in 6 infants. supravalvular AS was </text>
<text top="538" left="668" width="412" height="20" font="4">diagnosed in 32/44 (73%), PAS in 18/44 (41%), aortic or mitral valve defect </text>
<text top="555" left="668" width="221" height="20" font="4">in 5/44 (11%), and TOF in 1 (2%) case.  </text>
<text top="573" left="668" width="395" height="20" font="4">● 17/44 pts (39%) underwent surgery or intervention. Surgery was most </text>
<text top="590" left="668" width="372" height="20" font="4">frequently performed in the infant group (6% v 21% v 0%; p=0.004). </text>
<text top="607" left="668" width="390" height="20" font="4">● After 1 y of age, 7 pts underwent supravalvular AS relief and 2 cases </text>
<text top="624" left="668" width="62" height="20" font="4">PAS relief. </text>
<text top="641" left="668" width="392" height="20" font="4">● Postoperatively there was no mortality (median follow-up time 6.9 y).  </text>
<text top="659" left="668" width="241" height="20" font="4">● Arterial HTN was found in 55% of adults.  </text>
<text top="676" left="668" width="381" height="20" font="4">● In 3 adults, arterial vasculopathy was not diagnosed until necropsy. </text>
<text top="694" left="64" width="79" height="20" font="4">Tani LY, et al. </text>
<text top="711" left="64" width="63" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(418)</a> </text>
<text top="728" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10867108?dopt=Citation">10867108</a></text>
<text top="728" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10867108?dopt=Citation"> </a></text>
<text top="694" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="711" left="170" width="107" height="20" font="4">single-center study </text>
<text top="694" left="296" width="54" height="20" font="4">n=18 pts  </text>
<text top="694" left="376" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="711" left="376" width="102" height="20" font="4">with echo/Doppler </text>
<text top="728" left="376" width="66" height="20" font="4">evidence of </text>
<text top="745" left="376" width="96" height="20" font="4">supravalvular AS </text>
<text top="763" left="376" width="89" height="20" font="4">within 2.5 mo of </text>
<text top="780" left="376" width="130" height="20" font="4">cardiac catheterization  </text>
<text top="694" left="515" width="99" height="20" font="4">Description of the </text>
<text top="711" left="515" width="104" height="20" font="4">echocardiographic </text>
<text top="728" left="515" width="139" height="20" font="4">findings and assessment </text>
<text top="745" left="515" width="114" height="20" font="4">of the relationship of </text>
<text top="763" left="515" width="100" height="20" font="4">directly measured </text>
<text top="780" left="515" width="135" height="20" font="4">catheterization pressure </text>
<text top="694" left="668" width="119" height="20" font="11">● A total of 26 paired </text>
<text top="694" left="787" width="27" height="20" font="4">echo</text>
<text top="694" left="814" width="259" height="20" font="11">s and catheterizations from 18 pts (12 males, 6 </text>
<text top="711" left="668" width="76" height="20" font="11">females) with </text>
<text top="711" left="744" width="93" height="20" font="4">supravalvular AS</text>
<text top="711" left="836" width="90" height="20" font="11"> were identified. </text>
<text top="728" left="668" width="232" height="20" font="11">● Age at catheterization ranged from 1 mo</text>
<text top="728" left="900" width="7" height="20" font="4">–</text>
<text top="728" left="907" width="165" height="20" font="11">18 y (median 2.5 y). From the </text>
<text top="745" left="668" width="125" height="20" font="11">aortic angiograms, the </text>
<text top="745" left="793" width="93" height="20" font="4">supravalvular AS</text>
<text top="745" left="886" width="171" height="20" font="11"> was discrete or localized in 20 </text>
<text top="763" left="668" width="181" height="20" font="11">cases, and diffuse in the other 6. </text>
</page>
<page number="114" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 114 </text>
<text top="107" left="515" width="114" height="20" font="4">gradients to Doppler </text>
<text top="124" left="515" width="111" height="20" font="4">estimated peak and </text>
<text top="141" left="515" width="88" height="20" font="4">mean gradients </text>
<text top="107" left="668" width="396" height="20" font="11">● The Doppler peak instantaneous gradient correlated with (r=0.74), but </text>
<text top="124" left="668" width="388" height="20" font="11">overestimated the catheter-measured peak gradient. Correcting for the </text>
<text top="141" left="668" width="373" height="20" font="11">proximal velocity (available in 14 pts) did not improve the correlation </text>
<text top="159" left="668" width="417" height="20" font="11">(r=0.66). Doppler peak gradients were consistently greater than the catheter </text>
<text top="176" left="668" width="377" height="20" font="11">peak gradients with a mean difference of 30 mm Hg (SD 18 mm Hg). </text>
<text top="193" left="668" width="375" height="20" font="11">● The Doppler mean gradient correlated with (r=0.72), but tended to </text>
<text top="210" left="668" width="235" height="20" font="11">underestimate, the catheter peak gradient. </text>
<text top="228" left="668" width="343" height="20" font="11">● A significant association was found between a Doppler peak </text>
<text top="245" left="668" width="387" height="20" font="11">instantaneous gradient of &gt;85 mm Hg (velocity 4.6 m/s) and a catheter </text>
<text top="262" left="668" width="324" height="20" font="11">peak gradient of &gt;50 mm Hg (p&lt;0.001). The specificity and </text>
<text top="262" left="992" width="25" height="20" font="4">NPV</text>
<text top="262" left="1017" width="28" height="20" font="11"> of a </text>
<text top="279" left="668" width="411" height="20" font="11">Doppler peak gradient of &gt;85 mm Hg in predicting a catheter peak gradient </text>
<text top="296" left="668" width="417" height="20" font="11">of &gt;50 mm Hg was 95%. The overall accuracy of a Doppler peak gradient of </text>
<text top="314" left="668" width="383" height="20" font="11">&gt;85 mm Hg in separating those with catheter peak gradients above or </text>
<text top="331" left="668" width="152" height="20" font="11">below 50 mm Hg was 92%. </text>
<text top="348" left="668" width="404" height="20" font="11">● There was no significant correlation between the Doppler peak gradient </text>
<text top="365" left="668" width="345" height="20" font="11">and indexed LV mass or the supravalvar aorta/annulus ratio by </text>
<text top="365" left="1013" width="27" height="20" font="4">echo</text>
<text top="365" left="1040" width="18" height="20" font="11"> or </text>
<text top="382" left="668" width="71" height="20" font="11">angiography.</text>
<text top="382" left="739" width="3" height="20" font="4"> </text>
<text top="400" left="64" width="87" height="20" font="4">Thiene G, et al. </text>
<text top="418" left="64" width="63" height="20" font="4">1986 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(419)</a> </text>
<text top="435" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3606885?dopt=Citation">3606885</a></text>
<text top="435" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3606885?dopt=Citation"> </a></text>
<text top="400" left="170" width="76" height="20" font="4">Single-center </text>
<text top="418" left="170" width="74" height="20" font="4">retrospective </text>
<text top="435" left="170" width="85" height="20" font="4">autopsy review </text>
<text top="400" left="296" width="44" height="20" font="4">n=6 pts </text>
<text top="400" left="376" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="418" left="376" width="111" height="20" font="4">Young pts who died </text>
<text top="435" left="376" width="76" height="20" font="4">suddenly and </text>
<text top="452" left="376" width="87" height="20" font="4">underwent post </text>
<text top="469" left="376" width="122" height="20" font="4">mortem autopsy were </text>
<text top="487" left="376" width="49" height="20" font="4">included </text>
<text top="400" left="515" width="78" height="20" font="4">Description of </text>
<text top="418" left="515" width="114" height="20" font="4">postmortem findings </text>
<text top="400" left="668" width="412" height="20" font="4">● Post-mortem findings in 6 young people who died suddenly are reported; </text>
<text top="418" left="668" width="217" height="20" font="4">ages ranged from 9–28 y (average 17). </text>
<text top="435" left="668" width="353" height="20" font="4">● All had practiced sport, and 2 died during strenuous exercise.  </text>
<text top="452" left="668" width="405" height="20" font="4">● 3 cases had been under observation for mild AS, while no CV disorders </text>
<text top="469" left="668" width="192" height="20" font="4">had been suspected in the others.  </text>
<text top="487" left="668" width="407" height="20" font="4">● Autopsy studies ruled out coronary atherosclerotic diseases, myocardial </text>
<text top="504" left="668" width="409" height="20" font="4">disarray or myocarditis as well as any extracardiac cause of death in every </text>
<text top="521" left="668" width="36" height="20" font="4">case.  </text>
<text top="538" left="668" width="416" height="20" font="4">● A stenotic BAV was found in 2; supravalvular AS and incomplete isolation </text>
<text top="555" left="668" width="417" height="20" font="4">of the left coronary ostium in 1; anomalous origin of the right coronary artery </text>
<text top="573" left="668" width="364" height="20" font="4">from the left sinus of Valsalva in 1, and dissecting aneurysm of the </text>
<text top="590" left="668" width="118" height="20" font="4">ascending aorta in 2. </text>
<text top="608" left="64" width="88" height="20" font="4">Stamm C, et al. </text>
<text top="625" left="64" width="63" height="20" font="4">1997 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(420)</a> </text>
<text top="642" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9240289?dopt=Citation">9240289</a></text>
<text top="642" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9240289?dopt=Citation"> </a></text>
<text top="608" left="170" width="76" height="20" font="4">Single-center </text>
<text top="625" left="170" width="113" height="20" font="4">retrospective review </text>
<text top="608" left="296" width="54" height="20" font="4">n=37 pts  </text>
<text top="608" left="376" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="625" left="376" width="121" height="20" font="4">with supravalvular AS </text>
<text top="642" left="376" width="112" height="20" font="4">who had undergone </text>
<text top="659" left="376" width="98" height="20" font="4">angiographic and </text>
<text top="677" left="376" width="104" height="20" font="4">echocardiographic </text>
<text top="694" left="376" width="99" height="20" font="4">assessment were </text>
<text top="711" left="376" width="122" height="20" font="4">compared to a control </text>
<text top="728" left="376" width="118" height="20" font="4">group. Additionally, 8 </text>
<text top="745" left="376" width="122" height="20" font="4">pathologic specimens </text>
<text top="763" left="376" width="90" height="20" font="4">were described. </text>
<text top="608" left="515" width="125" height="20" font="4">Description of imaging </text>
<text top="625" left="515" width="129" height="20" font="4">findings and pathologic </text>
<text top="642" left="515" width="46" height="20" font="4">findings </text>
<text top="608" left="668" width="394" height="20" font="4">● Partial adhesion of the leaflets to the stenosing ridge was observed in </text>
<text top="625" left="668" width="408" height="20" font="4">54% of the cases and the leaflets were thickened and less mobile in 30%.  </text>
<text top="642" left="668" width="398" height="20" font="4">● 45% of the angiograms showed evidence of coronary orifice stenosis.  </text>
<text top="659" left="668" width="408" height="20" font="4">● The sinuses of Valsalva were significantly enlarged in 75% of the cases. </text>
<text top="677" left="668" width="403" height="20" font="4">Changes in dimensions of the aortic root were demonstrated more clearly </text>
<text top="694" left="668" width="165" height="20" font="4">by angiography than by echo. </text>
<text top="711" left="668" width="385" height="20" font="4">● In all anatomic specimens, a marked redundancy of the leaflets was </text>
<text top="728" left="668" width="138" height="20" font="4">observed and quantified. </text>
</page>
<page number="115" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 115 </text>
<text top="107" left="64" width="79" height="20" font="4">Martin MM, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="63" height="20" font="4">1988 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(421)</a> </text>
<text top="159" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3337571?dopt=Citation">3337571</a></text>
<text top="159" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3337571?dopt=Citation"> </a></text>
<text top="107" left="170" width="76" height="20" font="4">Single-center </text>
<text top="124" left="170" width="87" height="20" font="4">description of 2 </text>
<text top="141" left="170" width="81" height="20" font="4">surgical cases </text>
<text top="107" left="296" width="48" height="20" font="4">n=2 pts  </text>
<text top="107" left="376" width="116" height="20" font="3"><b>Inclusion criteria</b>: 2 </text>
<text top="124" left="376" width="121" height="20" font="4">pts with supravalvular </text>
<text top="141" left="376" width="115" height="20" font="4">AS and left coronary </text>
<text top="159" left="376" width="96" height="20" font="4">ostial obstruction </text>
<text top="107" left="515" width="124" height="20" font="4">Description of surgical </text>
<text top="124" left="515" width="46" height="20" font="4">findings </text>
<text top="107" left="668" width="385" height="20" font="4">● 2 pts in whom obstruction to left coronary artery flow was caused by </text>
<text top="124" left="668" width="270" height="20" font="4">obliteration of the coronary ostium are described. </text>
<text top="141" left="668" width="417" height="20" font="4">● This mechanism differs from the more commonly recognized cause: valve </text>
<text top="159" left="668" width="308" height="20" font="4">leaflet adhesion to the obstructing ridge of aortic tissue.  </text>
<text top="176" left="668" width="380" height="20" font="4">● The coronary artery obstruction found in these 2 pts required direct </text>
<text top="193" left="668" width="264" height="20" font="4">enlargement of the left coronary ostium in both.  </text>
<text top="227" left="64" width="83" height="20" font="4">Doty DB, et al. </text>
<text top="244" left="64" width="63" height="20" font="4">1982 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(422)</a> </text>
<text top="261" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7083541?dopt=Citation">7083541</a></text>
<text top="261" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7083541?dopt=Citation"> </a></text>
<text top="227" left="170" width="105" height="20" font="4">Single-center case </text>
<text top="244" left="170" width="73" height="20" font="4">control study </text>
<text top="227" left="296" width="48" height="20" font="4">n=7 pts  </text>
<text top="227" left="376" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="244" left="376" width="121" height="20" font="4">with supravalvular AS </text>
<text top="261" left="376" width="111" height="20" font="4">undergoing surgical </text>
<text top="278" left="376" width="35" height="20" font="4">repair </text>
<text top="227" left="515" width="135" height="20" font="4">Assessment of coronary </text>
<text top="244" left="515" width="134" height="20" font="4">flow reserve and factors </text>
<text top="261" left="515" width="119" height="20" font="4">determining coronary </text>
<text top="278" left="515" width="83" height="20" font="4">flow reserve in </text>
<text top="295" left="515" width="96" height="20" font="4">supravalvular AS </text>
<text top="227" left="668" width="362" height="20" font="4">● To assess the relative effect of coronary ostial obstruction or LV </text>
<text top="244" left="668" width="409" height="20" font="4">hypertrophy on coronary reserve, 7 pts with supravalvular AS were studied </text>
<text top="261" left="668" width="219" height="20" font="4">intraoperatively before and after repair.  </text>
<text top="278" left="668" width="403" height="20" font="4">● 6 pts who underwent elective cardiac surgery for conditions that did not </text>
<text top="295" left="668" width="417" height="20" font="4">involve the left ventricle or the left anterior ascending coronary artery served </text>
<text top="313" left="668" width="166" height="20" font="4">as controls (control Group 1).  </text>
<text top="330" left="668" width="386" height="20" font="4">● 4 pts were studied before and after CPB to determine if CPB altered </text>
<text top="347" left="668" width="383" height="20" font="4">coronary reserve in normal vessels perfusing normal ventricle (control </text>
<text top="364" left="668" width="59" height="20" font="4">Group 2).  </text>
<text top="381" left="668" width="401" height="20" font="4">● Using a pulsed Doppler probe to determine coronary velocity, coronary </text>
<text top="399" left="668" width="395" height="20" font="4">reactive hyperemia was induced in the left anterior descending coronary </text>
<text top="416" left="668" width="405" height="20" font="4">artery (pts with supravalvular AS and Group 1 controls) or RV branches of </text>
<text top="433" left="668" width="417" height="20" font="4">the right coronary artery (Group 2 controls) during maximal coronary dilation </text>
<text top="450" left="668" width="218" height="20" font="4">produced by a 20-s coronary occlusion. </text>
<text top="467" left="668" width="402" height="20" font="4">● All pts with supravalvular AS underwent patch aortoplasty to relieve left </text>
<text top="485" left="668" width="399" height="20" font="4">coronary artery ostial obstruction and outflow tract obstruction; 3 pts also </text>
<text top="502" left="668" width="398" height="20" font="4">underwent aortic valvotomy and 1 pt also underwent valve replacement.  </text>
<text top="519" left="668" width="380" height="20" font="4">● Coronary reactive hyperemia was calculated as the ratio of peak to </text>
<text top="536" left="668" width="409" height="20" font="4">resting velocity. This ratio was 5.0 ± 0.6 (mean ± SEM) preoperatively and </text>
<text top="554" left="668" width="399" height="20" font="4">3.6 ± 0.3 postoperatively in control Group 2. Thus, coronary reserve was </text>
<text top="571" left="668" width="190" height="20" font="4">only modestly reduced after CPB.  </text>
<text top="588" left="668" width="407" height="20" font="4">● Before repair, the ratio of peak to resting velocity was markedly reduced </text>
<text top="605" left="668" width="402" height="20" font="4">in pts with supravalvular AS compared with control Group 1 (1.8 ± 0.3 vs. </text>
<text top="622" left="668" width="408" height="20" font="4">4.9 ± 0.5; p&lt;0.05) and did not change after repair (1.7 ± 0.2), even though </text>
<text top="640" left="668" width="399" height="20" font="4">the aortic gradient was reduced (80 ± 14 vs. 38 ± 6 mm Hg; p&lt;0.05) and </text>
<text top="657" left="668" width="419" height="20" font="4">real or potential coronary ostial obstruction was eliminated by the operation.  </text>
<text top="675" left="64" width="78" height="20" font="4">Thistlethwaite </text>
<text top="692" left="64" width="53" height="20" font="4">PA, et al. </text>
<text top="709" left="64" width="63" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(423)</a> </text>
<text top="726" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11088024?dopt=Citation">11088024</a></text>
<text top="726" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11088024?dopt=Citation"> </a></text>
<text top="675" left="170" width="76" height="20" font="4">Single-center </text>
<text top="692" left="170" width="113" height="20" font="4">retrospective review </text>
<text top="675" left="296" width="48" height="20" font="4">n=9 pts  </text>
<text top="675" left="376" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="692" left="376" width="111" height="20" font="4">with LMCA stenosis </text>
<text top="709" left="376" width="72" height="20" font="4">complicating </text>
<text top="726" left="376" width="120" height="20" font="4">supravalvular AS that </text>
<text top="744" left="376" width="107" height="20" font="4">underwent surgical </text>
<text top="761" left="376" width="119" height="20" font="4">repair between 1991–</text>
<text top="675" left="515" width="124" height="20" font="4">Description of surgical </text>
<text top="692" left="515" width="75" height="20" font="4">management </text>
<text top="675" left="668" width="368" height="20" font="4">● 9 pts underwent surgical repair of supravalvular AS and left main </text>
<text top="692" left="668" width="107" height="20" font="4">coronary stenosis.  </text>
<text top="709" left="668" width="399" height="20" font="4">● 5 pts (Group 1) had obstruction from near-circumferential thickening of </text>
<text top="726" left="668" width="392" height="20" font="4">the left main ostium, 2 pts (Group 2) had restricted coronary flow due to </text>
<text top="744" left="668" width="410" height="20" font="4">fusion of an aortic valve leaflet to the supravalvular ridge, and 2 pts (Group </text>
<text top="761" left="668" width="211" height="20" font="4">3) had diffuse narrowing of the LMCA. </text>
</page>
<page number="116" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 116 </text>
<text top="107" left="376" width="115" height="20" font="4">1998 at University of </text>
<text top="124" left="376" width="116" height="20" font="4">California San Diego </text>
<text top="107" left="668" width="397" height="20" font="4">● Group 1 pts were treated with patch aortoplasty encompassing the left </text>
<text top="124" left="668" width="406" height="20" font="4">main ostium and supravalvular AS. Group 2 pts were treated with excision </text>
<text top="141" left="668" width="376" height="20" font="4">of the fused leaflet from the aortic wall and patch aortoplasty. Group  </text>
<text top="159" left="668" width="318" height="20" font="4">● 3 pts were treated with bypass grafting and aortoplasty. </text>
<text top="176" left="668" width="361" height="20" font="4">● Surgical strategy was determined by coronary angiography and </text>
<text top="193" left="668" width="266" height="20" font="4">intraoperative assessment of coronary anatomy. </text>
<text top="210" left="668" width="155" height="20" font="4">● There was 1 early death.  </text>
<text top="227" left="668" width="351" height="20" font="4">● All surviving pts underwent echo with or without postoperative </text>
<text top="245" left="668" width="395" height="20" font="4">catheterization. The mean postoperative supravalvular gradient for 7 pts </text>
<text top="262" left="668" width="412" height="20" font="4">was 8 mm Hg (range 2–15 mm Hg). 1 pt required reoperation for a residual </text>
<text top="279" left="668" width="292" height="20" font="4">aortic gradient as a result of aortic arch involvement.  </text>
<text top="296" left="668" width="387" height="20" font="4">● No evidence of LMCA stenosis was seen in Groups 1 and 2; bypass </text>
<text top="314" left="668" width="355" height="20" font="4">grafts were patent in group 3 pts at a mean follow-up of 54.8 mo. </text>
<text top="332" left="64" width="82" height="20" font="4">Greutmann M, </text>
<text top="349" left="64" width="30" height="20" font="4">et al. </text>
<text top="366" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(424)</a> </text>
<text top="383" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22815328?dopt=Citation">22815328</a></text>
<text top="383" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22815328?dopt=Citation"> </a></text>
<text top="332" left="170" width="64" height="20" font="4">Multicenter </text>
<text top="349" left="170" width="107" height="20" font="4">retrospective study </text>
<text top="332" left="296" width="48" height="20" font="4">n=3,697 </text>
<text top="349" left="296" width="20" height="20" font="4">pts </text>
<text top="332" left="376" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="349" left="376" width="24" height="20" font="4">N/A </text>
<text top="332" left="515" width="131" height="20" font="4">Adverse cardiac events </text>
<text top="349" left="515" width="116" height="20" font="4">and need for cardiac </text>
<text top="366" left="515" width="115" height="20" font="4">surgery in adulthood </text>
<text top="332" left="668" width="408" height="20" font="4">● Little or no increased risk of stroke, VTE, or AMI associated with the use </text>
<text top="349" left="668" width="415" height="20" font="4">of oral or injectable progestogen-only or combined injectable contraceptives </text>
<text top="401" left="108" width="3" height="20" font="4"> </text>
<text top="418" left="108" width="3" height="20" font="4"> </text>
<text top="435" left="108" width="429" height="24" font="1"><b>Data Supplement 38. Coarctation of the Aorta – Section 4.2.6 </b></text>
<text top="457" left="73" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="474" left="73" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="457" left="180" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="457" left="273" width="82" height="20" font="3"><b>Study Design </b></text>
<text top="457" left="376" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="474" left="412" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="457" left="524" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="457" left="759" width="48" height="20" font="3"><b>Results </b></text>
<text top="457" left="988" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="492" left="64" width="85" height="20" font="4">Holzer R, et al. </text>
<text top="509" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(425)</a> </text>
<text top="527" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20882661?dopt=Citation">20882661</a></text>
<text top="527" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20882661?dopt=Citation"> </a></text>
<text top="492" left="172" width="61" height="20" font="4">n=302 pts  </text>
<text top="492" left="266" width="67" height="20" font="4">Prospective </text>
<text top="509" left="266" width="64" height="20" font="4">multicenter </text>
<text top="527" left="266" width="40" height="20" font="4">registry</text>
<text top="528" left="307" width="2" height="13" font="6"> </text>
<text top="492" left="374" width="106" height="20" font="4">Pts that underwent </text>
<text top="509" left="374" width="110" height="20" font="4">coarctation stenting </text>
<text top="527" left="374" width="75" height="20" font="4">at 34 centers </text>
<text top="544" left="374" width="83" height="20" font="4">included in the </text>
<text top="561" left="374" width="67" height="20" font="4">consortium. </text>
<text top="578" left="374" width="3" height="20" font="4"> </text>
<text top="595" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="613" left="374" width="69" height="20" font="4">Presence of </text>
<text top="630" left="374" width="121" height="20" font="4">significant coarctation </text>
<text top="647" left="374" width="110" height="20" font="4">based on 1 or more </text>
<text top="664" left="374" width="89" height="20" font="4">of the following: </text>
<text top="681" left="374" width="110" height="20" font="4">UL/LL peak to peak </text>
<text top="699" left="374" width="120" height="20" font="4">gradient ≥20 mm Hg, </text>
<text top="716" left="374" width="109" height="20" font="4">UL/LL gradient ≥10 </text>
<text top="733" left="374" width="103" height="20" font="4">mm Hg plus either </text>
<text top="750" left="374" width="79" height="20" font="4">decreased LV </text>
<text top="768" left="374" width="121" height="20" font="4">function or AR, UL/LL </text>
<text top="492" left="509" width="74" height="20" font="4">Evaluation of </text>
<text top="509" left="509" width="37" height="20" font="4">acute, </text>
<text top="527" left="509" width="99" height="20" font="4">intermediate- and </text>
<text top="544" left="509" width="55" height="20" font="4">long-term </text>
<text top="561" left="509" width="60" height="20" font="4">outcomes. </text>
<text top="578" left="509" width="63" height="20" font="4">Procedural </text>
<text top="595" left="509" width="91" height="20" font="4">success defined </text>
<text top="613" left="509" width="51" height="20" font="4">as upper </text>
<text top="630" left="509" width="100" height="20" font="4">extremity to lower </text>
<text top="647" left="509" width="97" height="20" font="4">extremity systolic </text>
<text top="664" left="509" width="74" height="20" font="4">peak to peak </text>
<text top="681" left="509" width="96" height="20" font="4">gradient &lt;20 mm </text>
<text top="699" left="509" width="61" height="20" font="4">Hg, lack of </text>
<text top="716" left="509" width="53" height="20" font="4">recurrent </text>
<text top="733" left="509" width="87" height="20" font="4">obstruction and </text>
<text top="750" left="509" width="77" height="20" font="4">freedom from </text>
<text top="768" left="509" width="99" height="20" font="4">unplanned repeat </text>
<text top="785" left="509" width="67" height="20" font="4">intervention </text>
<text top="492" left="624" width="292" height="20" font="4">● Data collected prospectively on 302 pts from 2000–</text>
<text top="509" left="624" width="127" height="20" font="4">2009, from 34 centers. </text>
<text top="527" left="624" width="290" height="20" font="4">● Median age 15 y (2–63), median weight 58 kg (11–</text>
<text top="544" left="624" width="31" height="20" font="4">156). </text>
<text top="561" left="624" width="309" height="20" font="4">● Arch hypoplasia in 10%, BAV in 41%, 55% native and </text>
<text top="578" left="624" width="148" height="20" font="4">45% recurrent coarctation. </text>
<text top="595" left="624" width="292" height="20" font="4">● 21% required &gt;1 stent, 5% of stents were covered. </text>
<text top="613" left="624" width="271" height="20" font="4">44% of pts completed intermediate follow-up with </text>
<text top="630" left="624" width="298" height="20" font="4">integrated imaging (catheter/CT/MRI), 21% completed </text>
<text top="647" left="624" width="164" height="20" font="4">long-term follow-up (&gt;18 mo). </text>
<text top="664" left="624" width="201" height="20" font="4">● Acute procedural success in 96%. </text>
<text top="682" left="624" width="308" height="20" font="4">● Cumulative intermediate success was 86%, long-term </text>
<text top="699" left="624" width="105" height="20" font="4">success was 77%. </text>
<text top="716" left="624" width="273" height="20" font="4">● Unplanned repeat interventions required in 4%. </text>
<text top="733" left="624" width="310" height="20" font="4">● Aortic wall complications in 1%, other complications in </text>
<text top="750" left="624" width="25" height="20" font="4">5%. </text>
<text top="492" left="955" width="168" height="20" font="4">● Transcatheter stenting is an </text>
<text top="509" left="955" width="172" height="20" font="4">effective treatment modality for </text>
<text top="527" left="955" width="146" height="20" font="4">native and recurrent aortic </text>
<text top="544" left="955" width="183" height="20" font="4">coarctation with good immediate, </text>
<text top="561" left="955" width="155" height="20" font="4">intermediate- and long-term </text>
<text top="578" left="955" width="60" height="20" font="4">outcomes. </text>
<text top="595" left="955" width="182" height="20" font="4">● There is a small risk of serious </text>
<text top="613" left="955" width="136" height="20" font="4">aortic wall complications </text>
<text top="630" left="955" width="203" height="20" font="4">● The majority of pts have long-term </text>
<text top="647" left="955" width="201" height="20" font="4">benefit with reduced systolic BP and </text>
<text top="664" left="955" width="152" height="20" font="4">systolic gradient across the </text>
<text top="681" left="955" width="67" height="20" font="4">coarctation. </text>
<text top="699" left="955" width="192" height="20" font="4">● In ~1/3 of pts, there continues to </text>
<text top="716" left="955" width="169" height="20" font="4">be a need for antihypertensive </text>
<text top="733" left="955" width="141" height="20" font="4">medical therapy following </text>
<text top="750" left="955" width="114" height="20" font="4">coarctation stenting. </text>
<text top="767" left="955" width="141" height="20" font="4">● Follow-up imaging with </text>
<text top="785" left="955" width="198" height="20" font="4">CTA/MRI/cath is important to detect </text>
</page>
<page number="117" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 117 </text>
<text top="107" left="374" width="94" height="20" font="4">≥10 mm Hg plus </text>
<text top="124" left="374" width="81" height="20" font="4">collateral flow. </text>
<text top="141" left="374" width="3" height="20" font="4"> </text>
<text top="159" left="374" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="176" left="374" width="86" height="20" font="4">Weight &lt;10 kg, </text>
<text top="193" left="374" width="113" height="20" font="4">known or suspected </text>
<text top="210" left="374" width="40" height="20" font="4">arteritis</text>
<text top="212" left="415" width="2" height="13" font="6"> </text>
<text top="107" left="624" width="277" height="20" font="4">● Preprocedure 77% of pts had systemic HTN &gt;95</text>
<text top="109" left="901" width="7" height="13" font="6">th</text>
<text top="107" left="907" width="3" height="20" font="4"> </text>
<text top="124" left="624" width="298" height="20" font="4">percentile, long-term post procedure this decreased to </text>
<text top="141" left="624" width="35" height="20" font="4">23%.  </text>
<text top="159" left="624" width="291" height="20" font="4">● Preprocedure 59% of pts had systemic systolic BP </text>
<text top="176" left="624" width="21" height="20" font="4">&gt;99</text>
<text top="178" left="645" width="7" height="13" font="6">th</text>
<text top="176" left="652" width="283" height="20" font="4"> percentile, long-term post procedure 6% of pts had </text>
<text top="193" left="624" width="21" height="20" font="4">&gt;99</text>
<text top="195" left="645" width="7" height="13" font="6">th</text>
<text top="193" left="652" width="127" height="20" font="4"> percentile systolic BP. </text>
<text top="210" left="624" width="311" height="20" font="4">● At long-term follow-up, 23% continued to have systolic </text>
<text top="227" left="624" width="40" height="20" font="4">BP &gt;95</text>
<text top="229" left="665" width="7" height="13" font="6">th</text>
<text top="227" left="671" width="252" height="20" font="4"> percentile, 9% had UL to lower limbs peak-to-</text>
<text top="245" left="624" width="267" height="20" font="4">peak gradient &gt;20 mm Hg, and 32% were taking </text>
<text top="262" left="624" width="165" height="20" font="4">antihypertensive medications. </text>
<text top="107" left="955" width="152" height="20" font="4">stent related complications, </text>
<text top="124" left="955" width="179" height="20" font="4">aneurysm formation or recurrent </text>
<text top="141" left="955" width="67" height="20" font="4">obstruction. </text>
<text top="280" left="64" width="85" height="20" font="4">Qureshi AM, et </text>
<text top="297" left="64" width="16" height="20" font="4">al. </text>
<text top="314" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(426)</a> </text>
<text top="332" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17319978?dopt=Citation">17319978</a></text>
<text top="332" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17319978?dopt=Citation"> </a></text>
<text top="280" left="172" width="61" height="20" font="4">n=153 pts  </text>
<text top="280" left="266" width="76" height="20" font="4">Single-center </text>
<text top="297" left="266" width="74" height="20" font="4">retrospective </text>
<text top="314" left="266" width="39" height="20" font="4">review </text>
<text top="280" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="297" left="374" width="106" height="20" font="4">Pts that underwent </text>
<text top="314" left="374" width="110" height="20" font="4">coarctation stenting </text>
<text top="332" left="374" width="115" height="20" font="4">between 1989–2005 </text>
<text top="280" left="509" width="74" height="20" font="4">Evaluation of </text>
<text top="297" left="509" width="99" height="20" font="4">intermediate- and </text>
<text top="314" left="509" width="55" height="20" font="4">long-term </text>
<text top="332" left="509" width="57" height="20" font="4">outcomes </text>
<text top="280" left="624" width="279" height="20" font="4">● 153 pts, median age 16 y underwent coarctation </text>
<text top="297" left="624" width="50" height="20" font="4">stenting. </text>
<text top="314" left="624" width="288" height="20" font="4">64% had prior aortic interventions (57% surgery, 7% </text>
<text top="332" left="624" width="312" height="20" font="4">balloon dilation along, 16% balloon dilation and surgery). </text>
<text top="349" left="624" width="306" height="20" font="4">● Isolated coarctation in 50%, 74% at the isthmus, 12% </text>
<text top="366" left="624" width="125" height="20" font="4">in the transverse arch. </text>
<text top="383" left="624" width="308" height="20" font="4">● 95% of pts had reduction of the peak to peak gradient </text>
<text top="401" left="624" width="84" height="20" font="4">to &lt;20 mm Hg. </text>
<text top="418" left="624" width="314" height="20" font="4">● 2% of pts with aortic wall injury, none required surgery. </text>
<text top="435" left="624" width="63" height="20" font="4">No deaths. </text>
<text top="452" left="624" width="307" height="20" font="4">● New aneurysms observed in 6% of pts over a median </text>
<text top="469" left="624" width="100" height="20" font="4">follow-up of 2.5 y. </text>
<text top="487" left="624" width="183" height="20" font="4">● Stent fractures noted in 12 pts. </text>
<text top="504" left="624" width="305" height="20" font="4">● Reintervention performed in 50% of pts at 5 y, mostly </text>
<text top="521" left="624" width="213" height="20" font="4">due to deliberate multistage approach. </text>
<text top="280" left="955" width="188" height="20" font="4">● Transcatheter stenting of native </text>
<text top="297" left="955" width="174" height="20" font="4">and recurrent aortic coarctation </text>
<text top="314" left="955" width="168" height="20" font="4">results in relief of the gradient. </text>
<text top="332" left="955" width="185" height="20" font="4">● Serious complications are rare. </text>
<text top="349" left="955" width="186" height="20" font="4">● Follow-up imaging is needed to </text>
<text top="366" left="955" width="201" height="20" font="4">evaluate for long-term complications </text>
<text top="383" left="955" width="202" height="20" font="4">such as aneurysm formation or stent </text>
<text top="400" left="955" width="49" height="20" font="4">fracture. </text>
<text top="539" left="64" width="92" height="20" font="4">Forbes TJ, et al. </text>
<text top="556" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(427)</a> </text>
<text top="573" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17896405?dopt=Citation">17896405</a></text>
<text top="573" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17896405?dopt=Citation"> </a></text>
<text top="539" left="172" width="61" height="20" font="4">n=578 pts  </text>
<text top="539" left="266" width="64" height="20" font="4">Multicenter </text>
<text top="556" left="266" width="74" height="20" font="4">retrospective </text>
<text top="573" left="266" width="66" height="20" font="4">case series </text>
<text top="539" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="556" left="374" width="106" height="20" font="4">Pts that underwent </text>
<text top="573" left="374" width="110" height="20" font="4">coarctation stenting </text>
<text top="591" left="374" width="100" height="20" font="4">at 17 participating </text>
<text top="608" left="374" width="62" height="20" font="4">institutions </text>
<text top="539" left="509" width="74" height="20" font="4">Evaluation of </text>
<text top="556" left="509" width="84" height="20" font="4">immediate and </text>
<text top="573" left="509" width="71" height="20" font="4">intermediate </text>
<text top="591" left="509" width="62" height="20" font="4">procedural </text>
<text top="608" left="509" width="57" height="20" font="4">outcomes </text>
<text top="539" left="624" width="309" height="20" font="4">● 578 pts at 17 institutions had 588 catheter procedures </text>
<text top="556" left="624" width="129" height="20" font="4">with 650 stents placed. </text>
<text top="573" left="624" width="240" height="20" font="4">● 160 pts available for follow-up underwent </text>
<text top="591" left="624" width="150" height="20" font="4">CT/MRI/catheter follow-up. </text>
<text top="608" left="624" width="254" height="20" font="4">● 10% underwent planned second procedure. </text>
<text top="625" left="624" width="213" height="20" font="4">● Median follow-up of 12 mo (0.5–92). </text>
<text top="642" left="624" width="249" height="20" font="4">● Of the pts with follow-up imaging, 29% had </text>
<text top="659" left="624" width="288" height="20" font="4">abnormalities: 11% with neo-intimal hyperplasia, 9% </text>
<text top="677" left="624" width="291" height="20" font="4">developed aneurysms, 3% developed dissection, 4% </text>
<text top="694" left="624" width="79" height="20" font="4">stent fracture. </text>
<text top="711" left="624" width="302" height="20" font="4">● 22% of pts with abnormal follow-up imaging required </text>
<text top="728" left="624" width="81" height="20" font="4">reintervention. </text>
<text top="745" left="624" width="313" height="20" font="4">● Smaller postintervention aortic diameter and persistent </text>
<text top="763" left="624" width="317" height="20" font="4">increased systolic pressure gradient were associated with </text>
<text top="780" left="624" width="174" height="20" font="4">increased risk of reintervention. </text>
<text top="539" left="955" width="152" height="20" font="4">● Transcatheter stenting of </text>
<text top="556" left="955" width="194" height="20" font="4">coarctation is associated with good </text>
<text top="573" left="955" width="155" height="20" font="4">immediate and intermediate </text>
<text top="591" left="955" width="60" height="20" font="4">outcomes. </text>
<text top="608" left="955" width="201" height="20" font="4">● 22% of pts required reintervention </text>
<text top="625" left="955" width="163" height="20" font="4">● Follow-up CT/MRI/catheter </text>
<text top="642" left="955" width="185" height="20" font="4">imaging is important in identifying </text>
<text top="659" left="955" width="131" height="20" font="4">potential complications. </text>
</page>
<page number="118" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 118 </text>
<text top="107" left="624" width="313" height="20" font="4">● Prestent angioplasty and balloon:coarctation ratio &gt;3.5 </text>
<text top="124" left="624" width="297" height="20" font="4">were associated with increased likelihood of abnormal </text>
<text top="141" left="624" width="103" height="20" font="4">follow-up imaging. </text>
<text top="228" left="64" width="92" height="20" font="4">Chessa M, et al. </text>
<text top="245" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(428)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16186136?dopt=Citation">16186136</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16186136?dopt=Citation"> </a></text>
<text top="228" left="172" width="54" height="20" font="4">n=71 pts  </text>
<text top="228" left="266" width="76" height="20" font="4">Single-center </text>
<text top="245" left="266" width="74" height="20" font="4">retrospective </text>
<text top="263" left="266" width="66" height="20" font="4">case series </text>
<text top="228" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="245" left="374" width="106" height="20" font="4">Pts that underwent </text>
<text top="263" left="374" width="110" height="20" font="4">coarctation stenting </text>
<text top="280" left="374" width="115" height="20" font="4">between 1997–2004 </text>
<text top="228" left="509" width="98" height="20" font="4">Evaluation of mid </text>
<text top="245" left="509" width="79" height="20" font="4">and long-term </text>
<text top="263" left="509" width="83" height="20" font="4">results of stent </text>
<text top="280" left="509" width="87" height="20" font="4">implantation for </text>
<text top="297" left="509" width="51" height="20" font="4">native or </text>
<text top="314" left="509" width="53" height="20" font="4">recurrent </text>
<text top="331" left="509" width="64" height="20" font="4">coarctation </text>
<text top="228" left="624" width="300" height="20" font="4">● 71 consecutive pts, mean age 22 y (7–66 y), 60% of </text>
<text top="245" left="624" width="194" height="20" font="4">pts &gt;18 y, 19 pts had prior surgery. </text>
<text top="263" left="624" width="126" height="20" font="4">● 74 stents implanted. </text>
<text top="280" left="624" width="313" height="20" font="4">● All pts had clinical evaluation, echo, and exercise ECG </text>
<text top="297" left="624" width="209" height="20" font="4">at 1 and 6 mo post stent implantation. </text>
<text top="314" left="624" width="317" height="20" font="4">● Peak Doppler systolic gradient decreased from 39 ± 15 </text>
<text top="331" left="624" width="135" height="20" font="4">mm Hg to 4 ± 6 mm Hg. </text>
<text top="349" left="624" width="293" height="20" font="4">● Minimal aortic diameter increased from 8 mm to 16 </text>
<text top="366" left="624" width="27" height="20" font="4">mm. </text>
<text top="383" left="624" width="317" height="20" font="4">● 1 death occurred due to aortic rupture immediately post </text>
<text top="400" left="624" width="94" height="20" font="4">stent placement. </text>
<text top="418" left="624" width="201" height="20" font="4">● Reintervention performed in 3 pts. </text>
<text top="228" left="955" width="199" height="20" font="4">● Transcatheter stenting of a native </text>
<text top="245" left="955" width="189" height="20" font="4">or recurrent coarctation is feasible </text>
<text top="263" left="955" width="169" height="20" font="4">and effective with a low rate of </text>
<text top="280" left="955" width="81" height="20" font="4">complications. </text>
<text top="435" left="64" width="89" height="20" font="4">Suarez de Lezo </text>
<text top="453" left="64" width="43" height="20" font="4">J, et al. </text>
<text top="470" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#230">(372)</a> </text>
<text top="487" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15868319?dopt=Citation">15868319</a></text>
<text top="487" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15868319?dopt=Citation"> </a></text>
<text top="435" left="172" width="58" height="20" font="4">n=172 pts </text>
<text top="435" left="266" width="76" height="20" font="4">Single-center </text>
<text top="453" left="266" width="74" height="20" font="4">retrospective </text>
<text top="470" left="266" width="39" height="20" font="4">review </text>
<text top="435" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="453" left="374" width="106" height="20" font="4">Pts that underwent </text>
<text top="470" left="374" width="78" height="20" font="4">percutaneous </text>
<text top="487" left="374" width="124" height="20" font="4">intervention over 21 y  </text>
<text top="435" left="509" width="74" height="20" font="4">Evaluation of </text>
<text top="453" left="509" width="97" height="20" font="4">clinical outcomes </text>
<text top="435" left="624" width="313" height="20" font="4">● The pts were divided into 4 groups. Group 1: neonates </text>
<text top="453" left="624" width="314" height="20" font="4">and infants that underwent balloon angioplasty due to HF </text>
<text top="470" left="624" width="288" height="20" font="4">(n=54). Group 2: Balloon angioplasty in children and </text>
<text top="487" left="624" width="289" height="20" font="4">adults before the stenting era (n=28). Group 3: Stent </text>
<text top="504" left="624" width="316" height="20" font="4">palliation in infants and children &lt;6 y old (n=17). Group 4: </text>
<text top="521" left="624" width="215" height="20" font="4">Stent placement in pts &gt;6 y old (n=73). </text>
<text top="539" left="624" width="287" height="20" font="4">● Outcomes of Group 2 (balloon angioplasty alone), </text>
<text top="556" left="624" width="308" height="20" font="4">mean age 13 ± 8 y. Decreased in peak to peak gradient </text>
<text top="573" left="624" width="310" height="20" font="4">immediately from 49 to 8 mm Hg. 29% of pts with intimal </text>
<text top="590" left="624" width="262" height="20" font="4">tears, late aneurysm formation occurred in 6%.  </text>
<text top="608" left="624" width="311" height="20" font="4">Outcomes of Group 4 (stenting), mean age 20 ± 12 y). 1 </text>
<text top="625" left="624" width="283" height="20" font="4">death 3 h post stenting, likely due to aortic rupture.  </text>
<text top="642" left="624" width="288" height="20" font="4">● All pts had relief of the gradient with a reduction in </text>
<text top="659" left="624" width="294" height="20" font="4">gradient from 39–3 mm Hg. Mean follow-up of 5 y, no </text>
<text top="676" left="624" width="189" height="20" font="4">restenosis or aneurysm formation. </text>
<text top="435" left="955" width="178" height="20" font="4">● Percutaneous interventions in </text>
<text top="453" left="955" width="154" height="20" font="4">coarctation are feasible and </text>
<text top="470" left="955" width="68" height="20" font="4">efficacious.  </text>
<text top="487" left="955" width="168" height="20" font="4">● Balloon angioplasty alone is </text>
<text top="504" left="955" width="174" height="20" font="4">associated with a higher rate of </text>
<text top="521" left="955" width="151" height="20" font="4">intimal tears and aneurysm </text>
<text top="539" left="955" width="157" height="20" font="4">formation compared to stent </text>
<text top="556" left="955" width="64" height="20" font="4">placement. </text>
</page>
<page number="119" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 119 </text>
<text top="107" left="64" width="82" height="20" font="4">Hager A, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(429)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17723827?dopt=Citation">17723827</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17723827?dopt=Citation"> </a></text>
<text top="107" left="172" width="58" height="20" font="4">n=273 pts </text>
<text top="107" left="266" width="76" height="20" font="4">Single-center </text>
<text top="124" left="266" width="74" height="20" font="4">retrospective </text>
<text top="141" left="266" width="39" height="20" font="4">review </text>
<text top="107" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="374" width="106" height="20" font="4">Pts that underwent </text>
<text top="141" left="374" width="98" height="20" font="4">surgical repair for </text>
<text top="159" left="374" width="79" height="20" font="4">isolated aortic </text>
<text top="176" left="374" width="64" height="20" font="4">coarctation </text>
<text top="107" left="509" width="74" height="20" font="4">Evaluation of </text>
<text top="124" left="509" width="96" height="20" font="4">long-term clinical </text>
<text top="141" left="509" width="57" height="20" font="4">outcomes </text>
<text top="107" left="624" width="315" height="20" font="4">● From 1974–2000, 404 pts born before 1985 underwent </text>
<text top="124" left="624" width="116" height="20" font="4">surgical intervention. </text>
<text top="141" left="624" width="289" height="20" font="4">● Of the 404 pts, 21 (5%) died, 1 at surgery, 6 in the </text>
<text top="159" left="624" width="310" height="20" font="4">perioperative period (perioperative mortality of 1.7%). 14 </text>
<text top="176" left="624" width="303" height="20" font="4">pts died during follow-up (3.5%) of various causes (3 of </text>
<text top="193" left="624" width="285" height="20" font="4">congenital HF, 1 of ruptured aortic root aneurysm, 8 </text>
<text top="210" left="624" width="60" height="20" font="4">unknown). </text>
<text top="228" left="624" width="294" height="20" font="4">● From 382 pt that were still alive, 273 pts underwent </text>
<text top="245" left="624" width="161" height="20" font="4">structured clinical evaluation. </text>
<text top="262" left="624" width="300" height="20" font="4">● Surgical resection with end-to-end anastomosis was </text>
<text top="279" left="624" width="295" height="20" font="4">the most common surgical intervention in 199/273 pts </text>
<text top="296" left="624" width="312" height="20" font="4">followed by resection and tube graft placement in 62/273 </text>
<text top="314" left="624" width="23" height="20" font="4">pts. </text>
<text top="331" left="624" width="288" height="20" font="4">29/273 (11%) underwent repeat intervention, 16 had </text>
<text top="348" left="624" width="311" height="20" font="4">surgery, 12 balloon angioplasty, 1 stent. Of these 29 pts, </text>
<text top="365" left="624" width="72" height="20" font="4">5 needed a 2</text>
<text top="367" left="696" width="9" height="13" font="6">nd</text>
<text top="365" left="705" width="122" height="20" font="4"> intervention and 1 a 3</text>
<text top="367" left="827" width="7" height="13" font="6">rd</text>
<text top="365" left="834" width="91" height="20" font="4"> intervention. All </text>
<text top="382" left="624" width="232" height="20" font="4">reinterventions were related to restenosis. </text>
<text top="400" left="624" width="279" height="20" font="4">25% of pts were taking antihypertensive drugs and </text>
<text top="417" left="624" width="304" height="20" font="4">another 23% had increased ambulatory BP, 10% had a </text>
<text top="434" left="624" width="308" height="20" font="4">BP during exercise exceeding 2 SD of reference values. </text>
<text top="451" left="624" width="157" height="20" font="4">● Only 43% had normal BP. </text>
<text top="469" left="624" width="289" height="20" font="4">● Of the 57% pts taking anti-HTN medication or with </text>
<text top="486" left="624" width="318" height="20" font="4">ambulatory or exercise-induced HTN, only 13% had UL to </text>
<text top="503" left="624" width="316" height="20" font="4">lower limbs systolic BP difference &gt;20 mm Hg suggesting </text>
<text top="520" left="624" width="63" height="20" font="4">restenosis. </text>
<text top="537" left="624" width="287" height="20" font="4">● Independent risk factors for HTN (in those without </text>
<text top="555" left="624" width="317" height="20" font="4">restenosis) were repair with prosthetic material, male sex, </text>
<text top="572" left="624" width="148" height="20" font="4">and older age at follow-up. </text>
<text top="107" left="955" width="176" height="20" font="4">● Long-term follow-up following </text>
<text top="124" left="955" width="192" height="20" font="4">successful surgical intervention for </text>
<text top="141" left="955" width="192" height="20" font="4">aortic coarctation reveals that 11% </text>
<text top="159" left="955" width="178" height="20" font="4">of pts required reintervention for </text>
<text top="176" left="955" width="63" height="20" font="4">restenosis. </text>
<text top="193" left="955" width="195" height="20" font="4">● Of those without restenosis, 57% </text>
<text top="210" left="955" width="194" height="20" font="4">either were taking antihypertensive </text>
<text top="228" left="955" width="146" height="20" font="4">medications, had elevated </text>
<text top="245" left="955" width="182" height="20" font="4">ambulatory BP or had a severely </text>
<text top="262" left="955" width="193" height="20" font="4">hypertensive response to exercise. </text>
<text top="279" left="955" width="194" height="20" font="4">● Independent risk factors for HTN </text>
<text top="296" left="955" width="187" height="20" font="4">(in those without restenosis) were </text>
<text top="314" left="955" width="198" height="20" font="4">repair with prosthetic material, male </text>
<text top="331" left="955" width="174" height="20" font="4">sex, and older age at follow-up. </text>
<text top="590" left="64" width="74" height="20" font="4">Toro-Salazar </text>
<text top="607" left="64" width="55" height="20" font="4">OH, et al. </text>
<text top="624" left="64" width="63" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(430)</a> </text>
<text top="641" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11867038?dopt=Citation">11867038</a></text>
<text top="641" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11867038?dopt=Citation"> </a></text>
<text top="590" left="172" width="61" height="20" font="4">n=274 pts  </text>
<text top="590" left="266" width="76" height="20" font="4">Single-center </text>
<text top="607" left="266" width="74" height="20" font="4">retrospective </text>
<text top="624" left="266" width="39" height="20" font="4">review </text>
<text top="590" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="607" left="374" width="106" height="20" font="4">Pts that underwent </text>
<text top="624" left="374" width="121" height="20" font="4">surgical repair of CoA </text>
<text top="641" left="374" width="105" height="20" font="4">at the University of </text>
<text top="659" left="374" width="60" height="20" font="4">Minnesota </text>
<text top="590" left="509" width="100" height="20" font="4">Long-term clinical </text>
<text top="607" left="509" width="57" height="20" font="4">outcomes </text>
<text top="624" left="509" width="97" height="20" font="4">following surgical </text>
<text top="641" left="509" width="35" height="20" font="4">repair </text>
<text top="590" left="624" width="308" height="20" font="4">● 274 pts had operative repair of coarctation from 1948–</text>
<text top="607" left="624" width="200" height="20" font="4">1976 at the University of Minnesota. </text>
<text top="624" left="624" width="270" height="20" font="4">● 7% died in the immediate perioperative period. </text>
<text top="641" left="624" width="245" height="20" font="4">● 252 survivors were available for follow-up. </text>
<text top="659" left="624" width="190" height="20" font="4">● 45/252 pts died late after repair. </text>
<text top="676" left="624" width="289" height="20" font="4">● Of the 207 survivors, 92 pts (44%) were evaluated </text>
<text top="693" left="624" width="317" height="20" font="4">clinically, 115 subjects only responded to a questionnaire. </text>
<text top="710" left="624" width="297" height="20" font="4">Group 1: 45 pts that died late after repair. Group 2: 92 </text>
<text top="727" left="624" width="296" height="20" font="4">subjects with clinical evaluation. Group 3: 115 pts that </text>
<text top="745" left="624" width="314" height="20" font="4">responded to the questionnaire. Mean age at follow-up of </text>
<text top="762" left="624" width="305" height="20" font="4">the 252 long-term survivors was 40 ± 10 y mean age at </text>
<text top="779" left="624" width="142" height="20" font="4">operation was 10 ± 9.5 y. </text>
<text top="590" left="955" width="202" height="20" font="4">● The majority of pts that underwent </text>
<text top="607" left="955" width="198" height="20" font="4">surgical repair survive to adulthood. </text>
<text top="624" left="955" width="174" height="20" font="4">Comorbidities are common and </text>
<text top="641" left="955" width="200" height="20" font="4">include systemic HTN in 30% of pts. </text>
<text top="659" left="955" width="185" height="20" font="4">● Pts repaired late (&gt;10 y of age) </text>
<text top="676" left="955" width="180" height="20" font="4">are more likely to have HTN and </text>
<text top="693" left="955" width="171" height="20" font="4">less likely to survive long-term. </text>
<text top="710" left="955" width="177" height="20" font="4">● Pts operated on early (&lt;1 y of </text>
<text top="727" left="955" width="172" height="20" font="4">age) are more likely to develop </text>
<text top="745" left="955" width="78" height="20" font="4">recoarctation. </text>
</page>
<page number="120" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 120 </text>
<text top="107" left="624" width="250" height="20" font="4">● 92% had surgical end-to-end resection and </text>
<text top="124" left="624" width="79" height="20" font="4">anastomosis.  </text>
<text top="141" left="624" width="309" height="20" font="4">● During follow-up, 20% of survivors underwent another </text>
<text top="159" left="624" width="291" height="20" font="4">cardiac operation, 14% died at the second operation. </text>
<text top="176" left="624" width="235" height="20" font="4">● 32/92 pts in Group 2 had systemic HTN. </text>
<text top="193" left="624" width="288" height="20" font="4">● Pts operated on at &gt;10 y of age were less likely to </text>
<text top="210" left="624" width="127" height="20" font="4">survive into adulthood. </text>
<text top="228" left="624" width="317" height="20" font="4">● Late deaths were attributable to CAD, repeat operation, </text>
<text top="245" left="624" width="297" height="20" font="4">aortic dissection and sudden unexplained death along </text>
<text top="262" left="624" width="166" height="20" font="4">with other noncardiac causes. </text>
<text top="279" left="624" width="270" height="20" font="4">● Predictors of recoarctation included end to end </text>
<text top="296" left="624" width="311" height="20" font="4">resection technique, early era of operation (before 1960) </text>
<text top="314" left="624" width="147" height="20" font="4">and age at operation &lt;1 y. </text>
<text top="107" left="955" width="177" height="20" font="4">● Leading causes of death long-</text>
<text top="124" left="955" width="200" height="20" font="4">term include CAD, repeat operation, </text>
<text top="141" left="955" width="119" height="20" font="4">and aortic dissection. </text>
<text top="332" left="64" width="89" height="20" font="4">Dodge-Khatami </text>
<text top="349" left="64" width="45" height="20" font="4">A, et al. </text>
<text top="366" left="64" width="63" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(431)</a> </text>
<text top="383" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11678458?dopt=Citation">11678458</a></text>
<text top="383" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11678458?dopt=Citation"> </a></text>
<text top="332" left="172" width="61" height="20" font="4">n=271 pts  </text>
<text top="332" left="266" width="76" height="20" font="4">Single-center </text>
<text top="349" left="266" width="74" height="20" font="4">retrospective </text>
<text top="366" left="266" width="39" height="20" font="4">review </text>
<text top="332" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="349" left="374" width="106" height="20" font="4">Pts that underwent </text>
<text top="366" left="374" width="109" height="20" font="4">surgical coarctation </text>
<text top="383" left="374" width="35" height="20" font="4">repair </text>
<text top="332" left="509" width="100" height="20" font="4">Long-term clinical </text>
<text top="349" left="509" width="53" height="20" font="4">follow-up </text>
<text top="332" left="624" width="306" height="20" font="4">● Between 1957-1998, 271 pts had surgical coarctation </text>
<text top="349" left="624" width="42" height="20" font="4">repair.  </text>
<text top="366" left="624" width="270" height="20" font="4">● Techniques included: patch aortoplasty in 118, </text>
<text top="383" left="624" width="300" height="20" font="4">resection with extended end to end anastomosis in 69, </text>
<text top="400" left="624" width="297" height="20" font="4">subclavian flap in 61, resection with simple end to end </text>
<text top="418" left="624" width="309" height="20" font="4">anastomosis in 18, resection with interposition graft in 4, </text>
<text top="435" left="624" width="139" height="20" font="4">extra-anatomic graft in 1. </text>
<text top="452" left="624" width="311" height="20" font="4">● Median age at repair was 156 d, 1% early and 2% late </text>
<text top="469" left="624" width="44" height="20" font="4">deaths. </text>
<text top="487" left="624" width="309" height="20" font="4">● Recoarctation occurred in 11%, most frequently in the </text>
<text top="504" left="624" width="315" height="20" font="4">extended end to end and subclavian flap groups. Pts with </text>
<text top="521" left="624" width="312" height="20" font="4">aortic arch hypoplasia were more likely to have recurrent </text>
<text top="538" left="624" width="67" height="20" font="4">coarctation. </text>
<text top="555" left="624" width="209" height="20" font="4">● No mortality for recoarctation repair </text>
<text top="332" left="955" width="189" height="20" font="4">● Recoarctation following surgical </text>
<text top="349" left="955" width="189" height="20" font="4">repair occurs in 11% of pts, and is </text>
<text top="366" left="955" width="198" height="20" font="4">most common in pts that underwent </text>
<text top="383" left="955" width="161" height="20" font="4">surgical extended end to end </text>
<text top="400" left="955" width="187" height="20" font="4">resection or subclavian flap repair </text>
<text top="418" left="955" width="139" height="20" font="4">as well as in those with a </text>
<text top="435" left="955" width="129" height="20" font="4">hypoplastic aortic arch. </text>
<text top="573" left="64" width="80" height="20" font="4">Zabal C, et al. </text>
<text top="591" left="64" width="63" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(432)</a> </text>
<text top="608" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12482798?dopt=Citation">12482798</a></text>
<text top="608" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12482798?dopt=Citation"> </a></text>
<text top="573" left="172" width="54" height="20" font="4">n=54 pts  </text>
<text top="573" left="266" width="76" height="20" font="4">Single-center </text>
<text top="591" left="266" width="74" height="20" font="4">retrospective </text>
<text top="608" left="266" width="39" height="20" font="4">review </text>
<text top="573" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="591" left="374" width="113" height="20" font="4">Adult pts with native </text>
<text top="608" left="374" width="87" height="20" font="4">coarctation that </text>
<text top="625" left="374" width="95" height="20" font="4">underwent either </text>
<text top="642" left="374" width="80" height="20" font="4">angioplasty or </text>
<text top="659" left="374" width="46" height="20" font="4">stenting </text>
<text top="573" left="509" width="101" height="20" font="4">Intermediate-term </text>
<text top="591" left="509" width="100" height="20" font="4">clinical outcomes. </text>
<text top="608" left="509" width="89" height="20" font="4">1° outcome is a </text>
<text top="625" left="509" width="92" height="20" font="4">composite index </text>
<text top="642" left="509" width="54" height="20" font="4">of failure, </text>
<text top="659" left="509" width="83" height="20" font="4">including heart </text>
<text top="677" left="509" width="89" height="20" font="4">related death, a </text>
<text top="694" left="509" width="94" height="20" font="4">residual gradient </text>
<text top="711" left="509" width="102" height="20" font="4">&gt;20 mm Hg, need </text>
<text top="728" left="509" width="99" height="20" font="4">for reintervention, </text>
<text top="745" left="509" width="81" height="20" font="4">and aneurysm </text>
<text top="763" left="509" width="58" height="20" font="4">formation. </text>
<text top="573" left="624" width="308" height="20" font="4">● 54 consecutive pts, 32 underwent balloon angioplasty </text>
<text top="591" left="624" width="315" height="20" font="4">from 1995–1997, 22 underwent stent placement between </text>
<text top="608" left="624" width="68" height="20" font="4">1997–1999. </text>
<text top="625" left="624" width="297" height="20" font="4">● Peak systolic gradient reduced in both groups (from </text>
<text top="642" left="624" width="318" height="20" font="4">63–11 mm Hg in the balloon group and from 64 mm Hg–3 </text>
<text top="659" left="624" width="149" height="20" font="4">mm Hg in the stent group). </text>
<text top="677" left="624" width="298" height="20" font="4">● Stent implantation was associated with a successful </text>
<text top="694" left="624" width="286" height="20" font="4">dilation in all pts (vs. 9% unsuccessful dilation in the </text>
<text top="711" left="624" width="296" height="20" font="4">balloon group), resolution of the gradient (&lt;20 mm Hg </text>
<text top="728" left="624" width="308" height="20" font="4">peak Doppler gradient) in all pts (vs. residual gradient in </text>
<text top="745" left="624" width="148" height="20" font="4">16% of the balloon group). </text>
<text top="763" left="624" width="283" height="20" font="4">● 6% of pts with balloon angioplasty had aneurysm </text>
<text top="780" left="624" width="314" height="20" font="4">formation, none of the stented pts developed aneurysms. </text>
<text top="573" left="955" width="187" height="20" font="4">● Stenting of native coarctation is </text>
<text top="591" left="955" width="161" height="20" font="4">has superior outcomes when </text>
<text top="608" left="955" width="180" height="20" font="4">compared to balloon angioplasty </text>
<text top="625" left="955" width="37" height="20" font="4">alone. </text>
</page>
<page number="121" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 121 </text>
<text top="107" left="64" width="93" height="20" font="4">Brown JW, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(433)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19932264?dopt=Citation">19932264</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19932264?dopt=Citation"> </a></text>
<text top="107" left="172" width="68" height="20" font="4">n=1,012 pts </text>
<text top="124" left="172" width="49" height="20" font="4">with 103 </text>
<text top="141" left="172" width="51" height="20" font="4">requiring </text>
<text top="159" left="172" width="81" height="20" font="4">reintervention; </text>
<text top="176" left="172" width="73" height="20" font="4">only 19 adult </text>
<text top="193" left="172" width="63" height="20" font="4">pts (2%) at </text>
<text top="210" left="172" width="44" height="20" font="4">the first </text>
<text top="227" left="172" width="67" height="20" font="4">intervention </text>
<text top="107" left="266" width="76" height="20" font="4">Single-center </text>
<text top="124" left="266" width="74" height="20" font="4">retrospective </text>
<text top="141" left="266" width="39" height="20" font="4">review </text>
<text top="107" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="374" width="108" height="20" font="4">All pts with isolated </text>
<text top="141" left="374" width="64" height="20" font="4">or complex </text>
<text top="159" left="374" width="64" height="20" font="4">coarctation </text>
<text top="107" left="509" width="53" height="20" font="4">Repair of </text>
<text top="124" left="509" width="53" height="20" font="4">recurrent </text>
<text top="141" left="509" width="64" height="20" font="4">coarctation </text>
<text top="159" left="509" width="72" height="20" font="4">compared to </text>
<text top="176" left="509" width="43" height="20" font="4">balloon </text>
<text top="193" left="509" width="66" height="20" font="4">angioplasty </text>
<text top="107" left="624" width="272" height="20" font="4">● Median age at reintervention 6.5 y (2 wk–44 y). </text>
<text top="124" left="624" width="242" height="20" font="4">● 98% survival at 15 and 40 y post surgery; </text>
<text top="141" left="624" width="142" height="20" font="4">91% at 15 y post balloon. </text>
<text top="107" left="955" width="181" height="20" font="4">● Surgical repair is safe and has </text>
<text top="124" left="955" width="201" height="20" font="4">excellent results with low recurrence </text>
<text top="141" left="955" width="28" height="20" font="4">rate. </text>
<text top="245" left="64" width="91" height="20" font="4">Reents W, et al. </text>
<text top="263" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(434)</a> </text>
<text top="280" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21476189?dopt=Citation">21476189</a></text>
<text top="280" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21476189?dopt=Citation"> </a></text>
<text top="245" left="172" width="31" height="20" font="4">n=13 </text>
<text top="263" left="172" width="68" height="20" font="4">consecutive </text>
<text top="280" left="172" width="56" height="20" font="4">pts adults </text>
<text top="297" left="172" width="78" height="20" font="4">aged 25–69 y </text>
<text top="245" left="266" width="76" height="20" font="4">Single-center </text>
<text top="263" left="266" width="38" height="20" font="4">cohort </text>
<text top="245" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="263" left="374" width="66" height="20" font="4">Coarctation </text>
<text top="280" left="374" width="115" height="20" font="4">coexistent with other </text>
<text top="297" left="374" width="89" height="20" font="4">cardiac disease </text>
<text top="314" left="374" width="88" height="20" font="4">operated on via </text>
<text top="332" left="374" width="122" height="20" font="4">median sternotomy; 2 </text>
<text top="349" left="374" width="98" height="20" font="4">pts with recurrent </text>
<text top="366" left="374" width="31" height="20" font="4">CoA. </text>
<text top="245" left="509" width="78" height="20" font="4">Early and late </text>
<text top="263" left="509" width="40" height="20" font="4">results </text>
<text top="245" left="624" width="250" height="20" font="4">● Early mortality 0% and 1 late death at 11 y. </text>
<text top="263" left="624" width="173" height="20" font="4">● Improvement in NYHA class. </text>
<text top="280" left="624" width="276" height="20" font="4">● Many pts still required antihypertensive therapy. </text>
<text top="245" left="955" width="199" height="20" font="4">● Excellent operative and long-term </text>
<text top="263" left="955" width="43" height="20" font="4">results. </text>
<text top="280" left="955" width="179" height="20" font="4">● Procedure of choice if already </text>
<text top="297" left="955" width="166" height="20" font="4">necessitating cardiac surgery. </text>
<text top="384" left="64" width="94" height="20" font="4">Roselli EE, et al. </text>
<text top="401" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(435)</a> </text>
<text top="418" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22704801?dopt=Citation">22704801</a></text>
<text top="418" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22704801?dopt=Citation"> </a></text>
<text top="384" left="172" width="61" height="20" font="4">n=110 pts: </text>
<text top="401" left="172" width="73" height="20" font="4">(40 open, 11 </text>
<text top="418" left="172" width="57" height="20" font="4">hybrid, 59 </text>
<text top="436" left="172" width="81" height="20" font="4">endovasc); 43 </text>
<text top="453" left="172" width="23" height="20" font="4">first </text>
<text top="470" left="172" width="67" height="20" font="4">coarctation, </text>
<text top="487" left="172" width="73" height="20" font="4">42 recurrent, </text>
<text top="504" left="172" width="75" height="20" font="4">25 aneurysm </text>
<text top="384" left="266" width="76" height="20" font="4">Single-center </text>
<text top="401" left="266" width="74" height="20" font="4">retrospective </text>
<text top="384" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="401" left="374" width="95" height="20" font="4">New or recurrent </text>
<text top="418" left="374" width="67" height="20" font="4">coarctation, </text>
<text top="436" left="374" width="116" height="20" font="4">postrepair aneurysm </text>
<text top="453" left="374" width="112" height="20" font="4">or pseudoaneurysm </text>
<text top="384" left="509" width="78" height="20" font="4">Early and late </text>
<text top="401" left="509" width="64" height="20" font="4">results and </text>
<text top="418" left="509" width="52" height="20" font="4">establish </text>
<text top="436" left="509" width="75" height="20" font="4">indications to </text>
<text top="453" left="509" width="89" height="20" font="4">guide treatment </text>
<text top="384" left="624" width="303" height="20" font="4">● 100% technical success no death, stroke, paraplegia </text>
<text top="401" left="624" width="260" height="20" font="4">22 pts required reinterventions; no difference in </text>
<text top="418" left="624" width="274" height="20" font="4">occurrence of reinterventions based on approach. </text>
<text top="436" left="624" width="192" height="20" font="4">● Survival at 1/5/8 y is 95/95/90%. </text>
<text top="384" left="955" width="173" height="20" font="4">● Can be safely and effectively </text>
<text top="401" left="955" width="143" height="20" font="4">managed with a variety of </text>
<text top="418" left="955" width="66" height="20" font="4">techniques. </text>
<text top="436" left="955" width="140" height="20" font="4">● Optimal results require </text>
<text top="453" left="955" width="187" height="20" font="4">multimodality approach tailored to </text>
<text top="470" left="955" width="179" height="20" font="4">surgical indication and anatomy. </text>
<text top="487" left="955" width="190" height="20" font="4">● Pts require lifelong surveillance. </text>
<text top="522" left="64" width="79" height="20" font="4">Carr JA, et al. </text>
<text top="540" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(436)</a> </text>
<text top="557" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16545637?dopt=Citation">16545637</a></text>
<text top="557" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16545637?dopt=Citation"> </a></text>
<text top="522" left="172" width="58" height="20" font="4">n=846 pts </text>
<text top="522" left="266" width="93" height="20" font="4">Meta-analysis of </text>
<text top="540" left="266" width="63" height="20" font="4">22 studies, </text>
<text top="557" left="266" width="52" height="20" font="4">including </text>
<text top="574" left="266" width="93" height="20" font="4">adolescents and </text>
<text top="591" left="266" width="57" height="20" font="4">adults; 16 </text>
<text top="608" left="266" width="90" height="20" font="4">endovascular; 6 </text>
<text top="626" left="266" width="87" height="20" font="4">surgical reports </text>
<text top="522" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="540" left="374" width="73" height="20" font="4">Treatment of </text>
<text top="557" left="374" width="76" height="20" font="4">coarctation in </text>
<text top="574" left="374" width="120" height="20" font="4">adolescents or adults </text>
<text top="522" left="509" width="57" height="20" font="4">Morbidity, </text>
<text top="540" left="509" width="94" height="20" font="4">restenosis, need </text>
<text top="557" left="509" width="99" height="20" font="4">for reintervention, </text>
<text top="574" left="509" width="29" height="20" font="4">HTN </text>
<text top="522" left="624" width="286" height="20" font="4">● 1° stenting had the lowest risk of complication but </text>
<text top="540" left="624" width="307" height="20" font="4">higher risk of restenosis and reintervention compared to </text>
<text top="557" left="624" width="48" height="20" font="4">surgery. </text>
<text top="574" left="624" width="243" height="20" font="4">● Both therapies had an equal cure of HTN. </text>
<text top="522" left="955" width="178" height="20" font="4">● 1° stenting or angioplasty has </text>
<text top="540" left="955" width="187" height="20" font="4">similar morbidity to surgical repair </text>
<text top="557" left="955" width="174" height="20" font="4">but reintervention rates higher.  </text>
<text top="644" left="64" width="70" height="20" font="4">Aris A, et al. </text>
<text top="661" left="64" width="63" height="20" font="4">1999 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(437)</a> </text>
<text top="678" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10355415?dopt=Citation">10355415</a></text>
<text top="678" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10355415?dopt=Citation"> </a></text>
<text top="644" left="172" width="75" height="20" font="4">n=8 pts aged </text>
<text top="661" left="172" width="47" height="20" font="4">51–73 y </text>
<text top="644" left="266" width="74" height="20" font="4">Cohort of pts </text>
<text top="661" left="266" width="34" height="20" font="4">&gt;50 y </text>
<text top="644" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="661" left="374" width="53" height="20" font="4">Older pts </text>
<text top="644" left="509" width="29" height="20" font="4">HTN </text>
<text top="644" left="624" width="197" height="20" font="4">● Improvement in BP with p&lt;0.001. </text>
<text top="644" left="955" width="159" height="20" font="4">● Surgical repair in older pts </text>
<text top="661" left="955" width="169" height="20" font="4">reduces HTN and the need for </text>
<text top="678" left="955" width="37" height="20" font="4">meds. </text>
<text top="696" left="64" width="65" height="20" font="4">Almeida de </text>
<text top="713" left="64" width="90" height="20" font="4">Oliveira S, et al. </text>
<text top="730" left="64" width="63" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(438)</a> </text>
<text top="748" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14667622?dopt=Citation">14667622</a></text>
<text top="748" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14667622?dopt=Citation"> </a></text>
<text top="696" left="172" width="31" height="20" font="4">n=18 </text>
<text top="713" left="172" width="68" height="20" font="4">consecutive </text>
<text top="730" left="172" width="78" height="20" font="4">pts compared </text>
<text top="748" left="172" width="73" height="20" font="4">to 81 treated </text>
<text top="765" left="172" width="81" height="20" font="4">conventionally </text>
<text top="696" left="266" width="73" height="20" font="4">Cohort study </text>
<text top="696" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="713" left="374" width="34" height="20" font="4">&gt;18 y </text>
<text top="696" left="509" width="87" height="20" font="4">Midterm results </text>
<text top="713" left="509" width="50" height="20" font="4">mortality </text>
<text top="730" left="509" width="29" height="20" font="4">HTN </text>
<text top="696" left="624" width="153" height="20" font="4">● 4% mortality in all 99 pts. </text>
<text top="713" left="624" width="260" height="20" font="4">● No mortality in extra-anatomic bypass group. </text>
<text top="730" left="624" width="272" height="20" font="4">● 2/3 of extra-anatomic bypass group returned to </text>
<text top="748" left="624" width="81" height="20" font="4">normotensive. </text>
<text top="696" left="955" width="180" height="20" font="4">● Extra-anatomic bypass is safe </text>
<text top="713" left="955" width="77" height="20" font="4">and effective. </text>
</page>
<page number="122" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 122 </text>
<text top="107" left="172" width="67" height="20" font="4">all aged 18–</text>
<text top="124" left="172" width="27" height="20" font="4">64 y </text>
<text top="206" left="64" width="81" height="20" font="4">Morgan GJ, et </text>
<text top="223" left="64" width="16" height="20" font="4">al. </text>
<text top="240" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(439)</a> </text>
<text top="257" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23428013?dopt=Citation">23428013</a></text>
<text top="257" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23428013?dopt=Citation"> </a></text>
<text top="206" left="172" width="51" height="20" font="4">n=31 pts </text>
<text top="206" left="266" width="73" height="20" font="4">Cohort study </text>
<text top="206" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="223" left="374" width="98" height="20" font="4">Mean age 12 y at </text>
<text top="240" left="374" width="87" height="20" font="4">time of stenting </text>
<text top="206" left="509" width="45" height="20" font="4">HTN by </text>
<text top="223" left="509" width="84" height="20" font="4">ambulatory BP </text>
<text top="240" left="509" width="61" height="20" font="4">monitoring </text>
<text top="206" left="624" width="311" height="20" font="4">● Mean time after stent implantation 5 y, HTN in 10% on </text>
<text top="223" left="624" width="317" height="20" font="4">single time BP, but 45% on ambulatory BP. BP correlated </text>
<text top="240" left="624" width="299" height="20" font="4">with LV mass by echo. Stent decreased in size from 48</text>
<text top="242" left="923" width="7" height="13" font="6">th</text>
<text top="240" left="930" width="3" height="20" font="4"> </text>
<text top="257" left="624" width="77" height="20" font="4">percentile to 4</text>
<text top="259" left="701" width="7" height="13" font="6">th</text>
<text top="257" left="708" width="215" height="20" font="4"> percentile with somatic growth, but did </text>
<text top="274" left="624" width="172" height="20" font="4">not relate to other parameters.  </text>
<text top="206" left="955" width="182" height="20" font="4">● HTN is common after stenting, </text>
<text top="223" left="955" width="163" height="20" font="4">without correlation to residual </text>
<text top="240" left="955" width="67" height="20" font="4">coarctation. </text>
<text top="292" left="64" width="86" height="20" font="4">Cook SC, et al. </text>
<text top="310" left="64" width="56" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(32)</a> </text>
<text top="327" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23279961?dopt=Citation">23279961</a></text>
<text top="327" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23279961?dopt=Citation"> </a></text>
<text top="292" left="172" width="54" height="20" font="4">n=43 pts  </text>
<text top="292" left="266" width="76" height="20" font="4">Single-center </text>
<text top="310" left="266" width="70" height="20" font="4">cohort study </text>
<text top="292" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="310" left="374" width="81" height="20" font="4">Over age 18 y </text>
<text top="292" left="509" width="51" height="20" font="4">Cerebral </text>
<text top="310" left="509" width="96" height="20" font="4">aneurysms in pts </text>
<text top="327" left="509" width="53" height="20" font="4">with CoA </text>
<text top="292" left="624" width="307" height="20" font="4">● Increased prevalence of intercranial aneurysms in pts </text>
<text top="310" left="624" width="284" height="20" font="4">with CoA (11%), with increased age as the sole risk </text>
<text top="327" left="624" width="38" height="20" font="4">factor. </text>
<text top="292" left="955" width="193" height="20" font="4">● Intracranial aneurysms are more </text>
<text top="310" left="955" width="174" height="20" font="4">prevalent in CoA, particularly in </text>
<text top="327" left="955" width="7" height="20" font="4">4</text>
<text top="329" left="962" width="7" height="13" font="6">th</text>
<text top="327" left="968" width="10" height="20" font="4">/5</text>
<text top="329" left="979" width="7" height="13" font="6">th</text>
<text top="327" left="985" width="51" height="20" font="4"> decade. </text>
<text top="345" left="64" width="91" height="20" font="4">Connolly HM, et </text>
<text top="362" left="64" width="16" height="20" font="4">al. </text>
<text top="379" left="64" width="63" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(440)</a> </text>
<text top="396" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14661678?dopt=Citation">14661678</a></text>
<text top="396" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14661678?dopt=Citation"> </a></text>
<text top="345" left="172" width="61" height="20" font="4">n=277 pts  </text>
<text top="345" left="266" width="76" height="20" font="4">Single-center </text>
<text top="362" left="266" width="70" height="20" font="4">cohort study </text>
<text top="345" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="362" left="374" width="85" height="20" font="4">Mean age 41 y </text>
<text top="345" left="509" width="51" height="20" font="4">Cerebral </text>
<text top="362" left="509" width="96" height="20" font="4">aneurysms in pts </text>
<text top="379" left="509" width="89" height="20" font="4">with coarctation </text>
<text top="345" left="624" width="301" height="20" font="4">● Increased prevalence of intracranial aneurysm in pts </text>
<text top="362" left="624" width="228" height="20" font="4">with CoA, with no predictive risk factors.   </text>
<text top="379" left="624" width="138" height="20" font="4">● 1 needed intervention. </text>
<text top="345" left="955" width="191" height="20" font="4">● Increased intracranial aneurysm </text>
<text top="362" left="955" width="192" height="20" font="4">prevalence in CoA, but only 1 pt of </text>
<text top="379" left="955" width="183" height="20" font="4">277 (10 with aneurysms) needed </text>
<text top="396" left="955" width="189" height="20" font="4">intervention. Notably pt population </text>
<text top="414" left="955" width="124" height="20" font="4">with mean age of 40s. </text>
<text top="432" left="64" width="80" height="20" font="4">Correia AS, et </text>
<text top="449" left="64" width="16" height="20" font="4">al. </text>
<text top="466" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(441)</a> </text>
<text top="483" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24239395?dopt=Citation">24239395</a></text>
<text top="483" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24239395?dopt=Citation"> </a></text>
<text top="432" left="172" width="51" height="20" font="4">n=65 pts </text>
<text top="432" left="266" width="76" height="20" font="4">Single-center </text>
<text top="449" left="266" width="70" height="20" font="4">cohort study </text>
<text top="432" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="449" left="374" width="111" height="20" font="4">Age &gt;18. Mean age </text>
<text top="466" left="374" width="27" height="20" font="4">30 y </text>
<text top="432" left="509" width="78" height="20" font="4">Prevalence of </text>
<text top="449" left="509" width="96" height="20" font="4">exercise-induced </text>
<text top="466" left="509" width="87" height="20" font="4">HTN in pts with </text>
<text top="483" left="509" width="27" height="20" font="4">CoA </text>
<text top="432" left="624" width="298" height="20" font="4">● 18% with medical treatment for HTN, 22% had HTN </text>
<text top="449" left="624" width="268" height="20" font="4">with exercise of whom only 1/3 had HTN at rest.  </text>
<text top="466" left="624" width="283" height="20" font="4">● Risk factors were peak aortic gradient and use of </text>
<text top="483" left="624" width="35" height="20" font="4">ACEI. </text>
<text top="432" left="955" width="202" height="20" font="4">● Exercise-induced HTN is common </text>
<text top="449" left="955" width="89" height="20" font="4">in pts with CoA. </text>
<text top="501" left="64" width="83" height="20" font="4">Said SM, et al. </text>
<text top="518" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(442)</a> </text>
<text top="536" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22093693?dopt=Citation">22093693</a></text>
<text top="536" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22093693?dopt=Citation"> </a></text>
<text top="501" left="172" width="51" height="20" font="4">n=61 pts </text>
<text top="501" left="266" width="68" height="20" font="4">Case series </text>
<text top="501" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="518" left="374" width="100" height="20" font="4">Pts between Nov. </text>
<text top="536" left="374" width="98" height="20" font="4">1970―Feb. 2008 </text>
<text top="553" left="374" width="122" height="20" font="4">who underwent repair </text>
<text top="570" left="374" width="52" height="20" font="4">of DCRV </text>
<text top="501" left="509" width="60" height="20" font="4">Long-term </text>
<text top="518" left="509" width="96" height="20" font="4">surgical outcome </text>
<text top="501" left="624" width="305" height="20" font="4">● 2 early deaths from postoperative low cardiac output. </text>
<text top="518" left="624" width="257" height="20" font="4">● Mean postoperative gradient: 2±4.5 mm Hg. </text>
<text top="536" left="624" width="281" height="20" font="4">● Late survival was 90% at 10 y. There were 3 late </text>
<text top="553" left="624" width="304" height="20" font="4">deaths due to HF in 2 pts and SCD in 1 pt, all occurring </text>
<text top="570" left="624" width="76" height="20" font="4">before 1997.  </text>
<text top="587" left="624" width="317" height="20" font="4">● No pts required reoperation for residual or recurrent RV </text>
<text top="604" left="624" width="67" height="20" font="4">obstruction. </text>
<text top="501" left="955" width="170" height="20" font="4">● Surgical correction of DCRV </text>
<text top="518" left="955" width="185" height="20" font="4">results in excellent functional and </text>
<text top="536" left="955" width="178" height="20" font="4">hemodynamic long-term results, </text>
<text top="553" left="955" width="163" height="20" font="4">with complete relief of the RV </text>
<text top="570" left="955" width="170" height="20" font="4">obstruction. The presence of a </text>
<text top="587" left="955" width="172" height="20" font="4">DCRV should be considered in </text>
<text top="604" left="955" width="182" height="20" font="4">anomalies with high or persistent </text>
<text top="622" left="955" width="51" height="20" font="4">RVOTO. </text>
<text top="640" left="64" width="83" height="20" font="4">Kahr PC, et al. </text>
<text top="657" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(443)</a> </text>
<text top="674" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24836684?dopt=Citation">24836684</a></text>
<text top="674" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24836684?dopt=Citation"> </a></text>
<text top="640" left="172" width="51" height="20" font="4">n=50 pts </text>
<text top="640" left="266" width="78" height="20" font="4">Retrospective </text>
<text top="657" left="266" width="39" height="20" font="4">review </text>
<text top="640" left="374" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="657" left="374" width="120" height="20" font="4">Pts with DCRV under </text>
<text top="674" left="374" width="53" height="20" font="4">follow-up </text>
<text top="640" left="509" width="59" height="20" font="4">● Survival </text>
<text top="657" left="509" width="57" height="20" font="4">outcomes </text>
<text top="640" left="624" width="265" height="20" font="4">● 96% of pts had VSD as underlying diagnosis.  </text>
<text top="657" left="624" width="312" height="20" font="4">● 8 pts remained completely asymptomatic during follow-</text>
<text top="674" left="624" width="24" height="20" font="4">up.  </text>
<text top="691" left="624" width="302" height="20" font="4">● The remaining pts developed symptoms at a median </text>
<text top="708" left="624" width="71" height="20" font="4">age of 26 y.  </text>
<text top="726" left="624" width="300" height="20" font="4">● Surgical correction was performed in 33 pts (median </text>
<text top="743" left="624" width="130" height="20" font="4">age at operation 27 y).  </text>
<text top="640" left="955" width="182" height="20" font="4">● Contemporary adult DCRV pts </text>
<text top="657" left="955" width="187" height="20" font="4">have good survival prospects and </text>
<text top="674" left="955" width="137" height="20" font="4">low long-term morbidity.  </text>
<text top="691" left="955" width="180" height="20" font="4">● Although asymptomatic adults </text>
<text top="708" left="955" width="171" height="20" font="4">may be encountered even with </text>
<text top="726" left="955" width="161" height="20" font="4">severe obstruction; symptom </text>
<text top="743" left="955" width="174" height="20" font="4">development is common during </text>
<text top="760" left="955" width="56" height="20" font="4">adult life.  </text>
</page>
<page number="123" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 123 </text>
<text top="107" left="624" width="314" height="20" font="4">● No residual intraventricular gradient was present at the </text>
<text top="124" left="624" width="310" height="20" font="4">latest follow-up in 91% of operated pts and FC improved </text>
<text top="141" left="624" width="305" height="20" font="4">significantly with only 6 pts remaining in NYHA class 2.  </text>
<text top="159" left="624" width="317" height="20" font="4">● There was no early or late operative mortality and no pt </text>
<text top="176" left="624" width="314" height="20" font="4">required reoperation for DCRV during a median follow-up </text>
<text top="193" left="624" width="37" height="20" font="4">of 8 y. </text>
<text top="107" left="955" width="188" height="20" font="4">● Cardiac surgery in this cohort is </text>
<text top="124" left="955" width="190" height="20" font="4">inherently low risk and offers good </text>
<text top="141" left="955" width="159" height="20" font="4">long-term hemodynamic and </text>
<text top="159" left="955" width="177" height="20" font="4">functional results justifying early </text>
<text top="176" left="955" width="191" height="20" font="4">intervention in consideration of the </text>
<text top="193" left="955" width="167" height="20" font="4">progressive nature of this rare </text>
<text top="210" left="955" width="98" height="20" font="4">congenital lesion. </text>
<text top="228" left="108" width="3" height="20" font="4"> </text>
<text top="245" left="108" width="463" height="24" font="1"><b>Data Supplement 39. Valvular Pulmonary Stenosis – Section 4.3.1 </b></text>
<text top="267" left="92" width="38" height="20" font="3"><b>Study </b></text>
<text top="284" left="67" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="301" left="95" width="30" height="20" font="3"><b>Year </b></text>
<text top="267" left="177" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="284" left="191" width="44" height="20" font="3"><b>Design </b></text>
<text top="267" left="274" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="267" left="360" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="284" left="396" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="267" left="509" width="74" height="20" font="3"><b>Intervention </b></text>
<text top="267" left="625" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="267" left="770" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="267" left="936" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="319" left="64" width="89" height="20" font="4">Johnson AM, et </text>
<text top="336" left="64" width="16" height="20" font="4">al. </text>
<text top="354" left="64" width="63" height="20" font="4">1962 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(444)</a> </text>
<text top="371" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14451995?dopt=Citation">14451995</a></text>
<text top="371" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14451995?dopt=Citation"> </a></text>
<text top="319" left="170" width="67" height="20" font="4">Prospective </text>
<text top="336" left="170" width="76" height="20" font="4">observational </text>
<text top="354" left="170" width="41" height="20" font="4">cohort  </text>
<text top="319" left="270" width="72" height="20" font="4">n=32 pts (19 </text>
<text top="336" left="270" width="20" height="20" font="4">pts </text>
<text top="354" left="270" width="73" height="20" font="4">operated; 13 </text>
<text top="371" left="270" width="70" height="20" font="4">unoperated) </text>
<text top="319" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="336" left="356" width="125" height="20" font="4">Presence of valvar PS </text>
<text top="354" left="356" width="114" height="20" font="4">pre- or postoperation</text>
<text top="355" left="470" width="2" height="13" font="6"> </text>
<text top="319" left="496" width="50" height="20" font="4">Exercise </text>
<text top="336" left="496" width="83" height="20" font="4">catheterization </text>
<text top="319" left="608" width="88" height="20" font="4">Hemodynamics </text>
<text top="319" left="728" width="181" height="20" font="4">● Impaired stroke volume due to </text>
<text top="336" left="728" width="184" height="20" font="4">impaired filling appears common. </text>
<text top="319" left="926" width="113" height="20" font="4">● Impaired exercise </text>
<text top="336" left="926" width="146" height="20" font="4">tolerance was found in pts </text>
<text top="354" left="926" width="133" height="20" font="4">with native PS and after </text>
<text top="371" left="926" width="62" height="20" font="4">valvotomy. </text>
<text top="389" left="64" width="88" height="20" font="4">Lewis JM, et al. </text>
<text top="406" left="64" width="63" height="20" font="4">1964 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(445)</a> </text>
<text top="423" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14172094?dopt=Citation">14172094</a></text>
<text top="423" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14172094?dopt=Citation"> </a></text>
<text top="389" left="170" width="67" height="20" font="4">Prospective </text>
<text top="406" left="170" width="76" height="20" font="4">observational </text>
<text top="423" left="170" width="41" height="20" font="4">cohort  </text>
<text top="389" left="270" width="51" height="20" font="4">n=13 pts </text>
<text top="389" left="356" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="406" left="356" width="32" height="20" font="4">≥21 y</text>
<text top="408" left="387" width="2" height="13" font="6"> </text>
<text top="389" left="496" width="50" height="20" font="4">Exercise </text>
<text top="406" left="496" width="83" height="20" font="4">catheterization </text>
<text top="389" left="608" width="88" height="20" font="4">Hemodynamics </text>
<text top="389" left="728" width="178" height="20" font="4">● If RVP ≥80 mm Hg, abnormal </text>
<text top="406" left="728" width="172" height="20" font="4">exercise hemodynamics (lower </text>
<text top="423" left="728" width="179" height="20" font="4">stroke volume at rest, inability to </text>
<text top="440" left="728" width="151" height="20" font="4">augment cardiac output via </text>
<text top="458" left="728" width="87" height="20" font="4">stroke volume). </text>
<text top="389" left="926" width="120" height="20" font="4">● Pts with subnormal </text>
<text top="406" left="926" width="141" height="20" font="4">response to exercise had </text>
<text top="423" left="926" width="144" height="20" font="4">RV pressure ≥80 mm Hg. </text>
<text top="476" left="64" width="78" height="20" font="4">Jonsson B, et </text>
<text top="493" left="64" width="16" height="20" font="4">al. </text>
<text top="510" left="64" width="66" height="20" font="4">1968 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(446)</a>  </text>
<text top="527" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/5637559?dopt=Citation">5637559</a></text>
<text top="527" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/5637559?dopt=Citation"> </a></text>
<text top="476" left="170" width="79" height="20" font="4">Observational </text>
<text top="493" left="170" width="38" height="20" font="4">cohort </text>
<text top="510" left="170" width="66" height="20" font="4">prospective </text>
<text top="476" left="270" width="65" height="20" font="4">n=17 pts (9 </text>
<text top="493" left="270" width="62" height="20" font="4">pts without </text>
<text top="510" left="270" width="70" height="20" font="4">atrial defect, </text>
<text top="527" left="270" width="66" height="20" font="4">12 pts with) </text>
<text top="476" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="493" left="356" width="112" height="20" font="4">≥21 y postoperative </text>
<text top="510" left="356" width="55" height="20" font="4">valvotomy</text>
<text top="512" left="411" width="2" height="13" font="6"> </text>
<text top="476" left="496" width="50" height="20" font="4">Exercise </text>
<text top="493" left="496" width="87" height="20" font="4">catheterization  </text>
<text top="476" left="608" width="91" height="20" font="4">Hemodynamics, </text>
<text top="493" left="608" width="63" height="20" font="4">SV, peak O</text>
<text top="499" left="671" width="7" height="13" font="6">2 </text>
<text top="493" left="678" width="33" height="20" font="4">pulse </text>
<text top="476" left="728" width="183" height="20" font="4">● Group without atrial defect had </text>
<text top="493" left="728" width="174" height="20" font="4">no increase in SV or low output </text>
<text top="510" left="728" width="161" height="20" font="4">with exercise, whereas those </text>
<text top="527" left="728" width="166" height="20" font="4">with residual defect improved. </text>
<text top="476" left="926" width="152" height="20" font="4">● The tendency for low CO </text>
<text top="493" left="926" width="113" height="20" font="4">during exercise post </text>
<text top="510" left="926" width="138" height="20" font="4">operatively resulted from </text>
<text top="527" left="926" width="135" height="20" font="4">adaptive mechanisms in </text>
<text top="544" left="926" width="120" height="20" font="4">peripheral circulation. </text>
<text top="562" left="64" width="79" height="20" font="4">Driscoll DJ, et </text>
<text top="580" left="64" width="16" height="20" font="4">al. </text>
<text top="597" left="64" width="66" height="20" font="4">1993 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(447)</a>  </text>
<text top="614" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8425316?dopt=Citation">8425316</a></text>
<text top="614" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8425316?dopt=Citation"> </a></text>
<text top="562" left="170" width="79" height="20" font="4">Observational </text>
<text top="580" left="170" width="38" height="20" font="4">cohort </text>
<text top="597" left="170" width="66" height="20" font="4">prospective </text>
<text top="562" left="270" width="58" height="20" font="4">n=194 pts </text>
<text top="562" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="580" left="356" width="88" height="20" font="4">Second Natural </text>
<text top="597" left="356" width="116" height="20" font="4">History Study, valvar </text>
<text top="614" left="356" width="16" height="20" font="4">PS</text>
<text top="616" left="372" width="2" height="13" font="6"> </text>
<text top="562" left="496" width="90" height="20" font="4">Exercise testing </text>
<text top="562" left="608" width="50" height="20" font="4">Duration </text>
<text top="562" left="728" width="177" height="20" font="4">● Normal compared to controls. </text>
<text top="562" left="926" width="114" height="20" font="4">● Although exercise </text>
<text top="580" left="926" width="135" height="20" font="4">duration was preserved, </text>
<text top="597" left="926" width="128" height="20" font="4">exercise tolerance was </text>
<text top="614" left="926" width="68" height="20" font="4">subnormal.  </text>
<text top="632" left="64" width="91" height="20" font="4">Romeih S, et al. </text>
<text top="649" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(448)</a> </text>
<text top="667" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22892196?dopt=Citation">22892196</a></text>
<text top="667" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22892196?dopt=Citation"> </a></text>
<text top="632" left="170" width="79" height="20" font="4">Observational </text>
<text top="649" left="170" width="38" height="20" font="4">cohort </text>
<text top="667" left="170" width="66" height="20" font="4">prospective </text>
<text top="632" left="270" width="51" height="20" font="4">n=20 pts </text>
<text top="649" left="270" width="48" height="20" font="4">(2/7 late </text>
<text top="667" left="270" width="28" height="20" font="4">after </text>
<text top="684" left="270" width="69" height="20" font="4">surgical/cath</text>
<text top="701" left="270" width="63" height="20" font="4">eter repair, </text>
<text top="718" left="270" width="59" height="20" font="4">11 without </text>
<text top="735" left="270" width="49" height="20" font="4">surgery) </text>
<text top="632" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="649" left="356" width="108" height="20" font="4">Moderate valvar PS</text>
<text top="651" left="464" width="2" height="13" font="6"> </text>
<text top="632" left="496" width="97" height="20" font="4">Cardiopulmonary </text>
<text top="649" left="496" width="89" height="20" font="4">exercise testing </text>
<text top="632" left="608" width="105" height="20" font="4">CPET parameters, </text>
<text top="649" left="608" width="95" height="20" font="4">MRI parameters, </text>
<text top="667" left="608" width="104" height="20" font="4">dobutamine stress </text>
<text top="684" left="608" width="66" height="20" font="4">parameters </text>
<text top="632" left="728" width="174" height="20" font="4">● Postoperative mod valvar PS </text>
<text top="649" left="728" width="148" height="20" font="4">with impaired myocardial O</text>
<text top="655" left="876" width="4" height="13" font="6">2</text>
<text top="649" left="880" width="3" height="20" font="4"> </text>
<text top="667" left="728" width="86" height="20" font="4">consumption, O</text>
<text top="673" left="814" width="4" height="13" font="6">2</text>
<text top="667" left="818" width="70" height="20" font="4"> pulse, peak </text>
<text top="684" left="728" width="169" height="20" font="4">heart rate, inability to augment </text>
<text top="701" left="728" width="175" height="20" font="4">stroke volume, native moderate </text>
<text top="718" left="728" width="64" height="20" font="4">PS normal. </text>
<text top="632" left="926" width="113" height="20" font="4">● Impaired exercise </text>
<text top="649" left="926" width="137" height="20" font="4">capacity in moderate PS </text>
<text top="667" left="926" width="146" height="20" font="4">restenosis may be caused </text>
<text top="684" left="926" width="146" height="20" font="4">by inability to augment the </text>
<text top="701" left="926" width="107" height="20" font="4">RV stroke volume.  </text>
<text top="753" left="64" width="70" height="20" font="4">Luijinenberg </text>
<text top="771" left="64" width="53" height="20" font="4">SE, et al. </text>
<text top="753" left="170" width="79" height="20" font="4">Observational </text>
<text top="771" left="170" width="38" height="20" font="4">cohort </text>
<text top="788" left="170" width="66" height="20" font="4">prospective </text>
<text top="753" left="270" width="63" height="20" font="4">21 valvular </text>
<text top="771" left="270" width="68" height="20" font="4">PS, 12 TOF </text>
<text top="753" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="771" left="356" width="110" height="20" font="4">Valvular PS or TOF </text>
<text top="788" left="356" width="68" height="20" font="4">post surgery</text>
<text top="789" left="424" width="2" height="13" font="6"> </text>
<text top="753" left="496" width="97" height="20" font="4">Cardiopulmonary </text>
<text top="771" left="496" width="89" height="20" font="4">exercise testing </text>
<text top="753" left="608" width="288" height="20" font="4">CPET parameters  ● Valvular PS (with mild PR in </text>
<text top="771" left="728" width="116" height="20" font="4">80%) worse peak VO</text>
<text top="777" left="844" width="4" height="13" font="6">2</text>
<text top="771" left="848" width="31" height="20" font="4">, HR, </text>
<text top="753" left="926" width="133" height="20" font="4">● Despite more PR and </text>
<text top="771" left="926" width="131" height="20" font="4">larger RV volumes in pt </text>
<text top="788" left="926" width="126" height="20" font="4">with TOF, the exercise </text>
</page>
<page number="124" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 124 </text>
<text top="107" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(449)</a> </text>
<text top="124" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22871643?dopt=Citation">22871643</a></text>
<text top="124" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22871643?dopt=Citation"> </a></text>
<text top="107" left="728" width="142" height="20" font="4">anaerobic threshold, than </text>
<text top="124" left="728" width="177" height="20" font="4">controls, no different, than TOF. </text>
<text top="107" left="926" width="142" height="20" font="4">capacity and biventricular </text>
<text top="124" left="926" width="139" height="20" font="4">function are similar in pts </text>
<text top="141" left="926" width="144" height="20" font="4">with valvar PS and TOF.   </text>
<text top="159" left="64" width="82" height="20" font="4">De Meester P, </text>
<text top="177" left="64" width="30" height="20" font="4">et al. </text>
<text top="194" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(450)</a> </text>
<text top="211" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24780907?dopt=Citation">24780907</a></text>
<text top="211" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24780907?dopt=Citation"> </a></text>
<text top="159" left="170" width="83" height="20" font="4">Observational, </text>
<text top="177" left="170" width="41" height="20" font="4">cohort, </text>
<text top="194" left="170" width="66" height="20" font="4">prospective </text>
<text top="159" left="270" width="51" height="20" font="4">n=19 pts </text>
<text top="159" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="177" left="356" width="79" height="20" font="4">≥16 y, mild-to-</text>
<text top="194" left="356" width="109" height="20" font="4">moderate valvar PR</text>
<text top="196" left="465" width="2" height="13" font="6"> </text>
<text top="159" left="496" width="97" height="20" font="4">Cardiopulmonary </text>
<text top="177" left="496" width="89" height="20" font="4">exercise testing </text>
<text top="159" left="608" width="181" height="20" font="4">CPET parameters  ● Peak VO</text>
<text top="166" left="789" width="4" height="13" font="6">2</text>
<text top="159" left="794" width="111" height="20" font="4">, heart rate reserve, </text>
<text top="177" left="728" width="109" height="20" font="4">peak power, VE/CO</text>
<text top="183" left="836" width="4" height="13" font="6">2</text>
<text top="177" left="841" width="36" height="20" font="4"> slope </text>
<text top="194" left="728" width="174" height="20" font="4">impaired in contrast to controls; </text>
<text top="211" left="728" width="40" height="20" font="4">peak O</text>
<text top="217" left="767" width="4" height="13" font="6">2</text>
<text top="211" left="772" width="104" height="20" font="4"> pulse unchanged. </text>
<text top="159" left="926" width="129" height="20" font="4">● Afterload reserve vs. </text>
<text top="177" left="926" width="116" height="20" font="4">ventilation/ perfusion </text>
<text top="194" left="926" width="150" height="20" font="4">mismatch may be impaired </text>
<text top="211" left="926" width="125" height="20" font="4">even in mild-moderate </text>
<text top="228" left="926" width="59" height="20" font="4">valvar PS. </text>
<text top="246" left="64" width="92" height="20" font="4">Kopecky S et al. </text>
<text top="263" left="64" width="66" height="20" font="4">1988 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(451)</a>  </text>
<text top="281" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3180374?dopt=Citation">3180374</a></text>
<text top="281" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3180374?dopt=Citation"> </a></text>
<text top="246" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="263" left="170" width="39" height="20" font="4">review </text>
<text top="246" left="270" width="61" height="20" font="4">n=191 pts  </text>
<text top="246" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="263" left="356" width="89" height="20" font="4">Mayo long-term </text>
<text top="281" left="356" width="85" height="20" font="4">results surgical </text>
<text top="298" left="356" width="124" height="20" font="4">valvotomy 1956–1967 </text>
<text top="246" left="496" width="46" height="20" font="4">Surgery </text>
<text top="246" left="608" width="105" height="20" font="4">Long-term survival </text>
<text top="263" left="608" width="80" height="20" font="4">and functional </text>
<text top="281" left="608" width="36" height="20" font="4">status </text>
<text top="246" left="728" width="164" height="20" font="4">● Those with operative repair </text>
<text top="263" left="728" width="176" height="20" font="4">prior to age 21 y had normal life </text>
<text top="281" left="728" width="73" height="20" font="4">expectancy.  </text>
<text top="298" left="728" width="159" height="20" font="4">● Those after 21 y had good </text>
<text top="315" left="728" width="186" height="20" font="4">outcome but earlier mortality than </text>
<text top="332" left="728" width="108" height="20" font="4">general population. </text>
<text top="246" left="926" width="140" height="20" font="4">● Even in earlier surgical </text>
<text top="263" left="926" width="130" height="20" font="4">era, good outcomes for </text>
<text top="281" left="926" width="42" height="20" font="4">repair.  </text>
<text top="298" left="926" width="148" height="20" font="4">● Earlier age at repair had </text>
<text top="315" left="926" width="95" height="20" font="4">better outcomes. </text>
<text top="350" left="64" width="90" height="20" font="4">Hayes CJ, et al. </text>
<text top="368" left="64" width="66" height="20" font="4">1993 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(452)</a>  </text>
<text top="385" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8425320?dopt=Citation">8425320</a></text>
<text top="385" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8425320?dopt=Citation"> </a></text>
<text top="350" left="170" width="79" height="20" font="4">Observational </text>
<text top="368" left="170" width="41" height="20" font="4">cohort; </text>
<text top="385" left="170" width="77" height="20" font="4">retrospective  </text>
<text top="350" left="270" width="58" height="20" font="4">n=592 pts </text>
<text top="350" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="368" left="356" width="88" height="20" font="4">Second Natural </text>
<text top="385" left="356" width="107" height="20" font="4">History Study, long-</text>
<text top="402" left="356" width="123" height="20" font="4">term results valvar PS </text>
<text top="419" left="356" width="41" height="20" font="4">surgery</text>
<text top="421" left="397" width="2" height="13" font="6"> </text>
<text top="350" left="496" width="61" height="20" font="4">Surgery or </text>
<text top="368" left="496" width="46" height="20" font="4">medical </text>
<text top="385" left="496" width="89" height="20" font="4">management of </text>
<text top="402" left="496" width="56" height="20" font="4">valvar PS </text>
<text top="350" left="608" width="76" height="20" font="4">To determine </text>
<text top="368" left="608" width="55" height="20" font="4">long-term </text>
<text top="385" left="608" width="70" height="20" font="4">outcomes of </text>
<text top="402" left="608" width="70" height="20" font="4">medical and </text>
<text top="419" left="608" width="46" height="20" font="4">surgical </text>
<text top="436" left="608" width="75" height="20" font="4">management </text>
<text top="350" left="728" width="165" height="20" font="4">● 25-y survival of 96% unless </text>
<text top="368" left="728" width="186" height="20" font="4">entered study &gt;12 y (then 80%).   </text>
<text top="385" left="728" width="164" height="20" font="4">● Minimal need for surgery in </text>
<text top="402" left="728" width="180" height="20" font="4">medical management group and </text>
<text top="419" left="728" width="173" height="20" font="4">minimal need for reoperation in </text>
<text top="436" left="728" width="174" height="20" font="4">surgical group. 97% were class </text>
<text top="454" left="728" width="48" height="20" font="4">NYHA I. </text>
<text top="350" left="926" width="135" height="20" font="4">● Pts with low gradients </text>
<text top="368" left="926" width="131" height="20" font="4">can be safely medically </text>
<text top="385" left="926" width="137" height="20" font="4">managed and those with </text>
<text top="402" left="926" width="149" height="20" font="4">high gradients do very well </text>
<text top="419" left="926" width="141" height="20" font="4">with surgery. The optimal </text>
<text top="436" left="926" width="149" height="20" font="4">management of the middle </text>
<text top="454" left="926" width="130" height="20" font="4">gradient group remains </text>
<text top="471" left="926" width="47" height="20" font="4">unclear. </text>
<text top="489" left="64" width="89" height="20" font="4">Roos-Hesselink </text>
<text top="506" left="64" width="55" height="20" font="4">JW, et al. </text>
<text top="523" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(453)</a> </text>
<text top="540" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16361324?dopt=Citation">16361324</a></text>
<text top="540" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16361324?dopt=Citation"> </a></text>
<text top="489" left="170" width="83" height="20" font="4">Observational, </text>
<text top="506" left="170" width="74" height="20" font="4">single-center </text>
<text top="523" left="170" width="41" height="20" font="4">cohort; </text>
<text top="540" left="170" width="74" height="20" font="4">retrospective </text>
<text top="489" left="270" width="51" height="20" font="4">n=90 pts </text>
<text top="489" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="506" left="356" width="96" height="20" font="4">Surgical repair of </text>
<text top="523" left="356" width="104" height="20" font="4">isolated PS (1968–</text>
<text top="540" left="356" width="66" height="20" font="4">1980) ≤15 y</text>
<text top="542" left="422" width="2" height="13" font="6"> </text>
<text top="489" left="496" width="94" height="20" font="4">Long-term follow </text>
<text top="506" left="496" width="79" height="20" font="4">(median 16 y) </text>
<text top="489" left="608" width="74" height="20" font="4">Reoperation, </text>
<text top="506" left="608" width="61" height="20" font="4">death, PR, </text>
<text top="523" left="608" width="65" height="20" font="4">arrhythmia, </text>
<text top="540" left="608" width="60" height="20" font="4">ventricular </text>
<text top="558" left="608" width="89" height="20" font="4">parameters, FC </text>
<text top="489" left="728" width="124" height="20" font="4">● 15% reoperation for </text>
<text top="506" left="728" width="172" height="20" font="4">symptomatic residuae (PS 6%, </text>
<text top="523" left="728" width="176" height="20" font="4">PR 9%), perceived health lower </text>
<text top="540" left="728" width="84" height="20" font="4">than expected. </text>
<text top="489" left="926" width="157" height="20" font="4">● Most reoperation for PR.   </text>
<text top="506" left="926" width="135" height="20" font="4">● Overall good exercise </text>
<text top="523" left="926" width="140" height="20" font="4">ability but relatively lower </text>
<text top="540" left="926" width="76" height="20" font="4">NYHA class.  </text>
<text top="558" left="926" width="84" height="20" font="4">● Need further </text>
<text top="575" left="926" width="128" height="20" font="4">understanding of lower </text>
<text top="592" left="926" width="97" height="20" font="4">perceived health. </text>
<text top="610" left="64" width="85" height="20" font="4">McCrindle BW, </text>
<text top="627" left="64" width="30" height="20" font="4">et al. </text>
<text top="644" left="64" width="66" height="20" font="4">1991 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(454)</a>  </text>
<text top="662" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2040044?dopt=Citation">2040044</a></text>
<text top="662" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2040044?dopt=Citation"> </a></text>
<text top="610" left="170" width="83" height="20" font="4">Observational, </text>
<text top="627" left="170" width="74" height="20" font="4">single-center </text>
<text top="644" left="170" width="41" height="20" font="4">cohort, </text>
<text top="662" left="170" width="77" height="20" font="4">retrospective  </text>
<text top="610" left="270" width="51" height="20" font="4">n=46 pts </text>
<text top="610" left="356" width="125" height="20" font="3"><b>Inclusion criteria</b>: PS </text>
<text top="627" left="356" width="61" height="20" font="4">for balloon </text>
<text top="644" left="356" width="111" height="20" font="4">valvuloplasty, 6/81– </text>
<text top="662" left="356" width="34" height="20" font="4">12/86 </text>
<text top="610" left="496" width="44" height="20" font="4">Balloon </text>
<text top="627" left="496" width="74" height="20" font="4">valvuloplasty </text>
<text top="610" left="608" width="105" height="20" font="4">Gradient relief and </text>
<text top="627" left="608" width="74" height="20" font="4">sustainability </text>
<text top="610" left="728" width="181" height="20" font="4">● Good relief in most pts acutely </text>
<text top="627" left="728" width="176" height="20" font="4">(89%) and at &gt;2 y-follow (86%). </text>
<text top="644" left="728" width="164" height="20" font="4">Those &lt;2 y of age had higher </text>
<text top="662" left="728" width="104" height="20" font="4">residual gradients. </text>
<text top="610" left="926" width="134" height="20" font="4">● Mostly pediatric study </text>
<text top="627" left="926" width="152" height="20" font="4">with good results of balloon </text>
<text top="644" left="926" width="147" height="20" font="4">valvuloplasty in pts &gt;2 y at </text>
<text top="662" left="926" width="67" height="20" font="4">this center.  </text>
<text top="679" left="64" width="74" height="20" font="4">Voet A, et al. </text>
<text top="697" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(455)</a> </text>
<text top="714" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21078529?dopt=Citation">21078529</a></text>
<text top="714" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21078529?dopt=Citation"> </a></text>
<text top="679" left="170" width="83" height="20" font="4">Observational, </text>
<text top="697" left="170" width="74" height="20" font="4">single-center </text>
<text top="714" left="170" width="41" height="20" font="4">cohort, </text>
<text top="731" left="170" width="77" height="20" font="4">retrospective  </text>
<text top="679" left="270" width="61" height="20" font="4">n=218 pts  </text>
<text top="679" left="356" width="125" height="20" font="3"><b>Inclusion criteria</b>: PS </text>
<text top="697" left="356" width="126" height="20" font="4">with 79 surgical repair, </text>
<text top="714" left="356" width="67" height="20" font="4">139 balloon </text>
<text top="731" left="356" width="74" height="20" font="4">valvuloplasty </text>
<text top="679" left="496" width="48" height="20" font="4">Surgical </text>
<text top="697" left="496" width="73" height="20" font="4">valvotomy or </text>
<text top="714" left="496" width="43" height="20" font="4">balloon </text>
<text top="731" left="496" width="74" height="20" font="4">valvuloplasty </text>
<text top="679" left="608" width="105" height="20" font="4">Gradient relief and </text>
<text top="697" left="608" width="74" height="20" font="4">sustainability </text>
<text top="714" left="608" width="75" height="20" font="4">(median 22 y-</text>
<text top="731" left="608" width="39" height="20" font="4">follow) </text>
<text top="679" left="728" width="183" height="20" font="4">● Good acute relief in all. 20% of </text>
<text top="697" left="728" width="165" height="20" font="4">surgical had reintervention for </text>
<text top="714" left="728" width="178" height="20" font="4">regurgitation; 9% of catheter pts </text>
<text top="731" left="728" width="162" height="20" font="4">had reintervention, mostly for </text>
<text top="748" left="728" width="52" height="20" font="4">stenosis. </text>
<text top="679" left="926" width="145" height="20" font="4">● Both interventions good </text>
<text top="697" left="926" width="103" height="20" font="4">for gradient relief.  </text>
<text top="714" left="926" width="116" height="20" font="4">● Surgery with more </text>
<text top="731" left="926" width="142" height="20" font="4">residual regurgitation and </text>
<text top="748" left="926" width="151" height="20" font="4">catheter with more residual </text>
<text top="766" left="926" width="55" height="20" font="4">stenosis.  </text>
</page>
<page number="125" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 125 </text>
<text top="107" left="64" width="87" height="20" font="4">Taggart NW, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(456)</a> </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23613310?dopt=Citation">23613310</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23613310?dopt=Citation"> </a></text>
<text top="107" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="124" left="170" width="44" height="20" font="4">cohort.  </text>
<text top="107" left="270" width="38" height="20" font="4">n=132 </text>
<text top="124" left="270" width="43" height="20" font="4">balloon </text>
<text top="141" left="270" width="61" height="20" font="4">pulmonary </text>
<text top="159" left="270" width="64" height="20" font="4">valvuloplast</text>
<text top="176" left="270" width="51" height="20" font="4">y pts (89 </text>
<text top="193" left="270" width="67" height="20" font="4">children, 40 </text>
<text top="210" left="270" width="40" height="20" font="4">adults) </text>
<text top="107" left="356" width="125" height="20" font="3"><b>Inclusion criteria</b>: PS </text>
<text top="124" left="356" width="122" height="20" font="4">for balloon pulmonary </text>
<text top="141" left="356" width="111" height="20" font="4">valvuloplasty 12/93–</text>
<text top="159" left="356" width="41" height="20" font="4">7/2012 </text>
<text top="107" left="496" width="44" height="20" font="4">Balloon </text>
<text top="124" left="496" width="61" height="20" font="4">pulmonary </text>
<text top="141" left="496" width="74" height="20" font="4">valvuloplasty </text>
<text top="107" left="608" width="105" height="20" font="4">Gradient relief and </text>
<text top="124" left="608" width="78" height="20" font="4">reintervention </text>
<text top="107" left="728" width="137" height="20" font="4">● Good gradient relief in </text>
<text top="124" left="728" width="161" height="20" font="4">symptomatic adults with over </text>
<text top="141" left="728" width="121" height="20" font="4">80% having symptom </text>
<text top="159" left="728" width="81" height="20" font="4">improvement.  </text>
<text top="176" left="728" width="162" height="20" font="4">● At 2 y, 50% were symptom </text>
<text top="193" left="728" width="35" height="20" font="4">free.   </text>
<text top="107" left="926" width="145" height="20" font="4">● Good short-term effects </text>
<text top="124" left="926" width="118" height="20" font="4">of balloon pulmonary </text>
<text top="141" left="926" width="124" height="20" font="4">valvuloplasty for PS in </text>
<text top="159" left="926" width="85" height="20" font="4">adults. Minimal </text>
<text top="176" left="926" width="85" height="20" font="4">complications.  </text>
<text top="228" left="64" width="82" height="20" font="4">Kaul UA, et al. </text>
<text top="245" left="64" width="66" height="20" font="4">1993 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(457)</a>  </text>
<text top="263" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8237759?dopt=Citation">8237759</a></text>
<text top="263" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8237759?dopt=Citation"> </a></text>
<text top="228" left="170" width="79" height="20" font="4">Observational </text>
<text top="245" left="170" width="38" height="20" font="4">cohort </text>
<text top="228" left="270" width="54" height="20" font="4">n=40 pts, </text>
<text top="245" left="270" width="73" height="20" font="4">single center </text>
<text top="228" left="356" width="125" height="20" font="3"><b>Inclusion criteria</b>: PS </text>
<text top="245" left="356" width="61" height="20" font="4">for balloon </text>
<text top="263" left="356" width="108" height="20" font="4">valvuloplasty, 3/85–</text>
<text top="280" left="356" width="112" height="20" font="4">12/91; age 18–56 y  </text>
<text top="228" left="496" width="44" height="20" font="4">Balloon </text>
<text top="245" left="496" width="74" height="20" font="4">valvuloplasty </text>
<text top="228" left="608" width="78" height="20" font="4">Acute and 2 y </text>
<text top="245" left="608" width="70" height="20" font="4">outcomes of </text>
<text top="263" left="608" width="78" height="20" font="4">gradient relief </text>
<text top="228" left="728" width="179" height="20" font="4">● 32 pts with good acute results </text>
<text top="245" left="728" width="172" height="20" font="4">and sustained at 2 y; 8 pts with </text>
<text top="263" left="728" width="186" height="20" font="4">high acute gradient that improved </text>
<text top="280" left="728" width="40" height="20" font="4">at 2 y.  </text>
<text top="297" left="728" width="139" height="20" font="4">● NYHA class improved, </text>
<text top="314" left="728" width="158" height="20" font="4">cyanosis improved, 1 pt with </text>
<text top="332" left="728" width="183" height="20" font="4">RVOT tear and surgery required. </text>
<text top="228" left="926" width="149" height="20" font="4">● Good acute outcomes in </text>
<text top="245" left="926" width="126" height="20" font="4">pts with PS for balloon </text>
<text top="263" left="926" width="143" height="20" font="4">valvuloplasty and minimal </text>
<text top="280" left="926" width="81" height="20" font="4">complications. </text>
<text top="350" left="64" width="87" height="20" font="4">Chen CR, et al. </text>
<text top="367" left="64" width="66" height="20" font="4">1996 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(458)</a>  </text>
<text top="384" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8637537?dopt=Citation">8637537</a></text>
<text top="384" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8637537?dopt=Citation"> </a></text>
<text top="350" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="367" left="170" width="38" height="20" font="4">cohort </text>
<text top="350" left="270" width="51" height="20" font="4">n=53 pts </text>
<text top="350" left="356" width="125" height="20" font="3"><b>Inclusion criteria</b>: PS </text>
<text top="367" left="356" width="61" height="20" font="4">for balloon </text>
<text top="384" left="356" width="115" height="20" font="4">valvuloplasty; 12/85–</text>
<text top="401" left="356" width="122" height="20" font="4">7/1995; ages 13–55 y </text>
<text top="350" left="496" width="44" height="20" font="4">Balloon </text>
<text top="367" left="496" width="74" height="20" font="4">valvuloplasty </text>
<text top="350" left="608" width="97" height="20" font="4">Acute and longer-</text>
<text top="367" left="608" width="85" height="20" font="4">term outcomes </text>
<text top="350" left="728" width="161" height="20" font="4">Good immediate reduction in </text>
<text top="367" left="728" width="174" height="20" font="4">gradient (mean 107 mm Hg–50 </text>
<text top="384" left="728" width="168" height="20" font="4">mm Hg) then further decrease </text>
<text top="401" left="728" width="157" height="20" font="4">over time (mean 30 mm Hg) </text>
<text top="350" left="926" width="131" height="20" font="4">● Balloon valvuloplasty </text>
<text top="367" left="926" width="149" height="20" font="4">provides satisfactory acute </text>
<text top="384" left="926" width="149" height="20" font="4">and long-term outcomes in </text>
<text top="401" left="926" width="109" height="20" font="4">adolescents/adults. </text>
<text top="419" left="64" width="78" height="20" font="4">Fawzy ME, et </text>
<text top="436" left="64" width="16" height="20" font="4">al. </text>
<text top="454" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(459)</a> </text>
<text top="471" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17307424?dopt=Citation">17307424</a></text>
<text top="471" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17307424?dopt=Citation"> </a></text>
<text top="419" left="170" width="78" height="20" font="4">Single center, </text>
<text top="436" left="170" width="74" height="20" font="4">retrospective </text>
<text top="454" left="170" width="76" height="20" font="4">observational </text>
<text top="471" left="170" width="38" height="20" font="4">cohort </text>
<text top="419" left="270" width="51" height="20" font="4">n=90 pts </text>
<text top="419" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="436" left="356" width="119" height="20" font="4">Adults with valvar PS </text>
<text top="454" left="356" width="111" height="20" font="4">and infundibular PS </text>
<text top="471" left="356" width="98" height="20" font="4">and/or severe TR </text>
<text top="488" left="356" width="126" height="20" font="4">undergoing pulmonary </text>
<text top="505" left="356" width="117" height="20" font="4">balloon valvuloplasty </text>
<text top="419" left="496" width="44" height="20" font="4">Balloon </text>
<text top="436" left="496" width="74" height="20" font="4">valvuloplasty </text>
<text top="419" left="608" width="86" height="20" font="4">Acute and long-</text>
<text top="436" left="608" width="85" height="20" font="4">term outcomes </text>
<text top="419" left="728" width="111" height="20" font="4">30% with ≥mild PR, </text>
<text top="436" left="728" width="173" height="20" font="4">preintervention, 28% more with </text>
<text top="454" left="728" width="166" height="20" font="4">new ≥mild PR post procedure </text>
<text top="419" left="926" width="134" height="20" font="4">● Successful procedure </text>
<text top="436" left="926" width="134" height="20" font="4">also served to decrease </text>
<text top="454" left="926" width="134" height="20" font="4">infundibular PS and TR. </text>
<text top="523" left="64" width="79" height="20" font="4">Earing MG, et </text>
<text top="540" left="64" width="16" height="20" font="4">al. </text>
<text top="558" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(460)</a> </text>
<text top="575" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16007892?dopt=Citation">16007892</a></text>
<text top="575" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16007892?dopt=Citation"> </a></text>
<text top="523" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="540" left="170" width="38" height="20" font="4">cohort </text>
<text top="523" left="270" width="61" height="20" font="4">n=53 adult </text>
<text top="540" left="270" width="20" height="20" font="4">pts </text>
<text top="523" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="540" left="356" width="116" height="20" font="4">Long-term outcomes </text>
<text top="558" left="356" width="98" height="20" font="4">for surgical repair </text>
<text top="523" left="496" width="33" height="20" font="4">None </text>
<text top="523" left="608" width="51" height="20" font="4">Need for </text>
<text top="540" left="608" width="78" height="20" font="4">reintervention </text>
<text top="523" left="728" width="186" height="20" font="4">● 35 interventions in 28 pts; most </text>
<text top="540" left="728" width="88" height="20" font="4">for residual PR. </text>
<text top="523" left="926" width="132" height="20" font="4">● Survival excellent but </text>
<text top="540" left="926" width="142" height="20" font="4">need lifelong follow-up as </text>
<text top="558" left="926" width="137" height="20" font="4">many interventions quite </text>
<text top="575" left="926" width="113" height="20" font="4">late (up to 30 y after </text>
<text top="592" left="926" width="52" height="20" font="4">surgery). </text>
<text top="610" left="54" width="3" height="20" font="4"> </text>
<text top="627" left="54" width="3" height="20" font="4"> </text>
<text top="644" left="108" width="564" height="24" font="1"><b>Data Supplement 40. Branch and Peripheral Pulmonary Stenosis – Section 4.3.2 </b></text>
<text top="666" left="93" width="38" height="20" font="3"><b>Study </b></text>
<text top="683" left="68" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="700" left="96" width="30" height="20" font="3"><b>Year </b></text>
<text top="666" left="178" width="70" height="20" font="3"><b>Study Type </b></text>
<text top="666" left="278" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="666" left="369" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="683" left="405" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="666" left="524" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="666" left="695" width="48" height="20" font="3"><b>Results </b></text>
<text top="666" left="877" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="718" left="64" width="84" height="20" font="4">Hallbergson A, </text>
<text top="735" left="64" width="30" height="20" font="4">et al. </text>
<text top="753" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(461)</a> </text>
<text top="770" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24433604?dopt=Citation">24433604</a></text>
<text top="770" left="119" width="7" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24433604?dopt=Citation"> </a> </text>
<text top="718" left="172" width="44" height="20" font="4">Review </text>
<text top="718" left="266" width="86" height="20" font="4">n=104 pts (124 </text>
<text top="735" left="266" width="40" height="20" font="4">stents) </text>
<text top="718" left="368" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="735" left="368" width="117" height="20" font="4">Stenosis narrower or </text>
<text top="753" left="368" width="121" height="20" font="4">equal to distal vessel; </text>
<text top="770" left="368" width="86" height="20" font="4">age (0.1–64 y); </text>
<text top="787" left="368" width="102" height="20" font="4">average age 5.5 y </text>
<text top="718" left="503" width="105" height="20" font="4">In-stent stenosis is </text>
<text top="735" left="503" width="99" height="20" font="4">25% narrowing of </text>
<text top="753" left="503" width="96" height="20" font="4">the contrast filled </text>
<text top="770" left="503" width="94" height="20" font="4">lumen relative to </text>
<text top="718" left="631" width="160" height="20" font="4">● In-stent stenosis in 24% of </text>
<text top="735" left="631" width="23" height="20" font="4">pts. </text>
<text top="753" left="631" width="154" height="20" font="4">● Highest incidence in TOF </text>
<text top="770" left="631" width="127" height="20" font="4">with multiple collateral, </text>
<text top="787" left="631" width="126" height="20" font="4">Williams, and Alagilles </text>
<text top="718" left="820" width="213" height="20" font="4">● In-stent stenosis more frequent than </text>
<text top="735" left="820" width="213" height="20" font="4">previously reported; more in inherently </text>
<text top="753" left="820" width="78" height="20" font="4">abnormal PA. </text>
<text top="770" left="820" width="213" height="20" font="4">● Increased clinical surveillance; need </text>
<text top="787" left="820" width="206" height="20" font="4">investigation of preventive strategies. </text>
</page>
<page number="126" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 126 </text>
<text top="107" left="503" width="98" height="20" font="4">stent diameter by </text>
<text top="124" left="503" width="66" height="20" font="4">fluoroscopy </text>
<text top="142" left="64" width="79" height="20" font="4">Gonzalez I, et </text>
<text top="159" left="64" width="16" height="20" font="4">al. </text>
<text top="177" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(462)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22843203?dopt=Citation">22843203</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22843203?dopt=Citation"> </a></text>
<text top="142" left="172" width="152" height="20" font="4">Retrospective  26 pts, 62 </text>
<text top="159" left="266" width="74" height="20" font="4">stents; 2001–</text>
<text top="177" left="266" width="68" height="20" font="4">2012, mean </text>
<text top="194" left="266" width="83" height="20" font="4">age 9.5 ± 12 y </text>
<text top="142" left="368" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="159" left="368" width="63" height="20" font="4">All pts who </text>
<text top="177" left="368" width="107" height="20" font="4">underwent bilateral </text>
<text top="194" left="368" width="100" height="20" font="4">stents; 3 pts were </text>
<text top="211" left="368" width="36" height="20" font="4">adults </text>
<text top="142" left="503" width="74" height="20" font="4">Mortality and </text>
<text top="159" left="503" width="62" height="20" font="4">procedural </text>
<text top="177" left="503" width="57" height="20" font="4">outcomes </text>
<text top="142" left="631" width="173" height="20" font="4">● Right PA gradient decreased </text>
<text top="159" left="631" width="166" height="20" font="4">from 35 ± 22–11 ± 12; left PA </text>
<text top="177" left="631" width="166" height="20" font="4">gradient decreased from 32 ± </text>
<text top="194" left="631" width="66" height="20" font="4">17–10 ± 12 </text>
<text top="211" left="631" width="136" height="20" font="4">● 4 intra-procedural AE. </text>
<text top="228" left="631" width="145" height="20" font="4">● Mean follow-up 41 ± 23 </text>
<text top="245" left="631" width="173" height="20" font="4">2 deaths; further intervention in </text>
<text top="263" left="631" width="40" height="20" font="4">12 pts. </text>
<text top="142" left="820" width="239" height="20" font="4">● Bilateral PA stenting is effective and safe </text>
<text top="159" left="820" width="230" height="20" font="4">with instantaneous decrease in pressure.  </text>
<text top="177" left="820" width="243" height="20" font="4">● Need for reintervention is common; follow-</text>
<text top="194" left="820" width="79" height="20" font="4">up warranted. </text>
<text top="281" left="64" width="94" height="20" font="4">Takao CM, et al. </text>
<text top="298" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(463)</a> </text>
<text top="315" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23073978?dopt=Citation">23073978</a></text>
<text top="315" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23073978?dopt=Citation"> </a></text>
<text top="281" left="172" width="78" height="20" font="4">Retrospective </text>
<text top="298" left="172" width="62" height="20" font="4">from 1998–</text>
<text top="315" left="172" width="31" height="20" font="4">2005 </text>
<text top="281" left="266" width="86" height="20" font="4">Compared with </text>
<text top="298" left="266" width="71" height="20" font="4">contralateral </text>
<text top="315" left="266" width="20" height="20" font="4">PA </text>
<text top="281" left="368" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="298" left="368" width="99" height="20" font="4">Excluded pts with </text>
<text top="315" left="368" width="90" height="20" font="4">interventions on </text>
<text top="332" left="368" width="98" height="20" font="4">contralateral lung </text>
<text top="281" left="503" width="73" height="20" font="4">● 84 pts had </text>
<text top="298" left="503" width="83" height="20" font="4">unilateral stent </text>
<text top="315" left="503" width="70" height="20" font="4">implantation </text>
<text top="332" left="503" width="100" height="20" font="4">● 22 excluded for </text>
<text top="350" left="503" width="84" height="20" font="4">intervention on </text>
<text top="367" left="503" width="98" height="20" font="4">contralateral lung </text>
<text top="384" left="503" width="98" height="20" font="4">● 23 excluded as </text>
<text top="401" left="503" width="106" height="20" font="4">did not have follow-</text>
<text top="418" left="503" width="44" height="20" font="4">up cath </text>
<text top="436" left="503" width="73" height="20" font="4">● 39 pts met </text>
<text top="453" left="503" width="92" height="20" font="4">inclusion criteria </text>
<text top="281" left="631" width="172" height="20" font="4">● Age single ventricle pts 3.5 y </text>
<text top="298" left="631" width="83" height="20" font="4">(4.6 mo–32 y). </text>
<text top="315" left="631" width="172" height="20" font="4">● Age 2 ventricle pts 4.8 y (4.5 </text>
<text top="332" left="631" width="58" height="20" font="4">mo–17 y). </text>
<text top="350" left="631" width="164" height="20" font="4">● On cath follow-up: 14 ± 9.6 </text>
<text top="367" left="631" width="156" height="20" font="4">mo after stent implantation). </text>
<text top="384" left="631" width="172" height="20" font="4">● Stent PA diameter increased </text>
<text top="401" left="631" width="115" height="20" font="4">118% approximating </text>
<text top="418" left="631" width="94" height="20" font="4">contralateral PA. </text>
<text top="281" left="820" width="226" height="20" font="4">● Stent implantation effective to promote </text>
<text top="298" left="820" width="205" height="20" font="4">lobar growth in 1 and 2 ventricle pts.  </text>
<text top="315" left="820" width="194" height="20" font="4">● Lobar growth &gt; in 2 ventricle pts. </text>
<text top="471" left="64" width="91" height="20" font="4">Holzer RJ, et al. </text>
<text top="488" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(464)</a> </text>
<text top="505" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21521836?dopt=Citation">21521836</a></text>
<text top="505" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21521836?dopt=Citation"> </a></text>
<text top="471" left="172" width="67" height="20" font="4">Prospective </text>
<text top="488" left="172" width="64" height="20" font="4">multicenter </text>
<text top="471" left="266" width="48" height="20" font="4">n=1,315 </text>
<text top="488" left="266" width="65" height="20" font="4">procedures </text>
<text top="471" left="368" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="488" left="368" width="109" height="20" font="4">balloon angioplasty </text>
<text top="505" left="368" width="68" height="20" font="4">and/or stent </text>
<text top="522" left="368" width="93" height="20" font="4">implantation in a </text>
<text top="540" left="368" width="118" height="20" font="4">proximal or lobar PA; </text>
<text top="557" left="368" width="98" height="20" font="4">median age 3.5 y </text>
<text top="574" left="368" width="87" height="20" font="4">(range: 0–70 y) </text>
<text top="471" left="503" width="72" height="20" font="4">Independent </text>
<text top="488" left="503" width="115" height="20" font="4">predictors of AE and </text>
<text top="505" left="503" width="79" height="20" font="4">need for early </text>
<text top="522" left="503" width="81" height="20" font="4">reintervention. </text>
<text top="471" left="631" width="153" height="20" font="4">● AE in 22% (high in 10%). </text>
<text top="471" left="820" width="235" height="20" font="4">● Hemodynamic vulnerability, age &lt; 1 mo, </text>
<text top="488" left="820" width="196" height="20" font="4">use of cutting balloon, and operator </text>
<text top="505" left="820" width="222" height="20" font="4">experience of &lt;10 y were risk factors for </text>
<text top="522" left="820" width="88" height="20" font="4">procedural AE.  </text>
<text top="540" left="820" width="224" height="20" font="4">● Reintervention during the study period </text>
<text top="557" left="820" width="191" height="20" font="4">occurred in 22% of pts undergoing </text>
<text top="574" left="820" width="138" height="20" font="4">pulmonary rehabilitation. </text>
<text top="592" left="64" width="84" height="20" font="4">Kenny D, et al. </text>
<text top="609" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#234">(465)</a> </text>
<text top="626" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21414031?dopt=Citation">21414031</a></text>
<text top="626" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21414031?dopt=Citation"> </a></text>
<text top="592" left="172" width="126" height="20" font="4">Retrospective  n=15 </text>
<text top="609" left="266" width="65" height="20" font="4">procedures </text>
<text top="592" left="368" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="609" left="368" width="113" height="20" font="4">23 stents, 12 adults; </text>
<text top="626" left="368" width="105" height="20" font="4">median age 32.5 y </text>
<text top="644" left="368" width="105" height="20" font="4">(range: 18.7–56.7) </text>
<text top="592" left="503" width="57" height="20" font="4">Review of </text>
<text top="609" left="503" width="112" height="20" font="4">procedural outcome </text>
<text top="626" left="503" width="44" height="20" font="4">and AE </text>
<text top="592" left="631" width="157" height="20" font="4">● Systolic pressure reduced </text>
<text top="609" left="631" width="148" height="20" font="4">from 24 mm Hg–3 mm Hg  </text>
<text top="626" left="631" width="171" height="20" font="4">3 pts had stent embolization (1 </text>
<text top="644" left="631" width="100" height="20" font="4">required surgery). </text>
<text top="592" left="820" width="222" height="20" font="4">● PA stenting provided effective relief of </text>
<text top="609" left="820" width="165" height="20" font="4">narrowing in adults with CHD. </text>
<text top="626" left="820" width="248" height="20" font="4">● Stent embolization may occur especially in </text>
<text top="644" left="820" width="189" height="20" font="4">pts with associated significant PR. </text>
<text top="662" left="64" width="92" height="20" font="4">Angtuaco MJ, et </text>
<text top="679" left="64" width="16" height="20" font="4">al. </text>
<text top="696" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(466)</a> </text>
<text top="713" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20853358?dopt=Citation">20853358</a></text>
<text top="713" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20853358?dopt=Citation"> </a></text>
<text top="662" left="172" width="78" height="20" font="4">Retrospective </text>
<text top="679" left="172" width="39" height="20" font="4">review </text>
<text top="662" left="266" width="72" height="20" font="4">n=67 pts (96 </text>
<text top="679" left="266" width="40" height="20" font="4">stents) </text>
<text top="662" left="368" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="679" left="368" width="108" height="20" font="4">Pts who underwent </text>
<text top="696" left="368" width="98" height="20" font="4">intraoperative PA </text>
<text top="713" left="368" width="108" height="20" font="4">stent placement for </text>
<text top="730" left="368" width="109" height="20" font="4">branch PA stenosis </text>
<text top="662" left="503" width="60" height="20" font="4">Long-term </text>
<text top="679" left="503" width="103" height="20" font="4">outcomes and risk </text>
<text top="696" left="503" width="96" height="20" font="4">for reintervention </text>
<text top="662" left="631" width="140" height="20" font="4">● Actuarial freedom from </text>
<text top="679" left="631" width="170" height="20" font="4">reintervention at 2, 5, and 10 y </text>
<text top="696" left="631" width="143" height="20" font="4">was 68%, 49%, and 40%, </text>
<text top="713" left="631" width="72" height="20" font="4">respectively. </text>
<text top="662" left="820" width="239" height="20" font="4">● Analysis showed age &lt;2 y (p&lt;0.005) and </text>
<text top="679" left="820" width="212" height="20" font="4">diagnosis of TOF (p&lt;0.002) or truncus </text>
<text top="696" left="820" width="225" height="20" font="4">arteriosus (p&lt;0.007) to be significant risk </text>
<text top="713" left="820" width="139" height="20" font="4">factors for reintervention. </text>
<text top="748" left="64" width="95" height="20" font="4">Menon SC, et al. </text>
<text top="766" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(467)</a> </text>
<text top="783" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19064034?dopt=Citation">19064034</a></text>
<text top="783" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19064034?dopt=Citation"> </a></text>
<text top="748" left="172" width="78" height="20" font="4">Retrospective </text>
<text top="766" left="172" width="48" height="20" font="4">analysis </text>
<text top="748" left="266" width="72" height="20" font="4">n=24 pts (27 </text>
<text top="766" left="266" width="44" height="20" font="4">stents)  </text>
<text top="748" left="368" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="766" left="368" width="105" height="20" font="4">1997–2006; hybrid </text>
<text top="783" left="368" width="118" height="20" font="4">PA stent procedures; </text>
<text top="748" left="503" width="78" height="20" font="4">Review of the </text>
<text top="766" left="503" width="71" height="20" font="4">clinical data, </text>
<text top="748" left="631" width="170" height="20" font="4">● There were 2 cases of distal </text>
<text top="766" left="631" width="161" height="20" font="4">stent migration. Repeat stent </text>
<text top="748" left="820" width="239" height="20" font="4">● Hybrid PA stenting can play an important </text>
<text top="766" left="820" width="202" height="20" font="4">role in the management of CHD with </text>
<text top="783" left="820" width="168" height="20" font="4">complex branch PA anatomy.  </text>
</page>
<page number="127" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 127 </text>
<text top="107" left="368" width="94" height="20" font="4">median age 15 y </text>
<text top="124" left="368" width="90" height="20" font="4">(range: 3–67 y)  </text>
<text top="107" left="503" width="89" height="20" font="4">procedural, and </text>
<text top="124" left="503" width="109" height="20" font="4">long-term outcome  </text>
<text top="107" left="631" width="144" height="20" font="4">dilations within 6 mo were </text>
<text top="124" left="631" width="106" height="20" font="4">performed in 3 pts. </text>
<text top="107" left="820" width="246" height="20" font="4">● Hybrid procedures were safe and effective </text>
<text top="124" left="820" width="209" height="20" font="4">in most pts, although stent positioning </text>
<text top="141" left="820" width="234" height="20" font="4">remains critical. Intraoperative fluoroscopy </text>
<text top="159" left="820" width="224" height="20" font="4">and active suture fixation of the proximal </text>
<text top="176" left="820" width="190" height="20" font="4">stent may reduce the need for late </text>
<text top="193" left="820" width="81" height="20" font="4">reintervention. </text>
<text top="211" left="64" width="87" height="20" font="4">Bergersen L, et </text>
<text top="228" left="64" width="16" height="20" font="4">al. </text>
<text top="245" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(468)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22042887?dopt=Citation">22042887</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22042887?dopt=Citation"> </a></text>
<text top="211" left="172" width="71" height="20" font="4">Prospective, </text>
<text top="228" left="172" width="71" height="20" font="4">randomized, </text>
<text top="245" left="172" width="67" height="20" font="4">multicenter, </text>
<text top="263" left="172" width="81" height="20" font="4">investigational </text>
<text top="211" left="266" width="79" height="20" font="4">n=73 pts (173 </text>
<text top="228" left="266" width="49" height="20" font="4">vessels) </text>
<text top="211" left="368" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="228" left="368" width="108" height="20" font="4">Included is 1) &gt; 1/2 </text>
<text top="245" left="368" width="72" height="20" font="4">systemic RV </text>
<text top="263" left="368" width="116" height="20" font="4">pressure, 2) regional </text>
<text top="280" left="368" width="67" height="20" font="4">decrease in </text>
<text top="297" left="368" width="120" height="20" font="4">pulmonary blood flow </text>
<text top="314" left="368" width="90" height="20" font="4">by lung scan, 3) </text>
<text top="332" left="368" width="70" height="20" font="4">elevated PA </text>
<text top="349" left="368" width="122" height="20" font="4">pressures (20 mm Hg </text>
<text top="366" left="368" width="75" height="20" font="4">mean), or (4) </text>
<text top="383" left="368" width="118" height="20" font="4">cyanosis due at least </text>
<text top="401" left="368" width="71" height="20" font="4">in part to PA </text>
<text top="418" left="368" width="70" height="20" font="4">obstruction.  </text>
<text top="435" left="368" width="3" height="20" font="4"> </text>
<text top="452" left="368" width="120" height="20" font="3"><b>Exclusion criteria:</b> If </text>
<text top="469" left="368" width="96" height="20" font="4">pregnant or if PA </text>
<text top="487" left="368" width="116" height="20" font="4">surgery in the prior 6 </text>
<text top="504" left="368" width="19" height="20" font="4">wk </text>
<text top="211" left="503" width="114" height="20" font="4">Review of the safety </text>
<text top="228" left="503" width="83" height="20" font="4">and efficacy of </text>
<text top="245" left="503" width="83" height="20" font="4">cutting balloon </text>
<text top="211" left="631" width="164" height="20" font="4">● Cutting balloon had greater </text>
<text top="228" left="631" width="158" height="20" font="4">increase in lumen diameter.  </text>
<text top="245" left="631" width="99" height="20" font="4">● Only 1 adult pt. </text>
<text top="211" left="820" width="249" height="20" font="4">● Cutting balloon therapy for PA stenosis not </text>
<text top="228" left="820" width="237" height="20" font="4">responsive to low-pressure balloon is more </text>
<text top="245" left="820" width="214" height="20" font="4">effective than HPB therapy and has an </text>
<text top="263" left="820" width="136" height="20" font="4">equivalent safety profile. </text>
<text top="522" left="64" width="81" height="20" font="4">Monge MC, et </text>
<text top="539" left="64" width="16" height="20" font="4">al. </text>
<text top="556" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(469)</a> </text>
<text top="573" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23228407?dopt=Citation">23228407</a></text>
<text top="573" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23228407?dopt=Citation"> </a></text>
<text top="522" left="172" width="78" height="20" font="4">Retrospective </text>
<text top="539" left="172" width="39" height="20" font="4">review </text>
<text top="522" left="266" width="65" height="20" font="4">n=16 pts (7 </text>
<text top="539" left="266" width="63" height="20" font="4">Williams, 6 </text>
<text top="556" left="266" width="43" height="20" font="4">Alagille </text>
<text top="573" left="266" width="85" height="20" font="4">syndrome, and </text>
<text top="591" left="266" width="27" height="20" font="4">3 no </text>
<text top="608" left="266" width="62" height="20" font="4">identifiable </text>
<text top="625" left="266" width="62" height="20" font="4">syndrome) </text>
<text top="522" left="368" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="539" left="368" width="119" height="20" font="4">Pts who had surgery; </text>
<text top="556" left="368" width="110" height="20" font="4">median age was 14 </text>
<text top="573" left="368" width="118" height="20" font="4">mo, and concomitant </text>
<text top="591" left="368" width="65" height="20" font="4">procedures </text>
<text top="608" left="368" width="100" height="20" font="4">performed in 9/16 </text>
<text top="625" left="368" width="23" height="20" font="4">pts. </text>
<text top="522" left="503" width="104" height="20" font="4">Review the results </text>
<text top="539" left="503" width="103" height="20" font="4">and outcome after </text>
<text top="556" left="503" width="46" height="20" font="4">surgical </text>
<text top="573" left="503" width="94" height="20" font="4">reconstruction of </text>
<text top="591" left="503" width="78" height="20" font="4">peripheral PA </text>
<text top="608" left="503" width="49" height="20" font="4">stenosis </text>
<text top="522" left="631" width="143" height="20" font="4">● The mean preoperative </text>
<text top="539" left="631" width="170" height="20" font="4">RV/LV pressure ratio was 0.88 </text>
<text top="556" left="631" width="170" height="20" font="4">± 0.07. All peripheral stenoses </text>
<text top="573" left="631" width="140" height="20" font="4">were augmented with PA </text>
<text top="591" left="631" width="101" height="20" font="4">homograft tissue.  </text>
<text top="608" left="631" width="165" height="20" font="4">● There was a 55% reduction </text>
<text top="625" left="631" width="176" height="20" font="4">compared with the preoperative </text>
<text top="642" left="631" width="164" height="20" font="4">values with median 5-y follow-</text>
<text top="659" left="631" width="21" height="20" font="4">up. </text>
<text top="522" left="820" width="233" height="20" font="4">● Surgical reconstruction of the peripheral </text>
<text top="539" left="820" width="197" height="20" font="4">PA stenosis resulted in a significant </text>
<text top="556" left="820" width="142" height="20" font="4">decrease in RV pressure. </text>
<text top="677" left="64" width="90" height="20" font="4">Badiu CC, et al. </text>
<text top="694" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(470)</a> </text>
<text top="712" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19695893?dopt=Citation">19695893</a></text>
<text top="712" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19695893?dopt=Citation"> </a></text>
<text top="677" left="172" width="78" height="20" font="4">Retrospective </text>
<text top="694" left="172" width="76" height="20" font="4">cohort, single </text>
<text top="712" left="172" width="38" height="20" font="4">center </text>
<text top="677" left="266" width="58" height="20" font="4">n=130 pts </text>
<text top="677" left="368" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="694" left="368" width="108" height="20" font="4">Pts who underwent </text>
<text top="712" left="368" width="98" height="20" font="4">surgical repair for </text>
<text top="729" left="368" width="103" height="20" font="4">Ebstein’s anomaly </text>
<text top="746" left="368" width="120" height="20" font="4">between 1976―2007 </text>
<text top="677" left="503" width="94" height="20" font="4">Repair feasibility </text>
<text top="677" left="631" width="112" height="20" font="4">● 2 hospital deaths. </text>
<text top="694" left="631" width="125" height="20" font="4">● Overall survival was </text>
<text top="712" left="631" width="165" height="20" font="4">87.2%+/-3.6%, 85.1%+/-4.1% </text>
<text top="729" left="631" width="159" height="20" font="4">and 81.2%+/-5.4% at 10, 20, </text>
<text top="746" left="631" width="168" height="20" font="4">and 25 y, respectively, without </text>
<text top="763" left="631" width="165" height="20" font="4">significant difference between </text>
<text top="677" left="820" width="223" height="20" font="4">● Repair, as opposed to replacement, is </text>
<text top="694" left="820" width="246" height="20" font="4">feasible in the vast majority of pts presenting </text>
<text top="712" left="820" width="216" height="20" font="4">with Ebstein's anomaly with a low early </text>
<text top="729" left="820" width="81" height="20" font="4">mortality rate.  </text>
<text top="746" left="820" width="248" height="20" font="4">● Outcome, in terms of survival and freedom </text>
<text top="763" left="820" width="194" height="20" font="4">from reoperation in the long term is </text>
</page>
<page number="128" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 128 </text>
<text top="107" left="631" width="150" height="20" font="4">the repair and replacement </text>
<text top="124" left="631" width="88" height="20" font="4">group (p=0.31). </text>
<text top="141" left="631" width="161" height="20" font="4">● NYHA FC &gt;II (p=0.01) and </text>
<text top="159" left="631" width="135" height="20" font="4">cardiothoracic ratio &gt;0.6 </text>
<text top="176" left="631" width="160" height="20" font="4">(p=0.02) were significant risk </text>
<text top="193" left="631" width="111" height="20" font="4">factors for mortality. </text>
<text top="210" left="631" width="131" height="20" font="4">● Overall freedom from </text>
<text top="228" left="631" width="164" height="20" font="4">reoperation was 79.9+/-4.6%, </text>
<text top="245" left="631" width="164" height="20" font="4">61.9+/-6.8% and 58.0+/-7.4% </text>
<text top="262" left="631" width="109" height="20" font="4">at 10, 20, and 25 y, </text>
<text top="279" left="631" width="72" height="20" font="4">respectively. </text>
<text top="296" left="631" width="153" height="20" font="4">● Age ≤12 y (p=0.005) and </text>
<text top="314" left="631" width="135" height="20" font="4">cardiothoracic ratio &gt;0.6 </text>
<text top="331" left="631" width="167" height="20" font="4">(p=0.009) were significant risk </text>
<text top="348" left="631" width="127" height="20" font="4">factors for reoperation. </text>
<text top="107" left="820" width="247" height="20" font="4">determined by the clinical state at the time of </text>
<text top="124" left="820" width="48" height="20" font="4">surgery. </text>
<text top="366" left="108" width="3" height="20" font="4"> </text>
<text top="383" left="108" width="519" height="24" font="1"><b>Data Supplement 41. Double-Chambered Right Ventricular – Section 4.3.3 </b></text>
<text top="405" left="92" width="38" height="20" font="3"><b>Study </b></text>
<text top="422" left="67" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="439" left="96" width="30" height="20" font="3"><b>Year </b></text>
<text top="405" left="173" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="422" left="188" width="44" height="20" font="3"><b>Design </b></text>
<text top="405" left="274" width="38" height="20" font="3"><b>Study </b></text>
<text top="422" left="279" width="28" height="20" font="3"><b>Size </b></text>
<text top="405" left="346" width="165" height="20" font="3"><b>Inclusion/Exclusion Criteria </b></text>
<text top="405" left="572" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="405" left="743" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="405" left="921" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="457" left="64" width="91" height="20" font="4">Hachiro Y, et al. </text>
<text top="474" left="64" width="63" height="20" font="4">2001 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(471)</a> </text>
<text top="491" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11722036?dopt=Citation">11722036</a></text>
<text top="491" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11722036?dopt=Citation"> </a></text>
<text top="457" left="170" width="78" height="20" font="4">Single center, </text>
<text top="474" left="170" width="74" height="20" font="4">retrospective </text>
<text top="457" left="263" width="226" height="20" font="4">n=40 pts   <b>Inclusion criteria</b>: Surgical </text>
<text top="474" left="336" width="161" height="20" font="4">repair DCRV, age 3 mo–52 y </text>
<text top="491" left="336" width="98" height="20" font="4">(only 4 pts &gt;30 y) </text>
<text top="457" left="535" width="131" height="20" font="4">Mortality, reintervention </text>
<text top="457" left="694" width="188" height="20" font="4">● Surgical success with reduction </text>
<text top="474" left="694" width="68" height="20" font="4">in gradient.  </text>
<text top="491" left="694" width="180" height="20" font="4">● No deaths, no reinterventions. </text>
<text top="457" left="906" width="159" height="20" font="4">● Surgery can be performed </text>
<text top="474" left="906" width="163" height="20" font="4">successfully at multiple ages. </text>
<text top="509" left="64" width="87" height="20" font="4">McIhenney DB, </text>
<text top="527" left="64" width="30" height="20" font="4">et al. </text>
<text top="544" left="64" width="63" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(472)</a> </text>
<text top="561" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10921695?dopt=Citation">10921695</a></text>
<text top="561" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10921695?dopt=Citation"> </a></text>
<text top="509" left="170" width="78" height="20" font="4">Single center, </text>
<text top="527" left="170" width="74" height="20" font="4">retrospective </text>
<text top="509" left="263" width="48" height="20" font="4">n=3 pts  </text>
<text top="509" left="336" width="133" height="20" font="3"><b>Inclusion criteria</b>: New </text>
<text top="527" left="336" width="164" height="20" font="4">diagnosis DCRV in adulthood </text>
<text top="509" left="535" width="64" height="20" font="4">Descriptive </text>
<text top="509" left="694" width="24" height="20" font="4">N/A </text>
<text top="509" left="906" width="24" height="20" font="4">N/A </text>
<text top="579" left="64" width="79" height="20" font="4">Kveselis D, et </text>
<text top="596" left="64" width="16" height="20" font="4">al. </text>
<text top="613" left="64" width="66" height="20" font="4">1984 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(473)</a>  </text>
<text top="631" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6507300?dopt=Citation">6507300</a></text>
<text top="631" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6507300?dopt=Citation"> </a></text>
<text top="579" left="170" width="78" height="20" font="4">Single center, </text>
<text top="596" left="170" width="74" height="20" font="4">retrospective </text>
<text top="579" left="263" width="51" height="20" font="4">n=20 pts </text>
<text top="579" left="336" width="143" height="20" font="3"><b>Inclusion criteria</b>: DCRV </text>
<text top="596" left="336" width="185" height="20" font="4">surgery in 1959–1966 (mean age </text>
<text top="613" left="336" width="114" height="20" font="4">14 y, 33 y-follow-up) </text>
<text top="579" left="535" width="116" height="20" font="4">Descriptive: survival, </text>
<text top="596" left="535" width="139" height="20" font="4">cardiac residual disease, </text>
<text top="613" left="535" width="20" height="20" font="4">FC </text>
<text top="579" left="694" width="102" height="20" font="4">● No late deaths.  </text>
<text top="596" left="694" width="134" height="20" font="4">● Mild residual disease. </text>
<text top="579" left="906" width="24" height="20" font="4">N/A </text>
<text top="649" left="64" width="84" height="20" font="4">Steadman CD, </text>
<text top="666" left="64" width="30" height="20" font="4">et al. </text>
<text top="683" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(474)</a> </text>
<text top="700" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19925548?dopt=Citation">19925548</a></text>
<text top="700" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19925548?dopt=Citation"> </a></text>
<text top="649" left="170" width="58" height="20" font="4">Dual case </text>
<text top="666" left="170" width="36" height="20" font="4">report </text>
<text top="649" left="263" width="44" height="20" font="4">n=2 pts </text>
<text top="649" left="336" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="649" left="535" width="64" height="20" font="4">Descriptive </text>
<text top="649" left="694" width="186" height="20" font="4">● Stents placed successfully with </text>
<text top="666" left="694" width="187" height="20" font="4">relief of RVOTO in the short term. </text>
<text top="649" left="906" width="128" height="20" font="4">● May be an option for </text>
<text top="666" left="906" width="157" height="20" font="4">selected pts deemed unable </text>
<text top="683" left="906" width="165" height="20" font="4">or unlikely to tolerate surgery. </text>
<text top="718" left="64" width="83" height="20" font="4">Said SM, et al. </text>
<text top="735" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#233">(442)</a> </text>
<text top="753" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22093693?dopt=Citation">22093693</a></text>
<text top="753" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22093693?dopt=Citation"> </a></text>
<text top="718" left="170" width="78" height="20" font="4">Retrospective </text>
<text top="735" left="170" width="39" height="20" font="4">review </text>
<text top="718" left="263" width="217" height="20" font="4">n=61 pts   <b>Inclusion criteria</b>: DCRV </text>
<text top="735" left="336" width="181" height="20" font="4">surgery 1970–2008; (mean 13 y, </text>
<text top="753" left="336" width="165" height="20" font="4">range 2 mo–64 y); associated </text>
<text top="770" left="336" width="70" height="20" font="4">VSD in 82% </text>
<text top="718" left="535" width="113" height="20" font="4">Descriptive, survival </text>
<text top="718" left="694" width="100" height="20" font="4">● 92% follow-up.  </text>
<text top="735" left="694" width="148" height="20" font="4">● 90% survival at 10 y. No </text>
<text top="753" left="694" width="85" height="20" font="4">reintervention.  </text>
<text top="770" left="694" width="174" height="20" font="4">● Pts were symptomatic or had </text>
<text top="787" left="694" width="156" height="20" font="4">gradient &gt;40 mm Hg at rest. </text>
<text top="718" left="906" width="142" height="20" font="4">● Surgical relief of DCRV </text>
<text top="735" left="906" width="150" height="20" font="4">and closure of VSD can be </text>
<text top="753" left="906" width="160" height="20" font="4">done successfully at multiple </text>
<text top="770" left="906" width="37" height="20" font="4">ages.  </text>
</page>
<page number="129" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 129 </text>
<text top="106" left="108" width="3" height="20" font="4"> </text>
<text top="123" left="108" width="3" height="20" font="4"> </text>
<text top="140" left="108" width="380" height="24" font="1"><b>Data Supplement 42. Ebstein Anomaly – Section 4.3.4 </b></text>
<text top="162" left="86" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="179" left="86" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="162" left="203" width="79" height="20" font="3"><b>Aim of Study </b></text>
<text top="162" left="305" width="105" height="20" font="3"><b>Study Type (Size, </b></text>
<text top="179" left="350" width="16" height="20" font="3"><b>N) </b></text>
<text top="162" left="434" width="111" height="20" font="3"><b>Patient Population </b></text>
<text top="162" left="579" width="130" height="20" font="3"><b>Study Intervention (n) </b></text>
<text top="162" left="881" width="48" height="20" font="3"><b>Results </b></text>
<text top="213" left="64" width="71" height="20" font="4">Chauvaud S </text>
<text top="230" left="64" width="63" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(475)</a> </text>
<text top="247" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11005596?dopt=Citation">11005596</a></text>
<text top="247" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11005596?dopt=Citation"><b> </b></a></text>
<text top="213" left="199" width="46" height="20" font="4">Surgery </text>
<text top="230" left="199" width="51" height="20" font="4">outcome<b> </b></text>
<text top="213" left="300" width="58" height="20" font="4">n=142 pts<b> </b></text>
<text top="213" left="428" width="120" height="20" font="4">Age 1–65 y, mean 25 </text>
<text top="230" left="428" width="10" height="20" font="4">y<b> </b></text>
<text top="213" left="563" width="124" height="20" font="4">● TV repair ± BDCPA </text>
<text top="213" left="739" width="159" height="20" font="4">● All repaired; BDCPA 21%. </text>
<text top="230" left="739" width="149" height="20" font="4">● Plication 79%; ring 64%. </text>
<text top="247" left="739" width="122" height="20" font="4">● 1 y 88%; 10 y 75%. </text>
<text top="264" left="739" width="235" height="20" font="4">● Late TR: I: 15%, II: 73%, III: 4%, IV: 8%. </text>
<text top="282" left="739" width="329" height="20" font="4">● Late reoperation n=13 at 3.4 y; free of reoperation 87% at </text>
<text top="299" left="739" width="30" height="20" font="4">14 y. </text>
<text top="317" left="64" width="86" height="20" font="4">Chen JM, et al. </text>
<text top="334" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(476)</a> </text>
<text top="351" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15052195?dopt=Citation">15052195</a></text>
<text top="351" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15052195?dopt=Citation"><b> </b></a></text>
<text top="317" left="199" width="46" height="20" font="4">Surgery </text>
<text top="334" left="199" width="51" height="20" font="4">outcome<b> </b></text>
<text top="317" left="300" width="51" height="20" font="4">n=25 pts<b> </b></text>
<text top="317" left="428" width="85" height="20" font="4">Mean age 14 y<b> </b></text>
<text top="317" left="563" width="66" height="20" font="4">● TV repair<b> </b></text>
<text top="317" left="739" width="315" height="20" font="4">● All repaired; 2 reoperation had TV replace at 4 and 8 y; </text>
<text top="334" left="739" width="232" height="20" font="4">40% had grade III TR early postoperation. </text>
<text top="351" left="739" width="263" height="20" font="4">● Exercise capacity improve 83%; 2 late SCDs.<b> </b></text>
<text top="369" left="64" width="98" height="20" font="4">Dearani JA, et al. </text>
<text top="386" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(477)</a> </text>
<text top="404" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23200240?dopt=Citation">23200240</a></text>
<text top="404" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23200240?dopt=Citation"><b> </b></a></text>
<text top="369" left="199" width="46" height="20" font="4">Surgery </text>
<text top="386" left="199" width="51" height="20" font="4">outcome<b> </b></text>
<text top="369" left="300" width="51" height="20" font="4">n=89 pts<b> </b></text>
<text top="369" left="428" width="120" height="20" font="4">Age 19 d–68 y; mean </text>
<text top="386" left="428" width="51" height="20" font="4">age 19 y<b> </b></text>
<text top="369" left="563" width="80" height="20" font="4">● Cone repair<b> </b></text>
<text top="369" left="739" width="82" height="20" font="4">● All repaired. </text>
<text top="386" left="739" width="292" height="20" font="4">● Modifications: ring 64%; leaflet augmentation 31%, </text>
<text top="404" left="739" width="143" height="20" font="4">autologous chordae 19%. </text>
<text top="421" left="739" width="90" height="20" font="4">● BDCPA 24%. </text>
<text top="438" left="739" width="313" height="20" font="4">● Early reoperation 13%; rerepair 50%, TV replace 50%. </text>
<text top="455" left="739" width="221" height="20" font="4">● Ringed annuloplasty less TR p=0.01. <b> </b></text>
<text top="473" left="64" width="98" height="20" font="4">Dearani JA, et al. </text>
<text top="490" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(478)</a> </text>
<text top="508" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23743062?dopt=Citation">23743062</a></text>
<text top="508" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23743062?dopt=Citation"><b> </b></a></text>
<text top="473" left="199" width="46" height="20" font="4">Surgery </text>
<text top="490" left="199" width="54" height="20" font="4">outcome <b> </b></text>
<text top="473" left="300" width="51" height="20" font="4">n=20 pts<b> </b></text>
<text top="473" left="428" width="120" height="20" font="4">Age 4–68 y; mean 15 </text>
<text top="490" left="428" width="10" height="20" font="4">y<b> </b></text>
<text top="473" left="563" width="49" height="20" font="4">● Cone. </text>
<text top="490" left="563" width="81" height="20" font="4">● TV rerepair.<b> </b></text>
<text top="473" left="739" width="200" height="20" font="4">● Preoperation congestive HF 40%. </text>
<text top="490" left="739" width="113" height="20" font="4">● RV plication 30%. </text>
<text top="508" left="739" width="145" height="20" font="4">● Ring annuloplasty 80%. </text>
<text top="525" left="739" width="90" height="20" font="4">● BDCPA 15%. </text>
<text top="542" left="739" width="77" height="20" font="4">● Maze 50%. </text>
<text top="559" left="739" width="107" height="20" font="4">● No reoperations. </text>
<text top="577" left="739" width="99" height="20" font="4">● No late deaths.<b> </b></text>
<text top="594" left="64" width="105" height="20" font="4">Malhotra SP, et al. </text>
<text top="612" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(479)</a> </text>
<text top="629" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19932271?dopt=Citation">19932271</a></text>
<text top="629" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19932271?dopt=Citation"> </a></text>
<text top="594" left="199" width="64" height="20" font="4">Surgery for </text>
<text top="612" left="199" width="82" height="20" font="4">congestive HF<b> </b></text>
<text top="594" left="300" width="51" height="20" font="4">n=57 pts<b> </b></text>
<text top="594" left="428" width="78" height="20" font="4">Mean age 8 y<b> </b></text>
<text top="594" left="563" width="153" height="20" font="4">● TV repair – “play it where </text>
<text top="612" left="563" width="39" height="20" font="4">it lies.” </text>
<text top="629" left="563" width="156" height="20" font="4">● TV replace 5.4%; BDCPA </text>
<text top="646" left="563" width="31" height="20" font="4">55%.<b> </b></text>
<text top="594" left="739" width="128" height="20" font="4">● Protocol for BDCPA. </text>
<text top="612" left="739" width="133" height="20" font="4">● 7% early reoperation. </text>
<text top="629" left="739" width="165" height="20" font="4">● 4 y free of TV replace 92%.<b> </b></text>
<text top="664" left="64" width="74" height="20" font="4">Raju V, et al. </text>
<text top="681" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(480)</a> </text>
<text top="698" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24811983?dopt=Citation">24811983</a></text>
<text top="698" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24811983?dopt=Citation"><b> </b></a></text>
<text top="664" left="199" width="64" height="20" font="4">Surgery for </text>
<text top="681" left="199" width="82" height="20" font="4">congestive HF<b> </b></text>
<text top="664" left="300" width="51" height="20" font="4">n=62 pts<b> </b></text>
<text top="664" left="428" width="89" height="20" font="4">Age 9 mo–57 y; </text>
<text top="681" left="428" width="85" height="20" font="4">mean age 21 y<b> </b></text>
<text top="664" left="563" width="90" height="20" font="4">● 73% children. </text>
<text top="681" left="563" width="80" height="20" font="4">● 27% adults. </text>
<text top="698" left="563" width="96" height="20" font="4">● BDCPA 100%.<b> </b></text>
<text top="664" left="739" width="265" height="20" font="4">● Severe RV enlargement or dysfunction 100%. </text>
<text top="681" left="739" width="110" height="20" font="4">● NYHA III/IV 70%. </text>
<text top="698" left="739" width="181" height="20" font="4">● Heart therapy evaluation 32%. </text>
<text top="716" left="739" width="192" height="20" font="4">● TV repair 52%; TV replace 48%. </text>
<text top="733" left="739" width="310" height="20" font="4">● BDCPA planned 86%; added intraoperation after CPB </text>
<text top="750" left="739" width="202" height="20" font="4">11%; added early postoperation 3%. </text>
<text top="767" left="739" width="84" height="20" font="4">● 1 late death. </text>
<text top="784" left="739" width="142" height="20" font="4">● Late reintervention 8%. </text>
</page>
<page number="130" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 130 </text>
<text top="107" left="739" width="272" height="20" font="4">● Operation mortality 1.6%; mean follow-up 3.6 y </text>
<text top="124" left="739" width="175" height="20" font="4">NYHA I/II in 88% late follow-up.<b> </b></text>
<text top="158" left="64" width="113" height="20" font="4">Al-Najashi KS, et al. </text>
<text top="175" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(481)</a> </text>
<text top="192" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19559211?dopt=Citation">19559211</a></text>
<text top="192" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19559211?dopt=Citation"><b> </b></a></text>
<text top="158" left="199" width="87" height="20" font="4">1.5 valve repair </text>
<text top="175" left="199" width="57" height="20" font="4">outcomes<b> </b></text>
<text top="158" left="300" width="51" height="20" font="4">n=40 pts<b> </b></text>
<text top="158" left="428" width="85" height="20" font="4">Mean age 42 y<b> </b></text>
<text top="158" left="563" width="161" height="20" font="4">● 23 pts with cavopulmonary </text>
<text top="175" left="563" width="138" height="20" font="4">shunt (42 y ± 12); 17 pts </text>
<text top="192" left="563" width="113" height="20" font="4">without (39 y, ± 19).<b> </b></text>
<text top="158" left="739" width="288" height="20" font="4">● 2 early death (right HF); arrhythmia most common </text>
<text top="175" left="739" width="281" height="20" font="4">complication; groups with similar 5 y survival (83%–</text>
<text top="192" left="739" width="275" height="20" font="4">86%)/HF/arrhythmia; differ in need for reoperation </text>
<text top="209" left="739" width="128" height="20" font="4">concomitant operation.<b> </b></text>
<text top="227" left="64" width="94" height="20" font="4">Stulak, JM, et al. </text>
<text top="244" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#221">(177)</a> </text>
<text top="262" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22098921?dopt=Citation">22098921</a></text>
<text top="262" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22098921?dopt=Citation"><b> </b></a></text>
<text top="227" left="199" width="64" height="20" font="4">AF surgery </text>
<text top="244" left="199" width="57" height="20" font="4">outcomes<b> </b></text>
<text top="227" left="300" width="61" height="20" font="4">n=245 pts <b> </b></text>
<text top="227" left="428" width="103" height="20" font="4">Age 1–75 y; mean </text>
<text top="244" left="428" width="122" height="20" font="4">age 45 y; 134 female; </text>
<text top="262" left="428" width="107" height="20" font="4">43 pts with Ebstein </text>
<text top="279" left="428" width="50" height="20" font="4">anomaly<b> </b></text>
<text top="227" left="563" width="140" height="20" font="4">● Success of AF surgery </text>
<text top="244" left="563" width="124" height="20" font="4">during redo operation.<b> </b></text>
<text top="227" left="739" width="322" height="20" font="4">● Endpoint of sinus rhythm: 39 pt with pacemaker, in CHD </text>
<text top="244" left="739" width="268" height="20" font="4">pts 89% in sinus rhythm at median 4-y follow-up.<b> </b></text>
<text top="297" left="64" width="106" height="20" font="4">Khositseth A, et al. </text>
<text top="314" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(482)</a> </text>
<text top="331" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15573066?dopt=Citation">15573066</a></text>
<text top="331" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15573066?dopt=Citation"><b> </b></a></text>
<text top="297" left="199" width="27" height="20" font="4">SVT </text>
<text top="314" left="199" width="75" height="20" font="4">management<b> </b></text>
<text top="297" left="300" width="83" height="20" font="4">n=130 pts with </text>
<text top="314" left="300" width="94" height="20" font="4">Ebstein anomaly </text>
<text top="331" left="300" width="77" height="20" font="4">and history of </text>
<text top="348" left="300" width="94" height="20" font="4">tachyarrhythmia <b> </b></text>
<text top="297" left="428" width="117" height="20" font="4">Retrospective review </text>
<text top="314" left="428" width="85" height="20" font="4">mean age 25 y<b> </b></text>
<text top="297" left="563" width="139" height="20" font="4">● Evaluate SVT therapy.<b> </b></text>
<text top="297" left="739" width="282" height="20" font="4">● 24 with AF/atrial flutter + 106 with EP majority &gt;1 </text>
<text top="314" left="739" width="70" height="20" font="4">mechanism. </text>
<text top="331" left="739" width="326" height="20" font="4">● 83/130 had surgical intervention for arrhythmia combined </text>
<text top="348" left="739" width="225" height="20" font="4">with surgery: 75% recurrence free at 4 y.<b> </b></text>
<text top="366" left="64" width="73" height="20" font="4">Wei W, et al. </text>
<text top="384" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(483)</a> </text>
<text top="401" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24614573?dopt=Citation">24614573</a></text>
<text top="401" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24614573?dopt=Citation"><b> </b></a></text>
<text top="366" left="199" width="78" height="20" font="4">Description of </text>
<text top="384" left="199" width="59" height="20" font="4">accessory </text>
<text top="401" left="199" width="68" height="20" font="4">pathways in </text>
<text top="418" left="199" width="44" height="20" font="4">Ebstein </text>
<text top="435" left="199" width="50" height="20" font="4">anomaly<b> </b></text>
<text top="366" left="300" width="51" height="20" font="4">n=17 pts<b> </b></text>
<text top="366" left="428" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="384" left="428" width="76" height="20" font="4">Adult Ebstein </text>
<text top="401" left="428" width="114" height="20" font="4">anomaly; referral for </text>
<text top="418" left="428" width="116" height="20" font="4">EPS from November </text>
<text top="435" left="428" width="92" height="20" font="4">2011–May 2013<b> </b></text>
<text top="366" left="563" width="118" height="20" font="4">● Type of arrhythmia </text>
<text top="384" left="563" width="64" height="20" font="4">substrates.<b> </b></text>
<text top="366" left="739" width="242" height="20" font="4">● 35.3% had multiple accessory pathways.  </text>
<text top="384" left="739" width="196" height="20" font="4">● 91% of pathways were manifest.  </text>
<text top="401" left="739" width="286" height="20" font="4">● 26% were broad and 87% were nondecremental.  </text>
<text top="418" left="739" width="124" height="20" font="4">● All were right-sided.<b> </b></text>
<text top="453" left="64" width="94" height="20" font="4">Iturralde P, et al. </text>
<text top="470" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(484)</a> </text>
<text top="488" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17239096?dopt=Citation">17239096</a></text>
<text top="488" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17239096?dopt=Citation"><b> </b></a></text>
<text top="453" left="199" width="80" height="20" font="4">ECG changes </text>
<text top="470" left="199" width="62" height="20" font="4">before and </text>
<text top="488" left="199" width="88" height="20" font="4">after ablation of </text>
<text top="505" left="199" width="59" height="20" font="4">accessory </text>
<text top="522" left="199" width="82" height="20" font="4">pathway in pts </text>
<text top="539" left="199" width="69" height="20" font="4">with Ebstein </text>
<text top="557" left="199" width="50" height="20" font="4">anomaly<b> </b></text>
<text top="453" left="300" width="51" height="20" font="4">n=60 pts<b> </b></text>
<text top="453" left="428" width="98" height="20" font="4">Ebstein anomaly; </text>
<text top="470" left="428" width="108" height="20" font="4">accessory pathway<b> </b></text>
<text top="453" left="563" width="124" height="20" font="4">● ECG characteristics </text>
<text top="470" left="563" width="150" height="20" font="4">before and after ablation of </text>
<text top="488" left="563" width="111" height="20" font="4">accessory pathway.<b> </b></text>
<text top="453" left="739" width="330" height="20" font="4">● Of 30 pts with recurrent tachycardia and single right-sided </text>
<text top="470" left="739" width="329" height="20" font="4">accessory pathway, 62% had typical preexcitation, although </text>
<text top="488" left="739" width="289" height="20" font="4">none had right bundle branch block in sinus rhythm.  </text>
<text top="505" left="739" width="320" height="20" font="4">● Catheter ablation resulted in appearance of right bundle </text>
<text top="522" left="739" width="312" height="20" font="4">branch block in 94% 1/3 of pts with Ebstein anomaly and </text>
<text top="539" left="739" width="300" height="20" font="4">symptomatic tachyarrhythmias have minimal or absent </text>
<text top="557" left="739" width="140" height="20" font="4">ventricular preexcitation.  </text>
<text top="574" left="739" width="306" height="20" font="4">● The absence of right bundle branch block pattern is a </text>
<text top="591" left="739" width="231" height="20" font="4">strong predictor of an accessory pathway.<b> </b></text>
<text top="609" left="64" width="87" height="20" font="4">Reich JD, et al. </text>
<text top="626" left="64" width="63" height="20" font="4">1998 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(485)</a> </text>
<text top="643" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9869537?dopt=Citation">9869537</a></text>
<text top="643" left="112" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9869537?dopt=Citation"><b> </b></a></text>
<text top="609" left="199" width="80" height="20" font="4">Radiofrequenc</text>
<text top="626" left="199" width="56" height="20" font="4">y ablation </text>
<text top="643" left="199" width="57" height="20" font="4">outcomes<b> </b></text>
<text top="609" left="300" width="54" height="20" font="4">n=65 pts; </text>
<text top="626" left="300" width="64" height="20" font="4">multicenter </text>
<text top="643" left="300" width="74" height="20" font="4">retrospective </text>
<text top="661" left="300" width="44" height="20" font="4">registry<b> </b></text>
<text top="609" left="428" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="626" left="428" width="116" height="20" font="4">Pediatric Ebstein pts </text>
<text top="609" left="563" width="148" height="20" font="4">● Arrhythmia mechanisms </text>
<text top="626" left="563" width="139" height="20" font="4">and acute success rates.<b> </b></text>
<text top="609" left="739" width="296" height="20" font="4">● 29% of pts had multiple accessory pathways. Other </text>
<text top="626" left="739" width="281" height="20" font="4">common arrhythmia mechanisms included Mahaim </text>
<text top="643" left="739" width="267" height="20" font="4">pathways (n=5), IART (n=4), and AVNRT (n=7).  </text>
<text top="661" left="739" width="316" height="20" font="4">● Acute success rates ranged from 75%–89% depending </text>
<text top="678" left="739" width="324" height="20" font="4">on arrhythmia substrate with recurrence rates of 27%–32% </text>
<text top="695" left="739" width="312" height="20" font="4">on follow-up life-threatening arrhythmias and multiple EP </text>
<text top="712" left="739" width="315" height="20" font="4">substrates are commonly encountered in pts with Ebstein </text>
<text top="729" left="739" width="212" height="20" font="4">anomaly referred for catheter ablation.<b> </b></text>
<text top="747" left="64" width="110" height="20" font="4">Shivapour JK, et al. </text>
<text top="765" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(486)</a> </text>
<text top="782" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24513916?dopt=Citation">24513916</a></text>
<text top="782" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24513916?dopt=Citation"><b> </b></a></text>
<text top="747" left="199" width="47" height="20" font="4">Utility of </text>
<text top="765" left="199" width="72" height="20" font="4">preoperative </text>
<text top="782" left="199" width="34" height="20" font="4">EPSs<b> </b></text>
<text top="747" left="300" width="54" height="20" font="4">n=74 pts; </text>
<text top="765" left="300" width="113" height="20" font="4">retrospective review<b> </b></text>
<text top="747" left="428" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="765" left="428" width="92" height="20" font="4">All pts at Boston </text>
<text top="782" left="428" width="106" height="20" font="4">Children’s Hospital </text>
<text top="747" left="563" width="110" height="20" font="4">● Preoperation and </text>
<text top="765" left="563" width="149" height="20" font="4">postoperation arrhythmias.<b> </b></text>
<text top="747" left="739" width="261" height="20" font="4">● 29/42 (69%) with significant findings on EPS  </text>
<text top="765" left="739" width="183" height="20" font="4">● 17/29 with successful ablation.<b> </b></text>
</page>
<page number="131" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 131 </text>
<text top="107" left="428" width="79" height="20" font="4">with Ebstein’s </text>
<text top="124" left="428" width="100" height="20" font="4">anomaly who had </text>
<text top="141" left="428" width="118" height="20" font="4">cone procedure Dec. </text>
<text top="159" left="428" width="97" height="20" font="4">2006–Sept. 2012<b> </b></text>
<text top="177" left="64" width="101" height="20" font="4">Bharucha T, et al. </text>
<text top="194" left="64" width="66" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(487)</a>  </text>
<text top="211" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20085664?dopt=Citation">20085664</a></text>
<text top="211" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20085664?dopt=Citation"><b> </b></a></text>
<text top="177" left="199" width="67" height="20" font="4">Prospective </text>
<text top="194" left="199" width="67" height="20" font="4">comparison<b> </b></text>
<text top="177" left="300" width="54" height="20" font="4">n=23 pts <b> </b></text>
<text top="177" left="428" width="83" height="20" font="4">3D multiplanar </text>
<text top="194" left="428" width="114" height="20" font="4">echocardiography in </text>
<text top="211" left="428" width="89" height="20" font="4">pts with Ebstein </text>
<text top="228" left="428" width="122" height="20" font="4">anomaly compared to </text>
<text top="245" left="428" width="115" height="20" font="4">2D TTE and surgical </text>
<text top="263" left="428" width="51" height="20" font="4">anatomy<b> </b></text>
<text top="177" left="563" width="145" height="20" font="4">● Agreement between 3D </text>
<text top="194" left="563" width="125" height="20" font="4">echocardiography and </text>
<text top="211" left="563" width="130" height="20" font="4">TTE/operative findings.<b> </b></text>
<text top="177" left="739" width="301" height="20" font="4">● Use of 3D resulted in reclassification of 11 pts as TV </text>
<text top="194" left="739" width="62" height="20" font="4">dysplasia.  </text>
<text top="211" left="739" width="299" height="20" font="4">● Surgery undertaken on 10/23 with good correlation.  </text>
<text top="228" left="739" width="317" height="20" font="4">● Rotational abnormalities identified on 3D, other findings </text>
<text top="245" left="739" width="105" height="20" font="4">were similar to 2D.<b> </b></text>
<text top="281" left="64" width="111" height="20" font="4">Attenhofer Jost CH, </text>
<text top="298" left="64" width="30" height="20" font="4">et al. </text>
<text top="315" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(488)</a> </text>
<text top="332" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21822629?dopt=Citation">21822629</a></text>
<text top="332" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21822629?dopt=Citation"><b> </b></a></text>
<text top="281" left="199" width="83" height="20" font="4">Comparison of </text>
<text top="298" left="199" width="85" height="20" font="4">echocardiograp</text>
<text top="315" left="199" width="79" height="20" font="4">hy and MRI in </text>
<text top="332" left="199" width="44" height="20" font="4">Ebstein </text>
<text top="350" left="199" width="50" height="20" font="4">anomaly<b> </b></text>
<text top="281" left="300" width="51" height="20" font="4">n=16 pts<b> </b></text>
<text top="281" left="428" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="298" left="428" width="91" height="20" font="4">Pts with Ebstein </text>
<text top="315" left="428" width="115" height="20" font="4">anomaly undergoing </text>
<text top="332" left="428" width="50" height="20" font="4">MRI and </text>
<text top="350" left="428" width="101" height="20" font="4">echocardiography<b> </b></text>
<text top="281" left="563" width="142" height="20" font="4">● Comparison of imaging </text>
<text top="298" left="563" width="156" height="20" font="4">data with operative findings.<b> </b></text>
<text top="281" left="739" width="291" height="20" font="4">● MRI better demonstrated right heart chamber size, </text>
<text top="298" left="739" width="322" height="20" font="4">degree of TR and valve anatomy, echocardiography better </text>
<text top="315" left="739" width="121" height="20" font="4">showed small shunts.<b> </b></text>
<text top="368" left="64" width="109" height="20" font="4">Zachariah JP, et al. </text>
<text top="385" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(489)</a> </text>
<text top="402" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23237138?dopt=Citation">23237138</a></text>
<text top="402" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23237138?dopt=Citation"> </a></text>
<text top="368" left="199" width="85" height="20" font="4">Characteristics </text>
<text top="385" left="199" width="59" height="20" font="4">of multiple </text>
<text top="402" left="199" width="59" height="20" font="4">accessory </text>
<text top="419" left="199" width="55" height="20" font="4">pathways </text>
<text top="368" left="300" width="68" height="20" font="4">n=1,088 pts </text>
<text top="368" left="428" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="385" left="428" width="96" height="20" font="4">Pediatric pts with </text>
<text top="402" left="428" width="114" height="20" font="4">accessory pathways </text>
<text top="368" left="563" width="162" height="20" font="4">● Outcomes of ablation were </text>
<text top="385" left="563" width="135" height="20" font="4">negatively influenced by </text>
<text top="402" left="563" width="125" height="20" font="4">multiple pathways and </text>
<text top="419" left="563" width="79" height="20" font="4">structural HD. </text>
<text top="368" left="739" width="302" height="20" font="4">● Multiple accessory pathways were present in 10% of </text>
<text top="385" left="739" width="312" height="20" font="4">pediatric pts and more common in pts with structural HD. </text>
<text top="437" left="64" width="92" height="20" font="4">Brown ML, et al. </text>
<text top="454" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(490)</a> </text>
<text top="472" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18455593?dopt=Citation">18455593</a></text>
<text top="472" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18455593?dopt=Citation"> </a></text>
<text top="437" left="199" width="59" height="20" font="4">Long term </text>
<text top="454" left="199" width="70" height="20" font="4">outcomes of </text>
<text top="472" left="199" width="62" height="20" font="4">surgery for </text>
<text top="489" left="199" width="44" height="20" font="4">Ebstein </text>
<text top="506" left="199" width="50" height="20" font="4">anomaly </text>
<text top="437" left="300" width="86" height="20" font="4">n=539 pts (604 </text>
<text top="454" left="300" width="58" height="20" font="4">surgeries) </text>
<text top="437" left="428" width="109" height="20" font="4">Single -center case </text>
<text top="454" left="428" width="36" height="20" font="4">series </text>
<text top="437" left="563" width="140" height="20" font="4">● Survey sent to pts who </text>
<text top="454" left="563" width="138" height="20" font="4">underwent TV surgery at </text>
<text top="472" left="563" width="129" height="20" font="4">Mayo Clinic from 1972–</text>
<text top="489" left="563" width="161" height="20" font="4">2006. 30-d mortality of 5.9%, </text>
<text top="506" left="563" width="150" height="20" font="4">late survival 84.7% at 10 y, </text>
<text top="523" left="563" width="143" height="20" font="4">71.2% at 20 y. 83% of pts </text>
<text top="540" left="563" width="148" height="20" font="4">responding to surveys had </text>
<text top="558" left="563" width="141" height="20" font="4">NYHA I and II symptoms. </text>
<text top="575" left="563" width="149" height="20" font="4">TV repair and replacement </text>
<text top="592" left="563" width="148" height="20" font="4">were associated with good </text>
<text top="609" left="563" width="104" height="20" font="4">long-term survival. </text>
<text top="437" left="739" width="321" height="20" font="4">● Single center but very large experience in operations for </text>
<text top="454" left="739" width="101" height="20" font="4">Ebstein anomaly.  </text>
<text top="472" left="739" width="302" height="20" font="4">● Suggests both repair and replacement have similarly </text>
<text top="489" left="739" width="153" height="20" font="4">good long-term outcomes.   </text>
<text top="627" left="64" width="92" height="20" font="4">Hasan BS, et al. </text>
<text top="644" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(491)</a> </text>
<text top="662" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22075926?dopt=Citation">22075926</a></text>
<text top="662" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22075926?dopt=Citation"> </a></text>
<text top="627" left="199" width="54" height="20" font="4">n=30 pts  </text>
<text top="627" left="300" width="102" height="20" font="4">Pts at 5 centers in </text>
<text top="644" left="300" width="65" height="20" font="4">the U.S: 23 </text>
<text top="662" left="300" width="111" height="20" font="4">pulmonary, 5 native </text>
<text top="679" left="300" width="111" height="20" font="4">aortic, 1 LV to Ao, 1 </text>
<text top="696" left="300" width="33" height="20" font="4">mitral </text>
<text top="713" left="300" width="51" height="20" font="4">n=30 pts </text>
<text top="627" left="428" width="75" height="20" font="4">Melody valve </text>
<text top="644" left="428" width="109" height="20" font="4">implantation in high </text>
<text top="662" left="428" width="100" height="20" font="4">pressure systems </text>
<text top="627" left="563" width="134" height="20" font="4">● Short-term outcomes. </text>
<text top="627" left="739" width="315" height="20" font="4">● High pressure environment in PA circulation defined as </text>
<text top="644" left="739" width="133" height="20" font="4">mean PAP &gt;25 mm Hg. </text>
<text top="662" left="739" width="322" height="20" font="4">● In the pulmonary position 10 implants in homografts and </text>
<text top="679" left="739" width="321" height="20" font="4">13 in bioprosthetic valves or bioprosthetic valved conduits. </text>
<text top="696" left="739" width="275" height="20" font="4">● 3 pts died<b>; </b>2 with Melody valves in the systemic </text>
<text top="713" left="739" width="309" height="20" font="4">circulation, 1 in the pulmonary circulation who died 8 mo </text>
<text top="730" left="739" width="206" height="20" font="4">after the procedure of drug overdose. </text>
<text top="748" left="739" width="310" height="20" font="4">● At 1 y, freedom from moderate-to-severe regurgitation </text>
<text top="765" left="739" width="291" height="20" font="4">was 100%, freedom from mild regurgitation was 90% </text>
</page>
<page number="132" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 132 </text>
<text top="107" left="64" width="100" height="20" font="4">Roberts PA, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(492)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21718905?dopt=Citation">21718905</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21718905?dopt=Citation"> </a></text>
<text top="107" left="199" width="84" height="20" font="4">n=15 pts; multi-</text>
<text top="124" left="199" width="65" height="20" font="4">institutional </text>
<text top="107" left="300" width="67" height="20" font="4">Clinical and </text>
<text top="124" left="300" width="89" height="20" font="4">procedural data </text>
<text top="107" left="428" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="428" width="108" height="20" font="4">Prior TV prosthesis </text>
<text top="141" left="428" width="112" height="20" font="4">or RA to RV conduit </text>
<text top="107" left="563" width="136" height="20" font="4">● Procedural outcomes. </text>
<text top="107" left="739" width="314" height="20" font="4">● Mean tricuspid gradient 13 mm Hg preoperation; mean </text>
<text top="124" left="739" width="236" height="20" font="4">tricuspid gradient 4 mm Hg postprocedure. </text>
<text top="141" left="739" width="259" height="20" font="4">● 1 major complication – complete heart block. </text>
<text top="159" left="739" width="224" height="20" font="4">● 1 pt developed IE 2 mo postoperation. </text>
<text top="176" left="739" width="319" height="20" font="4">● 1 pt with preoperation multiorgan failure did not improve </text>
<text top="193" left="739" width="109" height="20" font="4">and died 20 d later. </text>
<text top="210" left="739" width="278" height="20" font="4">● Remaining pts doing well at 4 mo postoperation. </text>
<text top="228" left="64" width="94" height="20" font="4">Cullen MN, et al. </text>
<text top="245" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(493)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23683739?dopt=Citation">23683739</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23683739?dopt=Citation"> </a></text>
<text top="228" left="199" width="54" height="20" font="4">n=19 pts; </text>
<text top="245" left="199" width="73" height="20" font="4">single center </text>
<text top="228" left="300" width="46" height="20" font="4">Pts with </text>
<text top="245" left="300" width="106" height="20" font="4">degenerated mitral </text>
<text top="263" left="300" width="64" height="20" font="4">or tricuspid </text>
<text top="280" left="300" width="111" height="20" font="4">bioprosthetic valves </text>
<text top="228" left="428" width="98" height="20" font="4">Median age 65 y; </text>
<text top="245" left="428" width="106" height="20" font="4">degenerated mitral </text>
<text top="263" left="428" width="100" height="20" font="4">(9); tricuspid (10); </text>
<text top="280" left="428" width="78" height="20" font="4">valve-in-valve </text>
<text top="297" left="428" width="95" height="20" font="4">implantation with </text>
<text top="314" left="428" width="108" height="20" font="4">Melody; mean STS </text>
<text top="332" left="428" width="100" height="20" font="4">mortality score 13 </text>
<text top="228" left="563" width="136" height="20" font="4">● Procedural outcomes. </text>
<text top="228" left="739" width="329" height="20" font="4">● Mitral gradient decreased from 12–5 mm Hg; residual MR </text>
<text top="245" left="739" width="243" height="20" font="4">mild (6), mild-to-moderate (2), moderate (1). </text>
<text top="263" left="739" width="318" height="20" font="4">● Tricuspid gradient decreased 10–5 mm Hg; residual TR </text>
<text top="280" left="739" width="199" height="20" font="4">trivial-mild (9), mild-to-moderate (1). </text>
<text top="297" left="739" width="261" height="20" font="4">● No periprocedural deaths, MI, stroke or valve </text>
<text top="314" left="739" width="76" height="20" font="4">embolization. </text>
<text top="332" left="739" width="253" height="20" font="4">● Vascular access site complications in 4 pts. </text>
<text top="350" left="64" width="90" height="20" font="4">Badiu CC, et al. </text>
<text top="367" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#235">(470)</a> </text>
<text top="384" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19695893?dopt=Citation">19695893</a></text>
<text top="384" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19695893?dopt=Citation"> </a></text>
<text top="350" left="199" width="78" height="20" font="4">Retrospective </text>
<text top="367" left="199" width="76" height="20" font="4">cohort, single </text>
<text top="384" left="199" width="38" height="20" font="4">center </text>
<text top="350" left="300" width="58" height="20" font="4">n=130 pts </text>
<text top="350" left="428" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="367" left="428" width="108" height="20" font="4">Pts who underwent </text>
<text top="384" left="428" width="98" height="20" font="4">surgical repair for </text>
<text top="401" left="428" width="103" height="20" font="4">Ebstein’s anomaly </text>
<text top="418" left="428" width="120" height="20" font="4">between 1976―2007 </text>
<text top="350" left="563" width="94" height="20" font="4">Repair feasibility </text>
<text top="350" left="739" width="112" height="20" font="4">● 2 hospital deaths. </text>
<text top="367" left="739" width="314" height="20" font="4">● Overall survival was 87.2%+/-3.6%, 85.1%+/-4.1% and </text>
<text top="384" left="739" width="304" height="20" font="4">81.2%+/-5.4% at 10, 20, and 25 y, respectively, without </text>
<text top="401" left="739" width="316" height="20" font="4">significant difference between the repair and replacement </text>
<text top="418" left="739" width="88" height="20" font="4">group (p=0.31). </text>
<text top="436" left="739" width="296" height="20" font="4">● NYHA FC &gt;II (p=0.01) and cardiothoracic ratio &gt;0.6 </text>
<text top="453" left="739" width="272" height="20" font="4">(p=0.02) were significant risk factors for mortality. </text>
<text top="470" left="739" width="296" height="20" font="4">● Overall freedom from reoperation was 79.9+/-4.6%, </text>
<text top="487" left="739" width="273" height="20" font="4">61.9+/-6.8% and 58.0+/-7.4% at 10, 20, and 25 y, </text>
<text top="504" left="739" width="72" height="20" font="4">respectively. </text>
<text top="522" left="739" width="288" height="20" font="4">● Age ≤12 y (p=0.005) and cardiothoracic ratio &gt;0.6 </text>
<text top="539" left="739" width="294" height="20" font="4">(p=0.009) were significant risk factors for reoperation. </text>
<text top="557" left="54" width="3" height="20" font="4"> </text>
<text top="574" left="54" width="3" height="20" font="4"> </text>
<text top="591" left="108" width="388" height="24" font="1"><b>Data Supplement 43. Tetralogy of Fallot – Section 4.3.5 </b></text>
<text top="613" left="69" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="630" left="69" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="613" left="168" width="73" height="20" font="3"><b>Study (Size, </b></text>
<text top="630" left="196" width="16" height="20" font="3"><b>N) </b></text>
<text top="613" left="259" width="82" height="20" font="3"><b>Study Design </b></text>
<text top="613" left="369" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="630" left="406" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="613" left="528" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="613" left="720" width="48" height="20" font="3"><b>Results </b></text>
<text top="613" left="925" width="77" height="20" font="3"><b>Conclusions </b></text>
<text top="663" left="64" width="84" height="20" font="4">Valente AM, et </text>
<text top="680" left="64" width="16" height="20" font="4">al. </text>
<text top="698" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(494)</a> </text>
<text top="715" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24179163?dopt=Citation">24179163</a></text>
<text top="715" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24179163?dopt=Citation"> </a></text>
<text top="663" left="165" width="61" height="20" font="4">n=873 pts; </text>
<text top="680" left="165" width="72" height="20" font="4">TOF/PA 131 </text>
<text top="698" left="165" width="36" height="20" font="4">(15%) </text>
<text top="663" left="257" width="82" height="20" font="4">Retrospective, </text>
<text top="680" left="257" width="82" height="20" font="4">Multicenter (4) </text>
<text top="663" left="356" width="137" height="20" font="3"><b>Inclusion criteria</b>: TOF, </text>
<text top="680" left="356" width="140" height="20" font="4">CMR and ECG within 1 y </text>
<text top="698" left="356" width="31" height="20" font="4">apart </text>
<text top="715" left="356" width="3" height="20" font="4"> </text>
<text top="732" left="356" width="129" height="20" font="3"><b>Exclusion criteria</b>: PV </text>
<text top="749" left="356" width="113" height="20" font="4">replacement prior to </text>
<text top="767" left="356" width="127" height="20" font="4">CMR; outcome prior to </text>
<text top="784" left="356" width="31" height="20" font="4">CRM </text>
<text top="663" left="514" width="81" height="20" font="4">Sustained VT, </text>
<text top="680" left="514" width="34" height="20" font="4">death </text>
<text top="663" left="628" width="226" height="20" font="4">● 32 (3.7%) reached the 1° outcome (28 </text>
<text top="680" left="628" width="133" height="20" font="4">deaths, 4 sustained VT. </text>
<text top="698" left="628" width="214" height="20" font="4">● Cox proportional hazards regression </text>
<text top="715" left="628" width="220" height="20" font="4">identified RV mass-to-volume ratio ≥0.3 </text>
<text top="732" left="628" width="192" height="20" font="4">g/mL (HR: 5.04; 95% CI: 2.3–11.0; </text>
<text top="749" left="628" width="225" height="20" font="4">p&lt;0.001), LVEF z-score &lt;-2.0 (HR: 3.34; </text>
<text top="767" left="628" width="228" height="20" font="4">95% CI: 1.59–7.01; p=0.001), and history </text>
<text top="784" left="628" width="222" height="20" font="4">of atrial tachyarrhythmia (HR: 3.65; 95% </text>
<text top="663" left="874" width="165" height="20" font="4">● RV hypertrophy, ventricular </text>
<text top="680" left="874" width="123" height="20" font="4">dysfunction, and atrial </text>
<text top="698" left="874" width="174" height="20" font="4">tachyarrhythmias are predictive </text>
<text top="715" left="874" width="160" height="20" font="4">of death and sustained VT in </text>
<text top="732" left="874" width="141" height="20" font="4">adults with repaired TOF. </text>
</page>
<page number="133" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="14" size="12" family="Times" color="#252526"/>
	<fontspec id="15" size="12" family="Times" color="#252526"/>
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 133 </text>
<text top="107" left="628" width="200" height="20" font="4">CI: 1.75–7.62; p=0.001) as outcome </text>
<text top="124" left="628" width="228" height="20" font="4">predictors. RV dysfunction was predictive </text>
<text top="141" left="628" width="228" height="20" font="4">of the outcome similar to LV dysfunction.  </text>
<text top="159" left="628" width="218" height="20" font="4">● TOF/PA was a univariate predictor of </text>
<text top="176" left="628" width="107" height="20" font="4">outcome (HR: 3.3). </text>
<text top="194" left="64" width="83" height="20" font="4">Aboulhosn JA, </text>
<text top="211" left="64" width="30" height="20" font="4">et al. </text>
<text top="228" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(495)</a> </text>
<text top="245" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23369488?dopt=Citation">23369488</a></text>
<text top="245" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23369488?dopt=Citation"> </a></text>
<text top="194" left="165" width="61" height="20" font="4">n=325 pts; </text>
<text top="211" left="165" width="48" height="20" font="4">TOF/PA </text>
<text top="228" left="165" width="69" height="20" font="4">8.3% of 556 </text>
<text top="194" left="257" width="82" height="20" font="4">Retrospective, </text>
<text top="211" left="257" width="33" height="20" font="4">cross-</text>
<text top="228" left="257" width="55" height="20" font="4">sectional, </text>
<text top="246" left="257" width="64" height="20" font="4">multicenter </text>
<text top="263" left="257" width="25" height="20" font="4">(11) </text>
<text top="194" left="356" width="130" height="20" font="3"><b>Inclusion criteria</b>: Age </text>
<text top="211" left="356" width="126" height="20" font="4">≥18 y, Doppler data to </text>
<text top="228" left="356" width="108" height="20" font="4">assess LV diastolic </text>
<text top="246" left="356" width="69" height="20" font="4">dysfunction  </text>
<text top="263" left="356" width="3" height="20" font="4"> </text>
<text top="280" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="297" left="356" width="110" height="20" font="4">Complex coexisting </text>
<text top="314" left="356" width="136" height="20" font="4">congenital abnormalities </text>
<text top="332" left="356" width="130" height="20" font="4">or uninterpretable ECG </text>
<text top="194" left="514" width="99" height="20" font="4">Clinical variables: </text>
<text top="211" left="514" width="57" height="20" font="4">figure 1 is </text>
<text top="228" left="514" width="75" height="20" font="4">sustained VT </text>
<text top="194" left="628" width="211" height="20" font="14">● Sustained VT was present in 28.9% </text>
<text top="211" left="628" width="215" height="20" font="14">with LV diastolic dysfunction vs. 10.6% </text>
<text top="228" left="628" width="174" height="20" font="14">without LV diastolic dysfunction </text>
<text top="246" left="628" width="225" height="20" font="14">(p<i>&lt;</i>0.0001); sustained VT was present in </text>
<text top="263" left="628" width="217" height="20" font="14">24.1% with RV diastolic dysfunction vs. </text>
<text top="280" left="628" width="215" height="20" font="14">14.3% without RV diastolic dysfunction </text>
<text top="297" left="628" width="50" height="20" font="14">(p<i>=</i>0.04).</text>
<text top="297" left="677" width="3" height="20" font="4"> </text>
<text top="194" left="874" width="123" height="20" font="4">● LV and RV diastolic </text>
<text top="211" left="874" width="174" height="20" font="4">dysfunction are associated with </text>
<text top="228" left="874" width="148" height="20" font="4">a higher prevalence of VT. </text>
<text top="350" left="64" width="73" height="20" font="4">Bonello B, et </text>
<text top="367" left="64" width="16" height="20" font="4">al. </text>
<text top="384" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(496)</a> </text>
<text top="401" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23643427?dopt=Citation">23643427</a></text>
<text top="401" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23643427?dopt=Citation"> </a></text>
<text top="350" left="165" width="61" height="20" font="4">n=154 pts, </text>
<text top="367" left="165" width="59" height="20" font="4">not known </text>
<text top="384" left="165" width="51" height="20" font="4">TOF/PA  </text>
<text top="350" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="367" left="257" width="74" height="20" font="4">single-center </text>
<text top="384" left="257" width="70" height="20" font="4">cohort study </text>
<text top="350" left="354" width="130" height="20" font="3"><b>Inclusion criteria</b>: Age </text>
<text top="367" left="354" width="135" height="20" font="4">≥18 y, CMR 2002–2008 </text>
<text top="384" left="354" width="3" height="20" font="4"> </text>
<text top="401" left="354" width="139" height="20" font="3"><b>Exclusion criteria</b>: Prior </text>
<text top="418" left="354" width="83" height="20" font="4">history of atrial </text>
<text top="436" left="354" width="68" height="20" font="4">arrhythmias </text>
<text top="350" left="514" width="88" height="20" font="4">Sustained atrial </text>
<text top="367" left="514" width="96" height="20" font="4">arrhythmia (atrial </text>
<text top="384" left="514" width="49" height="20" font="4">flutter or </text>
<text top="401" left="514" width="59" height="20" font="4">fibrillation; </text>
<text top="418" left="514" width="81" height="20" font="4">paroxysmal or </text>
<text top="436" left="514" width="73" height="20" font="4">established). </text>
<text top="453" left="514" width="77" height="20" font="4">Sustained VT </text>
<text top="470" left="514" width="66" height="20" font="4">(≥30 s), VT </text>
<text top="487" left="514" width="87" height="20" font="4">associated with </text>
<text top="504" left="514" width="81" height="20" font="4">presyncope or </text>
<text top="522" left="514" width="86" height="20" font="4">syncope or VF. </text>
<text top="539" left="514" width="33" height="20" font="4">SCD  </text>
<text top="350" left="628" width="206" height="20" font="4">● During a median follow-up of 5.6 y, </text>
<text top="367" left="628" width="219" height="20" font="4">sustained VT occurred in 9 pts and was </text>
<text top="384" left="628" width="213" height="20" font="4">predicted by CMR RVOT akinetic area </text>
<text top="401" left="628" width="180" height="20" font="4">length (cut off value 30 mm) and </text>
<text top="418" left="628" width="100" height="20" font="4">decreased RVEF. </text>
<text top="350" left="874" width="170" height="20" font="4">● RVOT akinetic region length </text>
<text top="367" left="874" width="168" height="20" font="4">predicts ventricular arrhythmia </text>
<text top="384" left="874" width="157" height="20" font="4">in late follow-up of surgically </text>
<text top="401" left="874" width="80" height="20" font="4">repaired TOF. </text>
<text top="557" left="64" width="86" height="20" font="4">Diller GP, et al. </text>
<text top="574" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(497)</a> </text>
<text top="591" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22496160?dopt=Citation">22496160</a></text>
<text top="591" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22496160?dopt=Citation"> </a></text>
<text top="557" left="165" width="58" height="20" font="4">n=413 pts </text>
<text top="574" left="165" width="59" height="20" font="4">not known </text>
<text top="591" left="165" width="51" height="20" font="4">TOF/PA  </text>
<text top="557" left="257" width="64" height="20" font="4">Multicenter </text>
<text top="574" left="257" width="74" height="20" font="4">retrospective </text>
<text top="591" left="257" width="70" height="20" font="4">cohort study </text>
<text top="557" left="355" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="574" left="355" width="131" height="20" font="4">Echocardiograph 2004–</text>
<text top="591" left="355" width="31" height="20" font="4">2010 </text>
<text top="557" left="514" width="81" height="20" font="4">Sustained VT, </text>
<text top="574" left="514" width="47" height="20" font="4">SCD, or </text>
<text top="591" left="514" width="90" height="20" font="4">appropriate ICD </text>
<text top="608" left="514" width="44" height="20" font="4">therapy </text>
<text top="557" left="628" width="235" height="20" font="4">● Pts were followed for a median of 2.9 y.  </text>
<text top="574" left="628" width="222" height="20" font="4">● On bi-variable analysis, mitral annular </text>
<text top="591" left="628" width="215" height="20" font="4">plane systolic excursion, and LV global </text>
<text top="608" left="628" width="203" height="20" font="4">longitudinal 2D strain were related to </text>
<text top="626" left="628" width="230" height="20" font="4">outcome. Independently of QRS duration. </text>
<text top="557" left="874" width="162" height="20" font="4">● LV longitudinal dysfunction </text>
<text top="574" left="874" width="178" height="20" font="4">was associated with greater risk </text>
<text top="591" left="874" width="90" height="20" font="4">of VA and SCD. </text>
<text top="644" left="64" width="85" height="20" font="4">Broberg CS, et </text>
<text top="661" left="64" width="16" height="20" font="4">al. </text>
<text top="678" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(498)</a> </text>
<text top="695" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21349477?dopt=Citation">21349477</a></text>
<text top="695" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21349477?dopt=Citation"> </a></text>
<text top="644" left="165" width="61" height="20" font="4">n=511 pts, </text>
<text top="661" left="165" width="59" height="20" font="4">not known </text>
<text top="678" left="165" width="51" height="20" font="4">TOF/PA  </text>
<text top="644" left="257" width="82" height="20" font="4">Retrospective, </text>
<text top="661" left="257" width="64" height="20" font="4">multicenter </text>
<text top="678" left="257" width="85" height="20" font="4">cross-sectional </text>
<text top="644" left="354" width="130" height="20" font="3"><b>Inclusion criteria</b>: Age </text>
<text top="661" left="354" width="93" height="20" font="4">≥18 y, adequate </text>
<text top="678" left="354" width="147" height="20" font="4">echocardiographic images </text>
<text top="695" left="354" width="3" height="20" font="4"> </text>
<text top="712" left="354" width="129" height="20" font="3"><b>Exclusion criteria</b>: PA </text>
<text top="730" left="354" width="106" height="20" font="4">with VSD, complex </text>
<text top="747" left="354" width="76" height="20" font="4">abnormalities </text>
<text top="644" left="514" width="62" height="20" font="4">LV systolic </text>
<text top="661" left="514" width="69" height="20" font="4">dysfunction  </text>
<text top="644" left="628" width="207" height="20" font="4">● LV systolic dysfunction prevalent in </text>
<text top="661" left="628" width="228" height="20" font="4">20.9%, with moderate/severe dysfunction </text>
<text top="678" left="628" width="200" height="20" font="4">in 6.3%; VT was more common with </text>
<text top="695" left="628" width="224" height="20" font="4">moderate or severe LV dysfunction (OR: </text>
<text top="712" left="628" width="80" height="20" font="4">2.3; p=0.030). </text>
<text top="644" left="874" width="148" height="20" font="4">● VT is associated with an </text>
<text top="661" left="874" width="175" height="20" font="4">LVEF &lt;45% in adults with TOF. </text>
</page>
<page number="134" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="16" size="12" family="Times" color="#292526"/>
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 134 </text>
<text top="107" left="64" width="75" height="20" font="4">Ortega, M, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(499)</a> </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21414597?dopt=Citation">21414597</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21414597?dopt=Citation"> </a></text>
<text top="107" left="165" width="75" height="20" font="4">n=39 pts, not </text>
<text top="124" left="165" width="39" height="20" font="4">known </text>
<text top="141" left="165" width="51" height="20" font="4">TOF/PA  </text>
<text top="107" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="124" left="257" width="38" height="20" font="4">cohort </text>
<text top="107" left="356" width="137" height="20" font="3"><b>Inclusion criteria</b>: CMR </text>
<text top="124" left="356" width="143" height="20" font="4">&gt;10 y between repair and </text>
<text top="141" left="356" width="31" height="20" font="4">CMR </text>
<text top="107" left="514" width="92" height="20" font="4">Sustained VT or </text>
<text top="124" left="514" width="34" height="20" font="4">death </text>
<text top="107" left="628" width="116" height="20" font="4">● LV dyssynchrony.  </text>
<text top="107" left="874" width="155" height="20" font="4">● Tissue tracking applied to </text>
<text top="124" left="874" width="172" height="20" font="4">CMR images identifies indexes </text>
<text top="141" left="874" width="179" height="20" font="4">of LV synchrony associated with </text>
<text top="159" left="874" width="135" height="20" font="4">death and VT in pts with </text>
<text top="176" left="874" width="80" height="20" font="4">repaired TOF. </text>
<text top="206" left="64" width="83" height="20" font="4">Khairy P, et al. </text>
<text top="224" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(500)</a> </text>
<text top="241" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20713900?dopt=Citation">20713900</a></text>
<text top="241" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20713900?dopt=Citation"> </a></text>
<text top="206" left="165" width="61" height="20" font="4">n=556 pts, </text>
<text top="224" left="165" width="32" height="20" font="4">8.1% </text>
<text top="241" left="165" width="48" height="20" font="4">TOF/PA </text>
<text top="206" left="257" width="82" height="20" font="4">Retrospective, </text>
<text top="224" left="257" width="67" height="20" font="4">multicenter, </text>
<text top="241" left="257" width="89" height="20" font="4">cross-sectional  </text>
<text top="206" left="356" width="130" height="20" font="3"><b>Inclusion criteria</b>: Age </text>
<text top="224" left="356" width="35" height="20" font="4">≥18 y </text>
<text top="241" left="356" width="3" height="20" font="4"> </text>
<text top="258" left="356" width="129" height="20" font="3"><b>Exclusion criteria</b>: PA </text>
<text top="275" left="356" width="106" height="20" font="4">with VSD, complex </text>
<text top="292" left="356" width="76" height="20" font="4">abnormalities </text>
<text top="206" left="514" width="79" height="20" font="4">Atrial and VA  </text>
<text top="206" left="628" width="186" height="20" font="4">● VT was prevalent in 14.6% and </text>
<text top="224" left="628" width="226" height="20" font="4">independently associated with number of </text>
<text top="241" left="628" width="214" height="20" font="4">cardiac surgeries (OR: 1.3), QRS (OR: </text>
<text top="258" left="628" width="211" height="20" font="4">1.02 per 1 mo), and LV DD (OR: 3.3).  </text>
<text top="275" left="628" width="233" height="20" font="4">● Prevalence markedly increased after 45 </text>
<text top="292" left="628" width="13" height="20" font="4">y. </text>
<text top="206" left="874" width="166" height="20" font="4">● Prevalence of VT increases </text>
<text top="224" left="874" width="169" height="20" font="4">with age (especially over 45 y) </text>
<text top="241" left="874" width="152" height="20" font="4">and is associated with prior </text>
<text top="258" left="874" width="130" height="20" font="4">cardiac surgeries, QRS </text>
<text top="275" left="874" width="141" height="20" font="4">duration, and LV diastolic </text>
<text top="292" left="874" width="69" height="20" font="4">dysfunction. </text>
<text top="310" left="64" width="69" height="20" font="4">Lu JC, et al. </text>
<text top="328" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(501)</a> </text>
<text top="345" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21126623?dopt=Citation">21126623</a></text>
<text top="345" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21126623?dopt=Citation"> </a></text>
<text top="310" left="165" width="75" height="20" font="4">n=62 pts, not </text>
<text top="328" left="165" width="39" height="20" font="4">known </text>
<text top="345" left="165" width="51" height="20" font="4">TOF/PA  </text>
<text top="310" left="257" width="36" height="20" font="4">Cross-</text>
<text top="328" left="257" width="52" height="20" font="4">sectional </text>
<text top="310" left="356" width="130" height="20" font="3"><b>Inclusion criteria</b>: Age </text>
<text top="328" left="356" width="134" height="20" font="4">&gt;14 y, CMR 2008–2009 </text>
<text top="345" left="356" width="3" height="20" font="4"> </text>
<text top="362" left="356" width="141" height="20" font="3"><b>Exclusion criteria</b>: AVC, </text>
<text top="379" left="356" width="117" height="20" font="4">cognit<b>i</b>ve impairment </text>
<text top="310" left="514" width="29" height="20" font="4">QOL </text>
<text top="310" left="628" width="78" height="20" font="4">● Low RVEF. </text>
<text top="328" left="628" width="117" height="20" font="4">● Age at repair &gt;1 y. </text>
<text top="310" left="874" width="175" height="20" font="4">● RVEF and age of repair were </text>
<text top="328" left="874" width="161" height="20" font="4">the best predictors of QOL in </text>
<text top="345" left="874" width="160" height="20" font="4">this population, in whom end-</text>
<text top="362" left="874" width="145" height="20" font="4">diastolic forward flow; and </text>
<text top="379" left="874" width="176" height="20" font="4">associated diastolic parameters </text>
<text top="396" left="874" width="123" height="20" font="4">appeared to reflect an </text>
<text top="414" left="874" width="168" height="20" font="4">overdistended ventricle, which </text>
<text top="431" left="874" width="162" height="20" font="4">might suggest a role for early </text>
<text top="448" left="874" width="94" height="20" font="4">PV replacement. </text>
<text top="466" left="64" width="87" height="20" font="4">Wald RM, et al. </text>
<text top="483" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(502)</a> </text>
<text top="500" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19255342?dopt=Citation">19255342</a></text>
<text top="500" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19255342?dopt=Citation"> </a></text>
<text top="466" left="165" width="75" height="20" font="4">n=62 pts, not </text>
<text top="483" left="165" width="39" height="20" font="4">known </text>
<text top="500" left="165" width="51" height="20" font="4">TOF/PA  </text>
<text top="466" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="483" left="257" width="40" height="20" font="4">Cohort </text>
<text top="466" left="356" width="137" height="20" font="3"><b>Inclusion criteria</b>: CMR </text>
<text top="483" left="356" width="3" height="20" font="4"> </text>
<text top="500" left="356" width="128" height="20" font="3"><b>Exclusion criteria</b>: No </text>
<text top="518" left="356" width="76" height="20" font="4">follow-up, PV </text>
<text top="535" left="356" width="141" height="20" font="4">replacement before CMR </text>
<text top="466" left="514" width="41" height="20" font="4">Peak O</text>
<text top="472" left="555" width="4" height="13" font="6">2</text>
<text top="466" left="560" width="3" height="20" font="4"> </text>
<text top="483" left="514" width="73" height="20" font="4">consumption </text>
<text top="466" left="628" width="136" height="20" font="4">● Decreased RVOT EF. </text>
<text top="466" left="874" width="164" height="20" font="4">● A greater extent of regional </text>
<text top="483" left="874" width="148" height="20" font="4">abnormalities in the RVOT </text>
<text top="500" left="874" width="152" height="20" font="4">adversely affects global RV </text>
<text top="518" left="874" width="168" height="20" font="4">function and exercise capacity </text>
<text top="535" left="874" width="91" height="20" font="4">after TOF repair </text>
<text top="553" left="64" width="75" height="20" font="4">Hickey EJ, et </text>
<text top="570" left="64" width="16" height="20" font="4">al. </text>
<text top="587" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(503)</a> </text>
<text top="604" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18848456?dopt=Citation">18848456</a></text>
<text top="604" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18848456?dopt=Citation"> </a></text>
<text top="553" left="165" width="71" height="20" font="4">n=1,181 pts, </text>
<text top="570" left="165" width="46" height="20" font="4">81 (8%) </text>
<text top="587" left="165" width="48" height="20" font="4">TOF/PA </text>
<text top="553" left="257" width="53" height="20" font="4">Inception </text>
<text top="570" left="257" width="38" height="20" font="4">cohort </text>
<text top="553" left="356" width="123" height="20" font="3"><b>Inclusion criteria</b>: All-</text>
<text top="570" left="356" width="144" height="20" font="4">inclusive inception, cohort </text>
<text top="587" left="356" width="141" height="20" font="4">of children with TOF born </text>
<text top="604" left="356" width="73" height="20" font="4">prior to 1984 </text>
<text top="622" left="356" width="3" height="20" font="4"> </text>
<text top="639" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="656" left="356" width="49" height="20" font="4">PA/VSD </text>
<text top="553" left="514" width="40" height="20" font="4">Death, </text>
<text top="570" left="514" width="89" height="20" font="4">reoperation, PV </text>
<text top="587" left="514" width="71" height="20" font="4">replacement </text>
<text top="553" left="628" width="220" height="20" font="4">● Pulmonary atresia variant (n=88) was </text>
<text top="570" left="628" width="219" height="20" font="4">associated with 3-fold higher late risk of </text>
<text top="587" left="628" width="190" height="20" font="4">death than classic TOF (n=1069).  </text>
<text top="604" left="628" width="227" height="20" font="4">● Presence of associated branch PAS or </text>
<text top="622" left="628" width="194" height="20" font="4">AVSD conferred a less optimal late </text>
<text top="639" left="628" width="60" height="20" font="4">prognosis. </text>
<text top="553" left="874" width="161" height="20" font="4">● Reduction of early surgical </text>
<text top="570" left="874" width="170" height="20" font="4">mortality to &lt;2% is responsible </text>
<text top="587" left="874" width="173" height="20" font="4">for excellent late survival &gt;90% </text>
<text top="604" left="874" width="40" height="20" font="4">overall </text>
<text top="674" left="64" width="77" height="20" font="4">Rosianu S, et </text>
<text top="691" left="64" width="16" height="20" font="4">al. </text>
<text top="708" left="64" width="66" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(504)</a>  </text>
<text top="726" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18611966?dopt=Citation">18611966</a></text>
<text top="726" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18611966?dopt=Citation"> </a></text>
<text top="674" left="165" width="71" height="20" font="4">n=52 pts not </text>
<text top="691" left="165" width="39" height="20" font="4">known </text>
<text top="708" left="165" width="48" height="20" font="4">TOF/PA </text>
<text top="674" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="691" left="257" width="38" height="20" font="4">cohort </text>
<text top="674" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="691" left="356" width="71" height="20" font="16">Adults, ECG </text>
<text top="674" left="514" width="75" height="20" font="4">Atrial and VA </text>
<text top="674" left="628" width="216" height="20" font="4">● In univariate analyses of pts with VT, </text>
<text top="691" left="628" width="191" height="20" font="4">LVEDD, left arterial size, and QRS </text>
<text top="708" left="628" width="221" height="20" font="4">duration are significantly higher than pts </text>
<text top="726" left="628" width="68" height="20" font="4">without VT.  </text>
<text top="674" left="874" width="179" height="20" font="4">● VT is associated with LVEDD, </text>
<text top="691" left="874" width="143" height="20" font="4">left arterial size, and QRS </text>
<text top="708" left="874" width="173" height="20" font="4">duration in univariate analyses. </text>
<text top="744" left="64" width="78" height="20" font="4">Knauth AL, et </text>
<text top="761" left="64" width="16" height="20" font="4">al. </text>
<text top="744" left="165" width="71" height="20" font="4">n=88 pts, 29 </text>
<text top="761" left="165" width="48" height="20" font="4">TOF/PA </text>
<text top="744" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="761" left="257" width="38" height="20" font="4">cohort </text>
<text top="744" left="356" width="131" height="20" font="3"><b>Inclusion criteria</b>: Sub-</text>
<text top="761" left="356" width="127" height="20" font="4">study of Geva T, et al., </text>
<text top="778" left="356" width="63" height="20" font="4">2004 (507)<a href="http://www.ncbi.nlm.nih.gov/pubmed/15028368?dopt=Citation"> </a></text>
<text top="778" left="419" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15028368?dopt=Citation">15028368 </a></text>
<text top="744" left="514" width="76" height="20" font="4">Composite of </text>
<text top="761" left="514" width="78" height="20" font="4">sustained VT, </text>
<text top="744" left="628" width="90" height="20" font="4">● RVEDV z ≥7. </text>
<text top="761" left="628" width="85" height="20" font="4">● LVEF &lt;55%. </text>
<text top="778" left="628" width="87" height="20" font="4">● RVEF &lt;45%. </text>
<text top="744" left="874" width="152" height="20" font="4">● Severe RV dilatation and </text>
<text top="761" left="874" width="153" height="20" font="4">either LV or RV dysfunction </text>
</page>
<page number="135" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 135 </text>
<text top="107" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(505)</a> </text>
<text top="124" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17135219?dopt=Citation">17135219</a></text>
<text top="124" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17135219?dopt=Citation"> </a></text>
<text top="107" left="356" width="3" height="20" font="4"> </text>
<text top="124" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="141" left="356" width="116" height="20" font="4">Incomplete follow-up </text>
<text top="107" left="514" width="92" height="20" font="4">death, decrease </text>
<text top="124" left="514" width="69" height="20" font="4">NYHA class </text>
<text top="107" left="874" width="157" height="20" font="4">assessed by CMR predicted </text>
<text top="124" left="874" width="165" height="20" font="4">major adverse clinical events. </text>
<text top="159" left="64" width="83" height="20" font="4">Khairy P, et al. </text>
<text top="177" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(506)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18172030?dopt=Citation">18172030</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18172030?dopt=Citation"> </a></text>
<text top="159" left="165" width="61" height="20" font="4">n=121 pts, </text>
<text top="177" left="165" width="59" height="20" font="4">not known </text>
<text top="194" left="165" width="48" height="20" font="4">TOF/PA </text>
<text top="159" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="177" left="257" width="38" height="20" font="4">cohort </text>
<text top="194" left="257" width="64" height="20" font="4">multicenter </text>
<text top="211" left="257" width="25" height="20" font="4">(11) </text>
<text top="159" left="356" width="130" height="20" font="3"><b>Inclusion criteria</b>: ICD </text>
<text top="177" left="356" width="126" height="20" font="4">implanted before 2006 </text>
<text top="194" left="356" width="3" height="20" font="4"> </text>
<text top="211" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="228" left="356" width="124" height="20" font="4">Unrepaired TOF, AVC </text>
<text top="159" left="514" width="60" height="20" font="4">ICD shock </text>
<text top="159" left="628" width="128" height="20" font="4">● LVEDP ≥12 mm Hg. </text>
<text top="177" left="628" width="114" height="20" font="4">● Nonsustained VT. </text>
<text top="159" left="874" width="121" height="20" font="4">● Factors that predict </text>
<text top="177" left="874" width="136" height="20" font="4">appropriate shocks in 1° </text>
<text top="194" left="874" width="167" height="20" font="4">prevention ICD recipients with </text>
<text top="211" left="874" width="31" height="20" font="4">TOF. </text>
<text top="246" left="64" width="83" height="20" font="4">Babu-Narayan </text>
<text top="263" left="64" width="53" height="20" font="4">SV, et al. </text>
<text top="281" left="64" width="66" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(507)</a>  </text>
<text top="298" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16432072?dopt=Citation">16432072</a></text>
<text top="298" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16432072?dopt=Citation"> </a></text>
<text top="246" left="165" width="75" height="20" font="4">n=92 pts, not </text>
<text top="263" left="165" width="39" height="20" font="4">known </text>
<text top="281" left="165" width="48" height="20" font="4">TOF/PA </text>
<text top="246" left="257" width="36" height="20" font="4">Cross-</text>
<text top="263" left="257" width="52" height="20" font="4">sectional </text>
<text top="246" left="356" width="143" height="20" font="3"><b>Inclusion criteria</b>: ACHD </text>
<text top="263" left="356" width="96" height="20" font="4">clinic 2002–2005 </text>
<text top="281" left="356" width="3" height="20" font="4"> </text>
<text top="298" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="315" left="356" width="72" height="20" font="4">Pacemakers </text>
<text top="246" left="514" width="3" height="20" font="4"> </text>
<text top="246" left="628" width="122" height="20" font="4">● Older age at repair. </text>
<text top="263" left="628" width="182" height="20" font="4">● Decreased exercise tolerance. </text>
<text top="281" left="628" width="207" height="20" font="4">● Increased neurohormonal markers, </text>
<text top="298" left="628" width="111" height="20" font="4">clinical arrhythmias. </text>
<text top="246" left="874" width="161" height="20" font="4">● RV and LV late gadolinium </text>
<text top="263" left="874" width="172" height="20" font="4">were common after TOF repair </text>
<text top="281" left="874" width="156" height="20" font="4">and were related to adverse </text>
<text top="298" left="874" width="143" height="20" font="4">clinical markers, including </text>
<text top="315" left="874" width="178" height="20" font="4">ventricular dysfunction, exercise </text>
<text top="332" left="874" width="177" height="20" font="4">intolerance, and neurohormonal </text>
<text top="350" left="874" width="59" height="20" font="4">activation. </text>
<text top="367" left="874" width="161" height="20" font="4">● Furthermore, RV LGE was </text>
<text top="384" left="874" width="154" height="20" font="4">significantly associated with </text>
<text top="401" left="874" width="105" height="20" font="4">clinical arrhythmia. </text>
<text top="419" left="64" width="83" height="20" font="4">Khairy P, et al. </text>
<text top="436" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(508)</a> </text>
<text top="454" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15051640?dopt=Citation">15051640</a></text>
<text top="454" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15051640?dopt=Citation"> </a></text>
<text top="419" left="165" width="58" height="20" font="4">n=252 pts </text>
<text top="419" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="436" left="257" width="38" height="20" font="4">cohort </text>
<text top="454" left="257" width="82" height="20" font="4">multicenter (6) </text>
<text top="419" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="436" left="356" width="135" height="20" font="4">Programmed ventricular </text>
<text top="454" left="356" width="112" height="20" font="4">stimulation between </text>
<text top="471" left="356" width="65" height="20" font="4">1985–2002 </text>
<text top="488" left="356" width="3" height="20" font="4"> </text>
<text top="505" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="522" left="356" width="119" height="20" font="4">Unrepaired TOF, PA, </text>
<text top="540" left="356" width="29" height="20" font="4">AVC </text>
<text top="419" left="514" width="76" height="20" font="4">Composite of </text>
<text top="436" left="514" width="89" height="20" font="4">sustained VT or </text>
<text top="454" left="514" width="29" height="20" font="4">SCD </text>
<text top="419" left="628" width="215" height="20" font="4">● Age at EPS ≥18 y, palpitations, prior </text>
<text top="436" left="628" width="204" height="20" font="4">palliative surgery, modified Lown ≥2, </text>
<text top="454" left="628" width="139" height="20" font="4">cardiothoracic ratio ≥0.6. </text>
<text top="419" left="874" width="147" height="20" font="4">● Programmed ventricular </text>
<text top="436" left="874" width="171" height="20" font="4">stimulation is of diagnostic and </text>
<text top="454" left="874" width="128" height="20" font="4">prognostic value in risk </text>
<text top="471" left="874" width="150" height="20" font="4">stratifying pts with repaired </text>
<text top="488" left="874" width="31" height="20" font="4">TOF. </text>
<text top="558" left="64" width="77" height="20" font="4">Geva T, et al. </text>
<text top="575" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(509)</a> </text>
<text top="592" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15028368?dopt=Citation">15028368</a></text>
<text top="592" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15028368?dopt=Citation"> </a></text>
<text top="558" left="165" width="78" height="20" font="4">n=100 pts; 29 </text>
<text top="575" left="165" width="48" height="20" font="4">TOF/PA </text>
<text top="558" left="257" width="36" height="20" font="4">Cross-</text>
<text top="575" left="257" width="52" height="20" font="4">sectional </text>
<text top="558" left="356" width="139" height="20" font="3"><b>Inclusion criteria</b>: &gt;10 y </text>
<text top="575" left="356" width="135" height="20" font="4">after repair, CMR, 1997–</text>
<text top="592" left="356" width="31" height="20" font="4">2001 </text>
<text top="609" left="356" width="3" height="20" font="4"> </text>
<text top="626" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="644" left="356" width="139" height="20" font="4">Incomplete clinical follow-</text>
<text top="661" left="356" width="17" height="20" font="4">up </text>
<text top="558" left="514" width="58" height="20" font="4">NYHA &gt;III </text>
<text top="558" left="628" width="122" height="20" font="4">● Older age at repair. </text>
<text top="575" left="628" width="148" height="20" font="4">● Decreased LV or RVEF. </text>
<text top="592" left="628" width="212" height="20" font="4">● Increased RV mass-to-volume ratio. </text>
<text top="558" left="874" width="24" height="20" font="4">N/A </text>
<text top="679" left="64" width="82" height="20" font="4">Davlouros PA, </text>
<text top="696" left="64" width="30" height="20" font="4">et al. </text>
<text top="713" left="64" width="63" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(510)</a> </text>
<text top="730" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12475468?dopt=Citation">12475468</a></text>
<text top="730" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12475468?dopt=Citation"> </a></text>
<text top="679" left="165" width="51" height="20" font="4">n=26 pts </text>
<text top="696" left="165" width="64" height="20" font="4">control, not </text>
<text top="713" left="165" width="39" height="20" font="4">known </text>
<text top="730" left="165" width="48" height="20" font="4">TOF/PA </text>
<text top="679" left="257" width="36" height="20" font="4">Cross-</text>
<text top="696" left="257" width="54" height="20" font="4">Sectional </text>
<text top="679" left="356" width="130" height="20" font="3"><b>Inclusion criteria</b>: Age </text>
<text top="696" left="356" width="35" height="20" font="4">≥15 y </text>
<text top="713" left="356" width="3" height="20" font="4"> </text>
<text top="730" left="356" width="129" height="20" font="3"><b>Exclusion criteria</b>: PV </text>
<text top="748" left="356" width="71" height="20" font="4">replacement </text>
<text top="679" left="514" width="85" height="20" font="4">RV wall motion </text>
<text top="679" left="628" width="213" height="20" font="4">● Pts had larger CMR volumes, mass, </text>
<text top="696" left="628" width="79" height="20" font="4">and lower EF. </text>
<text top="679" left="874" width="152" height="20" font="4">● PR and RVOT aneurysm </text>
<text top="696" left="874" width="172" height="20" font="4">were independently associated </text>
<text top="713" left="874" width="95" height="20" font="4">with RV dilation.  </text>
<text top="766" left="64" width="75" height="20" font="4">Ghai A, et al. </text>
<text top="766" left="165" width="78" height="20" font="4">n=137 pts; 12 </text>
<text top="783" left="165" width="56" height="20" font="4">cases not </text>
<text top="766" left="257" width="73" height="20" font="4">Case-control </text>
<text top="766" left="356" width="133" height="20" font="3"><b>Inclusion criteria</b>: TOF </text>
<text top="783" left="356" width="3" height="20" font="4"> </text>
<text top="766" left="514" width="29" height="20" font="4">SCD </text>
<text top="766" left="628" width="167" height="20" font="4">● ≥ Moderate LV dysfunction. </text>
<text top="783" left="628" width="81" height="20" font="4">QRS duration. </text>
<text top="766" left="874" width="174" height="20" font="4">● The combination of QRS 180 </text>
<text top="783" left="874" width="165" height="20" font="4">mo and significant LV systolic </text>
</page>
<page number="136" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 136 </text>
<text top="107" left="64" width="63" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(511)</a> </text>
<text top="124" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12427422?dopt=Citationv">12427422</a></text>
<text top="124" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12427422?dopt=Citationv"> </a></text>
<text top="107" left="165" width="39" height="20" font="4">known </text>
<text top="124" left="165" width="51" height="20" font="4">TOF/PA  </text>
<text top="107" left="356" width="109" height="20" font="3"><b>Exclusion criteri</b>a: </text>
<text top="124" left="356" width="102" height="20" font="4">Death before 30 d </text>
<text top="141" left="356" width="121" height="20" font="4">following initial repair; </text>
<text top="159" left="356" width="116" height="20" font="4">incomplete follow-up </text>
<text top="107" left="874" width="161" height="20" font="4">dysfunction has high positive </text>
<text top="124" left="874" width="103" height="20" font="4">and NPV for SCD. </text>
<text top="177" left="64" width="75" height="20" font="4">Bacha EA, et </text>
<text top="194" left="64" width="16" height="20" font="4">al. </text>
<text top="211" left="64" width="63" height="20" font="4">2001 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(512)</a> </text>
<text top="228" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11436049?dopt=Citation">11436049</a></text>
<text top="228" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11436049?dopt=Citation"> </a></text>
<text top="177" left="165" width="51" height="20" font="4">n=57 pts </text>
<text top="177" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="194" left="257" width="38" height="20" font="4">cohort </text>
<text top="177" left="356" width="121" height="20" font="3"><b>Inclusion criteria</b>: 1° </text>
<text top="194" left="356" width="119" height="20" font="4">repair between 1972–</text>
<text top="211" left="356" width="142" height="20" font="4">1977 prior to less than 24 </text>
<text top="228" left="356" width="119" height="20" font="4">mo at time of primary </text>
<text top="246" left="356" width="35" height="20" font="4">repair </text>
<text top="263" left="356" width="3" height="20" font="4"> </text>
<text top="280" left="356" width="139" height="20" font="3"><b>Exclusion criteria</b>: Prior </text>
<text top="297" left="356" width="134" height="20" font="4">shunts, TOF/PA, absent </text>
<text top="314" left="356" width="52" height="20" font="4">PV, AVC </text>
<text top="177" left="514" width="36" height="20" font="4">Death </text>
<text top="177" left="628" width="100" height="20" font="4">● Early death (8). </text>
<text top="194" left="628" width="96" height="20" font="4">● Late death (1). </text>
<text top="177" left="874" width="147" height="20" font="4">● No difference in survival </text>
<text top="194" left="874" width="179" height="20" font="4">between transannular patch and </text>
<text top="211" left="874" width="122" height="20" font="4">nontransanular patch. </text>
<text top="332" left="64" width="80" height="20" font="4">Gatzoulis MA, </text>
<text top="350" left="64" width="30" height="20" font="4">et al. </text>
<text top="367" left="64" width="63" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(513)</a> </text>
<text top="384" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11041398?dopt=Citation">11041398</a></text>
<text top="384" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11041398?dopt=Citation"> </a></text>
<text top="332" left="165" width="58" height="20" font="4">n=793 pts </text>
<text top="332" left="257" width="79" height="20" font="4">Retrospective </text>
<text top="332" left="356" width="122" height="20" font="3"><b>Inclusion criteria</b>: All </text>
<text top="350" left="356" width="124" height="20" font="4">rTOF pts alive in 1985 </text>
<text top="367" left="356" width="3" height="20" font="4"> </text>
<text top="384" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="401" left="356" width="136" height="20" font="4">TOF/PA, complete heart </text>
<text top="418" left="356" width="82" height="20" font="4">block (9); prior </text>
<text top="436" left="356" width="86" height="20" font="4">arrhythmias (2) </text>
<text top="332" left="514" width="93" height="20" font="4">Arrhythmias and </text>
<text top="350" left="514" width="29" height="20" font="4">SCD </text>
<text top="332" left="628" width="60" height="20" font="4">● VT (33). </text>
<text top="350" left="628" width="71" height="20" font="4">● SCD (16). </text>
<text top="367" left="628" width="60" height="20" font="4">● AF (29). </text>
<text top="332" left="874" width="146" height="20" font="4">● QRS duration ≥180 ms. </text>
<text top="350" left="874" width="122" height="20" font="4">● Older age at repair. </text>
<text top="367" left="874" width="125" height="20" font="4">● Transannular patch. </text>
<text top="454" left="64" width="85" height="20" font="4">Nollert G, et al. </text>
<text top="471" left="64" width="63" height="20" font="4">1997 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(514)</a> </text>
<text top="488" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9323819?dopt=Citation">9323819</a></text>
<text top="488" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9323819?dopt=Citation"> </a></text>
<text top="454" left="165" width="58" height="20" font="4">n=490 pts </text>
<text top="454" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="471" left="257" width="38" height="20" font="4">cohort </text>
<text top="454" left="356" width="137" height="20" font="3"><b>Inclusion criteria</b>: rTOF </text>
<text top="471" left="356" width="139" height="20" font="4">1958–1977, University of </text>
<text top="488" left="356" width="43" height="20" font="4">Munich </text>
<text top="505" left="356" width="3" height="20" font="4"> </text>
<text top="522" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="540" left="356" width="48" height="20" font="4">TOF/PA </text>
<text top="454" left="514" width="24" height="20" font="4">N/A </text>
<text top="454" left="628" width="232" height="20" font="4">● Mortality increased 25 y postoperatively </text>
<text top="471" left="628" width="111" height="20" font="4">from 0.24%–0.94%. </text>
<text top="454" left="874" width="161" height="20" font="4">● Preoperative polycythemia </text>
<text top="471" left="874" width="75" height="20" font="4">RVOT patch. </text>
<text top="488" left="874" width="132" height="20" font="4">● Date of repair &lt;1970. </text>
<text top="558" left="64" width="87" height="20" font="4">Harrison DA, et </text>
<text top="575" left="64" width="16" height="20" font="4">al. </text>
<text top="592" left="64" width="63" height="20" font="4">1997 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(515)</a> </text>
<text top="609" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9350941?dopt=Citation">9350941</a></text>
<text top="609" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9350941?dopt=Citation"> </a></text>
<text top="558" left="165" width="78" height="20" font="4">n=210 pts; 18 </text>
<text top="575" left="165" width="36" height="20" font="4">cases </text>
<text top="592" left="165" width="59" height="20" font="4">not known </text>
<text top="609" left="165" width="51" height="20" font="4">TOF/PA  </text>
<text top="558" left="257" width="73" height="20" font="4">Case control </text>
<text top="558" left="356" width="139" height="20" font="3"><b>Inclusion criteria</b>: 1990–</text>
<text top="575" left="356" width="90" height="20" font="4">1994 at Toronto </text>
<text top="592" left="356" width="3" height="20" font="4"> </text>
<text top="609" left="356" width="141" height="20" font="3"><b>Exclusion criteria</b>: Atrial </text>
<text top="626" left="356" width="125" height="20" font="4">arrhythmia (17), PVCs </text>
<text top="644" left="356" width="123" height="20" font="4">(11), prior tachycardia </text>
<text top="661" left="356" width="25" height="20" font="4">(16) </text>
<text top="558" left="514" width="67" height="20" font="4">1) VT &gt;30 s </text>
<text top="575" left="514" width="81" height="20" font="4">2) Palpitations </text>
<text top="592" left="514" width="89" height="20" font="4">with syncope or </text>
<text top="609" left="514" width="78" height="20" font="4">near-syncope </text>
<text top="558" left="628" width="145" height="20" font="4">● Frequent ectopic beats. </text>
<text top="575" left="628" width="58" height="20" font="4">● Low CI. </text>
<text top="592" left="628" width="111" height="20" font="4">● RVOT aneurysm. </text>
<text top="609" left="628" width="134" height="20" font="4">● ≥Moderate TR or PR. </text>
<text top="558" left="874" width="138" height="20" font="4">● ≥ Moderate TR or PR. </text>
<text top="575" left="874" width="111" height="20" font="4">● RVOT aneurysm. </text>
<text top="679" left="64" width="80" height="20" font="4">Gatzoulis MA, </text>
<text top="696" left="64" width="30" height="20" font="4">et al. </text>
<text top="713" left="64" width="63" height="20" font="4">1995 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(516)</a> </text>
<text top="730" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7600655?dopt=Citation">7600655</a></text>
<text top="730" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7600655?dopt=Citation"> </a></text>
<text top="679" left="165" width="58" height="20" font="4">n=178 pts </text>
<text top="679" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="696" left="257" width="38" height="20" font="4">cohort </text>
<text top="679" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="696" left="356" width="131" height="20" font="4">Surgery between 1958–</text>
<text top="713" left="356" width="31" height="20" font="4">1979 </text>
<text top="730" left="356" width="3" height="20" font="4"> </text>
<text top="748" left="356" width="144" height="20" font="3"><b>Exclusion criteria</b>: &lt;15-y </text>
<text top="765" left="356" width="53" height="20" font="4">follow-up </text>
<text top="679" left="514" width="19" height="20" font="4">VT </text>
<text top="679" left="628" width="53" height="20" font="4">● VT (9). </text>
<text top="696" left="628" width="96" height="20" font="4">● RVRP (20/41). </text>
<text top="679" left="874" width="87" height="20" font="4">● QRS&gt;180 m. </text>
</page>
<page number="137" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 137 </text>
<text top="107" left="64" width="81" height="20" font="4">Murphy JG, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="63" height="20" font="4">1993 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(517)</a> </text>
<text top="159" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7688102?dopt=Citation">7688102</a></text>
<text top="159" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7688102?dopt=Citation"> </a></text>
<text top="107" left="165" width="58" height="20" font="4">n=163 pts </text>
<text top="107" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="124" left="257" width="38" height="20" font="4">cohort </text>
<text top="107" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="356" width="132" height="20" font="4">Surgical repair between </text>
<text top="141" left="356" width="139" height="20" font="4">1955 –1960, Mayo Clinic </text>
<text top="159" left="356" width="3" height="20" font="4"> </text>
<text top="176" left="356" width="131" height="20" font="3"><b>Exclusion criteria</b>: Did </text>
<text top="193" left="356" width="117" height="20" font="4">not survive 30 d post </text>
<text top="210" left="356" width="134" height="20" font="4">repair (50), international </text>
<text top="227" left="356" width="96" height="20" font="4">pts (33), CHB (5) </text>
<text top="107" left="514" width="24" height="20" font="4">N/A </text>
<text top="107" left="628" width="188" height="20" font="4">● 32-y actuarial survival rate 86% </text>
<text top="107" left="874" width="125" height="20" font="4">● Older age at repair.  </text>
<text top="124" left="874" width="152" height="20" font="4">● Increased RV:LV systolic </text>
<text top="141" left="874" width="82" height="20" font="4">pressure ratio. </text>
<text top="159" left="874" width="91" height="20" font="4">● History of HF. </text>
<text top="245" left="64" width="77" height="20" font="4">Mongeon FP, </text>
<text top="263" left="64" width="30" height="20" font="4">et al. </text>
<text top="280" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(398)</a> </text>
<text top="297" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23224208?dopt=Citation">23224208</a></text>
<text top="297" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23224208?dopt=Citation"> </a></text>
<text top="245" left="165" width="58" height="20" font="4">n=474 pts </text>
<text top="245" left="257" width="82" height="20" font="4">Retrospective, </text>
<text top="263" left="257" width="64" height="20" font="4">multicenter </text>
<text top="280" left="257" width="85" height="20" font="4">cross-sectional </text>
<text top="297" left="257" width="58" height="20" font="4">study (11) </text>
<text top="245" left="356" width="130" height="20" font="3"><b>Inclusion criteria</b>: Age </text>
<text top="263" left="356" width="93" height="20" font="4">≥18 y; adequate </text>
<text top="280" left="356" width="104" height="20" font="4">echocardiographic </text>
<text top="297" left="356" width="43" height="20" font="4">images </text>
<text top="314" left="356" width="3" height="20" font="4"> </text>
<text top="332" left="356" width="129" height="20" font="3"><b>Exclusion criteria</b>: PA </text>
<text top="349" left="356" width="106" height="20" font="4">with VSD, complex </text>
<text top="366" left="356" width="76" height="20" font="4">abnormalities </text>
<text top="245" left="514" width="60" height="20" font="4">Aortic size </text>
<text top="245" left="628" width="229" height="20" font="4">● The aortic root dimension was ≥40 mm </text>
<text top="263" left="628" width="193" height="20" font="4">in 28.9% (95% CI: 26.9%–30.9%).  </text>
<text top="280" left="628" width="194" height="20" font="4">● In multivariate analyses, the only </text>
<text top="297" left="628" width="232" height="20" font="4">independently associated factor was male </text>
<text top="314" left="628" width="198" height="20" font="4">sex (OR: 4.48; 95% CI: 1.55–12.89; </text>
<text top="332" left="628" width="175" height="20" font="4">p=0.006). The prevalence of an </text>
<text top="349" left="628" width="181" height="20" font="4">observed-to-expected aortic root </text>
<text top="366" left="628" width="222" height="20" font="4">dimension ratio &gt;1.5 was 6.6% (95% CI: </text>
<text top="383" left="628" width="197" height="20" font="4">5.3%–7.9%). It was associated with </text>
<text top="401" left="628" width="195" height="20" font="4">pulmonary atresia and moderate or </text>
<text top="418" left="628" width="215" height="20" font="4">severe aortic regurgitation in univariate </text>
<text top="435" left="628" width="215" height="20" font="4">analyses, but no independent predictor </text>
<text top="452" left="628" width="85" height="20" font="4">was identified.  </text>
<text top="469" left="628" width="224" height="20" font="4">● The prevalence of moderate or severe </text>
<text top="487" left="628" width="201" height="20" font="4">aortic root was 3.5% (95% CI: 2.7%–</text>
<text top="504" left="628" width="36" height="20" font="4">4.2%) </text>
<text top="245" left="874" width="172" height="20" font="4">● Although nearly 1/3 of adults </text>
<text top="263" left="874" width="149" height="20" font="4">with repaired TOF have an </text>
<text top="280" left="874" width="162" height="20" font="4">aortic root diameter ≥40 mm, </text>
<text top="297" left="874" width="148" height="20" font="4">the prevalence of a dilated </text>
<text top="314" left="874" width="172" height="20" font="4">aortic root, when defined by an </text>
<text top="332" left="874" width="157" height="20" font="4">indexed ratio of observed-to-</text>
<text top="349" left="874" width="137" height="20" font="4">expected values, is low.  </text>
<text top="366" left="874" width="176" height="20" font="4">● Similarly, moderate or severe </text>
<text top="383" left="874" width="138" height="20" font="4">aortic root is uncommon. </text>
<text top="522" left="64" width="79" height="20" font="4">Ait-Ali L, et al. </text>
<text top="539" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(518)</a> </text>
<text top="556" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25260437?dopt=Citation">25260437</a></text>
<text top="556" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25260437?dopt=Citation"> </a></text>
<text top="522" left="165" width="61" height="20" font="4">n=109 pts; </text>
<text top="539" left="165" width="50" height="20" font="4">9 (7.3%) </text>
<text top="556" left="165" width="48" height="20" font="4">TOF/PA </text>
<text top="522" left="257" width="67" height="20" font="4">Prospective </text>
<text top="539" left="257" width="50" height="20" font="4">study ex-</text>
<text top="556" left="257" width="78" height="20" font="4">echocardiogra</text>
<text top="573" left="257" width="58" height="20" font="4">phy CMR, </text>
<text top="591" left="257" width="68" height="20" font="4">CPET, BNP </text>
<text top="522" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="539" left="356" width="128" height="20" font="4">Consecutive pts, mean </text>
<text top="556" left="356" width="51" height="20" font="4">age 26 y </text>
<text top="573" left="356" width="3" height="20" font="4"> </text>
<text top="591" left="356" width="134" height="20" font="3"><b>Exclusion criteria</b>: Age </text>
<text top="608" left="356" width="127" height="20" font="4">&lt;10 y, contraindication </text>
<text top="625" left="356" width="143" height="20" font="4">CMR, complex anomalies </text>
<text top="642" left="356" width="37" height="20" font="4">(AVC) </text>
<text top="522" left="514" width="70" height="20" font="4">Death for all </text>
<text top="539" left="514" width="89" height="20" font="4">causes, cardiac </text>
<text top="556" left="514" width="38" height="20" font="4">death, </text>
<text top="573" left="514" width="88" height="20" font="4">development or </text>
<text top="591" left="514" width="81" height="20" font="4">progression of </text>
<text top="608" left="514" width="47" height="20" font="4">HF, and </text>
<text top="625" left="514" width="100" height="20" font="4">tachyarrhythmias. </text>
<text top="522" left="628" width="188" height="20" font="4">● Tricuspid annular plane systolic </text>
<text top="539" left="628" width="217" height="20" font="4">excursion increased significantly during </text>
<text top="556" left="628" width="224" height="20" font="4">peak exercise in responders from 17.2 ± </text>
<text top="573" left="628" width="179" height="20" font="4">3.4 mm at rest to 19.7 ± 4.3 mm </text>
<text top="591" left="628" width="223" height="20" font="4">(p&lt;0.0001) but did not in nonresponders </text>
<text top="608" left="628" width="234" height="20" font="4">(from 16.9 ± 4.7–18.1 ± 4.6 mm; p=0.20).  </text>
<text top="625" left="628" width="205" height="20" font="4">●LV end-diastolic volume at rest and </text>
<text top="642" left="628" width="214" height="20" font="4">LVEF &lt;50% were related to the lack of </text>
<text top="659" left="628" width="220" height="20" font="4">increased RV fractional area change on </text>
<text top="677" left="628" width="53" height="20" font="4">exercise. </text>
<text top="522" left="874" width="176" height="20" font="4">● Exercise echocardiography is </text>
<text top="539" left="874" width="152" height="20" font="4">feasible in pts with repaired </text>
<text top="556" left="874" width="168" height="20" font="4">TOF and allows the integrated </text>
<text top="573" left="874" width="166" height="20" font="4">assessment of variation in RV </text>
<text top="591" left="874" width="154" height="20" font="4">systolic pressure, area, and </text>
<text top="608" left="874" width="172" height="20" font="4">function during exercise, which </text>
<text top="625" left="874" width="147" height="20" font="4">usefully complement more </text>
<text top="642" left="874" width="128" height="20" font="4">conventional indices of </text>
<text top="659" left="874" width="168" height="20" font="4">hemodynamic burden in these </text>
<text top="677" left="874" width="23" height="20" font="4">pts. </text>
<text top="694" left="64" width="80" height="20" font="4">Freling HG, et </text>
<text top="712" left="64" width="16" height="20" font="4">al. </text>
<text top="729" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(519)</a> </text>
<text top="746" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24355311?dopt=Citation">24355311</a></text>
<text top="746" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24355311?dopt=Citation"> </a></text>
<text top="694" left="165" width="51" height="20" font="4">n=42 pts </text>
<text top="694" left="257" width="79" height="20" font="4">Retrospective </text>
<text top="694" left="356" width="140" height="20" font="3"><b>Inclusion criteria</b>: Echo, </text>
<text top="712" left="356" width="137" height="20" font="4">CMR and CPET within 6 </text>
<text top="729" left="356" width="14" height="20" font="4">m </text>
<text top="746" left="356" width="3" height="20" font="4"> </text>
<text top="694" left="514" width="49" height="20" font="4">Peak VO</text>
<text top="701" left="564" width="4" height="13" font="6">2</text>
<text top="694" left="568" width="3" height="20" font="4"> </text>
<text top="694" left="628" width="217" height="20" font="4">● Multivariate analysis showed that the </text>
<text top="712" left="628" width="187" height="20" font="4">peak RVOT gradient was the only </text>
<text top="729" left="628" width="185" height="20" font="4">independent predictor of exercise </text>
<text top="746" left="628" width="55" height="20" font="4">capacity.  </text>
<text top="694" left="874" width="170" height="20" font="4">● Exercise capacity is lower in </text>
<text top="712" left="874" width="175" height="20" font="4">pts with RVOTO compared with </text>
<text top="729" left="874" width="176" height="20" font="4">those without RVOTO despite a </text>
<text top="746" left="874" width="177" height="20" font="4">less dilated RV and comparable </text>
<text top="763" left="874" width="79" height="20" font="4">degree of PR. </text>
</page>
<page number="138" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 138 </text>
<text top="107" left="356" width="143" height="20" font="3"><b>Exclusion criteria</b>: Other </text>
<text top="124" left="356" width="90" height="20" font="4">significant valve </text>
<text top="141" left="356" width="126" height="20" font="4">regurgitation or shunts </text>
<text top="159" left="64" width="83" height="20" font="4">Babu-Narayan </text>
<text top="177" left="64" width="53" height="20" font="4">SV, et al. </text>
<text top="194" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(520)</a> </text>
<text top="211" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24146254?dopt=Citation">24146254</a></text>
<text top="211" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24146254?dopt=Citation"> </a></text>
<text top="159" left="165" width="78" height="20" font="4">n=220 pts, 11 </text>
<text top="177" left="165" width="73" height="20" font="4">with TOF/PA </text>
<text top="159" left="257" width="79" height="20" font="4">Retrospective </text>
<text top="159" left="356" width="137" height="20" font="3"><b>Inclusion criteria</b>: rTOF </text>
<text top="177" left="356" width="91" height="20" font="4">with surgical PV </text>
<text top="194" left="356" width="71" height="20" font="4">replacement </text>
<text top="159" left="514" width="54" height="20" font="4">All-cause </text>
<text top="177" left="514" width="50" height="20" font="4">mortality </text>
<text top="159" left="628" width="62" height="20" font="4">● Peak VO</text>
<text top="166" left="689" width="4" height="13" font="6">2</text>
<text top="159" left="694" width="45" height="20" font="4">, VE/CO</text>
<text top="166" left="739" width="4" height="13" font="6">2</text>
<text top="159" left="743" width="105" height="20" font="4"> slope (ratio of min </text>
<text top="177" left="628" width="91" height="20" font="4">ventilation to CO</text>
<text top="183" left="719" width="4" height="13" font="6">2</text>
<text top="177" left="723" width="127" height="20" font="4"> production), and heart </text>
<text top="194" left="628" width="219" height="20" font="4">rate reserve during CPET predicted risk </text>
<text top="211" left="628" width="204" height="20" font="4">of early mortality when analyzed with </text>
<text top="228" left="628" width="201" height="20" font="4">logistic regression analysis; peak VO</text>
<text top="234" left="829" width="4" height="13" font="6">2</text>
<text top="228" left="833" width="3" height="20" font="4"> </text>
<text top="245" left="628" width="211" height="20" font="4">emerged as the strongest predictor on </text>
<text top="263" left="628" width="221" height="20" font="4">multivariable analysis (OR: 0.65/1 mL/kg</text>
<text top="264" left="849" width="3" height="13" font="6">-</text>
<text top="282" left="628" width="4" height="13" font="6">1</text>
<text top="280" left="632" width="24" height="20" font="4">·min</text>
<text top="282" left="656" width="7" height="13" font="6">-1</text>
<text top="280" left="663" width="59" height="20" font="4">; p=0.041) </text>
<text top="159" left="874" width="168" height="20" font="4">● Preoperative CPET predicts </text>
<text top="177" left="874" width="163" height="20" font="4">surgical outcome and should, </text>
<text top="194" left="874" width="156" height="20" font="4">therefore, be included in the </text>
<text top="211" left="874" width="157" height="20" font="4">routine assessment of these </text>
<text top="228" left="874" width="23" height="20" font="4">pts. </text>
<text top="298" left="64" width="39" height="20" font="4">Ferraz </text>
<text top="315" left="64" width="84" height="20" font="4">Cavalcanti PE, </text>
<text top="332" left="64" width="30" height="20" font="4">et al. </text>
<text top="350" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(521)</a> </text>
<text top="367" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24080109?dopt=Citation">24080109</a></text>
<text top="367" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24080109?dopt=Citation"> </a></text>
<text top="298" left="165" width="68" height="20" font="4">n=3,118 pts </text>
<text top="315" left="165" width="59" height="20" font="4">not known </text>
<text top="332" left="165" width="48" height="20" font="4">TOF/PA </text>
<text top="298" left="257" width="226" height="20" font="4">Meta-analysis   <b>Inclusion criteria</b>: Pts </text>
<text top="315" left="356" width="140" height="20" font="4">enrolled from 1960–2011 </text>
<text top="332" left="356" width="3" height="20" font="4"> </text>
<text top="350" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="367" left="356" width="107" height="20" font="4">Repaired TOF with </text>
<text top="384" left="356" width="126" height="20" font="4">moderate insufficiency </text>
<text top="401" left="356" width="85" height="20" font="4">undergoing PV </text>
<text top="418" left="356" width="71" height="20" font="4">replacement </text>
<text top="298" left="514" width="24" height="20" font="4">N/A </text>
<text top="298" left="628" width="142" height="20" font="4">● 30-d mortality of 0.87% </text>
<text top="315" left="628" width="128" height="20" font="4">● 5-y mortality of 2.2% </text>
<text top="332" left="628" width="170" height="20" font="4">● 5-y re-PV replacement 4.9% </text>
<text top="298" left="874" width="158" height="20" font="4">● PV replacement post TOF </text>
<text top="315" left="874" width="91" height="20" font="4">repair results in: </text>
<text top="332" left="874" width="173" height="20" font="4">- Decrease in regurgitant factor </text>
<text top="350" left="874" width="167" height="20" font="4">- Improved RV volume but not </text>
<text top="367" left="874" width="19" height="20" font="4">EF </text>
<text top="384" left="874" width="161" height="20" font="4">- Improved LVEF, decreased </text>
<text top="401" left="874" width="44" height="20" font="4">LVEDV </text>
<text top="418" left="874" width="141" height="20" font="4">- Decrease QRS duration </text>
<text top="436" left="874" width="159" height="20" font="4">- Improvement of symptoms. </text>
<text top="454" left="64" width="79" height="20" font="4">Morray BH, et </text>
<text top="471" left="64" width="16" height="20" font="4">al. </text>
<text top="488" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(522)</a> </text>
<text top="505" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24065444?dopt=Citation">24065444</a></text>
<text top="505" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24065444?dopt=Citation"> </a></text>
<text top="454" left="165" width="61" height="20" font="4">n=404 pts; </text>
<text top="471" left="165" width="73" height="20" font="4">226 TOF, 84 </text>
<text top="488" left="165" width="48" height="20" font="4">TOF/PA </text>
<text top="454" left="257" width="85" height="20" font="4">Multicenter, (4) </text>
<text top="471" left="257" width="74" height="20" font="4">retrospective </text>
<text top="454" left="356" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="471" left="356" width="100" height="20" font="4">referred for TPVR </text>
<text top="454" left="514" width="70" height="20" font="4">Presence or </text>
<text top="471" left="514" width="64" height="20" font="4">absence of </text>
<text top="488" left="514" width="86" height="20" font="4">coronary artery </text>
<text top="505" left="514" width="73" height="20" font="4">compression </text>
<text top="454" left="628" width="204" height="20" font="4"> ● 21 (5%) had evidence of coronary </text>
<text top="471" left="628" width="209" height="20" font="4">artery compression with simultaneous </text>
<text top="488" left="628" width="178" height="20" font="4">RVOT angioplasty and coronary </text>
<text top="505" left="628" width="206" height="20" font="4">angiography. 68 (17%) had abnormal </text>
<text top="522" left="628" width="176" height="20" font="4">coronary angiography anatomy. </text>
<text top="454" left="874" width="152" height="20" font="4">● Preimplantation coronary </text>
<text top="471" left="874" width="172" height="20" font="4">angiography with simultaneous </text>
<text top="488" left="874" width="173" height="20" font="4">test angioplasty is an important </text>
<text top="505" left="874" width="129" height="20" font="4">step to evaluate for the </text>
<text top="522" left="874" width="119" height="20" font="4">presence of coronary </text>
<text top="540" left="874" width="144" height="20" font="4">angiography compression </text>
<text top="557" left="874" width="68" height="20" font="4">during TPV. </text>
<text top="575" left="64" width="72" height="20" font="4">Ong K, et al. </text>
<text top="592" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(523)</a> </text>
<text top="609" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23481618?dopt=Citation">23481618</a></text>
<text top="609" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23481618?dopt=Citation"> </a></text>
<text top="575" left="165" width="78" height="20" font="4">n=49 pts; 106 </text>
<text top="592" left="165" width="49" height="20" font="4">conduits </text>
<text top="609" left="165" width="53" height="20" font="4">16 (33%) </text>
<text top="626" left="165" width="48" height="20" font="4">TOF/PA </text>
<text top="575" left="257" width="205" height="20" font="4">Retrospective   <b>Inclusion criteria</b>: </text>
<text top="592" left="356" width="137" height="20" font="4">Review from 1974–2011 </text>
<text top="609" left="356" width="3" height="20" font="4"> </text>
<text top="626" left="356" width="144" height="20" font="3"><b>Exclusion criteria</b>: RV to </text>
<text top="644" left="356" width="135" height="20" font="4">PA conduit reoperations </text>
<text top="661" left="356" width="100" height="20" font="4">in pts with TOF or </text>
<text top="678" left="356" width="49" height="20" font="4">PA/VSD </text>
<text top="575" left="514" width="70" height="20" font="4">Reoperation </text>
<text top="575" left="628" width="215" height="20" font="4">● Significant independent predictors of </text>
<text top="592" left="628" width="229" height="20" font="4">shorter conduit longevity included smaller </text>
<text top="609" left="628" width="224" height="20" font="4">conduit and conduit type (homograft and </text>
<text top="626" left="628" width="105" height="20" font="4">other vs. Dacron).  </text>
<text top="575" left="874" width="142" height="20" font="4">● Multiple RV-PA conduit </text>
<text top="592" left="874" width="163" height="20" font="4">revisions were required in pts </text>
<text top="609" left="874" width="175" height="20" font="4">who survived to adulthood, with </text>
<text top="626" left="874" width="147" height="20" font="4">many replacements taking </text>
<text top="644" left="874" width="146" height="20" font="4">place during adolescence. </text>
<text top="696" left="64" width="83" height="20" font="4">Adamson L, et </text>
<text top="713" left="64" width="16" height="20" font="4">al. </text>
<text top="730" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(524)</a> </text>
<text top="748" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19567499?dopt=Citation">19567499</a></text>
<text top="748" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19567499?dopt=Citation"> </a></text>
<text top="696" left="165" width="71" height="20" font="4">n=1,070 pts; </text>
<text top="713" left="165" width="59" height="20" font="4">not known </text>
<text top="730" left="165" width="48" height="20" font="4">TOF/PA </text>
<text top="696" left="257" width="32" height="20" font="4">“Best </text>
<text top="713" left="257" width="58" height="20" font="4">Evidence” </text>
<text top="730" left="257" width="79" height="20" font="4">Meta-analysis </text>
<text top="696" left="356" width="139" height="20" font="3"><b>Inclusion criteria</b>: 1950–</text>
<text top="713" left="356" width="142" height="20" font="4">2009; 19 papers selected </text>
<text top="696" left="514" width="85" height="20" font="4">Explore clinical </text>
<text top="713" left="514" width="70" height="20" font="4">and imaging </text>
<text top="730" left="514" width="67" height="20" font="4">result of PV </text>
<text top="748" left="514" width="71" height="20" font="4">replacement </text>
<text top="696" left="628" width="224" height="20" font="4">● PV replacement improves RV function </text>
<text top="713" left="628" width="174" height="20" font="4">and offers symptomatic benefit. </text>
<text top="730" left="628" width="211" height="20" font="4">● Consistent reduction in RVEDV and </text>
<text top="748" left="628" width="49" height="20" font="4">RVESV. </text>
<text top="696" left="874" width="177" height="20" font="4">● PV replacement improves RV </text>
<text top="713" left="874" width="177" height="20" font="4">function and offers symptomatic </text>
<text top="730" left="874" width="44" height="20" font="4">benefit. </text>
<text top="748" left="874" width="141" height="20" font="4">● Consistent reduction in </text>
<text top="765" left="874" width="118" height="20" font="4">RVEDV and RVESV. </text>
</page>
<page number="139" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 139 </text>
<text top="107" left="628" width="197" height="20" font="4">● PV replacement improves clinical </text>
<text top="124" left="628" width="194" height="20" font="4">outcome and is performed with low </text>
<text top="141" left="628" width="53" height="20" font="4">mortality. </text>
<text top="107" left="874" width="157" height="20" font="4">● PV replacement improves </text>
<text top="124" left="874" width="127" height="20" font="4">clinical outcome and is </text>
<text top="141" left="874" width="160" height="20" font="4">performed with low mortality. </text>
<text top="159" left="64" width="87" height="20" font="4">Cheung EW, et </text>
<text top="177" left="64" width="16" height="20" font="4">al. </text>
<text top="194" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(525)</a> </text>
<text top="211" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20691315?dopt=Citation">20691315</a></text>
<text top="211" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20691315?dopt=Citation"> </a></text>
<text top="159" left="165" width="68" height="20" font="4">n=1,083 pts </text>
<text top="159" left="257" width="79" height="20" font="4">Meta-analysis </text>
<text top="159" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="177" left="356" width="140" height="20" font="4">PubMed Inception: 2009; </text>
<text top="194" left="356" width="107" height="20" font="4">15 papers selected </text>
<text top="211" left="356" width="3" height="20" font="4"> </text>
<text top="228" left="356" width="141" height="20" font="3"><b>Exclusion criteria</b>: Case </text>
<text top="245" left="356" width="105" height="20" font="4">reports and review </text>
<text top="263" left="356" width="124" height="20" font="4">articles; percutaneous </text>
<text top="280" left="356" width="102" height="20" font="4">valves; image and </text>
<text top="297" left="356" width="104" height="20" font="4">biomarker studies; </text>
<text top="314" left="356" width="109" height="20" font="4">comparison studies </text>
<text top="159" left="514" width="73" height="20" font="4">Children and </text>
<text top="177" left="514" width="87" height="20" font="4">adults following </text>
<text top="194" left="514" width="57" height="20" font="4">outcomes </text>
<text top="211" left="514" width="85" height="20" font="4">measures after </text>
<text top="228" left="514" width="65" height="20" font="4">surgical PV </text>
<text top="246" left="514" width="71" height="20" font="4">replacement </text>
<text top="159" left="628" width="129" height="20" font="4">● Early mortality 2.1%. </text>
<text top="177" left="628" width="135" height="20" font="4">Late mortality 0.5%/pt y. </text>
<text top="194" left="628" width="161" height="20" font="4">RVEDV reduction of 63 mL/m</text>
<text top="196" left="789" width="4" height="13" font="6">2</text>
<text top="194" left="794" width="7" height="20" font="4">. </text>
<text top="211" left="628" width="161" height="20" font="4">RVESV reduction of 37 mL/m</text>
<text top="213" left="788" width="4" height="13" font="6">2</text>
<text top="211" left="793" width="7" height="20" font="4">. </text>
<text top="228" left="628" width="208" height="20" font="4">No change in RVEF or QRS duration. </text>
<text top="159" left="874" width="169" height="20" font="4">● Low early and late mortality. </text>
<text top="177" left="874" width="166" height="20" font="4">● Significant decreases in RV </text>
<text top="194" left="874" width="46" height="20" font="4">volume. </text>
<text top="211" left="874" width="169" height="20" font="4">● No change in RVEF or QRS </text>
<text top="228" left="874" width="51" height="20" font="4">duration. </text>
<text top="332" left="64" width="69" height="20" font="4">Lee C, el al. </text>
<text top="350" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(526)</a> </text>
<text top="367" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22921969?dopt=Citation">22921969</a></text>
<text top="367" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22921969?dopt=Citation"> </a></text>
<text top="332" left="165" width="65" height="20" font="4">n=170; 139 </text>
<text top="350" left="165" width="67" height="20" font="4">TOF (82%), </text>
<text top="367" left="165" width="62" height="20" font="4">15 PA with </text>
<text top="384" left="165" width="58" height="20" font="4">VSD (9%) </text>
<text top="332" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="350" left="257" width="38" height="20" font="4">cohort </text>
<text top="332" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="350" left="356" width="87" height="20" font="4">Undergoing PV </text>
<text top="367" left="356" width="132" height="20" font="4">replacement for chronic </text>
<text top="384" left="356" width="126" height="20" font="4">PR after TOF repair or </text>
<text top="401" left="356" width="128" height="20" font="4">similar physiology from </text>
<text top="418" left="356" width="119" height="20" font="4">January 1998–March </text>
<text top="436" left="356" width="31" height="20" font="4">2011 </text>
<text top="453" left="356" width="3" height="20" font="4"> </text>
<text top="470" left="356" width="113" height="20" font="3"><b>Exclusion criteria</b>:  </text>
<text top="487" left="356" width="97" height="20" font="4">Pts with valvar or </text>
<text top="504" left="356" width="143" height="20" font="4">subvalvular PS, RV to PA </text>
<text top="522" left="356" width="84" height="20" font="4">conduits, other </text>
<text top="539" left="356" width="92" height="20" font="4">confounding HD </text>
<text top="332" left="514" width="78" height="20" font="4">Prosthetic PV </text>
<text top="350" left="514" width="97" height="20" font="4">failure, prosthetic </text>
<text top="367" left="514" width="89" height="20" font="4">PV dysfunction, </text>
<text top="384" left="514" width="68" height="20" font="4">arrhythmias </text>
<text top="332" left="628" width="232" height="20" font="4">● More PR associated with increasing RV </text>
<text top="350" left="628" width="140" height="20" font="4">volumes but not function. </text>
<text top="367" left="628" width="136" height="20" font="4">● 2 early deaths (1.2%). </text>
<text top="384" left="628" width="159" height="20" font="4">● 10-y survival 97.5 ± 1.6%. </text>
<text top="401" left="628" width="226" height="20" font="4">● Freedom from redo PV replacement at </text>
<text top="418" left="628" width="101" height="20" font="4">10 y 74.7±10.0%. </text>
<text top="436" left="628" width="233" height="20" font="4">● Freedom from prosthetic valve failure at </text>
<text top="453" left="628" width="129" height="20" font="4">10 y was 50.3 ± 10.1% </text>
<text top="470" left="628" width="204" height="20" font="4">MRI cutoff for RVED volume indexed </text>
<text top="487" left="628" width="198" height="20" font="4">normalization after surgery was 168 </text>
<text top="504" left="628" width="31" height="20" font="4">mL/m</text>
<text top="506" left="659" width="4" height="13" font="6">2</text>
<text top="504" left="663" width="7" height="20" font="4">. </text>
<text top="332" left="874" width="150" height="20" font="4">● Midterm outcomes of PV </text>
<text top="350" left="874" width="138" height="20" font="4">replacement acceptable. </text>
<text top="367" left="874" width="160" height="20" font="4">● PV replacement should be </text>
<text top="384" left="874" width="160" height="20" font="4">considered before RVEDV is </text>
<text top="401" left="874" width="62" height="20" font="4">&gt;163 mL/m</text>
<text top="403" left="935" width="4" height="13" font="6">2</text>
<text top="401" left="940" width="90" height="20" font="4">, or RVESV &gt;80 </text>
<text top="418" left="874" width="31" height="20" font="4">mL/m</text>
<text top="420" left="904" width="4" height="13" font="6">2</text>
<text top="418" left="909" width="7" height="20" font="4">. </text>
<text top="557" left="64" width="85" height="20" font="4">Fiore AC, et al. </text>
<text top="574" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(527)</a> </text>
<text top="591" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18442571?dopt=Citation">18442571</a></text>
<text top="591" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18442571?dopt=Citation"> </a></text>
<text top="557" left="165" width="51" height="20" font="4">n=82 pts </text>
<text top="574" left="165" width="59" height="20" font="4">not known </text>
<text top="591" left="165" width="48" height="20" font="4">TOF/PA </text>
<text top="557" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="574" left="257" width="38" height="20" font="4">cohort </text>
<text top="557" left="356" width="125" height="20" font="3"><b>Inclusion criteria</b>: PV </text>
<text top="574" left="356" width="132" height="20" font="4">replacement with tissue </text>
<text top="591" left="356" width="109" height="20" font="4">prosthesis between </text>
<text top="608" left="356" width="123" height="20" font="4">January 1995–August </text>
<text top="626" left="356" width="31" height="20" font="4">2006 </text>
<text top="643" left="356" width="3" height="20" font="4"> </text>
<text top="660" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="677" left="356" width="124" height="20" font="4">Extracardiac conduits; </text>
<text top="694" left="356" width="143" height="20" font="4">Ross; monocuspid valves </text>
<text top="557" left="514" width="345" height="20" font="4">Valve dysfunction  ● Mean age 22.7 y with mean 15.3 y after </text>
<text top="574" left="628" width="70" height="20" font="4">initial repair. </text>
<text top="591" left="628" width="222" height="20" font="4">● All 3 reduced PR but late insufficiency </text>
<text top="608" left="628" width="220" height="20" font="4">greater with homograft’s (54%) followed </text>
<text top="626" left="628" width="220" height="20" font="4">by porcine (19%) and pericardial (5.5%) </text>
<text top="643" left="628" width="41" height="20" font="4">p&lt;005. </text>
<text top="660" left="628" width="218" height="20" font="4">● RV dimension reduced in stented but </text>
<text top="677" left="628" width="77" height="20" font="4">not allografts. </text>
<text top="694" left="628" width="175" height="20" font="4">● FC and TR improved with PV </text>
<text top="712" left="628" width="202" height="20" font="4">replacement; early and late mortality </text>
<text top="729" left="628" width="90" height="20" font="4">3.6% and 1.2%. </text>
<text top="557" left="874" width="149" height="20" font="4">● All 3 prostheses perform </text>
<text top="574" left="874" width="92" height="20" font="4">similarly for 3 y.  </text>
<text top="591" left="874" width="125" height="20" font="4">● PR developed more </text>
<text top="608" left="874" width="168" height="20" font="4">frequently in homografts albeit </text>
<text top="626" left="874" width="94" height="20" font="4">longer follow-up. </text>
<text top="747" left="64" width="77" height="20" font="4">Gengsakul A, </text>
<text top="764" left="64" width="30" height="20" font="4">et al. </text>
<text top="747" left="165" width="58" height="20" font="4">n=164 pts </text>
<text top="747" left="257" width="51" height="20" font="4">Matched </text>
<text top="764" left="257" width="38" height="20" font="4">cohort </text>
<text top="747" left="356" width="125" height="20" font="3"><b>Inclusion criteria</b>: PV </text>
<text top="764" left="356" width="127" height="20" font="4">replacement after TOF </text>
<text top="781" left="356" width="128" height="20" font="4">compared with non-PV </text>
<text top="747" left="514" width="24" height="20" font="4">N/A </text>
<text top="747" left="628" width="209" height="20" font="4">● SCD in 4 non- PV replacement with </text>
<text top="764" left="628" width="193" height="20" font="4">none in PV replacement group. PV </text>
<text top="781" left="628" width="184" height="20" font="4">replacement pts more likely to be </text>
<text top="747" left="874" width="172" height="20" font="4">● Symptoms and FC improved </text>
<text top="764" left="874" width="168" height="20" font="4">after late PV replacement with </text>
<text top="781" left="874" width="130" height="20" font="4">reduction in PV and TV </text>
</page>
<page number="140" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 140 </text>
<text top="107" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(528)</a> </text>
<text top="124" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17627832?dopt=Citation">17627832</a></text>
<text top="124" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17627832?dopt=Citation"> </a></text>
<text top="107" left="356" width="142" height="20" font="4">replacement pts from Jan </text>
<text top="124" left="356" width="133" height="20" font="4">1974–Dec 2003, DORV </text>
<text top="141" left="356" width="68" height="20" font="4">of TOF type </text>
<text top="159" left="356" width="3" height="20" font="4"> </text>
<text top="176" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="193" left="356" width="127" height="20" font="4">Ventricular arrhythmia, </text>
<text top="210" left="356" width="124" height="20" font="4">automatic intracardiac </text>
<text top="228" left="356" width="135" height="20" font="4">cardioverter defibrillator, </text>
<text top="245" left="356" width="135" height="20" font="4">multiple aortopulmonary </text>
<text top="262" left="356" width="136" height="20" font="4">collaterals, nonconfluent </text>
<text top="279" left="356" width="133" height="20" font="4">PA, Single ventricle; PV </text>
<text top="296" left="356" width="139" height="20" font="4">replacement occurring at </text>
<text top="314" left="356" width="107" height="20" font="4">time of initial repair </text>
<text top="107" left="628" width="217" height="20" font="4">symptomatic, non-VA, lower FC, longer </text>
<text top="124" left="628" width="215" height="20" font="4">QRS, lower RVEF, higher RV pressure </text>
<text top="141" left="628" width="176" height="20" font="4">and reduced exercise duration.  </text>
<text top="107" left="874" width="164" height="20" font="4">insufficiency and RV size and </text>
<text top="124" left="874" width="169" height="20" font="4">function improved; no SCDs in </text>
<text top="141" left="874" width="172" height="20" font="4">PV replacement population but </text>
<text top="159" left="874" width="139" height="20" font="4">no impact on arrhythmia. </text>
<text top="332" left="64" width="85" height="20" font="4">Oosterhof T, et </text>
<text top="349" left="64" width="16" height="20" font="4">al. </text>
<text top="366" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(529)</a> </text>
<text top="383" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17620511?dopt=Citation">17620511</a></text>
<text top="383" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17620511?dopt=Citation"> </a></text>
<text top="332" left="165" width="51" height="20" font="4">n=71 pts </text>
<text top="332" left="257" width="71" height="20" font="4">Prospective, </text>
<text top="349" left="257" width="62" height="20" font="4">nationwide </text>
<text top="332" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="349" left="356" width="85" height="20" font="4">Corrected TOF </text>
<text top="366" left="356" width="85" height="20" font="4">undergoing PV </text>
<text top="383" left="356" width="133" height="20" font="4">replacement from 1993–</text>
<text top="400" left="356" width="31" height="20" font="4">2007 </text>
<text top="332" left="514" width="70" height="20" font="4">RV volumes </text>
<text top="332" left="628" width="233" height="20" font="4">● RV volumes decreased a mean of 28%. </text>
<text top="349" left="628" width="203" height="20" font="4">● RVEF did not change significantly. </text>
<text top="366" left="628" width="225" height="20" font="4">● RVOT reduction altered RV volume by </text>
<text top="383" left="628" width="31" height="20" font="4">25%. </text>
<text top="400" left="628" width="188" height="20" font="4">● Cutoff values RVEDV 160 mL/m</text>
<text top="402" left="816" width="4" height="13" font="6">2</text>
<text top="400" left="821" width="3" height="20" font="4"> </text>
<text top="418" left="628" width="93" height="20" font="4">RVESV 82 mL/m</text>
<text top="419" left="721" width="4" height="13" font="6">2</text>
<text top="418" left="725" width="7" height="20" font="4">. </text>
<text top="332" left="874" width="165" height="20" font="4">● RV volume decreased in all </text>
<text top="349" left="874" width="143" height="20" font="4">pts, especially with RVOT </text>
<text top="366" left="874" width="54" height="20" font="4">reduction </text>
<text top="383" left="874" width="145" height="20" font="4">Cutoff values RVEDV 160 </text>
<text top="400" left="874" width="31" height="20" font="4">mL/m</text>
<text top="402" left="904" width="7" height="13" font="6">2 </text>
<text top="400" left="911" width="93" height="20" font="4">RVESV 82 mL/m</text>
<text top="402" left="1004" width="4" height="13" font="6">2</text>
<text top="400" left="1008" width="7" height="20" font="4">. </text>
<text top="436" left="64" width="72" height="20" font="4">Frigiola A, et </text>
<text top="453" left="64" width="16" height="20" font="4">al. </text>
<text top="470" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(530)</a> </text>
<text top="487" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18539471?dopt=Citation">18539471</a></text>
<text top="487" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18539471?dopt=Citation"> </a></text>
<text top="436" left="165" width="31" height="20" font="4">n=36 </text>
<text top="453" left="165" width="41" height="20" font="4">(25 PV </text>
<text top="470" left="165" width="74" height="20" font="4">replacement, </text>
<text top="487" left="165" width="53" height="20" font="4">11 PPVI) </text>
<text top="436" left="257" width="68" height="20" font="4">Prospective </text>
<text top="436" left="356" width="125" height="20" font="3"><b>Inclusion criteria</b>: 1 y </text>
<text top="453" left="356" width="133" height="20" font="4">after PV replacement or </text>
<text top="470" left="356" width="31" height="20" font="4">PPVI </text>
<text top="487" left="356" width="3" height="20" font="4"> </text>
<text top="504" left="356" width="131" height="20" font="3"><b>Exclusion criteria</b>: For </text>
<text top="522" left="356" width="133" height="20" font="4">PPVI: &lt;20 kg, presence </text>
<text top="539" left="356" width="129" height="20" font="4">of a transannular patch </text>
<text top="436" left="514" width="87" height="20" font="4">To evaluate EF </text>
<text top="453" left="514" width="73" height="20" font="4">and volumes </text>
<text top="470" left="514" width="66" height="20" font="4">after RVOT </text>
<text top="487" left="514" width="81" height="20" font="4">reconstruction </text>
<text top="504" left="514" width="45" height="20" font="4">with PV </text>
<text top="522" left="514" width="95" height="20" font="4">replacement and </text>
<text top="539" left="514" width="31" height="20" font="4">PPVI </text>
<text top="436" left="628" width="226" height="20" font="4">● Significant reduction in RVEDV in both </text>
<text top="453" left="628" width="44" height="20" font="4">groups. </text>
<text top="470" left="628" width="201" height="20" font="4">● Improvement in RV and LV stroke </text>
<text top="487" left="628" width="46" height="20" font="4">volume. </text>
<text top="436" left="874" width="160" height="20" font="4">● Significant reduction in RV </text>
<text top="453" left="874" width="117" height="20" font="4">volume and function. </text>
<text top="470" left="874" width="160" height="20" font="4">● LV effective stroke volume </text>
<text top="487" left="874" width="174" height="20" font="4">should be used to judge benefit </text>
<text top="504" left="874" width="76" height="20" font="4">of procedure. </text>
<text top="522" left="874" width="113" height="20" font="4">● Supports PPVI as </text>
<text top="539" left="874" width="122" height="20" font="4">intervention for RVOT </text>
<text top="556" left="874" width="79" height="20" font="4">management. </text>
<text top="574" left="64" width="66" height="20" font="4">Yin S, et al. </text>
<text top="591" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(531)</a> </text>
<text top="608" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15905342?dopt=Citation">15905342</a></text>
<text top="608" left="119" width="7" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15905342?dopt=Citation"> </a> </text>
<text top="574" left="165" width="51" height="20" font="4">n=10 pts </text>
<text top="574" left="257" width="79" height="20" font="4">Retrospective </text>
<text top="574" left="356" width="135" height="20" font="3"><b>Inclusion criteria</b>: June </text>
<text top="591" left="356" width="93" height="20" font="4">2002–April 2004 </text>
<text top="608" left="356" width="108" height="20" font="4">undergoing late PV </text>
<text top="626" left="356" width="71" height="20" font="4">replacement </text>
<text top="574" left="514" width="87" height="20" font="4">LVEF, RV size, </text>
<text top="591" left="514" width="81" height="20" font="4">QRS duration, </text>
<text top="608" left="514" width="64" height="20" font="4">QT interval </text>
<text top="574" left="628" width="185" height="20" font="4">● Interval between repair and PV </text>
<text top="591" left="628" width="140" height="20" font="4">replacement 20 ± 12.3 y. </text>
<text top="608" left="628" width="196" height="20" font="4">● LVEF improved significantly from </text>
<text top="626" left="628" width="80" height="20" font="4">62.1%–70.2% </text>
<text top="643" left="628" width="227" height="20" font="4">QT decreased (460.9 vs. 451.9 ms);2 pts </text>
<text top="660" left="628" width="178" height="20" font="4">required defibrillators; only 3 pts </text>
<text top="677" left="628" width="90" height="20" font="4">underwent MRI. </text>
<text top="574" left="874" width="166" height="20" font="4">● Significant benefits with low </text>
<text top="591" left="874" width="80" height="20" font="4">operative risk. </text>
<text top="695" left="64" width="66" height="20" font="4">Mainwaring </text>
<text top="712" left="64" width="55" height="20" font="4">RD, et al. </text>
<text top="730" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(532)</a> </text>
<text top="747" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22269747?dopt=Citation">22269747</a></text>
<text top="747" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22269747?dopt=Citation"> </a></text>
<text top="695" left="165" width="44" height="20" font="4">n=5 pts </text>
<text top="695" left="257" width="72" height="20" font="4"> Case series </text>
<text top="695" left="356" width="143" height="20" font="3"><b>Inclusion criteria</b>: March </text>
<text top="712" left="356" width="121" height="20" font="4">2009–April 2011, with </text>
<text top="730" left="356" width="113" height="20" font="4">previous TOF repair </text>
<text top="747" left="356" width="126" height="20" font="4">undergoing pulmonary </text>
<text top="764" left="356" width="74" height="20" font="4">valvuloplasty </text>
<text top="695" left="514" width="62" height="20" font="4">Pulmonary </text>
<text top="712" left="514" width="74" height="20" font="4">insufficiency  </text>
<text top="695" left="628" width="107" height="20" font="4">● Median age 9 y.  </text>
<text top="712" left="628" width="196" height="20" font="4">● For bicuspid native PV s and had </text>
<text top="730" left="628" width="193" height="20" font="4">undergone transannular patch with </text>
<text top="747" left="628" width="185" height="20" font="4">retention of native leaflets and no </text>
<text top="764" left="628" width="205" height="20" font="4">pulmonary stenosis and transannular </text>
<text top="781" left="628" width="113" height="20" font="4">gradient of &lt;10 mm. </text>
<text top="695" left="874" width="111" height="20" font="4">● New technique of </text>
<text top="712" left="874" width="174" height="20" font="4">bicuspidization of the native PV </text>
<text top="730" left="874" width="46" height="20" font="4">leaflets. </text>
</page>
<page number="141" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 141 </text>
<text top="107" left="628" width="204" height="20" font="4">● Majority of pts went from severe to </text>
<text top="124" left="628" width="165" height="20" font="4">trace pulmonary insufficiency. </text>
<text top="142" left="64" width="84" height="20" font="4">Graham TP, et </text>
<text top="159" left="64" width="16" height="20" font="4">al. </text>
<text top="177" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(533)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18557878?dopt=Citation">18557878</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18557878?dopt=Citation"> </a></text>
<text top="142" left="165" width="51" height="20" font="4">n=93 pts </text>
<text top="142" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="159" left="257" width="30" height="20" font="4">multi-</text>
<text top="177" left="257" width="79" height="20" font="4">institutional (7 </text>
<text top="194" left="257" width="48" height="20" font="4">centers) </text>
<text top="142" left="356" width="139" height="20" font="3"><b>Inclusion criteria</b>: &gt;18 y </text>
<text top="159" left="356" width="131" height="20" font="4">of age, TOF post repair </text>
<text top="177" left="356" width="135" height="20" font="4">with main artery present </text>
<text top="194" left="356" width="89" height="20" font="4">and isolated PV </text>
<text top="211" left="356" width="72" height="20" font="4">regurgitation </text>
<text top="228" left="356" width="3" height="20" font="4"> </text>
<text top="245" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="263" left="356" width="135" height="20" font="4">Multiple aortopulmonary </text>
<text top="280" left="356" width="112" height="20" font="4">collaterals TOF with </text>
<text top="297" left="356" width="60" height="20" font="4">absent PV </text>
<text top="142" left="514" width="40" height="20" font="4">Death, </text>
<text top="159" left="514" width="92" height="20" font="4">reoperations RV </text>
<text top="177" left="514" width="96" height="20" font="4">size, ability index </text>
<text top="142" left="628" width="157" height="20" font="4">● PV replacement at 2.61 y. </text>
<text top="159" left="628" width="129" height="20" font="4">● No operative deaths. </text>
<text top="177" left="628" width="218" height="20" font="4">● Overall mortality 2.1% (1 from V Fib). </text>
<text top="194" left="628" width="221" height="20" font="4">● Median follow-up 3 y (4 d–26 y) so 10 </text>
<text top="211" left="628" width="222" height="20" font="4">pts underwent 2 PV replacements, 3 pts </text>
<text top="228" left="628" width="136" height="20" font="4">with 3 PV replacements. </text>
<text top="246" left="628" width="171" height="20" font="4">● Valve durability 50% at 11 y. </text>
<text top="142" left="874" width="137" height="20" font="4">● PV replacement is low </text>
<text top="159" left="874" width="53" height="20" font="4">mortality. </text>
<text top="177" left="874" width="151" height="20" font="4">● Decrease in RV size and </text>
<text top="194" left="874" width="159" height="20" font="4">improvement in ability index. </text>
<text top="211" left="874" width="145" height="20" font="4">● Average durability 11 y. </text>
<text top="228" left="874" width="164" height="20" font="4">● Criteria for PV replacement </text>
<text top="246" left="874" width="54" height="20" font="4">not clear. </text>
<text top="315" left="64" width="82" height="20" font="4">Ovcina I, et al. </text>
<text top="332" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(534)</a> </text>
<text top="350" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21429868?dopt=Citation">21429868</a></text>
<text top="350" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21429868?dopt=Citation"> </a></text>
<text top="315" left="165" width="51" height="20" font="4">n=24 pts </text>
<text top="332" left="165" width="67" height="20" font="4">(17 with RV </text>
<text top="350" left="165" width="43" height="20" font="4">volume </text>
<text top="367" left="165" width="54" height="20" font="4">reduction </text>
<text top="384" left="165" width="40" height="20" font="4">plasty) </text>
<text top="315" left="257" width="68" height="20" font="4">Prospective </text>
<text top="315" left="356" width="133" height="20" font="3"><b>Inclusion criteria</b>: April </text>
<text top="332" left="356" width="118" height="20" font="4">2004–2009; pts were </text>
<text top="350" left="356" width="139" height="20" font="4">offered mechanical valve </text>
<text top="367" left="356" width="74" height="20" font="4">as an option: </text>
<text top="384" left="356" width="98" height="20" font="4">symptomatic with </text>
<text top="401" left="356" width="130" height="20" font="4">moderate-to-severe PV </text>
<text top="418" left="356" width="69" height="20" font="4">dysfunction: </text>
<text top="436" left="356" width="104" height="20" font="4">asymptomatic with </text>
<text top="453" left="356" width="111" height="20" font="4">moderate-to-severe </text>
<text top="470" left="356" width="89" height="20" font="4">dysfunction and </text>
<text top="487" left="356" width="78" height="20" font="4">significant RV </text>
<text top="504" left="356" width="132" height="20" font="4">dysfunction: RV volume </text>
<text top="522" left="356" width="107" height="20" font="4">reduction plasty for </text>
<text top="539" left="356" width="121" height="20" font="4">RVEDV of &gt;170 mL/m</text>
<text top="541" left="477" width="4" height="13" font="6">2</text>
<text top="539" left="482" width="11" height="20" font="4">): </text>
<text top="556" left="356" width="105" height="20" font="4">pts given choice of </text>
<text top="573" left="356" width="98" height="20" font="4">mechanical valve </text>
<text top="591" left="356" width="3" height="20" font="4"> </text>
<text top="608" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="625" left="356" width="126" height="20" font="4">Candidates for Melody </text>
<text top="642" left="356" width="63" height="20" font="4">since 2006 </text>
<text top="315" left="514" width="94" height="20" font="4">Midterm surgical </text>
<text top="332" left="514" width="94" height="20" font="4">results for use of </text>
<text top="350" left="514" width="65" height="20" font="4">mechanical </text>
<text top="367" left="514" width="85" height="20" font="4">prosthesis with </text>
<text top="384" left="514" width="87" height="20" font="4">and without RV </text>
<text top="401" left="514" width="97" height="20" font="4">volume reduction </text>
<text top="418" left="514" width="36" height="20" font="4">plasty </text>
<text top="315" left="628" width="138" height="20" font="4">● Follow-up 6.9–67.1 m. </text>
<text top="332" left="628" width="143" height="20" font="4">● Mean age 23.1 ± 6.6 y. </text>
<text top="350" left="628" width="222" height="20" font="4">● Perioperative and midterm mortality is </text>
<text top="367" left="628" width="14" height="20" font="4">0. </text>
<text top="384" left="628" width="194" height="20" font="4">● 1 prosthetic thrombosis at 11 mo </text>
<text top="401" left="628" width="211" height="20" font="4">postop due to Coumadin cessation for </text>
<text top="418" left="628" width="62" height="20" font="4">procedure. </text>
<text top="315" left="874" width="168" height="20" font="4">● Aggressive PV replacement </text>
<text top="332" left="874" width="76" height="20" font="4">at &gt;160 mL/m</text>
<text top="334" left="949" width="7" height="13" font="6">2 </text>
<text top="350" left="874" width="148" height="20" font="4">● Concomitant RV volume </text>
<text top="367" left="874" width="140" height="20" font="4">reduction plasty safe and </text>
<text top="384" left="874" width="152" height="20" font="4">effective to remove inactive </text>
<text top="401" left="874" width="79" height="20" font="4">fibrous tissue. </text>
<text top="418" left="874" width="3" height="20" font="4"> </text>
<text top="660" left="64" width="87" height="20" font="4">Dave HH, et al. </text>
<text top="677" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(535)</a> </text>
<text top="694" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16242426?dopt=Citation">16242426</a></text>
<text top="694" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16242426?dopt=Citation"> </a></text>
<text top="660" left="165" width="51" height="20" font="4">n=39 pts </text>
<text top="660" left="257" width="67" height="20" font="4">Prospective </text>
<text top="677" left="257" width="72" height="20" font="4">using valved </text>
<text top="694" left="257" width="46" height="20" font="4">conduit: </text>
<text top="712" left="257" width="73" height="20" font="4">homograft or </text>
<text top="729" left="257" width="80" height="20" font="4">bovine jugular </text>
<text top="660" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="677" left="356" width="107" height="20" font="4">RVEDV &gt;150 mL/m</text>
<text top="679" left="464" width="4" height="13" font="6">2</text>
<text top="677" left="468" width="3" height="20" font="4"> </text>
<text top="660" left="514" width="91" height="20" font="4">Define objective </text>
<text top="677" left="514" width="76" height="20" font="4">guidelines for </text>
<text top="694" left="514" width="69" height="20" font="4">timing of PV </text>
<text top="712" left="514" width="71" height="20" font="4">replacement </text>
<text top="729" left="514" width="89" height="20" font="4">MRI changes in </text>
<text top="746" left="514" width="92" height="20" font="4">morphology and </text>
<text top="763" left="514" width="84" height="20" font="4">function at 6 m </text>
<text top="660" left="628" width="150" height="20" font="4">● No early nor late deaths. </text>
<text top="677" left="628" width="183" height="20" font="4">● Good conduit function at 15 m. </text>
<text top="694" left="628" width="185" height="20" font="4">● Significant reduction in RV size </text>
<text top="712" left="628" width="101" height="20" font="4">Increase in LVEF. </text>
<text top="729" left="628" width="215" height="20" font="4">● Pts who achieved post op RV size of </text>
<text top="746" left="628" width="62" height="20" font="4">&lt;100 mL/m</text>
<text top="748" left="690" width="4" height="13" font="6">2</text>
<text top="746" left="694" width="146" height="20" font="4"> had beginning RVEDVi of </text>
<text top="763" left="628" width="70" height="20" font="4">170 vs. 203. </text>
<text top="660" left="874" width="161" height="20" font="4">● Improvement in ventricular </text>
<text top="677" left="874" width="178" height="20" font="4">function and size correlates with </text>
<text top="694" left="874" width="166" height="20" font="4">timing of PV replacement with </text>
<text top="712" left="874" width="137" height="20" font="4">early insertion leading to </text>
<text top="729" left="874" width="80" height="20" font="4">normalization. </text>
<text top="746" left="874" width="174" height="20" font="4">● Low morbidity justifies earlier </text>
<text top="763" left="874" width="81" height="20" font="4">reintervention. </text>
<text top="781" left="874" width="120" height="20" font="4">● RVEDV &lt;150 mL/m</text>
<text top="782" left="994" width="4" height="13" font="6">2</text>
<text top="781" left="998" width="7" height="20" font="4">. </text>
</page>
<page number="142" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 142 </text>
<text top="107" left="64" width="77" height="20" font="4">Meijboom FJ, </text>
<text top="124" left="64" width="30" height="20" font="4">et al. </text>
<text top="141" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(536)</a> </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18179918?dopt=Citation">18179918</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18179918?dopt=Citation"> </a></text>
<text top="107" left="165" width="51" height="20" font="4">n=67 pts </text>
<text top="107" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="124" left="257" width="85" height="20" font="4">follow-up study </text>
<text top="107" left="356" width="145" height="20" font="3"><b>Inclusion criteria</b>: Repair </text>
<text top="124" left="356" width="115" height="20" font="4">between 1968–1990 </text>
<text top="107" left="514" width="99" height="20" font="4">Long-term results </text>
<text top="124" left="514" width="65" height="20" font="4">of selective </text>
<text top="141" left="514" width="94" height="20" font="4">strategy towards </text>
<text top="159" left="514" width="91" height="20" font="4">PV replacement </text>
<text top="176" left="514" width="56" height="20" font="4">looking at </text>
<text top="193" left="514" width="87" height="20" font="4">improvement in </text>
<text top="210" left="514" width="33" height="20" font="4">ECG, </text>
<text top="228" left="514" width="92" height="20" font="4">echocardiograph</text>
<text top="245" left="514" width="89" height="20" font="4">y, exercise, and </text>
<text top="262" left="514" width="89" height="20" font="4">no deterioration </text>
<text top="279" left="514" width="75" height="20" font="4">in pts treated </text>
<text top="296" left="514" width="81" height="20" font="4">conservatively </text>
<text top="107" left="628" width="173" height="20" font="4">● Follow-up 15 ± 3 y–27 ± 3 y  </text>
<text top="124" left="628" width="209" height="20" font="4">45 pts with severe PR: 62% remained </text>
<text top="141" left="628" width="210" height="20" font="4">symptom free and did not undergo PV </text>
<text top="159" left="628" width="219" height="20" font="4">replacement and had no changes in RV </text>
<text top="176" left="628" width="141" height="20" font="4">size or exercise capacity. </text>
<text top="193" left="628" width="218" height="20" font="4">● 17 pts had symptoms and underwent </text>
<text top="210" left="628" width="224" height="20" font="4">PV replacement; of these 54% improved </text>
<text top="228" left="628" width="199" height="20" font="4">clinically and echocardiographically. </text>
<text top="107" left="874" width="176" height="20" font="4">● Only operate on symptomatic </text>
<text top="124" left="874" width="20" height="20" font="4">pts </text>
<text top="141" left="874" width="178" height="20" font="4">Refraining from PV replacement </text>
<text top="159" left="874" width="163" height="20" font="4">in asymptomatic pts led to no </text>
<text top="176" left="874" width="143" height="20" font="4">measurable deterioration. </text>
<text top="314" left="64" width="25" height="20" font="4">Van </text>
<text top="332" left="64" width="72" height="20" font="4">Huysduynen </text>
<text top="349" left="64" width="54" height="20" font="4">BH, et al. </text>
<text top="366" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(537)</a> </text>
<text top="383" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15716288?dopt=Citation">15716288</a></text>
<text top="383" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15716288?dopt=Citation"> </a></text>
<text top="314" left="165" width="51" height="20" font="4">n=26 pts </text>
<text top="314" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="332" left="257" width="48" height="20" font="4">analysis </text>
<text top="314" left="356" width="139" height="20" font="3"><b>Inclusion criteria</b>: 1997–</text>
<text top="332" left="356" width="31" height="20" font="4">2002 </text>
<text top="314" left="514" width="74" height="20" font="4">Effects of PV </text>
<text top="332" left="514" width="88" height="20" font="4">replacement on </text>
<text top="349" left="514" width="74" height="20" font="4">QRS and RV </text>
<text top="366" left="514" width="43" height="20" font="4">volume </text>
<text top="314" left="628" width="218" height="20" font="4">● QRS duration shortened by 6 ± 8 mo </text>
<text top="332" left="628" width="100" height="20" font="4">(p=0.002) overall. </text>
<text top="349" left="628" width="209" height="20" font="4">QRS duration decreased in 18/26 pts. </text>
<text top="366" left="628" width="225" height="20" font="4">● RVEDV significantly reduced from 305 </text>
<text top="383" left="628" width="175" height="20" font="4">± 87 to 210 ± 62 (p=0.000004). </text>
<text top="400" left="628" width="219" height="20" font="4">● QRS duration correlated with RVEDV </text>
<text top="418" left="628" width="145" height="20" font="4">changes (r=0.54; p=0.01). </text>
<text top="314" left="874" width="150" height="20" font="4">● PV replacement reduces </text>
<text top="332" left="874" width="162" height="20" font="4">QRS duration and expressed </text>
<text top="349" left="874" width="159" height="20" font="4">also by reduction of RVEDV. </text>
<text top="436" left="64" width="70" height="20" font="4">Lee C, et al. </text>
<text top="453" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(538)</a> </text>
<text top="470" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21281951?dopt=Citation">21281951</a></text>
<text top="470" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21281951?dopt=Citation"> </a></text>
<text top="436" left="165" width="58" height="20" font="4">n=181 pts </text>
<text top="436" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="453" left="257" width="48" height="20" font="4">analysis </text>
<text top="436" left="356" width="139" height="20" font="3"><b>Inclusion criteria</b>: 1993–</text>
<text top="453" left="356" width="127" height="20" font="4">2004, bioprosthetic PV </text>
<text top="470" left="356" width="71" height="20" font="4">replacement </text>
<text top="487" left="356" width="3" height="20" font="4"> </text>
<text top="504" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="522" left="356" width="98" height="20" font="4">Valved conduit or </text>
<text top="539" left="356" width="59" height="20" font="4">homograft </text>
<text top="436" left="514" width="99" height="20" font="4">Long-term results </text>
<text top="453" left="514" width="33" height="20" font="4">of PV </text>
<text top="470" left="514" width="74" height="20" font="4">replacement; </text>
<text top="487" left="514" width="95" height="20" font="4">mean age 14.2 y </text>
<text top="436" left="628" width="154" height="20" font="4">● 3 early and 7 late deaths. </text>
<text top="453" left="628" width="225" height="20" font="4">● Mean follow-up duration was 7.3 ± 2.9 </text>
<text top="470" left="628" width="13" height="20" font="4">y. </text>
<text top="487" left="628" width="233" height="20" font="4">● 43 pts underwent redo PV replacement. </text>
<text top="504" left="628" width="226" height="20" font="4">● Freedom from redo PV replacement at </text>
<text top="522" left="628" width="190" height="20" font="4">5 and 10 y was 93.9% and 51.7%. </text>
<text top="539" left="628" width="186" height="20" font="4">● Freedom from valve failure and </text>
<text top="556" left="628" width="228" height="20" font="4">dysfunction at 5 and 10 y was 92.2% and </text>
<text top="573" left="628" width="42" height="20" font="4">20.2%. </text>
<text top="591" left="628" width="225" height="20" font="4">● Risk factors are younger age, PAVSD, </text>
<text top="608" left="628" width="94" height="20" font="4">stentless valves. </text>
<text top="436" left="874" width="161" height="20" font="4">● Durability of bioprostheses </text>
<text top="453" left="874" width="87" height="20" font="4">are suboptimal. </text>
<text top="470" left="874" width="155" height="20" font="4">● Valve function was stable </text>
<text top="487" left="874" width="127" height="20" font="4">until 5 y postoperation. </text>
<text top="504" left="874" width="147" height="20" font="4">● By 10 y 80% will require </text>
<text top="522" left="874" width="130" height="20" font="4">reoperation or manifest </text>
<text top="539" left="874" width="155" height="20" font="4">dysfunction. Stentless valve </text>
<text top="556" left="874" width="73" height="20" font="4">less durable. </text>
<text top="626" left="64" width="87" height="20" font="4">Chen PC, et al. </text>
<text top="643" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(539)</a> </text>
<text top="660" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22153723?dopt=Citation">22153723</a></text>
<text top="660" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22153723?dopt=Citation"> </a></text>
<text top="626" left="165" width="58" height="20" font="4">n=227 pts </text>
<text top="626" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="643" left="257" width="48" height="20" font="4">analysis </text>
<text top="626" left="356" width="139" height="20" font="3"><b>Inclusion criteria</b>: 1994–</text>
<text top="643" left="356" width="78" height="20" font="4">2009, stented </text>
<text top="660" left="356" width="73" height="20" font="4">bioprosthetic </text>
<text top="677" left="356" width="3" height="20" font="4"> </text>
<text top="694" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="712" left="356" width="135" height="20" font="4">Pulmonary homograft or </text>
<text top="729" left="356" width="98" height="20" font="4">mechanical valve </text>
<text top="626" left="514" width="72" height="20" font="4">Predictors of </text>
<text top="643" left="514" width="54" height="20" font="4">structural </text>
<text top="660" left="514" width="72" height="20" font="4">deterioration </text>
<text top="626" left="628" width="115" height="20" font="4">● No early mortality. </text>
<text top="643" left="628" width="231" height="20" font="4">● Freedom from reintervention and single </text>
<text top="660" left="628" width="209" height="20" font="4">ventricle defects 94% and 74% at 5 y. </text>
<text top="677" left="628" width="226" height="20" font="4">● Younger age and higher indexed valve </text>
<text top="694" left="628" width="196" height="20" font="4">internal diameter were predictors of </text>
<text top="712" left="628" width="219" height="20" font="4">reduced time to single ventricle defects. </text>
<text top="626" left="874" width="160" height="20" font="4">● Younger age at time of PV </text>
<text top="643" left="874" width="167" height="20" font="4">replacement and oversizing of </text>
<text top="660" left="874" width="174" height="20" font="4">valve in pts less than 20 y were </text>
<text top="677" left="874" width="165" height="20" font="4">significant predictors of single </text>
<text top="694" left="874" width="96" height="20" font="4">ventricle defects. </text>
<text top="747" left="64" width="87" height="20" font="4">Discigil B, et al. </text>
<text top="764" left="64" width="63" height="20" font="4">2001 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(540)</a> </text>
<text top="781" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11174741?dopt=Citation">11174741</a></text>
<text top="781" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11174741?dopt=Citation"> </a></text>
<text top="747" left="165" width="51" height="20" font="4">n=42 pts </text>
<text top="747" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="764" left="257" width="48" height="20" font="4">analysis </text>
<text top="747" left="356" width="139" height="20" font="3"><b>Inclusion criteria</b>: 1974–</text>
<text top="764" left="356" width="31" height="20" font="4">1998 </text>
<text top="747" left="514" width="44" height="20" font="4">Review </text>
<text top="764" left="514" width="89" height="20" font="4">experience with </text>
<text top="747" left="628" width="213" height="20" font="4">● Interval between TOF repair and PV </text>
<text top="764" left="628" width="226" height="20" font="4">replacement was 10.8 y (1.6 mo to 33 y). </text>
<text top="747" left="874" width="131" height="20" font="4">● Late PV replacement </text>
<text top="764" left="874" width="177" height="20" font="4">improves RV function, FC, atrial </text>
<text top="781" left="874" width="65" height="20" font="4">arrhythmia. </text>
</page>
<page number="143" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 143 </text>
<text top="107" left="514" width="43" height="20" font="4">late PV </text>
<text top="124" left="514" width="71" height="20" font="4">replacement </text>
<text top="107" left="628" width="204" height="20" font="4">● Decreased exercise tolerance was </text>
<text top="124" left="628" width="100" height="20" font="4">indication in 58%. </text>
<text top="141" left="628" width="206" height="20" font="4">● 1 early death and 6 late (3 cardiac) </text>
<text top="159" left="628" width="221" height="20" font="4">Survival was 95.1% and 76.4% at 5 and </text>
<text top="176" left="628" width="30" height="20" font="4">10 y. </text>
<text top="193" left="628" width="157" height="20" font="4">● FC improved significantly. </text>
<text top="210" left="628" width="211" height="20" font="4">● Moderate-to-severe reduction in RV </text>
<text top="228" left="628" width="219" height="20" font="4">function improved from 59% pre to 18% </text>
<text top="245" left="628" width="30" height="20" font="4">post. </text>
<text top="262" left="628" width="227" height="20" font="4">● Freedom to rereplacement 9.0 ± 4.2 y; </text>
<text top="279" left="628" width="221" height="20" font="4">freedom from rereplacement 93.1% and </text>
<text top="296" left="628" width="116" height="20" font="4">69.8% at 5 and 10 y. </text>
<text top="314" left="628" width="199" height="20" font="4">● Risk factor for rereplacement was </text>
<text top="331" left="628" width="177" height="20" font="4">younger age at time of initial PV </text>
<text top="348" left="628" width="131" height="20" font="4">replacement (p=0.023). </text>
<text top="107" left="874" width="162" height="20" font="4">● Can be performed with low </text>
<text top="124" left="874" width="53" height="20" font="4">mortality. </text>
<text top="141" left="874" width="173" height="20" font="4">● Rereplacement may become </text>
<text top="159" left="874" width="63" height="20" font="4">necessary. </text>
<text top="366" left="64" width="87" height="20" font="4">Zubairi R, et al. </text>
<text top="383" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(541)</a> </text>
<text top="400" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21256315?dopt=Citation">21256315</a></text>
<text top="400" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21256315?dopt=Citation"> </a></text>
<text top="366" left="165" width="58" height="20" font="4">n=169 pts </text>
<text top="366" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="383" left="257" width="48" height="20" font="4">analysis </text>
<text top="366" left="356" width="139" height="20" font="3"><b>Inclusion criteria</b>: 1987–</text>
<text top="383" left="356" width="136" height="20" font="4">2007 after prior repair of </text>
<text top="400" left="356" width="91" height="20" font="4">PV replacement </text>
<text top="366" left="514" width="66" height="20" font="4">Identify risk </text>
<text top="383" left="514" width="74" height="20" font="4">factors of PV </text>
<text top="400" left="514" width="41" height="20" font="4">Failure </text>
<text top="366" left="628" width="203" height="20" font="4">● Indication for PV replacement was </text>
<text top="383" left="628" width="115" height="20" font="4">insufficiency in 79%. </text>
<text top="400" left="628" width="132" height="20" font="4">● Median follow-up 8 y. </text>
<text top="418" left="628" width="210" height="20" font="4">● Freedom from failure at 10 y overall </text>
<text top="435" left="628" width="210" height="20" font="4">72% and best for bovine pericardial at </text>
<text top="452" left="628" width="31" height="20" font="4">78%. </text>
<text top="469" left="628" width="213" height="20" font="4">● Risk factors for PV failure are young </text>
<text top="487" left="628" width="232" height="20" font="4">age, use of homograft for early failure and </text>
<text top="504" left="628" width="116" height="20" font="4">younger age for late. </text>
<text top="366" left="874" width="142" height="20" font="4">● Excellent freedom from </text>
<text top="383" left="874" width="109" height="20" font="4">reoperation at 10 y. </text>
<text top="400" left="874" width="146" height="20" font="4">● Risk factors for PVF are </text>
<text top="418" left="874" width="178" height="20" font="4">young age, use of homograft for </text>
<text top="435" left="874" width="163" height="20" font="4">early failure and younger age </text>
<text top="452" left="874" width="44" height="20" font="4">for late. </text>
<text top="522" left="64" width="86" height="20" font="4">Babu-Narayan, </text>
<text top="539" left="64" width="53" height="20" font="4">SV, et al. </text>
<text top="556" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(249)</a> </text>
<text top="573" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20970202?dopt=Citation">20970202</a></text>
<text top="573" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20970202?dopt=Citation"> </a></text>
<text top="522" left="165" width="54" height="20" font="4">n=64 pts; </text>
<text top="539" left="165" width="59" height="20" font="4">not known </text>
<text top="556" left="165" width="51" height="20" font="4">TOF/PA  </text>
<text top="522" left="257" width="43" height="20" font="4">Double-</text>
<text top="539" left="257" width="46" height="20" font="4">blinded, </text>
<text top="556" left="257" width="47" height="20" font="4">placebo-</text>
<text top="573" left="257" width="60" height="20" font="4">controlled, </text>
<text top="591" left="257" width="29" height="20" font="4">RCT </text>
<text top="522" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="539" left="356" width="120" height="20" font="4">Moderate-severe PR; </text>
<text top="556" left="356" width="31" height="20" font="4">CMR </text>
<text top="573" left="356" width="3" height="20" font="4"> </text>
<text top="591" left="356" width="133" height="20" font="3"><b>Exclusion criteria</b>: PS, </text>
<text top="608" left="356" width="102" height="20" font="4">drug allergy, renal </text>
<text top="625" left="356" width="66" height="20" font="4">dysfunction </text>
<text top="522" left="514" width="68" height="20" font="4">CMR RVEF </text>
<text top="522" left="628" width="198" height="20" font="4">● There was no difference in the 1° </text>
<text top="539" left="628" width="224" height="20" font="4">endpoint RVEF. RV long-axis shortening </text>
<text top="556" left="628" width="198" height="20" font="4">significantly improved in the ramipril </text>
<text top="573" left="628" width="214" height="20" font="4">group compared to placebo (RV: 2.3 ± </text>
<text top="591" left="628" width="215" height="20" font="4">3.8 vs. 0.02 ± 2.7 mm; p=0.017) as did </text>
<text top="608" left="628" width="233" height="20" font="4">LV long-axis shortening (1.9 ± 4.5 vs. -0.2 </text>
<text top="625" left="628" width="233" height="20" font="4">± 3.7 mm respectively; p=0.030). No clear </text>
<text top="642" left="628" width="194" height="20" font="4">differences were detected between </text>
<text top="659" left="628" width="224" height="20" font="4">ramipril and placebo for other measures. </text>
<text top="677" left="628" width="214" height="20" font="4">In a subgroup of pts with restrictive RV </text>
<text top="694" left="628" width="223" height="20" font="4">physiology, ramipril resulted in decrease </text>
<text top="711" left="628" width="199" height="20" font="4">in LV end systolic volume index and </text>
<text top="728" left="628" width="230" height="20" font="4">increase in LVEF (-2.4 ± 5.0 vs. 2.7 ± 3.6 </text>
<text top="745" left="628" width="31" height="20" font="4">mL/m</text>
<text top="747" left="659" width="4" height="13" font="6">2</text>
<text top="745" left="663" width="166" height="20" font="4">; p=0.005, 2.5 ± 5.0 vs. -1.3 ± </text>
<text top="763" left="628" width="87" height="20" font="4">3.5%; p=0.03).  </text>
<text top="522" left="874" width="160" height="20" font="4">● Ramipril is a well-tolerated </text>
<text top="539" left="874" width="171" height="20" font="4">therapy, improves biventricular </text>
<text top="556" left="874" width="161" height="20" font="4">function in pts with rTOF and </text>
<text top="573" left="874" width="178" height="20" font="4">may have a particular role in pts </text>
<text top="591" left="874" width="170" height="20" font="4">with restrictive RV physiology.  </text>
<text top="608" left="874" width="164" height="20" font="4">● Larger, longer-term studies </text>
<text top="625" left="874" width="147" height="20" font="4">are needed to determine if </text>
<text top="642" left="874" width="136" height="20" font="4">ACEIs can improve both </text>
<text top="659" left="874" width="148" height="20" font="4">ventricular remodeling and </text>
<text top="677" left="874" width="100" height="20" font="4">clinical outcomes. </text>
</page>
<page number="144" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 144 </text>
<text top="107" left="628" width="231" height="20" font="4">● Ramipril did not cause AE and was well </text>
<text top="124" left="628" width="55" height="20" font="4">tolerated. </text>
<text top="142" left="64" width="87" height="20" font="4">Norozi, K, et al. </text>
<text top="159" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#224">(248)</a> </text>
<text top="177" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17572925?dopt=Citation">17572925</a></text>
<text top="177" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17572925?dopt=Citation"> </a></text>
<text top="142" left="165" width="51" height="20" font="4">n=33 pts </text>
<text top="142" left="257" width="43" height="20" font="4">Double-</text>
<text top="159" left="257" width="46" height="20" font="4">blinded, </text>
<text top="177" left="257" width="47" height="20" font="4">placebo-</text>
<text top="194" left="257" width="60" height="20" font="4">controlled, </text>
<text top="211" left="257" width="29" height="20" font="4">RCT </text>
<text top="142" left="356" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="159" left="356" width="51" height="20" font="4">14–50 y  </text>
<text top="177" left="356" width="3" height="20" font="4"> </text>
<text top="194" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="211" left="356" width="131" height="20" font="4">Significant bradycardia, </text>
<text top="228" left="356" width="128" height="20" font="4">average heart rate &lt;50 </text>
<text top="245" left="356" width="141" height="20" font="4">beats/min, already on BB </text>
<text top="142" left="514" width="86" height="20" font="4">Cardiac failure: </text>
<text top="159" left="514" width="96" height="20" font="4">present if level of </text>
<text top="177" left="514" width="96" height="20" font="4">BNP significantly </text>
<text top="194" left="514" width="69" height="20" font="4">&gt;100 pg/mL </text>
<text top="142" left="628" width="229" height="20" font="4">● Beta blockade with bisoprolol seems to </text>
<text top="159" left="628" width="233" height="20" font="4">have no beneficial effect on asymptomatic </text>
<text top="177" left="628" width="187" height="20" font="4">or mildly symptomatic pts with RV </text>
<text top="194" left="628" width="197" height="20" font="4">dysfunction secondary to rTOF with </text>
<text top="211" left="628" width="128" height="20" font="4">residual PR and/or PS. </text>
<text top="142" left="874" width="175" height="20" font="4">● Beta blockade with bisoprolol </text>
<text top="159" left="874" width="156" height="20" font="4">seems to have no beneficial </text>
<text top="177" left="874" width="179" height="20" font="4">effect on asymptomatic or mildly </text>
<text top="194" left="874" width="138" height="20" font="4">symptomatic pts with RV </text>
<text top="211" left="874" width="172" height="20" font="4">dysfunction secondary to rTOF </text>
<text top="228" left="874" width="154" height="20" font="4">with residual PR and/or PS. </text>
<text top="263" left="64" width="77" height="20" font="4">Geva T, et al. </text>
<text top="281" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(542)</a> </text>
<text top="298" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20837914?dopt=Citation">20837914</a></text>
<text top="298" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20837914?dopt=Citation"> </a></text>
<text top="263" left="165" width="51" height="20" font="4">n=64 pts </text>
<text top="263" left="257" width="69" height="20" font="4">Randomize, </text>
<text top="281" left="257" width="66" height="20" font="4">prospective </text>
<text top="298" left="257" width="64" height="20" font="4">clinical trial </text>
<text top="263" left="356" width="139" height="20" font="3"><b>Inclusion criteria</b>: Older </text>
<text top="281" left="356" width="117" height="20" font="4">than 10 y of age with </text>
<text top="298" left="356" width="128" height="20" font="4">chronic PR referred for </text>
<text top="315" left="356" width="91" height="20" font="4">PV replacement </text>
<text top="332" left="356" width="3" height="20" font="4"> </text>
<text top="350" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="367" left="356" width="133" height="20" font="4">Severe RVOTO, severe </text>
<text top="384" left="356" width="109" height="20" font="4">RV HTN, additional </text>
<text top="401" left="356" width="124" height="20" font="4">sources of RV volume </text>
<text top="418" left="356" width="54" height="20" font="4">overload, </text>
<text top="436" left="356" width="141" height="20" font="4">contraindications to CMR </text>
<text top="263" left="514" width="68" height="20" font="4">CMR RVEF </text>
<text top="263" left="628" width="224" height="20" font="4">● No significant difference in RVEF or in </text>
<text top="281" left="628" width="219" height="20" font="4">any of the secondary outcomes at 6 mo </text>
<text top="298" left="628" width="201" height="20" font="4">postoperative. Multivariable analysis </text>
<text top="315" left="628" width="195" height="20" font="4">identified preoperative RVEDV &gt;90 </text>
<text top="332" left="628" width="31" height="20" font="4">mL/m</text>
<text top="334" left="659" width="4" height="13" font="6">2</text>
<text top="332" left="663" width="187" height="20" font="4"> and QRS duration &lt;140 ms to be </text>
<text top="350" left="628" width="211" height="20" font="4">associated with optional postoperative </text>
<text top="367" left="628" width="57" height="20" font="4">outcome.  </text>
<text top="263" left="874" width="143" height="20" font="4">● The addition of surgical </text>
<text top="281" left="874" width="152" height="20" font="4">remodeling of the RV to PV </text>
<text top="298" left="874" width="172" height="20" font="4">replacement in pts with chronic </text>
<text top="315" left="874" width="154" height="20" font="4">PR did not result in an early </text>
<text top="332" left="874" width="111" height="20" font="4">measurable benefit. </text>
<text top="454" left="64" width="76" height="20" font="4">Therrien J, et </text>
<text top="471" left="64" width="16" height="20" font="4">al. </text>
<text top="488" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(543)</a> </text>
<text top="505" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15757612?dopt=Citation">15757612</a></text>
<text top="505" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15757612?dopt=Citation"> </a></text>
<text top="454" left="165" width="51" height="20" font="4">n=17 pts </text>
<text top="454" left="257" width="79" height="20" font="4">Retrospective </text>
<text top="454" left="356" width="133" height="20" font="3"><b>Inclusion criteria</b>: TOF </text>
<text top="471" left="356" width="126" height="20" font="4">pts who underwent PV </text>
<text top="488" left="356" width="71" height="20" font="4">replacement </text>
<text top="454" left="514" width="70" height="20" font="4">RV volumes </text>
<text top="454" left="628" width="191" height="20" font="4">● RV volumes decreased after PV </text>
<text top="471" left="628" width="221" height="20" font="4">replacement, yet RVEF systolic function </text>
<text top="488" left="628" width="109" height="20" font="4">remain unchanged. </text>
<text top="454" left="874" width="177" height="20" font="4">● Pts with an RVEDV &gt;170 mL/ </text>
<text top="471" left="874" width="10" height="20" font="4">m</text>
<text top="472" left="884" width="4" height="13" font="6">2</text>
<text top="471" left="888" width="118" height="20" font="4"> or RVESV &gt;85 mL/m</text>
<text top="472" left="1006" width="4" height="13" font="6">2</text>
<text top="471" left="1011" width="42" height="20" font="4"> before </text>
<text top="488" left="874" width="163" height="20" font="4">PV replacement “normalized” </text>
<text top="505" left="874" width="121" height="20" font="4">after pulmonary valve </text>
<text top="522" left="874" width="75" height="20" font="4">replacement. </text>
<text top="540" left="64" width="87" height="20" font="4">Quail MA, et al. </text>
<text top="558" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(544)</a> </text>
<text top="575" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22959579?dopt=Citation">22959579</a></text>
<text top="575" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22959579?dopt=Citation"> </a></text>
<text top="540" left="165" width="51" height="20" font="4">n=87 pts </text>
<text top="540" left="257" width="61" height="20" font="4">Propensity </text>
<text top="558" left="257" width="33" height="20" font="4">score </text>
<text top="575" left="257" width="53" height="20" font="4">matching </text>
<text top="592" left="257" width="38" height="20" font="4">cohort </text>
<text top="540" left="356" width="133" height="20" font="3"><b>Inclusion criteria</b>: TOF </text>
<text top="558" left="356" width="114" height="20" font="4">with severe PR from </text>
<text top="575" left="356" width="65" height="20" font="4">2003–2010 </text>
<text top="540" left="514" width="87" height="20" font="4">Ventricular size </text>
<text top="558" left="514" width="70" height="20" font="4">and function </text>
<text top="540" left="628" width="228" height="20" font="4">● No significant deterioration in RV or LV </text>
<text top="558" left="628" width="224" height="20" font="4">measurements in the matched untreated </text>
<text top="575" left="628" width="148" height="20" font="4">pts over a median of 1.8 y. </text>
<text top="592" left="628" width="219" height="20" font="4">● No absolute ceiling beyond which the </text>
<text top="609" left="628" width="228" height="20" font="4">RV did not normalize could be discerned. </text>
<text top="540" left="874" width="177" height="20" font="4">● TOF pts with intermediate RV </text>
<text top="558" left="874" width="162" height="20" font="4">dilation and severe PR are at </text>
<text top="575" left="874" width="120" height="20" font="4">low risk for significant </text>
<text top="592" left="874" width="163" height="20" font="4">progression in the short term. </text>
<text top="627" left="64" width="80" height="20" font="4">Blalock SE, et </text>
<text top="644" left="64" width="16" height="20" font="4">al. </text>
<text top="662" left="64" width="56" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#216">(75)</a> </text>
<text top="679" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23418153?dopt=Citation">23418153</a></text>
<text top="679" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23418153?dopt=Citation"> </a></text>
<text top="627" left="165" width="51" height="20" font="4">n=30 pts </text>
<text top="627" left="257" width="67" height="20" font="4">Prospective </text>
<text top="644" left="257" width="33" height="20" font="4">study </text>
<text top="627" left="356" width="133" height="20" font="3"><b>Inclusion criteria</b>: TOF </text>
<text top="644" left="356" width="124" height="20" font="4">undergoing CMR from </text>
<text top="662" left="356" width="65" height="20" font="4">2009–2010 </text>
<text top="679" left="356" width="3" height="20" font="4"> </text>
<text top="696" left="356" width="141" height="20" font="3"><b>Exclusion criteria</b>: CMR </text>
<text top="713" left="356" width="35" height="20" font="4">under </text>
<text top="730" left="356" width="116" height="20" font="4">sedation/anesthesia, </text>
<text top="748" left="356" width="101" height="20" font="4">imaging artifact or </text>
<text top="765" left="356" width="62" height="20" font="4">arrhythmia </text>
<text top="627" left="514" width="87" height="20" font="4">Ventricular size </text>
<text top="644" left="514" width="70" height="20" font="4">and function </text>
<text top="627" left="628" width="214" height="20" font="4">● Agreement for measurements better </text>
<text top="644" left="628" width="129" height="20" font="4">with a single observer.  </text>
<text top="662" left="628" width="178" height="20" font="4">● Effect was most prominent on </text>
<text top="679" left="628" width="149" height="20" font="4">measurement of RV mass. </text>
<text top="627" left="874" width="142" height="20" font="4">● CMR measurements of </text>
<text top="644" left="874" width="156" height="20" font="4">ventricular size and function </text>
<text top="662" left="874" width="172" height="20" font="4">have acceptable reproducibility </text>
<text top="679" left="874" width="141" height="20" font="4">in pts with repaired TOF.  </text>
<text top="696" left="874" width="172" height="20" font="4">● RV mass measurements are </text>
<text top="713" left="874" width="152" height="20" font="4">subject to higher variability. </text>
</page>
<page number="145" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 145 </text>
<text top="107" left="64" width="88" height="20" font="4">Mercer-Rosa L, </text>
<text top="124" left="64" width="30" height="20" font="4">et al. </text>
<text top="141" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(545)</a> </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22869820?dopt=Citation">22869820</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22869820?dopt=Citation"> </a></text>
<text top="107" left="165" width="58" height="20" font="4">n=143 pts </text>
<text top="107" left="257" width="68" height="20" font="4">Prospective </text>
<text top="107" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="356" width="135" height="20" font="4">Repaired TOF 8–18 y of </text>
<text top="141" left="356" width="128" height="20" font="4">age; echocardiography </text>
<text top="159" left="356" width="121" height="20" font="4">and CMR within 3 mo </text>
<text top="107" left="514" width="91" height="20" font="4">RV function and </text>
<text top="124" left="514" width="21" height="20" font="4">PR </text>
<text top="107" left="628" width="226" height="20" font="4">● Echocardiography had good sensitivity </text>
<text top="124" left="628" width="226" height="20" font="4">identifying cases with regurgitant fraction </text>
<text top="141" left="628" width="215" height="20" font="4">&gt;20% but overestimated the amount of </text>
<text top="159" left="628" width="201" height="20" font="4">PR when regurgitant fraction &lt;20%.  </text>
<text top="176" left="628" width="224" height="20" font="4">● The diastolic and systolic time-velocity </text>
<text top="193" left="628" width="198" height="20" font="4">integrals on echo showed moderate </text>
<text top="210" left="628" width="209" height="20" font="4">correlation with regurgitant fraction on </text>
<text top="227" left="628" width="35" height="20" font="4">CMR. </text>
<text top="107" left="874" width="148" height="20" font="4">● Echocardiography has a </text>
<text top="124" left="874" width="178" height="20" font="4">limited ability to quantify PR and </text>
<text top="141" left="874" width="155" height="20" font="4">RV function as compared to </text>
<text top="159" left="874" width="152" height="20" font="4">CMR. Diastolic and systolic </text>
<text top="176" left="874" width="149" height="20" font="4">time-velocity integrals ratio </text>
<text top="193" left="874" width="168" height="20" font="4">make a modest contribution to </text>
<text top="210" left="874" width="167" height="20" font="4">the overall assessment of PR. </text>
<text top="245" left="64" width="84" height="20" font="4">Hallbergson A, </text>
<text top="263" left="64" width="30" height="20" font="4">et al. </text>
<text top="280" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(546)</a> </text>
<text top="297" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25483002?dopt=Citation">25483002</a></text>
<text top="297" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25483002?dopt=Citation"> </a></text>
<text top="245" left="165" width="58" height="20" font="4">n=101 pts </text>
<text top="245" left="257" width="79" height="20" font="4">Retrospective </text>
<text top="245" left="356" width="133" height="20" font="3"><b>Inclusion criteria</b>: TOF </text>
<text top="263" left="356" width="91" height="20" font="4">with surgical PV </text>
<text top="280" left="356" width="120" height="20" font="4">replacement, pre and </text>
<text top="297" left="356" width="117" height="20" font="4">post CMR, RVEDV z-</text>
<text top="314" left="356" width="52" height="20" font="4">score ≥3 </text>
<text top="332" left="356" width="3" height="20" font="4"> </text>
<text top="349" left="356" width="134" height="20" font="3"><b>Exclusion criteria</b>: Age </text>
<text top="366" left="356" width="135" height="20" font="4">at PV replacement &lt;4 y; </text>
<text top="383" left="356" width="136" height="20" font="4">prior surgical or catheter </text>
<text top="400" left="356" width="128" height="20" font="4">PV replacement; acute </text>
<text top="418" left="356" width="79" height="20" font="4">dysfunction of </text>
<text top="435" left="356" width="93" height="20" font="4">bioprosthetic PV </text>
<text top="245" left="514" width="89" height="20" font="4">RV dimensions, </text>
<text top="263" left="514" width="21" height="20" font="4">PR </text>
<text top="245" left="628" width="193" height="20" font="4">● By 7–10 y after PV replacement, </text>
<text top="263" left="628" width="211" height="20" font="4">RVEDV index and RVESV index were </text>
<text top="280" left="628" width="221" height="20" font="4">significantly increased and had returned </text>
<text top="297" left="628" width="114" height="20" font="4">to 84% and 104% of </text>
<text top="314" left="628" width="165" height="20" font="4">pre-PV replacement volumes, </text>
<text top="332" left="628" width="209" height="20" font="4">respectively, and RV EF had declined </text>
<text top="349" left="628" width="42" height="20" font="4">further. </text>
<text top="245" left="874" width="157" height="20" font="4">● Early reduction in RV size </text>
<text top="263" left="874" width="176" height="20" font="4">showed a gradual return toward </text>
<text top="280" left="874" width="127" height="20" font="4">preoperative values by </text>
<text top="297" left="874" width="166" height="20" font="4">7–10 y after PV replacement.  </text>
<text top="314" left="874" width="128" height="20" font="4">● The late adverse RV </text>
<text top="332" left="874" width="177" height="20" font="4">remodeling was associated with </text>
<text top="349" left="874" width="144" height="20" font="4">increased RV volume and </text>
<text top="366" left="874" width="87" height="20" font="4">pressure loads. </text>
<text top="453" left="64" width="79" height="20" font="4">Harrild DM, et </text>
<text top="470" left="64" width="16" height="20" font="4">al. </text>
<text top="487" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(547)</a> </text>
<text top="504" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19139389?dopt=Citation">19139389</a></text>
<text top="504" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19139389?dopt=Citation"> </a></text>
<text top="453" left="165" width="51" height="20" font="4">n=77 pts </text>
<text top="453" left="257" width="72" height="20" font="4">Case control </text>
<text top="470" left="257" width="33" height="20" font="4">study </text>
<text top="453" left="356" width="133" height="20" font="3"><b>Inclusion criteria</b>: TOF </text>
<text top="470" left="356" width="143" height="20" font="4">with PV replacement &gt;5 y </text>
<text top="487" left="356" width="28" height="20" font="4">prior </text>
<text top="504" left="356" width="3" height="20" font="4"> </text>
<text top="522" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="539" left="356" width="127" height="20" font="4">Confounding structural </text>
<text top="556" left="356" width="106" height="20" font="4">HD (AVC, Ebstein) </text>
<text top="453" left="514" width="59" height="20" font="4">Death, VT </text>
<text top="453" left="628" width="231" height="20" font="4">● No significant differences were found in </text>
<text top="470" left="628" width="207" height="20" font="4">age, QRS duration, type or decade of </text>
<text top="487" left="628" width="188" height="20" font="4">initial repair, age at TOF repair, or </text>
<text top="504" left="628" width="203" height="20" font="4">presence of pre- PV replacement VT </text>
<text top="522" left="628" width="125" height="20" font="4">between the 2 groups. </text>
<text top="453" left="874" width="149" height="20" font="4">● Late PV replacement for </text>
<text top="470" left="874" width="174" height="20" font="4">symptomatic PR did not reduce </text>
<text top="487" left="874" width="161" height="20" font="4">the incidence of VT or death. </text>
<text top="574" left="64" width="79" height="20" font="4">Tsai SF, et al. </text>
<text top="591" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(548)</a> </text>
<text top="608" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20723654?dopt=Citation">20723654</a></text>
<text top="608" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20723654?dopt=Citation"> </a></text>
<text top="574" left="165" width="54" height="20" font="4">n=80 pts  </text>
<text top="574" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="591" left="257" width="38" height="20" font="4">cohort </text>
<text top="574" left="356" width="135" height="20" font="3"><b>Inclusion criteria</b>: CHD </text>
<text top="591" left="356" width="130" height="20" font="4">pts with screening EPS </text>
<text top="574" left="514" width="46" height="20" font="4">Positive </text>
<text top="591" left="514" width="85" height="20" font="4">screening EPS </text>
<text top="608" left="514" width="78" height="20" font="4">for ventricular </text>
<text top="626" left="514" width="65" height="20" font="4">arrhythmia  </text>
<text top="574" left="628" width="228" height="20" font="4">● 23 pts with positive screening EPS and </text>
<text top="591" left="628" width="224" height="20" font="4">correlated with QRS duration, fibrosis on </text>
<text top="608" left="628" width="160" height="20" font="4">CMR and exercise capacity.  </text>
<text top="574" left="874" width="149" height="20" font="4">● Almost 30% of pts had a </text>
<text top="591" left="874" width="167" height="20" font="4">positive screening EPS for VA </text>
<text top="608" left="874" width="178" height="20" font="4">and combined exercise capacity </text>
<text top="626" left="874" width="129" height="20" font="4">and myocardial fibrosis </text>
<text top="643" left="874" width="146" height="20" font="4">predicted a positive study. </text>
<text top="661" left="64" width="87" height="20" font="4">Lucron H, et al. </text>
<text top="678" left="64" width="63" height="20" font="4">1999 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(549)</a> </text>
<text top="695" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10235097?dopt=Citation">10235097</a></text>
<text top="695" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10235097?dopt=Citation"> </a></text>
<text top="661" left="165" width="54" height="20" font="4">n=89 pts  </text>
<text top="661" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="678" left="257" width="41" height="20" font="4">cohort  </text>
<text top="661" left="356" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="678" left="356" width="126" height="20" font="4">with s/p repair for TOF </text>
<text top="695" left="356" width="118" height="20" font="4">who underwent EPS  </text>
<text top="661" left="514" width="64" height="20" font="4">Positive for </text>
<text top="678" left="514" width="52" height="20" font="4">inducible </text>
<text top="695" left="514" width="75" height="20" font="4">sustained VT </text>
<text top="661" left="628" width="223" height="20" font="4">● Compared the group that was positive </text>
<text top="678" left="628" width="212" height="20" font="4">n=21 vs. 68 that were negative. Those </text>
<text top="695" left="628" width="183" height="20" font="4">positive were older, had previous </text>
<text top="712" left="628" width="190" height="20" font="4">palliative shunt, higher RV systolic </text>
<text top="730" left="628" width="214" height="20" font="4">pressure, and had symptoms. In follow-</text>
<text top="747" left="628" width="194" height="20" font="4">up, no pt with a negative study had </text>
<text top="764" left="628" width="66" height="20" font="4">clinical VT.  </text>
<text top="661" left="874" width="146" height="20" font="4">● A negative EPS may be </text>
<text top="678" left="874" width="162" height="20" font="4">helpful in the management of </text>
<text top="695" left="874" width="159" height="20" font="4">postoperative TOF pts and a </text>
<text top="712" left="874" width="164" height="20" font="4">positive should be interpreted </text>
<text top="730" left="874" width="75" height="20" font="4">with caution.  </text>
</page>
<page number="146" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 146 </text>
<text top="107" left="64" width="82" height="20" font="4">Dietl CA, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">1994 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(550)</a> </text>
<text top="141" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7955286?dopt=Citation">7955286</a></text>
<text top="141" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7955286?dopt=Citation"> </a></text>
<text top="107" left="165" width="61" height="20" font="4">n=107 pts  </text>
<text top="107" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="124" left="257" width="41" height="20" font="4">cohort  </text>
<text top="107" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="356" width="141" height="20" font="4">Postoperative repair TOF </text>
<text top="141" left="356" width="104" height="20" font="4">who underwent 24 </text>
<text top="159" left="356" width="112" height="20" font="4">ambulatory monitor  </text>
<text top="107" left="514" width="84" height="20" font="4">Comparing RV </text>
<text top="124" left="514" width="76" height="20" font="4">vs. right atrial </text>
<text top="141" left="514" width="101" height="20" font="4">approach for TOF </text>
<text top="159" left="514" width="83" height="20" font="4">repair for atrial </text>
<text top="176" left="514" width="85" height="20" font="4">and VA on 24h </text>
<text top="193" left="514" width="64" height="20" font="4">ambulatory </text>
<text top="210" left="514" width="58" height="20" font="4">monitor.    </text>
<text top="107" left="628" width="209" height="20" font="4">● Pts who underwent RV approach to </text>
<text top="124" left="628" width="218" height="20" font="4">TOF repair vs. right atrial approach had </text>
<text top="141" left="628" width="207" height="20" font="4">significantly greater atrial and VA, RV </text>
<text top="159" left="628" width="224" height="20" font="4">dysfunction and pulmonary insufficiency. </text>
<text top="107" left="874" width="153" height="20" font="4">● Right atrial approach had </text>
<text top="124" left="874" width="174" height="20" font="4">significantly reduced risk for life </text>
<text top="141" left="874" width="92" height="20" font="4">threatening VA.  </text>
<text top="228" left="64" width="83" height="20" font="4">Khairy P, et al. </text>
<text top="245" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(551)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17522719?dopt=Citation">17522719</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17522719?dopt=Citation"> </a></text>
<text top="228" left="165" width="24" height="20" font="4">N/A </text>
<text top="228" left="257" width="50" height="20" font="4">Applying </text>
<text top="245" left="257" width="54" height="20" font="4">Bayesian </text>
<text top="263" left="257" width="51" height="20" font="4">theory to </text>
<text top="280" left="257" width="85" height="20" font="4">screening EPS </text>
<text top="297" left="257" width="66" height="20" font="4">for repaired </text>
<text top="314" left="257" width="28" height="20" font="4">TOF </text>
<text top="228" left="356" width="129" height="20" font="3"><b>Inclusion criteria</b>: N/A </text>
<text top="228" left="514" width="24" height="20" font="4">N/A </text>
<text top="228" left="628" width="195" height="20" font="4">● To identify pts with TOF in whom </text>
<text top="245" left="628" width="197" height="20" font="4">inducing VT would increase the risk </text>
<text top="263" left="628" width="220" height="20" font="4">category sufficiently to contemplate ICD </text>
<text top="280" left="628" width="188" height="20" font="4">implantation, the minimum pretest </text>
<text top="297" left="628" width="205" height="20" font="4">probability for SCD should be 0.95%, </text>
<text top="314" left="628" width="226" height="20" font="4">which corresponds to a positive post-test </text>
<text top="332" left="628" width="111" height="20" font="4">probability of 3.5%.  </text>
<text top="349" left="628" width="213" height="20" font="4">● A combination of static and dynamic </text>
<text top="366" left="628" width="208" height="20" font="4">noninvasive risk factors, such as age, </text>
<text top="383" left="628" width="208" height="20" font="4">transannular patch, nonsustained VT, </text>
<text top="400" left="628" width="171" height="20" font="4">syncope, and hemodynamic or </text>
<text top="418" left="628" width="231" height="20" font="4">echocardiographic data is, however, likely </text>
<text top="435" left="628" width="217" height="20" font="4">to identify a subgroup with a sufficiently </text>
<text top="452" left="628" width="224" height="20" font="4">high pretest probability to warrant further </text>
<text top="469" left="628" width="161" height="20" font="4">stratification with EP testing.  </text>
<text top="228" left="874" width="133" height="20" font="4">● Bayesian perspective </text>
<text top="245" left="874" width="172" height="20" font="4">indicates that PVS need not be </text>
<text top="263" left="874" width="146" height="20" font="4">routinely performed to risk-</text>
<text top="280" left="874" width="132" height="20" font="4">stratify all pts with TOF. </text>
<text top="487" left="64" width="82" height="20" font="4">Koyak Z, et al. </text>
<text top="504" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(552)</a> </text>
<text top="522" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22608897?dopt=Citation">22608897</a></text>
<text top="522" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22608897?dopt=Citation"> </a></text>
<text top="487" left="165" width="54" height="20" font="4">n=36 pts  </text>
<text top="487" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="504" left="257" width="41" height="20" font="4">cohort  </text>
<text top="487" left="356" width="133" height="20" font="3"><b>Inclusion criteria</b>: TOF </text>
<text top="504" left="356" width="103" height="20" font="4">pts with ICD for 1° </text>
<text top="522" left="356" width="64" height="20" font="4">prevention  </text>
<text top="487" left="514" width="91" height="20" font="4">Appropriate ICD </text>
<text top="504" left="514" width="66" height="20" font="4">shocks and </text>
<text top="522" left="514" width="87" height="20" font="4">compare to risk </text>
<text top="539" left="514" width="40" height="20" font="4">model  </text>
<text top="487" left="628" width="226" height="20" font="4">● 7 pts (19%) received ICD shock during </text>
<text top="504" left="628" width="208" height="20" font="4">median follow-up of 5.5 y. Only NSVT </text>
<text top="522" left="628" width="217" height="20" font="4">was associated with appropriate shock. </text>
<text top="539" left="628" width="211" height="20" font="4">The risk model predicted low, medium </text>
<text top="556" left="628" width="100" height="20" font="4">and high-risk pts.  </text>
<text top="487" left="874" width="162" height="20" font="4">● The risk model was able to </text>
<text top="504" left="874" width="180" height="20" font="4">stratify risk, but event rates were </text>
<text top="522" left="874" width="121" height="20" font="4">lower than predicted.  </text>
<text top="574" left="64" width="85" height="20" font="4">Witte KK, et al. </text>
<text top="591" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(553)</a> </text>
<text top="608" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18442962?dopt=Citation">18442962</a></text>
<text top="608" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18442962?dopt=Citation"> </a></text>
<text top="574" left="165" width="59" height="20" font="4">n=29 TOF </text>
<text top="591" left="165" width="61" height="20" font="4">pts and 39 </text>
<text top="608" left="165" width="57" height="20" font="4">with DCM </text>
<text top="574" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="591" left="257" width="38" height="20" font="4">cohort </text>
<text top="574" left="356" width="133" height="20" font="3"><b>Inclusion criteria</b>: TOF </text>
<text top="591" left="356" width="142" height="20" font="4">and DCM pts with an ICD </text>
<text top="574" left="514" width="64" height="20" font="4">Death, ICD </text>
<text top="591" left="514" width="90" height="20" font="4">therapy delivery </text>
<text top="574" left="628" width="201" height="20" font="4">● TOF pts had a higher incidence of </text>
<text top="591" left="628" width="220" height="20" font="4">inappropriate therapies and lower death </text>
<text top="608" left="628" width="28" height="20" font="4">rate  </text>
<text top="574" left="874" width="174" height="20" font="4">● TOF pts have a higher risk of </text>
<text top="591" left="874" width="153" height="20" font="4">inappropriate therapies and </text>
<text top="608" left="874" width="172" height="20" font="4">other complications yet a lower </text>
<text top="626" left="874" width="135" height="20" font="4">incidence of appropriate </text>
<text top="643" left="874" width="161" height="20" font="4">therapies from their ICD than </text>
<text top="660" left="874" width="55" height="20" font="4">DCM pts. </text>
<text top="678" left="64" width="77" height="20" font="4">Geva T, et al. </text>
<text top="695" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(554)</a> </text>
<text top="712" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24065609?dopt=Citation">24065609</a></text>
<text top="712" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24065609?dopt=Citation"> </a></text>
<text top="678" left="165" width="3" height="20" font="4"> </text>
<text top="678" left="257" width="49" height="20" font="4">Opinion  </text>
<text top="678" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="695" left="356" width="81" height="20" font="4">Repaired TOF </text>
<text top="678" left="514" width="94" height="20" font="4">Indication for PV </text>
<text top="695" left="514" width="71" height="20" font="4">replacement </text>
<text top="678" left="628" width="187" height="20" font="4">● Indications for PV replacement. </text>
<text top="678" left="874" width="178" height="20" font="4">● Large multicenter trials will be </text>
<text top="695" left="874" width="166" height="20" font="4">necessary to better determine </text>
<text top="712" left="874" width="117" height="20" font="4">optimal timing for PV </text>
<text top="730" left="874" width="78" height="20" font="4">replacement.  </text>
<text top="748" left="64" width="77" height="20" font="4">Gengsakul A, </text>
<text top="765" left="64" width="30" height="20" font="4">et al. </text>
<text top="782" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(528)</a> </text>
<text top="748" left="165" width="54" height="20" font="4">n=82 pts  </text>
<text top="748" left="257" width="78" height="20" font="4">Retrospective </text>
<text top="765" left="257" width="41" height="20" font="4">cohort  </text>
<text top="748" left="356" width="133" height="20" font="3"><b>Inclusion criteria</b>: TOF </text>
<text top="765" left="356" width="136" height="20" font="4">pts with PV replacement </text>
<text top="748" left="514" width="91" height="20" font="4">PV replacement </text>
<text top="765" left="514" width="57" height="20" font="4">on clinical </text>
<text top="782" left="514" width="60" height="20" font="4">outcomes  </text>
<text top="748" left="628" width="204" height="20" font="4">● Symptoms, FC, pulmonary and TV </text>
<text top="765" left="628" width="179" height="20" font="4">regurgitation improved in the PV </text>
<text top="782" left="628" width="113" height="20" font="4">replacement group.  </text>
<text top="748" left="874" width="154" height="20" font="4">● Symptoms and functional </text>
<text top="765" left="874" width="163" height="20" font="4">status are improved after late </text>
<text top="782" left="874" width="130" height="20" font="4">PV replacement, with a </text>
</page>
<page number="147" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 147 </text>
<text top="107" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17627832?dopt=Citation">17627832</a></text>
<text top="107" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17627832?dopt=Citation"> </a></text>
<text top="107" left="356" width="139" height="20" font="4">matched control TOF pts </text>
<text top="124" left="356" width="137" height="20" font="4">without PV replacement  </text>
<text top="107" left="874" width="171" height="20" font="4">reduction in pulmonary and TV </text>
<text top="124" left="874" width="165" height="20" font="4">regurgitation and RV size and </text>
<text top="141" left="874" width="69" height="20" font="4">dysfunction. </text>
<text top="159" left="108" width="3" height="20" font="4"> </text>
<text top="177" left="108" width="3" height="20" font="4"> </text>
<text top="197" left="108" width="9" height="20" font="3"><b>D</b></text>
<text top="194" left="117" width="559" height="24" font="1"><b>ata Supplement 44. Right Ventricle to Pulmonary Artery Conduit – Section 4.3.6 </b></text>
<text top="215" left="76" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="233" left="76" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="215" left="188" width="82" height="20" font="3"><b>Study Design </b></text>
<text top="215" left="302" width="38" height="20" font="3"><b>Study </b></text>
<text top="233" left="307" width="28" height="20" font="3"><b>Size </b></text>
<text top="215" left="372" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="233" left="409" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="215" left="520" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="215" left="732" width="48" height="20" font="3"><b>Results </b></text>
<text top="215" left="925" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="254" left="64" width="99" height="20" font="4">Boshoff DE, et al. </text>
<text top="271" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(555)</a>  </text>
<text top="288" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22887796?dopt=Citation">22887796</a></text>
<text top="288" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22887796?dopt=Citation"> </a></text>
<text top="254" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="271" left="179" width="65" height="20" font="4">case review</text>
<text top="273" left="243" width="2" height="13" font="6"> </text>
<text top="271" left="246" width="3" height="20" font="4"> </text>
<text top="254" left="293" width="173" height="20" font="4">n=23 pts   <b>Inclusion criteria</b>: </text>
<text top="271" left="361" width="122" height="20" font="4">Conduit free RVOT or </text>
<text top="288" left="361" width="117" height="20" font="4">undersized RV to PA </text>
<text top="305" left="361" width="96" height="20" font="4">conduit (&lt;16 mm)</text>
<text top="307" left="457" width="2" height="13" font="6"> </text>
<text top="254" left="516" width="63" height="20" font="4">Procedural </text>
<text top="271" left="516" width="69" height="20" font="4">efficacy and </text>
<text top="288" left="516" width="36" height="20" font="4">safety </text>
<text top="254" left="611" width="282" height="20" font="4">● 21 Melody valves and 2 Sapien valves implanted </text>
<text top="271" left="611" width="123" height="20" font="4">successfully in 23 pts. </text>
<text top="288" left="611" width="192" height="20" font="4">● Mean age is 17 y, range 6–81 y. </text>
<text top="305" left="611" width="285" height="20" font="4">● Group 1 (n=8) had conduit free RVOT and all had </text>
<text top="323" left="611" width="198" height="20" font="4">presenting prior to valve placement. </text>
<text top="340" left="611" width="274" height="20" font="4">● Group 2 (n=2) elderly pts with severe native PS </text>
<text top="357" left="611" width="132" height="20" font="4">and RVOT calcification. </text>
<text top="374" left="611" width="281" height="20" font="4">● Group 3 (n=13) with existing conduit (nominal 16 </text>
<text top="391" left="611" width="235" height="20" font="4">mm, range 10–20 mm), all had presenting. </text>
<text top="254" left="914" width="153" height="20" font="4">● PPVI safe and feasible in </text>
<text top="271" left="914" width="129" height="20" font="4">selected pts with an off-</text>
<text top="288" left="914" width="88" height="20" font="4">label indication. </text>
<text top="305" left="914" width="134" height="20" font="4">● Creating an adequate </text>
<text top="323" left="914" width="98" height="20" font="4">“landing zone” by </text>
<text top="340" left="914" width="121" height="20" font="4">presenting makes the </text>
<text top="357" left="914" width="109" height="20" font="4">procedure safe and </text>
<text top="374" left="914" width="67" height="20" font="4">predictable. </text>
<text top="409" left="64" width="79" height="20" font="4">Buber J, et al. </text>
<text top="427" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(556)</a>  </text>
<text top="444" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23756696?dopt=Citation">23756696</a></text>
<text top="444" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23756696?dopt=Citation"> </a></text>
<text top="409" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="427" left="179" width="74" height="20" font="4">single-center </text>
<text top="444" left="179" width="39" height="20" font="4">review </text>
<text top="409" left="293" width="38" height="20" font="4">n=147 </text>
<text top="427" left="293" width="23" height="20" font="4">pts  </text>
<text top="409" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="427" left="361" width="119" height="20" font="4">Consecutive pts from </text>
<text top="444" left="361" width="94" height="20" font="4">2007―2012 that </text>
<text top="461" left="361" width="136" height="20" font="4">underwent Melody valve </text>
<text top="478" left="361" width="115" height="20" font="4">placement at Boston </text>
<text top="496" left="361" width="106" height="20" font="4">Children’s Hospital </text>
<text top="409" left="516" width="76" height="20" font="4">Blood stream </text>
<text top="427" left="516" width="55" height="20" font="4">infections </text>
<text top="444" left="516" width="60" height="20" font="4">defined as </text>
<text top="461" left="516" width="50" height="20" font="4">bacterial </text>
<text top="478" left="516" width="49" height="20" font="4">infection </text>
<text top="496" left="516" width="67" height="20" font="4">treated with </text>
<text top="513" left="516" width="51" height="20" font="4">≥4 wk of </text>
<text top="530" left="516" width="62" height="20" font="4">antibiotics  </text>
<text top="409" left="611" width="275" height="20" font="4">● Mean age at implant was 21.5 ± 11 y, 59% with </text>
<text top="427" left="611" width="31" height="20" font="4">TOF. </text>
<text top="444" left="611" width="280" height="20" font="4">● During median follow-up of 19 mo, 14 pts (9.5%) </text>
<text top="461" left="611" width="151" height="20" font="4">had blood stream infection. </text>
<text top="478" left="611" width="233" height="20" font="4">● Of these, 4 (2.7%) had Melody valve IE. </text>
<text top="496" left="611" width="268" height="20" font="4">● 2 pts died during the event, neither had known </text>
<text top="513" left="611" width="105" height="20" font="4">valve involvement. </text>
<text top="530" left="611" width="273" height="20" font="4">● Medical procedure to infection time was 15 mo. </text>
<text top="547" left="611" width="283" height="20" font="4">● Univariate predictors were male sex, previous IE, </text>
<text top="564" left="611" width="287" height="20" font="4">in situ stents in RVOT, and presence of outflow tract </text>
<text top="582" left="611" width="170" height="20" font="4">irregularities at the implant site </text>
<text top="409" left="914" width="144" height="20" font="4">● Blood stream infections </text>
<text top="427" left="914" width="129" height="20" font="4">occurred in 9.5% of pts </text>
<text top="444" left="914" width="94" height="20" font="4">following Melody </text>
<text top="461" left="914" width="64" height="20" font="4">placement. </text>
<text top="478" left="914" width="122" height="20" font="4">● Minority (2.7%) had </text>
<text top="496" left="914" width="135" height="20" font="4">proven Melody valve IE. </text>
<text top="513" left="914" width="104" height="20" font="4">● Pt and nonvalve </text>
<text top="530" left="914" width="137" height="20" font="4">anatomic factors may be </text>
<text top="547" left="914" width="121" height="20" font="4">associated with blood </text>
<text top="564" left="914" width="100" height="20" font="4">stream infections. </text>
<text top="599" left="64" width="86" height="20" font="4">Butera G, et al. </text>
<text top="617" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(557)</a>  </text>
<text top="634" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22718682?dopt=Citation">22718682</a></text>
<text top="634" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22718682?dopt=Citation"> </a></text>
<text top="599" left="179" width="64" height="20" font="4">Multicenter </text>
<text top="617" left="179" width="44" height="20" font="4">registry </text>
<text top="634" left="179" width="70" height="20" font="4">prospective, </text>
<text top="651" left="179" width="76" height="20" font="4">observational </text>
<text top="668" left="179" width="33" height="20" font="4">study </text>
<text top="599" left="293" width="173" height="20" font="4">n=63 pts  <b>Inclusion criteria</b>: </text>
<text top="617" left="361" width="142" height="20" font="4">Between 2007―2010, 63 </text>
<text top="634" left="361" width="134" height="20" font="4">pts were included in this </text>
<text top="651" left="361" width="137" height="20" font="4">Italian registry of Melody </text>
<text top="668" left="361" width="81" height="20" font="4">valve implants </text>
<text top="599" left="516" width="61" height="20" font="4">Immediate </text>
<text top="617" left="516" width="24" height="20" font="4">and </text>
<text top="634" left="516" width="72" height="20" font="4">intermediate-</text>
<text top="651" left="516" width="28" height="20" font="4">term </text>
<text top="668" left="516" width="57" height="20" font="4">outcomes </text>
<text top="599" left="611" width="281" height="20" font="4">● 63 pts were included in the registry (median age: </text>
<text top="617" left="611" width="123" height="20" font="4">24 y; range 11–65 y).  </text>
<text top="634" left="611" width="273" height="20" font="4">● 40 pts were in NYHA class I–II while 23 were in </text>
<text top="651" left="611" width="270" height="20" font="4">NYHA class III-IV. Pts included had a history of a </text>
<text top="668" left="611" width="259" height="20" font="4">median 3 previous surgeries (range 1–5) and a </text>
<text top="686" left="611" width="283" height="20" font="4">median of 1 previous cardiac catheterization (range </text>
<text top="703" left="611" width="35" height="20" font="4">0–4).  </text>
<text top="720" left="611" width="260" height="20" font="4">● A conotruncal disease was present in 39 pts, </text>
<text top="737" left="611" width="286" height="20" font="4">previous Ross operation in 9, and other diagnosis in </text>
<text top="754" left="611" width="24" height="20" font="4">15.  </text>
<text top="599" left="914" width="130" height="20" font="4">● Early results suggest </text>
<text top="617" left="914" width="98" height="20" font="4">Melody implant is </text>
<text top="634" left="914" width="64" height="20" font="4">successful. </text>
<text top="651" left="914" width="94" height="20" font="4">11% risk of early </text>
<text top="668" left="914" width="81" height="20" font="4">complications. </text>
<text top="686" left="914" width="121" height="20" font="4">● Major concerns are </text>
<text top="703" left="914" width="154" height="20" font="4">related to stent fracture and </text>
<text top="720" left="914" width="68" height="20" font="4">bacterial IE. </text>
</page>
<page number="148" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 148 </text>
<text top="107" left="611" width="286" height="20" font="4">● Indication to valve implantation was pure stenosis </text>
<text top="124" left="611" width="265" height="20" font="4">in 21 pts, pure regurgitation in 12, association of </text>
<text top="141" left="611" width="178" height="20" font="4">stenosis and regurgitation in 30. </text>
<text top="159" left="611" width="286" height="20" font="4">● Implantation was performed in 61 subjects (97%). </text>
<text top="176" left="611" width="241" height="20" font="4">Presenting was performed in 85% of cases. </text>
<text top="193" left="611" width="267" height="20" font="4">● No significant regurgitation was recorded after </text>
<text top="210" left="611" width="247" height="20" font="4">procedure while the transpulmonary gradient </text>
<text top="228" left="611" width="122" height="20" font="4">reduced significantly.  </text>
<text top="245" left="611" width="267" height="20" font="4">Early major complications occurred in 7 subjects </text>
<text top="262" left="611" width="276" height="20" font="4">(11%). 1 death occurred in the early postoperative </text>
<text top="279" left="611" width="171" height="20" font="4">period in a severely ill subject.  </text>
<text top="296" left="611" width="290" height="20" font="4">● At a median follow-up of 30 mo (range 12–48 mo), </text>
<text top="314" left="611" width="207" height="20" font="4">3 pts died due to underlying disease.  </text>
<text top="331" left="611" width="257" height="20" font="4">● Major complications occurred in 6 pts during </text>
<text top="348" left="611" width="254" height="20" font="4">follow-up (external electric cardioversion: 1 pt; </text>
<text top="365" left="611" width="266" height="20" font="4">herpes virus encephalitis: 2 pts; Melody valve IE </text>
<text top="383" left="611" width="272" height="20" font="4">needing surgical explant: 2 pts; major fractures of </text>
<text top="400" left="611" width="224" height="20" font="4">the stent and need second Melody valve </text>
<text top="417" left="611" width="114" height="20" font="4">implantation: 2 pts).  </text>
<text top="434" left="611" width="286" height="20" font="4">● Freedom from valve failure at latest follow-up was </text>
<text top="451" left="611" width="75" height="20" font="4">81.4% ± 9%. </text>
<text top="469" left="64" width="96" height="20" font="4">Cheatham SL, et </text>
<text top="487" left="64" width="16" height="20" font="4">al. </text>
<text top="504" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(558)</a>  </text>
<text top="521" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23359563?dopt=Citation">23359563</a></text>
<text top="521" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23359563?dopt=Citation"> </a></text>
<text top="469" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="487" left="179" width="70" height="20" font="4">chart review </text>
<text top="469" left="293" width="173" height="20" font="4">n=11 pts   <b>Inclusion criteria</b>: </text>
<text top="487" left="361" width="138" height="20" font="4">Melody valves implanted </text>
<text top="504" left="361" width="127" height="20" font="4">on a 24-mm balloon or </text>
<text top="521" left="361" width="118" height="20" font="4">postdilated to 24 mm </text>
<text top="538" left="361" width="121" height="20" font="4">following implantation </text>
<text top="469" left="516" width="61" height="20" font="4">Immediate </text>
<text top="487" left="516" width="24" height="20" font="4">and </text>
<text top="504" left="516" width="72" height="20" font="4">intermediate-</text>
<text top="521" left="516" width="28" height="20" font="4">term </text>
<text top="538" left="516" width="57" height="20" font="4">outcomes </text>
<text top="469" left="611" width="289" height="20" font="4">● Between April 2008―Dec 2011, 13 Melody valves </text>
<text top="487" left="611" width="278" height="20" font="4">were successfully implanted in 11 pts, median age </text>
<text top="504" left="611" width="215" height="20" font="4">35 y (range 16–61 y), in the pulmonary </text>
<text top="521" left="611" width="269" height="20" font="4">(bioprosthetic valve, right ventricle to PA conduit, </text>
<text top="538" left="611" width="249" height="20" font="4">native valve) position (n=9), tricuspid position </text>
<text top="555" left="611" width="244" height="20" font="4">(bioprosthetic valve n=3), and aortic position </text>
<text top="573" left="611" width="145" height="20" font="4">(bioprosthetic valve n=1).  </text>
<text top="590" left="611" width="276" height="20" font="4">● 10 valves were delivered on a 24-mm balloon in </text>
<text top="607" left="611" width="276" height="20" font="4">balloon catheter, and 3 were implanted using a 22-</text>
<text top="624" left="611" width="282" height="20" font="4">mm Ensemble balloon delivery system, followed by </text>
<text top="641" left="611" width="267" height="20" font="4">post dilation using a 24 mm × 2 cm Atlas balloon </text>
<text top="659" left="611" width="55" height="20" font="4">catheter.  </text>
<text top="676" left="611" width="274" height="20" font="4">● Post-implant, the median peak systolic gradient </text>
<text top="693" left="611" width="274" height="20" font="4">across the PV was 7 mm Hg and median gradient </text>
<text top="710" left="611" width="283" height="20" font="4">across the TV was 3 mm Hg. There was no change </text>
<text top="727" left="611" width="263" height="20" font="4">in gradient across the Melody valve in the aortic </text>
<text top="745" left="611" width="269" height="20" font="4">position where valve prosthesis pt mismatch was </text>
<text top="762" left="611" width="48" height="20" font="4">present. </text>
<text top="469" left="914" width="152" height="20" font="4">● The Melody valve can be </text>
<text top="487" left="914" width="145" height="20" font="4">implanted at 24 mm in the </text>
<text top="504" left="914" width="108" height="20" font="4">stenotic/regurgitant </text>
<text top="521" left="914" width="137" height="20" font="4">bioprosthetic pulmonary, </text>
<text top="538" left="914" width="145" height="20" font="4">tricuspid, and aortic valve, </text>
<text top="555" left="914" width="152" height="20" font="4">dysfunctional right ventricle </text>
<text top="573" left="914" width="124" height="20" font="4">to PA conduit, and the </text>
<text top="590" left="914" width="130" height="20" font="4">native RV outflow tract. </text>
<text top="607" left="914" width="148" height="20" font="4">● At 9.5 mo median follow-</text>
<text top="624" left="914" width="117" height="20" font="4">up the valve remains </text>
<text top="641" left="914" width="112" height="20" font="4">competent with mild </text>
<text top="659" left="914" width="75" height="20" font="4">regurgitation. </text>
</page>
<page number="149" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 149 </text>
<text top="107" left="611" width="290" height="20" font="4">● Post-implant ICE demonstrated none or mild valve </text>
<text top="124" left="611" width="79" height="20" font="4">regurgitation.  </text>
<text top="141" left="611" width="272" height="20" font="4">● No more than mild regurgitation was noted at a </text>
<text top="159" left="611" width="151" height="20" font="4">median follow-up of 9.5 mo </text>
<text top="214" left="64" width="76" height="20" font="4">Faza N, et al. </text>
<text top="231" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(559)</a> </text>
<text top="248" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23008193?dopt=Citation">23008193</a></text>
<text top="248" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23008193?dopt=Citation"> </a></text>
<text top="214" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="231" left="179" width="89" height="20" font="4">data analysis of </text>
<text top="248" left="179" width="85" height="20" font="4">pts undergoing </text>
<text top="265" left="179" width="86" height="20" font="4">TPVR between </text>
<text top="283" left="179" width="85" height="20" font="4">2008 and 2012 </text>
<text top="214" left="293" width="43" height="20" font="4">Melody </text>
<text top="231" left="293" width="39" height="20" font="4">(n=13) </text>
<text top="248" left="293" width="42" height="20" font="4">Sapien </text>
<text top="265" left="293" width="43" height="20" font="4">(n=20)  </text>
<text top="283" left="293" width="52" height="20" font="4">Total=33 </text>
<text top="214" left="361" width="122" height="20" font="3"><b>Inclusion criteria</b>: All </text>
<text top="231" left="361" width="115" height="20" font="4">TPVRs performed at </text>
<text top="248" left="361" width="139" height="20" font="4">Rush University between </text>
<text top="265" left="361" width="127" height="20" font="4">April 2008―April 2012 </text>
<text top="214" left="516" width="61" height="20" font="4">Short- and </text>
<text top="231" left="516" width="72" height="20" font="4">intermediate-</text>
<text top="248" left="516" width="28" height="20" font="4">term </text>
<text top="265" left="516" width="57" height="20" font="4">outcomes </text>
<text top="214" left="611" width="260" height="20" font="4">● 33 pts underwent successful TPVR (SAPIEN </text>
<text top="231" left="611" width="120" height="20" font="4">n=20, Melody n=13).  </text>
<text top="248" left="611" width="264" height="20" font="4">● Pt age and weight were similar between the 2 </text>
<text top="265" left="611" width="48" height="20" font="4">groups.  </text>
<text top="283" left="611" width="280" height="20" font="4">1° indication included regurgitation (SAPIEN [n=2], </text>
<text top="300" left="611" width="291" height="20" font="4">Melody [n=3]), stenosis (SAPIEN [n=13], M [n=7]), or </text>
<text top="317" left="611" width="209" height="20" font="4">mixed (SAPIEN [n=5], Melody [n= 3]). </text>
<text top="334" left="611" width="270" height="20" font="4">● There was no difference in preprocedural peak </text>
<text top="351" left="611" width="264" height="20" font="4">Doppler gradients across the pulmonary outflow </text>
<text top="369" left="611" width="289" height="20" font="4">(SAPIEN = 47.73 ± 21.14 mm Hg, Melody = 42.62 ± </text>
<text top="386" left="611" width="130" height="20" font="4">15.59 mm Hg; p=0.46). </text>
<text top="403" left="611" width="270" height="20" font="4">● All but 1 pt underwent presenting prior to valve </text>
<text top="420" left="611" width="226" height="20" font="4">implantation. Immediately following valve </text>
<text top="437" left="611" width="248" height="20" font="4">deployment, the transvalvar gradient was not </text>
<text top="455" left="611" width="285" height="20" font="4">statistically different between the 2 groups (SAPEIN </text>
<text top="472" left="611" width="290" height="20" font="4">= 11.5 ± 8.07 mm Hg, Melody = 8.15 ± 4.56 mm Hg; </text>
<text top="489" left="611" width="52" height="20" font="4">p=0.18).  </text>
<text top="506" left="611" width="257" height="20" font="4">● There were no procedural deaths. Follow-up </text>
<text top="524" left="611" width="288" height="20" font="4">mean pulmonary Doppler gradients were higher with </text>
<text top="541" left="611" width="284" height="20" font="4">the SAPIEN cohort (18.43 ± 9.06 mm Hg (SAPIEN) </text>
<text top="558" left="611" width="251" height="20" font="4">and 11.17 ± 5.24 mm Hg (Melody); p=0.016); </text>
<text top="575" left="611" width="266" height="20" font="4">however, no differences were seen when similar </text>
<text top="592" left="611" width="197" height="20" font="4">procedural epochs were assessed.  </text>
<text top="610" left="611" width="231" height="20" font="4">● All but 1 pt remained with PR grade ≤2. </text>
<text top="214" left="914" width="150" height="20" font="4">● In a single-center series, </text>
<text top="231" left="914" width="136" height="20" font="4">the SAPIEN and Melody </text>
<text top="248" left="914" width="117" height="20" font="4">valves demonstrated </text>
<text top="265" left="914" width="144" height="20" font="4">comparable medium-term </text>
<text top="283" left="914" width="85" height="20" font="4">valve function.  </text>
<text top="300" left="914" width="104" height="20" font="4">● Greater residual </text>
<text top="317" left="914" width="148" height="20" font="4">gradients with the SAPIEN </text>
<text top="334" left="914" width="156" height="20" font="4">valve may represent a more </text>
<text top="351" left="914" width="102" height="20" font="4">conservative early </text>
<text top="369" left="914" width="141" height="20" font="4">presenting approach with </text>
<text top="386" left="914" width="58" height="20" font="4">this valve. </text>
<text top="627" left="64" width="86" height="20" font="4">Haas NA, et al. </text>
<text top="645" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(560)</a>  </text>
<text top="662" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22932954?dopt=Citation">22932954</a></text>
<text top="662" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22932954?dopt=Citation"> </a></text>
<text top="627" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="645" left="179" width="68" height="20" font="4">case review </text>
<text top="627" left="293" width="190" height="20" font="4">n=22 pts  <b>Inclusion criteria</b>: All </text>
<text top="645" left="361" width="139" height="20" font="4">SAPIEN PV replacement </text>
<text top="662" left="361" width="132" height="20" font="4">cases at a single center </text>
<text top="679" left="361" width="47" height="20" font="4">over 1 y </text>
<text top="627" left="516" width="61" height="20" font="4">Immediate </text>
<text top="645" left="516" width="55" height="20" font="4">and short-</text>
<text top="662" left="516" width="28" height="20" font="4">term </text>
<text top="679" left="516" width="57" height="20" font="4">outcomes </text>
<text top="627" left="611" width="233" height="20" font="4">● 22 pts with various RVOT morphologies </text>
<text top="645" left="611" width="253" height="20" font="4">transannular patch (n=4), bioprosthesis (n=2), </text>
<text top="662" left="611" width="278" height="20" font="4">homograft (n=5), and Contegra conduit (n=11). PS </text>
<text top="679" left="611" width="263" height="20" font="4">(n=2), PR (n=11) and a combined PS/PR (n=9). </text>
<text top="696" left="611" width="281" height="20" font="4">● 21/22 pts with successful PV replacement, mean </text>
<text top="713" left="611" width="64" height="20" font="4">age 21.7 y. </text>
<text top="731" left="611" width="277" height="20" font="4">● Decrease in mean RV systolic pressure from 61 </text>
<text top="748" left="611" width="261" height="20" font="4">mm Hg to 41 mm Hg, reduction in peak systolic </text>
<text top="765" left="611" width="282" height="20" font="4">gradient from 37 mm Hg to 7 mm Hg. Resolution of </text>
<text top="782" left="611" width="88" height="20" font="4">PR in all cases. </text>
<text top="627" left="914" width="126" height="20" font="4">● TPVR with Edwards-</text>
<text top="645" left="914" width="114" height="20" font="4">Sapien valve can be </text>
<text top="662" left="914" width="151" height="20" font="4">performed safely with good </text>
<text top="679" left="914" width="144" height="20" font="4">immediate and short-term </text>
<text top="696" left="914" width="141" height="20" font="4">results in pts with PS/PR. </text>
</page>
<page number="150" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 150 </text>
<text top="107" left="611" width="265" height="20" font="4">● 5.7 mo follow-up, no change in valve function. </text>
<text top="234" left="64" width="96" height="20" font="4">Hainstock NR, et </text>
<text top="251" left="64" width="16" height="20" font="4">al. </text>
<text top="268" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(561)</a> </text>
<text top="286" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24254707?dopt=Citation">24254707</a></text>
<text top="286" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24254707?dopt=Citation"> </a></text>
<text top="234" left="179" width="79" height="20" font="4">Single-center, </text>
<text top="251" left="179" width="74" height="20" font="4">retrospective </text>
<text top="268" left="179" width="61" height="20" font="4">analysis of </text>
<text top="286" left="179" width="79" height="20" font="4">angioplasty of </text>
<text top="303" left="179" width="98" height="20" font="4">obstructed RVOT </text>
<text top="320" left="179" width="59" height="20" font="4">homograft </text>
<text top="337" left="179" width="49" height="20" font="4">conduits </text>
<text top="234" left="293" width="194" height="20" font="4">n=70 pts   <b>Inclusion criteria</b>: Pts </text>
<text top="251" left="361" width="85" height="20" font="4">that underwent </text>
<text top="268" left="361" width="102" height="20" font="4">homograft conduit </text>
<text top="286" left="361" width="119" height="20" font="4">angioplasty with ultra-</text>
<text top="303" left="361" width="129" height="20" font="4">noncompliant balloons  </text>
<text top="234" left="516" width="61" height="20" font="4">Immediate </text>
<text top="251" left="516" width="57" height="20" font="4">outcomes </text>
<text top="234" left="611" width="196" height="20" font="4">● 70 pts underwent 76 procedures. </text>
<text top="251" left="611" width="258" height="20" font="4">● All pts with RV to PA obstructed homografts, </text>
<text top="268" left="611" width="256" height="20" font="4">underwent angioplasty with ultra-noncompliant </text>
<text top="286" left="611" width="268" height="20" font="4">balloons, outcomes compared to 81 pts who had </text>
<text top="303" left="611" width="216" height="20" font="4">angioplasty with conventional balloons. </text>
<text top="320" left="611" width="285" height="20" font="4">● Acute hemodynamic changes after angioplasty of </text>
<text top="337" left="611" width="244" height="20" font="4">homografts with ultra-noncompliant balloons </text>
<text top="354" left="611" width="268" height="20" font="4">included significantly reduced RV:aorta pressure </text>
<text top="372" left="611" width="245" height="20" font="4">ratio (p=0.02) and RV outflow tract gradients </text>
<text top="389" left="611" width="250" height="20" font="4">(p≤0.001). Balloon waist resolution was more </text>
<text top="406" left="611" width="261" height="20" font="4">frequently achieved with noncompliant balloons </text>
<text top="423" left="611" width="270" height="20" font="4">(p=0.04), and balloon rupture occurred less often </text>
<text top="440" left="611" width="63" height="20" font="4">(p&lt;0.001).  </text>
<text top="458" left="611" width="278" height="20" font="4">● Conduit tears of any severity occurred in 22% of </text>
<text top="475" left="611" width="256" height="20" font="4">pts overall and were more common in the ultra </text>
<text top="492" left="611" width="284" height="20" font="4">noncompliant balloon group (p=0.001). Pts with any </text>
<text top="509" left="611" width="268" height="20" font="4">conduit tear had significantly greater reduction in </text>
<text top="527" left="611" width="279" height="20" font="4">their RV: aorta pressure ratio (p&lt;0.001) and RVOT </text>
<text top="544" left="611" width="239" height="20" font="4">gradient (p=0.004) than those with no tear.  </text>
<text top="561" left="611" width="263" height="20" font="4">● There were 4 unconfined tears, all in the ultra-</text>
<text top="578" left="611" width="234" height="20" font="4">noncompliant balloon group, with no acute </text>
<text top="595" left="611" width="272" height="20" font="4">decompensations or deaths, 1 pt needed surgical </text>
<text top="613" left="611" width="67" height="20" font="4">intervention </text>
<text top="234" left="914" width="119" height="20" font="4">● Ultra-noncompliant </text>
<text top="251" left="914" width="122" height="20" font="4">balloon angioplasty of </text>
<text top="268" left="914" width="152" height="20" font="4">stenotic RV-PA homografts </text>
<text top="286" left="914" width="120" height="20" font="4">is more effective than </text>
<text top="303" left="914" width="91" height="20" font="4">angioplasty with </text>
<text top="320" left="914" width="135" height="20" font="4">conventional balloons in </text>
<text top="337" left="914" width="103" height="20" font="4">reducing stenosis. </text>
<text top="354" left="914" width="147" height="20" font="4">● The risk of conduit tears </text>
<text top="372" left="914" width="152" height="20" font="4">is higher with noncompliant </text>
<text top="389" left="914" width="149" height="20" font="4">balloons. Unconfined tears </text>
<text top="406" left="914" width="102" height="20" font="4">only occurred with </text>
<text top="423" left="914" width="129" height="20" font="4">noncompliant balloons. </text>
</page>
<page number="151" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 151 </text>
<text top="107" left="64" width="91" height="20" font="4">McElhinney DB, </text>
<text top="124" left="64" width="30" height="20" font="4">et al. </text>
<text top="141" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(562)</a>  </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23735475?dopt=Citation">23735475</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23735475?dopt=Citation"> </a></text>
<text top="107" left="179" width="88" height="20" font="4">Cross-sectional </text>
<text top="124" left="179" width="66" height="20" font="4">case series </text>
<text top="141" left="179" width="93" height="20" font="4">Multicenter case </text>
<text top="159" left="179" width="75" height="20" font="4">series from 3 </text>
<text top="176" left="179" width="47" height="20" font="4">ongoing </text>
<text top="193" left="179" width="66" height="20" font="4">prospective </text>
<text top="210" left="179" width="93" height="20" font="4">multicenter trials </text>
<text top="228" left="179" width="85" height="20" font="4">in the U.S. and </text>
<text top="245" left="179" width="43" height="20" font="4">Europe </text>
<text top="107" left="293" width="38" height="20" font="4">n=311 </text>
<text top="124" left="293" width="23" height="20" font="4">pts  </text>
<text top="107" left="361" width="140" height="20" font="3"><b>Inclusion criteria</b>: Pts at </text>
<text top="124" left="361" width="115" height="20" font="4">multiple centers who </text>
<text top="141" left="361" width="135" height="20" font="4">have undergone Melody </text>
<text top="159" left="361" width="132" height="20" font="4">PV replacement as part </text>
<text top="176" left="361" width="90" height="20" font="4">of 3 prospective </text>
<text top="193" left="361" width="131" height="20" font="4">multicenter center trials </text>
<text top="107" left="516" width="75" height="20" font="4">intermediate- </text>
<text top="124" left="516" width="79" height="20" font="4">and long-term </text>
<text top="141" left="516" width="57" height="20" font="4">outcomes </text>
<text top="107" left="611" width="274" height="20" font="4">● Any clinical episode with positive blood cultures </text>
<text top="124" left="611" width="265" height="20" font="4">and fever was considered IE regardless of valve </text>
<text top="141" left="611" width="73" height="20" font="4">involvement. </text>
<text top="159" left="611" width="291" height="20" font="4">● 3 trials included 311 pts with a median follow-up of </text>
<text top="176" left="611" width="30" height="20" font="4">2.5 y </text>
<text top="193" left="611" width="269" height="20" font="4">16 pts diagnosed with IE between 50 d and 4.7 y </text>
<text top="210" left="611" width="207" height="20" font="4">post Melody implant, median of 1.3 y. </text>
<text top="228" left="611" width="262" height="20" font="4">● 6 pts with evidence of valve related IE (3 with </text>
<text top="245" left="611" width="277" height="20" font="4">vegetations, 2 with valve dysfunction, 1 with both). </text>
<text top="262" left="611" width="262" height="20" font="4">Annualized rate of IE episodes is 2.4% per pt y. </text>
<text top="279" left="611" width="260" height="20" font="4">● All pts treated with IV antibiotics, 4 with valve </text>
<text top="296" left="611" width="269" height="20" font="4">explanted and 2 received a second transcatheter </text>
<text top="314" left="611" width="36" height="20" font="4">valve. </text>
<text top="331" left="611" width="227" height="20" font="4">● 1 pt died of sepsis, 1 pt died of sudden </text>
<text top="348" left="611" width="254" height="20" font="4">hemoptysis, and 2 pts developed recurrent IE. </text>
<text top="107" left="914" width="146" height="20" font="4">● IE occurred in 5% of pts </text>
<text top="124" left="914" width="140" height="20" font="4">post-Melody implantation </text>
<text top="141" left="914" width="143" height="20" font="4">with an annualized rate of </text>
<text top="159" left="914" width="146" height="20" font="4">2.4%/pt y, valve related IE </text>
<text top="176" left="914" width="122" height="20" font="4">occurred in 2% of pts. </text>
<text top="193" left="914" width="150" height="20" font="4">● Most cases respond well </text>
<text top="210" left="914" width="139" height="20" font="4">to IV antibiotic treatment. </text>
<text top="366" left="64" width="86" height="20" font="4">Batra AS, et al. </text>
<text top="383" left="64" width="66" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(563)</a>  </text>
<text top="400" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22305848?dopt=Citation">22305848</a></text>
<text top="400" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22305848?dopt=Citation"> </a></text>
<text top="366" left="179" width="93" height="20" font="4">Multicenter case </text>
<text top="383" left="179" width="36" height="20" font="4">series </text>
<text top="366" left="293" width="38" height="20" font="4">n=150 </text>
<text top="383" left="293" width="23" height="20" font="4">pts  </text>
<text top="366" left="361" width="140" height="20" font="3"><b>Inclusion criteria</b>: Pts at </text>
<text top="383" left="361" width="115" height="20" font="4">multiple centers who </text>
<text top="400" left="361" width="137" height="20" font="4">underwent CPET testing </text>
<text top="418" left="361" width="93" height="20" font="4">before and 6 mo </text>
<text top="435" left="361" width="114" height="20" font="4">following Melody PV </text>
<text top="452" left="361" width="60" height="20" font="4">placement </text>
<text top="366" left="516" width="59" height="20" font="4">Change in </text>
<text top="383" left="516" width="74" height="20" font="4">cardiopulmon</text>
<text top="400" left="516" width="70" height="20" font="4">ary exercise </text>
<text top="418" left="516" width="73" height="20" font="4">performance </text>
<text top="435" left="516" width="70" height="20" font="4">post Melody </text>
<text top="452" left="516" width="32" height="20" font="4">valve </text>
<text top="469" left="516" width="60" height="20" font="4">placement </text>
<text top="366" left="611" width="194" height="20" font="4">● No significant change in peak VO</text>
<text top="372" left="805" width="4" height="13" font="6">2</text>
<text top="366" left="809" width="27" height="20" font="4"> or O</text>
<text top="372" left="837" width="4" height="13" font="6">2</text>
<text top="366" left="841" width="40" height="20" font="4"> pulse. </text>
<text top="383" left="611" width="282" height="20" font="4">● Small but significant improvements noted in work </text>
<text top="400" left="611" width="142" height="20" font="4">rate achieved and VE/ VO</text>
<text top="407" left="753" width="4" height="13" font="6">2</text>
<text top="400" left="757" width="123" height="20" font="4"> ratio at the anaerobic </text>
<text top="418" left="611" width="57" height="20" font="4">threshold. </text>
<text top="435" left="611" width="219" height="20" font="4">● Post-Melody improvement in peak VO</text>
<text top="441" left="830" width="4" height="13" font="6">2</text>
<text top="435" left="834" width="29" height="20" font="4"> was </text>
<text top="452" left="611" width="262" height="20" font="4">greatest in pts with the lowest baseline peak VO</text>
<text top="458" left="872" width="4" height="13" font="6">2</text>
<text top="452" left="877" width="7" height="20" font="4">. </text>
<text top="366" left="914" width="154" height="20" font="4">● Transcatheter Melody PV </text>
<text top="383" left="914" width="145" height="20" font="4">replacement is associated </text>
<text top="400" left="914" width="150" height="20" font="4">with modest improvements </text>
<text top="418" left="914" width="134" height="20" font="4">in exercise capacity and </text>
<text top="435" left="914" width="138" height="20" font="4">gas exchange efficiency. </text>
<text top="487" left="64" width="80" height="20" font="4">Muller J, et al. </text>
<text top="504" left="64" width="66" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(564)</a>  </text>
<text top="522" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24713459?dopt=Citation">24713459</a></text>
<text top="522" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24713459?dopt=Citation"> </a></text>
<text top="487" left="179" width="76" height="20" font="4">Single-center </text>
<text top="504" left="179" width="74" height="20" font="4">retrospective </text>
<text top="522" left="179" width="68" height="20" font="4">case review </text>
<text top="487" left="293" width="173" height="20" font="4">n=59 pts  <b>Inclusion criteria</b>: </text>
<text top="504" left="361" width="125" height="20" font="4">Between 2007―2013, </text>
<text top="522" left="361" width="117" height="20" font="4">pts at a single center </text>
<text top="539" left="361" width="123" height="20" font="4">who underwent TPVR </text>
<text top="556" left="361" width="121" height="20" font="4">and underwent CPET </text>
<text top="573" left="361" width="122" height="20" font="4">testing, MRI and QOL </text>
<text top="591" left="361" width="141" height="20" font="4">assessment pre and post </text>
<text top="608" left="361" width="103" height="20" font="4">valve replacement </text>
<text top="487" left="516" width="66" height="20" font="4">Changes in </text>
<text top="504" left="516" width="74" height="20" font="4">cardiopulmon</text>
<text top="522" left="516" width="70" height="20" font="4">ary exercise </text>
<text top="539" left="516" width="73" height="20" font="4">performance </text>
<text top="556" left="516" width="79" height="20" font="4">and QOL pre- </text>
<text top="573" left="516" width="51" height="20" font="4">and post-</text>
<text top="591" left="516" width="32" height="20" font="4">valve </text>
<text top="608" left="516" width="71" height="20" font="4">replacement </text>
<text top="487" left="611" width="283" height="20" font="4">● 59 pts, mean age 22.8 y, 46 with PS, 13 with PR. </text>
<text top="504" left="611" width="260" height="20" font="4">56 had Melody valve placement, 3 with Sapient </text>
<text top="522" left="611" width="96" height="20" font="4">valve placement. </text>
<text top="539" left="611" width="201" height="20" font="4">● All pts had dysfunctional conduits. </text>
<text top="556" left="611" width="62" height="20" font="4">● Peak VO</text>
<text top="562" left="672" width="4" height="13" font="6">2</text>
<text top="556" left="677" width="214" height="20" font="4"> improved from 27.2 to 29.2 mL/kg/min </text>
<text top="573" left="611" width="275" height="20" font="4">(p&lt;0.001), improvements seen in both PS and PR </text>
<text top="591" left="611" width="64" height="20" font="4">subgroups. </text>
<text top="608" left="611" width="260" height="20" font="4">● QOL was good before valve replacement but </text>
<text top="625" left="611" width="288" height="20" font="4">improved in multiple domains post- PV replacement, </text>
<text top="642" left="611" width="250" height="20" font="4">especially in physical function, general health </text>
<text top="659" left="611" width="182" height="20" font="4">perception, and health transition. </text>
<text top="487" left="914" width="144" height="20" font="4">● QOL improvements are </text>
<text top="504" left="914" width="101" height="20" font="4">noted post-TPVR. </text>
<text top="522" left="914" width="114" height="20" font="4">● There is a modest </text>
<text top="539" left="914" width="127" height="20" font="4">improvement in peak O</text>
<text top="545" left="1041" width="4" height="13" font="6">2</text>
<text top="539" left="1046" width="3" height="20" font="4"> </text>
<text top="556" left="914" width="124" height="20" font="4">consumption following </text>
<text top="573" left="914" width="107" height="20" font="4">transcatheter PVR. </text>
</page>
<page number="152" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 152 </text>
<text top="107" left="64" width="87" height="20" font="4">Gillespie MJ, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="66" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#239">(565)</a>  </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23212395?dopt=Citation">23212395</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23212395?dopt=Citation"> </a></text>
<text top="107" left="179" width="93" height="20" font="4">Multicenter case </text>
<text top="124" left="179" width="36" height="20" font="4">series </text>
<text top="107" left="293" width="38" height="20" font="4">n=104 </text>
<text top="124" left="293" width="23" height="20" font="4">pts  </text>
<text top="107" left="361" width="140" height="20" font="3"><b>Inclusion criteria</b>: Pts at </text>
<text top="124" left="361" width="110" height="20" font="4">8 U.S. Centers who </text>
<text top="141" left="361" width="140" height="20" font="4">underwent Melody TPVR </text>
<text top="159" left="361" width="132" height="20" font="4">in a failing bioprosthetic </text>
<text top="176" left="361" width="82" height="20" font="4">valve between </text>
<text top="193" left="361" width="70" height="20" font="4">2007―2012 </text>
<text top="107" left="516" width="61" height="20" font="4">Short- and </text>
<text top="124" left="516" width="72" height="20" font="4">intermediate-</text>
<text top="141" left="516" width="28" height="20" font="4">term </text>
<text top="159" left="516" width="57" height="20" font="4">outcomes </text>
<text top="176" left="516" width="51" height="20" font="4">following </text>
<text top="193" left="516" width="36" height="20" font="4">TPVR </text>
<text top="107" left="611" width="241" height="20" font="4">● 104 pts underwent TPVR in dysfunctional </text>
<text top="124" left="611" width="106" height="20" font="4">bioprosthetic PV s. </text>
<text top="141" left="611" width="185" height="20" font="4">● 100% procedural success rate. </text>
<text top="159" left="611" width="282" height="20" font="4">● Peak RV-PA conduit gradient decreased from 39 </text>
<text top="176" left="611" width="154" height="20" font="4">mm Hg to 11 mm Hg mean. </text>
<text top="193" left="611" width="257" height="20" font="4">● No serious procedural morbidity or mortality. </text>
<text top="210" left="611" width="273" height="20" font="4">● Median of 12 mo follow-up, no significant PR, 4 </text>
<text top="228" left="611" width="72" height="20" font="4">pts with PS.  </text>
<text top="245" left="611" width="198" height="20" font="4">● 2 stent fractures during follow-up. </text>
<text top="262" left="611" width="240" height="20" font="4">● 3 cases of IE, 2 needing surgical explant. </text>
<text top="107" left="914" width="105" height="20" font="4">● Melody TPVR in </text>
<text top="124" left="914" width="148" height="20" font="4">dysfunctional bioprosthetic </text>
<text top="141" left="914" width="157" height="20" font="4">valves can be accomplished </text>
<text top="159" left="914" width="135" height="20" font="4">with a high success rate </text>
<text top="176" left="914" width="114" height="20" font="4">and good short- and </text>
<text top="193" left="914" width="100" height="20" font="4">intermediate-term </text>
<text top="210" left="914" width="60" height="20" font="4">outcomes. </text>
<text top="280" left="64" width="85" height="20" font="4">Eicken A, et al. </text>
<text top="297" left="64" width="66" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(566)</a>  </text>
<text top="314" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21273201?dopt=Citation">21273201</a></text>
<text top="314" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21273201?dopt=Citation"> </a></text>
<text top="280" left="179" width="48" height="20" font="4">2 center </text>
<text top="297" left="179" width="74" height="20" font="4">retrospective </text>
<text top="314" left="179" width="66" height="20" font="4">case series </text>
<text top="280" left="293" width="38" height="20" font="4">n=102 </text>
<text top="297" left="293" width="23" height="20" font="4">pts  </text>
<text top="280" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="297" left="361" width="96" height="20" font="4">Combined TPVR </text>
<text top="314" left="361" width="135" height="20" font="4">experience of 2 German </text>
<text top="332" left="361" width="118" height="20" font="4">Centers (Munich and </text>
<text top="349" left="361" width="42" height="20" font="4">Berlin)  </text>
<text top="280" left="516" width="61" height="20" font="4">Short- and </text>
<text top="297" left="516" width="72" height="20" font="4">intermediate-</text>
<text top="314" left="516" width="28" height="20" font="4">term </text>
<text top="332" left="516" width="57" height="20" font="4">outcomes </text>
<text top="349" left="516" width="51" height="20" font="4">following </text>
<text top="366" left="516" width="36" height="20" font="4">TPVR </text>
<text top="280" left="611" width="272" height="20" font="4">● 102 pts with dysfunctional RVOTs, median age </text>
<text top="297" left="611" width="40" height="20" font="4">21.5 y. </text>
<text top="314" left="611" width="143" height="20" font="4">● Median follow-up 352 d </text>
<text top="332" left="611" width="216" height="20" font="4">● Prestenting performed in 95% of pts. </text>
<text top="349" left="611" width="276" height="20" font="4">● Median peak systolic RVOT gradient decreased </text>
<text top="366" left="611" width="165" height="20" font="4">from 37 mm Hg to 14 mm Hg. </text>
<text top="383" left="611" width="280" height="20" font="4">● Median MRI measured RVEDV index decreased </text>
<text top="401" left="611" width="83" height="20" font="4">from 106 mL/m</text>
<text top="402" left="693" width="4" height="13" font="6">2</text>
<text top="400" left="698" width="65" height="20" font="4"> to 90 mL/m</text>
<text top="402" left="763" width="4" height="13" font="6">2</text>
<text top="400" left="767" width="7" height="20" font="4">. </text>
<text top="418" left="611" width="200" height="20" font="4">● PR significantly reduced in all pts. </text>
<text top="435" left="611" width="225" height="20" font="4">● 1 pt died of left coronary compression. </text>
<text top="452" left="611" width="181" height="20" font="4">● 5% incidence of stent fracture. </text>
<text top="469" left="611" width="287" height="20" font="4">● 1 pt with IE on the Melody valve requiring surgical </text>
<text top="487" left="611" width="51" height="20" font="4">removal. </text>
<text top="504" left="611" width="272" height="20" font="4">● Repeat intervention needed in 8/102 pts, 4/102 </text>
<text top="521" left="611" width="185" height="20" font="4">pts with valve in valve procedure. </text>
<text top="280" left="914" width="105" height="20" font="4">● Melody TPVR in </text>
<text top="297" left="914" width="113" height="20" font="4">dysfunctional RVOT </text>
<text top="314" left="914" width="131" height="20" font="4">conduits is feasible and </text>
<text top="332" left="914" width="119" height="20" font="4">effective in improving </text>
<text top="349" left="914" width="122" height="20" font="4">stenosis and relieving </text>
<text top="366" left="914" width="75" height="20" font="4">regurgitation. </text>
<text top="383" left="914" width="134" height="20" font="4">● The rate of short- and </text>
<text top="400" left="914" width="100" height="20" font="4">intermediate-term </text>
<text top="418" left="914" width="116" height="20" font="4">complications is low. </text>
<text top="539" left="64" width="92" height="20" font="4">Hasan BS, et al. </text>
<text top="556" left="64" width="66" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#236">(491)</a>  </text>
<text top="573" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22075926?dopt=Citation">22075926</a></text>
<text top="573" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22075926?dopt=Citation"> </a></text>
<text top="539" left="179" width="93" height="20" font="4">Multicenter case </text>
<text top="556" left="179" width="36" height="20" font="4">series </text>
<text top="539" left="293" width="173" height="20" font="4">n=30 pts   <b>Inclusion criteria</b>: </text>
<text top="556" left="361" width="75" height="20" font="4">Melody valve </text>
<text top="573" left="361" width="109" height="20" font="4">implantation in high </text>
<text top="591" left="361" width="100" height="20" font="4">pressure systems </text>
<text top="539" left="516" width="61" height="20" font="4">Short-term </text>
<text top="556" left="516" width="57" height="20" font="4">outcomes </text>
<text top="539" left="611" width="178" height="20" font="4">● 30 pts at 5 centers in the U.S. </text>
<text top="556" left="611" width="285" height="20" font="4">● 23 pulmonary, 5 native aortic, 1 LV to Ao, 1 mitral </text>
<text top="573" left="611" width="284" height="20" font="4">high pressure environment in PA circulation defined </text>
<text top="591" left="611" width="149" height="20" font="4">as mean PAP &gt;25 mm Hg. </text>
<text top="608" left="611" width="233" height="20" font="4">● In the pulmonary position 10 implants in </text>
<text top="625" left="611" width="245" height="20" font="4">homografts and 13 in bioprosthetic valves or </text>
<text top="642" left="611" width="165" height="20" font="4">bioprosthetic valved conduits. </text>
<text top="659" left="611" width="275" height="20" font="4">● 3 pts died<b>; </b>2 with Melody valves in the systemic </text>
<text top="677" left="611" width="288" height="20" font="4">circulation, 1 in the pulmonary circulation who died 8 </text>
<text top="694" left="611" width="234" height="20" font="4">mon after the procedure of drug overdose. </text>
<text top="711" left="611" width="238" height="20" font="4">● At 1 y, freedom from moderate-to-severe </text>
<text top="728" left="611" width="238" height="20" font="4">regurgitation was 100%; freedom from mild </text>
<text top="745" left="611" width="129" height="20" font="4">regurgitation was 90%. </text>
<text top="539" left="914" width="147" height="20" font="4">● Short-term performance </text>
<text top="556" left="914" width="149" height="20" font="4">of the Melody valve in high </text>
<text top="573" left="914" width="141" height="20" font="4">pressure environments is </text>
<text top="591" left="914" width="34" height="20" font="4">good. </text>
</page>
<page number="153" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 153 </text>
<text top="107" left="64" width="84" height="20" font="4">Kenny D, et al. </text>
<text top="124" left="64" width="66" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(567)</a>  </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22078433?dopt=Citation">22078433</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22078433?dopt=Citation"> </a></text>
<text top="107" left="179" width="72" height="20" font="4">Case series, </text>
<text top="124" left="179" width="66" height="20" font="4">prospective </text>
<text top="141" left="179" width="67" height="20" font="4">multicenter, </text>
<text top="159" left="179" width="88" height="20" font="4">nonrandomized </text>
<text top="107" left="293" width="173" height="20" font="4">n=36 pts   <b>Inclusion criteria</b>: </text>
<text top="124" left="361" width="130" height="20" font="4">Edwards-Sapien TPVR </text>
<text top="107" left="516" width="61" height="20" font="4">Immediate </text>
<text top="124" left="516" width="55" height="20" font="4">and short-</text>
<text top="141" left="516" width="28" height="20" font="4">term </text>
<text top="159" left="516" width="57" height="20" font="4">outcomes </text>
<text top="107" left="611" width="135" height="20" font="4">● 36 pts from 4 centers. </text>
<text top="124" left="611" width="240" height="20" font="4">● All pts with dysfunctional RVOT conduits. </text>
<text top="141" left="611" width="101" height="20" font="4">● Mean age 30 y. </text>
<text top="159" left="611" width="263" height="20" font="4">● Successful TPVR in 33 of 34 attempts (97%). </text>
<text top="176" left="611" width="252" height="20" font="4">● Valve migration in 3 pts, 2 required surgical </text>
<text top="193" left="611" width="51" height="20" font="4">retrieval. </text>
<text top="210" left="611" width="185" height="20" font="4">● Pulmonary hemorrhage in 1 pt. </text>
<text top="228" left="611" width="277" height="20" font="4">● Decreased RV to PA peak gradient from 27 mm </text>
<text top="245" left="611" width="187" height="20" font="4">Hg to 12 mm Hg, reduction in PR. </text>
<text top="262" left="611" width="264" height="20" font="4">● No deaths. All pts alive at 6 mo. Improved FC </text>
<text top="279" left="611" width="97" height="20" font="4">noted in most pts </text>
<text top="107" left="914" width="130" height="20" font="4">● The Edwards-Sapien </text>
<text top="124" left="914" width="139" height="20" font="4">transcatheter heart valve </text>
<text top="141" left="914" width="130" height="20" font="4">can be used safely and </text>
<text top="159" left="914" width="146" height="20" font="4">effectively in dysfunctional </text>
<text top="176" left="914" width="107" height="20" font="4">RV to PA conduits. </text>
<text top="297" left="64" width="73" height="20" font="4">Lurz P, et al. </text>
<text top="314" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(568)</a> </text>
<text top="332" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21292132?dopt=Citation">21292132</a></text>
<text top="332" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21292132?dopt=Citation"> </a></text>
<text top="297" left="179" width="68" height="20" font="4">Case series </text>
<text top="314" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="332" left="179" width="77" height="20" font="4">single- center </text>
<text top="349" left="179" width="39" height="20" font="4">review </text>
<text top="297" left="293" width="194" height="20" font="4">n=65 pts   <b>Inclusion criteria</b>: Pts </text>
<text top="314" left="361" width="136" height="20" font="4">who had TPVR who had </text>
<text top="332" left="361" width="93" height="20" font="4">MR imaging and </text>
<text top="349" left="361" width="94" height="20" font="4">cardiopulmonary </text>
<text top="366" left="361" width="134" height="20" font="4">exercise testing within 1 </text>
<text top="383" left="361" width="133" height="20" font="4">mo before TPVR, within </text>
<text top="401" left="361" width="134" height="20" font="4">1 mo post TPVR and 12 </text>
<text top="418" left="361" width="85" height="20" font="4">mo after TPVR </text>
<text top="297" left="516" width="61" height="20" font="4">Immediate </text>
<text top="314" left="516" width="24" height="20" font="4">and </text>
<text top="332" left="516" width="71" height="20" font="4">intermediate </text>
<text top="349" left="516" width="57" height="20" font="4">outcomes </text>
<text top="297" left="611" width="259" height="20" font="4">● 65 pts included, divided into predominant PS </text>
<text top="314" left="611" width="117" height="20" font="4">(n=35) or PR (n=30). </text>
<text top="332" left="611" width="256" height="20" font="4">● Significant early decrease in RVEDV in both </text>
<text top="349" left="611" width="44" height="20" font="4">groups. </text>
<text top="366" left="611" width="243" height="20" font="4">● Improved early RVEF by MRI in PS group </text>
<text top="383" left="611" width="71" height="20" font="4">(51%&gt;58%). </text>
<text top="400" left="611" width="289" height="20" font="4">● No late improvements or changes by MRI in either </text>
<text top="418" left="611" width="38" height="20" font="4">group. </text>
<text top="435" left="611" width="145" height="20" font="4">● Improved early peak VO</text>
<text top="441" left="755" width="4" height="13" font="6">2</text>
<text top="435" left="760" width="131" height="20" font="4"> in PS group, no further </text>
<text top="452" left="611" width="157" height="20" font="4">change with retesting at 1 y. </text>
<text top="469" left="611" width="49" height="20" font="4">● No VO</text>
<text top="475" left="660" width="4" height="13" font="6">2</text>
<text top="469" left="664" width="209" height="20" font="4"> changes noted early or late in the PR </text>
<text top="487" left="611" width="38" height="20" font="4">group. </text>
<text top="297" left="914" width="143" height="20" font="4">● Early (1 mo) reductions </text>
<text top="314" left="914" width="154" height="20" font="4">are noted in RV size in both </text>
<text top="332" left="914" width="156" height="20" font="4">PS and PR groups following </text>
<text top="349" left="914" width="94" height="20" font="4">TPVR, these are </text>
<text top="366" left="914" width="101" height="20" font="4">maintained at 1 y. </text>
<text top="383" left="914" width="138" height="20" font="4">● Pts with preprocedural </text>
<text top="400" left="914" width="82" height="20" font="4">PS show early </text>
<text top="418" left="914" width="154" height="20" font="4">improvements in RVEF and </text>
<text top="435" left="914" width="48" height="20" font="4">peak VO</text>
<text top="441" left="962" width="4" height="13" font="6">2</text>
<text top="435" left="967" width="70" height="20" font="4"> post TPVR. </text>
<text top="452" left="914" width="137" height="20" font="4">● No evidence of further </text>
<text top="469" left="914" width="101" height="20" font="4">positive functional </text>
<text top="487" left="914" width="152" height="20" font="4">remodeling noted beyond 1 </text>
<text top="504" left="914" width="111" height="20" font="4">mo following TPVR. </text>
<text top="522" left="64" width="91" height="20" font="4">McElhinney DB, </text>
<text top="539" left="64" width="30" height="20" font="4">et al. </text>
<text top="556" left="64" width="66" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(569)</a>  </text>
<text top="573" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22075927?dopt=Citation">22075927</a></text>
<text top="573" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22075927?dopt=Citation"> </a></text>
<text top="522" left="179" width="72" height="20" font="4">Case series; </text>
<text top="539" left="179" width="66" height="20" font="4">prospective </text>
<text top="556" left="179" width="64" height="20" font="4">multicenter </text>
<text top="573" left="179" width="88" height="20" font="4">nonrandomized </text>
<text top="591" left="179" width="23" height="20" font="4">trial </text>
<text top="522" left="293" width="38" height="20" font="4">n=150 </text>
<text top="539" left="293" width="23" height="20" font="4">pts  </text>
<text top="522" left="361" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="539" left="361" width="130" height="20" font="4">who underwent Melody </text>
<text top="556" left="361" width="111" height="20" font="4">TPVR as part of the </text>
<text top="573" left="361" width="77" height="20" font="4">Melody Valve </text>
<text top="591" left="361" width="123" height="20" font="4">Investigational Device </text>
<text top="608" left="361" width="89" height="20" font="4">Exemption Trial </text>
<text top="522" left="516" width="61" height="20" font="4">Immediate </text>
<text top="539" left="516" width="24" height="20" font="4">and </text>
<text top="556" left="516" width="72" height="20" font="4">intermediate-</text>
<text top="573" left="516" width="28" height="20" font="4">term </text>
<text top="591" left="516" width="57" height="20" font="4">outcomes </text>
<text top="522" left="611" width="274" height="20" font="4">● 150 pts, median age 19 y, all with dysfunctional </text>
<text top="539" left="611" width="94" height="20" font="4">RV-PA conduits. </text>
<text top="556" left="611" width="259" height="20" font="4">● Existing conduit stents in 37 pts (25%), 12 of </text>
<text top="573" left="611" width="133" height="20" font="4">these already fractured. </text>
<text top="591" left="611" width="262" height="20" font="4">● 1 or more stents placed at the time of Melody </text>
<text top="608" left="611" width="146" height="20" font="4">valve placement in 51 pts. </text>
<text top="625" left="611" width="256" height="20" font="4">● Median follow-up of 30 mo, 39 pts with stent </text>
<text top="642" left="611" width="85" height="20" font="4">fracture (26%). </text>
<text top="659" left="611" width="284" height="20" font="4">Freedom from stent fracture was 77% at 14 mo and </text>
<text top="677" left="611" width="83" height="20" font="4">60% at 39 mo. </text>
<text top="694" left="611" width="235" height="20" font="4">● Multivariable analysis demonstrated that </text>
<text top="711" left="611" width="276" height="20" font="4">implantation of the Melody valve within an existing </text>
<text top="728" left="611" width="251" height="20" font="4">stent, new prestent, or bioprosthetic valve are </text>
<text top="745" left="611" width="284" height="20" font="4">associated with longer freedom from stent fracture.  </text>
<text top="522" left="914" width="143" height="20" font="4">● Melody stent fracture is </text>
<text top="539" left="914" width="138" height="20" font="4">common following TPVR </text>
<text top="556" left="914" width="141" height="20" font="4">implant and is more likely </text>
<text top="573" left="914" width="135" height="20" font="4">with severely obstructed </text>
<text top="591" left="914" width="146" height="20" font="4">conduits that are adherent </text>
<text top="608" left="914" width="140" height="20" font="4">to the anterior chest wall. </text>
<text top="625" left="914" width="102" height="20" font="4">● Prestenting and </text>
<text top="642" left="914" width="137" height="20" font="4">implantation of a Melody </text>
<text top="659" left="914" width="148" height="20" font="4">within a previously stented </text>
<text top="677" left="914" width="102" height="20" font="4">conduit or within a </text>
<text top="694" left="914" width="154" height="20" font="4">bioprosthetic valve all lower </text>
<text top="711" left="914" width="130" height="20" font="4">the risk of Melody stent </text>
<text top="728" left="914" width="49" height="20" font="4">fracture. </text>
</page>
<page number="154" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 154 </text>
<text top="107" left="611" width="274" height="20" font="4">● TPV compression and conduit apposition to the </text>
<text top="124" left="611" width="262" height="20" font="4">anterior chest wall were associated with shorter </text>
<text top="141" left="611" width="155" height="20" font="4">freedom from stent fracture. </text>
<text top="159" left="64" width="91" height="20" font="4">McElhinney DB, </text>
<text top="177" left="64" width="30" height="20" font="4">et al. </text>
<text top="194" left="64" width="66" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(570)</a>  </text>
<text top="211" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20644013?dopt=Citation">20644013</a></text>
<text top="211" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20644013?dopt=Citation"> </a></text>
<text top="159" left="179" width="67" height="20" font="4">Prospective </text>
<text top="177" left="179" width="64" height="20" font="4">multicenter </text>
<text top="194" left="179" width="88" height="20" font="4">nonrandomized </text>
<text top="211" left="179" width="23" height="20" font="4">trial </text>
<text top="159" left="293" width="38" height="20" font="4">n=124 </text>
<text top="177" left="293" width="20" height="20" font="4">pts </text>
<text top="159" left="361" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="177" left="361" width="138" height="20" font="4">with dysfunctional RVOT </text>
<text top="194" left="361" width="134" height="20" font="4">conduits that underwent </text>
<text top="211" left="361" width="134" height="20" font="4">Melody PV replacement </text>
<text top="228" left="361" width="95" height="20" font="4">at 5 U.S. centers </text>
<text top="246" left="361" width="115" height="20" font="4">between 2007–2009 </text>
<text top="159" left="516" width="61" height="20" font="4">Short- and </text>
<text top="177" left="516" width="72" height="20" font="4">intermediate-</text>
<text top="194" left="516" width="28" height="20" font="4">term </text>
<text top="211" left="516" width="57" height="20" font="4">outcomes </text>
<text top="159" left="611" width="272" height="20" font="4">● 136 pts underwent catheter for Melody implant, </text>
<text top="177" left="611" width="266" height="20" font="4">124 pts had Melody implanted in a dysfunctional </text>
<text top="194" left="611" width="84" height="20" font="4">RVOT conduit. </text>
<text top="211" left="611" width="101" height="20" font="4">● Mean age 19 y. </text>
<text top="228" left="611" width="233" height="20" font="4">● 1 death after coronary artery dissection. </text>
<text top="246" left="611" width="238" height="20" font="4">● 1 conduit rupture requiring valve explant. </text>
<text top="263" left="611" width="291" height="20" font="4">● RVOT peak gradient decreased from 27 mm Hg to </text>
<text top="280" left="611" width="179" height="20" font="4">12 mm Hg after TPV placement. </text>
<text top="297" left="611" width="291" height="20" font="4">● No pt with more than mild PR post Melody or up to </text>
<text top="314" left="611" width="76" height="20" font="4">1 y follow-up. </text>
<text top="332" left="611" width="247" height="20" font="4">● Freedom from stent fix was 78% at 14 mo, </text>
<text top="349" left="611" width="232" height="20" font="4">freedom from Melody valve dysfunction or </text>
<text top="366" left="611" width="179" height="20" font="4">reintervention was 93.5% at 1 y. </text>
<text top="383" left="611" width="289" height="20" font="4">● All reinterventions were for RVOTO, mostly due to </text>
<text top="400" left="611" width="79" height="20" font="4">stent fracture. </text>
<text top="159" left="914" width="141" height="20" font="4">● High rate of procedural </text>
<text top="177" left="914" width="150" height="20" font="4">success, low morbidity and </text>
<text top="194" left="914" width="155" height="20" font="4">mortality rates, encouraging </text>
<text top="211" left="914" width="138" height="20" font="4">short- and medium- term </text>
<text top="228" left="914" width="151" height="20" font="4">outcomes following Melody </text>
<text top="246" left="914" width="105" height="20" font="4">valve placement in </text>
<text top="263" left="914" width="116" height="20" font="4">dysfunctional RV-PA </text>
<text top="280" left="914" width="53" height="20" font="4">conduits. </text>
<text top="297" left="914" width="143" height="20" font="4">● Melody stent fracture is </text>
<text top="314" left="914" width="109" height="20" font="4">the major cause for </text>
<text top="332" left="914" width="81" height="20" font="4">reintervention. </text>
<text top="418" left="64" width="87" height="20" font="4">Zahn EM, et al. </text>
<text top="436" left="64" width="66" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(571)</a>  </text>
<text top="453" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19850214?dopt=Citation">19850214</a></text>
<text top="453" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19850214?dopt=Citation"> </a></text>
<text top="418" left="179" width="67" height="20" font="4">Prospective </text>
<text top="436" left="179" width="64" height="20" font="4">multicenter </text>
<text top="453" left="179" width="88" height="20" font="4">nonrandomized </text>
<text top="470" left="179" width="23" height="20" font="4">trial </text>
<text top="418" left="293" width="194" height="20" font="4">n=34 pts   <b>Inclusion criteria</b>: Pts </text>
<text top="436" left="361" width="138" height="20" font="4">with dysfunctional RVOT </text>
<text top="453" left="361" width="134" height="20" font="4">conduits that underwent </text>
<text top="470" left="361" width="134" height="20" font="4">Melody PV replacement </text>
<text top="487" left="361" width="139" height="20" font="4">at 3 U.S. centers in 2007 </text>
<text top="418" left="516" width="63" height="20" font="4">Procedural </text>
<text top="436" left="516" width="55" height="20" font="4">and short-</text>
<text top="453" left="516" width="28" height="20" font="4">term </text>
<text top="470" left="516" width="57" height="20" font="4">outcomes </text>
<text top="418" left="611" width="265" height="20" font="4">● 34 pts underwent catheter for Melody implant, </text>
<text top="436" left="611" width="157" height="20" font="4">successful implant in 29 pts. </text>
<text top="453" left="611" width="101" height="20" font="4">● Mean age 19 y. </text>
<text top="470" left="611" width="279" height="20" font="4">● Procedural complications were 1 conduit rupture </text>
<text top="487" left="611" width="256" height="20" font="4">requiring surgical intervention, 1 wide complex </text>
<text top="504" left="611" width="257" height="20" font="4">tachycardia, 1 distal PA guide wire perforation. </text>
<text top="522" left="611" width="284" height="20" font="4">● Peak conduit gradient decreased from 37 mm Hg </text>
<text top="539" left="611" width="241" height="20" font="4">to 17 mm Hg, no pt had more than mild PR. </text>
<text top="418" left="914" width="87" height="20" font="4">● Melody valve </text>
<text top="436" left="914" width="110" height="20" font="4">implantation can be </text>
<text top="453" left="914" width="111" height="20" font="4">performed with high </text>
<text top="470" left="914" width="134" height="20" font="4">procedural success, low </text>
<text top="487" left="914" width="148" height="20" font="4">mortality rates, and results </text>
<text top="504" left="914" width="157" height="20" font="4">in improved hemodynamics. </text>
<text top="522" left="914" width="143" height="20" font="4">● Melody stent fracture is </text>
<text top="539" left="914" width="139" height="20" font="4">common and occurred in </text>
<text top="556" left="914" width="65" height="20" font="4">27% of pts. </text>
<text top="574" left="64" width="91" height="20" font="4">Nordmeyer J, et </text>
<text top="591" left="64" width="16" height="20" font="4">al. </text>
<text top="608" left="64" width="66" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(572)</a>  </text>
<text top="626" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20965979?dopt=Citation">20965979</a></text>
<text top="626" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20965979?dopt=Citation"> </a></text>
<text top="574" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="591" left="179" width="74" height="20" font="4">single-center </text>
<text top="608" left="179" width="61" height="20" font="4">analysis of </text>
<text top="626" left="179" width="75" height="20" font="4">prospectively </text>
<text top="643" left="179" width="79" height="20" font="4">collected data </text>
<text top="574" left="293" width="38" height="20" font="4">n=108 </text>
<text top="591" left="293" width="23" height="20" font="4">pts  </text>
<text top="574" left="361" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="591" left="361" width="142" height="20" font="4">with CHD who underwent </text>
<text top="608" left="361" width="135" height="20" font="4">Melody valve placement </text>
<text top="626" left="361" width="140" height="20" font="4">in the pulmonary position </text>
<text top="643" left="361" width="115" height="20" font="4">at a single institution </text>
<text top="574" left="516" width="61" height="20" font="4">Short- and </text>
<text top="591" left="516" width="72" height="20" font="4">intermediate-</text>
<text top="608" left="516" width="28" height="20" font="4">term </text>
<text top="626" left="516" width="57" height="20" font="4">outcomes </text>
<text top="574" left="611" width="265" height="20" font="4">● 108 consecutive pts underwent Melody TPVR </text>
<text top="591" left="611" width="280" height="20" font="4">from 2005–2008 for dysfunctional RV-PA conduits. </text>
<text top="608" left="611" width="281" height="20" font="4">● 54 pts with Melody alone, 54 pts with prestenting </text>
<text top="626" left="611" width="148" height="20" font="4">prior to Melody placement. </text>
<text top="643" left="611" width="236" height="20" font="4">● Prestenting associated with lower RVOT </text>
<text top="660" left="611" width="57" height="20" font="4">velocities. </text>
<text top="677" left="611" width="263" height="20" font="4">Prestenting associated with a lower risk of stent </text>
<text top="694" left="611" width="160" height="20" font="4">fracture (HR: 0.35; p=0.024). </text>
<text top="712" left="611" width="277" height="20" font="4">● The probability of freedom from serious adverse </text>
<text top="729" left="611" width="281" height="20" font="4">follow-up events (death, device explanation, repeat </text>
<text top="746" left="611" width="265" height="20" font="4">intervention) was not statistically different at 1 y. </text>
<text top="574" left="914" width="92" height="20" font="4">● Prestenting of </text>
<text top="591" left="914" width="129" height="20" font="4">dysfunctional RV to PA </text>
<text top="608" left="914" width="134" height="20" font="4">conduits prior to Melody </text>
<text top="626" left="914" width="140" height="20" font="4">TPVR reduces the risk of </text>
<text top="643" left="914" width="122" height="20" font="4">Melody stent fracture. </text>
<text top="764" left="64" width="89" height="20" font="4">Frigiola A, et al. </text>
<text top="781" left="64" width="66" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(530)</a>  </text>
<text top="764" left="179" width="67" height="20" font="4">Prospective </text>
<text top="781" left="179" width="74" height="20" font="4">single-center </text>
<text top="764" left="293" width="194" height="20" font="4">n=36 pts   <b>Inclusion criteria</b>: Pts </text>
<text top="781" left="361" width="124" height="20" font="4">with severe PR due to </text>
<text top="764" left="516" width="61" height="20" font="4">Short- and </text>
<text top="781" left="516" width="72" height="20" font="4">intermediate-</text>
<text top="764" left="611" width="280" height="20" font="4">● 25 pts (mean age 21 y) with dysfunctional RVOT </text>
<text top="781" left="611" width="195" height="20" font="4">conduits underwent surgical TPVR. </text>
<text top="764" left="914" width="129" height="20" font="4">● Surgical or TPVR for </text>
<text top="781" left="914" width="130" height="20" font="4">severe PR caused by a </text>
</page>
<page number="155" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 155 </text>
<text top="107" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18539471?dopt=Citation">18539471</a></text>
<text top="107" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18539471?dopt=Citation"> </a></text>
<text top="107" left="179" width="91" height="20" font="4">case series with </text>
<text top="124" left="179" width="70" height="20" font="4">surgical and </text>
<text top="141" left="179" width="67" height="20" font="4">TPVR arms </text>
<text top="107" left="361" width="116" height="20" font="4">dysfunctional RV-PA </text>
<text top="124" left="361" width="128" height="20" font="4">conduit that underwent </text>
<text top="141" left="361" width="120" height="20" font="4">surgical or TPVR and </text>
<text top="159" left="361" width="96" height="20" font="4">had pre and post </text>
<text top="176" left="361" width="120" height="20" font="4">intervention MRI data </text>
<text top="107" left="516" width="28" height="20" font="4">term </text>
<text top="124" left="516" width="57" height="20" font="4">outcomes </text>
<text top="107" left="611" width="243" height="20" font="4">● 11 pts (mean age 20 y) underwent TPVR. </text>
<text top="124" left="611" width="235" height="20" font="4">● MRI performed prior to and 1 y following </text>
<text top="141" left="611" width="70" height="20" font="4">intervention. </text>
<text top="159" left="611" width="258" height="20" font="4">● Following intervention, there were significant </text>
<text top="176" left="611" width="228" height="20" font="4">reductions in RV volumes in both groups. </text>
<text top="193" left="611" width="263" height="20" font="4">● Both groups had improvements in LV and RV </text>
<text top="210" left="611" width="83" height="20" font="4">stroke volume. </text>
<text top="107" left="914" width="116" height="20" font="4">dysfunctional RV-PA </text>
<text top="124" left="914" width="156" height="20" font="4">conduit results in decreased </text>
<text top="141" left="914" width="141" height="20" font="4">RV volume and improved </text>
<text top="159" left="914" width="146" height="20" font="4">RV and LV stroke volume. </text>
<text top="228" left="64" width="73" height="20" font="4">Lurz P, et al. </text>
<text top="245" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(573)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18391109?dopt=Citation">18391109</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18391109?dopt=Citation"> </a></text>
<text top="228" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="245" left="179" width="98" height="20" font="4">analysis of TPVR </text>
<text top="263" left="179" width="84" height="20" font="4">performed at 2 </text>
<text top="280" left="179" width="100" height="20" font="4">European centers </text>
<text top="297" left="179" width="50" height="20" font="4">between </text>
<text top="314" left="179" width="70" height="20" font="4">2000―2007 </text>
<text top="228" left="293" width="38" height="20" font="4">n=155 </text>
<text top="245" left="293" width="23" height="20" font="4">pts  </text>
<text top="228" left="361" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="245" left="361" width="141" height="20" font="4">with dysfunctional RV-PA </text>
<text top="263" left="361" width="136" height="20" font="4">conduits who underwent </text>
<text top="280" left="361" width="36" height="20" font="4">TPVR </text>
<text top="228" left="516" width="40" height="20" font="4">Short-, </text>
<text top="245" left="516" width="75" height="20" font="4">intermediate- </text>
<text top="263" left="516" width="79" height="20" font="4">and long-term </text>
<text top="280" left="516" width="57" height="20" font="4">outcomes </text>
<text top="228" left="611" width="273" height="20" font="4">● 155 pts with PS and/or PR due to dysfunctional </text>
<text top="245" left="611" width="107" height="20" font="4">conduit had TPVR. </text>
<text top="263" left="611" width="289" height="20" font="4">● Significant reduction in RVOT gradient (37 mm Hg </text>
<text top="280" left="611" width="282" height="20" font="4">to 17 mm Hg) and RV systolic pressure (63 mm Hg </text>
<text top="297" left="611" width="81" height="20" font="4">to 45 mm Hg). </text>
<text top="314" left="611" width="287" height="20" font="4">Follow-up ranged from 0–83.7 mo, median 28.4 mo. </text>
<text top="332" left="611" width="267" height="20" font="4">● Freedom from reoperation was 95% at 10 mo, </text>
<text top="349" left="611" width="227" height="20" font="4">87% at 30 mo and 73% at 50 and 70 mo. </text>
<text top="366" left="611" width="168" height="20" font="4">● Survival at 83 mo was 97%. </text>
<text top="383" left="611" width="276" height="20" font="4">● Time dependent analysis demonstrated that the </text>
<text top="401" left="611" width="261" height="20" font="4">first 50 cases performed and pts with a residual </text>
<text top="418" left="611" width="281" height="20" font="4">gradient &gt;25 mm Hg were associated with a higher </text>
<text top="435" left="611" width="105" height="20" font="4">risk of reoperation. </text>
<text top="452" left="611" width="274" height="20" font="4">● Reintervention was primarily for the “hammock” </text>
<text top="469" left="611" width="228" height="20" font="4">effect in 7 pts and stent fractures in 9 pts. </text>
<text top="228" left="914" width="151" height="20" font="4">● Long-term follow-up post </text>
<text top="245" left="914" width="138" height="20" font="4">TPVR demonstrates that </text>
<text top="263" left="914" width="141" height="20" font="4">73% of pts do not require </text>
<text top="280" left="914" width="133" height="20" font="4">reintervention at 70 mo. </text>
<text top="297" left="914" width="154" height="20" font="4">Excellent long-term survival </text>
<text top="314" left="914" width="66" height="20" font="4">post TPVR. </text>
<text top="332" left="914" width="144" height="20" font="4">● There is a higher risk of </text>
<text top="349" left="914" width="142" height="20" font="4">reoperation if the residual </text>
<text top="366" left="914" width="146" height="20" font="4">RVOT gradient is &gt;25 mm </text>
<text top="383" left="914" width="152" height="20" font="4">Hg and in the first 50 cases </text>
<text top="400" left="914" width="63" height="20" font="4">performed. </text>
<text top="487" left="64" width="91" height="20" font="4">Nordmeyer J, et </text>
<text top="504" left="64" width="16" height="20" font="4">al. </text>
<text top="522" left="64" width="66" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(574)</a>  </text>
<text top="539" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17339542?dopt=Citation">17339542</a></text>
<text top="539" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17339542?dopt=Citation"> </a></text>
<text top="487" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="504" left="179" width="74" height="20" font="4">single-center </text>
<text top="522" left="179" width="66" height="20" font="4">case series </text>
<text top="487" left="293" width="38" height="20" font="4">n=123 </text>
<text top="504" left="293" width="23" height="20" font="4">pts  </text>
<text top="487" left="361" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="504" left="361" width="138" height="20" font="4">with dysfunctional RVOT </text>
<text top="522" left="361" width="107" height="20" font="4">who underwent PV </text>
<text top="539" left="361" width="119" height="20" font="4">replacement and had </text>
<text top="556" left="361" width="136" height="20" font="4">structured follow-up with </text>
<text top="573" left="361" width="83" height="20" font="4">CXR and echo </text>
<text top="487" left="516" width="40" height="20" font="4">Short-, </text>
<text top="504" left="516" width="75" height="20" font="4">intermediate- </text>
<text top="522" left="516" width="79" height="20" font="4">and long-term </text>
<text top="539" left="516" width="57" height="20" font="4">outcomes </text>
<text top="487" left="611" width="266" height="20" font="4">● 123 pts included, 26 (21%) developed Melody </text>
<text top="504" left="611" width="212" height="20" font="4">stent fracture 0–843 d post procedure. </text>
<text top="522" left="611" width="278" height="20" font="4">● Melody stent fracture free survival at 1 y is 85%, </text>
<text top="539" left="611" width="179" height="20" font="4">at 2 y is 75%, and at 3 y is 69%. </text>
<text top="556" left="611" width="273" height="20" font="4">● The majority (n=17) of pts had mild type 1 stent </text>
<text top="573" left="611" width="267" height="20" font="4">fractures with no loss of stent integrity, 8 pts had </text>
<text top="591" left="611" width="253" height="20" font="4">type II stent fractures with loss of integrity and </text>
<text top="608" left="611" width="252" height="20" font="4">restenosis, 1 pt had type III stent fracture with </text>
<text top="625" left="611" width="233" height="20" font="4">separation of fragments and embolization. </text>
<text top="642" left="611" width="229" height="20" font="4">● Multivariate analysis demonstrated that </text>
<text top="659" left="611" width="285" height="20" font="4">implantation into “native” RVOT, absence of conduit </text>
<text top="677" left="611" width="265" height="20" font="4">calcification, and recoil of the Melody stent were </text>
<text top="694" left="611" width="276" height="20" font="4">associated with an increased risk of stent fracture. </text>
<text top="487" left="914" width="131" height="20" font="4">● Melody stent fracture </text>
<text top="504" left="914" width="150" height="20" font="4">occurs in 21% of pts and is </text>
<text top="522" left="914" width="132" height="20" font="4">associated with “native” </text>
<text top="539" left="914" width="142" height="20" font="4">RVOT, absence of RVOT </text>
<text top="556" left="914" width="157" height="20" font="4">calcification and stent recoil. </text>
</page>
<page number="156" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 156 </text>
<text top="107" left="64" width="79" height="20" font="4">Coats L, et al. </text>
<text top="124" left="64" width="66" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(575)</a>  </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16636174?dopt=Citation">16636174</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16636174?dopt=Citation"> </a></text>
<text top="107" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="124" left="179" width="74" height="20" font="4">single-center </text>
<text top="141" left="179" width="66" height="20" font="4">case series </text>
<text top="107" left="293" width="194" height="20" font="4">n=18 pts   <b>Inclusion criteria</b>: Pts </text>
<text top="124" left="361" width="137" height="20" font="4">with RVOTO (defined as </text>
<text top="141" left="361" width="140" height="20" font="4">RVOT peak gradient &gt;50 </text>
<text top="159" left="361" width="140" height="20" font="4">mm Hg by echo/Doppler) </text>
<text top="176" left="361" width="123" height="20" font="4">who underwent TPVR </text>
<text top="193" left="361" width="135" height="20" font="4">and underwent MRI and </text>
<text top="210" left="361" width="130" height="20" font="4">CPET. Excluded if they </text>
<text top="228" left="361" width="129" height="20" font="4">had more than mild PR </text>
<text top="107" left="516" width="61" height="20" font="4">Short-term </text>
<text top="124" left="516" width="57" height="20" font="4">outcomes </text>
<text top="107" left="611" width="256" height="20" font="4">● 18 pts with RVOTO, 17 with conduits, 1 with </text>
<text top="124" left="611" width="185" height="20" font="4">native RVOTO, median age 20 y. </text>
<text top="141" left="611" width="284" height="20" font="4">● TPVR reduced RVOT gradient from 51 mm Hg to </text>
<text top="159" left="611" width="288" height="20" font="4">22 mm Hg and RV systolic pressure from 73 mm Hg </text>
<text top="176" left="611" width="77" height="20" font="4">to 47 mm Hg. </text>
<text top="193" left="611" width="102" height="20" font="4">Improved peak VO</text>
<text top="199" left="713" width="4" height="13" font="6">2</text>
<text top="193" left="717" width="142" height="20" font="4"> and anaerobic threshold. </text>
<text top="210" left="611" width="280" height="20" font="4">● Decreased RV volume, improved RVEF, and RV </text>
<text top="228" left="611" width="122" height="20" font="4">stoke volume by MRI. </text>
<text top="107" left="914" width="123" height="20" font="4">● TPVR is effective in </text>
<text top="124" left="914" width="135" height="20" font="4">relieving RVOT stenosis </text>
<text top="141" left="914" width="130" height="20" font="4">and results in improved </text>
<text top="159" left="914" width="150" height="20" font="4">hemodynamics, decreased </text>
<text top="176" left="914" width="123" height="20" font="4">RV size, improved RV </text>
<text top="193" left="914" width="147" height="20" font="4">stroke volume and RVEF.  </text>
<text top="210" left="914" width="62" height="20" font="4">● Peak VO</text>
<text top="217" left="976" width="4" height="13" font="6">2</text>
<text top="210" left="980" width="85" height="20" font="4"> and anaerobic </text>
<text top="227" left="914" width="101" height="20" font="4">threshold are also </text>
<text top="245" left="914" width="57" height="20" font="4">improved. </text>
<text top="264" left="64" width="79" height="20" font="4">Coats L, et al. </text>
<text top="281" left="64" width="66" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(576)</a>  </text>
<text top="299" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15784347?dopt=Citation">15784347</a></text>
<text top="299" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15784347?dopt=Citation"> </a></text>
<text top="264" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="281" left="179" width="93" height="20" font="4">multicenter case </text>
<text top="299" left="179" width="39" height="20" font="4">review </text>
<text top="264" left="293" width="38" height="20" font="4">n=129 </text>
<text top="281" left="293" width="23" height="20" font="4">pts  </text>
<text top="264" left="361" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="281" left="361" width="131" height="20" font="4">that underwent surgical </text>
<text top="299" left="361" width="134" height="20" font="4">or TPVR between 1998–</text>
<text top="316" left="361" width="31" height="20" font="4">2004 </text>
<text top="264" left="516" width="61" height="20" font="4">Short- and </text>
<text top="281" left="516" width="72" height="20" font="4">intermediate-</text>
<text top="299" left="516" width="28" height="20" font="4">term </text>
<text top="316" left="516" width="57" height="20" font="4">outcomes </text>
<text top="264" left="611" width="289" height="20" font="4">● 94 pts underwent surgical reintervention for RVOT </text>
<text top="281" left="611" width="172" height="20" font="4">dysfunction (median age 26 y). </text>
<text top="299" left="611" width="233" height="20" font="4">● 35 underwent TPVR (median age 16 y). </text>
<text top="316" left="611" width="259" height="20" font="4">● 1.1% early mortality in the surgical group, no </text>
<text top="333" left="611" width="158" height="20" font="4">mortality in the TPVR group. </text>
<text top="350" left="611" width="278" height="20" font="4">● Procedural complications in 8.5% of the surgical </text>
<text top="368" left="611" width="193" height="20" font="4">group vs. 5.7% in the TPVR group. </text>
<text top="385" left="611" width="278" height="20" font="4">● Freedom from reintervention was 100% at 1 y in </text>
<text top="402" left="611" width="285" height="20" font="4">the surgical group and 86% in the TPVR group, due </text>
<text top="419" left="611" width="135" height="20" font="4">to late stenosis/stent fix. </text>
<text top="436" left="611" width="288" height="20" font="4">● Median hospital stay was 7 d in the surgical group </text>
<text top="454" left="611" width="190" height="20" font="4">vs. 2 d in the percutaneous group. </text>
<text top="264" left="914" width="147" height="20" font="4">● Both surgical and TPVR </text>
<text top="281" left="914" width="152" height="20" font="4">are safe and effective ways </text>
<text top="299" left="914" width="108" height="20" font="4">of intervening upon </text>
<text top="316" left="914" width="116" height="20" font="4">dysfunctional RVOT. </text>
<text top="472" left="64" width="93" height="20" font="4">Brown JW, et al. </text>
<text top="489" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(577)</a> </text>
<text top="506" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19049758?dopt=Citation">19049758</a></text>
<text top="506" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19049758?dopt=Citation"> </a></text>
<text top="472" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="489" left="179" width="74" height="20" font="4">single-center </text>
<text top="506" left="179" width="39" height="20" font="4">review </text>
<text top="472" left="293" width="38" height="20" font="4">n=186 </text>
<text top="489" left="293" width="23" height="20" font="4">pts  </text>
<text top="472" left="361" width="142" height="20" font="3"><b>Inclusion criteria</b>: All pts </text>
<text top="489" left="361" width="125" height="20" font="4">undergoing Ross AVR </text>
<text top="506" left="361" width="119" height="20" font="4">from June 1993–May </text>
<text top="523" left="361" width="31" height="20" font="4">2007 </text>
<text top="472" left="516" width="60" height="20" font="4">Long-term </text>
<text top="489" left="516" width="57" height="20" font="4">outcomes </text>
<text top="472" left="611" width="271" height="20" font="4">● 183 consecutive pts underwent Ross AVR with </text>
<text top="489" left="611" width="235" height="20" font="4">RVOT reconstruction (median age 23.3 y). </text>
<text top="506" left="611" width="286" height="20" font="4">● 156 pts with cryopreserved pulmonary homograft; </text>
<text top="523" left="611" width="213" height="20" font="4">22 pts decellularized; 5 bovine jugular. </text>
<text top="541" left="611" width="133" height="20" font="4">● Mean follow-up 5.7 y. </text>
<text top="558" left="611" width="67" height="20" font="4">● 3 deaths. </text>
<text top="575" left="611" width="270" height="20" font="4">● 24 pts (13%) with peak RVOT &gt;20 mm; 5 (3%) </text>
<text top="592" left="611" width="265" height="20" font="4">with gradient &gt;40 mm; 7 (4%) had more than 2+ </text>
<text top="609" left="611" width="111" height="20" font="4">RVOT insufficiency. </text>
<text top="627" left="611" width="282" height="20" font="4">● Freedom from reoperation and RV dysfunction at </text>
<text top="644" left="611" width="58" height="20" font="4">10 y 96%. </text>
<text top="661" left="611" width="258" height="20" font="4">● Predictors of dysfunction are grafts &lt;14 mm. </text>
<text top="472" left="914" width="128" height="20" font="4">● Good outcomes with </text>
<text top="489" left="914" width="133" height="20" font="4">pulmonary homograft in </text>
<text top="506" left="914" width="128" height="20" font="4">RVOT position in Ross </text>
<text top="523" left="914" width="62" height="20" font="4">procedure. </text>
<text top="679" left="64" width="96" height="20" font="4">Niemantsverdriet </text>
<text top="696" left="64" width="55" height="20" font="4">MB, et al. </text>
<text top="713" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(578)</a> </text>
<text top="731" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18557880?dopt=Citation">18557880</a></text>
<text top="731" left="119" width="7" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18557880?dopt=Citation"> </a> </text>
<text top="679" left="179" width="64" height="20" font="4">Multicenter </text>
<text top="696" left="179" width="70" height="20" font="4">international </text>
<text top="713" left="179" width="33" height="20" font="4">study </text>
<text top="731" left="179" width="74" height="20" font="4">retrospective </text>
<text top="748" left="179" width="39" height="20" font="4">review </text>
<text top="679" left="293" width="38" height="20" font="4">n=194 </text>
<text top="696" left="293" width="23" height="20" font="4">pts  </text>
<text top="679" left="361" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="696" left="361" width="115" height="20" font="4">undergoing 1°RVOT </text>
<text top="713" left="361" width="134" height="20" font="4">reconstruction using RV </text>
<text top="731" left="361" width="128" height="20" font="4">to PA conduit from Jan </text>
<text top="748" left="361" width="108" height="20" font="4">1987―March 2003 </text>
<text top="679" left="516" width="60" height="20" font="4">Long-term </text>
<text top="696" left="516" width="57" height="20" font="4">outcomes </text>
<text top="679" left="611" width="211" height="20" font="4">● 194 pts with median follow-up 4.7 y. </text>
<text top="696" left="611" width="282" height="20" font="4">● 57% had aortic homografts, 25% pulmonary, and </text>
<text top="713" left="611" width="89" height="20" font="4">12% Contegra.  </text>
<text top="731" left="611" width="285" height="20" font="4">● Average size of conduits between 11 and 13 mm. </text>
<text top="748" left="611" width="285" height="20" font="4">● Freedom from conduit failure at 5 y was 50% with </text>
<text top="765" left="611" width="213" height="20" font="4">128 pts having surgery for obstruction. </text>
<text top="679" left="914" width="138" height="20" font="4">● Longevity increased in </text>
<text top="696" left="914" width="120" height="20" font="4">those with pulmonary </text>
<text top="713" left="914" width="151" height="20" font="4">homograft, largest possible </text>
<text top="731" left="914" width="46" height="20" font="4">conduit. </text>
<text top="748" left="914" width="140" height="20" font="4">● Consider transcatheter </text>
<text top="765" left="914" width="128" height="20" font="4">intervention for conduit </text>
<text top="782" left="914" width="67" height="20" font="4">obstruction. </text>
</page>
<page number="157" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 157 </text>
<text top="107" left="64" width="72" height="20" font="4">Ong K, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(523)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23481618?dopt=Citation">23481618</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23481618?dopt=Citation"> </a></text>
<text top="107" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="124" left="179" width="68" height="20" font="4">case review </text>
<text top="107" left="293" width="201" height="20" font="4">n=49 pts   <b>Inclusion criteria</b>: TOF </text>
<text top="124" left="361" width="141" height="20" font="4">with pulmonary atresia or </text>
<text top="141" left="361" width="134" height="20" font="4">stenosis undergoing RV </text>
<text top="159" left="361" width="111" height="20" font="4">to PA conduits from </text>
<text top="176" left="361" width="70" height="20" font="4">1974―2011 </text>
<text top="107" left="516" width="60" height="20" font="4">Long-term </text>
<text top="124" left="516" width="57" height="20" font="4">outcomes </text>
<text top="107" left="611" width="139" height="20" font="4">● 106 conduits in 49 pts. </text>
<text top="124" left="611" width="279" height="20" font="4">● Freedom from reoperation in 10 y: first conduit = </text>
<text top="141" left="611" width="186" height="20" font="4">50%, second = 74%, third = 86%. </text>
<text top="107" left="914" width="157" height="20" font="4">● Most pts undergo revision </text>
<text top="124" left="914" width="74" height="20" font="4">in adulthood. </text>
<text top="141" left="914" width="141" height="20" font="4">● Most conduits in adults </text>
<text top="159" left="914" width="89" height="20" font="4">meet criteria for </text>
<text top="176" left="914" width="105" height="20" font="4">percutaneous PV.  </text>
<text top="194" left="64" width="96" height="20" font="4">Morray BH, et al. </text>
<text top="211" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(522)</a> </text>
<text top="228" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24065444?dopt=Citation">24065444</a></text>
<text top="228" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24065444?dopt=Citation"> </a></text>
<text top="194" left="179" width="85" height="20" font="4">Multicenter, (4) </text>
<text top="211" left="179" width="74" height="20" font="4">retrospective </text>
<text top="194" left="293" width="38" height="20" font="4">n=404 </text>
<text top="211" left="293" width="47" height="20" font="4">pts: 226 </text>
<text top="228" left="293" width="49" height="20" font="4">TOF, 84 </text>
<text top="246" left="293" width="48" height="20" font="4">TOF/PA </text>
<text top="194" left="361" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="211" left="361" width="140" height="20" font="4">referred for transcatheter </text>
<text top="228" left="361" width="91" height="20" font="4">PV replacement </text>
<text top="194" left="516" width="24" height="20" font="4">N/A </text>
<text top="194" left="611" width="232" height="20" font="4">● Presence or absence of coronary artery </text>
<text top="211" left="611" width="76" height="20" font="4">compression. </text>
<text top="194" left="914" width="149" height="20" font="4">● 21 (5%) had evidence of </text>
<text top="211" left="914" width="86" height="20" font="4">coronary artery </text>
<text top="228" left="914" width="98" height="20" font="4">compression with </text>
<text top="246" left="914" width="113" height="20" font="4">simultaneous RVOT </text>
<text top="263" left="914" width="141" height="20" font="4">angioplasty and coronary </text>
<text top="280" left="914" width="78" height="20" font="4">angiography.  </text>
<text top="297" left="914" width="144" height="20" font="4">● 68 (17%) had abnormal </text>
<text top="314" left="914" width="122" height="20" font="4">coronary angiography </text>
<text top="332" left="914" width="54" height="20" font="4">anatomy. </text>
<text top="350" left="64" width="79" height="20" font="4">Ait-Ali L, et al. </text>
<text top="367" left="64" width="66" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(518)</a>  </text>
<text top="384" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25260437?dopt=Citation">25260437</a></text>
<text top="384" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25260437?dopt=Citation"> </a></text>
<text top="350" left="179" width="100" height="20" font="4">Prospective study </text>
<text top="367" left="179" width="17" height="20" font="4">ex-</text>
<text top="384" left="179" width="101" height="20" font="4">echocardiography </text>
<text top="401" left="179" width="74" height="20" font="4">CMR, CPET, </text>
<text top="418" left="179" width="29" height="20" font="4">BNP </text>
<text top="350" left="293" width="38" height="20" font="4">n=109 </text>
<text top="367" left="293" width="33" height="20" font="4">pts, 9 </text>
<text top="384" left="293" width="39" height="20" font="4">(7.3%) </text>
<text top="401" left="293" width="48" height="20" font="4">TOF/PA </text>
<text top="350" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="367" left="361" width="128" height="20" font="4">Consecutive pts; mean </text>
<text top="384" left="361" width="115" height="20" font="4">age 26 y; age &lt;10 y; </text>
<text top="401" left="361" width="124" height="20" font="4">contraindication CMR; </text>
<text top="418" left="361" width="109" height="20" font="4">complex anomalies </text>
<text top="436" left="361" width="37" height="20" font="4">(AVC) </text>
<text top="350" left="516" width="70" height="20" font="4">Death for all </text>
<text top="367" left="516" width="46" height="20" font="4">causes, </text>
<text top="384" left="516" width="81" height="20" font="4">cardiac death, </text>
<text top="401" left="516" width="74" height="20" font="4">development </text>
<text top="418" left="516" width="14" height="20" font="4">or </text>
<text top="436" left="516" width="81" height="20" font="4">progression of </text>
<text top="453" left="516" width="76" height="20" font="4">HF, and TAs. </text>
<text top="350" left="611" width="244" height="20" font="4">● Tricuspid annular plane systolic excursion </text>
<text top="367" left="611" width="254" height="20" font="4">increased significantly during peak exercise in </text>
<text top="384" left="611" width="287" height="20" font="4">responders from 17.2 ± 3.4 mm at rest to 19.7 ± 4.3 </text>
<text top="401" left="611" width="279" height="20" font="4">mm (p&lt;0.0001) but did not in nonresponders (from </text>
<text top="418" left="611" width="202" height="20" font="4">16.9 ± 4.7–18.1 ± 4.6 mm; p=0.20).  </text>
<text top="436" left="611" width="277" height="20" font="4">● LV end-diastolic volume at rest and LVEF &lt;50% </text>
<text top="453" left="611" width="275" height="20" font="4">were related to the lack of increased RV fractional </text>
<text top="470" left="611" width="142" height="20" font="4">area change on exercise. </text>
<text top="350" left="914" width="151" height="20" font="4">● Exercise echo is feasible </text>
<text top="367" left="914" width="135" height="20" font="4">in pts with repaired TOF </text>
<text top="384" left="914" width="140" height="20" font="4">and allows the integrated </text>
<text top="401" left="914" width="145" height="20" font="4">assessment of variation in </text>
<text top="418" left="914" width="150" height="20" font="4">RV systolic pressure, area, </text>
<text top="436" left="914" width="108" height="20" font="4">and function during </text>
<text top="453" left="914" width="132" height="20" font="4">exercise, which usefully </text>
<text top="470" left="914" width="102" height="20" font="4">complement more </text>
<text top="487" left="914" width="128" height="20" font="4">conventional indices of </text>
<text top="504" left="914" width="135" height="20" font="4">hemodynamic burden in </text>
<text top="522" left="914" width="57" height="20" font="4">these pts. </text>
<text top="540" left="64" width="96" height="20" font="4">Freling HG, et al. </text>
<text top="557" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(519)</a> </text>
<text top="574" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24355311?dopt=Citation">24355311</a></text>
<text top="574" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24355311?dopt=Citation"> </a></text>
<text top="540" left="179" width="79" height="20" font="4">Retrospective </text>
<text top="540" left="293" width="54" height="20" font="4">n=42 pts; </text>
<text top="557" left="293" width="20" height="20" font="4">not </text>
<text top="574" left="293" width="39" height="20" font="4">known </text>
<text top="591" left="293" width="48" height="20" font="4">TOF/PA </text>
<text top="540" left="361" width="140" height="20" font="3"><b>Inclusion criteria</b>: Echo, </text>
<text top="557" left="361" width="137" height="20" font="4">CMR and CPET within 6 </text>
<text top="574" left="361" width="17" height="20" font="4">m. </text>
<text top="591" left="361" width="124" height="20" font="4">Other significant valve </text>
<text top="608" left="361" width="126" height="20" font="4">regurgitation or shunts </text>
<text top="540" left="516" width="49" height="20" font="4">Peak VO</text>
<text top="546" left="565" width="4" height="13" font="6">2</text>
<text top="540" left="570" width="3" height="20" font="4"> </text>
<text top="540" left="611" width="284" height="20" font="4">● Multivariate analysis showed that the peak RVOT </text>
<text top="557" left="611" width="256" height="20" font="4">gradient was the only independent predictor of </text>
<text top="574" left="611" width="105" height="20" font="4">exercise capacity.  </text>
<text top="540" left="914" width="157" height="20" font="4">● Exercise capacity is lower </text>
<text top="557" left="914" width="105" height="20" font="4">in pts with RVOTO </text>
<text top="574" left="914" width="117" height="20" font="4">compared with those </text>
<text top="591" left="914" width="143" height="20" font="4">without RVOTO despite a </text>
<text top="608" left="914" width="109" height="20" font="4">less dilated RV and </text>
<text top="626" left="914" width="147" height="20" font="4">comparable degree of PR. </text>
<text top="644" left="64" width="83" height="20" font="4">Babu-Narayan </text>
<text top="661" left="64" width="53" height="20" font="4">SV, et al. </text>
<text top="678" left="64" width="66" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#237">(520)</a>  </text>
<text top="695" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24146254?dopt=Citation">24146254</a></text>
<text top="695" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24146254?dopt=Citation"> </a></text>
<text top="644" left="179" width="79" height="20" font="4">Retrospective </text>
<text top="644" left="293" width="41" height="20" font="4">n=220, </text>
<text top="661" left="293" width="42" height="20" font="4">11 with </text>
<text top="678" left="293" width="48" height="20" font="4">TOF/PA </text>
<text top="644" left="361" width="137" height="20" font="3"><b>Inclusion criteria</b>: rTOF </text>
<text top="661" left="361" width="91" height="20" font="4">with surgical PV </text>
<text top="678" left="361" width="71" height="20" font="4">replacement </text>
<text top="644" left="516" width="54" height="20" font="4">All-cause </text>
<text top="661" left="516" width="50" height="20" font="4">mortality </text>
<text top="644" left="611" width="62" height="20" font="4">● Peak VO</text>
<text top="650" left="672" width="4" height="13" font="6">2</text>
<text top="644" left="677" width="48" height="20" font="4">, VE/ CO</text>
<text top="650" left="725" width="7" height="13" font="6">2 </text>
<text top="644" left="732" width="118" height="20" font="4">slope (ratio of minute </text>
<text top="661" left="611" width="91" height="20" font="4">ventilation to CO</text>
<text top="667" left="701" width="4" height="13" font="6">2</text>
<text top="661" left="706" width="152" height="20" font="4"> production), and heart rate </text>
<text top="678" left="611" width="288" height="20" font="4">reserve during CPET predicted risk of early mortality </text>
<text top="695" left="611" width="264" height="20" font="4">when analyzed with logistic regression analysis; </text>
<text top="712" left="611" width="48" height="20" font="4">peak VO</text>
<text top="719" left="658" width="4" height="13" font="6">2</text>
<text top="712" left="663" width="215" height="20" font="4"> emerged as the strongest predictor on </text>
<text top="730" left="611" width="221" height="20" font="4">multivariable analysis (OR: 0.65/1 mL/kg</text>
<text top="731" left="831" width="7" height="13" font="6">-1</text>
<text top="730" left="839" width="24" height="20" font="4">·min</text>
<text top="731" left="863" width="7" height="13" font="6">-1</text>
<text top="730" left="870" width="7" height="20" font="4">; </text>
<text top="747" left="611" width="56" height="20" font="4">p=0.041). </text>
<text top="644" left="914" width="122" height="20" font="4">● Preoperative CPET </text>
<text top="661" left="914" width="143" height="20" font="4">predicts surgical outcome </text>
<text top="678" left="914" width="133" height="20" font="4">and should therefore be </text>
<text top="695" left="914" width="124" height="20" font="4">included in the routine </text>
<text top="712" left="914" width="139" height="20" font="4">assessment of these pts. </text>
</page>
<page number="158" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 158 </text>
<text top="107" left="64" width="91" height="20" font="4">Mainwaring RD, </text>
<text top="124" left="64" width="30" height="20" font="4">et al. </text>
<text top="141" left="64" width="66" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#238">(532)</a>  </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22269747?dopt=Citation">22269747</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22269747?dopt=Citation"> </a></text>
<text top="107" left="179" width="72" height="20" font="4"> Case series </text>
<text top="107" left="293" width="44" height="20" font="4">n=5 pts </text>
<text top="107" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="361" width="139" height="20" font="4">March 2009―April 2011; </text>
<text top="141" left="361" width="133" height="20" font="4">5 pts with previous TOF </text>
<text top="159" left="361" width="100" height="20" font="4">repair undergoing </text>
<text top="176" left="361" width="135" height="20" font="4">pulmonary valvuloplasty </text>
<text top="107" left="516" width="62" height="20" font="4">Pulmonary </text>
<text top="124" left="516" width="74" height="20" font="4">insufficiency  </text>
<text top="107" left="611" width="103" height="20" font="4">● Median age 9 y  </text>
<text top="124" left="611" width="259" height="20" font="4">● For bicuspid native PV s and had undergone </text>
<text top="141" left="611" width="274" height="20" font="4">transannular patch with retention of native leaflets </text>
<text top="159" left="611" width="270" height="20" font="4">and no PS and transannular gradient of &lt;10 mm. </text>
<text top="176" left="611" width="235" height="20" font="4">● Majority of pts went from severe to trace </text>
<text top="193" left="611" width="135" height="20" font="4">pulmonary insufficiency. </text>
<text top="107" left="914" width="111" height="20" font="4">● New technique of </text>
<text top="124" left="914" width="154" height="20" font="4">bicuspidization of the native </text>
<text top="141" left="914" width="66" height="20" font="4">PV leaflets. </text>
<text top="211" left="64" width="89" height="20" font="4">Fraisse A, et al. </text>
<text top="228" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(579)</a> </text>
<text top="245" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24619978?dopt=Citation">24619978</a></text>
<text top="245" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24619978?dopt=Citation"> </a></text>
<text top="211" left="179" width="68" height="20" font="4">Case series </text>
<text top="211" left="293" width="38" height="20" font="4">n=100 </text>
<text top="228" left="293" width="20" height="20" font="4">pts </text>
<text top="211" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="228" left="361" width="91" height="20" font="4">Consecutive pts </text>
<text top="245" left="361" width="140" height="20" font="4">undergoing transcatheter </text>
<text top="263" left="361" width="139" height="20" font="4">PV implantation between </text>
<text top="280" left="361" width="133" height="20" font="4">2008―2012. Incidence, </text>
<text top="297" left="361" width="130" height="20" font="4">diagnosis and outcome </text>
<text top="314" left="361" width="141" height="20" font="4">of coronary compression. </text>
<text top="211" left="516" width="54" height="20" font="4">Coronary </text>
<text top="228" left="516" width="73" height="20" font="4">compression </text>
<text top="211" left="611" width="291" height="20" font="4">● 6 pts, median age 24.5 y, compression of left main </text>
<text top="228" left="611" width="278" height="20" font="4">in 4, of left anterior descending from right coronary </text>
<text top="245" left="611" width="262" height="20" font="4">in 2. Diagnosis made by coronary angiogram or </text>
<text top="263" left="611" width="120" height="20" font="4">aortic root angiogram </text>
<text top="211" left="914" width="144" height="20" font="4">● Recommend aortic root </text>
<text top="228" left="914" width="114" height="20" font="4">angio during balloon </text>
<text top="245" left="914" width="150" height="20" font="4">inflation to ensure proximal </text>
<text top="263" left="914" width="157" height="20" font="4">compression isn’t missed by </text>
<text top="280" left="914" width="102" height="20" font="4">selective coronary </text>
<text top="297" left="914" width="75" height="20" font="4">angiography. </text>
<text top="332" left="64" width="90" height="20" font="4">Bauer BS, et al. </text>
<text top="350" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(580)</a> </text>
<text top="367" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25363190?dopt=Citation">25363190</a></text>
<text top="367" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25363190?dopt=Citation"> </a></text>
<text top="332" left="179" width="68" height="20" font="4">Case series </text>
<text top="332" left="293" width="194" height="20" font="4">n=42 pts  <b>Inclusion criteria</b>: Pts </text>
<text top="350" left="361" width="130" height="20" font="4">who underwent Melody </text>
<text top="367" left="361" width="105" height="20" font="4">valve implantation. </text>
<text top="384" left="361" width="83" height="20" font="4">Comparison of </text>
<text top="401" left="361" width="128" height="20" font="4">echocardiographic and </text>
<text top="418" left="361" width="119" height="20" font="4">invasive measures of </text>
<text top="436" left="361" width="95" height="20" font="4">RVOT gradients. </text>
<text top="332" left="516" width="37" height="20" font="4">RVOT </text>
<text top="350" left="516" width="48" height="20" font="4">gradient </text>
<text top="367" left="516" width="51" height="20" font="4">following </text>
<text top="384" left="516" width="43" height="20" font="4">Melody </text>
<text top="401" left="516" width="70" height="20" font="4">implantation </text>
<text top="332" left="611" width="104" height="20" font="4">● Mean age 22 y.  </text>
<text top="350" left="611" width="276" height="20" font="4">● Echo using Doppler had higher estimates of RV-</text>
<text top="367" left="611" width="247" height="20" font="4">PA gradients than those assessed invasively </text>
<text top="384" left="611" width="213" height="20" font="4">immediately after Melody implantation. </text>
<text top="332" left="914" width="138" height="20" font="4">● Echo estimated higher </text>
<text top="350" left="914" width="136" height="20" font="4">gradients than cath after </text>
<text top="367" left="914" width="148" height="20" font="4">Melody valve implantation, </text>
<text top="384" left="914" width="156" height="20" font="4">though measurements were </text>
<text top="401" left="914" width="100" height="20" font="4">not simultaneous. </text>
<text top="454" left="54" width="222" height="20" font="4">*Aortic homografts calcify more quickly.  </text>
<text top="471" left="108" width="3" height="20" font="4"> </text>
<text top="488" left="108" width="3" height="20" font="4"> </text>
<text top="505" left="108" width="648" height="24" font="1"><b>Data Supplement 45. Transposition of the Great Arteries with Atrial Switch – Section 4.4.1.1  </b></text>
<text top="527" left="89" width="38" height="20" font="3"><b>Study </b></text>
<text top="544" left="64" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="561" left="93" width="30" height="20" font="3"><b>Year </b></text>
<text top="527" left="169" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="544" left="183" width="44" height="20" font="3"><b>Design </b></text>
<text top="527" left="265" width="188" height="20" font="3"><b>Study Size  Inclusion Criteria </b></text>
<text top="527" left="487" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="527" left="642" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="527" left="844" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="579" left="64" width="87" height="20" font="4">Hesslein PS, et </text>
<text top="596" left="64" width="16" height="20" font="4">al. </text>
<text top="613" left="64" width="63" height="20" font="4">1982 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(581)</a> </text>
<text top="631" left="64" width="48" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7064768%5Buid%5D">7064768</a></text>
<text top="631" left="112" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7064768%5Buid%5D"> </a></text>
<text top="579" left="165" width="68" height="20" font="4">Prospective </text>
<text top="579" left="260" width="51" height="20" font="4">n=29 pts </text>
<text top="579" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="596" left="349" width="96" height="20" font="3"><b>criteria</b>: TGA s/p </text>
<text top="613" left="349" width="48" height="20" font="4">Mustard </text>
<text top="579" left="466" width="105" height="20" font="4">Exercise response </text>
<text top="579" left="593" width="196" height="20" font="4">● 83% demonstrated depression of </text>
<text top="596" left="593" width="81" height="20" font="4">maximum HR. </text>
<text top="579" left="805" width="205" height="20" font="4">● Maximal exercise testing may be a </text>
<text top="596" left="805" width="178" height="20" font="4">sensitive noninvasive method to </text>
<text top="613" left="805" width="204" height="20" font="4">identify sinoatrial node dysfunction in </text>
<text top="631" left="805" width="127" height="20" font="4">postoperative children. </text>
<text top="649" left="64" width="82" height="20" font="4">Flinn CJ, et al. </text>
<text top="666" left="64" width="63" height="20" font="4">1984 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(582)</a> </text>
<text top="683" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6727935?dopt=Citation">6727935</a></text>
<text top="683" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6727935?dopt=Citation"> </a></text>
<text top="649" left="165" width="153" height="20" font="4">Retrospective  n=372 pts </text>
<text top="649" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="666" left="349" width="96" height="20" font="3"><b>criteria</b>: Mustard </text>
<text top="683" left="349" width="59" height="20" font="4">procedure </text>
<text top="700" left="349" width="53" height="20" font="4">survivors </text>
<text top="649" left="466" width="552" height="20" font="4">Rhythm at follow-up  ● 43% loss of sinus rhythm by 8 y.  ● Over time, decreasing prevalence of </text>
<text top="666" left="805" width="76" height="20" font="4">sinus rhythm. </text>
<text top="718" left="64" width="79" height="20" font="4">Duster MC, et </text>
<text top="735" left="64" width="16" height="20" font="4">al. </text>
<text top="753" left="64" width="63" height="20" font="4">1985 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(583)</a> </text>
<text top="770" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4003242?dopt=Citation">4003242</a></text>
<text top="770" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4003242?dopt=Citation"> </a></text>
<text top="718" left="165" width="153" height="20" font="4">Retrospective  n=120 pts </text>
<text top="718" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="735" left="349" width="96" height="20" font="3"><b>criteria</b>: Mustard </text>
<text top="753" left="349" width="59" height="20" font="4">procedure </text>
<text top="770" left="349" width="90" height="20" font="4">survivors over 3 </text>
<text top="787" left="349" width="73" height="20" font="4">surgical eras </text>
<text top="718" left="466" width="307" height="20" font="4">Rhythm at follow-up  ● After 8 y, less than 50% of the </text>
<text top="735" left="593" width="113" height="20" font="4">rhythms were sinus. </text>
<text top="718" left="805" width="202" height="20" font="4">● Despite efforts to protect the sinus </text>
<text top="735" left="805" width="187" height="20" font="4">node, late occurring dysrhythmias </text>
<text top="753" left="805" width="191" height="20" font="4">remain a significant problem in the </text>
<text top="770" left="805" width="142" height="20" font="4">postoperative Mustard pt. </text>
</page>
<page number="159" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 159 </text>
<text top="107" left="64" width="82" height="20" font="4">Kramer HH, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="63" height="20" font="4">1991 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(584)</a> </text>
<text top="159" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1864669?dopt=Citation">1864669</a></text>
<text top="159" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1864669?dopt=Citation"> </a></text>
<text top="107" left="165" width="126" height="20" font="4">Retrospective  n=47 </text>
<text top="124" left="260" width="48" height="20" font="4">Mustard </text>
<text top="141" left="260" width="59" height="20" font="4">procedure </text>
<text top="159" left="260" width="23" height="20" font="4">pts  </text>
<text top="107" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="124" left="349" width="96" height="20" font="3"><b>criteria</b>: Mustard </text>
<text top="141" left="349" width="72" height="20" font="4">procedure in </text>
<text top="159" left="349" width="87" height="20" font="4">infancy or older </text>
<text top="176" left="349" width="24" height="20" font="4">age </text>
<text top="107" left="466" width="316" height="20" font="4">Rhythm at follow-up  ● Normal findings were present in </text>
<text top="124" left="593" width="190" height="20" font="4">only 51% of the cases at follow-up </text>
<text top="141" left="593" width="192" height="20" font="4">repaired by the Mustard procedure </text>
<text top="159" left="593" width="193" height="20" font="4">in infancy, and in 29% of the group </text>
<text top="176" left="593" width="174" height="20" font="4">having the Mustard repair at an </text>
<text top="193" left="593" width="58" height="20" font="4">older age. </text>
<text top="107" left="805" width="174" height="20" font="4">● The arterial switch procedure </text>
<text top="124" left="805" width="211" height="20" font="4">essentially solved the problem of SND </text>
<text top="141" left="805" width="181" height="20" font="4">after surgery for d-TGA, and that </text>
<text top="159" left="805" width="206" height="20" font="4">problem is biggest in pts who had the </text>
<text top="176" left="805" width="209" height="20" font="4">Mustard procedure outside of infancy. </text>
<text top="211" left="64" width="80" height="20" font="4">Hucin B, et al. </text>
<text top="228" left="64" width="63" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(585)</a> </text>
<text top="245" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10901527?dopt=Citation">10901527</a></text>
<text top="245" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10901527?dopt=Citation"> </a></text>
<text top="211" left="165" width="153" height="20" font="4">Retrospective  n=177 pts </text>
<text top="211" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="228" left="349" width="98" height="20" font="3"><b>criteria</b>: Exercise </text>
<text top="245" left="349" width="102" height="20" font="4">response Mustard </text>
<text top="263" left="349" width="68" height="20" font="4">1979–1984, </text>
<text top="280" left="349" width="100" height="20" font="4">follow-up 12–18 y </text>
<text top="211" left="466" width="269" height="20" font="4">Rhythm at follow-up  ● 10 SCDs. SND in 51%. </text>
<text top="211" left="805" width="203" height="20" font="4">● SND is very common following the </text>
<text top="228" left="805" width="110" height="20" font="4">Mustard procedure. </text>
<text top="298" left="64" width="83" height="20" font="4">Khairy P, et al. </text>
<text top="315" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(586)</a> </text>
<text top="332" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15680022?dopt=Citation">15680022</a></text>
<text top="332" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15680022?dopt=Citation"> </a></text>
<text top="298" left="165" width="153" height="20" font="4">Meta-analysis  n=885 pts </text>
<text top="315" left="260" width="28" height="20" font="4">(369 </text>
<text top="332" left="260" width="75" height="20" font="4">Mustard, 474 </text>
<text top="350" left="260" width="53" height="20" font="4">Senning) </text>
<text top="298" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="315" left="349" width="101" height="20" font="3"><b>criteria</b>: 7 studies </text>
<text top="298" left="466" width="29" height="20" font="4">SND </text>
<text top="298" left="593" width="134" height="20" font="4">● No separate analysis. </text>
<text top="298" left="805" width="203" height="20" font="4">● Sinus nodal dysfunction was more </text>
<text top="315" left="805" width="206" height="20" font="4">common after the Mustard procedure </text>
<text top="332" left="805" width="100" height="20" font="4">than the Senning. </text>
<text top="368" left="64" width="86" height="20" font="4">Diller GP, et al. </text>
<text top="385" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#231">(376)</a> </text>
<text top="402" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16979014?dopt=Citation">16979014</a></text>
<text top="402" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16979014?dopt=Citation"> </a></text>
<text top="368" left="165" width="153" height="20" font="4">Retrospective  n=727 pts </text>
<text top="368" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="385" left="349" width="48" height="20" font="3"><b>criteria</b>: </text>
<text top="402" left="349" width="101" height="20" font="4">Consecutive adult </text>
<text top="419" left="349" width="92" height="20" font="4">CHD pts without </text>
<text top="436" left="349" width="74" height="20" font="4">pacemakers, </text>
<text top="454" left="349" width="90" height="20" font="4">1999–2005 with </text>
<text top="471" left="349" width="89" height="20" font="4">exercise testing </text>
<text top="488" left="349" width="74" height="20" font="4">for heart rate </text>
<text top="505" left="349" width="44" height="20" font="4">reserve </text>
<text top="368" left="466" width="104" height="20" font="4">All-cause mortality </text>
<text top="368" left="593" width="169" height="20" font="4">● Heart rate reserve predicted </text>
<text top="385" left="593" width="143" height="20" font="4">mortality independently of </text>
<text top="402" left="593" width="176" height="20" font="4">antiarrhythmic therapy, FC, and </text>
<text top="419" left="593" width="48" height="20" font="4">peak VO</text>
<text top="425" left="641" width="4" height="13" font="6">2</text>
<text top="419" left="645" width="107" height="20" font="4">. A lower heart rate </text>
<text top="436" left="593" width="167" height="20" font="4">reserve was associated with a </text>
<text top="454" left="593" width="171" height="20" font="4">greater risk of death in pts with </text>
<text top="471" left="593" width="145" height="20" font="4">complex anatomy, Fontan </text>
<text top="488" left="593" width="177" height="20" font="4">circulation, and TOF (p&lt;0.05 for </text>
<text top="505" left="593" width="38" height="20" font="4">each). </text>
<text top="368" left="805" width="209" height="20" font="4">● An abnormal heart rate response to </text>
<text top="385" left="805" width="195" height="20" font="4">exercise identifies ACHD pts with a </text>
<text top="402" left="805" width="209" height="20" font="4">higher risk of mortality in the midterm. </text>
<text top="523" left="64" width="86" height="20" font="4">Diller GP, et al. </text>
<text top="540" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(587)</a> </text>
<text top="558" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18495265?dopt=Citation">18495265</a></text>
<text top="558" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18495265?dopt=Citation"> </a></text>
<text top="523" left="165" width="166" height="20" font="4">Retrospective  SRV (n=32), </text>
<text top="540" left="260" width="76" height="20" font="4">univentricular </text>
<text top="558" left="260" width="59" height="20" font="4">circulation </text>
<text top="575" left="260" width="39" height="20" font="4">(n=32) </text>
<text top="523" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="540" left="349" width="79" height="20" font="3"><b>criteria</b>: Adult </text>
<text top="558" left="349" width="104" height="20" font="4">CHD pts with SRV </text>
<text top="575" left="349" width="91" height="20" font="4">or univentricular </text>
<text top="592" left="349" width="103" height="20" font="4">circulation, age 28 </text>
<text top="609" left="349" width="75" height="20" font="4">± 11.3 y who </text>
<text top="626" left="349" width="61" height="20" font="4">underwent </text>
<text top="644" left="349" width="92" height="20" font="4">exercise testing. </text>
<text top="661" left="349" width="58" height="20" font="4">Paced pts </text>
<text top="678" left="349" width="53" height="20" font="4">excluded </text>
<text top="523" left="466" width="102" height="20" font="4">Exercise capacity, </text>
<text top="540" left="466" width="71" height="20" font="4">chronotropic </text>
<text top="558" left="466" width="70" height="20" font="4">competence </text>
<text top="523" left="593" width="179" height="20" font="4">● Chronotropic incompetence in </text>
<text top="540" left="593" width="178" height="20" font="4">59% of systemic RV pts, 84% of </text>
<text top="558" left="593" width="159" height="20" font="4">univentricular circulation pts. </text>
<text top="523" left="805" width="178" height="20" font="4">● Chronotropic incompetence is </text>
<text top="540" left="805" width="211" height="20" font="4">common and associated with exercise </text>
<text top="558" left="805" width="163" height="20" font="4">limitation in pts with a SRV or </text>
<text top="575" left="805" width="139" height="20" font="4">univentricular circulation. </text>
<text top="696" left="64" width="67" height="20" font="4">Champsaur </text>
<text top="713" left="64" width="53" height="20" font="4">GL, et al. </text>
<text top="730" left="64" width="63" height="20" font="4">1973 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(588)</a> </text>
<text top="748" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4705569?dopt=Citation">4705569</a></text>
<text top="748" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4705569?dopt=Citation"> </a></text>
<text top="696" left="165" width="153" height="20" font="4">Retrospective  n=123 pts </text>
<text top="696" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="713" left="349" width="99" height="20" font="3"><b>criteria</b>: Pediatric </text>
<text top="730" left="349" width="96" height="20" font="4">survivors of atrial </text>
<text top="748" left="349" width="96" height="20" font="4">switch in Toronto </text>
<text top="696" left="466" width="78" height="20" font="4">Early and late </text>
<text top="713" left="466" width="40" height="20" font="4">deaths </text>
<text top="696" left="593" width="165" height="20" font="4">● 21% died, 12 late deaths, 2 </text>
<text top="713" left="593" width="177" height="20" font="4">sudden attributed to arrhythmia. </text>
<text top="696" left="805" width="208" height="20" font="4">● Some deaths following the Mustard </text>
<text top="713" left="805" width="127" height="20" font="4">procedure are sudden. </text>
<text top="766" left="64" width="76" height="20" font="4">Thornback P, </text>
<text top="783" left="64" width="30" height="20" font="4">et al. </text>
<text top="766" left="165" width="242" height="20" font="4">Retrospective  n=18,000 pts  <b>Inclusion </b></text>
<text top="783" left="349" width="97" height="20" font="3"><b>criteria</b>: Children </text>
<text top="766" left="466" width="113" height="20" font="4">Sudden unexpected </text>
<text top="783" left="466" width="34" height="20" font="4">death </text>
<text top="766" left="593" width="188" height="20" font="4">● 33 SCDs, 3 in transposition pts. </text>
<text top="766" left="805" width="208" height="20" font="4">● Some deaths following the Mustard </text>
<text top="783" left="805" width="127" height="20" font="4">procedure are sudden. </text>
</page>
<page number="160" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 160 </text>
<text top="107" left="64" width="63" height="20" font="4">1975 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(589)</a> </text>
<text top="124" left="64" width="41" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/803125?dopt=Citation">803125</a></text>
<text top="124" left="105" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/803125?dopt=Citation"> </a></text>
<text top="107" left="349" width="59" height="20" font="4">with HD in </text>
<text top="124" left="349" width="46" height="20" font="4">Toronto </text>
<text top="142" left="64" width="82" height="20" font="4">Flinn CJ, et al. </text>
<text top="159" left="64" width="63" height="20" font="4">1984 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#240">(582)</a> </text>
<text top="177" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6727935?dopt=Citation">6727935</a></text>
<text top="177" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6727935?dopt=Citation"> </a></text>
<text top="142" left="165" width="153" height="20" font="4">Retrospective  n=372 pts </text>
<text top="142" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="159" left="349" width="96" height="20" font="3"><b>criteria</b>: Mustard </text>
<text top="177" left="349" width="59" height="20" font="4">procedure </text>
<text top="194" left="349" width="53" height="20" font="4">survivors </text>
<text top="142" left="466" width="104" height="20" font="4">Rhythm and death </text>
<text top="142" left="593" width="62" height="20" font="4">● 9 SCDs. </text>
<text top="142" left="805" width="184" height="20" font="4">● Over time, a small risk of SCD. </text>
<text top="212" left="64" width="72" height="20" font="4">Vetter VL, et </text>
<text top="229" left="64" width="16" height="20" font="4">al. </text>
<text top="246" left="64" width="63" height="20" font="4">1987 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(590)</a> </text>
<text top="263" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3680795?dopt=Citation">3680795</a></text>
<text top="263" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3680795?dopt=Citation"> </a></text>
<text top="212" left="165" width="146" height="20" font="4">Retrospective  n=64 pts </text>
<text top="212" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="229" left="349" width="96" height="20" font="3"><b>criteria</b>: Mustard </text>
<text top="246" left="349" width="46" height="20" font="4">children </text>
<text top="263" left="349" width="93" height="20" font="4">undergoing EPS </text>
<text top="212" left="466" width="87" height="20" font="4">Inducible flutter </text>
<text top="212" left="593" width="193" height="20" font="4">● 51% had IART inducible, 48% of </text>
<text top="229" left="593" width="168" height="20" font="4">them went on the have clinical </text>
<text top="246" left="593" width="38" height="20" font="4">flutter. </text>
<text top="212" left="805" width="181" height="20" font="4">● Alone or in combination, these </text>
<text top="229" left="805" width="202" height="20" font="4">abnormalities, which result in severe </text>
<text top="246" left="805" width="208" height="20" font="4">bradycardia or rapid atrial arrhythmia, </text>
<text top="263" left="805" width="100" height="20" font="4">may lead to SCD. </text>
<text top="281" left="64" width="74" height="20" font="4">Hayes CL, et </text>
<text top="299" left="64" width="16" height="20" font="4">al. </text>
<text top="316" left="64" width="63" height="20" font="4">1986 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(591)</a> </text>
<text top="333" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3941200?dopt=Citation">3941200</a></text>
<text top="333" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3941200?dopt=Citation"> </a></text>
<text top="281" left="165" width="146" height="20" font="4">Retrospective  n=95 pts </text>
<text top="281" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="299" left="349" width="96" height="20" font="3"><b>criteria</b>: Mustard </text>
<text top="316" left="349" width="53" height="20" font="4">survivors </text>
<text top="281" left="466" width="87" height="20" font="4">Arrhythmia and </text>
<text top="299" left="466" width="29" height="20" font="4">SCD </text>
<text top="281" left="593" width="197" height="20" font="4">● 75% with atrial arrhythmia by 6 y. </text>
<text top="299" left="593" width="123" height="20" font="4">3% incidence of SCD. </text>
<text top="281" left="805" width="201" height="20" font="4">● Elimination of arrhythmias caused </text>
<text top="299" left="805" width="211" height="20" font="4">by extensive intra-atrial surgery is 1 of </text>
<text top="316" left="805" width="201" height="20" font="4">the potential advantages of the ASO </text>
<text top="333" left="805" width="121" height="20" font="4">for correction of TGA. </text>
<text top="351" left="64" width="82" height="20" font="4">Deanfield J, et </text>
<text top="368" left="64" width="16" height="20" font="4">al. </text>
<text top="385" left="64" width="63" height="20" font="4">1988 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(592)</a> </text>
<text top="403" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3172804?dopt=Citation">3172804</a></text>
<text top="403" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3172804?dopt=Citation"> </a></text>
<text top="351" left="165" width="153" height="20" font="4">Retrospective  n=100 pts </text>
<text top="351" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="368" left="349" width="96" height="20" font="3"><b>criteria</b>: Mustard </text>
<text top="385" left="349" width="72" height="20" font="4">and Senning </text>
<text top="403" left="349" width="53" height="20" font="4">survivors </text>
<text top="351" left="466" width="93" height="20" font="4">Arrhythmias and </text>
<text top="368" left="466" width="90" height="20" font="4">SCD comparing </text>
<text top="385" left="466" width="78" height="20" font="4">Mustards and </text>
<text top="403" left="466" width="55" height="20" font="4">Sennings </text>
<text top="351" left="593" width="155" height="20" font="4">● 4% SCD, equally divided. </text>
<text top="351" left="805" width="192" height="20" font="4">● Because late death could not be </text>
<text top="368" left="805" width="169" height="20" font="4">predicted by ECG analysis; an </text>
<text top="385" left="805" width="213" height="20" font="4">alternative approach involving detailed </text>
<text top="403" left="805" width="208" height="20" font="4">hemodynamic and EP measurements </text>
<text top="420" left="805" width="198" height="20" font="4">may be required to identify high-risk </text>
<text top="437" left="805" width="23" height="20" font="4">pts. </text>
<text top="455" left="64" width="83" height="20" font="4">Janousek J, et </text>
<text top="472" left="64" width="16" height="20" font="4">al. </text>
<text top="489" left="64" width="63" height="20" font="4">1994 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(593)</a> </text>
<text top="507" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7846933?dopt=Citation">7846933</a></text>
<text top="507" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7846933?dopt=Citation"> </a></text>
<text top="455" left="165" width="153" height="20" font="4">Retrospective  n=359 pts </text>
<text top="455" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="472" left="349" width="96" height="20" font="3"><b>criteria</b>: Mustard </text>
<text top="489" left="349" width="72" height="20" font="4">and Senning </text>
<text top="507" left="349" width="53" height="20" font="4">survivors </text>
<text top="455" left="466" width="93" height="20" font="4">Arrhythmias and </text>
<text top="472" left="466" width="29" height="20" font="4">SCD </text>
<text top="455" left="593" width="144" height="20" font="4">● SND in 63%, 4.2% died </text>
<text top="472" left="593" width="56" height="20" font="4">suddenly. </text>
<text top="455" left="805" width="205" height="20" font="4">● By multivariate analysis severe TR </text>
<text top="472" left="805" width="148" height="20" font="4">and/or RV dysfunction and </text>
<text top="489" left="805" width="197" height="20" font="4">uncontrolled SVT were identified as </text>
<text top="507" left="805" width="202" height="20" font="4">the 2 significant risk factors for SCD. </text>
<text top="525" left="64" width="85" height="20" font="4">Helbing WA, et </text>
<text top="542" left="64" width="16" height="20" font="4">al. </text>
<text top="559" left="64" width="63" height="20" font="4">1994 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(594)</a> </text>
<text top="576" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8041184?dopt=Citation">8041184</a></text>
<text top="576" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8041184?dopt=Citation"> </a></text>
<text top="525" left="165" width="153" height="20" font="4">Retrospective  n=122 pts </text>
<text top="525" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="542" left="349" width="96" height="20" font="3"><b>criteria</b>: Mustard </text>
<text top="559" left="349" width="72" height="20" font="4">and Senning </text>
<text top="576" left="349" width="53" height="20" font="4">survivors </text>
<text top="525" left="466" width="93" height="20" font="4">Arrhythmias and </text>
<text top="542" left="466" width="90" height="20" font="4">SCD comparing </text>
<text top="559" left="466" width="78" height="20" font="4">Mustards and </text>
<text top="576" left="466" width="55" height="20" font="4">Sennings </text>
<text top="525" left="593" width="172" height="20" font="4">● 6% incidence of SCD in both </text>
<text top="542" left="593" width="44" height="20" font="4">groups. </text>
<text top="525" left="805" width="210" height="20" font="4">● Apart from the difference in the loss </text>
<text top="542" left="805" width="201" height="20" font="4">of sinus rhythm, no differences were </text>
<text top="559" left="805" width="203" height="20" font="4">found in the long-term clinical results </text>
<text top="576" left="805" width="155" height="20" font="4">of the 2 types of operations. </text>
<text top="594" left="64" width="84" height="20" font="4">Gelatt M, et al. </text>
<text top="611" left="64" width="63" height="20" font="4">1997 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(595)</a> </text>
<text top="629" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8996314?dopt=Citation">8996314</a></text>
<text top="629" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8996314?dopt=Citation"> </a></text>
<text top="594" left="165" width="153" height="20" font="4">Retrospective  n=534 pts </text>
<text top="594" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="611" left="349" width="96" height="20" font="3"><b>criteria</b>: Mustard </text>
<text top="629" left="349" width="91" height="20" font="4">survivors, single </text>
<text top="646" left="349" width="38" height="20" font="4">center </text>
<text top="594" left="466" width="109" height="20" font="4">Risk factors for late </text>
<text top="611" left="466" width="92" height="20" font="4">mortality, loss of </text>
<text top="629" left="466" width="97" height="20" font="4">sinus rhythm and </text>
<text top="646" left="466" width="113" height="20" font="4">atrial flutter after the </text>
<text top="663" left="466" width="103" height="20" font="4">Mustard operation </text>
<text top="594" left="593" width="136" height="20" font="4">● SCD in 31/534 (5.8%) </text>
<text top="611" left="593" width="152" height="20" font="4">Independent risk factors for </text>
<text top="629" left="593" width="192" height="20" font="4">unexpected SCD among operative </text>
<text top="646" left="593" width="165" height="20" font="4">survivors were smaller size at </text>
<text top="663" left="593" width="193" height="20" font="4">operation (OR: 1.28; 95% CI: 1.07–</text>
<text top="680" left="593" width="158" height="20" font="4">1.53; p&lt;0.008 for each 0.1 m</text>
<text top="682" left="751" width="7" height="13" font="6">2 </text>
<text top="697" left="593" width="184" height="20" font="4">decrement in body surface area); </text>
<text top="715" left="593" width="189" height="20" font="4">presence of atrial tachyarrhythmia </text>
<text top="732" left="593" width="179" height="20" font="4">during the operative period (OR: </text>
<text top="749" left="593" width="195" height="20" font="4">3.56; 95% CI: 1.56–8.12; p&lt;0.003); </text>
<text top="766" left="593" width="185" height="20" font="4">and presence of permanent heart </text>
<text top="594" left="805" width="199" height="20" font="4">● Ongoing loss of sinus rhythm and </text>
<text top="611" left="805" width="194" height="20" font="4">late peaks in the risk of atrial flutter </text>
<text top="629" left="805" width="180" height="20" font="4">and death necessitate continued </text>
<text top="646" left="805" width="56" height="20" font="4">follow-up. </text>
</page>
<page number="161" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 161 </text>
<text top="107" left="593" width="170" height="20" font="4">block (OR: 5.71; 95% CI: 1.32–</text>
<text top="124" left="593" width="80" height="20" font="4">24.8; p&lt;0.02). </text>
<text top="142" left="64" width="80" height="20" font="4">Puley G, et al. </text>
<text top="159" left="64" width="63" height="20" font="4">1999 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(596)</a> </text>
<text top="177" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10190524?dopt=Citation">10190524</a></text>
<text top="177" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10190524?dopt=Citation"> </a></text>
<text top="142" left="165" width="146" height="20" font="4">Retrospective  n=86 pts </text>
<text top="142" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="159" left="349" width="79" height="20" font="3"><b>criteria</b>: Adult </text>
<text top="177" left="349" width="66" height="20" font="4">survivors of </text>
<text top="194" left="349" width="48" height="20" font="4">Mustard </text>
<text top="211" left="349" width="59" height="20" font="4">procedure </text>
<text top="142" left="466" width="87" height="20" font="4">Arrhythmia and </text>
<text top="159" left="466" width="45" height="20" font="4">survival </text>
<text top="142" left="593" width="136" height="20" font="4">● 48% with SVT, 2 SCD </text>
<text top="142" left="805" width="179" height="20" font="4">● Adult survivors of the Mustard </text>
<text top="159" left="805" width="194" height="20" font="4">procedure continue to be at risk for </text>
<text top="177" left="805" width="203" height="20" font="4">premature death, congestive HF and </text>
<text top="194" left="805" width="185" height="20" font="4">supraventricular tachyarrhythmia. </text>
<text top="229" left="64" width="79" height="20" font="4">Sun ZH, et al. </text>
<text top="246" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(597)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15219528?dopt=Citation">15219528</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15219528?dopt=Citation"> </a></text>
<text top="229" left="165" width="78" height="20" font="4">Retrospective </text>
<text top="246" left="165" width="70" height="20" font="4">case-control </text>
<text top="229" left="260" width="51" height="20" font="4">n=22 pts </text>
<text top="229" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="246" left="349" width="77" height="20" font="3"><b>criteria</b>: SCD </text>
<text top="263" left="349" width="66" height="20" font="4">victims with </text>
<text top="281" left="349" width="62" height="20" font="4">Mustard or </text>
<text top="298" left="349" width="49" height="20" font="4">Senning </text>
<text top="229" left="466" width="109" height="20" font="4">QT dispersion, loss </text>
<text top="246" left="466" width="87" height="20" font="4">of sinus rhythm </text>
<text top="229" left="593" width="197" height="20" font="4">● QT dispersion p&lt;0.01 vs. control, </text>
<text top="246" left="593" width="160" height="20" font="4">loss of sinus rhythm p&lt;0.002 </text>
<text top="229" left="805" width="185" height="20" font="4">● A combination of increased QT </text>
<text top="246" left="805" width="197" height="20" font="4">dispersion with loss of sinus rhythm </text>
<text top="263" left="805" width="211" height="20" font="4">increases the positive predictive value </text>
<text top="281" left="805" width="210" height="20" font="4">for SCD in pts with TGA after Mustard </text>
<text top="298" left="805" width="141" height="20" font="4">and Senning procedures. </text>
<text top="316" left="64" width="83" height="20" font="4">Khairy P, et al. </text>
<text top="333" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(598)</a> </text>
<text top="350" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19808416?dopt=Citation">19808416</a></text>
<text top="350" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19808416?dopt=Citation"> </a></text>
<text top="316" left="165" width="64" height="20" font="4">Multicenter </text>
<text top="333" left="165" width="70" height="20" font="4">cohort study </text>
<text top="316" left="260" width="51" height="20" font="4">n=37 pts </text>
<text top="316" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="333" left="349" width="76" height="20" font="3"><b>criteria</b>: TGA </text>
<text top="350" left="349" width="89" height="20" font="4">atrial baffle with </text>
<text top="368" left="349" width="25" height="20" font="4">ICD </text>
<text top="316" left="466" width="85" height="20" font="4">Risk factors for </text>
<text top="333" left="466" width="42" height="20" font="4">shocks </text>
<text top="316" left="593" width="164" height="20" font="4">● Annual rates of appropriate </text>
<text top="333" left="593" width="188" height="20" font="4">shocks were 0.5% and 6.0% in 1° </text>
<text top="350" left="593" width="173" height="20" font="4">and 2° prevention, respectively </text>
<text top="368" left="593" width="67" height="20" font="4">(p=0.0366). </text>
<text top="316" left="805" width="214" height="20" font="4">● High rates of appropriate shocks are </text>
<text top="333" left="805" width="165" height="20" font="4">noted in secondary but not 1° </text>
<text top="350" left="805" width="208" height="20" font="4">prevention. SVA may be implicated in </text>
<text top="368" left="805" width="140" height="20" font="4">the etiology of ventricular </text>
<text top="385" left="805" width="211" height="20" font="4">tachyarrhythmias; beta-blockers seem </text>
<text top="402" left="805" width="206" height="20" font="4">protective, and inducible VT does not </text>
<text top="419" left="805" width="165" height="20" font="4">seem to predict future events. </text>
<text top="437" left="64" width="79" height="20" font="4">Van Hare GF, </text>
<text top="454" left="64" width="30" height="20" font="4">et al. </text>
<text top="472" left="64" width="63" height="20" font="4">1996 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(599)</a> </text>
<text top="489" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8644650?dopt=Citation">8644650</a></text>
<text top="489" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8644650?dopt=Citation"> </a></text>
<text top="437" left="165" width="78" height="20" font="4">Retrospective </text>
<text top="454" left="165" width="66" height="20" font="4">case series </text>
<text top="437" left="260" width="51" height="20" font="4">n=10 pts </text>
<text top="437" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="454" left="349" width="97" height="20" font="3"><b>criteria</b>: Children </text>
<text top="472" left="349" width="20" height="20" font="4">s/p </text>
<text top="489" left="349" width="96" height="20" font="4">Mustard/Senning </text>
<text top="506" left="349" width="65" height="20" font="4">undergoing </text>
<text top="523" left="349" width="96" height="20" font="4">ablation for IART </text>
<text top="437" left="466" width="87" height="20" font="4">Success/failure </text>
<text top="437" left="593" width="154" height="20" font="4">● 10/13 IARTs successfully </text>
<text top="454" left="593" width="47" height="20" font="4">ablated. </text>
<text top="437" left="805" width="203" height="20" font="4">● Ablation of IART after the Senning </text>
<text top="454" left="805" width="212" height="20" font="4">or Mustard procedure is feasible using </text>
<text top="472" left="805" width="178" height="20" font="4">concealed entrainment mapping </text>
<text top="489" left="805" width="192" height="20" font="4">techniques, but requires a detailed </text>
<text top="506" left="805" width="197" height="20" font="4">knowledge of the individual surgical </text>
<text top="523" left="805" width="198" height="20" font="4">anatomy and the ability to approach </text>
<text top="540" left="805" width="165" height="20" font="4">the pulmonary venous atrium. </text>
<text top="558" left="64" width="75" height="20" font="4">Kanter RJ, et </text>
<text top="575" left="64" width="16" height="20" font="4">al. </text>
<text top="593" left="64" width="63" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(600)</a> </text>
<text top="610" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10676691?dopt=Citation">10676691</a></text>
<text top="610" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10676691?dopt=Citation"> </a></text>
<text top="558" left="165" width="78" height="20" font="4">Retrospective </text>
<text top="575" left="165" width="66" height="20" font="4">case series </text>
<text top="558" left="260" width="51" height="20" font="4">n=11 pts </text>
<text top="558" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="575" left="349" width="97" height="20" font="3"><b>criteria</b>: Children </text>
<text top="593" left="349" width="20" height="20" font="4">s/p </text>
<text top="610" left="349" width="96" height="20" font="4">Mustard/Senning </text>
<text top="627" left="349" width="65" height="20" font="4">undergoing </text>
<text top="644" left="349" width="96" height="20" font="4">ablation for IART </text>
<text top="558" left="466" width="87" height="20" font="4">Success/failure </text>
<text top="558" left="593" width="177" height="20" font="4">● 8/11 pts successfully ablated. </text>
<text top="558" left="805" width="196" height="20" font="4">● Radiofrequency catheter ablation </text>
<text top="575" left="805" width="158" height="20" font="4">can be effectively and safely </text>
<text top="593" left="805" width="191" height="20" font="4">performed for certain SVT types in </text>
<text top="610" left="805" width="163" height="20" font="4">addition to intra-atrial reentry. </text>
<text top="662" left="64" width="86" height="20" font="4">Kriebel T, et al. </text>
<text top="679" left="64" width="63" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(601)</a> </text>
<text top="697" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12395221?dopt=Citation">12395221</a></text>
<text top="697" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12395221?dopt=Citation"> </a></text>
<text top="662" left="165" width="78" height="20" font="4">Retrospective </text>
<text top="679" left="165" width="66" height="20" font="4">case series </text>
<text top="662" left="260" width="51" height="20" font="4">n=13 pts </text>
<text top="662" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="679" left="349" width="89" height="20" font="3"><b>criteria</b>: Pts s/p </text>
<text top="697" left="349" width="96" height="20" font="4">Mustard/Senning </text>
<text top="714" left="349" width="65" height="20" font="4">undergoing </text>
<text top="731" left="349" width="96" height="20" font="4">ablation for IART </text>
<text top="662" left="466" width="87" height="20" font="4">Success/failure </text>
<text top="662" left="593" width="154" height="20" font="4">● 14/15 IARTs successfully </text>
<text top="679" left="593" width="47" height="20" font="4">ablated. </text>
<text top="662" left="805" width="198" height="20" font="4">● In the majority of our pts, curative </text>
<text top="679" left="805" width="209" height="20" font="4">treatment was feasible by induction of </text>
<text top="697" left="805" width="202" height="20" font="4">linear radiofrequency current lesions </text>
<text top="714" left="805" width="169" height="20" font="4">by primarily targeting electrical </text>
<text top="731" left="805" width="202" height="20" font="4">protected areas of atrial tissue in the </text>
<text top="748" left="805" width="135" height="20" font="4">systemic venous atrium. </text>
<text top="766" left="64" width="75" height="20" font="4">Zrenner B, et </text>
<text top="784" left="64" width="16" height="20" font="4">al. </text>
<text top="766" left="165" width="78" height="20" font="4">Retrospective </text>
<text top="784" left="165" width="66" height="20" font="4">case series </text>
<text top="766" left="260" width="51" height="20" font="4">n=12 pts </text>
<text top="766" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="784" left="349" width="85" height="20" font="3"><b>criteria</b>: Adults </text>
<text top="766" left="466" width="87" height="20" font="4">Success/failure </text>
<text top="766" left="593" width="154" height="20" font="4">● 12/14 IARTs successfully </text>
<text top="784" left="593" width="47" height="20" font="4">ablated. </text>
<text top="766" left="805" width="213" height="20" font="4">● In Mustard pts, the TA serves as the </text>
<text top="784" left="805" width="210" height="20" font="4">most frequent central barrier of IART.  </text>
</page>
<page number="162" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 162 </text>
<text top="107" left="64" width="63" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(602)</a> </text>
<text top="124" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14678105?dopt=Citation">14678105</a></text>
<text top="124" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14678105?dopt=Citation"> </a></text>
<text top="107" left="349" width="20" height="20" font="4">s/p </text>
<text top="124" left="349" width="96" height="20" font="4">Mustard/Senning </text>
<text top="141" left="349" width="65" height="20" font="4">undergoing </text>
<text top="159" left="349" width="96" height="20" font="4">ablation for IART </text>
<text top="107" left="805" width="194" height="20" font="4">● Biatrial electroanatomic mapping </text>
<text top="124" left="805" width="201" height="20" font="4">combined with entrainment mapping </text>
<text top="141" left="805" width="204" height="20" font="4">facilitates delineation of IART circuits </text>
<text top="159" left="805" width="196" height="20" font="4">in relation to their anatomic barriers </text>
<text top="176" left="805" width="199" height="20" font="4">and enables the design of individual </text>
<text top="193" left="805" width="190" height="20" font="4">ablation strategies to achieve high </text>
<text top="210" left="805" width="51" height="20" font="4">success. </text>
<text top="228" left="64" width="65" height="20" font="4">Wu J, et al. </text>
<text top="245" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#241">(603)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23355133?dopt=Citation">23355133</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23355133?dopt=Citation"> </a></text>
<text top="228" left="165" width="78" height="20" font="4">Retrospective </text>
<text top="245" left="165" width="66" height="20" font="4">case series </text>
<text top="228" left="260" width="51" height="20" font="4">n=26 pts </text>
<text top="228" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="245" left="349" width="85" height="20" font="3"><b>criteria</b>: Adults </text>
<text top="263" left="349" width="20" height="20" font="4">s/p </text>
<text top="280" left="349" width="96" height="20" font="4">Mustard/Senning </text>
<text top="297" left="349" width="98" height="20" font="4">following ablation </text>
<text top="314" left="349" width="49" height="20" font="4">for IART </text>
<text top="228" left="466" width="67" height="20" font="4">Recurrence </text>
<text top="228" left="593" width="136" height="20" font="4">● Recurrence rate 30%. </text>
<text top="228" left="805" width="214" height="20" font="4">● Catheter ablation of IART or AVNRT </text>
<text top="245" left="805" width="211" height="20" font="4">in pts post-Mustard/Senning operation </text>
<text top="263" left="805" width="199" height="20" font="4">for d-TGA has a high acute success </text>
<text top="280" left="805" width="31" height="20" font="4">rate.  </text>
<text top="297" left="805" width="185" height="20" font="4">● The recurrence rate for IART is </text>
<text top="314" left="805" width="200" height="20" font="4">about 30%; however, after a second </text>
<text top="332" left="805" width="166" height="20" font="4">ablation, long-term results are </text>
<text top="349" left="805" width="55" height="20" font="4">excellent. </text>
<text top="367" left="64" width="87" height="20" font="4">Correa R, et al. </text>
<text top="384" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(604)</a> </text>
<text top="401" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24052498?dopt=Citation">24052498</a></text>
<text top="401" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24052498?dopt=Citation"> </a></text>
<text top="367" left="165" width="78" height="20" font="4">Retrospective </text>
<text top="384" left="165" width="66" height="20" font="4">case series </text>
<text top="367" left="260" width="51" height="20" font="4">n=29 pts </text>
<text top="384" left="260" width="76" height="20" font="4">(Mustard and </text>
<text top="401" left="260" width="53" height="20" font="4">Senning) </text>
<text top="367" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="384" left="349" width="87" height="20" font="3"><b>criteria</b>: Use of </text>
<text top="401" left="349" width="61" height="20" font="4">transbaffle </text>
<text top="418" left="349" width="51" height="20" font="4">puncture </text>
<text top="367" left="466" width="111" height="20" font="4">Success/failure and </text>
<text top="384" left="466" width="78" height="20" font="4">complications </text>
<text top="367" left="593" width="134" height="20" font="4">● Overall success 77%. </text>
<text top="367" left="805" width="213" height="20" font="4">● Transbaffle access is feasible in this </text>
<text top="384" left="805" width="211" height="20" font="4">population; its use was not associated </text>
<text top="401" left="805" width="165" height="20" font="4">with a higher incidence of AE. </text>
<text top="436" left="64" width="47" height="20" font="3"><b>Testing </b></text>
<text top="454" left="64" width="74" height="20" font="4">Giardini A, et </text>
<text top="472" left="64" width="16" height="20" font="4">al. </text>
<text top="489" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(605)</a> </text>
<text top="506" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19389567?dopt=Citation">19389567</a></text>
<text top="506" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19389567?dopt=Citation"> </a></text>
<text top="454" left="165" width="153" height="20" font="4">Observational  n=274 pts </text>
<text top="454" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="472" left="349" width="85" height="20" font="3"><b>criteria</b>: Adults </text>
<text top="489" left="349" width="93" height="20" font="4">with d-TGA after </text>
<text top="506" left="349" width="91" height="20" font="4">atrial redirection </text>
<text top="523" left="349" width="44" height="20" font="4">surgery </text>
<text top="454" left="466" width="103" height="20" font="4">Assess prognostic </text>
<text top="472" left="466" width="83" height="20" font="4">value of CPET </text>
<text top="454" left="593" width="155" height="20" font="4">● If ventilatory equivalent of </text>
<text top="472" left="593" width="119" height="20" font="4">elimination rate of CO</text>
<text top="478" left="712" width="7" height="13" font="6">2 </text>
<text top="472" left="719" width="58" height="20" font="4">&gt;35.4 and </text>
<text top="489" left="593" width="48" height="20" font="4">peak VO</text>
<text top="495" left="641" width="4" height="13" font="6">2</text>
<text top="489" left="645" width="143" height="20" font="4">&lt;52%, predicted high-risk </text>
<text top="506" left="593" width="94" height="20" font="4">4-y event (78%). </text>
<text top="454" left="805" width="197" height="20" font="4">● CPET good prognostic value. Pts </text>
<text top="472" left="805" width="205" height="20" font="4">with enhanced ventilator response or </text>
<text top="489" left="805" width="185" height="20" font="4">with poor exercise capacity had a </text>
<text top="506" left="805" width="214" height="20" font="4">substantially higher 4 y risk of death or </text>
<text top="523" left="805" width="130" height="20" font="4">emergency admission.  </text>
<text top="541" left="64" width="84" height="20" font="4">Plymen CM, et </text>
<text top="558" left="64" width="16" height="20" font="4">al. </text>
<text top="575" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(606)</a> </text>
<text top="593" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20720248?dopt=Citation">20720248</a></text>
<text top="593" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20720248?dopt=Citation"> </a></text>
<text top="541" left="165" width="67" height="20" font="4">Prospective </text>
<text top="558" left="165" width="65" height="20" font="4">longitudinal </text>
<text top="575" left="165" width="76" height="20" font="4">observational </text>
<text top="593" left="165" width="33" height="20" font="4">study </text>
<text top="541" left="260" width="51" height="20" font="4">n=35 pts </text>
<text top="541" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="558" left="349" width="85" height="20" font="3"><b>criteria</b>: Adults </text>
<text top="575" left="349" width="93" height="20" font="4">with d-TGA after </text>
<text top="593" left="349" width="91" height="20" font="4">atrial redirection </text>
<text top="610" left="349" width="44" height="20" font="4">surgery </text>
<text top="541" left="466" width="105" height="20" font="4">Evaluate Systemic </text>
<text top="558" left="466" width="93" height="20" font="4">RV performance </text>
<text top="575" left="466" width="107" height="20" font="4">using ECG and NT-</text>
<text top="593" left="466" width="46" height="20" font="4">proBNP </text>
<text top="541" left="593" width="129" height="20" font="4">● Mean age 29 ± 6.5 y </text>
<text top="558" left="593" width="181" height="20" font="4">● Relationship between diastolic </text>
<text top="575" left="593" width="179" height="20" font="4">and systolic RV function and NT-</text>
<text top="593" left="593" width="152" height="20" font="4">proBNP and QRS duration. </text>
<text top="541" left="805" width="195" height="20" font="4">● Circulating NT-proBNP and ECG </text>
<text top="558" left="805" width="172" height="20" font="4">Parameters offer safe and cost </text>
<text top="575" left="805" width="170" height="20" font="4">effective surrogate markers for </text>
<text top="593" left="805" width="156" height="20" font="4">systemic RV failure and HF. </text>
<text top="628" left="64" width="86" height="20" font="4">Westhoff-Bleck </text>
<text top="645" left="64" width="47" height="20" font="4">M, et al. </text>
<text top="662" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#219">(126)</a> </text>
<text top="679" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24207068?dopt=Citation">24207068</a></text>
<text top="679" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24207068?dopt=Citation"> </a></text>
<text top="628" left="165" width="29" height="20" font="4">RCT </text>
<text top="628" left="260" width="51" height="20" font="4">n=48 pts </text>
<text top="628" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="645" left="349" width="85" height="20" font="3"><b>criteria</b>: Adults </text>
<text top="662" left="349" width="93" height="20" font="4">with d-TGA after </text>
<text top="679" left="349" width="91" height="20" font="4">atrial redirection </text>
<text top="697" left="349" width="97" height="20" font="4">surgery. 24 wk of </text>
<text top="714" left="349" width="58" height="20" font="4">structured </text>
<text top="731" left="349" width="93" height="20" font="4">exercise training </text>
<text top="748" left="349" width="75" height="20" font="4">or usual care </text>
<text top="628" left="466" width="91" height="20" font="4">Change in Peak </text>
<text top="645" left="466" width="18" height="20" font="4">VO</text>
<text top="651" left="484" width="4" height="13" font="6">2</text>
<text top="645" left="488" width="3" height="20" font="4"> </text>
<text top="662" left="466" width="113" height="20" font="4">Secondary endpoint </text>
<text top="679" left="466" width="97" height="20" font="4">was systemic RV </text>
<text top="697" left="466" width="99" height="20" font="4">diameter by CMR </text>
<text top="628" left="593" width="163" height="20" font="4">● Exercise training increased </text>
<text top="645" left="593" width="150" height="20" font="4">exercise capacity (peak VO</text>
<text top="651" left="743" width="4" height="13" font="6">2</text>
<text top="645" left="747" width="24" height="20" font="4"> 3.8 </text>
<text top="662" left="593" width="180" height="20" font="4">mL/kg/min, work load, maximum </text>
<text top="679" left="593" width="145" height="20" font="4">exercise time and NYHA). </text>
<text top="697" left="593" width="176" height="20" font="4">● No change in RV volume and </text>
<text top="714" left="593" width="50" height="20" font="4">function. </text>
<text top="628" left="805" width="210" height="20" font="4">● Aerobic exercise improved exercise </text>
<text top="645" left="805" width="155" height="20" font="4">capacity and HF symptoms. </text>
<text top="766" left="64" width="86" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Westhoff-Bleck%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24169536">Westhoff-Bleck </a></text>
<text top="784" left="64" width="47" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Westhoff-Bleck%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24169536">M, e</a>t al. </text>
<text top="766" left="165" width="67" height="20" font="4">Prospective </text>
<text top="784" left="165" width="65" height="20" font="4">longitudinal </text>
<text top="766" left="260" width="61" height="20" font="4">n=116 pts  </text>
<text top="766" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="784" left="349" width="85" height="20" font="3"><b>criteria</b>: Adults </text>
<text top="766" left="466" width="95" height="20" font="4">Evaluation of NT-</text>
<text top="784" left="466" width="103" height="20" font="4">proBNP relative to </text>
<text top="766" left="593" width="190" height="20" font="4">● Observational time was 7.3 y (± </text>
<text top="784" left="593" width="38" height="20" font="4">2.4 y). </text>
<text top="766" left="805" width="191" height="20" font="4">● In systemic RV, NT-proBNP is a </text>
<text top="784" left="805" width="177" height="20" font="4">useful predictor for all causes of </text>
</page>
<page number="163" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 163 </text>
<text top="107" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(607)</a> </text>
<text top="124" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24169536?dopt=Citation">24169536</a></text>
<text top="124" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24169536?dopt=Citation"> </a></text>
<text top="107" left="165" width="76" height="20" font="4">observational </text>
<text top="124" left="165" width="33" height="20" font="4">study </text>
<text top="107" left="349" width="93" height="20" font="4">with d-TGA after </text>
<text top="124" left="349" width="91" height="20" font="4">atrial redirection </text>
<text top="141" left="349" width="44" height="20" font="4">surgery </text>
<text top="107" left="466" width="101" height="20" font="4">all cardiac causes </text>
<text top="124" left="466" width="98" height="20" font="4">of hospitalization, </text>
<text top="141" left="466" width="107" height="20" font="4">HF, transplantation </text>
<text top="159" left="466" width="58" height="20" font="4">and death </text>
<text top="107" left="593" width="186" height="20" font="4">● NT-proBNP detected pts at risk </text>
<text top="124" left="593" width="187" height="20" font="4">for HF, transplantation and death. </text>
<text top="107" left="805" width="132" height="20" font="4">hospitalization, and HF, </text>
<text top="124" left="805" width="210" height="20" font="4">transplantation and death. It may be a </text>
<text top="141" left="805" width="155" height="20" font="4">useful risk assessment tool. </text>
<text top="177" left="64" width="86" height="20" font="4">Diller GP, et al. </text>
<text top="194" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(608)</a> </text>
<text top="211" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22607865?dopt=Citation">22607865</a></text>
<text top="211" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22607865?dopt=Citation"> </a></text>
<text top="177" left="165" width="162" height="20" font="4">Observational  n=87 with d-</text>
<text top="194" left="260" width="70" height="20" font="4">TGA and 42 </text>
<text top="211" left="260" width="72" height="20" font="4">with CCTGA </text>
<text top="177" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="194" left="349" width="99" height="20" font="3"><b>criteria</b>: Adult pts </text>
<text top="211" left="349" width="97" height="20" font="4">with systemic RV </text>
<text top="177" left="466" width="71" height="20" font="4">Biventricular </text>
<text top="194" left="466" width="63" height="20" font="4">myocardial </text>
<text top="211" left="466" width="94" height="20" font="4">deformation was </text>
<text top="228" left="466" width="83" height="20" font="4">compared with </text>
<text top="246" left="466" width="63" height="20" font="4">healthy pts </text>
<text top="177" left="593" width="192" height="20" font="4">● Systemic ventricular longitudinal </text>
<text top="194" left="593" width="152" height="20" font="4">2D peak systolic strain was </text>
<text top="211" left="593" width="198" height="20" font="4">significantly reduced compared with </text>
<text top="228" left="593" width="50" height="20" font="4">controls. </text>
<text top="245" left="593" width="185" height="20" font="4">● Systemic 2D-longitudinal strain </text>
<text top="263" left="593" width="167" height="20" font="4">was related to adverse clinical </text>
<text top="280" left="593" width="180" height="20" font="4">outcome independently of EF on </text>
<text top="297" left="593" width="197" height="20" font="4">CMR, history of relevant arrhythmia </text>
<text top="314" left="593" width="38" height="20" font="4">or FC. </text>
<text top="177" left="805" width="207" height="20" font="4">● Global longitudinal systolic strain is </text>
<text top="194" left="805" width="173" height="20" font="4">significantly reduced in pts with </text>
<text top="211" left="805" width="142" height="20" font="4">systemic RV, is related to </text>
<text top="228" left="805" width="211" height="20" font="4">subpulmonary ventricular function and </text>
<text top="246" left="805" width="212" height="20" font="4">predicts clinical outcome in adults with </text>
<text top="263" left="805" width="71" height="20" font="4">atrial switch. </text>
<text top="332" left="64" width="78" height="20" font="4">Hoffman P, et </text>
<text top="350" left="64" width="16" height="20" font="4">al. </text>
<text top="367" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(609)</a> </text>
<text top="384" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18651400?dopt=Citation">18651400</a></text>
<text top="384" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18651400?dopt=Citation"> </a></text>
<text top="332" left="165" width="146" height="20" font="4">Observational  n=60 pts </text>
<text top="332" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="350" left="349" width="79" height="20" font="3"><b>criteria</b>: Atrial </text>
<text top="367" left="349" width="83" height="20" font="4">switch pts who </text>
<text top="384" left="349" width="86" height="20" font="4">had Mustard or </text>
<text top="401" left="349" width="76" height="20" font="4">Senning from </text>
<text top="418" left="349" width="68" height="20" font="4">1982–1990. </text>
<text top="436" left="349" width="90" height="20" font="4">Pts were 14.9 ± </text>
<text top="453" left="349" width="91" height="20" font="4">3.5 y at the time </text>
<text top="470" left="349" width="67" height="20" font="4">of the study </text>
<text top="332" left="466" width="102" height="20" font="4">Echocardiography </text>
<text top="350" left="466" width="87" height="20" font="4">and myocardial </text>
<text top="367" left="466" width="100" height="20" font="4">perfusion imaging </text>
<text top="384" left="466" width="109" height="20" font="4">performed. Systolic </text>
<text top="401" left="466" width="67" height="20" font="4">RV function </text>
<text top="418" left="466" width="83" height="20" font="4">assessed from </text>
<text top="436" left="466" width="83" height="20" font="4">subcostal view </text>
<text top="332" left="593" width="196" height="20" font="4">● 21 pts had significant impairment </text>
<text top="350" left="593" width="128" height="20" font="4">of RV systolic function. </text>
<text top="367" left="593" width="191" height="20" font="4">● RV area change ≤0.35 detected </text>
<text top="384" left="593" width="163" height="20" font="4">moderate to severe perfusion </text>
<text top="401" left="593" width="187" height="20" font="4">abnormalities with 78% sensitivity </text>
<text top="418" left="593" width="112" height="20" font="4">and 62% specificity. </text>
<text top="332" left="805" width="215" height="20" font="4">● RV fractional area change evaluated </text>
<text top="350" left="805" width="161" height="20" font="4">from subcostal view provides </text>
<text top="367" left="805" width="170" height="20" font="4">significant clinical information.  </text>
<text top="384" left="805" width="202" height="20" font="4">● A cutoff value of 0.35 can be used </text>
<text top="401" left="805" width="182" height="20" font="4">as an indicator of RV impairment </text>
<text top="418" left="805" width="200" height="20" font="4">associated with significant perfusion </text>
<text top="436" left="805" width="80" height="20" font="4">abnormalities. </text>
<text top="488" left="64" width="74" height="20" font="4">Khattab K, et </text>
<text top="505" left="64" width="16" height="20" font="4">al. </text>
<text top="522" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(610)</a> </text>
<text top="540" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23276471?dopt=Citation">23276471</a></text>
<text top="540" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23276471?dopt=Citation"> </a></text>
<text top="488" left="165" width="146" height="20" font="4">Observational  n=37 pts </text>
<text top="505" left="260" width="62" height="20" font="4">(56 echos) </text>
<text top="488" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="505" left="349" width="85" height="20" font="3"><b>criteria</b>: Adults </text>
<text top="522" left="349" width="89" height="20" font="4">with d-TGA and </text>
<text top="540" left="349" width="80" height="20" font="4">previous atrial </text>
<text top="557" left="349" width="101" height="20" font="4">switch (26.9 ± 7.4 </text>
<text top="574" left="349" width="17" height="20" font="4">y)  </text>
<text top="488" left="466" width="85" height="20" font="4">Fractional area </text>
<text top="505" left="466" width="84" height="20" font="4">change, lateral </text>
<text top="522" left="466" width="94" height="20" font="4">tricuspid annular </text>
<text top="540" left="466" width="77" height="20" font="4">plane systolic </text>
<text top="557" left="466" width="96" height="20" font="4">excursion, lateral </text>
<text top="574" left="466" width="104" height="20" font="4">RV systolic motion </text>
<text top="591" left="466" width="106" height="20" font="4">velocities by tissue </text>
<text top="608" left="466" width="70" height="20" font="4">Doppler, RV </text>
<text top="626" left="466" width="63" height="20" font="4">myocardial </text>
<text top="643" left="466" width="109" height="20" font="4">performance index, </text>
<text top="660" left="466" width="110" height="20" font="4">and dp/dt assessed </text>
<text top="677" left="466" width="107" height="20" font="4">and compared with </text>
<text top="694" left="466" width="84" height="20" font="4">RVEF by CMR </text>
<text top="488" left="593" width="136" height="20" font="4">● Routine nongeometric </text>
<text top="505" left="593" width="167" height="20" font="4">echocardiography parameters </text>
<text top="522" left="593" width="193" height="20" font="4">correlate weakly with CMR derived </text>
<text top="540" left="593" width="22" height="20" font="4">EF. </text>
<text top="488" left="805" width="191" height="20" font="4">● RV pressure increase should be </text>
<text top="505" left="805" width="211" height="20" font="4">preferentially used to assess systemic </text>
<text top="522" left="805" width="165" height="20" font="4">systolic function in adults with </text>
<text top="540" left="805" width="77" height="20" font="4">subaortic RV. </text>
<text top="712" left="64" width="84" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Poerner%20TC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=17604961">Poerner TC, e</a>t </text>
<text top="730" left="64" width="16" height="20" font="4">al. </text>
<text top="747" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(611)</a> </text>
<text top="764" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17604961?dopt=Citation">17604961</a></text>
<text top="764" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17604961?dopt=Citation"> </a></text>
<text top="712" left="165" width="146" height="20" font="4">Observational  n=24 pts </text>
<text top="712" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="730" left="349" width="94" height="20" font="3"><b>criteria</b>: Pts with </text>
<text top="747" left="349" width="98" height="20" font="4">d-TGA after atrial </text>
<text top="764" left="349" width="94" height="20" font="4">switch. Aged 12–</text>
<text top="781" left="349" width="94" height="20" font="4">33 y. 10 controls </text>
<text top="712" left="466" width="98" height="20" font="4">Evaluate regional </text>
<text top="730" left="466" width="109" height="20" font="4">myocardial function </text>
<text top="712" left="593" width="194" height="20" font="4">● In d-TGA both ventricles showed </text>
<text top="730" left="593" width="194" height="20" font="4">reduced peak systolic strain rate at </text>
<text top="747" left="593" width="31" height="20" font="4">rest.  </text>
<text top="764" left="593" width="160" height="20" font="4">● The increase in peak early </text>
<text top="781" left="593" width="178" height="20" font="4">diastolic velocity was reduced in </text>
<text top="712" left="805" width="145" height="20" font="4">● Exercise tissue Doppler </text>
<text top="730" left="805" width="206" height="20" font="4">echocardiography/strain rate imaging </text>
<text top="747" left="805" width="202" height="20" font="4">identified reduced relaxation reserve </text>
<text top="764" left="805" width="210" height="20" font="4">of both ventricles after atrial switch for </text>
<text top="781" left="805" width="43" height="20" font="4">d-TGA. </text>
</page>
<page number="164" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 164 </text>
<text top="107" left="349" width="91" height="20" font="4">subjects. Tissue </text>
<text top="124" left="349" width="46" height="20" font="4">Doppler </text>
<text top="141" left="349" width="101" height="20" font="4">echocardiography </text>
<text top="159" left="349" width="99" height="20" font="4">at rest and during </text>
<text top="176" left="349" width="97" height="20" font="4">bicycle exercise.  </text>
<text top="107" left="593" width="198" height="20" font="4">the systemic ventricle and absent in </text>
<text top="124" left="593" width="150" height="20" font="4">the subpulmonary ventricle </text>
<text top="194" left="64" width="80" height="20" font="4">Winter MM, et </text>
<text top="211" left="64" width="16" height="20" font="4">al. </text>
<text top="228" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(612)</a> </text>
<text top="245" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18713464?dopt=Citation">18713464</a></text>
<text top="245" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18713464?dopt=Citation"> </a></text>
<text top="194" left="165" width="167" height="20" font="4">Observational  n=29 pts (17 </text>
<text top="211" left="260" width="75" height="20" font="4">Mustards, 12 </text>
<text top="228" left="260" width="51" height="20" font="4">CCTGA) </text>
<text top="194" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="211" left="349" width="99" height="20" font="3"><b>criteria</b>: Measure </text>
<text top="228" left="349" width="83" height="20" font="4">of RV volumes </text>
<text top="245" left="349" width="73" height="20" font="4">including our </text>
<text top="263" left="349" width="55" height="20" font="4">excluding </text>
<text top="280" left="349" width="98" height="20" font="4">trabeculation and </text>
<text top="297" left="349" width="92" height="20" font="4">papillary muscle </text>
<text top="194" left="466" width="105" height="20" font="4">Compare methods </text>
<text top="211" left="466" width="111" height="20" font="4">of cavity delineation </text>
<text top="228" left="466" width="85" height="20" font="4">in systemic RV </text>
<text top="194" left="593" width="183" height="20" font="4">● Including structures resulted in </text>
<text top="211" left="593" width="155" height="20" font="4">shorter time and better inter </text>
<text top="228" left="593" width="163" height="20" font="4">observer reproducibility of EF </text>
<text top="194" left="805" width="202" height="20" font="4">● Choice of method for systemic RV </text>
<text top="211" left="805" width="183" height="20" font="4">delineation affected RV volumes. </text>
<text top="228" left="805" width="200" height="20" font="4">Recommend delineation outside the </text>
<text top="246" left="805" width="185" height="20" font="4">trabeculation (less time and more </text>
<text top="263" left="805" width="79" height="20" font="4">reproducible). </text>
<text top="315" left="64" width="75" height="20" font="4">Dore A, et al. </text>
<text top="332" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(252)</a> </text>
<text top="350" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16216961?dopt=Citation">16216961</a></text>
<text top="350" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16216961?dopt=Citation"> </a></text>
<text top="315" left="165" width="64" height="20" font="4">Multicenter </text>
<text top="332" left="165" width="68" height="20" font="4">randomized </text>
<text top="350" left="165" width="70" height="20" font="4">double-blind </text>
<text top="315" left="260" width="51" height="20" font="4">n=29 pts </text>
<text top="315" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="332" left="349" width="99" height="20" font="3"><b>criteria</b>: Adult pts </text>
<text top="350" left="349" width="83" height="20" font="4">(21 Mustard, 8 </text>
<text top="367" left="349" width="51" height="20" font="4">CCTGA) </text>
<text top="315" left="466" width="100" height="20" font="4">Impact of ARB on </text>
<text top="332" left="466" width="72" height="20" font="4">systemic RV </text>
<text top="315" left="593" width="174" height="20" font="4">● Losartan and placebo did not </text>
<text top="332" left="593" width="143" height="20" font="4">show any difference in VO</text>
<text top="338" left="737" width="4" height="13" font="6">2</text>
<text top="332" left="741" width="7" height="20" font="4">, </text>
<text top="350" left="593" width="182" height="20" font="4">exercise duration or NT-proBNP. </text>
<text top="315" left="805" width="201" height="20" font="4">● Losartan did not improve exercise </text>
<text top="332" left="805" width="174" height="20" font="4">capacity or reduce NT-proBNP. </text>
<text top="385" left="64" width="69" height="20" font="4">Dos L, et al. </text>
<text top="402" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(259)</a> </text>
<text top="419" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23972966?dopt=Citation">23972966</a></text>
<text top="419" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23972966?dopt=Citation"> </a></text>
<text top="385" left="165" width="76" height="20" font="4">Double-blind, </text>
<text top="402" left="165" width="47" height="20" font="4">placebo-</text>
<text top="419" left="165" width="57" height="20" font="4">controlled </text>
<text top="385" left="260" width="51" height="20" font="4">n=26 pts </text>
<text top="385" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="402" left="349" width="79" height="20" font="3"><b>criteria</b>: Atrial </text>
<text top="419" left="349" width="78" height="20" font="4">switch pts, 14 </text>
<text top="436" left="349" width="85" height="20" font="4">eplerenone, 12 </text>
<text top="454" left="349" width="91" height="20" font="4">placebo, and 14 </text>
<text top="471" left="349" width="103" height="20" font="4">healthy volunteers </text>
<text top="385" left="466" width="97" height="20" font="4">CMR parameters </text>
<text top="402" left="466" width="101" height="20" font="4">(systolic RV mass </text>
<text top="419" left="466" width="71" height="20" font="4">and EF) and </text>
<text top="436" left="466" width="110" height="20" font="4">neurohormonal and </text>
<text top="454" left="466" width="98" height="20" font="4">collagen turnover </text>
<text top="471" left="466" width="96" height="20" font="4">biomarker levels. </text>
<text top="385" left="593" width="174" height="20" font="4">● Pts had good baseline profile </text>
<text top="402" left="593" width="156" height="20" font="4">(systemic RV mass and EF) </text>
<text top="419" left="593" width="182" height="20" font="4">Elevated NT-proBNP, C-terminal </text>
<text top="436" left="593" width="179" height="20" font="4">propeptide of type I procollagen, </text>
<text top="454" left="593" width="150" height="20" font="4">and C terminal telopeptide. </text>
<text top="471" left="593" width="165" height="20" font="4">● After 1 y of therapy, a trend </text>
<text top="488" left="593" width="174" height="20" font="4">towards reduction of C-terminal </text>
<text top="505" left="593" width="179" height="20" font="4">propeptide of type I procollagen, </text>
<text top="522" left="593" width="146" height="20" font="4">NT-pro Metalloproteinase. </text>
<text top="385" left="805" width="202" height="20" font="4">● Eplerenone pts improved baseline </text>
<text top="402" left="805" width="165" height="20" font="4">collagen turnover biomarkers, </text>
<text top="419" left="805" width="194" height="20" font="4">suggesting reduction of myocardial </text>
<text top="436" left="805" width="184" height="20" font="4">fibrosis. No other improvements.  </text>
<text top="540" left="64" width="75" height="20" font="4">Hill KD, et al. </text>
<text top="558" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(613)</a> </text>
<text top="575" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22419517?dopt=Citation%5d">22419517</a></text>
<text top="575" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22419517?dopt=Citation%5d"> </a></text>
<text top="540" left="165" width="146" height="20" font="4">Retrospective  n=22 pts </text>
<text top="540" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="558" left="349" width="85" height="20" font="3"><b>criteria</b>: Adults </text>
<text top="575" left="349" width="98" height="20" font="4">with Mustard with </text>
<text top="592" left="349" width="74" height="20" font="4">baffle leak or </text>
<text top="609" left="349" width="64" height="20" font="4">obstruction </text>
<text top="540" left="466" width="103" height="20" font="4">Assess safety and </text>
<text top="558" left="466" width="59" height="20" font="4">efficacy of </text>
<text top="575" left="466" width="78" height="20" font="4">percutaneous </text>
<text top="592" left="466" width="73" height="20" font="4">interventions </text>
<text top="540" left="593" width="106" height="20" font="4">● 29 interventions. </text>
<text top="558" left="593" width="194" height="20" font="4">● Stent placement successful in all </text>
<text top="575" left="593" width="40" height="20" font="4">18 pts. </text>
<text top="592" left="593" width="192" height="20" font="4">● 1 death secondary to arrhythmia </text>
<text top="609" left="593" width="141" height="20" font="4">2 d post pulmonary baffle </text>
<text top="626" left="593" width="69" height="20" font="4">angioplasty. </text>
<text top="540" left="805" width="214" height="20" font="4">● Stent placement for SVB obstruction </text>
<text top="558" left="805" width="189" height="20" font="4">is effective and safer than surgical </text>
<text top="575" left="805" width="70" height="20" font="4">intervention. </text>
<text top="592" left="805" width="204" height="20" font="4">● Baffle leak occlusion can be safely </text>
<text top="609" left="805" width="178" height="20" font="4">accomplished but residual leaks </text>
<text top="626" left="805" width="126" height="20" font="4">common in short term. </text>
<text top="644" left="64" width="77" height="20" font="4">Van Der Bom </text>
<text top="662" left="64" width="44" height="20" font="4">T, et al. </text>
<text top="679" left="64" width="31" height="20" font="4">2013 </text>
<text top="696" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23247302?dopt=Citation">23247302</a></text>
<text top="696" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23247302?dopt=Citation"> </a></text>
<text top="644" left="165" width="64" height="20" font="4">Multicenter </text>
<text top="662" left="165" width="29" height="20" font="4">RCT </text>
<text top="644" left="260" width="51" height="20" font="4">n=88 pts </text>
<text top="644" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="662" left="349" width="94" height="20" font="3"><b>criteria</b>: Pts with </text>
<text top="679" left="349" width="60" height="20" font="4">surgical or </text>
<text top="696" left="349" width="59" height="20" font="4">congenital </text>
<text top="713" left="349" width="72" height="20" font="4">systemic RV </text>
<text top="644" left="466" width="88" height="20" font="4">Role of ARB on </text>
<text top="662" left="466" width="72" height="20" font="4">systemic RV </text>
<text top="644" left="593" width="199" height="20" font="4">● No effect of 3 y Valsartan therapy </text>
<text top="662" left="593" width="169" height="20" font="4">on RVEF, exercise capacity or </text>
<text top="679" left="593" width="36" height="20" font="4">QOL.  </text>
<text top="696" left="593" width="196" height="20" font="4">● The RVEDV and mass increased </text>
<text top="713" left="593" width="150" height="20" font="4">more in the placebo group. </text>
<text top="644" left="805" width="192" height="20" font="4">● No significant treatment effect of </text>
<text top="662" left="805" width="213" height="20" font="4">Valsartan on RVEF, exercise capacity, </text>
<text top="679" left="805" width="51" height="20" font="4">or QOL.  </text>
<text top="696" left="805" width="174" height="20" font="4">● Small differences seen in RV </text>
<text top="713" left="805" width="103" height="20" font="4">volume and mass. </text>
<text top="731" left="64" width="80" height="20" font="4">Winter MM, et </text>
<text top="748" left="64" width="16" height="20" font="4">al. </text>
<text top="766" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(258)</a> </text>
<text top="783" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22036871?dopt=Citation">22036871</a></text>
<text top="783" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22036871?dopt=Citation"> </a></text>
<text top="731" left="165" width="64" height="20" font="4">Multicenter </text>
<text top="748" left="165" width="29" height="20" font="4">RCT </text>
<text top="731" left="260" width="51" height="20" font="4">n=54 pts </text>
<text top="731" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="748" left="349" width="85" height="20" font="3"><b>criteria</b>: Adults </text>
<text top="766" left="349" width="97" height="20" font="4">with systemic RV </text>
<text top="731" left="466" width="90" height="20" font="4">Assess whether </text>
<text top="748" left="466" width="106" height="20" font="4">exercise training in </text>
<text top="766" left="466" width="113" height="20" font="4">adults with systemic </text>
<text top="783" left="466" width="74" height="20" font="4">RV improves </text>
<text top="731" left="593" width="159" height="20" font="4">● 46 pts analyzed. At 10 wk, </text>
<text top="748" left="593" width="72" height="20" font="4">Improved VO</text>
<text top="755" left="665" width="4" height="13" font="6">2</text>
<text top="748" left="670" width="116" height="20" font="4"> (3.4 mL/kg/min) and </text>
<text top="766" left="593" width="159" height="20" font="4">decreased BP (-7 mm Hg) in </text>
<text top="783" left="593" width="91" height="20" font="4">exercise group.  </text>
<text top="731" left="805" width="212" height="20" font="4">● In adults with systemic RV, exercise </text>
<text top="748" left="805" width="198" height="20" font="4">training improves exercise capacity. </text>
</page>
<page number="165" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 165 </text>
<text top="107" left="466" width="98" height="20" font="4">exercise capacity </text>
<text top="124" left="466" width="77" height="20" font="4">and QOL and </text>
<text top="141" left="466" width="106" height="20" font="4">lowers NT-proBNP </text>
<text top="107" left="593" width="190" height="20" font="4">● No significant change in QOL or </text>
<text top="124" left="593" width="70" height="20" font="4">NT-proBNP. </text>
<text top="141" left="593" width="198" height="20" font="4">● None had to discontinue exercise </text>
<text top="159" left="593" width="61" height="20" font="4">due to AE. </text>
<text top="177" left="64" width="87" height="20" font="4">Josephson CB, </text>
<text top="194" left="64" width="30" height="20" font="4">et al. </text>
<text top="211" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(614)</a> </text>
<text top="228" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16835671?dopt=Citation">16835671</a></text>
<text top="228" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16835671?dopt=Citation"> </a></text>
<text top="177" left="165" width="139" height="20" font="4">Observational  n=8 pts </text>
<text top="177" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="194" left="349" width="85" height="20" font="3"><b>criteria</b>: Adults </text>
<text top="211" left="349" width="93" height="20" font="4">with d-TGA after </text>
<text top="228" left="349" width="91" height="20" font="4">atrial redirection </text>
<text top="245" left="349" width="44" height="20" font="4">surgery </text>
<text top="177" left="466" width="102" height="20" font="4">Events after 3 y of </text>
<text top="194" left="466" width="56" height="20" font="4">follow-up  </text>
<text top="177" left="593" width="176" height="20" font="4">● 2 of 5 had improved systemic </text>
<text top="194" left="593" width="187" height="20" font="4">ventricular dysfunction, 2 of 4 had </text>
<text top="211" left="593" width="156" height="20" font="4">improved TR and 4 of 6 had </text>
<text top="228" left="593" width="175" height="20" font="4">improved FC, as determined by </text>
<text top="245" left="593" width="146" height="20" font="4">history or exercise testing. </text>
<text top="177" left="805" width="204" height="20" font="4">● 1 pt not accounted for in follow-up. </text>
<text top="194" left="805" width="214" height="20" font="4">Medication given for RV dysfunction or </text>
<text top="211" left="805" width="65" height="20" font="4">arrhythmia. </text>
<text top="263" left="64" width="83" height="20" font="4">Khairy P, et al. </text>
<text top="281" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(615)</a> </text>
<text top="298" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16702467?dopt=Citation">16702467</a></text>
<text top="298" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16702467?dopt=Citation"> </a></text>
<text top="263" left="165" width="82" height="20" font="4">Retrospective, </text>
<text top="281" left="165" width="64" height="20" font="4">multicenter </text>
<text top="263" left="260" width="51" height="20" font="4">n=37 pts </text>
<text top="263" left="349" width="58" height="20" font="3"><b>Inclusion </b></text>
<text top="281" left="349" width="96" height="20" font="3"><b>criteria</b>: TGA s/p </text>
<text top="298" left="349" width="93" height="20" font="4">atrial switch with </text>
<text top="315" left="349" width="94" height="20" font="4">ICD implantation </text>
<text top="263" left="466" width="91" height="20" font="4">Appropriate ICD </text>
<text top="281" left="466" width="54" height="20" font="4">therapies </text>
<text top="263" left="593" width="188" height="20" font="4">● Annual rate of shock was 6% in </text>
<text top="281" left="593" width="185" height="20" font="4">those with a secondary indication </text>
<text top="298" left="593" width="190" height="20" font="4">for a device. 0.5% in those with 1° </text>
<text top="315" left="593" width="59" height="20" font="4">indication. </text>
<text top="263" left="805" width="209" height="20" font="4">● SVT preceded or coexisted with VT </text>
<text top="281" left="805" width="179" height="20" font="4">in 50% of those with appropriate </text>
<text top="298" left="805" width="52" height="20" font="4">shocks.   </text>
<text top="333" left="108" width="3" height="20" font="4"> </text>
<text top="350" left="108" width="3" height="20" font="4"> </text>
<text top="367" left="108" width="658" height="24" font="1"><b>Data Supplement 46. Transposition of the Great Arteries with Arterial Switch – Section 4.4.1.2 </b></text>
<text top="389" left="69" width="85" height="20" font="3"><b>Study Author, </b></text>
<text top="406" left="67" width="88" height="20" font="3"><b>Year, Location </b></text>
<text top="389" left="176" width="79" height="20" font="3"><b>Aim of Study </b></text>
<text top="389" left="280" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="406" left="302" width="21" height="20" font="3"><b>(N) </b></text>
<text top="389" left="373" width="52" height="20" font="3"><b>Surgical </b></text>
<text top="406" left="388" width="23" height="20" font="3"><b>Era </b></text>
<text top="389" left="456" width="35" height="20" font="3"><b>Mean </b></text>
<text top="406" left="452" width="40" height="20" font="3"><b>follow-</b></text>
<text top="423" left="464" width="19" height="20" font="3"><b>up </b></text>
<text top="389" left="518" width="66" height="20" font="3"><b>Late Death </b></text>
<text top="389" left="611" width="115" height="20" font="3"><b>Late complications </b></text>
<text top="389" left="807" width="77" height="20" font="3"><b>Risk Factors </b></text>
<text top="389" left="1007" width="67" height="20" font="3"><b>Comments </b></text>
<text top="441" left="64" width="94" height="20" font="4">DiDonato RM, et </text>
<text top="458" left="64" width="16" height="20" font="4">al. </text>
<text top="476" left="64" width="66" height="20" font="4">1989 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(616)</a>  </text>
<text top="493" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2598431?dopt=Citation">2598431</a></text>
<text top="493" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2598431?dopt=Citation"> </a></text>
<text top="441" left="172" width="60" height="20" font="4">Long-term </text>
<text top="458" left="172" width="57" height="20" font="4">outcomes </text>
<text top="441" left="273" width="51" height="20" font="4">n=62 pts </text>
<text top="441" left="365" width="38" height="20" font="4">83–87 </text>
<text top="441" left="446" width="21" height="20" font="4">2.3 </text>
<text top="441" left="513" width="21" height="20" font="4">5% </text>
<text top="441" left="601" width="87" height="20" font="4">3 with coronary </text>
<text top="458" left="601" width="118" height="20" font="4">problems, pulmonary </text>
<text top="476" left="601" width="83" height="20" font="4">stenosis in 7% </text>
<text top="441" left="748" width="24" height="20" font="4">N/A </text>
<text top="441" left="956" width="24" height="20" font="4">N/A </text>
<text top="511" left="64" width="91" height="20" font="4">El-Segaier M, et </text>
<text top="528" left="64" width="16" height="20" font="4">al. </text>
<text top="545" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(617)</a> </text>
<text top="562" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20506518?dopt=Citation">20506518</a></text>
<text top="562" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20506518?dopt=Citation"> </a></text>
<text top="511" left="172" width="54" height="20" font="4">Coronary </text>
<text top="528" left="172" width="57" height="20" font="4">screening </text>
<text top="545" left="172" width="79" height="20" font="4">(angiography) </text>
<text top="562" left="172" width="66" height="20" font="4">in survivors </text>
<text top="511" left="273" width="51" height="20" font="4">n=81 pts </text>
<text top="511" left="365" width="51" height="20" font="4">80–2010 </text>
<text top="511" left="446" width="24" height="20" font="4">N/A </text>
<text top="511" left="513" width="24" height="20" font="4">N/A </text>
<text top="511" left="601" width="98" height="20" font="4">7% with coronary </text>
<text top="528" left="601" width="54" height="20" font="4">problems </text>
<text top="511" left="748" width="24" height="20" font="4">N/A </text>
<text top="511" left="956" width="165" height="20" font="4">● Coronary interventions with </text>
<text top="528" left="956" width="152" height="20" font="4">stents performed in 6 pts, 3 </text>
<text top="545" left="956" width="103" height="20" font="4">pts asymptomatic. </text>
<text top="580" left="64" width="90" height="20" font="4">Fricke TA, et al. </text>
<text top="598" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(406)</a> </text>
<text top="615" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22607787?dopt=Citation">22607787</a></text>
<text top="615" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22607787?dopt=Citation"> </a></text>
<text top="580" left="172" width="60" height="20" font="4">Long-term </text>
<text top="598" left="172" width="57" height="20" font="4">outcomes </text>
<text top="580" left="273" width="58" height="20" font="4">n=618 pts </text>
<text top="580" left="365" width="38" height="20" font="4">83–00 </text>
<text top="580" left="446" width="27" height="20" font="4">10.6 </text>
<text top="580" left="513" width="21" height="20" font="4">1% </text>
<text top="580" left="601" width="88" height="20" font="4">Neoaortic valve </text>
<text top="598" left="601" width="130" height="20" font="4">intervention in 1%, mild </text>
<text top="615" left="601" width="99" height="20" font="4">aortic root in 26% </text>
<text top="580" left="748" width="130" height="20" font="4">LVOT obstruction, arch </text>
<text top="598" left="748" width="169" height="20" font="4">abnormalities, and prematurity </text>
<text top="580" left="956" width="167" height="20" font="4">● No arrhythmia or congenital </text>
<text top="598" left="956" width="23" height="20" font="4">HF. </text>
<text top="633" left="64" width="84" height="20" font="4">Kempney A, et </text>
<text top="650" left="64" width="16" height="20" font="4">al. </text>
<text top="667" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(405)</a> </text>
<text top="685" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22884697?dopt=Citation">22884697</a></text>
<text top="685" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22884697?dopt=Citation"> </a></text>
<text top="633" left="172" width="60" height="20" font="4">Long-term </text>
<text top="650" left="172" width="57" height="20" font="4">outcomes </text>
<text top="633" left="273" width="58" height="20" font="4">n=145 pts </text>
<text top="633" left="365" width="24" height="20" font="4">N/A </text>
<text top="633" left="446" width="24" height="20" font="4">N/A </text>
<text top="633" left="513" width="21" height="20" font="4">3% </text>
<text top="633" left="601" width="88" height="20" font="4">Neoaortic valve </text>
<text top="650" left="601" width="124" height="20" font="4">intervention in 1%, PV </text>
<text top="667" left="601" width="122" height="20" font="4">intervention in 6%, no </text>
<text top="685" left="601" width="121" height="20" font="4">late coronary events.  </text>
<text top="633" left="748" width="156" height="20" font="4">Cardiac interventions during </text>
<text top="650" left="748" width="56" height="20" font="4">childhood </text>
<text top="633" left="956" width="136" height="20" font="4">● All adult survivors, not </text>
<text top="650" left="956" width="53" height="20" font="4">children.  </text>
<text top="667" left="956" width="148" height="20" font="4">● Mild root enlargement in </text>
<text top="685" left="956" width="70" height="20" font="4">the majority. </text>
<text top="703" left="64" width="83" height="20" font="4">Khairy P, et al. </text>
<text top="720" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(618)</a> </text>
<text top="737" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23239839?dopt=Citation">23239839</a></text>
<text top="737" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23239839?dopt=Citation"> </a></text>
<text top="703" left="172" width="60" height="20" font="4">Long-term </text>
<text top="720" left="172" width="57" height="20" font="4">outcomes </text>
<text top="703" left="273" width="58" height="20" font="4">n=400 pts </text>
<text top="703" left="365" width="38" height="20" font="4">83–99 </text>
<text top="703" left="446" width="27" height="20" font="4">18.7 </text>
<text top="703" left="513" width="21" height="20" font="4">2% </text>
<text top="703" left="601" width="126" height="20" font="4">5% coronary problems </text>
<text top="720" left="601" width="95" height="20" font="4">including several </text>
<text top="737" left="601" width="118" height="20" font="4">deaths, 3.4% with 3+ </text>
<text top="754" left="601" width="128" height="20" font="4">neoaortic insufficiency, </text>
<text top="771" left="601" width="114" height="20" font="4">10% with pulmonary </text>
<text top="789" left="601" width="52" height="20" font="4">stenosis. </text>
<text top="703" left="748" width="354" height="20" font="4">Single coronary, postoperative HF  ● Most events occurred in </text>
<text top="720" left="956" width="60" height="20" font="4">childhood. </text>
</page>
<page number="166" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 166 </text>
<text top="107" left="64" width="70" height="20" font="4">Kim H, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(619)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22263137?dopt=Citation">22263137</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22263137?dopt=Citation"> </a></text>
<text top="107" left="172" width="60" height="20" font="4">Long-term </text>
<text top="124" left="172" width="57" height="20" font="4">outcomes </text>
<text top="107" left="273" width="58" height="20" font="4">n=158 pts </text>
<text top="107" left="365" width="38" height="20" font="4">94–10 </text>
<text top="107" left="446" width="21" height="20" font="4">4.3 </text>
<text top="107" left="513" width="21" height="20" font="4">0% </text>
<text top="107" left="601" width="115" height="20" font="4">8.9% with intramural </text>
<text top="124" left="601" width="109" height="20" font="4">coronary arteries, 1 </text>
<text top="141" left="601" width="67" height="20" font="4">intervention </text>
<text top="107" left="748" width="24" height="20" font="4">N/A </text>
<text top="107" left="956" width="161" height="20" font="4">● Coronary problems at time </text>
<text top="124" left="956" width="133" height="20" font="4">of ASO, but rarely after. </text>
<text top="159" left="64" width="92" height="20" font="4">Lalezari S, et al. </text>
<text top="177" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(620)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21871285?dopt=Citation">21871285</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21871285?dopt=Citation"> </a></text>
<text top="159" left="172" width="60" height="20" font="4">Long-term </text>
<text top="177" left="172" width="57" height="20" font="4">outcomes </text>
<text top="159" left="273" width="58" height="20" font="4">n=332 pts </text>
<text top="159" left="365" width="24" height="20" font="4">N/A </text>
<text top="159" left="446" width="17" height="20" font="4">15 </text>
<text top="159" left="513" width="21" height="20" font="4">4% </text>
<text top="159" left="601" width="96" height="20" font="4">Moderate-severe </text>
<text top="177" left="601" width="86" height="20" font="4">neoaortic valve </text>
<text top="194" left="601" width="117" height="20" font="4">regurgitation in 3-4% </text>
<text top="159" left="748" width="172" height="20" font="4"> Older age, arch abnormalities, </text>
<text top="177" left="748" width="133" height="20" font="4">and coronary problems. </text>
<text top="159" left="956" width="24" height="20" font="4">N/A </text>
<text top="212" left="64" width="84" height="20" font="4">Legendre A, et </text>
<text top="229" left="64" width="16" height="20" font="4">al. </text>
<text top="246" left="64" width="63" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(621)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12970230?dopt=Citation">12970230</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12970230?dopt=Citation"> </a></text>
<text top="212" left="172" width="54" height="20" font="4">Coronary </text>
<text top="229" left="172" width="40" height="20" font="4">events </text>
<text top="212" left="273" width="65" height="20" font="4">n=1198 pts </text>
<text top="212" left="365" width="38" height="20" font="4">82–01 </text>
<text top="212" left="446" width="10" height="20" font="4">5 </text>
<text top="198" left="513" width="3" height="20" font="4"> </text>
<text top="212" left="601" width="98" height="20" font="4">7% with coronary </text>
<text top="229" left="601" width="119" height="20" font="4">events, most in first y </text>
<text top="246" left="601" width="112" height="20" font="4">after repair, multiple </text>
<text top="264" left="601" width="66" height="20" font="4">stenosis on </text>
<text top="281" left="601" width="71" height="20" font="4">angiography </text>
<text top="212" left="748" width="174" height="20" font="4">Coronary pattern, perioperative </text>
<text top="229" left="748" width="175" height="20" font="4">events. Perfusion abnormalities </text>
<text top="246" left="748" width="194" height="20" font="4">often not present despite stenosis.  </text>
<text top="212" left="956" width="117" height="20" font="4">● 324 pts underwent </text>
<text top="229" left="956" width="78" height="20" font="4">angiography.  </text>
<text top="246" left="956" width="122" height="20" font="4">● Sensitivity for ECG, </text>
<text top="263" left="956" width="145" height="20" font="4">treadmill, echo, or nuclear </text>
<text top="281" left="956" width="147" height="20" font="4">study were all low (&lt;50%), </text>
<text top="298" left="956" width="95" height="20" font="4">better combined. </text>
<text top="316" left="64" width="79" height="20" font="4">Lim HG, et al. </text>
<text top="333" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(407)</a> </text>
<text top="350" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22573720?dopt=Citation">22573720</a></text>
<text top="350" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22573720?dopt=Citation"> </a></text>
<text top="316" left="172" width="60" height="20" font="4">Long-term </text>
<text top="333" left="172" width="57" height="20" font="4">outcomes </text>
<text top="316" left="273" width="58" height="20" font="4">n=220 pts </text>
<text top="316" left="365" width="38" height="20" font="4">87–11 </text>
<text top="316" left="446" width="21" height="20" font="4">8.6 </text>
<text top="316" left="513" width="21" height="20" font="4">3% </text>
<text top="316" left="601" width="118" height="20" font="4">88% free of coronary </text>
<text top="333" left="601" width="98" height="20" font="4">events after 23 y, </text>
<text top="350" left="601" width="86" height="20" font="4">neoaortic valve </text>
<text top="368" left="601" width="124" height="20" font="4">problems in 2%, PS in </text>
<text top="385" left="601" width="21" height="20" font="4">5% </text>
<text top="316" left="748" width="186" height="20" font="4">Aortic size, Tausig-Bing anomaly, </text>
<text top="333" left="748" width="136" height="20" font="4">or single coronary artery </text>
<text top="316" left="956" width="131" height="20" font="4">● Of 95 pts undergoing </text>
<text top="333" left="956" width="158" height="20" font="4">coronary assessment, 5 had </text>
<text top="350" left="956" width="80" height="20" font="4">abnormalities. </text>
<text top="403" left="64" width="79" height="20" font="4">Losay J, et al. </text>
<text top="420" left="64" width="66" height="20" font="4">1990 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(622)</a>  </text>
<text top="437" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2225399?dopt=Citation">2225399</a></text>
<text top="437" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2225399?dopt=Citation"> </a></text>
<text top="403" left="172" width="60" height="20" font="4">Long-term </text>
<text top="420" left="172" width="57" height="20" font="4">outcomes </text>
<text top="403" left="273" width="58" height="20" font="4">n=138 pts </text>
<text top="403" left="365" width="38" height="20" font="4">84–87 </text>
<text top="403" left="446" width="21" height="20" font="4">4.3 </text>
<text top="403" left="513" width="21" height="20" font="4">1% </text>
<text top="403" left="601" width="88" height="20" font="4">2 deaths due to </text>
<text top="420" left="601" width="105" height="20" font="4">coronary problems </text>
<text top="437" left="601" width="112" height="20" font="4">within first 2 mo. PS </text>
<text top="454" left="601" width="101" height="20" font="4">intervention in 1% </text>
<text top="403" left="748" width="24" height="20" font="4">N/A </text>
<text top="403" left="956" width="24" height="20" font="4">N/A </text>
<text top="472" left="64" width="72" height="20" font="4">Oda S, et al. </text>
<text top="489" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(623)</a> </text>
<text top="507" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22334628?dopt=Citation">22334628</a></text>
<text top="507" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22334628?dopt=Citation"> </a></text>
<text top="472" left="172" width="60" height="20" font="4">Long-term </text>
<text top="489" left="172" width="57" height="20" font="4">outcomes </text>
<text top="472" left="273" width="58" height="20" font="4">n=387 pts </text>
<text top="472" left="365" width="38" height="20" font="4">84–10 </text>
<text top="472" left="446" width="17" height="20" font="4">10 </text>
<text top="472" left="513" width="21" height="20" font="4">8% </text>
<text top="472" left="601" width="105" height="20" font="4">Coronary issues in </text>
<text top="489" left="601" width="118" height="20" font="4">~5%, neoaortic valve </text>
<text top="507" left="601" width="124" height="20" font="4">problems in 8%, PS in </text>
<text top="524" left="601" width="31" height="20" font="4">17%. </text>
<text top="472" left="748" width="172" height="20" font="4">LV outflow obstruction was risk </text>
<text top="489" left="748" width="138" height="20" font="4">factor for neoaortic valve </text>
<text top="507" left="748" width="66" height="20" font="4">dysfunction </text>
<text top="472" left="956" width="161" height="20" font="4">● Use of equine patch was a </text>
<text top="489" left="956" width="64" height="20" font="4">risk for PS. </text>
<text top="542" left="64" width="65" height="20" font="4">Ou P, et al. </text>
<text top="559" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(624)</a> </text>
<text top="576" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22795438?dopt=Citation">22795438</a></text>
<text top="576" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22795438?dopt=Citation"> </a></text>
<text top="542" left="172" width="73" height="20" font="4">CT scanning </text>
<text top="542" left="273" width="58" height="20" font="4">n=190 pts </text>
<text top="542" left="365" width="24" height="20" font="4">N/A </text>
<text top="542" left="446" width="24" height="20" font="4">N/A </text>
<text top="542" left="513" width="24" height="20" font="4">N/A </text>
<text top="542" left="601" width="121" height="20" font="4">Coronary problems in </text>
<text top="559" left="601" width="21" height="20" font="4">9% </text>
<text top="542" left="748" width="24" height="20" font="4">N/A </text>
<text top="542" left="956" width="150" height="20" font="4">● Describes problems with </text>
<text top="559" left="956" width="111" height="20" font="4">proximal coronaries </text>
<text top="576" left="956" width="84" height="20" font="4">predominantly. </text>
<text top="610" left="64" width="94" height="20" font="4">Planche C, et al. </text>
<text top="627" left="64" width="66" height="20" font="4">1988 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(625)</a>  </text>
<text top="645" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9636253?dopt=Citation">9636253</a></text>
<text top="645" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9636253?dopt=Citation"> </a></text>
<text top="610" left="172" width="60" height="20" font="4">Long-term </text>
<text top="627" left="172" width="57" height="20" font="4">outcomes </text>
<text top="610" left="273" width="58" height="20" font="4">n=110 pts </text>
<text top="610" left="365" width="38" height="20" font="4">84–87 </text>
<text top="610" left="446" width="24" height="20" font="4">N/A </text>
<text top="610" left="513" width="21" height="20" font="4">2% </text>
<text top="610" left="601" width="122" height="20" font="4">Both late deaths were </text>
<text top="627" left="601" width="96" height="20" font="4">coronary related. </text>
<text top="610" left="748" width="24" height="20" font="4">N/A </text>
<text top="610" left="956" width="24" height="20" font="4">N/A </text>
<text top="663" left="64" width="91" height="20" font="4">Popov AF, et al. </text>
<text top="680" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(626)</a> </text>
<text top="697" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22958234?dopt=Citation">22958234</a></text>
<text top="697" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22958234?dopt=Citation"> </a></text>
<text top="663" left="172" width="60" height="20" font="4">Long-term </text>
<text top="680" left="172" width="57" height="20" font="4">outcomes </text>
<text top="663" left="273" width="51" height="20" font="4">n=52 pts </text>
<text top="663" left="365" width="38" height="20" font="4">91–99 </text>
<text top="663" left="446" width="10" height="20" font="4">5 </text>
<text top="663" left="513" width="24" height="20" font="4">N/A </text>
<text top="663" left="601" width="121" height="20" font="4">Coronary problems in </text>
<text top="680" left="601" width="111" height="20" font="4">2%, neoaortic valve </text>
<text top="697" left="601" width="104" height="20" font="4">intervention in 4%, </text>
<text top="714" left="601" width="109" height="20" font="4">pulmonary stenosis </text>
<text top="731" left="601" width="105" height="20" font="4">intervention in 6%. </text>
<text top="663" left="748" width="166" height="20" font="4">Age at time of repair, need for </text>
<text top="680" left="748" width="76" height="20" font="4">other surgery </text>
<text top="663" left="956" width="24" height="20" font="4">N/A </text>
<text top="749" left="64" width="74" height="20" font="4">Raju V, et al. </text>
<text top="766" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(627)</a> </text>
<text top="784" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23618522?dopt=Citation">23618522</a></text>
<text top="784" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23618522?dopt=Citation"> </a></text>
<text top="749" left="172" width="76" height="20" font="4">Reoperations </text>
<text top="749" left="273" width="51" height="20" font="4">n=32 pts </text>
<text top="766" left="273" width="80" height="20" font="4">(reoperations) </text>
<text top="749" left="365" width="51" height="20" font="4">84–2012 </text>
<text top="749" left="446" width="24" height="20" font="4">N/A </text>
<text top="749" left="513" width="21" height="20" font="4">0% </text>
<text top="749" left="601" width="121" height="20" font="4">Coronary problems in </text>
<text top="766" left="601" width="21" height="20" font="4">9% </text>
<text top="749" left="748" width="24" height="20" font="4">N/A </text>
<text top="749" left="956" width="24" height="20" font="4">N/A </text>
</page>
<page number="167" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 167 </text>
<text top="107" left="64" width="82" height="20" font="4">Serraf A, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">1991 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(628)</a> </text>
<text top="141" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2072712?dopt=Citation">2072712</a></text>
<text top="141" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2072712?dopt=Citation"> </a></text>
<text top="107" left="172" width="60" height="20" font="4">Long-term </text>
<text top="124" left="172" width="57" height="20" font="4">outcomes </text>
<text top="107" left="273" width="58" height="20" font="4">n=118 pts </text>
<text top="107" left="365" width="38" height="20" font="4">83–90 </text>
<text top="107" left="446" width="21" height="20" font="4">2.5 </text>
<text top="107" left="513" width="21" height="20" font="4">1% </text>
<text top="107" left="601" width="121" height="20" font="4">PS intervention in 6% </text>
<text top="107" left="748" width="98" height="20" font="4">Coarctation, VSD </text>
<text top="107" left="956" width="161" height="20" font="4">● 2 pts needed pacemakers. </text>
<text top="159" left="64" width="90" height="20" font="4">Soszyn N, et al. </text>
<text top="177" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(629)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21801920?dopt=Citation">21801920</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21801920?dopt=Citation"> </a></text>
<text top="159" left="172" width="60" height="20" font="4">Long-term </text>
<text top="177" left="172" width="57" height="20" font="4">outcomes </text>
<text top="194" left="172" width="83" height="20" font="4">(Taussig-Bing) </text>
<text top="159" left="273" width="51" height="20" font="4">n=57 pts </text>
<text top="159" left="365" width="38" height="20" font="4">83–90 </text>
<text top="159" left="446" width="21" height="20" font="4">9.8 </text>
<text top="159" left="513" width="21" height="20" font="4">0% </text>
<text top="159" left="601" width="118" height="20" font="4">24% reoperation rate </text>
<text top="159" left="748" width="118" height="20" font="4">Surgery prior to ASO </text>
<text top="159" left="956" width="24" height="20" font="4">N/A </text>
<text top="223" left="64" width="83" height="20" font="4">Stoica S, et al. </text>
<text top="240" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(630)</a> </text>
<text top="258" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22365263?dopt=Citation">22365263</a></text>
<text top="258" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22365263?dopt=Citation"> </a></text>
<text top="223" left="172" width="60" height="20" font="4">Long-term </text>
<text top="240" left="172" width="57" height="20" font="4">outcomes </text>
<text top="223" left="273" width="58" height="20" font="4">n=101 pts </text>
<text top="223" left="365" width="38" height="20" font="4">03–11 </text>
<text top="223" left="446" width="21" height="20" font="4">4.1 </text>
<text top="209" left="513" width="3" height="20" font="4"> </text>
<text top="223" left="601" width="121" height="20" font="4">Coronary problems in </text>
<text top="240" left="601" width="21" height="20" font="4">2% </text>
<text top="223" left="748" width="192" height="20" font="4">Arch abnormalities and malaligned </text>
<text top="240" left="748" width="79" height="20" font="4">commissures. </text>
<text top="223" left="956" width="128" height="20" font="4">● Arch and malaligned </text>
<text top="240" left="956" width="79" height="20" font="4">commissures. </text>
<text top="276" left="64" width="91" height="20" font="4">Schwartz ML, et </text>
<text top="293" left="64" width="16" height="20" font="4">al. </text>
<text top="310" left="64" width="56" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(22)</a> </text>
<text top="327" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15364851">15364851</a></text>
<text top="327" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15364851"> </a></text>
<text top="276" left="172" width="60" height="20" font="4">Long-term </text>
<text top="293" left="172" width="57" height="20" font="4">outcomes </text>
<text top="276" left="273" width="58" height="20" font="4">n=335 pts </text>
<text top="276" left="365" width="38" height="20" font="4">96–09 </text>
<text top="276" left="446" width="21" height="20" font="4">5.5 </text>
<text top="276" left="513" width="24" height="20" font="4">N/A </text>
<text top="276" left="601" width="88" height="20" font="4">Neoaortic valve </text>
<text top="293" left="601" width="104" height="20" font="4">intervention in 5%, </text>
<text top="310" left="601" width="109" height="20" font="4">pulmonary stenosis </text>
<text top="327" left="601" width="101" height="20" font="4">intervention in 5% </text>
<text top="276" left="748" width="181" height="20" font="4">VSD, age at repair, and need for </text>
<text top="293" left="748" width="67" height="20" font="4">PA banding </text>
<text top="276" left="956" width="159" height="20" font="4">● Average peak PS gradient </text>
<text top="293" left="956" width="89" height="20" font="4">was 23 mm Hg. </text>
<text top="345" left="64" width="95" height="20" font="4">Thrupp SF, et al. </text>
<text top="362" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(631)</a> </text>
<text top="380" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22981257?dopt=Citation">22981257</a></text>
<text top="380" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22981257?dopt=Citation"> </a></text>
<text top="345" left="172" width="60" height="20" font="4">Long-term </text>
<text top="362" left="172" width="57" height="20" font="4">outcomes </text>
<text top="345" left="273" width="58" height="20" font="4">n=215 pts </text>
<text top="345" left="365" width="38" height="20" font="4">96–06 </text>
<text top="345" left="446" width="24" height="20" font="4">N/A </text>
<text top="345" left="513" width="24" height="20" font="4">N/A </text>
<text top="345" left="601" width="121" height="20" font="4">Coronary problems in </text>
<text top="362" left="601" width="21" height="20" font="4">8% </text>
<text top="345" left="748" width="174" height="20" font="4">5.6% death if coronary problem </text>
<text top="345" left="956" width="163" height="20" font="4">● Focus exclusively on those </text>
<text top="362" left="956" width="135" height="20" font="4">with intramural coronary </text>
<text top="380" left="956" width="48" height="20" font="4">arteries. </text>
<text top="398" left="64" width="87" height="20" font="4">van der Bom T, </text>
<text top="415" left="64" width="30" height="20" font="4">et al. </text>
<text top="432" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#232">(408)</a> </text>
<text top="449" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24837983?dopt=Citation">24837983</a></text>
<text top="449" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24837983?dopt=Citation"> </a></text>
<text top="398" left="172" width="76" height="20" font="4">Reoperations </text>
<text top="398" left="273" width="58" height="20" font="4">n=116 pts </text>
<text top="398" left="365" width="24" height="20" font="4">&lt;95 </text>
<text top="398" left="446" width="21" height="20" font="4">7.2 </text>
<text top="398" left="513" width="24" height="20" font="4">N/A </text>
<text top="398" left="601" width="107" height="20" font="4">4% neoaortic valve </text>
<text top="415" left="601" width="67" height="20" font="4">intervention </text>
<text top="398" left="748" width="170" height="20" font="4">Linear growth of the neo-aortic </text>
<text top="415" left="748" width="120" height="20" font="4">root in adult survivors </text>
<text top="398" left="956" width="161" height="20" font="4">● Showed some progressive </text>
<text top="415" left="956" width="135" height="20" font="4">root dilatation over time. </text>
<text top="467" left="64" width="93" height="20" font="4">Vouhe PR, et al. </text>
<text top="484" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(632)</a> </text>
<text top="502" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22564800?dopt=Citation">22564800</a></text>
<text top="502" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22564800?dopt=Citation"> </a></text>
<text top="467" left="172" width="60" height="20" font="4">Long-term </text>
<text top="484" left="172" width="57" height="20" font="4">outcomes </text>
<text top="467" left="273" width="58" height="20" font="4">n=101 pts </text>
<text top="467" left="365" width="38" height="20" font="4">03–11 </text>
<text top="467" left="446" width="24" height="20" font="4">N/A </text>
<text top="467" left="513" width="21" height="20" font="4">5% </text>
<text top="467" left="601" width="83" height="20" font="4">5.3% coronary </text>
<text top="484" left="601" width="54" height="20" font="4">problems </text>
<text top="467" left="748" width="24" height="20" font="4">N/A </text>
<text top="467" left="956" width="24" height="20" font="4">N/A </text>
<text top="519" left="64" width="78" height="20" font="4">Delmo Walter </text>
<text top="537" left="64" width="55" height="20" font="4">EM, et al. </text>
<text top="554" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(633)</a> </text>
<text top="571" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21044157?dopt=Citation">21044157</a></text>
<text top="571" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21044157?dopt=Citation"> </a></text>
<text top="519" left="172" width="60" height="20" font="4">Long-term </text>
<text top="537" left="172" width="57" height="20" font="4">outcomes </text>
<text top="519" left="273" width="58" height="20" font="4">n=324 pts </text>
<text top="506" left="365" width="3" height="20" font="4"> </text>
<text top="519" left="446" width="27" height="20" font="4">14.4 </text>
<text top="506" left="513" width="3" height="20" font="4"> </text>
<text top="519" left="601" width="88" height="20" font="4">Neoaortic valve </text>
<text top="537" left="601" width="101" height="20" font="4">intervention in 1% </text>
<text top="519" left="748" width="126" height="20" font="4">VSD, PA banding, and </text>
<text top="537" left="748" width="163" height="20" font="4">postoperative neoaortic valve </text>
<text top="554" left="748" width="72" height="20" font="4">regurgitation </text>
<text top="519" left="956" width="24" height="20" font="4">N/A </text>
<text top="591" left="47" width="3" height="20" font="4"> </text>
<text top="608" left="47" width="3" height="20" font="4"> </text>
<text top="625" left="108" width="683" height="24" font="1"><b>Data Supplement 47. Congenitally Corrected Transposition of the Great Arteries – Section 4.4.1.4 </b></text>
<text top="647" left="72" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="664" left="72" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="647" left="170" width="73" height="20" font="3"><b>Study (Size, </b></text>
<text top="664" left="199" width="16" height="20" font="3"><b>N) </b></text>
<text top="647" left="259" width="220" height="20" font="3"><b>Study Design  Inclusion/Exclusion </b></text>
<text top="664" left="396" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="647" left="509" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="647" left="694" width="48" height="20" font="3"><b>Results </b></text>
<text top="647" left="868" width="77" height="20" font="3"><b>Conclusions </b></text>
<text top="708" left="64" width="67" height="20" font="4">Cui B, et al. </text>
<text top="725" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(634)</a> </text>
<text top="742" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25173927?dopt=Citation">25173927</a></text>
<text top="742" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25173927?dopt=Citation"> </a></text>
<text top="708" left="170" width="51" height="20" font="4">n=14 pts </text>
<text top="725" left="170" width="50" height="20" font="4">between </text>
<text top="742" left="170" width="62" height="20" font="4">2.5–72 mo </text>
<text top="760" left="170" width="38" height="20" font="4">of age </text>
<text top="708" left="256" width="205" height="20" font="4">Observational  <b>Inclusion criteria</b>: </text>
<text top="725" left="356" width="75" height="20" font="4">Consecutive  </text>
<text top="708" left="495" width="24" height="20" font="4">N/A </text>
<text top="708" left="608" width="211" height="20" font="4">● 2 pts died after ASO. The causes of </text>
<text top="725" left="608" width="169" height="20" font="4">death included serious cardiac </text>
<text top="742" left="608" width="219" height="20" font="4">arrhythmia with circulatory collapse and </text>
<text top="760" left="608" width="209" height="20" font="4">SCD. The others were followed up for </text>
<text top="777" left="608" width="202" height="20" font="4">2–8 y: 1 pt died from serious cardiac </text>
<text top="708" left="841" width="127" height="20" font="4">● For CCTGA children </text>
<text top="725" left="841" width="81" height="20" font="4">with degraded </text>
<text top="742" left="841" width="124" height="20" font="4">morphologic LV, the 2-</text>
<text top="760" left="841" width="111" height="20" font="4">stage double switch </text>
<text top="777" left="841" width="99" height="20" font="4">procedure can be </text>
</page>
<page number="168" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 168 </text>
<text top="107" left="170" width="69" height="20" font="4">(mean: 34.4 </text>
<text top="124" left="170" width="64" height="20" font="4">± 24.0 mo) </text>
<text top="107" left="608" width="214" height="20" font="4">arrhythmias with circulatory collapse in </text>
<text top="124" left="608" width="215" height="20" font="4">the follow-up period. With regard to the </text>
<text top="141" left="608" width="219" height="20" font="4">others, 8 were evaluated as NYHA FC I </text>
<text top="159" left="608" width="203" height="20" font="4">and the other 3 as class II. Moderate </text>
<text top="176" left="608" width="220" height="20" font="4">aortic valve regurgitation was noted in 3 </text>
<text top="193" left="608" width="162" height="20" font="4">pts and moderate MR in 1 pt. </text>
<text top="107" left="841" width="107" height="20" font="4">performed with low </text>
<text top="124" left="841" width="127" height="20" font="4">mortality and morbidity </text>
<text top="141" left="841" width="85" height="20" font="4">and may be an </text>
<text top="159" left="841" width="131" height="20" font="4">appealing alternative to </text>
<text top="176" left="841" width="114" height="20" font="4">conventional repair.  </text>
<text top="193" left="841" width="101" height="20" font="4">● Morphologic LV </text>
<text top="210" left="841" width="111" height="20" font="4">retraining should be </text>
<text top="228" left="841" width="122" height="20" font="4">performed as early as </text>
<text top="245" left="841" width="52" height="20" font="4">possible. </text>
<text top="263" left="64" width="66" height="20" font="4">Ma K, et al. </text>
<text top="280" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(635)</a> </text>
<text top="297" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24529731?dopt=Citation">24529731</a></text>
<text top="297" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24529731?dopt=Citation"> </a></text>
<text top="263" left="170" width="54" height="20" font="4">n=40 pts; </text>
<text top="280" left="170" width="62" height="20" font="4">(15 double </text>
<text top="297" left="170" width="58" height="20" font="4">switch; 25 </text>
<text top="314" left="170" width="55" height="20" font="4">PA band) </text>
<text top="263" left="256" width="70" height="20" font="4">Comparison </text>
<text top="263" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="280" left="356" width="123" height="20" font="4">Child pts with CCTGA </text>
<text top="263" left="495" width="60" height="20" font="4">In-hospital </text>
<text top="280" left="495" width="81" height="20" font="4">mortality, long-</text>
<text top="297" left="495" width="81" height="20" font="4">term mortality, </text>
<text top="314" left="495" width="55" height="20" font="4">and heart </text>
<text top="332" left="495" width="46" height="20" font="4">function </text>
<text top="263" left="608" width="201" height="20" font="4">● Overall survival rate was 66.7% in </text>
<text top="280" left="608" width="204" height="20" font="4">the double-switch group vs. 96.0% in </text>
<text top="297" left="608" width="211" height="20" font="4">the PA band group (p=0.03). The ratio </text>
<text top="314" left="608" width="192" height="20" font="4">of NYHA FC I-II (80.0% vs. 95.9%; </text>
<text top="332" left="608" width="214" height="20" font="4">p=0.02) and the mean functional LVEF </text>
<text top="349" left="608" width="190" height="20" font="4">(51.4% ± 9.6% vs. 61.0% ± 6.4%; </text>
<text top="366" left="608" width="197" height="20" font="4">p=0.01) were higher in the PA band </text>
<text top="383" left="608" width="108" height="20" font="4">group at follow-up.  </text>
<text top="400" left="608" width="192" height="20" font="4">● In univariate analysis, age at PA </text>
<text top="418" left="608" width="200" height="20" font="4">band was the only risk factor for late </text>
<text top="435" left="608" width="188" height="20" font="4">deaths (OR: 7.30; p=0.01) and LV </text>
<text top="452" left="608" width="220" height="20" font="4">dysfunction (OR: 4.77; p=0.03) after the </text>
<text top="469" left="608" width="81" height="20" font="4">double switch. </text>
<text top="263" left="841" width="119" height="20" font="4">● Compared with the </text>
<text top="280" left="841" width="78" height="20" font="4">double-switch </text>
<text top="297" left="841" width="107" height="20" font="4">procedure after PA </text>
<text top="314" left="841" width="92" height="20" font="4">band, prolonged </text>
<text top="332" left="841" width="118" height="20" font="4">palliative PA banding </text>
<text top="349" left="841" width="94" height="20" font="4">provided a lower </text>
<text top="366" left="841" width="98" height="20" font="4">mortality rate and </text>
<text top="383" left="841" width="131" height="20" font="4">indicated better cardiac </text>
<text top="401" left="841" width="50" height="20" font="4">function. </text>
<text top="487" left="64" width="92" height="20" font="4">Myers PO, et al. </text>
<text top="504" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(636)</a> </text>
<text top="522" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24267780?dopt=Citation">24267780</a></text>
<text top="522" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24267780?dopt=Citation"> </a></text>
<text top="487" left="170" width="41" height="20" font="4">n=106; </text>
<text top="504" left="170" width="68" height="20" font="4">median age </text>
<text top="522" left="170" width="58" height="20" font="4">at surgery </text>
<text top="539" left="170" width="55" height="20" font="4">was 1.2 y </text>
<text top="556" left="170" width="53" height="20" font="4">(range, 2 </text>
<text top="573" left="170" width="55" height="20" font="4">mo–43 y) </text>
<text top="487" left="256" width="82" height="20" font="4">Retrospective, </text>
<text top="504" left="256" width="73" height="20" font="4">single center </text>
<text top="487" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="504" left="356" width="96" height="20" font="4">Surgery between </text>
<text top="522" left="356" width="65" height="20" font="4">1992–2012 </text>
<text top="487" left="495" width="70" height="20" font="4">Moderate or </text>
<text top="504" left="495" width="86" height="20" font="4">greater TR and </text>
<text top="522" left="495" width="85" height="20" font="4">TV reoperation </text>
<text top="539" left="495" width="81" height="20" font="4">after anatomic </text>
<text top="556" left="495" width="35" height="20" font="4">repair </text>
<text top="487" left="608" width="192" height="20" font="4">● Of the 106 pts, 6 (5.6%) with TR </text>
<text top="504" left="608" width="198" height="20" font="4">underwent tricuspid valvuloplasty at </text>
<text top="522" left="608" width="198" height="20" font="4">anatomic repair, 5 with (21%) and 1 </text>
<text top="539" left="608" width="194" height="20" font="4">without (11%) Ebsteinoid dysplasia </text>
<text top="556" left="608" width="63" height="20" font="4">(p&lt;0.001).  </text>
<text top="573" left="608" width="210" height="20" font="4">● During a median follow-up period of </text>
<text top="591" left="608" width="196" height="20" font="4">32 mo, of the 24 pts with TR before </text>
<text top="608" left="608" width="167" height="20" font="4">anatomic repair, all 6 who had </text>
<text top="625" left="608" width="209" height="20" font="4">undergone tricuspid valvuloplasty had </text>
<text top="642" left="608" width="205" height="20" font="4">mild TR or less at the latest follow-up </text>
<text top="659" left="608" width="175" height="20" font="4">visit; 15 of the 18 (83%) without </text>
<text top="677" left="608" width="183" height="20" font="4">valvuloplasty had mild TR or less </text>
<text top="694" left="608" width="217" height="20" font="4">(p=0.4) and 3 (16.7%) had moderate or </text>
<text top="711" left="608" width="165" height="20" font="4">greater TR. Of the 14 pts with </text>
<text top="728" left="608" width="173" height="20" font="4">Ebsteinoid dysplasia and TR, 5 </text>
<text top="745" left="608" width="200" height="20" font="4">underwent valvuloplasty and had no </text>
<text top="763" left="608" width="216" height="20" font="4">significant TR during follow-up; 2 of the </text>
<text top="487" left="841" width="78" height="20" font="4">● TV function </text>
<text top="504" left="841" width="121" height="20" font="4">significantly improved </text>
<text top="522" left="841" width="120" height="20" font="4">after anatomic repair, </text>
<text top="539" left="841" width="118" height="20" font="4">independent of direct </text>
<text top="556" left="841" width="116" height="20" font="4">surgical intervention. </text>
<text top="573" left="841" width="100" height="20" font="4">For significant TR </text>
<text top="591" left="841" width="87" height="20" font="4">associated with </text>
<text top="608" left="841" width="119" height="20" font="4">Ebsteinoid dysplasia, </text>
<text top="625" left="841" width="131" height="20" font="4">valvuloplasty should be </text>
<text top="642" left="841" width="67" height="20" font="4">considered. </text>
</page>
<page number="169" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 169 </text>
<text top="107" left="608" width="197" height="20" font="4">9 (22.2%) without valvuloplasty had </text>
<text top="124" left="608" width="188" height="20" font="4">moderate or greater TR (p=0.51).  </text>
<text top="141" left="608" width="218" height="20" font="4">● Valvuloplasty was associated with an </text>
<text top="159" left="608" width="215" height="20" font="4">absolute risk of TR reduction of 16.7%, </text>
<text top="176" left="608" width="215" height="20" font="4">which was further reduced by 22.2% in </text>
<text top="193" left="608" width="168" height="20" font="4">pts with associated Ebsteinoid </text>
<text top="210" left="608" width="58" height="20" font="4">dysplasia. </text>
<text top="228" left="64" width="48" height="20" font="4">Bautista-</text>
<text top="245" left="64" width="92" height="20" font="4">Hernandez V, et </text>
<text top="263" left="64" width="16" height="20" font="4">al. </text>
<text top="280" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(637)</a> </text>
<text top="297" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24100093?dopt=Citation">24100093</a></text>
<text top="297" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24100093?dopt=Citation"> </a></text>
<text top="228" left="170" width="61" height="20" font="4">n=106 pts; </text>
<text top="245" left="170" width="68" height="20" font="4">median age </text>
<text top="263" left="170" width="62" height="20" font="4">at surgery, </text>
<text top="280" left="170" width="72" height="20" font="4">1.2 y; range, </text>
<text top="297" left="170" width="61" height="20" font="4">2 mo–43 y </text>
<text top="228" left="256" width="82" height="20" font="4">Retrospective, </text>
<text top="245" left="256" width="73" height="20" font="4">single center </text>
<text top="228" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="245" left="356" width="96" height="20" font="4">Surgery between </text>
<text top="263" left="356" width="65" height="20" font="4">1992–2012 </text>
<text top="228" left="495" width="84" height="20" font="4">LV dysfunction </text>
<text top="228" left="608" width="216" height="20" font="4">● 12 pts (12%) developed moderate or </text>
<text top="245" left="608" width="40" height="20" font="4">severe </text>
<text top="245" left="648" width="15" height="20" font="11">LV</text>
<text top="245" left="663" width="76" height="20" font="4"> dysfunction.  </text>
<text top="263" left="608" width="144" height="20" font="4">● Factors associated with </text>
<text top="263" left="752" width="15" height="20" font="11">LV</text>
<text top="263" left="767" width="3" height="20" font="4"> </text>
<text top="280" left="608" width="199" height="20" font="4">dysfunction were age at repair older </text>
<text top="297" left="608" width="203" height="20" font="4">than 10 y, weight greater than 20 kg, </text>
<text top="314" left="608" width="202" height="20" font="4">pacemaker implantation, and severe </text>
<text top="332" left="608" width="133" height="20" font="4">neo-aortic regurgitation. </text>
<text top="228" left="841" width="40" height="20" font="4">● Late </text>
<text top="228" left="881" width="15" height="20" font="11">LV</text>
<text top="228" left="896" width="69" height="20" font="4"> dysfunction </text>
<text top="245" left="841" width="130" height="20" font="4">after anatomic repair of </text>
<text top="263" left="841" width="79" height="20" font="4">CCTGA is not </text>
<text top="280" left="841" width="122" height="20" font="4">uncommon, occurring </text>
<text top="297" left="841" width="124" height="20" font="4">most often in older pts </text>
<text top="314" left="841" width="122" height="20" font="4">and in those requiring </text>
<text top="332" left="841" width="43" height="20" font="4">pacing. </text>
<text top="350" left="64" width="89" height="20" font="4">Van der Bom T, </text>
<text top="367" left="64" width="30" height="20" font="4">et al. </text>
<text top="384" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(638)</a> </text>
<text top="401" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23850923?dopt=Citation">23850923</a></text>
<text top="401" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23850923?dopt=Citation"> </a></text>
<text top="350" left="170" width="54" height="20" font="4">n=88 pts, </text>
<text top="367" left="170" width="58" height="20" font="4">mean age </text>
<text top="384" left="170" width="71" height="20" font="4">was 33 ± 10 </text>
<text top="401" left="170" width="10" height="20" font="4">y </text>
<text top="350" left="256" width="76" height="20" font="4">Double-blind, </text>
<text top="367" left="256" width="71" height="20" font="4">randomized, </text>
<text top="384" left="256" width="47" height="20" font="4">placebo-</text>
<text top="401" left="256" width="80" height="20" font="4">controlled trial </text>
<text top="418" left="256" width="67" height="20" font="4">of valsartan </text>
<text top="350" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="367" left="356" width="65" height="20" font="4">2006–2009 </text>
<text top="350" left="495" width="62" height="20" font="4">Composite </text>
<text top="367" left="495" width="64" height="20" font="4">endpoint of </text>
<text top="384" left="495" width="83" height="20" font="4">clinical events: </text>
<text top="401" left="495" width="100" height="20" font="4">death; NSVT, VT; </text>
<text top="418" left="495" width="89" height="20" font="4">vascular events </text>
<text top="436" left="495" width="83" height="20" font="4">(CVA, TIA, MI) </text>
<text top="453" left="495" width="71" height="20" font="4">TR requiring </text>
<text top="470" left="495" width="48" height="20" font="4">invasive </text>
<text top="487" left="495" width="59" height="20" font="4">treatment; </text>
<text top="504" left="495" width="97" height="20" font="4">worsening NYHA </text>
<text top="522" left="495" width="83" height="20" font="4">FC, or hospital </text>
<text top="539" left="495" width="76" height="20" font="4">admission for </text>
<text top="556" left="495" width="59" height="20" font="4">worsening </text>
<text top="573" left="495" width="96" height="20" font="4">symptoms of HF; </text>
<text top="591" left="495" width="85" height="20" font="4">and arrhythmia </text>
<text top="608" left="495" width="93" height="20" font="4">requiring DCCV, </text>
<text top="625" left="495" width="50" height="20" font="4">ablation, </text>
<text top="642" left="495" width="94" height="20" font="4">implantation of a </text>
<text top="659" left="495" width="92" height="20" font="4">pacemaker, or a </text>
<text top="677" left="495" width="62" height="20" font="4">permanent </text>
<text top="694" left="495" width="57" height="20" font="4">change of </text>
<text top="711" left="495" width="81" height="20" font="4">antiarrhythmic </text>
<text top="728" left="495" width="63" height="20" font="4">medication </text>
<text top="350" left="608" width="217" height="20" font="4">● During a follow-up period of 4.3 y, 31 </text>
<text top="367" left="608" width="184" height="20" font="4">pts (35%) experienced 46 clinical </text>
<text top="384" left="608" width="183" height="20" font="4">events for an annual risk of 12%. </text>
<text top="350" left="841" width="122" height="20" font="4">● RVEDV index &gt;150 </text>
<text top="367" left="841" width="31" height="20" font="4">mL/m</text>
<text top="368" left="872" width="4" height="13" font="6">2</text>
<text top="367" left="876" width="57" height="20" font="4"> and peak </text>
<text top="384" left="841" width="113" height="20" font="4">exercise systolic BP </text>
<text top="401" left="841" width="126" height="20" font="4">below 180 mm Hg had </text>
<text top="418" left="841" width="129" height="20" font="4">a 20-fold higher annual </text>
<text top="436" left="841" width="105" height="20" font="4">event rate than pts </text>
<text top="453" left="841" width="98" height="20" font="4">without these risk </text>
<text top="470" left="841" width="44" height="20" font="4">factors. </text>
<text top="746" left="64" width="80" height="20" font="4">Book W, et al. </text>
<text top="763" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(639)</a> </text>
<text top="781" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23350927?dopt=Citation">23350927</a></text>
<text top="781" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23350927?dopt=Citation"> </a></text>
<text top="746" left="170" width="54" height="20" font="4">n=51 pts; </text>
<text top="763" left="170" width="68" height="20" font="4">median age </text>
<text top="781" left="170" width="52" height="20" font="4">was 30 y </text>
<text top="746" left="256" width="68" height="20" font="4">Prospective </text>
<text top="746" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="763" left="356" width="125" height="20" font="4">TGA pts with systemic </text>
<text top="781" left="356" width="21" height="20" font="4">RV </text>
<text top="746" left="495" width="40" height="20" font="4">6MWT </text>
<text top="746" left="608" width="193" height="20" font="4">● The pt's self-assessment of poor </text>
<text top="763" left="608" width="205" height="20" font="4">health, as measured by an increased </text>
<text top="781" left="608" width="209" height="20" font="4">NYHA FC (p=0.003) and a decreased </text>
<text top="746" left="841" width="128" height="20" font="4">● Pt's self-assessment </text>
<text top="763" left="841" width="126" height="20" font="4">of functional status did </text>
</page>
<page number="170" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 170 </text>
<text top="107" left="170" width="60" height="20" font="4">(range 19–</text>
<text top="124" left="170" width="67" height="20" font="4">65); 11 with </text>
<text top="141" left="170" width="46" height="20" font="4">CCTGA </text>
<text top="107" left="608" width="198" height="20" font="4">Minnesota Living With Heart Failure </text>
<text top="124" left="608" width="177" height="20" font="4">Questionnaire score (p&gt;0.0001) </text>
<text top="141" left="608" width="178" height="20" font="4">correlated with a shorter 6MWT. </text>
<text top="107" left="841" width="128" height="20" font="4">correlate with objective </text>
<text top="124" left="841" width="96" height="20" font="4">functional status. </text>
<text top="159" left="64" width="91" height="20" font="4">Mongeon FP, et </text>
<text top="177" left="64" width="16" height="20" font="4">al. </text>
<text top="194" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(640)</a> </text>
<text top="211" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21565637?dopt=Citation">21565637</a></text>
<text top="211" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21565637?dopt=Citation"> </a></text>
<text top="159" left="170" width="54" height="20" font="4">n=46 pts; </text>
<text top="177" left="170" width="72" height="20" font="4">mean age of </text>
<text top="194" left="170" width="66" height="20" font="4">40.8 ± 14.8 </text>
<text top="211" left="170" width="10" height="20" font="4">y </text>
<text top="159" left="256" width="79" height="20" font="4">Retrospective </text>
<text top="159" left="356" width="120" height="20" font="3"><b>Inclusion criteria</b>: 1) </text>
<text top="177" left="356" width="73" height="20" font="4">Systemic AV </text>
<text top="194" left="356" width="96" height="20" font="4">regurgitation that </text>
<text top="211" left="356" width="81" height="20" font="4">required valve </text>
<text top="228" left="356" width="71" height="20" font="4">replacement </text>
<text top="246" left="356" width="107" height="20" font="4">performed at Mayo </text>
<text top="263" left="356" width="124" height="20" font="4">Clinic; and 2) a known </text>
<text top="280" left="356" width="111" height="20" font="4">systemic ventricular </text>
<text top="297" left="356" width="94" height="20" font="4">EF at the time of </text>
<text top="314" left="356" width="103" height="20" font="4">systemic AV valve </text>
<text top="332" left="356" width="75" height="20" font="4">replacement. </text>
<text top="159" left="495" width="92" height="20" font="4">Late mortality or </text>
<text top="177" left="495" width="43" height="20" font="4">cardiac </text>
<text top="194" left="495" width="61" height="20" font="4">transplant. </text>
<text top="211" left="495" width="55" height="20" font="4">2 groups: </text>
<text top="228" left="495" width="72" height="20" font="4">preoperative </text>
<text top="246" left="495" width="51" height="20" font="4">systemic </text>
<text top="263" left="495" width="79" height="20" font="4">ventricular EF </text>
<text top="280" left="495" width="85" height="20" font="4">&gt;40% in 27 pts </text>
<text top="297" left="495" width="89" height="20" font="4">and &lt;40% in 19 </text>
<text top="314" left="495" width="24" height="20" font="4">pts) </text>
<text top="159" left="608" width="201" height="20" font="4">● Preoperative variables associated </text>
<text top="177" left="608" width="180" height="20" font="4">with late mortality were systemic </text>
<text top="194" left="608" width="209" height="20" font="4">ventricular EF &lt;40%, a subpulmonary </text>
<text top="211" left="608" width="203" height="20" font="4">ventricular systolic pressure &gt;50 mm </text>
<text top="228" left="608" width="162" height="20" font="4">Hg, AF, and NYHA FC III–IV. </text>
<text top="159" left="841" width="104" height="20" font="4">● For best results, </text>
<text top="177" left="841" width="111" height="20" font="4">operation should be </text>
<text top="194" left="841" width="132" height="20" font="4">considered at an earlier </text>
<text top="211" left="841" width="96" height="20" font="4">stage, before the </text>
<text top="228" left="841" width="131" height="20" font="4">systemic ventricular EF </text>
<text top="246" left="841" width="113" height="20" font="4">falls below 40% and </text>
<text top="263" left="841" width="101" height="20" font="4">the subpulmonary </text>
<text top="280" left="841" width="104" height="20" font="4">ventricular systolic </text>
<text top="297" left="841" width="118" height="20" font="4">pressure rises above </text>
<text top="314" left="841" width="64" height="20" font="4">50 mm Hg. </text>
<text top="350" left="64" width="84" height="20" font="4">Graham TP, et </text>
<text top="367" left="64" width="16" height="20" font="4">al. </text>
<text top="384" left="64" width="63" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(641)</a> </text>
<text top="401" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10898443?dopt=Citation">10898443</a></text>
<text top="401" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10898443?dopt=Citation"> </a></text>
<text top="350" left="170" width="58" height="20" font="4">n=182 pts </text>
<text top="350" left="256" width="82" height="20" font="4">Retrospective, </text>
<text top="367" left="256" width="64" height="20" font="4">multicenter </text>
<text top="384" left="298" width="3" height="20" font="4"> </text>
<text top="350" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="367" left="356" width="117" height="20" font="4">Group I: 132 pts with </text>
<text top="384" left="356" width="120" height="20" font="4">significant associated </text>
<text top="401" left="356" width="109" height="20" font="4">lesions (large VSD, </text>
<text top="418" left="356" width="110" height="20" font="4">moderate or severe </text>
<text top="436" left="356" width="113" height="20" font="4">PS, PA moderate or </text>
<text top="453" left="356" width="84" height="20" font="4">severe TR and </text>
<text top="470" left="356" width="117" height="20" font="4">Ebstein-like anomaly </text>
<text top="487" left="356" width="105" height="20" font="4">of the TV. Group II </text>
<text top="504" left="356" width="106" height="20" font="4">consisted of 50 pts </text>
<text top="522" left="356" width="100" height="20" font="4">with no significant </text>
<text top="539" left="356" width="42" height="20" font="4">lesions </text>
<text top="350" left="495" width="76" height="20" font="4">Mortality, HF, </text>
<text top="367" left="495" width="66" height="20" font="4">RV, and LV </text>
<text top="384" left="495" width="66" height="20" font="4">dysfunction </text>
<text top="350" left="608" width="161" height="20" font="4">● By age 45, 67% of pts with </text>
<text top="367" left="608" width="213" height="20" font="4">associated lesions had congestive HF, </text>
<text top="384" left="608" width="190" height="20" font="4">and 25% of pts without associated </text>
<text top="401" left="608" width="167" height="20" font="4">lesions had this complication.  </text>
<text top="418" left="608" width="193" height="20" font="4">● The rates of systemic ventricular </text>
<text top="436" left="608" width="202" height="20" font="4">dysfunction and HF were higher with </text>
<text top="453" left="608" width="175" height="20" font="4">increasing age, the presence of </text>
<text top="470" left="608" width="209" height="20" font="4">significant associated cardiac lesions, </text>
<text top="487" left="608" width="182" height="20" font="4">history of arrhythmia, pacemaker </text>
<text top="504" left="608" width="213" height="20" font="4">implantation, prior surgery of any type, </text>
<text top="522" left="608" width="161" height="20" font="4">and particularly with tricuspid </text>
<text top="539" left="608" width="163" height="20" font="4">valvuloplasty or replacement. </text>
<text top="350" left="841" width="121" height="20" font="4">● Tricuspid (systemic </text>
<text top="367" left="841" width="70" height="20" font="4">AV) valvular </text>
<text top="384" left="841" width="131" height="20" font="4">regurgitation is strongly </text>
<text top="401" left="841" width="108" height="20" font="4">associated with RV </text>
<text top="418" left="841" width="94" height="20" font="4">(anatomical right </text>
<text top="436" left="841" width="123" height="20" font="4">ventricle connected to </text>
<text top="453" left="841" width="114" height="20" font="4">aorta in CCTGA pts; </text>
<text top="470" left="841" width="113" height="20" font="4">systemic ventricle in </text>
<text top="487" left="841" width="116" height="20" font="4">CCTGA) dysfunction </text>
<text top="504" left="841" width="47" height="20" font="4">and HF. </text>
<text top="557" left="64" width="88" height="20" font="4">Prieto LR, et al. </text>
<text top="574" left="64" width="63" height="20" font="4">1998 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(642)</a> </text>
<text top="591" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9737520?dopt=Citation">9737520</a></text>
<text top="591" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9737520?dopt=Citation"> </a></text>
<text top="557" left="170" width="51" height="20" font="4">n=40 pts </text>
<text top="557" left="256" width="79" height="20" font="4">Retrospective </text>
<text top="557" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="574" left="356" width="85" height="20" font="4">Since 1958, 40 </text>
<text top="591" left="356" width="113" height="20" font="4">consecutive pts with </text>
<text top="608" left="356" width="122" height="20" font="4">CCTGA and 2 normal-</text>
<text top="626" left="356" width="117" height="20" font="4">sized ventricles have </text>
<text top="643" left="356" width="93" height="20" font="4">been followed at </text>
<text top="660" left="356" width="55" height="20" font="4">Columbia </text>
<text top="557" left="495" width="36" height="20" font="4">Death </text>
<text top="557" left="608" width="174" height="20" font="4">● Poor long-term postoperative </text>
<text top="574" left="608" width="219" height="20" font="4">outcome was due to TI(s) in all but 1 pt; </text>
<text top="591" left="608" width="218" height="20" font="4">20-y survival rates for operated pts with </text>
<text top="608" left="608" width="205" height="20" font="4">and without TI(s)were 34% and 90%, </text>
<text top="626" left="608" width="132" height="20" font="4">respectively (p=0.002).  </text>
<text top="643" left="608" width="187" height="20" font="4">● Similarly, 20-y survival rates for </text>
<text top="660" left="608" width="206" height="20" font="4">unoperated pts with and without TI(s) </text>
<text top="677" left="608" width="192" height="20" font="4">were 60% and 100%, respectively, </text>
<text top="694" left="608" width="202" height="20" font="4">whether or not attempts to repair the </text>
<text top="712" left="608" width="184" height="20" font="4">tricuspid insufficiency were made </text>
<text top="729" left="608" width="53" height="20" font="4">(p=0.08). </text>
<text top="557" left="841" width="122" height="20" font="4">● Significant tricuspid </text>
<text top="574" left="841" width="132" height="20" font="4">insufficiency represents </text>
<text top="591" left="841" width="129" height="20" font="4">the major risk factor for </text>
<text top="608" left="841" width="81" height="20" font="4">CTGA pts; RV </text>
<text top="626" left="841" width="127" height="20" font="4">dysfunction appears to </text>
<text top="643" left="841" width="98" height="20" font="4">be almost always </text>
<text top="660" left="841" width="101" height="20" font="4">secondary to long-</text>
<text top="677" left="841" width="73" height="20" font="4">standing TR. </text>
<text top="747" left="64" width="82" height="20" font="4">Lewis M, et al. </text>
<text top="764" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#243">(643)</a> </text>
<text top="781" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24814545?dopt=Citation">24814545</a></text>
<text top="781" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24814545?dopt=Citation"> </a></text>
<text top="747" left="170" width="54" height="20" font="4">n=33 pts; </text>
<text top="764" left="170" width="72" height="20" font="4">mean age at </text>
<text top="781" left="170" width="57" height="20" font="4">CMR was </text>
<text top="747" left="256" width="78" height="20" font="4">Retrospective </text>
<text top="764" left="256" width="76" height="20" font="4">observational </text>
<text top="781" left="256" width="33" height="20" font="4">study </text>
<text top="747" left="356" width="126" height="20" font="3"><b>Inclusion criteria</b>: Pts </text>
<text top="764" left="356" width="121" height="20" font="4">with CCTGA who had </text>
<text top="781" left="356" width="94" height="20" font="4">undergone CMR </text>
<text top="747" left="495" width="69" height="20" font="4">RV size and </text>
<text top="764" left="495" width="46" height="20" font="4">function </text>
<text top="747" left="608" width="213" height="20" font="4">● Mean RVEF (45% vs. 41% vs. 42%; </text>
<text top="764" left="608" width="196" height="20" font="4">p=0.68) and mean indexed RVEDV </text>
<text top="781" left="608" width="59" height="20" font="4">(122 mL/m</text>
<text top="783" left="667" width="4" height="13" font="6">2</text>
<text top="781" left="671" width="77" height="20" font="4"> vs. 136 mL/m</text>
<text top="783" left="748" width="4" height="13" font="6">2</text>
<text top="781" left="753" width="43" height="20" font="4"> vs.138 </text>
<text top="747" left="841" width="96" height="20" font="4">● No association </text>
<text top="764" left="841" width="126" height="20" font="4">between the degree of </text>
</page>
<page number="171" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 171 </text>
<text top="107" left="170" width="68" height="20" font="4">38 y (23–64 </text>
<text top="124" left="170" width="17" height="20" font="4">y). </text>
<text top="107" left="608" width="31" height="20" font="4">mL/m</text>
<text top="109" left="639" width="4" height="13" font="6">2</text>
<text top="107" left="643" width="166" height="20" font="4"> p=0.36) were not significantly </text>
<text top="124" left="608" width="172" height="20" font="4">different for pts with ≥ mild TR, </text>
<text top="141" left="608" width="157" height="20" font="4">moderate TR or severe TR.  </text>
<text top="107" left="841" width="121" height="20" font="4">TR and RV volume or </text>
<text top="124" left="841" width="22" height="20" font="4">EF. </text>
<text top="159" left="64" width="85" height="20" font="4">Grewal J, et al. </text>
<text top="177" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(644)</a> </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22981226?dopt=Citation">22981226</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22981226?dopt=Citation"> </a></text>
<text top="159" left="170" width="54" height="20" font="4">n=26 pts; </text>
<text top="177" left="170" width="62" height="20" font="4">mean age, </text>
<text top="194" left="170" width="59" height="20" font="4">38 ± 16 y: </text>
<text top="211" left="170" width="64" height="20" font="4">20 controls </text>
<text top="159" left="256" width="67" height="20" font="4">Prospective </text>
<text top="177" left="256" width="33" height="20" font="4">study </text>
<text top="159" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="177" left="356" width="127" height="20" font="4">Echo, CMR and CPET </text>
<text top="194" left="356" width="3" height="20" font="4"> </text>
<text top="211" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="228" left="356" width="126" height="20" font="4">Devices of mechanical </text>
<text top="245" left="356" width="38" height="20" font="4">valves </text>
<text top="159" left="495" width="93" height="20" font="4">RV volumes and </text>
<text top="177" left="495" width="89" height="20" font="4">EF, fibrosis, RV </text>
<text top="194" left="495" width="86" height="20" font="4">strain, exercise </text>
<text top="211" left="495" width="49" height="20" font="4">capacity </text>
<text top="159" left="608" width="212" height="20" font="4">● There was a significant difference in </text>
<text top="177" left="608" width="197" height="20" font="4">diastolic volumes among those with </text>
<text top="194" left="608" width="212" height="20" font="4">RVEFs &gt;40% vs. 40% (173 ± 6 29 mL </text>
<text top="211" left="608" width="165" height="20" font="4">vs. 233 ± 65 mL; p=0.02) and </text>
<text top="228" left="608" width="206" height="20" font="4">moderate or severe vs. no or mild TR </text>
<text top="246" left="608" width="173" height="20" font="4">(240 ± 80 mL vs. 190 ± 38 mL; </text>
<text top="263" left="608" width="52" height="20" font="4">p=0.04).  </text>
<text top="280" left="608" width="206" height="20" font="4">● RV apical longitudinal and mid free </text>
<text top="297" left="608" width="167" height="20" font="4">wall circumferential strain was </text>
<text top="314" left="608" width="181" height="20" font="4">decreased compared with these. </text>
<text top="159" left="841" width="111" height="20" font="4">● Exercise capacity </text>
<text top="177" left="841" width="92" height="20" font="4">was significantly </text>
<text top="194" left="841" width="106" height="20" font="4">reduced in pts with </text>
<text top="211" left="841" width="130" height="20" font="4">CCTGA compared with </text>
<text top="228" left="841" width="121" height="20" font="4">normal subjects (20.9 </text>
<text top="246" left="841" width="131" height="20" font="4">± 6 6.0 vs. 30.8 ± 6 9.2 </text>
<text top="263" left="841" width="123" height="20" font="4">mL/kg/min; p=0.001).  </text>
<text top="280" left="841" width="117" height="20" font="4">● The majority of pts </text>
<text top="297" left="841" width="128" height="20" font="4">(61%) had RVEF 40%. </text>
<text top="332" left="64" width="86" height="20" font="4">Diller GP, et al. </text>
<text top="350" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(608)</a> </text>
<text top="367" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22607865?dopt=Citation">22607865</a></text>
<text top="367" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22607865?dopt=Citation"> </a></text>
<text top="332" left="170" width="61" height="20" font="4">n=129 pts; </text>
<text top="350" left="170" width="58" height="20" font="4">mean age </text>
<text top="367" left="170" width="63" height="20" font="4">35 ± 12 y); </text>
<text top="384" left="170" width="42" height="20" font="4">42 with </text>
<text top="401" left="170" width="46" height="20" font="4">CCTGA </text>
<text top="332" left="256" width="79" height="20" font="4">Retrospective </text>
<text top="332" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="350" left="356" width="103" height="20" font="4">Echocardiography </text>
<text top="332" left="495" width="59" height="20" font="4">Combined </text>
<text top="350" left="495" width="71" height="20" font="4">endpoint: an </text>
<text top="367" left="495" width="63" height="20" font="4">increase in </text>
<text top="384" left="495" width="89" height="20" font="4">NYHA FC to ≥3 </text>
<text top="401" left="495" width="96" height="20" font="4">or new signs and </text>
<text top="418" left="495" width="93" height="20" font="4">symptoms of HF </text>
<text top="436" left="495" width="85" height="20" font="4">- occurrence of </text>
<text top="453" left="495" width="96" height="20" font="4">clinically relevant </text>
<text top="470" left="495" width="89" height="20" font="4">arrhythmia (i.e., </text>
<text top="487" left="495" width="72" height="20" font="4">symptomatic </text>
<text top="504" left="495" width="62" height="20" font="4">arrhythmia </text>
<text top="522" left="495" width="97" height="20" font="4">requiring medical </text>
<text top="539" left="495" width="91" height="20" font="4">or interventional </text>
<text top="556" left="495" width="66" height="20" font="4">therapy); or </text>
<text top="573" left="495" width="72" height="20" font="4">death during </text>
<text top="591" left="495" width="56" height="20" font="4">follow-up. </text>
<text top="608" left="495" width="72" height="20" font="4">Predictors of </text>
<text top="625" left="495" width="81" height="20" font="4">outcome were </text>
<text top="642" left="495" width="65" height="20" font="4">determined </text>
<text top="659" left="495" width="98" height="20" font="4">separately for pts </text>
<text top="677" left="495" width="82" height="20" font="4">with TGA after </text>
<text top="694" left="495" width="91" height="20" font="4">atrial switch and </text>
<text top="711" left="495" width="92" height="20" font="4">pts with CCTGA </text>
<text top="332" left="608" width="211" height="20" font="4">● Systemic ventricular longitudinal 2D </text>
<text top="350" left="608" width="217" height="20" font="4">peak systolic strain (RV 2D-longitudinal </text>
<text top="367" left="608" width="178" height="20" font="4">strain) was significantly reduced </text>
<text top="384" left="608" width="201" height="20" font="4">compared with controls (−12.9 ± 3.6 </text>
<text top="401" left="608" width="190" height="20" font="4">and −15.4 ± 5.1 vs. −21.0 ± 5.5 in </text>
<text top="418" left="608" width="168" height="20" font="4">TGAs, CCTGAs, and controls; </text>
<text top="436" left="608" width="201" height="20" font="4">p&lt;0.0001). Systemic and pulmonary </text>
<text top="453" left="608" width="220" height="20" font="4">2D-longitudinal strain were correlated in </text>
<text top="470" left="608" width="203" height="20" font="4">pts with TGA (r=0.46; p&lt;0.0001) and </text>
<text top="487" left="608" width="218" height="20" font="4">CCTGA (r=0.64; p&lt;0.0001), suggesting </text>
<text top="504" left="608" width="219" height="20" font="4">interventricular interaction, and this was </text>
<text top="522" left="608" width="178" height="20" font="4">confirmed when EF on MRI was </text>
<text top="539" left="608" width="164" height="20" font="4">assessed (r=0.53; p&lt;0.0001). </text>
<text top="332" left="841" width="117" height="20" font="4">● Global longitudinal </text>
<text top="350" left="841" width="89" height="20" font="4">systolic strain is </text>
<text top="367" left="841" width="128" height="20" font="4">significantly reduced in </text>
<text top="384" left="841" width="127" height="20" font="4">pts with a systemic RV </text>
<text top="401" left="841" width="67" height="20" font="4">is related to </text>
<text top="418" left="841" width="81" height="20" font="4">subpulmonary </text>
<text top="436" left="841" width="110" height="20" font="4">ventricular function. </text>
<text top="729" left="64" width="81" height="20" font="4">Yeo WT, et al. </text>
<text top="746" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(645)</a> </text>
<text top="763" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24374205?dopt=Citation">24374205</a></text>
<text top="763" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24374205?dopt=Citation"> </a></text>
<text top="729" left="170" width="64" height="20" font="4">56 (22 with </text>
<text top="746" left="170" width="72" height="20" font="4">LV pacing; 7 </text>
<text top="763" left="170" width="25" height="20" font="4">with </text>
<text top="781" left="170" width="70" height="20" font="4">biventricular </text>
<text top="729" left="256" width="79" height="20" font="4">Retrospective </text>
<text top="729" left="356" width="116" height="20" font="3"><b>Inclusion criteria</b>: 2 </text>
<text top="746" left="356" width="115" height="20" font="4">echocardiographs at </text>
<text top="763" left="356" width="122" height="20" font="4">least 6 mo apart were </text>
<text top="781" left="356" width="49" height="20" font="4">included </text>
<text top="729" left="495" width="87" height="20" font="4">Deterioration in </text>
<text top="746" left="495" width="72" height="20" font="4">systemic RV </text>
<text top="763" left="495" width="46" height="20" font="4">function </text>
<text top="781" left="495" width="81" height="20" font="4">measuring RV </text>
<text top="729" left="608" width="199" height="20" font="4">● The LV-paced group experienced </text>
<text top="746" left="608" width="207" height="20" font="4">deterioration in the RV fractional area </text>
<text top="763" left="608" width="198" height="20" font="4">change (RV fractional area change) </text>
<text top="781" left="608" width="219" height="20" font="4">(28.7 ± 10.0 vs. 21.9 ± 9.1%; p=0.003), </text>
<text top="729" left="841" width="91" height="20" font="4">● Univentricular </text>
<text top="746" left="841" width="99" height="20" font="4">subpulmonary LV </text>
<text top="763" left="841" width="98" height="20" font="4">pacing in pts with </text>
<text top="781" left="841" width="100" height="20" font="4">CCTGA predicted </text>
</page>
<page number="172" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 172 </text>
<text top="107" left="170" width="68" height="20" font="4">pacing) age </text>
<text top="124" left="170" width="55" height="20" font="4">39 ± 16 y </text>
<text top="107" left="495" width="81" height="20" font="4">fractional area </text>
<text top="124" left="495" width="47" height="20" font="4">change, </text>
<text top="141" left="495" width="75" height="20" font="4">systemic, RV </text>
<text top="159" left="495" width="79" height="20" font="4">size (RVEDA) </text>
<text top="176" left="495" width="95" height="20" font="4">and systemic AV </text>
<text top="193" left="495" width="32" height="20" font="4">valve </text>
<text top="210" left="495" width="88" height="20" font="4">regurgitation by </text>
<text top="228" left="495" width="88" height="20" font="4">at least 1 grade </text>
<text top="107" left="608" width="175" height="20" font="4">systemic AV valve regurgitation </text>
<text top="124" left="608" width="181" height="20" font="4">(p=0.019) and RV dilatation (end </text>
<text top="141" left="608" width="214" height="20" font="4">diastolic area 32.7 ± 8.7 vs. 37.2 ± 9.0 </text>
<text top="159" left="608" width="16" height="20" font="4">cm</text>
<text top="160" left="624" width="4" height="13" font="6">2</text>
<text top="159" left="629" width="66" height="20" font="4">; p=0.004).  </text>
<text top="176" left="608" width="165" height="20" font="4">● There was a corresponding </text>
<text top="193" left="608" width="206" height="20" font="4">deterioration in NYHA FC (p=0.013).  </text>
<text top="210" left="608" width="213" height="20" font="4">● Multivariate Cox regression analysis </text>
<text top="228" left="608" width="152" height="20" font="4">showed that pacing was an </text>
<text top="245" left="608" width="208" height="20" font="4">independent predictor of deteriorating </text>
<text top="262" left="608" width="203" height="20" font="4">RV function and RV dilation (HR: 2.7 </text>
<text top="280" left="608" width="154" height="20" font="4">[10–7.0] and 4.7 [1.1–20.6], </text>
<text top="298" left="608" width="79" height="20" font="4">respectively).  </text>
<text top="315" left="608" width="209" height="20" font="4">● None of these parameters changed </text>
<text top="332" left="608" width="202" height="20" font="4">significantly in the Un-paced Group.  </text>
<text top="349" left="608" width="149" height="20" font="4">● The CRT Group showed </text>
<text top="366" left="608" width="189" height="20" font="4">improvement in RV fractional area </text>
<text top="384" left="608" width="208" height="20" font="4">change (22.0%–30.7% (p=0.030) and </text>
<text top="401" left="608" width="200" height="20" font="4">NYHA FC (p=0.030), despite having </text>
<text top="418" left="608" width="184" height="20" font="4">lower baseline RV fractional area </text>
<text top="435" left="608" width="190" height="20" font="4">change (22.0 ± 5.7 vs. 31 ± 9.7%; </text>
<text top="452" left="608" width="197" height="20" font="4">p=0.025) and greater dyssynchrony </text>
<text top="470" left="608" width="217" height="20" font="4">(RV total isovolumic time 13.4 ± 2.1 vs. </text>
<text top="487" left="608" width="174" height="20" font="4">9.3 ± 4.2 s/min; p=0.016) when </text>
<text top="504" left="608" width="181" height="20" font="4">compared to the unpaced group. </text>
<text top="107" left="841" width="105" height="20" font="4">deterioration in RV </text>
<text top="124" left="841" width="91" height="20" font="4">function and RV </text>
<text top="141" left="841" width="107" height="20" font="4">dilatation over time </text>
<text top="159" left="841" width="87" height="20" font="4">associated with </text>
<text top="176" left="841" width="109" height="20" font="4">deteriorating NYHA </text>
<text top="193" left="841" width="23" height="20" font="4">FC. </text>
<text top="522" left="64" width="80" height="20" font="4">Winter MM, et </text>
<text top="539" left="64" width="16" height="20" font="4">al. </text>
<text top="556" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(646)</a> </text>
<text top="574" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22036871?dopt=Citation">22036871</a></text>
<text top="574" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22036871?dopt=Citation"> </a></text>
<text top="522" left="170" width="51" height="20" font="4">n=54 pts </text>
<text top="539" left="170" width="58" height="20" font="4">mean age </text>
<text top="556" left="170" width="63" height="20" font="4">32.5 ± 9.9; </text>
<text top="574" left="170" width="42" height="20" font="4">18 with </text>
<text top="591" left="170" width="46" height="20" font="4">CCTGA </text>
<text top="522" left="256" width="64" height="20" font="4">Multicenter </text>
<text top="539" left="256" width="85" height="20" font="4">parallel RCT to </text>
<text top="556" left="256" width="49" height="20" font="4">10 wk of </text>
<text top="574" left="256" width="49" height="20" font="4">exercise </text>
<text top="591" left="256" width="54" height="20" font="4">training 3 </text>
<text top="608" left="256" width="51" height="20" font="4">times/wk </text>
<text top="522" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="539" left="356" width="76" height="20" font="4">Adult pts with </text>
<text top="556" left="356" width="72" height="20" font="4">systemic RV </text>
<text top="574" left="356" width="3" height="20" font="4"> </text>
<text top="591" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="608" left="356" width="78" height="20" font="4">Incapability to </text>
<text top="625" left="356" width="118" height="20" font="4">participate in a home-</text>
<text top="642" left="356" width="86" height="20" font="4">based exercise </text>
<text top="660" left="356" width="117" height="20" font="4">training program, the </text>
<text top="677" left="356" width="118" height="20" font="4">presence of exercise-</text>
<text top="694" left="356" width="111" height="20" font="4">induced arrhythmia, </text>
<text top="711" left="356" width="103" height="20" font="4">symptomatic MI, a </text>
<text top="728" left="356" width="104" height="20" font="4">resting systolic BP </text>
<text top="746" left="356" width="112" height="20" font="4">&gt;200 mm Hg and/or </text>
<text top="763" left="356" width="123" height="20" font="4">diastolic BP &gt;110 mm </text>
<text top="780" left="356" width="126" height="20" font="4">Hg, NYHA FC III or IV, </text>
<text top="522" left="495" width="49" height="20" font="4">Peak VO</text>
<text top="528" left="544" width="4" height="13" font="6">2</text>
<text top="522" left="549" width="3" height="20" font="4"> </text>
<text top="522" left="608" width="170" height="20" font="4">● A significant difference in VO</text>
<text top="528" left="778" width="4" height="13" font="6">2</text>
<text top="522" left="783" width="34" height="20" font="4"> peak </text>
<text top="539" left="608" width="183" height="20" font="4">(3.4 mL/kg/min; 95% CI: 0.2–6.7; </text>
<text top="556" left="608" width="202" height="20" font="4">p=0.04) and resting systolic BP (-7.6 </text>
<text top="574" left="608" width="211" height="20" font="4">mm Hg; 95% CI: -14.0–1.3; p=0.03) in </text>
<text top="591" left="608" width="156" height="20" font="4">favor of the exercise group.  </text>
<text top="608" left="608" width="217" height="20" font="4">● No significant changes were found in </text>
<text top="625" left="608" width="217" height="20" font="4">serum NT-proBNP levels or QOL in the </text>
<text top="642" left="608" width="190" height="20" font="4">intervention group or in the control </text>
<text top="660" left="608" width="150" height="20" font="4">group nor between groups. </text>
<text top="522" left="841" width="122" height="20" font="4">● In pts with systemic </text>
<text top="539" left="841" width="117" height="20" font="4">RV, exercise training </text>
<text top="556" left="841" width="102" height="20" font="4">improves exercise </text>
<text top="574" left="841" width="52" height="20" font="4">capacity. </text>
</page>
<page number="173" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 173 </text>
<text top="107" left="356" width="88" height="20" font="4">pregnancy, and </text>
<text top="124" left="356" width="64" height="20" font="4">noncardiac </text>
<text top="141" left="356" width="123" height="20" font="4">comorbidity that could </text>
<text top="159" left="356" width="124" height="20" font="4">aggravate by exercise </text>
<text top="177" left="64" width="89" height="20" font="4">Van der Bom T, </text>
<text top="194" left="64" width="30" height="20" font="4">et al. </text>
<text top="211" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(258)</a> </text>
<text top="228" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23247302?dopt=Citation">23247302</a></text>
<text top="228" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23247302?dopt=Citation"> </a></text>
<text top="177" left="170" width="71" height="20" font="4">n=88 pts, 25 </text>
<text top="194" left="170" width="72" height="20" font="4">with CCTGA </text>
<text top="177" left="256" width="67" height="20" font="4">Multicenter, </text>
<text top="194" left="256" width="74" height="20" font="4">double-blind, </text>
<text top="211" left="256" width="75" height="20" font="4">parallel, RCT </text>
<text top="228" left="256" width="80" height="20" font="4">of angiotensin </text>
<text top="246" left="256" width="59" height="20" font="4">II receptor </text>
<text top="263" left="256" width="43" height="20" font="4">blocker </text>
<text top="280" left="256" width="77" height="20" font="4">valsartan 160 </text>
<text top="297" left="256" width="80" height="20" font="4">mg twice daily </text>
<text top="314" left="256" width="83" height="20" font="4">compared with </text>
<text top="332" left="256" width="46" height="20" font="4">placebo </text>
<text top="177" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="194" left="356" width="74" height="20" font="4">Systemic RV </text>
<text top="211" left="356" width="3" height="20" font="4"> </text>
<text top="228" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="245" left="356" width="114" height="20" font="4">Incapability of giving </text>
<text top="263" left="356" width="101" height="20" font="4">informed consent; </text>
<text top="280" left="356" width="101" height="20" font="4">hypersensitivity to </text>
<text top="297" left="356" width="120" height="20" font="4">valsartan or any of its </text>
<text top="314" left="356" width="96" height="20" font="4">help substances; </text>
<text top="332" left="356" width="116" height="20" font="4">hypersensitivity to IV </text>
<text top="349" left="356" width="124" height="20" font="4">contrast agent; known </text>
<text top="366" left="356" width="112" height="20" font="4">bilateral renal artery </text>
<text top="383" left="356" width="113" height="20" font="4">stenosis; MI, stroke, </text>
<text top="401" left="356" width="121" height="20" font="4">or open heart surgery </text>
<text top="418" left="356" width="115" height="20" font="4">in the previous 4 wk; </text>
<text top="435" left="356" width="81" height="20" font="4">previous heart </text>
<text top="452" left="356" width="75" height="20" font="4">transplant, or </text>
<text top="469" left="356" width="85" height="20" font="4">expected heart </text>
<text top="487" left="356" width="113" height="20" font="4">transplant within the </text>
<text top="504" left="356" width="104" height="20" font="4">next 6 mo; plasma </text>
<text top="521" left="356" width="85" height="20" font="4">creatinine level </text>
<text top="538" left="356" width="103" height="20" font="4">&gt;mcmol/L; plasma </text>
<text top="555" left="356" width="116" height="20" font="4">potassium level &gt;5.5 </text>
<text top="573" left="356" width="92" height="20" font="4">mmol/L; Current </text>
<text top="590" left="356" width="123" height="20" font="4">treatment of HTN with </text>
<text top="607" left="356" width="81" height="20" font="4">an ACEI or an </text>
<text top="624" left="356" width="125" height="20" font="4">angiotensin II receptor </text>
<text top="641" left="356" width="121" height="20" font="4">blocker, which cannot </text>
<text top="659" left="356" width="93" height="20" font="4">be discontinued; </text>
<text top="676" left="356" width="110" height="20" font="4">pregnant or nursing </text>
<text top="693" left="356" width="118" height="20" font="4">women (a pregnancy </text>
<text top="710" left="356" width="104" height="20" font="4">test was offered to </text>
<text top="728" left="356" width="122" height="20" font="4">every female pt within </text>
<text top="745" left="356" width="116" height="20" font="4">fertile age); desire to </text>
<text top="762" left="356" width="114" height="20" font="4">have children during </text>
<text top="779" left="356" width="53" height="20" font="4">follow-up </text>
<text top="177" left="495" width="94" height="20" font="4">RVEF measured </text>
<text top="194" left="495" width="48" height="20" font="4">by CMR </text>
<text top="177" left="608" width="216" height="20" font="4">● There was no significant effect of 3-y </text>
<text top="194" left="608" width="202" height="20" font="4">valsartan therapy on systemic RVEF </text>
<text top="211" left="608" width="182" height="20" font="4">(treatment effect, 1.3%; 95% CI: -</text>
<text top="228" left="608" width="175" height="20" font="4">1.3%–3.9%; p=0.34), maximum </text>
<text top="246" left="608" width="219" height="20" font="4">exercise capacity, or QOL. There was a </text>
<text top="263" left="608" width="191" height="20" font="4">larger increase in RV end-diastolic </text>
<text top="280" left="608" width="190" height="20" font="4">volume (15 mL; 95% CI: 3–28 mL; </text>
<text top="297" left="608" width="208" height="20" font="4">p&lt;0.01) and mass (8 g; 95% CI: 2–14 </text>
<text top="314" left="608" width="214" height="20" font="4">g; p=0.01) in the placebo group than in </text>
<text top="332" left="608" width="112" height="20" font="4">the valsartan group. </text>
<text top="177" left="841" width="90" height="20" font="4">● There was no </text>
<text top="194" left="841" width="113" height="20" font="4">significant treatment </text>
<text top="211" left="841" width="118" height="20" font="4">effect of valsartan on </text>
<text top="228" left="841" width="89" height="20" font="4">RVEF, exercise </text>
<text top="246" left="841" width="99" height="20" font="4">capacity, or QOL. </text>
</page>
<page number="174" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="17" size="12" family="Times" color="#121212"/>
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 174 </text>
<text top="107" left="64" width="75" height="20" font="4">Dore A, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(252)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16216961?dopt=Citation">16216961</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16216961?dopt=Citation"> </a></text>
<text top="107" left="170" width="51" height="20" font="4">n=29 pts </text>
<text top="124" left="170" width="66" height="20" font="4">30.3 ± 10.9 </text>
<text top="141" left="170" width="61" height="20" font="4">y of age; 8 </text>
<text top="159" left="170" width="36" height="20" font="4">(28%) </text>
<text top="176" left="170" width="46" height="20" font="4">CCTGA </text>
<text top="107" left="256" width="78" height="20" font="4">A multicenter, </text>
<text top="124" left="256" width="71" height="20" font="4">randomized, </text>
<text top="141" left="256" width="74" height="20" font="4">double-blind, </text>
<text top="159" left="256" width="47" height="20" font="4">placebo-</text>
<text top="176" left="256" width="60" height="20" font="4">controlled, </text>
<text top="193" left="256" width="57" height="20" font="4">crossover </text>
<text top="210" left="256" width="63" height="20" font="4">clinical trial </text>
<text top="228" left="256" width="73" height="20" font="4">with losartan </text>
<text top="107" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="356" width="106" height="20" font="4">Echocardiography, </text>
<text top="141" left="356" width="68" height="20" font="4">CPET, BNP </text>
<text top="159" left="356" width="3" height="20" font="4"> </text>
<text top="176" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="193" left="356" width="114" height="20" font="4">Adults with systemic </text>
<text top="210" left="356" width="21" height="20" font="4">RV </text>
<text top="107" left="495" width="87" height="20" font="17">(NYHA class III </text>
<text top="124" left="495" width="91" height="20" font="17">or IV), unable to </text>
<text top="141" left="495" width="83" height="20" font="17">exercise, were </text>
<text top="159" left="495" width="90" height="20" font="17">pregnant, had a </text>
<text top="176" left="495" width="55" height="20" font="17">fixed-rate </text>
<text top="193" left="495" width="92" height="20" font="17">pacemaker, had </text>
<text top="210" left="495" width="96" height="20" font="17">a creatinine level </text>
<text top="228" left="495" width="93" height="20" font="17">&gt;250 mmol/L, or </text>
<text top="245" left="495" width="87" height="20" font="17">had a history of </text>
<text top="262" left="495" width="74" height="20" font="17">angioedema, </text>
<text top="279" left="495" width="62" height="20" font="17">right-to-left </text>
<text top="296" left="495" width="53" height="20" font="17">shunting; </text>
<text top="314" left="495" width="83" height="20" font="17">substantial left-</text>
<text top="331" left="495" width="92" height="20" font="17">to-right shunting </text>
<text top="348" left="495" width="75" height="20" font="17">(Qp/Qs&gt;1.5); </text>
<text top="365" left="495" width="77" height="20" font="17">severe mitral, </text>
<text top="383" left="495" width="75" height="20" font="17">aortic, or PR; </text>
<text top="400" left="495" width="66" height="20" font="17">systemic or </text>
<text top="417" left="495" width="96" height="20" font="17">pulmonary inflow </text>
<text top="434" left="495" width="99" height="20" font="17">obstruction with a </text>
<text top="451" left="495" width="74" height="20" font="17">peak velocity </text>
<text top="469" left="495" width="97" height="20" font="17">&gt;1.5 m/s by TTE; </text>
<text top="486" left="495" width="64" height="20" font="17">and severe </text>
<text top="503" left="495" width="70" height="20" font="17">outflow tract </text>
<text top="520" left="495" width="99" height="20" font="17">obstruction with a </text>
<text top="537" left="495" width="74" height="20" font="17">peak systolic </text>
<text top="555" left="495" width="96" height="20" font="17">gradient &gt;80 mm </text>
<text top="572" left="495" width="16" height="20" font="17">Hg</text>
<text top="572" left="511" width="3" height="20" font="4"> </text>
<text top="107" left="608" width="183" height="20" font="4">● Comparing losartan to placebo </text>
<text top="124" left="608" width="157" height="20" font="4">showed no differences in VO</text>
<text top="130" left="765" width="4" height="13" font="6">2</text>
<text top="124" left="770" width="30" height="20" font="4"> max </text>
<text top="141" left="608" width="213" height="20" font="4">(29.9 ± 5.4 vs. 29.4 ± 6.2 mL · kg<b>/</b>min; </text>
<text top="159" left="608" width="196" height="20" font="4">p=0.43), exercise duration (632.3 ± </text>
<text top="176" left="608" width="219" height="20" font="4">123.0 vs. 629.9 ± 140.7 s; p=0.76), and </text>
<text top="193" left="608" width="205" height="20" font="4">NT-proBNP levels (201.2 ± 267.8 vs. </text>
<text top="210" left="608" width="213" height="20" font="4">229.7 ± 291.5 pg/mL; p=0.10), despite </text>
<text top="228" left="608" width="215" height="20" font="4">a trend toward increased angiotensin II </text>
<text top="245" left="608" width="184" height="20" font="4">levels (15.2 ± 13.8 vs. 8.8 ± 12.5 </text>
<text top="262" left="608" width="90" height="20" font="4">pg/mL; p=0.08). </text>
<text top="107" left="841" width="87" height="20" font="4">● In adults with </text>
<text top="124" left="841" width="128" height="20" font="4">systemic RVs, losartan </text>
<text top="141" left="841" width="87" height="20" font="4">did not improve </text>
<text top="159" left="841" width="112" height="20" font="4">exercise capacity or </text>
<text top="176" left="841" width="108" height="20" font="4">reduce NT-proBNP </text>
<text top="193" left="841" width="38" height="20" font="4">levels. </text>
<text top="590" left="64" width="82" height="20" font="4">Huhta C, et al. </text>
<text top="607" left="64" width="66" height="20" font="4">1983 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(647)</a>  </text>
<text top="624" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6851033?dopt=Citation">6851033</a></text>
<text top="624" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6851033?dopt=Citation"> </a></text>
<text top="590" left="170" width="58" height="20" font="4">n=107 pts </text>
<text top="590" left="256" width="78" height="20" font="4">Retrospective </text>
<text top="607" left="256" width="33" height="20" font="4">study </text>
<text top="590" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="607" left="356" width="80" height="20" font="4">Confirmed AV </text>
<text top="624" left="356" width="105" height="20" font="4">discordance with 2 </text>
<text top="641" left="356" width="99" height="20" font="4">ventricles seen at </text>
<text top="659" left="356" width="117" height="20" font="4">Mayo Clinic between </text>
<text top="676" left="356" width="115" height="20" font="4">January 1951 –June </text>
<text top="693" left="356" width="31" height="20" font="4">1981 </text>
<text top="710" left="356" width="3" height="20" font="4"> </text>
<text top="727" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="745" left="356" width="94" height="20" font="4">Situs ambiguous </text>
<text top="590" left="495" width="76" height="20" font="4">Complete AV </text>
<text top="607" left="495" width="32" height="20" font="4">block </text>
<text top="590" left="608" width="218" height="20" font="4">● 23 pts (22%) had complete AV block. </text>
<text top="607" left="608" width="206" height="20" font="4">This condition was present in 4 pts at </text>
<text top="624" left="608" width="215" height="20" font="4">birth and developed in 19 pts at ages 4 </text>
<text top="641" left="608" width="137" height="20" font="4">mo–53 y (mean 18.1 y).  </text>
<text top="590" left="841" width="79" height="20" font="4">● Pts with AV </text>
<text top="607" left="841" width="127" height="20" font="4">discordance are at risk </text>
<text top="624" left="841" width="130" height="20" font="4">of developing complete </text>
<text top="641" left="841" width="114" height="20" font="4">AV block throughout </text>
<text top="659" left="841" width="59" height="20" font="4">their lives. </text>
<text top="763" left="64" width="92" height="20" font="4">Green CE, et al. </text>
<text top="780" left="64" width="63" height="20" font="4">1983 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(648)</a> </text>
<text top="763" left="170" width="24" height="20" font="4">N/A </text>
<text top="763" left="256" width="103" height="20" font="4">Review article   </text>
<text top="763" left="495" width="24" height="20" font="4">N/A </text>
<text top="763" left="608" width="24" height="20" font="4">N/A </text>
<text top="763" left="841" width="97" height="20" font="4">● The majority of </text>
<text top="780" left="841" width="112" height="20" font="4">adults with CHD will </text>
</page>
<page number="175" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 175 </text>
<text top="107" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6544144?dopt=Citation">6544144</a></text>
<text top="107" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6544144?dopt=Citation"> </a></text>
<text top="107" left="841" width="102" height="20" font="4">have some telltale </text>
<text top="124" left="841" width="105" height="20" font="4">abnormality on the </text>
<text top="141" left="841" width="119" height="20" font="4">chest radiograph that </text>
<text top="159" left="841" width="131" height="20" font="4">will occasionally furnish </text>
<text top="176" left="841" width="104" height="20" font="4">the first clue to the </text>
<text top="193" left="841" width="78" height="20" font="4">presence of a </text>
<text top="210" left="841" width="113" height="20" font="4">congenital anomaly. </text>
<text top="228" left="64" width="82" height="20" font="4">Silverman NH, </text>
<text top="245" left="64" width="30" height="20" font="4">et al. </text>
<text top="263" left="64" width="63" height="20" font="4">1995 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(649)</a> </text>
<text top="280" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7503010?dopt=Citation">7503010</a></text>
<text top="280" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7503010?dopt=Citation"> </a></text>
<text top="228" left="170" width="31" height="20" font="4">n=14 </text>
<text top="245" left="170" width="59" height="20" font="4">pathologic </text>
<text top="263" left="170" width="62" height="20" font="4">specimens </text>
<text top="228" left="256" width="64" height="20" font="4">Descriptive </text>
<text top="228" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="245" left="356" width="24" height="20" font="4">N/A </text>
<text top="228" left="495" width="24" height="20" font="4">N/A </text>
<text top="228" left="608" width="203" height="20" font="4">● The TV plane was rotated 47 ± 21 </text>
<text top="245" left="608" width="214" height="20" font="4">degrees from its usual position into the </text>
<text top="263" left="608" width="56" height="20" font="4">ventricle.  </text>
<text top="280" left="608" width="213" height="20" font="4">● The TV tissue was variably attached </text>
<text top="297" left="608" width="214" height="20" font="4">to the underlying myocardium, with the </text>
<text top="314" left="608" width="216" height="20" font="4">most severely affected lesion being the </text>
<text top="332" left="608" width="192" height="20" font="4">mural leaflet followed by the septal </text>
<text top="349" left="608" width="165" height="20" font="4">leaflet, and the anterior leaflet </text>
<text top="366" left="608" width="165" height="20" font="4">attachment the least affected. </text>
<text top="228" left="841" width="84" height="20" font="4">● The plane of </text>
<text top="245" left="841" width="110" height="20" font="4">displacement of the </text>
<text top="263" left="841" width="100" height="20" font="4">valve in corrected </text>
<text top="280" left="841" width="121" height="20" font="4">transposition appears </text>
<text top="297" left="841" width="107" height="20" font="4">less amenable to 4-</text>
<text top="314" left="841" width="51" height="20" font="4">chamber </text>
<text top="332" left="841" width="129" height="20" font="4">echocardiography than </text>
<text top="349" left="841" width="124" height="20" font="4">other forms of Ebstein </text>
<text top="366" left="841" width="57" height="20" font="4">anomaly.  </text>
<text top="383" left="841" width="129" height="20" font="4">● Changes in the echo </text>
<text top="400" left="841" width="121" height="20" font="4">planes should display </text>
<text top="418" left="841" width="112" height="20" font="4">the morphology and </text>
<text top="435" left="841" width="103" height="20" font="4">also provide some </text>
<text top="452" left="841" width="80" height="20" font="4">hemodynamic </text>
<text top="469" left="841" width="68" height="20" font="4">information. </text>
<text top="487" left="64" width="88" height="20" font="4">MacDonald ST, </text>
<text top="504" left="64" width="30" height="20" font="4">et al. </text>
<text top="522" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(650)</a> </text>
<text top="539" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21108556?dopt=Citation">21108556</a></text>
<text top="539" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21108556?dopt=Citation"> </a></text>
<text top="487" left="170" width="24" height="20" font="4">N/A </text>
<text top="487" left="256" width="44" height="20" font="4">Review </text>
<text top="487" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="504" left="356" width="24" height="20" font="4">N/A </text>
<text top="487" left="495" width="24" height="20" font="4">N/A </text>
<text top="487" left="608" width="24" height="20" font="4">N/A </text>
<text top="487" left="841" width="98" height="20" font="4">● ACHD pts offer </text>
<text top="504" left="841" width="104" height="20" font="4">distinct challenges </text>
<text top="522" left="841" width="92" height="20" font="4">such as unusual </text>
<text top="539" left="841" width="132" height="20" font="4">anatomy and demands, </text>
<text top="556" left="841" width="131" height="20" font="4">such as pregnancy and </text>
<text top="573" left="841" width="128" height="20" font="4">exercise tolerability not </text>
<text top="591" left="841" width="120" height="20" font="4">found in conventional </text>
<text top="608" left="841" width="121" height="20" font="4">pediatric or traditional </text>
<text top="625" left="841" width="133" height="20" font="4">adult interventional pts.  </text>
<text top="643" left="64" width="79" height="20" font="4">Buber J, et al. </text>
<text top="660" left="64" width="63" height="20" font="4">2015 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(651)</a> </text>
<text top="677" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25661908?dopt=Citation">25661908</a></text>
<text top="677" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25661908?dopt=Citation"> </a></text>
<text top="643" left="170" width="51" height="20" font="4">n=38 pts </text>
<text top="643" left="256" width="78" height="20" font="4">Retrospective </text>
<text top="660" left="256" width="33" height="20" font="4">study </text>
<text top="643" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="660" left="356" width="94" height="20" font="4">(S,L,L) or (I,D,D) </text>
<text top="677" left="356" width="111" height="20" font="4">segmental anatomy </text>
<text top="694" left="356" width="117" height="20" font="4">and AV discordance: </text>
<text top="712" left="356" width="116" height="20" font="4">either TGA or DORV </text>
<text top="729" left="356" width="3" height="20" font="4"> </text>
<text top="746" left="356" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="763" left="356" width="102" height="20" font="4">Surgical TV repair </text>
<text top="781" left="356" width="117" height="20" font="4">prior to or at the time </text>
<text top="643" left="495" width="89" height="20" font="4">TR severity and </text>
<text top="660" left="495" width="67" height="20" font="4">RV function </text>
<text top="643" left="608" width="207" height="20" font="4">● Worsening TR was associated with </text>
<text top="660" left="608" width="196" height="20" font="4">the degree of change in RV and LV </text>
<text top="677" left="608" width="213" height="20" font="4">diameters, change in tricuspid annulus </text>
<text top="694" left="608" width="198" height="20" font="4">size and tethering distance, and the </text>
<text top="712" left="608" width="204" height="20" font="4">degree of septal shift, as reflected by </text>
<text top="729" left="608" width="199" height="20" font="4">the RV sphericity index (all p≤0.04). </text>
<text top="643" left="841" width="130" height="20" font="4">● Intervention for LV to </text>
<text top="660" left="841" width="128" height="20" font="4">PA conduit dysfunction </text>
<text top="677" left="841" width="73" height="20" font="4">may result in </text>
<text top="694" left="841" width="123" height="20" font="4">worsening TR and RV </text>
<text top="712" left="841" width="118" height="20" font="4">function, likely due in </text>
<text top="729" left="841" width="116" height="20" font="4">part to altered septal </text>
<text top="746" left="841" width="126" height="20" font="4">shift due to changes in </text>
<text top="763" left="841" width="105" height="20" font="4">the interventricular </text>
<text top="781" left="841" width="82" height="20" font="4">pressure ratio. </text>
</page>
<page number="176" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 176 </text>
<text top="107" left="356" width="57" height="20" font="4">of conduit </text>
<text top="124" left="356" width="70" height="20" font="4">intervention; </text>
<text top="141" left="356" width="112" height="20" font="4">operations involving </text>
<text top="159" left="356" width="107" height="20" font="4">switching the LV to </text>
<text top="176" left="356" width="72" height="20" font="4">the systemic </text>
<text top="193" left="356" width="98" height="20" font="4">circulation, single </text>
<text top="210" left="356" width="115" height="20" font="4">ventricle conversion, </text>
<text top="228" left="356" width="118" height="20" font="4">deliberate banding of </text>
<text top="245" left="356" width="85" height="20" font="4">LV-PA conduit, </text>
<text top="262" left="356" width="111" height="20" font="4">residual shunting or </text>
<text top="279" left="356" width="97" height="20" font="4">aortic coarctation </text>
<text top="297" left="64" width="83" height="20" font="4">Casso P, et al. </text>
<text top="314" left="64" width="63" height="20" font="4">1998 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(652)</a> </text>
<text top="332" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9453520?dopt=Citation">9453520</a></text>
<text top="332" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9453520?dopt=Citation"> </a></text>
<text top="297" left="170" width="51" height="20" font="4">n=12 pts </text>
<text top="297" left="256" width="68" height="20" font="4">Prospective </text>
<text top="297" left="356" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="314" left="356" width="36" height="20" font="4">LTGA </text>
<text top="297" left="495" width="24" height="20" font="4">N/A </text>
<text top="297" left="608" width="192" height="20" font="4">● The chordal attachments of both </text>
<text top="314" left="608" width="210" height="20" font="4">valves were clearly elucidated by TEE </text>
<text top="332" left="608" width="202" height="20" font="4">in all pts; whereas, TTE could obtain </text>
<text top="349" left="608" width="163" height="20" font="4">images of these in only 3 pts. </text>
<text top="297" left="841" width="114" height="20" font="4">● TEE is superior to </text>
<text top="314" left="841" width="120" height="20" font="4">transthoracic imaging </text>
<text top="332" left="841" width="111" height="20" font="4">in studying LTGA in </text>
<text top="349" left="841" width="131" height="20" font="4">adult pts; the horizontal </text>
<text top="366" left="841" width="122" height="20" font="4">plane is best suited to </text>
<text top="383" left="841" width="124" height="20" font="4">the evaluation of atrial </text>
<text top="401" left="841" width="93" height="20" font="4">situs and the AV </text>
<text top="418" left="841" width="123" height="20" font="4">junction; whereas, the </text>
<text top="435" left="841" width="111" height="20" font="4">longitudinal plane is </text>
<text top="452" left="841" width="113" height="20" font="4">most valuable in the </text>
<text top="469" left="841" width="67" height="20" font="4">study of the </text>
<text top="487" left="841" width="132" height="20" font="4">morphologic features of </text>
<text top="504" left="841" width="114" height="20" font="4">the ventriculoarterial </text>
<text top="521" left="841" width="76" height="20" font="4">connections.  </text>
<text top="539" left="108" width="3" height="20" font="4"> </text>
<text top="556" left="108" width="922" height="24" font="1"><b>Data Supplement 48. Fontan Palliation of Single Ventricle Physiology Including Tricuspid Atresia and Double Inlet Right Ventricle – </b></text>
<text top="576" left="108" width="94" height="24" font="1"><b>Section 4.4.2 </b></text>
<text top="598" left="76" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="615" left="76" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="598" left="182" width="300" height="20" font="3"><b>Study Design  Study Size   Inclusion/Exclusion </b></text>
<text top="615" left="399" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="598" left="507" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="598" left="715" width="48" height="20" font="3"><b>Results </b></text>
<text top="598" left="889" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="637" left="64" width="82" height="20" font="4">Hebert A et al. </text>
<text top="654" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(653)</a> </text>
<text top="671" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25446057">25446057</a></text>
<text top="671" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25446057"> </a></text>
<text top="637" left="179" width="72" height="20" font="4">Randomized </text>
<text top="654" left="179" width="37" height="20" font="4">trial of </text>
<text top="671" left="179" width="82" height="20" font="4">bosentan × 14 </text>
<text top="688" left="179" width="19" height="20" font="4">wk </text>
<text top="637" left="280" width="51" height="20" font="4">n=69 pts </text>
<text top="637" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="654" left="361" width="94" height="20" font="4">Adolescent/adult </text>
<text top="671" left="361" width="42" height="20" font="4">Fontan </text>
<text top="637" left="496" width="87" height="20" font="4">QOL, Exercise, </text>
<text top="654" left="496" width="38" height="20" font="4">NYHA </text>
<text top="637" left="604" width="115" height="20" font="4">● Improved peak VO</text>
<text top="643" left="719" width="4" height="13" font="6">2</text>
<text top="637" left="723" width="3" height="20" font="4"> </text>
<text top="637" left="887" width="24" height="20" font="4">N/A </text>
<text top="706" left="64" width="87" height="20" font="4">Giardini A et al. </text>
<text top="723" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(261)</a> </text>
<text top="741" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18534975">18534975</a></text>
<text top="741" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18534975"> </a></text>
<text top="706" left="179" width="71" height="20" font="4">Single dose, </text>
<text top="723" left="179" width="68" height="20" font="4">randomized </text>
<text top="741" left="179" width="57" height="20" font="4">controlled </text>
<text top="758" left="179" width="33" height="20" font="4">study </text>
<text top="706" left="280" width="51" height="20" font="4">n=27 pts </text>
<text top="706" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="723" left="361" width="94" height="20" font="4">Adolescent/adult </text>
<text top="741" left="361" width="42" height="20" font="4">Fontan </text>
<text top="706" left="496" width="90" height="20" font="4">Exercise testing </text>
<text top="723" left="496" width="60" height="20" font="4">in cath lab </text>
<text top="706" left="604" width="62" height="20" font="4">● Peak VO</text>
<text top="712" left="665" width="4" height="13" font="6">2</text>
<text top="706" left="670" width="3" height="20" font="4"> </text>
<text top="723" left="604" width="134" height="20" font="4">● Pulmonary blood flow </text>
<text top="741" left="604" width="41" height="20" font="4">● PVR </text>
<text top="706" left="887" width="24" height="20" font="4">N/A </text>
</page>
<page number="177" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 177 </text>
<text top="107" left="64" width="86" height="20" font="4">Goldberg DJ et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(262)</a> </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21382896">21382896</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21382896"> </a></text>
<text top="107" left="179" width="66" height="20" font="4">RCT--cross </text>
<text top="124" left="179" width="41" height="20" font="4">over of </text>
<text top="141" left="179" width="51" height="20" font="4">sildenafil </text>
<text top="107" left="280" width="51" height="20" font="4">n=28 pts </text>
<text top="107" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="361" width="106" height="20" font="4">Adolescent Fontan </text>
<text top="107" left="496" width="142" height="20" font="4">Exercise testing  ● MV </text>
<text top="124" left="604" width="34" height="20" font="4">● RR </text>
<text top="141" left="604" width="22" height="20" font="4">● O</text>
<text top="148" left="626" width="4" height="13" font="6">2</text>
<text top="141" left="630" width="109" height="20" font="4"> consumption at AT </text>
<text top="159" left="604" width="62" height="20" font="4">● Peak VO</text>
<text top="165" left="665" width="4" height="13" font="6">2</text>
<text top="159" left="670" width="188" height="20" font="4"> and peak HR were not significant </text>
<text top="107" left="887" width="24" height="20" font="4">N/A </text>
<text top="177" left="64" width="83" height="20" font="4">Ovaert C et al. </text>
<text top="194" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(654)</a> </text>
<text top="211" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19519964">19519964</a></text>
<text top="211" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19519964"> </a></text>
<text top="177" left="179" width="67" height="20" font="4">Prospective </text>
<text top="194" left="179" width="25" height="20" font="4">non-</text>
<text top="211" left="179" width="68" height="20" font="4">randomized </text>
<text top="228" left="179" width="37" height="20" font="4">trial of </text>
<text top="246" left="179" width="82" height="20" font="4">bosentan × 16 </text>
<text top="263" left="179" width="19" height="20" font="4">wk </text>
<text top="177" left="280" width="51" height="20" font="4">n=10 pts </text>
<text top="177" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="194" left="361" width="81" height="20" font="4">Failing Fontan </text>
<text top="177" left="496" width="10" height="20" font="4">O</text>
<text top="183" left="505" width="4" height="13" font="6">2</text>
<text top="177" left="510" width="61" height="20" font="4"> sat at rest </text>
<text top="194" left="496" width="73" height="20" font="4">and exercise </text>
<text top="177" left="604" width="106" height="20" font="4">● No improvement </text>
<text top="177" left="887" width="66" height="20" font="4">● 5 pts had </text>
<text top="194" left="887" width="97" height="20" font="4">improvement in O</text>
<text top="200" left="984" width="4" height="13" font="6">2</text>
<text top="194" left="989" width="38" height="20" font="4"> sat or </text>
<text top="211" left="887" width="98" height="20" font="4">exercise capacity </text>
<text top="228" left="887" width="117" height="20" font="4">(worsened after drug </text>
<text top="246" left="887" width="60" height="20" font="4">cessation) </text>
<text top="281" left="64" width="98" height="20" font="4">Bowater SE et al. </text>
<text top="298" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(655)</a> </text>
<text top="315" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22348734">22348734</a></text>
<text top="315" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22348734"> </a></text>
<text top="281" left="179" width="67" height="20" font="4">Prospective </text>
<text top="298" left="179" width="25" height="20" font="4">non-</text>
<text top="315" left="179" width="68" height="20" font="4">randomized </text>
<text top="332" left="179" width="37" height="20" font="4">trial of </text>
<text top="350" left="179" width="75" height="20" font="4">bosentan × 6 </text>
<text top="367" left="179" width="21" height="20" font="4">mo </text>
<text top="281" left="280" width="44" height="20" font="4">n=8 pts </text>
<text top="281" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="298" left="361" width="73" height="20" font="4">Adult Fontan </text>
<text top="281" left="496" width="93" height="20" font="4">Exercise testing, </text>
<text top="298" left="496" width="30" height="20" font="4">echo </text>
<text top="281" left="604" width="235" height="20" font="4">● Improved NYHA and ventricular ejection </text>
<text top="298" left="604" width="44" height="20" font="4">fraction </text>
<text top="281" left="887" width="122" height="20" font="4">● Only 6 completed 6 </text>
<text top="298" left="887" width="79" height="20" font="4">mo of therapy </text>
<text top="385" left="64" width="73" height="20" font="4">Derk G et al. </text>
<text top="402" left="64" width="63" height="20" font="4">2015 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(656)</a> </text>
<text top="419" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24890846">24890846</a></text>
<text top="419" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24890846"> </a></text>
<text top="385" left="179" width="76" height="20" font="4">Bosentan × 4 </text>
<text top="402" left="179" width="24" height="20" font="4">mo, </text>
<text top="419" left="179" width="77" height="20" font="4">observational </text>
<text top="385" left="280" width="51" height="20" font="4">n=10 pts </text>
<text top="385" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="402" left="361" width="73" height="20" font="4">Adult Fontan </text>
<text top="385" left="496" width="75" height="20" font="4">6MWT, BNP, </text>
<text top="402" left="496" width="31" height="20" font="4">CMR </text>
<text top="385" left="604" width="239" height="20" font="4">● 6MWT distance improved, cardiac output </text>
<text top="402" left="604" width="54" height="20" font="4">improved </text>
<text top="385" left="887" width="119" height="20" font="4">● 7 completed study  </text>
<text top="437" left="64" width="92" height="20" font="4">Schuuring MJ et </text>
<text top="454" left="64" width="16" height="20" font="4">al. </text>
<text top="472" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(657)</a> </text>
<text top="489" left="64" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23361871">23361871</a></text>
<text top="489" left="119" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23361871"> </a></text>
<text top="437" left="179" width="72" height="20" font="4">Randomized </text>
<text top="454" left="179" width="58" height="20" font="4">trial (3 mo </text>
<text top="472" left="179" width="46" height="20" font="4">delay in </text>
<text top="489" left="179" width="54" height="20" font="4">bosentan </text>
<text top="506" left="179" width="79" height="20" font="4">therapy), total </text>
<text top="523" left="179" width="75" height="20" font="4">6 mo therapy </text>
<text top="437" left="280" width="51" height="20" font="4">n=32 pts </text>
<text top="437" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="454" left="361" width="73" height="20" font="4">Adult Fontan </text>
<text top="437" left="496" width="18" height="20" font="4">VO</text>
<text top="443" left="514" width="4" height="13" font="6">2</text>
<text top="437" left="518" width="39" height="20" font="4">, BNP, </text>
<text top="454" left="496" width="70" height="20" font="4">NYHA, QOL </text>
<text top="472" left="496" width="40" height="20" font="4">scores </text>
<text top="437" left="604" width="136" height="20" font="4">● No significant findings </text>
<text top="437" left="887" width="135" height="20" font="4">● 10 pts didn't complete </text>
<text top="454" left="887" width="118" height="20" font="4">the study, and half of </text>
<text top="472" left="887" width="124" height="20" font="4">eligible pts declined to </text>
<text top="489" left="887" width="70" height="20" font="4">participate.   </text>
<text top="541" left="64" width="89" height="20" font="4">Cordina R et al. </text>
<text top="558" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#218">(120)</a> </text>
<text top="575" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23846614?dopt=Citation">23846614</a></text>
<text top="575" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23846614?dopt=Citation"> </a></text>
<text top="541" left="179" width="73" height="20" font="4">Cohort study </text>
<text top="541" left="280" width="51" height="20" font="4">n=16 pts </text>
<text top="541" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="558" left="361" width="86" height="20" font="4">NYHA class I/II </text>
<text top="575" left="361" width="78" height="20" font="4">Fontan adults </text>
<text top="541" left="496" width="53" height="20" font="4">Reduced </text>
<text top="558" left="496" width="87" height="20" font="4">skeletal muscle </text>
<text top="575" left="496" width="71" height="20" font="4">mass and/or </text>
<text top="593" left="496" width="56" height="20" font="4">metabolic </text>
<text top="610" left="496" width="76" height="20" font="4">abnormalities </text>
<text top="541" left="604" width="62" height="20" font="4">● Peak VO</text>
<text top="547" left="665" width="4" height="13" font="6">2</text>
<text top="541" left="670" width="169" height="20" font="4"> was 1.9±0.1 L/min (66±3% of </text>
<text top="558" left="604" width="104" height="20" font="4">predicted values).  </text>
<text top="575" left="604" width="250" height="20" font="4">● Skeletal muscle mass assessed by relative </text>
<text top="593" left="604" width="258" height="20" font="4">appendicular lean mass index was significantly </text>
<text top="610" left="604" width="254" height="20" font="4">reduced compared with age-matched and sex-</text>
<text top="627" left="604" width="261" height="20" font="4">matched reference values (Z-score -1.46±0.22; </text>
<text top="644" left="604" width="267" height="20" font="4">p&lt;0.0001). Low skeletal muscle mass correlated </text>
<text top="662" left="604" width="82" height="20" font="4">with poorer VO</text>
<text top="668" left="686" width="4" height="13" font="6">2</text>
<text top="662" left="690" width="136" height="20" font="4"> max (r=0.67; p=0.004).  </text>
<text top="679" left="604" width="224" height="20" font="4">● Overall, skeletal muscle mass T-score </text>
<text top="696" left="604" width="246" height="20" font="4">(derived from comparison with young normal </text>
<text top="713" left="604" width="255" height="20" font="4">reference mean) was -1.47±0.21; 4/16 Fontan </text>
<text top="730" left="604" width="258" height="20" font="4">subjects had sarcopenic range muscle wasting </text>
<text top="748" left="604" width="254" height="20" font="4">(T-score &lt;-2.0) and 9/16 had less marked, but </text>
<text top="765" left="604" width="267" height="20" font="4">clinically significant wasting (T-score &lt;-1.0 but ≥-</text>
<text top="782" left="604" width="31" height="20" font="4">2.0).  </text>
<text top="541" left="887" width="104" height="20" font="4">● Fontan pts have </text>
<text top="558" left="887" width="135" height="20" font="4">reduced skeletal muscle </text>
<text top="575" left="887" width="102" height="20" font="4">mass and intrinsic </text>
<text top="593" left="887" width="98" height="20" font="4">muscle metabolic </text>
<text top="610" left="887" width="80" height="20" font="4">abnormalities. </text>
</page>
<page number="178" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 178 </text>
<text top="107" left="604" width="270" height="20" font="4">● Muscle aerobic capacity, measured by the rate </text>
<text top="124" left="604" width="252" height="20" font="4">constant (k) of post-exercise phosphocreatine </text>
<text top="141" left="604" width="267" height="20" font="4">resynthesis, was significantly impaired in Fontan </text>
<text top="159" left="604" width="264" height="20" font="4">adults vs. controls (1.48±0.13 vs. 2.40±0.33 min</text>
<text top="160" left="868" width="3" height="13" font="6">-</text>
<text top="178" left="604" width="4" height="13" font="6">1</text>
<text top="176" left="608" width="56" height="20" font="4">; p=0.02). </text>
<text top="194" left="64" width="98" height="20" font="4">Brassard P, et al. </text>
<text top="211" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(658)</a> </text>
<text top="228" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16046016?dopt=Citation">16046016</a></text>
<text top="228" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16046016?dopt=Citation"> </a></text>
<text top="194" left="179" width="81" height="20" font="4">Matched case-</text>
<text top="211" left="179" width="40" height="20" font="4">control </text>
<text top="194" left="280" width="65" height="20" font="4">n=14 pts (7 </text>
<text top="211" left="280" width="49" height="20" font="4">cases; 7 </text>
<text top="228" left="280" width="43" height="20" font="4">healthy </text>
<text top="246" left="280" width="51" height="20" font="4">controls) </text>
<text top="194" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="211" left="361" width="101" height="20" font="4">Fontan procedure </text>
<text top="194" left="496" width="89" height="20" font="4">Skeletal muscle </text>
<text top="211" left="496" width="87" height="20" font="4">functioning and </text>
<text top="228" left="496" width="49" height="20" font="4">exercise </text>
<text top="246" left="496" width="54" height="20" font="4">tolerance </text>
<text top="194" left="604" width="254" height="20" font="4">● The ergoreflex contribution to absolute DBP </text>
<text top="211" left="604" width="244" height="20" font="4">was higher (12.5+/-4.8 vs. 5.6+/-4.2 mm Hg; </text>
<text top="228" left="604" width="234" height="20" font="4">p=0.04) in Fontan pts vs. healthy subjects; </text>
<text top="246" left="604" width="268" height="20" font="4">whereas, a trend was encountered regarding the </text>
<text top="263" left="604" width="253" height="20" font="4">ergoreflex contribution to absolute SBP (9.0+/-</text>
<text top="280" left="604" width="262" height="20" font="4">7.0 vs. 0.4+/-9.0 mm Hg; p=0.09). Furthermore, </text>
<text top="297" left="604" width="235" height="20" font="4">time to fatigue of the nondominant forearm </text>
<text top="314" left="604" width="252" height="20" font="4">muscles was shorter in Fontan pts vs. healthy </text>
<text top="332" left="604" width="255" height="20" font="4">subjects (431+/-290 vs. 847+/-347 s; p=0.03).  </text>
<text top="349" left="604" width="231" height="20" font="4">● Following exercise training, there was a </text>
<text top="366" left="604" width="204" height="20" font="4">significant reduction of the ergoreflex </text>
<text top="383" left="604" width="268" height="20" font="4">contribution to absolute values of SBP (9.8+/-0.9 </text>
<text top="400" left="604" width="245" height="20" font="4">vs. 0.3+/-2.7 mm Hg; p&lt;0.05). There was an </text>
<text top="418" left="604" width="247" height="20" font="4">association between muscle strength and VO</text>
<text top="424" left="851" width="4" height="13" font="6">2</text>
<text top="418" left="855" width="3" height="20" font="4"> </text>
<text top="435" left="604" width="267" height="20" font="4">peak in Fontan pts (upper limb: r=0.895; p&lt;0.01; </text>
<text top="452" left="604" width="238" height="20" font="4">lower limbs: r=0.838; p&lt;0.05, respectively). </text>
<text top="194" left="887" width="102" height="20" font="4">● Skeletal muscle </text>
<text top="211" left="887" width="133" height="20" font="4">function in Fontan pts is </text>
<text top="228" left="887" width="116" height="20" font="4">abnormal which may </text>
<text top="246" left="887" width="120" height="20" font="4">have an impact in the </text>
<text top="263" left="887" width="97" height="20" font="4">reduced exercise </text>
<text top="280" left="887" width="139" height="20" font="4">tolerance encountered in </text>
<text top="297" left="887" width="60" height="20" font="4">these pts.  </text>
<text top="314" left="887" width="133" height="20" font="4">● Exercise training may </text>
<text top="332" left="887" width="135" height="20" font="4">be beneficial on skeletal </text>
<text top="349" left="887" width="124" height="20" font="4">muscle function in this </text>
<text top="366" left="887" width="64" height="20" font="4">population. </text>
<text top="470" left="64" width="68" height="20" font="4">Inai K, et al. </text>
<text top="487" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(659)</a> </text>
<text top="504" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15019898?dopt=Citation">15019898</a></text>
<text top="504" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15019898?dopt=Citation"> </a></text>
<text top="470" left="179" width="73" height="20" font="4">Cohort study </text>
<text top="470" left="280" width="3" height="20" font="4"> </text>
<text top="470" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="487" left="361" width="96" height="20" font="4">Fontan operation </text>
<text top="470" left="496" width="50" height="20" font="4">Exercise </text>
<text top="487" left="496" width="49" height="20" font="4">capacity </text>
<text top="470" left="604" width="3" height="20" font="4"> </text>
<text top="470" left="887" width="91" height="20" font="4">● In Fontan pts, </text>
<text top="487" left="887" width="111" height="20" font="4">diminished exercise </text>
<text top="504" left="887" width="139" height="20" font="4">capacity was related to a </text>
<text top="522" left="887" width="107" height="20" font="4">reduced blood flow </text>
<text top="539" left="887" width="80" height="20" font="4">supply and an </text>
<text top="556" left="887" width="138" height="20" font="4">attenuated post-exercise </text>
<text top="573" left="887" width="10" height="20" font="4">O</text>
<text top="579" left="897" width="7" height="13" font="6">2 </text>
<text top="573" left="904" width="103" height="20" font="4">resaturation of the </text>
<text top="591" left="887" width="137" height="20" font="4">working skeletal muscle, </text>
<text top="608" left="887" width="127" height="20" font="4">which also was related </text>
<text top="625" left="887" width="135" height="20" font="4">to impaired endothelium-</text>
<text top="642" left="887" width="133" height="20" font="4">dependent vasodilation. </text>
<text top="660" left="64" width="81" height="20" font="4">Wang A, et al. </text>
<text top="677" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#222">(195)</a> </text>
<text top="694" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17920376?dopt=Citation">17920376</a></text>
<text top="694" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17920376?dopt=Citation"> </a></text>
<text top="660" left="179" width="73" height="20" font="4">Cohort study </text>
<text top="660" left="280" width="58" height="20" font="4">n=198 pts </text>
<text top="660" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="677" left="361" width="100" height="20" font="4">All ACHD pts with </text>
<text top="694" left="361" width="117" height="20" font="4">surgery prior to 1992 </text>
<text top="660" left="496" width="63" height="20" font="4">Hepatitis C </text>
<text top="677" left="496" width="90" height="20" font="4">antibody testing </text>
<text top="660" left="604" width="252" height="20" font="4">● 17 (8.6%) had positive Hepatitis C antibody </text>
<text top="677" left="604" width="249" height="20" font="4">results, and 8 (4.0%) had positive Hepatitis C </text>
<text top="694" left="604" width="131" height="20" font="4">ribonucleic acid results. </text>
<text top="660" left="887" width="114" height="20" font="4">● Positivity rate was </text>
<text top="677" left="887" width="136" height="20" font="4">nearly 5-fold higher than </text>
<text top="694" left="887" width="108" height="20" font="4">general population. </text>
<text top="712" left="887" width="3" height="20" font="4"> </text>
<text top="730" left="64" width="92" height="20" font="4">Kiesewetter CH, </text>
<text top="747" left="64" width="30" height="20" font="4">et al. </text>
<text top="764" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(660)</a> </text>
<text top="781" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17005713?dopt=Citation">17005713</a></text>
<text top="781" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17005713?dopt=Citation"> </a></text>
<text top="730" left="179" width="76" height="20" font="4">Cohort study, </text>
<text top="747" left="179" width="74" height="20" font="4">retrospective </text>
<text top="730" left="280" width="51" height="20" font="4">n=12 pts </text>
<text top="730" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="747" left="361" width="71" height="20" font="4">Prior Fontan </text>
<text top="764" left="361" width="52" height="20" font="4">palliation </text>
<text top="730" left="496" width="30" height="20" font="4">Liver </text>
<text top="747" left="496" width="69" height="20" font="4">assessment </text>
<text top="764" left="496" width="92" height="20" font="4">protocol with CT </text>
<text top="781" left="496" width="76" height="20" font="4">and histology </text>
<text top="730" left="604" width="251" height="20" font="4">● Various pathologic findings in 4–7 of the 12 </text>
<text top="747" left="604" width="30" height="20" font="4">pts.   </text>
<text top="764" left="604" width="239" height="20" font="4">● Degree of hepatic fibrosis correlated with </text>
<text top="781" left="604" width="107" height="20" font="4">duration of Fontan. </text>
<text top="730" left="887" width="110" height="20" font="4">● PLE in 5/12 pts.   </text>
</page>
<page number="179" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 179 </text>
<text top="107" left="64" width="87" height="20" font="4">Potter BJ, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(661)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23870650?dopt=Citation">23870650</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23870650?dopt=Citation"> </a></text>
<text top="107" left="179" width="76" height="20" font="4">Cohort study, </text>
<text top="124" left="179" width="74" height="20" font="4">retrospective </text>
<text top="107" left="280" width="58" height="20" font="4">n=210 pts </text>
<text top="107" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="361" width="71" height="20" font="4">Prior Fontan </text>
<text top="141" left="361" width="52" height="20" font="4">palliation </text>
<text top="107" left="496" width="95" height="20" font="4">Thromboembolic </text>
<text top="124" left="496" width="40" height="20" font="4">events </text>
<text top="107" left="604" width="264" height="20" font="4">● 24.3% received aspirin, and 25.7% warfarin.   </text>
<text top="124" left="604" width="211" height="20" font="4">● Use of either was protective against </text>
<text top="141" left="604" width="184" height="20" font="4">thromboembolic events (HR: 8.5) </text>
<text top="107" left="887" width="139" height="20" font="4">● No difference between </text>
<text top="124" left="887" width="54" height="20" font="4">aspirin or </text>
<text top="141" left="887" width="93" height="20" font="4">anticoagulation.  </text>
<text top="159" left="887" width="140" height="20" font="4">● AF or atrial flutter were </text>
<text top="176" left="887" width="107" height="20" font="4">also risk factors for </text>
<text top="193" left="887" width="43" height="20" font="4">events. </text>
<text top="211" left="64" width="96" height="20" font="4">Davies RR, et al. </text>
<text top="228" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(272)</a> </text>
<text top="245" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22500594?dopt=Citation">22500594</a></text>
<text top="245" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22500594?dopt=Citation"> </a></text>
<text top="211" left="179" width="73" height="20" font="4">Cohort study </text>
<text top="211" left="280" width="51" height="20" font="4">n=43 pts </text>
<text top="211" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="228" left="361" width="107" height="20" font="4">Fontan undergoing </text>
<text top="245" left="361" width="57" height="20" font="4">transplant </text>
<text top="211" left="496" width="50" height="20" font="4">Mortality </text>
<text top="211" left="604" width="243" height="20" font="4">● 90-d mortality was greater in Fontan pts.   </text>
<text top="211" left="887" width="120" height="20" font="4">● Renal failure was a </text>
<text top="228" left="887" width="95" height="20" font="4">predictor of early </text>
<text top="245" left="887" width="53" height="20" font="4">mortality. </text>
<text top="263" left="64" width="88" height="20" font="4">Aboulhosn J, et </text>
<text top="281" left="64" width="16" height="20" font="4">al. </text>
<text top="298" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(662)</a> </text>
<text top="315" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21087427?dopt=Citation">21087427</a></text>
<text top="315" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21087427?dopt=Citation"> </a></text>
<text top="263" left="179" width="73" height="20" font="4">Cohort study </text>
<text top="263" left="280" width="51" height="20" font="4">n=27 pts </text>
<text top="263" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="281" left="361" width="86" height="20" font="4">Pts undergoing </text>
<text top="298" left="361" width="105" height="20" font="4">Fontan conversion </text>
<text top="315" left="361" width="44" height="20" font="4">surgery </text>
<text top="263" left="496" width="63" height="20" font="4">Arrhythmia </text>
<text top="281" left="496" width="62" height="20" font="4">recurrence </text>
<text top="263" left="604" width="263" height="20" font="4">● 2 postoperative deaths, both with liver failure. </text>
<text top="281" left="604" width="248" height="20" font="4">Early postoperative atrial arrhythmia in 22%.  </text>
<text top="263" left="887" width="138" height="20" font="4">● 14% of those who had </text>
<text top="281" left="887" width="131" height="20" font="4">concomitant arrhythmia </text>
<text top="298" left="887" width="131" height="20" font="4">surgery had recurrence </text>
<text top="315" left="887" width="69" height="20" font="4">&gt;3 mo later. </text>
<text top="333" left="64" width="90" height="20" font="4">Elder RW, et al. </text>
<text top="350" left="64" width="66" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(663)</a>  </text>
<text top="368" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25130602?dopt=Citation">25130602</a></text>
<text top="368" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25130602?dopt=Citation"><b> </b></a></text>
<text top="333" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="350" left="179" width="80" height="20" font="4">observational, </text>
<text top="368" left="179" width="73" height="20" font="4">single center<b> </b></text>
<text top="333" left="280" width="58" height="20" font="4">n=123 pts </text>
<text top="333" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="350" left="361" width="112" height="20" font="4">Adult pts &gt;15 y post </text>
<text top="368" left="361" width="42" height="20" font="4">Fontan </text>
<text top="333" left="496" width="94" height="20" font="4">Late major AE in </text>
<text top="350" left="496" width="83" height="20" font="4">adult survivors </text>
<text top="333" left="604" width="263" height="20" font="4">● Major AE in 15%; transplant free survival rate </text>
<text top="350" left="604" width="200" height="20" font="4">95%, 83%, 60% at 20, 25, and 30 y, </text>
<text top="368" left="604" width="75" height="20" font="4">respectively.  </text>
<text top="385" left="604" width="254" height="20" font="4">● No difference in adverse outcome based on </text>
<text top="402" left="604" width="257" height="20" font="4">morphology of systemic ventricle, Fontan type, </text>
<text top="419" left="604" width="266" height="20" font="4">or systolic ventricular function.  Independent risk </text>
<text top="436" left="604" width="205" height="20" font="4">factors for major AE were portal HTN </text>
<text top="454" left="604" width="242" height="20" font="4">(p&lt;0.0001), need for permanent pacemaker </text>
<text top="471" left="604" width="121" height="20" font="4">(p=0.002), systemic O</text>
<text top="477" left="725" width="4" height="13" font="6">2</text>
<text top="471" left="729" width="127" height="20" font="4"> desaturation (p=0.02). </text>
<text top="333" left="887" width="80" height="20" font="4">● Portal HTN, </text>
<text top="350" left="887" width="123" height="20" font="4">desaturation, need for </text>
<text top="368" left="887" width="127" height="20" font="4">permanent pacemaker </text>
<text top="385" left="887" width="120" height="20" font="4">were predictive of AE </text>
<text top="489" left="64" width="83" height="20" font="4">Said SM, et al. </text>
<text top="506" left="64" width="66" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(664)</a>  </text>
<text top="523" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24786860?dopt=Citation">24786860</a></text>
<text top="523" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24786860?dopt=Citation"><b> </b></a></text>
<text top="489" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="506" left="179" width="80" height="20" font="4">observational, </text>
<text top="523" left="179" width="73" height="20" font="4">single center<b> </b></text>
<text top="489" left="280" width="51" height="20" font="4">n=70 pts </text>
<text top="489" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="506" left="361" width="105" height="20" font="4">Fontan conversion </text>
<text top="523" left="361" width="116" height="20" font="4">surgery, median age </text>
<text top="540" left="361" width="94" height="20" font="4">23 y, 5 y median </text>
<text top="558" left="361" width="59" height="20" font="4">follow-up.  </text>
<text top="489" left="496" width="85" height="20" font="4">Risk factors for </text>
<text top="506" left="496" width="42" height="20" font="4">Fontan </text>
<text top="523" left="496" width="63" height="20" font="4">conversion </text>
<text top="489" left="604" width="259" height="20" font="4">● Early mortality 14%; independent risk factors </text>
<text top="506" left="604" width="255" height="20" font="4">for early death, age &gt;20 y (p=0.009); AV valve </text>
<text top="523" left="604" width="263" height="20" font="4">regurgitation (p=0.016); lack of Maze procedure </text>
<text top="540" left="604" width="159" height="20" font="4">(p=0.04); male sex (p=0.02). </text>
<text top="558" left="604" width="269" height="20" font="4">● Late survival at 1, 5 10 y was 81%, 70%, 67%. </text>
<text top="489" left="887" width="114" height="20" font="4">● Older age and AV </text>
<text top="506" left="887" width="104" height="20" font="4">valve regurgitation </text>
<text top="523" left="887" width="121" height="20" font="4">increased risk of poor </text>
<text top="540" left="887" width="54" height="20" font="4">outcome. </text>
<text top="575" left="64" width="83" height="20" font="4">Khairy P, et al. </text>
<text top="593" left="64" width="66" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(665)</a>  </text>
<text top="610" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18071068?dopt=Citation">18071068</a></text>
<text top="610" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18071068?dopt=Citation"><b> </b></a></text>
<text top="575" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="593" left="179" width="80" height="20" font="4">observational, </text>
<text top="610" left="179" width="73" height="20" font="4">single center<b> </b></text>
<text top="575" left="280" width="58" height="20" font="4">n=261 pts </text>
<text top="575" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="593" left="361" width="112" height="20" font="4">Fontan, pts, median </text>
<text top="610" left="361" width="54" height="20" font="4">age 7.9 y </text>
<text top="575" left="496" width="85" height="20" font="4">Risk factors for </text>
<text top="593" left="496" width="50" height="20" font="4">mortality </text>
<text top="575" left="604" width="254" height="20" font="4">● Late survival free of death or transplant was </text>
<text top="593" left="604" width="217" height="20" font="4">94%, 90%, 87%, 83% at 5, 10, 15, 20 y </text>
<text top="610" left="604" width="79" height="20" font="4">respectively.   </text>
<text top="627" left="604" width="258" height="20" font="4">● No difference between right aortic peripheral </text>
<text top="644" left="604" width="234" height="20" font="4">artery vs. total cavopulmonary connection; </text>
<text top="662" left="604" width="243" height="20" font="4">independent risk factors for thromboembolic </text>
<text top="679" left="604" width="257" height="20" font="4">death were lack of antiplatelet or anticoagulant </text>
<text top="696" left="604" width="259" height="20" font="4">medication (p=0.0041) and clinically diagnosed </text>
<text top="713" left="604" width="192" height="20" font="4">intracardiac thrombus (p=0.0002).  </text>
<text top="730" left="604" width="270" height="20" font="4">● Independent predictors for HF death were PLE </text>
<text top="748" left="604" width="270" height="20" font="4">(p=0.0043), single morphologic RV (p=0.04), and </text>
<text top="765" left="604" width="165" height="20" font="4">higher RA pressure (0.0016).  </text>
<text top="575" left="887" width="136" height="20" font="4">● Right aortic peripheral </text>
<text top="593" left="887" width="111" height="20" font="4">artery connection in </text>
<text top="610" left="887" width="136" height="20" font="4">52%; right atrial to RV in </text>
<text top="627" left="887" width="58" height="20" font="4">10%; total </text>
<text top="644" left="887" width="87" height="20" font="4">cavopulmonary </text>
<text top="662" left="887" width="98" height="20" font="4">connection 39%.  </text>
</page>
<page number="180" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 180 </text>
<text top="107" left="64" width="89" height="20" font="4">Mavroudis C, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="66" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(666)</a>  </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17954046?dopt=Citation">17954046</a></text>
<text top="159" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17954046?dopt=Citation"><b> </b></a></text>
<text top="107" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="124" left="179" width="80" height="20" font="4">observational, </text>
<text top="141" left="179" width="73" height="20" font="4">single center<b> </b></text>
<text top="107" left="280" width="58" height="20" font="4">n=111 pts </text>
<text top="107" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="361" width="108" height="20" font="4">Fontan conversion, </text>
<text top="141" left="361" width="95" height="20" font="4">mean age 22.5 y </text>
<text top="107" left="496" width="66" height="20" font="4">Identify risk </text>
<text top="124" left="496" width="58" height="20" font="4">factors for </text>
<text top="141" left="496" width="42" height="20" font="4">Fontan </text>
<text top="159" left="496" width="88" height="20" font="4">conversion with </text>
<text top="176" left="496" width="33" height="20" font="4">Maze </text>
<text top="107" left="604" width="265" height="20" font="4">● Early mortality, 0.9%; late deaths, 5.4%; need </text>
<text top="124" left="604" width="190" height="20" font="4">for cardiac transplantation, 5.4%.   </text>
<text top="141" left="604" width="156" height="20" font="4">● Mean hospital stay: 14 d.  </text>
<text top="159" left="604" width="261" height="20" font="4">● Risk factors for death or transplantation were </text>
<text top="176" left="604" width="251" height="20" font="4">RV or ambiguous ventricle, preop PLE, preop </text>
<text top="193" left="604" width="252" height="20" font="4">moderate-to-severe aortic valve regurgitation, </text>
<text top="210" left="604" width="123" height="20" font="4">and long bypass time. </text>
<text top="107" left="887" width="116" height="20" font="4">● Late recurrence of </text>
<text top="124" left="887" width="121" height="20" font="4">atrial tachycardia was </text>
<text top="141" left="887" width="39" height="20" font="4">~15%. </text>
<text top="228" left="64" width="74" height="20" font="4">Ono M, et al. </text>
<text top="245" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(667)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17074498?dopt=Citation">17074498</a></text>
<text top="263" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17074498?dopt=Citation"><b> </b></a></text>
<text top="228" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="245" left="179" width="80" height="20" font="4">observational, </text>
<text top="263" left="179" width="73" height="20" font="4">single center<b> </b></text>
<text top="228" left="280" width="58" height="20" font="4">n=121 pts </text>
<text top="228" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="245" left="361" width="107" height="20" font="4">Fontan, mean age, </text>
<text top="263" left="361" width="30" height="20" font="4">5.8 y </text>
<text top="228" left="496" width="81" height="20" font="4">Late morbidity </text>
<text top="245" left="496" width="74" height="20" font="4">and mortality </text>
<text top="263" left="496" width="70" height="20" font="4">after Fontan </text>
<text top="228" left="604" width="261" height="20" font="4">● Late survival, 87% at 20 y; 10 early deaths, 5 </text>
<text top="245" left="604" width="70" height="20" font="4">late deaths.  </text>
<text top="263" left="604" width="254" height="20" font="4">● Heterotaxy and AV valve anomaly were risk </text>
<text top="280" left="604" width="246" height="20" font="4">factors for late failure and tachyarrhythmias.  </text>
<text top="297" left="604" width="258" height="20" font="4">● Fenestrated total cavopulmonary connection </text>
<text top="314" left="604" width="244" height="20" font="4">and aortopulmonary collaterals had reduced </text>
<text top="332" left="604" width="193" height="20" font="4">incidence of late tachyarrhythmias. </text>
<text top="228" left="887" width="123" height="20" font="4">● Fenestrated Fontan </text>
<text top="245" left="887" width="129" height="20" font="4">provided better cardiac </text>
<text top="263" left="887" width="94" height="20" font="4">output and lower </text>
<text top="280" left="887" width="92" height="20" font="4">incidence of late </text>
<text top="297" left="887" width="100" height="20" font="4">tachyarrhythmias. </text>
<text top="350" left="64" width="86" height="20" font="4">Kaulitz R, et al. </text>
<text top="367" left="64" width="66" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(668)</a>  </text>
<text top="384" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12238839?dopt=Citation">12238839</a></text>
<text top="384" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12238839?dopt=Citation"><b> </b></a></text>
<text top="350" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="367" left="179" width="80" height="20" font="4">observational, </text>
<text top="384" left="179" width="73" height="20" font="4">single center<b> </b></text>
<text top="350" left="280" width="51" height="20" font="4">n=88 pts </text>
<text top="350" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="367" left="361" width="121" height="20" font="4">Fontan survivors &gt;5 y </text>
<text top="384" left="361" width="89" height="20" font="4">postoperatively. </text>
<text top="401" left="361" width="120" height="20" font="4">Mean follow-up 9.6 y. </text>
<text top="350" left="496" width="51" height="20" font="4">Need for </text>
<text top="367" left="496" width="78" height="20" font="4">reintervention </text>
<text top="384" left="496" width="70" height="20" font="4">after Fontan </text>
<text top="401" left="496" width="52" height="20" font="4">palliation </text>
<text top="350" left="604" width="245" height="20" font="4">● Freedom from reop at 5 y=82%; 8 y=76%. </text>
<text top="367" left="604" width="237" height="20" font="4">Interventions included total cavopulmonary </text>
<text top="384" left="604" width="251" height="20" font="4">connection conversion in 2, PPM in 11%; Coil </text>
<text top="401" left="604" width="256" height="20" font="4">occlusion of aortopulmonary collaterals in 6/17 </text>
<text top="418" left="604" width="23" height="20" font="4">pts. </text>
<text top="436" left="604" width="267" height="20" font="4">● Freedom from transcatheter interventions was </text>
<text top="453" left="604" width="230" height="20" font="4">94% and 82% at 5 and 10 y respectively   </text>
<text top="350" left="887" width="116" height="20" font="4">● All pts had cardiac </text>
<text top="367" left="887" width="123" height="20" font="4">cath as part of regular </text>
<text top="384" left="887" width="102" height="20" font="4">postop protocol or </text>
<text top="401" left="887" width="102" height="20" font="4">symptomatic atrial </text>
<text top="418" left="887" width="130" height="20" font="4">tachycardia or increase </text>
<text top="436" left="887" width="68" height="20" font="4">in cyanosis. </text>
<text top="471" left="64" width="70" height="20" font="4">Yeh T, et al. </text>
<text top="488" left="64" width="63" height="20" font="4">1999 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(669)</a> </text>
<text top="505" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10485406?dopt=Citation">10485406</a></text>
<text top="505" left="119" width="3" height="20" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10485406?dopt=Citation"><b> </b></a></text>
<text top="471" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="488" left="179" width="80" height="20" font="4">observational, </text>
<text top="505" left="179" width="73" height="20" font="4">single center<b> </b></text>
<text top="471" left="280" width="58" height="20" font="4">n=407 pts </text>
<text top="471" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="488" left="361" width="112" height="20" font="4">Adult pts &gt;15 y post </text>
<text top="505" left="361" width="45" height="20" font="4">Fontan  </text>
<text top="471" left="496" width="60" height="20" font="4">Long-term </text>
<text top="488" left="496" width="73" height="20" font="4">survival after </text>
<text top="505" left="496" width="61" height="20" font="4">Fontan vs. </text>
<text top="522" left="496" width="87" height="20" font="4">cavopulmonary </text>
<text top="540" left="496" width="33" height="20" font="4">shunt </text>
<text top="471" left="604" width="210" height="20" font="4">● Long-term survival, 20 y survival for </text>
<text top="488" left="604" width="240" height="20" font="4">cavopulmonary shunt-Fontan 65% (n=220); </text>
<text top="505" left="604" width="263" height="20" font="4">whereas, 20 y survival cavopulmonary shunt-no </text>
<text top="522" left="604" width="263" height="20" font="4">Fontan 50% (n=187). On multivariable analysis, </text>
<text top="540" left="604" width="267" height="20" font="4">proceeding to Fontan has small survival benefit.  </text>
<text top="471" left="887" width="107" height="20" font="4">● Independent risk </text>
<text top="488" left="887" width="110" height="20" font="4">factors for death for </text>
<text top="505" left="887" width="130" height="20" font="4">common aortic valve or </text>
<text top="522" left="887" width="70" height="20" font="4">PA banding. </text>
<text top="558" left="64" width="95" height="20" font="4">Harper AR, et al. </text>
<text top="575" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#226">(274)</a>  </text>
<text top="592" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22588032">22588032</a></text>
<text top="592" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22588032"> </a></text>
<text top="558" left="179" width="75" height="20" font="4">Single center </text>
<text top="558" left="280" width="58" height="20" font="4">n=126 pts </text>
<text top="558" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="575" left="361" width="74" height="20" font="4">Median 1.2 y </text>
<text top="558" left="496" width="83" height="20" font="4">Comparison of </text>
<text top="575" left="496" width="76" height="20" font="4">transplant vs. </text>
<text top="592" left="496" width="78" height="20" font="4">nontransplant </text>
<text top="609" left="496" width="46" height="20" font="4">surgical </text>
<text top="626" left="496" width="67" height="20" font="4">intervention </text>
<text top="558" left="604" width="268" height="20" font="4">● 14 pts who underwent surgery instead; still 1 y </text>
<text top="575" left="604" width="81" height="20" font="4">mortality 28%. </text>
<text top="558" left="887" width="110" height="20" font="4">● Best outcomes in </text>
<text top="575" left="887" width="110" height="20" font="4">those with normal 2 </text>
<text top="592" left="887" width="110" height="20" font="4">ventricle anatomy.   </text>
<text top="644" left="64" width="209" height="20" font="3"><b>Bradyarrhythmias and Pacemakers</b> </text>
<text top="663" left="64" width="89" height="20" font="4">Takahashi K, et </text>
<text top="681" left="64" width="16" height="20" font="4">al. </text>
<text top="698" left="64" width="66" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(670)</a>  </text>
<text top="715" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19545341?dopt=Citation">19545341</a></text>
<text top="715" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19545341?dopt=Citation"> </a></text>
<text top="663" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="681" left="179" width="74" height="20" font="4">single-center </text>
<text top="698" left="179" width="70" height="20" font="4">cohort study </text>
<text top="663" left="280" width="51" height="20" font="4">n=78 pts </text>
<text top="663" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="681" left="361" width="120" height="20" font="4">Fontan surgery; atrial </text>
<text top="698" left="361" width="96" height="20" font="4">lead implantation </text>
<text top="715" left="361" width="120" height="20" font="4">between 1992―2007 </text>
<text top="663" left="496" width="83" height="20" font="4">Comparison of </text>
<text top="681" left="496" width="27" height="20" font="4">lead </text>
<text top="698" left="496" width="73" height="20" font="4">performance </text>
<text top="715" left="496" width="76" height="20" font="4">and longevity </text>
<text top="732" left="496" width="50" height="20" font="4">between </text>
<text top="749" left="496" width="94" height="20" font="4">transvenous and </text>
<text top="767" left="496" width="92" height="20" font="4">epicardial leads  </text>
<text top="663" left="604" width="244" height="20" font="4">● Acute complication rates were similar (8% </text>
<text top="681" left="604" width="248" height="20" font="4">transvenous vs. 19% epicardial), but hospital </text>
<text top="698" left="604" width="239" height="20" font="4">stay was shorter for transvenous (2 vs. 5 d; </text>
<text top="715" left="604" width="52" height="20" font="4">p=0.03).  </text>
<text top="732" left="604" width="267" height="20" font="4">● Lead survival was similar (transvenous 9.9 vs. </text>
<text top="749" left="604" width="235" height="20" font="4">epicardial 7.8 y). Thresholds were lower at </text>
<text top="767" left="604" width="228" height="20" font="4">implant for transvenous leads (0.9 vs. 2.2 </text>
<text top="663" left="887" width="87" height="20" font="4">● Compared to </text>
<text top="681" left="887" width="92" height="20" font="4">epicardial leads, </text>
<text top="698" left="887" width="140" height="20" font="4">transvenous atrial pacing </text>
<text top="715" left="887" width="129" height="20" font="4">leads may be placed in </text>
<text top="732" left="887" width="120" height="20" font="4">Fontan pts with lower </text>
<text top="749" left="887" width="139" height="20" font="4">procedural morbidity and </text>
<text top="767" left="887" width="139" height="20" font="4">equivalent expectation of </text>
</page>
<page number="181" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 181 </text>
<text top="107" left="604" width="269" height="20" font="4">microjoule; p=0.049), but similar at follow-up (1.2 </text>
<text top="124" left="604" width="90" height="20" font="4">vs. 2.6 microJ).  </text>
<text top="141" left="604" width="251" height="20" font="4">● Atrial sensing was unchanged over time for </text>
<text top="159" left="604" width="254" height="20" font="4">transvenous (2.2 to 2.1 mV) but decreased for </text>
<text top="176" left="604" width="189" height="20" font="4">epicardial (3.3 to 2.5 mV; p=0.02). </text>
<text top="107" left="887" width="123" height="20" font="4">lead performance and </text>
<text top="124" left="887" width="55" height="20" font="4">longevity. </text>
<text top="194" left="64" width="89" height="20" font="4">Dodge-Khatami </text>
<text top="211" left="64" width="45" height="20" font="4">A, et al. </text>
<text top="228" left="64" width="66" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(671)</a>  </text>
<text top="245" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16181884?dopt=Citation">16181884</a></text>
<text top="245" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16181884?dopt=Citation"> </a></text>
<text top="194" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="211" left="179" width="74" height="20" font="4">single-center </text>
<text top="228" left="179" width="70" height="20" font="4">cohort study </text>
<text top="194" left="280" width="44" height="20" font="4">n=9 pts </text>
<text top="194" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="211" left="361" width="116" height="20" font="4">Fontan surgery; dual </text>
<text top="228" left="361" width="116" height="20" font="4">chamber pacemaker </text>
<text top="246" left="361" width="120" height="20" font="4">between 1997―2004 </text>
<text top="194" left="496" width="77" height="20" font="4">Morbidity and </text>
<text top="211" left="496" width="50" height="20" font="4">mortality </text>
<text top="194" left="604" width="242" height="20" font="4">● There was no mortality or morbidity. Lead </text>
<text top="211" left="604" width="221" height="20" font="4">survival was 100% at 3.3 y. Arrhythmias </text>
<text top="228" left="604" width="209" height="20" font="4">subsided in all and no longer required </text>
<text top="246" left="604" width="256" height="20" font="4">medication in 3 pts. Protein-losing enteropathy </text>
<text top="263" left="604" width="248" height="20" font="4">improved in 1 pt and disappeared in another. </text>
<text top="280" left="604" width="249" height="20" font="4">Exercise intolerance diminished, and HF was </text>
<text top="297" left="604" width="60" height="20" font="4">controlled. </text>
<text top="194" left="887" width="132" height="20" font="4">● Dual chamber pacing </text>
<text top="211" left="887" width="138" height="20" font="4">improves single ventricle </text>
<text top="228" left="887" width="133" height="20" font="4">hemodynamics and can </text>
<text top="246" left="887" width="118" height="20" font="4">help decompensated </text>
<text top="263" left="887" width="68" height="20" font="4">Fontan pts.  </text>
<text top="315" left="64" width="90" height="20" font="4">Hansky B, et al. </text>
<text top="332" left="64" width="66" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(672)</a>  </text>
<text top="350" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15679644?dopt=Citation">15679644</a></text>
<text top="350" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15679644?dopt=Citation"> </a></text>
<text top="315" left="179" width="76" height="20" font="4">Single-center </text>
<text top="332" left="179" width="66" height="20" font="4">case series </text>
<text top="315" left="280" width="44" height="20" font="4">n=7 pts </text>
<text top="315" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="332" left="361" width="90" height="20" font="4">Fontan surgery; </text>
<text top="350" left="361" width="83" height="20" font="4">implantation of </text>
<text top="367" left="361" width="107" height="20" font="4">endocardial pacing </text>
<text top="384" left="361" width="62" height="20" font="4">leads via a </text>
<text top="401" left="361" width="85" height="20" font="4">transvenous or </text>
<text top="418" left="361" width="119" height="20" font="4">transatrial approach.  </text>
<text top="315" left="496" width="58" height="20" font="4">Feasibility </text>
<text top="315" left="604" width="270" height="20" font="4">● Endocardial leads were successfully implanted </text>
<text top="332" left="604" width="52" height="20" font="4">in all pts. </text>
<text top="315" left="887" width="87" height="20" font="4">● Transvenous </text>
<text top="332" left="887" width="94" height="20" font="4">endocardial lead </text>
<text top="350" left="887" width="129" height="20" font="4">implantation avoids the </text>
<text top="367" left="887" width="121" height="20" font="4">problem of increasing </text>
<text top="384" left="887" width="105" height="20" font="4">capture thresholds </text>
<text top="401" left="887" width="126" height="20" font="4">typically observed with </text>
<text top="418" left="887" width="96" height="20" font="4">epicardial leads.  </text>
<text top="436" left="64" width="90" height="20" font="4">Cohen MI, et al. </text>
<text top="454" left="64" width="63" height="20" font="4">2001 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(673)</a> </text>
<text top="471" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11279424?dopt=Citation">11279424</a></text>
<text top="471" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11279424?dopt=Citation"> </a></text>
<text top="436" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="454" left="179" width="74" height="20" font="4">single-center </text>
<text top="471" left="179" width="70" height="20" font="4">cohort study </text>
<text top="436" left="280" width="31" height="20" font="4">n=31 </text>
<text top="454" left="280" width="65" height="20" font="4">Fontan pts, </text>
<text top="471" left="280" width="64" height="20" font="4">56 controls </text>
<text top="436" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="454" left="361" width="84" height="20" font="4">Epicardial lead </text>
<text top="471" left="361" width="107" height="20" font="4">implanted between </text>
<text top="488" left="361" width="93" height="20" font="4">Jan 1983―June </text>
<text top="505" left="361" width="120" height="20" font="4">2000; Fontan surgery </text>
<text top="522" left="361" width="121" height="20" font="4">or non-Fontan control </text>
<text top="436" left="496" width="76" height="20" font="4">Perioperative </text>
<text top="454" left="496" width="64" height="20" font="4">course and </text>
<text top="471" left="496" width="83" height="20" font="4">epicardial lead </text>
<text top="488" left="496" width="45" height="20" font="4">survival </text>
<text top="436" left="604" width="256" height="20" font="4">● There was no difference in the perioperative </text>
<text top="454" left="604" width="231" height="20" font="4">course for Fontan pts and controls and no </text>
<text top="471" left="604" width="267" height="20" font="4">difference in epicardial lead survival (1 y, 96%; 2 </text>
<text top="488" left="604" width="103" height="20" font="4">y, 90%; 5 y, 70%). </text>
<text top="436" left="887" width="126" height="20" font="4">● Epicardial leads can </text>
<text top="454" left="887" width="105" height="20" font="4">be safely placed in </text>
<text top="471" left="887" width="92" height="20" font="4">Fontan pts at no </text>
<text top="488" left="887" width="137" height="20" font="4">additional risk compared </text>
<text top="505" left="887" width="128" height="20" font="4">to pts with biventricular </text>
<text top="522" left="887" width="65" height="20" font="4">physiology. </text>
<text top="540" left="64" width="90" height="20" font="4">Cohen MI, et al. </text>
<text top="558" left="64" width="66" height="20" font="4">1998 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(674)</a>  </text>
<text top="575" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9852926?dopt=Citation">9852926</a></text>
<text top="575" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9852926?dopt=Citation"> </a></text>
<text top="540" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="558" left="179" width="74" height="20" font="4">single-center </text>
<text top="575" left="179" width="70" height="20" font="4">cohort study </text>
<text top="540" left="280" width="58" height="20" font="4">n=287 pts </text>
<text top="540" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="558" left="361" width="84" height="20" font="4">Staged Fontan </text>
<text top="575" left="361" width="118" height="20" font="4">surgery between Jan </text>
<text top="592" left="361" width="96" height="20" font="4">1990―Dec 1995 </text>
<text top="540" left="496" width="87" height="20" font="4">Early incidence </text>
<text top="558" left="496" width="43" height="20" font="4">of SND </text>
<text top="540" left="604" width="203" height="20" font="4">● Overall, 23% had SND in the early </text>
<text top="558" left="604" width="269" height="20" font="4">postoperative period after Fontan surgery. Of the </text>
<text top="575" left="604" width="250" height="20" font="4">95 pts followed for &gt;4 y, 44% had SND, 6.7% </text>
<text top="592" left="604" width="260" height="20" font="4">had received a PM, and 4.1% had documented </text>
<text top="609" left="604" width="68" height="20" font="4">atrial flutter. </text>
<text top="540" left="887" width="130" height="20" font="4">● Perioperative SND is </text>
<text top="558" left="887" width="99" height="20" font="4">common after the </text>
<text top="575" left="887" width="104" height="20" font="4">Fontan procedure. </text>
<text top="627" left="64" width="92" height="20" font="4">Fisberger SB, et </text>
<text top="644" left="64" width="16" height="20" font="4">al. </text>
<text top="662" left="64" width="66" height="20" font="4">1996 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(675)</a>  </text>
<text top="679" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8623749?dopt=Citation">8623749</a></text>
<text top="679" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8623749?dopt=Citation"> </a></text>
<text top="627" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="644" left="179" width="74" height="20" font="4">single-center </text>
<text top="662" left="179" width="70" height="20" font="4">cohort study </text>
<text top="627" left="280" width="58" height="20" font="4">n=500 pts </text>
<text top="627" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="644" left="361" width="86" height="20" font="4">Fontan surgery </text>
<text top="662" left="361" width="78" height="20" font="4">between April </text>
<text top="679" left="361" width="96" height="20" font="4">1973―July 1991 </text>
<text top="627" left="496" width="78" height="20" font="4">Prevalence of </text>
<text top="644" left="496" width="64" height="20" font="4">pacemaker </text>
<text top="662" left="496" width="57" height="20" font="4">implanted </text>
<text top="627" left="604" width="267" height="20" font="4">● Overall, 9.2% of pts received pacemaker 5.4 y </text>
<text top="644" left="604" width="75" height="20" font="4">post Fontan.  </text>
<text top="662" left="604" width="260" height="20" font="4">● Pts with pacemaker compared favorably with </text>
<text top="679" left="604" width="212" height="20" font="4">nonpaced pts with respect to survival.  </text>
<text top="696" left="604" width="269" height="20" font="4">● In pts with AV block, dual chamber pacing was </text>
<text top="713" left="604" width="247" height="20" font="4">superior to ventricle paced, ventricle sensed, </text>
<text top="730" left="604" width="132" height="20" font="4">pacing inhibited pacing. </text>
<text top="627" left="887" width="135" height="20" font="4">● PM are often required </text>
<text top="644" left="887" width="134" height="20" font="4">post Fontan surgery are </text>
<text top="662" left="887" width="87" height="20" font="4">associated with </text>
<text top="679" left="887" width="103" height="20" font="4">favorable survival. </text>
<text top="748" left="64" width="89" height="20" font="4">Dodge-Khatami </text>
<text top="766" left="64" width="45" height="20" font="4">A, et al. </text>
<text top="783" left="64" width="66" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(671)</a>  </text>
<text top="748" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="766" left="179" width="74" height="20" font="4">single-center </text>
<text top="783" left="179" width="70" height="20" font="4">cohort study </text>
<text top="748" left="280" width="44" height="20" font="4">n=9 pts </text>
<text top="748" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="766" left="361" width="116" height="20" font="4">Fontan surgery; dual </text>
<text top="748" left="496" width="77" height="20" font="4">Morbidity and </text>
<text top="766" left="496" width="50" height="20" font="4">mortality </text>
<text top="748" left="604" width="242" height="20" font="4">● There was no mortality or morbidity. Lead </text>
<text top="766" left="604" width="156" height="20" font="4">survival was 100% at 3.3 y.  </text>
<text top="748" left="887" width="132" height="20" font="4">● Dual chamber pacing </text>
<text top="766" left="887" width="138" height="20" font="4">improves single ventricle </text>
<text top="783" left="887" width="133" height="20" font="4">hemodynamics and can </text>
</page>
<page number="182" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="18" size="12" family="Times" color="#0b0b0b"/>
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 182 </text>
<text top="107" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16181884?dopt=Citation">16181884</a></text>
<text top="107" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16181884?dopt=Citation"> </a></text>
<text top="107" left="361" width="116" height="20" font="4">chamber pacemaker </text>
<text top="124" left="361" width="120" height="20" font="4">between 1997―2004 </text>
<text top="107" left="604" width="242" height="20" font="4">● Arrhythmias subsided in all and no longer </text>
<text top="124" left="604" width="236" height="20" font="4">required medication in 3 pts. Protein-losing </text>
<text top="141" left="604" width="267" height="20" font="4">enteropathy improved in 1 pt and disappeared in </text>
<text top="159" left="604" width="252" height="20" font="4">another. Exercise intolerance diminished, and </text>
<text top="176" left="604" width="105" height="20" font="4">HF was controlled. </text>
<text top="107" left="887" width="118" height="20" font="4">help decompensated </text>
<text top="124" left="887" width="68" height="20" font="4">Fontan pts.  </text>
<text top="194" left="64" width="311" height="20" font="3"><b>Atrial Tachyarrhythmias (Excluding Anticoagulation) </b></text>
<text top="213" left="64" width="87" height="20" font="4">d’Udekem Y, et </text>
<text top="230" left="64" width="16" height="20" font="4">al. </text>
<text top="247" left="64" width="66" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(676)</a>  </text>
<text top="264" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25200053?dopt=Citation">25200053</a></text>
<text top="264" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25200053?dopt=Citation"> </a></text>
<text top="213" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="230" left="179" width="64" height="20" font="4">multicenter </text>
<text top="247" left="179" width="70" height="20" font="4">cohort study </text>
<text top="264" left="179" width="76" height="20" font="4">prior to 2008, </text>
<text top="282" left="179" width="66" height="20" font="4">prospective </text>
<text top="299" left="179" width="60" height="20" font="4">until 2013  </text>
<text top="213" left="280" width="186" height="20" font="4">n=1,006 pts  <b>Inclusion criteria</b>: </text>
<text top="230" left="361" width="101" height="20" font="4">Fontan procedure </text>
<text top="247" left="361" width="50" height="20" font="4">between </text>
<text top="264" left="361" width="109" height="20" font="4">1975―2010; follow-</text>
<text top="282" left="361" width="96" height="20" font="4">up in Australia or </text>
<text top="299" left="361" width="76" height="20" font="4">New Zealand </text>
<text top="213" left="496" width="60" height="20" font="4">Long-term </text>
<text top="230" left="496" width="57" height="20" font="4">outcomes </text>
<text top="247" left="496" width="93" height="20" font="4">following Fontan </text>
<text top="264" left="496" width="79" height="20" font="4">surgery (SVT, </text>
<text top="282" left="496" width="94" height="20" font="4">mortality, failure, </text>
<text top="299" left="496" width="68" height="20" font="4">pacemaker, </text>
<text top="316" left="496" width="88" height="20" font="4">thromboembolis</text>
<text top="333" left="496" width="18" height="20" font="4">m) </text>
<text top="213" left="604" width="240" height="20" font="18">● A total of 94 pts required a pacemaker. ● </text>
<text top="230" left="604" width="268" height="20" font="18">Sustained episodes of SVT were reported in 100 </text>
<text top="247" left="604" width="27" height="20" font="18">pts.  </text>
<text top="264" left="604" width="258" height="20" font="18">● SVT was associated with atrial isomerism. ● </text>
<text top="282" left="604" width="230" height="20" font="18">Arrhythmias were not associated with late </text>
<text top="299" left="604" width="124" height="20" font="18">mortality or late failure.</text>
<text top="299" left="728" width="3" height="20" font="4"> </text>
<text top="213" left="887" width="105" height="20" font="4">● While brady and </text>
<text top="230" left="887" width="118" height="20" font="4">tachyarrhythmias are </text>
<text top="247" left="887" width="105" height="20" font="4">prevalent following </text>
<text top="264" left="887" width="138" height="20" font="4">Fontan surgery, they are </text>
<text top="282" left="887" width="131" height="20" font="4">not associated with late </text>
<text top="299" left="887" width="129" height="20" font="4">mortality or late Fontan </text>
<text top="316" left="887" width="40" height="20" font="4">failure. </text>
<text top="351" left="64" width="87" height="20" font="4">Correa R, et al. </text>
<text top="368" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#242">(604)</a>  </text>
<text top="386" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24052498?dopt=Citation">24052498</a></text>
<text top="386" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24052498?dopt=Citation"> </a></text>
<text top="351" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="368" left="179" width="48" height="20" font="4">catheter </text>
<text top="386" left="179" width="76" height="20" font="4">ablation case </text>
<text top="403" left="179" width="36" height="20" font="4">series </text>
<text top="351" left="280" width="31" height="20" font="4">n=89 </text>
<text top="368" left="280" width="62" height="20" font="4">Fontan pts </text>
<text top="351" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="368" left="361" width="118" height="20" font="4">Mustard, Senning, or </text>
<text top="386" left="361" width="110" height="20" font="4">Fontan; Referred to </text>
<text top="403" left="361" width="100" height="20" font="4">Boston Children’s </text>
<text top="420" left="361" width="113" height="20" font="4">Hospital for catheter </text>
<text top="437" left="361" width="73" height="20" font="4">ablation; Jan </text>
<text top="455" left="361" width="96" height="20" font="4">2006―Dec 2010 </text>
<text top="351" left="496" width="86" height="20" font="4">AE; changes in </text>
<text top="368" left="496" width="74" height="20" font="4">clinical score </text>
<text top="351" left="604" width="255" height="20" font="4">● AE rates similar with and without transbaffle </text>
<text top="368" left="604" width="49" height="20" font="4">access.  </text>
<text top="386" left="604" width="228" height="20" font="4">● Pts with and without transbaffle access </text>
<text top="403" left="604" width="189" height="20" font="4">experienced clinical improvement. </text>
<text top="351" left="887" width="137" height="20" font="4">● Transbaffle access for </text>
<text top="368" left="887" width="107" height="20" font="4">catheter ablation is </text>
<text top="386" left="887" width="90" height="20" font="4">feasible and not </text>
<text top="403" left="887" width="135" height="20" font="4">associated with a higher </text>
<text top="420" left="887" width="96" height="20" font="4">incidence of AE.  </text>
<text top="437" left="887" width="98" height="20" font="4">● Desaturation is </text>
<text top="454" left="887" width="124" height="20" font="4">observed in some and </text>
<text top="472" left="887" width="115" height="20" font="4">warrants monitoring. </text>
<text top="490" left="64" width="95" height="20" font="4">Giannakoulas G, </text>
<text top="507" left="64" width="30" height="20" font="4">et al. </text>
<text top="524" left="64" width="60" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#213">(17)</a>  </text>
<text top="541" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21196055?dopt=Citation">21196055</a></text>
<text top="541" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21196055?dopt=Citation"> </a></text>
<text top="490" left="179" width="76" height="20" font="4">Single-center </text>
<text top="507" left="179" width="74" height="20" font="4">retrospective </text>
<text top="524" left="179" width="38" height="20" font="4">cohort </text>
<text top="490" left="280" width="51" height="20" font="4">n=98 pts </text>
<text top="490" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="507" left="361" width="100" height="20" font="4">Fontan operation; </text>
<text top="524" left="361" width="101" height="20" font="4">follow-up at Royal </text>
<text top="541" left="361" width="120" height="20" font="4">Brompton since 1999 </text>
<text top="490" left="496" width="54" height="20" font="4">All-cause </text>
<text top="507" left="496" width="53" height="20" font="4">mortality; </text>
<text top="524" left="496" width="81" height="20" font="4">hospitalization </text>
<text top="490" left="604" width="248" height="20" font="4">● Atrial tachyarrhythmia was an independent </text>
<text top="507" left="604" width="256" height="20" font="4">predictor of death (adjusted HR: 9.35; 95% CI: </text>
<text top="524" left="604" width="260" height="20" font="4">1.10–79.18; p=0.04) and composite of death or </text>
<text top="541" left="604" width="238" height="20" font="4">hospitalization (adjusted HR: 5.00; 95% CI: </text>
<text top="559" left="604" width="131" height="20" font="4">2.47–10.09; p&lt;0.0001). </text>
<text top="490" left="887" width="135" height="20" font="4">● The presence of atrial </text>
<text top="507" left="887" width="109" height="20" font="4">tachyarrhythmias is </text>
<text top="524" left="887" width="125" height="20" font="4">associated with higher </text>
<text top="541" left="887" width="127" height="20" font="4">morbidity and mortality </text>
<text top="559" left="887" width="118" height="20" font="4">at midterm follow-up. </text>
<text top="577" left="64" width="83" height="20" font="4">Khairy P, et al. </text>
<text top="594" left="64" width="66" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#244">(665)</a>  </text>
<text top="611" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18071068?dopt=Citation">18071068</a></text>
<text top="611" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18071068?dopt=Citation"> </a></text>
<text top="577" left="179" width="76" height="20" font="4">Single-center </text>
<text top="594" left="179" width="74" height="20" font="4">retrospective </text>
<text top="611" left="179" width="38" height="20" font="4">cohort </text>
<text top="577" left="280" width="58" height="20" font="4">n=261 pts </text>
<text top="577" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="594" left="361" width="105" height="20" font="4">Born before Jan 1, </text>
<text top="611" left="361" width="106" height="20" font="4">1985; reside within </text>
<text top="628" left="361" width="108" height="20" font="4">New England area; </text>
<text top="645" left="361" width="86" height="20" font="4">Fontan surgery </text>
<text top="577" left="496" width="60" height="20" font="18">Long-term </text>
<text top="594" left="496" width="42" height="20" font="18">survival</text>
<text top="594" left="537" width="7" height="20" font="4">; </text>
<text top="594" left="544" width="40" height="20" font="18">modes </text>
<text top="611" left="496" width="44" height="20" font="18">of death</text>
<text top="611" left="540" width="7" height="20" font="4">; </text>
<text top="628" left="496" width="71" height="20" font="18">predictors of </text>
<text top="645" left="496" width="46" height="20" font="18">mortality</text>
<text top="645" left="542" width="3" height="20" font="4"> </text>
<text top="577" left="604" width="256" height="20" font="4">● AF was associated with a 5.4-fold increased </text>
<text top="594" left="604" width="191" height="20" font="4">risk of thromboembolic death. SCD</text>
<text top="594" left="795" width="79" height="20" font="18"> occurred at a </text>
<text top="611" left="604" width="125" height="20" font="18">median age of 20.2 y.  </text>
<text top="628" left="604" width="261" height="20" font="18">● IART with rapid 1:1 conduction was identified </text>
<text top="645" left="604" width="154" height="20" font="18">as a cause of cardiac arrest.</text>
<text top="645" left="759" width="3" height="20" font="4"> </text>
<text top="577" left="887" width="44" height="20" font="4">● Atrial </text>
<text top="594" left="887" width="122" height="20" font="4">tachyarrhythmias with </text>
<text top="611" left="887" width="135" height="20" font="4">rapid AV conduction are </text>
<text top="628" left="887" width="115" height="20" font="4">a rare cause of SCD </text>
<text top="645" left="887" width="93" height="20" font="4">following Fontan </text>
<text top="663" left="887" width="48" height="20" font="4">surgery. </text>
<text top="681" left="64" width="98" height="20" font="4">Abrams DJ, et al. </text>
<text top="698" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(677)</a> </text>
<text top="715" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17372177?dopt=Citation">17372177</a></text>
<text top="715" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17372177?dopt=Citation"> </a></text>
<text top="681" left="179" width="76" height="20" font="4">Single-center </text>
<text top="698" left="179" width="48" height="20" font="4">catheter </text>
<text top="715" left="179" width="76" height="20" font="4">ablation case </text>
<text top="732" left="179" width="36" height="20" font="4">series </text>
<text top="681" left="280" width="51" height="20" font="4">n=26 pts </text>
<text top="681" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="698" left="361" width="90" height="20" font="4">Fontan surgery; </text>
<text top="715" left="361" width="101" height="20" font="4">documented atrial </text>
<text top="732" left="361" width="91" height="20" font="4">tachyarrhythmia </text>
<text top="749" left="361" width="117" height="20" font="4">resistant to at least 1 </text>
<text top="767" left="361" width="81" height="20" font="4">antiarrhythmic </text>
<text top="681" left="496" width="89" height="20" font="4">Comparisons of </text>
<text top="698" left="496" width="67" height="20" font="4">contact and </text>
<text top="715" left="496" width="78" height="20" font="4">reconstructed </text>
<text top="732" left="496" width="47" height="20" font="4">unipolar </text>
<text top="749" left="496" width="74" height="20" font="4">electrograms </text>
<text top="767" left="496" width="28" height="20" font="4">from </text>
<text top="784" left="496" width="90" height="20" font="4">electroanatomic </text>
<text top="681" left="604" width="250" height="20" font="4">● A significant decrease in electrogram cross </text>
<text top="698" left="604" width="241" height="20" font="4">correlation (p=0.003), timing (p=0.012), and </text>
<text top="715" left="604" width="205" height="20" font="4">amplitude (p=0.003) of reconstructed </text>
<text top="732" left="604" width="250" height="20" font="4">electrograms, but not of contact electrograms </text>
<text top="749" left="604" width="249" height="20" font="4">(p=0.742), was seen at endocardial sites &gt;40 </text>
<text top="767" left="604" width="191" height="20" font="4">mm from the multielectrode array.  </text>
<text top="681" left="887" width="104" height="20" font="4">● Electroanatomic </text>
<text top="698" left="887" width="124" height="20" font="4">mapping is superior to </text>
<text top="715" left="887" width="118" height="20" font="4">noncontact mapping, </text>
<text top="732" left="887" width="139" height="20" font="4">particularly &gt;40 mm from </text>
<text top="749" left="887" width="130" height="20" font="4">for arrhythmia mapping </text>
<text top="767" left="887" width="120" height="20" font="4">late after the mo from </text>
<text top="784" left="887" width="135" height="20" font="4">the multielectrode array. </text>
</page>
<page number="183" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 183 </text>
<text top="107" left="361" width="119" height="20" font="4">medication (including </text>
<text top="124" left="361" width="73" height="20" font="4">amiodarone) </text>
<text top="107" left="496" width="70" height="20" font="4">mapping vs. </text>
<text top="124" left="496" width="64" height="20" font="4">noncontact </text>
<text top="141" left="496" width="51" height="20" font="4">mapping </text>
<text top="159" left="496" width="49" height="20" font="4">systems </text>
<text top="107" left="604" width="204" height="20" font="4">● Successful arrhythmia mapping by </text>
<text top="124" left="604" width="249" height="20" font="4">electroanatomic vs. noncontact mapping was </text>
<text top="141" left="604" width="254" height="20" font="4">superior in 15 pts (58%), the same in 6 (23%), </text>
<text top="159" left="604" width="179" height="20" font="4">and inferior in 5 (19%; p=0.044). </text>
<text top="107" left="887" width="122" height="20" font="4">Areas of scar and low-</text>
<text top="124" left="887" width="139" height="20" font="4">voltage endocardium are </text>
<text top="141" left="887" width="106" height="20" font="4">less well identified. </text>
<text top="177" left="64" width="93" height="20" font="4">Friedman RA, et </text>
<text top="194" left="64" width="16" height="20" font="4">al. </text>
<text top="211" left="64" width="63" height="20" font="4">2005 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(678)</a> </text>
<text top="228" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15673382?dopt=Citation">15673382</a></text>
<text top="228" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15673382?dopt=Citation"> </a></text>
<text top="177" left="179" width="76" height="20" font="4">Single-center </text>
<text top="194" left="179" width="74" height="20" font="4">retrospective </text>
<text top="211" left="179" width="66" height="20" font="4">case series </text>
<text top="177" left="280" width="44" height="20" font="4">n=7 pts </text>
<text top="177" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="194" left="361" width="80" height="20" font="4">Fontan; IART; </text>
<text top="211" left="361" width="120" height="20" font="4">attempted regurgitant </text>
<text top="228" left="361" width="104" height="20" font="4">fraction ablation of </text>
<text top="246" left="361" width="86" height="20" font="4">the AV junction </text>
<text top="177" left="496" width="58" height="20" font="4">Feasibility </text>
<text top="177" left="604" width="246" height="20" font="4">● Ablation of the AV junction was successful </text>
<text top="194" left="604" width="222" height="20" font="4">(n=6) or partially successful (n=1) in all.  </text>
<text top="211" left="604" width="252" height="20" font="4">● Normal AV conduction was not seen during </text>
<text top="228" left="604" width="59" height="20" font="4">follow-up.  </text>
<text top="246" left="604" width="246" height="20" font="4">● The number of antiarrhythmic medications </text>
<text top="263" left="604" width="251" height="20" font="4">decreased from 2.8 ± 1.5–0.7 ± 0.8 (p&lt;0.05). </text>
<text top="177" left="887" width="113" height="20" font="4">● In Fontan pts with </text>
<text top="194" left="887" width="113" height="20" font="4">drug-resistant IART, </text>
<text top="211" left="887" width="106" height="20" font="4">regurgitant fraction </text>
<text top="228" left="887" width="100" height="20" font="4">ablation of the AV </text>
<text top="246" left="887" width="99" height="20" font="4">junction with prior </text>
<text top="263" left="887" width="130" height="20" font="4">pacemaker implant is a </text>
<text top="280" left="887" width="110" height="20" font="4">feasible therapeutic </text>
<text top="297" left="887" width="40" height="20" font="4">option. </text>
<text top="315" left="64" width="80" height="20" font="4">Wong T, et al. </text>
<text top="332" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(679)</a> </text>
<text top="350" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15136502?dopt=Citation">15136502</a></text>
<text top="350" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15136502?dopt=Citation"> </a></text>
<text top="315" left="179" width="76" height="20" font="4">Single-center </text>
<text top="332" left="179" width="85" height="20" font="4">cross-sectional </text>
<text top="350" left="179" width="48" height="20" font="4">analysis </text>
<text top="315" left="280" width="51" height="20" font="4">n=33 pts </text>
<text top="315" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="332" left="361" width="90" height="20" font="4">Fontan surgery; </text>
<text top="350" left="361" width="101" height="20" font="4">follow-up at Royal </text>
<text top="367" left="361" width="101" height="20" font="4">Brompton in 2000 </text>
<text top="315" left="496" width="63" height="20" font="4">Mechanico-</text>
<text top="332" left="496" width="52" height="20" font="4">electrical </text>
<text top="350" left="496" width="66" height="20" font="4">interactions </text>
<text top="315" left="604" width="252" height="20" font="4">● Pts with atrial tachyarrhythmia had longer p-</text>
<text top="332" left="604" width="226" height="20" font="4">wave duration (159 ± 28 vs. 123 ± 28 m; </text>
<text top="350" left="604" width="263" height="20" font="4">p&lt;0.001), greater p-wave dispersion (9 ± 30 vs. </text>
<text top="367" left="604" width="235" height="20" font="4">50 ± 19 m; p&lt;0.001), and larger right atrial </text>
<text top="384" left="604" width="266" height="20" font="4">dimensions (6.4 ± 1.4 vs. 5.0 ± 1.0 cm; p=0.01). </text>
<text top="315" left="887" width="89" height="20" font="4">● Pts with atrial </text>
<text top="332" left="887" width="124" height="20" font="4">tachyarrhythmia s late </text>
<text top="350" left="887" width="125" height="20" font="4">after Fontan operation </text>
<text top="367" left="887" width="111" height="20" font="4">have longer p-wave </text>
<text top="384" left="887" width="115" height="20" font="4">duration and p-wave </text>
<text top="401" left="887" width="118" height="20" font="4">dispersion and larger </text>
<text top="418" left="887" width="117" height="20" font="4">right atrial dimension </text>
<text top="436" left="887" width="103" height="20" font="4">than those without </text>
<text top="453" left="887" width="71" height="20" font="4">arrhythmias. </text>
<text top="471" left="64" width="87" height="20" font="4">Van den Bosch </text>
<text top="488" left="64" width="53" height="20" font="4">AE, et al. </text>
<text top="505" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(680)</a> </text>
<text top="522" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15110207?dopt=Citation">15110207</a></text>
<text top="522" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15110207?dopt=Citation"> </a></text>
<text top="471" left="179" width="76" height="20" font="4">Single-center </text>
<text top="488" left="179" width="74" height="20" font="4">retrospective </text>
<text top="505" left="179" width="70" height="20" font="4">cohort study </text>
<text top="471" left="280" width="51" height="20" font="4">n=36 pts </text>
<text top="471" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="488" left="361" width="104" height="20" font="4">Fontan procedure; </text>
<text top="505" left="361" width="103" height="20" font="4">followed in Thorax </text>
<text top="522" left="361" width="114" height="20" font="4">Center, Netherlands </text>
<text top="471" left="496" width="60" height="20" font="4">Long-term </text>
<text top="488" left="496" width="81" height="20" font="4">outcomes and </text>
<text top="505" left="496" width="29" height="20" font="4">QOL </text>
<text top="471" left="604" width="266" height="20" font="4">● Atrial tachyarrhythmias were observed in 56% </text>
<text top="488" left="604" width="225" height="20" font="4">and were associated with impaired QOL. </text>
<text top="471" left="887" width="44" height="20" font="4">● Atrial </text>
<text top="488" left="887" width="118" height="20" font="4">tachyarrhythmias are </text>
<text top="505" left="887" width="117" height="20" font="4">highly prevalent and, </text>
<text top="522" left="887" width="131" height="20" font="4">along with reoperations </text>
<text top="540" left="887" width="115" height="20" font="4">and thromboembolic </text>
<text top="557" left="887" width="126" height="20" font="4">events, are associated </text>
<text top="574" left="887" width="135" height="20" font="4">with a reduction in QOL. </text>
<text top="592" left="64" width="89" height="20" font="4">Weipert J, et al. </text>
<text top="609" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(681)</a> </text>
<text top="626" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14762355?dopt=Citation">14762355</a></text>
<text top="626" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14762355?dopt=Citation"> </a></text>
<text top="592" left="179" width="76" height="20" font="4">Single-center </text>
<text top="609" left="179" width="74" height="20" font="4">retrospective </text>
<text top="626" left="179" width="70" height="20" font="4">cohort study </text>
<text top="592" left="280" width="58" height="20" font="4">n=162 pts </text>
<text top="592" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="609" left="361" width="104" height="20" font="4">Fontan procedure; </text>
<text top="626" left="361" width="114" height="20" font="4">follow-up at German </text>
<text top="644" left="361" width="120" height="20" font="4">Heart Center, Munich </text>
<text top="592" left="496" width="69" height="20" font="4">Late Fontan </text>
<text top="609" left="496" width="44" height="20" font="4">failure;  </text>
<text top="626" left="496" width="70" height="20" font="4">Incidence of </text>
<text top="644" left="496" width="31" height="20" font="4">IART </text>
<text top="592" left="604" width="265" height="20" font="4">● At 20 y, overall freedom from tachycardia was </text>
<text top="609" left="604" width="247" height="20" font="4">46%. Acute success of catheter ablation was </text>
<text top="626" left="604" width="242" height="20" font="4">(83%; 25 of 30) with freedom from recurrent </text>
<text top="644" left="604" width="148" height="20" font="4">tachycardia of 81% at 3 y.  </text>
<text top="661" left="604" width="248" height="20" font="4">● Duration of Fontan circulation was the only </text>
<text top="678" left="604" width="174" height="20" font="4">independent predictor of IART.  </text>
<text top="592" left="887" width="92" height="20" font="4">● IART is highly </text>
<text top="609" left="887" width="140" height="20" font="4">prevalent and associated </text>
<text top="626" left="887" width="107" height="20" font="4">with duration of the </text>
<text top="644" left="887" width="107" height="20" font="4">Fontan circulation.  </text>
<text top="661" left="887" width="109" height="20" font="4">● Catheter ablation </text>
<text top="678" left="887" width="78" height="20" font="4">outcomes are </text>
<text top="695" left="887" width="119" height="20" font="4">reasonable in Fontan </text>
<text top="712" left="887" width="23" height="20" font="4">pts. </text>
<text top="730" left="64" width="93" height="20" font="4">Davos CH, et al. </text>
<text top="748" left="64" width="63" height="20" font="4">2003 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(682)</a> </text>
<text top="765" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12970229?dopt=Citation">12970229</a></text>
<text top="765" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12970229?dopt=Citation"> </a></text>
<text top="730" left="179" width="76" height="20" font="4">Single-center </text>
<text top="748" left="179" width="85" height="20" font="4">cross-sectional </text>
<text top="765" left="179" width="48" height="20" font="4">analysis </text>
<text top="730" left="280" width="51" height="20" font="4">n=22 pts </text>
<text top="730" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="748" left="361" width="100" height="20" font="4">Fontan operation; </text>
<text top="765" left="361" width="75" height="20" font="4">age- and sex-</text>
<text top="782" left="361" width="97" height="20" font="4">matched controls </text>
<text top="730" left="496" width="58" height="20" font="4">Heart rate </text>
<text top="748" left="496" width="78" height="20" font="4">variability and </text>
<text top="765" left="496" width="58" height="20" font="4">baroreflex </text>
<text top="782" left="496" width="57" height="20" font="4">sensitivity </text>
<text top="730" left="604" width="263" height="20" font="4">● Baroreflex sensitivity and heart rate variability </text>
<text top="748" left="604" width="239" height="20" font="4">were significantly depressed in Fontan pts.  </text>
<text top="730" left="887" width="130" height="20" font="4">● Relative suppression </text>
<text top="748" left="887" width="104" height="20" font="4">of the sympathetic-</text>
<text top="765" left="887" width="104" height="20" font="4">compared with the </text>
<text top="782" left="887" width="137" height="20" font="4">parasympathetic-system </text>
</page>
<page number="184" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 184 </text>
<text top="107" left="604" width="225" height="20" font="4">● Those with a history of sustained atrial </text>
<text top="124" left="604" width="259" height="20" font="4">tachyarrhythmia stronger baroreflex than those </text>
<text top="141" left="604" width="102" height="20" font="4">without (p=0.005). </text>
<text top="107" left="887" width="134" height="20" font="4">was observed in Fontan </text>
<text top="124" left="887" width="27" height="20" font="4">pts.  </text>
<text top="141" left="887" width="134" height="20" font="4">● Stronger baroreflexes </text>
<text top="159" left="887" width="132" height="20" font="4">were seen in those with </text>
<text top="176" left="887" width="86" height="20" font="4">sustained atrial </text>
<text top="193" left="887" width="94" height="20" font="4">tachyarrhythmia, </text>
<text top="210" left="887" width="114" height="20" font="4">implying that SND is </text>
<text top="228" left="887" width="96" height="20" font="4">unlikely to be the </text>
<text top="245" left="887" width="124" height="20" font="4">dominant mechanism. </text>
<text top="263" left="64" width="75" height="20" font="4">Ghai A, et al. </text>
<text top="280" left="64" width="63" height="20" font="4">2001 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(683)</a> </text>
<text top="297" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11216983?dopt=Citation">11216983</a></text>
<text top="297" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11216983?dopt=Citation"> </a></text>
<text top="263" left="179" width="76" height="20" font="4">Single-center </text>
<text top="280" left="179" width="74" height="20" font="4">retrospective </text>
<text top="297" left="179" width="70" height="20" font="4">cohort study </text>
<text top="263" left="280" width="51" height="20" font="4">n=94 pts </text>
<text top="263" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="280" left="361" width="86" height="20" font="4">Fontan surgery </text>
<text top="297" left="361" width="50" height="20" font="4">between </text>
<text top="314" left="361" width="109" height="20" font="4">1977―1994; follow-</text>
<text top="332" left="361" width="115" height="20" font="4">up at Toronto ACHD </text>
<text top="349" left="361" width="38" height="20" font="4">center </text>
<text top="263" left="496" width="78" height="20" font="4">Prevalence of </text>
<text top="280" left="496" width="30" height="20" font="4">atrial </text>
<text top="297" left="496" width="91" height="20" font="4">tachyarrhythmia </text>
<text top="263" left="604" width="196" height="20" font="4">● 39 pts (41%) had sustained atrial </text>
<text top="280" left="604" width="255" height="20" font="4">tachyarrhythmia compared to pts without atrial </text>
<text top="297" left="604" width="183" height="20" font="4">tachyarrhythmia, those with atrial </text>
<text top="314" left="604" width="263" height="20" font="4">tachyarrhythmia were more likely to develop HF </text>
<text top="332" left="604" width="251" height="20" font="4">(46% vs. 13%) and right atrial thrombus (31% </text>
<text top="349" left="604" width="263" height="20" font="4">vs. 4%), exhibit right and left atrial enlargement, </text>
<text top="366" left="604" width="248" height="20" font="4">and have moderate-to-severe systemic valve </text>
<text top="383" left="604" width="155" height="20" font="4">regurgitation (31% vs. 7%).  </text>
<text top="263" left="887" width="135" height="20" font="4">● Atrial tachyarrhythmia </text>
<text top="280" left="887" width="128" height="20" font="4">is highly prevalent post </text>
<text top="297" left="887" width="140" height="20" font="4">Fontan and is associated </text>
<text top="314" left="887" width="66" height="20" font="4">aortic valve </text>
<text top="332" left="887" width="115" height="20" font="4">regurgitation, biatrial </text>
<text top="349" left="887" width="133" height="20" font="4">enlargement, right atrial </text>
<text top="366" left="887" width="105" height="20" font="4">thrombus, and HF. </text>
<text top="401" left="64" width="82" height="20" font="4">Tuzcu V, et al. </text>
<text top="418" left="64" width="66" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(684)</a>  </text>
<text top="436" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10933377?dopt=Citation">10933377</a></text>
<text top="436" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10933377?dopt=Citation"> </a></text>
<text top="401" left="179" width="78" height="20" font="4">Prospective 2-</text>
<text top="418" left="179" width="73" height="20" font="4">group cohort </text>
<text top="436" left="179" width="33" height="20" font="4">study </text>
<text top="401" left="280" width="31" height="20" font="4">n=24 </text>
<text top="418" left="280" width="65" height="20" font="4">Fontan pts; </text>
<text top="436" left="280" width="60" height="20" font="4">15 healthy </text>
<text top="453" left="280" width="50" height="20" font="4">controls  </text>
<text top="401" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="418" left="361" width="114" height="20" font="4">Fontan surgery; age-</text>
<text top="436" left="361" width="94" height="20" font="4">matched healthy </text>
<text top="453" left="361" width="50" height="20" font="4">controls. </text>
<text top="401" left="496" width="80" height="20" font="4">P-wave signal-</text>
<text top="418" left="496" width="85" height="20" font="4">averaged ECG </text>
<text top="436" left="496" width="54" height="20" font="4">and atrial </text>
<text top="453" left="496" width="91" height="20" font="4">tachyarrhythmia </text>
<text top="401" left="604" width="240" height="20" font="4">● Filtered p-wave duration was significantly </text>
<text top="418" left="604" width="265" height="20" font="4">longer in Fontan pts with atrial tachyarrhythmias </text>
<text top="436" left="604" width="231" height="20" font="4">compared to no atrial tachyarrhythmias. A </text>
<text top="453" left="604" width="239" height="20" font="4">filtered p-wave duration cut point of 135 mo </text>
<text top="470" left="604" width="260" height="20" font="4">resulted in a sensitivity of 71% and a specificity </text>
<text top="487" left="604" width="49" height="20" font="4">of 81%.  </text>
<text top="504" left="604" width="253" height="20" font="4">● The p-wave vector integral was significantly </text>
<text top="522" left="604" width="234" height="20" font="4">greater in Fontan pts with and without ATs </text>
<text top="539" left="604" width="130" height="20" font="4">compared with controls </text>
<text top="401" left="887" width="116" height="20" font="4">● Signal-averaged p-</text>
<text top="418" left="887" width="92" height="20" font="4">wave duration is </text>
<text top="436" left="887" width="138" height="20" font="4">significantly prolonged in </text>
<text top="453" left="887" width="139" height="20" font="4">postoperative Fontan pts </text>
<text top="470" left="887" width="124" height="20" font="4">and is associated with </text>
<text top="487" left="887" width="131" height="20" font="4">atrial tachyarrhythmias. </text>
<text top="557" left="64" width="85" height="20" font="4">Betts TR, et al. </text>
<text top="574" left="64" width="66" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(685)</a>  </text>
<text top="591" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10908214?dopt=Citation">10908214</a></text>
<text top="591" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10908214?dopt=Citation"> </a></text>
<text top="557" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="574" left="179" width="74" height="20" font="4">single-center </text>
<text top="591" left="179" width="66" height="20" font="4">case series </text>
<text top="557" left="280" width="44" height="20" font="4">n=6 pts </text>
<text top="557" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="574" left="361" width="90" height="20" font="4">Fontan surgery; </text>
<text top="591" left="361" width="104" height="20" font="4">IART; Referred for </text>
<text top="608" left="361" width="94" height="20" font="4">catheter ablation </text>
<text top="557" left="496" width="83" height="20" font="4">Acute success </text>
<text top="574" left="496" width="62" height="20" font="4">of catheter </text>
<text top="591" left="496" width="79" height="20" font="4">ablation using </text>
<text top="608" left="496" width="64" height="20" font="4">noncontact </text>
<text top="626" left="496" width="46" height="20" font="4">system; </text>
<text top="643" left="496" width="62" height="20" font="4">arrhythmia </text>
<text top="660" left="496" width="66" height="20" font="4">recurrence  </text>
<text top="557" left="604" width="260" height="20" font="4">● Noncontact mapping improved recognition of </text>
<text top="574" left="604" width="233" height="20" font="4">arrhythmia substrates. Acute success was </text>
<text top="591" left="604" width="251" height="20" font="4">achieved in 3 of 5 pts with regurgitant fraction </text>
<text top="608" left="604" width="260" height="20" font="4">ablation. 2 had a recurrence at 6.4 mo of follow-</text>
<text top="626" left="604" width="24" height="20" font="4">up.  </text>
<text top="557" left="887" width="129" height="20" font="4">● Noncontact mapping </text>
<text top="574" left="887" width="127" height="20" font="4">can identify arrhythmia </text>
<text top="591" left="887" width="99" height="20" font="4">circuits and guide </text>
<text top="608" left="887" width="120" height="20" font="4">placement of ablation </text>
<text top="626" left="887" width="49" height="20" font="4">lesions.  </text>
<text top="643" left="887" width="138" height="20" font="4">● Arrhythmia recurrence </text>
<text top="660" left="887" width="42" height="20" font="4">is high. </text>
<text top="678" left="64" width="96" height="20" font="4">Durongpisitkul K, </text>
<text top="695" left="64" width="30" height="20" font="4">et al. </text>
<text top="712" left="64" width="66" height="20" font="4">1998 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#245">(686)</a>  </text>
<text top="730" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9736597?dopt=Citation">9736597</a></text>
<text top="730" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9736597?dopt=Citation"> </a></text>
<text top="678" left="179" width="76" height="20" font="4">Single-center </text>
<text top="695" left="179" width="74" height="20" font="4">retrospective </text>
<text top="712" left="179" width="70" height="20" font="4">cohort study </text>
<text top="678" left="280" width="58" height="20" font="4">n=499 pts </text>
<text top="678" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="695" left="361" width="86" height="20" font="4">Fontan surgery </text>
<text top="712" left="361" width="120" height="20" font="4">between 1985―1993 </text>
<text top="678" left="496" width="60" height="20" font="4">Determine </text>
<text top="695" left="496" width="77" height="20" font="4">prevalence of </text>
<text top="712" left="496" width="56" height="20" font="4">SVA after </text>
<text top="730" left="496" width="86" height="20" font="4">Fontan surgery </text>
<text top="678" left="604" width="265" height="20" font="4">●17% of pts developed SVA by 5 y of follow-up. </text>
<text top="695" left="604" width="265" height="20" font="4">Arrhythmias were associated with older age and </text>
<text top="712" left="604" width="259" height="20" font="4">systemic aortic valve replacement, but not type </text>
<text top="730" left="604" width="59" height="20" font="4">of Fontan. </text>
<text top="678" left="887" width="140" height="20" font="4">● SVA are common after </text>
<text top="695" left="887" width="124" height="20" font="4">Fontan surgery but do </text>
<text top="712" left="887" width="134" height="20" font="4">not appear to be related </text>
<text top="730" left="887" width="96" height="20" font="4">to type of Fontan </text>
<text top="747" left="887" width="62" height="20" font="4">procedure. </text>
</page>
<page number="185" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 185 </text>
<text top="107" left="64" width="94" height="20" font="4">Backer CL, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(687)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23987899?dopt=Citation">23987899</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23987899?dopt=Citation"> </a></text>
<text top="107" left="179" width="75" height="20" font="4">Single center </text>
<text top="107" left="280" width="51" height="20" font="4">n=22 pts </text>
<text top="107" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="361" width="120" height="20" font="4">Transplant in pts with </text>
<text top="141" left="361" width="83" height="20" font="4">Fontan repairs </text>
<text top="107" left="496" width="73" height="20" font="4">Outcomes of </text>
<text top="124" left="496" width="75" height="20" font="4">transplant for </text>
<text top="141" left="496" width="59" height="20" font="4">those with </text>
<text top="159" left="496" width="83" height="20" font="4">Fontan repairs </text>
<text top="107" left="604" width="263" height="20" font="4">● Median age 12.2 y at transplant, interval from </text>
<text top="124" left="604" width="79" height="20" font="4">Fontan, 7.1 y. </text>
<text top="141" left="604" width="225" height="20" font="4">● 5/22 died (23%) early, 1 graft failure, 1 </text>
<text top="159" left="604" width="260" height="20" font="4">pulmonary HTN, 1 infection. Those with PLE or </text>
<text top="176" left="604" width="269" height="20" font="4">plastic bronchitis had complete resolution of their </text>
<text top="193" left="604" width="255" height="20" font="4">symptoms. 1, 5, 10 y survival were 77%, 66%, </text>
<text top="210" left="604" width="28" height="20" font="4">45% </text>
<text top="107" left="887" width="133" height="20" font="4">● Transplantation in pts </text>
<text top="124" left="887" width="125" height="20" font="4">with Fontan repair has </text>
<text top="141" left="887" width="126" height="20" font="4">high mortality, and this </text>
<text top="159" left="887" width="100" height="20" font="4">series is relatively </text>
<text top="176" left="887" width="40" height="20" font="4">young. </text>
<text top="228" left="64" width="86" height="20" font="4">Seddio F, et al. </text>
<text top="245" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(265)</a>  </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22733841">22733841</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22733841"> </a></text>
<text top="228" left="179" width="75" height="20" font="4">Single center </text>
<text top="228" left="280" width="51" height="20" font="4">n=33 pts </text>
<text top="228" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="245" left="361" width="92" height="20" font="4">Mean 7.8 y post-</text>
<text top="263" left="361" width="57" height="20" font="4">transplant </text>
<text top="228" left="496" width="91" height="20" font="4">Risks factors for </text>
<text top="245" left="496" width="45" height="20" font="4">survival </text>
<text top="228" left="604" width="263" height="20" font="4">● PLE and pretransplant mechanical ventilation </text>
<text top="245" left="604" width="267" height="20" font="4">were risk factors for mortality, but transplant was </text>
<text top="263" left="604" width="83" height="20" font="4">also curative.   </text>
<text top="228" left="887" width="126" height="20" font="4">● Data also presented </text>
<text top="245" left="887" width="136" height="20" font="4">for pediatric age groups, </text>
<text top="263" left="887" width="96" height="20" font="4">but not all results </text>
<text top="280" left="887" width="118" height="20" font="4">differentiated by age. </text>
<text top="298" left="64" width="93" height="20" font="4">Gatzoulis MA, et </text>
<text top="315" left="64" width="16" height="20" font="4">al. </text>
<text top="332" left="64" width="63" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(688)</a> </text>
<text top="350" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10618336?dopt=Citation">10618336</a></text>
<text top="350" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10618336?dopt=Citation"> </a></text>
<text top="298" left="179" width="75" height="20" font="4">Single center </text>
<text top="298" left="280" width="51" height="20" font="4">n=50 pts </text>
<text top="298" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="315" left="361" width="96" height="20" font="4">Pts palliated with </text>
<text top="332" left="361" width="101" height="20" font="4">cavopulmonary or </text>
<text top="350" left="361" width="89" height="20" font="4">aortopulmonary </text>
<text top="367" left="361" width="81" height="20" font="4">shunts but not </text>
<text top="384" left="361" width="94" height="20" font="4">Fontan palliated. </text>
<text top="401" left="361" width="110" height="20" font="4">Mean 13 y of follow-</text>
<text top="418" left="361" width="68" height="20" font="4">up at center </text>
<text top="298" left="496" width="77" height="20" font="4">Morbidity and </text>
<text top="315" left="496" width="50" height="20" font="4">mortality </text>
<text top="298" left="604" width="232" height="20" font="4">● Survival was 89% at 10 y, 52% at 20 y.  </text>
<text top="315" left="604" width="224" height="20" font="4">● Arrhythmias were common, mean SpO</text>
<text top="321" left="828" width="4" height="13" font="6">2</text>
<text top="315" left="833" width="35" height="20" font="4"> 82%, </text>
<text top="332" left="604" width="267" height="20" font="4">42% in NYHA II-II, 50% NYHA III. ● Arrhythmias </text>
<text top="350" left="604" width="268" height="20" font="4">and decline in ventricular function more common </text>
<text top="367" left="604" width="155" height="20" font="4">in aortopulmonary shunting. </text>
<text top="298" left="887" width="117" height="20" font="4">● Aortopulmonary or </text>
<text top="315" left="887" width="137" height="20" font="4">cavopulmonary (or both) </text>
<text top="332" left="887" width="115" height="20" font="4">shunts have survival </text>
<text top="350" left="887" width="123" height="20" font="4">comparable to Fontan </text>
<text top="367" left="887" width="46" height="20" font="4">series.   </text>
<text top="384" left="887" width="135" height="20" font="4">● Cavopulmonary shunt </text>
<text top="401" left="887" width="129" height="20" font="4">have a beneficial effect </text>
<text top="418" left="887" width="124" height="20" font="4">on ventricular function </text>
<text top="436" left="887" width="72" height="20" font="4">compared to </text>
<text top="453" left="887" width="132" height="20" font="4">aortopulmonary shunts. </text>
<text top="471" left="64" width="81" height="20" font="4">Dulfer K, et al. </text>
<text top="488" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(689)</a> </text>
<text top="505" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24491873?dopt=Citation">2449187</a></text>
<text top="505" left="112" width="10" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24491873?dopt=Citation">3</a> </text>
<text top="471" left="179" width="29" height="20" font="4">RCT </text>
<text top="471" left="280" width="51" height="20" font="4">n=71 pts </text>
<text top="471" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="488" left="361" width="105" height="20" font="4">Teens with TOF or </text>
<text top="505" left="361" width="104" height="20" font="4">Fontan circulation, </text>
<text top="522" left="361" width="81" height="20" font="4">randomized to </text>
<text top="540" left="361" width="113" height="20" font="4">exercise program or </text>
<text top="557" left="361" width="69" height="20" font="4">usual habits </text>
<text top="471" left="496" width="82" height="20" font="4">Emotional and </text>
<text top="488" left="496" width="60" height="20" font="4">behavioral </text>
<text top="505" left="496" width="70" height="20" font="4">problems as </text>
<text top="522" left="496" width="72" height="20" font="4">assessed by </text>
<text top="540" left="496" width="77" height="20" font="4">questionnaire </text>
<text top="471" left="604" width="237" height="20" font="4">● 3 training sessions, 1 h/wk resulted in no </text>
<text top="488" left="604" width="239" height="20" font="4">significant difference between exercise and </text>
<text top="505" left="604" width="269" height="20" font="4">control groups in behavioral/emotional problems. </text>
<text top="522" left="604" width="262" height="20" font="4">Such problems were infrequent in the groups at </text>
<text top="540" left="604" width="53" height="20" font="4">baseline. </text>
<text top="471" left="887" width="129" height="20" font="4">● Though randomized, </text>
<text top="488" left="887" width="131" height="20" font="4">the study may not have </text>
<text top="505" left="887" width="123" height="20" font="4">selected pts for whom </text>
<text top="522" left="887" width="140" height="20" font="4">the intervention would be </text>
<text top="540" left="887" width="135" height="20" font="4">of benefit and only 71 of </text>
<text top="557" left="887" width="99" height="20" font="4">362 eligible teens </text>
<text top="574" left="887" width="70" height="20" font="4">participated. </text>
<text top="592" left="64" width="89" height="20" font="4">Gamba A, et al. </text>
<text top="609" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(690)</a> </text>
<text top="626" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14762368?dopt=Citation">14762368</a></text>
<text top="626" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14762368?dopt=Citation"> </a></text>
<text top="592" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="609" left="179" width="66" height="20" font="4">case series </text>
<text top="592" left="280" width="51" height="20" font="4">n=14 pts </text>
<text top="592" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="609" left="361" width="72" height="20" font="4">Mean age at </text>
<text top="626" left="361" width="84" height="20" font="4">transplant 17 y </text>
<text top="592" left="496" width="78" height="20" font="4">Mortality after </text>
<text top="609" left="496" width="84" height="20" font="4">transplantation </text>
<text top="626" left="496" width="58" height="20" font="4">in pts with </text>
<text top="644" left="496" width="42" height="20" font="4">Fontan </text>
<text top="661" left="496" width="62" height="20" font="4">physiology </text>
<text top="592" left="604" width="246" height="20" font="4">● 7 pts transplanted for PLE 5 for ventricular </text>
<text top="609" left="604" width="73" height="20" font="4">dysfunction.  </text>
<text top="626" left="604" width="266" height="20" font="4">● 2 hospital deaths, 1 of graft rejection the other </text>
<text top="644" left="604" width="252" height="20" font="4">of a neurologic event. 2 late deaths, 1of acute </text>
<text top="661" left="604" width="258" height="20" font="4">rejection, the other of chronic rejection and IE.  </text>
<text top="678" left="604" width="252" height="20" font="4">● 10 survivors are NYHA class I without PLE. </text>
<text top="592" left="887" width="123" height="20" font="4">● Transplantation is a </text>
<text top="609" left="887" width="121" height="20" font="4">good option for failing </text>
<text top="626" left="887" width="127" height="20" font="4">Fontan’s and results in </text>
<text top="644" left="887" width="132" height="20" font="4">resolution of PLE in this </text>
<text top="661" left="887" width="122" height="20" font="4">relatively small group. </text>
<text top="696" left="64" width="100" height="20" font="4">Jayakumar KA, et </text>
<text top="713" left="64" width="16" height="20" font="4">al. </text>
<text top="730" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(691)</a> </text>
<text top="748" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15542293?dopt=Citation">15542293</a></text>
<text top="748" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15542293?dopt=Citation"> </a></text>
<text top="696" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="713" left="179" width="66" height="20" font="4">case series </text>
<text top="696" left="280" width="51" height="20" font="4">n=35 pts </text>
<text top="696" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="713" left="361" width="72" height="20" font="4">Mean age at </text>
<text top="730" left="361" width="84" height="20" font="4">transplant 15 y </text>
<text top="696" left="496" width="78" height="20" font="4">Mortality after </text>
<text top="713" left="496" width="90" height="20" font="4">transplant in pts </text>
<text top="730" left="496" width="81" height="20" font="4">with Fontan or </text>
<text top="748" left="496" width="70" height="20" font="4">Glenn shunt </text>
<text top="696" left="604" width="259" height="20" font="4">● Mean follow-up 54 mo, 11 pts with Glenn, 24 </text>
<text top="713" left="604" width="74" height="20" font="4">with Fontan.  </text>
<text top="730" left="604" width="259" height="20" font="4">● Indications for transplant included ventricular </text>
<text top="748" left="604" width="250" height="20" font="4">dysfunction, Fontan failure, and cyanosis. 1-y </text>
<text top="765" left="604" width="177" height="20" font="4">survival 71%, 5-y survival 67%.  </text>
<text top="696" left="887" width="138" height="20" font="4">● Transplant in Glenn or </text>
<text top="713" left="887" width="124" height="20" font="4">Fontan pts has similar </text>
<text top="730" left="887" width="95" height="20" font="4">mortality to other </text>
<text top="748" left="887" width="140" height="20" font="4">indications for transplant. </text>
</page>
<page number="186" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 186 </text>
<text top="107" left="604" width="238" height="20" font="4">● Survival not different between Glenn and </text>
<text top="124" left="604" width="65" height="20" font="4">Fontan pts. </text>
<text top="173" left="64" width="90" height="20" font="4">Triedman JK, et </text>
<text top="190" left="64" width="16" height="20" font="4">al. </text>
<text top="208" left="64" width="63" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(692)</a> </text>
<text top="225" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12039499?dopt=Citation">12039499</a></text>
<text top="225" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12039499?dopt=Citation"> </a></text>
<text top="173" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="190" left="179" width="66" height="20" font="4">case series </text>
<text top="173" left="280" width="61" height="20" font="4">n=134 pts, </text>
<text top="190" left="280" width="24" height="20" font="4">177 </text>
<text top="208" left="280" width="65" height="20" font="4">procedures </text>
<text top="173" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="190" left="361" width="100" height="20" font="4">Pts with CHD and </text>
<text top="208" left="361" width="96" height="20" font="4">IART undergoing </text>
<text top="225" left="361" width="46" height="20" font="4">ablation </text>
<text top="173" left="496" width="44" height="20" font="4">Factors </text>
<text top="190" left="496" width="62" height="20" font="4">influencing </text>
<text top="208" left="496" width="70" height="20" font="4">outcomes of </text>
<text top="225" left="496" width="46" height="20" font="4">ablation </text>
<text top="173" left="604" width="231" height="20" font="4">● Acute success associated with irrigated </text>
<text top="190" left="604" width="250" height="20" font="4">ablation and lack of AF. Mean follow-up of 25 </text>
<text top="208" left="604" width="235" height="20" font="4">mo, 42% had recurrence of IART and 28% </text>
<text top="225" left="604" width="135" height="20" font="4">required cardioversion.   </text>
<text top="242" left="604" width="219" height="20" font="4">● Better outcomes seen with higher RA </text>
<text top="259" left="604" width="248" height="20" font="4">saturations, use of electroanatomic mapping, </text>
<text top="276" left="604" width="226" height="20" font="4">fewer IART circuits and acute procedural </text>
<text top="294" left="604" width="51" height="20" font="4">success. </text>
<text top="173" left="887" width="101" height="20" font="4">● IART frequently </text>
<text top="190" left="887" width="134" height="20" font="4">recurs, though this is an </text>
<text top="208" left="887" width="91" height="20" font="4">older series and </text>
<text top="225" left="887" width="117" height="20" font="4">improved technology </text>
<text top="242" left="887" width="131" height="20" font="4">may improve outcomes </text>
<text top="312" left="64" width="79" height="20" font="4">Yap SC, et al. </text>
<text top="329" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(693)</a> </text>
<text top="346" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21029876?dopt=Citation">21029876</a></text>
<text top="346" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21029876?dopt=Citation"> </a></text>
<text top="312" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="329" left="179" width="66" height="20" font="4">case series </text>
<text top="312" left="280" width="58" height="20" font="4">n=130 pts </text>
<text top="329" left="280" width="49" height="20" font="4">with 193 </text>
<text top="346" left="280" width="65" height="20" font="4">procedures </text>
<text top="312" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="329" left="361" width="100" height="20" font="4">Pts with CHD and </text>
<text top="346" left="361" width="96" height="20" font="4">IART undergoing </text>
<text top="363" left="361" width="46" height="20" font="4">ablation </text>
<text top="312" left="496" width="86" height="20" font="4">Acute and long-</text>
<text top="329" left="496" width="85" height="20" font="4">term outcomes </text>
<text top="346" left="496" width="95" height="20" font="4">and predictors of </text>
<text top="363" left="496" width="78" height="20" font="4">IART ablation </text>
<text top="312" left="604" width="255" height="20" font="4">● Mean age 40 y, 69% initially with successful </text>
<text top="329" left="604" width="42" height="20" font="4">IART.   </text>
<text top="346" left="604" width="254" height="20" font="4">● Use of electroanatomic mapping associated </text>
<text top="363" left="604" width="250" height="20" font="4">with successful ablation, Fontan and Mustard </text>
<text top="381" left="604" width="253" height="20" font="4">repairs associated with unsuccessful ablation. </text>
<text top="398" left="604" width="214" height="20" font="4">Median follow-up of 3.7 y in 77 pts had </text>
<text top="415" left="604" width="268" height="20" font="4">recurrence in 48%, cardioversion or reablation in </text>
<text top="432" left="604" width="131" height="20" font="4">42% and death in 4%.   </text>
<text top="449" left="604" width="246" height="20" font="4">● Age and Fontan were risks for recurrence. </text>
<text top="312" left="887" width="103" height="20" font="4">● IART ablation is </text>
<text top="329" left="887" width="136" height="20" font="4">successful in short term, </text>
<text top="346" left="887" width="121" height="20" font="4">but recurs commonly, </text>
<text top="363" left="887" width="126" height="20" font="4">particularly in older pts </text>
<text top="381" left="887" width="124" height="20" font="4">and those with Fontan </text>
<text top="398" left="887" width="44" height="20" font="4">repairs. </text>
<text top="467" left="64" width="91" height="20" font="4">de Groot NM, et </text>
<text top="485" left="64" width="16" height="20" font="4">al. </text>
<text top="502" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(694)</a> </text>
<text top="519" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20194797?dopt=Citation">20194797</a></text>
<text top="519" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20194797?dopt=Citation"> </a></text>
<text top="467" left="179" width="78" height="20" font="4">Retrospective </text>
<text top="485" left="179" width="66" height="20" font="4">case series </text>
<text top="467" left="280" width="51" height="20" font="4">n=53 pts </text>
<text top="467" left="361" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="485" left="361" width="100" height="20" font="4">Pts with CHD and </text>
<text top="502" left="361" width="121" height="20" font="4">atrial tachyarrhythmia </text>
<text top="467" left="496" width="85" height="20" font="4">Characteristics </text>
<text top="485" left="496" width="66" height="20" font="4">of recurrent </text>
<text top="502" left="496" width="30" height="20" font="4">atrial </text>
<text top="519" left="496" width="91" height="20" font="4">tachyarrhythmia </text>
<text top="536" left="496" width="87" height="20" font="4">after ablation in </text>
<text top="553" left="496" width="75" height="20" font="4">pts with CHD </text>
<text top="467" left="604" width="214" height="20" font="4">● Mean age 38 y, mean follow-up 5 y.  </text>
<text top="485" left="604" width="241" height="20" font="4">● AT recurred in 59% in the first y. Different </text>
<text top="502" left="604" width="265" height="20" font="4">arrhythmogenic substrates were found as cause </text>
<text top="519" left="604" width="251" height="20" font="4">of recurrence in majority. 31 pts were in sinus </text>
<text top="536" left="604" width="262" height="20" font="4">rhythm at follow-up, with 57% on antiarrhythmic </text>
<text top="553" left="604" width="73" height="20" font="4">medications. </text>
<text top="467" left="887" width="135" height="20" font="4">● Atrial tachyarrhythmia </text>
<text top="485" left="887" width="122" height="20" font="4">is frequently recurrent </text>
<text top="502" left="887" width="135" height="20" font="4">and cause is not usually </text>
<text top="519" left="887" width="114" height="20" font="4">arrhythmogenicity of </text>
<text top="536" left="887" width="122" height="20" font="4">prior ablative lesions.  </text>
<text top="553" left="887" width="140" height="20" font="4">● Sinus rhythm is able to </text>
<text top="571" left="887" width="100" height="20" font="4">maintain in many, </text>
<text top="588" left="887" width="103" height="20" font="4">though with use of </text>
<text top="605" left="887" width="74" height="20" font="4">antiarrhytmic </text>
<text top="622" left="887" width="116" height="20" font="4">medications in most. </text>
<text top="640" left="54" width="3" height="20" font="3"><b> </b></text>
<text top="657" left="54" width="3" height="20" font="4"> </text>
<text top="674" left="108" width="556" height="24" font="1"><b>Data Supplement 49. Severe Pulmonary Arterial Hypertension – Section 4.4.6.1 </b></text>
<text top="696" left="76" width="78" height="20" font="3"><b>Study Name, </b></text>
<text top="713" left="76" width="77" height="20" font="3"><b>Author, Year </b></text>
<text top="696" left="201" width="38" height="20" font="3"><b>Study </b></text>
<text top="713" left="197" width="44" height="20" font="3"><b>Design </b></text>
<text top="696" left="288" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="696" left="393" width="38" height="20" font="3"><b>Study </b></text>
<text top="713" left="390" width="44" height="20" font="3"><b>Design </b></text>
<text top="696" left="457" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="713" left="493" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="696" left="618" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="696" left="830" width="48" height="20" font="3"><b>Results </b></text>
<text top="696" left="1005" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
</page>
<page number="187" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 187 </text>
<text top="107" left="64" width="83" height="20" font="4">D’Alto M, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#229">(339)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23850317?dopt=Citation">23850317</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23850317?dopt=Citation"> </a></text>
<text top="107" left="179" width="76" height="20" font="4">Single-center </text>
<text top="124" left="179" width="61" height="20" font="4">open-label </text>
<text top="141" left="179" width="38" height="20" font="4">cohort </text>
<text top="107" left="273" width="51" height="20" font="4">n=22 pts </text>
<text top="107" left="381" width="3" height="20" font="4"> </text>
<text top="107" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="455" width="98" height="20" font="4">Presence of PAH </text>
<text top="141" left="455" width="117" height="20" font="4">after closure of ASD, </text>
<text top="159" left="455" width="104" height="20" font="4">VSD, PDA, AVSD, </text>
<text top="176" left="455" width="105" height="20" font="4">with pre- and post- </text>
<text top="193" left="455" width="43" height="20" font="4">closure </text>
<text top="210" left="455" width="86" height="20" font="4">hemodynamics </text>
<text top="107" left="590" width="86" height="20" font="4">Demographics, </text>
<text top="124" left="590" width="86" height="20" font="4">hemodynamics </text>
<text top="141" left="590" width="117" height="20" font="4">(catheterization) pre- </text>
<text top="159" left="590" width="92" height="20" font="4">and post- defect </text>
<text top="176" left="590" width="43" height="20" font="4">closure </text>
<text top="107" left="732" width="218" height="20" font="4">● Mean age at closure 25.3 ± 20.1 y (3 </text>
<text top="124" left="732" width="68" height="20" font="4">mo–56.7 y). </text>
<text top="141" left="732" width="232" height="20" font="4">mean age at PAH diagnosis 37.0 ± 20.8 y </text>
<text top="159" left="732" width="66" height="20" font="4">(5–61.2 y).  </text>
<text top="176" left="732" width="206" height="20" font="4">● At preclosure catheterization 18/22 </text>
<text top="193" left="732" width="222" height="20" font="4">subjects had PVR ≥5 U, 21/22 had PVR </text>
<text top="210" left="732" width="84" height="20" font="4">index ≥6 U × m</text>
<text top="212" left="816" width="4" height="13" font="6">2</text>
<text top="210" left="821" width="114" height="20" font="4">, 21/22 Rp/Rs≥0.33. </text>
<text top="107" left="989" width="146" height="20" font="4">● Preclosure PVR (≥5 U), </text>
<text top="124" left="989" width="117" height="20" font="4">PVR index (≥6 U × m</text>
<text top="126" left="1106" width="4" height="13" font="6">2</text>
<text top="124" left="1110" width="31" height="20" font="4">) and </text>
<text top="141" left="989" width="139" height="20" font="4">Rp/Rs≥0.33 appeared to </text>
<text top="159" left="989" width="156" height="20" font="4">correlate with PAH late after </text>
<text top="176" left="989" width="80" height="20" font="4">shunt closure. </text>
<text top="228" left="64" width="84" height="20" font="4">Barst RJ, et al. </text>
<text top="245" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(695)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24176071?dopt=Citation">24176071</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24176071?dopt=Citation"> </a></text>
<text top="228" left="179" width="64" height="20" font="4">Multicenter </text>
<text top="245" left="179" width="66" height="20" font="4">prospective </text>
<text top="263" left="179" width="44" height="20" font="4">registry </text>
<text top="228" left="273" width="83" height="20" font="4">n=353 pts with </text>
<text top="245" left="273" width="73" height="20" font="4">CHD-PAH of </text>
<text top="263" left="273" width="34" height="20" font="4">1979  </text>
<text top="230" left="381" width="2" height="13" font="6"> </text>
<text top="228" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="245" left="455" width="111" height="20" font="4">New and previously </text>
<text top="263" left="455" width="117" height="20" font="4">defined subjects with </text>
<text top="280" left="455" width="110" height="20" font="4">WHO Group 1 PAH </text>
<text top="297" left="455" width="87" height="20" font="4">(catheterization </text>
<text top="314" left="455" width="96" height="20" font="4">based diagnosis) </text>
<text top="332" left="455" width="91" height="20" font="4">followed at PAH </text>
<text top="349" left="455" width="96" height="20" font="4">treatment centers</text>
<text top="351" left="551" width="2" height="13" font="6"> </text>
<text top="228" left="590" width="108" height="20" font="4">Survival (4 y, 7 y of </text>
<text top="245" left="590" width="57" height="20" font="4">follow-up) </text>
<text top="263" left="590" width="85" height="20" font="4">Secondary EP: </text>
<text top="280" left="590" width="84" height="20" font="4">demographics, </text>
<text top="297" left="590" width="89" height="20" font="4">hemodynamics, </text>
<text top="314" left="590" width="40" height="20" font="4">6MWT </text>
<text top="228" left="732" width="229" height="20" font="4">● Survival was similar between idiopathic </text>
<text top="245" left="732" width="239" height="20" font="4">PAH and CHD associated PAH cohorts (74 </text>
<text top="265" left="732" width="8" height="18" font="4">±</text>
<text top="264" left="740" width="227" height="20" font="4"> 1 vs. 78 ± 4% p=0.69) at 4 y, (55 ± 2 vs. </text>
<text top="282" left="732" width="92" height="20" font="4">70 ± 8% p=0.3). </text>
<text top="299" left="732" width="233" height="20" font="4">● For the CHD associated PAH cohort 4 y </text>
<text top="317" left="732" width="219" height="20" font="4">survival was correlated with (univariate) </text>
<text top="334" left="732" width="232" height="20" font="4">6MWT (HR:0.68 per 100 m; 95% CI: 0.56–</text>
<text top="351" left="732" width="225" height="20" font="4">0.83; p&lt;0.001), lower mean RA pressure </text>
<text top="368" left="732" width="224" height="20" font="4">(HR: 1.09; 95% CI: 1.04–1.14; p&lt;0.001), </text>
<text top="386" left="732" width="228" height="20" font="4">BNP &lt;50 pg/mL (HR&lt;0.28; 95% CI: 0.11–</text>
<text top="403" left="732" width="199" height="20" font="4">0.69; p&lt;0.006), and the presence of </text>
<text top="420" left="732" width="234" height="20" font="4">vasoreactivity at entry catheterization (HR: </text>
<text top="437" left="732" width="212" height="20" font="4">0.33; 95%CI: 0.11–0.98; p&lt;0.046) and </text>
<text top="454" left="732" width="224" height="20" font="4">(multivariate) age at diagnosis (HR: 1.11 </text>
<text top="472" left="732" width="230" height="20" font="4">per 5 y; 95% CI: 1.04–1.18; p&lt;0.002) and </text>
<text top="489" left="732" width="212" height="20" font="4">mean RA pressure (HR: 1.05; 95% CI: </text>
<text top="506" left="732" width="117" height="20" font="4">1.00–1.10; p&lt;0.042). </text>
<text top="228" left="989" width="146" height="20" font="4">● CHD associated PAH in </text>
<text top="245" left="989" width="143" height="20" font="4">subjects cared for at PAH </text>
<text top="263" left="989" width="139" height="20" font="4">treatment centers carries </text>
<text top="280" left="989" width="155" height="20" font="4">similarly profound diagnosis </text>
<text top="297" left="989" width="104" height="20" font="4">as idiopathic PAH. </text>
<text top="314" left="989" width="150" height="20" font="4">● Time from diagnosis and </text>
<text top="332" left="989" width="140" height="20" font="4">higher RA pressure carry </text>
<text top="349" left="989" width="152" height="20" font="4">worse long-term prognosis. </text>
<text top="524" left="64" width="98" height="20" font="4">Duffels MG, et al. </text>
<text top="541" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(696)</a> </text>
<text top="558" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17182132?dopt=Citation">17182132</a></text>
<text top="558" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17182132?dopt=Citation"> </a></text>
<text top="524" left="179" width="64" height="20" font="4">Multicenter </text>
<text top="541" left="179" width="74" height="20" font="4">retrospective </text>
<text top="558" left="179" width="44" height="20" font="4">registry </text>
<text top="524" left="273" width="63" height="20" font="4">n=112 with </text>
<text top="541" left="273" width="73" height="20" font="4">CHD-PAH of </text>
<text top="558" left="273" width="34" height="20" font="4">5,970 </text>
<text top="524" left="381" width="3" height="20" font="4"> </text>
<text top="524" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="541" left="455" width="105" height="20" font="4">Echocardiographic </text>
<text top="558" left="455" width="117" height="20" font="4">estimation of systolic </text>
<text top="576" left="455" width="96" height="20" font="4">PAP ≥40 mm Hg </text>
<text top="524" left="590" width="86" height="20" font="4">Demographics, </text>
<text top="541" left="590" width="90" height="20" font="4">prevalence, FC  </text>
<text top="524" left="732" width="224" height="20" font="4">● PAH prevalence by echo estimation of </text>
<text top="541" left="732" width="225" height="20" font="4">PAP was 4.2%. Of subjects with a septal </text>
<text top="558" left="732" width="212" height="20" font="4">defect 6.1% had PAH; of subjects with </text>
<text top="576" left="732" width="219" height="20" font="4">previously closed septal defect, 3% had </text>
<text top="593" left="732" width="39" height="20" font="4">PAH.   </text>
<text top="610" left="732" width="240" height="20" font="4">● Female sex (OR=1.5; p=0.001) and echo </text>
<text top="627" left="732" width="214" height="20" font="4">estimation of PAP (OR=0.04; p=0.001) </text>
<text top="644" left="732" width="202" height="20" font="4">were associated with decreased FC. </text>
<text top="524" left="989" width="170" height="20" font="4">● PAH occurs with reasonable </text>
<text top="541" left="989" width="162" height="20" font="4">frequency in adults with CHD </text>
<text top="558" left="989" width="70" height="20" font="4">and shunts.  </text>
<text top="576" left="989" width="149" height="20" font="4">● Decreased FC may be a </text>
<text top="593" left="989" width="129" height="20" font="4">marker for higher PAP. </text>
</page>
<page number="188" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 188 </text>
<text top="107" left="64" width="94" height="20" font="4">Engelfriet PM, et </text>
<text top="124" left="64" width="16" height="20" font="4">al. </text>
<text top="141" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(697)</a> </text>
<text top="159" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17164490?dopt=Citation">17164490</a></text>
<text top="159" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17164490?dopt=Citation"> </a></text>
<text top="107" left="179" width="64" height="20" font="4">Multicenter </text>
<text top="124" left="179" width="74" height="20" font="4">retrospective </text>
<text top="141" left="179" width="44" height="20" font="4">registry </text>
<text top="107" left="273" width="68" height="20" font="4">n=1,877 pts </text>
<text top="107" left="381" width="3" height="20" font="4"> </text>
<text top="107" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="455" width="94" height="20" font="4">All pts with ASD, </text>
<text top="141" left="455" width="105" height="20" font="4">VSD, cyanotic HD; </text>
<text top="159" left="455" width="107" height="20" font="4">PAH defined either </text>
<text top="176" left="455" width="100" height="20" font="4">by catheterization </text>
<text top="193" left="455" width="121" height="20" font="4">systolic PAP ≥25 mm </text>
<text top="210" left="455" width="116" height="20" font="4">or echocardiography </text>
<text top="228" left="455" width="121" height="20" font="4">systolic PAP ≥35 mm </text>
<text top="107" left="590" width="86" height="20" font="4">Demographics, </text>
<text top="124" left="590" width="111" height="20" font="4">prevalence, FC, RV </text>
<text top="141" left="590" width="106" height="20" font="4">contractile function </text>
<text top="159" left="590" width="90" height="20" font="4">(echo), survival  </text>
<text top="107" left="732" width="226" height="20" font="4">● Open defects: 34% with ASD and 28% </text>
<text top="124" left="732" width="110" height="20" font="4">with VSD had PAH. </text>
<text top="141" left="732" width="228" height="20" font="4">● Closed defect, 12% with ASD and 13% </text>
<text top="159" left="732" width="110" height="20" font="4">with VSD had PAH. </text>
<text top="176" left="732" width="197" height="20" font="4">● 5-y survival with vs. without PAH: </text>
<text top="193" left="732" width="241" height="20" font="4">  closed ASD: 94.8% vs. 98.4%, (p=0.036);  </text>
<text top="210" left="732" width="225" height="20" font="4">  open ASD: 97.2% vs. 99.6% (p=0.118); </text>
<text top="228" left="732" width="234" height="20" font="4">  closed VSD: 93.1% vs. 99.1% (p=0.021); </text>
<text top="245" left="732" width="225" height="20" font="4">  open VSD: 96.7% vs. 98.7% (p=0.299). </text>
<text top="262" left="732" width="226" height="20" font="4">● Each increase in systolic PAP of 1 mm </text>
<text top="279" left="732" width="194" height="20" font="4">Hg, increased the probability of RV </text>
<text top="296" left="732" width="226" height="20" font="4">dysfunction by a factor of 1.073 (95% CI: </text>
<text top="314" left="732" width="131" height="20" font="4">1.045–1.102; p=0.001). </text>
<text top="107" left="989" width="146" height="20" font="4">● CHD associated PAH in </text>
<text top="124" left="989" width="158" height="20" font="4">subjects with open or closed </text>
<text top="141" left="989" width="145" height="20" font="4">septal defects cared for at </text>
<text top="159" left="989" width="137" height="20" font="4">ACHD treatment centers </text>
<text top="176" left="989" width="149" height="20" font="4">appear to carry less mortal </text>
<text top="193" left="989" width="161" height="20" font="4">prognosis than expected in 5-</text>
<text top="210" left="989" width="133" height="20" font="4">y follow-up. Incremental </text>
<text top="228" left="989" width="150" height="20" font="4">elevation of systolic PAP is </text>
<text top="245" left="989" width="165" height="20" font="4">associated with worsened RV </text>
<text top="262" left="989" width="94" height="20" font="4">systolic function. </text>
<text top="332" left="64" width="95" height="20" font="4">Gabriels C, et al. </text>
<text top="349" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(698)</a> </text>
<text top="366" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25149406?dopt=Citation">25149406</a></text>
<text top="366" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25149406?dopt=Citation"> </a></text>
<text top="332" left="179" width="64" height="20" font="4">Multicenter </text>
<text top="349" left="179" width="74" height="20" font="4">retrospective </text>
<text top="366" left="179" width="44" height="20" font="4">registry </text>
<text top="332" left="273" width="76" height="20" font="4">n=47 pts with </text>
<text top="349" left="273" width="66" height="20" font="4">PAH of 295 </text>
<text top="332" left="381" width="3" height="20" font="4"> </text>
<text top="332" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="349" left="455" width="91" height="20" font="4">All subjects with </text>
<text top="366" left="455" width="113" height="20" font="4">ASD; PH defined by </text>
<text top="383" left="455" width="120" height="20" font="4">TR velocity ≥2.9 m/s. </text>
<text top="332" left="590" width="86" height="20" font="4">Demographics, </text>
<text top="349" left="590" width="126" height="20" font="4">hemodynamics at past </text>
<text top="366" left="590" width="93" height="20" font="4">catheterizations, </text>
<text top="383" left="590" width="104" height="20" font="4">echocardiographic </text>
<text top="400" left="590" width="128" height="20" font="4">estimate of TR velocity </text>
<text top="418" left="590" width="88" height="20" font="4">and RV systolic </text>
<text top="435" left="590" width="80" height="20" font="4">function, atrial </text>
<text top="452" left="590" width="62" height="20" font="4">arrhythmia </text>
<text top="332" left="732" width="237" height="20" font="4">● PH prevalence was 15.9% in all subjects </text>
<text top="349" left="732" width="212" height="20" font="4">with open or closed ASD, vs. 13.3% in </text>
<text top="366" left="732" width="152" height="20" font="4">subjects after ASD closure. </text>
<text top="383" left="732" width="242" height="20" font="4">● Mean PAP at catheterization prior to ASD </text>
<text top="400" left="732" width="243" height="20" font="4">closure was related to PH after closure (HR: </text>
<text top="418" left="732" width="35" height="20" font="4">1.09). </text>
<text top="435" left="732" width="224" height="20" font="4">● Age at ASD closure was related to PH </text>
<text top="452" left="732" width="135" height="20" font="4">after closure (HR: 1.11). </text>
<text top="469" left="732" width="213" height="20" font="4">● PH after ASD closure was related to </text>
<text top="487" left="732" width="201" height="20" font="4">mortality (p=0.001), atrial arrhythmia </text>
<text top="504" left="732" width="187" height="20" font="4">(p&lt;0.001) and right HF (p=0.019). </text>
<text top="332" left="989" width="129" height="20" font="4">● PH as defined by TR </text>
<text top="349" left="989" width="141" height="20" font="4">velocity elevation may be </text>
<text top="366" left="989" width="163" height="20" font="4">more common than expected </text>
<text top="383" left="989" width="154" height="20" font="4">in adults with ASD, whether </text>
<text top="400" left="989" width="91" height="20" font="4">open or closed.  </text>
<text top="418" left="989" width="147" height="20" font="4">● Age at ASD closure and </text>
<text top="435" left="989" width="145" height="20" font="4">mean PAP at time of ASD </text>
<text top="452" left="989" width="165" height="20" font="4">closure may be related to late </text>
<text top="469" left="989" width="163" height="20" font="4">presence of PH after closure. </text>
<text top="522" left="64" width="86" height="20" font="4">Lowe BS, et al. </text>
<text top="539" left="64" width="56" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(27)</a> </text>
<text top="556" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21777753?dopt=Citation">21777753</a></text>
<text top="556" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21777753?dopt=Citation"> </a></text>
<text top="522" left="179" width="57" height="20" font="4">Provincial </text>
<text top="539" left="179" width="79" height="20" font="4">administrative </text>
<text top="556" left="179" width="74" height="20" font="4">retrospective </text>
<text top="573" left="179" width="47" height="20" font="4">registry: </text>
<text top="591" left="179" width="65" height="20" font="4">longitudinal </text>
<text top="608" left="179" width="38" height="20" font="4">cohort </text>
<text top="625" left="179" width="66" height="20" font="4">multivariate </text>
<text top="642" left="179" width="48" height="20" font="4">analysis </text>
<text top="659" left="179" width="67" height="20" font="4">matched by </text>
<text top="677" left="179" width="78" height="20" font="4">age and CHD </text>
<text top="694" left="179" width="62" height="20" font="4">lesion type </text>
<text top="522" left="273" width="90" height="20" font="4">n=2212 pts with </text>
<text top="539" left="273" width="68" height="20" font="4">PH of 3,843 </text>
<text top="522" left="381" width="3" height="20" font="4"> </text>
<text top="522" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="539" left="455" width="80" height="20" font="4">PH defined by </text>
<text top="556" left="455" width="99" height="20" font="4">treating physician </text>
<text top="573" left="455" width="64" height="20" font="4">specialists. </text>
<text top="522" left="590" width="113" height="20" font="4">Mortality, HF, health </text>
<text top="539" left="590" width="109" height="20" font="4">resource utilization: </text>
<text top="556" left="590" width="80" height="20" font="4">23-y follow-up </text>
<text top="522" left="732" width="40" height="20" font="4">● PH:  </text>
<text top="539" left="732" width="222" height="20" font="4">- All-cause mortality was increased (HR: </text>
<text top="556" left="732" width="195" height="20" font="4">2.69; 95% CI: 2.41–2.99). - HF and </text>
<text top="573" left="732" width="219" height="20" font="4">arrhythmia burden were increased (HR: </text>
<text top="591" left="732" width="140" height="20" font="4">3.01; 95% CI: 2.80–3.22) </text>
<text top="608" left="732" width="218" height="20" font="4">- Overall health resource utilization was </text>
<text top="625" left="732" width="226" height="20" font="4">increased (RR: 5.04; 95% CI: 4.27–5.93) </text>
<text top="642" left="732" width="165" height="20" font="4">- Coronary and intensive care </text>
<text top="659" left="732" width="230" height="20" font="4">hospitalizations were increased (RR 5.03; </text>
<text top="677" left="732" width="113" height="20" font="4">95% CI: 4.86–5.20). </text>
<text top="522" left="989" width="100" height="20" font="4">● Clinician-based </text>
<text top="539" left="989" width="163" height="20" font="4">categorization of PH in adults </text>
<text top="556" left="989" width="165" height="20" font="4">with CHD raises use of health </text>
<text top="573" left="989" width="147" height="20" font="4">resources, risks of HF and </text>
<text top="591" left="989" width="138" height="20" font="4">arrhythmia and all-cause </text>
<text top="608" left="989" width="53" height="20" font="4">mortality. </text>
</page>
<page number="189" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 189 </text>
<text top="107" left="64" width="85" height="20" font="4">Manes A, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(699)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23455361?dopt=Citation">23455361</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23455361?dopt=Citation"> </a></text>
<text top="107" left="179" width="76" height="20" font="4">Single-center </text>
<text top="124" left="179" width="74" height="20" font="4">retrospective </text>
<text top="141" left="179" width="38" height="20" font="4">cohort </text>
<text top="107" left="273" width="58" height="20" font="4">n=192 pts </text>
<text top="107" left="381" width="3" height="20" font="4"> </text>
<text top="107" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="455" width="111" height="20" font="4">Presence of current </text>
<text top="141" left="455" width="117" height="20" font="4">or repaired CHD and </text>
<text top="159" left="455" width="120" height="20" font="4">catheterization based </text>
<text top="176" left="455" width="29" height="20" font="4">PAH </text>
<text top="107" left="590" width="86" height="20" font="4">Demographics, </text>
<text top="124" left="590" width="127" height="20" font="4">hemodynamics, FC,1-, </text>
<text top="141" left="590" width="94" height="20" font="4">5-, 10-, and 20-y </text>
<text top="159" left="590" width="45" height="20" font="4">survival </text>
<text top="107" left="732" width="206" height="20" font="4">● Overall population, 1-, 5-, 10-, 20-y </text>
<text top="124" left="732" width="221" height="20" font="4">survival rates (95% CI) were 99% (96%–</text>
<text top="141" left="732" width="241" height="20" font="4">100%), 91% (85%–94%), 85% (78%–90%), </text>
<text top="159" left="732" width="123" height="20" font="4">and 77% (68%–84%). </text>
<text top="176" left="732" width="239" height="20" font="4">● Eisenmenger Syndrome, 1-, 5-, 10-, 20-y </text>
<text top="193" left="732" width="240" height="20" font="4">survival rates were 99% (92%–100%), 93% </text>
<text top="210" left="732" width="222" height="20" font="4">(85%–97%), 89% (79%–94%), and 87% </text>
<text top="228" left="732" width="71" height="20" font="4">(77%–93%). </text>
<text top="245" left="732" width="195" height="20" font="4">● PAH associated with systemic-to-</text>
<text top="262" left="732" width="237" height="20" font="4">pulmonary shunts, 1-, 5-, 10-, 20-y survival </text>
<text top="279" left="732" width="226" height="20" font="4">rates were 100%, 93% (76%–98%), 93% </text>
<text top="296" left="732" width="194" height="20" font="4">(76%–99%), and 86% (60%–96%). </text>
<text top="314" left="732" width="243" height="20" font="4">● PAH associated with small defects, 1-, 5-, </text>
<text top="331" left="732" width="221" height="20" font="4">10-,15-y survival rates were 100%, 88% </text>
<text top="348" left="732" width="215" height="20" font="4">(39%–98%), 8% (39%–98%), and 66% </text>
<text top="365" left="732" width="143" height="20" font="4">(16%–91%), respectively. </text>
<text top="382" left="732" width="228" height="20" font="4">● PAH after cardiac defect correction, 1-, </text>
<text top="400" left="732" width="239" height="20" font="4">5-, 10-, 20-y survival rates were 98% (85%–</text>
<text top="417" left="732" width="241" height="20" font="4">100%), 83% (66%–92%), 65% (43%–80%), </text>
<text top="434" left="732" width="123" height="20" font="4">and 36% (12%–62%). </text>
<text top="107" left="989" width="116" height="20" font="4">● Pts with PAH after </text>
<text top="124" left="989" width="163" height="20" font="4">congenital heart defect repair </text>
<text top="141" left="989" width="165" height="20" font="4">may have worse survival than </text>
<text top="159" left="989" width="141" height="20" font="4">subjects who remain with </text>
<text top="176" left="989" width="114" height="20" font="4">open septal defects. </text>
<text top="452" left="64" width="87" height="20" font="4">O’Donnell C, et </text>
<text top="469" left="64" width="16" height="20" font="4">al. </text>
<text top="487" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(700)</a> </text>
<text top="504" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20869312?dopt=Citation">20869312</a></text>
<text top="504" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20869312?dopt=Citation"> </a></text>
<text top="452" left="179" width="76" height="20" font="4">Single-center </text>
<text top="469" left="179" width="61" height="20" font="4">open-label </text>
<text top="487" left="179" width="74" height="20" font="4">retrospective </text>
<text top="504" left="179" width="38" height="20" font="4">cohort </text>
<text top="452" left="273" width="51" height="20" font="4">n=11 pts </text>
<text top="452" left="381" width="3" height="20" font="4"> </text>
<text top="452" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="469" left="455" width="110" height="20" font="4">Mean PAP &gt;30 mm </text>
<text top="487" left="455" width="83" height="20" font="4">at time of ASD </text>
<text top="504" left="455" width="43" height="20" font="4">closure </text>
<text top="452" left="590" width="70" height="20" font="4">Survival, FC </text>
<text top="469" left="590" width="96" height="20" font="4">symptomatic HF, </text>
<text top="487" left="590" width="124" height="20" font="4">echocardiographic TR </text>
<text top="504" left="590" width="44" height="20" font="4">velocity </text>
<text top="452" left="732" width="207" height="20" font="4">● 8/11 post closure with symptomatic </text>
<text top="469" left="732" width="183" height="20" font="4">improvement with no evidence of </text>
<text top="487" left="732" width="192" height="20" font="4">progressive PH. 1/11 with death of </text>
<text top="504" left="732" width="241" height="20" font="4">unrelated causes. 2/11 with progressive PH </text>
<text top="521" left="732" width="194" height="20" font="4">with ½ deaths associated with PH.  </text>
<text top="538" left="732" width="236" height="20" font="4">● Recurrent PH appeared to correlate with </text>
<text top="555" left="732" width="216" height="20" font="4">lesser Qp/Qs at time of catheterization. </text>
<text top="452" left="989" width="154" height="20" font="4">● Pts with PH at the time of </text>
<text top="469" left="989" width="129" height="20" font="4">ASD closure may be at </text>
<text top="487" left="989" width="124" height="20" font="4">increased risk for later </text>
<text top="504" left="989" width="168" height="20" font="4">development of PH and worse </text>
<text top="521" left="989" width="154" height="20" font="4">outcome after ASD closure. </text>
<text top="573" left="64" width="92" height="20" font="4">Van de Bruaene </text>
<text top="591" left="64" width="45" height="20" font="4">A, et al. </text>
<text top="608" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(701)</a> </text>
<text top="625" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20674051?dopt=Citation">20674051</a></text>
<text top="625" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20674051?dopt=Citation"> </a></text>
<text top="573" left="179" width="64" height="20" font="4">Multicenter </text>
<text top="591" left="179" width="74" height="20" font="4">retrospective </text>
<text top="608" left="179" width="61" height="20" font="4">open-label </text>
<text top="625" left="179" width="70" height="20" font="4">case control </text>
<text top="573" left="273" width="79" height="20" font="4">n=155 pts (24 </text>
<text top="591" left="273" width="92" height="20" font="4">surgical closure, </text>
<text top="608" left="273" width="24" height="20" font="4">131 </text>
<text top="625" left="273" width="75" height="20" font="4">transcatheter </text>
<text top="642" left="273" width="47" height="20" font="4">closure) </text>
<text top="573" left="381" width="3" height="20" font="4"> </text>
<text top="573" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="591" left="455" width="115" height="20" font="4">ASD closure, clinical </text>
<text top="608" left="455" width="96" height="20" font="4">presentation with </text>
<text top="625" left="455" width="92" height="20" font="4">atrial arrhythmia </text>
<text top="642" left="455" width="90" height="20" font="4">during follow-up </text>
<text top="573" left="590" width="86" height="20" font="4">Demographics, </text>
<text top="591" left="590" width="126" height="20" font="4">hemodynamics at time </text>
<text top="608" left="590" width="89" height="20" font="4">of ASD closure, </text>
<text top="625" left="590" width="102" height="20" font="4">clinical arrhythmia </text>
<text top="642" left="590" width="95" height="20" font="4">within 5 y of post </text>
<text top="659" left="590" width="96" height="20" font="4">closure follow-up </text>
<text top="573" left="732" width="206" height="20" font="4">● 25.2% of subjects undergoing ASD </text>
<text top="591" left="732" width="233" height="20" font="4">closure developed atrial arrhythmia &gt;1 mo </text>
<text top="608" left="732" width="75" height="20" font="4">after closure. </text>
<text top="625" left="732" width="235" height="20" font="4">● Univariate risks for development of atrial </text>
<text top="642" left="732" width="238" height="20" font="4">arrhythmia were male (p=0.008), creatinine </text>
<text top="659" left="732" width="203" height="20" font="4">(p=0.002), atrial arrhythmia either for </text>
<text top="677" left="732" width="238" height="20" font="4">closure (p&lt;0.0001) or during the 1 mo after </text>
<text top="694" left="732" width="242" height="20" font="4">closure (p=0.001), and mean PAP) ≥25 mm </text>
<text top="711" left="732" width="89" height="20" font="4">Hg (p&lt;0.0001).  </text>
<text top="728" left="732" width="243" height="20" font="4">● Multivariate risks for development of atrial </text>
<text top="745" left="732" width="237" height="20" font="4">arrhythmia were mean PAP ≥25 mm at the </text>
<text top="763" left="732" width="204" height="20" font="4">time of closure (HR: 3.72; 1.82–7.59; </text>
<text top="780" left="732" width="236" height="20" font="4">p&lt;0.0001) and either the presence of atrial </text>
<text top="573" left="989" width="163" height="20" font="4">● Presence of PH at the time </text>
<text top="591" left="989" width="163" height="20" font="4">of ASD closure may correlate </text>
<text top="608" left="989" width="166" height="20" font="4">with late development of atrial </text>
<text top="625" left="989" width="65" height="20" font="4">arrhythmia. </text>
</page>
<page number="190" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 190 </text>
<text top="107" left="732" width="236" height="20" font="4">arrhythmia prior to closure (HR: 3.22; 1.56–</text>
<text top="124" left="732" width="214" height="20" font="4">6.66; p=0.002) or during the 1 mo after </text>
<text top="141" left="732" width="227" height="20" font="4">closure (HR: 2.08; 2.08–15.92; p=0.001). </text>
<text top="234" left="64" width="92" height="20" font="4">Van de Bruaene </text>
<text top="251" left="64" width="45" height="20" font="4">A, et al. </text>
<text top="268" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(702)</a> </text>
<text top="286" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21802750?dopt=Citation">21802750</a></text>
<text top="286" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21802750?dopt=Citation"> </a></text>
<text top="234" left="179" width="64" height="20" font="4">Multicenter </text>
<text top="251" left="179" width="74" height="20" font="4">retrospective </text>
<text top="268" left="179" width="61" height="20" font="4">open-label </text>
<text top="286" left="179" width="73" height="20" font="4">case control: </text>
<text top="303" left="179" width="25" height="20" font="4">Cox </text>
<text top="320" left="179" width="75" height="20" font="4">regression to </text>
<text top="337" left="179" width="47" height="20" font="4">define a </text>
<text top="354" left="179" width="66" height="20" font="4">multivariate </text>
<text top="372" left="179" width="75" height="20" font="4">weighted risk </text>
<text top="389" left="179" width="37" height="20" font="4">model </text>
<text top="234" left="273" width="79" height="20" font="4">n=155 pts (24 </text>
<text top="251" left="273" width="92" height="20" font="4">surgical closure, </text>
<text top="268" left="273" width="24" height="20" font="4">131 </text>
<text top="286" left="273" width="75" height="20" font="4">transcatheter </text>
<text top="303" left="273" width="47" height="20" font="4">closure) </text>
<text top="234" left="381" width="3" height="20" font="4"> </text>
<text top="234" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="251" left="455" width="115" height="20" font="4">ASD closure, clinical </text>
<text top="268" left="455" width="96" height="20" font="4">presentation with </text>
<text top="286" left="455" width="92" height="20" font="4">atrial arrhythmia </text>
<text top="303" left="455" width="90" height="20" font="4">during follow-up </text>
<text top="234" left="590" width="86" height="20" font="4">Demographics, </text>
<text top="251" left="590" width="126" height="20" font="4">hemodynamics at time </text>
<text top="268" left="590" width="89" height="20" font="4">of ASD closure, </text>
<text top="286" left="590" width="102" height="20" font="4">clinical arrhythmia </text>
<text top="303" left="590" width="95" height="20" font="4">within 5 y of post </text>
<text top="320" left="590" width="96" height="20" font="4">closure follow-up </text>
<text top="234" left="732" width="243" height="20" font="4">● Multivariate risks for development of atrial </text>
<text top="251" left="732" width="243" height="20" font="4">arrhythmia were mean PAP ≥25 mm at time </text>
<text top="268" left="732" width="241" height="20" font="4">of closure (HR: 4.39; 2.17–9.09; p&lt;0.0001), </text>
<text top="286" left="732" width="238" height="20" font="4">and either the presence of atrial arrhythmia </text>
<text top="303" left="732" width="206" height="20" font="4">prior to closure (HR: 3.52; 1.75–7.14; </text>
<text top="320" left="732" width="227" height="20" font="4">p=0.002) or during the 1 mo after closure </text>
<text top="337" left="732" width="214" height="20" font="4">(HR: 6.62; 2.38–20.00; p&lt;0.0001), and </text>
<text top="354" left="732" width="155" height="20" font="4">male (HR: 2.18; 1.11–4.35). </text>
<text top="372" left="732" width="242" height="20" font="4">● A points system was developed to predict </text>
<text top="389" left="732" width="233" height="20" font="4">the risk for developing atrial arrhythmia &gt;1 </text>
<text top="406" left="732" width="239" height="20" font="4">mo after ASD repair and at 1, 2, 3, 4, and 5-</text>
<text top="423" left="732" width="242" height="20" font="4">y (integrated Brier score 0.10 with R²: 0.41). </text>
<text top="234" left="989" width="163" height="20" font="4">● Presence of PH at the time </text>
<text top="251" left="989" width="163" height="20" font="4">of ASD closure may correlate </text>
<text top="268" left="989" width="166" height="20" font="4">with late development of atrial </text>
<text top="286" left="989" width="65" height="20" font="4">arrhythmia. </text>
<text top="441" left="64" width="90" height="20" font="4">Balint OH, et al. </text>
<text top="458" left="64" width="63" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(703)</a> </text>
<text top="476" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17932093?dopt=Citation">17932093</a></text>
<text top="476" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17932093?dopt=Citation"> </a></text>
<text top="441" left="179" width="76" height="20" font="4">Single-center </text>
<text top="458" left="179" width="74" height="20" font="4">retrospective </text>
<text top="476" left="179" width="61" height="20" font="4">open-label </text>
<text top="493" left="179" width="38" height="20" font="4">cohort </text>
<text top="441" left="273" width="83" height="20" font="4">n=54 pts (11% </text>
<text top="458" left="273" width="66" height="20" font="4">of all adults </text>
<text top="476" left="273" width="93" height="20" font="4">referred for ASD </text>
<text top="493" left="273" width="47" height="20" font="4">closure) </text>
<text top="441" left="381" width="3" height="20" font="4"> </text>
<text top="441" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="458" left="455" width="97" height="20" font="4">Moderate (50–59 </text>
<text top="476" left="455" width="112" height="20" font="4">mm) or severe (≥60 </text>
<text top="493" left="455" width="95" height="20" font="4">mm) PH by echo </text>
<text top="510" left="455" width="85" height="20" font="4">determined TR </text>
<text top="527" left="455" width="86" height="20" font="4">velocity prior to </text>
<text top="545" left="455" width="104" height="20" font="4">transcatheter ASD </text>
<text top="562" left="455" width="43" height="20" font="4">closure </text>
<text top="441" left="590" width="86" height="20" font="4">Demographics, </text>
<text top="458" left="590" width="124" height="20" font="4">echocardiographic TR </text>
<text top="476" left="590" width="119" height="20" font="4">velocity, measures of </text>
<text top="493" left="590" width="64" height="20" font="4">RV systolic </text>
<text top="510" left="590" width="127" height="20" font="4">dysfunction, subjective </text>
<text top="527" left="590" width="68" height="20" font="4">FC, survival </text>
<text top="442" left="732" width="135" height="20" font="4">● 31 ± 15 mo follow-up. </text>
<text top="460" left="732" width="234" height="20" font="4">● RV systolic pressure decreased from 58 </text>
<text top="479" left="732" width="8" height="18" font="4">±</text>
<text top="478" left="740" width="212" height="20" font="4"> 10 mm to 44 ± 16 mm (p=0.004), and </text>
<text top="495" left="732" width="223" height="20" font="4">were not related to duration of follow-up; </text>
<text top="512" left="732" width="232" height="20" font="4">only 44% had normalization of RV systolic </text>
<text top="530" left="732" width="55" height="20" font="4">pressure. </text>
<text top="547" left="732" width="237" height="20" font="4">● While NYHA class decreased regardless </text>
<text top="564" left="732" width="209" height="20" font="4">of pre- and postprocedure RV systolic </text>
<text top="581" left="732" width="232" height="20" font="4">pressure, subjects with residual PH by RV </text>
<text top="598" left="732" width="214" height="20" font="4">systolic pressure were more frequently </text>
<text top="616" left="732" width="234" height="20" font="4">symptomatic after device closure (15% vs. </text>
<text top="633" left="732" width="80" height="20" font="4">67%; p=0.02). </text>
<text top="650" left="732" width="223" height="20" font="4">● RV dilation and subjectively described </text>
<text top="667" left="732" width="198" height="20" font="4">systolic dysfunction decreased from </text>
<text top="685" left="732" width="241" height="20" font="4">presence in 96% and 41% to 36% and 23% </text>
<text top="702" left="732" width="60" height="20" font="4">(p&lt;0.001). </text>
<text top="441" left="989" width="156" height="20" font="4">● Presence of severe PH at </text>
<text top="458" left="989" width="156" height="20" font="4">the time of ASD closure and </text>
<text top="476" left="989" width="146" height="20" font="4">impaired subjective NYHA </text>
<text top="493" left="989" width="164" height="20" font="4">postclosure FC may correlate </text>
<text top="510" left="989" width="136" height="20" font="4">with greater likelihood of </text>
<text top="527" left="989" width="158" height="20" font="4">moderate-to-severe PH post </text>
<text top="545" left="989" width="62" height="20" font="4">procedure. </text>
</page>
<page number="191" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 191 </text>
<text top="107" left="64" width="92" height="20" font="4">Balzer DT, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2002 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(704)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12354713?dopt=Citation">12354713</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12354713?dopt=Citation"> </a></text>
<text top="107" left="179" width="64" height="20" font="4">Multicenter </text>
<text top="124" left="179" width="61" height="20" font="4">open-label </text>
<text top="141" left="179" width="66" height="20" font="4">prospective </text>
<text top="159" left="179" width="41" height="20" font="4">cohort: </text>
<text top="176" left="179" width="46" height="20" font="4">children </text>
<text top="107" left="273" width="58" height="20" font="4">n=124 pts </text>
<text top="107" left="381" width="3" height="20" font="4"> </text>
<text top="107" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="455" width="73" height="20" font="4">Preoperative </text>
<text top="141" left="455" width="74" height="20" font="4">congenital or </text>
<text top="159" left="455" width="75" height="20" font="4">acquired HD, </text>
<text top="176" left="455" width="86" height="20" font="4">hemodynamics </text>
<text top="193" left="455" width="118" height="20" font="4">sufficient to calculate </text>
<text top="210" left="455" width="118" height="20" font="4">Rp, Rs, under all test </text>
<text top="228" left="455" width="62" height="20" font="4">conditions, </text>
<text top="245" left="455" width="107" height="20" font="4">Rp:Rs≥0.33 during </text>
<text top="262" left="455" width="49" height="20" font="4">baseline </text>
<text top="279" left="455" width="88" height="20" font="4">measurements. </text>
<text top="107" left="590" width="86" height="20" font="4">Demographics, </text>
<text top="124" left="590" width="89" height="20" font="4">hemodynamics, </text>
<text top="141" left="590" width="111" height="20" font="4">postoperative HF or </text>
<text top="159" left="590" width="34" height="20" font="4">death </text>
<text top="107" left="732" width="242" height="20" font="4">● Ability to demonstrate Rp/Rs&lt;0.33 with or </text>
<text top="124" left="732" width="227" height="20" font="4">without iNO yielded positive and NPVs of </text>
<text top="141" left="732" width="235" height="20" font="4">95% (87, 99) and 32% (19, 51) for survival </text>
<text top="159" left="732" width="239" height="20" font="4">without right HF and 92% (84, 97) and 78% </text>
<text top="176" left="732" width="213" height="20" font="4">(52, 97) for survival without right HF or </text>
<text top="193" left="732" width="208" height="20" font="4">death over 26 (3–97) mo of follow-up. </text>
<text top="107" left="989" width="164" height="20" font="4">● Ability to lower Rp/Rs&lt;0.33 </text>
<text top="124" left="989" width="169" height="20" font="4">during preoperative evaluation </text>
<text top="141" left="989" width="42" height="20" font="4">using O</text>
<text top="148" left="1031" width="4" height="13" font="6">2</text>
<text top="141" left="1035" width="119" height="20" font="4"> and iNO may predict </text>
<text top="159" left="989" width="165" height="20" font="4">postoperative survival without </text>
<text top="176" left="989" width="148" height="20" font="4">HF in adults with CHD and </text>
<text top="193" left="989" width="73" height="20" font="4">severe PAH. </text>
<text top="297" left="64" width="87" height="20" font="4">Berner M, et al. </text>
<text top="314" left="64" width="63" height="20" font="4">1996 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(705)</a> </text>
<text top="332" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8629600?dopt=Citation">8629600</a></text>
<text top="332" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8629600?dopt=Citation"> </a></text>
<text top="297" left="179" width="76" height="20" font="4">Single-center </text>
<text top="314" left="179" width="61" height="20" font="4">open-label </text>
<text top="332" left="179" width="74" height="20" font="4">retrospective </text>
<text top="349" left="179" width="41" height="20" font="4">cohort: </text>
<text top="366" left="179" width="46" height="20" font="4">children </text>
<text top="297" left="273" width="51" height="20" font="4">n=13 pts </text>
<text top="297" left="381" width="3" height="20" font="4"> </text>
<text top="297" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="314" left="455" width="73" height="20" font="4">Preoperative </text>
<text top="332" left="455" width="80" height="20" font="4">hemodynamic </text>
<text top="349" left="455" width="83" height="20" font="4">assessment of </text>
<text top="366" left="455" width="102" height="20" font="4">children with CHD </text>
<text top="383" left="455" width="74" height="20" font="4">with baseline </text>
<text top="401" left="455" width="63" height="20" font="4">Rp/Rs≥0.3 </text>
<text top="297" left="590" width="86" height="20" font="4">Demographics, </text>
<text top="314" left="590" width="86" height="20" font="4">hemodynamics </text>
<text top="332" left="590" width="116" height="20" font="4">(selective pulmonary </text>
<text top="349" left="590" width="121" height="20" font="4">vasoreactivity defined </text>
<text top="366" left="590" width="92" height="20" font="4">as simultaneous </text>
<text top="383" left="590" width="123" height="20" font="4">decrease in both PVR </text>
<text top="401" left="590" width="124" height="20" font="4">and Rp/Rs of &gt;10% to </text>
<text top="418" left="590" width="126" height="20" font="4">administration of iNO); </text>
<text top="435" left="590" width="122" height="20" font="4">postoperative survival </text>
<text top="297" left="732" width="219" height="20" font="4">● 9/13 had decrease in PVR from 9.5 + </text>
<text top="316" left="732" width="117" height="20" font="4">1.5–7.2 ± 1.2 WU l m</text>
<text top="317" left="849" width="4" height="13" font="6">2</text>
<text top="316" left="853" width="114" height="20" font="4"> (-24 ± 7%; p&lt;0.05), </text>
<text top="333" left="732" width="141" height="20" font="4">and in Rp/Rs from 0.46 + </text>
<text top="350" left="732" width="224" height="20" font="4">0.11–0.35 + 0.10 (-25 + 8%; &lt;0.05), with </text>
<text top="367" left="732" width="239" height="20" font="4">height of preoperative Rp/Rs and older age </text>
<text top="384" left="732" width="235" height="20" font="4">correlated with lack of selective pulmonary </text>
<text top="402" left="732" width="85" height="20" font="4">vasoreactivity.  </text>
<text top="419" left="732" width="194" height="20" font="4">● Presence of selective pulmonary </text>
<text top="436" left="732" width="243" height="20" font="4">vasoreactivity correlated with survival in 2–5 </text>
<text top="453" left="732" width="90" height="20" font="4">mo of follow-up. </text>
<text top="297" left="989" width="167" height="20" font="4">● Ability to lower preoperative </text>
<text top="314" left="989" width="147" height="20" font="4">PVR and Rp/Rs&gt;10% with </text>
<text top="332" left="989" width="170" height="20" font="4">iNO as well as Rp/Rs&lt;0.3 may </text>
<text top="349" left="989" width="145" height="20" font="4">predict short-term survival </text>
<text top="366" left="989" width="127" height="20" font="4">after surgery to correct </text>
<text top="383" left="989" width="164" height="20" font="4">congenital septal defects with </text>
<text top="401" left="989" width="130" height="20" font="4">intracardiac shunting in </text>
<text top="418" left="989" width="50" height="20" font="4">children. </text>
<text top="471" left="64" width="98" height="20" font="4">Gorenflo M, et al. </text>
<text top="488" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#246">(706)</a> </text>
<text top="506" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20424447?dopt=Citation">20424447</a></text>
<text top="506" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20424447?dopt=Citation"> </a></text>
<text top="471" left="179" width="76" height="20" font="4">Single-center </text>
<text top="488" left="179" width="61" height="20" font="4">open-label </text>
<text top="506" left="179" width="74" height="20" font="4">retrospective </text>
<text top="523" left="179" width="38" height="20" font="4">cohort </text>
<text top="471" left="273" width="54" height="20" font="4">n=46 pts  </text>
<text top="471" left="381" width="3" height="20" font="4"> </text>
<text top="471" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="488" left="455" width="73" height="20" font="4">Preoperative </text>
<text top="506" left="455" width="80" height="20" font="4">hemodynamic </text>
<text top="523" left="455" width="83" height="20" font="4">assessment of </text>
<text top="540" left="455" width="104" height="20" font="4">subjects with CHD </text>
<text top="557" left="455" width="98" height="20" font="4">with intravascular </text>
<text top="574" left="455" width="74" height="20" font="4">shunting and </text>
<text top="592" left="455" width="100" height="20" font="4">preoperative PVR </text>
<text top="609" left="455" width="101" height="20" font="4">index indicative of </text>
<text top="626" left="455" width="77" height="20" font="4">“severe PAH” </text>
<text top="643" left="455" width="107" height="20" font="4">(implied ≥10 WU*m</text>
<text top="645" left="563" width="4" height="13" font="6">2</text>
<text top="643" left="567" width="8" height="20" font="4">) </text>
<text top="471" left="590" width="86" height="20" font="4">Demographics, </text>
<text top="488" left="590" width="86" height="20" font="4">hemodynamics </text>
<text top="506" left="590" width="65" height="20" font="4">(pulmonary </text>
<text top="523" left="590" width="121" height="20" font="4">vasoreactivity defined </text>
<text top="540" left="590" width="112" height="20" font="4">as reduction in PVR </text>
<text top="557" left="590" width="127" height="20" font="4">index ≥20% compared </text>
<text top="574" left="590" width="105" height="20" font="4">to baseline without </text>
<text top="592" left="590" width="115" height="20" font="4">decreaseof systemic </text>
<text top="609" left="590" width="74" height="20" font="4">arterial BP to </text>
<text top="626" left="590" width="94" height="20" font="4">administration of </text>
<text top="643" left="590" width="90" height="20" font="4">inhaled iloprost) </text>
<text top="471" left="732" width="108" height="20" font="4">● Ages 9 mo–43 y. </text>
<text top="488" left="732" width="207" height="20" font="4">● 29/46 pts had positive preoperative </text>
<text top="506" left="732" width="226" height="20" font="4">pulmonary vasoreactivity with PVR index </text>
<text top="524" left="732" width="201" height="20" font="4">14.91 ± 5.98 reduced to 8.92 ± 4.09 </text>
<text top="541" left="732" width="35" height="20" font="4">WU*m</text>
<text top="543" left="767" width="4" height="13" font="6">2</text>
<text top="541" left="772" width="197" height="20" font="4"> (p&lt;0.05); 21/29 underwent surgical </text>
<text top="558" left="732" width="228" height="20" font="4">correction with 21/21 alive at 3 y of follow-</text>
<text top="576" left="732" width="21" height="20" font="4">up. </text>
<text top="471" left="989" width="167" height="20" font="4">● Ability to lower preoperative </text>
<text top="488" left="989" width="170" height="20" font="4">PVR index ≥20% compared to </text>
<text top="506" left="989" width="168" height="20" font="4">baseline using inhaled iloprost </text>
<text top="523" left="989" width="126" height="20" font="4">may predict short- and </text>
<text top="540" left="989" width="145" height="20" font="4">intermediate-term survival </text>
<text top="557" left="989" width="127" height="20" font="4">after surgery to correct </text>
<text top="574" left="989" width="164" height="20" font="4">congenital septal defects with </text>
<text top="592" left="989" width="120" height="20" font="4">intracardiac shunting. </text>
<text top="661" left="64" width="91" height="20" font="4">Huang JB, et al. </text>
<text top="678" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(707)</a> </text>
<text top="696" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20494465?dopt=Citation">20494465</a></text>
<text top="696" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20494465?dopt=Citation"> </a></text>
<text top="661" left="179" width="76" height="20" font="4">Single-center </text>
<text top="678" left="179" width="61" height="20" font="4">open-label </text>
<text top="696" left="179" width="74" height="20" font="4">retrospective </text>
<text top="713" left="179" width="41" height="20" font="4">cohort: </text>
<text top="730" left="179" width="46" height="20" font="4">children </text>
<text top="661" left="273" width="51" height="20" font="4">n=49 pts </text>
<text top="661" left="381" width="3" height="20" font="4"> </text>
<text top="661" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="678" left="455" width="73" height="20" font="4">Preoperative </text>
<text top="696" left="455" width="80" height="20" font="4">hemodynamic </text>
<text top="713" left="455" width="102" height="20" font="4">assessment of pts </text>
<text top="730" left="455" width="80" height="20" font="4">with CHD with </text>
<text top="747" left="455" width="73" height="20" font="4">intravascular </text>
<text top="764" left="455" width="74" height="20" font="4">shunting and </text>
<text top="782" left="455" width="102" height="20" font="4">preoperative PAM </text>
<text top="661" left="590" width="86" height="20" font="4">Demographics, </text>
<text top="678" left="590" width="120" height="20" font="4">hemodynamics, open </text>
<text top="696" left="590" width="115" height="20" font="4">lung biopsy findings, </text>
<text top="713" left="590" width="45" height="20" font="4">survival </text>
<text top="661" left="732" width="233" height="20" font="4">● In 49 pts (mean age at operation 36.5 ± </text>
<text top="678" left="732" width="231" height="20" font="4">23.8 mo (8–96), who met “treat and repair </text>
<text top="696" left="732" width="221" height="20" font="4">criteria” after use of PAH therapy for 16–</text>
<text top="713" left="732" width="232" height="20" font="4">150 d, all survived surgical defect closure; </text>
<text top="730" left="732" width="212" height="20" font="4">at 117.6 ± 56.6 mo (range, 13–167) of </text>
<text top="747" left="732" width="59" height="20" font="4">follow-up.  </text>
<text top="764" left="732" width="242" height="20" font="4">● 49/49 were alive; 98% were WHO class I. </text>
<text top="782" left="732" width="220" height="20" font="4">1 pt with residual PH was WHO class II. </text>
<text top="661" left="989" width="144" height="20" font="4">● Ability to raise systemic </text>
<text top="678" left="989" width="159" height="20" font="4">arterial saturation by defined </text>
<text top="696" left="989" width="159" height="20" font="4">criteria using PAH therapy in </text>
<text top="713" left="989" width="126" height="20" font="4">children with CHD and </text>
<text top="730" left="989" width="148" height="20" font="4">intravascular shunting with </text>
<text top="747" left="989" width="167" height="20" font="4">preoperative severe PAH may </text>
<text top="764" left="989" width="140" height="20" font="4">predict intermediate-term </text>
<text top="782" left="989" width="131" height="20" font="4">survival after surgery to </text>
</page>
<page number="192" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 192 </text>
<text top="107" left="455" width="74" height="20" font="4">&gt;50 mm who </text>
<text top="124" left="455" width="122" height="20" font="4">received preoperative </text>
<text top="141" left="455" width="120" height="20" font="4">“treat and repair” with </text>
<text top="159" left="455" width="116" height="20" font="4">PAH therapy leading </text>
<text top="176" left="455" width="120" height="20" font="4">to a) systemic arterial </text>
<text top="193" left="455" width="94" height="20" font="4">saturation rise in </text>
<text top="210" left="455" width="117" height="20" font="4">subjects with “simple </text>
<text top="228" left="455" width="115" height="20" font="4">CHD” to &gt;93%, or b) </text>
<text top="245" left="455" width="114" height="20" font="4">increase in systemic </text>
<text top="262" left="455" width="115" height="20" font="4">arterial saturation by </text>
<text top="279" left="455" width="87" height="20" font="4">≥5% in pts with </text>
<text top="296" left="455" width="87" height="20" font="4">“complex CHD” </text>
<text top="107" left="989" width="137" height="20" font="4">correct congenital septal </text>
<text top="124" left="989" width="46" height="20" font="4">defects. </text>
<text top="314" left="64" width="96" height="20" font="4">Neutze JM, et al. </text>
<text top="332" left="64" width="63" height="20" font="4">1989 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(708)</a> </text>
<text top="349" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2913735?dopt=Citation">2913735</a></text>
<text top="349" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2913735?dopt=Citation"> </a></text>
<text top="314" left="179" width="76" height="20" font="4">Single-center </text>
<text top="332" left="179" width="61" height="20" font="4">open-label </text>
<text top="349" left="179" width="74" height="20" font="4">retrospective </text>
<text top="366" left="179" width="41" height="20" font="4">cohort: </text>
<text top="383" left="179" width="46" height="20" font="4">children </text>
<text top="314" left="273" width="71" height="20" font="4">n=87 pts, 36 </text>
<text top="332" left="273" width="95" height="20" font="4">with moderate or </text>
<text top="349" left="273" width="40" height="20" font="4">severe </text>
<text top="366" left="273" width="72" height="20" font="4">preoperative </text>
<text top="383" left="273" width="77" height="20" font="4">PAH (&gt;7 U* m</text>
<text top="385" left="350" width="4" height="13" font="6">2</text>
<text top="383" left="355" width="8" height="20" font="4">) </text>
<text top="314" left="381" width="3" height="20" font="4"> </text>
<text top="314" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="332" left="455" width="73" height="20" font="4">Preoperative </text>
<text top="349" left="455" width="80" height="20" font="4">hemodynamic </text>
<text top="366" left="455" width="83" height="20" font="4">assessment of </text>
<text top="383" left="455" width="74" height="20" font="4">subjects with </text>
<text top="400" left="455" width="88" height="20" font="4">congenital VSD </text>
<text top="314" left="590" width="86" height="20" font="4">Demographics, </text>
<text top="332" left="590" width="89" height="20" font="4">hemodynamics, </text>
<text top="349" left="590" width="116" height="20" font="4">vasodilator testing to </text>
<text top="366" left="590" width="94" height="20" font="4">administration of </text>
<text top="383" left="590" width="124" height="20" font="4">isoproterenol (positive </text>
<text top="400" left="590" width="114" height="20" font="4">response defined as </text>
<text top="418" left="590" width="110" height="20" font="4">ability to lower PVR </text>
<text top="435" left="590" width="89" height="20" font="4">index &lt;7 WU* m</text>
<text top="437" left="680" width="4" height="13" font="6">2</text>
<text top="435" left="684" width="11" height="20" font="4">), </text>
<text top="452" left="590" width="45" height="20" font="4">survival </text>
<text top="314" left="732" width="237" height="20" font="4">● Positive pulmonary vasodilator response </text>
<text top="332" left="732" width="217" height="20" font="4">to isoproterenol correlated with survival </text>
<text top="349" left="732" width="80" height="20" font="4">(1.8–162 mo). </text>
<text top="366" left="732" width="243" height="20" font="4">● Rp/Rs&lt;0.75 did not correlate with positive </text>
<text top="383" left="732" width="181" height="20" font="4">pulmonary vasodilator response; </text>
<text top="400" left="732" width="237" height="20" font="4">Rp/Rs≥0.75 correlated with lack of positive </text>
<text top="418" left="732" width="192" height="20" font="4">pulmonary vasodilator response to </text>
<text top="435" left="732" width="78" height="20" font="4">isoproterenol. </text>
<text top="314" left="989" width="170" height="20" font="4">● Ability to lower PVR index to </text>
<text top="332" left="989" width="40" height="20" font="4">&lt;7 U/m</text>
<text top="333" left="1029" width="7" height="13" font="6">2 </text>
<text top="332" left="1035" width="120" height="20" font="4">using isoproterenol in </text>
<text top="349" left="989" width="127" height="20" font="4">children with CHD with </text>
<text top="366" left="989" width="142" height="20" font="4">preoperative moderate-to-</text>
<text top="383" left="989" width="136" height="20" font="4">severe PAH may predict </text>
<text top="400" left="989" width="159" height="20" font="4">short- and intermediate-term </text>
<text top="418" left="989" width="121" height="20" font="4">survival after surgery. </text>
<text top="470" left="64" width="94" height="20" font="4">Steele PM, et al. </text>
<text top="487" left="64" width="63" height="20" font="4">1987 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(709)</a> </text>
<text top="504" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3664992?dopt=Citation">3664992</a></text>
<text top="504" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3664992?dopt=Citation"> </a></text>
<text top="470" left="179" width="76" height="20" font="4">Single-center </text>
<text top="487" left="179" width="61" height="20" font="4">open-label </text>
<text top="504" left="179" width="74" height="20" font="4">retrospective </text>
<text top="522" left="179" width="38" height="20" font="4">cohort </text>
<text top="470" left="273" width="78" height="20" font="4">n=702 pts, 40 </text>
<text top="487" left="273" width="86" height="20" font="4">with pulmonary </text>
<text top="504" left="273" width="95" height="20" font="4">vascular disease </text>
<text top="470" left="381" width="3" height="20" font="4"> </text>
<text top="470" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="487" left="455" width="121" height="20" font="4">Isolated secundum or </text>
<text top="504" left="455" width="120" height="20" font="4">venous ASD; surgery </text>
<text top="522" left="455" width="83" height="20" font="4">at discretion of </text>
<text top="539" left="455" width="92" height="20" font="4">treating clinician </text>
<text top="470" left="590" width="86" height="20" font="4">Demographics, </text>
<text top="487" left="590" width="86" height="20" font="4">hemodynamics </text>
<text top="504" left="590" width="103" height="20" font="4">(preoperative total </text>
<text top="522" left="590" width="125" height="20" font="4">peripheral resistance), </text>
<text top="539" left="590" width="123" height="20" font="4">preoperative systemic </text>
<text top="556" left="590" width="98" height="20" font="4">arterial saturation </text>
<text top="470" left="732" width="218" height="20" font="4">● Median follow-up 12 y, 17/40 dead at </text>
<text top="487" left="732" width="56" height="20" font="4">follow-up. </text>
<text top="504" left="732" width="212" height="20" font="4">● In 26 pts undergoing surgical repair, </text>
<text top="522" left="732" width="232" height="20" font="4">correlates of longer-term survival included </text>
<text top="539" left="732" width="237" height="20" font="4">total peripheral resistance (p&lt;0.00001), PA </text>
<text top="556" left="732" width="231" height="20" font="4">resistance (p&lt;0.00001), Rp/Rs (p=0.004), </text>
<text top="573" left="732" width="117" height="20" font="4">systemic arterial SpO</text>
<text top="579" left="849" width="4" height="13" font="6">2</text>
<text top="573" left="853" width="108" height="20" font="4"> (p=0.005), PA SpO</text>
<text top="579" left="961" width="4" height="13" font="6">2</text>
<text top="573" left="966" width="3" height="20" font="4"> </text>
<text top="591" left="732" width="60" height="20" font="4">(p=0.007). </text>
<text top="608" left="732" width="202" height="20" font="4">● Both systemic arterial and PA SpO</text>
<text top="614" left="934" width="4" height="13" font="6">2</text>
<text top="608" left="938" width="3" height="20" font="4"> </text>
<text top="625" left="732" width="146" height="20" font="4">varied inversely with PVR. </text>
<text top="642" left="732" width="239" height="20" font="4">● Longer-term survival after surgical defect </text>
<text top="659" left="732" width="209" height="20" font="4">closure appeared correlated with total </text>
<text top="677" left="732" width="164" height="20" font="4">peripheral resistance &lt;15 U/m</text>
<text top="678" left="896" width="4" height="13" font="6">2</text>
<text top="677" left="901" width="69" height="20" font="4"> or systemic </text>
<text top="694" left="732" width="66" height="20" font="4">arterial SpO</text>
<text top="700" left="798" width="4" height="13" font="6">2</text>
<text top="694" left="802" width="47" height="20" font="4"> ≥92%.  </text>
<text top="470" left="989" width="152" height="20" font="4">● Preoperative resting total </text>
<text top="487" left="989" width="142" height="20" font="4">peripheral resistance &lt;15 </text>
<text top="504" left="989" width="22" height="20" font="4">U/m</text>
<text top="506" left="1011" width="4" height="13" font="6">2</text>
<text top="504" left="1016" width="120" height="20" font="4"> or systemic arterial O</text>
<text top="511" left="1135" width="4" height="13" font="6">2</text>
<text top="504" left="1140" width="3" height="20" font="4"> </text>
<text top="522" left="989" width="161" height="20" font="4">saturation ≥92% may predict </text>
<text top="539" left="989" width="145" height="20" font="4">intermediate-term survival </text>
<text top="556" left="989" width="160" height="20" font="4">after secundum ASD or VSD </text>
<text top="573" left="989" width="84" height="20" font="4">surgical repair. </text>
</page>
<page number="193" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 193 </text>
<text top="107" left="64" width="79" height="20" font="4">Yong G, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(710)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20031756?dopt=Citation">20031756</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20031756?dopt=Citation"> </a></text>
<text top="107" left="179" width="76" height="20" font="4">Single-center </text>
<text top="124" left="179" width="61" height="20" font="4">open-label </text>
<text top="141" left="179" width="74" height="20" font="4">retrospective </text>
<text top="159" left="179" width="38" height="20" font="4">cohort </text>
<text top="107" left="273" width="58" height="20" font="4">n=215 pts </text>
<text top="107" left="381" width="3" height="20" font="4"> </text>
<text top="107" left="455" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="455" width="107" height="20" font="4">Isolated secundum </text>
<text top="141" left="455" width="94" height="20" font="4">ASD undergoing </text>
<text top="159" left="455" width="114" height="20" font="4">catheter-based ASD </text>
<text top="176" left="455" width="43" height="20" font="4">closure </text>
<text top="107" left="590" width="86" height="20" font="4">Demographics, </text>
<text top="124" left="590" width="89" height="20" font="4">hemodynamics, </text>
<text top="141" left="590" width="104" height="20" font="4">echocardiographic </text>
<text top="159" left="590" width="113" height="20" font="4">estimates of TR, RV </text>
<text top="176" left="590" width="113" height="20" font="4">systolic function, TR </text>
<text top="193" left="590" width="106" height="20" font="4">velocity, subjective </text>
<text top="210" left="590" width="57" height="20" font="4">NYHA FC </text>
<text top="227" left="590" width="3" height="20" font="4"> </text>
<text top="245" left="590" width="120" height="20" font="4">Moderate PH defined </text>
<text top="262" left="590" width="94" height="20" font="4">as PASP 50–59, </text>
<text top="279" left="590" width="113" height="20" font="4">severe PAH defined </text>
<text top="296" left="590" width="102" height="20" font="4">as PASP ≥60 mm </text>
<text top="107" left="732" width="140" height="20" font="4">● Mean follow-up 15 mo. </text>
<text top="124" left="732" width="231" height="20" font="4">● Pts with moderate and severe PAH had </text>
<text top="141" left="732" width="83" height="20" font="4">higher Qp/Qs,  </text>
<text top="159" left="732" width="242" height="20" font="4">2.8 (1.8, 3.4) and 3.5 (2.0, 4.1), respectively </text>
<text top="176" left="732" width="63" height="20" font="4">(p=0.0045) </text>
<text top="193" left="732" width="216" height="20" font="4">● Independent predictors of preclosure </text>
<text top="210" left="732" width="215" height="20" font="4">moderate or severe PH were older age </text>
<text top="228" left="732" width="217" height="20" font="4">(OR: 1.10 per y; p=0.0001), larger ASD </text>
<text top="245" left="732" width="238" height="20" font="4">(OR: 1.13 per mm; p=0.0052), female (OR: </text>
<text top="262" left="732" width="227" height="20" font="4">3.9; p=0.0313), ≥ moderate TR (OR: 3.6; </text>
<text top="279" left="732" width="63" height="20" font="4">p=0.0043). </text>
<text top="296" left="732" width="228" height="20" font="4">● Increasing preclosure PASP correlated </text>
<text top="314" left="732" width="223" height="20" font="4">with post closure lowering of PASP ≥5% </text>
<text top="331" left="732" width="193" height="20" font="4">(p&lt;0.0001) but also with inability to </text>
<text top="348" left="732" width="229" height="20" font="4">normalize post closure PASP (p&lt;0.0001). </text>
<text top="365" left="732" width="235" height="20" font="4">● NYHA FC improved post ASD closure in </text>
<text top="382" left="732" width="240" height="20" font="4">subjects with moderate or severe PH, lower </text>
<text top="400" left="732" width="221" height="20" font="4">preclosure PASP (OR: 0.91 per mm Hg; </text>
<text top="417" left="732" width="201" height="20" font="4">p=0.0418) and ≤ mild TR (OR: 0.14; </text>
<text top="434" left="732" width="191" height="20" font="4">p=0.0420) correlated with ability to </text>
<text top="451" left="732" width="166" height="20" font="4">normalize post closure PASP. </text>
<text top="107" left="989" width="156" height="20" font="4">● Preoperative moderate-to-</text>
<text top="124" left="989" width="154" height="20" font="4">severe PH may carry risk of </text>
<text top="141" left="989" width="158" height="20" font="4">late PH in adults undergoing </text>
<text top="159" left="989" width="150" height="20" font="4">transcatheter ASD closure. </text>
<text top="469" left="54" width="3" height="20" font="4"> </text>
<text top="487" left="54" width="3" height="20" font="4"> </text>
<text top="503" left="108" width="445" height="24" font="1"><b>Data Supplement 50. Eisenmenger Syndrome – Section 4.4.6.2  </b></text>
<text top="525" left="95" width="38" height="20" font="3"><b>Study </b></text>
<text top="542" left="70" width="87" height="20" font="3"><b>Name, Author, </b></text>
<text top="559" left="99" width="30" height="20" font="3"><b>Year </b></text>
<text top="525" left="183" width="73" height="20" font="3"><b>Study Type/ </b></text>
<text top="542" left="198" width="44" height="20" font="3"><b>Design </b></text>
<text top="525" left="293" width="66" height="20" font="3"><b>Study Size </b></text>
<text top="525" left="393" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="542" left="429" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="525" left="545" width="74" height="20" font="3"><b>Intervention </b></text>
<text top="525" left="665" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="525" left="799" width="102" height="20" font="3"><b>Results/p Values </b></text>
<text top="525" left="952" width="137" height="20" font="3"><b>Summary/Conclusions </b></text>
<text top="577" left="64" width="59" height="20" font="3"><b>Bosentan </b></text>
<text top="595" left="64" width="78" height="20" font="4">Galiè N, et al. </text>
<text top="613" left="64" width="63" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#225">(264)</a> </text>
<text top="630" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16801459?dopt=Citation">16801459</a></text>
<text top="630" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16801459?dopt=Citation"> </a></text>
<text top="595" left="177" width="76" height="20" font="4">Double-blind, </text>
<text top="613" left="177" width="47" height="20" font="4">placebo-</text>
<text top="630" left="177" width="89" height="20" font="4">controlled RCT  </text>
<text top="595" left="276" width="96" height="20" font="4">54 (37 bosentan, </text>
<text top="613" left="276" width="62" height="20" font="4">17 control) </text>
<text top="595" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="613" left="389" width="89" height="20" font="4">≥12 y, WHO III, </text>
<text top="630" left="389" width="101" height="20" font="4">echocardiography </text>
<text top="647" left="389" width="55" height="20" font="4">diagnosis </text>
<text top="664" left="389" width="76" height="20" font="4">Eisenmenger </text>
<text top="681" left="389" width="109" height="20" font="4">syndrome, catheter </text>
<text top="699" left="389" width="55" height="20" font="4">diagnosis </text>
<text top="716" left="389" width="76" height="20" font="4">Eisenmenger </text>
<text top="733" left="389" width="85" height="20" font="4">syndrome, SpO</text>
<text top="739" left="474" width="4" height="13" font="6">2</text>
<text top="733" left="479" width="3" height="20" font="4"> </text>
<text top="750" left="389" width="102" height="20" font="4">70%–90%, 6MWT </text>
<text top="768" left="389" width="111" height="20" font="4">150–450 mo, stable </text>
<text top="785" left="389" width="19" height="20" font="4">Rx </text>
<text top="595" left="528" width="103" height="20" font="4">Bosentan 62.5 mg </text>
<text top="613" left="528" width="90" height="20" font="4">PO BID × 1 mo, </text>
<text top="630" left="528" width="97" height="20" font="4">125 twice a d × 3 </text>
<text top="647" left="528" width="21" height="20" font="4">mo </text>
<text top="595" left="648" width="57" height="20" font="4">● 1°: SpO</text>
<text top="602" left="704" width="4" height="13" font="6">2</text>
<text top="595" left="709" width="3" height="20" font="4"> </text>
<text top="613" left="648" width="98" height="20" font="4">baseline to wk 16 </text>
<text top="630" left="648" width="91" height="20" font="4">s-1°: PVR if first </text>
<text top="647" left="648" width="91" height="20" font="4">1°endpoint met. </text>
<text top="664" left="648" width="32" height="20" font="4">● 2°: </text>
<text top="681" left="648" width="89" height="20" font="4">hemodynamics, </text>
<text top="699" left="648" width="40" height="20" font="4">6MWT </text>
<text top="595" left="767" width="114" height="20" font="4">● Bosentan Rx: SpO</text>
<text top="602" left="881" width="4" height="13" font="6">2</text>
<text top="595" left="886" width="3" height="20" font="4"> </text>
<text top="613" left="767" width="161" height="20" font="4">(corrected for placebo effect) </text>
<text top="630" left="767" width="146" height="20" font="4">=1.0% (95% CI: -0.7–2.8). </text>
<text top="647" left="767" width="139" height="20" font="4">Bosentan Rx: PVR index </text>
<text top="664" left="767" width="141" height="20" font="4">472.0 dynes (p=0.0383).  </text>
<text top="681" left="767" width="131" height="20" font="4">● Bosentan Rx: mPAP  </text>
<text top="699" left="767" width="134" height="20" font="4">5.5 mm Hg (p=0.0363),  </text>
<text top="716" left="767" width="144" height="20" font="4">Bosentan Rx: 6MWT 53.1 </text>
<text top="733" left="767" width="90" height="20" font="4">min (p=0.0079). </text>
<text top="595" left="946" width="121" height="20" font="4">● Bosentan improves </text>
<text top="613" left="946" width="64" height="20" font="4">6MWT and </text>
<text top="630" left="946" width="128" height="20" font="4">hemodynamics without </text>
<text top="647" left="946" width="111" height="20" font="4">worsening systemic </text>
<text top="664" left="946" width="131" height="20" font="4">arterial saturation in pts </text>
<text top="681" left="946" width="139" height="20" font="4">with typical Eisenmenger </text>
<text top="699" left="946" width="145" height="20" font="4">Syndrome and FC III after </text>
<text top="716" left="946" width="132" height="20" font="4">administration for 4 mo. </text>
</page>
<page number="194" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 194 </text>
<text top="107" left="389" width="3" height="20" font="4"> </text>
<text top="124" left="389" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="141" left="389" width="115" height="20" font="4">PDA, complex CHD, </text>
<text top="159" left="389" width="126" height="20" font="4">LVEF &lt;40%, total lung </text>
<text top="176" left="389" width="125" height="20" font="4">capacity &lt;70%, forced </text>
<text top="193" left="389" width="124" height="20" font="4">expiratory volume in 1 </text>
<text top="210" left="389" width="86" height="20" font="4">s &lt;70%, forced </text>
<text top="228" left="389" width="124" height="20" font="4">expiratory volume in 1 </text>
<text top="245" left="389" width="121" height="20" font="4">s/forced vital capacity </text>
<text top="262" left="389" width="110" height="20" font="4">&lt;60%, known CAD. </text>
<text top="279" left="389" width="70" height="20" font="4">No prior use </text>
<text top="296" left="389" width="106" height="20" font="4">prostanoids, PDE5 </text>
<text top="314" left="389" width="93" height="20" font="4">inhibitors, ERA’s </text>
<text top="331" left="389" width="122" height="20" font="4">within 1 mo screening </text>
<text top="349" left="64" width="93" height="20" font="4">Gatzoulis MA, et </text>
<text top="366" left="64" width="16" height="20" font="4">al. </text>
<text top="383" left="64" width="66" height="20" font="4">2008 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(711)</a>  </text>
<text top="400" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17658633?dopt=Citation">17658633</a></text>
<text top="400" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17658633?dopt=Citation"> </a></text>
<text top="349" left="177" width="82" height="20" font="4">OLE (of RCT), </text>
<text top="366" left="177" width="80" height="20" font="4">observational, </text>
<text top="383" left="177" width="41" height="20" font="4">cohort, </text>
<text top="400" left="177" width="77" height="20" font="4">retrospective  </text>
<text top="349" left="276" width="51" height="20" font="4">n=37 pts </text>
<text top="349" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="366" left="389" width="106" height="20" font="4">Participation within </text>
<text top="383" left="389" width="72" height="20" font="4">BREATHE-5 </text>
<text top="349" left="528" width="68" height="20" font="4">Bosentan in </text>
<text top="366" left="528" width="76" height="20" font="4">BREATHE-5: </text>
<text top="383" left="528" width="97" height="20" font="4">continuation × 24 </text>
<text top="400" left="528" width="19" height="20" font="4">wk </text>
<text top="418" left="528" width="92" height="20" font="4">Bosentan naïve: </text>
<text top="435" left="528" width="102" height="20" font="4">bosentan 62.5 mg </text>
<text top="452" left="528" width="88" height="20" font="4">PO BID × 4 wk, </text>
<text top="469" left="528" width="90" height="20" font="4">125 mg PO BID </text>
<text top="487" left="528" width="56" height="20" font="4">thereafter </text>
<text top="349" left="648" width="53" height="20" font="4">6MWT, O</text>
<text top="355" left="700" width="4" height="13" font="6">2</text>
<text top="349" left="705" width="3" height="20" font="4"> </text>
<text top="366" left="648" width="96" height="20" font="4">saturations, Borg </text>
<text top="383" left="648" width="81" height="20" font="4">dyspnea class </text>
<text top="349" left="767" width="156" height="20" font="4">● 6MWT: + 33.2 ± 23.9 min </text>
<text top="366" left="767" width="157" height="20" font="4">ex-placebo group (95% CI: [-</text>
<text top="383" left="767" width="160" height="20" font="4">21.9–88.4]; n=9) +6.7 ± 10.0 </text>
<text top="400" left="767" width="155" height="20" font="4">mo for open-label extension </text>
<text top="418" left="767" width="163" height="20" font="4">period for ex-Bosentan group </text>
<text top="435" left="767" width="152" height="20" font="4">(95% CI: -13.9–27.4; n=26) </text>
<text top="452" left="767" width="138" height="20" font="4">and overall improvement </text>
<text top="469" left="767" width="156" height="20" font="4">(OLE + B5) + 61.3 ± 8.1 mo </text>
<text top="487" left="767" width="152" height="20" font="4">(95% CI: 44.7–78.0; n=26). </text>
<text top="504" left="767" width="37" height="20" font="4">● SpO</text>
<text top="510" left="804" width="4" height="13" font="6">2</text>
<text top="504" left="809" width="78" height="20" font="4">: +0.8 ± 1.3% </text>
<text top="521" left="767" width="149" height="20" font="4">(95% CI: -2.3–3.9; n=9) ex-</text>
<text top="538" left="767" width="149" height="20" font="4">placebo group -1.0 ± 0.8% </text>
<text top="555" left="767" width="160" height="20" font="4">(95% CI: -2.5–0.6]; n=26) for </text>
<text top="573" left="767" width="157" height="20" font="4">ex-Bosentan group for open-</text>
<text top="590" left="767" width="150" height="20" font="4">label extension period, and </text>
<text top="607" left="767" width="152" height="20" font="4">overall +1.4 +/= 0.7% (95% </text>
<text top="624" left="767" width="152" height="20" font="4">CI: 0.0–2.8; n=26) for open-</text>
<text top="641" left="767" width="109" height="20" font="4">label extension and </text>
<text top="659" left="767" width="76" height="20" font="4">BREATHE-5. </text>
<text top="676" left="767" width="163" height="20" font="4">● BORG: -0.9 ± 0.3 (95% CI: </text>
<text top="693" left="767" width="123" height="20" font="4">-1.5– -0.3; n=9) for ex-</text>
<text top="710" left="767" width="46" height="20" font="4">placebo </text>
<text top="727" left="767" width="163" height="20" font="4">+0.4 ± 0.3 (95% CI: -0.1–1.0; </text>
<text top="745" left="767" width="138" height="20" font="4">n=26) for ex-Bosentan in </text>
<text top="762" left="767" width="153" height="20" font="4">open-label extension study, </text>
<text top="779" left="767" width="152" height="20" font="4">overall -0.5 ± 0.4 (95% CI: -</text>
<text top="349" left="946" width="107" height="20" font="4">● Sustained use of </text>
<text top="366" left="946" width="143" height="20" font="4">Bosentan in subjects who </text>
<text top="383" left="946" width="143" height="20" font="4">participated in the original </text>
<text top="400" left="946" width="102" height="20" font="4">RCT involving this </text>
<text top="418" left="946" width="119" height="20" font="4">medication for typical </text>
<text top="435" left="946" width="135" height="20" font="4">Eisenmenger Syndrome </text>
<text top="452" left="946" width="113" height="20" font="4">and FC III maintains </text>
<text top="469" left="946" width="112" height="20" font="4">improvement over 5 </text>
<text top="487" left="946" width="145" height="20" font="4">additional y of follow-up in </text>
<text top="504" left="946" width="43" height="20" font="4">6MWT. </text>
</page>
<page number="195" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 195 </text>
<text top="107" left="767" width="162" height="20" font="4">1.3–0.2; n=26) for open-label </text>
<text top="124" left="767" width="143" height="20" font="4">extension + BREATHE-5. </text>
<text top="142" left="64" width="96" height="20" font="4">Berger RM, et al. </text>
<text top="159" left="64" width="66" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(712)</a>  </text>
<text top="177" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19464064?dopt=Citation">19464064</a></text>
<text top="177" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19464064?dopt=Citation"> </a></text>
<text top="142" left="177" width="51" height="20" font="4">Post hoc </text>
<text top="159" left="177" width="61" height="20" font="4">analysis of </text>
<text top="177" left="177" width="74" height="20" font="4">double-blind, </text>
<text top="194" left="177" width="47" height="20" font="4">placebo-</text>
<text top="211" left="177" width="85" height="20" font="4">controlled RCT </text>
<text top="142" left="276" width="72" height="20" font="4">n=54 pts (37 </text>
<text top="159" left="276" width="76" height="20" font="4">Bosentan, 17 </text>
<text top="177" left="276" width="44" height="20" font="4">control) </text>
<text top="142" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="159" left="389" width="106" height="20" font="4">Participation within </text>
<text top="177" left="389" width="72" height="20" font="4">BREATHE-5 </text>
<text top="142" left="528" width="103" height="20" font="4">Bosentan 62.5 mg </text>
<text top="159" left="528" width="90" height="20" font="4">PO BID × 1 mo, </text>
<text top="177" left="528" width="100" height="20" font="4">125 mg PO BID × </text>
<text top="194" left="528" width="31" height="20" font="4">3 mo </text>
<text top="142" left="648" width="104" height="20" font="4">PVR index 6MWT, </text>
<text top="159" left="648" width="42" height="20" font="4">mPAP, </text>
<text top="177" left="648" width="50" height="20" font="4">Qpi, SpO</text>
<text top="183" left="698" width="4" height="13" font="6">2</text>
<text top="177" left="703" width="7" height="20" font="4">  </text>
<text top="142" left="767" width="152" height="20" font="4">● PVR index: -544.0 dynes </text>
<text top="159" left="767" width="138" height="20" font="4">(95% CI: -1593.8–344.7) </text>
<text top="177" left="767" width="162" height="20" font="4">ASD, -436.4 dynes (95% CI: -</text>
<text top="194" left="767" width="108" height="20" font="4">960.0–167.0) VSD. </text>
<text top="211" left="767" width="142" height="20" font="4">6MWT +32 min (95% CI: -</text>
<text top="228" left="767" width="98" height="20" font="4">16.3–325.5) ASD </text>
<text top="246" left="767" width="158" height="20" font="4">+34 min (95% CI: -1.9, 65.5) </text>
<text top="263" left="767" width="32" height="20" font="4">VSD  </text>
<text top="280" left="767" width="152" height="20" font="4">mPAP. -9.0 (85% CI: -26.6–</text>
<text top="297" left="767" width="57" height="20" font="4">1.1) ASD: </text>
<text top="314" left="767" width="161" height="20" font="4">-4.0 (95% CI: -8.6–1.0) VSD. </text>
<text top="332" left="767" width="119" height="20" font="4">● No changes in SpO</text>
<text top="338" left="886" width="7" height="13" font="6">2 </text>
<text top="332" left="893" width="37" height="20" font="4">or Qpi </text>
<text top="349" left="767" width="129" height="20" font="4">in Bosentan or placebo </text>
<text top="366" left="767" width="64" height="20" font="4">subgroups. </text>
<text top="142" left="946" width="102" height="20" font="4">● No difference in </text>
<text top="159" left="946" width="87" height="20" font="4">improvement in </text>
<text top="177" left="946" width="94" height="20" font="4">hemodynamic or </text>
<text top="194" left="946" width="143" height="20" font="4">functional outcomes were </text>
<text top="211" left="946" width="147" height="20" font="4">apparent between pts with </text>
<text top="228" left="946" width="116" height="20" font="4">pre- or post-tricuspid </text>
<text top="246" left="946" width="141" height="20" font="4">shunts with Eisenmenger </text>
<text top="263" left="946" width="143" height="20" font="4">Syndrome and FC III who </text>
<text top="280" left="946" width="122" height="20" font="4">participated in RCT of </text>
<text top="297" left="946" width="103" height="20" font="4">Bosentan therapy. </text>
<text top="384" left="64" width="89" height="20" font="4">Abd El Rahman </text>
<text top="401" left="64" width="55" height="20" font="4">MY, et al. </text>
<text top="418" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(713)</a> </text>
<text top="436" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24682249?dopt=Citation">24682249</a></text>
<text top="436" left="119" width="7" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24682249?dopt=Citation"> </a> </text>
<text top="384" left="177" width="79" height="20" font="4">Observational </text>
<text top="401" left="177" width="83" height="20" font="4">cohort multiple </text>
<text top="418" left="177" width="38" height="20" font="4">center </text>
<text top="436" left="177" width="70" height="20" font="4">uncontrolled </text>
<text top="453" left="177" width="61" height="20" font="4">open-label </text>
<text top="470" left="177" width="66" height="20" font="4">prospective </text>
<text top="384" left="276" width="51" height="20" font="4">n=40 pts </text>
<text top="384" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="401" left="389" width="48" height="20" font="4">≥18 y, O</text>
<text top="407" left="437" width="4" height="13" font="6">2</text>
<text top="401" left="441" width="61" height="20" font="4"> saturation </text>
<text top="418" left="389" width="124" height="20" font="4">≤93%; PAH (catheter) </text>
<text top="436" left="389" width="73" height="20" font="4">Rp:Rs ≥0.75 </text>
<text top="453" left="389" width="120" height="20" font="4">presence of PAH due </text>
<text top="470" left="389" width="120" height="20" font="4">to noncorrected large </text>
<text top="487" left="389" width="109" height="20" font="4">congenital shunting </text>
<text top="504" left="389" width="84" height="20" font="4">defect at atrial, </text>
<text top="522" left="389" width="116" height="20" font="4">ventricular or arterial </text>
<text top="539" left="389" width="36" height="20" font="4">level.  </text>
<text top="556" left="389" width="3" height="20" font="4"> </text>
<text top="573" left="389" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="591" left="389" width="114" height="20" font="4">PH for other reason, </text>
<text top="608" left="389" width="124" height="20" font="4">acute decompensated </text>
<text top="625" left="389" width="111" height="20" font="4">HF within 7 d, LV or </text>
<text top="642" left="389" width="124" height="20" font="4">non-TV or PV valvular </text>
<text top="659" left="389" width="55" height="20" font="4">diseases, </text>
<text top="677" left="389" width="105" height="20" font="4">bronchopulmonary </text>
<text top="694" left="389" width="100" height="20" font="4">dysplasia or other </text>
<text top="711" left="389" width="125" height="20" font="4">chronic lung diseases, </text>
<text top="728" left="389" width="28" height="20" font="4">poor </text>
<text top="745" left="389" width="101" height="20" font="4">echocardiography </text>
<text top="763" left="389" width="54" height="20" font="4">windows. </text>
<text top="384" left="528" width="91" height="20" font="4">Bosentan 24 wk </text>
<text top="401" left="528" width="103" height="20" font="4">62.5 mg PO BID × </text>
<text top="418" left="528" width="100" height="20" font="4">4 wk then 125 mg </text>
<text top="436" left="528" width="94" height="20" font="4">PO BID × 20 wk, </text>
<text top="453" left="528" width="105" height="20" font="4">catheterization pre </text>
<text top="470" left="528" width="54" height="20" font="4">and post, </text>
<text top="487" left="528" width="101" height="20" font="4">echocardiography </text>
<text top="504" left="528" width="87" height="20" font="4">parameters pre </text>
<text top="522" left="528" width="51" height="20" font="4">and post </text>
<text top="384" left="648" width="102" height="20" font="4">Echocardiography </text>
<text top="401" left="648" width="100" height="20" font="4">parameters of RV </text>
<text top="418" left="648" width="92" height="20" font="4">and LV function, </text>
<text top="436" left="648" width="72" height="20" font="4">6MWT, BNP </text>
<text top="384" left="767" width="142" height="20" font="4">● Pre vs. post measures: </text>
<text top="401" left="767" width="147" height="20" font="4">-TAPSE 19 (15–21) vs. 20 </text>
<text top="418" left="767" width="94" height="20" font="4">(16–22); p=0.01; </text>
<text top="436" left="767" width="136" height="20" font="4">RV Tei index 0.55 (0.45–</text>
<text top="453" left="767" width="148" height="20" font="4">0.65) vs. 0.48 (0.41–0.63); </text>
<text top="470" left="767" width="52" height="20" font="4">p=0.043; </text>
<text top="487" left="767" width="159" height="20" font="4">LV Tei index 0.46 (0.35–0.6) </text>
<text top="504" left="767" width="116" height="20" font="4">vs. 0.37 (0.28–0.52); </text>
<text top="522" left="767" width="52" height="20" font="4">p=0.001; </text>
<text top="539" left="767" width="152" height="20" font="4">RV mean strain (%) 18 (13–</text>
<text top="556" left="767" width="155" height="20" font="4">22) vs.19 (15–25); p=0.004; </text>
<text top="573" left="767" width="150" height="20" font="4">LV mean strain (%) 16 (12–</text>
<text top="591" left="767" width="165" height="20" font="4">21) vs. 17 (16–22); p=0.0001. </text>
<text top="384" left="946" width="118" height="20" font="4">● Echocardiographic </text>
<text top="401" left="946" width="142" height="20" font="4">parameters of RV and LV </text>
<text top="418" left="946" width="102" height="20" font="4">function appeared </text>
<text top="436" left="946" width="137" height="20" font="4">improved after Bosentan </text>
<text top="453" left="946" width="100" height="20" font="4">therapy for typical </text>
<text top="470" left="946" width="146" height="20" font="4">Eisenmenger syndrome in </text>
<text top="487" left="946" width="131" height="20" font="4">open-label uncontrolled </text>
<text top="504" left="946" width="36" height="20" font="4">study. </text>
</page>
<page number="196" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 196 </text>
<text top="107" left="64" width="94" height="20" font="4">Baptista R, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(714)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23351920?dopt=Citation">23351920</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23351920?dopt=Citation"> </a></text>
<text top="107" left="177" width="76" height="20" font="4">Single-center </text>
<text top="124" left="177" width="61" height="20" font="4">open-label </text>
<text top="141" left="177" width="66" height="20" font="4">prospective </text>
<text top="107" left="276" width="51" height="20" font="4">n=14 pts </text>
<text top="107" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="389" width="76" height="20" font="4">Eisenmenger </text>
<text top="141" left="389" width="110" height="20" font="4">syndrome, FC II-IV, </text>
<text top="159" left="389" width="109" height="20" font="4">nonisolated ASD or </text>
<text top="176" left="389" width="102" height="20" font="4">isolated VSD, iron-</text>
<text top="193" left="389" width="113" height="20" font="4">deficiency corrected </text>
<text top="107" left="528" width="103" height="20" font="4">Bosentan 62.5 mg </text>
<text top="124" left="528" width="88" height="20" font="4">PO BID × 4 wk, </text>
<text top="141" left="528" width="93" height="20" font="4">then 125 mg PO </text>
<text top="159" left="528" width="79" height="20" font="4">BID, sildenafil </text>
<text top="176" left="528" width="91" height="20" font="4">addition allowed </text>
<text top="193" left="528" width="58" height="20" font="4">for clinical </text>
<text top="210" left="528" width="59" height="20" font="4">worsening </text>
<text top="107" left="648" width="67" height="20" font="4">6MWT, SpO</text>
<text top="113" left="715" width="4" height="13" font="6">2</text>
<text top="107" left="720" width="27" height="20" font="4"> at 6 </text>
<text top="124" left="648" width="79" height="20" font="4">min, FC, Borg </text>
<text top="107" left="767" width="112" height="20" font="4">● Pre vs. bosentan: </text>
<text top="124" left="767" width="135" height="20" font="4">6MWT: 371.9 ± 90.3 vs. </text>
<text top="141" left="767" width="128" height="20" font="4">428.4 ± 98.3; p=0.005; </text>
<text top="159" left="767" width="24" height="20" font="4">SpO</text>
<text top="165" left="792" width="4" height="13" font="6">2</text>
<text top="159" left="796" width="125" height="20" font="4">: 82.0 ± 6.9 vs. 81.9 ± </text>
<text top="176" left="767" width="76" height="20" font="4">6.6; p=0.956; </text>
<text top="193" left="767" width="24" height="20" font="4">SpO</text>
<text top="199" left="792" width="4" height="13" font="6">2</text>
<text top="193" left="796" width="86" height="20" font="4"> peak exercise: </text>
<text top="210" left="767" width="155" height="20" font="4">73.4 ± 13.2 vs. 72.8 ± 10.6; </text>
<text top="228" left="767" width="52" height="20" font="4">p=0.832; </text>
<text top="245" left="767" width="164" height="20" font="4">BORG baseline: 2.4 ± 1.7 vs. </text>
<text top="262" left="767" width="108" height="20" font="4">3.3 ± 2.3; p=0.271; </text>
<text top="279" left="767" width="116" height="20" font="4">BORG end exercise: </text>
<text top="296" left="767" width="128" height="20" font="4">6.7 ± 1.8 vs. 7.5 ± 1.5; </text>
<text top="314" left="767" width="52" height="20" font="4">p=0.108. </text>
<text top="107" left="946" width="120" height="20" font="4">● In pts with complex </text>
<text top="124" left="946" width="132" height="20" font="4">CHD (truncus, TOF/PA, </text>
<text top="141" left="946" width="89" height="20" font="4">PDA, TGA) and </text>
<text top="159" left="946" width="133" height="20" font="4">Eisenmenger syndrome </text>
<text top="176" left="946" width="141" height="20" font="4">with FC I–IV, observed in </text>
<text top="193" left="946" width="127" height="20" font="4">open-label prospective </text>
<text top="210" left="946" width="124" height="20" font="4">study, improvement in </text>
<text top="228" left="946" width="145" height="20" font="4">6MWT with Bosentan was </text>
<text top="245" left="946" width="139" height="20" font="4">sustained to 4 y of follow-</text>
<text top="262" left="946" width="21" height="20" font="4">up. </text>
<text top="332" left="64" width="85" height="20" font="4">Díaz-Caraballo </text>
<text top="349" left="64" width="45" height="20" font="4">E, et al. </text>
<text top="366" left="64" width="66" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(715)</a>  </text>
<text top="383" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24775365?dopt=Citation">24775365</a></text>
<text top="383" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24775365?dopt=Citation"> </a></text>
<text top="332" left="177" width="76" height="20" font="4">Single-center </text>
<text top="349" left="177" width="61" height="20" font="4">open-label </text>
<text top="366" left="177" width="66" height="20" font="4">prospective </text>
<text top="332" left="276" width="51" height="20" font="4">n=10 pts </text>
<text top="332" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="349" left="389" width="76" height="20" font="4">Eisenmenger </text>
<text top="366" left="389" width="118" height="20" font="4">syndrome, &gt;18 y, FC </text>
<text top="383" left="389" width="98" height="20" font="4">II–IV, nonisolated </text>
<text top="400" left="389" width="118" height="20" font="4">ASD or isolated VSD </text>
<text top="332" left="528" width="103" height="20" font="4">Bosentan 62.5 mg </text>
<text top="349" left="528" width="88" height="20" font="4">PO BID × 4 wk, </text>
<text top="366" left="528" width="93" height="20" font="4">then 125 mg PO </text>
<text top="383" left="528" width="24" height="20" font="4">BID </text>
<text top="332" left="648" width="67" height="20" font="4">6MWT, SpO</text>
<text top="338" left="715" width="4" height="13" font="6">2</text>
<text top="332" left="720" width="27" height="20" font="4"> at 6 </text>
<text top="349" left="648" width="44" height="20" font="4">mo, FC </text>
<text top="332" left="767" width="112" height="20" font="4">● Pre vs. bosentan: </text>
<text top="349" left="767" width="152" height="20" font="4">6MWT: 266 ± 161 to 347 ± </text>
<text top="366" left="767" width="99" height="20" font="4">133 min p=0.015; </text>
<text top="383" left="767" width="24" height="20" font="4">SpO</text>
<text top="389" left="792" width="4" height="13" font="6">2</text>
<text top="383" left="796" width="73" height="20" font="4">: No change; </text>
<text top="400" left="767" width="153" height="20" font="4">NYHA: 3.3 ± 0.7–2.5 ± 0.9; </text>
<text top="418" left="767" width="52" height="20" font="4">p=0.002. </text>
<text top="332" left="946" width="120" height="20" font="4">● In pts with complex </text>
<text top="349" left="946" width="92" height="20" font="4">CHD (truncus or </text>
<text top="366" left="946" width="123" height="20" font="4">pseudotruncus, single </text>
<text top="383" left="946" width="117" height="20" font="4">ventricle, TGA, AVC, </text>
<text top="400" left="946" width="76" height="20" font="4">TOF/PA) and </text>
<text top="418" left="946" width="133" height="20" font="4">Eisenmenger syndrome </text>
<text top="435" left="946" width="133" height="20" font="4">with FC II-IV followed in </text>
<text top="452" left="946" width="127" height="20" font="4">open-label prospective </text>
<text top="469" left="946" width="134" height="20" font="4">fashion, improvement in </text>
<text top="487" left="946" width="141" height="20" font="4">6MWT and subjective FC </text>
<text top="504" left="946" width="115" height="20" font="4">without worsening of </text>
<text top="521" left="946" width="92" height="20" font="4">systemic arterial </text>
<text top="538" left="946" width="144" height="20" font="4">saturation, was noted at 6 </text>
<text top="555" left="946" width="90" height="20" font="4">mo of follow-up. </text>
<text top="573" left="64" width="58" height="20" font="3"><b>Sildenafil </b></text>
<text top="591" left="64" width="92" height="20" font="4">Zhang ZN, et al. </text>
<text top="608" left="64" width="66" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(716)</a>  </text>
<text top="626" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21948962?dopt=Citation">21948962</a></text>
<text top="626" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21948962?dopt=Citation"> </a></text>
<text top="591" left="177" width="67" height="20" font="4">Multicenter, </text>
<text top="608" left="177" width="64" height="20" font="4">open-label, </text>
<text top="626" left="177" width="70" height="20" font="4">prospective  </text>
<text top="591" left="276" width="51" height="20" font="4">n=84 pts </text>
<text top="591" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="608" left="389" width="76" height="20" font="4">Eisenmenger </text>
<text top="626" left="389" width="114" height="20" font="4">syndrome, WHO FC </text>
<text top="643" left="389" width="29" height="20" font="4">II–IV </text>
<text top="591" left="528" width="94" height="20" font="4">Sildenafil, 20 mg </text>
<text top="608" left="528" width="86" height="20" font="4">PO TID × 12 m </text>
<text top="591" left="648" width="64" height="20" font="4">6MWT SpO</text>
<text top="597" left="712" width="4" height="13" font="6">2</text>
<text top="591" left="716" width="7" height="20" font="4">, </text>
<text top="608" left="648" width="86" height="20" font="4">hemodynamics </text>
<text top="591" left="767" width="47" height="20" font="4">● 12 m: </text>
<text top="608" left="767" width="145" height="20" font="4">6MWT: + 56 min (95% CI: </text>
<text top="626" left="767" width="104" height="20" font="4">42–69; p&lt;0.0001); </text>
<text top="643" left="767" width="24" height="20" font="4">SpO</text>
<text top="649" left="792" width="4" height="13" font="6">2</text>
<text top="643" left="796" width="100" height="20" font="4">: + 2.4% (95% CI: </text>
<text top="660" left="767" width="132" height="20" font="4">1.8%–2.9%; p&lt;0.0001); </text>
<text top="677" left="767" width="160" height="20" font="4">mPAP: -4.7 mm Hg (95% CI: </text>
<text top="694" left="767" width="115" height="20" font="4">-7.5– -1.9; p=0.001). </text>
<text top="712" left="767" width="152" height="20" font="4">● PVR index: -474 dynes m</text>
<text top="713" left="919" width="4" height="13" font="6">2</text>
<text top="712" left="923" width="3" height="20" font="4"> </text>
<text top="729" left="767" width="118" height="20" font="4">(95% CI: -634– -314; </text>
<text top="746" left="767" width="63" height="20" font="4">p&lt;0.0001). </text>
<text top="591" left="946" width="135" height="20" font="4">● Sildenafil appeared to </text>
<text top="608" left="946" width="111" height="20" font="4">improve 6MWT and </text>
<text top="626" left="946" width="92" height="20" font="4">systemic arterial </text>
<text top="643" left="946" width="135" height="20" font="4">oxygenation at 12 mo of </text>
<text top="660" left="946" width="149" height="20" font="4">follow-up in pts with typical </text>
<text top="677" left="946" width="133" height="20" font="4">Eisenmenger syndrome </text>
<text top="694" left="946" width="134" height="20" font="4">and FC II–IV followed in </text>
<text top="712" left="946" width="127" height="20" font="4">open-label prospective </text>
<text top="729" left="946" width="46" height="20" font="4">fashion. </text>
</page>
<page number="197" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="19" size="12" family="Times" color="#231f20"/>
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 197 </text>
<text top="107" left="64" width="76" height="20" font="4">Garg N, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(717)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21729508?dopt=Citation">21729508</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21729508?dopt=Citation"> </a></text>
<text top="107" left="177" width="63" height="20" font="4">Open label </text>
<text top="124" left="177" width="61" height="20" font="4">single-arm </text>
<text top="141" left="177" width="70" height="20" font="4">prospective  </text>
<text top="107" left="276" width="51" height="20" font="4">n=22 pts </text>
<text top="107" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="389" width="76" height="20" font="4">Eisenmenger </text>
<text top="141" left="389" width="122" height="20" font="4">syndrome, age &gt;12 y, </text>
<text top="159" left="389" width="87" height="20" font="4">FC II, III, stable </text>
<text top="176" left="389" width="121" height="20" font="4">medications, no other </text>
<text top="193" left="389" width="123" height="20" font="4">PAH targeted medical </text>
<text top="210" left="389" width="22" height="20" font="4">Rx. </text>
<text top="227" left="389" width="3" height="20" font="4"> </text>
<text top="245" left="389" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="262" left="389" width="122" height="20" font="4">PDA or complex CHD </text>
<text top="107" left="528" width="102" height="20" font="4">Sildenafil 12.5 PO </text>
<text top="124" left="528" width="95" height="20" font="4">TID × 1 mo, then </text>
<text top="141" left="528" width="82" height="20" font="4">25 mg PO TID </text>
<text top="107" left="648" width="53" height="20" font="4">6MWT, O</text>
<text top="113" left="700" width="7" height="13" font="6">2 </text>
<text top="124" left="648" width="67" height="20" font="4">saturations, </text>
<text top="141" left="648" width="103" height="20" font="4">mPAP, PVR index </text>
<text top="107" left="767" width="129" height="20" font="4">● 6MWT: 305.3 ± 60.1 </text>
<text top="124" left="767" width="114" height="20" font="4">to 476.9 ± 73.6 min; </text>
<text top="141" left="767" width="67" height="20" font="4">(p&lt;0.0001). </text>
<text top="159" left="767" width="37" height="20" font="4">● SpO</text>
<text top="165" left="804" width="4" height="13" font="6">2</text>
<text top="159" left="809" width="120" height="20" font="4">: 86% ± 2% to 91.1 ± </text>
<text top="176" left="767" width="95" height="20" font="4">1.1%; (p&lt;0.001). </text>
<text top="193" left="767" width="161" height="20" font="4">● mPAP: 69.6 ± 10.0 to 62.2 </text>
<text top="210" left="767" width="149" height="20" font="4">± 11.5 mm Hg; (p&lt;0.001).  </text>
<text top="228" left="767" width="140" height="20" font="4">● PVR index: 21.4 ± 3.9–</text>
<text top="245" left="767" width="145" height="20" font="4">15.4 ± 3.9 WU; p&lt;0.0001. </text>
<text top="107" left="946" width="97" height="20" font="4">● Pts with typical </text>
<text top="124" left="946" width="135" height="20" font="4">Eisenmenger Syndrome </text>
<text top="141" left="946" width="138" height="20" font="4">and FC II–III treated with </text>
<text top="159" left="946" width="148" height="20" font="4">sildenafil improved 6MWT, </text>
<text top="176" left="946" width="113" height="20" font="4">hemodynamics, and </text>
<text top="193" left="946" width="92" height="20" font="4">systemic arterial </text>
<text top="210" left="946" width="130" height="20" font="4">saturation after 6 mo of </text>
<text top="228" left="946" width="127" height="20" font="4">open-label prospective </text>
<text top="245" left="946" width="104" height="20" font="4">follow-up; ASD pts </text>
<text top="262" left="946" width="142" height="20" font="4">appeared to have greater </text>
<text top="279" left="946" width="133" height="20" font="4">response than VSD pts. </text>
<text top="297" left="64" width="83" height="20" font="4">D'Alto M, et al. </text>
<text top="314" left="64" width="66" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(718)</a>  </text>
<text top="332" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21081251?dopt=Citation">21081251</a></text>
<text top="332" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21081251?dopt=Citation"> </a></text>
<text top="297" left="177" width="79" height="20" font="4">Single-center, </text>
<text top="314" left="177" width="64" height="20" font="4">open-label, </text>
<text top="332" left="177" width="64" height="20" font="4">single-arm, </text>
<text top="349" left="177" width="70" height="20" font="4">prospective  </text>
<text top="297" left="276" width="54" height="20" font="4">n=28 pts; </text>
<text top="314" left="276" width="76" height="20" font="4">Eisenmenger </text>
<text top="332" left="276" width="88" height="20" font="4">syndrome of 32 </text>
<text top="349" left="276" width="51" height="20" font="4">CHD-PH </text>
<text top="297" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="314" left="389" width="120" height="20" font="4">Clinical worsening on </text>
<text top="332" left="389" width="124" height="20" font="4">Bosentan for CHD-PH </text>
<text top="349" left="389" width="90" height="20" font="4">or Eisenmenger </text>
<text top="366" left="389" width="123" height="20" font="4">syndrome: death from </text>
<text top="383" left="389" width="63" height="20" font="4">any cause, </text>
<text top="401" left="389" width="65" height="20" font="4">nonelective </text>
<text top="418" left="389" width="99" height="20" font="4">hospitalization for </text>
<text top="435" left="389" width="113" height="20" font="4">PAH and/or disease </text>
<text top="452" left="389" width="106" height="20" font="4">progression = 15% </text>
<text top="469" left="389" width="82" height="20" font="4">decrease from </text>
<text top="487" left="389" width="119" height="20" font="4">baseline in 6MWT on </text>
<text top="504" left="389" width="99" height="20" font="4">2 tests performed </text>
<text top="521" left="389" width="76" height="20" font="4">within 2 wk in </text>
<text top="538" left="389" width="90" height="20" font="4">association with </text>
<text top="555" left="389" width="121" height="20" font="4">worsening FC; weight </text>
<text top="573" left="389" width="41" height="20" font="4">&gt;40 kg </text>
<text top="297" left="528" width="64" height="20" font="4">Right heart </text>
<text top="314" left="528" width="83" height="20" font="4">catheterization </text>
<text top="332" left="528" width="65" height="20" font="4">followed by </text>
<text top="349" left="528" width="91" height="20" font="4">Sildenafil 20 mg </text>
<text top="366" left="528" width="44" height="20" font="4">PO TID </text>
<text top="297" left="648" width="48" height="20" font="4">FC, SpO</text>
<text top="303" left="696" width="4" height="13" font="6">2</text>
<text top="297" left="700" width="50" height="20" font="4">, 6MWT, </text>
<text top="314" left="648" width="89" height="20" font="4">hemodynamics, </text>
<text top="332" left="648" width="60" height="20" font="4">serologies </text>
<text top="297" left="767" width="154" height="20" font="4">● WHO FC 2.9 ± 0.3–2.1 ± </text>
<text top="314" left="767" width="76" height="20" font="4">0.4; p=0.042. </text>
<text top="332" left="767" width="9" height="20" font="4">●</text>
<text top="333" left="776" width="2" height="13" font="6"> </text>
<text top="332" left="778" width="24" height="20" font="4">SpO</text>
<text top="338" left="803" width="4" height="13" font="6">2</text>
<text top="332" left="807" width="110" height="20" font="4">: no change 80 ± 9–</text>
<text top="349" left="767" width="87" height="20" font="4">82 ± 8; p=0.48. </text>
<text top="366" left="767" width="164" height="20" font="4">● 6MWT: 293 ± 68 to 3–60 ± </text>
<text top="383" left="767" width="72" height="20" font="4">51; p=0.005. </text>
<text top="400" left="767" width="24" height="20" font="4">SpO</text>
<text top="407" left="792" width="4" height="13" font="6">2</text>
<text top="400" left="796" width="136" height="20" font="4"> post 6MWT 63 ± 15–72 </text>
<text top="418" left="767" width="84" height="20" font="4">± 10; p=0.047. </text>
<text top="435" left="767" width="154" height="20" font="4">● Borg 4.4 ± 2.3–2.9 ± 1.5; </text>
<text top="452" left="767" width="52" height="20" font="4">p=0.036. </text>
<text top="469" left="767" width="148" height="20" font="4">● Qp: 3.1 ± 1.2–3.4 ± 1.0; </text>
<text top="487" left="767" width="58" height="20" font="4">p=0.0002. </text>
<text top="504" left="767" width="166" height="20" font="4">● RA: 13 ± 4–11 ± 3; p=0.09. </text>
<text top="521" left="767" width="153" height="20" font="4">● mPAP: 73 ± 20–71 ± 17; </text>
<text top="538" left="767" width="45" height="20" font="4">p=0.09. </text>
<text top="555" left="767" width="155" height="20" font="4">● PVR index: 24 ± 16–19 ± </text>
<text top="573" left="767" width="65" height="20" font="4">9; p=0.003. </text>
<text top="590" left="767" width="162" height="20" font="4">● ProBNP: 760 ± 943–303 ± </text>
<text top="607" left="767" width="76" height="20" font="4">366; p=0.008 </text>
<text top="297" left="946" width="143" height="20" font="4">● Combination therapy of </text>
<text top="314" left="946" width="102" height="20" font="4">sildenafil added to </text>
<text top="332" left="946" width="138" height="20" font="4">baseline Bosentan in the </text>
<text top="349" left="946" width="94" height="20" font="4">setting of clinical </text>
<text top="366" left="946" width="129" height="20" font="4">worsening appeared to </text>
<text top="383" left="946" width="90" height="20" font="4">improve 6MWT, </text>
<text top="401" left="946" width="142" height="20" font="4">hemodynamics, BNP and </text>
<text top="418" left="946" width="120" height="20" font="4">subjective FC without </text>
<text top="435" left="946" width="124" height="20" font="4">worsening of systemic </text>
<text top="452" left="946" width="146" height="20" font="4">arterial saturation during 6 </text>
<text top="469" left="946" width="95" height="20" font="4">mo of open-label </text>
<text top="487" left="946" width="122" height="20" font="4">prospective follow-up. </text>
<text top="625" left="64" width="89" height="20" font="4">Iversen K, et al. </text>
<text top="642" left="64" width="66" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(719)</a>  </text>
<text top="659" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20202971?dopt=Citation">20202971</a></text>
<text top="659" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20202971?dopt=Citation"> </a></text>
<text top="625" left="177" width="72" height="20" font="4">Randomized </text>
<text top="642" left="177" width="47" height="20" font="4">placebo-</text>
<text top="659" left="177" width="60" height="20" font="4">controlled, </text>
<text top="677" left="177" width="41" height="20" font="4">double-</text>
<text top="694" left="177" width="80" height="20" font="4">blinded, cross-</text>
<text top="711" left="177" width="66" height="20" font="4">over, single </text>
<text top="728" left="177" width="38" height="20" font="4">center </text>
<text top="625" left="276" width="72" height="20" font="4">n=21 pts (19 </text>
<text top="642" left="276" width="57" height="20" font="4">complete) </text>
<text top="625" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="642" left="389" width="114" height="20" font="4">≥18 y, Eisenmenger </text>
<text top="659" left="389" width="121" height="20" font="4">syndrome, defined as </text>
<text top="677" left="389" width="124" height="20" font="4">PH by cath right to left </text>
<text top="694" left="389" width="95" height="20" font="4">shunting through </text>
<text top="711" left="389" width="114" height="20" font="4">nonrestrictive defect </text>
<text top="625" left="528" width="103" height="20" font="4">Bosentan 62.5 mg </text>
<text top="642" left="528" width="88" height="20" font="4">PO BID × 2 wk, </text>
<text top="659" left="528" width="89" height="20" font="4">125 mg PO BID </text>
<text top="677" left="528" width="101" height="20" font="4">thereafter × 9 mo, </text>
<text top="694" left="528" width="81" height="20" font="4">at 12 wk, after </text>
<text top="711" left="528" width="52" height="20" font="4">repeated </text>
<text top="728" left="528" width="61" height="20" font="4">measures, </text>
<text top="745" left="528" width="89" height="20" font="4">sildenafil 25 mg </text>
<text top="763" left="528" width="103" height="20" font="4">PO TID added × 2 </text>
<text top="780" left="528" width="87" height="20" font="4">wk, then 50 mg </text>
<text top="625" left="648" width="59" height="20" font="4">1°6MWT,  </text>
<text top="642" left="648" width="41" height="20" font="4">2° SpO</text>
<text top="648" left="689" width="4" height="13" font="6">2</text>
<text top="642" left="693" width="51" height="20" font="4"> rest and </text>
<text top="659" left="648" width="105" height="20" font="4">exercise, NT-BNP, </text>
<text top="677" left="648" width="87" height="20" font="4">NYHA FC, MRI </text>
<text top="694" left="648" width="85" height="20" font="4">blood flow, Qp, </text>
<text top="711" left="648" width="104" height="20" font="4">Qp/Qs, PVR index </text>
<text top="625" left="767" width="105" height="20" font="4">● Bosentan alone: </text>
<text top="642" left="767" width="165" height="20" font="4">6MWT 377–414 min (95% CI: </text>
<text top="659" left="767" width="113" height="20" font="4">17–58 min); p=0.01; </text>
<text top="677" left="767" width="72" height="20" font="4">Qp (catheter)</text>
<text top="677" left="840" width="3" height="20" font="19"> </text>
<text top="677" left="843" width="88" height="20" font="4">2.6–3.5 change </text>
<text top="694" left="767" width="127" height="20" font="4">0.9; (95% CI: 0.3–1.6); </text>
<text top="711" left="767" width="45" height="20" font="4">p=0.01; </text>
<text top="729" left="767" width="145" height="20" font="4">Qp/Qs 0.64–0.79  change </text>
<text top="747" left="767" width="148" height="20" font="4">0.16; (95% CI: 0.03–0.28); </text>
<text top="764" left="767" width="45" height="20" font="4">p=0.02; </text>
<text top="625" left="946" width="94" height="20" font="4">● In randomized </text>
<text top="642" left="946" width="113" height="20" font="4">controlled crossover </text>
<text top="659" left="946" width="117" height="20" font="4">study, the addition of </text>
<text top="677" left="946" width="133" height="20" font="4">sildenafil to Bosentan in </text>
<text top="694" left="946" width="112" height="20" font="4">subjects with typical </text>
<text top="711" left="946" width="133" height="20" font="4">Eisenmenger syndrome </text>
<text top="728" left="946" width="111" height="20" font="4">followed for 3 mo of </text>
<text top="745" left="946" width="114" height="20" font="4">combination therapy </text>
<text top="763" left="946" width="131" height="20" font="4">improved only systemic </text>
<text top="780" left="946" width="141" height="20" font="4">arterial saturation without </text>
</page>
<page number="198" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 198 </text>
<text top="107" left="528" width="90" height="20" font="4">PO TID × 10 wk </text>
<text top="124" left="528" width="69" height="20" font="4">vs. placebo; </text>
<text top="141" left="528" width="52" height="20" font="4">repeated </text>
<text top="159" left="528" width="61" height="20" font="4">measures, </text>
<text top="176" left="528" width="102" height="20" font="4">sildenafil switched </text>
<text top="193" left="528" width="104" height="20" font="4">for placebo or vice </text>
<text top="210" left="528" width="103" height="20" font="4">versa × 2 wk, then </text>
<text top="228" left="528" width="77" height="20" font="4">10 wk, repeat </text>
<text top="245" left="528" width="57" height="20" font="4">measures </text>
<text top="107" left="767" width="123" height="20" font="4">PVR index: 28.3–21.8 </text>
<text top="126" left="767" width="4" height="18" font="4"> </text>
<text top="125" left="771" width="154" height="20" font="4">change -6.5; (95% CI: 11.3–</text>
<text top="143" left="767" width="73" height="20" font="4">1.7); p=0.01; </text>
<text top="160" left="767" width="141" height="20" font="4">With add on therapy: SpO</text>
<text top="166" left="908" width="4" height="13" font="6">2</text>
<text top="160" left="913" width="3" height="20" font="4"> </text>
<text top="177" left="767" width="165" height="20" font="4">placebo vs. sildenafil -1.8–2.9 </text>
<text top="194" left="767" width="143" height="20" font="4">change 4.7; (95% CI: 1.9–</text>
<text top="211" left="767" width="73" height="20" font="4">7.5); p=0.01; </text>
<text top="229" left="767" width="24" height="20" font="4">SpO</text>
<text top="235" left="792" width="4" height="13" font="6">2</text>
<text top="229" left="796" width="125" height="20" font="4"> end exercise -2.9–3.9 </text>
<text top="246" left="767" width="150" height="20" font="4">change 6.8; (95% CI: 20.5–</text>
<text top="263" left="767" width="80" height="20" font="4">14.2); p=0.07; </text>
<text top="280" left="767" width="129" height="20" font="4">No change 6MWT, Qp, </text>
<text top="298" left="767" width="42" height="20" font="4">Qp/Qs. </text>
<text top="107" left="946" width="120" height="20" font="4">evidence of improved </text>
<text top="124" left="946" width="100" height="20" font="4">hemodynamics or </text>
<text top="141" left="946" width="130" height="20" font="4">exercise capacity when </text>
<text top="159" left="946" width="121" height="20" font="4">compared to baseline </text>
<text top="176" left="946" width="148" height="20" font="4">measures performed while </text>
<text top="193" left="946" width="95" height="20" font="4">taking Bosentan. </text>
<text top="316" left="64" width="87" height="20" font="4">Singh TP, et al. </text>
<text top="333" left="64" width="66" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(720)</a>  </text>
<text top="350" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16569546?dopt=Citation">16569546</a></text>
<text top="350" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16569546?dopt=Citation"> </a></text>
<text top="316" left="177" width="76" height="20" font="4">Randomized, </text>
<text top="333" left="177" width="74" height="20" font="4">double-blind, </text>
<text top="350" left="177" width="47" height="20" font="4">placebo-</text>
<text top="367" left="177" width="60" height="20" font="4">controlled, </text>
<text top="384" left="177" width="57" height="20" font="4">crossover </text>
<text top="316" left="276" width="83" height="20" font="4">n=10 PAH pts, </text>
<text top="333" left="276" width="93" height="20" font="4">10 Eisenmenger </text>
<text top="350" left="276" width="77" height="20" font="4">syndrome pts </text>
<text top="316" left="389" width="122" height="20" font="3"><b>Inclusion criteria</b>: All </text>
<text top="333" left="389" width="76" height="20" font="4">ages, PAH or </text>
<text top="350" left="389" width="76" height="20" font="4">Eisenmenger </text>
<text top="367" left="389" width="101" height="20" font="4">syndrome; clinical </text>
<text top="384" left="389" width="100" height="20" font="4">exclusion of other </text>
<text top="402" left="389" width="42" height="20" font="4">causes </text>
<text top="316" left="528" width="78" height="20" font="4">Adults: 25 mg </text>
<text top="333" left="528" width="74" height="20" font="4">sildenafil trial </text>
<text top="350" left="528" width="105" height="20" font="4">dose, then 100 mg </text>
<text top="367" left="528" width="97" height="20" font="4">PO TID × 6 wk, 2 </text>
<text top="384" left="528" width="98" height="20" font="4">wk washout, then </text>
<text top="402" left="528" width="86" height="20" font="4">placebo × 6 wk </text>
<text top="316" left="648" width="53" height="20" font="4">1°6MWT </text>
<text top="333" left="648" width="97" height="20" font="4">2°: SBP exercise </text>
<text top="350" left="648" width="81" height="20" font="4">tolerance test, </text>
<text top="367" left="648" width="73" height="20" font="4">TTE Doppler </text>
<text top="384" left="648" width="91" height="20" font="4">measures of TR </text>
<text top="402" left="648" width="106" height="20" font="4">velocity and RVOT </text>
<text top="419" left="648" width="44" height="20" font="4">velocity </text>
<text top="316" left="767" width="108" height="20" font="4">● All Comers Only: </text>
<text top="333" left="767" width="158" height="20" font="4">6MWT: baseline vs. placebo </text>
<text top="350" left="767" width="138" height="20" font="4">31.4 ± 9.2; (95% CI: 7.2–</text>
<text top="367" left="767" width="87" height="20" font="4">55.6; p=0.009); </text>
<text top="384" left="767" width="128" height="20" font="4">Baseline vs. sildenafil:  </text>
<text top="402" left="767" width="152" height="20" font="4">96.9 ± 11.3; (95% CI: 67.2–</text>
<text top="419" left="767" width="100" height="20" font="4">126.6; p=0.0001); </text>
<text top="436" left="767" width="125" height="20" font="4">Placebo vs. sildenafil:  </text>
<text top="453" left="767" width="152" height="20" font="4">65.5 ± 11.0; (95% CI: 36.7–</text>
<text top="470" left="767" width="93" height="20" font="4">94.4; p=0.0001). </text>
<text top="488" left="767" width="147" height="20" font="4">● Echocardiography PAP: </text>
<text top="505" left="767" width="116" height="20" font="4">Baseline vs. placebo </text>
<text top="522" left="767" width="146" height="20" font="4">- 3.9 ± 2.0; (95% CI: -9.2 –</text>
<text top="539" left="767" width="80" height="20" font="4">1.3; p=0.189); </text>
<text top="557" left="767" width="121" height="20" font="4">Baseline vs. sildenafil </text>
<text top="574" left="767" width="161" height="20" font="4">- 20.6 ± 2.9 (95% CI: -28.2– -</text>
<text top="591" left="767" width="93" height="20" font="4">13.0; p=0.0001); </text>
<text top="608" left="767" width="118" height="20" font="4">Placebo vs. sildenafil </text>
<text top="625" left="767" width="157" height="20" font="4">-16.6 ± 2.2 (95% CI: -22.4– -</text>
<text top="643" left="767" width="93" height="20" font="4">10.9; p=0.0001). </text>
<text top="660" left="767" width="152" height="20" font="4">● No change SBP exercise </text>
<text top="677" left="767" width="126" height="20" font="4">tolerance test exercise </text>
<text top="694" left="767" width="107" height="20" font="4">duration, metabolic </text>
<text top="711" left="767" width="113" height="20" font="4">equivalent improved </text>
<text top="729" left="767" width="67" height="20" font="4">(p=0.0001). </text>
<text top="746" left="767" width="114" height="20" font="4">● No data regarding </text>
<text top="763" left="767" width="165" height="20" font="4">Eisenmenger syndrome other </text>
<text top="316" left="946" width="131" height="20" font="4">● Use of sildenafil for 6 </text>
<text top="333" left="946" width="115" height="20" font="4">wk in pts with typical </text>
<text top="350" left="946" width="133" height="20" font="4">Eisenmenger syndrome </text>
<text top="367" left="946" width="147" height="20" font="4">appeared, when assessed </text>
<text top="384" left="946" width="129" height="20" font="4">in aggregate with other </text>
<text top="402" left="946" width="129" height="20" font="4">subjects with idiopathic </text>
<text top="419" left="946" width="113" height="20" font="4">PAH, in randomized </text>
<text top="436" left="946" width="117" height="20" font="4">crossover fashion, to </text>
<text top="453" left="946" width="141" height="20" font="4">improve 6MWT and echo-</text>
<text top="470" left="946" width="133" height="20" font="4">derived estimates of PA </text>
<text top="488" left="946" width="141" height="20" font="4">pressure, without change </text>
<text top="505" left="946" width="120" height="20" font="4">in measured exercise </text>
<text top="522" left="946" width="69" height="20" font="4">parameters. </text>
</page>
<page number="199" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 199 </text>
<text top="107" left="767" width="128" height="20" font="4">than NS differences on </text>
<text top="124" left="767" width="56" height="20" font="4">substudy. </text>
<text top="411" left="64" width="91" height="20" font="4">Bharani A, et al. </text>
<text top="428" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(721)</a> </text>
<text top="445" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19126937?dopt=Citation">19126937</a></text>
<text top="445" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19126937?dopt=Citation"> </a></text>
<text top="411" left="177" width="44" height="20" font="4">Blinded </text>
<text top="428" left="177" width="57" height="20" font="4">crossover </text>
<text top="445" left="177" width="33" height="20" font="4">study </text>
<text top="411" left="276" width="65" height="20" font="4">n=11 pts, 8 </text>
<text top="428" left="276" width="53" height="20" font="4">analyzed </text>
<text top="411" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="428" left="389" width="115" height="20" font="4">PAH in pts with prior </text>
<text top="445" left="389" width="75" height="20" font="4">shunt lesions </text>
<text top="411" left="528" width="87" height="20" font="4">Tadalafil 20 mg </text>
<text top="428" left="528" width="90" height="20" font="4">daily or placebo </text>
<text top="411" left="648" width="83" height="20" font="4">6MWT, PASP, </text>
<text top="428" left="648" width="84" height="20" font="4">Who class and </text>
<text top="445" left="648" width="81" height="20" font="4">Borg Dyspnea </text>
<text top="462" left="648" width="33" height="20" font="4">Index </text>
<text top="411" left="767" width="148" height="20" font="4">● 8 pts analyzed. Tadalafil </text>
<text top="428" left="767" width="147" height="20" font="4">was compared to Tadalafil </text>
<text top="445" left="767" width="154" height="20" font="4">associated with an increase </text>
<text top="462" left="767" width="163" height="20" font="4">in 6MWT (mean: 409.25, SD: </text>
<text top="480" left="767" width="166" height="20" font="4">40.25 m vs. 319.37 SD: 42.39 </text>
<text top="497" left="767" width="147" height="20" font="4">m; p&lt;0.0001), reduction in </text>
<text top="514" left="767" width="156" height="20" font="4">PASP (88.75 SD: 23.26 mm </text>
<text top="531" left="767" width="151" height="20" font="4">Hg vs. 109.5 SD 23.78 mm </text>
<text top="548" left="767" width="160" height="20" font="4">Hg; p&lt;0.0001), improvement </text>
<text top="566" left="767" width="164" height="20" font="4">in BMI (4.62 SD 2.56 vs. 6.37 </text>
<text top="583" left="767" width="161" height="20" font="4">SD 2.61; p=0.021) and WHO </text>
<text top="600" left="767" width="125" height="20" font="4">Class (6 pts vs. 2 pts), </text>
<text top="617" left="767" width="125" height="20" font="4">compared to placebo.  </text>
<text top="411" left="946" width="101" height="20" font="4">● Use of Tadalafil </text>
<text top="428" left="946" width="87" height="20" font="4">associated with </text>
<text top="445" left="946" width="120" height="20" font="4">improvement in small </text>
<text top="462" left="946" width="135" height="20" font="4">series, short-term follow-</text>
<text top="480" left="946" width="24" height="20" font="4">up.  </text>
<text top="635" left="64" width="79" height="20" font="3"><b>Ambrisentan </b></text>
<text top="653" left="64" width="91" height="20" font="4">Zuckerman WA, </text>
<text top="670" left="64" width="30" height="20" font="4">et al. </text>
<text top="688" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(722)</a> </text>
<text top="705" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21371683?dopt=Citation">21371683</a></text>
<text top="705" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21371683?dopt=Citation"> </a></text>
<text top="653" left="177" width="66" height="20" font="4">Open label, </text>
<text top="670" left="177" width="76" height="20" font="4">cohort, single </text>
<text top="688" left="177" width="41" height="20" font="4">center, </text>
<text top="705" left="177" width="74" height="20" font="4">retrospective </text>
<text top="653" left="276" width="51" height="20" font="4">n=17 pts </text>
<text top="653" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="670" left="389" width="76" height="20" font="4">Eisenmenger </text>
<text top="688" left="389" width="103" height="20" font="4">syndrome, treated </text>
<text top="705" left="389" width="96" height="20" font="4">with ambrisentan </text>
<text top="653" left="528" width="103" height="20" font="4">Ambrisentan 5–10 </text>
<text top="670" left="528" width="102" height="20" font="4">mg PO daily, after </text>
<text top="688" left="528" width="73" height="20" font="4">pretreatment </text>
<text top="705" left="528" width="59" height="20" font="4">either with </text>
<text top="722" left="528" width="68" height="20" font="4">bosentan or </text>
<text top="739" left="528" width="66" height="20" font="4">sitaxsentan </text>
<text top="653" left="648" width="67" height="20" font="4">6MWT, SpO</text>
<text top="659" left="715" width="4" height="13" font="6">2</text>
<text top="653" left="720" width="3" height="20" font="4"> </text>
<text top="653" left="767" width="163" height="20" font="4">● 6MWT: 389 ± 74 vs. 417 ± </text>
<text top="670" left="767" width="151" height="20" font="4">77 min at 3–9 mo follow-up </text>
<text top="688" left="767" width="53" height="20" font="4">(p=0.03). </text>
<text top="705" left="767" width="158" height="20" font="4">● 420 ± 88 vs. 401 ± 68 mo </text>
<text top="722" left="767" width="146" height="20" font="4">at &gt;1 y follow-up (p=0.15). </text>
<text top="739" left="767" width="37" height="20" font="4">● SpO</text>
<text top="745" left="804" width="4" height="13" font="6">2</text>
<text top="739" left="809" width="107" height="20" font="4">: No change in 3–9 </text>
<text top="757" left="767" width="118" height="20" font="4">mo or &gt;1 y follow-up. </text>
<text top="653" left="946" width="135" height="20" font="4">● Use of ambrisentan in </text>
<text top="670" left="946" width="112" height="20" font="4">subjects with typical </text>
<text top="688" left="946" width="133" height="20" font="4">Eisenmenger syndrome </text>
<text top="705" left="946" width="117" height="20" font="4">studied in open-label </text>
<text top="722" left="946" width="117" height="20" font="4">retrospective fashion </text>
<text top="739" left="946" width="135" height="20" font="4">demonstrated decline at </text>
<text top="757" left="946" width="121" height="20" font="4">&gt;1 y of follow-up from </text>
<text top="774" left="946" width="124" height="20" font="4">early improved 6MWT </text>
</page>
<page number="200" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 200 </text>
<text top="107" left="946" width="120" height="20" font="4">measured at 3–9 mo, </text>
<text top="124" left="946" width="115" height="20" font="4">without worsening of </text>
<text top="141" left="946" width="92" height="20" font="4">systemic arterial </text>
<text top="159" left="946" width="143" height="20" font="4">saturation during therapy. </text>
<text top="177" left="64" width="53" height="20" font="3"><b>Tadalafil </b></text>
<text top="195" left="64" width="87" height="20" font="4">Mukhopadhyay </text>
<text top="212" left="64" width="45" height="20" font="4">S, et al. </text>
<text top="229" left="64" width="66" height="20" font="4">2006 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(723)</a>  </text>
<text top="246" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17030688?dopt=Citation">17030688</a></text>
<text top="246" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17030688?dopt=Citation"> </a></text>
<text top="195" left="177" width="66" height="20" font="4">Open label, </text>
<text top="212" left="177" width="64" height="20" font="4">single-arm, </text>
<text top="229" left="177" width="66" height="20" font="4">prospective </text>
<text top="195" left="276" width="51" height="20" font="4">n=16 pts </text>
<text top="195" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="212" left="389" width="119" height="20" font="4">Clinical Eisenmenger </text>
<text top="229" left="389" width="120" height="20" font="4">syndrome, cath when </text>
<text top="246" left="389" width="63" height="20" font="4">necessary, </text>
<text top="264" left="389" width="73" height="20" font="4">symptomatic </text>
<text top="281" left="389" width="3" height="20" font="4"> </text>
<text top="298" left="389" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="315" left="389" width="122" height="20" font="4">WHOFC IV, overt HF, </text>
<text top="332" left="389" width="109" height="20" font="4">pulmonary capillary </text>
<text top="350" left="389" width="119" height="20" font="4">wedge pressure &gt;15, </text>
<text top="367" left="389" width="107" height="20" font="4">abnormal serologic </text>
<text top="384" left="389" width="63" height="20" font="4">profile, AF, </text>
<text top="401" left="389" width="101" height="20" font="4">hypersensitivity to </text>
<text top="418" left="389" width="88" height="20" font="4">PDE5 inhibitors </text>
<text top="195" left="528" width="58" height="20" font="4">Acute: PA </text>
<text top="212" left="528" width="98" height="20" font="4">catheter, 1 mg/kg </text>
<text top="229" left="528" width="94" height="20" font="4">tadalafil followed </text>
<text top="246" left="528" width="105" height="20" font="4">by measures, then </text>
<text top="264" left="528" width="66" height="20" font="4">40 mg daily </text>
<text top="281" left="528" width="97" height="20" font="4">tadalafil measure </text>
<text top="298" left="528" width="67" height="20" font="4">mo × 12 wk </text>
<text top="195" left="648" width="91" height="20" font="4">Acute: Systemic </text>
<text top="212" left="648" width="49" height="20" font="4">vascular </text>
<text top="229" left="648" width="63" height="20" font="4">resistance, </text>
<text top="246" left="648" width="80" height="20" font="4">PVR/systemic </text>
<text top="264" left="648" width="49" height="20" font="4">vascular </text>
<text top="281" left="648" width="90" height="20" font="4">resistance ratio, </text>
<text top="298" left="648" width="24" height="20" font="4">SpO</text>
<text top="304" left="672" width="4" height="13" font="6">2</text>
<text top="298" left="677" width="55" height="20" font="4"> systemic </text>
<text top="315" left="648" width="89" height="20" font="4">and PA, mPAP, </text>
<text top="332" left="648" width="100" height="20" font="4">sPAP, right-to-left </text>
<text top="350" left="648" width="97" height="20" font="4">shunt, Qpeff, FC, </text>
<text top="367" left="648" width="40" height="20" font="4">6MWT </text>
<text top="195" left="767" width="79" height="20" font="4">12 wk results: </text>
<text top="212" left="767" width="134" height="20" font="4">● Tadalafil vs. baseline: </text>
<text top="229" left="767" width="159" height="20" font="4">PVR: 17.02 ± 6.19 vs. 24.75 </text>
<text top="246" left="767" width="94" height="20" font="4">± 8.49; p&lt;0.005; </text>
<text top="264" left="767" width="129" height="20" font="4">PVR/systemic vascular </text>
<text top="281" left="767" width="148" height="20" font="4">resistance: 0.71 ± 0.26 vs. </text>
<text top="298" left="767" width="121" height="20" font="4">1.09 ± 0.34; p&lt;0.005; </text>
<text top="315" left="767" width="134" height="20" font="4">mPAP: 75.5 ± 15.09 vs. </text>
<text top="332" left="767" width="135" height="20" font="4">81.75 ± 14.21; p&lt;0.005; </text>
<text top="350" left="767" width="24" height="20" font="4">SpO</text>
<text top="356" left="792" width="4" height="13" font="6">2</text>
<text top="350" left="796" width="127" height="20" font="4">: 89.16 ± 3.8 vs. 87.39 </text>
<text top="367" left="767" width="94" height="20" font="4">± 4.34; p&lt;0.005; </text>
<text top="384" left="767" width="161" height="20" font="4">Qpeff: 2.82 ± 0.88 vs. 2.46 ± </text>
<text top="401" left="767" width="76" height="20" font="4">0.69; p&lt;0.08; </text>
<text top="418" left="767" width="143" height="20" font="4">Right-to-left shunt: 1.16 ± </text>
<text top="436" left="767" width="137" height="20" font="4">0.62 vs. 1.71 ± 0.92 mo; </text>
<text top="453" left="767" width="52" height="20" font="4">p=0.018; </text>
<text top="470" left="767" width="148" height="20" font="4">FC: 1.25 ± 0.44 vs. 2.31 ± </text>
<text top="487" left="767" width="98" height="20" font="4">0.47; (p&lt;0.0001); </text>
<text top="504" left="767" width="156" height="20" font="4">6MWT: 387.56 ± 117.18 vs. </text>
<text top="522" left="767" width="157" height="20" font="4">344.56 ± 119.06; (p&lt;0.001). </text>
<text top="195" left="946" width="124" height="20" font="4">● Tadalafil for 3 mo in </text>
<text top="212" left="946" width="112" height="20" font="4">subjects with typical </text>
<text top="229" left="946" width="93" height="20" font="4">clinically defined </text>
<text top="246" left="946" width="133" height="20" font="4">Eisenmenger syndrome </text>
<text top="264" left="946" width="140" height="20" font="4">FC II–III followed in open-</text>
<text top="281" left="946" width="139" height="20" font="4">label prospective fashion </text>
<text top="298" left="946" width="116" height="20" font="4">appeared to improve </text>
<text top="315" left="946" width="110" height="20" font="4">hemodynamics and </text>
<text top="332" left="946" width="92" height="20" font="4">systemic arterial </text>
<text top="350" left="946" width="61" height="20" font="4">saturation. </text>
<text top="540" left="64" width="87" height="20" font="4">Mukhopadhyay </text>
<text top="557" left="64" width="45" height="20" font="4">S, et al. </text>
<text top="574" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(724)</a> </text>
<text top="591" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21914136?dopt=Citation">21914136</a></text>
<text top="591" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21914136?dopt=Citation"> </a></text>
<text top="540" left="177" width="76" height="20" font="4">Single-center </text>
<text top="557" left="177" width="68" height="20" font="4">randomized </text>
<text top="574" left="177" width="57" height="20" font="4">controlled </text>
<text top="591" left="177" width="57" height="20" font="4">crossover </text>
<text top="540" left="276" width="51" height="20" font="4">n=28 pts </text>
<text top="540" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="557" left="389" width="124" height="20" font="4">Catheterization-based </text>
<text top="574" left="389" width="69" height="20" font="4">diagnosis of </text>
<text top="591" left="389" width="76" height="20" font="4">Eisenmenger </text>
<text top="608" left="389" width="121" height="20" font="4">syndrome with mPAP </text>
<text top="626" left="389" width="112" height="20" font="4">&gt;40 mm, pulmonary </text>
<text top="643" left="389" width="88" height="20" font="4">capillary wedge </text>
<text top="660" left="389" width="103" height="20" font="4">pressure &lt;15 mm, </text>
<text top="677" left="389" width="99" height="20" font="4">and PVR &gt;10 U/m</text>
<text top="679" left="488" width="4" height="13" font="6">2</text>
<text top="677" left="493" width="7" height="20" font="4">, </text>
<text top="694" left="389" width="84" height="20" font="4">systemic pulse </text>
<text top="712" left="389" width="122" height="20" font="4">oximetry 70% and 90, </text>
<text top="729" left="389" width="116" height="20" font="4">baseline 6MWT 150–</text>
<text top="746" left="389" width="38" height="20" font="4">450 m </text>
<text top="763" left="389" width="3" height="20" font="4"> </text>
<text top="540" left="528" width="105" height="20" font="4">Pts given 40 mg of </text>
<text top="557" left="528" width="60" height="20" font="4">tadalafil or </text>
<text top="574" left="528" width="100" height="20" font="4">matching placebo </text>
<text top="591" left="528" width="95" height="20" font="4">for 6 wk followed </text>
<text top="608" left="528" width="89" height="20" font="4">by washout of 2 </text>
<text top="626" left="528" width="83" height="20" font="4">wk followed by </text>
<text top="643" left="528" width="91" height="20" font="4">crossover to the </text>
<text top="660" left="528" width="63" height="20" font="4">other drug  </text>
<text top="540" left="648" width="76" height="20" font="4">1°EP: 6MWT </text>
<text top="557" left="648" width="83" height="20" font="4">compared with </text>
<text top="574" left="648" width="106" height="20" font="4">baseline after 6 wk </text>
<text top="591" left="648" width="22" height="20" font="4">Rx. </text>
<text top="608" left="648" width="3" height="20" font="4"> </text>
<text top="626" left="648" width="67" height="20" font="4">2° EP:  SpO</text>
<text top="632" left="715" width="4" height="13" font="6">2</text>
<text top="626" left="720" width="7" height="20" font="4">, </text>
<text top="643" left="648" width="94" height="20" font="4">pulmonary blood </text>
<text top="660" left="648" width="61" height="20" font="4">flow, PVR, </text>
<text top="677" left="648" width="100" height="20" font="4">systemic vascular </text>
<text top="694" left="648" width="96" height="20" font="4">resistance, WHO </text>
<text top="712" left="648" width="20" height="20" font="4">FC </text>
<text top="540" left="767" width="127" height="20" font="4">● 6MWT: tadalafil was </text>
<text top="557" left="767" width="162" height="20" font="4">associated with improvement </text>
<text top="575" left="767" width="166" height="20" font="4">404.18 ± 69.54 m vs. placebo </text>
<text top="594" left="767" width="156" height="20" font="4">357.75 ± 73.25 m; p&lt;0.001. </text>
<text top="611" left="767" width="146" height="20" font="4">● PVR: tadalafil treatment </text>
<text top="628" left="767" width="162" height="20" font="4">was associated with lowering </text>
<text top="646" left="767" width="107" height="20" font="4">by 7.32 ± 1.58 U*m</text>
<text top="648" left="874" width="4" height="13" font="6">2</text>
<text top="646" left="878" width="55" height="20" font="4">; p&lt;0.001 </text>
<text top="665" left="767" width="163" height="20" font="4">with increase in EPBF 0.12 ± </text>
<text top="682" left="767" width="76" height="20" font="4">0.05; p=0.03. </text>
<text top="699" left="767" width="37" height="20" font="4">● SpO</text>
<text top="705" left="804" width="4" height="13" font="6">2</text>
<text top="699" left="809" width="119" height="20" font="4">%: tadalafil treatment </text>
<text top="716" left="767" width="113" height="20" font="4">was associated with </text>
<text top="735" left="767" width="154" height="20" font="4">increased by 1.72 ± 0.58%; </text>
<text top="752" left="767" width="52" height="20" font="4">p=0.007. </text>
<text top="769" left="767" width="159" height="20" font="4">● WHO FC: tadalafil therapy </text>
<text top="786" left="767" width="113" height="20" font="4">was associated with </text>
<text top="540" left="946" width="144" height="20" font="4">● Short-term therapy with </text>
<text top="557" left="946" width="137" height="20" font="4">tadalafil for subjects with </text>
<text top="574" left="946" width="114" height="20" font="4">typical Eisenmenger </text>
<text top="591" left="946" width="138" height="20" font="4">syndrome WHO FC II–III </text>
<text top="608" left="946" width="116" height="20" font="4">appeared to improve </text>
<text top="626" left="946" width="145" height="20" font="4">6MWT and subjective FC, </text>
<text top="643" left="946" width="98" height="20" font="4">and PVR, without </text>
<text top="660" left="946" width="124" height="20" font="4">worsening of systemic </text>
<text top="677" left="946" width="66" height="20" font="4">arterial SpO</text>
<text top="684" left="1012" width="4" height="13" font="6">2</text>
<text top="677" left="1016" width="7" height="20" font="4">. </text>
</page>
<page number="201" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 201 </text>
<text top="107" left="389" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="124" left="389" width="126" height="20" font="4">WHO IV, clinical HF or </text>
<text top="141" left="389" width="109" height="20" font="4">pulmonary capillary </text>
<text top="159" left="389" width="115" height="20" font="4">wedge pressure &gt;15 </text>
<text top="176" left="389" width="123" height="20" font="4">mm, LVEF &lt;40%, AF, </text>
<text top="193" left="389" width="124" height="20" font="4">PDA or other complex </text>
<text top="210" left="389" width="91" height="20" font="4">congenital heart </text>
<text top="228" left="389" width="102" height="20" font="4">defects, restrictive </text>
<text top="245" left="389" width="103" height="20" font="4">lung disease (total </text>
<text top="262" left="389" width="118" height="20" font="4">lung capacity &lt;70%), </text>
<text top="279" left="389" width="89" height="20" font="4">obstructive lung </text>
<text top="296" left="389" width="87" height="20" font="4">disease (forced </text>
<text top="314" left="389" width="124" height="20" font="4">expiratory volume in 1 </text>
<text top="331" left="389" width="107" height="20" font="4">s &lt;70% with forced </text>
<text top="348" left="389" width="124" height="20" font="4">expiratory volume in 1 </text>
<text top="365" left="389" width="121" height="20" font="4">s/forced vital capacity </text>
<text top="383" left="389" width="101" height="20" font="4">&lt;60%), previously </text>
<text top="400" left="389" width="89" height="20" font="4">diagnosed CAD </text>
<text top="417" left="389" width="98" height="20" font="4">requiring nitrates, </text>
<text top="434" left="389" width="123" height="20" font="4">abnormal biochemical </text>
<text top="451" left="389" width="40" height="20" font="4">profile, </text>
<text top="469" left="389" width="101" height="20" font="4">hypersensitivity to </text>
<text top="486" left="389" width="92" height="20" font="4">PDE5 inhibitors. </text>
<text top="108" left="767" width="163" height="20" font="4">improvement, 1.96 ± 0.18 vs. </text>
<text top="125" left="767" width="117" height="20" font="4">2.14; 0.44; p=0.025). </text>
<text top="143" left="767" width="115" height="20" font="4">● Systemic vascular </text>
<text top="160" left="767" width="154" height="20" font="4">resistance: tadalafil was not </text>
<text top="177" left="767" width="144" height="20" font="4">associated with change in </text>
<text top="194" left="767" width="160" height="20" font="4">systemic vascular resistance </text>
<text top="211" left="767" width="46" height="20" font="4">(p=NS). </text>
<text top="504" left="64" width="189" height="20" font="3"><b>Dual/Combination PAH Therapy </b></text>
<text top="522" left="64" width="86" height="20" font="4">Diller GP, et al. </text>
<text top="539" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#247">(725)</a> </text>
<text top="556" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22390966?dopt=Citation">22390966</a></text>
<text top="556" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22390966?dopt=Citation"> </a></text>
<text top="522" left="177" width="37" height="20" font="4">Single </text>
<text top="539" left="177" width="55" height="20" font="4">institution </text>
<text top="556" left="177" width="61" height="20" font="4">open-label </text>
<text top="573" left="177" width="38" height="20" font="4">cohort </text>
<text top="591" left="177" width="77" height="20" font="4">observational </text>
<text top="522" left="276" width="88" height="20" font="4">79 total (63 ES, </text>
<text top="539" left="276" width="65" height="20" font="4">16 DS+ES) </text>
<text top="522" left="389" width="122" height="20" font="3"><b>Inclusion criteria</b>: All </text>
<text top="539" left="389" width="76" height="20" font="4">Eisenmenger </text>
<text top="556" left="389" width="101" height="20" font="4">syndrome on dual </text>
<text top="573" left="389" width="93" height="20" font="4">targeted therapy </text>
<text top="522" left="528" width="77" height="20" font="4">Dual targeted </text>
<text top="539" left="528" width="61" height="20" font="4">therapy by </text>
<text top="556" left="528" width="47" height="20" font="4">clinician </text>
<text top="573" left="528" width="62" height="20" font="4">preference </text>
<text top="522" left="648" width="67" height="20" font="4">6MWT, SpO</text>
<text top="528" left="715" width="4" height="13" font="6">2</text>
<text top="522" left="720" width="27" height="20" font="4">, FC </text>
<text top="522" left="767" width="148" height="20" font="4">Post dual targeted therapy </text>
<text top="539" left="767" width="61" height="20" font="4">vs. before: </text>
<text top="556" left="767" width="52" height="20" font="4">● 6MWT </text>
<text top="573" left="767" width="124" height="20" font="4">50 mo increase at 8 y; </text>
<text top="591" left="767" width="52" height="20" font="4">p=0.009. </text>
<text top="608" left="767" width="134" height="20" font="4">● Increase correlates to </text>
<text top="625" left="767" width="125" height="20" font="4">worse baseline 6MWT </text>
<text top="642" left="767" width="58" height="20" font="4">p=0.0047. </text>
<text top="659" left="767" width="154" height="20" font="4">● Improved with up-titration </text>
<text top="677" left="767" width="21" height="20" font="4">or 3</text>
<text top="678" left="788" width="7" height="13" font="6">rd</text>
<text top="677" left="796" width="48" height="20" font="4"> therapy </text>
<text top="694" left="767" width="24" height="20" font="4">SpO</text>
<text top="700" left="792" width="4" height="13" font="6">2</text>
<text top="694" left="796" width="7" height="20" font="4">. </text>
<text top="711" left="767" width="154" height="20" font="4">● Nonsignificant rise in SpO</text>
<text top="717" left="921" width="4" height="13" font="6">2</text>
<text top="711" left="926" width="7" height="20" font="4">. </text>
<text top="728" left="767" width="138" height="20" font="4">● In those who rose SpO</text>
<text top="734" left="905" width="4" height="13" font="6">2</text>
<text top="728" left="909" width="7" height="20" font="4">, </text>
<text top="745" left="767" width="74" height="20" font="4">baseline SpO</text>
<text top="752" left="841" width="4" height="13" font="6">2</text>
<text top="745" left="845" width="87" height="20" font="4"> correlated with </text>
<text top="763" left="767" width="82" height="20" font="4">rise p=0.0047. </text>
<text top="780" left="767" width="36" height="20" font="4">● FC: </text>
<text top="522" left="946" width="122" height="20" font="4">● Use of dual or triple </text>
<text top="539" left="946" width="121" height="20" font="4">targeted PAH specific </text>
<text top="556" left="946" width="131" height="20" font="4">therapy in subjects with </text>
<text top="573" left="946" width="93" height="20" font="4">clinically defined </text>
<text top="591" left="946" width="120" height="20" font="4">Eisenmenger therapy </text>
<text top="608" left="946" width="122" height="20" font="4">followed in open-label </text>
<text top="625" left="946" width="109" height="20" font="4">prospective fashion </text>
<text top="642" left="946" width="99" height="20" font="4">appeared to have </text>
<text top="659" left="946" width="118" height="20" font="4">improved 6MWT and </text>
<text top="677" left="946" width="142" height="20" font="4">subjective FC, correlating </text>
<text top="694" left="946" width="124" height="20" font="4">in inverse fashion with </text>
<text top="711" left="946" width="92" height="20" font="4">baseline 6MWT. </text>
</page>
<page number="202" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 202 </text>
<text top="107" left="767" width="147" height="20" font="4">FC ”appeared” to increase </text>
<text top="124" left="767" width="151" height="20" font="4">early, sustained, correlated </text>
<text top="141" left="767" width="115" height="20" font="4">with worse 6MWT at </text>
<text top="159" left="767" width="147" height="20" font="4">baseline, on uptitration did </text>
<text top="176" left="767" width="71" height="20" font="4">not improve. </text>
<text top="194" left="64" width="97" height="20" font="4">Dimopoulos K, et </text>
<text top="211" left="64" width="16" height="20" font="4">al. </text>
<text top="228" left="64" width="60" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#214">(30)</a>  </text>
<text top="245" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20026774?dopt=Citation">20026774</a></text>
<text top="245" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20026774?dopt=Citation"> </a></text>
<text top="194" left="177" width="78" height="20" font="4">Retrospective </text>
<text top="211" left="177" width="73" height="20" font="4">single center </text>
<text top="228" left="177" width="60" height="20" font="4">propensity </text>
<text top="246" left="177" width="51" height="20" font="4">matched </text>
<text top="263" left="177" width="76" height="20" font="4">observational </text>
<text top="280" left="177" width="38" height="20" font="4">cohort </text>
<text top="194" left="276" width="58" height="20" font="4">n=229 pts </text>
<text top="194" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="211" left="389" width="112" height="20" font="4">Clinical diagnosis of </text>
<text top="228" left="389" width="76" height="20" font="4">Eisenmenger </text>
<text top="246" left="389" width="115" height="20" font="4">syndrome as PAH in </text>
<text top="263" left="389" width="74" height="20" font="4">the setting of </text>
<text top="280" left="389" width="120" height="20" font="4">nonrestrictive cardiac </text>
<text top="297" left="389" width="62" height="20" font="4">defect (not </text>
<text top="314" left="389" width="124" height="20" font="4">catheterization based) </text>
<text top="332" left="389" width="109" height="20" font="4">allowing inclusion if </text>
<text top="349" left="389" width="113" height="20" font="4">surgical closure had </text>
<text top="366" left="389" width="111" height="20" font="4">occurred in past but </text>
<text top="383" left="389" width="94" height="20" font="4">subject had near </text>
<text top="401" left="389" width="100" height="20" font="4">systemic levels of </text>
<text top="418" left="389" width="28" height="20" font="4">PAP </text>
<text top="194" left="528" width="81" height="20" font="4">Targeted PAH </text>
<text top="211" left="528" width="90" height="20" font="4">medical therapy </text>
<text top="228" left="528" width="101" height="20" font="4">(68) v no targeted </text>
<text top="246" left="528" width="79" height="20" font="4">PAH Rx (161) </text>
<text top="194" left="648" width="61" height="20" font="4">Propensity </text>
<text top="211" left="648" width="95" height="20" font="4">adjusted survival </text>
<text top="194" left="767" width="140" height="20" font="4">● Risk of death: targeted </text>
<text top="211" left="767" width="120" height="20" font="4">medical PAH Rx use: </text>
<text top="228" left="767" width="149" height="20" font="4">Unadjusted HR: 0.21; 95% </text>
<text top="245" left="767" width="125" height="20" font="4">CI: 0.05–0.86; p=0.03. </text>
<text top="263" left="767" width="154" height="20" font="4">Adjusted HR: 0.16; 95% CI: </text>
<text top="280" left="767" width="117" height="20" font="4">0.04–0.71; p=0.015.  </text>
<text top="194" left="946" width="118" height="20" font="4">● Mortality appeared </text>
<text top="211" left="946" width="111" height="20" font="4">lessened in pts with </text>
<text top="228" left="946" width="131" height="20" font="4">clinically defined typical </text>
<text top="246" left="946" width="141" height="20" font="4">Eisenmenger when using </text>
<text top="263" left="946" width="121" height="20" font="4">targeted PAH therapy </text>
<text top="280" left="946" width="143" height="20" font="4">based upon care provider </text>
<text top="297" left="946" width="92" height="20" font="4">determination of </text>
<text top="314" left="946" width="109" height="20" font="4">appropriateness for </text>
<text top="332" left="946" width="132" height="20" font="4">treatment. Pts receiving </text>
<text top="349" left="946" width="134" height="20" font="4">PAH specific treatments </text>
<text top="366" left="946" width="123" height="20" font="4">were more likely to be </text>
<text top="383" left="946" width="135" height="20" font="4">receiving anticoagulants </text>
<text top="401" left="946" width="129" height="20" font="4">(p=0.0001), statistically </text>
<text top="418" left="946" width="147" height="20" font="4">older, more likely to be FC </text>
<text top="435" left="946" width="136" height="20" font="4">impaired, or to have had </text>
<text top="452" left="946" width="53" height="20" font="4">syncope. </text>
<text top="469" left="946" width="132" height="20" font="4">● 74% using Bosentan; </text>
<text top="487" left="946" width="116" height="20" font="4">25% using sildenafil. </text>
<text top="504" left="946" width="124" height="20" font="4">● Results similar after </text>
<text top="521" left="946" width="131" height="20" font="4">exclusion of 13 pts who </text>
<text top="538" left="946" width="136" height="20" font="4">had shunts repaired, not </text>
<text top="555" left="946" width="104" height="20" font="4">pure Eisenmenger </text>
<text top="573" left="946" width="61" height="20" font="4">syndrome. </text>
<text top="591" left="64" width="201" height="20" font="3"><b>Pulmonary Vasoreactivity Testing </b></text>
<text top="608" left="64" width="83" height="20" font="4">D'Alto M, et al. </text>
<text top="626" left="64" width="63" height="20" font="4">2010 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(726)</a> </text>
<text top="643" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20668108?dopt=Citation">20668108</a></text>
<text top="643" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20668108?dopt=Citation"> </a></text>
<text top="608" left="177" width="63" height="20" font="4">Open label </text>
<text top="626" left="177" width="74" height="20" font="4">single-center </text>
<text top="643" left="177" width="74" height="20" font="4">retrospective </text>
<text top="608" left="276" width="51" height="20" font="4">n=40 pts </text>
<text top="608" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="626" left="389" width="120" height="20" font="4">Clinical nonrestrictive </text>
<text top="643" left="389" width="121" height="20" font="4">defect consistent with </text>
<text top="660" left="389" width="76" height="20" font="4">Eisenmenger </text>
<text top="677" left="389" width="109" height="20" font="4">syndrome and right-</text>
<text top="694" left="389" width="118" height="20" font="4">to-left or bidirectional </text>
<text top="712" left="389" width="105" height="20" font="4">shunting, FC II–IV, </text>
<text top="729" left="389" width="24" height="20" font="4">SpO</text>
<text top="735" left="413" width="4" height="13" font="6">2</text>
<text top="729" left="418" width="59" height="20" font="4">&gt;60%, not </text>
<text top="746" left="389" width="118" height="20" font="4">pregnant, age ≥16 y, </text>
<text top="763" left="389" width="48" height="20" font="4">&gt;40 kg   </text>
<text top="608" left="528" width="103" height="20" font="4">Epoprostenol 2 ng </text>
<text top="626" left="528" width="104" height="20" font="4">increments to max </text>
<text top="643" left="528" width="101" height="20" font="4">12 ng/kg/min q 10 </text>
<text top="660" left="528" width="23" height="20" font="4">min </text>
<text top="608" left="648" width="106" height="20" font="4">Clinical worsening: </text>
<text top="626" left="648" width="34" height="20" font="4">death </text>
<text top="643" left="648" width="91" height="20" font="4">from any cause, </text>
<text top="660" left="648" width="100" height="20" font="4">heart-lung or lung </text>
<text top="677" left="648" width="103" height="20" font="4">transplantation (or </text>
<text top="694" left="648" width="68" height="20" font="4">waiting list), </text>
<text top="712" left="648" width="96" height="20" font="4">hospital for PAH, </text>
<text top="729" left="648" width="59" height="20" font="4">symptoms </text>
<text top="746" left="648" width="76" height="20" font="4">worsening by </text>
<text top="763" left="648" width="103" height="20" font="4">≥20% decrease in </text>
<text top="781" left="648" width="100" height="20" font="4">6MWT on 2 tests, </text>
<text top="608" left="767" width="161" height="20" font="4">● Initial response of lowering </text>
<text top="626" left="767" width="162" height="20" font="4">of PVR index to acute testing </text>
<text top="643" left="767" width="152" height="20" font="4">of pulmonary vasoreactivity </text>
<text top="660" left="767" width="155" height="20" font="4">with epoprostenol appeared </text>
<text top="677" left="767" width="132" height="20" font="4">to predict occurrence of </text>
<text top="694" left="767" width="161" height="20" font="4">clinical worsening regardless </text>
<text top="712" left="767" width="152" height="20" font="4">of use of PAH therapy after </text>
<text top="729" left="767" width="156" height="20" font="4">mean 33 mo of follow-up for </text>
<text top="746" left="767" width="138" height="20" font="4">pts with clinically defined </text>
<text top="763" left="767" width="158" height="20" font="4">Eisenmenger syndrome with </text>
<text top="608" left="946" width="146" height="20" font="4">● Benefit of epoprostenol. </text>
</page>
<page number="203" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 203 </text>
<text top="107" left="648" width="103" height="20" font="4">increase WHO FC </text>
<text top="124" left="648" width="98" height="20" font="4">or worse right HF </text>
<text top="107" left="767" width="141" height="20" font="4">FC II–IV followed in open-</text>
<text top="124" left="767" width="150" height="20" font="4">label retrospective fashion. </text>
<text top="142" left="64" width="413" height="20" font="3"><b>Therapy for Adults With Down Syndrome and Eisenmenger Syndrome </b></text>
<text top="160" left="64" width="98" height="20" font="4">Duffels MG, et al. </text>
<text top="177" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(727)</a> </text>
<text top="195" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18579234?dopt=Citation">18579234</a></text>
<text top="195" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18579234?dopt=Citation"> </a></text>
<text top="160" left="177" width="83" height="20" font="4">Observational, </text>
<text top="177" left="177" width="41" height="20" font="4">cohort, </text>
<text top="195" left="177" width="74" height="20" font="4">retrospective </text>
<text top="160" left="276" width="51" height="20" font="4">n=24 pts </text>
<text top="160" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="177" left="389" width="58" height="20" font="4">&gt;18 y, DS </text>
<text top="160" left="528" width="55" height="20" font="4">Bosentan </text>
<text top="160" left="648" width="73" height="20" font="4">6MWT, QOL </text>
<text top="160" left="767" width="157" height="20" font="4">● 11.5-mo follow-up: 6MWT </text>
<text top="177" left="767" width="135" height="20" font="4">increased 296 to 325 m; </text>
<text top="195" left="767" width="112" height="20" font="4">p&lt;0.05 after 12 wk.  </text>
<text top="212" left="767" width="155" height="20" font="4">● 276 m; p=0.6 after 26 wk, </text>
<text top="229" left="767" width="158" height="20" font="4">287 m; p=0.3 at 52 wk. QOL </text>
<text top="246" left="767" width="96" height="20" font="4">stable during Rx. </text>
<text top="160" left="946" width="125" height="20" font="4">● Use of Bosentan for </text>
<text top="177" left="946" width="109" height="20" font="4">subjects with Down </text>
<text top="195" left="946" width="81" height="20" font="4">syndrome and </text>
<text top="212" left="946" width="133" height="20" font="4">Eisenmenger syndrome </text>
<text top="229" left="946" width="116" height="20" font="4">treated up to 1 y and </text>
<text top="246" left="946" width="122" height="20" font="4">followed in open-label </text>
<text top="264" left="946" width="117" height="20" font="4">retrospective fashion </text>
<text top="281" left="946" width="116" height="20" font="4">appeared to improve </text>
<text top="298" left="946" width="149" height="20" font="4">6MWT and to sustain such </text>
<text top="315" left="946" width="112" height="20" font="4">improvement during </text>
<text top="332" left="946" width="56" height="20" font="4">follow-up. </text>
<text top="350" left="64" width="98" height="20" font="4">Monfredi O, et al. </text>
<text top="368" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(728)</a> </text>
<text top="385" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21943933?dopt=Citation">21943933</a></text>
<text top="385" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21943933?dopt=Citation"> </a></text>
<text top="350" left="177" width="83" height="20" font="4">Observational, </text>
<text top="368" left="177" width="41" height="20" font="4">cohort, </text>
<text top="385" left="177" width="77" height="20" font="4">retrospective  </text>
<text top="350" left="276" width="66" height="20" font="4">n=10 Down </text>
<text top="368" left="276" width="98" height="20" font="4">syndrome pts, 29 </text>
<text top="385" left="276" width="65" height="20" font="4">non-DS pts </text>
<text top="350" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="368" left="389" width="114" height="20" font="4">≥18 y, Eisenmenger </text>
<text top="385" left="389" width="57" height="20" font="4">syndrome </text>
<text top="350" left="528" width="103" height="20" font="4">Bosentan 62.5 mg </text>
<text top="368" left="528" width="88" height="20" font="4">PO BID × 4 wk, </text>
<text top="385" left="528" width="90" height="20" font="4">125 mg PO BID </text>
<text top="402" left="528" width="56" height="20" font="4">thereafter </text>
<text top="350" left="648" width="53" height="20" font="4">6MWT, O</text>
<text top="356" left="700" width="7" height="13" font="6">2 </text>
<text top="368" left="648" width="64" height="20" font="4">saturations </text>
<text top="350" left="767" width="138" height="20" font="4">● 2.1 ± 1.5 y, 6MWT not </text>
<text top="368" left="767" width="100" height="20" font="4">reported for DS, O</text>
<text top="374" left="868" width="4" height="13" font="6">2</text>
<text top="368" left="872" width="3" height="20" font="4"> </text>
<text top="385" left="767" width="151" height="20" font="4">saturations did not change. </text>
<text top="350" left="946" width="135" height="20" font="4">● Team did not feel that </text>
<text top="368" left="946" width="139" height="20" font="4">6MWT could be tested in </text>
<text top="385" left="946" width="92" height="20" font="4">Down syndrome </text>
<text top="402" left="946" width="64" height="20" font="4">population. </text>
<text top="420" left="64" width="83" height="20" font="4">Troost E, et al. </text>
<text top="437" left="64" width="66" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(160)</a>  </text>
<text top="454" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21744698?dopt=Citation">21744698</a></text>
<text top="454" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21744698?dopt=Citation"> </a></text>
<text top="420" left="177" width="79" height="20" font="4">Observational </text>
<text top="437" left="177" width="41" height="20" font="4">cohort, </text>
<text top="454" left="177" width="77" height="20" font="4">retrospective  </text>
<text top="420" left="276" width="79" height="20" font="4">n=134 pts (60 </text>
<text top="437" left="276" width="25" height="20" font="4">DS) </text>
<text top="420" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="437" left="389" width="107" height="20" font="4">Adult Eisenmenger </text>
<text top="454" left="389" width="57" height="20" font="4">syndrome </text>
<text top="420" left="528" width="96" height="20" font="4">Standard of local </text>
<text top="437" left="528" width="27" height="20" font="4">care </text>
<text top="420" left="648" width="50" height="20" font="4">Survival, </text>
<text top="437" left="648" width="72" height="20" font="4">medications, </text>
<text top="454" left="648" width="65" height="20" font="4">arrhythmia, </text>
<text top="472" left="648" width="67" height="20" font="4">thrombosis, </text>
<text top="489" left="648" width="50" height="20" font="4">bleeding </text>
<text top="420" left="767" width="144" height="20" font="4">● DS pts were younger at </text>
<text top="437" left="767" width="153" height="20" font="4">latest follow 28.6 ± 11.1 vs. </text>
<text top="454" left="767" width="166" height="20" font="4">36.9 ± 14.4 y, less likely to be </text>
<text top="472" left="767" width="163" height="20" font="4">treated with diuretics 20% vs. </text>
<text top="489" left="767" width="165" height="20" font="4">40.5% (p=0.004) or Vitamin K </text>
<text top="506" left="767" width="134" height="20" font="4">antagonists 0 vs. 17.6% </text>
<text top="523" left="767" width="163" height="20" font="4">(p=0.0001); equal distribution </text>
<text top="540" left="767" width="148" height="20" font="4">of ERA and PDE5 inhibitor </text>
<text top="558" left="767" width="136" height="20" font="4">Down syndrome vs. non-</text>
<text top="575" left="767" width="143" height="20" font="4">Down syndrome (18.3 vs. </text>
<text top="592" left="767" width="163" height="20" font="4">24.3%; p=0.335 ERA and 3.3 </text>
<text top="609" left="767" width="154" height="20" font="4">vs. 10.8 sildenafil p=0.084). </text>
<text top="626" left="767" width="142" height="20" font="4">● Equal survival between </text>
<text top="644" left="767" width="141" height="20" font="4">Down syndrome and non-</text>
<text top="661" left="767" width="152" height="20" font="4">Down syndrome 44.5 ± 2.6 </text>
<text top="678" left="767" width="154" height="20" font="4">vs. 44.5 ± 2.9 y (p=0.8). No </text>
<text top="695" left="767" width="122" height="20" font="4">difference arrhythmia, </text>
<text top="712" left="767" width="138" height="20" font="4">thrombotic events, major </text>
<text top="730" left="767" width="117" height="20" font="4">bleeding, CVA Down </text>
<text top="747" left="767" width="141" height="20" font="4">syndrome and non-Down </text>
<text top="764" left="767" width="64" height="20" font="4">syndrome.  </text>
<text top="420" left="946" width="116" height="20" font="4">● When assessed in </text>
<text top="437" left="946" width="135" height="20" font="4">open-label retrospective </text>
<text top="454" left="946" width="134" height="20" font="4">fashion, no difference in </text>
<text top="472" left="946" width="104" height="20" font="4">survival was noted </text>
<text top="489" left="946" width="95" height="20" font="4">between pts with </text>
<text top="506" left="946" width="133" height="20" font="4">Eisenmenger syndrome </text>
<text top="523" left="946" width="117" height="20" font="4">with or without Down </text>
<text top="540" left="946" width="147" height="20" font="4">syndrome when controlled </text>
<text top="558" left="946" width="93" height="20" font="4">for other factors. </text>
</page>
<page number="204" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 204 </text>
<text top="107" left="767" width="163" height="20" font="4">● Diuretic use, creatine, BMI, </text>
<text top="124" left="767" width="133" height="20" font="4">cigarettes correlate with </text>
<text top="141" left="767" width="49" height="20" font="4">survival. </text>
<text top="159" left="64" width="85" height="20" font="4">Serino G, et al. </text>
<text top="177" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(729)</a>  </text>
<text top="194" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23440179?dopt=Citation">23440179</a></text>
<text top="194" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23440179?dopt=Citation"> </a></text>
<text top="159" left="177" width="79" height="20" font="4">Observational </text>
<text top="177" left="177" width="41" height="20" font="4">cohort, </text>
<text top="194" left="177" width="74" height="20" font="4">retrospective </text>
<text top="159" left="276" width="44" height="20" font="4">n=7 pts </text>
<text top="159" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="177" left="389" width="124" height="20" font="4">Adult Down syndrome </text>
<text top="194" left="389" width="99" height="20" font="4">pts; Eisenmenger </text>
<text top="211" left="389" width="57" height="20" font="4">syndrome </text>
<text top="159" left="528" width="107" height="20" font="4">Bosentan, 62.5 mg </text>
<text top="177" left="528" width="84" height="20" font="4">PO BID × 4 wk </text>
<text top="194" left="528" width="93" height="20" font="4">then 125 mg PO </text>
<text top="211" left="528" width="24" height="20" font="4">BID </text>
<text top="159" left="648" width="67" height="20" font="4">6MWT, SpO</text>
<text top="166" left="715" width="4" height="13" font="6">2</text>
<text top="159" left="720" width="7" height="20" font="4">, </text>
<text top="177" left="648" width="101" height="20" font="4">echocardiography </text>
<text top="194" left="648" width="102" height="20" font="4">parameters, WHO </text>
<text top="211" left="648" width="20" height="20" font="4">FC </text>
<text top="159" left="767" width="140" height="20" font="4">● 68 min improvement in </text>
<text top="177" left="767" width="160" height="20" font="4">6MWT (p=0.1), no change in </text>
<text top="194" left="767" width="24" height="20" font="4">SpO</text>
<text top="200" left="792" width="4" height="13" font="6">2</text>
<text top="194" left="796" width="128" height="20" font="4">; improvement in WHO </text>
<text top="211" left="767" width="73" height="20" font="4">FC (p=0.01). </text>
<text top="228" left="767" width="75" height="20" font="4">● No change </text>
<text top="245" left="767" width="146" height="20" font="4">echocardiography indices. </text>
<text top="159" left="946" width="116" height="20" font="4">● When assessed in </text>
<text top="177" left="946" width="135" height="20" font="4">open-label retrospective </text>
<text top="194" left="946" width="102" height="20" font="4">fashion, Bosentan </text>
<text top="211" left="946" width="125" height="20" font="4">treatment appeared to </text>
<text top="228" left="946" width="148" height="20" font="4">improve 6MWT in subjects </text>
<text top="246" left="946" width="141" height="20" font="4">with Down syndrome and </text>
<text top="263" left="946" width="137" height="20" font="4">Eisenmenger syndrome. </text>
<text top="281" left="64" width="89" height="20" font="4">Crepaz R, et al. </text>
<text top="298" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#220">(159)</a>  </text>
<text top="315" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24047157?dopt=Citation">24047157</a></text>
<text top="315" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24047157?dopt=Citation"> </a></text>
<text top="281" left="177" width="79" height="20" font="4">Observational </text>
<text top="298" left="177" width="38" height="20" font="4">cohort </text>
<text top="315" left="177" width="77" height="20" font="4">retrospective, </text>
<text top="332" left="177" width="61" height="20" font="4">open-label </text>
<text top="281" left="276" width="44" height="20" font="4">n=7 pts </text>
<text top="281" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="298" left="389" width="100" height="20" font="4">DS, Eisenmenger </text>
<text top="315" left="389" width="123" height="20" font="4">syndrome with clinical </text>
<text top="332" left="389" width="55" height="20" font="4">diagnosis </text>
<text top="281" left="528" width="63" height="20" font="4">Open label </text>
<text top="298" left="528" width="103" height="20" font="4">Bosentan 62.5 mg </text>
<text top="315" left="528" width="86" height="20" font="4">PO BID × 1 mo </text>
<text top="332" left="528" width="93" height="20" font="4">then 125 mg PO </text>
<text top="350" left="528" width="80" height="20" font="4">BID thereafter </text>
<text top="281" left="648" width="40" height="20" font="4">6MWT </text>
<text top="281" left="767" width="138" height="20" font="4">● 52.2 ± 3.9 min; 6MWT </text>
<text top="298" left="767" width="157" height="21" font="4">increased from 199.6 ± 69.1 </text>
<text top="315" left="767" width="133" height="21" font="4">min to 303.7 ± 99.9 min </text>
<text top="332" left="767" width="78" height="20" font="4">(p&lt;0.05); SpO</text>
<text top="339" left="845" width="4" height="13" font="6">2</text>
<text top="332" left="849" width="75" height="20" font="4"> at end of the </text>
<text top="350" left="767" width="124" height="20" font="4">6MWT increased from </text>
<text top="367" left="767" width="153" height="21" font="4">61.6 ± 7.6% to 74.7 ± 6.2% </text>
<text top="384" left="767" width="56" height="20" font="4">(p&lt;0.05).  </text>
<text top="401" left="767" width="135" height="20" font="4">● TTE acceleration time </text>
<text top="418" left="767" width="150" height="21" font="4">increased from 62.9 ± 11.6 </text>
<text top="436" left="767" width="119" height="21" font="4">m/s to 83.0 ± 9.6 m/s </text>
<text top="453" left="767" width="136" height="20" font="4">(p=0.0156), acceleration </text>
<text top="470" left="767" width="154" height="20" font="4">time/ejection time ratio from </text>
<text top="487" left="767" width="143" height="20" font="4">pulmonary flow increased </text>
<text top="505" left="767" width="157" height="21" font="4">from 0.24 ± 0.04 at baseline </text>
<text top="522" left="767" width="146" height="21" font="4">to 0.30 ± 0.02 (p=0.0156). </text>
<text top="281" left="946" width="122" height="20" font="4">● Recognizing limited </text>
<text top="298" left="946" width="108" height="20" font="4">numbers of studied </text>
<text top="315" left="946" width="140" height="20" font="4">subjects, when assessed </text>
<text top="332" left="946" width="148" height="20" font="4">in open-label retrospective </text>
<text top="350" left="946" width="143" height="20" font="4">fashion, adults with Down </text>
<text top="367" left="946" width="81" height="20" font="4">syndrome and </text>
<text top="384" left="946" width="133" height="20" font="4">Eisenmenger syndrome </text>
<text top="401" left="946" width="116" height="20" font="4">appeared to improve </text>
<text top="418" left="946" width="139" height="20" font="4">functional ability and SpO</text>
<text top="424" left="1086" width="4" height="13" font="6">2</text>
<text top="418" left="1090" width="3" height="20" font="4"> </text>
<text top="436" left="946" width="142" height="20" font="4">after exercise after use of </text>
<text top="453" left="946" width="148" height="20" font="4">Bosentan for mean 52 mo. </text>
<text top="540" left="64" width="83" height="20" font="4">D'Alto M, et al. </text>
<text top="557" left="64" width="66" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(730)</a>  </text>
<text top="574" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21802156?dopt=Citation">21802156</a></text>
<text top="574" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21802156?dopt=Citation"> </a></text>
<text top="540" left="177" width="79" height="20" font="4">Observational </text>
<text top="557" left="177" width="38" height="20" font="4">cohort </text>
<text top="574" left="177" width="74" height="20" font="4">retrospective </text>
<text top="540" left="276" width="91" height="20" font="4">n=18 with Down </text>
<text top="557" left="276" width="79" height="20" font="4">syndrome (56 </text>
<text top="574" left="276" width="67" height="20" font="4">without DS) </text>
<text top="540" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="557" left="389" width="97" height="20" font="4">Adults &gt;16 y with </text>
<text top="574" left="389" width="76" height="20" font="4">Eisenmenger </text>
<text top="591" left="389" width="57" height="20" font="4">syndrome </text>
<text top="540" left="528" width="59" height="20" font="4">Bosentan  </text>
<text top="540" left="648" width="84" height="20" font="4">6MWT, NYHA, </text>
<text top="557" left="648" width="86" height="20" font="4">hemodynamics </text>
<text top="540" left="767" width="112" height="20" font="4">● WHO FC, 6MWT, </text>
<text top="557" left="767" width="158" height="20" font="4">hemodynamics improve with </text>
<text top="574" left="767" width="163" height="20" font="4">bosentan: WHO FC 2.9 ± 0.6 </text>
<text top="591" left="767" width="161" height="20" font="4">to 2.5 ± 0.5; p=0.005; 6MWT </text>
<text top="609" left="767" width="146" height="20" font="4">239 ± 74 to 288 ± 71 min; </text>
<text top="626" left="767" width="150" height="20" font="4">p=0.0007; Qp 3.5 ± 1.4 vs. </text>
<text top="643" left="767" width="83" height="20" font="4">4.0 ± 1.6 l/m/m</text>
<text top="645" left="850" width="4" height="13" font="6">2</text>
<text top="643" left="854" width="58" height="20" font="4">; p=0.006; </text>
<text top="660" left="767" width="143" height="20" font="4">Qp/Qs 1.0 ± 0.4 vs. 1.4 ± </text>
<text top="678" left="767" width="154" height="20" font="4">0.7; p=0.003; PVR index 20 </text>
<text top="695" left="767" width="117" height="20" font="4">±13 vs. 15 ± 9 WU m</text>
<text top="696" left="885" width="4" height="13" font="6">2</text>
<text top="695" left="889" width="7" height="20" font="4">; </text>
<text top="712" left="767" width="139" height="20" font="4">p=0.007; no difference in </text>
<text top="729" left="767" width="152" height="20" font="4">benefit Down syndrome vs. </text>
<text top="746" left="767" width="44" height="20" font="4">control. </text>
<text top="540" left="946" width="140" height="20" font="4">● The presence of Down </text>
<text top="557" left="946" width="140" height="20" font="4">syndrome did not appear </text>
<text top="574" left="946" width="101" height="20" font="4">to alter benefits of </text>
<text top="591" left="946" width="132" height="20" font="4">Bosentan therapy in pts </text>
<text top="609" left="946" width="101" height="20" font="4">with Eisenmenger </text>
<text top="626" left="946" width="146" height="20" font="4">syndrome when studied in </text>
<text top="643" left="946" width="135" height="20" font="4">open-label retrospective </text>
<text top="660" left="946" width="46" height="20" font="4">fashion. </text>
</page>
<page number="205" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 205 </text>
<text top="107" left="64" width="86" height="20" font="4">Diller GP, et al. </text>
<text top="124" left="64" width="66" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(731)</a>  </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22397941?dopt=Citation">22397941</a></text>
<text top="141" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22397941?dopt=Citation"> </a></text>
<text top="107" left="177" width="79" height="20" font="4">Observational </text>
<text top="124" left="177" width="41" height="20" font="4">cohort, </text>
<text top="141" left="177" width="74" height="20" font="4">retrospective </text>
<text top="107" left="276" width="79" height="20" font="4">n=181 pts (56 </text>
<text top="124" left="276" width="50" height="20" font="4">with DS) </text>
<text top="107" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="389" width="83" height="20" font="4">Adults with DS </text>
<text top="107" left="528" width="83" height="20" font="4">PAH therapies </text>
<text top="107" left="648" width="66" height="20" font="4">BNP, death </text>
<text top="107" left="767" width="112" height="20" font="4">● 20 deaths (7 DS). </text>
<text top="107" left="946" width="115" height="20" font="4">● BNP absolute and </text>
<text top="124" left="946" width="105" height="20" font="4">temporal predicted </text>
<text top="141" left="946" width="130" height="20" font="4">survival independent of </text>
<text top="159" left="946" width="144" height="20" font="4">renal function, DS, 6MWT </text>
<text top="176" left="946" width="67" height="20" font="4">(p&lt;0.0004). </text>
<text top="194" left="64" width="265" height="20" font="3"><b>Data Regarding Palliative Medical Therapies  </b></text>
<text top="212" left="64" width="76" height="20" font="4">Tay EL, et al. </text>
<text top="229" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(732)</a> </text>
<text top="246" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20304507?dopt=Citation">20304507</a></text>
<text top="246" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20304507?dopt=Citation"> </a></text>
<text top="212" left="177" width="83" height="20" font="4">Observational, </text>
<text top="229" left="177" width="41" height="20" font="4">cohort, </text>
<text top="246" left="177" width="70" height="20" font="4">prospective, </text>
<text top="264" left="177" width="64" height="20" font="4">open-label, </text>
<text top="281" left="177" width="61" height="20" font="4">single-arm </text>
<text top="212" left="276" width="72" height="20" font="4">n=25 pts (14 </text>
<text top="229" left="276" width="76" height="20" font="4">Eisenmenger </text>
<text top="246" left="276" width="62" height="20" font="4">syndrome) </text>
<text top="212" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="229" left="389" width="86" height="20" font="4">&gt;18 y, cyanotic </text>
<text top="246" left="389" width="92" height="20" font="4">complex CHD, O</text>
<text top="252" left="481" width="4" height="13" font="6">2</text>
<text top="246" left="486" width="3" height="20" font="4"> </text>
<text top="263" left="389" width="127" height="20" font="4">saturation ≤90, able to </text>
<text top="281" left="389" width="98" height="20" font="4">undergo exercise </text>
<text top="298" left="389" width="115" height="20" font="4">testing serum ferritin </text>
<text top="315" left="389" width="113" height="20" font="4">&lt;30 mcg/L or serum </text>
<text top="332" left="389" width="123" height="20" font="4">ferritin &lt;50 mcg/L and </text>
<text top="350" left="389" width="116" height="20" font="4">transferrin saturation </text>
<text top="367" left="389" width="35" height="20" font="4">&lt;15% </text>
<text top="384" left="389" width="3" height="20" font="4"> </text>
<text top="401" left="389" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="418" left="389" width="103" height="20" font="4">Pregnant, anemic, </text>
<text top="436" left="389" width="101" height="20" font="4">hypersensitivity to </text>
<text top="453" left="389" width="121" height="20" font="4">iron, recent start PAH </text>
<text top="470" left="389" width="48" height="20" font="4">therapy, </text>
<text top="487" left="389" width="85" height="20" font="4">“hyperviscosity </text>
<text top="504" left="389" width="64" height="20" font="4">symptoms” </text>
<text top="212" left="528" width="98" height="20" font="4">Ferrous fumarate </text>
<text top="229" left="528" width="98" height="20" font="4">200 mg PO QD × </text>
<text top="246" left="528" width="104" height="20" font="4">1 wk, then 200 mg </text>
<text top="264" left="528" width="88" height="20" font="4">PO BID × 1 wk, </text>
<text top="281" left="528" width="93" height="20" font="4">then 200 mg PO </text>
<text top="298" left="528" width="61" height="20" font="4">TID; if “not </text>
<text top="315" left="528" width="94" height="20" font="4">tolerated,” single </text>
<text top="332" left="528" width="69" height="20" font="4">dose IV iron </text>
<text top="350" left="528" width="91" height="20" font="4">sucrose 200 mg </text>
<text top="367" left="528" width="103" height="20" font="4">followed by repeat </text>
<text top="384" left="528" width="89" height="20" font="4">iron chemistries </text>
<text top="401" left="528" width="104" height="20" font="4">and if still deficient </text>
<text top="418" left="528" width="97" height="20" font="4">repeated IV dose </text>
<text top="436" left="528" width="44" height="20" font="4">at 1 mo </text>
<text top="212" left="648" width="72" height="20" font="4">6MWT, QOL </text>
<text top="229" left="648" width="100" height="20" font="4">(Camphor Scale), </text>
<text top="246" left="648" width="36" height="20" font="4">CPET </text>
<text top="212" left="767" width="161" height="20" font="4">● 3-mo follow-up: improved.  </text>
<text top="229" left="767" width="116" height="20" font="4">● CAMPHOR score  </text>
<text top="246" left="767" width="154" height="20" font="4">(20.7 ± 10.9 to 16.2 ± 10.4; </text>
<text top="264" left="767" width="56" height="20" font="4">p=0.001). </text>
<text top="281" left="767" width="56" height="20" font="4">● 6MWT  </text>
<text top="298" left="767" width="159" height="20" font="4">(371.7 ± 84.7 min to 402.8.0 </text>
<text top="315" left="767" width="121" height="20" font="4">± 74.9 min; p=0.001). </text>
<text top="332" left="767" width="130" height="20" font="4">● Unchanged: peak VO</text>
<text top="338" left="897" width="4" height="13" font="6">2</text>
<text top="332" left="902" width="3" height="20" font="4"> </text>
<text top="350" left="767" width="165" height="20" font="4">(40.7 ± 9.2% to 43.8 ± 12.4% </text>
<text top="367" left="767" width="120" height="20" font="4">of predicted; p=0.15). </text>
<text top="212" left="946" width="101" height="20" font="4">● Iron repletion in </text>
<text top="229" left="946" width="122" height="20" font="4">subjects with cyanotic </text>
<text top="246" left="946" width="114" height="20" font="4">CHD, the majority of </text>
<text top="264" left="946" width="136" height="20" font="4">whom had Eisenmenger </text>
<text top="281" left="946" width="127" height="20" font="4">syndrome appeared to </text>
<text top="298" left="946" width="111" height="20" font="4">improve 6MWT and </text>
<text top="315" left="946" width="120" height="20" font="4">subjective QOL index </text>
<text top="332" left="946" width="143" height="20" font="4">when tested in open-label </text>
<text top="350" left="946" width="140" height="20" font="4">prospective fashion 3 mo </text>
<text top="367" left="946" width="82" height="20" font="4">after repletion. </text>
<text top="522" left="64" width="98" height="20" font="4">Sandoval J, et al. </text>
<text top="540" left="64" width="63" height="20" font="4">2001 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(733)</a> </text>
<text top="557" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11719310?dopt=Citation">11719310</a></text>
<text top="557" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11719310?dopt=Citation"> </a></text>
<text top="522" left="177" width="76" height="20" font="4">Randomized, </text>
<text top="540" left="177" width="60" height="20" font="4">controlled, </text>
<text top="557" left="177" width="66" height="20" font="4">prospective </text>
<text top="522" left="276" width="72" height="20" font="4">n=23 pts (14 </text>
<text top="540" left="276" width="76" height="20" font="4">Eisenmenger </text>
<text top="557" left="276" width="62" height="20" font="4">syndrome) </text>
<text top="522" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="540" left="389" width="116" height="20" font="4">Age 20–50 y, clinical </text>
<text top="557" left="389" width="96" height="20" font="4">diagnosis of post </text>
<text top="574" left="389" width="125" height="20" font="4">tricuspid Eisenmenger </text>
<text top="591" left="389" width="101" height="20" font="4">syndrome, severe </text>
<text top="608" left="389" width="113" height="20" font="4">pulmonary HTN and </text>
<text top="626" left="389" width="114" height="20" font="4">predominant right-to-</text>
<text top="643" left="389" width="53" height="20" font="4">left shunt </text>
<text top="660" left="389" width="3" height="20" font="4"> </text>
<text top="677" left="389" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="694" left="389" width="98" height="20" font="4">Obstructive sleep </text>
<text top="712" left="389" width="87" height="20" font="4">apnea, obesity, </text>
<text top="729" left="389" width="77" height="20" font="4">cigarette use, </text>
<text top="746" left="389" width="70" height="20" font="4">restrictive or </text>
<text top="763" left="389" width="89" height="20" font="4">obstructive lung </text>
<text top="781" left="389" width="50" height="20" font="4">disease” </text>
<text top="522" left="528" width="68" height="20" font="4">≥8 h/night O</text>
<text top="529" left="597" width="4" height="13" font="6">2</text>
<text top="522" left="601" width="17" height="20" font="4"> at </text>
<text top="540" left="528" width="102" height="20" font="4">flow rate sufficient </text>
<text top="557" left="528" width="53" height="20" font="4">to raise O</text>
<text top="563" left="582" width="4" height="13" font="6">2</text>
<text top="557" left="586" width="3" height="20" font="4"> </text>
<text top="574" left="528" width="105" height="20" font="4">saturation 79 to 88 </text>
<text top="591" left="528" width="100" height="20" font="4">for the group as a </text>
<text top="608" left="528" width="100" height="20" font="4">whole (typically 2–</text>
<text top="626" left="528" width="53" height="20" font="4">3 L nasal </text>
<text top="643" left="528" width="98" height="20" font="4">cannula); therapy </text>
<text top="660" left="528" width="102" height="20" font="4">was withheld from </text>
<text top="677" left="528" width="100" height="20" font="4">control group (12) </text>
<text top="522" left="648" width="96" height="20" font="4">Mortality, 6MWT, </text>
<text top="540" left="648" width="61" height="20" font="4">pulmonary </text>
<text top="557" left="648" width="76" height="20" font="4">function tests </text>
<text top="522" left="767" width="134" height="20" font="4">● 19.8-mo follow-up: no </text>
<text top="540" left="767" width="47" height="20" font="4">change: </text>
<text top="557" left="767" width="152" height="20" font="4">Survival: (20.7 vs. 20.8 mo; </text>
<text top="574" left="767" width="142" height="20" font="4">chi-square log rank, 0.08; </text>
<text top="591" left="767" width="42" height="20" font="4">p=NS). </text>
<text top="608" left="767" width="157" height="20" font="4">● No change over course of </text>
<text top="626" left="767" width="141" height="20" font="4">study or between not and </text>
<text top="643" left="767" width="135" height="20" font="4">controls in 6MWT, QOL, </text>
<text top="660" left="767" width="150" height="20" font="4">PFTs, Hob and hematocrit, </text>
<text top="677" left="767" width="124" height="20" font="4">blood urea nitrogen or </text>
<text top="694" left="767" width="57" height="20" font="4">creatinine </text>
<text top="522" left="946" width="138" height="20" font="4">● The use of overnight O</text>
<text top="529" left="1084" width="4" height="13" font="6">2</text>
<text top="522" left="1088" width="3" height="20" font="4"> </text>
<text top="540" left="946" width="94" height="20" font="4">failed to improve </text>
<text top="557" left="946" width="113" height="20" font="4">measured indices of </text>
<text top="574" left="946" width="126" height="20" font="4">mortality, 6MWT, QOL </text>
<text top="591" left="946" width="83" height="20" font="4">when tested in </text>
<text top="608" left="946" width="124" height="20" font="4">randomized controlled </text>
<text top="626" left="946" width="121" height="20" font="4">fashion in very limited </text>
<text top="643" left="946" width="114" height="20" font="4">numbers of clinically </text>
<text top="660" left="946" width="89" height="20" font="4">defined pts with </text>
<text top="677" left="946" width="133" height="20" font="4">Eisenmenger syndrome </text>
<text top="694" left="946" width="147" height="20" font="4">followed for short term (&lt;2 </text>
<text top="712" left="946" width="17" height="20" font="4">y). </text>
</page>
<page number="206" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 206 </text>
<text top="107" left="64" width="98" height="20" font="4">Sandoval J, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#227">(301)</a> </text>
<text top="141" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22360787?dopt=Citation">22360787</a></text>
<text top="141" left="119" width="7" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22360787?dopt=Citation"> </a> </text>
<text top="107" left="177" width="78" height="20" font="4">Retrospective </text>
<text top="124" left="177" width="70" height="20" font="4">cohort study </text>
<text top="107" left="276" width="38" height="20" font="4">n=144 </text>
<text top="124" left="276" width="76" height="20" font="4">Eisenmenger </text>
<text top="141" left="276" width="98" height="20" font="4">syndrome pts (48 </text>
<text top="159" left="276" width="97" height="20" font="4">anticoagulant, 44 </text>
<text top="176" left="276" width="94" height="20" font="4">nonanticoagulant</text>
<text top="193" left="276" width="8" height="20" font="4">) </text>
<text top="107" left="389" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="389" width="81" height="20" font="4">Adults, clinical </text>
<text top="141" left="389" width="69" height="20" font="4">diagnosis of </text>
<text top="159" left="389" width="76" height="20" font="4">Eisenmenger </text>
<text top="176" left="389" width="118" height="20" font="4">syndrome, saturation </text>
<text top="193" left="389" width="111" height="20" font="4">≤90%, predominant </text>
<text top="210" left="389" width="118" height="20" font="4">right-to-left shunt, ≥2 </text>
<text top="228" left="389" width="63" height="20" font="4">y-follow-up </text>
<text top="107" left="528" width="70" height="20" font="4">Comparison </text>
<text top="124" left="528" width="50" height="20" font="4">between </text>
<text top="141" left="528" width="102" height="20" font="4">anticoagulated vs. </text>
<text top="159" left="528" width="104" height="20" font="4">nonanticoagulated </text>
<text top="176" left="528" width="23" height="20" font="4">pts, </text>
<text top="193" left="528" width="100" height="20" font="4">anticoagulation at </text>
<text top="210" left="528" width="70" height="20" font="4">discretion of </text>
<text top="228" left="528" width="92" height="20" font="4">treating clinician </text>
<text top="107" left="648" width="82" height="20" font="4">Mortality since </text>
<text top="124" left="648" width="42" height="20" font="4">referral </text>
<text top="107" left="767" width="153" height="20" font="4">● 7-y follow-up: no change: </text>
<text top="124" left="767" width="47" height="20" font="4">Survival </text>
<text top="141" left="767" width="123" height="20" font="4">Log rank = 0.19–0.22. </text>
<text top="107" left="946" width="98" height="20" font="4">● The use of oral </text>
<text top="124" left="946" width="132" height="20" font="4">anticoagulation (without </text>
<text top="141" left="946" width="148" height="20" font="4">estimation of time in target </text>
<text top="159" left="946" width="114" height="20" font="4">range) started at the </text>
<text top="176" left="946" width="135" height="20" font="4">discretion of the treating </text>
<text top="193" left="946" width="148" height="20" font="4">physician failed to improve </text>
<text top="210" left="946" width="125" height="20" font="4">survival over 7 y when </text>
<text top="228" left="946" width="111" height="20" font="4">tested in open-label </text>
<text top="245" left="946" width="130" height="20" font="4">retrospective fashion in </text>
<text top="262" left="946" width="141" height="20" font="4">clinically defined subjects </text>
<text top="279" left="946" width="101" height="20" font="4">with Eisenmenger </text>
<text top="296" left="946" width="144" height="20" font="4">syndrome free of targeted </text>
<text top="314" left="946" width="93" height="20" font="4">PAH therapies.   </text>
<text top="332" left="108" width="3" height="20" font="4"> </text>
<text top="349" left="108" width="3" height="20" font="4"> </text>
<text top="366" left="108" width="549" height="24" font="1"><b>Data Supplement 51. Anomalous Coronary Artery Evaluation – Section 4.4.7.1 </b></text>
<text top="387" left="88" width="75" height="20" font="3"><b>Study Name </b></text>
<text top="387" left="201" width="165" height="20" font="3"><b>Study Design  Study Size </b></text>
<text top="405" left="322" width="21" height="20" font="3"><b>(N) </b></text>
<text top="387" left="382" width="119" height="20" font="3"><b>Inclusion/Exclusion </b></text>
<text top="405" left="419" width="46" height="20" font="3"><b>Criteria </b></text>
<text top="387" left="536" width="73" height="20" font="3"><b>1° Endpoint </b></text>
<text top="387" left="717" width="48" height="20" font="3"><b>Results </b></text>
<text top="387" left="925" width="77" height="20" font="3"><b>Conclusions </b></text>
<text top="449" left="64" width="92" height="20" font="4">Sharma V, et al. </text>
<text top="466" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(734)</a> </text>
<text top="483" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25038010?dopt=Citation">25038010</a></text>
<text top="483" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25038010?dopt=Citation"> </a></text>
<text top="449" left="200" width="76" height="20" font="4">Single-center </text>
<text top="466" left="200" width="74" height="20" font="4">retrospective </text>
<text top="483" left="200" width="68" height="20" font="4">case review </text>
<text top="449" left="296" width="51" height="20" font="4">n=75 pts </text>
<text top="449" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="466" left="382" width="119" height="20" font="4">Pts with AAOCA who </text>
<text top="483" left="382" width="116" height="20" font="4">underwent unroofing </text>
<text top="500" left="382" width="98" height="20" font="4">from 1992―2011 </text>
<text top="449" left="515" width="105" height="20" font="4">Surgical outcomes </text>
<text top="449" left="643" width="191" height="20" font="4">● Mean age: 39 y: 32% under age </text>
<text top="466" left="643" width="24" height="20" font="4">30.  </text>
<text top="483" left="643" width="184" height="20" font="4">● Angina, shortness of breath, or </text>
<text top="500" left="643" width="177" height="20" font="4">syncope in 72%. SCD in 3%. Of </text>
<text top="517" left="643" width="186" height="20" font="4">53% who had preoperative stress </text>
<text top="535" left="643" width="182" height="20" font="4">testing, half were abnormal. 92% </text>
<text top="552" left="643" width="190" height="20" font="4">had right coronary arising from left </text>
<text top="569" left="643" width="193" height="20" font="4">sinus, 8% with left coronary arising </text>
<text top="586" left="643" width="98" height="20" font="4">from right sinus.   </text>
<text top="603" left="643" width="187" height="20" font="4">● No early deaths, 1 late death of </text>
<text top="621" left="643" width="113" height="20" font="4">noncardiac causes.  </text>
<text top="638" left="643" width="140" height="20" font="4">● Mean follow-up 18 mo, </text>
<text top="655" left="643" width="184" height="20" font="4">maximum 7 y, all pts were free of </text>
<text top="672" left="643" width="106" height="20" font="4">cardiac symptoms. </text>
<text top="449" left="852" width="206" height="20" font="4">● Surgical unroofing has low surgical </text>
<text top="466" left="852" width="223" height="20" font="4">morbidity and mortality with resolution of </text>
<text top="483" left="852" width="211" height="20" font="4">symptoms at mean follow-up of 18 mo </text>
<text top="500" left="852" width="137" height="20" font="4">and no SCD in that time. </text>
<text top="690" left="64" width="83" height="20" font="4">Basso C, et al. </text>
<text top="707" left="64" width="63" height="20" font="4">2000 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(735)</a> </text>
<text top="725" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10807452?dopt=Citation">10807452</a></text>
<text top="725" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10807452?dopt=Citation"> </a></text>
<text top="690" left="200" width="78" height="20" font="4">Retrospective </text>
<text top="707" left="200" width="66" height="20" font="4">case series </text>
<text top="725" left="200" width="38" height="20" font="4">from 2 </text>
<text top="742" left="200" width="53" height="20" font="4">registries </text>
<text top="690" left="296" width="51" height="20" font="4">n=27 pts </text>
<text top="690" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="707" left="382" width="102" height="20" font="4">Athletes with SCD </text>
<text top="725" left="382" width="87" height="20" font="4">and anomalous </text>
<text top="742" left="382" width="120" height="20" font="4">coronary artery origin </text>
<text top="759" left="382" width="113" height="20" font="4">identified at autopsy </text>
<text top="690" left="515" width="93" height="20" font="4">Clinical profile of </text>
<text top="707" left="515" width="46" height="20" font="4">AAOCA </text>
<text top="690" left="643" width="174" height="20" font="4">● 23 pts with left coronary from </text>
<text top="707" left="643" width="177" height="20" font="4">right sinus, 4 with right coronary </text>
<text top="725" left="643" width="87" height="20" font="4">from left sinus.  </text>
<text top="742" left="643" width="151" height="20" font="4">● Death was during (25) or </text>
<text top="759" left="643" width="173" height="20" font="4">immediately after (2) strenuous </text>
<text top="776" left="643" width="56" height="20" font="4">exercise.  </text>
<text top="690" left="852" width="214" height="20" font="4">● Resting ECG and stress testing may </text>
<text top="707" left="852" width="201" height="20" font="4">be normal in athletes at risk for SCD </text>
<text top="725" left="852" width="192" height="20" font="4">due to anomalous aortic origin of a </text>
<text top="742" left="852" width="191" height="20" font="4">coronary artery and symptoms are </text>
<text top="759" left="852" width="196" height="20" font="4">common prior to SCD, thus warrant </text>
<text top="776" left="852" width="70" height="20" font="4">evaluation.   </text>
</page>
<page number="207" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 207 </text>
<text top="107" left="643" width="162" height="20" font="4">● 55% were not evaluated or </text>
<text top="124" left="643" width="184" height="20" font="4">known to have symptoms prior to </text>
<text top="141" left="643" width="181" height="20" font="4">death. 45%, mean age 16 y, had </text>
<text top="159" left="643" width="149" height="20" font="4">data prior to death: 10 with </text>
<text top="176" left="643" width="196" height="20" font="4">premonitory symptoms (syncope or </text>
<text top="193" left="643" width="70" height="20" font="4">chest pain).  </text>
<text top="210" left="643" width="189" height="20" font="4">● All resting ECG (9/9) and stress </text>
<text top="227" left="643" width="141" height="20" font="4">testing was normal (8/8).  </text>
<text top="245" left="64" width="98" height="20" font="4">Frescura C, et al. </text>
<text top="263" left="64" width="63" height="20" font="4">1998 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(736)</a> </text>
<text top="280" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9670825?dopt=Citation%5C">9670825</a></text>
<text top="280" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9670825?dopt=Citation%5C"> </a></text>
<text top="245" left="200" width="48" height="20" font="4">Autopsy </text>
<text top="263" left="200" width="62" height="20" font="4">specimens </text>
<text top="245" left="296" width="191" height="20" font="4">n=1,200 pts  <b>Inclusion criteria</b>: </text>
<text top="263" left="382" width="113" height="20" font="4">Coronary anomalies </text>
<text top="280" left="382" width="120" height="20" font="4">in autopsy population </text>
<text top="297" left="382" width="44" height="20" font="4">of CHD </text>
<text top="245" left="515" width="112" height="20" font="4">Anatomic descriptor </text>
<text top="263" left="515" width="108" height="20" font="4">and cause of death </text>
<text top="245" left="643" width="169" height="20" font="4">● 27 (2.2%) of specimens had </text>
<text top="263" left="643" width="161" height="20" font="4">isolated anomalous coronary </text>
<text top="280" left="643" width="192" height="20" font="4">takeoff. ALCAPA in 5, wrong sinus </text>
<text top="297" left="643" width="184" height="20" font="4">in 12 (left from the right in 5, right </text>
<text top="314" left="643" width="187" height="20" font="4">from the left in 7), median age 14, </text>
<text top="332" left="643" width="177" height="20" font="4">range 2 mo–53 y. SCD in all left </text>
<text top="349" left="643" width="184" height="20" font="4">coronary from right sinus, 43% of </text>
<text top="366" left="643" width="183" height="20" font="4">right coronary from left sinus and </text>
<text top="383" left="643" width="193" height="20" font="4">40% of ALCAPA. SCD precipitated </text>
<text top="401" left="643" width="139" height="20" font="4">by effort in 50%, and first </text>
<text top="418" left="643" width="184" height="20" font="4">manifestation of disease in 50%.  </text>
<text top="435" left="643" width="190" height="20" font="4">● 5 athlete’s prodromic symptoms </text>
<text top="452" left="643" width="194" height="20" font="4">included palpitations, syncope, VA. </text>
<text top="245" left="852" width="192" height="20" font="4">● AAOCA is associated with SCD, </text>
<text top="263" left="852" width="217" height="20" font="4">particularly with exercise and often with </text>
<text top="280" left="852" width="131" height="20" font="4">premonitory symptoms. </text>
<text top="470" left="64" width="105" height="20" font="4">Krasuski RA, et al. </text>
<text top="487" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(737)</a> </text>
<text top="504" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21200009?dopt=Citation">21200009</a></text>
<text top="504" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21200009?dopt=Citation"> </a></text>
<text top="470" left="200" width="78" height="20" font="4">Retrospective </text>
<text top="487" left="200" width="74" height="20" font="4">single-center </text>
<text top="504" left="200" width="66" height="20" font="4">case series </text>
<text top="470" left="296" width="58" height="20" font="4">n=301 pts </text>
<text top="470" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="487" left="382" width="86" height="20" font="4">Pts undergoing </text>
<text top="504" left="382" width="43" height="20" font="4">cardiac </text>
<text top="522" left="382" width="111" height="20" font="4">catheterization over </text>
<text top="539" left="382" width="65" height="20" font="4">35-y period </text>
<text top="470" left="515" width="50" height="20" font="4">Mortality </text>
<text top="470" left="643" width="149" height="20" font="4">● 0.14% of pts undergoing </text>
<text top="487" left="643" width="171" height="20" font="4">catheterization had anomalous </text>
<text top="504" left="643" width="183" height="20" font="4">coronary origin from the opposite </text>
<text top="522" left="643" width="185" height="20" font="4">sinus. 79% with right from the left </text>
<text top="539" left="643" width="198" height="20" font="4">cusp, 18% with interarterial course.  </text>
<text top="556" left="643" width="194" height="20" font="4">● Pts with interarterial course were </text>
<text top="573" left="643" width="184" height="20" font="4">slightly younger (52 vs. 59 y) and </text>
<text top="591" left="643" width="176" height="20" font="4">more likely to undergo surgery.  </text>
<text top="608" left="643" width="186" height="20" font="4">● Surgical pts were more likely to </text>
<text top="625" left="643" width="174" height="20" font="4">have abnormal stress tests and </text>
<text top="642" left="643" width="180" height="20" font="4">more extensive atherosclerosis.  </text>
<text top="659" left="643" width="177" height="20" font="4">● Mortality was similar amongst </text>
<text top="677" left="643" width="161" height="20" font="4">groups. No operative deaths. </text>
<text top="470" left="852" width="171" height="20" font="4">● Older adults with anomalous </text>
<text top="487" left="852" width="181" height="20" font="4">coronaries warrant further study. </text>
<text top="694" left="64" width="92" height="20" font="4">Davies JE, et al. </text>
<text top="712" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(738)</a> </text>
<text top="729" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19699909?dopt=Citation">19699909</a></text>
<text top="729" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19699909?dopt=Citation"> </a></text>
<text top="694" left="200" width="78" height="20" font="4">Retrospective </text>
<text top="712" left="200" width="74" height="20" font="4">single-center </text>
<text top="729" left="200" width="66" height="20" font="4">case series </text>
<text top="694" left="296" width="51" height="20" font="4">n=36 pts </text>
<text top="694" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="712" left="382" width="108" height="20" font="4">Pts who underwent </text>
<text top="729" left="382" width="109" height="20" font="4">surgery for AAOCA </text>
<text top="694" left="515" width="74" height="20" font="4">Mortality and </text>
<text top="712" left="515" width="53" height="20" font="4">morbidity </text>
<text top="694" left="643" width="154" height="20" font="4">● Median age 47 y, angina, </text>
<text top="712" left="643" width="174" height="20" font="4">shortness of breath, syncope in </text>
<text top="729" left="643" width="175" height="20" font="4">81%, 43% with abnormal stress </text>
<text top="746" left="643" width="182" height="20" font="4">test. Left from right sinus in 36%, </text>
<text top="763" left="643" width="160" height="20" font="4">right from left in 58% and left </text>
<text top="781" left="643" width="192" height="20" font="4">anterior descending from right with </text>
<text top="694" left="852" width="191" height="20" font="4">● Unroofing is feasible and safe in </text>
<text top="712" left="852" width="83" height="20" font="4">majority of pts. </text>
</page>
<page number="208" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 208 </text>
<text top="107" left="643" width="143" height="20" font="4">interarterial course in 5%. </text>
<text top="124" left="643" width="147" height="20" font="4">Intramural course in 94%.  </text>
<text top="141" left="643" width="107" height="20" font="4">● 14 with prior MI.  </text>
<text top="159" left="643" width="129" height="20" font="4">● No pt with significant </text>
<text top="176" left="643" width="136" height="20" font="4">atherosclerotic disease.  </text>
<text top="193" left="643" width="179" height="20" font="4">Unroofing in 22, CABG in 14, no </text>
<text top="210" left="643" width="194" height="20" font="4">cardiac deaths at mean follow-up 1 </text>
<text top="227" left="643" width="13" height="20" font="4">y. </text>
<text top="245" left="64" width="97" height="20" font="4">Poynter JA, et al. </text>
<text top="263" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(739)</a> </text>
<text top="280" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24403351?dopt=Citation">24403351</a></text>
<text top="280" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24403351?dopt=Citation"> </a></text>
<text top="245" left="200" width="62" height="20" font="4">Congenital </text>
<text top="263" left="200" width="33" height="20" font="4">Heart </text>
<text top="280" left="200" width="56" height="20" font="4">Surgeons </text>
<text top="297" left="200" width="44" height="20" font="4">Society </text>
<text top="314" left="200" width="44" height="20" font="4">registry </text>
<text top="245" left="296" width="58" height="20" font="4">n=198 pts </text>
<text top="245" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="263" left="382" width="93" height="20" font="4">Pts with AAOCA </text>
<text top="245" left="515" width="74" height="20" font="4">Mortality and </text>
<text top="263" left="515" width="75" height="20" font="4">management </text>
<text top="245" left="643" width="179" height="20" font="4">● Median age at diagnosis 10 y, </text>
<text top="263" left="643" width="192" height="20" font="4">54% symptomatic at presentation.  </text>
<text top="280" left="643" width="194" height="20" font="4">● Diagnosed at autopsy in 2. Right </text>
<text top="297" left="643" width="180" height="20" font="4">from left sinus (AAORCA) in 144 </text>
<text top="314" left="643" width="192" height="20" font="4">pts, left from right sinus (AAOLCA) </text>
<text top="332" left="643" width="37" height="20" font="4">in 51.  </text>
<text top="349" left="643" width="162" height="20" font="4">● Surgery or autopsy without </text>
<text top="366" left="643" width="196" height="20" font="4">surgery in in 106 pts. Surgery more </text>
<text top="383" left="643" width="180" height="20" font="4">common in AAOLCA (67%) than </text>
<text top="401" left="643" width="171" height="20" font="4">AAORCA (52%). Most surgical </text>
<text top="418" left="643" width="157" height="20" font="4">reports described intramural </text>
<text top="435" left="643" width="57" height="20" font="4">segment.  </text>
<text top="452" left="643" width="139" height="20" font="4">●Surgery correlated with </text>
<text top="469" left="643" width="189" height="20" font="4">symptoms, older age, presence of </text>
<text top="487" left="643" width="178" height="20" font="4">intramural segment in AAOLCA. </text>
<text top="245" left="852" width="198" height="20" font="4">● Management decisions, including </text>
<text top="263" left="852" width="189" height="20" font="4">surgical referral, are influenced by </text>
<text top="280" left="852" width="206" height="20" font="4">symptoms and coronary morphology, </text>
<text top="297" left="852" width="181" height="20" font="4">and surgery is more common for </text>
<text top="314" left="852" width="57" height="20" font="4">AAOLCA. </text>
<text top="504" left="64" width="109" height="20" font="4">Frommelt PC, et al. </text>
<text top="522" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(740)</a> </text>
<text top="539" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21439578?dopt=Citation">21439578</a></text>
<text top="539" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21439578?dopt=Citation"> </a></text>
<text top="504" left="200" width="76" height="20" font="4">Single-center </text>
<text top="522" left="200" width="74" height="20" font="4">retrospective </text>
<text top="539" left="200" width="66" height="20" font="4">case series </text>
<text top="504" left="296" width="51" height="20" font="4">n=27 pts </text>
<text top="504" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="522" left="382" width="86" height="20" font="4">Pts undergoing </text>
<text top="539" left="382" width="109" height="20" font="4">surgery for AAOCA </text>
<text top="504" left="515" width="74" height="20" font="4">Mortality and </text>
<text top="522" left="515" width="72" height="20" font="4">preoperative </text>
<text top="539" left="515" width="82" height="20" font="4">characteristics </text>
<text top="504" left="643" width="186" height="20" font="4">● Mean age 12.6 y. Left coronary </text>
<text top="522" left="643" width="196" height="20" font="4">from the right in 26%, right from the </text>
<text top="539" left="643" width="195" height="20" font="4">left in 74%. 26/27 with diagnosis by </text>
<text top="556" left="643" width="164" height="20" font="4">echo. Resuscitated SCD in 3, </text>
<text top="573" left="643" width="179" height="20" font="4">syncope in 8, chest pain in 4, no </text>
<text top="591" left="643" width="184" height="20" font="4">symptoms in 12 of “serendipitous </text>
<text top="608" left="643" width="192" height="20" font="4">diagnosis”. Unroofing performed in </text>
<text top="625" left="643" width="190" height="20" font="4">all. Slit-like orifice in 12 at surgery, </text>
<text top="642" left="643" width="152" height="20" font="4">7 with right from left and no </text>
<text top="659" left="643" width="183" height="20" font="4">symptoms. Mean follow-up 1.8 y, </text>
<text top="677" left="643" width="187" height="20" font="4">all have normal stress testing and </text>
<text top="694" left="643" width="177" height="20" font="4">normal echocardiograph and no </text>
<text top="711" left="643" width="63" height="20" font="4">symptoms. </text>
<text top="504" left="852" width="196" height="20" font="4">● Pts referred for surgery can have </text>
<text top="522" left="852" width="212" height="20" font="4">unroofing with low morbidity/mortality.  </text>
<text top="539" left="852" width="220" height="20" font="4">● Symptoms of ischemia occur in some </text>
<text top="556" left="852" width="210" height="20" font="4">pts prior to surgery, and are alleviated </text>
<text top="573" left="852" width="58" height="20" font="4">afterward. </text>
<text top="729" left="64" width="103" height="20" font="4">Mumtaz MA, et al. </text>
<text top="746" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(741)</a> </text>
<text top="763" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21353004?dopt=Citation">21353004</a></text>
<text top="763" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21353004?dopt=Citation"> </a></text>
<text top="729" left="200" width="76" height="20" font="4">Single-center </text>
<text top="746" left="200" width="74" height="20" font="4">retrospective </text>
<text top="763" left="200" width="66" height="20" font="4">case series </text>
<text top="729" left="296" width="51" height="20" font="4">n=22 pts </text>
<text top="729" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="746" left="382" width="86" height="20" font="4">Pts undergoing </text>
<text top="763" left="382" width="109" height="20" font="4">surgery for AAOCA </text>
<text top="729" left="515" width="74" height="20" font="4">Mortality and </text>
<text top="746" left="515" width="72" height="20" font="4">preoperative </text>
<text top="763" left="515" width="82" height="20" font="4">characteristics </text>
<text top="729" left="643" width="186" height="20" font="4">● 7 pts with left from right cusp, 4 </text>
<text top="746" left="643" width="185" height="20" font="4">had chest pain, 1 with syncope, 1 </text>
<text top="763" left="643" width="183" height="20" font="4">MI, 1 asymptomatic. 15 with right </text>
<text top="781" left="643" width="189" height="20" font="4">from left, 11 with chest pain 4 with </text>
<text top="729" left="852" width="188" height="20" font="4">● Unroofing can be done with low </text>
<text top="746" left="852" width="131" height="20" font="4">morbidity and mortality. </text>
</page>
<page number="209" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 209 </text>
<text top="107" left="643" width="185" height="20" font="4">syncope. Median age 15 y, mean </text>
<text top="124" left="643" width="100" height="20" font="4">follow-up 17 mo.   </text>
<text top="168" left="64" width="121" height="20" font="4">Mainwaring RD, et al. </text>
<text top="185" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(742)</a> </text>
<text top="203" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21718962?dopt=Citation">21718962</a></text>
<text top="203" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21718962?dopt=Citation"> </a></text>
<text top="168" left="200" width="76" height="20" font="4">Single-center </text>
<text top="185" left="200" width="74" height="20" font="4">retrospective </text>
<text top="203" left="200" width="66" height="20" font="4">case series </text>
<text top="168" left="296" width="51" height="20" font="4">n=50 pts </text>
<text top="168" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="185" left="382" width="86" height="20" font="4">Pts undergoing </text>
<text top="203" left="382" width="109" height="20" font="4">surgery for AAOCA </text>
<text top="168" left="515" width="74" height="20" font="4">Mortality and </text>
<text top="185" left="515" width="72" height="20" font="4">preoperative </text>
<text top="203" left="515" width="82" height="20" font="4">characteristics </text>
<text top="168" left="643" width="196" height="20" font="4">● Median age 14 (5 d–47 y), 31 pts </text>
<text top="185" left="643" width="178" height="20" font="4">with right from left sinus, 17 with </text>
<text top="203" left="643" width="146" height="20" font="4">left from right sinus, 2 with </text>
<text top="220" left="643" width="189" height="20" font="4">eccentric single ostium. 26/50 had </text>
<text top="237" left="643" width="155" height="20" font="4">ischemic symptoms, 14 had </text>
<text top="254" left="643" width="107" height="20" font="4">concomitant CHD.  </text>
<text top="271" left="643" width="196" height="20" font="4">● Unroofing in 35, reimplantation in </text>
<text top="289" left="643" width="137" height="20" font="4">6, PA translocation in 9.  </text>
<text top="306" left="643" width="142" height="20" font="4">● No operative mortality.  </text>
<text top="323" left="643" width="189" height="20" font="4">● Median follow-up 5.7 y. 2 lost to </text>
<text top="340" left="643" width="192" height="20" font="4">follow-up, 1 underwent transplant.  </text>
<text top="357" left="643" width="165" height="20" font="4">● No symptoms or SCD in 47 </text>
<text top="375" left="643" width="41" height="20" font="4">others. </text>
<text top="168" left="852" width="218" height="20" font="4">● Surgical repair of AAOCA is safe and </text>
<text top="185" left="852" width="164" height="20" font="4">may be effective in alleviating </text>
<text top="203" left="852" width="63" height="20" font="4">symptoms. </text>
<text top="393" left="64" width="81" height="20" font="4">Gulati R, et al. </text>
<text top="410" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(743)</a> </text>
<text top="427" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17976445?dopt=Citation">17976445</a></text>
<text top="427" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17976445?dopt=Citation"> </a></text>
<text top="393" left="200" width="76" height="20" font="4">Single-center </text>
<text top="410" left="200" width="74" height="20" font="4">retrospective </text>
<text top="427" left="200" width="66" height="20" font="4">case series </text>
<text top="393" left="296" width="51" height="20" font="4">n=18 pts </text>
<text top="393" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="410" left="382" width="86" height="20" font="4">Pts undergoing </text>
<text top="427" left="382" width="109" height="20" font="4">surgery for AAOCA </text>
<text top="393" left="515" width="50" height="20" font="4">Mortality </text>
<text top="393" left="643" width="163" height="20" font="4">● Mean age 8 y, all with intra-</text>
<text top="410" left="643" width="176" height="20" font="4">arterial anomalous coronary. 10 </text>
<text top="427" left="643" width="187" height="20" font="4">with right from left, 8 with left from </text>
<text top="444" left="643" width="195" height="20" font="4">right, 4 with single coronary without </text>
<text top="462" left="643" width="154" height="20" font="4">intramural course. 56% had </text>
<text top="479" left="643" width="66" height="20" font="4">symptoms.  </text>
<text top="496" left="643" width="197" height="20" font="4">● Unroofing in 11, reimplantation in </text>
<text top="513" left="643" width="137" height="20" font="4">3, PA translocation in 4.  </text>
<text top="530" left="643" width="182" height="20" font="4">● No mortality at mean follow-up </text>
<text top="548" left="643" width="33" height="20" font="4">2.2 y. </text>
<text top="393" left="852" width="198" height="20" font="4">● Description of successful surgical </text>
<text top="410" left="852" width="153" height="20" font="4">options for different specific </text>
<text top="427" left="852" width="83" height="20" font="4">abnormalities.  </text>
<text top="444" left="852" width="222" height="20" font="4">● Note that this is likely an earlier report </text>
<text top="461" left="852" width="213" height="20" font="4">of pts also included in Mainwaring RD, </text>
<text top="479" left="852" width="96" height="20" font="4">et al., 2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(742)</a> </text>
<text top="496" left="852" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21718962?dopt=Citation">21718962</a></text>
<text top="496" left="907" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21718962?dopt=Citation"> </a></text>
<text top="566" left="64" width="93" height="20" font="4">Brothers J, et al. </text>
<text top="583" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(744)</a> </text>
<text top="600" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19488806?dopt=Citation">19488806</a></text>
<text top="600" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19488806?dopt=Citation"> </a></text>
<text top="566" left="200" width="80" height="20" font="4">Questionnaire </text>
<text top="583" left="200" width="55" height="20" font="4">regarding </text>
<text top="600" left="200" width="46" height="20" font="4">AAOCA </text>
<text top="617" left="200" width="75" height="20" font="4">management </text>
<text top="566" left="296" width="38" height="20" font="4">n=113 </text>
<text top="583" left="296" width="60" height="20" font="4">responses </text>
<text top="566" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="583" left="382" width="68" height="20" font="4">Members of </text>
<text top="600" left="382" width="96" height="20" font="4">Congenital Heart </text>
<text top="617" left="382" width="100" height="20" font="4">Surgeons Society </text>
<text top="634" left="382" width="73" height="20" font="4">and affiliated </text>
<text top="652" left="382" width="54" height="20" font="4">providers </text>
<text top="566" left="515" width="75" height="20" font="4">Management </text>
<text top="583" left="515" width="57" height="20" font="4">strategies </text>
<text top="566" left="643" width="156" height="20" font="4">● Almost all agree ischemia </text>
<text top="583" left="643" width="194" height="20" font="4">warrants surgery. Over half believe </text>
<text top="600" left="643" width="159" height="20" font="4">any pt with symptoms but no </text>
<text top="617" left="643" width="154" height="20" font="4">ischemia warrants surgery.  </text>
<text top="634" left="643" width="183" height="20" font="4">● In pts awaiting surgery, activity </text>
<text top="652" left="643" width="127" height="20" font="4">restriction is common.  </text>
<text top="669" left="643" width="189" height="20" font="4">● Among medical managed pts, 6 </text>
<text top="686" left="643" width="174" height="20" font="4">died, with 2 deaths in surgically </text>
<text top="703" left="643" width="78" height="20" font="4">managed pts. </text>
<text top="566" left="852" width="203" height="20" font="4">● Marked heterogeneity in physician </text>
<text top="583" left="852" width="139" height="20" font="4">management of AAOCA. </text>
<text top="721" left="64" width="92" height="20" font="4">Angelini P, et al. </text>
<text top="738" left="64" width="63" height="20" font="4">2015 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#248">(745)</a> </text>
<text top="756" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26178792?dopt=Citation">26178792</a></text>
<text top="756" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26178792?dopt=Citation"> </a></text>
<text top="721" left="200" width="76" height="20" font="4">Single-center </text>
<text top="738" left="200" width="66" height="20" font="4">case series </text>
<text top="721" left="296" width="51" height="20" font="4">n=67 pts </text>
<text top="721" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="738" left="382" width="86" height="20" font="4">Pts undergoing </text>
<text top="756" left="382" width="73" height="20" font="4">intravascular </text>
<text top="773" left="382" width="79" height="20" font="4">ultrasound for </text>
<text top="790" left="382" width="55" height="20" font="4">AAORCA </text>
<text top="721" left="515" width="55" height="20" font="4">Anatomic </text>
<text top="738" left="515" width="63" height="20" font="4">description </text>
<text top="721" left="643" width="172" height="20" font="4">● All anomalous right coronary </text>
<text top="738" left="643" width="148" height="20" font="4">from opposite cusp had an </text>
<text top="756" left="643" width="190" height="20" font="4">intramural segment and had some </text>
<text top="773" left="643" width="163" height="20" font="4">proximal intramural stenosis.  </text>
<text top="721" left="852" width="184" height="20" font="4">● All AAORCA had an intramural </text>
<text top="738" left="852" width="180" height="20" font="4">segment. In this series, over half </text>
<text top="756" left="852" width="88" height="20" font="4">underwent PCI. </text>
</page>
<page number="210" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 210 </text>
<text top="107" left="643" width="131" height="20" font="4">● 62% underwent stent </text>
<text top="124" left="643" width="73" height="20" font="4">implantation. </text>
<text top="168" left="64" width="90" height="20" font="4">Maron BJ, et al. </text>
<text top="185" left="64" width="63" height="20" font="4">2009 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#249">(746)</a> </text>
<text top="203" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19221222?dopt=Citation">19221222</a></text>
<text top="203" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19221222?dopt=Citation"> </a></text>
<text top="168" left="200" width="287" height="20" font="4">Registry data  n=1,866 pts  <b>Inclusion criteria</b>: </text>
<text top="185" left="382" width="103" height="20" font="4">Athletes with SCD </text>
<text top="168" left="515" width="43" height="20" font="4">Clinical </text>
<text top="185" left="515" width="82" height="20" font="4">characteristics </text>
<text top="168" left="643" width="181" height="20" font="4">● 690 confirmed cardiac deaths, </text>
<text top="185" left="643" width="178" height="20" font="4">coronary anomaly in 119–65 left </text>
<text top="203" left="643" width="163" height="20" font="4">main from right cusp, 16 right </text>
<text top="220" left="643" width="132" height="20" font="4">coronary from left cusp. </text>
<text top="168" left="852" width="178" height="20" font="4">● Coronary anomalies are not a </text>
<text top="185" left="852" width="90" height="20" font="4">common cause. </text>
<text top="238" left="64" width="100" height="20" font="4">Opolski MP, et al. </text>
<text top="255" left="64" width="63" height="20" font="4">2013 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#249">(747)</a> </text>
<text top="272" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23411107?dopt=Citation">23411107</a></text>
<text top="272" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23411107?dopt=Citation"> </a></text>
<text top="238" left="200" width="76" height="20" font="4">Single-center </text>
<text top="255" left="200" width="69" height="20" font="4">case series  </text>
<text top="238" left="296" width="191" height="20" font="4">n=8,522 pts  <b>Inclusion criteria</b>: </text>
<text top="255" left="382" width="86" height="20" font="4">Pts undergoing </text>
<text top="272" left="382" width="71" height="20" font="4">coronary CT </text>
<text top="238" left="515" width="55" height="20" font="4">Anatomic </text>
<text top="255" left="515" width="63" height="20" font="4">description </text>
<text top="238" left="643" width="196" height="20" font="4">● Anomalous coronary arising from </text>
<text top="255" left="643" width="175" height="20" font="4">the opposite sinus in 0.84% (72 </text>
<text top="272" left="643" width="190" height="20" font="4">pts). Right from left cusp in 11, left </text>
<text top="289" left="643" width="196" height="20" font="4">from right in 20. 24 with interarterial </text>
<text top="307" left="643" width="165" height="20" font="4">course, 12 showed significant </text>
<text top="324" left="643" width="118" height="20" font="4">vessel compression.  </text>
<text top="341" left="643" width="173" height="20" font="4">●Interarterial compression was </text>
<text top="358" left="643" width="196" height="20" font="4">seen only in right coronary from left </text>
<text top="375" left="643" width="139" height="20" font="4">sinus and correlated with </text>
<text top="393" left="643" width="167" height="20" font="4">symptoms at 15 mo follow-up. </text>
<text top="238" left="852" width="217" height="20" font="4">● Anomalous coronary arising from the </text>
<text top="255" left="852" width="169" height="20" font="4">opposite sinus is not common. </text>
<text top="411" left="64" width="76" height="20" font="4">Lee HJ, et al. </text>
<text top="428" left="64" width="63" height="20" font="4">2012 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#249">(748)</a> </text>
<text top="445" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22056684?dopt=Citation">22056684</a></text>
<text top="445" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22056684?dopt=Citation"> </a></text>
<text top="411" left="200" width="76" height="20" font="4">Single-center </text>
<text top="428" left="200" width="66" height="20" font="4">case series </text>
<text top="411" left="296" width="55" height="20" font="4">n=22,925 </text>
<text top="428" left="296" width="20" height="20" font="4">pts </text>
<text top="411" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="428" left="382" width="86" height="20" font="4">Pts undergoing </text>
<text top="445" left="382" width="71" height="20" font="4">coronary CT </text>
<text top="411" left="515" width="55" height="20" font="4">Anatomic </text>
<text top="428" left="515" width="63" height="20" font="4">description </text>
<text top="411" left="643" width="196" height="20" font="4">● 124 pts with anomalous origin on </text>
<text top="428" left="643" width="161" height="20" font="4">right coronary artery from left </text>
<text top="445" left="643" width="183" height="20" font="4">sinus, 87 enrolled after excluding </text>
<text top="462" left="643" width="158" height="20" font="4">those with combined cardiac </text>
<text top="480" left="643" width="53" height="20" font="4">disease.  </text>
<text top="497" left="643" width="132" height="20" font="4">● Of 87, 59% had “high </text>
<text top="514" left="643" width="185" height="20" font="4">interarterial course” and 41% had </text>
<text top="531" left="643" width="142" height="20" font="4">“low interarterial course.”  </text>
<text top="548" left="643" width="153" height="20" font="4">● High course had a higher </text>
<text top="566" left="643" width="194" height="20" font="4">prevalence of angina (43% vs. 6%) </text>
<text top="583" left="643" width="143" height="20" font="4">and MACE (28% vs. 6%). </text>
<text top="411" left="852" width="211" height="20" font="4">● Typical angina and MACE are more </text>
<text top="428" left="852" width="200" height="20" font="4">common in pts with high interarterial </text>
<text top="445" left="852" width="113" height="20" font="4">course of AAORCA. </text>
<text top="601" left="64" width="93" height="20" font="4">Kaushal S, et al. </text>
<text top="618" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#249">(749)</a> </text>
<text top="635" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21871287?dopt=Citation">21871287</a></text>
<text top="635" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21871287?dopt=Citation"> </a></text>
<text top="601" left="200" width="76" height="20" font="4">Single-center </text>
<text top="618" left="200" width="74" height="20" font="4">retrospective </text>
<text top="635" left="200" width="66" height="20" font="4">case series </text>
<text top="601" left="296" width="51" height="20" font="4">n=27 pts </text>
<text top="601" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="618" left="382" width="86" height="20" font="4">Pts undergoing </text>
<text top="635" left="382" width="109" height="20" font="4">surgery for AAOCA </text>
<text top="601" left="515" width="53" height="20" font="4">Mortality  </text>
<text top="601" left="643" width="163" height="20" font="4">● Mean age 14 y, 25 pts with </text>
<text top="618" left="643" width="195" height="20" font="4">AAORCA, 14 with chest pain and 4 </text>
<text top="635" left="643" width="165" height="20" font="4">with syncope. 2 AAOLCA had </text>
<text top="652" left="643" width="70" height="20" font="4">chest pain.   </text>
<text top="670" left="643" width="159" height="20" font="4">● Intramural coronary length </text>
<text top="687" left="643" width="155" height="20" font="4">correlated with preoperative </text>
<text top="704" left="643" width="63" height="20" font="4">symptoms. </text>
<text top="601" left="852" width="177" height="20" font="4">● Length of intramural coronary </text>
<text top="618" left="852" width="196" height="20" font="4">segment correlates with symptoms. </text>
<text top="722" left="64" width="92" height="20" font="4">Eckart RE, et al. </text>
<text top="739" left="64" width="63" height="20" font="4">2004 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#249">(750)</a> </text>
<text top="756" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15583223?dopt=Citation">15583223</a></text>
<text top="756" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15583223?dopt=Citation"> </a></text>
<text top="722" left="200" width="48" height="20" font="4">Registry </text>
<text top="739" left="200" width="36" height="20" font="4">series </text>
<text top="722" left="296" width="58" height="20" font="4">n=126 pts </text>
<text top="722" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="739" left="382" width="112" height="20" font="4">Nontraumatic SCDs </text>
<text top="756" left="382" width="99" height="20" font="4">in military recruits </text>
<text top="722" left="515" width="55" height="20" font="4">Anatomic </text>
<text top="739" left="515" width="63" height="20" font="4">description </text>
<text top="722" left="643" width="149" height="20" font="4">● 86% of deaths related to </text>
<text top="739" left="643" width="148" height="20" font="4">exercise, 51% of SCD had </text>
<text top="756" left="643" width="165" height="20" font="4">identifiable underlying cardiac </text>
<text top="774" left="643" width="43" height="20" font="4">cause.  </text>
<text top="722" left="852" width="175" height="20" font="4">● Left coronary from right sinus </text>
<text top="739" left="852" width="217" height="20" font="4">accounted for all coronary anomalies in </text>
<text top="756" left="852" width="204" height="20" font="4">this autopsy series of SCD in military </text>
<text top="774" left="852" width="47" height="20" font="4">recruits. </text>
</page>
<page number="211" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 211 </text>
<text top="107" left="643" width="163" height="20" font="4">● 61% of those had coronary </text>
<text top="124" left="643" width="165" height="20" font="4">anomalies (39 pts) all with left </text>
<text top="141" left="643" width="163" height="20" font="4">coronary from the right sinus. </text>
<text top="168" left="64" width="92" height="20" font="4">Eckart RE, et al. </text>
<text top="185" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#249">(751)</a> </text>
<text top="203" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21903060?dopt=Citation">21903060</a></text>
<text top="203" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21903060?dopt=Citation"> </a></text>
<text top="168" left="200" width="48" height="20" font="4">Registry </text>
<text top="185" left="200" width="36" height="20" font="4">series </text>
<text top="168" left="296" width="58" height="20" font="4">n=902 pts </text>
<text top="168" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="185" left="382" width="119" height="20" font="4">Nontraumatic SCD in </text>
<text top="203" left="382" width="97" height="20" font="4">adults in the U.S. </text>
<text top="220" left="382" width="42" height="20" font="4">military </text>
<text top="168" left="515" width="55" height="20" font="4">Anatomic </text>
<text top="185" left="515" width="64" height="20" font="4">descriptors </text>
<text top="168" left="643" width="163" height="20" font="4">● Anomalous coronary artery </text>
<text top="185" left="643" width="190" height="20" font="4">accounted for 4% of SCD &lt;35 y of </text>
<text top="203" left="643" width="120" height="20" font="4">age and 0.2% &gt;35 y.  </text>
<text top="220" left="643" width="182" height="20" font="4">● Anomalous take-off defined as </text>
<text top="237" left="643" width="170" height="20" font="4">any left coronary from the right </text>
<text top="254" left="643" width="194" height="20" font="4">sinus or right coronary from the left </text>
<text top="271" left="643" width="165" height="20" font="4">sinus with oblique takeoff and </text>
<text top="289" left="643" width="172" height="20" font="4">corresponding acute or chronic </text>
<text top="306" left="643" width="55" height="20" font="4">ischemia. </text>
<text top="168" left="852" width="178" height="20" font="4">● Coronary anomalies are not a </text>
<text top="185" left="852" width="165" height="20" font="4">common cause of SCD in this </text>
<text top="203" left="852" width="64" height="20" font="4">population. </text>
<text top="324" left="64" width="113" height="20" font="4">Rajbanshi BG, et al. </text>
<text top="341" left="64" width="63" height="20" font="4">2014 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#249">(752)</a> </text>
<text top="358" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24079879?dopt=Citation">24079879</a></text>
<text top="358" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24079879?dopt=Citation"> </a></text>
<text top="324" left="200" width="79" height="20" font="4">Observational </text>
<text top="341" left="200" width="41" height="20" font="4">cohort, </text>
<text top="358" left="200" width="74" height="20" font="4">retrospective </text>
<text top="324" left="296" width="57" height="20" font="4">10 (7 with </text>
<text top="341" left="296" width="64" height="20" font="4">anomalous </text>
<text top="358" left="296" width="71" height="20" font="4">left coronary </text>
<text top="375" left="296" width="49" height="20" font="4">artery, 1 </text>
<text top="393" left="296" width="25" height="20" font="4">with </text>
<text top="410" left="296" width="64" height="20" font="4">anomalous </text>
<text top="427" left="296" width="65" height="20" font="4">left anterior </text>
<text top="444" left="296" width="70" height="20" font="4">descending) </text>
<text top="324" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="341" left="382" width="94" height="20" font="4">≥18 y, ALCAPA, </text>
<text top="358" left="382" width="81" height="20" font="4">surgical repair </text>
<text top="324" left="515" width="99" height="20" font="4">Surgical coronary </text>
<text top="341" left="515" width="49" height="20" font="4">transfer, </text>
<text top="358" left="515" width="101" height="20" font="4">interposition graft, </text>
<text top="375" left="515" width="110" height="20" font="4">or CABG with ostial </text>
<text top="393" left="515" width="92" height="20" font="4">ligation/oversew </text>
<text top="324" left="643" width="170" height="20" font="4">● Survival, reoperation, LVEF, </text>
<text top="341" left="643" width="116" height="20" font="4">recurrent symptoms. </text>
<text top="324" left="852" width="133" height="20" font="4">● Mean follow-up 8.6 y. </text>
<text top="341" left="852" width="165" height="20" font="4">● 2 late deaths (noncardiac).  </text>
<text top="358" left="852" width="215" height="20" font="4">● 1 with recurrent ischemic symptoms: </text>
<text top="375" left="852" width="206" height="20" font="4">reoperation CABG for ostial stenosis. </text>
<text top="393" left="852" width="186" height="20" font="4">● Postoperation all subjects were </text>
<text top="410" left="852" width="59" height="20" font="4">NYHA I-II. </text>
<text top="427" left="852" width="207" height="20" font="4">● Postoperation no change in LVEF.  </text>
<text top="462" left="64" width="79" height="20" font="4">Yau JM, et al. </text>
<text top="479" left="64" width="63" height="20" font="4">2011 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#249">(753)</a> </text>
<text top="497" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21462214?dopt=Citation">21462214</a></text>
<text top="497" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21462214?dopt=Citation"> </a></text>
<text top="462" left="200" width="79" height="20" font="4">Observational </text>
<text top="479" left="200" width="41" height="20" font="4">cohort, </text>
<text top="497" left="200" width="74" height="20" font="4">retrospective </text>
<text top="462" left="296" width="61" height="20" font="4">n=151 pts, </text>
<text top="479" left="296" width="46" height="20" font="4">Medline </text>
<text top="497" left="296" width="39" height="20" font="4">review </text>
<text top="514" left="296" width="67" height="20" font="4">1908―2008</text>
<text top="531" left="296" width="7" height="20" font="4">, </text>
<text top="548" left="296" width="64" height="20" font="4">retrospectiv</text>
<text top="566" left="296" width="40" height="20" font="4">e case </text>
<text top="583" left="296" width="36" height="20" font="4">series </text>
<text top="462" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="479" left="382" width="119" height="20" font="4">≥18 y, ALCAPA, with </text>
<text top="497" left="382" width="102" height="20" font="4">or without surgical </text>
<text top="514" left="382" width="98" height="20" font="4">repair, diagnosed </text>
<text top="531" left="382" width="72" height="20" font="4">pre- (133) or </text>
<text top="548" left="382" width="94" height="20" font="4">postmortem (18) </text>
<text top="462" left="515" width="111" height="20" font="4">Coronary ligation or </text>
<text top="479" left="515" width="111" height="20" font="4">coronary transfer or </text>
<text top="497" left="515" width="105" height="20" font="4">CABG and ligation </text>
<text top="462" left="643" width="154" height="20" font="4">● Description of symptoms, </text>
<text top="479" left="643" width="49" height="20" font="4">survival. </text>
<text top="462" left="852" width="126" height="20" font="4">● Surgical repair: 119  </text>
<text top="479" left="852" width="94" height="20" font="4">  Ligation in 21% </text>
<text top="497" left="852" width="166" height="20" font="4">  Dual coronary repair in 79%. </text>
<text top="514" left="852" width="185" height="20" font="4">● Surgical mortality was 1%–4%. </text>
<text top="531" left="852" width="117" height="20" font="4">● Medical follow: 32. </text>
<text top="548" left="852" width="70" height="20" font="4">● Of cohort, </text>
<text top="566" left="852" width="211" height="20" font="4">103/151 &lt;50 y (4% treated medically); </text>
<text top="583" left="852" width="212" height="20" font="4">48/151 ≥50 y (37% treated medically). </text>
<text top="601" left="64" width="93" height="20" font="4">Wilson CL, et al. </text>
<text top="618" left="64" width="63" height="20" font="4">1979 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#249">(754)</a> </text>
<text top="635" left="64" width="41" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/484430?dopt=Citation">484430</a></text>
<text top="635" left="105" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/484430?dopt=Citation"> </a></text>
<text top="601" left="200" width="79" height="20" font="4">Observational </text>
<text top="618" left="200" width="41" height="20" font="4">cohort, </text>
<text top="635" left="200" width="74" height="20" font="4">retrospective </text>
<text top="601" left="296" width="52" height="20" font="4">n=29 (13 </text>
<text top="618" left="296" width="68" height="20" font="4">with ligation </text>
<text top="635" left="296" width="14" height="20" font="4">of </text>
<text top="652" left="296" width="64" height="20" font="4">anomalous </text>
<text top="670" left="296" width="51" height="20" font="4">coronary </text>
<text top="687" left="296" width="55" height="20" font="4">artery, 16 </text>
<text top="704" left="296" width="25" height="20" font="4">with </text>
<text top="721" left="296" width="66" height="20" font="4">simultaneou</text>
<text top="738" left="296" width="52" height="20" font="4">s ligation </text>
<text top="756" left="296" width="24" height="20" font="4">and </text>
<text top="773" left="296" width="51" height="20" font="4">coronary </text>
<text top="790" left="296" width="46" height="20" font="4">bypass) </text>
<text top="601" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="618" left="382" width="94" height="20" font="4">≥13 y, ALCAPA, </text>
<text top="635" left="382" width="96" height="20" font="4">surgical repair all </text>
<text top="652" left="382" width="85" height="20" font="4">simultaneously </text>
<text top="670" left="382" width="3" height="20" font="4"> </text>
<text top="687" left="382" width="109" height="20" font="3"><b>Exclusion criteria</b>: </text>
<text top="704" left="382" width="116" height="20" font="4">surgical components </text>
<text top="721" left="382" width="101" height="20" font="4">separated in time; </text>
<text top="738" left="382" width="51" height="20" font="4">coronary </text>
<text top="756" left="382" width="81" height="20" font="4">reimplantation </text>
<text top="601" left="515" width="80" height="20" font="4">Surgical ostial </text>
<text top="618" left="515" width="111" height="20" font="4">ligation/oversew vs. </text>
<text top="635" left="515" width="78" height="20" font="4">ostial ligation/ </text>
<text top="652" left="515" width="74" height="20" font="4">oversew with </text>
<text top="670" left="515" width="108" height="20" font="4">concomitant CABG </text>
<text top="601" left="643" width="63" height="20" font="4">● Survival. </text>
<text top="601" left="852" width="133" height="20" font="4">● Mean follow-up 9.2 y. </text>
<text top="618" left="852" width="212" height="20" font="4">● Ligation alone: 3/13 deaths at mean </text>
<text top="635" left="852" width="76" height="20" font="4">5-y follow-up. </text>
<text top="652" left="852" width="206" height="20" font="4">● Ligation and CABG: 0/16 deaths at </text>
<text top="670" left="852" width="111" height="20" font="4">mean 5-y follow-up. </text>
</page>
<page number="212" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 212 </text>
<text top="107" left="64" width="100" height="20" font="4">El-Said GM, et al. </text>
<text top="124" left="64" width="63" height="20" font="4">1973 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#249">(755)</a> </text>
<text top="141" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4541750?dopt=Citation">4541750</a></text>
<text top="141" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4541750?dopt=Citation"> </a></text>
<text top="107" left="200" width="79" height="20" font="4">Observational </text>
<text top="124" left="200" width="41" height="20" font="4">cohort, </text>
<text top="141" left="200" width="74" height="20" font="4">retrospective </text>
<text top="107" left="296" width="65" height="20" font="4">n=10 pts, 4 </text>
<text top="124" left="296" width="46" height="20" font="4">medical </text>
<text top="141" left="296" width="68" height="20" font="4">managemen</text>
<text top="159" left="296" width="70" height="20" font="4">t, and 6 with </text>
<text top="176" left="296" width="46" height="20" font="4">surgical </text>
<text top="193" left="296" width="68" height="20" font="4">managemen</text>
<text top="210" left="296" width="7" height="20" font="4">t </text>
<text top="107" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="124" left="382" width="71" height="20" font="4">ALCAPA, all </text>
<text top="141" left="382" width="50" height="20" font="4">pediatric </text>
<text top="107" left="515" width="108" height="20" font="4">SVG to ALCAPA in </text>
<text top="124" left="515" width="109" height="20" font="4">6 (5 left main and 1 </text>
<text top="141" left="515" width="65" height="20" font="4">left anterior </text>
<text top="159" left="515" width="96" height="20" font="4">descending) with </text>
<text top="176" left="515" width="92" height="20" font="4">proximal ligation </text>
<text top="107" left="643" width="160" height="20" font="4">● Survival, reoperation, graft </text>
<text top="124" left="643" width="52" height="20" font="4">stenosis. </text>
<text top="107" left="852" width="148" height="20" font="4">● 6-mo angio and variable </text>
<text top="124" left="852" width="185" height="20" font="4">postoperative study with treadmill </text>
<text top="141" left="852" width="214" height="20" font="4">exercise test; ischemia found in pt with </text>
<text top="159" left="852" width="94" height="20" font="4">distal occlusion.  </text>
<text top="228" left="64" width="84" height="20" font="4">Lange R, et al. </text>
<text top="245" left="64" width="63" height="20" font="4">2007 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#249">(756)</a> </text>
<text top="263" left="64" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17383358?dopt=Citation">17383358</a></text>
<text top="263" left="119" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17383358?dopt=Citation"> </a></text>
<text top="228" left="200" width="79" height="20" font="4">Observational </text>
<text top="245" left="200" width="41" height="20" font="4">cohort, </text>
<text top="263" left="200" width="74" height="20" font="4">retrospective </text>
<text top="228" left="296" width="54" height="20" font="4">n=56 pts, </text>
<text top="245" left="296" width="58" height="20" font="4">mean age </text>
<text top="263" left="296" width="48" height="20" font="4">16.2 mo </text>
<text top="228" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="245" left="382" width="55" height="20" font="4">ALCAPA  </text>
<text top="228" left="515" width="99" height="20" font="4">Coronary transfer </text>
<text top="245" left="515" width="101" height="20" font="4">(31) or subclavian </text>
<text top="263" left="515" width="107" height="20" font="4">artery anastomosis </text>
<text top="280" left="515" width="25" height="20" font="4">(25) </text>
<text top="228" left="643" width="126" height="20" font="4">● Operative outcomes </text>
<text top="228" left="852" width="159" height="20" font="4">● Maximum follow-up 23.8 y </text>
<text top="245" left="852" width="215" height="20" font="4">Pts older (mean 27.8 y) presented with </text>
<text top="263" left="852" width="100" height="20" font="4">higher EF (&gt;35%) </text>
<text top="298" left="64" width="101" height="20" font="4">Paridon SM, et al. </text>
<text top="315" left="64" width="63" height="20" font="4">1990 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#249">(757)</a> </text>
<text top="332" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2317910?dopt=Citation">2317910</a></text>
<text top="332" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2317910?dopt=Citation"> </a></text>
<text top="298" left="200" width="79" height="20" font="4">Observational </text>
<text top="315" left="200" width="41" height="20" font="4">cohort, </text>
<text top="332" left="200" width="74" height="20" font="4">retrospective </text>
<text top="298" left="296" width="54" height="20" font="4">n=11 pts, </text>
<text top="315" left="296" width="64" height="20" font="4">infants and </text>
<text top="332" left="296" width="50" height="20" font="4">children  </text>
<text top="298" left="382" width="118" height="20" font="4">Exercise testing after </text>
<text top="315" left="382" width="100" height="20" font="4">repair of ALCAPA </text>
<text top="298" left="515" width="99" height="20" font="4">Surgical repair by </text>
<text top="315" left="515" width="96" height="20" font="4">SVG, Subclavian </text>
<text top="332" left="515" width="97" height="20" font="4">artery graft or AP </text>
<text top="350" left="515" width="107" height="20" font="4">window with baffle; </text>
<text top="367" left="515" width="92" height="20" font="4">1 pt with ligation </text>
<text top="298" left="643" width="103" height="20" font="4">● Exercise testing </text>
<text top="298" left="852" width="192" height="20" font="4">● Frequently associated with ECG </text>
<text top="315" left="852" width="175" height="20" font="4">evidence of abnormal perfusion </text>
<text top="332" left="852" width="201" height="20" font="4">regardless of age and type of repair. </text>
<text top="385" left="64" width="111" height="20" font="4">Cochrane AD, et al. </text>
<text top="402" left="64" width="63" height="20" font="4">1999 <a href="ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.html#249">(758)</a> </text>
<text top="419" left="64" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9918975?dopt=Citation">9918975</a></text>
<text top="419" left="112" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9918975?dopt=Citation"> </a></text>
<text top="385" left="200" width="83" height="20" font="4">Observational, </text>
<text top="402" left="200" width="41" height="20" font="4">cohort, </text>
<text top="419" left="200" width="77" height="20" font="4">retrospective  </text>
<text top="385" left="296" width="65" height="20" font="4">n=21 pts (6 </text>
<text top="402" left="296" width="59" height="20" font="4">wk.–26 y)  </text>
<text top="385" left="382" width="105" height="20" font="3"><b>Inclusion criteria</b>: </text>
<text top="402" left="382" width="52" height="20" font="4">ALCAPA </text>
<text top="385" left="515" width="48" height="20" font="4">Surgical </text>
<text top="402" left="515" width="95" height="20" font="4">reimplantation or </text>
<text top="419" left="515" width="106" height="20" font="4">Takeuchi; 1 pt with </text>
<text top="436" left="515" width="94" height="20" font="4">coronary ligation </text>
<text top="385" left="643" width="147" height="20" font="4">● Survival, exercise ability </text>
<text top="385" left="852" width="211" height="20" font="4">● Median follow-up 6.5 y; all survived; </text>
<text top="402" left="852" width="216" height="20" font="4">all but 3 NYHA class I and normal level </text>
<text top="419" left="852" width="66" height="20" font="4">of exercise. </text>
<text top="454" left="108" width="3" height="20" font="4"> </text>
<text top="473" left="108" width="3" height="19" font="4"> </text>
<text top="473" left="324" width="3" height="19" font="4"> </text>
</page>
<page number="213" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 213 </text>
<text top="106" left="108" width="84" height="24" font="1"><b>References </b></text>
<text top="129" left="108" width="3" height="19" font="4"> </text>
<text top="147" left="108" width="3" height="19" font="4"> </text>
<text top="165" left="108" width="15" height="19" font="4">1. </text>
<text top="165" left="162" width="899" height="19" font="4">Afilalo J, Therrien J, Pilote L, et al. Geriatric congenital heart disease: burden of disease and predictors of mortality. J Am Coll Cardiol. 2011;58:1509-</text>
<text top="184" left="108" width="22" height="19" font="4">15. </text>
<text top="202" left="108" width="15" height="19" font="4">2. </text>
<text top="202" left="162" width="891" height="19" font="4">Tutarel O, Kempny A, Alonso-Gonzalez R, et al. Congenital heart disease beyond the age of 60: emergence of a new population with high resource </text>
<text top="220" left="108" width="460" height="19" font="4">utilization, high morbidity, and high mortality. Eur Heart J. 2014;35:725-32. </text>
<text top="239" left="108" width="15" height="19" font="4">3. </text>
<text top="239" left="162" width="865" height="19" font="4">Kim YY, Gauvreau K, Bacha EA, et al. Resource use among adult congenital heart surgery admissions in pediatric hospitals: risk factors for high </text>
<text top="257" left="108" width="636" height="19" font="4">resource utilization and association with inpatient death. Circ Cardiovasc Qual Outcomes. 2011;4:634-9. </text>
<text top="275" left="108" width="15" height="19" font="4">4. </text>
<text top="275" left="162" width="907" height="19" font="4">Kim YY, Gauvreau K, Bacha EA, et al. Risk factors for death after adult congenital heart surgery in pediatric hospitals. Circ Cardiovasc Qual Outcomes. </text>
<text top="293" left="108" width="88" height="19" font="4">2011;4:433-9. </text>
<text top="312" left="108" width="15" height="19" font="4">5. </text>
<text top="312" left="162" width="888" height="19" font="4">Opotowsky AR, Siddiqi OK, D’Souza B, et al. Maternal cardiovascular events during childbirth among women with congenital heart disease. Heart. </text>
<text top="330" left="108" width="103" height="19" font="4">2012;98:145-51. </text>
<text top="348" left="108" width="15" height="19" font="4">6. </text>
<text top="348" left="162" width="905" height="19" font="4">Gurvitz M, Valente AM, Broberg C, et al. Prevalence and predictors of gaps in care among adult congenital heart disease patients: HEART-ACHD (The </text>
<text top="367" left="108" width="495" height="19" font="4">Health, Education, and Access Research Trial). J Am Coll Cardiol. 2013;61:2180-4. </text>
<text top="385" left="108" width="15" height="19" font="4">7. </text>
<text top="385" left="162" width="912" height="19" font="4">Mylotte D, Pilote L, Ionescu-Ittu R, et al. Specialized adult congenital heart disease care: the impact of policy on mortality. Circulation. 2014;129:1804-</text>
<text top="403" left="108" width="22" height="19" font="4">12. </text>
<text top="422" left="108" width="15" height="19" font="4">8. </text>
<text top="422" left="162" width="908" height="19" font="4">Zomer AC, Vaartjes I, van der Velde ET, et al. Heart failure admissions in adults with congenital heart disease; risk factors and prognosis. Int J Cardiol. </text>
<text top="440" left="108" width="119" height="19" font="4">2013;168:2487-93. </text>
<text top="458" left="108" width="15" height="19" font="4">9. </text>
<text top="458" left="162" width="893" height="19" font="4">Rodriguez FHr, Moodie DS, Parekh DR, et al. Outcomes of heart failure-related hospitalization in adults with congenital heart disease in the United </text>
<text top="476" left="108" width="254" height="19" font="4">States. Congenit Heart Dis. 2013;8:513-9. </text>
<text top="495" left="108" width="22" height="19" font="4">10. </text>
<text top="495" left="162" width="904" height="19" font="4">Opotowsky AR, Siddiqi OK, Webb GD. Trends in hospitalizations for adults with congenital heart disease in the U.S. J Am Coll Cardiol. 2009;54:460-7. </text>
<text top="513" left="108" width="22" height="19" font="4">11. </text>
<text top="513" left="162" width="920" height="19" font="4">O’Leary JM, Siddiqi OK, de FS, et al. The Changing Demographics of Congenital Heart Disease Hospitalizations in the United States, 1998 Through 2010. </text>
<text top="531" left="108" width="146" height="19" font="4">JAMA. 2013;309:984-6. </text>
<text top="550" left="108" width="22" height="19" font="4">12. </text>
<text top="550" left="162" width="905" height="19" font="4">Marelli AJ, Ionescu-Ittu R, Mackie AS, et al. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. </text>
<text top="568" left="108" width="111" height="19" font="4">2014;130:749-56. </text>
<text top="586" left="108" width="22" height="19" font="4">13. </text>
<text top="586" left="162" width="916" height="19" font="4">Koyak Z, Achterbergh RC, de Groot JR, et al. Postoperative arrhythmias in adults with congenital heart disease: incidence and risk factors. Int J Cardiol. </text>
<text top="605" left="108" width="111" height="19" font="4">2013;169:139-44. </text>
<text top="623" left="108" width="22" height="19" font="4">14. </text>
<text top="623" left="162" width="780" height="19" font="4">Bouchardy J, Therrien J, Pilote L, et al. Atrial arrhythmias in adults with congenital heart disease. Circulation. 2009;120:1679-86. </text>
<text top="641" left="108" width="22" height="19" font="4">15. </text>
<text top="641" left="162" width="750" height="19" font="4">Koyak Z, Harris L, de Groot JR, et al. Sudden cardiac death in adult congenital heart disease. Circulation. 2012;126:1944-54. </text>
<text top="660" left="108" width="22" height="19" font="4">16. </text>
<text top="660" left="162" width="908" height="19" font="4">Yap S-C, Harris L, Chauhan VS, et al. Identifying high risk in adults with congenital heart disease and atrial arrhythmias. Am J Cardiol. 2011;108:723-8. </text>
<text top="678" left="108" width="22" height="19" font="4">17. </text>
<text top="678" left="162" width="841" height="19" font="4">Giannakoulas G, Dimopoulos K, Yuksel S, et al. Atrial tachyarrhythmias late after Fontan operation are related to increase in mortality and </text>
<text top="696" left="108" width="279" height="19" font="4">hospitalization. Int J Cardiol. 2012;157:221-6. </text>
<text top="715" left="108" width="22" height="19" font="4">18. </text>
<text top="715" left="162" width="900" height="19" font="4">Collins RT, Fram RY, Tang X, et al. Hospital Utilization in Adults with Single Ventricle Congenital Heart Disease and Cardiac Arrhythmias. J Cardiovasc </text>
<text top="733" left="108" width="131" height="19" font="4">Electrophysiol. 2013; </text>
<text top="751" left="108" width="22" height="19" font="4">19. </text>
<text top="751" left="162" width="895" height="19" font="4">Diller G-P, Giardini A, Dimopoulos K, et al. Predictors of morbidity and mortality in contemporary Fontan patients: results from a multicenter study </text>
<text top="770" left="108" width="547" height="19" font="4">including cardiopulmonary exercise testing in 321 patients. Eur Heart J. 2010;31:3073-83. </text>
</page>
<page number="214" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 214 </text>
<text top="108" left="108" width="22" height="19" font="4">20. </text>
<text top="108" left="162" width="855" height="19" font="4">Shamszad P, Barnes JN, Morris SA. Aortic dissection in hospitalized children and young adults: a multiinstitutional study. Congenit Heart Dis. </text>
<text top="126" left="108" width="88" height="19" font="4">2014;9:54-62. </text>
<text top="145" left="108" width="22" height="19" font="4">21. </text>
<text top="145" left="162" width="868" height="19" font="4">Roberts CS, Roberts WC. Dissection of the aorta associated with congenital malformation of the aortic valve. J Am Coll Cardiol. 1991;17:712-6. </text>
<text top="163" left="108" width="22" height="19" font="4">22. </text>
<text top="163" left="162" width="870" height="19" font="4">Schwartz ML, Gauvreau K, del Nido P, et al. Long-term predictors of aortic root dilation and aortic regurgitation after arterial switch operation. </text>
<text top="181" left="108" width="199" height="19" font="4">Circulation. 2004;110:II128-II32. </text>
<text top="199" left="108" width="22" height="19" font="4">23. </text>
<text top="199" left="162" width="918" height="19" font="4">Cohen MS, Marino BS, McElhinney DB, et al. Neo-aortic root dilation and valve regurgitation up to 21 years after staged reconstruction for hypoplastic </text>
<text top="218" left="108" width="340" height="19" font="4">left heart syndrome. J Am Coll Cardiol. 2003;42:533-40. </text>
<text top="236" left="108" width="22" height="19" font="4">24. </text>
<text top="236" left="162" width="738" height="19" font="4">Carlo WF, McKenzie ED, Slesnick TC. Root dilation in patients with truncus arteriosus. Congenit Heart Dis. 2011;6:228-33. </text>
<text top="255" left="108" width="22" height="19" font="4">25. </text>
<text top="255" left="162" width="773" height="19" font="4">Egan M, Phillips A, Cook SC. Aortic dissection in the adult Fontan with aortic root enlargement. Pediatr Cardiol. 2009;30:562-3. </text>
<text top="273" left="108" width="22" height="19" font="4">26. </text>
<text top="273" left="162" width="919" height="19" font="4">van der Linde D, Andrinopoulou ER, Oechslin EN, et al. Congenital valvular aortic stenosis in young adults: predictors for rate of progression of stenosis </text>
<text top="291" left="108" width="320" height="19" font="4">and aortic dilatation. Int J Cardiol. 2013;168:863-70. </text>
<text top="309" left="108" width="22" height="19" font="4">27. </text>
<text top="309" left="162" width="917" height="19" font="4">Lowe BS, Therrien J, Ionescu-Ittu R, et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J </text>
<text top="328" left="108" width="204" height="19" font="4">Am Coll Cardiol. 2011;58:538-46. </text>
<text top="346" left="108" width="22" height="19" font="4">28. </text>
<text top="346" left="162" width="772" height="19" font="4">Verheugt CL, Uiterwaal CSPM, van der Velde ET, et al. Mortality in adult congenital heart disease. Eur Heart J. 2010;31:1220-9. </text>
<text top="364" left="108" width="22" height="19" font="4">29. </text>
<text top="364" left="162" width="913" height="19" font="4">Chen SS, Dimopoulos K, Alonso-Gonzalez R, et al. Prevalence and prognostic implication of restenosis or dilatation at the aortic coarctation repair site </text>
<text top="383" left="108" width="663" height="19" font="4">assessed by cardiovascular MRI in adult patients late after coarctation repair. Int J Cardiol. 2014;173:209-15. </text>
<text top="401" left="108" width="22" height="19" font="4">30. </text>
<text top="401" left="162" width="905" height="19" font="4">Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary </text>
<text top="419" left="108" width="304" height="19" font="4">arterial hypertension. Circulation. 2010;121:20-5. </text>
<text top="438" left="108" width="22" height="19" font="4">31. </text>
<text top="438" left="162" width="906" height="19" font="4">Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J. 2010;31:2124-32. </text>
<text top="456" left="108" width="22" height="19" font="4">32. </text>
<text top="456" left="162" width="899" height="19" font="4">Cook SC, Hickey J, Maul TM, et al. Assessment of the cerebral circulation in adults with coarctation of the aorta. Congenit Heart Dis. 2013;8:289-95. </text>
<text top="474" left="108" width="22" height="19" font="4">33. </text>
<text top="474" left="162" width="895" height="19" font="4">Bottega NA, Silversides CK, Oechslin EN, et al. Stenosis of the superior limb of the systemic venous baffle following a Mustard procedure: an under-</text>
<text top="493" left="108" width="303" height="19" font="4">recognized problem. Int J Cardiol. 2012;154:32-7. </text>
<text top="511" left="108" width="22" height="19" font="4">34. </text>
<text top="511" left="162" width="762" height="19" font="4">Gupte PA, Vaideeswar P, Kandalkar BM. Cyanotic nephropathy—a morphometric analysis. Congenit Heart Dis. 2014;9:280-5. </text>
<text top="529" left="108" width="22" height="19" font="4">35. </text>
<text top="529" left="162" width="850" height="19" font="4">Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol. 1996;28:768-72. </text>
<text top="547" left="108" width="22" height="19" font="4">36. </text>
<text top="547" left="162" width="893" height="19" font="4">Meijboom F, Mulder B. Problems in the organization of care for patients with adult congenital heart disease. Arch Cardiovasc Dis. 2010;103:411-5. </text>
<text top="566" left="108" width="22" height="19" font="4">37. </text>
<text top="566" left="162" width="871" height="19" font="4">Beauchesne LM, Therrien J, Alvarez N, et al. Structure and process measures of quality of care in adult congenital heart disease patients: a pan-</text>
<text top="584" left="108" width="275" height="19" font="4">Canadian study. Int J Cardiol. 2012;157:70-4. </text>
<text top="602" left="108" width="22" height="19" font="4">38. </text>
<text top="602" left="162" width="865" height="19" font="4">Patel MS, Kogon BE. Care of the adult congenital heart disease patient in the United States: a summary of the current system. Pediatr Cardiol. </text>
<text top="621" left="108" width="96" height="19" font="4">2010;31:511-4. </text>
<text top="639" left="108" width="22" height="19" font="4">39. </text>
<text top="639" left="162" width="871" height="19" font="4">Marelli AJ, Therrien J, Mackie AS, et al. Planning the specialized care of adult congenital heart disease patients: from numbers to guidelines; an </text>
<text top="657" left="108" width="316" height="19" font="4">epidemiologic approach. Am Heart J. 2009;157:1-8. </text>
<text top="676" left="108" width="22" height="19" font="4">40. </text>
<text top="676" left="162" width="878" height="19" font="4">Gurvitz MZ, Inkelas M, Lee M, et al. Changes in hospitalization patterns among patients with congenital heart disease during the transition from </text>
<text top="694" left="108" width="377" height="19" font="4">adolescence to adulthood. J Am Coll Cardiol. 2007;49:875-82. </text>
<text top="712" left="108" width="22" height="19" font="4">41. </text>
<text top="712" left="162" width="914" height="19" font="4">Shirodaria CC, Gwilt DJ, Gatzoulis MA. Joint outpatient clinics for the adult with congenital heart disease at the district general hospital: an alternative </text>
<text top="730" left="108" width="273" height="19" font="4">model of care. Int J Cardiol. 2005;103:47-50. </text>
<text top="749" left="108" width="22" height="19" font="4">42. </text>
<text top="749" left="162" width="797" height="19" font="4">Mackie AS, Islam S, Magill-Evans J, et al. Healthcare transition for youth with heart disease: a clinical trial. Heart. 2014;100:1113-8. </text>
<text top="767" left="108" width="22" height="19" font="4">43. </text>
<text top="767" left="162" width="874" height="19" font="4">Sable C, Foster E, Uzark K, et al. Best practices in managing transition to adulthood for adolescents with congenital heart disease: the transition </text>
<text top="786" left="108" width="836" height="19" font="4">process and medical and psychosocial issues: a scientific statement from the American Heart Association. Circulation. 2011;123:1454-85. </text>
</page>
<page number="215" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 215 </text>
<text top="108" left="108" width="22" height="19" font="4">44. </text>
<text top="108" left="162" width="866" height="19" font="4">Christman MP, Castro-Zarraga M, DeFaria YD, et al. Adequacy of cancer screening in adult women with congenital heart disease. ISRN Cardiol. </text>
<text top="126" left="108" width="122" height="19" font="4">2013;2013:827696. </text>
<text top="145" left="108" width="22" height="19" font="4">45. </text>
<text top="145" left="162" width="878" height="19" font="4">Karamlou T, Diggs BS, Person T, et al. National practice patterns for management of adult congenital heart disease: operation by pediatric heart </text>
<text top="163" left="108" width="425" height="19" font="4">surgeons decreases in-hospital death. Circulation. 2008;118:2345-52. </text>
<text top="181" left="108" width="22" height="19" font="4">46. </text>
<text top="181" left="162" width="914" height="19" font="4">Ruiz CE, Feldman TE, Hijazi ZM, et al. Interventional fellowship in structural and congenital heart disease for adults. JACC Cardiovasc Interv. 2010;3:e1-</text>
<text top="199" left="108" width="22" height="19" font="4">15. </text>
<text top="218" left="108" width="22" height="19" font="4">47. </text>
<text top="218" left="162" width="906" height="19" font="4">Armsby L, Beekman RHr, Benson L, et al. SCAI expert consensus statement for advanced training programs in pediatric and congenital interventional </text>
<text top="236" left="108" width="419" height="19" font="4">cardiac catheterization. Catheter Cardiovasc Interv. 2014;84:779-84. </text>
<text top="255" left="108" width="22" height="19" font="4">48. </text>
<text top="255" left="162" width="907" height="19" font="4">Lamour JM, Kanter KR, Naftel DC, et al. The effect of age, diagnosis, and previous surgery in children and adults undergoing heart transplantation for </text>
<text top="273" left="108" width="360" height="19" font="4">congenital heart disease. J Am Coll Cardiol. 2009;54:160-5. </text>
<text top="291" left="108" width="22" height="19" font="4">49. </text>
<text top="291" left="162" width="898" height="19" font="4">Mascio CE, Pasquali SK, Jacobs JP, et al. Outcomes in adult congenital heart surgery: analysis of the Society of Thoracic Surgeons database. J Thorac </text>
<text top="309" left="108" width="215" height="19" font="4">Cardiovasc Surg. 2011;142:1090-7. </text>
<text top="328" left="108" width="22" height="19" font="4">50. </text>
<text top="328" left="162" width="889" height="19" font="4">Hörer J, Vogt M, Wottke M, et al. Evaluation of the Aristotle complexity models in adult patients with congenital heart disease. Eur J Cardiothorac </text>
<text top="346" left="108" width="138" height="19" font="4">Surg. 2013;43:128-34. </text>
<text top="364" left="108" width="22" height="19" font="4">51. </text>
<text top="364" left="162" width="886" height="19" font="4">van Gameren M, Putman LM, Takkenberg JJM, et al. Risk stratification for adult congenital heart surgery. Eur J Cardiothorac Surg. 2011;39:490-4. </text>
<text top="383" left="108" width="22" height="19" font="4">52. </text>
<text top="383" left="162" width="918" height="19" font="4">Kogon B, Oster M. Assessing surgical risk for adults with congenital heart disease: are pediatric scoring systems appropriate? J Thorac Cardiovasc Surg. </text>
<text top="401" left="108" width="111" height="19" font="4">2014;147:666-71. </text>
<text top="419" left="108" width="22" height="19" font="4">53. </text>
<text top="419" left="162" width="906" height="19" font="4">Gajjar TP, Hiremath CS, Desai NB. Surgical closure of sinus venosus atrial septal defect using a single patch—transcaval repair technique. J Card Surg. </text>
<text top="438" left="108" width="103" height="19" font="4">2011;26:429-34. </text>
<text top="456" left="108" width="22" height="19" font="4">54. </text>
<text top="456" left="162" width="910" height="19" font="4">Johnson JN, Hornik CP, Li JS, et al. Cumulative radiation exposure and cancer risk estimation in children with heart disease. Circulation. 2014;130:161-</text>
<text top="474" left="108" width="15" height="19" font="4">7. </text>
<text top="493" left="108" width="22" height="19" font="4">55. </text>
<text top="493" left="162" width="920" height="19" font="4">Glatz AC, Purrington KS, Klinger A, et al. Cumulative exposure to medical radiation for children requiring surgery for congenital heart disease. J Pediatr. </text>
<text top="511" left="108" width="137" height="19" font="4">2014;164:789-94.e10. </text>
<text top="529" left="108" width="22" height="19" font="4">56. </text>
<text top="529" left="162" width="884" height="19" font="4">Eisenberg MJ, Afilalo J, Lawler PR, et al. Cancer risk related to low-dose ionizing radiation from cardiac imaging in patients after acute myocardial </text>
<text top="547" left="108" width="211" height="19" font="4">infarction. CMAJ. 2011;183:430-6. </text>
<text top="566" left="108" width="22" height="19" font="4">57. </text>
<text top="566" left="162" width="913" height="19" font="4">Yakoumakis E, Kostopoulou H, Makri T, et al. Estimation of radiation dose and risk to children undergoing cardiac catheterization for the treatment of </text>
<text top="584" left="108" width="551" height="19" font="4">a congenital heart disease using Monte Carlo simulations. Pediatr Radiol. 2013;43:339-46. </text>
<text top="602" left="108" width="22" height="19" font="4">58. </text>
<text top="602" left="162" width="908" height="19" font="4">Brenner DJ, Doll R, Goodhead DT, et al. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci </text>
<text top="621" left="108" width="151" height="19" font="4">USA. 2003;100:13761-6. </text>
<text top="639" left="108" width="22" height="19" font="4">59. </text>
<text top="639" left="162" width="886" height="19" font="4">Andreassi MG, Ait-Ali L, Botto N, et al. Cardiac catheterization and long-term chromosomal damage in children with congenital heart disease. Eur </text>
<text top="657" left="108" width="153" height="19" font="4">Heart J. 2006;27:2703-8. </text>
<text top="676" left="108" width="22" height="19" font="4">60. </text>
<text top="676" left="162" width="878" height="19" font="4">Bartel T, Konorza T, Neudorf U, et al. Intracardiac echocardiography: an ideal guiding tool for device closure of interatrial communications. Eur J </text>
<text top="694" left="108" width="168" height="19" font="4">Echocardiogr. 2005;6:92-6. </text>
<text top="712" left="108" width="22" height="19" font="4">61. </text>
<text top="712" left="162" width="915" height="19" font="4">Boccalandro F, Muench A, Salloum J, et al. Interatrial defect sizing by intracardiac and transesophageal echocardiography compared with fluoroscopic </text>
<text top="730" left="108" width="733" height="19" font="4">measurements in patients undergoing percutaneous transcatheter closure. Catheter Cardiovasc Interv. 2004;62:415-20. </text>
<text top="749" left="108" width="22" height="19" font="4">62. </text>
<text top="749" left="162" width="868" height="19" font="4">Cao Q, Radtke W, Berger F, et al. Transcatheter closure of multiple atrial septal defects. Initial results and value of two- and three-dimensional </text>
<text top="767" left="108" width="398" height="19" font="4">transoesophageal echocardiography. Eur Heart J. 2000;21:941-7. </text>
<text top="786" left="108" width="22" height="19" font="4">63. </text>
<text top="786" left="162" width="921" height="19" font="4">Chien JC, Hwang B, Fu YC, et al. Sizing of atrial septal defects by intracardiac echocardiography for device closures. J Chin Med Assoc. 2008;71:399-405. </text>
</page>
<page number="216" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 216 </text>
<text top="108" left="108" width="22" height="19" font="4">64. </text>
<text top="108" left="162" width="896" height="19" font="4">Mullen MJ, Dias BF, Walker F, et al. Intracardiac echocardiography guided device closure of atrial septal defects. J Am Coll Cardiol. 2003;41:285-92. </text>
<text top="126" left="108" width="22" height="19" font="4">65. </text>
<text top="126" left="162" width="869" height="19" font="4">Ewert P, Berger F, Daehnert I, et al. Transcatheter closure of atrial septal defects without fluoroscopy: feasibility of a new method. Circulation. </text>
<text top="145" left="108" width="103" height="19" font="4">2000;101:847-9. </text>
<text top="163" left="108" width="22" height="19" font="4">66. </text>
<text top="163" left="162" width="907" height="19" font="4">Grewal J, Majdalany D, Syed I, et al. Three-dimensional echocardiographic assessment of right ventricular volume and function in adult patients with </text>
<text top="181" left="108" width="690" height="19" font="4">congenital heart disease: comparison with magnetic resonance imaging. J Am Soc Echocardiogr. 2010;23:127-33. </text>
<text top="199" left="108" width="22" height="19" font="4">67. </text>
<text top="199" left="162" width="912" height="19" font="4">van der Zwaan HB, Helbing WA, McGhie JS, et al. Clinical value of real-time three-dimensional echocardiography for right ventricular quantification in </text>
<text top="218" left="108" width="726" height="19" font="4">congenital heart disease: validation with cardiac magnetic resonance imaging. J Am Soc Echocardiogr. 2010;23:134-40. </text>
<text top="236" left="108" width="22" height="19" font="4">68. </text>
<text top="236" left="162" width="892" height="19" font="4">Kaku K, Takeuchi M, Segeng L, et al. Assessment of atrial septal defect size and residual rim using real-time 3D transesophageal echocardiography. </text>
<text top="255" left="108" width="268" height="19" font="4">Journal of Echocardiography. 2009;7:48-54. </text>
<text top="273" left="108" width="22" height="19" font="4">69. </text>
<text top="273" left="162" width="914" height="19" font="4">Lodato JA, Cao QL, Weinert L, et al. Feasibility of real-time three-dimensional transoesophageal echocardiography for guidance of percutaneous atrial </text>
<text top="291" left="108" width="349" height="19" font="4">septal defect closure. Eur J Echocardiogr. 2009;10:543-8. </text>
<text top="309" left="108" width="22" height="19" font="4">70. </text>
<text top="309" left="162" width="912" height="19" font="4">Mojadidi MK, Winoker JS, Roberts SC, et al. Two-dimensional echocardiography using second harmonic imaging for the diagnosis of intracardiac right-</text>
<text top="328" left="108" width="579" height="19" font="4">to-left shunt: a meta-analysis of prospective studies. Int J Cardiovasc Imaging. 2014;30:911-23. </text>
<text top="346" left="108" width="22" height="19" font="4">71. </text>
<text top="346" left="162" width="899" height="19" font="4">Randolph GR, Hagler DJ, Connolly HM, et al. Intraoperative transesophageal echocardiography during surgery for congenital heart defects. J Thorac </text>
<text top="364" left="108" width="222" height="19" font="4">Cardiovasc Surg. 2002;124:1176-82. </text>
<text top="383" left="108" width="22" height="19" font="4">72. </text>
<text top="383" left="162" width="910" height="19" font="4">Rigatelli G, Cardaioli P, Roncon L, et al. Impact of intracardiac echocardiography on radiation exposure during adult congenital heart disease catheter-</text>
<text top="401" left="108" width="385" height="19" font="4">based interventions. Int J Cardiovasc Imaging. 2007;23:139-42. </text>
<text top="419" left="108" width="22" height="19" font="4">73. </text>
<text top="419" left="162" width="907" height="19" font="4">Rigatelli G, Dell' Avvocata F, Cardaioli P, et al. Five-year follow-up of intracardiac echocardiography-assisted transcatheter closure of complex ostium </text>
<text top="438" left="108" width="405" height="19" font="4">secundum atrial septal defect. Congenit Heart Dis. 2012;7:103-10. </text>
<text top="456" left="108" width="22" height="19" font="4">74. </text>
<text top="456" left="162" width="879" height="19" font="4">Arheden H, Holmqvist C, Thilen U, et al. Left-to-right cardiac shunts: comparison of measurements obtained with MR velocity mapping and with </text>
<text top="474" left="108" width="333" height="19" font="4">radionuclide angiography. Radiology. 1999;211:453-8. </text>
<text top="493" left="108" width="22" height="19" font="4">75. </text>
<text top="493" left="162" width="872" height="19" font="4">Blalock SE, Banka P, Geva T, et al. Interstudy variability in cardiac magnetic resonance imaging measurements of ventricular volume, mass, and </text>
<text top="511" left="108" width="748" height="19" font="4">ejection fraction in repaired tetralogy of Fallot: a prospective observational study. J Magn Reson Imaging. 2013;38:829-35. </text>
<text top="529" left="108" width="22" height="19" font="4">76. </text>
<text top="529" left="162" width="904" height="19" font="4">Bonello B, Kilner PJ. Review of the role of cardiovascular magnetic resonance in congenital heart disease, with a focus on right ventricle assessment. </text>
<text top="547" left="108" width="238" height="19" font="4">Arch Cardiovasc Dis. 2012;105:605-13. </text>
<text top="566" left="108" width="22" height="19" font="4">77. </text>
<text top="566" left="162" width="843" height="19" font="4">Boxt LM. Magnetic resonance and computed tomographic evaluation of congenital heart disease. J Magn Reson Imaging. 2004;19:827-47. </text>
<text top="584" left="108" width="22" height="19" font="4">78. </text>
<text top="584" left="162" width="876" height="19" font="4">Bunce NH, Lorenz CH, Keegan J, et al. Coronary artery anomalies: assessment with free-breathing three-dimensional coronary MR angiography. </text>
<text top="602" left="108" width="170" height="19" font="4">Radiology. 2003;227:201-8. </text>
<text top="621" left="108" width="22" height="19" font="4">79. </text>
<text top="621" left="162" width="865" height="19" font="4">Crean AM, Maredia N, Ballard G, et al. 3D Echo systematically underestimates right ventricular volumes compared to cardiovascular magnetic </text>
<text top="639" left="108" width="797" height="19" font="4">resonance in adult congenital heart disease patients with moderate or severe RV dilatation. J Cardiovasc Magn Reson. 2011;13:78. </text>
<text top="657" left="108" width="22" height="19" font="4">80. </text>
<text top="657" left="162" width="904" height="19" font="4">Festa P, Ait-Ali L, Cerillo AG, et al. Magnetic resonance imaging is the diagnostic tool of choice in the preoperative evaluation of patients with partial </text>
<text top="676" left="108" width="490" height="19" font="4">anomalous pulmonary venous return. Int J Cardiovasc Imaging. 2006;22:685-93. </text>
<text top="694" left="108" width="22" height="19" font="4">81. </text>
<text top="694" left="162" width="566" height="19" font="4">Kilner PJ. Imaging congenital heart disease in adults. Br J Radiol. 2011;84 Spec No 3:S258-68. </text>
<text top="712" left="108" width="22" height="19" font="4">82. </text>
<text top="712" left="162" width="908" height="19" font="4">Lewis MJ, Hecht E, Ginns J, et al. Serial cardiac MRIs in adult Fontan patients detect progressive hepatic enlargement and congestion. Congenit Heart </text>
<text top="730" left="108" width="121" height="19" font="4">Dis. 2017;12:153-8. </text>
<text top="749" left="108" width="22" height="19" font="4">83. </text>
<text top="749" left="162" width="880" height="19" font="4">van der Linde D, Rossi A, Yap SC, et al. Ascending aortic diameters in congenital aortic stenosis: cardiac magnetic resonance versus transthoracic </text>
<text top="767" left="108" width="344" height="19" font="4">echocardiography. Echocardiography. 2013;30:497-504. </text>
</page>
<page number="217" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 217 </text>
<text top="108" left="108" width="22" height="19" font="4">84. </text>
<text top="108" left="162" width="882" height="19" font="4">Prasad SK, Soukias N, Hornung T, et al. Role of magnetic resonance angiography in the diagnosis of major aortopulmonary collateral arteries and </text>
<text top="126" left="108" width="475" height="19" font="4">partial anomalous pulmonary venous drainage. Circulation. 2004;109:207-14. </text>
<text top="145" left="108" width="22" height="19" font="4">85. </text>
<text top="145" left="162" width="893" height="19" font="4">Puchalski MD, Williams RV, Askovich B, et al. Assessment of right ventricular size and function: echo versus magnetic resonance imaging. Congenit </text>
<text top="163" left="108" width="152" height="19" font="4">Heart Dis. 2007;2:27-31. </text>
<text top="181" left="108" width="22" height="19" font="4">86. </text>
<text top="181" left="162" width="903" height="19" font="4">Taylor AM, Thorne SA, Rubens MB, et al. Coronary artery imaging in grown up congenital heart disease: complementary role of magnetic resonance </text>
<text top="199" left="108" width="385" height="19" font="4">and x-ray coronary angiography. Circulation. 2000;101:1670-8. </text>
<text top="218" left="108" width="22" height="19" font="4">87. </text>
<text top="218" left="162" width="746" height="19" font="4">Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med. 2007;357:2277-84. </text>
<text top="236" left="108" width="22" height="19" font="4">88. </text>
<text top="236" left="162" width="898" height="19" font="4">Bazzocchi G, Romagnoli A, Sperandio M, et al. Evaluation with 64-slice CT of the prevalence of coronary artery variants and congenital anomalies: a </text>
<text top="255" left="108" width="420" height="19" font="4">retrospective study of 3,236 patients. Radiol Med. 2011;116:675-89. </text>
<text top="273" left="108" width="22" height="19" font="4">89. </text>
<text top="273" left="162" width="864" height="19" font="4">Cheng Z, Wang X, Duan Y, et al. Detection of coronary artery anomalies by dual-source CT coronary angiography. Clin Radiol. 2010;65:815-22. </text>
<text top="291" left="108" width="22" height="19" font="4">90. </text>
<text top="291" left="162" width="883" height="19" font="4">Doganay S, Karaman A, Gundogdu F, et al. Usefulness of multidetector computed tomography coronary venous angiography examination before </text>
<text top="309" left="108" width="387" height="19" font="4">cardiac resynchronization therapy. Jpn J Radiol. 2011;29:342-7. </text>
<text top="328" left="108" width="22" height="19" font="4">91. </text>
<text top="328" left="162" width="921" height="19" font="4">Ghoshhajra BB, Sidhu MS, El-Sherief A, et al. Adult congenital heart disease imaging with second-generation dual-source computed tomography: initial </text>
<text top="346" left="108" width="375" height="19" font="4">experiences and findings. Congenit Heart Dis. 2012;7:516-25. </text>
<text top="364" left="108" width="22" height="19" font="4">92. </text>
<text top="364" left="162" width="868" height="19" font="4">Torres FS, Nguyen ET, Dennie CJ, et al. Role of MDCT coronary angiography in the evaluation of septal vs interarterial course of anomalous left </text>
<text top="383" left="108" width="392" height="19" font="4">coronary arteries. J Cardiovasc Comput Tomogr. 2010;4:246-54. </text>
<text top="401" left="108" width="22" height="19" font="4">93. </text>
<text top="401" left="162" width="892" height="19" font="4">Moore JW, Vincent RN, Beekman RHr, et al. Procedural results and safety of common interventional procedures in congenital heart disease: initial </text>
<text top="419" left="108" width="555" height="19" font="4">report from the National Cardiovascular Data Registry. J Am Coll Cardiol. 2014;64:2439-51. </text>
<text top="438" left="108" width="22" height="19" font="4">94. </text>
<text top="438" left="162" width="909" height="19" font="4">Learn CP, Holzer RJ, Daniels CJ, et al. Adverse events rates and risk factors in adults undergoing cardiac catheterization at pediatric hospitals—results </text>
<text top="456" left="108" width="385" height="19" font="4">from the C3PO. Catheter Cardiovasc Interv. 2013;81:997-1005. </text>
<text top="474" left="108" width="22" height="19" font="4">95. </text>
<text top="474" left="162" width="895" height="19" font="4">Sutton NJ, Greenberg MA, Menegus MA, et al. Caring for the adult with congenital heart disease in an adult catheterization laboratory by pediatric </text>
<text top="493" left="108" width="450" height="19" font="4">interventionalists—safety and efficacy. Congenit Heart Dis. 2013;8:111-6. </text>
<text top="511" left="108" width="22" height="19" font="4">96. </text>
<text top="511" left="162" width="911" height="19" font="4">Opotowsky AR, Landzberg MJ, Kimmel SE, et al. Percutaneous closure of patent foramen ovale and atrial septal defect in adults: the impact of clinical </text>
<text top="529" left="108" width="622" height="19" font="4">variables and hospital procedure volume on in-hospital adverse events. Am Heart J. 2009;157:867-74. </text>
<text top="547" left="108" width="22" height="19" font="4">97. </text>
<text top="547" left="162" width="904" height="19" font="4">Gilard M, Cornily J-C, Pennec P-Y, et al. Accuracy of multislice computed tomography in the preoperative assessment of coronary disease in patients </text>
<text top="566" left="108" width="373" height="19" font="4">with aortic valve stenosis. J Am Coll Cardiol. 2006;47:2020-4. </text>
<text top="584" left="108" width="22" height="19" font="4">98. </text>
<text top="584" left="162" width="914" height="19" font="4">Manghat NE, Morgan-Hughes GJ, Broadley AJ, et al. 16-Detector row computed tomographic coronary angiography in patients undergoing evaluation </text>
<text top="602" left="108" width="598" height="19" font="4">for aortic valve replacement: comparison with catheter angiography. Clin Radiol. 2006;61:749-57. </text>
<text top="621" left="108" width="22" height="19" font="4">99. </text>
<text top="621" left="162" width="909" height="19" font="4">Meijboom WB, Mollet NR, Van Mieghem CAG, et al. Pre-operative computed tomography coronary angiography to detect significant coronary artery </text>
<text top="639" left="108" width="546" height="19" font="4">disease in patients referred for cardiac valve surgery. J Am Coll Cardiol. 2006;48:1658-65. </text>
<text top="657" left="108" width="30" height="19" font="4">100. </text>
<text top="657" left="162" width="919" height="19" font="4">Reant P, Brunot S, Lafitte S, et al. Predictive value of noninvasive coronary angiography with multidetector computed tomography to detect significant </text>
<text top="676" left="108" width="436" height="19" font="4">coronary stenosis before valve surgery. Am J Cardiol. 2006;97:1506-10. </text>
<text top="694" left="108" width="30" height="19" font="4">101. </text>
<text top="694" left="162" width="904" height="19" font="4">Scheffel H, Leschka S, Plass A, et al. Accuracy of 64-slice computed tomography for the preoperative detection of coronary artery disease in patients </text>
<text top="712" left="108" width="390" height="19" font="4">with chronic aortic regurgitation. Am J Cardiol. 2007;100:701-6. </text>
<text top="730" left="108" width="30" height="19" font="4">102. </text>
<text top="730" left="162" width="910" height="19" font="4">Galas A, Hryniewiecki T, Kępka C, et al. May dual-source computed tomography angiography replace invasive coronary angiography in the evaluation </text>
<text top="749" left="108" width="476" height="19" font="4">of patients referred for valvular disease surgery? Kardiol Pol. 2012;70:877-82. </text>
<text top="767" left="108" width="30" height="19" font="4">103. </text>
<text top="767" left="162" width="886" height="19" font="4">Diller G-P, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic </text>
<text top="786" left="108" width="259" height="19" font="4">implication. Circulation. 2005;112:828-35. </text>
</page>
<page number="218" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 218 </text>
<text top="108" left="108" width="30" height="19" font="4">104. </text>
<text top="108" left="162" width="892" height="19" font="4">Hager A, Hess J. Comparison of health related quality of life with cardiopulmonary exercise testing in adolescents and adults with congenital heart </text>
<text top="126" left="108" width="197" height="19" font="4">disease. Heart. 2005;91:517-20. </text>
<text top="145" left="108" width="30" height="19" font="4">105. </text>
<text top="145" left="162" width="917" height="19" font="4">Gungor H, Fatih Ayik M, Engin C, et al. Transthoracic echocardiographic and cardiopulmonary exercise testing parameters in Eisenmenger’s syndrome. </text>
<text top="163" left="108" width="418" height="19" font="4">Association with six-minute walk test distance. Herz. 2014;39:633-7. </text>
<text top="181" left="108" width="30" height="19" font="4">106. </text>
<text top="181" left="162" width="854" height="19" font="4">Ross RM, Murthy JN, Wollak ID, et al. The six minute walk test accurately estimates mean peak oxygen uptake. BMC Pulm Med. 2010;10:31. </text>
<text top="199" left="108" width="30" height="19" font="4">107. </text>
<text top="199" left="162" width="790" height="19" font="4">Wray J, Frigiola A, Bull C. Loss to specialist follow-up in congenital heart disease; out of sight, out of mind. Heart. 2013;99:485-90. </text>
<text top="218" left="108" width="30" height="19" font="4">108. </text>
<text top="218" left="162" width="871" height="19" font="4">Goossens E, Van Deyk K, Zupancic N, et al. Effectiveness of structured patient education on the knowledge level of adolescents and adults with </text>
<text top="236" left="108" width="388" height="19" font="4">congenital heart disease. Eur J Cardiovasc Nurs. 2014;13:63-70. </text>
<text top="255" left="108" width="30" height="19" font="4">109. </text>
<text top="255" left="162" width="911" height="19" font="4">Lotstein DS, Seid M, Klingensmith G, et al. Transition from pediatric to adult care for youth diagnosed with type 1 diabetes in adolescence. Pediatrics. </text>
<text top="273" left="108" width="134" height="19" font="4">2013;131:e1062-e70. </text>
<text top="291" left="108" width="30" height="19" font="4">110. </text>
<text top="291" left="162" width="814" height="19" font="4">Myers J, Kaykha A, George S, et al. Fitness versus physical activity patterns in predicting mortality in men. Am J Med. 2004;117:912-8. </text>
<text top="309" left="108" width="30" height="19" font="4">111. </text>
<text top="309" left="162" width="686" height="19" font="4">Warburton DER, Nicol CW, Bredin SSD. Health benefits of physical activity: the evidence. CMAJ. 2006;174:801-9. </text>
<text top="328" left="108" width="30" height="19" font="4">112. </text>
<text top="328" left="162" width="896" height="19" font="4">King AC, Taylor CB, Haskell WL, et al. Influence of regular aerobic exercise on psychological health: a randomized, controlled trial of healthy middle-</text>
<text top="346" left="108" width="270" height="19" font="4">aged adults. Health Psychol. 1989;8:305-24. </text>
<text top="364" left="108" width="30" height="19" font="4">113. </text>
<text top="364" left="162" width="910" height="19" font="4">Reybrouck T, Mertens L. Physical performance and physical activity in grown-up congenital heart disease. Eur J Cardiovasc Prev Rehabil. 2005;12:498-</text>
<text top="383" left="108" width="30" height="19" font="4">502. </text>
<text top="401" left="108" width="30" height="19" font="4">114. </text>
<text top="401" left="162" width="852" height="19" font="4">Pemberton VL, McCrindle BW, Barkin S, et al. Report of the National Heart, Lung, and Blood Institute’s Working Group on obesity and other </text>
<text top="419" left="108" width="516" height="19" font="4">cardiovascular risk factors in congenital heart disease. Circulation. 2010;121:1153-9. </text>
<text top="438" left="108" width="30" height="19" font="4">115. </text>
<text top="438" left="162" width="733" height="19" font="4">Graham T, Jr, Driscoll DJ, Gersony WM, et al. Task Force 2: congenital heart disease. J Am Coll Cardiol. 2005;45:1326-33. </text>
<text top="456" left="108" width="30" height="19" font="4">116. </text>
<text top="456" left="162" width="906" height="19" font="4">Pelliccia A, Fagard R, Bjørnstad HH, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus </text>
<text top="474" left="108" width="929" height="19" font="4">document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of </text>
<text top="493" left="108" width="643" height="19" font="4">Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J. 2005;26:1422-45. </text>
<text top="511" left="108" width="30" height="19" font="4">117. </text>
<text top="511" left="162" width="911" height="19" font="4">Duppen N, Takken T, Hopman MTE, et al. Systematic review of the effects of physical exercise training programmes in children and young adults with </text>
<text top="529" left="108" width="353" height="19" font="4">congenital heart disease. Int J Cardiol. 2013;168:1779-87. </text>
<text top="547" left="108" width="30" height="19" font="4">118. </text>
<text top="547" left="162" width="887" height="19" font="4">Dua JS, Cooper AR, Fox KR, et al. Exercise training in adults with congenital heart disease: feasibility and benefits. Int J Cardiol. 2010;138:196-205. </text>
<text top="566" left="108" width="30" height="19" font="4">119. </text>
<text top="566" left="162" width="856" height="19" font="4">Holloway TM, Chesssex C, Grace SL, et al. A call for adult congenital heart disease patient participation in cardiac rehabilitation. Int J Cardiol. </text>
<text top="584" left="108" width="103" height="19" font="4">2011;150:345-6. </text>
<text top="602" left="108" width="30" height="19" font="4">120. </text>
<text top="602" left="162" width="919" height="19" font="4">Cordina R, O’Meagher S, Gould H, et al. Skeletal muscle abnormalities and exercise capacity in adults with a Fontan circulation. Heart. 2013;99:1530-4. </text>
<text top="621" left="108" width="30" height="19" font="4">121. </text>
<text top="621" left="162" width="909" height="19" font="4">Cordina RL, O’Meagher S, Karmali A, et al. Resistance training improves cardiac output, exercise capacity and tolerance to positive airway pressure in </text>
<text top="639" left="108" width="300" height="19" font="4">Fontan physiology. Int J Cardiol. 2013;168:780-8. </text>
<text top="657" left="108" width="30" height="19" font="4">122. </text>
<text top="657" left="162" width="907" height="19" font="4">Kempny A, Dimopoulos K, Uebing A, et al. Reference values for exercise limitations among adults with congenital heart disease. Relation to activities </text>
<text top="676" left="108" width="601" height="19" font="4">of daily life—single centre experience and review of published data. Eur Heart J. 2012;33:1386-96. </text>
<text top="694" left="108" width="30" height="19" font="4">123. </text>
<text top="694" left="162" width="885" height="19" font="4">Takken T, Giardini A, Reybrouck T, et al. Recommendations for physical activity, recreation sport, and exercise training in paediatric patients with </text>
<text top="712" left="108" width="940" height="19" font="4">congenital heart disease: a report from the Exercise, Basic &amp; Translational Research Section of the European Association of Cardiovascular Prevention and </text>
<text top="730" left="108" width="898" height="19" font="4">Rehabilitation, the European Congenital Heart and Lung Exercise Group, and the Association for European Paediatric Cardiology. Eur J Prev Cardiol. </text>
<text top="749" left="108" width="111" height="19" font="4">2012;19:1034-65. </text>
<text top="767" left="108" width="30" height="19" font="4">124. </text>
<text top="767" left="162" width="911" height="19" font="4">Longmuir PE. Creating inclusive physical activity opportunities: an abilities-based approach. In: Steadward RE, Watkinson EJ and Wheeler GD, editors. </text>
<text top="786" left="108" width="535" height="19" font="4">Adapted physical activity. Edmonton, Canada: University of Alberta Press, 2003:363-82. </text>
</page>
<page number="219" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 219 </text>
<text top="108" left="108" width="30" height="19" font="4">125. </text>
<text top="108" left="162" width="660" height="19" font="4">Mitchell JH, Haskell W, Snell P, et al. Task Force 8: classification of sports. J Am Coll Cardiol. 2005;45:1364-7. </text>
<text top="126" left="108" width="30" height="19" font="4">126. </text>
<text top="126" left="162" width="915" height="19" font="4">Westhoff-Bleck M, Schieffer B, Tegtbur U, et al. Aerobic training in adults after atrial switch procedure for transposition of the great arteries improves </text>
<text top="145" left="108" width="609" height="19" font="4">exercise capacity without impairing systemic right ventricular function. Int J Cardiol. 2013;170:24-9. </text>
<text top="163" left="108" width="30" height="19" font="4">127. </text>
<text top="163" left="162" width="917" height="19" font="4">Tikkanen AU, Opotowsky AR, Bhatt AB, et al. Physical activity is associated with improved aerobic exercise capacity over time in adults with congenital </text>
<text top="181" left="108" width="286" height="19" font="4">heart disease. Int J Cardiol. 2013;168:4685-91. </text>
<text top="199" left="108" width="30" height="19" font="4">128. </text>
<text top="199" left="162" width="867" height="19" font="4">Amianto F, Bergui G, Abbate-Daga G, et al. Growing up with a congenital heart disease: neuro-cognitive, psychopathological and quality of life </text>
<text top="218" left="108" width="283" height="19" font="4">outcomes. Panminerva Med. 2011;53:109-27. </text>
<text top="236" left="108" width="30" height="19" font="4">129. </text>
<text top="236" left="162" width="907" height="19" font="4">Granberg M, Rydberg A, Fisher AG. Activities in daily living and schoolwork task performance in children with complex congenital heart disease. Acta </text>
<text top="255" left="108" width="162" height="19" font="4">Paediatr. 2008;97:1270-4. </text>
<text top="273" left="108" width="30" height="19" font="4">130. </text>
<text top="273" left="162" width="895" height="19" font="4">Karsdorp PA, Everaerd W, Kindt M, et al. Psychological and cognitive functioning in children and adolescents with congenital heart disease: a meta-</text>
<text top="291" left="108" width="267" height="19" font="4">analysis. J Pediatr Psychol. 2007;32:527-41. </text>
<text top="309" left="108" width="30" height="19" font="4">131. </text>
<text top="309" left="162" width="901" height="19" font="4">van der Rijken REA, Maassen BAM, Walk TLM, et al. Outcome after surgical repair of congenital cardiac malformations at school age. Cardiol Young. </text>
<text top="328" left="108" width="96" height="19" font="4">2007;17:64-71. </text>
<text top="346" left="108" width="30" height="19" font="4">132. </text>
<text top="346" left="162" width="904" height="19" font="4">Kirshbom PM, Flynn TB, Clancy RR, et al. Late neurodevelopmental outcome after repair of total anomalous pulmonary venous connection. J Thorac </text>
<text top="364" left="108" width="215" height="19" font="4">Cardiovasc Surg. 2005;129:1091-7. </text>
<text top="383" left="108" width="30" height="19" font="4">133. </text>
<text top="383" left="162" width="754" height="19" font="4">Wernovsky G, Stiles KM, Gauvreau K, et al. Cognitive development after the Fontan operation. Circulation. 2000;102:883-9. </text>
<text top="401" left="108" width="30" height="19" font="4">134. </text>
<text top="401" left="162" width="856" height="19" font="4">Callus E, Quadri E, Ricci C, et al. Update on psychological functioning in adults with congenital heart disease: a systematic review. Expert Rev </text>
<text top="419" left="108" width="208" height="19" font="4">Cardiovasc Ther. 2013;11:785-91. </text>
<text top="438" left="108" width="30" height="19" font="4">135. </text>
<text top="438" left="162" width="919" height="19" font="4">Kovacs AH, Saidi AS, Kuhl EA, et al. Depression and anxiety in adult congenital heart disease: predictors and prevalence. Int J Cardiol. 2009;137:158-64. </text>
<text top="456" left="108" width="30" height="19" font="4">136. </text>
<text top="456" left="162" width="912" height="19" font="4">Kovacs AH, Sears SF, Saidi AS. Biopsychosocial experiences of adults with congenital heart disease: review of the literature. Am Heart J. 2005;150:193-</text>
<text top="474" left="108" width="30" height="19" font="4">201. </text>
<text top="493" left="108" width="30" height="19" font="4">137. </text>
<text top="493" left="162" width="898" height="19" font="4">van Rijen EHM, Utens EMWJ, Roos-Hesselink JW, et al. Psychosocial functioning of the adult with congenital heart disease: a 20-33 years follow-up. </text>
<text top="511" left="108" width="177" height="19" font="4">Eur Heart J. 2003;24:673-83. </text>
<text top="529" left="108" width="30" height="19" font="4">138. </text>
<text top="529" left="162" width="882" height="19" font="4">Chirouze C, Athan E, Alla F, et al. Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on </text>
<text top="547" left="108" width="475" height="19" font="4">Endocarditis-Prospective Cohort Study. Clin Microbiol Infect. 2013;19:1140-7. </text>
<text top="566" left="108" width="30" height="19" font="4">139. </text>
<text top="566" left="162" width="852" height="19" font="4">Thuny F, Giorgi R, Habachi R, et al. Excess mortality and morbidity in patients surviving infective endocarditis. Am Heart J. 2012;164:94-101. </text>
<text top="584" left="108" width="30" height="19" font="4">140. </text>
<text top="584" left="162" width="904" height="19" font="4">Verheugt CL, Uiterwaal CSPM, van der Velde ET, et al. Turning 18 with congenital heart disease: prediction of infective endocarditis based on a large </text>
<text top="602" left="108" width="258" height="19" font="4">population. Eur Heart J. 2011;32:1926-34. </text>
<text top="621" left="108" width="30" height="19" font="4">141. </text>
<text top="621" left="162" width="842" height="19" font="4">Lalani T, Kanafani ZA, Chu VH, et al. Prosthetic valve endocarditis due to coagulase-negative staphylococci: findings from the International </text>
<text top="639" left="108" width="579" height="19" font="4">Collaboration on Endocarditis Merged Database. Eur J Clin Microbiol Infect Dis. 2006;25:365-8. </text>
<text top="657" left="108" width="30" height="19" font="4">142. </text>
<text top="657" left="162" width="860" height="19" font="4">Anderson DJ, Olaison L, McDonald JR, et al. Enterococcal prosthetic valve infective endocarditis: report of 45 episodes from the International </text>
<text top="676" left="108" width="586" height="19" font="4">Collaboration on Endocarditis-merged database. Eur J Clin Microbiol Infect Dis. 2005;24:665-70. </text>
<text top="694" left="108" width="30" height="19" font="4">143. </text>
<text top="694" left="162" width="835" height="19" font="4">Chu VH, Sexton DJ, Cabell CH, et al. Repeat infective endocarditis: differentiating relapse from reinfection. Clin Infect Dis. 2005;41:406-9. </text>
<text top="712" left="108" width="30" height="19" font="4">144. </text>
<text top="712" left="162" width="865" height="19" font="4">McDonald JR, Olaison L, Anderson DJ, et al. Enterococcal endocarditis: 107 cases from the international collaboration on endocarditis merged </text>
<text top="730" left="108" width="241" height="19" font="4">database. Am J Med. 2005;118:759-66. </text>
<text top="749" left="108" width="30" height="19" font="4">145. </text>
<text top="749" left="162" width="902" height="19" font="4">Chu VH, Cabell CH, Abrutyn E, et al. Native valve endocarditis due to coagulase-negative staphylococci: report of 99 episodes from the International </text>
<text top="767" left="108" width="501" height="19" font="4">Collaboration on Endocarditis Merged Database. Clin Infect Dis. 2004;39:1527-30. </text>
</page>
<page number="220" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 220 </text>
<text top="108" left="108" width="30" height="19" font="4">146. </text>
<text top="108" left="162" width="908" height="19" font="4">Renzulli A, Carozza A, Romano G, et al. Recurrent infective endocarditis: a multivariate analysis of 21 years of experience. arenzul@tin.it. Ann Thorac </text>
<text top="126" left="108" width="130" height="19" font="4">Surg. 2001;72:39-43. </text>
<text top="145" left="108" width="30" height="19" font="4">147. </text>
<text top="145" left="162" width="896" height="19" font="4">Mansur AJ, Dal Bo CM, Fukushima JT, et al. Relapses, recurrences, valve replacements, and mortality during the long-term follow-up after infective </text>
<text top="163" left="108" width="260" height="19" font="4">endocarditis. Am Heart J. 2001;141:78-86. </text>
<text top="181" left="108" width="30" height="19" font="4">148. </text>
<text top="181" left="162" width="889" height="19" font="4">van Engelen K, Topf A, Keavney BD, et al. 22q11.2 Deletion syndrome is under-recognised in adult patients with tetralogy of Fallot and pulmonary </text>
<text top="199" left="108" width="186" height="19" font="4">atresia. Heart. 2010;96:621-4. </text>
<text top="218" left="108" width="30" height="19" font="4">149. </text>
<text top="218" left="162" width="879" height="19" font="4">Piran S, Bassett AS, Grewal J, et al. Patterns of cardiac and extracardiac anomalies in adults with tetralogy of Fallot. Am Heart J. 2011;161:131-7. </text>
<text top="236" left="108" width="30" height="19" font="4">150. </text>
<text top="236" left="162" width="894" height="19" font="4">Fung WLA, Chow EWC, Webb GD, et al. Extracardiac features predicting 22q11.2 deletion syndrome in adult congenital heart disease. Int J Cardiol. </text>
<text top="255" left="108" width="96" height="19" font="4">2008;131:51-8. </text>
<text top="273" left="108" width="30" height="19" font="4">151. </text>
<text top="273" left="162" width="919" height="19" font="4">Swaby JA, Silversides CK, Bekeschus SC, et al. Complex congenital heart disease in unaffected relatives of adults with 22q11.2 deletion syndrome. Am J </text>
<text top="291" left="108" width="161" height="19" font="4">Cardiol. 2011;107:466-71. </text>
<text top="309" left="108" width="30" height="19" font="4">152. </text>
<text top="309" left="162" width="921" height="19" font="4">Liu AP, Chow PC, Lee PP, et al. Under-recognition of 22q11.2 deletion in adult Chinese patients with conotruncal anomalies: implications in transitional </text>
<text top="328" left="108" width="245" height="19" font="4">care. Eur J Med Genet. 2014;57:306-11. </text>
<text top="346" left="108" width="30" height="19" font="4">153. </text>
<text top="346" left="162" width="857" height="19" font="4">Monteiro FP, Vieira TP, Sgardioli IC, et al. Defining new guidelines for screening the 22q11.2 deletion based on a clinical and dysmorphologic </text>
<text top="364" left="108" width="547" height="19" font="4">evaluation of 194 individuals and review of the literature. Eur J Pediatr. 2013;172:927-45. </text>
<text top="383" left="108" width="30" height="19" font="4">154. </text>
<text top="383" left="162" width="755" height="19" font="4">Hinton RB, Jr, Martin LJ, Tabangin ME, et al. Hypoplastic left heart syndrome is heritable. J Am Coll Cardiol. 2007;50:1590-5. </text>
<text top="401" left="108" width="30" height="19" font="4">155. </text>
<text top="401" left="162" width="892" height="19" font="4">Robledo-Carmona J, Rodriguez-Bailon I, Carrasco-Chinchilla F, et al. Hereditary patterns of bicuspid aortic valve in a hundred families. Int J Cardiol. </text>
<text top="419" left="108" width="111" height="19" font="4">2013;168:3443-9. </text>
<text top="438" left="108" width="30" height="19" font="4">156. </text>
<text top="438" left="162" width="864" height="19" font="4">Panayotova R, Macnab A, Waterworth PD. A pilot project of familial screening in patients with bicuspid aortic valve disease. J Heart Valve Dis. </text>
<text top="456" left="108" width="96" height="19" font="4">2013;22:150-5. </text>
<text top="474" left="108" width="30" height="19" font="4">157. </text>
<text top="474" left="162" width="877" height="19" font="4">McBride KL, Pignatelli R, Lewin M, et al. Inheritance analysis of congenital left ventricular outflow tract obstruction malformations: Segregation, </text>
<text top="493" left="108" width="470" height="19" font="4">multiplex relative risk, and heritability. Am J Med Genet A. 2005;134A:180-6. </text>
<text top="511" left="108" width="30" height="19" font="4">158. </text>
<text top="511" left="162" width="917" height="19" font="4">Majdalany DS, Burkhart HM, Connolly HM, et al. Adults with Down syndrome: safety and long-term outcome of cardiac operation. Congenit Heart Dis. </text>
<text top="529" left="108" width="88" height="19" font="4">2010;5:38-43. </text>
<text top="547" left="108" width="30" height="19" font="4">159. </text>
<text top="547" left="162" width="866" height="19" font="4">Crepaz R, Romeo C, Montanaro D, et al. Long-term results of treatment with bosentan in adult Eisenmenger’s syndrome patients with Down’s </text>
<text top="566" left="108" width="508" height="19" font="4">syndrome related to congenital heart disease. BMC Cardiovasc Disord. 2013;13:74. </text>
<text top="584" left="108" width="30" height="19" font="4">160. </text>
<text top="584" left="162" width="879" height="19" font="4">Troost E, Van De Bruaene A, Lampropoulos K, et al. The outcome of Eisenmenger patients with trisomy 21 does not differ from patients without </text>
<text top="602" left="108" width="264" height="19" font="4">trisomy 21. Acta Cardiol. 2011;66:293-301. </text>
<text top="621" left="108" width="30" height="19" font="4">161. </text>
<text top="621" left="162" width="908" height="19" font="4">Carlson M, Airhart N, Lopez L, et al. Moderate aortic enlargement and bicuspid aortic valve are associated with aortic dissection in Turner syndrome: </text>
<text top="639" left="108" width="620" height="19" font="4">report of the International Turner Syndrome Aortic Dissection Registry. Circulation. 2012;126:2220-6. </text>
<text top="657" left="108" width="30" height="19" font="4">162. </text>
<text top="657" left="162" width="897" height="19" font="4">Pillutla P, Shetty KD, Foster E. Mortality associated with adult congenital heart disease: trends in the US population from 1979 to 2005. Am Heart J. </text>
<text top="676" left="108" width="103" height="19" font="4">2009;158:874-9. </text>
<text top="694" left="108" width="30" height="19" font="4">163. </text>
<text top="694" left="162" width="902" height="19" font="4">Lin YS, Liu PH, Wu LS, et al. Major adverse cardiovascular events in adult congenital heart disease: a population-based follow-up study from Taiwan. </text>
<text top="712" left="108" width="224" height="19" font="4">BMC Cardiovasc Disord. 2014;14:38. </text>
<text top="730" left="108" width="30" height="19" font="4">164. </text>
<text top="730" left="162" width="885" height="19" font="4">Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up </text>
<text top="749" left="108" width="581" height="19" font="4">period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J. 2005;26:2325-33. </text>
<text top="767" left="108" width="30" height="19" font="4">165. </text>
<text top="767" left="162" width="915" height="19" font="4">Zomer AC, Uiterwaal CSPM, van der Velde ET, et al. Mortality in adult congenital heart disease: are national registries reliable for cause of death? Int J </text>
<text top="786" left="108" width="154" height="19" font="4">Cardiol. 2011;152:212-7. </text>
</page>
<page number="221" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 221 </text>
<text top="108" left="108" width="30" height="19" font="4">166. </text>
<text top="108" left="162" width="829" height="19" font="4">Nieminen HP, Jokinen EV, Sairanen HI. Causes of late deaths after pediatric cardiac surgery: a population-based study. J Am Coll Cardiol. </text>
<text top="126" left="108" width="111" height="19" font="4">2007;50:1263-71. </text>
<text top="145" left="108" width="30" height="19" font="4">167. </text>
<text top="145" left="162" width="888" height="19" font="4">Bradley E, Parker J, Novak E, et al. Cardiovascular disease in late survivors of tetralogy of Fallot: a tertiary care center experience. Tex Heart Inst J. </text>
<text top="163" left="108" width="103" height="19" font="4">2013;40:418-23. </text>
<text top="181" left="108" width="30" height="19" font="4">168. </text>
<text top="181" left="162" width="887" height="19" font="4">Stuart AG. Changing lesion demographics of the adult with congenital heart disease: an emerging population with complex needs. Future Cardiol. </text>
<text top="199" left="108" width="96" height="19" font="4">2012;8:305-13. </text>
<text top="218" left="108" width="30" height="19" font="4">169. </text>
<text top="218" left="162" width="878" height="19" font="4">Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart </text>
<text top="236" left="108" width="964" height="19" font="4">Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, </text>
<text top="255" left="108" width="951" height="19" font="4">Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working </text>
<text top="273" left="108" width="502" height="19" font="4">Group on Quality of Care and Outcomes Research. Circulation. 2006;114:2710-38. </text>
<text top="291" left="108" width="30" height="19" font="4">170. </text>
<text top="291" left="162" width="873" height="19" font="4">James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel </text>
<text top="309" left="108" width="571" height="19" font="4">members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-20. </text>
<text top="328" left="108" width="30" height="19" font="4">171. </text>
<text top="328" left="162" width="907" height="19" font="4">Rabus MB, Kayalar N, Sareyyupoglu B, et al. Hypercholesterolemia association with aortic stenosis of various etiologies. J Card Surg. 2009;24:146-50. </text>
<text top="346" left="108" width="30" height="19" font="4">172. </text>
<text top="346" left="162" width="874" height="19" font="4">Smith-Parrish M, Yu S, Rocchini A. Obesity and elevated blood pressure following repair of coarctation of the aorta. J Pediatr. 2014;164:1074-8. </text>
<text top="364" left="108" width="30" height="19" font="4">173. </text>
<text top="364" left="162" width="863" height="19" font="4">Shustak RJ, McGuire SB, October TW, et al. Prevalence of obesity among patients with congenital and acquired heart disease. Pediatr Cardiol. </text>
<text top="383" left="108" width="88" height="19" font="4">2012;33:8-14. </text>
<text top="401" left="108" width="30" height="19" font="4">174. </text>
<text top="401" left="162" width="550" height="19" font="4">Pedersen TA. Late morbidity after repair of aortic coarctation. Dan Med J. 2012;59:B4436. </text>
<text top="419" left="108" width="30" height="19" font="4">175. </text>
<text top="419" left="162" width="876" height="19" font="4">Zomer AC, Vaartjes I, Uiterwaal CSPM, et al. Social burden and lifestyle in adults with congenital heart disease. Am J Cardiol. 2012;109:1657-63. </text>
<text top="438" left="108" width="30" height="19" font="4">176. </text>
<text top="438" left="162" width="866" height="19" font="4">Longmuir PE, Brothers JA, de Ferranti SD, et al. Promotion of physical activity for children and adults with congenital heart disease: a scientific </text>
<text top="456" left="108" width="491" height="19" font="4">statement from the American Heart Association. Circulation. 2013;127:2147-59. </text>
<text top="474" left="108" width="30" height="19" font="4">177. </text>
<text top="474" left="162" width="899" height="19" font="4">Stulak JM, Dearani JA, Burkhart HM, et al. Coronary artery disease in adult congenital heart disease: outcome after coronary artery bypass grafting. </text>
<text top="493" left="108" width="211" height="19" font="4">Ann Thorac Surg. 2012;93:116-22. </text>
<text top="511" left="108" width="30" height="19" font="4">178. </text>
<text top="511" left="162" width="906" height="19" font="4">Giannakoulas G, Dimopoulos K, Engel R, et al. Burden of coronary artery disease in adults with congenital heart disease and its relation to congenital </text>
<text top="529" left="108" width="405" height="19" font="4">and traditional heart risk factors. Am J Cardiol. 2009;103:1445-50. </text>
<text top="547" left="108" width="30" height="19" font="4">179. </text>
<text top="547" left="162" width="886" height="19" font="4">Deva DP, Torres FS, Wald RM, et al. The value of stress perfusion cardiovascular magnetic resonance imaging for patients referred from the adult </text>
<text top="566" left="108" width="699" height="19" font="4">congenital heart disease clinic: 5-year experience at the Toronto General Hospital. Cardiol Young. 2014;24:822-30. </text>
<text top="584" left="108" width="30" height="19" font="4">180. </text>
<text top="584" left="162" width="858" height="19" font="4">Niazi I, Dhala A, Choudhuri I, et al. Cardiac resynchronization therapy in patients with challenging anatomy due to venous anomalies or adult </text>
<text top="602" left="108" width="421" height="19" font="4">congenital heart disease. Pacing Clin Electrophysiol. 2014;37:1181-8. </text>
<text top="621" left="108" width="30" height="19" font="4">181. </text>
<text top="621" left="162" width="917" height="19" font="4">Stefanescu A, Macklin EA, Lin E, et al. Usefulness of the Seattle Heart Failure Model to identify adults with congenital heart disease at high risk of poor </text>
<text top="639" left="108" width="255" height="19" font="4">outcome. Am J Cardiol. 2014;113:865-70. </text>
<text top="657" left="108" width="30" height="19" font="4">182. </text>
<text top="657" left="162" width="907" height="19" font="4">Mylotte D, Martucci G, Piazza N, et al. Percutaneous options for heart failure in adults with congenital heart disease. Heart Fail Clin. 2014;10:179-96. </text>
<text top="676" left="108" width="30" height="19" font="4">183. </text>
<text top="676" left="162" width="894" height="19" font="4">Motonaga KS, Khairy P, Dubin AM. Electrophysiologic therapeutics in heart failure in adult congenital heart disease. Heart Fail Clin. 2014;10:69-89. </text>
<text top="694" left="108" width="30" height="19" font="4">184. </text>
<text top="694" left="162" width="672" height="19" font="4">Ohuchi H, Diller G-P. Biomarkers in adult congenital heart disease heart failure. Heart Fail Clin. 2014;10:43-56. </text>
<text top="712" left="108" width="30" height="19" font="4">185. </text>
<text top="712" left="162" width="857" height="19" font="4">Alonso-Gonzalez R, Dimopoulos K. Biomarkers in congenital heart disease: do natriuretic peptides hold the key? Expert Rev Cardiovasc Ther. </text>
<text top="730" left="108" width="103" height="19" font="4">2013;11:773-84. </text>
<text top="749" left="108" width="30" height="19" font="4">186. </text>
<text top="749" left="162" width="742" height="19" font="4">Dinardo JA. Heart failure associated with adult congenital heart disease. Semin Cardiothorac Vasc Anesth. 2013;17:44-54. </text>
<text top="767" left="108" width="30" height="19" font="4">187. </text>
<text top="767" left="162" width="856" height="19" font="4">Shaddy RE, Webb G. Applying heart failure guidelines to adult congenital heart disease patients. Expert Rev Cardiovasc Ther. 2008;6:165-74. </text>
</page>
<page number="222" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 222 </text>
<text top="108" left="108" width="30" height="19" font="4">188. </text>
<text top="108" left="162" width="829" height="19" font="4">Piran S, Veldtman G, Siu S, et al. Heart failure and ventricular dysfunction in patients with single or systemic right ventricles. Circulation. </text>
<text top="126" left="108" width="119" height="19" font="4">2002;105:1189-94. </text>
<text top="145" left="108" width="30" height="19" font="4">189. </text>
<text top="145" left="162" width="896" height="19" font="4">Reardon LC, Williams RJ, Houser LS, et al. Usefulness of serum brain natriuretic peptide to predict adverse events in patients with the Eisenmenger </text>
<text top="163" left="108" width="262" height="19" font="4">syndrome. Am J Cardiol. 2012;110:1523-6. </text>
<text top="181" left="108" width="30" height="19" font="4">190. </text>
<text top="181" left="162" width="755" height="19" font="4">Parekh DR. A review of heart failure in adults with congenital heart disease. Methodist Debakey Cardiovasc J. 2011;7:26-32. </text>
<text top="199" left="108" width="30" height="19" font="4">191. </text>
<text top="199" left="162" width="919" height="19" font="4">Bolger AP, Sharma R, Li W, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation. </text>
<text top="218" left="108" width="96" height="19" font="4">2002;106:92-9. </text>
<text top="236" left="108" width="30" height="19" font="4">192. </text>
<text top="236" left="162" width="885" height="19" font="4">Norozi K, Buchhorn R, Kaiser C, et al. Plasma N-terminal pro-brain natriuretic peptide as a marker of right ventricular dysfunction in patients with </text>
<text top="255" left="108" width="398" height="19" font="4">tetralogy of Fallot after surgical repair. Chest. 2005;128:2563-70. </text>
<text top="273" left="108" width="30" height="19" font="4">193. </text>
<text top="273" left="162" width="913" height="19" font="4">Norozi K, Buchhorn R, Bartmus D, et al. Elevated brain natriuretic peptide and reduced exercise capacity in adult patients operated on for tetralogy of </text>
<text top="291" left="108" width="769" height="19" font="4">Fallot is due to biventricular dysfunction as determined by the myocardial performance index. Am J Cardiol. 2006;97:1377-82. </text>
<text top="309" left="108" width="30" height="19" font="4">194. </text>
<text top="309" left="162" width="872" height="19" font="4">Krieger EV, Valente AM. Heart failure treatment in adults with congenital heart disease: where do we stand in 2014? Heart. 2014;100:1329-34. </text>
<text top="328" left="108" width="30" height="19" font="4">195. </text>
<text top="328" left="162" width="861" height="19" font="4">Wang A, Book WM, McConnell M, et al. Prevalence of hepatitis C infection in adult patients who underwent congenital heart surgery prior to </text>
<text top="346" left="108" width="308" height="19" font="4">screening in 1992. Am J Cardiol. 2007;100:1307-9. </text>
<text top="364" left="108" width="30" height="19" font="4">196. </text>
<text top="364" left="162" width="876" height="19" font="4">Maxwell BG, Wong JK, Kin C, et al. Perioperative outcomes of major noncardiac surgery in adults with congenital heart disease. Anesthesiology. </text>
<text top="383" left="108" width="103" height="19" font="4">2013;119:762-9. </text>
<text top="401" left="108" width="30" height="19" font="4">197. </text>
<text top="401" left="162" width="894" height="19" font="4">Maxwell BG, Wong JK, Lobato RL. Perioperative morbidity and mortality after noncardiac surgery in young adults with congenital or early acquired </text>
<text top="419" left="108" width="831" height="19" font="4">heart disease: a retrospective cohort analysis of the National Surgical Quality Improvement Program database. Am Surg. 2014;80:321-6. </text>
<text top="438" left="108" width="30" height="19" font="4">198. </text>
<text top="438" left="162" width="921" height="19" font="4">Christensen RE, Gholami AS, Reynolds PI, et al. Anaesthetic management and outcomes after noncardiac surgery in patients with hypoplastic left heart </text>
<text top="456" left="108" width="433" height="19" font="4">syndrome: a retrospective review. Eur J Anaesthesiol. 2012;29:425-30. </text>
<text top="474" left="108" width="30" height="19" font="4">199. </text>
<text top="474" left="162" width="901" height="19" font="4">Christensen RE, Reynolds PI, Bukowski BK, et al. Anaesthetic management and outcomes in patients with surgically corrected D-transposition of the </text>
<text top="493" left="108" width="465" height="19" font="4">great arteries undergoing non-cardiac surgery. Br J Anaesth. 2010;104:12-5. </text>
<text top="511" left="108" width="30" height="19" font="4">200. </text>
<text top="511" left="162" width="863" height="19" font="4">Rabbitts JA, Groenewald CB, Mauermann WJ, et al. Outcomes of general anesthesia for noncardiac surgery in a series of patients with Fontan </text>
<text top="529" left="108" width="272" height="19" font="4">palliation. Paediatr Anaesth. 2013;23:180-7. </text>
<text top="547" left="108" width="30" height="19" font="4">201. </text>
<text top="547" left="162" width="916" height="19" font="4">Eagle SS, Daves SM. The adult with Fontan physiology: systematic approach to perioperative management for noncardiac surgery. J Cardiothorac Vasc </text>
<text top="566" left="108" width="153" height="19" font="4">Anesth. 2011;25:320-34. </text>
<text top="584" left="108" width="30" height="19" font="4">202. </text>
<text top="584" left="162" width="758" height="19" font="4">Ammash NM, Connolly HM, Abel MD, et al. Noncardiac surgery in Eisenmenger syndrome. J Am Coll Cardiol. 1999;33:222-7. </text>
<text top="602" left="108" width="30" height="19" font="4">203. </text>
<text top="602" left="162" width="877" height="19" font="4">Warner MA, Lunn RJ, O’Leary PW, et al. Outcomes of noncardiac surgical procedures in children and adults with congenital heart disease. Mayo </text>
<text top="621" left="108" width="399" height="19" font="4">Perioperative Outcomes Group. Mayo Clin Proc. 1998;73:728-34. </text>
<text top="639" left="108" width="30" height="19" font="4">204. </text>
<text top="639" left="162" width="916" height="19" font="4">Maxwell BG, Williams GD, Ramamoorthy C. Knowledge and attitudes of anesthesia providers about noncardiac surgery in adults with congenital heart </text>
<text top="657" left="108" width="262" height="19" font="4">disease. Congenit Heart Dis. 2014;9:45-53. </text>
<text top="676" left="108" width="30" height="19" font="4">205. </text>
<text top="676" left="162" width="854" height="19" font="4">Kaemmerer H, Bauer U, Pensl U, et al. Management of emergencies in adults with congenital cardiac disease. Am J Cardiol. 2008;101:521-5. </text>
<text top="694" left="108" width="30" height="19" font="4">206. </text>
<text top="694" left="162" width="897" height="19" font="4">Niwa K, Perloff JK, Webb GD, et al. Survey of specialized tertiary care facilities for adults with congenital heart disease. Int J Cardiol. 2004;96:211-6. </text>
<text top="712" left="108" width="30" height="19" font="4">207. </text>
<text top="712" left="162" width="896" height="19" font="4">Mott AR, Fraser CD, Jr, McKenzie ED, et al. Perioperative care of the adult with congenital heart disease in a free-standing tertiary pediatric facility. </text>
<text top="730" left="108" width="201" height="19" font="4">Pediatr Cardiol. 2002;23:624-30. </text>
<text top="749" left="108" width="30" height="19" font="4">208. </text>
<text top="749" left="162" width="887" height="19" font="4">Maxwell BG, Maxwell TG, Wong JK. Decentralization of care for adults with congenital heart disease in the United States: a geographic analysis of </text>
<text top="767" left="108" width="292" height="19" font="4">outpatient surgery. PLoS One. 2014;9:e106730. </text>
</page>
<page number="223" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 223 </text>
<text top="108" left="108" width="30" height="19" font="4">209. </text>
<text top="108" left="162" width="913" height="19" font="4">Mylotte D, Quenneville SP, Kotowycz MA, et al. Long-term cost-effectiveness of transcatheter versus surgical closure of secundum atrial septal defect </text>
<text top="126" left="108" width="249" height="19" font="4">in adults. Int J Cardiol. 2014;172:109-14. </text>
<text top="145" left="108" width="30" height="19" font="4">210. </text>
<text top="145" left="162" width="903" height="19" font="4">Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern </text>
<text top="163" left="108" width="139" height="19" font="4">Med. 2000;160:191-6. </text>
<text top="181" left="108" width="30" height="19" font="4">211. </text>
<text top="181" left="162" width="912" height="19" font="4">Pieper PG, Balci A, Aarnoudse JG, et al. Uteroplacental blood flow, cardiac function, and pregnancy outcome in women with congenital heart disease. </text>
<text top="199" left="108" width="191" height="19" font="4">Circulation. 2013;128:2478-87. </text>
<text top="218" left="108" width="30" height="19" font="4">212. </text>
<text top="218" left="162" width="898" height="19" font="4">Roos-Hesselink JW, Ruys TPE, Stein JI, et al. Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the </text>
<text top="236" left="108" width="374" height="19" font="4">European Society of Cardiology. Eur Heart J. 2013;34:657-65. </text>
<text top="255" left="108" width="30" height="19" font="4">213. </text>
<text top="255" left="162" width="879" height="19" font="4">Liu H, Huang T, Zhao W, et al. Pregnancy outcomes and relative risk factors among Chinese women with congenital heart disease. Int J Gynaecol </text>
<text top="273" left="108" width="152" height="19" font="4">Obstet. 2013;120:245-8. </text>
<text top="291" left="108" width="30" height="19" font="4">214. </text>
<text top="291" left="162" width="892" height="19" font="4">Wacker-Gussmann A, Thriemer M, Yigitbasi M, et al. Women with congenital heart disease: long-term outcomes after pregnancy. Clin Res Cardiol. </text>
<text top="309" left="108" width="111" height="19" font="4">2013;102:215-22. </text>
<text top="328" left="108" width="30" height="19" font="4">215. </text>
<text top="328" left="162" width="908" height="19" font="4">Ohuchi H, Tanabe Y, Kamiya C, et al. Cardiopulmonary variables during exercise predict pregnancy outcome in women with congenital heart disease. </text>
<text top="346" left="108" width="134" height="19" font="4">Circ J. 2013;77:470-6. </text>
<text top="364" left="108" width="30" height="19" font="4">216. </text>
<text top="364" left="162" width="895" height="19" font="4">Jastrow N, Meyer P, Khairy P, et al. Prediction of complications in pregnant women with cardiac diseases referred to a tertiary center. Int J Cardiol. </text>
<text top="383" left="108" width="111" height="19" font="4">2011;151:209-13. </text>
<text top="401" left="108" width="30" height="19" font="4">217. </text>
<text top="401" left="162" width="878" height="19" font="4">Ouyang DW, Khairy P, Fernandes SM, et al. Obstetric outcomes in pregnant women with congenital heart disease. Int J Cardiol. 2010;144:195-9. </text>
<text top="419" left="108" width="30" height="19" font="4">218. </text>
<text top="419" left="162" width="921" height="19" font="4">Lui GK, Silversides CK, Khairy P, et al. Heart rate response during exercise and pregnancy outcome in women with congenital heart disease. Circulation. </text>
<text top="438" left="108" width="103" height="19" font="4">2011;123:242-8. </text>
<text top="456" left="108" width="30" height="19" font="4">219. </text>
<text top="456" left="162" width="814" height="19" font="4">Balint OH, Siu SC, Mason J, et al. Cardiac outcomes after pregnancy in women with congenital heart disease. Heart. 2010;96:1656-61. </text>
<text top="474" left="108" width="30" height="19" font="4">220. </text>
<text top="474" left="162" width="839" height="19" font="4">Uebing A, Arvanitis P, Li W, et al. Effect of pregnancy on clinical status and ventricular function in women with heart disease. Int J Cardiol. </text>
<text top="493" left="108" width="96" height="19" font="4">2010;139:50-9. </text>
<text top="511" left="108" width="30" height="19" font="4">221. </text>
<text top="511" left="162" width="829" height="19" font="4">Khairy P, Ouyang DW, Fernandes SM, et al. Pregnancy outcomes in women with congenital heart disease. Circulation. 2006;113:517-24. </text>
<text top="529" left="108" width="30" height="19" font="4">222. </text>
<text top="529" left="162" width="916" height="19" font="4">Siu SC, Colman JM, Sorensen S, et al. Adverse neonatal and cardiac outcomes are more common in pregnant women with cardiac disease. Circulation. </text>
<text top="547" left="108" width="119" height="19" font="4">2002;105:2179-84. </text>
<text top="566" left="108" width="30" height="19" font="4">223. </text>
<text top="566" left="162" width="919" height="19" font="4">Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. 2001;104:515-21. </text>
<text top="584" left="108" width="30" height="19" font="4">224. </text>
<text top="584" left="162" width="909" height="19" font="4">Egidy Assenza G, Cassater D, Landzberg M, et al. The effects of pregnancy on right ventricular remodeling in women with repaired tetralogy of Fallot. </text>
<text top="602" left="108" width="197" height="19" font="4">Int J Cardiol. 2013;168:1847-52. </text>
<text top="621" left="108" width="30" height="19" font="4">225. </text>
<text top="621" left="162" width="849" height="19" font="4">Kamiya CA, Iwamiya T, Neki R, et al. Outcome of pregnancy and effects on the right heart in women with repaired tetralogy of Fallot. Circ J. </text>
<text top="639" left="108" width="103" height="19" font="4">2012;76:957-63. </text>
<text top="657" left="108" width="30" height="19" font="4">226. </text>
<text top="657" left="162" width="903" height="19" font="4">Jain VD, Moghbeli N, Webb G, et al. Pregnancy in women with congenital heart disease: the impact of a systemic right ventricle. Congenit Heart Dis. </text>
<text top="676" left="108" width="96" height="19" font="4">2011;6:147-56. </text>
<text top="694" left="108" width="30" height="19" font="4">227. </text>
<text top="694" left="162" width="911" height="19" font="4">Balci A, Drenthen W, Mulder BJ, et al. Pregnancy in women with corrected tetralogy of Fallot: occurrence and predictors of adverse events. Am Heart </text>
<text top="712" left="108" width="123" height="19" font="4">J. 2011;161:307-13. </text>
<text top="730" left="108" width="30" height="19" font="4">228. </text>
<text top="730" left="162" width="900" height="19" font="4">Tobler D, Fernandes SM, Wald RM, et al. Pregnancy outcomes in women with transposition of the great arteries and arterial switch operation. Am J </text>
<text top="749" left="108" width="161" height="19" font="4">Cardiol. 2010;106:417-20. </text>
<text top="767" left="108" width="30" height="19" font="4">229. </text>
<text top="767" left="162" width="890" height="19" font="4">Greutmann M, K. VK, Brooks R, et al. Pregnancy outcome in women with congenital heart disease and residual haemodynamic lesions of the right </text>
<text top="786" left="108" width="341" height="19" font="4">ventricular outflow tract. Eur Heart J. 2010;31:1764-70. </text>
</page>
<page number="224" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 224 </text>
<text top="108" left="108" width="30" height="19" font="4">230. </text>
<text top="108" left="162" width="835" height="19" font="4">Tzemos N, Silversides CK, Colman JM, et al. Late cardiac outcomes after pregnancy in women with congenital aortic stenosis. Am Heart J. </text>
<text top="126" left="108" width="111" height="19" font="4">2009;157:474-80. </text>
<text top="145" left="108" width="30" height="19" font="4">231. </text>
<text top="145" left="162" width="904" height="19" font="4">Kampman MA, Balci A, van Veldhuisen DJ, et al. N-terminal pro-B-type natriuretic peptide predicts cardiovascular complications in pregnant women </text>
<text top="163" left="108" width="363" height="19" font="4">with congenital heart disease. Eur Heart J. 2014;35:708-15. </text>
<text top="181" left="108" width="30" height="19" font="4">232. </text>
<text top="181" left="162" width="888" height="19" font="4">Gill HK, Splitt M, Sharland GK, et al. Patterns of recurrence of congenital heart disease: an analysis of 6,640 consecutive pregnancies evaluated by </text>
<text top="199" left="108" width="406" height="19" font="4">detailed fetal echocardiography. J Am Coll Cardiol. 2003;42:923-9. </text>
<text top="218" left="108" width="30" height="19" font="4">233. </text>
<text top="218" left="162" width="874" height="19" font="4">Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll </text>
<text top="236" left="108" width="161" height="19" font="4">Cardiol. 2007;49:2303-11. </text>
<text top="255" left="108" width="30" height="19" font="4">234. </text>
<text top="255" left="162" width="843" height="19" font="4">Cutts BA, Dasgupta D, Hunt BJ. New directions in the diagnosis and treatment of pulmonary embolism in pregnancy. Am J Obstet Gynecol. </text>
<text top="273" left="108" width="103" height="19" font="4">2013;208:102-8. </text>
<text top="291" left="108" width="30" height="19" font="4">235. </text>
<text top="291" left="162" width="913" height="19" font="4">Holland BJ, Myers JA, Woods CR, Jr. Prenatal diagnosis of critical congenital heart disease reduces risk of death from cardiovascular compromise prior </text>
<text top="309" left="108" width="597" height="19" font="4">to planned neonatal cardiac surgery: a meta-analysis. Ultrasound Obstet Gynecol. 2015;45:631-8. </text>
<text top="328" left="108" width="30" height="19" font="4">236. </text>
<text top="328" left="162" width="920" height="19" font="4">Pijuan-Domènech A, Baró-Mariné F, Rojas-Torrijos M, et al. Usefulness of progesterone-only components for contraception in patients with congenital </text>
<text top="346" left="108" width="274" height="19" font="4">heart disease. Am J Cardiol. 2013;112:590-3. </text>
<text top="364" left="108" width="30" height="19" font="4">237. </text>
<text top="364" left="162" width="882" height="19" font="4">Hinze A, Kutty S, Sayles H, et al. Reproductive and contraceptive counseling received by adult women with congenital heart disease: a risk-based </text>
<text top="383" left="108" width="264" height="19" font="4">analysis. Congenit Heart Dis. 2013;8:20-31. </text>
<text top="401" left="108" width="30" height="19" font="4">238. </text>
<text top="401" left="162" width="862" height="19" font="4">Kaemmerer M, Vigl M, Seifert-Klauss V, et al. Counseling reproductive health issues in women with congenital heart disease. Clin Res Cardiol. </text>
<text top="419" left="108" width="103" height="19" font="4">2012;101:901-7. </text>
<text top="438" left="108" width="30" height="19" font="4">239. </text>
<text top="438" left="162" width="818" height="19" font="4">Vigl M, Kaemmerer M, Seifert-Klauss V, et al. Contraception in women with congenital heart disease. Am J Cardiol. 2010;106:1317-21. </text>
<text top="456" left="108" width="30" height="19" font="4">240. </text>
<text top="456" left="162" width="876" height="19" font="4">Kovacs AH, Harrison JL, Colman JM, et al. Pregnancy and contraception in congenital heart disease: what women are not told. J Am Coll Cardiol. </text>
<text top="474" left="108" width="96" height="19" font="4">2008;52:577-8. </text>
<text top="493" left="108" width="30" height="19" font="4">241. </text>
<text top="493" left="162" width="862" height="19" font="4">Lidegaard Ø, Løkkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. </text>
<text top="511" left="108" width="107" height="19" font="4">2009;339:b2890. </text>
<text top="529" left="108" width="30" height="19" font="4">242. </text>
<text top="529" left="162" width="919" height="19" font="4">Famuyide AO, Hopkins MR, El-Nashar SA, et al. Hysteroscopic sterilization in women with severe cardiac disease: experience at a tertiary center. Mayo </text>
<text top="547" left="108" width="156" height="19" font="4">Clin Proc. 2008;83:431-8. </text>
<text top="566" left="108" width="30" height="19" font="4">243. </text>
<text top="566" left="162" width="884" height="19" font="4">Moons P, Van Deyk K, Marquet K, et al. Sexual functioning and congenital heart disease: something to worry about? Int J Cardiol. 2007;121:30-5. </text>
<text top="584" left="108" width="30" height="19" font="4">244. </text>
<text top="584" left="162" width="806" height="19" font="4">Cook SC, Arnott LM, Nicholson LM, et al. Erectile dysfunction in men with congenital heart disease. Am J Cardiol. 2008;102:1728-30. </text>
<text top="602" left="108" width="30" height="19" font="4">245. </text>
<text top="602" left="162" width="843" height="19" font="4">Vigl M, Hager A, Bauer U, et al. Sexuality and subjective wellbeing in male patients with congenital heart disease. Heart. 2009;95:1179-83. </text>
<text top="621" left="108" width="30" height="19" font="4">246. </text>
<text top="621" left="162" width="907" height="19" font="4">Winter MM, Reisma C, Kedde H, et al. Sexuality in adult patients with congenital heart disease and their partners. Am J Cardiol. 2010;106:1163-8, e1-</text>
<text top="639" left="108" width="15" height="19" font="4">8. </text>
<text top="657" left="108" width="30" height="19" font="4">247. </text>
<text top="657" left="162" width="907" height="19" font="4">Opić P, Roos-Hesselink JW, Cuypers JAAC, et al. Sexual functioning is impaired in adults with congenital heart disease. Int J Cardiol. 2013;168:3872-7. </text>
<text top="676" left="108" width="30" height="19" font="4">248. </text>
<text top="676" left="162" width="855" height="19" font="4">Norozi K, Bahlmann J, Raab B, et al. A prospective, randomized, double-blind, placebo controlled trial of beta-blockade in patients who have </text>
<text top="694" left="108" width="505" height="19" font="4">undergone surgical correction of tetralogy of Fallot. Cardiol Young. 2007;17:372-9. </text>
<text top="712" left="108" width="30" height="19" font="4">249. </text>
<text top="712" left="162" width="860" height="19" font="4">Babu-Narayan SV, Uebing A, Davlouros PA, et al. Randomised trial of ramipril in repaired tetralogy of Fallot and pulmonary regurgitation: the </text>
<text top="730" left="108" width="965" height="19" font="4">APPROPRIATE study (Ace inhibitors for Potential PRevention Of the deleterious effects of Pulmonary Regurgitation In Adults with repaired TEtralogy of Fallot). </text>
<text top="749" left="108" width="197" height="19" font="4">Int J Cardiol. 2012;154:299-305. </text>
<text top="767" left="108" width="30" height="19" font="4">250. </text>
<text top="767" left="162" width="914" height="19" font="4">Lester SJ, McElhinney DB, Viloria E, et al. Effects of losartan in patients with a systemically functioning morphologic right ventricle after atrial repair of </text>
<text top="786" left="108" width="399" height="19" font="4">transposition of the great arteries. Am J Cardiol. 2001;88:1314-6. </text>
</page>
<page number="225" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 225 </text>
<text top="108" left="108" width="30" height="19" font="4">251. </text>
<text top="108" left="162" width="909" height="19" font="4">Hechter SJ, Fredriksen PM, Liu P, et al. Angiotensin-converting enzyme inhibitors in adults after the Mustard procedure. Am J Cardiol. 2001;87:660-3, </text>
<text top="126" left="108" width="31" height="19" font="4">A11. </text>
<text top="145" left="108" width="30" height="19" font="4">252. </text>
<text top="145" left="162" width="855" height="19" font="4">Dore A, Houde C, Chan K-L, et al. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, </text>
<text top="163" left="108" width="459" height="19" font="4">randomized, placebo-controlled clinical trial. Circulation. 2005;112:2411-6. </text>
<text top="181" left="108" width="30" height="19" font="4">253. </text>
<text top="181" left="162" width="894" height="19" font="4">Giardini A, Lovato L, Donti A, et al. A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with </text>
<text top="199" left="108" width="330" height="19" font="4">systemic right ventricle. Int J Cardiol. 2007;114:241-6. </text>
<text top="218" left="108" width="30" height="19" font="4">254. </text>
<text top="218" left="162" width="881" height="19" font="4">Doughan ARK, McConnell ME, Book WM. Effect of beta blockers (carvedilol or metoprolol XL) in patients with transposition of great arteries and </text>
<text top="236" left="108" width="441" height="19" font="4">dysfunction of the systemic right ventricle. Am J Cardiol. 2007;99:704-6. </text>
<text top="255" left="108" width="30" height="19" font="4">255. </text>
<text top="255" left="162" width="893" height="19" font="4">Therrien J, Provost Y, Harrison J, et al. Effect of angiotensin receptor blockade on systemic right ventricular function and size: a small, randomized, </text>
<text top="273" left="108" width="349" height="19" font="4">placebo-controlled study. Int J Cardiol. 2008;129:187-92. </text>
<text top="291" left="108" width="30" height="19" font="4">256. </text>
<text top="291" left="162" width="886" height="19" font="4">Bouallal R, Godart F, Francart C, et al. Interest of β-blockers in patients with right ventricular systemic dysfunction. Cardiol Young. 2010;20:615-9. </text>
<text top="309" left="108" width="30" height="19" font="4">257. </text>
<text top="309" left="162" width="877" height="19" font="4">Tutarel O, Meyer GP, Bertram H, et al. Safety and efficiency of chronic ACE inhibition in symptomatic heart failure patients with a systemic right </text>
<text top="328" left="108" width="234" height="19" font="4">ventricle. Int J Cardiol. 2012;154:14-6. </text>
<text top="346" left="108" width="30" height="19" font="4">258. </text>
<text top="346" left="162" width="917" height="19" font="4">van der Bom T, Winter MM, Bouma BJ, et al. Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled </text>
<text top="364" left="108" width="247" height="19" font="4">pilot trial. Circulation. 2013;127:322-30. </text>
<text top="383" left="108" width="30" height="19" font="4">259. </text>
<text top="383" left="162" width="872" height="19" font="4">Dos L, Pujadas S, Estruch M, et al. Eplerenone in systemic right ventricle: double blind randomized clinical trial. The EVEDES Study. Int J Cardiol. </text>
<text top="401" left="108" width="119" height="19" font="4">2013;168:5167-73. </text>
<text top="419" left="108" width="30" height="19" font="4">260. </text>
<text top="419" left="162" width="914" height="19" font="4">Kouatli AA, García JA, Zellers TM, et al. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation. 1997;96:1507-12. </text>
<text top="438" left="108" width="30" height="19" font="4">261. </text>
<text top="438" left="162" width="912" height="19" font="4">Giardini A, Balducci A, Specchia S, et al. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart </text>
<text top="456" left="108" width="115" height="19" font="4">J. 2008;29:1681-7. </text>
<text top="474" left="108" width="30" height="19" font="4">262. </text>
<text top="474" left="162" width="917" height="19" font="4">Goldberg DJ, French B, McBride MG, et al. Impact of oral sildenafil on exercise performance in children and young adults after the Fontan operation: a </text>
<text top="493" left="108" width="572" height="19" font="4">randomized, double-blind, placebo-controlled, crossover trial. Circulation. 2011;123:1185-93. </text>
<text top="511" left="108" width="30" height="19" font="4">263. </text>
<text top="511" left="162" width="891" height="19" font="4">Rhodes J, Ubeda-Tikkanen A, Clair M, et al. Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept. Int J </text>
<text top="529" left="108" width="169" height="19" font="4">Cardiol. 2013;168:2435-40. </text>
<text top="547" left="108" width="30" height="19" font="4">264. </text>
<text top="547" left="162" width="915" height="19" font="4">Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-</text>
<text top="566" left="108" width="283" height="19" font="4">controlled study. Circulation. 2006;114:48-54. </text>
<text top="584" left="108" width="30" height="19" font="4">265. </text>
<text top="584" left="162" width="864" height="19" font="4">Seddio F, Gorislavets N, Iacovoni A, et al. Is heart transplantation for complex congenital heart disease a good option? A 25-year single centre </text>
<text top="602" left="108" width="327" height="19" font="4">experience. Eur J Cardiothorac Surg. 2013;43:605-11. </text>
<text top="621" left="108" width="30" height="19" font="4">266. </text>
<text top="621" left="162" width="854" height="19" font="4">Boucek D, Yetman AT, Yeung E, et al. Survival based on patient selection for heart transplant in adults with congenital heart disease: a multi-</text>
<text top="639" left="108" width="314" height="19" font="4">institutional study. Int J Cardiol. 2014;172:e89-e90. </text>
<text top="657" left="108" width="30" height="19" font="4">267. </text>
<text top="657" left="162" width="891" height="19" font="4">Patel ND, Weiss ES, Allen JG, et al. Heart transplantation for adults with congenital heart disease: analysis of the United network for organ sharing </text>
<text top="676" left="108" width="274" height="19" font="4">database. Ann Thorac Surg. 2009;88:814-21. </text>
<text top="694" left="108" width="30" height="19" font="4">268. </text>
<text top="694" left="162" width="886" height="19" font="4">Karamlou T, Hirsch J, Welke K, et al. A United Network for Organ Sharing analysis of heart transplantation in adults with congenital heart disease: </text>
<text top="712" left="108" width="694" height="19" font="4">outcomes and factors associated with mortality and retransplantation. J Thorac Cardiovasc Surg. 2010;140:161-8. </text>
<text top="730" left="108" width="30" height="19" font="4">269. </text>
<text top="730" left="162" width="890" height="19" font="4">Gelow JM, Song HK, Weiss JB, et al. Organ allocation in adults with congenital heart disease listed for heart transplant: impact of ventricular assist </text>
<text top="749" left="108" width="314" height="19" font="4">devices. J Heart Lung Transplant. 2013;32:1059-64. </text>
<text top="767" left="108" width="30" height="19" font="4">270. </text>
<text top="767" left="162" width="896" height="19" font="4">Everitt MD, Donaldson AE, Stehlik J, et al. Would access to device therapies improve transplant outcomes for adults with congenital heart disease? </text>
<text top="786" left="108" width="618" height="19" font="4">Analysis of the United Network for Organ Sharing (UNOS). J Heart Lung Transplant. 2011;30:395-401. </text>
</page>
<page number="226" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 226 </text>
<text top="108" left="108" width="30" height="19" font="4">271. </text>
<text top="108" left="162" width="773" height="19" font="4">Davies RR, Russo MJ, Yang J, et al. Listing and transplanting adults with congenital heart disease. Circulation. 2011;123:759-67. </text>
<text top="126" left="108" width="30" height="19" font="4">272. </text>
<text top="126" left="162" width="894" height="19" font="4">Davies RR, Sorabella RA, Yang J, et al. Outcomes after transplantation for “failed” Fontan: a single-institution experience. J Thorac Cardiovasc Surg. </text>
<text top="145" left="108" width="141" height="19" font="4">2012;143:1183-92, e4. </text>
<text top="163" left="108" width="30" height="19" font="4">273. </text>
<text top="163" left="162" width="917" height="19" font="4">Goerler H, Simon A, Gohrbandt B, et al. Heart-lung and lung transplantation in grown-up congenital heart disease: long-term single centre experience. </text>
<text top="181" left="108" width="252" height="19" font="4">Eur J Cardiothorac Surg. 2007;32:926-31. </text>
<text top="199" left="108" width="30" height="19" font="4">274. </text>
<text top="199" left="162" width="883" height="19" font="4">Harper AR, Crossland DS, Perri G, et al. Is alternative cardiac surgery an option in adults with congenital heart disease referred for thoracic organ </text>
<text top="218" left="108" width="357" height="19" font="4">transplantation? Eur J Cardiothorac Surg. 2013;43:344-51. </text>
<text top="236" left="108" width="30" height="19" font="4">275. </text>
<text top="236" left="162" width="917" height="19" font="4">Karamlou T, Diggs BS, Welke K, et al. Impact of single-ventricle physiology on death after heart transplantation in adults with congenital heart disease. </text>
<text top="255" left="108" width="211" height="19" font="4">Ann Thorac Surg. 2012;94:1281-7. </text>
<text top="273" left="108" width="30" height="19" font="4">276. </text>
<text top="273" left="162" width="887" height="19" font="4">Maxwell BG, Wong JK, Sheikh AY, et al. Heart transplantation with or without prior mechanical circulatory support in adults with congenital heart </text>
<text top="291" left="108" width="297" height="19" font="4">disease. Eur J Cardiothorac Surg. 2014;45:842-6. </text>
<text top="309" left="108" width="30" height="19" font="4">277. </text>
<text top="309" left="162" width="888" height="19" font="4">Paniagua Martin MJ, Almenar L, Brossa V, et al. Transplantation for complex congenital heart disease in adults: a subanalysis of the Spanish Heart </text>
<text top="328" left="108" width="326" height="19" font="4">Transplant Registry. Clin Transplant. 2012;26:755-63. </text>
<text top="346" left="108" width="30" height="19" font="4">278. </text>
<text top="346" left="162" width="839" height="19" font="4">Tobler D, Greutmann M, Colman JM, et al. End-of-life in adults with congenital heart disease: a call for early communication. Int J Cardiol. </text>
<text top="364" left="108" width="103" height="19" font="4">2012;155:383-7. </text>
<text top="383" left="108" width="30" height="19" font="4">279. </text>
<text top="383" left="162" width="894" height="19" font="4">Tobler D, Greutmann M, Colman JM, et al. End-of-life care in hospitalized adults with complex congenital heart disease: care delayed, care denied. </text>
<text top="401" left="108" width="164" height="19" font="4">Palliat Med. 2012;26:72-9. </text>
<text top="419" left="108" width="30" height="19" font="4">280. </text>
<text top="419" left="162" width="882" height="19" font="4">Tobler D, Greutmann M, Colman JM, et al. Knowledge of and preference for advance care planning by adults with congenital heart disease. Am J </text>
<text top="438" left="108" width="177" height="19" font="4">Cardiol. 2012;109:1797-800. </text>
<text top="456" left="108" width="30" height="19" font="4">281. </text>
<text top="456" left="162" width="906" height="19" font="4">Greutmann M, Tobler D, Colman JM, et al. Facilitators of and barriers to advance care planning in adult congenital heart disease. Congenit Heart Dis. </text>
<text top="474" left="108" width="88" height="19" font="4">2013;8:281-8. </text>
<text top="493" left="108" width="30" height="19" font="4">282. </text>
<text top="493" left="162" width="848" height="19" font="4">Dedkov EI, Perloff JK, Tomanek RJ, et al. The coronary microcirculation in cyanotic congenital heart disease. Circulation. 2006;114:196-200. </text>
<text top="511" left="108" width="30" height="19" font="4">283. </text>
<text top="511" left="162" width="801" height="19" font="4">Duffels MGJ, Mulder KM, Trip MD, et al. Atherosclerosis in patients with cyanotic congenital heart disease. Circ J. 2010;74:1436-41. </text>
<text top="529" left="108" width="30" height="19" font="4">284. </text>
<text top="529" left="162" width="908" height="19" font="4">Hirth A, Nightingale S, Wilmshurst P, et al. Prevalence of migraine in adults with cyanotic congenital heart disease. Congenit Heart Dis. 2008;3:124-7. </text>
<text top="547" left="108" width="30" height="19" font="4">285. </text>
<text top="547" left="162" width="901" height="19" font="4">Horigome H, Iwasaki N, Anno I, et al. Magnetic resonance imaging of the brain and haematological profile in adult cyanotic congenital heart disease </text>
<text top="566" left="108" width="234" height="19" font="4">without stroke. Heart. 2006;92:263-5. </text>
<text top="584" left="108" width="30" height="19" font="4">286. </text>
<text top="584" left="162" width="896" height="19" font="4">Jensen AS, Johansson PI, Bochsen L, et al. Fibrinogen function is impaired in whole blood from patients with cyanotic congenital heart disease. Int J </text>
<text top="602" left="108" width="161" height="19" font="4">Cardiol. 2013;167:2210-4. </text>
<text top="621" left="108" width="30" height="19" font="4">287. </text>
<text top="621" left="162" width="915" height="19" font="4">Jensen AS, Johansson PI, Idorn L, et al. The haematocrit—an important factor causing impaired haemostasis in patients with cyanotic congenital heart </text>
<text top="639" left="108" width="250" height="19" font="4">disease. Int J Cardiol. 2013;167:1317-21. </text>
<text top="657" left="108" width="30" height="19" font="4">288. </text>
<text top="657" left="162" width="889" height="19" font="4">Kajimoto H, Nakazawa M, Murasaki K, et al. Increased thrombogenesity in patients with cyanotic congenital heart disease. Circ J. 2007;71:948-53. </text>
<text top="676" left="108" width="30" height="19" font="4">289. </text>
<text top="676" left="162" width="811" height="19" font="4">Legault S, Lanfranchi P, Montplaisir J, et al. Nocturnal breathing in cyanotic congenital heart disease. Int J Cardiol. 2008;128:197-200. </text>
<text top="694" left="108" width="30" height="19" font="4">290. </text>
<text top="694" left="162" width="921" height="19" font="4">Martinez-Quintana E, Rodriguez-Gonzalez F, Fabregas-Brouard M, et al. Serum and 24-hour urine analysis in adult cyanotic and noncyanotic congenital </text>
<text top="712" left="108" width="359" height="19" font="4">heart disease patients. Congenit Heart Dis. 2009;4:147-52. </text>
<text top="730" left="108" width="30" height="19" font="4">291. </text>
<text top="730" left="162" width="890" height="19" font="4">Pedersen CM, Schmidt MR, Mortensen B, et al. Preserved flow-mediated dilation in adults with cyanotic congenital heart disease. Pediatr Cardiol. </text>
<text top="749" left="108" width="103" height="19" font="4">2009;30:965-70. </text>
<text top="767" left="108" width="30" height="19" font="4">292. </text>
<text top="767" left="162" width="919" height="19" font="4">Reiss UM, Bensimhon P, Zimmerman SA, et al. Hydroxyurea therapy for management of secondary erythrocytosis in cyanotic congenital heart disease. </text>
<text top="786" left="108" width="188" height="19" font="4">Am J Hematol. 2007;82:740-3. </text>
</page>
<page number="227" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 227 </text>
<text top="108" left="108" width="30" height="19" font="4">293. </text>
<text top="108" left="162" width="882" height="19" font="4">Tay ELW, Peset A, Papaphylactou M, et al. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with </text>
<text top="126" left="108" width="615" height="19" font="4">cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol. 2011;151:307-12. </text>
<text top="145" left="108" width="30" height="19" font="4">294. </text>
<text top="145" left="162" width="909" height="19" font="4">Trojnarska O, Gwizdala A, Katarzynski S, et al. The BNP concentrations and exercise capacity assessment with cardiopulmonary stress test in cyanotic </text>
<text top="163" left="108" width="462" height="19" font="4">adult patients with congenital heart diseases. Int J Cardiol. 2010;139:241-7. </text>
<text top="181" left="108" width="30" height="19" font="4">295. </text>
<text top="181" left="162" width="868" height="19" font="4">Tsui I, Shamsa K, Perloff JK, et al. Retinal vascular patterns in adults with cyanotic congenital heart disease. Semin Ophthalmol. 2009;24:262-5. </text>
<text top="199" left="108" width="30" height="19" font="4">296. </text>
<text top="199" left="162" width="909" height="19" font="4">Wykretowicz A, Trojnarska O, Guzik P, et al. Arterial stiffness in adult patients with cyanotic congenital heart disease. Congenit Heart Dis. 2007;2:134-</text>
<text top="218" left="108" width="15" height="19" font="4">8. </text>
<text top="236" left="108" width="30" height="19" font="4">297. </text>
<text top="236" left="162" width="906" height="19" font="4">Broberg CS, Van Woerkom RC, Swallow E, et al. Lung function and gas exchange in Eisenmenger syndrome and their impact on exercise capacity and </text>
<text top="255" left="108" width="228" height="19" font="4">survival. Int J Cardiol. 2014;171:73-7. </text>
<text top="273" left="108" width="30" height="19" font="4">298. </text>
<text top="273" left="162" width="920" height="19" font="4">Broberg CS, Uebing A, Cuomo L, et al. Adult patients with Eisenmenger syndrome report flying safely on commercial airlines. Heart. 2007;93:1599-603. </text>
<text top="291" left="108" width="30" height="19" font="4">299. </text>
<text top="291" left="162" width="903" height="19" font="4">Broberg CS, Bax BE, Okonko DO, et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic </text>
<text top="309" left="108" width="368" height="19" font="4">congenital heart disease. J Am Coll Cardiol. 2006;48:356-65. </text>
<text top="328" left="108" width="30" height="19" font="4">300. </text>
<text top="328" left="162" width="913" height="19" font="4">Broberg CS, Jayaweera AR, Diller GP, et al. Seeking optimal relation between oxygen saturation and hemoglobin concentration in adults with cyanosis </text>
<text top="346" left="108" width="375" height="19" font="4">from congenital heart disease. Am J Cardiol. 2011;107:595-9. </text>
<text top="364" left="108" width="30" height="19" font="4">301. </text>
<text top="364" left="162" width="912" height="19" font="4">Sandoval J, Santos LE, Córdova J, et al. Does anticoagulation in Eisenmenger syndrome impact long-term survival? Congenit Heart Dis. 2012;7:268-76. </text>
<text top="383" left="108" width="30" height="19" font="4">302. </text>
<text top="383" left="162" width="911" height="19" font="4">Peirone A, Contreras A, Ferrero A, et al. Immediate and short-term outcomes after percutaneous atrial septal defect closure using the new nit-occlud </text>
<text top="401" left="108" width="360" height="19" font="4">ASD-R device. Catheter Cardiovasc Interv. 2014;84:464-70. </text>
<text top="419" left="108" width="30" height="19" font="4">303. </text>
<text top="419" left="162" width="916" height="19" font="4">Ströker E, Van De Bruaene A, P. DM, et al. Transcatheter device closure of atrial septal defects in patients above age 60. Acta Cardiol. 2013;68:127-32. </text>
<text top="438" left="108" width="30" height="19" font="4">304. </text>
<text top="438" left="162" width="920" height="19" font="4">Rhodes JF, Jr, Goble J. Combined prospective United States clinical study data for the GORE((R)) HELEX((R)) septal occluder device. Catheter Cardiovasc </text>
<text top="456" left="108" width="147" height="19" font="4">Interv. 2014;83:944-52. </text>
<text top="474" left="108" width="30" height="19" font="4">305. </text>
<text top="474" left="162" width="884" height="19" font="4">Aytemir K, Oto A, Ozkutlu S, et al. Transcatheter interatrial septal defect closure in a large cohort: midterm follow-up results. Congenit Heart Dis. </text>
<text top="493" left="108" width="96" height="19" font="4">2013;8:418-27. </text>
<text top="511" left="108" width="30" height="19" font="4">306. </text>
<text top="511" left="162" width="910" height="19" font="4">Du Z-D, Hijazi ZM, Kleinman CS, et al. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: </text>
<text top="529" left="108" width="496" height="19" font="4">results of a multicenter nonrandomized trial. J Am Coll Cardiol. 2002;39:1836-44. </text>
<text top="547" left="108" width="30" height="19" font="4">307. </text>
<text top="547" left="162" width="884" height="19" font="4">Kutty S, Hazeem AA, Brown K, et al. Long-term (5- to 20-year) outcomes after transcatheter or surgical treatment of hemodynamically significant </text>
<text top="566" left="108" width="440" height="19" font="4">isolated secundum atrial septal defect. Am J Cardiol. 2012;109:1348-52. </text>
<text top="584" left="108" width="30" height="19" font="4">308. </text>
<text top="584" left="162" width="882" height="19" font="4">Roos-Hesselink JW, Meijboom FJ, Spitaels SEC, et al. Excellent survival and low incidence of arrhythmias, stroke and heart failure long-term after </text>
<text top="602" left="108" width="660" height="19" font="4">surgical ASD closure at young age. A prospective follow-up study of 21-33 years. Eur Heart J. 2003;24:190-7. </text>
<text top="621" left="108" width="30" height="19" font="4">309. </text>
<text top="621" left="162" width="855" height="19" font="4">Konstantinides S, Geibel A, Olschewski M, et al. A comparison of surgical and medical therapy for atrial septal defect in adults. N Engl J Med. </text>
<text top="639" left="108" width="111" height="19" font="4">1995;333:469-73. </text>
<text top="657" left="108" width="30" height="19" font="4">310. </text>
<text top="657" left="162" width="909" height="19" font="4">Engelfriet P, Meijboom F, Boersma E, et al. Repaired and open atrial septal defects type II in adulthood: an epidemiological study of a large European </text>
<text top="676" left="108" width="237" height="19" font="4">cohort. Int J Cardiol. 2008;126:379-85. </text>
<text top="694" left="108" width="30" height="19" font="4">311. </text>
<text top="694" left="162" width="856" height="19" font="4">Kardon RE, Sokoloski MC, Levi DS, et al. Transthoracic echocardiographic guidance of transcatheter atrial septal defect closure. Am J Cardiol. </text>
<text top="712" left="108" width="103" height="19" font="4">2004;94:256-60. </text>
<text top="730" left="108" width="30" height="19" font="4">312. </text>
<text top="730" left="162" width="861" height="19" font="4">Mazic U, Gavora P, Masura J. The role of transesophageal echocardiography in transcatheter closure of secundum atrial septal defects by the </text>
<text top="749" left="108" width="343" height="19" font="4">Amplatzer septal occluder. Am Heart J. 2001;142:482-8. </text>
<text top="767" left="108" width="30" height="19" font="4">313. </text>
<text top="767" left="162" width="813" height="19" font="4">Teo KSL, Disney PJ, Dundon BK, et al. Assessment of atrial septal defects in adults comparing cardiovascular magnetic resonance with </text>
<text top="786" left="108" width="465" height="19" font="4">transoesophageal echocardiography. J Cardiovasc Magn Reson. 2010;12:44. </text>
</page>
<page number="228" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 228 </text>
<text top="108" left="108" width="30" height="19" font="4">314. </text>
<text top="108" left="162" width="914" height="19" font="4">Zanchetta M, Rigatelli G, Pedon L, et al. Transcatheter atrial septal defect closure assisted by intracardiac echocardiography: 3-year follow-up. J Interv </text>
<text top="126" left="108" width="139" height="19" font="4">Cardiol. 2004;17:95-8. </text>
<text top="145" left="108" width="30" height="19" font="4">315. </text>
<text top="145" left="162" width="900" height="19" font="4">Ammash NM, Seward JB, Warnes CA, et al. Partial anomalous pulmonary venous connection: diagnosis by transesophageal echocardiography. J Am </text>
<text top="163" left="108" width="180" height="19" font="4">Coll Cardiol. 1997;29:1351-8. </text>
<text top="181" left="108" width="30" height="19" font="4">316. </text>
<text top="181" left="162" width="920" height="19" font="4">Haramati LB, Moche IE, Rivera VT, et al. Computed tomography of partial anomalous pulmonary venous connection in adults. J Comput Assist Tomogr. </text>
<text top="199" left="108" width="96" height="19" font="4">2003;27:743-9. </text>
<text top="218" left="108" width="30" height="19" font="4">317. </text>
<text top="218" left="162" width="907" height="19" font="4">Nordmeyer S, Berger F, Kuehne T, et al. Flow-sensitive four-dimensional magnetic resonance imaging facilitates and improves the accurate diagnosis </text>
<text top="236" left="108" width="502" height="19" font="4">of partial anomalous pulmonary venous drainage. Cardiol Young. 2011;21:528-35. </text>
<text top="255" left="108" width="30" height="19" font="4">318. </text>
<text top="255" left="162" width="921" height="19" font="4">Altındag  T, Roos-Hesselink JW, Cuypers JA, et al. Transcatheter device closure of atrial septal defects in patients aged 40 years and older. Neth Heart J. </text>
<text top="273" left="108" width="103" height="19" font="4">2010;18:537-42. </text>
<text top="291" left="108" width="30" height="19" font="4">319. </text>
<text top="291" left="162" width="898" height="19" font="4">Attie F, Rosas M, Granados N, et al. Surgical treatment for secundum atrial septal defects in patients &gt;40 years old. A randomized clinical trial. J Am </text>
<text top="309" left="108" width="188" height="19" font="4">Coll Cardiol. 2001;38:2035-42. </text>
<text top="328" left="108" width="30" height="19" font="4">320. </text>
<text top="328" left="162" width="870" height="19" font="4">Brochu M-C, Baril J-F, Dore A, et al. Improvement in exercise capacity in asymptomatic and mildly symptomatic adults after atrial septal defect </text>
<text top="346" left="108" width="323" height="19" font="4">percutaneous closure. Circulation. 2002;106:1821-6. </text>
<text top="364" left="108" width="30" height="19" font="4">321. </text>
<text top="364" left="162" width="854" height="19" font="4">Shah D, Azhar M, Oakley CM, et al. Natural history of secundum atrial septal defect in adults after medical or surgical treatment: a historical </text>
<text top="383" left="108" width="278" height="19" font="4">prospective study. Br Heart J. 1994;71:224-7. </text>
<text top="401" left="108" width="30" height="19" font="4">322. </text>
<text top="401" left="162" width="907" height="19" font="4">Varma C, Benson LN, Silversides C, et al. Outcomes and alternative techniques for device closure of the large secundum atrial septal defect. Catheter </text>
<text top="419" left="108" width="208" height="19" font="4">Cardiovasc Interv. 2004;61:131-9. </text>
<text top="438" left="108" width="30" height="19" font="4">323. </text>
<text top="438" left="162" width="881" height="19" font="4">Amin Z, Hijazi ZM, Bass JL, et al. Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of </text>
<text top="456" left="108" width="655" height="19" font="4">complications and recommendations to minimize future risk. Catheter Cardiovasc Interv. 2004;63:496-502. </text>
<text top="474" left="108" width="30" height="19" font="4">324. </text>
<text top="474" left="162" width="909" height="19" font="4">Lopez K, Dalvi BV, Balzer D, et al. Transcatheter closure of large secundum atrial septal defects using the 40 mm Amplatzer septal occluder: results of </text>
<text top="493" left="108" width="419" height="19" font="4">an international registry. Catheter Cardiovasc Interv. 2005;66:580-4. </text>
<text top="511" left="108" width="30" height="19" font="4">325. </text>
<text top="511" left="162" width="872" height="19" font="4">Bradley EA, Chakinala M, Billadello JJ. Usefulness of medical therapy for pulmonary hypertension and delayed atrial septal defect closure. Am J </text>
<text top="529" left="108" width="161" height="19" font="4">Cardiol. 2013;112:1471-6. </text>
<text top="547" left="108" width="30" height="19" font="4">326. </text>
<text top="547" left="162" width="858" height="19" font="4">Cho YH, Jun T-G, Yang J-H, et al. Surgical strategy in patients with atrial septal defect and severe pulmonary hypertension. Heart Surg Forum. </text>
<text top="566" left="108" width="103" height="19" font="4">2012;15:E111-5. </text>
<text top="584" left="108" width="30" height="19" font="4">327. </text>
<text top="584" left="162" width="899" height="19" font="4">Shim H, Yang JH, Park PW, et al. Efficacy of the maze procedure for atrial fibrillation associated with atrial septal defect. Korean J Thorac Cardiovasc </text>
<text top="602" left="108" width="138" height="19" font="4">Surg. 2013;46:98-103. </text>
<text top="621" left="108" width="30" height="19" font="4">328. </text>
<text top="621" left="162" width="885" height="19" font="4">Giamberti A, Chessa M, Foresti S, et al. Combined atrial septal defect surgical closure and irrigated radiofrequency ablation in adult patients. Ann </text>
<text top="639" left="108" width="191" height="19" font="4">Thorac Surg. 2006;82:1327-31. </text>
<text top="657" left="108" width="30" height="19" font="4">329. </text>
<text top="657" left="162" width="891" height="19" font="4">Kouchoukos NT, Blackstone EH, Kirklin JW. Surgical implications of pulmonary hypertension in congenital heart disease. Adv Cardiol. 1978;225-31. </text>
<text top="676" left="108" width="30" height="19" font="4">330. </text>
<text top="676" left="162" width="863" height="19" font="4">Shohtsu A, Takeuchi S, Inoue T. Surgical indications and results for congenital cardiac anomalies associated with left to right shunt and severe </text>
<text top="694" left="108" width="323" height="19" font="4">pulmonary hypertension. Jpn Circ J. 1976;40:629-32. </text>
<text top="712" left="108" width="30" height="19" font="4">331. </text>
<text top="712" left="162" width="886" height="19" font="4">Dyme JL, Prakash A, Printz BF, et al. Physiology of isolated anomalous pulmonary venous connection of a single pulmonary vein as determined by </text>
<text top="730" left="108" width="414" height="19" font="4">cardiac magnetic resonance imaging. Am J Cardiol. 2006;98:107-10. </text>
<text top="749" left="108" width="30" height="19" font="4">332. </text>
<text top="749" left="162" width="894" height="19" font="4">Majdalany DS, Phillips SD, Dearani JA, et al. Isolated partial anomalous pulmonary venous connections in adults: twenty-year experience. Congenit </text>
<text top="767" left="108" width="159" height="19" font="4">Heart Dis. 2010;5:537-45. </text>
</page>
<page number="229" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 229 </text>
<text top="108" left="108" width="30" height="19" font="4">333. </text>
<text top="108" left="162" width="915" height="19" font="4">Jemielity M, Perek B, Paluszkiewicz L, et al. Results of repair of partial anomalous pulmonary venous connection and sinus venosus atrial septal defect </text>
<text top="126" left="108" width="256" height="19" font="4">in adults. J Heart Valve Dis. 1998;7:410-4. </text>
<text top="145" left="108" width="30" height="19" font="4">334. </text>
<text top="145" left="162" width="871" height="19" font="4">Brink J, Yong MS, d’Udekem Y, et al. Surgery for scimitar syndrome: the Melbourne experience. Interact Cardiovasc Thorac Surg. 2015;20:31-4. </text>
<text top="163" left="108" width="30" height="19" font="4">335. </text>
<text top="163" left="162" width="903" height="19" font="4">Sachweh JS, Daebritz SH, Hermanns B, et al. Hypertensive pulmonary vascular disease in adults with secundum or sinus venosus atrial septal defect. </text>
<text top="181" left="108" width="211" height="19" font="4">Ann Thorac Surg. 2006;81:207-13. </text>
<text top="199" left="108" width="30" height="19" font="4">336. </text>
<text top="199" left="162" width="878" height="19" font="4">Dusenbery SM, Geva T, Seale A, et al. Outcome predictors and implications for management of scimitar syndrome. Am Heart J. 2013;165:770-7. </text>
<text top="218" left="108" width="30" height="19" font="4">337. </text>
<text top="218" left="162" width="841" height="19" font="4">Corone P, Doyon F, Gaudeau S, et al. Natural history of ventricular septal defect. A study involving 790 cases. Circulation. 1977;55:908-15. </text>
<text top="236" left="108" width="30" height="19" font="4">338. </text>
<text top="236" left="162" width="891" height="19" font="4">Yoshimura N, Hori Y, Horii Y, et al. Comparison of magnetic resonance imaging with transthoracic echocardiography in the diagnosis of ventricular </text>
<text top="255" left="108" width="562" height="19" font="4">septal defect-associated coronary cusp prolapse. J Magn Reson Imaging. 2010;32:1099-103. </text>
<text top="273" left="108" width="30" height="19" font="4">339. </text>
<text top="273" left="162" width="866" height="19" font="4">D’Alto M, Romeo E, Argiento P, et al. Hemodynamics of patients developing pulmonary arterial hypertension after shunt closure. Int J Cardiol. </text>
<text top="291" left="108" width="126" height="19" font="4">2013;168:3797-801. </text>
<text top="309" left="108" width="30" height="19" font="4">340. </text>
<text top="309" left="162" width="905" height="19" font="4">Janjua AM, Saleem K, Khan I, et al. Double flap patch closure of VSD with elevated pulmonary vascular resistance: an experience at AFIC/NIHD. J Coll </text>
<text top="328" left="108" width="236" height="19" font="4">Physicians Surg Pak. 2011;21:197-201. </text>
<text top="346" left="108" width="30" height="19" font="4">341. </text>
<text top="346" left="162" width="919" height="19" font="4">Talwar S, Keshri VK, Choudhary SK, et al. Unidirectional valved patch closure of ventricular septal defects with severe pulmonary arterial hypertension: </text>
<text top="364" left="108" width="425" height="19" font="4">hemodynamic outcomes. J Thorac Cardiovasc Surg. 2014;148:2570-5. </text>
<text top="383" left="108" width="30" height="19" font="4">342. </text>
<text top="383" left="162" width="869" height="19" font="4">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the </text>
<text top="401" left="108" width="778" height="19" font="4">American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:e521-643. </text>
<text top="419" left="108" width="30" height="19" font="4">343. </text>
<text top="419" left="162" width="920" height="19" font="4">Hoohenkerk GJF, Wenink AC, Schoof PH, et al. Results of surgical repair of atrioventricular septal defect with double-orifice left atrioventricular valve. J </text>
<text top="438" left="108" width="267" height="19" font="4">Thorac Cardiovasc Surg. 2009;138:1167-71. </text>
<text top="456" left="108" width="30" height="19" font="4">344. </text>
<text top="456" left="162" width="899" height="19" font="4">Liberman L, Pass RH, Hordof AJ, et al. Late onset of heart block after open heart surgery for congenital heart disease. Pediatr Cardiol. 2008;29:56-9. </text>
<text top="474" left="108" width="30" height="19" font="4">345. </text>
<text top="474" left="162" width="913" height="19" font="4">Agarwal V, Aggarwal SK, Voleti CD. Factors predicting the progress of mitral valve disease in surgically treated adults with ostium primum atrial septal </text>
<text top="493" left="108" width="312" height="19" font="4">defects. J Thorac Cardiovasc Surg. 2009;137:543-7. </text>
<text top="511" left="108" width="30" height="19" font="4">346. </text>
<text top="511" left="162" width="921" height="19" font="4">Malhotra SP, Lacour-Gayet F, Mitchell MB, et al. Reoperation for left atrioventricular valve regurgitation after atrioventricular septal defect repair. Ann </text>
<text top="529" left="108" width="183" height="19" font="4">Thorac Surg. 2008;86:147-51. </text>
<text top="547" left="108" width="30" height="19" font="4">347. </text>
<text top="547" left="162" width="896" height="19" font="4">Bianchi G, Bevilacqua S, Solinas M, et al. In adult patients undergoing redo surgery for left atrioventricular valve regurgitation after atrioventricular </text>
<text top="566" left="108" width="667" height="19" font="4">septal defect correction, is replacement superior to repair? Interact Cardiovasc Thorac Surg. 2011;12:1033-9. </text>
<text top="584" left="108" width="30" height="19" font="4">348. </text>
<text top="584" left="162" width="918" height="19" font="4">Hoohenkerk GJF, Bruggemans EF, Koolbergen DR, et al. Long-term results of reoperation for left atrioventricular valve regurgitation after correction of </text>
<text top="602" left="108" width="401" height="19" font="4">atrioventricular septal defects. Ann Thorac Surg. 2012;93:849-55. </text>
<text top="621" left="108" width="30" height="19" font="4">349. </text>
<text top="621" left="162" width="903" height="19" font="4">Stulak JM, Burkhart HM, Dearani JA. Reoperations after repair of partial and complete atrioventricular septal defect. World J Pediatr Congenit Heart </text>
<text top="639" left="108" width="130" height="19" font="4">Surg. 2010;1:97-104. </text>
<text top="657" left="108" width="30" height="19" font="4">350. </text>
<text top="657" left="162" width="813" height="19" font="4">Digilio MC, Romana LF, Dentici ML, et al. Atrioventricular canal defect in patients with RASopathies. Eur J Hum Genet. 2013;21:200-4. </text>
<text top="676" left="108" width="30" height="19" font="4">351. </text>
<text top="676" left="162" width="853" height="19" font="4">Bando K, Turrentine MW, Sun K, et al. Surgical management of complete atrioventricular septal defects. A twenty-year experience. J Thorac </text>
<text top="694" left="108" width="222" height="19" font="4">Cardiovasc Surg. 1995;110:1543-52. </text>
<text top="712" left="108" width="30" height="19" font="4">352. </text>
<text top="712" left="162" width="917" height="19" font="4">El Said HG, Bratincsak A, Foerster SR, et al. Safety of percutaneous patent ductus arteriosus closure: an unselected multicenter population experience. </text>
<text top="730" left="108" width="218" height="19" font="4">J Am Heart Assoc. 2013;2:e000424. </text>
<text top="749" left="108" width="30" height="19" font="4">353. </text>
<text top="749" left="162" width="873" height="19" font="4">Chen LY, Cai P, Cheng ZD, et al. Comparison of transvenous versus transthoracic catheter-based device closure of patent ductus arteriosus with </text>
<text top="767" left="108" width="362" height="19" font="4">amplatzer duct occluder. J Invasive Cardiol. 2013;25:502-6. </text>
</page>
<page number="230" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 230 </text>
<text top="108" left="108" width="30" height="19" font="4">354. </text>
<text top="108" left="162" width="913" height="19" font="4">Chen H, Weng G, Chen Z, et al. Comparison of long-term clinical outcomes and costs between video-assisted thoracoscopic surgery and transcatheter </text>
<text top="126" left="108" width="522" height="19" font="4">amplatzer occlusion of the patent ductus arteriosus. Pediatr Cardiol. 2012;33:316-21. </text>
<text top="145" left="108" width="30" height="19" font="4">355. </text>
<text top="145" left="162" width="884" height="19" font="4">Brunetti MA, Ringel R, Owada C, et al. Percutaneous closure of patent ductus arteriosus: a multiinstitutional registry comparing multiple devices. </text>
<text top="163" left="108" width="280" height="19" font="4">Catheter Cardiovasc Interv. 2010;76:696-702. </text>
<text top="181" left="108" width="30" height="19" font="4">356. </text>
<text top="181" left="162" width="837" height="19" font="4">Fortescue EB, Lock JE, Galvin T, et al. To close or not to close: the very small patent ductus arteriosus. Congenit Heart Dis. 2010;5:354-65. </text>
<text top="199" left="108" width="30" height="19" font="4">357. </text>
<text top="199" left="162" width="882" height="19" font="4">Gamboa R, Rios-Méndez RE, Mollón FP, et al. Percutaneous closure of patent ductus arteriosus in adults using different devices. Rev Esp Cardiol. </text>
<text top="218" left="108" width="96" height="19" font="4">2010;63:726-9. </text>
<text top="236" left="108" width="30" height="19" font="4">358. </text>
<text top="236" left="162" width="822" height="19" font="4">Zabal C, García-Montes JA, Buendía-Hernández A, et al. Percutaneous closure of hypertensive ductus arteriosus. Heart. 2010;96:625-9. </text>
<text top="255" left="108" width="30" height="19" font="4">359. </text>
<text top="255" left="162" width="882" height="19" font="4">Jeong Y-H, Yun T-J, Song J-M, et al. Left ventricular remodeling and change of systolic function after closure of patent ductus arteriosus in adults: </text>
<text top="273" left="108" width="355" height="19" font="4">device and surgical closure. Am Heart J. 2007;154:436-40. </text>
<text top="291" left="108" width="30" height="19" font="4">360. </text>
<text top="291" left="162" width="850" height="19" font="4">Yan C, Zhao S, Jiang S, et al. Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults. Heart. </text>
<text top="309" left="108" width="96" height="19" font="4">2007;93:514-8. </text>
<text top="328" left="108" width="30" height="19" font="4">361. </text>
<text top="328" left="162" width="891" height="19" font="4">Ozyuksel A, Yildirim O, Avsar M, et al. Surgical correction of cor triatriatum sinister in the paediatric population: mid-term results in 15 cases. Eur J </text>
<text top="346" left="108" width="213" height="19" font="4">Cardiothorac Surg. 2015;47:e25-8. </text>
<text top="364" left="108" width="30" height="19" font="4">362. </text>
<text top="364" left="162" width="916" height="19" font="4">Saxena P, Burkhart HM, Schaff HV, et al. Surgical repair of cor triatriatum sinister: the Mayo Clinic 50-year experience. Ann Thorac Surg. 2014;97:1659-</text>
<text top="383" left="108" width="22" height="19" font="4">63. </text>
<text top="401" left="108" width="30" height="19" font="4">363. </text>
<text top="401" left="162" width="698" height="19" font="4">Yaroglu Kazanci S, Emani S, McElhinney DB. Outcome after repair of cor triatriatum. Am J Cardiol. 2012;109:412-6. </text>
<text top="419" left="108" width="30" height="19" font="4">364. </text>
<text top="419" left="162" width="882" height="19" font="4">Marino BS, Kruge LE, Cho CJ, et al. Parachute mitral valve: morphologic descriptors, associated lesions, and outcomes after biventricular repair. J </text>
<text top="438" left="108" width="279" height="19" font="4">Thorac Cardiovasc Surg. 2009;137:385-93.e4. </text>
<text top="456" left="108" width="30" height="19" font="4">365. </text>
<text top="456" left="162" width="888" height="19" font="4">Schaverien MV, Freedom RM, McCrindle BW. Independent factors associated with outcomes of parachute mitral valve in 84 patients. Circulation. </text>
<text top="474" left="108" width="119" height="19" font="4">2004;109:2309-13. </text>
<text top="493" left="108" width="30" height="19" font="4">366. </text>
<text top="493" left="162" width="869" height="19" font="4">Brauner RA, Laks H, Drinkwater DCJ, et al. Multiple left heart obstructions (Shone's anomaly) with mitral valve involvement: long-term surgical </text>
<text top="511" left="108" width="265" height="19" font="4">outcome. Ann Thorac Surg. 1997;64:721-9. </text>
<text top="529" left="108" width="30" height="19" font="4">367. </text>
<text top="529" left="162" width="910" height="19" font="4">Alphonso N, Nørgaard MA, Newcomb A, et al. Cor triatriatum: presentation, diagnosis and long-term surgical results. Ann Thorac Surg. 2005;80:1666-</text>
<text top="547" left="108" width="22" height="19" font="4">71. </text>
<text top="566" left="108" width="30" height="19" font="4">368. </text>
<text top="566" left="162" width="912" height="19" font="4">Oliver JM, González A, Gallego P, et al. Discrete subaortic stenosis in adults: increased prevalence and slow rate of progression of the obstruction and </text>
<text top="584" left="108" width="338" height="19" font="4">aortic regurgitation. J Am Coll Cardiol. 2001;38:835-42. </text>
<text top="602" left="108" width="30" height="19" font="4">369. </text>
<text top="602" left="162" width="905" height="19" font="4">McMahon CJ, Gauvreau K, Edwards JC, et al. Risk factors for aortic valve dysfunction in children with discrete subvalvar aortic stenosis. Am J Cardiol. </text>
<text top="621" left="108" width="103" height="19" font="4">2004;94:459-64. </text>
<text top="639" left="108" width="30" height="19" font="4">370. </text>
<text top="639" left="162" width="825" height="19" font="4">Brauner R, Laks H, Drinkwater DCJ, et al. Benefits of early surgical repair in fixed subaortic stenosis. J Am Coll Cardiol. 1997;30:1835-42. </text>
<text top="657" left="108" width="30" height="19" font="4">371. </text>
<text top="657" left="162" width="842" height="19" font="4">Parry AJ, Kovalchin JP, Suda K, et al. Resection of subaortic stenosis; can a more aggressive approach be justified? Eur J Cardiothorac Surg. </text>
<text top="676" left="108" width="96" height="19" font="4">1999;15:631-8. </text>
<text top="694" left="108" width="30" height="19" font="4">372. </text>
<text top="694" left="162" width="877" height="19" font="4">Suárez de Lezo J, Pan M, Romero M, et al. Percutaneous interventions on severe coarctation of the aorta: a 21-year experience. Pediatr Cardiol. </text>
<text top="712" left="108" width="103" height="19" font="4">2005;26:176-89. </text>
<text top="730" left="108" width="30" height="19" font="4">373. </text>
<text top="730" left="162" width="851" height="19" font="4">Geva A, McMahon CJ, Gauvreau K, et al. Risk factors for reoperation after repair of discrete subaortic stenosis in children. J Am Coll Cardiol. </text>
<text top="749" left="108" width="119" height="19" font="4">2007;50:1498-504. </text>
<text top="767" left="108" width="30" height="19" font="4">374. </text>
<text top="767" left="162" width="920" height="19" font="4">Trinchero R, Demarie D, Orzan F, et al. Fixed subaortic stenosis. Natural history of patients with mild obstruction and follow-up of operated patients. G </text>
<text top="786" left="108" width="177" height="19" font="4">Ital Cardiol. 1988;18:738-44. </text>
</page>
<page number="231" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 231 </text>
<text top="108" left="108" width="30" height="19" font="4">375. </text>
<text top="108" left="162" width="899" height="19" font="4">Dall'Agata A, Cromme-Dijkhuis AH, Meijboom FJ, et al. Use of three-dimensional echocardiography for analysis of outflow obstruction in congenital </text>
<text top="126" left="108" width="267" height="19" font="4">heart disease. Am J Cardiol. 1999;83:921-5. </text>
<text top="145" left="108" width="30" height="19" font="4">376. </text>
<text top="145" left="162" width="880" height="19" font="4">Diller G-P, Dimopoulos K, Okonko D, et al. Heart rate response during exercise predicts survival in adults with congenital heart disease. J Am Coll </text>
<text top="163" left="108" width="154" height="19" font="4">Cardiol. 2006;48:1250-6. </text>
<text top="181" left="108" width="30" height="19" font="4">377. </text>
<text top="181" left="162" width="822" height="19" font="4">Mookadam F, Thota VR, García-Lopez AM, et al. Unicuspid aortic valve in adults: a systematic review. J Heart Valve Dis. 2010;19:79-85. </text>
<text top="199" left="108" width="30" height="19" font="4">378. </text>
<text top="199" left="162" width="889" height="19" font="4">Gleason TG. Bicuspid aortic valve repair by complete conversion from &#34;raphe'd&#34; (type 1) to &#34;symmetric&#34; (type 0) morphology. J Thorac Cardiovasc </text>
<text top="218" left="108" width="72" height="19" font="4">Surg. 2014; </text>
<text top="236" left="108" width="30" height="19" font="4">379. </text>
<text top="236" left="162" width="879" height="19" font="4">Kari FA, Liang DH, Kvitting JP, et al. Tirone David valve-sparing aortic root replacement and cusp repair for bicuspid aortic valve disease. J Thorac </text>
<text top="255" left="108" width="221" height="19" font="4">Cardiovasc Surg. 2013;145:S35-S40. </text>
<text top="273" left="108" width="30" height="19" font="4">380. </text>
<text top="273" left="162" width="916" height="19" font="4">Alsoufi B, Borger MA, Armstrong S, et al. Results of valve preservation and repair for bicuspid aortic valve insufficiency. J Heart Valve Dis. 2005;14:752-</text>
<text top="291" left="108" width="15" height="19" font="4">8. </text>
<text top="309" left="108" width="30" height="19" font="4">381. </text>
<text top="309" left="162" width="919" height="19" font="4">Davierwala PM, David TE, Armstrong S, et al. Aortic valve repair versus replacement in bicuspid aortic valve disease. J Heart Valve Dis. 2003;12:679-86. </text>
<text top="328" left="108" width="30" height="19" font="4">382. </text>
<text top="328" left="162" width="799" height="19" font="4">Svensson LG, Al Kindi AH, Vivacqua A, et al. Long-term durability of bicuspid aortic valve repair. Ann Thorac Surg. 2014;97:1539-47. </text>
<text top="346" left="108" width="30" height="19" font="4">383. </text>
<text top="346" left="162" width="836" height="19" font="4">Biner S, Rafique AM, Ray I, et al. Aortopathy is prevalent in relatives of bicuspid aortic valve patients. J Am Coll Cardiol. 2009;53:2288-95. </text>
<text top="364" left="108" width="30" height="19" font="4">384. </text>
<text top="364" left="162" width="881" height="19" font="4">Tutar E, Ekici F, Atalay S, et al. The prevalence of bicuspid aortic valve in newborns by echocardiographic screening. Am Heart J. 2005;150:513-5. </text>
<text top="383" left="108" width="30" height="19" font="4">385. </text>
<text top="383" left="162" width="884" height="19" font="4">Huntington K, Hunter AG, Chan KL. A prospective study to assess the frequency of familial clustering of congenital bicuspid aortic valve. J Am Coll </text>
<text top="401" left="108" width="161" height="19" font="4">Cardiol. 1997;30:1809-12. </text>
<text top="419" left="108" width="30" height="19" font="4">386. </text>
<text top="419" left="162" width="891" height="19" font="4">Sandhu SK, Lloyd TR, Crowley DC, et al. Effectiveness of balloon valvuloplasty in the young adult with congenital aortic stenosis. Cathet Cardiovasc </text>
<text top="438" left="108" width="138" height="19" font="4">Diagn. 1995;36:122-7. </text>
<text top="456" left="108" width="30" height="19" font="4">387. </text>
<text top="456" left="162" width="897" height="19" font="4">Arora R, Jolly N, Bhat A, et al. Follow-up of balloon aortic valvuloplasty in young adults—a combined hemodynamic and Doppler echocardiographic </text>
<text top="474" left="108" width="227" height="19" font="4">study. Indian Heart J. 1989;41:314-7. </text>
<text top="493" left="108" width="30" height="19" font="4">388. </text>
<text top="493" left="162" width="873" height="19" font="4">Fernandes SM, Sanders SP, Khairy P, et al. Morphology of bicuspid aortic valve in children and adolescents. J Am Coll Cardiol. 2004;44:1648-51. </text>
<text top="511" left="108" width="30" height="19" font="4">389. </text>
<text top="511" left="162" width="865" height="19" font="4">Nistri S, Sorbo MD, Marin M, et al. Aortic root dilatation in young men with normally functioning bicuspid aortic valves. Heart. 1999;82:19-22. </text>
<text top="529" left="108" width="30" height="19" font="4">390. </text>
<text top="529" left="162" width="907" height="19" font="4">Della CA, Bancone C, Quarto C, et al. Predictors of ascending aortic dilatation with bicuspid aortic valve: a wide spectrum of disease expression. Eur J </text>
<text top="547" left="108" width="228" height="19" font="4">Cardiothorac Surg. 2007;31:397-404. </text>
<text top="566" left="108" width="30" height="19" font="4">391. </text>
<text top="566" left="162" width="836" height="19" font="4">Lin AE, Lippe B, Rosenfeld RG. Further delineation of aortic dilation, dissection, and rupture in patients with Turner syndrome. Pediatrics. </text>
<text top="584" left="108" width="91" height="19" font="4">1998;102:e12. </text>
<text top="602" left="108" width="30" height="19" font="4">392. </text>
<text top="602" left="162" width="651" height="19" font="4">Sybert VP. Cardiovascular malformations and complications in Turner syndrome. Pediatrics. 1998;101:E11. </text>
<text top="621" left="108" width="30" height="19" font="4">393. </text>
<text top="621" left="162" width="729" height="19" font="4">Matura LA, Ho VB, Rosing DR, et al. Aortic dilatation and dissection in Turner syndrome. Circulation. 2007;116:1663-70. </text>
<text top="639" left="108" width="30" height="19" font="4">394. </text>
<text top="639" left="162" width="917" height="19" font="4">Hjerrild BE, Mortensen KH, Sorensen KE, et al. Thoracic aortopathy in Turner syndrome and the influence of bicuspid aortic valves and blood pressure: </text>
<text top="657" left="108" width="320" height="19" font="4">a CMR study. J Cardiovasc Magn Reson. 2010;12:12. </text>
<text top="676" left="108" width="30" height="19" font="4">395. </text>
<text top="676" left="162" width="901" height="19" font="4">Cleemann L, Mortensen KH, Holm K, et al. Aortic dimensions in girls and young women with turner syndrome: a magnetic resonance imaging study. </text>
<text top="694" left="108" width="209" height="19" font="4">Pediatr Cardiol. 2010;31:497-504. </text>
<text top="712" left="108" width="30" height="19" font="4">396. </text>
<text top="712" left="162" width="917" height="19" font="4">Rutz T, Max F, Wahl A, et al. Distensibility and diameter of ascending aorta assessed by cardiac magnetic resonance imaging in adults with tetralogy of </text>
<text top="730" left="108" width="388" height="19" font="4">Fallot or complete transposition. Am J Cardiol. 2012;110:103-8. </text>
<text top="749" left="108" width="30" height="19" font="4">397. </text>
<text top="749" left="162" width="921" height="19" font="4">Christensen JT, Lu JC, Donohue J, et al. Relation of aortic stiffness and strain by cardiovascular magnetic resonance imaging to age in repaired tetralogy </text>
<text top="767" left="108" width="251" height="19" font="4">of Fallot. Am J Cardiol. 2014;113:1031-5. </text>
</page>
<page number="232" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 232 </text>
<text top="108" left="108" width="30" height="19" font="4">398. </text>
<text top="108" left="162" width="898" height="19" font="4">Mongeon F-P, Gurvitz MZ, Broberg CS, et al. Aortic root dilatation in adults with surgically repaired tetralogy of Fallot: a multicenter cross-sectional </text>
<text top="126" left="108" width="217" height="19" font="4">study. Circulation. 2013;127:172-9. </text>
<text top="145" left="108" width="30" height="19" font="4">399. </text>
<text top="145" left="162" width="866" height="19" font="4">Niwa K, Siu SC, Webb GD, et al. Progressive aortic root dilatation in adults late after repair of tetralogy of Fallot. Circulation. 2002;106:1374-8. </text>
<text top="163" left="108" width="30" height="19" font="4">400. </text>
<text top="163" left="162" width="898" height="19" font="4">Stulak JM, Dearani JA, Burkhart HM, et al. Does the dilated ascending aorta in an adult with congenital heart disease require intervention? J Thorac </text>
<text top="181" left="108" width="206" height="19" font="4">Cardiovasc Surg. 2010;140:S52-7. </text>
<text top="199" left="108" width="30" height="19" font="4">401. </text>
<text top="199" left="162" width="851" height="19" font="4">Aljassim O, Svensson G, Perrotta S, et al. Dilatation of the pulmonary autograft and native aorta after the Ross procedure: a comprehensive </text>
<text top="218" left="108" width="447" height="19" font="4">echocardiographic study. J Thorac Cardiovasc Surg. 2011;142:634-40, 40. </text>
<text top="236" left="108" width="30" height="19" font="4">402. </text>
<text top="236" left="162" width="921" height="19" font="4">de Kerchove L, Rubay J, Pasquet A, et al. Ross operation in the adult: long-term outcomes after root replacement and inclusion techniques. Ann Thorac </text>
<text top="255" left="108" width="138" height="19" font="4">Surg. 2009;87:95-102. </text>
<text top="273" left="108" width="30" height="19" font="4">403. </text>
<text top="273" left="162" width="798" height="19" font="4">Luciani GB, Favaro A, Casali G, et al. Reoperations for aortic aneurysm after the Ross procedure. J Heart Valve Dis. 2005;14:766-72. </text>
<text top="291" left="108" width="30" height="19" font="4">404. </text>
<text top="291" left="162" width="747" height="19" font="4">Luciani GB, Casali G, Favaro A, et al. Fate of the aortic root late after Ross operation. Circulation. 2003;108 Suppl 1:II61-II7. </text>
<text top="309" left="108" width="30" height="19" font="4">405. </text>
<text top="309" left="162" width="906" height="19" font="4">Kempny A, Wustmann K, Borgia F, et al. Outcome in adult patients after arterial switch operation for transposition of the great arteries. Int J Cardiol. </text>
<text top="328" left="108" width="119" height="19" font="4">2013;167:2588-93. </text>
<text top="346" left="108" width="30" height="19" font="4">406. </text>
<text top="346" left="162" width="906" height="19" font="4">Fricke TA, d’Udekem Y, Richardson M, et al. Outcomes of the arterial switch operation for transposition of the great arteries: 25 years of experience. </text>
<text top="364" left="108" width="211" height="19" font="4">Ann Thorac Surg. 2012;94:139-45. </text>
<text top="383" left="108" width="30" height="19" font="4">407. </text>
<text top="383" left="162" width="864" height="19" font="4">Lim H-G, Kim W-H, Lee JR, et al. Long-term results of the arterial switch operation for ventriculo-arterial discordance. Eur J Cardiothorac Surg. </text>
<text top="401" left="108" width="103" height="19" font="4">2013;43:325-34. </text>
<text top="419" left="108" width="30" height="19" font="4">408. </text>
<text top="419" left="162" width="908" height="19" font="4">van der Bom T, van der Palen RL, Bouma BJ, et al. Persistent neo-aortic growth during adulthood in patients after an arterial switch operation. Heart. </text>
<text top="438" left="108" width="111" height="19" font="4">2014;100:1360-5. </text>
<text top="456" left="108" width="30" height="19" font="4">409. </text>
<text top="456" left="162" width="914" height="19" font="4">Avadhani SA, Martin-Doyle W, Shaikh AY, et al. Predictors of Ascending Aortic Dilation in Bicuspid Aortic Valve Disease: A Five-year Prospective Study. </text>
<text top="474" left="108" width="179" height="19" font="4">Am J Med. 2015;128:647-52. </text>
<text top="493" left="108" width="30" height="19" font="4">410. </text>
<text top="493" left="162" width="903" height="19" font="4">Ohnemus D, Oster ME, Gatlin S, et al. The effect of angiotensin-converting enzyme inhibitors on the rate of ascending aorta dilation in patients with </text>
<text top="511" left="108" width="348" height="19" font="4">bicuspid aortic valve. Congenit Heart Dis. 2015;10:E1-E5. </text>
<text top="529" left="108" width="30" height="19" font="4">411. </text>
<text top="529" left="162" width="881" height="19" font="4">Roberts WC, Vowels TJ, Ko JM. Natural history of adults with congenitally malformed aortic valves (unicuspid or bicuspid). Medicine (Baltimore). </text>
<text top="547" left="108" width="111" height="19" font="4">2012;91:287-308. </text>
<text top="566" left="108" width="30" height="19" font="4">412. </text>
<text top="566" left="162" width="874" height="19" font="4">Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA. 2011;306:1104-12. </text>
<text top="584" left="108" width="30" height="19" font="4">413. </text>
<text top="584" left="162" width="899" height="19" font="4">Oliver JM, Alonso-Gonzalez R, Gonzalez AE, et al. Risk of aortic root or ascending aorta complications in patients with bicuspid aortic valve with and </text>
<text top="602" left="108" width="397" height="19" font="4">without coarctation of the aorta. Am J Cardiol. 2009;104:1001-6. </text>
<text top="621" left="108" width="30" height="19" font="4">414. </text>
<text top="621" left="162" width="879" height="19" font="4">Davies RR, Kaple RK, Mandapati D, et al. Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann </text>
<text top="639" left="108" width="191" height="19" font="4">Thorac Surg. 2007;83:1338-44. </text>
<text top="657" left="108" width="30" height="19" font="4">415. </text>
<text top="657" left="162" width="873" height="19" font="4">Bruno E, Rossi N, Thüer O, et al. Cardiovascular findings, and clinical course, in patients with Williams syndrome. Cardiol Young. 2003;13:532-6. </text>
<text top="676" left="108" width="30" height="19" font="4">416. </text>
<text top="676" left="162" width="859" height="19" font="4">Wren C, Oslizlok P, Bull C. Natural history of supravalvular aortic stenosis and pulmonary artery stenosis. J Am Coll Cardiol. 1990;15:1625-30. </text>
<text top="694" left="108" width="30" height="19" font="4">417. </text>
<text top="694" left="162" width="843" height="19" font="4">Eronen M, Peippo M, Hiippala A, et al. Cardiovascular manifestations in 75 patients with Williams syndrome. J Med Genet. 2002;39:554-8. </text>
<text top="712" left="108" width="30" height="19" font="4">418. </text>
<text top="712" left="162" width="907" height="19" font="4">Tani LY, Minich LL, Pagotto LT, et al. Usefulness of doppler echocardiography to determine the timing of surgery for supravalvar aortic stenosis. Am J </text>
<text top="730" left="108" width="146" height="19" font="4">Cardiol. 2000;86:114-6. </text>
<text top="749" left="108" width="30" height="19" font="4">419. </text>
<text top="749" left="162" width="772" height="19" font="4">Thiene G, Ho SY. Aortic root pathology and sudden death in youth: review of anatomical varieties. Appl Pathol. 1986;4:237-45. </text>
<text top="767" left="108" width="30" height="19" font="4">420. </text>
<text top="767" left="162" width="921" height="19" font="4">Stamm C, Li J, Ho SY, et al. The aortic root in supravalvular aortic stenosis: the potential surgical relevance of morphologic findings. J Thorac Cardiovasc </text>
<text top="786" left="108" width="138" height="19" font="4">Surg. 1997;114:16-24. </text>
</page>
<page number="233" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 233 </text>
<text top="108" left="108" width="30" height="19" font="4">421. </text>
<text top="108" left="162" width="863" height="19" font="4">Martin MM, Lemmer JH, Jr, Shaffer E, et al. Obstruction to left coronary artery blood flow secondary to obliteration of the coronary ostium in </text>
<text top="126" left="108" width="384" height="19" font="4">supravalvular aortic stenosis. Ann Thorac Surg. 1988;45:16-20. </text>
<text top="145" left="108" width="30" height="19" font="4">422. </text>
<text top="145" left="162" width="916" height="19" font="4">Doty DB, Eastham CL, Hiratzka LF, et al. Determination of coronary reserve in patients with supravalvular aortic stenosis. Circulation. 1982;66:I186-92. </text>
<text top="163" left="108" width="30" height="19" font="4">423. </text>
<text top="163" left="162" width="896" height="19" font="4">Thistlethwaite PA, Madani MM, Kriett JM, et al. Surgical management of congenital obstruction of the left main coronary artery with supravalvular </text>
<text top="181" left="108" width="363" height="19" font="4">aortic stenosis. J Thorac Cardiovasc Surg. 2000;120:1040-6. </text>
<text top="199" left="108" width="30" height="19" font="4">424. </text>
<text top="199" left="162" width="812" height="19" font="4">Greutmann M, Tobler D, Sharma NC, et al. Cardiac outcomes in adults with supravalvar aortic stenosis. Eur Heart J. 2012;33:2442-50. </text>
<text top="218" left="108" width="30" height="19" font="4">425. </text>
<text top="218" left="162" width="891" height="19" font="4">Holzer R, Qureshi S, Ghasemi A, et al. Stenting of aortic coarctation: acute, intermediate, and long-term results of a prospective multi-institutional </text>
<text top="236" left="108" width="747" height="19" font="4">registry—Congenital Cardiovascular Interventional Study Consortium (CCISC). Catheter Cardiovasc Interv. 2010;76:553-63. </text>
<text top="255" left="108" width="30" height="19" font="4">426. </text>
<text top="255" left="162" width="866" height="19" font="4">Qureshi AM, McElhinney DB, Lock JE, et al. Acute and intermediate outcomes, and evaluation of injury to the aortic wall, as based on 15 years </text>
<text top="273" left="108" width="555" height="19" font="4">experience of implanting stents to treat aortic coarctation. Cardiol Young. 2007;17:307-18. </text>
<text top="291" left="108" width="30" height="19" font="4">427. </text>
<text top="291" left="162" width="871" height="19" font="4">Forbes TJ, Moore P, Pedra CA, et al. Intermediate follow-up following intravascular stenting for treatment of coarctation of the aorta. Catheter </text>
<text top="309" left="108" width="216" height="19" font="4">Cardiovasc Interv. 2007;70:569-77. </text>
<text top="328" left="108" width="30" height="19" font="4">428. </text>
<text top="328" left="162" width="921" height="19" font="4">Chessa M, Carrozza M, Butera G, et al. Results and mid-long-term follow-up of stent implantation for native and recurrent coarctation of the aorta. Eur </text>
<text top="346" left="108" width="161" height="19" font="4">Heart J. 2005;26:2728-32. </text>
<text top="364" left="108" width="30" height="19" font="4">429. </text>
<text top="364" left="162" width="907" height="19" font="4">Hager A, Kanz S, Kaemmerer H, et al. Coarctation Long-term Assessment (COALA): significance of arterial hypertension in a cohort of 404 patients up </text>
<text top="383" left="108" width="926" height="19" font="4">to 27 years after surgical repair of isolated coarctation of the aorta, even in the absence of restenosis and prosthetic material. J Thorac Cardiovasc Surg. </text>
<text top="401" left="108" width="111" height="19" font="4">2007;134:738-45. </text>
<text top="419" left="108" width="30" height="19" font="4">430. </text>
<text top="419" left="162" width="899" height="19" font="4">Toro-Salazar OH, Steinberger J, Thomas W, et al. Long-term follow-up of patients after coarctation of the aorta repair. Am J Cardiol. 2002;89:541-7. </text>
<text top="438" left="108" width="30" height="19" font="4">431. </text>
<text top="438" left="162" width="896" height="19" font="4">Dodge-Khatami A, Backer CL, Mavroudis C. Risk factors for recoarctation and results of reoperation: a 40-year review. J Card Surg. 2000;15:369-77. </text>
<text top="456" left="108" width="30" height="19" font="4">432. </text>
<text top="456" left="162" width="910" height="19" font="4">Zabal C, Attie F, Rosas M, et al. The adult patient with native coarctation of the aorta: balloon angioplasty or primary stenting? Heart. 2003;89:77-83. </text>
<text top="474" left="108" width="30" height="19" font="4">433. </text>
<text top="474" left="162" width="916" height="19" font="4">Brown JW, Ruzmetov M, Hoyer MH, et al. Recurrent coarctation: is surgical repair of recurrent coarctation of the aorta safe and effective? Ann Thorac </text>
<text top="493" left="108" width="145" height="19" font="4">Surg. 2009;88:1923-30. </text>
<text top="511" left="108" width="30" height="19" font="4">434. </text>
<text top="511" left="162" width="920" height="19" font="4">Reents W, Froehner S, Diegeler A, et al. Ascending-to-descending bypass for simultaneous surgery of aortic coarctation with other cardiac pathologies. </text>
<text top="529" left="108" width="244" height="19" font="4">Thorac Cardiovasc Surg. 2012;60:210-4. </text>
<text top="547" left="108" width="30" height="19" font="4">435. </text>
<text top="547" left="162" width="887" height="19" font="4">Roselli EE, Qureshi A, Idrees J, et al. Open, hybrid, and endovascular treatment for aortic coarctation and postrepair aneurysm in adolescents and </text>
<text top="566" left="108" width="248" height="19" font="4">adults. Ann Thorac Surg. 2012;94:751-6. </text>
<text top="584" left="108" width="30" height="19" font="4">436. </text>
<text top="584" left="162" width="846" height="19" font="4">Carr JA. The results of catheter-based therapy compared with surgical repair of adult aortic coarctation. J Am Coll Cardiol. 2006;47:1101-7. </text>
<text top="602" left="108" width="30" height="19" font="4">437. </text>
<text top="602" left="162" width="832" height="19" font="4">Aris A, Subirana MT, Ferres P, et al. Repair of aortic coarctation in patients more than 50 years of age. Ann Thorac Surg. 1999;67:1376-9. </text>
<text top="621" left="108" width="30" height="19" font="4">438. </text>
<text top="621" left="162" width="878" height="19" font="4">Almeida de OS, Lisboa LA, Dallan LA, et al. Extraanatomic aortic bypass for repair of aortic arch coarctation via sternotomy: midterm clinical and </text>
<text top="639" left="108" width="437" height="19" font="4">magnetic resonance imaging results. Ann Thorac Surg. 2003;76:1962-6. </text>
<text top="657" left="108" width="30" height="19" font="4">439. </text>
<text top="657" left="162" width="874" height="19" font="4">Morgan GJ, Lee KJ, Chaturvedi R, et al. Systemic blood pressure after stent management for arch coarctation implications for clinical care. JACC </text>
<text top="676" left="108" width="216" height="19" font="4">Cardiovasc Interv. 2013;6:192-201. </text>
<text top="694" left="108" width="30" height="19" font="4">440. </text>
<text top="694" left="162" width="874" height="19" font="4">Connolly HM, Huston Jr, Brown RD, Jr, et al. Intracranial aneurysms in patients with coarctation of the aorta: a prospective magnetic resonance </text>
<text top="712" left="108" width="420" height="19" font="4">angiographic study of 100 patients. Mayo Clin Proc. 2003;78:1491-9. </text>
<text top="730" left="108" width="30" height="19" font="4">441. </text>
<text top="730" left="162" width="910" height="19" font="4">Correia AS, Gonçalves A, Paiva M, et al. Long-term follow-up after aortic coarctation repair: the unsolved issue of exercise-induced hypertension. Rev </text>
<text top="749" left="108" width="183" height="19" font="4">Port Cardiol. 2013;32:879-83. </text>
<text top="767" left="108" width="30" height="19" font="4">442. </text>
<text top="767" left="162" width="865" height="19" font="4">Said SM, Burkhart HM, Dearani JA, et al. Outcomes of surgical repair of double-chambered right ventricle. Ann Thorac Surg. 2012;93:197-200. </text>
</page>
<page number="234" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 234 </text>
<text top="108" left="108" width="30" height="19" font="4">443. </text>
<text top="108" left="162" width="914" height="19" font="4">Kahr PC, Alonso-Gonzalez R, Kempny A, et al. Long-term natural history and postoperative outcome of double-chambered right ventricle—experience </text>
<text top="126" left="108" width="653" height="19" font="4">from two tertiary adult congenital heart centres and review of the literature. Int J Cardiol. 2014;174:662-8. </text>
<text top="145" left="108" width="30" height="19" font="4">444. </text>
<text top="145" left="162" width="776" height="19" font="4">Johnson AM. Impaired exercise response and other residua of pulmonary stenosis after valvotomy. Br Heart J. 1962;24:375-88. </text>
<text top="163" left="108" width="30" height="19" font="4">445. </text>
<text top="163" left="162" width="847" height="19" font="4">Lewis JM, Montero AC, Kinard SA, Jr, et al. Hemondynamic response to exercise in isolated pulmonic stenosis. Circulation. 1964;29:854-61. </text>
<text top="181" left="108" width="30" height="19" font="4">446. </text>
<text top="181" left="162" width="822" height="19" font="4">Jonsson B, Lee SJ. Haemodynamic effects of exercise in isolated pulmonary stenosis before and after surgery. Br Heart J. 1968;30:60-6. </text>
<text top="199" left="108" width="30" height="19" font="4">447. </text>
<text top="199" left="162" width="915" height="19" font="4">Driscoll DJ, Wolfe RR, Gersony WM, et al. Cardiorespiratory responses to exercise of patients with aortic stenosis, pulmonary stenosis, and ventricular </text>
<text top="218" left="108" width="270" height="19" font="4">septal defect. Circulation. 1993;87:I102-I13. </text>
<text top="236" left="108" width="30" height="19" font="4">448. </text>
<text top="236" left="162" width="918" height="19" font="4">Romeih S, Blom NA, Van der Plas MN, et al. Impaired cardiac reserve in asymptomatic patients with moderate pulmonary restenosis late after relief of </text>
<text top="255" left="108" width="579" height="19" font="4">severe pulmonary stenosis: evidence for diastolic dysfunction. Int J Cardiol. 2013;167:2836-40. </text>
<text top="273" left="108" width="30" height="19" font="4">449. </text>
<text top="273" left="162" width="908" height="19" font="4">Luijnenburg SE, de Koning WB, Romeih S, et al. Exercise capacity and ventricular function in patients treated for isolated pulmonary valve stenosis or </text>
<text top="291" left="108" width="305" height="19" font="4">tetralogy of Fallot. Int J Cardiol. 2012;158:359-63. </text>
<text top="309" left="108" width="30" height="19" font="4">450. </text>
<text top="309" left="162" width="907" height="19" font="4">De Meester P, Buys R, Van De Bruaene A, et al. Functional and haemodynamic assessment of mild-to-moderate pulmonary valve stenosis at rest and </text>
<text top="328" left="108" width="252" height="19" font="4">during exercise. Heart. 2014;100:1354-9. </text>
<text top="346" left="108" width="30" height="19" font="4">451. </text>
<text top="346" left="162" width="918" height="19" font="4">Kopecky SL, Gersh BJ, McGoon MD, et al. Long-term outcome of patients undergoing surgical repair of isolated pulmonary valve stenosis. Follow-up at </text>
<text top="364" left="108" width="254" height="19" font="4">20-30 years. Circulation. 1988;78:1150-6. </text>
<text top="383" left="108" width="30" height="19" font="4">452. </text>
<text top="383" left="162" width="896" height="19" font="4">Hayes CJ, Gersony WM, Driscoll DJ, et al. Second natural history study of congenital heart defects. Results of treatment of patients with pulmonary </text>
<text top="401" left="108" width="273" height="19" font="4">valvar stenosis. Circulation. 1993;87:I28-I37. </text>
<text top="419" left="108" width="30" height="19" font="4">453. </text>
<text top="419" left="162" width="920" height="19" font="4">Roos-Hesselink JW, Meijboom FJ, Spitaels SEC, et al. Long-term outcome after surgery for pulmonary stenosis (a longitudinal study of 22-33 years). Eur </text>
<text top="438" left="108" width="145" height="19" font="4">Heart J. 2006;27:482-8. </text>
<text top="456" left="108" width="30" height="19" font="4">454. </text>
<text top="456" left="162" width="673" height="19" font="4">McCrindle BW, Kan JS. Long-term results after balloon pulmonary valvuloplasty. Circulation. 1991;83:1915-22. </text>
<text top="474" left="108" width="30" height="19" font="4">455. </text>
<text top="474" left="162" width="853" height="19" font="4">Voet A, Rega F, de Bruaene AV, et al. Long-term outcome after treatment of isolated pulmonary valve stenosis. Int J Cardiol. 2012;156:11-5. </text>
<text top="493" left="108" width="30" height="19" font="4">456. </text>
<text top="493" left="162" width="878" height="19" font="4">Taggart NW, Cetta F, Cabalka AK, et al. Outcomes for balloon pulmonary valvuloplasty in adults: comparison with a concurrent pediatric cohort. </text>
<text top="511" left="108" width="265" height="19" font="4">Catheter Cardiovasc Interv. 2013;82:811-5. </text>
<text top="529" left="108" width="30" height="19" font="4">457. </text>
<text top="529" left="162" width="779" height="19" font="4">Kaul UA, Singh B, Tyagi S, et al. Long-term results after balloon pulmonary valvuloplasty in adults. Am Heart J. 1993;126:1152-5. </text>
<text top="547" left="108" width="30" height="19" font="4">458. </text>
<text top="547" left="162" width="911" height="19" font="4">Chen CR, Cheng TO, Huang T, et al. Percutaneous balloon valvuloplasty for pulmonic stenosis in adolescents and adults. N Engl J Med. 1996;335:21-5. </text>
<text top="566" left="108" width="30" height="19" font="4">459. </text>
<text top="566" left="162" width="905" height="19" font="4">Fawzy ME, Hassan W, Fadel BM, et al. Long-term results (up to 17 years) of pulmonary balloon valvuloplasty in adults and its effects on concomitant </text>
<text top="584" left="108" width="521" height="19" font="4">severe infundibular stenosis and tricuspid regurgitation. Am Heart J. 2007;153:433-8. </text>
<text top="602" left="108" width="30" height="19" font="4">460. </text>
<text top="602" left="162" width="906" height="19" font="4">Earing MG, Connolly HM, Dearani JA, et al. Long-term follow-up of patients after surgical treatment for isolated pulmonary valve stenosis. Mayo Clin </text>
<text top="621" left="108" width="130" height="19" font="4">Proc. 2005;80:871-6. </text>
<text top="639" left="108" width="30" height="19" font="4">461. </text>
<text top="639" left="162" width="872" height="19" font="4">Hallbergson A, Lock JE, Marshall AC. Frequency and risk of in-stent stenosis following pulmonary artery stenting. Am J Cardiol. 2014;113:541-5. </text>
<text top="657" left="108" width="30" height="19" font="4">462. </text>
<text top="657" left="162" width="907" height="19" font="4">Gonzalez I, Kenny D, Slyder S, et al. Medium and long-term outcomes after bilateral pulmonary artery stenting in children and adults with congenital </text>
<text top="676" left="108" width="290" height="19" font="4">heart disease. Pediatr Cardiol. 2013;34:179-84. </text>
<text top="694" left="108" width="30" height="19" font="4">463. </text>
<text top="694" left="162" width="843" height="19" font="4">Takao CM, El SH, Connolly D, et al. Impact of stent implantation on pulmonary artery growth. Catheter Cardiovasc Interv. 2013;82:445-52. </text>
<text top="712" left="108" width="30" height="19" font="4">464. </text>
<text top="712" left="162" width="915" height="19" font="4">Holzer RJ, Gauvreau K, Kreutzer J, et al. Balloon angioplasty and stenting of branch pulmonary arteries: adverse events and procedural characteristics: </text>
<text top="730" left="108" width="472" height="19" font="4">results of a multi-institutional registry. Circ Cardiovasc Interv. 2011;4:287-96. </text>
<text top="749" left="108" width="30" height="19" font="4">465. </text>
<text top="749" left="162" width="888" height="19" font="4">Kenny D, Amin Z, Slyder S, et al. Medium-term outcomes for peripheral pulmonary artery stenting in adults with congenital heart disease. J Interv </text>
<text top="767" left="108" width="146" height="19" font="4">Cardiol. 2011;24:373-7. </text>
</page>
<page number="235" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 235 </text>
<text top="108" left="108" width="30" height="19" font="4">466. </text>
<text top="108" left="162" width="893" height="19" font="4">Angtuaco MJ, Sachdeva R, Jaquiss RD, et al. Long-term outcomes of intraoperative pulmonary artery stent placement for congenital heart disease. </text>
<text top="126" left="108" width="265" height="19" font="4">Catheter Cardiovasc Interv. 2011;77:395-9. </text>
<text top="145" left="108" width="30" height="19" font="4">467. </text>
<text top="145" left="162" width="831" height="19" font="4">Menon SC, Cetta F, Dearani JA, et al. Hybrid intraoperative pulmonary artery stent placement for congenital heart disease. Am J Cardiol. </text>
<text top="163" left="108" width="119" height="19" font="4">2008;102:1737-41. </text>
<text top="181" left="108" width="30" height="19" font="4">468. </text>
<text top="181" left="162" width="909" height="19" font="4">Bergersen L, Gauvreau K, Justino H, et al. Randomized trial of cutting balloon compared with high-pressure angioplasty for the treatment of resistant </text>
<text top="199" left="108" width="358" height="19" font="4">pulmonary artery stenosis. Circulation. 2011;124:2388-96. </text>
<text top="218" left="108" width="30" height="19" font="4">469. </text>
<text top="218" left="162" width="891" height="19" font="4">Monge MC, Mainwaring RD, Sheikh AY, et al. Surgical reconstruction of peripheral pulmonary artery stenosis in Williams and Alagille syndromes. J </text>
<text top="236" left="108" width="260" height="19" font="4">Thorac Cardiovasc Surg. 2013;145:476-81. </text>
<text top="255" left="108" width="30" height="19" font="4">470. </text>
<text top="255" left="162" width="918" height="19" font="4">Badiu CC, Schreiber C, Hörer J, et al. Early timing of surgical intervention in patients with Ebstein’s anomaly predicts superior long-term outcome. Eur J </text>
<text top="273" left="108" width="220" height="19" font="4">Cardiothorac Surg. 2010;37:186-92. </text>
<text top="291" left="108" width="30" height="19" font="4">471. </text>
<text top="291" left="162" width="859" height="19" font="4">Hachiro Y, Takagi N, Koyanagi T, et al. Repair of double-chambered right ventricle: surgical results and long-term follow-up. Ann Thorac Surg. </text>
<text top="309" left="108" width="103" height="19" font="4">2001;72:1520-2. </text>
<text top="328" left="108" width="30" height="19" font="4">472. </text>
<text top="328" left="162" width="831" height="19" font="4">McElhinney DB, Chatterjee KM, Reddy VM. Double-chambered right ventricle presenting in adulthood. Ann Thorac Surg. 2000;70:124-7. </text>
<text top="346" left="108" width="30" height="19" font="4">473. </text>
<text top="346" left="162" width="885" height="19" font="4">Kveselis D, Rosenthal A, Ferguson P, et al. Long-term prognosis after repair of double-chamber right ventricle with ventricular septal defect. Am J </text>
<text top="364" left="108" width="154" height="19" font="4">Cardiol. 1984;54:1292-5. </text>
<text top="383" left="108" width="30" height="19" font="4">474. </text>
<text top="383" left="162" width="858" height="19" font="4">Steadman CD, Clift PF, Thorne SA, et al. Treatment of dynamic subvalvar muscular obstruction in the native right ventricular outflow tract by </text>
<text top="401" left="108" width="409" height="19" font="4">percutaneous stenting in adults. Congenit Heart Dis. 2009;4:494-8. </text>
<text top="419" left="108" width="30" height="19" font="4">475. </text>
<text top="419" left="162" width="662" height="19" font="4">Chauvaud S. Ebstein’s malformation. Surgical treatment and results. Thorac Cardiovasc Surg. 2000;48:220-3. </text>
<text top="438" left="108" width="30" height="19" font="4">476. </text>
<text top="438" left="162" width="866" height="19" font="4">Chen JM, Mosca RS, Altmann K, et al. Early and medium-term results for repair of Ebstein anomaly. J Thorac Cardiovasc Surg. 2004;127:990-8. </text>
<text top="456" left="108" width="30" height="19" font="4">477. </text>
<text top="456" left="162" width="871" height="19" font="4">Dearani JA, Said SM, O’Leary PW, et al. Anatomic repair of Ebstein’s malformation: lessons learned with cone reconstruction. Ann Thorac Surg. </text>
<text top="474" left="108" width="96" height="19" font="4">2013;95:220-6. </text>
<text top="493" left="108" width="30" height="19" font="4">478. </text>
<text top="493" left="162" width="864" height="19" font="4">Dearani JA, Said SM, Burkhart HM, et al. Strategies for tricuspid re-repair in Ebstein malformation using the cone technique. Ann Thorac Surg. </text>
<text top="511" left="108" width="96" height="19" font="4">2013;96:202-8. </text>
<text top="529" left="108" width="30" height="19" font="4">479. </text>
<text top="529" left="162" width="909" height="19" font="4">Malhotra SP, Petrossian E, Reddy VM, et al. Selective right ventricular unloading and novel technical concepts in Ebstein’s anomaly. Ann Thorac Surg. </text>
<text top="547" left="108" width="111" height="19" font="4">2009;88:1975-81. </text>
<text top="566" left="108" width="30" height="19" font="4">480. </text>
<text top="566" left="162" width="919" height="19" font="4">Raju V, Dearani JA, Burkhart HM, et al. Right ventricular unloading for heart failure related to Ebstein malformation. Ann Thorac Surg. 2014;98:167-73. </text>
<text top="584" left="108" width="30" height="19" font="4">481. </text>
<text top="584" left="162" width="850" height="19" font="4">Al-Najashi KS, Balint OH, Oechslin E, et al. Mid-term outcomes in adults with ebstein anomaly and cavopulmonary shunts. Ann Thorac Surg. </text>
<text top="602" left="108" width="96" height="19" font="4">2009;88:131-6. </text>
<text top="621" left="108" width="30" height="19" font="4">482. </text>
<text top="621" left="162" width="909" height="19" font="4">Khositseth A, Danielson GK, Dearani JA, et al. Supraventricular tachyarrhythmias in Ebstein anomaly: management and outcome. J Thorac Cardiovasc </text>
<text top="639" left="108" width="145" height="19" font="4">Surg. 2004;128:826-33. </text>
<text top="657" left="108" width="30" height="19" font="4">483. </text>
<text top="657" left="162" width="710" height="19" font="4">Wei W, Zhan X, Xue Y, et al. Features of accessory pathways in adult Ebstein’s anomaly. Europace. 2014;16:1619-25. </text>
<text top="676" left="108" width="30" height="19" font="4">484. </text>
<text top="676" left="162" width="894" height="19" font="4">Iturralde P, Nava S, Sálica G, et al. Electrocardiographic characteristics of patients with Ebstein’s anomaly before and after ablation of an accessory </text>
<text top="694" left="108" width="432" height="19" font="4">atrioventricular pathway. J Cardiovasc Electrophysiol. 2006;17:1332-6. </text>
<text top="712" left="108" width="30" height="19" font="4">485. </text>
<text top="712" left="162" width="877" height="19" font="4">Reich JD, Auld D, Hulse E, et al. The Pediatric Radiofrequency Ablation Registry’s experience with Ebstein’s anomaly. Pediatric Electrophysiology </text>
<text top="730" left="108" width="317" height="19" font="4">Society. J Cardiovasc Electrophysiol. 1998;9:1370-7. </text>
<text top="749" left="108" width="30" height="19" font="4">486. </text>
<text top="749" left="162" width="901" height="19" font="4">Shivapour JKL, Sherwin ED, Alexander ME, et al. Utility of preoperative electrophysiologic studies in patients with Ebstein’s anomaly undergoing the </text>
<text top="767" left="108" width="292" height="19" font="4">cone procedure. Heart Rhythm. 2014;11:182-6. </text>
</page>
<page number="236" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 236 </text>
<text top="108" left="108" width="30" height="19" font="4">487. </text>
<text top="108" left="162" width="864" height="19" font="4">Bharucha T, Anderson RH, Lim ZS, et al. Multiplanar review of three-dimensional echocardiography gives new insights into the morphology of </text>
<text top="126" left="108" width="336" height="19" font="4">Ebstein’s malformation. Cardiol Young. 2010;20:49-53. </text>
<text top="145" left="108" width="30" height="19" font="4">488. </text>
<text top="145" left="162" width="873" height="19" font="4">Attenhofer Jost CH, Edmister WD, Julsrud PR, et al. Prospective comparison of echocardiography versus cardiac magnetic resonance imaging in </text>
<text top="163" left="108" width="465" height="19" font="4">patients with Ebstein’s anomaly. Int J Cardiovasc Imaging. 2012;28:1147-59. </text>
<text top="181" left="108" width="30" height="19" font="4">489. </text>
<text top="181" left="162" width="914" height="19" font="4">Zachariah JP, Walsh EP, Triedman JK, et al. Multiple accessory pathways in the young: the impact of structural heart disease. Am Heart J. 2013;165:87-</text>
<text top="199" left="108" width="22" height="19" font="4">92. </text>
<text top="218" left="108" width="30" height="19" font="4">490. </text>
<text top="218" left="162" width="833" height="19" font="4">Brown ML, Dearani JA, Danielson GK, et al. The outcomes of operations for 539 patients with Ebstein anomaly. J Thorac Cardiovasc Surg. </text>
<text top="236" left="108" width="153" height="19" font="4">2008;135:1120-36, e1-7. </text>
<text top="255" left="108" width="30" height="19" font="4">491. </text>
<text top="255" left="162" width="913" height="19" font="4">Hasan BS, McElhinney DB, Brown DW, et al. Short-term performance of the transcatheter Melody valve in high-pressure hemodynamic environments </text>
<text top="273" left="108" width="503" height="19" font="4">in the pulmonary and systemic circulations. Circ Cardiovasc Interv. 2011;4:615-20. </text>
<text top="291" left="108" width="30" height="19" font="4">492. </text>
<text top="291" left="162" width="910" height="19" font="4">Roberts PA, Boudjemline Y, Cheatham JP, et al. Percutaneous tricuspid valve replacement in congenital and acquired heart disease. J Am Coll Cardiol. </text>
<text top="309" left="108" width="103" height="19" font="4">2011;58:117-22. </text>
<text top="328" left="108" width="30" height="19" font="4">493. </text>
<text top="328" left="162" width="864" height="19" font="4">Cullen MW, Cabalka AK, Alli OO, et al. Transvenous, antegrade Melody valve-in-valve implantation for bioprosthetic mitral and tricuspid valve </text>
<text top="346" left="108" width="546" height="19" font="4">dysfunction: a case series in children and adults. JACC Cardiovasc Interv. 2013;6:598-605. </text>
<text top="364" left="108" width="30" height="19" font="4">494. </text>
<text top="364" left="162" width="863" height="19" font="4">Valente AM, Gauvreau K, Assenza GE, et al. Contemporary predictors of death and sustained ventricular tachycardia in patients with repaired </text>
<text top="383" left="108" width="476" height="19" font="4">tetralogy of Fallot enrolled in the INDICATOR cohort. Heart. 2014;100:247-53. </text>
<text top="401" left="108" width="30" height="19" font="4">495. </text>
<text top="401" left="162" width="870" height="19" font="4">Aboulhosn JA, Lluri G, Gurvitz MZ, et al. Left and right ventricular diastolic function in adults with surgically repaired tetralogy of Fallot: a multi-</text>
<text top="419" left="108" width="306" height="19" font="4">institutional study. Can J Cardiol. 2013;29:866-72. </text>
<text top="438" left="108" width="30" height="19" font="4">496. </text>
<text top="438" left="162" width="917" height="19" font="4">Bonello B, Kempny A, Uebing A, et al. Right atrial area and right ventricular outflow tract akinetic length predict sustained tachyarrhythmia in repaired </text>
<text top="456" left="108" width="305" height="19" font="4">tetralogy of Fallot. Int J Cardiol. 2013;168:3280-6. </text>
<text top="474" left="108" width="30" height="19" font="4">497. </text>
<text top="474" left="162" width="903" height="19" font="4">Diller G-P, Kempny A, Liodakis E, et al. Left ventricular longitudinal function predicts life-threatening ventricular arrhythmia and death in adults with </text>
<text top="493" left="108" width="355" height="19" font="4">repaired tetralogy of Fallot. Circulation. 2012;125:2440-6. </text>
<text top="511" left="108" width="30" height="19" font="4">498. </text>
<text top="511" left="162" width="914" height="19" font="4">Broberg CS, Aboulhosn J, Mongeon FP, et al. Prevalence of left ventricular systolic dysfunction in adults with repaired tetralogy of Fallot. Am J Cardiol. </text>
<text top="529" left="108" width="119" height="19" font="4">2011;107:1215-20. </text>
<text top="547" left="108" width="30" height="19" font="4">499. </text>
<text top="547" left="162" width="895" height="19" font="4">Ortega M, Triedman JK, Geva T, et al. Relation of left ventricular dyssynchrony measured by cardiac magnetic resonance tissue tracking in repaired </text>
<text top="566" left="108" width="541" height="19" font="4">tetralogy of Fallot to ventricular tachycardia and death. Am J Cardiol. 2011;107:1535-40. </text>
<text top="584" left="108" width="30" height="19" font="4">500. </text>
<text top="584" left="162" width="920" height="19" font="4">Khairy P, Aboulhosn J, Gurvitz MZ, et al. Arrhythmia burden in adults with surgically repaired tetralogy of Fallot: a multi-institutional study. Circulation. </text>
<text top="602" left="108" width="111" height="19" font="4">2010;122:868-75. </text>
<text top="621" left="108" width="30" height="19" font="4">501. </text>
<text top="621" left="162" width="911" height="19" font="4">Lu JC, Cotts TB, Agarwal PP, et al. Relation of right ventricular dilation, age of repair, and restrictive right ventricular physiology with patient-reported </text>
<text top="639" left="108" width="651" height="19" font="4">quality of life in adolescents and adults with repaired tetralogy of Fallot. Am J Cardiol. 2010;106:1798-802. </text>
<text top="657" left="108" width="30" height="19" font="4">502. </text>
<text top="657" left="162" width="894" height="19" font="4">Wald RM, Haber I, Wald R, et al. Effects of regional dysfunction and late gadolinium enhancement on global right ventricular function and exercise </text>
<text top="676" left="108" width="506" height="19" font="4">capacity in patients with repaired tetralogy of Fallot. Circulation. 2009;119:1370-7. </text>
<text top="694" left="108" width="30" height="19" font="4">503. </text>
<text top="694" left="162" width="881" height="19" font="4">Hickey EJ, Veldtman G, Bradley TJ, et al. Late risk of outcomes for adults with repaired tetralogy of Fallot from an inception cohort spanning four </text>
<text top="712" left="108" width="310" height="19" font="4">decades. Eur J Cardiothorac Surg. 2009;35:156-64. </text>
<text top="730" left="108" width="30" height="19" font="4">504. </text>
<text top="730" left="162" width="921" height="19" font="4">Rosianu S, Paprika D, Osztheimer I, et al. Echocardiographic evaluation of patients with undocumented arrhythmias occurring in adults late after repair </text>
<text top="749" left="108" width="354" height="19" font="4">of tetralogy of Fallot. Eur J Echocardiogr. 2009;10:139-43. </text>
<text top="767" left="108" width="30" height="19" font="4">505. </text>
<text top="767" left="162" width="878" height="19" font="4">Knauth AL, Gauvreau K, Powell AJ, et al. Ventricular size and function assessed by cardiac MRI predict major adverse clinical outcomes late after </text>
<text top="786" left="108" width="292" height="19" font="4">tetralogy of Fallot repair. Heart. 2008;94:211-6. </text>
</page>
<page number="237" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 237 </text>
<text top="108" left="108" width="30" height="19" font="4">506. </text>
<text top="108" left="162" width="786" height="19" font="4">Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation. 2008;117:363-70. </text>
<text top="126" left="108" width="30" height="19" font="4">507. </text>
<text top="126" left="162" width="910" height="19" font="4">Babu-Narayan SV, Kilner PJ, Li W, et al. Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of Fallot </text>
<text top="145" left="108" width="547" height="19" font="4">and its relationship to adverse markers of clinical outcome. Circulation. 2006;113:405-13. </text>
<text top="163" left="108" width="30" height="19" font="4">508. </text>
<text top="163" left="162" width="862" height="19" font="4">Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed ventricular stimulation after tetralogy of Fallot repair: a multicenter study. </text>
<text top="181" left="108" width="207" height="19" font="4">Circulation. 2004;109:1994-2000. </text>
<text top="199" left="108" width="30" height="19" font="4">509. </text>
<text top="199" left="162" width="912" height="19" font="4">Geva T, Sandweiss BM, Gauvreau K, et al. Factors associated with impaired clinical status in long-term survivors of tetralogy of Fallot repair evaluated </text>
<text top="218" left="108" width="419" height="19" font="4">by magnetic resonance imaging. J Am Coll Cardiol. 2004;43:1068-74. </text>
<text top="236" left="108" width="30" height="19" font="4">510. </text>
<text top="236" left="162" width="908" height="19" font="4">Davlouros PA, Kilner PJ, Hornung TS, et al. Right ventricular function in adults with repaired tetralogy of Fallot assessed with cardiovascular magnetic </text>
<text top="255" left="108" width="936" height="19" font="4">resonance imaging: detrimental role of right ventricular outflow aneurysms or akinesia and adverse right-to-left ventricular interaction. J Am Coll Cardiol. </text>
<text top="273" left="108" width="111" height="19" font="4">2002;40:2044-52. </text>
<text top="291" left="108" width="30" height="19" font="4">511. </text>
<text top="291" left="162" width="916" height="19" font="4">Ghai A, Silversides C, Harris L, et al. Left ventricular dysfunction is a risk factor for sudden cardiac death in adults late after repair of tetralogy of Fallot. </text>
<text top="309" left="108" width="220" height="19" font="4">J Am Coll Cardiol. 2002;40:1675-80. </text>
<text top="328" left="108" width="30" height="19" font="4">512. </text>
<text top="328" left="162" width="910" height="19" font="4">Bacha EA, Scheule AM, Zurakowski D, et al. Long-term results after early primary repair of tetralogy of Fallot. J Thorac Cardiovasc Surg. 2001;122:154-</text>
<text top="346" left="108" width="22" height="19" font="4">61. </text>
<text top="364" left="108" width="30" height="19" font="4">513. </text>
<text top="364" left="162" width="890" height="19" font="4">Gatzoulis MA, Balaji S, Webber SA, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre </text>
<text top="383" left="108" width="199" height="19" font="4">study. Lancet. 2000;356:975-81. </text>
<text top="401" left="108" width="30" height="19" font="4">514. </text>
<text top="401" left="162" width="872" height="19" font="4">Nollert G, Fischlein T, Bouterwek S, et al. Long-term results of total repair of tetralogy of Fallot in adulthood: 35 years follow-up in 104 patients </text>
<text top="419" left="108" width="469" height="19" font="4">corrected at the age of 18 or older. Thorac Cardiovasc Surg. 1997;45:178-81. </text>
<text top="438" left="108" width="30" height="19" font="4">515. </text>
<text top="438" left="162" width="859" height="19" font="4">Harrison DA, Harris L, Siu SC, et al. Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. J Am Coll Cardiol. </text>
<text top="456" left="108" width="111" height="19" font="4">1997;30:1368-73. </text>
<text top="474" left="108" width="30" height="19" font="4">516. </text>
<text top="474" left="162" width="885" height="19" font="4">Gatzoulis MA, Till JA, Somerville J, et al. Mechanoelectrical interaction in tetralogy of Fallot. QRS prolongation relates to right ventricular size and </text>
<text top="493" left="108" width="549" height="19" font="4">predicts malignant ventricular arrhythmias and sudden death. Circulation. 1995;92:231-7. </text>
<text top="511" left="108" width="30" height="19" font="4">517. </text>
<text top="511" left="162" width="900" height="19" font="4">Murphy JG, Gersh BJ, Mair DD, et al. Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. N Engl J Med. 1993;329:593-9. </text>
<text top="529" left="108" width="30" height="19" font="4">518. </text>
<text top="529" left="162" width="897" height="19" font="4">Ait-Ali L, Siciliano V, Passino C, et al. Role of stress echocardiography in operated Fallot: feasibility and detection of right ventricular response. J Am </text>
<text top="547" left="108" width="149" height="19" font="4">Soc Echocardiogr. 2014; </text>
<text top="566" left="108" width="30" height="19" font="4">519. </text>
<text top="566" left="162" width="898" height="19" font="4">Freling HG, Willems TP, van Melle JP, et al. Effect of right ventricular outflow tract obstruction on right ventricular volumes and exercise capacity in </text>
<text top="584" left="108" width="448" height="19" font="4">patients with repaired tetralogy of Fallot. Am J Cardiol. 2014;113:719-23. </text>
<text top="602" left="108" width="30" height="19" font="4">520. </text>
<text top="602" left="162" width="917" height="19" font="4">Babu-Narayan SV, Diller GP, Gheta RR, et al. Clinical outcomes of surgical pulmonary valve replacement after repair of tetralogy of Fallot and potential </text>
<text top="621" left="108" width="589" height="19" font="4">prognostic value of preoperative cardiopulmonary exercise testing. Circulation. 2014;129:18-27. </text>
<text top="639" left="108" width="30" height="19" font="4">521. </text>
<text top="639" left="162" width="895" height="19" font="4">Ferraz Cavalcanti PE, Sá MPBO, Santos CA, et al. Pulmonary valve replacement after operative repair of tetralogy of Fallot: meta-analysis and meta-</text>
<text top="657" left="108" width="496" height="19" font="4">regression of 3,118 patients from 48 studies. J Am Coll Cardiol. 2013;62:2227-43. </text>
<text top="676" left="108" width="30" height="19" font="4">522. </text>
<text top="676" left="162" width="879" height="19" font="4">Morray BH, McElhinney DB, Cheatham JP, et al. Risk of coronary artery compression among patients referred for transcatheter pulmonary valve </text>
<text top="694" left="108" width="480" height="19" font="4">implantation: a multicenter experience. Circ Cardiovasc Interv. 2013;6:535-42. </text>
<text top="712" left="108" width="30" height="19" font="4">523. </text>
<text top="712" left="162" width="873" height="19" font="4">Ong K, Boone R, Gao M, et al. Right ventricle to pulmonary artery conduit reoperations in patients with tetralogy of Fallot or pulmonary atresia </text>
<text top="730" left="108" width="455" height="19" font="4">associated with ventricular septal defect. Am J Cardiol. 2013;111:1638-43. </text>
<text top="749" left="108" width="30" height="19" font="4">524. </text>
<text top="749" left="162" width="882" height="19" font="4">Adamson L, Vohra HA, Haw MP. Does pulmonary valve replacement post repair of tetralogy of Fallot improve right ventricular function? Interact </text>
<text top="767" left="108" width="237" height="19" font="4">Cardiovasc Thorac Surg. 2009;9:520-7. </text>
</page>
<page number="238" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 238 </text>
<text top="108" left="108" width="30" height="19" font="4">525. </text>
<text top="108" left="162" width="855" height="19" font="4">Cheung EW, Wong WH, Cheung YF. Meta-analysis of pulmonary valve replacement after operative repair of tetralogy of Fallot. Am J Cardiol. </text>
<text top="126" left="108" width="103" height="19" font="4">2010;106:552-7. </text>
<text top="145" left="108" width="30" height="19" font="4">526. </text>
<text top="145" left="162" width="890" height="19" font="4">Lee C, Kim YM, Lee C-H, et al. Outcomes of pulmonary valve replacement in 170 patients with chronic pulmonary regurgitation after relief of right </text>
<text top="163" left="108" width="846" height="19" font="4">ventricular outflow tract obstruction: implications for optimal timing of pulmonary valve replacement. J Am Coll Cardiol. 2012;60:1005-14. </text>
<text top="181" left="108" width="30" height="19" font="4">527. </text>
<text top="181" left="162" width="902" height="19" font="4">Fiore AC, Rodefeld M, Turrentine M, et al. Pulmonary valve replacement: a comparison of three biological valves. Ann Thorac Surg. 2008;85:1712-8. </text>
<text top="199" left="108" width="30" height="19" font="4">528. </text>
<text top="199" left="162" width="877" height="19" font="4">Gengsakul A, Harris L, Bradley TJ, et al. The impact of pulmonary valve replacement after tetralogy of Fallot repair: a matched comparison. Eur J </text>
<text top="218" left="108" width="213" height="19" font="4">Cardiothorac Surg. 2007;32:462-8. </text>
<text top="236" left="108" width="30" height="19" font="4">529. </text>
<text top="236" left="162" width="910" height="19" font="4">Oosterhof T, van Straten A, Vliegen HW, et al. Preoperative thresholds for pulmonary valve replacement in patients with corrected tetralogy of Fallot </text>
<text top="255" left="108" width="441" height="19" font="4">using cardiovascular magnetic resonance. Circulation. 2007;116:545-51. </text>
<text top="273" left="108" width="30" height="19" font="4">530. </text>
<text top="273" left="162" width="786" height="19" font="4">Frigiola A, Tsang V, Nordmeyer J, et al. Current approaches to pulmonary regurgitation. Eur J Cardiothorac Surg. 2008;34:576-80. </text>
<text top="291" left="108" width="30" height="19" font="4">531. </text>
<text top="291" left="162" width="886" height="19" font="4">Yin S, Salazar J, Nolke L, et al. Late pulmonary valve implantation after repair of tetralogy of Fallot. Asian Cardiovasc Thorac Ann. 2005;13:139-42. </text>
<text top="309" left="108" width="30" height="19" font="4">532. </text>
<text top="309" left="162" width="916" height="19" font="4">Mainwaring RD, Pirolli T, Punn R, et al. Late repair of the native pulmonary valve in patients with pulmonary insufficiency after surgery for tetralogy of </text>
<text top="328" left="108" width="244" height="19" font="4">Fallot. Ann Thorac Surg. 2012;93:677-9. </text>
<text top="346" left="108" width="30" height="19" font="4">533. </text>
<text top="346" left="162" width="887" height="19" font="4">Graham TP, Jr, Bernard Y, Arbogast P, et al. Outcome of pulmonary valve replacements in adults after tetralogy repair: a multi-institutional study. </text>
<text top="364" left="108" width="210" height="19" font="4">Congenit Heart Dis. 2008;3:162-7. </text>
<text top="383" left="108" width="30" height="19" font="4">534. </text>
<text top="383" left="162" width="892" height="19" font="4">Ovcina I, Knez I, Curcic P, et al. Pulmonary valve replacement with mechanical prostheses in re-do Fallot patients. Interact Cardiovasc Thorac Surg. </text>
<text top="401" left="108" width="103" height="19" font="4">2011;12:987-91. </text>
<text top="419" left="108" width="30" height="19" font="4">535. </text>
<text top="419" left="162" width="849" height="19" font="4">Dave HH, Buechel ER, Dodge-Khatami A, et al. Early insertion of a pulmonary valve for chronic regurgitation helps restoration of ventricular </text>
<text top="438" left="108" width="295" height="19" font="4">dimensions. Ann Thorac Surg. 2005;80:1615-20. </text>
<text top="456" left="108" width="30" height="19" font="4">536. </text>
<text top="456" left="162" width="910" height="19" font="4">Meijboom FJ, Roos-Hesselink JW, McGhie JS, et al. Consequences of a selective approach toward pulmonary valve replacement in adult patients with </text>
<text top="474" left="108" width="547" height="19" font="4">tetralogy of Fallot and pulmonary regurgitation. J Thorac Cardiovasc Surg. 2008;135:50-5. </text>
<text top="493" left="108" width="30" height="19" font="4">537. </text>
<text top="493" left="162" width="886" height="19" font="4">van Huysduynen BH, van SA, Swenne CA, et al. Reduction of QRS duration after pulmonary valve replacement in adult Fallot patients is related to </text>
<text top="511" left="108" width="409" height="19" font="4">reduction of right ventricular volume. Eur Heart J. 2005;26:928-32. </text>
<text top="529" left="108" width="30" height="19" font="4">538. </text>
<text top="529" left="162" width="866" height="19" font="4">Lee C, Park CS, Lee CH, et al. Durability of bioprosthetic valves in the pulmonary position: long-term follow-up of 181 implants in patients with </text>
<text top="547" left="108" width="416" height="19" font="4">congenital heart disease. J Thorac Cardiovasc Surg. 2011;142:351-8. </text>
<text top="566" left="108" width="30" height="19" font="4">539. </text>
<text top="566" left="162" width="873" height="19" font="4">Chen PC, Sager MS, Zurakowski D, et al. Younger age and valve oversizing are predictors of structural valve deterioration after pulmonary valve </text>
<text top="584" left="108" width="563" height="19" font="4">replacement in patients with tetralogy of Fallot. J Thorac Cardiovasc Surg. 2012;143:352-60. </text>
<text top="602" left="108" width="30" height="19" font="4">540. </text>
<text top="602" left="162" width="905" height="19" font="4">Discigil B, Dearani JA, Puga FJ, et al. Late pulmonary valve replacement after repair of tetralogy of Fallot. J Thorac Cardiovasc Surg. 2001;121:344-51. </text>
<text top="621" left="108" width="30" height="19" font="4">541. </text>
<text top="621" left="162" width="834" height="19" font="4">Zubairi R, Malik S, Jaquiss RDB, et al. Risk factors for prosthesis failure in pulmonary valve replacement. Ann Thorac Surg. 2011;91:561-5. </text>
<text top="639" left="108" width="30" height="19" font="4">542. </text>
<text top="639" left="162" width="868" height="19" font="4">Geva T, Gauvreau K, Powell AJ, et al. Randomized trial of pulmonary valve replacement with and without right ventricular remodeling surgery. </text>
<text top="657" left="108" width="183" height="19" font="4">Circulation. 2010;122:S201-8. </text>
<text top="676" left="108" width="30" height="19" font="4">543. </text>
<text top="676" left="162" width="872" height="19" font="4">Therrien J, Provost Y, Merchant N, et al. Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair. Am J Cardiol. </text>
<text top="694" left="108" width="103" height="19" font="4">2005;95:779-82. </text>
<text top="712" left="108" width="30" height="19" font="4">544. </text>
<text top="712" left="162" width="891" height="19" font="4">Quail MA, Frigiola A, Giardini A, et al. Impact of pulmonary valve replacement in tetralogy of Fallot with pulmonary regurgitation: a comparison of </text>
<text top="730" left="108" width="430" height="19" font="4">intervention and nonintervention. Ann Thorac Surg. 2012;94:1619-26. </text>
<text top="749" left="108" width="30" height="19" font="4">545. </text>
<text top="749" left="162" width="898" height="19" font="4">Mercer-Rosa L, Yang W, Kutty S, et al. Quantifying pulmonary regurgitation and right ventricular function in surgically repaired tetralogy of Fallot: a </text>
<text top="767" left="108" width="715" height="19" font="4">comparative analysis of echocardiography and magnetic resonance imaging. Circ Cardiovasc Imaging. 2012;5:637-43. </text>
</page>
<page number="239" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 239 </text>
<text top="108" left="108" width="30" height="19" font="4">546. </text>
<text top="108" left="162" width="917" height="19" font="4">Hallbergson A, Gauvreau K, Powell AJ, et al. Right ventricular remodeling after pulmonary valve replacement: early gains, late losses. Ann Thorac Surg. </text>
<text top="126" left="108" width="96" height="19" font="4">2015;99:660-6. </text>
<text top="145" left="108" width="30" height="19" font="4">547. </text>
<text top="145" left="162" width="904" height="19" font="4">Harrild DM, Berul CI, Cecchin F, et al. Pulmonary valve replacement in tetralogy of Fallot: impact on survival and ventricular tachycardia. Circulation. </text>
<text top="163" left="108" width="111" height="19" font="4">2009;119:445-51. </text>
<text top="181" left="108" width="30" height="19" font="4">548. </text>
<text top="181" left="162" width="856" height="19" font="4">Tsai SF, Chan DP, Ro PS, et al. Rate of inducible ventricular arrhythmia in adults with congenital heart disease. Am J Cardiol. 2010;106:730-6. </text>
<text top="199" left="108" width="30" height="19" font="4">549. </text>
<text top="199" left="162" width="839" height="19" font="4">Lucron H, Marçon F, Bosser G, et al. Induction of sustained ventricular tachycardia after surgical repair of tetralogy of Fallot. Am J Cardiol. </text>
<text top="218" left="108" width="111" height="19" font="4">1999;83:1369-73. </text>
<text top="236" left="108" width="30" height="19" font="4">550. </text>
<text top="236" left="162" width="878" height="19" font="4">Dietl CA, Cazzaniga ME, Dubner SJ, et al. Life-threatening arrhythmias and RV dysfunction after surgical repair of tetralogy of Fallot. Comparison </text>
<text top="255" left="108" width="497" height="19" font="4">between transventricular and transatrial approaches. Circulation. 1994;90:II7-12. </text>
<text top="273" left="108" width="30" height="19" font="4">551. </text>
<text top="273" left="162" width="855" height="19" font="4">Khairy P. Programmed ventricular stimulation for risk stratification in patients with tetralogy of Fallot: a Bayesian perspective. Nat Clin Pract </text>
<text top="291" left="108" width="193" height="19" font="4">Cardiovasc Med. 2007;4:292-3. </text>
<text top="309" left="108" width="30" height="19" font="4">552. </text>
<text top="309" left="162" width="874" height="19" font="4">Koyak Z, de Groot JR, Bouma BJ, et al. Symptomatic but not asymptomatic non-sustained ventricular tachycardia is associated with appropriate </text>
<text top="328" left="108" width="525" height="19" font="4">implantable cardioverter therapy in tetralogy of Fallot. Int J Cardiol. 2013;167:1532-5. </text>
<text top="346" left="108" width="30" height="19" font="4">553. </text>
<text top="346" left="162" width="907" height="19" font="4">Witte KK, Pepper CB, Cowan JC, et al. Implantable cardioverter-defibrillator therapy in adult patients with tetralogy of Fallot. Europace. 2008;10:926-</text>
<text top="364" left="108" width="22" height="19" font="4">30. </text>
<text top="383" left="108" width="30" height="19" font="4">554. </text>
<text top="383" left="162" width="823" height="19" font="4">Geva T. Indications for pulmonary valve replacement in repaired tetralogy of Fallot: the quest continues. Circulation. 2013;128:1855-7. </text>
<text top="401" left="108" width="30" height="19" font="4">555. </text>
<text top="401" left="162" width="910" height="19" font="4">Boshoff DE, Cools BL, Heying R, et al. Off-label use of percutaneous pulmonary valved stents in the right ventricular outflow tract: time to rewrite the </text>
<text top="419" left="108" width="312" height="19" font="4">label? Catheter Cardiovasc Interv. 2013;81:987-95. </text>
<text top="438" left="108" width="30" height="19" font="4">556. </text>
<text top="438" left="162" width="885" height="19" font="4">Buber J, Bergersen L, Lock JE, et al. Bloodstream infections occurring in patients with percutaneously implanted bioprosthetic pulmonary valve: a </text>
<text top="456" left="108" width="392" height="19" font="4">single-center experience. Circ Cardiovasc Interv. 2013;6:301-10. </text>
<text top="474" left="108" width="30" height="19" font="4">557. </text>
<text top="474" left="162" width="910" height="19" font="4">Butera G, Milanesi O, Spadoni I, et al. Melody transcatheter pulmonary valve implantation. Results from the registry of the Italian Society of Pediatric </text>
<text top="493" left="108" width="337" height="19" font="4">Cardiology. Catheter Cardiovasc Interv. 2013;81:310-6. </text>
<text top="511" left="108" width="30" height="19" font="4">558. </text>
<text top="511" left="162" width="904" height="19" font="4">Cheatham SL, Holzer RJ, Chisolm JL, et al. The Medtronic Melody® transcatheter pulmonary valve implanted at 24-mm diameter—it works. Catheter </text>
<text top="529" left="108" width="216" height="19" font="4">Cardiovasc Interv. 2013;82:816-23. </text>
<text top="547" left="108" width="30" height="19" font="4">559. </text>
<text top="547" left="162" width="901" height="19" font="4">Faza N, Kenny D, Kavinsky C, et al. Single-center comparative outcomes of the Edwards SAPIEN and Medtronic Melody transcatheter heart valves in </text>
<text top="566" left="108" width="437" height="19" font="4">the pulmonary position. Catheter Cardiovasc Interv. 2013;82:E535-E41. </text>
<text top="584" left="108" width="30" height="19" font="4">560. </text>
<text top="584" left="162" width="902" height="19" font="4">Haas NA, Moysich A, Neudorf U, et al. Percutaneous implantation of the Edwards SAPIEN() pulmonic valve: initial results in the first 22 patients. Clin </text>
<text top="602" left="108" width="186" height="19" font="4">Res Cardiol. 2013;102:119-28. </text>
<text top="621" left="108" width="30" height="19" font="4">561. </text>
<text top="621" left="162" width="914" height="19" font="4">Hainstock MR, Marshall AC, Lock JE, et al. Angioplasty of obstructed homograft conduits in the right ventricular outflow tract with ultra-noncompliant </text>
<text top="639" left="108" width="614" height="19" font="4">balloons: assessment of therapeutic efficacy and conduit tears. Circ Cardiovasc Interv. 2013;6:671-9. </text>
<text top="657" left="108" width="30" height="19" font="4">562. </text>
<text top="657" left="162" width="915" height="19" font="4">McElhinney DB, Benson LN, Eicken A, et al. Infective endocarditis after transcatheter pulmonary valve replacement using the Melody valve: combined </text>
<text top="676" left="108" width="628" height="19" font="4">results of 3 prospective North American and European studies. Circ Cardiovasc Interv. 2013;6:292-300. </text>
<text top="694" left="108" width="30" height="19" font="4">563. </text>
<text top="694" left="162" width="912" height="19" font="4">Batra AS, McElhinney DB, Wang W, et al. Cardiopulmonary exercise function among patients undergoing transcatheter pulmonary valve implantation </text>
<text top="712" left="108" width="444" height="19" font="4">in the US Melody valve investigational trial. Am Heart J. 2012;163:280-7. </text>
<text top="730" left="108" width="30" height="19" font="4">564. </text>
<text top="730" left="162" width="919" height="19" font="4">Muller J, Engelhardt A, Fratz S, et al. Improved exercise performance and quality of life after percutaneous pulmonary valve implantation. Int J Cardiol. </text>
<text top="749" left="108" width="111" height="19" font="4">2014;173:388-92. </text>
<text top="767" left="108" width="30" height="19" font="4">565. </text>
<text top="767" left="162" width="911" height="19" font="4">Gillespie MJ, Rome JJ, Levi DS, et al. Melody valve implant within failed bioprosthetic valves in the pulmonary position: a multicenter experience. Circ </text>
<text top="786" left="108" width="208" height="19" font="4">Cardiovasc Interv. 2012;5:862-70. </text>
</page>
<page number="240" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 240 </text>
<text top="108" left="108" width="30" height="19" font="4">566. </text>
<text top="108" left="162" width="875" height="19" font="4">Eicken A, Ewert P, Hager A, et al. Percutaneous pulmonary valve implantation: two-centre experience with more than 100 patients. Eur Heart J. </text>
<text top="126" left="108" width="103" height="19" font="4">2011;32:1260-5. </text>
<text top="145" left="108" width="30" height="19" font="4">567. </text>
<text top="145" left="162" width="883" height="19" font="4">Kenny D, Hijazi ZM, Kar S, et al. Percutaneous implantation of the Edwards SAPIEN transcatheter heart valve for conduit failure in the pulmonary </text>
<text top="163" left="108" width="690" height="19" font="4">position: early phase 1 results from an international multicenter clinical trial. J Am Coll Cardiol. 2011;58:2248-56. </text>
<text top="181" left="108" width="30" height="19" font="4">568. </text>
<text top="181" left="162" width="914" height="19" font="4">Lurz P, Nordmeyer J, Giardini A, et al. Early versus late functional outcome after successful percutaneous pulmonary valve implantation: are the acute </text>
<text top="199" left="108" width="584" height="19" font="4">effects of altered right ventricular loading all we can expect? J Am Coll Cardiol. 2011;57:724-31. </text>
<text top="218" left="108" width="30" height="19" font="4">569. </text>
<text top="218" left="162" width="905" height="19" font="4">McElhinney DB, Cheatham JP, Jones TK, et al. Stent fracture, valve dysfunction, and right ventricular outflow tract reintervention after transcatheter </text>
<text top="236" left="108" width="866" height="19" font="4">pulmonary valve implantation: patient-related and procedural risk factors in the US Melody Valve Trial. Circ Cardiovasc Interv. 2011;4:602-14. </text>
<text top="255" left="108" width="30" height="19" font="4">570. </text>
<text top="255" left="162" width="913" height="19" font="4">McElhinney DB, Hellenbrand WE, Zahn EM, et al. Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded </text>
<text top="273" left="108" width="395" height="19" font="4">multicenter US Melody valve trial. Circulation. 2010;122:507-16. </text>
<text top="291" left="108" width="30" height="19" font="4">571. </text>
<text top="291" left="162" width="909" height="19" font="4">Zahn EM, Hellenbrand WE, Lock JE, et al. Implantation of the Melody transcatheter pulmonary valve in patients with a dysfunctional right ventricular </text>
<text top="309" left="108" width="584" height="19" font="4">outflow tract conduit early results from the U.S. clinical trial. J Am Coll Cardiol. 2009;54:1722-9. </text>
<text top="328" left="108" width="30" height="19" font="4">572. </text>
<text top="328" left="162" width="919" height="19" font="4">Nordmeyer J, Lurz P, Khambadkone S, et al. Pre-stenting with a bare metal stent before percutaneous pulmonary valve implantation: acute and 1-year </text>
<text top="346" left="108" width="212" height="19" font="4">outcomes. Heart. 2011;97:118-23. </text>
<text top="364" left="108" width="30" height="19" font="4">573. </text>
<text top="364" left="162" width="878" height="19" font="4">Lurz P, Coats L, Khambadkone S, et al. Percutaneous pulmonary valve implantation: impact of evolving technology and learning curve on clinical </text>
<text top="383" left="108" width="253" height="19" font="4">outcome. Circulation. 2008;117:1964-72. </text>
<text top="401" left="108" width="30" height="19" font="4">574. </text>
<text top="401" left="162" width="899" height="19" font="4">Nordmeyer J, Khambadkone S, Coats L, et al. Risk stratification, systematic classification, and anticipatory management strategies for stent fracture </text>
<text top="419" left="108" width="494" height="19" font="4">after percutaneous pulmonary valve implantation. Circulation. 2007;115:1392-7. </text>
<text top="438" left="108" width="30" height="19" font="4">575. </text>
<text top="438" left="162" width="921" height="19" font="4">Coats L, Khambadkone S, Derrick G, et al. Physiological and clinical consequences of relief of right ventricular outflow tract obstruction late after repair </text>
<text top="456" left="108" width="362" height="19" font="4">of congenital heart defects. Circulation. 2006;113:2037-44. </text>
<text top="474" left="108" width="30" height="19" font="4">576. </text>
<text top="474" left="162" width="902" height="19" font="4">Coats L, Tsang V, Khambadkone S, et al. The potential impact of percutaneous pulmonary valve stent implantation on right ventricular outflow tract </text>
<text top="493" left="108" width="352" height="19" font="4">re-intervention. Eur J Cardiothorac Surg. 2005;27:536-43. </text>
<text top="511" left="108" width="30" height="19" font="4">577. </text>
<text top="511" left="162" width="886" height="19" font="4">Brown JW, Ruzmetov M, Rodefeld MD, et al. Right ventricular outflow tract reconstruction in Ross patients: does the homograft fare better? Ann </text>
<text top="529" left="108" width="191" height="19" font="4">Thorac Surg. 2008;86:1607-12. </text>
<text top="547" left="108" width="30" height="19" font="4">578. </text>
<text top="547" left="162" width="894" height="19" font="4">Niemantsverdriet MBA, Ottenkamp J, Gauvreau K, et al. Determinants of right ventricular outflow tract conduit longevity: a multinational analysis. </text>
<text top="566" left="108" width="217" height="19" font="4">Congenit Heart Dis. 2008;3:176-84. </text>
<text top="584" left="108" width="30" height="19" font="4">579. </text>
<text top="584" left="162" width="904" height="19" font="4">Fraisse A, Assaidi A, Mauri L, et al. Coronary artery compression during intention to treat right ventricle outflow with percutaneous pulmonary valve </text>
<text top="602" left="108" width="575" height="19" font="4">implantation: incidence, diagnosis, and outcome. Catheter Cardiovasc Interv. 2014;83:E260-8. </text>
<text top="621" left="108" width="30" height="19" font="4">580. </text>
<text top="621" left="162" width="868" height="19" font="4">Bauer BS, Zachariah S, Levi D, et al. Evaluation of peak pressure gradients in patients after Melody valve implantation: a comparison of cardiac </text>
<text top="639" left="108" width="464" height="19" font="4">catheterization and doppler echocardiography. Echocardiography. 2015;32: </text>
<text top="657" left="108" width="30" height="19" font="4">581. </text>
<text top="657" left="162" width="836" height="19" font="4">Hesslein PS, Gutgesell HP, Gillette PC, et al. Exercise assessment of sinoatrial node function following the Mustard operation. Am Heart J. </text>
<text top="676" left="108" width="103" height="19" font="4">1982;103:351-7. </text>
<text top="694" left="108" width="30" height="19" font="4">582. </text>
<text top="694" left="162" width="849" height="19" font="4">Flinn CJ, Wolff GS, Dick M, et al. Cardiac rhythm after the Mustard operation for complete transposition of the great arteries. N Engl J Med. </text>
<text top="712" left="108" width="111" height="19" font="4">1984;310:1635-8. </text>
<text top="730" left="108" width="30" height="19" font="4">583. </text>
<text top="730" left="162" width="907" height="19" font="4">Duster MC, Bink-Boelkens MT, Wampler D, et al. Long-term follow-up of dysrhythmias following the Mustard procedure. Am Heart J. 1985;109:1323-</text>
<text top="749" left="108" width="15" height="19" font="4">6. </text>
<text top="767" left="108" width="30" height="19" font="4">584. </text>
<text top="767" left="162" width="897" height="19" font="4">Kramer HH, Rammos S, Krogmann O, et al. Cardiac rhythm after Mustard repair and after arterial switch operation for complete transposition. Int J </text>
<text top="786" left="108" width="139" height="19" font="4">Cardiol. 1991;32:5-12. </text>
</page>
<page number="241" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 241 </text>
<text top="108" left="108" width="30" height="19" font="4">585. </text>
<text top="108" left="162" width="907" height="19" font="4">Hucin B, Voriskova M, Hruda J, et al. Late complications and quality of life after atrial correction of transposition of the great arteries in 12 to 18 year </text>
<text top="126" left="108" width="329" height="19" font="4">follow-up. J Cardiovasc Surg (Torino ). 2000;41:233-9. </text>
<text top="145" left="108" width="30" height="19" font="4">586. </text>
<text top="145" left="162" width="919" height="19" font="4">Khairy P, Landzberg MJ, Lambert J, et al. Long-term outcomes after the atrial switch for surgical correction of transposition: a meta-analysis comparing </text>
<text top="163" left="108" width="429" height="19" font="4">the Mustard and Senning procedures. Cardiol Young. 2004;14:284-92. </text>
<text top="181" left="108" width="30" height="19" font="4">587. </text>
<text top="181" left="162" width="882" height="19" font="4">Diller G-P, Okonko DO, Uebing A, et al. Impaired heart rate response to exercise in adult patients with a systemic right ventricle or univentricular </text>
<text top="199" left="108" width="692" height="19" font="4">circulation: prevalence, relation to exercise, and potential therapeutic implications. Int J Cardiol. 2009;134:59-66. </text>
<text top="218" left="108" width="30" height="19" font="4">588. </text>
<text top="218" left="162" width="860" height="19" font="4">Champsaur GL, Sokol DM, Trusler GA, et al. Repair of transposition of the great arteries in 123 pediatric patients: early and long-term results. </text>
<text top="236" left="108" width="184" height="19" font="4">Circulation. 1973;47:1032-41. </text>
<text top="255" left="108" width="30" height="19" font="4">589. </text>
<text top="255" left="162" width="793" height="19" font="4">Thornback P, Fowler RS. Sudden unexpected death in children with congenital heart disease. Can Med Assoc J. 1975;113:745-6, 8. </text>
<text top="273" left="108" width="30" height="19" font="4">590. </text>
<text top="273" left="162" width="903" height="19" font="4">Vetter VL, Tanner CS, Horowitz LN. Electrophysiologic consequences of the Mustard repair of d-transposition of the great arteries. J Am Coll Cardiol. </text>
<text top="291" left="108" width="111" height="19" font="4">1987;10:1265-73. </text>
<text top="309" left="108" width="30" height="19" font="4">591. </text>
<text top="309" left="162" width="859" height="19" font="4">Hayes CJ, Gersony WM. Arrhythmias after the Mustard operation for transposition of the great arteries: a long-term study. J Am Coll Cardiol. </text>
<text top="328" left="108" width="88" height="19" font="4">1986;7:133-7. </text>
<text top="346" left="108" width="30" height="19" font="4">592. </text>
<text top="346" left="162" width="914" height="19" font="4">Deanfield J, Camm J, Macartney F, et al. Arrhythmia and late mortality after Mustard and Senning operation for transposition of the great arteries. An </text>
<text top="364" left="108" width="441" height="19" font="4">eight-year prospective study. J Thorac Cardiovasc Surg. 1988;96:569-76. </text>
<text top="383" left="108" width="30" height="19" font="4">593. </text>
<text top="383" left="162" width="904" height="19" font="4">Janousek J, Paul T, Luhmer I, et al. Atrial baffle procedures for complete transposition of the great arteries: natural course of sinus node dysfunction </text>
<text top="401" left="108" width="477" height="19" font="4">and risk factors for dysrhythmias and sudden death. Z Kardiol. 1994;83:933-8. </text>
<text top="419" left="108" width="30" height="19" font="4">594. </text>
<text top="419" left="162" width="898" height="19" font="4">Helbing WA, Hansen B, Ottenkamp J, et al. Long-term results of atrial correction for transposition of the great arteries. Comparison of Mustard and </text>
<text top="438" left="108" width="393" height="19" font="4">Senning operations. J Thorac Cardiovasc Surg. 1994;108:363-72. </text>
<text top="456" left="108" width="30" height="19" font="4">595. </text>
<text top="456" left="162" width="894" height="19" font="4">Gelatt M, Hamilton RM, McCrindle BW, et al. Arrhythmia and mortality after the Mustard procedure: a 30-year single-center experience. J Am Coll </text>
<text top="474" left="108" width="161" height="19" font="4">Cardiol. 1997;29:194-201. </text>
<text top="493" left="108" width="30" height="19" font="4">596. </text>
<text top="493" left="162" width="902" height="19" font="4">Puley G, Siu S, Connelly M, et al. Arrhythmia and survival in patients &gt;18 years of age after the mustard procedure for complete transposition of the </text>
<text top="511" left="108" width="275" height="19" font="4">great arteries. Am J Cardiol. 1999;83:1080-4. </text>
<text top="529" left="108" width="30" height="19" font="4">597. </text>
<text top="529" left="162" width="889" height="19" font="4">Sun ZH, Happonen JM, Bennhagen R, et al. Increased QT dispersion and loss of sinus rhythm as risk factors for late sudden death after Mustard or </text>
<text top="547" left="108" width="544" height="19" font="4">Senning procedures for transposition of the great arteries. Am J Cardiol. 2004;94:138-41. </text>
<text top="566" left="108" width="30" height="19" font="4">598. </text>
<text top="566" left="162" width="886" height="19" font="4">Khairy P, Harris L, Landzberg MJ, et al. Sudden death and defibrillators in transposition of the great arteries with intra-atrial baffles: a multicenter </text>
<text top="584" left="108" width="310" height="19" font="4">study. Circ Arrhythm Electrophysiol. 2008;1:250-7. </text>
<text top="602" left="108" width="30" height="19" font="4">599. </text>
<text top="602" left="162" width="861" height="19" font="4">Van Hare GF, Lesh MD, Ross BA, et al. Mapping and radiofrequency ablation of intraatrial reentrant tachycardia after the Senning or Mustard </text>
<text top="621" left="108" width="483" height="19" font="4">procedure for transposition ofthe great arteries. Am J Cardiol. 1996;77:985-91. </text>
<text top="639" left="108" width="30" height="19" font="4">600. </text>
<text top="639" left="162" width="896" height="19" font="4">Kanter RJ, Papagiannis J, Carboni MP, et al. Radiofrequency catheter ablation of supraventricular tachycardia substrates after mustard and senning </text>
<text top="657" left="108" width="528" height="19" font="4">operations for d-transposition of the great arteries. J Am Coll Cardiol. 2000;35:428-41. </text>
<text top="676" left="108" width="30" height="19" font="4">601. </text>
<text top="676" left="162" width="888" height="19" font="4">Kriebel T, Tebbenjohanns J, Janousek J, et al. Intraatrial reentrant tachycardias in patients after atrial switch procedures for d-transposition of the </text>
<text top="694" left="108" width="972" height="19" font="4">great arteries Endocardial mapping and radiofrequency catheter ablation primarily targeting protected areas of atrial tissue within the systemic venous atrium. </text>
<text top="712" left="108" width="164" height="19" font="4">Z Kardiol. 2002;91:806-17. </text>
<text top="730" left="108" width="30" height="19" font="4">602. </text>
<text top="730" left="162" width="892" height="19" font="4">Zrenner B, Dong J, Schreieck J, et al. Delineation of intra-atrial reentrant tachycardia circuits after mustard operation for transposition of the great </text>
<text top="749" left="108" width="740" height="19" font="4">arteries using biatrial electroanatomic mapping and entrainment mapping. J Cardiovasc Electrophysiol. 2003;14:1302-10. </text>
<text top="767" left="108" width="30" height="19" font="4">603. </text>
<text top="767" left="162" width="867" height="19" font="4">Wu J, Deisenhofer I, Ammar S, et al. Acute and long-term outcome after catheter ablation of supraventricular tachycardia in patients after the </text>
<text top="786" left="108" width="603" height="19" font="4">Mustard or Senning operation for D-transposition of the great arteries. Europace. 2013;15:886-91. </text>
</page>
<page number="242" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 242 </text>
<text top="108" left="108" width="30" height="19" font="4">604. </text>
<text top="108" left="162" width="907" height="19" font="4">Correa R, Walsh EP, Alexander ME, et al. Transbaffle mapping and ablation for atrial tachycardias after mustard, senning, or Fontan operations. J Am </text>
<text top="126" left="108" width="186" height="19" font="4">Heart Assoc. 2013;2:e000325. </text>
<text top="145" left="108" width="30" height="19" font="4">605. </text>
<text top="145" left="162" width="907" height="19" font="4">Giardini A, Hager A, Lammers AE, et al. Ventilatory efficiency and aerobic capacity predict event-free survival in adults with atrial repair for complete </text>
<text top="163" left="108" width="433" height="19" font="4">transposition of the great arteries. J Am Coll Cardiol. 2009;53:1548-55. </text>
<text top="181" left="108" width="30" height="19" font="4">606. </text>
<text top="181" left="162" width="913" height="19" font="4">Plymen CM, Hughes ML, Picaut N, et al. The relationship of systemic right ventricular function to ECG parameters and NT-proBNP levels in adults with </text>
<text top="199" left="108" width="598" height="19" font="4">transposition of the great arteries late after Senning or Mustard surgery. Heart. 2010;96:1569-73. </text>
<text top="218" left="108" width="30" height="19" font="4">607. </text>
<text top="218" left="162" width="919" height="19" font="4">Westhoff-Bleck M, Podewski E, Tutarel O, et al. Prognostic value of NT-proBNP in patients with systemic morphological right ventricles: a single-centre </text>
<text top="236" left="108" width="256" height="19" font="4">experience. Int J Cardiol. 2013;169:433-8. </text>
<text top="255" left="108" width="30" height="19" font="4">608. </text>
<text top="255" left="162" width="879" height="19" font="4">Diller G-P, Radojevic J, Kempny A, et al. Systemic right ventricular longitudinal strain is reduced in adults with transposition of the great arteries, </text>
<text top="273" left="108" width="702" height="19" font="4">relates to subpulmonary ventricular function, and predicts adverse clinical outcome. Am Heart J. 2012;163:859-66. </text>
<text top="291" left="108" width="30" height="19" font="4">609. </text>
<text top="291" left="162" width="906" height="19" font="4">Hoffman P, Szymanski P, Lubiszewska B, et al. Echocardiographic evaluation of the systemic ventricle after atrial switch procedure. The usefulness of </text>
<text top="309" left="108" width="278" height="19" font="4">subcostal imaging. Cardiol J. 2008;15:156-61. </text>
<text top="328" left="108" width="30" height="19" font="4">610. </text>
<text top="328" left="162" width="911" height="19" font="4">Khattab K, Schmidheiny P, Wustmann K, et al. Echocardiogram versus cardiac magnetic resonance imaging for assessing systolic function of subaortic </text>
<text top="346" left="108" width="841" height="19" font="4">right ventricle in adults with complete transposition of great arteries and previous atrial switch operation. Am J Cardiol. 2013;111:908-13. </text>
<text top="364" left="108" width="30" height="19" font="4">611. </text>
<text top="364" left="162" width="846" height="19" font="4">Poerner TC, Goebel B, Figulla HR, et al. Diastolic biventricular impairment at long-term follow-up after atrial switch operation for complete </text>
<text top="383" left="108" width="785" height="19" font="4">transposition of the great arteries: an exercise tissue Doppler echocardiography study. J Am Soc Echocardiogr. 2007;20:1285-93. </text>
<text top="401" left="108" width="30" height="19" font="4">612. </text>
<text top="401" left="162" width="910" height="19" font="4">Winter MM, Bernink FJ, Groenink M, et al. Evaluating the systemic right ventricle by CMR: the importance of consistent and reproducible delineation </text>
<text top="419" left="108" width="319" height="19" font="4">of the cavity. J Cardiovasc Magn Reson. 2008;10:40. </text>
<text top="438" left="108" width="30" height="19" font="4">613. </text>
<text top="438" left="162" width="877" height="19" font="4">Hill KD, Fleming G, Curt FJ, et al. Percutaneous interventions in high-risk patients following Mustard repair of transposition of the great arteries. </text>
<text top="456" left="108" width="273" height="19" font="4">Catheter Cardiovasc Interv. 2012;80:905-14. </text>
<text top="474" left="108" width="30" height="19" font="4">614. </text>
<text top="474" left="162" width="910" height="19" font="4">Josephson CB, Howlett JG, Jackson SD, et al. A case series of systemic right ventricular dysfunction post atrial switch for simple D-transposition of the </text>
<text top="493" left="108" width="457" height="19" font="4">great arteries: the impact of beta-blockade. Can J Cardiol. 2006;22:769-72. </text>
<text top="511" left="108" width="30" height="19" font="4">615. </text>
<text top="511" left="162" width="917" height="19" font="4">Khairy P, Landzberg MJ, Gatzoulis MA, et al. Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts: a multicenter </text>
<text top="529" left="108" width="225" height="19" font="4">study. Circulation. 2006;113:2391-7. </text>
<text top="547" left="108" width="30" height="19" font="4">616. </text>
<text top="547" left="162" width="888" height="19" font="4">Di Donato RM, Wernovsky G, Walsh EP, et al. Results of the arterial switch operation for transposition of the great arteries with ventricular septal </text>
<text top="566" left="108" width="560" height="19" font="4">defect. Surgical considerations and midterm follow-up data. Circulation. 1989;80:1689-705. </text>
<text top="584" left="108" width="30" height="19" font="4">617. </text>
<text top="584" left="162" width="920" height="19" font="4">El-Segaier M, Lundin A, Hochbergs P, et al. Late coronary complications after arterial switch operation and their treatment. Catheter Cardiovasc Interv. </text>
<text top="602" left="108" width="111" height="19" font="4">2010;76:1027-32. </text>
<text top="621" left="108" width="30" height="19" font="4">618. </text>
<text top="621" left="162" width="850" height="19" font="4">Khairy P, Clair M, Fernandes SM, et al. Cardiovascular outcomes after the arterial switch operation for D-transposition of the great arteries. </text>
<text top="639" left="108" width="176" height="19" font="4">Circulation. 2013;127:331-9. </text>
<text top="657" left="108" width="30" height="19" font="4">619. </text>
<text top="657" left="162" width="874" height="19" font="4">Kim H, Sung SC, Kim SH, et al. Arterial switch operation in patients with intramural coronary artery: early and mid-term results. Korean J Thorac </text>
<text top="676" left="108" width="207" height="19" font="4">Cardiovasc Surg. 2011;44:115-22. </text>
<text top="694" left="108" width="30" height="19" font="4">620. </text>
<text top="694" left="162" width="814" height="19" font="4">Lalezari S, Bruggemans EF, Blom NA, et al. Thirty-year experience with the arterial switch operation. Ann Thorac Surg. 2011;92:973-9. </text>
<text top="712" left="108" width="30" height="19" font="4">621. </text>
<text top="712" left="162" width="861" height="19" font="4">Legendre A, Losay J, Touchot-Koné A, et al. Coronary events after arterial switch operation for transposition of the great arteries. Circulation. </text>
<text top="730" left="108" width="175" height="19" font="4">2003;108 (suppl 1):II186-90. </text>
<text top="749" left="108" width="30" height="19" font="4">622. </text>
<text top="749" left="162" width="895" height="19" font="4">Losay J, Planche C, Gerardin B, et al. Midterm surgical results of arterial switch operation for transposition of the great arteries with intact septum. </text>
<text top="767" left="108" width="189" height="19" font="4">Circulation. 1990;82:IV146-50. </text>
</page>
<page number="243" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 243 </text>
<text top="108" left="108" width="30" height="19" font="4">623. </text>
<text top="108" left="162" width="859" height="19" font="4">Oda S, Nakano T, Sugiura J, et al. Twenty-eight years’ experience of arterial switch operation for transposition of the great arteries in a single </text>
<text top="126" left="108" width="315" height="19" font="4">institution. Eur J Cardiothorac Surg. 2012;42:674-9. </text>
<text top="145" left="108" width="30" height="19" font="4">624. </text>
<text top="145" left="162" width="913" height="19" font="4">Ou P, Khraiche D, Celermajer DS, et al. Mechanisms of coronary complications after the arterial switch for transposition of the great arteries. J Thorac </text>
<text top="163" left="108" width="215" height="19" font="4">Cardiovasc Surg. 2013;145:1263-9. </text>
<text top="181" left="108" width="30" height="19" font="4">625. </text>
<text top="181" left="162" width="525" height="19" font="4">Planche C, Lacour-Gayet F, Serraf A. Arterial switch. Pediatr Cardiol. 1998;19:297-307. </text>
<text top="199" left="108" width="30" height="19" font="4">626. </text>
<text top="199" left="162" width="847" height="19" font="4">Popov AF, Tirilomis T, Giesler M, et al. Midterm results after arterial switch operation for transposition of the great arteries: a single centre </text>
<text top="218" left="108" width="268" height="19" font="4">experience. J Cardiothorac Surg. 2012;7:83. </text>
<text top="236" left="108" width="30" height="19" font="4">627. </text>
<text top="236" left="162" width="805" height="19" font="4">Raju V, Burkhart HM, Durham LAr, et al. Reoperation after arterial switch: a 27-year experience. Ann Thorac Surg. 2013;95:2105-12. </text>
<text top="255" left="108" width="30" height="19" font="4">628. </text>
<text top="255" left="162" width="897" height="19" font="4">Serraf A, Bruniaux J, Lacour-Gayet F, et al. Anatomic correction of transposition of the great arteries with ventricular septal defect. Experience with </text>
<text top="273" left="108" width="326" height="19" font="4">118 cases. J Thorac Cardiovasc Surg. 1991;102:140-7. </text>
<text top="291" left="108" width="30" height="19" font="4">629. </text>
<text top="291" left="162" width="846" height="19" font="4">Soszyn N, Fricke TA, Wheaton GR, et al. Outcomes of the arterial switch operation in patients with Taussig-Bing anomaly. Ann Thorac Surg. </text>
<text top="309" left="108" width="96" height="19" font="4">2011;92:673-9. </text>
<text top="328" left="108" width="30" height="19" font="4">630. </text>
<text top="328" left="162" width="723" height="19" font="4">Stoica S, Carpenter E, Campbell D, et al. Morbidity of the arterial switch operation. Ann Thorac Surg. 2012;93:1977-83. </text>
<text top="346" left="108" width="30" height="19" font="4">631. </text>
<text top="346" left="162" width="838" height="19" font="4">Thrupp SF, Gentles TL, Kerr AR, et al. Arterial switch operation: early and late outcome for intramural coronary arteries. Ann Thorac Surg. </text>
<text top="364" left="108" width="111" height="19" font="4">2012;94:2084-90. </text>
<text top="383" left="108" width="30" height="19" font="4">632. </text>
<text top="383" left="162" width="681" height="19" font="4">Vouhe PR. Arterial switch operation: is the glass half full or half empty? Eur J Cardiothorac Surg. 2013;43:334-5. </text>
<text top="401" left="108" width="30" height="19" font="4">633. </text>
<text top="401" left="162" width="904" height="19" font="4">Delmo Walter EM, Huebler M, Alexi-Meshkishvili V, et al. Fate of the aortic valve following the arterial switch operation. J Card Surg. 2010;25:730-6. </text>
<text top="419" left="108" width="30" height="19" font="4">634. </text>
<text top="419" left="162" width="850" height="19" font="4">Cui B, Li S, Yan J, et al. The results of a two-stage double switch operation for congenital corrected transposition of the great arteries with a </text>
<text top="438" left="108" width="573" height="19" font="4">deconditioned morphologically left ventricle. Interact Cardiovasc Thorac Surg. 2014;19:921-5. </text>
<text top="456" left="108" width="30" height="19" font="4">635. </text>
<text top="456" left="162" width="918" height="19" font="4">Ma K, Gao H, Hua Z, et al. Palliative pulmonary artery banding versus anatomic correction for congenitally corrected transposition of the great arteries </text>
<text top="474" left="108" width="771" height="19" font="4">with regressed morphologic left ventricle: long-term results from a single center. J Thorac Cardiovasc Surg. 2014;148:1566-71. </text>
<text top="493" left="108" width="30" height="19" font="4">636. </text>
<text top="493" left="162" width="874" height="19" font="4">Myers PO, Bautista-Hernandez V, Baird CW, et al. Tricuspid regurgitation or Ebsteinoid dysplasia of the tricuspid valve in congenitally corrected </text>
<text top="511" left="108" width="638" height="19" font="4">transposition: is valvuloplasty necessary at anatomic repair? J Thorac Cardiovasc Surg. 2014;147:576-80. </text>
<text top="529" left="108" width="30" height="19" font="4">637. </text>
<text top="529" left="162" width="914" height="19" font="4">Bautista-Hernandez V, Myers PO, Cecchin F, et al. Late left ventricular dysfunction after anatomic repair of congenitally corrected transposition of the </text>
<text top="547" left="108" width="350" height="19" font="4">great arteries. J Thorac Cardiovasc Surg. 2014;148:254-8. </text>
<text top="566" left="108" width="30" height="19" font="4">638. </text>
<text top="566" left="162" width="887" height="19" font="4">van der Bom T, Winter MM, Groenink M, et al. Right ventricular end-diastolic volume combined with peak systolic blood pressure during exercise </text>
<text top="584" left="108" width="720" height="19" font="4">identifies patients at risk for complications in adults with a systemic right ventricle. J Am Coll Cardiol. 2013;62:926-36. </text>
<text top="602" left="108" width="30" height="19" font="4">639. </text>
<text top="602" left="162" width="900" height="19" font="4">Book W, McConnell M, Oster M, et al. Predicting functional capacity in patients with a systemic right ventricle: subjective patient self-assessment is </text>
<text top="621" left="108" width="716" height="19" font="4">better than B-type natriuretic peptide levels and right ventricular systolic function. Congenit Heart Dis. 2013;8:550-5. </text>
<text top="639" left="108" width="30" height="19" font="4">640. </text>
<text top="639" left="162" width="897" height="19" font="4">Mongeon F-P, Connolly HM, Dearani JA, et al. Congenitally corrected transposition of the great arteries ventricular function at the time of systemic </text>
<text top="657" left="108" width="678" height="19" font="4">atrioventricular valve replacement predicts long-term ventricular function. J Am Coll Cardiol. 2011;57:2008-17. </text>
<text top="676" left="108" width="30" height="19" font="4">641. </text>
<text top="676" left="162" width="888" height="19" font="4">Graham TP, Jr, Bernard YD, Mellen BG, et al. Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional </text>
<text top="694" left="108" width="253" height="19" font="4">study. J Am Coll Cardiol. 2000;36:255-61. </text>
<text top="712" left="108" width="30" height="19" font="4">642. </text>
<text top="712" left="162" width="880" height="19" font="4">Prieto LR, Hordof AJ, Secic M, et al. Progressive tricuspid valve disease in patients with congenitally corrected transposition of the great arteries. </text>
<text top="730" left="108" width="191" height="19" font="4">Circulation. 1998;98:997-1005. </text>
<text top="749" left="108" width="30" height="19" font="4">643. </text>
<text top="749" left="162" width="901" height="19" font="4">Lewis M, Ginns J, Rosenbaum M. Is systemic right ventricular function by cardiac MRI related to the degree of tricuspid regurgitation in congenitally </text>
<text top="767" left="108" width="461" height="19" font="4">corrected transposition of the great arteries? Int J Cardiol. 2014;174:586-9. </text>
</page>
<page number="244" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 244 </text>
<text top="108" left="108" width="30" height="19" font="4">644. </text>
<text top="108" left="162" width="850" height="19" font="4">Grewal J, Crean A, Garceau P, et al. Subaortic right ventricular characteristics and relationship to exercise capacity in congenitally corrected </text>
<text top="126" left="108" width="468" height="19" font="4">transposition of the great arteries. J Am Soc Echocardiogr. 2012;25:1215-21. </text>
<text top="145" left="108" width="30" height="19" font="4">645. </text>
<text top="145" left="162" width="913" height="19" font="4">Yeo WT, Jarman JW, Li W, et al. Adverse impact of chronic subpulmonary left ventricular pacing on systemic right ventricular function in patients with </text>
<text top="163" left="108" width="542" height="19" font="4">congenitally corrected transposition of the great arteries. Int J Cardiol. 2014;171:184-91. </text>
<text top="181" left="108" width="30" height="19" font="4">646. </text>
<text top="181" left="162" width="862" height="19" font="4">Winter MM, van der Bom T, de Vries LCS, et al. Exercise training improves exercise capacity in adult patients with a systemic right ventricle: a </text>
<text top="199" left="108" width="337" height="19" font="4">randomized clinical trial. Eur Heart J. 2012;33:1378-85. </text>
<text top="218" left="108" width="30" height="19" font="4">647. </text>
<text top="218" left="162" width="886" height="19" font="4">Huhta JC, Maloney JD, Ritter DG, et al. Complete atrioventricular block in patients with atrioventricular discordance. Circulation. 1983;67:1374-7. </text>
<text top="236" left="108" width="30" height="19" font="4">648. </text>
<text top="236" left="162" width="616" height="19" font="4">Green CE. Plain chest radiography of congenital heart disease in adults. Cardiol Clin. 1983;1:685-709. </text>
<text top="255" left="108" width="30" height="19" font="4">649. </text>
<text top="255" left="162" width="919" height="19" font="4">Silverman NH, Gerlis LM, Horowitz ES, et al. Pathologic elucidation of the echocardiographic features of Ebstein’s malformation of the morphologically </text>
<text top="273" left="108" width="547" height="19" font="4">tricuspid valve in discordant atrioventricular connections. Am J Cardiol. 1995;76:1277-83. </text>
<text top="291" left="108" width="30" height="19" font="4">650. </text>
<text top="291" left="162" width="901" height="19" font="4">Macdonald ST, Carminati M, Chessa M. Managing adults with congenital heart disease in the catheterization laboratory: state of the art. Expert Rev </text>
<text top="309" left="108" width="208" height="19" font="4">Cardiovasc Ther. 2010;8:1741-52. </text>
<text top="328" left="108" width="30" height="19" font="4">651. </text>
<text top="328" left="162" width="865" height="19" font="4">Buber J, McElhinney DB, Valente AM, et al. Tricuspid valve regurgitation in congenitally corrected transposition of the great arteries and a left </text>
<text top="346" left="108" width="454" height="19" font="4">ventricle to pulmonary artery conduit. Ann Thorac Surg. 2015;99:1348-56. </text>
<text top="364" left="108" width="30" height="19" font="4">652. </text>
<text top="364" left="162" width="904" height="19" font="4">Caso P, Ascione L, Lange A, et al. Diagnostic value of transesophageal echocardiography in the assessment of congenitally corrected transposition of </text>
<text top="383" left="108" width="393" height="19" font="4">the great arteries in adult patients. Am Heart J. 1998;135:43-50. </text>
<text top="401" left="108" width="30" height="19" font="4">653. </text>
<text top="401" left="162" width="919" height="19" font="4">Hebert A, Mikkelsen UR, Thilen U, et al. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment </text>
<text top="419" left="108" width="966" height="19" font="4">With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study. </text>
<text top="438" left="108" width="191" height="19" font="4">Circulation. 2014;130:2021-30. </text>
<text top="456" left="108" width="30" height="19" font="4">654. </text>
<text top="456" left="162" width="800" height="19" font="4">Ovaert C, Thijs D, Dewolf D, et al. The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young. 2009;19:331-9. </text>
<text top="474" left="108" width="30" height="19" font="4">655. </text>
<text top="474" left="162" width="905" height="19" font="4">Bowater SE, Weaver RA, Thorne SA, et al. The safety and effects of bosentan in patients with a Fontan circulation. Congenit Heart Dis. 2012;7:243-9. </text>
<text top="493" left="108" width="30" height="19" font="4">656. </text>
<text top="493" left="162" width="813" height="19" font="4">Derk G, Houser L, Miner P, et al. Efficacy of endothelin blockade in adults with Fontan physiology. Congenit Heart Dis. 2015;10:E11-6. </text>
<text top="511" left="108" width="30" height="19" font="4">657. </text>
<text top="511" left="162" width="904" height="19" font="4">Schuuring MJ, Vis JC, van Dijk APJ, et al. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. </text>
<text top="529" left="108" width="194" height="19" font="4">Eur J Heart Fail. 2013;15:690-8. </text>
<text top="547" left="108" width="30" height="19" font="4">658. </text>
<text top="547" left="162" width="876" height="19" font="4">Brassard P, Poirier P, Martin J, et al. Impact of exercise training on muscle function and ergoreflex in Fontan patients: a pilot study. Int J Cardiol. </text>
<text top="566" left="108" width="103" height="19" font="4">2006;107:85-94. </text>
<text top="584" left="108" width="30" height="19" font="4">659. </text>
<text top="584" left="162" width="907" height="19" font="4">Inai K, Saita Y, Takeda S, et al. Skeletal muscle hemodynamics and endothelial function in patients after Fontan operation. Am J Cardiol. 2004;93:792-</text>
<text top="602" left="108" width="15" height="19" font="4">7. </text>
<text top="621" left="108" width="30" height="19" font="4">660. </text>
<text top="621" left="162" width="731" height="19" font="4">Kiesewetter CH, Sheron N, Vettukattill JJ, et al. Hepatic changes in the failing Fontan circulation. Heart. 2007;93:579-84. </text>
<text top="639" left="108" width="30" height="19" font="4">661. </text>
<text top="639" left="162" width="920" height="19" font="4">Potter BJ, Leong-Sit P, Fernandes SM, et al. Effect of aspirin and warfarin therapy on thromboembolic events in patients with univentricular hearts and </text>
<text top="657" left="108" width="300" height="19" font="4">Fontan palliation. Int J Cardiol. 2013;168:3940-3. </text>
<text top="676" left="108" width="30" height="19" font="4">662. </text>
<text top="676" left="162" width="863" height="19" font="4">Aboulhosn J, Williams R, Shivkumar K, et al. Arrhythmia recurrence in adult patients with single ventricle physiology following surgical Fontan </text>
<text top="694" left="108" width="284" height="19" font="4">conversion. Congenit Heart Dis. 2010;5:430-4. </text>
<text top="712" left="108" width="30" height="19" font="4">663. </text>
<text top="712" left="162" width="803" height="19" font="4">Elder RW, McCabe NM, Veledar E, et al. Risk factors for major adverse events late after Fontan palliation. Congenit Heart Dis. 2014; </text>
<text top="730" left="108" width="30" height="19" font="4">664. </text>
<text top="730" left="162" width="778" height="19" font="4">Said SM, Burkhart HM, Schaff HV, et al. Fontan conversion: identifying the high-risk patient. Ann Thorac Surg. 2014;97:2115-21. </text>
<text top="749" left="108" width="30" height="19" font="4">665. </text>
<text top="749" left="162" width="852" height="19" font="4">Khairy P, Fernandes SM, Mayer JE, Jr, et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. </text>
<text top="767" left="108" width="176" height="19" font="4">Circulation. 2008;117:85-92. </text>
</page>
<page number="245" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 245 </text>
<text top="108" left="108" width="30" height="19" font="4">666. </text>
<text top="108" left="162" width="911" height="19" font="4">Mavroudis C, Deal BJ, Backer CL, et al. J. Maxwell Chamberlain Memorial Paper for congenital heart surgery. 111 Fontan conversions with arrhythmia </text>
<text top="126" left="108" width="463" height="19" font="4">surgery: surgical lessons and outcomes. Ann Thorac Surg. 2007;84:1457-65. </text>
<text top="145" left="108" width="30" height="19" font="4">667. </text>
<text top="145" left="162" width="874" height="19" font="4">Ono M, Boethig D, Goerler H, et al. Clinical outcome of patients 20 years after Fontan operation—effect of fenestration on late morbidity. Eur J </text>
<text top="163" left="108" width="213" height="19" font="4">Cardiothorac Surg. 2006;30:923-9. </text>
<text top="181" left="108" width="30" height="19" font="4">668. </text>
<text top="181" left="162" width="803" height="19" font="4">Kaulitz R, Ziemer G, Paul T, et al. Fontan-type procedures: residual lesions and late interventions. Ann Thorac Surg. 2002;74:778-85. </text>
<text top="199" left="108" width="30" height="19" font="4">669. </text>
<text top="199" left="162" width="859" height="19" font="4">Yeh T, Jr, Williams WG, McCrindle BW, et al. Equivalent survival following cavopulmonary shunt: with or without the Fontan procedure. Eur J </text>
<text top="218" left="108" width="213" height="19" font="4">Cardiothorac Surg. 1999;16:111-6. </text>
<text top="236" left="108" width="30" height="19" font="4">670. </text>
<text top="236" left="162" width="911" height="19" font="4">Takahashi K, Cecchin F, Fortescue E, et al. Permanent atrial pacing lead implant route after Fontan operation. Pacing Clin Electrophysiol. 2009;32:779-</text>
<text top="255" left="108" width="22" height="19" font="4">85. </text>
<text top="273" left="108" width="30" height="19" font="4">671. </text>
<text top="273" left="162" width="842" height="19" font="4">Dodge-Khatami A, Rahn M, Pretre R, et al. Dual chamber epicardial pacing for the failing atriopulmonary Fontan patient. Ann Thorac Surg. </text>
<text top="291" left="108" width="103" height="19" font="4">2005;80:1440-4. </text>
<text top="309" left="108" width="30" height="19" font="4">672. </text>
<text top="309" left="162" width="783" height="19" font="4">Hansky B, Blanz U, Peuster M, et al. Endocardial pacing after Fontan-type procedures. Pacing Clin Electrophysiol. 2005;28:140-8. </text>
<text top="328" left="108" width="30" height="19" font="4">673. </text>
<text top="328" left="162" width="862" height="19" font="4">Cohen MI, Vetter VL, Wernovsky G, et al. Epicardial pacemaker implantation and follow-up in patients with a single ventricle after the Fontan </text>
<text top="346" left="108" width="335" height="19" font="4">operation. J Thorac Cardiovasc Surg. 2001;121:804-11. </text>
<text top="364" left="108" width="30" height="19" font="4">674. </text>
<text top="364" left="162" width="846" height="19" font="4">Cohen MI, Wernovsky G, Vetter VL, et al. Sinus node function after a systematically staged Fontan procedure. Circulation. 1998;98:II352-8. </text>
<text top="383" left="108" width="30" height="19" font="4">675. </text>
<text top="383" left="162" width="862" height="19" font="4">Fishberger SB, Wernovsky G, Gentles TL, et al. Long-term outcome in patients with pacemakers following the Fontan operation. Am J Cardiol. </text>
<text top="401" left="108" width="96" height="19" font="4">1996;77:887-9. </text>
<text top="419" left="108" width="30" height="19" font="4">676. </text>
<text top="419" left="162" width="916" height="19" font="4">d’Udekem Y, Iyengar AJ, Galati JC, et al. Redefining expectations of long-term survival after the Fontan procedure: twenty-five years of follow-up from </text>
<text top="438" left="108" width="502" height="19" font="4">the entire population of Australia and New Zealand. Circulation. 2014;130:S32-S8. </text>
<text top="456" left="108" width="30" height="19" font="4">677. </text>
<text top="456" left="162" width="918" height="19" font="4">Abrams DJ, Earley MJ, Sporton SC, et al. Comparison of noncontact and electroanatomic mapping to identify scar and arrhythmia late after the Fontan </text>
<text top="474" left="108" width="262" height="19" font="4">procedure. Circulation. 2007;115:1738-46. </text>
<text top="493" left="108" width="30" height="19" font="4">678. </text>
<text top="493" left="162" width="813" height="19" font="4">Friedman RA, Will JC, Fenrich AL, et al. Atrioventricular junction ablation and pacemaker therapy in patients with drug-resistant atrial </text>
<text top="511" left="108" width="539" height="19" font="4">tachyarrhythmias after the Fontan operation. J Cardiovasc Electrophysiol. 2005;16:24-9. </text>
<text top="529" left="108" width="30" height="19" font="4">679. </text>
<text top="529" left="162" width="914" height="19" font="4">Wong T, Davlouros PA, Li W, et al. Mechano-electrical interaction late after Fontan operation: relation between P-wave duration and dispersion, right </text>
<text top="547" left="108" width="398" height="19" font="4">atrial size, and atrial arrhythmias. Circulation. 2004;109:2319-25. </text>
<text top="566" left="108" width="30" height="19" font="4">680. </text>
<text top="566" left="162" width="908" height="19" font="4">van den Bosch AE, Roos-Hesselink JW, van DR, et al. Long-term outcome and quality of life in adult patients after the Fontan operation. Am J Cardiol. </text>
<text top="584" left="108" width="103" height="19" font="4">2004;93:1141-5. </text>
<text top="602" left="108" width="30" height="19" font="4">681. </text>
<text top="602" left="162" width="898" height="19" font="4">Weipert J, Noebauer C, Schreiber C, et al. Occurrence and management of atrial arrhythmia after long-term Fontan circulation. J Thorac Cardiovasc </text>
<text top="621" left="108" width="145" height="19" font="4">Surg. 2004;127:457-64. </text>
<text top="639" left="108" width="30" height="19" font="4">682. </text>
<text top="639" left="162" width="870" height="19" font="4">Davos CH, Francis DP, Leenarts MF, et al. Global impairment of cardiac autonomic nervous activity late after the Fontan operation. Circulation. </text>
<text top="657" left="108" width="167" height="19" font="4">2003;108 Suppl 1:II180-II5. </text>
<text top="676" left="108" width="30" height="19" font="4">683. </text>
<text top="676" left="162" width="905" height="19" font="4">Ghai A, Harris L, Harrison DA, et al. Outcomes of late atrial tachyarrhythmias in adults after the Fontan operation. J Am Coll Cardiol. 2001;37:585-92. </text>
<text top="694" left="108" width="30" height="19" font="4">684. </text>
<text top="694" left="162" width="893" height="19" font="4">Tuzcu V, Ozkan B, Sullivan N, et al. P wave signal-averaged electrocardiogram as a new marker for atrial tachyarrhythmias in postoperative Fontan </text>
<text top="712" left="108" width="261" height="19" font="4">patients. J Am Coll Cardiol. 2000;36:602-7. </text>
<text top="730" left="108" width="30" height="19" font="4">685. </text>
<text top="730" left="162" width="912" height="19" font="4">Betts TR, Roberts PR, Allen SA, et al. Electrophysiological mapping and ablation of intra-atrial reentry tachycardia after Fontan surgery with the use of </text>
<text top="749" left="108" width="374" height="19" font="4">a noncontact mapping system. Circulation. 2000;102:419-25. </text>
<text top="767" left="108" width="30" height="19" font="4">686. </text>
<text top="767" left="162" width="897" height="19" font="4">Durongpisitkul K, Porter CJ, Cetta F, et al. Predictors of early- and late-onset supraventricular tachyarrhythmias after Fontan operation. Circulation. </text>
<text top="786" left="108" width="119" height="19" font="4">1998;98:1099-107. </text>
</page>
<page number="246" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 246 </text>
<text top="108" left="108" width="30" height="19" font="4">687. </text>
<text top="108" left="162" width="700" height="19" font="4">Backer CL, Russell HM, Pahl E, et al. Heart transplantation for the failing Fontan. Ann Thorac Surg. 2013;96:1413-9. </text>
<text top="126" left="108" width="30" height="19" font="4">688. </text>
<text top="126" left="162" width="876" height="19" font="4">Gatzoulis MA, Munk MD, Williams WG, et al. Definitive palliation with cavopulmonary or aortopulmonary shunts for adults with single ventricle </text>
<text top="145" left="108" width="202" height="19" font="4">physiology. Heart. 2000;83:51-7. </text>
<text top="163" left="108" width="30" height="19" font="4">689. </text>
<text top="163" left="162" width="882" height="19" font="4">Dulfer K, Duppen N, Blom NA, et al. Effects of exercise training on behavioral and emotional problems in adolescents with tetralogy of Fallot or a </text>
<text top="181" left="108" width="491" height="19" font="4">Fontan circulation: a randomized controlled trial. Int J Cardiol. 2014;172:e425-7. </text>
<text top="199" left="108" width="30" height="19" font="4">690. </text>
<text top="199" left="162" width="894" height="19" font="4">Gamba A, Merlo M, Fiocchi R, et al. Heart transplantation in patients with previous Fontan operations. J Thorac Cardiovasc Surg. 2004;127:555-62. </text>
<text top="218" left="108" width="30" height="19" font="4">691. </text>
<text top="218" left="162" width="908" height="19" font="4">Jayakumar KA, Addonizio LJ, Kichuk-Chrisant MR, et al. Cardiac transplantation after the Fontan or Glenn procedure. J Am Coll Cardiol. 2004;44:2065-</text>
<text top="236" left="108" width="22" height="19" font="4">72. </text>
<text top="255" left="108" width="30" height="19" font="4">692. </text>
<text top="255" left="162" width="889" height="19" font="4">Triedman JK, Alexander ME, Love BA, et al. Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-</text>
<text top="273" left="108" width="649" height="19" font="4">atrial re-entrant tachycardia in patients with congenital heart disease. J Am Coll Cardiol. 2002;39:1827-35. </text>
<text top="291" left="108" width="30" height="19" font="4">693. </text>
<text top="291" left="162" width="919" height="19" font="4">Yap S-C, Harris L, Silversides CK, et al. Outcome of intra-atrial re-entrant tachycardia catheter ablation in adults with congenital heart disease: negative </text>
<text top="309" left="108" width="475" height="19" font="4">impact of age and complex atrial surgery. J Am Coll Cardiol. 2010;56:1589-96. </text>
<text top="328" left="108" width="30" height="19" font="4">694. </text>
<text top="328" left="162" width="913" height="19" font="4">de Groot NMS, Atary JZ, Blom NA, et al. Long-term outcome after ablative therapy of postoperative atrial tachyarrhythmia in patients with congenital </text>
<text top="346" left="108" width="715" height="19" font="4">heart disease and characteristics of atrial tachyarrhythmia recurrences. Circ Arrhythm Electrophysiol. 2010;3:148-54. </text>
<text top="364" left="108" width="30" height="19" font="4">695. </text>
<text top="364" left="162" width="847" height="19" font="4">Barst RJ, Ivy DD, Foreman AJ, et al. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial </text>
<text top="383" left="108" width="449" height="19" font="4">hypertension (from the REVEAL Registry). Am J Cardiol. 2014;113:147-55. </text>
<text top="401" left="108" width="30" height="19" font="4">696. </text>
<text top="401" left="162" width="920" height="19" font="4">Duffels MGJ, Engelfriet PM, Berger RMF, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch </text>
<text top="419" left="108" width="251" height="19" font="4">registry. Int J Cardiol. 2007;120:198-204. </text>
<text top="438" left="108" width="30" height="19" font="4">697. </text>
<text top="438" left="162" width="906" height="19" font="4">Engelfriet PM, Duffels MGJ, Möller T, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult </text>
<text top="456" left="108" width="293" height="19" font="4">congenital heart disease. Heart. 2007;93:682-7. </text>
<text top="474" left="108" width="30" height="19" font="4">698. </text>
<text top="474" left="162" width="896" height="19" font="4">Gabriels C, De Meester P, Pasquet A, et al. A different view on predictors of pulmonary hypertension in secundum atrial septal defect. Int J Cardiol. </text>
<text top="493" left="108" width="111" height="19" font="4">2014;176:833-40. </text>
<text top="511" left="108" width="30" height="19" font="4">699. </text>
<text top="511" left="162" width="899" height="19" font="4">Manes A, Palazzini M, Leci E, et al. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a </text>
<text top="529" left="108" width="425" height="19" font="4">comparison between clinical subgroups. Eur Heart J. 2014;35:716-24. </text>
<text top="547" left="108" width="30" height="19" font="4">700. </text>
<text top="547" left="162" width="841" height="19" font="4">O’Donnell C, Ruygrok PN, Whyte K, et al. Progressive pulmonary hypertension post atrial septal defect device closure—early symptomatic </text>
<text top="566" left="108" width="445" height="19" font="4">improvement may not predict outcome. Heart Lung Circ. 2010;19:713-6. </text>
<text top="584" left="108" width="30" height="19" font="4">701. </text>
<text top="584" left="162" width="919" height="19" font="4">Van De Bruaene A, Delcroix M, Pasquet A, et al. The importance of pulmonary artery pressures on late atrial arrhythmia in transcatheter and surgically </text>
<text top="602" left="108" width="353" height="19" font="4">closed ASD type secundum. Int J Cardiol. 2011;152:192-5. </text>
<text top="621" left="108" width="30" height="19" font="4">702. </text>
<text top="621" left="162" width="857" height="19" font="4">Van De Bruaene A, Moons P, Belmans A, et al. Predictive model for late atrial arrhythmia after closure of an atrial septal defect. Int J Cardiol. </text>
<text top="639" left="108" width="111" height="19" font="4">2013;164:318-22. </text>
<text top="657" left="108" width="30" height="19" font="4">703. </text>
<text top="657" left="162" width="886" height="19" font="4">Balint OH, Samman A, Haberer K, et al. Outcomes in patients with pulmonary hypertension undergoing percutaneous atrial septal defect closure. </text>
<text top="676" left="108" width="152" height="19" font="4">Heart. 2008;94:1189-93. </text>
<text top="694" left="108" width="30" height="19" font="4">704. </text>
<text top="694" left="162" width="904" height="19" font="4">Balzer DT, Kort HW, Day RW, et al. Inhaled nitric oxide as a preoperative test (INOP Test I): the INOP Test Study Group. Circulation. 2002;106:I76-81. </text>
<text top="712" left="108" width="30" height="19" font="4">705. </text>
<text top="712" left="162" width="912" height="19" font="4">Berner M, Beghetti M, Spahr-Schopfer I, et al. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-</text>
<text top="730" left="108" width="570" height="19" font="4">standing pulmonary hypertension and congenital heart disease. Am J Cardiol. 1996;77:532-5. </text>
<text top="749" left="108" width="30" height="19" font="4">706. </text>
<text top="749" left="162" width="893" height="19" font="4">Gorenflo M, Gu H, Xu Z. Peri-operative pulmonary hypertension in paediatric patients: current strategies in children with congenital heart disease. </text>
<text top="767" left="108" width="168" height="19" font="4">Cardiology. 2010;116:10-7. </text>
</page>
<page number="247" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 247 </text>
<text top="108" left="108" width="30" height="19" font="4">707. </text>
<text top="108" left="162" width="916" height="19" font="4">Huang J-B, Liu Y-L, Yu C-T, et al. Lung biopsy findings in previously inoperable patients with severe pulmonary hypertension associated with congenital </text>
<text top="126" left="108" width="270" height="19" font="4">heart disease. Int J Cardiol. 2011;151:76-83. </text>
<text top="145" left="108" width="30" height="19" font="4">708. </text>
<text top="145" left="162" width="879" height="19" font="4">Neutze JM, Ishikawa T, Clarkson PM, et al. Assessment and follow-up of patients with ventricular septal defect and elevated pulmonary vascular </text>
<text top="163" left="108" width="255" height="19" font="4">resistance. Am J Cardiol. 1989;63:327-31. </text>
<text top="181" left="108" width="30" height="19" font="4">709. </text>
<text top="181" left="162" width="910" height="19" font="4">Steele PM, Fuster V, Cohen M, et al. Isolated atrial septal defect with pulmonary vascular obstructive disease—long-term follow-up and prediction of </text>
<text top="199" left="108" width="395" height="19" font="4">outcome after surgical correction. Circulation. 1987;76:1037-42. </text>
<text top="218" left="108" width="30" height="19" font="4">710. </text>
<text top="218" left="162" width="866" height="19" font="4">Yong G, Khairy P, De Guise P, et al. Pulmonary arterial hypertension in patients with transcatheter closure of secundum atrial septal defects: a </text>
<text top="236" left="108" width="351" height="19" font="4">longitudinal study. Circ Cardiovasc Interv. 2009;2:455-62. </text>
<text top="255" left="108" width="30" height="19" font="4">711. </text>
<text top="255" left="162" width="866" height="19" font="4">Gatzoulis MA, Beghetti M, Galiè N, et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the </text>
<text top="273" left="108" width="426" height="19" font="4">BREATHE-5 open-label extension study. Int J Cardiol. 2008;127:27-32. </text>
<text top="291" left="108" width="30" height="19" font="4">712. </text>
<text top="291" left="162" width="898" height="19" font="4">Berger RM, Beghetti M, Galie N, et al. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary </text>
<text top="309" left="108" width="664" height="19" font="4">arterial hypertension related to Eisenmenger’s syndrome: a subgroup analysis. Int J Cardiol. 2010;144:373-8. </text>
<text top="328" left="108" width="30" height="19" font="4">713. </text>
<text top="328" left="162" width="909" height="19" font="4">Abd El Rahman MY, Rentzsch A, Scherber P, et al. Effect of bosentan therapy on ventricular and atrial function in adults with Eisenmenger syndrome. </text>
<text top="346" left="108" width="778" height="19" font="4">A prospective, multicenter study using conventional and Speckle tracking echocardiography. Clin Res Cardiol. 2014;103:701-10. </text>
<text top="364" left="108" width="30" height="19" font="4">714. </text>
<text top="364" left="162" width="898" height="19" font="4">Baptista R, Castro G, da Silva AM, et al. Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease. </text>
<text top="383" left="108" width="201" height="19" font="4">Rev Port Cardiol. 2013;32:123-9. </text>
<text top="401" left="108" width="30" height="19" font="4">715. </text>
<text top="401" left="162" width="875" height="19" font="4">Diaz-Caraballo E, Gonzalez-Garcia AE, Renones M, et al. Long-term bosentan treatment of complex congenital heart disease and Eisenmenger’s </text>
<text top="419" left="108" width="329" height="19" font="4">syndrome. Rev Esp Cardiol (Engl Ed). 2009;62:1046-9. </text>
<text top="438" left="108" width="30" height="19" font="4">716. </text>
<text top="438" left="162" width="850" height="19" font="4">Zhang Z-N, Jiang X, Zhang R, et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart. </text>
<text top="456" left="108" width="111" height="19" font="4">2011;97:1876-81. </text>
<text top="474" left="108" width="30" height="19" font="4">717. </text>
<text top="474" left="162" width="902" height="19" font="4">Garg N, Tripathy N, Sinha N. Comparative efficacy of sildenafil in Eisenmenger’s syndrome secondary to atrial septal defect versus ventricular septal </text>
<text top="493" left="108" width="489" height="19" font="4">defect: a cardiac catheterisation follow-up study. Cardiol Young. 2011;21:631-8. </text>
<text top="511" left="108" width="30" height="19" font="4">718. </text>
<text top="511" left="162" width="918" height="19" font="4">D’Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension </text>
<text top="529" left="108" width="370" height="19" font="4">and Eisenmenger physiology. Int J Cardiol. 2012;155:378-82. </text>
<text top="547" left="108" width="30" height="19" font="4">719. </text>
<text top="547" left="162" width="918" height="19" font="4">Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, </text>
<text top="566" left="108" width="312" height="19" font="4">double-blinded trial. Eur Heart J. 2010;31:1124-31. </text>
<text top="584" left="108" width="30" height="19" font="4">720. </text>
<text top="584" left="162" width="920" height="19" font="4">Singh TP, Rohit M, Grover A, et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in </text>
<text top="602" left="108" width="438" height="19" font="4">severe pulmonary artery hypertension. Am Heart J. 2006;151:851.e1-5. </text>
<text top="621" left="108" width="30" height="19" font="4">721. </text>
<text top="621" left="162" width="884" height="19" font="4">Bharani A, Patel A, Saraf J, et al. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart J. 2007;59:323-8. </text>
<text top="639" left="108" width="30" height="19" font="4">722. </text>
<text top="639" left="162" width="862" height="19" font="4">Zuckerman WA, Leaderer D, Rowan CA, et al. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol. </text>
<text top="657" left="108" width="111" height="19" font="4">2011;107:1381-5. </text>
<text top="676" left="108" width="30" height="19" font="4">723. </text>
<text top="676" left="162" width="883" height="19" font="4">Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. </text>
<text top="694" left="108" width="191" height="19" font="4">Circulation. 2006;114:1807-10. </text>
<text top="712" left="108" width="30" height="19" font="4">724. </text>
<text top="712" left="162" width="875" height="19" font="4">Mukhopadhyay S, Nathani S, Yusuf J, et al. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome—a randomized, </text>
<text top="730" left="108" width="523" height="19" font="4">placebo-controlled, double-blind crossover study. Congenit Heart Dis. 2011;6:424-31. </text>
<text top="749" left="108" width="30" height="19" font="4">725. </text>
<text top="749" left="162" width="896" height="19" font="4">Diller G-P, Alonso-Gonzalez R, Dimopoulos K, et al. Disease targeting therapies in patients with Eisenmenger syndrome: response to treatment and </text>
<text top="767" left="108" width="312" height="19" font="4">long-term efficiency. Int J Cardiol. 2013;167:840-7. </text>
</page>
<page number="248" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 248 </text>
<text top="108" left="108" width="30" height="19" font="4">726. </text>
<text top="108" left="162" width="863" height="19" font="4">D’Alto M, Romeo E, Argiento P, et al. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving </text>
<text top="126" left="108" width="260" height="19" font="4">bosentan therapy. Heart. 2010;96:1475-9. </text>
<text top="145" left="108" width="30" height="19" font="4">727. </text>
<text top="145" left="162" width="914" height="19" font="4">Duffels MGJ, Vis JC, van Loon RLE, et al. Down patients with Eisenmenger syndrome: is bosentan treatment an option? Int J Cardiol. 2009;134:378-83. </text>
<text top="163" left="108" width="30" height="19" font="4">728. </text>
<text top="163" left="162" width="915" height="19" font="4">Monfredi O, Griffiths L, Clarke B, et al. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease. Am </text>
<text top="181" left="108" width="170" height="19" font="4">J Cardiol. 2011;108:1483-8. </text>
<text top="199" left="108" width="30" height="19" font="4">729. </text>
<text top="199" left="162" width="892" height="19" font="4">Serino G, Guazzi M, Micheletti A, et al. Effect of bosentan on exercise capacity and clinical worsening in patients with dual Down and Eisenmenger </text>
<text top="218" left="108" width="315" height="19" font="4">syndrome. Clin Med Insights Cardiol. 2013;7:29-34. </text>
<text top="236" left="108" width="30" height="19" font="4">730. </text>
<text top="236" left="162" width="919" height="19" font="4">D’Alto M, Romeo E, Argiento P, et al. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down’s syndrome. Int J Cardiol. </text>
<text top="255" left="108" width="103" height="19" font="4">2013;164:323-6. </text>
<text top="273" left="108" width="30" height="19" font="4">731. </text>
<text top="273" left="162" width="916" height="19" font="4">Diller G-P, Alonso-Gonzalez R, Kempny A, et al. B-type natriuretic peptide concentrations in contemporary Eisenmenger syndrome patients: predictive </text>
<text top="291" left="108" width="445" height="19" font="4">value and response to disease targeting therapy. Heart. 2012;98:736-42. </text>
<text top="309" left="108" width="30" height="19" font="4">732. </text>
<text top="309" left="162" width="909" height="19" font="4">Tay ELW, Papaphylactou M, Diller G-P, et al. Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral </text>
<text top="328" left="108" width="295" height="19" font="4">sildenafil therapy. Int J Cardiol. 2011;149:372-6. </text>
<text top="346" left="108" width="30" height="19" font="4">733. </text>
<text top="346" left="162" width="827" height="19" font="4">Sandoval J, Aguirre JS, Pulido T, et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med. </text>
<text top="364" left="108" width="111" height="19" font="4">2001;164:1682-7. </text>
<text top="383" left="108" width="30" height="19" font="4">734. </text>
<text top="383" left="162" width="903" height="19" font="4">Sharma V, Burkhart HM, Dearani JA, et al. Surgical unroofing of anomalous aortic origin of a coronary artery: a single-center experience. Ann Thorac </text>
<text top="401" left="108" width="130" height="19" font="4">Surg. 2014;98:941-5. </text>
<text top="419" left="108" width="30" height="19" font="4">735. </text>
<text top="419" left="162" width="911" height="19" font="4">Basso C, Maron BJ, Corrado D, et al. Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden </text>
<text top="438" left="108" width="454" height="19" font="4">death in young competitive athletes. J Am Coll Cardiol. 2000;35:1493-501. </text>
<text top="456" left="108" width="30" height="19" font="4">736. </text>
<text top="456" left="162" width="874" height="19" font="4">Frescura C, Basso C, Thiene G, et al. Anomalous origin of coronary arteries and risk of sudden death: a study based on an autopsy population of </text>
<text top="474" left="108" width="338" height="19" font="4">congenital heart disease. Hum Pathol. 1998;29:689-95. </text>
<text top="493" left="108" width="30" height="19" font="4">737. </text>
<text top="493" left="162" width="921" height="19" font="4">Krasuski RA, Magyar D, Hart S, et al. Long-term outcome and impact of surgery on adults with coronary arteries originating from the opposite coronary </text>
<text top="511" left="108" width="219" height="19" font="4">cusp. Circulation. 2011;123:154-62. </text>
<text top="529" left="108" width="30" height="19" font="4">738. </text>
<text top="529" left="162" width="884" height="19" font="4">Davies JE, Burkhart HM, Dearani JA, et al. Surgical management of anomalous aortic origin of a coronary artery. Ann Thorac Surg. 2009;88:844-7. </text>
<text top="547" left="108" width="30" height="19" font="4">739. </text>
<text top="547" left="162" width="921" height="19" font="4">Poynter JA, Williams WG, McIntyre S, et al. Anomalous aortic origin of a coronary artery: a report from the Congenital Heart Surgeons Society Registry. </text>
<text top="566" left="108" width="315" height="19" font="4">World J Pediatr Congenit Heart Surg. 2014;5:22-30. </text>
<text top="584" left="108" width="30" height="19" font="4">740. </text>
<text top="584" left="162" width="876" height="19" font="4">Frommelt PC, Sheridan DC, Berger S, et al. Ten-year experience with surgical unroofing of anomalous aortic origin of a coronary artery from the </text>
<text top="602" left="108" width="540" height="19" font="4">opposite sinus with an interarterial course. J Thorac Cardiovasc Surg. 2011;142:1046-51. </text>
<text top="621" left="108" width="30" height="19" font="4">741. </text>
<text top="621" left="162" width="803" height="19" font="4">Mumtaz MA, Lorber RE, Arruda J, et al. Surgery for anomalous aortic origin of the coronary artery. Ann Thorac Surg. 2011;91:811-4. </text>
<text top="639" left="108" width="30" height="19" font="4">742. </text>
<text top="639" left="162" width="906" height="19" font="4">Mainwaring RD, Reddy VM, Reinhartz O, et al. Anomalous aortic origin of a coronary artery: medium-term results after surgical repair in 50 patients. </text>
<text top="657" left="108" width="203" height="19" font="4">Ann Thorac Surg. 2011;92:691-7. </text>
<text top="676" left="108" width="30" height="19" font="4">743. </text>
<text top="676" left="162" width="888" height="19" font="4">Gulati R, Reddy VM, Culbertson C, et al. Surgical management of coronary artery arising from the wrong coronary sinus, using standard and novel </text>
<text top="694" left="108" width="346" height="19" font="4">approaches. J Thorac Cardiovasc Surg. 2007;134:1171-8. </text>
<text top="712" left="108" width="30" height="19" font="4">744. </text>
<text top="712" left="162" width="912" height="19" font="4">Brothers J, Gaynor JW, Paridon S, et al. Anomalous aortic origin of a coronary artery with an interarterial course: understanding current management </text>
<text top="730" left="108" width="443" height="19" font="4">strategies in children and young adults. Pediatr Cardiol. 2009;30:911-21. </text>
<text top="749" left="108" width="30" height="19" font="4">745. </text>
<text top="749" left="162" width="901" height="19" font="4">Angelini P, Uribe C, Monge J, et al. Origin of the right coronary artery from the opposite sinus of Valsalva in adults: characterization by intravascular </text>
<text top="767" left="108" width="624" height="19" font="4">ultrasonography at baseline and after stent angioplasty. Catheter Cardiovasc Interv. 2015;86:199-208. </text>
</page>
<page number="249" position="absolute" top="0" left="0" height="918" width="1188">
<text top="847" left="54" width="556" height="17" font="0">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="847" left="1030" width="53" height="17" font="0">Page 249 </text>
<text top="108" left="108" width="30" height="19" font="4">746. </text>
<text top="108" left="162" width="916" height="19" font="4">Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. </text>
<text top="126" left="108" width="119" height="19" font="4">2009;119:1085-92. </text>
<text top="145" left="108" width="30" height="19" font="4">747. </text>
<text top="145" left="162" width="904" height="19" font="4">Opolski MP, Pregowski J, Kruk M, et al. Prevalence and characteristics of coronary anomalies originating from the opposite sinus of Valsalva in 8,522 </text>
<text top="163" left="108" width="606" height="19" font="4">patients referred for coronary computed tomography angiography. Am J Cardiol. 2013;111:1361-7. </text>
<text top="181" left="108" width="30" height="19" font="4">748. </text>
<text top="181" left="162" width="900" height="19" font="4">Lee H-J, Hong YJ, Kim HY, et al. Anomalous origin of the right coronary artery from the left coronary sinus with an interarterial course: subtypes and </text>
<text top="199" left="108" width="293" height="19" font="4">clinical importance. Radiology. 2012;262:101-8. </text>
<text top="218" left="108" width="30" height="19" font="4">749. </text>
<text top="218" left="162" width="916" height="19" font="4">Kaushal S, Backer CL, Popescu AR, et al. Intramural coronary length correlates with symptoms in patients with anomalous aortic origin of the coronary </text>
<text top="236" left="108" width="255" height="19" font="4">artery. Ann Thorac Surg. 2011;92:986-91. </text>
<text top="255" left="108" width="30" height="19" font="4">750. </text>
<text top="255" left="162" width="843" height="19" font="4">Eckart RE, Scoville SL, Campbell CL, et al. Sudden death in young adults: a 25-year review of autopsies in military recruits. Ann Intern Med. </text>
<text top="273" left="108" width="111" height="19" font="4">2004;141:829-34. </text>
<text top="291" left="108" width="30" height="19" font="4">751. </text>
<text top="291" left="162" width="899" height="19" font="4">Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J Am Coll </text>
<text top="309" left="108" width="161" height="19" font="4">Cardiol. 2011;58:1254-61. </text>
<text top="328" left="108" width="30" height="19" font="4">752. </text>
<text top="328" left="162" width="886" height="19" font="4">Rajbanshi BG, Burkhart HM, Schaff HV, et al. Surgical strategies for anomalous origin of coronary artery from pulmonary artery in adults. J Thorac </text>
<text top="346" left="108" width="207" height="19" font="4">Cardiovasc Surg. 2014;148:220-4. </text>
<text top="364" left="108" width="30" height="19" font="4">753. </text>
<text top="364" left="162" width="900" height="19" font="4">Yau JM, Singh R, Halpern EJ, et al. Anomalous origin of the left coronary artery from the pulmonary artery in adults: a comprehensive review of 151 </text>
<text top="383" left="108" width="529" height="19" font="4">adult cases and a new diagnosis in a 53-year-old woman. Clin Cardiol. 2011;34:204-10. </text>
<text top="401" left="108" width="30" height="19" font="4">754. </text>
<text top="401" left="162" width="899" height="19" font="4">Wilson CL, Dlabal PW, McGuire SA. Surgical treatment of anomalous left coronary artery from pulmonary artery: follow-up in teenagers and adults. </text>
<text top="419" left="108" width="170" height="19" font="4">Am Heart J. 1979;98:440-6. </text>
<text top="438" left="108" width="30" height="19" font="4">755. </text>
<text top="438" left="162" width="894" height="19" font="4">el-Said GM, Ruzyllo W, Williams RL, et al. Early and late result of saphenous vein graft for anomalous origin of left coronary artery from pulmonary </text>
<text top="456" left="108" width="209" height="19" font="4">artery. Circulation. 1973;48:III2-6. </text>
<text top="474" left="108" width="30" height="19" font="4">756. </text>
<text top="474" left="162" width="888" height="19" font="4">Lange R, Vogt M, Hörer J, et al. Long-term results of repair of anomalous origin of the left coronary artery from the pulmonary artery. Ann Thorac </text>
<text top="493" left="108" width="145" height="19" font="4">Surg. 2007;83:1463-71. </text>
<text top="511" left="108" width="30" height="19" font="4">757. </text>
<text top="511" left="162" width="912" height="19" font="4">Paridon SM, Farooki ZQ, Kuhns LR, et al. Exercise performance after repair of anomalous origin of the left coronary artery from the pulmonary artery. </text>
<text top="529" left="108" width="184" height="19" font="4">Circulation. 1990;81:1287-92. </text>
<text top="547" left="108" width="30" height="19" font="4">758. </text>
<text top="547" left="162" width="901" height="19" font="4">Cochrane AD, Coleman DM, Davis AM, et al. Excellent long-term functional outcome after an operation for anomalous left coronary artery from the </text>
<text top="566" left="108" width="382" height="19" font="4">pulmonary artery. J Thorac Cardiovasc Surg. 1999;117:332-42. </text>
<text top="584" left="108" width="3" height="19" font="4"> </text>
</page>
<outline>
<item page="5">Data Supplement 1. Anatomic and Physiologic Terms – Section 2.1</item>
<item page="7">Data Supplement 2. Severity of ACHD – Section 2.2</item>
<item page="16">Data Supplement 3. Access to Care and Delivery of Care – Sections 3.2 and 3.3</item>
<item page="17">Data Supplement 4. Catheter Interventions</item>
<item page="18">Data Supplement 5. Surgery</item>
<item page="20">Data Supplement 6. Ionizing Radiation Principles – Section 3.4.2</item>
<item page="21">Data Supplement 7. Echocardiography – Section 3.4.3</item>
<item page="24">Data Supplement 8. CMR Imaging – Section 3.4.4</item>
<item page="28">Data Supplement 9. Cardiac Computed Tomography – Section 3.4.5</item>
<item page="30">Data Supplement 10. Cardiac Catheterization – Section 3.4.6</item>
<item page="34">Data Supplement 11. Exercise Testing – Section 3.4.7</item>
<item page="35">Data Supplement 12. Transition Education – Section 3.5</item>
<item page="36">Data Supplement 13. Exercise and Sports – Section 3.6</item>
<item page="39">Data Supplement 14. Mental Health and Neurodevelopmental Issues – Section 3.7</item>
<item page="41">Data Supplement 15. Endocarditis Prevention – Section 3.8</item>
<item page="43">Data Supplement 16. Concomitant Syndromes – Section 3.9</item>
<item page="45">Data Supplement 17. Acquired Cardiovascular Disease – Section 3.10</item>
<item page="54">Data Supplement 18. Noncardiac Medical Issues and Noncardiac Surgery – Sections 3.11 and 3.12</item>
<item page="58">Data Supplement 19. Pregnancy – Section 3.13.1</item>
<item page="69">Data Supplement 20. Contraception – Section 3.13.2</item>
<item page="70">Data Supplement 21. Sexual Function – Section 3.13.4</item>
<item page="71">Data Supplement 22. Pharmacological Therapy for ACHD – Section 3.17</item>
<item page="76">Data Supplement 23. Heart Failure and Transplant – Section 3.14.2</item>
<item page="78">Data Supplement 24. Palliative Care – Section 3.15</item>
<item page="78">Data Supplement 25. Cyanosis – Section 3.16</item>
<item page="80">Data Supplement 26. Atrial Septal Defect – Section 4.1.1</item>
<item page="92">Data Supplement 27. Anomalous Pulmonary Venous Connections – Section 4.1.2</item>
<item page="96">Data Supplement 28. Ventricular Septal Defect – Section 4.1.3</item>
<item page="98">Data Supplement 29. Atrioventricular Septal Defect – Section 4.1.4</item>
<item page="99">Data Supplement 30. Patent Ductus Arteriosus – Section 4.1.5</item>
<item page="101">Data Supplement 31. Cor Triatriatum – Section 4.2.1</item>
<item page="101">Data Supplement 32. Congenital Mitral Stenosis – Section 4.2.2</item>
<item page="102">Data Supplement 33. Subaortic Stenosis – Section 4.2.3</item>
<item page="108">Data Supplement 34. Congenital Valvular Aortic Stenosis – Sections 4.2.4</item>
<item page="109">Data Supplement 35. Turner Syndrome – Section 4.2.4.1</item>
<item page="110">Data Supplement 36. Aortopathies – Section 4.2.4.2</item>
<item page="112">Data Supplement 37. Supravalvular Aortic Stenosis – Section 4.2.5</item>
<item page="116">Data Supplement 38. Coarctation of the Aorta – Section 4.2.6</item>
<item page="123">Data Supplement 39. Valvular Pulmonary Stenosis – Section 4.3.1</item>
<item page="125">Data Supplement 40. Branch and Peripheral Pulmonary Stenosis – Section 4.3.2</item>
<item page="128">Data Supplement 41. Double-Chambered Right Ventricular – Section 4.3.3</item>
<item page="129">Data Supplement 42. Ebstein Anomaly – Section 4.3.4</item>
<item page="132">Data Supplement 43. Tetralogy of Fallot – Section 4.3.5</item>
<item page="147">Data Supplement 44. Right Ventricle to Pulmonary Artery Conduit – Section 4.3.6</item>
<item page="158">Data Supplement 45. Transposition of the Great Arteries with Atrial Switch – Section 4.4.1.1</item>
<item page="165">Data Supplement 46. Transposition of the Great Arteries with Arterial Switch – Section 4.4.1.2</item>
<item page="167">Data Supplement 47. Congenitally Corrected Transposition of the Great Arteries – Section 4.4.1.4</item>
<item page="176">Data Supplement 48. Fontan Palliation of Single Ventricle Physiology Including Tricuspid Atresia and Double Inlet Right Ventricle – Section 4.4.2</item>
<item page="186">Data Supplement 49. Severe Pulmonary Arterial Hypertension – Section 4.4.6.1</item>
<item page="193">Data Supplement 50. Eisenmenger Syndrome – Section 4.4.6.2</item>
<item page="206">Data Supplement 51. Anomalous Coronary Artery Evaluation – Section 4.4.7.1</item>
<item page="213">References</item>
</outline>
</pdf2xml>
